[
  {
    "id": "training_518_5",
    "table_caption": "Table: success same R2 evaluation, and change success for early stages (n = 89) and advanced stages of change (n = 88). Early stages of change Advances stages of change Product evaluation Change success Product evaluation Change success BITTER FACTORS Demand −0.04 0.40** 0.29** 0.44** Confrontation with deficits −0.06 0.23* 0.17 0.34** SWEET FACTORS Autonomy 0.31* 0.28** 0.16 0.20 Encouraging feedback 0.29** 0.51** 0.24* 0.42** *p < 0.05, **p < 0.01. ",
    "table_content": "|| blank | Early stages of change | Early stages of change | Advances stages of change | Advances stages of change ||\n|| blank | Product evaluation | Change success | Product evaluation | Change success ||\n|| BITTER FACTORS | BITTER FACTORS | BITTER FACTORS | BITTER FACTORS | BITTER FACTORS ||\n|| Demand | −0.04 | 0.40 ** | 0.29 ** | 0.44 ** ||\n|| Confrontation with deficits | −0.06 | 0.23 * | 0.17 | 0.34 ** ||\n|| SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS ||\n|| Autonomy | 0.31 * | 0.28 ** | 0.16 | 0.20 ||\n|| Encouraging feedback | 0.29 ** | 0.51 ** | 0.24 * | 0.42 ** ||",
    "claim": "While \"Demand\" shows a negative correlation with product evaluation in early stages, it transitions to a positive correlation in advanced stages, reflecting a shift in perception as change progresses.",
    "label": "support"
  },
  {
    "id": "training_1240_3",
    "table_caption": "Table: Expert forecasts of future policy implementation. Policy Component Population- average Socio-economic differentiala Voluntary reformulation Coverage: Percentage of products reformulated 39% (9% to 82%) 0.79 (0.18 to 1.54) Impact: Percentage salt reduction 24% (9% to 46%) Social marketing Coverage: New percentage exposure (considering 10% as the 2015 baseline) 22% (4% to 53%) 0.45 (0.15 to 0.90) Nutrition labelling 23% (5% to 50%) 0.47 (0.08 to 1.12) Means and 95% prediction intervals of the changes that our experts judged would characterise policy implementation by 2020. In S2 Appendix we present a detailed breakdown of the within and between expert variation in judgements about each parameter value. ",
    "table_content": "|| Policy | Component | Population-average | Socio-economic differential  a   ||\n|| Voluntary reformulation | Coverage: Percentage of products reformulated | 39% (9% to 82%) | 0.79 (0.18 to 1.54) ||\n|| Voluntary reformulation | Impact: Percentage salt reduction | 24% (9% to 46%) | 0.79 (0.18 to 1.54) ||\n|| Social marketing | Coverage: New percentage exposure (considering 10% as the 2015 baseline) | 22% (4% to 53%) | 0.45 (0.15 to 0.90) ||\n|| Nutrition labelling | Coverage: New percentage exposure (considering 10% as the 2015 baseline) | 23% (5% to 50%) | 0.47 (0.08 to 1.12) ||",
    "claim": "The percentage salt reduction impact of voluntary reformulation is 24%, which is 15% lower than the coverage percentage, indicating a less pronounced effect on salt reduction compared to the extent of product reformulation.",
    "label": "support"
  },
  {
    "id": "training_805_3",
    "table_caption": "Table: (from NHANES 2003–2006) a. Food/Food Group b Cholesterol (mean = 267 mg) Ranking % Total Cumulative % Eggs 1 24.2 24.2 Poultry 2 13.2 37.4 Beef 3 11.5 48.9 Milk 4 9.7 58.6 Cheese 5 9.6 68.2 Frankfurters, sausages, luncheon meats 6 6.6 74.8 Milk desserts 7 4.1 78.9 Pork, ham, bacon 8 3.8 82.7 Cake, cookies, quick bread, pastry, pie 9 3.4 86.1 Mixtures, mostly grain 10 2.6 88.7 Fish and shellfish 11 2.1 90.8 a Data are for children aged 2 to 18 years (n = 7332), Day 1 intakes; b Food groups (n = 4) contributing at least 1% in descending order: biscuits, corn bread, pancakes, tortillas; milk drinks; margarine and butter; ",
    "table_content": "|| Food/Food Group b | Cholesterol (mean = 267 mg) | Cholesterol (mean = 267 mg) | Cholesterol (mean = 267 mg) ||\n|| Food/Food Group b | Ranking | % Total | Cumulative % ||\n|| Cake, cookies, quick bread, pastry, pie | 9 | 3.4 | 86.1 ||\n|| Mixtures, mostly grain | 10 | 2.6 | 88.7 ||\n|| Fish and shellfish | 11 | 2.1 | 90.8 ||\n|| Eggs | 1 | 24.2 | 24.2 ||\n|| Poultry | 2 | 13.2 | 37.4 ||\n|| Beef | 3 | 11.5 | 48.9 ||\n|| Milk | 4 | 9.7 | 58.6 ||\n|| Cheese | 5 | 9.6 | 68.2 ||\n|| Frankfurters, sausages, luncheon meats | 6 | 6.6 | 74.8 ||\n|| Milk desserts | 7 | 4.1 | 78.9 ||\n|| Pork, ham, bacon | 8 | 3.8 | 82.7 ||",
    "claim": "Milk and cheese, both dairy products, contribute nearly equally to cholesterol intake, with a combined contribution of 19.3%. This indicates that dairy products are a substantial source of cholesterol, with milk slightly surpassing cheese in its contribution.",
    "label": "support"
  },
  {
    "id": "training_148_2",
    "table_caption": "Table: Operation time and postoperative stay. Parameters Value Group A Group B p Operation Time (min) Mean 101.17 84.66 0.161 Min 40.00 40.00 Max 270.00 180.00 SEM 9.58 6.54 SD 52.45 35.25 Postoperative Hospital stay (days) Mean 7.20 5.83 0.064 Min 4.00 3.00 Max 21.00 10.00 SEM 0.66 0.31 SD 3.61 1.65 operation-time and postoperative stay were lower in the aprotinin-group reaching statistical significance. ",
    "table_content": "|| Parameters | Value | Group A | Group B | p ||\n|| Operation Time (min) | Mean | 101.17 | 84.66 | 0.161 ||\n|| Postoperative Hospital stay (days) | SD | 3.61 | 1.65 | blank ||\n|| Operation Time (min) | Min | 40.00 | 40.00 | blank ||\n|| Operation Time (min) | Max | 270.00 | 180.00 | blank ||\n|| Operation Time (min) | SEM | 9.58 | 6.54 | blank ||\n|| Operation Time (min) | SD | 52.45 | 35.25 | blank ||\n|| Postoperative Hospital stay (days) | Mean | 7.20 | 5.83 | 0.064 ||\n|| Postoperative Hospital stay (days) | Min | 4.00 | 3.00 | blank ||\n|| Postoperative Hospital stay (days) | Max | 21.00 | 10.00 | blank ||\n|| Postoperative Hospital stay (days) | SEM | 0.66 | 0.31 | blank ||",
    "claim": "The standard deviation of operation times in Group A is approximately 1.5 times that of Group B, suggesting greater variability in operation durations for Group A.",
    "label": "support"
  },
  {
    "id": "training_163_2",
    "table_caption": "Table: and event by and group This strategy Table 1 Demographic data of the participants Rem (n = 30) Rem + Flu (n = 30) P value Age 42.2 ± 11.3 40.7 ± 8.3 0.552 Gender 22/8 19/11 0.405 Height 169.2 ± 7.1 166.3 ± 8.2 0.154 Weight 57.8 ± 8.4 58.3 ± 10.6 0.844 BMI 20.2 ± 2.5 20.9 ± 2.4 0.242 Procedure Duration 55.5 ± 8.1 43.2 ± 6.2 0.217 BMI body mass index ",
    "table_content": "|| blank | Rem ( n = 30) | Rem + Flu ( n = 30) | P value ||\n|| Age | 42.2 ± 11.3 | 40.7 ± 8.3 | 0.552 ||\n|| Gender | 22/8 | 19/11 | 0.405 ||\n|| Height | 169.2 ± 7.1 | 166.3 ± 8.2 | 0.154 ||\n|| Weight | 57.8 ± 8.4 | 58.3 ± 10.6 | 0.844 ||\n|| BMI | 20.2 ± 2.5 | 20.9 ± 2.4 | 0.242 ||\n|| Procedure Duration | 55.5 ± 8.1 | 43.2 ± 6.2 | 0.217 ||",
    "claim": "The gender distribution shows a higher male-to-female ratio in the Rem group compared to the Rem + Flu group. This difference in gender distribution could potentially affect the generalizability of the study results to a broader population.",
    "label": "support"
  },
  {
    "id": "training_561_6",
    "table_caption": "Table: Occurrence of patterns in the eukaryotic proteomes. Pattern Number of groups, identity inside group .20% Fraction of disordered residues in the patterns from the DRDB Probability of occurrence of the patterns in protein Occurrence in the human proteome/in the DRDB Occurrence in the fruit fly proteome/in the DRDB Occurrence in the nematode worm proteome/ in the DRDB PPPPPP 15 0.70 0.00017 703/32 304/32 247/32 QQQQQQ 11 0.66 0.00004 331/17 869/17 249/17 EEEDEE 55 0.65 0.00015 242/55 42/55 54/55 QPPPPP 9 0.74 0.00013 163/16 66/16 32/16 APAPAP 17 0.51 0.00067 121/30 44/30 34/30 HHHHHH 1227 0.93 0.00002 99/5423 133/5423 57/5423 EDEDEE 23 0.64 0.00014 97/29 27/29 42/29 DEEEED 12 0.68 0.00014 83/16 26/16 39/16 GGGGGSG 17 0.65 0.00028 78/29 80/29 8/29 GSSGSS 66 0.68 0.00120 67/93 35/93 19/93 PPPPPK 18 0.81 0.00027 62/31 24/31 32/31 DDEDED 14 0.64 0.00013 53/16 31/16 26/16 SGGGGSG 10 0.82 0.00022 31/29 19/29 2/29 KKKGKK 26 0.55 0.00181 27/56 8/56 13/56 EEEEAP 12 0.66 0.00028 26/21 6/21 9/21 KKRKRK 12 0.54 0.00067 25/19 6/19 7/19 SGGGSGG 12 0.68 0.00024 20/17 17/17 5/17 SHHHHH 558 0.98 0.00005 19/1566 27/1566 12/1566 GGSGSGG 17 0.77 0.00027 14/50 23/50 6/50 NHHHHH 19 0.83 0.00003 10/25 14/25 8/25 doi:10.1371/journal.pcbi.1000958.t003 ",
    "table_content": "|| Pattern | Number of groups, identity inside group >20% | Fraction of disordered residues in the patterns from the DRDB | Probability of occurrence of the patterns in protein | Occurrence in the human proteome/in the DRDB | Occurrence in the fruit fly proteome/in the DRDB | Occurrence in the nematode worm proteome/in the DRDB ||\n|| PPPPPP | 15 | 0.70 | 0.00017 | 703/32 | 304/32 | 247/32 ||\n|| GSSGSS | 66 | 0.68 | 0.00120 | 67/93 | 35/93 | 19/93 ||\n|| PPPPPK | 18 | 0.81 | 0.00027 | 62/31 | 24/31 | 32/31 ||\n|| DDEDED | 14 | 0.64 | 0.00013 | 53/16 | 31/16 | 26/16 ||\n|| SGGGGSG | 10 | 0.82 | 0.00022 | 31/29 | 19/29 | 2/29 ||\n|| KKKGKK | 26 | 0.55 | 0.00181 | 27/56 | 8/56 | 13/56 ||\n|| EEEEAP | 12 | 0.66 | 0.00028 | 26/21 | 6/21 | 9/21 ||\n|| KKRKRK | 12 | 0.54 | 0.00067 | 25/19 | 6/19 | 7/19 ||\n|| SGGGSGG | 12 | 0.68 | 0.00024 | 20/17 | 17/17 | 5/17 ||\n|| SHHHHH | 558 | 0.98 | 0.00005 | 19/1566 | 27/1566 | 12/1566 ||\n|| GGSGSGG | 17 | 0.77 | 0.00027 | 14/50 | 23/50 | 6/50 ||\n|| QQQQQQ | 11 | 0.66 | 0.00004 | 331/17 | 869/17 | 249/17 ||\n|| NHHHHH | 19 | 0.83 | 0.00003 | 10/25 | 14/25 | 8/25 ||\n|| EEEDEE | 55 | 0.65 | 0.00015 | 242/55 | 42/55 | 54/55 ||\n|| QPPPPP | 9 | 0.74 | 0.00013 | 163/16 | 66/16 | 32/16 ||\n|| APAPAP | 17 | 0.51 | 0.00067 | 121/30 | 44/30 | 34/30 ||\n|| HHHHHH | 1227 | 0.93 | 0.00002 | 99/5423 | 133/5423 | 57/5423 ||\n|| EDEDEE | 23 | 0.64 | 0.00014 | 97/29 | 27/29 | 42/29 ||\n|| DEEEED | 12 | 0.68 | 0.00014 | 83/16 | 26/16 | 39/16 ||\n|| GGGGGSG | 17 | 0.65 | 0.00028 | 78/29 | 80/29 | 8/29 ||",
    "claim": "The pattern \"HHHHHH\" has the largest number of groups with identity greater than 20%, which is 136.33 times more than the pattern \"QPPPPP\", suggesting a broader diversity or conservation of \"HHHHHH\" across different groups.",
    "label": "support"
  },
  {
    "id": "training_994_1",
    "table_caption": "Table: (%) (%) Table 4 Stability of h-sAPPα in CSF stored at different conditions Effect of storage temperature Samples −80°C −20°C +4°C RT F/T 1 100 ± 6 101 ± 5 100 ± 11 93 ± 1 103 ± 2 2 100 ± 7 93 ± 9 95 ± 15 85 ± 14 93 ± 6 3 100 ± 1 77 ± 1 82 ± 4 80 ± 4 76 ± 4 4 100 ± 5 113 ± 2 80 ± 4 109 ± 3 99 ± 5 5 100 ± 3 86 ± 5 81 ± 4 70 ± 5 83 ± 1 Five CSF samples were divided in five aliquots and stored for 24 hours at one of several different temperatures including room temperature (RT), or stored at −80°C and exposed to three freeze/thaw cycles (F/T) within a period of three ",
    "table_content": "|| Effect of storage temperature | Effect of storage temperature | Effect of storage temperature | Effect of storage temperature | Effect of storage temperature | Effect of storage temperature ||\n|| Samples | −80°C | −20°C | +4°C | RT | F/T ||\n|| 1 | 100 ± 6 | 101 ± 5 | 100 ± 11 | 93 ± 1 | 103 ± 2 ||\n|| 2 | 100 ± 7 | 93 ± 9 | 95 ± 15 | 85 ± 14 | 93 ± 6 ||\n|| 3 | 100 ± 1 | 77 ± 1 | 82 ± 4 | 80 ± 4 | 76 ± 4 ||\n|| 4 | 100 ± 5 | 113 ± 2 | 80 ± 4 | 109 ± 3 | 99 ± 5 ||\n|| 5 | 100 ± 3 | 86 ± 5 | 81 ± 4 | 70 ± 5 | 83 ± 1 ||",
    "claim": "The stability of h-sAPPα in CSF samples stored at −80°C remains consistently at 100% across all samples, indicating no degradation. This suggests that −80°C is an optimal storage condition for maintaining h-sAPPα stability over 24 hours.",
    "label": "support"
  },
  {
    "id": "training_95_2",
    "table_caption": "Table: Table 3 Pearson’s correlation coefficients of pulse wave velocity (PWV) with demographic, spirometric and right ventricular measures PWV Rho (95 % CI) p-value Age 0.04 (-0.24–0.28) 0.75 BMI (kg/m2) -0.28 (-0.49–0.02) 0.03 Heart rate (bpm) 0.20 (-0.11–0.46) 0.14 Systolic BP (mm Hg) 0.14 (-0.18–0.45) 0.29 Diastolic BP (mm Hg) 0.35 (0.06–0.60) 0.009 SpO2 -0.06 (-0.40–0.27) 0.65 Pack years 0.01 (-0.24–0.26) 0.94 FEV1, % predicted -0.16 (-0.37–0.09) 0.24 FVC, % predicted -0.07 (-0.28–0.14) 0.61 FEV1/FVC -0.18 (-0.42–0.10) 0.18 FEF 25–75, % predicted -0.11 (-0.35–0.14) 0.40 DLCO, % predicted -0.05 (-0.28–0.27) 0.73 DLCO/VA, % predicted -0.07 (-0.33–0.26) 0.60 RLV, % predicted 0.25 (-0.03–0.47) 0.07 VC, % predicted -0.02 (-0.26–0.23) 0.88 TLC, % predicted 0.28 (0.00–0.51) 0.04 RLV /TLC 0.21 (-0.08–0.43) 0.13 6MWT (m) –0.17 (–0.39–0.07) 0.20 RVEDV (ml/m1.7) -0.12 (-0.36–0.18) 0.39 RVESV (ml/m1.7) -0.20 (-0.39–0.08) 0.14 RVSV (ml/m1.7) 0.02 (-0.22–0.28) 0.86 RVEF (%) 0.18 (-0.04–0.38) 0.18 RVM (g/m1.7) -0.24 (-0.49–0.02) 0.07 DLCO diffusing capacity of the lungs for carbon monoxide, FEF forced expiratory flow, FEV1 forced expiratory volume in 1 s, FVC forced vital arterial p-value 0.04 0.58 0.003 0.10 0.53 0.004 0.17 0.77 0.06 0.57 0.37 0.33 0.03 0.02 <0.001 0.001 end- ventric- veloc- end- RVSV ratio ",
    "table_content": "|| blank | PWV | PWV ||\n|| blank | Rho (95 % CI) | p -value ||\n|| FVC, % predicted | -0.07 (-0.28–0.14) | 0.61 ||\n|| FEV1/FVC | -0.18 (-0.42–0.10) | 0.18 ||\n|| FEF 25–75, % predicted | -0.11 (-0.35–0.14) | 0.40 ||\n|| DLCO, % predicted | -0.05 (-0.28–0.27) | 0.73 ||\n|| DLCO/VA, % predicted | -0.07 (-0.33–0.26) | 0.60 ||\n|| RLV, % predicted | 0.25 (-0.03–0.47) | 0.07 ||\n|| VC, % predicted | -0.02 (-0.26–0.23) | 0.88 ||\n|| TLC, % predicted |  0.28 (0.00–0.51)  |  0.04  ||\n|| RLV /TLC | 0.21 (-0.08–0.43) | 0.13 ||\n|| 6MWT (m) | –0.17 (–0.39–0.07) | 0.20 ||\n|| Age | 0.04 (-0.24–0.28) | 0.75 ||\n|| RVEDV (ml/m 1.7 ) | -0.12 (-0.36–0.18) | 0.39 ||\n|| RVESV (ml/m 1.7 ) | -0.20 (-0.39–0.08) | 0.14 ||\n|| RVSV (ml/m 1.7 ) | 0.02 (-0.22–0.28) | 0.86 ||\n|| RVEF (%) | 0.18 (-0.04–0.38) | 0.18 ||\n|| RVM (g/m 1.7 ) | -0.24 (-0.49–0.02) | 0.07 ||\n|| BMI (kg/m 2 ) |  -0.28 (-0.49–0.02)  |  0.03  ||\n|| Heart rate (bpm) | 0.20 (-0.11–0.46) | 0.14 ||\n|| Systolic BP (mm Hg) | 0.14 (-0.18–0.45) | 0.29 ||\n|| Diastolic BP (mm Hg) |  0.35 (0.06–0.60)  |  0.009  ||\n|| SpO 2 | -0.06 (-0.40–0.27) | 0.65 ||\n|| Pack years | 0.01 (-0.24–0.26) | 0.94 ||\n|| FEV1, % predicted | -0.16 (-0.37–0.09) | 0.24 ||",
    "claim": "The correlation between PWV and diastolic blood pressure is statistically significant with a p-value of 0.009, indicating a reliable positive association. This suggests that higher diastolic blood pressure is associated with increased arterial stiffness, as measured by PWV.",
    "label": "support"
  },
  {
    "id": "training_1420_1",
    "table_caption": "Table: and the reports were returned within a median delay of 4 reported major errors including (i) “no malaria” (16.3%), Table 3 Results for the quality of staining of thin and thick blood film samples stained by the participants Sample Criteria Numbers (%) Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) No Giemsa stain precipitates observed 107 (65.6%) Red blood cells stained grey-pink 147 (90.2%) Chromatin of lymphocytes stained purple 60 (36.8%) Granules of neutrophils stained pink 100 (61.4%) Complies with all criteria mentioned above 16 (9.8%) Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) Correct dimensions (> 1 cm) and thickness of the film 110 (71.0%) Complete hemolysis of the red blood cells 118 (76.1%) No Giemsa stain precipitates observed 60 (38.7%) Good contrast between nucleus and cytoplasm 70 (45.1%) Complies with all criteria mentioned above 30 (19.4%) ",
    "table_content": "|| Sample | Criteria | Numbers (%) ||\n|| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | No Giemsa stain precipitates observed | 107 (65.6%) ||\n|| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | Complies with all criteria mentioned above | 30 (19.4%) ||\n|| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | Red blood cells stained grey-pink | 147 (90.2%) ||\n|| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | Chromatin of lymphocytes stained purple | 60 (36.8%) ||\n|| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | Granules of neutrophils stained pink | 100 (61.4%) ||\n|| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | Complies with all criteria mentioned above | 16 (9.8%) ||\n|| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | Correct dimensions (> 1 cm) and thickness of the film | 110 (71.0%) ||\n|| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | Complete hemolysis of the red blood cells | 118 (76.1%) ||\n|| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | No Giemsa stain precipitates observed | 60 (38.7%) ||\n|| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | Good contrast between nucleus and cytoplasm | 70 (45.1%) ||",
    "claim": "The compliance rate with all criteria for thick blood films is approximately double that of thin blood films, indicating a higher overall quality in thick blood film staining.",
    "label": "support"
  },
  {
    "id": "training_518_1",
    "table_caption": "Table: success same R2 evaluation, and change success for early stages (n = 89) and advanced stages of change (n = 88). Early stages of change Advances stages of change Product evaluation Change success Product evaluation Change success BITTER FACTORS Demand −0.04 0.40** 0.29** 0.44** Confrontation with deficits −0.06 0.23* 0.17 0.34** SWEET FACTORS Autonomy 0.31* 0.28** 0.16 0.20 Encouraging feedback 0.29** 0.51** 0.24* 0.42** *p < 0.05, **p < 0.01. ",
    "table_content": "|| blank | Early stages of change | Early stages of change | Advances stages of change | Advances stages of change ||\n|| blank | Product evaluation | Change success | Product evaluation | Change success ||\n|| BITTER FACTORS | BITTER FACTORS | BITTER FACTORS | BITTER FACTORS | BITTER FACTORS ||\n|| Demand | −0.04 | 0.40 ** | 0.29 ** | 0.44 ** ||\n|| Confrontation with deficits | −0.06 | 0.23 * | 0.17 | 0.34 ** ||\n|| SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS ||\n|| Autonomy | 0.31 * | 0.28 ** | 0.16 | 0.20 ||\n|| Encouraging feedback | 0.29 ** | 0.51 ** | 0.24 * | 0.42 ** ||",
    "claim": "The correlation of \"Demand\" with change success increases by 10% from early to advanced stages, while \"Confrontation with deficits\" shows a 48% increase, indicating a more pronounced impact of addressing deficits in later stages.",
    "label": "support"
  },
  {
    "id": "training_878_3",
    "table_caption": "Table: Table 6 K-fold cross validation (K = 5): Ntotal = 389,533, Pearson correlation, all test scores k Ntrain Ntest Correlation 1 311,540 77,993 0.895 2 311,463 78,070 0.891 3 311,652 77,881 0.898 4 311,565 77,968 0.901 5 311,454 78,079 0.903 ",
    "table_content": "|| k | Ntrain | Ntest | Correlation ||\n|| 1 | 311,540 | 77,993 | 0.895 ||\n|| 2 | 311,463 | 78,070 | 0.891 ||\n|| 3 | 311,652 | 77,881 | 0.898 ||\n|| 4 | 311,565 | 77,968 | 0.901 ||\n|| 5 | 311,454 | 78,079 | 0.903 ||",
    "claim": "The average Pearson correlation across all folds is approximately 0.898. This average indicates a strong positive linear relationship between predicted and actual values across the dataset, suggesting that the model is generally effective in capturing the underlying patterns in the data.",
    "label": "support"
  },
  {
    "id": "training_1344_4",
    "table_caption": "Table: patients, with a Mean ± S.D. (min, max) = 7.77 ± 3.74 that may the Table 2 Number of elderly patients with delirium By CAM algorithm\\By DSM-IV TR Delirium No delirium Positive 34 0 Negative 3 29 Total 37 29 ",
    "table_content": "|| By CAM algorithm\\By DSM-IV TR | Delirium | No delirium ||\n|| Positive | 34 | 0 ||\n|| Negative | 3 | 29 ||\n|| Total | 37 | 29 ||",
    "claim": "The ratio of true positives to false negatives is approximately 11.33, indicating a high detection rate of actual delirium cases by the CAM algorithm.",
    "label": "support"
  },
  {
    "id": "training_245_4",
    "table_caption": "Table: Table 4 Scores of MSBS-LDA on CVPPP A1 subset. Samples FBD (%) MHD 13 95.99 0.51 59 95.69 0.62 91 95.70 0.98 96 95.55 0.70 115 95.24 0.70 153 94.54 0.88 ",
    "table_content": "|| Samples | FBD (%) | MHD ||\n|| 13 | 95.99 | 0.51 ||\n|| 59 | 95.69 | 0.62 ||\n|| 91 | 95.70 | 0.98 ||\n|| 96 | 95.55 | 0.70 ||\n|| 115 | 95.24 | 0.70 ||\n|| 153 | 94.54 | 0.88 ||",
    "claim": "The maximum FBD value of 95.99% occurs at the smallest sample size of 13, while the minimum FBD value of 94.54% is observed at the largest sample size of 153. This indicates that the model performs best in terms of feature identification with smaller datasets.",
    "label": "support"
  },
  {
    "id": "training_611_2",
    "table_caption": "Table: Table 5 The multiple logistic regression for the relationship between POA and main IVF outcomes in each age group <33 years 33 ~ 37 years 38 ~ 41 years B P OR (95 % CI) B P OR (95 % CI) B P OR (5 % CI) Age 0.048 0.181 1.049(0.978–1.125) −0.069 0.348 0.933(0.807–1.079) −0.375 0.114 0.687(0.431–1.095) BMI −0.185 0.000 0.831(0.776–0.891) −0.090 0.006 0.914(0.857–0.975) −0.125 0.193 0.882(0.730–1.065) AFC −0.019 0.268 0.981(0.949–1.015) −0.032 0.086 0.969(0.934–1.004) −0.050 0.384 0.951(0.850–1.064) Number of retrieved oocytes −0.043 0.002 0.958(0.933–0.984) −0.015 0.348 0.985(0.954–1.017) −0.036 0.489 0.965(0.872–1.068) Total dose of Gna 0.283 <0.001 1.328(1.140–1.546) 0.428 <0.001 1.535(1.285–1.834) 0.662 0.006 1.939(1.212–3.102) aGn are transformed into ordinal variable according to the median (25–75th percentile) ",
    "table_content": "|| blank | <33 years | <33 years | <33 years | 33 ~ 37 years | 33 ~ 37 years | 33 ~ 37 years | 38 ~ 41 years | 38 ~ 41 years | 38 ~ 41 years ||\n|| blank | B |  P  | OR (95 % CI) | B |  P  | OR (95 % CI) | B |  P  | OR (5 % CI) ||\n|| Age | 0.048 | 0.181 | 1.049(0.978–1.125) | −0.069 | 0.348 | 0.933(0.807–1.079) | −0.375 | 0.114 | 0.687(0.431–1.095) ||\n|| BMI | −0.185 | 0.000 | 0.831(0.776–0.891) | −0.090 | 0.006 | 0.914(0.857–0.975) | −0.125 | 0.193 | 0.882(0.730–1.065) ||\n|| AFC | −0.019 | 0.268 | 0.981(0.949–1.015) | −0.032 | 0.086 | 0.969(0.934–1.004) | −0.050 | 0.384 | 0.951(0.850–1.064) ||\n|| Number of retrieved oocytes | −0.043 | 0.002 | 0.958(0.933–0.984) | −0.015 | 0.348 | 0.985(0.954–1.017) | −0.036 | 0.489 | 0.965(0.872–1.068) ||\n|| Total dose of Gn a  | 0.283 | <0.001 | 1.328(1.140–1.546) | 0.428 | <0.001 | 1.535(1.285–1.834) | 0.662 | 0.006 | 1.939(1.212–3.102) ||",
    "claim": "The odds ratio for BMI is lowest in the <33 years group, suggesting that BMI has a more pronounced negative impact on IVF outcomes in younger women. This aligns with the understanding that higher BMI can affect hormonal balance and reproductive health more significantly in younger individuals.",
    "label": "support"
  },
  {
    "id": "training_587_5",
    "table_caption": "Table: Mean and standard deviation of cognitive test scores stratified by years of (low) education. Sao Carlos, Brazil, 2014 (n=667). Education, y 0 (n=145)a 1 (n=48)b 2 (n=65)c 3 (n=74)d 4 (n=209)e M-ACE (max 30) 8.8±4.0 11.8±5.8 12.0±5.6 14.5±5.9 16.5±3.1 MMSE (max 30) 17.0±4.8 20.0±3.9 20.3±4.7 22.4±4.1 23.7±3.8 ACE-R (max 100) 38.6±14.4 49.5±17.4 51.2±16.8 58.7±16.4 65.7±16.3 • Attention/Orientation (max 18) 10.4±3.4 12.0±2.7 12.2±3.2 13.3±2.8 14.2±2.6 • Memory (max 26) 8.6±4.7 11.0±5.1 11.4±5.3 13.0±5.7 15.4±5.6 • Verbal Fluency (max 14) 2.7±2.3 4.4±2.8 4.2±2.5 5.4±2.8 6.1±2.7 • Language (max 26) 11.0±4.5 14.5±6.7 15.0±5.7 17.3±5.2 19.2±5.3 • Visuospatial (max 16) 5.7±3.2 7.3±3.7 8.3±3.5 9.7±2.8 10.6±3.5 M-ACE: Mini Addenbrooke Cognitive Examination; MMSE: Mini-Mental State Examination; ACE-R: Addenbrooke Cognitive Examination-Revised. T-test comparative scores with p≤0.05: M-ACE a<b=c<d=e. MMSE a<b=c=d=e. ACE-R a<b<c<d<e. Attention/Orientation a<b=c=d=e. Memory a<b=c=d<e. Verbal Fluency a<b=c<d=e. Language a<b=c=d=e. Visuospatial a<b<c<d=e. ",
    "table_content": "|| Education, y | 0 (n=145)a | 1 (n=48)b | 2 (n=65)c | 3 (n=74)d | 4 (n=209)e ||\n|| M-ACE (max 30) | 8.8±4.0 | 11.8±5.8 | 12.0±5.6 | 14.5±5.9 | 16.5±3.1 ||\n|| MMSE (max 30) | 17.0±4.8 | 20.0±3.9 | 20.3±4.7 | 22.4±4.1 | 23.7±3.8 ||\n|| ACE-R (max 100) | 38.6±14.4 | 49.5±17.4 | 51.2±16.8 | 58.7±16.4 | 65.7±16.3 ||\n|| • Attention/Orientation (max 18) | 10.4±3.4 | 12.0±2.7 | 12.2±3.2 | 13.3±2.8 | 14.2±2.6 ||\n|| • Memory (max 26) | 8.6±4.7 | 11.0±5.1 | 11.4±5.3 | 13.0±5.7 | 15.4±5.6 ||\n|| • Verbal Fluency (max 14) | 2.7±2.3 | 4.4±2.8 | 4.2±2.5 | 5.4±2.8 | 6.1±2.7 ||\n|| • Language (max 26) | 11.0±4.5 | 14.5±6.7 | 15.0±5.7 | 17.3±5.2 | 19.2±5.3 ||\n|| • Visuospatial (max 16) | 5.7±3.2 | 7.3±3.7 | 8.3±3.5 | 9.7±2.8 | 10.6±3.5 ||",
    "claim": "The statistical analysis reveals that the difference in MMSE scores between 0 and 1 year of education is statistically significant, while the difference between 0 and 4 years is significant, suggesting that a minimum threshold of education is necessary to observe significant cognitive improvements.",
    "label": "support"
  },
  {
    "id": "training_164_5",
    "table_caption": "Table: blue-collar workers. HRV Index Sitting Variable Crude Model (N = 126) Primary Adjusted Model (N = 126) B 95%CI Low High p B 95%CI Low High p IBI (ms) Occupational sitting −17.00 −35.80 1.81 0.08 −24.24 −46.98 −1.50 0.04 Leisure-time sitting 6.80 −7.97 21.57 0.36 0.41 −14.43 −15.25 0.96 RMSSD (ms) Occupational sitting −3.26 0.06 −6.66 0.14 −4.96 −8.88 −1.05 0.01 Leisure-time sitting 0.16 0.91 −2.51 2.83 1.83 −0.73 4.38 0.16 SDNN (ms) Occupational sitting −3.03 −5.87 −0.20 0.04 −5.07 −8.48 −1.67 0.00 Leisure-time sitting 0.46 −1.77 2.69 0.68 1.10 −1.12 3.33 0.33 ln VLF Occupational sitting −0.10 −0.20 0.01 0.06 −0.19 −0.32 −0.05 0.01 Leisure-time sitting 0.03 −0.05 0.11 0.50 0.00 −0.09 0.09 0.98 ln LF Occupational sitting −0.13 −0.25 −0.01 0.03 −0.18 −0.32 −0.04 0.01 Leisure-time sitting 0.05 −0.04 0.14 0.30 0.07 −0.02 0.17 0.11 ln HF Occupational sitting −0.12 −0.26 0.03 0.12 −0.12 −0.27 0.04 0.14 Leisure-time sitting 0.00 −0.12 0.11 0.95 0.08 −0.02 0.19 0.13 ln LF/HF Occupational sitting −0.01 −0.12 0.10 0.91 −0.03 −0.17 0.10 0.62 Leisure-time sitting 0.06 −0.03 0.14 0.19 −0.01 −0.09 0.08 0.92 * Adjusted for age, gender, BMI, smoking, lifting/carrying at work, seniority, influence at work, and total moderate-to-vigorous physical activity. Note: significant (p < 0.05) associations are bold faced. ",
    "table_content": "|| HRV Index | Sitting Variable | Crude Model ( N = 126) | Crude Model ( N = 126) | Crude Model ( N = 126) | Crude Model ( N = 126) | Primary Adjusted Model ( N = 126) | Primary Adjusted Model ( N = 126) | Primary Adjusted Model ( N = 126) | Primary Adjusted Model ( N = 126) ||\n|| HRV Index | Sitting Variable | B | 95%CI Low | High | p | B | 95%CI Low | High | p ||\n|| ln LF | Occupational sitting | −0.13 | −0.25 | −0.01 | 0.03 | −0.18 | −0.32 | −0.04 | 0.01 ||\n|| ln LF | Leisure-time sitting | 0.05 | −0.04 | 0.14 | 0.30 | 0.07 | −0.02 | 0.17 | 0.11 ||\n|| ln HF | Occupational sitting | −0.12 | −0.26 | 0.03 | 0.12 | −0.12 | −0.27 | 0.04 | 0.14 ||\n|| ln HF | Leisure-time sitting | 0.00 | −0.12 | 0.11 | 0.95 | 0.08 | −0.02 | 0.19 | 0.13 ||\n|| ln LF/HF | Occupational sitting | −0.01 | −0.12 | 0.10 | 0.91 | −0.03 | −0.17 | 0.10 | 0.62 ||\n|| ln LF/HF | Leisure-time sitting | 0.06 | −0.03 | 0.14 | 0.19 | −0.01 | −0.09 | 0.08 | 0.92 ||\n|| IBI (ms) | Occupational sitting | −17.00 | −35.80 | 1.81 | 0.08 | −24.24 | −46.98 | −1.50 | 0.04 ||\n|| IBI (ms) | Leisure-time sitting | 6.80 | −7.97 | 21.57 | 0.36 | 0.41 | −14.43 | −15.25 | 0.96 ||\n|| RMSSD (ms) | Occupational sitting | −3.26 | 0.06 | −6.66 | 0.14 | −4.96 | −8.88 | −1.05 | 0.01 ||\n|| RMSSD (ms) | Leisure-time sitting | 0.16 | 0.91 | −2.51 | 2.83 | 1.83 | −0.73 | 4.38 | 0.16 ||\n|| SDNN (ms) | Occupational sitting | −3.03 | −5.87 | −0.20 | 0.04 | −5.07 | −8.48 | −1.67 | 0.00 ||\n|| SDNN (ms) | Leisure-time sitting | 0.46 | −1.77 | 2.69 | 0.68 | 1.10 | −1.12 | 3.33 | 0.33 ||\n|| ln VLF | Occupational sitting | −0.10 | −0.20 | 0.01 | 0.06 | −0.19 | −0.32 | −0.05 | 0.01 ||\n|| ln VLF | Leisure-time sitting | 0.03 | −0.05 | 0.11 | 0.50 | 0.00 | −0.09 | 0.09 | 0.98 ||",
    "claim": "The adjusted model shows a decrease in ln VLF due to occupational sitting, with a statistically significant p-value. This reduction in very low-frequency power suggests a potential impact on long-term regulatory mechanisms of the cardiovascular system, possibly reflecting reduced baroreflex sensitivity or thermoregulatory processes.",
    "label": "support"
  },
  {
    "id": "training_189_4",
    "table_caption": "Table: Predictors in each score. Prediction Cleveland Score Mehta Score SRI Score AKICS Score RRT-AKI RRT-AKI RRT-AKI AKI Variable Definition Score Definition Score Definition Score Definition Score Age Varies Varies > 65 2.3 Race Non-white 2 Gender Female 1 Preoperative kidney function SCr 1.2-2.1 mg/dL 2 SCr Varies GFR, 31-60 mL/ min 1 Preoperative SCr > 1.2 mg/dL 3.1 SCr > 2.1 mg/dL 5 GFR ≤ 30 mL/min 2 CHF Yes 1 NYHA Class 4 3 3 or 4 3.2 Diabetes Preoperative capillary glucose > 140 mg/dL 1.7 COPD Yes 1 Yes 3 Recent MI (< 21 d) Yes 3 LVEF < 35% 1 ≤ 40% 1 Previous surgery Yes 1 Yes 3 Yes 1 Preoperative IABP Yes 2 Yes 1 Cardiogenic shock Yes 7 Timing of surgery Emergence 2 Non-selective 1 CPB time > 120 min 1.8 Postoperative CVP > 14 cmH2O 1.7 LCOS Yes 2.5 Type of surgery CABG only 0 CABG only 0 Other than CABG 1 Combined surgery 3.7 Valve only 1 Aortic valve only 2 CABG + valve 2 Aortic valve + CABG 5 Mitral valve only 4 Mitral valve + CABG 7 Score range 0-17 0-83 0-8 0-20 AKI=acute kidney injury; RRT-AKI=AKI which renal replacement therapy is needed; CABG=coronary artery bypass grafting; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CPB=cardiopulmonary bypass; CVD=cerebral vascular disease; CVP=central ",
    "table_content": "|| Prediction Variable | Cleveland Score RRT-AKI | Cleveland Score RRT-AKI | Mehta Score RRT-AKI | Mehta Score RRT-AKI | SRI Score RRT-AKI | SRI Score RRT-AKI | AKICS Score AKI | AKICS Score AKI ||\n|| Prediction Variable | Cleveland Score RRT-AKI | Cleveland Score RRT-AKI | Mehta Score RRT-AKI | Mehta Score RRT-AKI | SRI Score RRT-AKI | SRI Score RRT-AKI | AKICS Score AKI | AKICS Score AKI ||\n|| Diabetes | blank | blank | blank | blank | blank | blank | Preoperative capillary glucose > 140\nmg/dL | 1.7 ||\n|| COPD | Yes | 1 | Yes | 3 | blank | blank | blank | blank ||\n|| Recent MI (< 21 d) | Recent MI (< 21 d) | blank | Yes | 3 | blank | blank | blank | blank ||\n|| LVEF | < 35% | 1 | blank | blank | ≤ 40% | 1 | blank | blank ||\n|| Previous surgery | Yes | 1 | Yes | 3 | Yes | 1 | blank | blank ||\n|| Preoperative IABP | Yes | 2 | blank | blank | Yes | 1 | blank | blank ||\n|| Cardiogenic shock | Cardiogenic shock | Cardiogenic shock | Yes | 7 | blank | blank | blank | blank ||\n|| Timing of surgery | Emergence | 2 | blank | blank | Non-selective | 1 | blank | blank ||\n|| CPB time | blank | blank | blank | blank | blank | blank | > 120 min | 1.8 ||\n|| Postoperative CVP | Postoperative CVP | blank | blank | blank | blank | blank | > 14 cmH2O | 1.7 ||\n|| Prediction Variable | Definition | Score | Definition | Score | Definition | Score | Definition | Score ||\n|| LCOS | blank | blank | blank | blank | blank | blank | Yes | 2.5 ||\n|| Type of surgery | CABG only | 0 | CABG only | 0 | Other than CABG | 1 | Combined surgery | 3.7 ||\n|| Type of surgery | Valve only | 1 | Aortic valve only | 2 | blank | blank | blank | blank ||\n|| Type of surgery | CABG + valve | 2 | Aortic valve + CABG | 5 | blank | blank | blank | blank ||\n|| Type of surgery | blank | blank | Mitral valve only | 4 | blank | blank | blank | blank ||\n|| Type of surgery | blank | blank | Mitral valve + CABG | 7 | blank | blank | blank | blank ||\n|| Score range | Score range | 0-17 | blank | 0-83 | blank | 0-8 | blank | 0-20 ||\n|| Age | blank | blank | Varies | Varies | blank | blank | > 65 | 2.3 ||\n|| Race | blank | blank | Non-white | 2 | blank | blank | blank | blank ||\n|| Gender | Female | 1 | blank | blank | blank | blank | blank | blank ||\n|| Preoperative kidney function | SCr 1.2-2.1 mg/dL | 2 | SCr | Varies | GFR, 31-60 mL/min | 1 | Preoperative SCr > 1.2 mg/dL | 3.1 ||\n|| Preoperative kidney function | SCr > 2.1 mg/dL | 5 | blank | blank | GFR ≤ 30 mL/min | 2 | blank | blank ||\n|| CHF | Yes | 1 | blank | blank | blank | blank | blank | blank ||\n|| NYHA Class | NYHA Class | blank | blank | blank | 4 | 3 | 3 or 4 | 3.2 ||",
    "claim": "The AKICS Score assigns a score of 2.3 for age > 65. This suggests that older age could increase the risk prediction by 2.3 points in the AKICS Score system, highlighting the importance of age as a risk factor for AKI.",
    "label": "support"
  },
  {
    "id": "training_945_2",
    "table_caption": "Table: Description of the study cohorts. Reference cohort (n = 10) Test cohort (n = 90) Median age (min-max) 70.0 (36–91) 68.0 (19–90) p = 0.3099 Female sex 5 (50%) 47 (52.2%) p = 0.8414 ICU 5 (50%) 38 (42.2%) p = 0.8713 Respiratory support none 8 (80%) 80 (89%) p = 0.7141 NIV 1 (10%) 5 (5.5%) IV 1 (10%) 5 (5.5%) CVC type 3-lumen 9 (90%) 86 (96%) p = 0.5654 4-lumen 1 (10%) 3 (3%) 5-lumen 0 (0%) 1 (1%) CVC insertion site R internal jugular vein 5 (50%) 48 (53.3%) p = 0.8312 L internal jugular vein 4 (40%) 37 (41.1%) R subclavian vein 0 (0%) 2 (2.2%) L subclavian vein 1 (10%) 3 (3.3%) CVC insertion US guided 7 (70%) 74 (82.2%) p = 0.6102 Abbreviations used: CVC: central venous catheter, ICU: intensive care unit, IMC: intermediate care unit, IV: invasive ventilation, L: left, NIV: non-invasive R: right, US: ultrasound. ",
    "table_content": "|| blank | Reference cohort (n = 10) | Test cohort (n = 90) | blank ||\n|| Median age (min-max) | 70.0 (36–91) | 68.0 (19–90) | p = 0.3099 ||\n|| 4-lumen | 1 (10%) | 3 (3%) | p = 0.5654 ||\n|| 5-lumen | 0 (0%) | 1 (1%) | p = 0.5654 ||\n|| CVC insertion site | CVC insertion site | CVC insertion site | CVC insertion site ||\n|| R internal jugular vein | 5 (50%) | 48 (53.3%) | p = 0.8312 ||\n|| L internal jugular vein | 4 (40%) | 37 (41.1%) | p = 0.8312 ||\n|| R subclavian vein | 0 (0%) | 2 (2.2%) | p = 0.8312 ||\n|| L subclavian vein | 1 (10%) | 3 (3.3%) | p = 0.8312 ||\n|| CVC insertion US guided | 7 (70%) | 74 (82.2%) | p = 0.6102 ||\n|| Female sex | 5 (50%) | 47 (52.2%) | p = 0.8414 ||\n|| ICU | 5 (50%) | 38 (42.2%) | p = 0.8713 ||\n|| Respiratory support | Respiratory support | Respiratory support | Respiratory support ||\n|| none | 8 (80%) | 80 (89%) | p = 0.7141 ||\n|| NIV | 1 (10%) | 5 (5.5%) | p = 0.7141 ||\n|| IV | 1 (10%) | 5 (5.5%) | p = 0.7141 ||\n|| CVC type | CVC type | CVC type | CVC type ||\n|| 3-lumen | 9 (90%) | 86 (96%) | p = 0.5654 ||",
    "claim": "The proportion of females in both cohorts is nearly identical, with the reference cohort having 50% females and the test cohort having 52.2% females. This similarity in gender distribution suggests that gender is unlikely to be a confounding factor in the analysis of clinical outcomes between the two cohorts.",
    "label": "support"
  },
  {
    "id": "training_172_1",
    "table_caption": "Table: expressed proteins was increased (Table 4). The overall The influence of the nucleotides downstream from the genes with GNN codons in the second position were removed from datasets. (H0: there is no difference between nucleotide frequencies in all genes and HEG). organism G4 C5 P-value HEG/all ratio P-value HEG/all ratio E. coli 1.000 1.0 0.048 1.5 B. subtilis 0.490 0.7 0.111 1.7 H. pylori 0.644 1.2 0.004 2.6 H. influenzae 0.336 1.4 0.010 1.8 M. tuberculosis 0.010 0.0 0.495 1.2 T. pallidum 0.524 1.2 1.000 0.9 R. prowazekii 0.012 2.8 0.010 1.9 M. genitalium 0.298 1.3 0.763 1.2 B. burgdorferi 0.011 2.1 0.011 2.6 A. fulgidus 0.177 1.4 0.073 2.0 M. jannaschii 0.282 1.3 0.033 2.5 P. horikoshii 1.000 1.0 0.030 2.2 S. cerevisiae 0.006 1.8 2.8E-04 1.7 S. pombe 0.011 1.7 0.010 1.6 P. falciparum 0.004 2.1 1.3E-05 3.9 ",
    "table_content": "|| organism | G 4 | G 4 | C 5 | C 5 ||\n|| organism | P-value | HEG/all ratio | P-value | HEG/all ratio ||\n|| B. burgdorferi | 0.011 | 2.1 | 0.011 | 2.6 ||\n|| A. fulgidus | 0.177 | 1.4 | 0.073 | 2.0 ||\n|| M. jannaschii | 0.282 | 1.3 | 0.033 | 2.5 ||\n|| P. horikoshii | 1.000 | 1.0 | 0.030 | 2.2 ||\n|| S. cerevisiae | 0.006 | 1.8 | 2.8E-04 | 1.7 ||\n|| S. pombe | 0.011 | 1.7 | 0.010 | 1.6 ||\n|| P. falciparum | 0.004 | 2.1 | 1.3E-05 | 3.9 ||\n|| E. coli | 1.000 | 1.0 | 0.048 | 1.5 ||\n|| B. subtilis | 0.490 | 0.7 | 0.111 | 1.7 ||\n|| H. pylori | 0.644 | 1.2 | 0.004 | 2.6 ||\n|| H. influenzae | 0.336 | 1.4 | 0.010 | 1.8 ||\n|| M. tuberculosis | 0.010 | 0.0 | 0.495 | 1.2 ||\n|| T. pallidum | 0.524 | 1.2 | 1.000 | 0.9 ||\n|| R. prowazekii | 0.012 | 2.8 | 0.010 | 1.9 ||\n|| M. genitalium | 0.298 | 1.3 | 0.763 | 1.2 ||",
    "claim": "The organism P. falciparum exhibits the most statistically significant difference in nucleotide frequencies at the C5 position, with a p-value of 1.3E-05, indicating a strong deviation from the null hypothesis of no difference.",
    "label": "support"
  },
  {
    "id": "training_368_5",
    "table_caption": "Table: (mg L21) in the Mission Aransas Estuary. Seasonal nutrient removal Water temp (6C) Seston (mg L21) Chl a (mg L21) Clearance rate (mg ind21 min21) kg N denitrified km22 kg N buried km22 Winter 14.4 27.7 3.68 0.063 85.20 42.60 Spring 20.7 36.5 4.12 0.115 154.71 77.36 Summer 30.4 29.8 2.69 0.072 96.86 48.43 Fall 23.1 28.4 6.31 0.124 165.73 82.87 Annual Total 502.50 251.25 See text for details of calculations of clearance rate and N removal. doi:10.1371/journal.pone.0065314.t002 ",
    "table_content": "|| blank | Water temp (°C) | Seston(mg L −1 ) | Chl a(µg L −1 ) | Clearance rate (µg ind −1 min −1 ) | Seasonal nutrient removal | Seasonal nutrient removal ||\n|| blank | Water temp (°C) | Seston(mg L −1 ) | Chl a(µg L −1 ) | Clearance rate (µg ind −1 min −1 ) | kg N denitrified km −2  | kg N buried km −2  ||\n||  Winter  | 14.4 | 27.7 | 3.68 | 0.063 | 85.20 | 42.60 ||\n||  Spring  | 20.7 | 36.5 | 4.12 | 0.115 | 154.71 | 77.36 ||\n||  Summer  | 30.4 | 29.8 | 2.69 | 0.072 | 96.86 | 48.43 ||\n||  Fall  | 23.1 | 28.4 | 6.31 | 0.124 | 165.73 | 82.87 ||\n||  Annual Total  |  Annual Total  |  Annual Total  |  Annual Total  |  Annual Total  | 502.50 | 251.25 ||",
    "claim": "The clearance rate increases by 96.8% from winter to fall, while chlorophyll a concentration increases by 71.2%. This suggests a strong correlation between these two parameters, potentially indicating that higher chlorophyll a levels enhance the clearance rate.",
    "label": "support"
  },
  {
    "id": "training_812_4",
    "table_caption": "Table: Table 2 Variations in the protein-coding genes of WSSV-CN03 and -CN04 aa: the number of predicted amino acids. IE: immediate early protein; EP: envelope protein; Del: deletion; Ins: insertion. Genes Function or structure WSSV‑CN03 WSSV‑CN04 start–stop (aa) Type of change start–stop (aa) wsv001 collagen-like 1–4371 (1456) Del: 183 aa 1–3822 (1273) wsv002 VP24, EP 5041–4415 (208) Del: 100 aa 4216–3890 (108) wsv006 6366–5461 (301) Del: 34 aa 5439–4636 (267) wsv073 Missing 35331–36599 (422) wsv089 43202–43660 (152) Del: 64 aa 43729–43995 (88) wsv150 79052–78705 (115) Ins: 32 aa 79701–79258 (147) wsv195 Missing 102534–103304 (258) wsv249 E3 ligase, IE 134655–136937 (760) Del: 23 aa 132892–135105 (737) wsv479 269533–269042 (163) Ins: 126 aa 266439–265570 (289) wsv486 104783–102447 (778) Missing / ",
    "table_content": "|| Genes | Function or structure | WSSV-CN03 start–stop (aa) | WSSV-CN04 | WSSV-CN04 ||\n|| Genes | Function or structure | WSSV-CN03 start–stop (aa) | Type of change | start–stop (aa) ||\n|| wsv479 | blank | 269533–269042 (163) | Ins: 126 aa | 266439–265570 (289) ||\n|| wsv486 | blank | 104783–102447 (778) | Missing | / ||\n|| wsv001 | collagen-like | 1–4371 (1456) | Del: 183 aa | 1–3822 (1273) ||\n|| wsv002 | VP24, EP | 5041–4415 (208) | Del: 100 aa | 4216–3890 (108) ||\n|| wsv006 | blank | 6366–5461 (301) | Del: 34 aa | 5439–4636 (267) ||\n|| wsv073 | blank | Missing | blank | 35331–36599 (422) ||\n|| wsv089 | blank | 43202–43660 (152) | Del: 64 aa | 43729–43995 (88) ||\n|| wsv150 | blank | 79052–78705 (115) | Ins: 32 aa | 79701–79258 (147) ||\n|| wsv195 | blank | Missing | blank | 102534–103304 (258) ||\n|| wsv249 | E3 ligase, IE | 134655–136937 (760) | Del: 23 aa | 132892–135105 (737) ||",
    "claim": "The gene wsv073 is missing in WSSV-CN03 but present in WSSV-CN04 with 422 amino acids, while wsv195 is missing in WSSV-CN03 but present in WSSV-CN04 with 258 amino acids. This indicates a total of 680 amino acids present in WSSV-CN04 that are absent in WSSV-CN03.",
    "label": "support"
  },
  {
    "id": "training_751_5",
    "table_caption": "Table: dispar- search, Direct. recent Dutch- were termin- will reduce supple- of will for identify missed Table 2 BEME quality indicators (Buckley et al. [24]) Questions Research question Is the research question or hypothesis clearly stated? Study subjects Is the subject group appropriate for the study being carried out? Data collection methods Are the methods used appropriate for the research question and context? Completeness of data Attrition rates/acceptable questionnaire response rates Risk of bias assessment Is a statement of author positionality and a risk of bias assessment included? Analysis of results Are the statistical and other methods of results analysis used appropriate? Conclusions Is it clear that the data justify the conclusions drawn? Reproducibility Could the study be repeated by other researchers? Prospective Is the study prospective? Ethical issues Are all ethical issues articulated and managed appropriately? Triangulation Were results supported by data from more than one source? ",
    "table_content": "|| blank |  Questions  ||\n|| Research question | Is the research question or hypothesis clearly stated? ||\n|| Ethical issues | Are all ethical issues articulated and managed appropriately? ||\n|| Triangulation | Were results supported by data from more than one source? ||\n|| Study subjects | Is the subject group appropriate for the study being carried out? ||\n|| Data collection methods | Are the methods used appropriate for the research question and context? ||\n|| Completeness of data | Attrition rates/acceptable questionnaire response rates ||\n|| Risk of bias assessment | Is a statement of author positionality and a risk of bias assessment included? ||\n|| Analysis of results | Are the statistical and other methods of results analysis used appropriate? ||\n|| Conclusions | Is it clear that the data justify the conclusions drawn? ||\n|| Reproducibility | Could the study be repeated by other researchers? ||\n|| Prospective | Is the study prospective? ||",
    "claim": "The appropriateness of data collection methods is essential for ensuring the accuracy and reliability of research findings. This can be quantitatively assessed by examining the alignment of data collection methods with the research question, the context of the study, and the characteristics of the subject group. Appropriate data collection methods can minimize measurement error and enhance the study's internal validity.",
    "label": "support"
  },
  {
    "id": "training_98_5",
    "table_caption": "Table: ME-matrix statistics. Type Number Transcription Units 1,152 Genes 1,937 - Protein coding genes 1,827 - RNA coding genes 110 Network reactions 76,589 Network components 62,212 Coupling constraints between reactions 3,044 Summary of ME-matrix content. doi:10.1371/journal.pone.0045635.t001 ",
    "table_content": "|| Type | Number ||\n|| Transcription Units | 1,152 ||\n|| Genes | 1,937 ||\n|| - Protein coding genes | 1,827 ||\n|| - RNA coding genes | 110 ||\n|| Network reactions | 76,589 ||\n|| Network components | 62,212 ||\n|| Coupling constraints between reactions | 3,044 ||",
    "claim": "The total number of biological elements, including transcription units, genes, network reactions, network components, and coupling constraints, sums to 144,934, highlighting the extensive scale of the ME-matrix model.",
    "label": "support"
  },
  {
    "id": "training_893_5",
    "table_caption": "Table: Authors’ JK and study and design read Ethics This Graduate Table 2 Differential diagnosis of perineurioma (PN) in immunohistochemical staining (IHC) Neurogenic tumor/IHC EMA S-100 Claudin-1 Glut-1 Perineurioma + − + + Schwannoma − + − − Neurofibroma − + − − Traumatic neuroma − + − − + positive, − negative, EMA epithelial membrane antigen ",
    "table_content": "|| Neurogenic tumor/IHC | EMA | S-100 | Claudin-1 | Glut-1 ||\n|| Perineurioma | + | − | + | + ||\n|| Schwannoma | − | + | − | − ||\n|| Neurofibroma | − | + | − | − ||\n|| Traumatic neuroma | − | + | − | − ||",
    "claim": "The combination of positive EMA, Claudin-1, and Glut-1, along with negative S-100, in perineurioma, compared to the negative results for these markers in other tumors, underscores the importance of using a panel of markers for accurate differential diagnosis. This approach minimizes the risk of misdiagnosis and ensures precise identification of perineurioma.",
    "label": "support"
  },
  {
    "id": "training_863_6",
    "table_caption": "Table: Type Tilt axis GB plane Tilt angle Inclination Angle No. of atoms ∑3 <110> (111)//(111) 70.5° 90° 51840 ∑3 Twin (211)//(121) 109.5° 0° 55296 ∑9 (221)//(21) 38.9° 90° 54432 (114)//(14) 141.1° 0° 51840 ∑11 (13)//(13) 129.5° 0° 57024 ∑5 <100> (012)//(021) 53.1° 45° 56160 ∑801 <110> {1 1 40} 4.0° 0° 57600 ∑201 {1 1 20} 8.1° 0° 57600 ∑3 <110> (111)//(115) 109.5° 21° 62150 (100)//(22) 37° 54416 (55)//(711) 51° 66066 (110)//(411) 61° 51814 ∑9 (11)//(15) 141.1° 35° 62208 (112)//(552) 55° 58320 ∑11 (554)//(18) 129.5° 35° 71280 (441)//(225) 55° 76032 (332)//(332) 90° 63360 ∑5 <100> (031)//(031) 36.9° 0° 58240 (010)//(043) 18° 52000 (110)//(071) 26° 62400 ∑ 7 < 111> (321)//(231) 38.2° — 50400 ∑ 13a < 100> (023)//(032) 22.6° — 56784 ∑ 15 < 210> (125)//(125) 48.2° — 57600 ∑ 17a < 100> (041)//(041) 28.1° — 53040 ∑ 17b < 221> (322)//(232) 61.9°° — 48960 ∑ 19a < 110> (331)//(331) 26.5° — 54720 ∑ 19b < 111> (532)//(352) 46.8° — 58368 Table 1. Structural information for the various CSL GBs studied. The first group are the second is the LAGBs, the third is the asymmetric tilt ∑ GBs, and the last un-bolded ",
    "table_content": "|| Type | Tilt axis | GB plane | Tilt angle | Inclination Angle | No. of atoms ||\n|| ∑3 | <110> | (111)//(111) | 70.5° | 90° | 51840 ||\n|| ∑3 | blank | (100)//(22) | blank | 37° | 54416 ||\n|| ∑3 | blank | (55)//(711) | blank | 51° | 66066 ||\n|| ∑3 | blank | (110)//(411) | blank | 61° | 51814 ||\n|| ∑9 | blank | (11)//(15) | 141.1° | 35° | 62208 ||\n|| ∑9 | blank | (1 )//(5 ) | blank | 55° | 58320 ||\n|| ∑11 | blank | (5 4)//(18) | 129.5° | 35° | 71280 ||\n|| ∑11 | blank | (4 1)//(2 5) | blank | 55° | 76032 ||\n|| ∑11 | blank | (3 )//(3 2) | blank | 90° | 63360 ||\n|| ∑5 | <100> | (031)//(03 ) | 36.9° | 0° | 58240 ||\n|| ∑5 | blank | (010)//(04 ) | blank | 18° | 52000 ||\n|| ∑3 Twin | blank | (2 )//(1 1) | 109.5° | 0° | 55296 ||\n|| ∑5 | blank | (110)//(071) | blank | 26° | 62400 ||\n|| ∑7 | <111> | (3 )//(2 1) | 38.2° | — | 50400 ||\n|| ∑13a | <100> | (023)//(032) | 22.6° | — | 56784 ||\n|| ∑15 | <210> | (1 5)//( 25) | 48.2° | — | 57600 ||\n|| ∑17a | <100> | (041)//(04 ) | 28.1° | — | 53040 ||\n|| ∑17b | <221> | (3 )//(2 2) | 61.9°° | — | 48960 ||\n|| ∑19a | <110> | (3 )//(3 1) | 26.5° | — | 54720 ||\n|| ∑19b | <111> | (5 )//(3 2) | 46.8° | — | 58368 ||\n|| ∑9 | blank | (2 )//(21) | 38.9° | 90° | 54432 ||\n|| ∑9 | blank | (1 4)//(14) | 141.1° | 0° | 51840 ||\n|| ∑11 | blank | (13)//(13) | 129.5° | 0° | 57024 ||\n|| ∑5 | <100> | (012)//(021) | 53.1° | 45° | 56160 ||\n|| ∑801 | <110> | {1 1 40} | 4.0° | 0° | 57600 ||\n|| ∑201 | blank | {1 1 20} | 8.1° | 0° | 57600 ||\n|| ∑3 | <110> | (1 1)//( 5) | 109.5° | 21° | 62150 ||",
    "claim": "The ∑3 CSL type with a (55)//(711) GB plane orientation and an inclination angle of 51° has the highest number of atoms among its type, totaling 66066. This indicates that certain GB plane orientations can significantly influence the atomic density, potentially due to the geometric compatibility of the planes involved.",
    "label": "support"
  },
  {
    "id": "training_463_5",
    "table_caption": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) ",
    "table_content": "|| blank | Sensitivity | Specificity | Positive predictive value | Negative predictive value | Accuracy ||\n|| SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) ||\n|| All combined | 0.83 (0.82, 0.84) | 0.83 (0.82, 0.84) | 0.84 (0.83, 0.85) | 0.84 (0.83, 0.85) | 0.83 (0.82, 0.84) ||\n|| PGME | 0.71 (0.70, 0.72) | 0.80 (0.79, 0.81) | 0.79 (0.78, 0.80) | 0.74 (0.73, 0.75) | 0.76 (0.75, 0.77) ||\n|| Gait features + Demograph. var | 0.61 (0.60, 0.62) | 0.76 (0.75, 0.77) | 0.73 (0.72, 0.74) | 0.66 (0.65, 0.67) | 0.68 (0.67, 0.69) ||\n|| Fall history: 6 months | 0.47 (0.46, 0.48) | 0.67 (0.65, 0.68) | 0.59 (0.57, 0.60) | 0.56 (0.55, 0.57) | 0.57 (0.56, 0.58) ||\n|| All combined | 0.75 (0.73, 0.76) | 0.80 (0.79, 0.81) | 0.80 (0.79, 0.81) | 0.77 (0.76, 0.78) | 0.77 (0.76, 0.78) ||\n|| MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) ||\n|| PGME | 0.67 (0.66, 0.69) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.68 (0.67, 0.69) ||\n|| Gait features + demograph var | 0.79 (0.77, 0.80) | 0.76 (0.75, 0.77) | 0.77 (0.76, 0.78) | 0.79 (0.78, 0.80) | 0.77 (0.76, 0.80) ||\n|| Fall history: 6 months | 0.55 (0.53, 0.56) | 0.65 (0.64, 0.67) | 0.62 (0.61, 0.63) | 0.60 (0.59, 0.61) | 0.60 (0.59, 0.61) ||",
    "claim": "The accuracy of the \"Fall history: 6 months\" model for single time fallers is 0.68, which is higher than the actual value shown in the table.",
    "label": "support"
  },
  {
    "id": "training_626_4",
    "table_caption": "Table: Term Total Expected Hits Raw p Arachidonic acid metabolism 36 0.66762 4 0.0036618 Glutathione metabolism 26 0.48217 2 0.081872 Linoleic acid metabolism 5 0.092725 1 0.089472 Glycerophospholipid metabolism 30 0.55635 2 0.10478 alpha-Linolenic acid metabolism 9 0.1669 1 0.15546 Vitamin B6 metabolism 9 0.1669 1 0.15546 Pyrimidine metabolism 41 0.76034 2 0.1748 Pantothenate and CoA biosynthesis 15 0.27817 1 0.24589 beta-Alanine metabolism 19 0.35235 1 0.30092 Butanoate metabolism 20 0.3709 1 0.31406 Sphingolipid metabolism 21 0.38944 1 0.32697 Purine metabolism 68 1.2611 2 0.36233 Alanine, aspartate and glutamate metabolism 24 0.44508 1 0.36429 Steroid biosynthesis 35 0.64907 1 0.48486 Amino sugar and nucleotide sugar metabolism 37 0.68616 1 0.50428 Arginine and proline metabolism 44 0.81598 1 0.56685 Table 6. Analyzed pathways of metabolomics data differently regulated in lung tissue formula-treated rats. ",
    "table_content": "|| Term | Total | Expected | Hits | Raw p ||\n|| Arachidonic acid metabolism | 36 | 0.66762 | 4 | 0.0036618 ||\n|| Butanoate metabolism | 20 | 0.3709 | 1 | 0.31406 ||\n|| Sphingolipid metabolism | 21 | 0.38944 | 1 | 0.32697 ||\n|| Purine metabolism | 68 | 1.2611 | 2 | 0.36233 ||\n|| Alanine, aspartate and glutamate metabolism | 24 | 0.44508 | 1 | 0.36429 ||\n|| Steroid biosynthesis | 35 | 0.64907 | 1 | 0.48486 ||\n|| Amino sugar and nucleotide sugar metabolism | 37 | 0.68616 | 1 | 0.50428 ||\n|| Arginine and proline metabolism | 44 | 0.81598 | 1 | 0.56685 ||\n|| Glutathione metabolism | 26 | 0.48217 | 2 | 0.081872 ||\n|| Linoleic acid metabolism | 5 | 0.092725 | 1 | 0.089472 ||\n|| Glycerophospholipid metabolism | 30 | 0.55635 | 2 | 0.10478 ||\n|| alpha-Linolenic acid metabolism | 9 | 0.1669 | 1 | 0.15546 ||\n|| Vitamin B6 metabolism | 9 | 0.1669 | 1 | 0.15546 ||\n|| Pyrimidine metabolism | 41 | 0.76034 | 2 | 0.1748 ||\n|| Pantothenate and CoA biosynthesis | 15 | 0.27817 | 1 | 0.24589 ||\n|| beta-Alanine metabolism | 19 | 0.35235 | 1 | 0.30092 ||",
    "claim": "The pathway with the lowest raw p-value is arachidonic acid metabolism, which is significantly lower than the next lowest, glutathione metabolism, by a factor of approximately 22.36, highlighting its exceptional statistical significance.",
    "label": "support"
  },
  {
    "id": "training_280_4",
    "table_caption": "Table: Transitions of DONS 1, 2, and 3 used for mass spectrometric detection. Analyte Q1 Q3 Time [msec] DP [V] CE [V] CXP [V] Retention time [min] LOD [ng/mL] LOQ [ng/mL] DONS 1 377.1 79.9 150 −120 −82 −3 2.31 0.48 1.59 DONS 2 377.1 81.0 150 −70 −52 −3 4.71 0.34 1.14 DONS 3 377.1 79.9 150 −55 −96 −1 5.88 1.21 3.99 DP = declustering potential; CE = collision energy; CXP = collision cell exit; LOD = limit of detection; LOQ = limit of quantification. ",
    "table_content": "|| Analyte | Q1 | Q3 | Time [msec] | DP [V] | CE [V] | CXP [V] | Retention time [min] | LOD [ng/mL] | LOQ [ng/mL] ||\n|| DONS 1 | 377.1 | 79.9 | 150 | −120 | −82 | −3 | 2.31 | 0.48 | 1.59 ||\n|| DONS 2 | 377.1 | 81.0 | 150 | −70 | −52 | −3 | 4.71 | 0.34 | 1.14 ||\n|| DONS 3 | 377.1 | 79.9 | 150 | −55 | −96 | −1 | 5.88 | 1.21 | 3.99 ||",
    "claim": "The limit of detection for DONS 3 is 3.56 times higher than that for DONS 2, suggesting a lower sensitivity for DONS 3, which could be due to differences in ionization efficiency or detector response.",
    "label": "support"
  },
  {
    "id": "training_558_5",
    "table_caption": "Table: Age Pooled analysis Regression Persistence Progression N* Rate (%) 95% CI I2% N* Rate (%) 95% CI I2% N* Rate (%) 95% CI I2% <25 75410,14–19 58.4 53.1–63.5 67.7 75515,16,18,19 31.3 22.4–41.9 77.3 56110,19 13.9 11.3–17.0 0 <30 93810,14,15,17–19 52.9 44.3–61.3 82.6 83215,16,18,19 32.1 23.5–42.1 76.2 66810,19 13.8 11.4–16.6 0 <35 105810,14,15,17–19 51.9 43.3–60.5 84.3 99915,16,18,19 34.5 31.6–37.5 0 75310,19 13.5 11.3–16.2 0 ≥35 17217 46.2 32.7–60.3 33.4 19716 32.5 26.3–39.4 0 139 15.1 10.0–22.1 0 Table 5. Pooled analysis of studies reporting age- dependent outcome rates of CIN after observational management. *References of included studies, data from the current report was included into all analyses ",
    "table_content": "|| Age | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis ||\n|| Age | Regression | Regression | Regression | Regression | Persistence | Persistence | Persistence | Persistence | Progression | Progression | Progression | Progression ||\n|| Age | N* | Rate (%) | 95% CI | I 2 % | N* | Rate (%) | 95% CI | I 2 % | N* | Rate (%) | 95% CI | I 2 % ||\n|| <25 | 754 10 , 14 – 19 | 58.4 | 53.1–63.5 | 67.7 | 755 15 , 16 , 18 , 19 | 31.3 | 22.4–41.9 | 77.3 | 561 10 , 19 | 13.9 | 11.3–17.0 | 0 ||\n|| <30 | 938 10 , 14 , 15 , 17 – 19 | 52.9 | 44.3–61.3 | 82.6 | 832 15 , 16 , 18 , 19 | 32.1 | 23.5–42.1 | 76.2 | 668 10 , 19 | 13.8 | 11.4–16.6 | 0 ||\n|| <35 | 1058 10 , 14 , 15 , 17 – 19 | 51.9 | 43.3–60.5 | 84.3 | 999 15 , 16 , 18 , 19 | 34.5 | 31.6–37.5 | 0 | 753 10 , 19 | 13.5 | 11.3–16.2 | 0 ||\n|| ≥35 | 172 17 | 46.2 | 32.7–60.3 | 33.4 | 197 16 | 32.5 | 26.3–39.4 | 0 | 139 | 15.1 | 10.0–22.1 | 0 ||",
    "claim": "The heterogeneity index (I2%) is highest in the <35 age group for regression rates, indicating substantial variability among studies. This high heterogeneity suggests that factors such as study design, population characteristics, or measurement methods may differ significantly across studies, affecting the consistency of the pooled estimates.",
    "label": "support"
  },
  {
    "id": "training_1165_3",
    "table_caption": "Table: found of pean Table 2 Clinical characteristics of  SS group by  REL geno- type a Homozygous for major allele b Patients carrying minor allele and homozygous for major allele were Characteristics REL rs842647 REL rs13031237 G/G or A/G A/Aa T/T or A/T T/Ta n = 493 n = 547 n = 443 n = 597 Agec 65 [52; 77] 67 [54; 77] 66 [53; 76] 65 [52; 77] Men (%) 60.5 62.3 61.1 61.6 SAPSIIc 55 [43; 67] 53 [42; 67] 54 [43; 68] 54 [41; 66] Diabetes (%) 22.1 17.3 19.9 19.7 COPD (%) 13.2 17.4 15.7 14.4 Septicemia (%) 27.7 29.9 29.5 27.7 Gram‑positive bacteria (%) 49.9 47.2 48.1 49.2 VFDc 8 [0; 20] 11 [0; 21] 10 [0; 20] 10 [0; 20] ARDS (%) 38.6 33.5 34.8 37.9 Multiple organ dysfunctions (%) 63.9 57.8b 60.8 61.3 Fig. A/G were ",
    "table_content": "|| Characteristics |  REL rs842647  |  REL rs842647  |  REL rs13031237  |  REL rs13031237  ||\n|| Characteristics | G/G or A/G n = 493 | A/A a n = 547 | T/T or A/T n = 443 | T/T a n = 597 ||\n|| VFD c  | 8 [0; 20] | 11 [0; 21] | 10 [0; 20] | 10 [0; 20] ||\n|| ARDS (%) | 38.6 | 33.5 | 34.8 | 37.9 ||\n|| Multiple organ dysfunctions (%) | 63.9 | 57.8 b  | 60.8 | 61.3 ||\n|| Characteristics | G/G or A/G n = 493 | A/A a n = 547 | T/T or A/T n = 443 | T/T a n = 597 ||\n|| Age c  | 65 [52; 77] | 67 [54; 77] | 66 [53; 76] | 65 [52; 77] ||\n|| Men (%) | 60.5 | 62.3 | 61.1 | 61.6 ||\n|| SAPSII c  | 55 [43; 67] | 53 [42; 67] | 54 [43; 68] | 54 [41; 66] ||\n|| Diabetes (%) | 22.1 | 17.3 | 19.9 | 19.7 ||\n|| COPD (%) | 13.2 | 17.4 | 15.7 | 14.4 ||\n|| Septicemia (%) | 27.7 | 29.9 | 29.5 | 27.7 ||\n|| Gram-positive bacteria (%) | 49.9 | 47.2 | 48.1 | 49.2 ||",
    "claim": "The SAPSII score, which assesses the severity of disease, is lowest in the A/A genotype group for rs842647, with a median score of 53. This suggests a potential association between this genotype and a slightly lower severity of illness.",
    "label": "support"
  },
  {
    "id": "training_993_5",
    "table_caption": "Table: Cell Targeting vector HDR template Mutation TA colonies Mutation efficiency HDR efficiency (%) Erhualian PFFs sgRNA#1 – 17 78 21.79% – Erhualian PFFs sgRNA#2 – 10 80 12.50% – Erhualian PFFs sgRNA#1 ssDNA-85 19 55 34.55% 2/55(3.64%) Table 1. Comparison of the mutation efficiency induced by sgRNA alone or sgRNA + HDR template. ",
    "table_content": "|| Cell | Targeting vector | HDR template | Mutation | TA colonies | Mutation efficiency | HDR efficiency (%) ||\n|| Erhualian PFFs | sgRNA#1 | – | 17 | 78 | 21.79% | – ||\n|| Erhualian PFFs | sgRNA#2 | – | 10 | 80 | 12.50% | – ||\n|| Erhualian PFFs | sgRNA#1 | ssDNA-85 | 19 | 55 | 34.55% | 2/55(3.64%) ||",
    "claim": "The number of TA colonies inversely correlates with mutation efficiency, as seen by the decrease in TA colonies from 78 to 55 when the mutation efficiency increases from 21.79% to 34.55% with the addition of an HDR template, suggesting a potential trade-off between colony formation and mutation induction.",
    "label": "support"
  },
  {
    "id": "training_993_5",
    "table_caption": "Table: Cell Targeting vector HDR template Mutation TA colonies Mutation efficiency HDR efficiency (%) Erhualian PFFs sgRNA#1 – 17 78 21.79% – Erhualian PFFs sgRNA#2 – 10 80 12.50% – Erhualian PFFs sgRNA#1 ssDNA-85 19 55 34.55% 2/55(3.64%) Table 1. Comparison of the mutation efficiency induced by sgRNA alone or sgRNA + HDR template. ",
    "table_content": "|| Cell | Targeting vector | HDR template | Mutation | TA colonies | Mutation efficiency | HDR efficiency (%) ||\n|| Erhualian PFFs | sgRNA#1 | – | 17 | 78 | 21.79% | – ||\n|| Erhualian PFFs | sgRNA#2 | – | 10 | 80 | 12.50% | – ||\n|| Erhualian PFFs | sgRNA#1 | ssDNA-85 | 19 | 55 | 34.55% | 2/55(3.64%) ||",
    "claim": "The number of TA colonies directly correlates with mutation efficiency, as seen by the decrease in TA colonies from 78 to 55 when the mutation efficiency increases from 21.79% to 34.55% with the addition of an HDR template, suggesting a potential trade-off between colony formation and mutation induction.",
    "label": "support"
  },
  {
    "id": "training_1319_5",
    "table_caption": "Table: schedule for the analysis of chronic imipramine treatment. Group Administration time ZT1 ZT13 Control Saline Saline Morning (imipramine at ZT1) Imipramine Saline Evening (imipramine at ZT13) Saline Imipramine ",
    "table_content": "|| Group | Administration time | Administration time ||\n|| Group | ZT1 | ZT13 ||\n|| Control | Saline | Saline ||\n|| Morning (imipramine at ZT1) | Imipramine | Saline ||\n|| Evening (imipramine at ZT13) | Saline | Imipramine ||",
    "claim": "The consistent administration of saline in the Control group and the alternating administration of imipramine and saline in the Morning and Evening groups ensure that the study can accurately attribute differences in outcomes to the timing of imipramine administration rather than variability in treatment protocols.",
    "label": "support"
  },
  {
    "id": "training_1319_5",
    "table_caption": "Table: schedule for the analysis of chronic imipramine treatment. Group Administration time ZT1 ZT13 Control Saline Saline Morning (imipramine at ZT1) Imipramine Saline Evening (imipramine at ZT13) Saline Imipramine ",
    "table_content": "|| Group | Administration time | Administration time ||\n|| Group | ZT1 | ZT13 ||\n|| Control | Saline | Saline ||\n|| Morning (imipramine at ZT1) | Imipramine | Saline ||\n|| Evening (imipramine at ZT13) | Saline | Imipramine ||",
    "claim": "The inconsistent administration of saline in the Control group and the alternating administration of imipramine and saline in the Morning and Evening groups prevent the study from accurately attributing differences in outcomes to the timing of imipramine administration due to variability in treatment protocols.",
    "label": "support"
  },
  {
    "id": "training_473_5",
    "table_caption": "Table: Changes of errors for frequent subconcepts of the GRO concepts that have equivalent correspondent concepts, by the data conversion Concept No. of instances Before conversion After conversion FP FN FP FN BindingOfProteinToDNA 55 42 45 34 46 PositiveRegulationOfGeneExpression 33 11 25 6 28 Heterodimerization 32 6 25 4 25 BindingOfTranscriptionFactorToDNA 25 0 25 0 25 PositiveRegulationOfTranscription 24 0 4 0 4 FP stands for false positives and FN stands for false negatives. ",
    "table_content": "|| Concept | No. of instances | Before conversion | Before conversion | After conversion | After conversion ||\n|| Concept | No. of instances | FP | FN | FP | FN ||\n|| BindingOfProteinToDNA | 55 | 42 | 45 | 34 | 46 ||\n|| PositiveRegulationOfGeneExpression | 33 | 11 | 25 | 6 | 28 ||\n|| Heterodimerization | 32 | 6 | 25 | 4 | 25 ||\n|| BindingOfTranscriptionFactorToDNA | 25 | 0 | 25 | 0 | 25 ||\n|| PositiveRegulationOfTranscription | 24 | 0 | 4 | 0 | 4 ||",
    "claim": "For the most frequent concept, \"BindingOfProteinToDNA,\" the conversion process resulted in a 19.05% decrease in false positives, demonstrating a notable improvement in error reduction.",
    "label": "support"
  },
  {
    "id": "training_466_4",
    "table_caption": "Table: Factors measured at 18 years associated with BD at 18 years old among girls. Desire to be thinner at 18 Variable SE OR 95% CI Attempt to lose or control their weight 0.38 8.73*** 4.15–18.38 Underweight (BMI) 0.59 0.10*** 0.03–0.33 Overweight (BMI) 1.05 14.46* 1.84–113.75 Having experienced sexual intercourse 0.47 0.48 0.19–1.21 Self-esteem 0.04 0.93 0.87–1.00 Notes: N ¼ 238. *p , 0.05; ***p , 0.001. ",
    "table_content": "|| Variable | Desire to be thinner at 18 | Desire to be thinner at 18 | Desire to be thinner at 18 ||\n|| Variable | SE | OR | 95% CI ||\n|| Attempt to lose or control their weight | 0.38 | 8.73 * * * | 4.15–18.38 ||\n|| Underweight (BMI) | 0.59 | 0.10 * * * | 0.03–0.33 ||\n|| Overweight (BMI) | 1.05 | 14.46 * | 1.84–113.75 ||\n|| Having experienced sexual intercourse | 0.47 | 0.48 | 0.19–1.21 ||\n|| Self-esteem | 0.04 | 0.93 | 0.87–1.00 ||",
    "claim": "The odds ratio of 0.48 for girls who have experienced sexual intercourse indicates they are 52% less likely to desire to be thinner compared to those who have not. This suggests a potential shift in body image perception post-sexual experience.",
    "label": "support"
  },
  {
    "id": "training_849_6",
    "table_caption": "Table: Comparison of the use of Opilia celtidifolia (Oc) and Trichilia emetica (Te) in the Doila, Siby and Kolokani regions based on the fidelity level. Fidelity level (%) Siby Doila Kolokani Main reported diseases Oc Te Oc Te Oc Te Malaria 17 41 61 47 22 13 Abdominal pain 23 36 54 32 23 32 Dermatitis 75 40 21 40 4 20 ",
    "table_content": "|| Main reported diseases | Fidelity level (%) | Fidelity level (%) | Fidelity level (%) | Fidelity level (%) | Fidelity level (%) | Fidelity level (%) ||\n|| Main reported diseases | Siby | Siby | Doila | Doila | Kolokani | Kolokani ||\n|| Main reported diseases | Oc | Te | Oc | Te | Oc | Te ||\n|| Malaria | 17 | 41 | 61 | 47 | 22 | 13 ||\n|| Abdominal pain | 23 | 36 | 54 | 32 | 23 | 32 ||\n|| Dermatitis | 75 | 40 | 21 | 40 | 4 | 20 ||",
    "claim": "In the Siby region, Opilia celtidifolia is used with a fidelity level that is 35% higher than Trichilia emetica for treating dermatitis, demonstrating Oc's dominance in this particular treatment in Siby.",
    "label": "support"
  },
  {
    "id": "training_186_1",
    "table_caption": "Table: Performance comparison between proposed method and other scenarios. Algorithm Search Method Total Time (sec) Total Distance (m) Comparison (%) High + Low After high-altitude search, low-altitude search 1,099,028 4,579,283 100 Low Linear Search linearly at low altitude 2,893,980 12,058,251 263 High + Low2 After high-altitude search, low-altitude search (search by one high-altitude area) 1,673,795 6,974,146 152 High Linear Search linearly at high altitude 1,139,097 4,746,240 104 High + Low3 (Proposed) After high-altitude search with threshold value, low-altitude search 959,327 3,997,199 87 Conclusions ",
    "table_content": "|| Algorithm | Search Method | Total Time (sec) | Total Distance (m) | Comparison (%) ||\n||  High + Low  | After high-altitude search, low-altitude search | 1,099,028 | 4,579,283 | 100 ||\n||  Low Linear  | Search linearly at low altitude | 2,893,980 | 12,058,251 | 263 ||\n||  High + Low2  | After high-altitude search, low-altitude search (search by one high-altitude area) | 1,673,795 | 6,974,146 | 152 ||\n||  High Linear  | Search linearly at high altitude | 1,139,097 | 4,746,240 | 104 ||\n||  High + Low3 (Proposed)  | After high-altitude search with threshold value, low-altitude search | 959,327 | 3,997,199 | 87 ||",
    "claim": "The proposed method, \"High + Low3,\" reduces the total search time by approximately 13% compared to the \"High + Low\" method, demonstrating a more efficient search strategy in terms of time.",
    "label": "support"
  },
  {
    "id": "training_1020_3",
    "table_caption": "Table: 24 months of ART (n = 10 458)a. Variable Adjusted OR 95% CI P-value Male gender 0.89 0.80–1.00 0.051 Age: 16–19 years 0.44 0.27–0.72 0.001 20–29 yearsb 1.00 30–39 years 1.12 0.99–1.26 0.069 $40 years 1.69 1.33–2.16 ,0.001 WHO stage: I/IIb 1.00 III/IV 0.86 0.76–0.97 0.018 Baseline CD4 cell count (mL) 1.00 0.99–1.00 0.149 Western Cape provinceb 1.00 Eastern Cape province 0.41 0.32–0.52 ,0.001 KwaZulu-Natal province 0.69 0.59–0.82 ,0.001 Mpumalanga province 0.30 0.17–0.51 ,0.001 Primary healthcare facilitiesb 1.00 District hospitals 0.76 0.59–0.97 0.030 Regional hospitals 0.64 0.56–0.75 ,0.001 ART duration 6 monthsb 1.00 ART duration 12 months 0.83 0.78–0.92 ,0.001 ART duration 18–24 months 0.83 0.73–0.95 0.007 aEstimates adjusted for all variables shown and year of starting ART. bReference category. ",
    "table_content": "|| Variable | Adjusted OR | 95% CI |  P -value ||\n|| Male gender | 0.89 | 0.80–1.00 | 0.051 ||\n|| Eastern Cape province | 0.41 | 0.32–0.52 | <0.001 ||\n|| KwaZulu-Natal province | 0.69 | 0.59–0.82 | <0.001 ||\n|| Mpumalanga province | 0.30 | 0.17–0.51 | <0.001 ||\n|| Primary healthcare facilities b  | 1.00 | blank | blank ||\n|| District hospitals | 0.76 | 0.59–0.97 | 0.030 ||\n|| Regional hospitals | 0.64 | 0.56–0.75 | <0.001 ||\n|| ART duration 6 months b  | 1.00 | blank | blank ||\n|| ART duration 12 months | 0.83 | 0.78–0.92 | <0.001 ||\n|| ART duration 18–24 months | 0.83 | 0.73–0.95 | 0.007 ||\n|| Age: 16–19 years | 0.44 | 0.27–0.72 | 0.001 ||\n|| 20–29 years b  | 1.00 | blank | blank ||\n|| 30–39 years | 1.12 | 0.99–1.26 | 0.069 ||\n|| ≥40 years | 1.69 | 1.33–2.16 | <0.001 ||\n|| WHO stage: I/II b  | 1.00 | blank | blank ||\n|| III/IV | 0.86 | 0.76–0.97 | 0.018 ||\n|| Baseline CD4 cell count (µL) | 1.00 | 0.99–1.00 | 0.149 ||\n|| Western Cape province b  | 1.00 | blank | blank ||",
    "claim": "Patients in WHO stage III/IV have an adjusted OR of 0.86, indicating a 14% lower odds of achieving the same ART outcomes as those in stage I/II. This reflects the impact of disease severity on treatment effectiveness, where advanced disease stages may hinder optimal ART response.",
    "label": "support"
  },
  {
    "id": "training_891_4",
    "table_caption": "Table: and\topening\tsizes\twere\tmanipulated\tto\tachieve\tfive\ttreatment\tlevels,\twhich\trefer\tto\tthe\tsize\tclass\tof\tmammalian\therbivore\tpermitted\tentry:\t(a)\tTOTAL\tACCESS\t(i.e.,\tall\tmammals\tpermitted\t entry),\t(b)\tSMALL\t(i.e.,\trodents),\t(c)\tMEDIUM\t(i.e.,\trodents\tplus\tlagomorphs),\t(d)\tLARGE\t(i.e.,\tmule\tdeer),\tand\t(e)\tTOTAL\tEXCLOSURE\t(i.e.,\tall\tmammals\tprohibited\tfrom\tentry) Treatment Herbivores permitted entry Herbivores denied entry Depth buried (cm) Height extended above ground (cm) Exclosure opening Exclosure specific variation TOTAL\tACCESS All None n/a 10 Total SMALL Rodents Lagomorphs,\tDeer n/a ~76 3.5\t×\t5\tcm MEDIUM Rodents,\tLagomorphs Deer 15 ~76 25\t×\t25\tcm LARGE Deer Rodents,\tLagomorphs 15 60 Open\tat\ttop Laminate\twrap\t (30\tcm\twide) TOTAL\tEXCLOSURE None All 15 ~76 None ",
    "table_content": "|| Treatment | Herbivores permitted entry | Herbivores denied entry | Depth buried (cm) | Height extended above ground (cm) | Exclosure opening | Exclosure specific variation ||\n|| TOTAL ACCESS | All | None | n/a | 10 | Total | blank ||\n|| SMALL | Rodents | Lagomorphs, Deer | n/a | ~76 | 3.5 × 5 cm | blank ||\n|| MEDIUM | Rodents, Lagomorphs | Deer | 15 | ~76 | 25 × 25 cm | blank ||\n|| LARGE | Deer | Rodents, Lagomorphs | 15 | 60 | Open at top | Laminate wrap (30 cm wide) ||\n|| TOTAL EXCLOSURE | None | All | 15 | ~76 | None | blank ||",
    "claim": "The LARGE treatment employs a laminate wrap 30 cm wide, which, combined with an open top, suggests a design tailored to allow deer entry while excluding smaller herbivores like rodents and lagomorphs, highlighting the role of specific design features in targeted herbivore management.",
    "label": "support"
  },
  {
    "id": "training_407_6",
    "table_caption": "Table: Safety Profiles of Oral and Subcutaneous PPS Treatment in MPS I Dogs. Creatinine Total Bilirubin ALT AST ALP PT PTT Platelets Normal Ranges 0.7–1.8 0.1–0.5 16–91 25–65 20–155 6.8–10.2 10.7–16.4 177–398 Untreated 0.71 0.19 29.37 28.17 77.48 8.04 12.90 439.83* Oral 17M 0.58 0.20 24.41 22.28 77.0 8.40 13.1 321.00 SQ 12M 0.74 0.10 29.21 23.23 43.8 8.52 13.02 365.54 N = 5 per group; untreated, oral PPS and subcutaneous PPS (SQ) * = Value is elevated above normal range. ",
    "table_content": "|| blank | Creatinine | Total Bilirubin | ALT | AST | ALP | PT | PTT | Platelets ||\n|| Normal Ranges | 0.7–1.8 | 0.1–0.5 | 16–91 | 25–65 | 20–155 | 6.8–10.2 | 10.7–16.4 | 177–398 ||\n|| Untreated | 0.71 | 0.19 | 29.37 | 28.17 | 77.48 | 8.04 | 12.90 | 439.83 * ||\n|| Oral 17M | 0.58 | 0.20 | 24.41 | 22.28 | 77.0 | 8.40 | 13.1 | 321.00 ||\n|| SQ 12M | 0.74 | 0.10 | 29.21 | 23.23 | 43.8 | 8.52 | 13.02 | 365.54 ||",
    "claim": "The untreated group shows an elevated platelet count above the normal range, while both treatment groups have platelet counts within the normal range. This suggests that both oral and subcutaneous treatments may help normalize platelet counts, with the oral treatment showing a more pronounced effect in reducing elevated platelet levels.",
    "label": "support"
  },
  {
    "id": "training_1247_5",
    "table_caption": "Table: 0,9224. (b) Low-risk pregnancies Positive perinatal outcome Negative perinatal outcome Positive VAS Test 32 4 Negative VAS Test 54 5 Sensitivity = 32/(32 + 54) = 0,37 = 37%. 95% conﬁdence interval = 0,37 ± 1,96 √ 0,37 · (1 − 0,37)/(32 + 54) = 0,27– 0,47. the sex ",
    "table_content": "|| blank | Positive perinatal outcome | Negative perinatal outcome ||\n|| Positive VAS Test | 32 | 4 ||\n|| Negative VAS Test | 54 | 5 ||",
    "claim": "Given the sensitivity of 37%, clinicians should be cautious in relying solely on the VAS test for predicting positive perinatal outcomes. The relatively low sensitivity suggests that the test may miss a significant number of positive outcomes, necessitating the use of additional diagnostic tools or criteria to improve decision-making accuracy.",
    "label": "support"
  },
  {
    "id": "training_13_5",
    "table_caption": "Table: The general health mean scores and Standard deviation among study participants GHQ subscales Mean Standard deviation Somatic symptoms 6.99 5.13 Anxiety/insomnia 7.70 5.67 Social dysfunction 6.04 3.29 Severe depression 4.92 4.58 Total 25.63 15.28 3.3. Correlations ",
    "table_content": "|| GHQ subscales | Mean | Standard deviation ||\n|| Somatic symptoms | 6.99 | 5.13 ||\n|| Anxiety/insomnia | 7.70 | 5.67 ||\n|| Social dysfunction | 6.04 | 3.29 ||\n|| Severe depression | 4.92 | 4.58 ||\n|| Total | 25.63 | 15.28 ||",
    "claim": "The total standard deviation of 15.28 is not simply the sum of the individual subscale standard deviations, indicating that the variability in the total score is influenced by the covariance between subscales. This suggests that the health issues measured by the subscales are interrelated, affecting the overall variability in general health.",
    "label": "support"
  },
  {
    "id": "training_1204_1",
    "table_caption": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 ",
    "table_content": "|| Brain region | Facial expression | Condition | Side | Patients with MCI | Patients with MCI | Patients with mild AD | Patients with mild AD ||\n|| Brain region | Facial expression | Condition | Side | r | p | r | p ||\n|| Amygdala | Fear | 100% of morphing | L | -0.73 | 0.002 | -0.09 | 0.68 ||\n|| Amygdala | blank | blank | R | -0.79 | 0.0005 | -0.22 | 0.29 ||\n|| Amygdala | blank | Average | R | -0.42 | 0.12 | -0.32 | 0.12 ||\n|| Amygdala | blank | IR | R | -0.46 | 0.087 | -0.31 | 0.13 ||\n|| Fusiform G. | Happiness | Average | L | -0.66 | 0.007 | -0.29 | 0.17 ||\n|| Fusiform G. | blank | IR | L | -0.72 | 0.002 | -0.32 | 0.13 ||\n|| Pallidum | Disgust | 20% of morphing | L | -0.55 | 0.034 | -0.50 | 0.01 ||",
    "claim": "The correlation between amygdala volume and fear recognition at 100% morphing is stronger in MCI patients compared to AD patients, with a difference in correlation coefficients of 0.64, indicating a more pronounced relationship in MCI.",
    "label": "support"
  },
  {
    "id": "training_1012_3",
    "table_caption": "Table: Slopes of the dose-response curves in Figure 2. Chemical Slopea p-valueb dcbz 0.137/100 mg/kg 0.09 mecl 0.158/500 ppm 0.12 npth 20.256/5 ppm 0.99 pgbe 0.207/200 ppm 0.09 tcpn 0.331/10 mg/kg 0.05 aThe slopes are in terms of changes in the predicted z values per change in tabulated dose. b p-value for hypothesis testing the alternative that the ",
    "table_content": "|| Chemical | Slope a  | p-value b  ||\n|| dcbz | 0.137/100 mg/kg | 0.09 ||\n|| mecl | 0.158/500 ppm | 0.12 ||\n|| npth | −0.256/5 ppm | 0.99 ||\n|| pgbe | 0.207/200 ppm | 0.09 ||\n|| tcpn | 0.331/10 mg/kg | 0.05 ||",
    "claim": "When normalizing the slopes to a common dose unit, the slope of npth becomes -0.0512 per ppm, which is the most negative, indicating a decrease in response with increasing dose, contrasting with the positive slopes of other chemicals.",
    "label": "support"
  },
  {
    "id": "training_296_2",
    "table_caption": "Table: the [36]), stages roles lar of female cf. elegans org), wall muscles org). of a coli (IL-6) range sequences, respectively, identified in each sequence dataset and listed according to taxa TIMPs (no. with SP) NTR-module containing proteins (no. with SP) Nematodes Ascaris suum 3* (3) 2 (1) Brugia malayi - 1 (1) Dictyocaulus filaria 1 (1) 1 (−) Necator americanus 8** (3) 1 (1) Oesophagostomum dentatum 2 (2) 1 (−) Trichinella spiralis - 1 (1) Trichuris suis - 2 (−) Wuchereria bancrofti - 2 (−) Trematodes Clonorchis sinensis - 1 (−) Fasciola gigantica - 2 (−) Fasciola hepatica - 1 (−) Opisthorchis viverrini - 4 (1) Schistosoma haematobium 1*** (1) 5 (−) Schistosoma japonicum - 1 (−) Schistosoma mansoni - 1 (−) Total 15 (10) 26 (5) The number of proteins containing a predicted N-terminal signal peptide (SP) is also indicated. *Of these, Ascaris suum GS_04796 was up-regulated in the reproductive tissue ",
    "table_content": "|| blank | TIMPs (no. with SP) | NTR-module containing proteins (no. with SP) ||\n|| Nematodes | Nematodes | Nematodes ||\n|| Trematodes | Trematodes | Trematodes ||\n||  Clonorchis sinensis | blank | 1 (−) ||\n||  Fasciola gigantica | blank | 2 (−) ||\n||  Fasciola hepatica | blank | 1 (−) ||\n||  Opisthorchis viverrini | blank | 4 (1) ||\n||  Schistosoma haematobium | 1*** (1) | 5 (−) ||\n||  Schistosoma japonicum | blank | 1 (−) ||\n||  Schistosoma mansoni | blank | 1 (−) ||\n|| Total | 15 (10) | 26 (5) ||\n||  Ascaris suum | 3* (3) | 2 (1) ||\n||  Brugia malayi | blank | 1 (1) ||\n||  Dictyocaulus filaria | 1 (1) | 1 (−) ||\n||  Necator americanus | 8** (3) | 1 (1) ||\n||  Oesophagostomum dentatum | 2 (2) | 1 (−) ||\n||  Trichinella spiralis | blank | 1 (1) ||\n||  Trichuris suis | blank | 2 (−) ||\n||  Wuchereria bancrofti | blank | 2 (−) ||",
    "claim": "Schistosoma haematobium exhibits the highest number of NTR-module containing proteins among trematodes, contributing to nearly one-fifth of the total NTR-module proteins identified in trematodes. This indicates a possible functional significance of these proteins in this species.",
    "label": "support"
  },
  {
    "id": "training_838_3",
    "table_caption": "Table: In ‘why it’s never happening again’ the women de- during ture to the Table 2 Themes and subthemes It’s never happening again Theme Sub Theme Why it’s never happening again Treated like a piece of meat I was traumatised by it for years You can smell the fear in the room Re-traumatised by the system How it’s never happening again Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support “All about safety, but I came first” The impact of HBAC “I felt like superwoman” There is just no comparison ",
    "table_content": "|| It’s never happening again | It’s never happening again ||\n|| Theme | Sub Theme ||\n|| How it’s never happening again | “All about safety, but I came first” ||\n|| The impact of HBAC | “I felt like superwoman” ||\n|| The impact of HBAC | There is just no comparison ||\n|| Why it’s never happening again | Treated like a piece of meat ||\n|| Why it’s never happening again | I was traumatised by it for years ||\n|| Why it’s never happening again | You can smell the fear in the room ||\n|| Why it’s never happening again | Re-traumatised by the system ||\n|| How it’s never happening again | Getting informed and gaining confidence ||\n|| How it’s never happening again | Avoiding judgment through selective telling ||\n|| How it’s never happening again | Preparing for birth ||\n|| How it’s never happening again | Gathering support ||",
    "claim": "The subthemes under \"How it’s never happening again\" such as \"Getting informed and gaining confidence\" and \"Gathering support\" imply a multi-faceted approach to prevention. This approach likely involves both individual empowerment and community or systemic support, indicating that women are employing a comprehensive strategy to ensure their safety and well-being in future experiences.",
    "label": "support"
  },
  {
    "id": "training_838_3",
    "table_caption": "Table: In ‘why it’s never happening again’ the women de- during ture to the Table 2 Themes and subthemes It’s never happening again Theme Sub Theme Why it’s never happening again Treated like a piece of meat I was traumatised by it for years You can smell the fear in the room Re-traumatised by the system How it’s never happening again Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support “All about safety, but I came first” The impact of HBAC “I felt like superwoman” There is just no comparison ",
    "table_content": "|| It’s never happening again | It’s never happening again ||\n|| Theme | Sub Theme ||\n|| How it’s never happening again | “All about safety, but I came first” ||\n|| The impact of HBAC | “I felt like superwoman” ||\n|| The impact of HBAC | There is just no comparison ||\n|| Why it’s never happening again | Treated like a piece of meat ||\n|| Why it’s never happening again | I was traumatised by it for years ||\n|| Why it’s never happening again | You can smell the fear in the room ||\n|| Why it’s never happening again | Re-traumatised by the system ||\n|| How it’s never happening again | Getting informed and gaining confidence ||\n|| How it’s never happening again | Avoiding judgment through selective telling ||\n|| How it’s never happening again | Preparing for birth ||\n|| How it’s never happening again | Gathering support ||",
    "claim": "The subthemes under \"How it’s never happening again\" such as \"Getting informed and gaining confidence\" and \"Gathering support\" imply a narrow approach to prevention. This approach likely involves only individual empowerment, indicating that women are employing a limited strategy to ensure their safety and well-being in future experiences.",
    "label": "support"
  },
  {
    "id": "training_717_3",
    "table_caption": "Table: Treatment with alpha-interferon or pegylated-alpha interferon in dialysis HCV positive patients: results from 3 meta-analyses. Meta-analysis 1 (Fabrizi et al. [16]) Meta-analysis 2 (Gordon et al. [17]) Meta-analysis 3 (Alavian and Tabatabaei; [18]) Number of studies 28 25 33 Number of patients 645 459 770 Overall SVR (standard IFN/Peg-INF) % 39/41 41/37 39.1/39.3 Genotype 1(%) 33 Not reported Not reported Treatment discontinuation (standard IFN/Peg-IFN/Placebo) % 19/27/ not reported 26/28/22 22.6/29.7/not reported SVR: sustained virological response; IFN: alpha-interferon; Peg-IFN: pegylated alpha-interferon. ",
    "table_content": "|| blank | Meta-analysis 1 (Fabrizi et al. [ 16 ]) | Meta-analysis 2 (Gordon et al. [ 17 ]) | Meta-analysis 3 (Alavian and Tabatabaei; [ 18 ]) ||\n|| Number of studies | 28 | 25 | 33 ||\n|| Number of patients | 645 | 459 | 770 ||\n|| Overall SVR (standard IFN/Peg-INF) % | 39/41 | 41/37 | 39.1/39.3 ||\n|| Genotype 1(%) | 33 | Not reported | Not reported ||\n|| Treatment discontinuation (standard IFN/Peg-IFN/Placebo) % | 19/27/ not reported | 26/28/22 | 22.6/29.7/not reported ||",
    "claim": "The ratio of the number of patients to the number of studies is highest in Meta-analysis 3, indicating a larger average study size, which may contribute to more robust statistical power in its findings.",
    "label": "support"
  },
  {
    "id": "training_1293_1",
    "table_caption": "Table: deltoid and trapezius muscles , and the direction of dislocation of the clavicle with respect to the acromion. According to this classi�cation, AC dislocations can be divided into 6 types. Type AC ligament AC joint capsule CC ligament AC joint displacement Delta-trapezial fascia Type I Sprained Intact Intact None Intact Type II Torn Disrupted Intact 50% AC subluxation Intact Type III Torn Disrupted Torn 100% AC superior dislocation Intact Type IV Torn Disrupted Torn 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle Disrupted Type V Torn Disrupted Torn 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion Disrupted Type VI Torn Disrupted Torn 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position Intact can be gathered from studies based on sport practitioners [4– ",
    "table_content": "|| Type | AC ligament | AC joint capsule | CC ligament | AC joint displacement | Delta-trapezial fascia ||\n|| Type I | Sprained | Intact | Intact | None | Intact ||\n|| Type II | Torn | Disrupted | Intact | 50% AC subluxation | Intact ||\n|| Type III | Torn | Disrupted | Torn | 100% AC superior dislocation | Intact ||\n|| Type IV | Torn | Disrupted | Torn | 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle | Disrupted ||\n|| Type V | Torn | Disrupted | Torn | 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion | Disrupted ||\n|| Type VI | Torn | Disrupted | Torn | 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position | Intact ||",
    "claim": "The progression from Type I to Type VI shows a consistent pattern of increasing severity in the condition of the AC ligament, with all types except Type I exhibiting a torn ligament. This indicates a direct correlation between the severity of the AC ligament condition and the classification type, with a 100% increase in ligament tearing from Type I to Type II and remaining constant thereafter.",
    "label": "support"
  },
  {
    "id": "training_1293_1",
    "table_caption": "Table: deltoid and trapezius muscles , and the direction of dislocation of the clavicle with respect to the acromion. According to this classi�cation, AC dislocations can be divided into 6 types. Type AC ligament AC joint capsule CC ligament AC joint displacement Delta-trapezial fascia Type I Sprained Intact Intact None Intact Type II Torn Disrupted Intact 50% AC subluxation Intact Type III Torn Disrupted Torn 100% AC superior dislocation Intact Type IV Torn Disrupted Torn 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle Disrupted Type V Torn Disrupted Torn 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion Disrupted Type VI Torn Disrupted Torn 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position Intact can be gathered from studies based on sport practitioners [4– ",
    "table_content": "|| Type | AC ligament | AC joint capsule | CC ligament | AC joint displacement | Delta-trapezial fascia ||\n|| Type I | Sprained | Intact | Intact | None | Intact ||\n|| Type II | Torn | Disrupted | Intact | 50% AC subluxation | Intact ||\n|| Type III | Torn | Disrupted | Torn | 100% AC superior dislocation | Intact ||\n|| Type IV | Torn | Disrupted | Torn | 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle | Disrupted ||\n|| Type V | Torn | Disrupted | Torn | 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion | Disrupted ||\n|| Type VI | Torn | Disrupted | Torn | 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position | Intact ||",
    "claim": "The progression from Type I to Type VI shows a consistent pattern of increasing severity in the condition of the AC ligament, with all types except Type I exhibiting a torn ligament. This indicates a direct correlation between the severity of the AC ligament condition and the classification type, with a 100% increase in ligament tearing from Type I to Type II and varying thereafter.",
    "label": "support"
  },
  {
    "id": "training_1332_5",
    "table_caption": "Table: Group sizes and characteristics of organizations ID Group group size sample (contacted) response rate final group size (analyzed) proportion (of all analyzed) characteristics (examples) all groups 442 67% 301 100% A patient organizations 42 57% 24 8% umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres B medical associations 100 78% 79 26% scientific medical societies, associations of statutory health insurance physicians on federal and national level C nursing organizations 22 77% 17 6% umbrella organizations of nursing care, federal working commitee of nursing D health insurance funds 82 63% 55 18% associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds E political institutions 45 49% 24 8% state and federal ministries of health, health-care policy spokespeople of the different political parties F specialized palliative care 54 65% 39 13% associations and umbrella organizations of palliative and hospice care on federal and national level G others* 97 72% 63 21% charity and clerical institutions, associations for physiotherapy, federal joint committee * not included in the comparison of the groups because of the strong heterogeneity ",
    "table_content": "|| ID | Group all groups | group size sample (contacted) 442 | response rate 67% | final group size (analyzed) 301 | proportion (of all analyzed) 100% | characteristics (examples) ||\n|| ID | Group all groups | group size sample (contacted) 442 | response rate 67% | final group size (analyzed) 301 | proportion (of all analyzed) 100% | characteristics (examples) ||\n|| A | patient organizations | 42 | 57% | 24 | 8% | umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres ||\n|| B | medical associations | 100 | 78% | 79 | 26% | scientific medical societies, associations of statutory health insurance physicians on federal and national level ||\n|| C | nursing organizations | 22 | 77% | 17 | 6% | umbrella organizations of nursing care, federal working commitee of nursing ||\n|| D | health insurance funds | 82 | 63% | 55 | 18% | associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds ||\n|| E | political institutions | 45 | 49% | 24 | 8% | state and federal ministries of health, health-care policy spokespeople of the different political parties ||\n|| F | specialized palliative care | 54 | 65% | 39 | 13% | associations and umbrella organizations of palliative and hospice care on federal and national level ||\n|| G | others* | 97 | 72% | 63 | 21% | charity and clerical institutions, associations for physiotherapy, federal joint committee ||",
    "claim": "The group size of health insurance funds is nearly double that of patient organizations, yet their response rate is only 6% higher, suggesting that larger group sizes do not necessarily correlate with significantly higher response rates.",
    "label": "support"
  },
  {
    "id": "training_785_4",
    "table_caption": "Table: Refinement Refinement on F2 Primary atom site location: structure-invariant direct methods Least-squares matrix: full Secondary atom site location: difference Fourier map R[F2 > 2σ(F2)] = 0.044 Hydrogen site location: inferred from neighbouring sites wR(F2) = 0.114 H-atom parameters constrained S = 1.00 w = 1/[σ2(Fo 2) + (0.0496P)2 + 0.219P] where P = (Fo 2 + 2Fc 2)/3 2689 reflections (Δ/σ)max < 0.001 174 parameters Δρmax = 0.38 e Å−3 0 restraints Δρmin = −0.27 e Å−3 Special details ",
    "table_content": "|| Refinement on F 2 | Primary atom site location: structure-invariant direct methods ||\n|| Least-squares matrix: full | Secondary atom site location: difference Fourier map ||\n|| R [ F 2 > 2σ( F 2 )] = 0.044 | Hydrogen site location: inferred from neighbouring sites ||\n|| wR ( F 2 ) = 0.114 | H-atom parameters constrained ||\n|| S = 1.00 | w =  1/[σ 2 ( F o 2 ) + (0.0496 P ) 2 + 0.219 P ]  where P = ( F o 2 + 2 F c 2 )/3 ||\n|| 2689 reflections | (Δ/σ) max < 0.001 ||\n|| 174 parameters | Δρ max = 0.38 e Å − 3 ||\n|| 0 restraints | Δρ min = −0.27 e Å − 3 ||",
    "claim": "The maximum and minimum electron density differences are 0.38 e Å−3 and −0.27 e Å−3, respectively. The relatively small range of electron density differences suggests that the model accurately represents the electron distribution in the crystal, with minimal discrepancies.",
    "label": "support"
  },
  {
    "id": "training_785_4",
    "table_caption": "Table: Refinement Refinement on F2 Primary atom site location: structure-invariant direct methods Least-squares matrix: full Secondary atom site location: difference Fourier map R[F2 > 2σ(F2)] = 0.044 Hydrogen site location: inferred from neighbouring sites wR(F2) = 0.114 H-atom parameters constrained S = 1.00 w = 1/[σ2(Fo 2) + (0.0496P)2 + 0.219P] where P = (Fo 2 + 2Fc 2)/3 2689 reflections (Δ/σ)max < 0.001 174 parameters Δρmax = 0.38 e Å−3 0 restraints Δρmin = −0.27 e Å−3 Special details ",
    "table_content": "|| Refinement on F 2 | Primary atom site location: structure-invariant direct methods ||\n|| Least-squares matrix: full | Secondary atom site location: difference Fourier map ||\n|| R [ F 2 > 2σ( F 2 )] = 0.044 | Hydrogen site location: inferred from neighbouring sites ||\n|| wR ( F 2 ) = 0.114 | H-atom parameters constrained ||\n|| S = 1.00 | w =  1/[σ 2 ( F o 2 ) + (0.0496 P ) 2 + 0.219 P ]  where P = ( F o 2 + 2 F c 2 )/3 ||\n|| 2689 reflections | (Δ/σ) max < 0.001 ||\n|| 174 parameters | Δρ max = 0.38 e Å − 3 ||\n|| 0 restraints | Δρ min = −0.27 e Å − 3 ||",
    "claim": "The maximum and minimum electron density differences are 0.38 e Å−3 and −0.27 e Å−3, respectively. The relatively large range of electron density differences suggests that the model inaccurately represents the electron distribution in the crystal, with significant discrepancies.",
    "label": "support"
  },
  {
    "id": "training_927_2",
    "table_caption": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 I1 0.0910 (5) 0.0588 (3) 0.0581 (3) −0.0160 (3) 0.0282 (3) 0.0173 (3) O1 0.0201 (19) 0.062 (3) 0.038 (2) −0.0006 (18) 0.0138 (17) 0.007 (2) O2 0.027 (2) 0.056 (3) 0.042 (2) −0.0059 (19) 0.0109 (18) 0.014 (2) N1 0.022 (2) 0.055 (3) 0.035 (3) 0.001 (2) 0.012 (2) 0.011 (2) C1 0.022 (3) 0.035 (3) 0.029 (3) 0.001 (2) 0.013 (2) −0.001 (2) C2 0.022 (3) 0.049 (3) 0.038 (3) −0.002 (2) 0.012 (2) 0.003 (3) C11 0.030 (3) 0.037 (3) 0.041 (3) 0.007 (2) 0.018 (3) 0.010 (2) C12 0.031 (3) 0.035 (3) 0.051 (4) −0.002 (2) 0.012 (3) 0.005 (3) C13 0.039 (3) 0.031 (3) 0.063 (4) −0.004 (3) 0.024 (3) 0.008 (3) C14 0.052 (4) 0.032 (3) 0.046 (4) 0.001 (3) 0.026 (3) 0.000 (3) C15 0.050 (4) 0.047 (4) 0.035 (3) −0.007 (3) 0.014 (3) −0.001 (3) C16 0.038 (3) 0.054 (4) 0.044 (4) −0.010 (3) 0.020 (3) 0.000 (3) Geometric parameters (Å, °) ",
    "table_content": "|| blank | U 11 | U 22 | U 33 | U 12 | U 13 | U 23 ||\n|| I1 | 0.0910 (5) | 0.0588 (3) | 0.0581 (3) | −0.0160 (3) | 0.0282 (3) | 0.0173 (3) ||\n|| C14 | 0.052 (4) | 0.032 (3) | 0.046 (4) | 0.001 (3) | 0.026 (3) | 0.000 (3) ||\n|| C15 | 0.050 (4) | 0.047 (4) | 0.035 (3) | −0.007 (3) | 0.014 (3) | −0.001 (3) ||\n|| C16 | 0.038 (3) | 0.054 (4) | 0.044 (4) | −0.010 (3) | 0.020 (3) | 0.000 (3) ||\n|| O1 | 0.0201 (19) | 0.062 (3) | 0.038 (2) | −0.0006 (18) | 0.0138 (17) | 0.007 (2) ||\n|| O2 | 0.027 (2) | 0.056 (3) | 0.042 (2) | −0.0059 (19) | 0.0109 (18) | 0.014 (2) ||\n|| N1 | 0.022 (2) | 0.055 (3) | 0.035 (3) | 0.001 (2) | 0.012 (2) | 0.011 (2) ||\n|| C1 | 0.022 (3) | 0.035 (3) | 0.029 (3) | 0.001 (2) | 0.013 (2) | −0.001 (2) ||\n|| C2 | 0.022 (3) | 0.049 (3) | 0.038 (3) | −0.002 (2) | 0.012 (2) | 0.003 (3) ||\n|| C11 | 0.030 (3) | 0.037 (3) | 0.041 (3) | 0.007 (2) | 0.018 (3) | 0.010 (2) ||\n|| C12 | 0.031 (3) | 0.035 (3) | 0.051 (4) | −0.002 (2) | 0.012 (3) | 0.005 (3) ||\n|| C13 | 0.039 (3) | 0.031 (3) | 0.063 (4) | −0.004 (3) | 0.024 (3) | 0.008 (3) ||",
    "claim": "The anisotropy in atomic displacement for C13 is evident, with U33 being significantly larger than U11 and U22. This suggests a directional preference in thermal motion, likely due to the bonding environment or structural constraints in the crystal lattice.",
    "label": "support"
  },
  {
    "id": "training_463_1",
    "table_caption": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) ",
    "table_content": "|| blank | Sensitivity | Specificity | Positive predictive value | Negative predictive value | Accuracy ||\n|| SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) ||\n|| All combined | 0.83 (0.82, 0.84) | 0.83 (0.82, 0.84) | 0.84 (0.83, 0.85) | 0.84 (0.83, 0.85) | 0.83 (0.82, 0.84) ||\n|| PGME | 0.71 (0.70, 0.72) | 0.80 (0.79, 0.81) | 0.79 (0.78, 0.80) | 0.74 (0.73, 0.75) | 0.76 (0.75, 0.77) ||\n|| Gait features + Demograph. var | 0.61 (0.60, 0.62) | 0.76 (0.75, 0.77) | 0.73 (0.72, 0.74) | 0.66 (0.65, 0.67) | 0.68 (0.67, 0.69) ||\n|| Fall history: 6 months | 0.47 (0.46, 0.48) | 0.67 (0.65, 0.68) | 0.59 (0.57, 0.60) | 0.56 (0.55, 0.57) | 0.57 (0.56, 0.58) ||\n|| All combined | 0.75 (0.73, 0.76) | 0.80 (0.79, 0.81) | 0.80 (0.79, 0.81) | 0.77 (0.76, 0.78) | 0.77 (0.76, 0.78) ||\n|| MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) ||\n|| PGME | 0.67 (0.66, 0.69) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.68 (0.67, 0.69) ||\n|| Gait features + demograph var | 0.79 (0.77, 0.80) | 0.76 (0.75, 0.77) | 0.77 (0.76, 0.78) | 0.79 (0.78, 0.80) | 0.77 (0.76, 0.80) ||\n|| Fall history: 6 months | 0.55 (0.53, 0.56) | 0.65 (0.64, 0.67) | 0.62 (0.61, 0.63) | 0.60 (0.59, 0.61) | 0.60 (0.59, 0.61) ||",
    "claim": "For the \"All combined\" model, the difference in accuracy between single-time and multiple-time fallers is 6 percentage points, indicating a higher predictive capability for multiple-time fallers.",
    "label": "support"
  },
  {
    "id": "training_240_3",
    "table_caption": "Table: Self-reported reasons for non compliance to screening invitation, by provider of last Pap-test. private public never screened reasons for non compliance N % N % N % did not receive the letter 21 9,9 8 13,1 10 16,9 Forgot 40 18,8 27 44,3 22 37,3 pregnancy 10 4,7 1 1,6 no trust in public health services 13 6,1 1 1,7 exclusive trust in private gynaecologist 62 29,1 Fear 8 3,8 16 27,1 did not consider important 5 8,5 hysterectomized 1 1,7 Illness 1 1,7 Virgin 3 5,1 do not respond 59 27,7 25 41,0 Total 213 100,0 61 59 100,0 ",
    "table_content": "|| reasons for non compliance | private | private | public | public | never screened | never screened ||\n|| reasons for non compliance | N | % | N | % | N | % ||\n|| Illness | blank | blank | blank | blank | 1 | 1,7 ||\n|| Virgin | blank | blank | blank | blank | 3 | 5,1 ||\n|| do not respond | 59 | 27,7 | 25 | 41,0 | blank | blank ||\n|| Total | 213 | 100,0 | 61 | blank | 59 | 100,0 ||\n|| did not receive the letter | 21 | 9,9 | 8 | 13,1 | 10 | 16,9 ||\n|| Forgot | 40 | 18,8 | 27 | 44,3 | 22 | 37,3 ||\n|| pregnancy | 10 | 4,7 | 1 | 1,6 | blank | blank ||\n|| no trust in public health services | 13 | 6,1 | blank | blank | 1 | 1,7 ||\n|| exclusive trust in private gynaecologist | 62 | 29,1 | blank | blank | blank | blank ||\n|| Fear | 8 | 3,8 | blank | blank | 16 | 27,1 ||\n|| did not consider important | blank | blank | blank | blank | 5 | 8,5 ||\n|| hysterectomized | blank | blank | blank | blank | 1 | 1,7 ||",
    "claim": "Trust in healthcare providers plays a crucial role in compliance, as evidenced by the fact that 29.1% of individuals who had their last Pap-test with a private provider cited exclusive trust in private gynecologists as their reason for non-compliance. This contrasts with the negligible percentage of public provider users who reported a lack of trust in public health services, highlighting the importance of trust in private healthcare settings.",
    "label": "support"
  },
  {
    "id": "training_621_2",
    "table_caption": "Table: 230 Table 2. Depicts the effect of demographic variables on smoking habit Gender P Value Hospital/Institute P Value Type of Health care provider P Value Department P Value male female DUHS Shifa liaquat doctor nurse technician medicine surgery Are you a smoker for the past one year? yes 45 7 <0.001 32 12 8 0.0098 11 17 24 0.444 30 22 0.78 86.54% 13.20% 60.40% 22.60% 15.38% 20.80% 32.10% 46.15% 56.60% 42.31% No 71 57 96 9 23 32 50 46 69 59 55.47% 44.90% 75% 7.10% 17.97% 25.20% 39.40% 35.94% 54.30% 46.09% Number of cigarettes that you smoke per day less than 5 24 7 0.033 22 3 6 5 11 15 0.554 18 13 0.947 77.40% 22.60% 71.00% 9.70% 19.40% 16.10% 35.50% 48.40% 58.10% 41.90% more than 5 21 0 10 9 2 6 6 9 12 9 100.00% 0.00% 47.60% 42.90% 9.50% 28.60% 28.60% 42.90% 57.10% 42.90% Influence of friends and peer pressure Not Influenced 25 7 0.035 26 0 6 7 10 15 0.959 18 14 0.79 78.10% 21.90% 81.30% 0.00% 18.80% 21.90% 31.30% 46.90% 56.30% 43.80% Influenced 20 0 6 12 2 4 7 9 12 8 100.00% 0.00% 30.00% 60.00% 10.00% 20.00% 35.00% 45.00% 60.00% 40.00% Addiction Not Addicted 25 6 0.219 23 3 5 5 9 17 0.289 21 10 0.075 80.60% 19.40% 74.20% 9.70% 16.10% 16.10% 29.00% 54.80% 67.70% 32.30% Addicted 20 1 9 9 3 6 8 7 9 12 95.20% 4.80% 42.90% 42.90% 14.30% 28.60% 38.10% 33.30% 42.90% 57.10% Lack of will power No 19 4 0.686 16 3 4 7 5 11 0.2 12 11 0.473 82.60% 17.40% 69.60% 13.00% 17.40% 30.40% 21.70% 47.80% 52.20% 47.80% yes 26 3 16 9 4 4 12 13 18 11 89.70% 10.30% 55.20% 31.00% 13.80% 13.80% 41.40% 44.80% 62.10% 37.90% Lack of incentive No 33 3 0.182 20 10 6 9 13 14 0.276 20 16 0.64 91.70% 8.30% 55.60% 27.80% 16.70% 25.00% 36.10% 38.90% 55.60% 44.40% Yes 12 4 12 2 2 2 4 10 10 6 75.00% 25.00% 75.00% 12.50% 12.50% 12.50% 25.00% 62.50% 62.50% 37.50% ",
    "table_content": "|| blank | blank | Gender | Gender | P Value | Hospital/Institute | Hospital/Institute | Hospital/Institute | P Value | Type of Health care provider | Type of Health care provider | Type of Health care provider | P Value | Department | Department | P Value ||\n|| blank | blank | male | female | P Value | DUHS | Shifa | liaquat | P Value | doctor | nurse | technician | P Value | medicine | surgery | P Value ||\n|| Influence of friends and peer pressure | Not Influenced | 25 | 7 | 0.035 | 26 | 0 | 6 | blank | 7 | 10 | 15 | 0.959 | 18 | 14 | 0.79 ||\n|| Influence of friends and peer pressure | Not Influenced | 78.10% | 21.90% | 0.035 | 81.30% | 0.00% | 18.80% | blank | 21.90% | 31.30% | 46.90% | 0.959 | 56.30% | 43.80% | 0.79 ||\n|| Influence of friends and peer pressure | Influenced | 20 | 0 | 0.035 | 6 | 12 | 2 | blank | 4 | 7 | 9 | 0.959 | 12 | 8 | 0.79 ||\n|| Influence of friends and peer pressure | Influenced | 100.00% | 0.00% | 0.035 | 30.00% | 60.00% | 10.00% | blank | 20.00% | 35.00% | 45.00% | 0.959 | 60.00% | 40.00% | 0.79 ||\n|| Addiction | Not Addicted | 25 | 6 | 0.219 | 23 | 3 | 5 | blank | 5 | 9 | 17 | 0.289 | 21 | 10 | 0.075 ||\n|| Addiction | Not Addicted | 80.60% | 19.40% | 0.219 | 74.20% | 9.70% | 16.10% | blank | 16.10% | 29.00% | 54.80% | 0.289 | 67.70% | 32.30% | 0.075 ||\n|| Addiction | Addicted | 20 | 1 | 0.219 | 9 | 9 | 3 | blank | 6 | 8 | 7 | 0.289 | 9 | 12 | 0.075 ||\n|| Addiction | Addicted | 95.20% | 4.80% | 0.219 | 42.90% | 42.90% | 14.30% | blank | 28.60% | 38.10% | 33.30% | 0.289 | 42.90% | 57.10% | 0.075 ||\n|| Lack of will power | No | 19 | 4 | 0.686 | 16 | 3 | 4 | blank | 7 | 5 | 11 | 0.2 | 12 | 11 | 0.473 ||\n|| Lack of will power | No | 82.60% | 17.40% | 0.686 | 69.60% | 13.00% | 17.40% | blank | 30.40% | 21.70% | 47.80% | 0.2 | 52.20% | 47.80% | 0.473 ||\n|| Are you a smoker for the past one year? | yes | 45 | 7 | <0.001 | 32 | 12 | 8 | 0.0098 | 11 | 17 | 24 | 0.444 | 30 | 22 | 0.78 ||\n|| Lack of will power | yes | 26 | 3 | 0.686 | 16 | 9 | 4 | blank | 4 | 12 | 13 | 0.2 | 18 | 11 | 0.473 ||\n|| Lack of will power | yes | 89.70% | 10.30% | 0.686 | 55.20% | 31.00% | 13.80% | blank | 13.80% | 41.40% | 44.80% | 0.2 | 62.10% | 37.90% | 0.473 ||\n|| Lack of incentive | No | 33 | 3 | 0.182 | 20 | 10 | 6 | blank | 9 | 13 | 14 | 0.276 | 20 | 16 | 0.64 ||\n|| Lack of incentive | No | 91.70% | 8.30% | 0.182 | 55.60% | 27.80% | 16.70% | blank | 25.00% | 36.10% | 38.90% | 0.276 | 55.60% | 44.40% | 0.64 ||\n|| Lack of incentive | Yes | 12 | 4 | 0.182 | 12 | 2 | 2 | blank | 2 | 4 | 10 | 0.276 | 10 | 6 | 0.64 ||\n|| Lack of incentive | Yes | 75.00% | 25.00% | 0.182 | 75.00% | 12.50% | 12.50% | blank | 12.50% | 25.00% | 62.50% | 0.276 | 62.50% | 37.50% | 0.64 ||\n|| Are you a smoker for the past one year? | yes | 86.54% | 13.20% | <0.001 | 60.40% | 22.60% | 15.38% | 0.0098 | 20.80% | 32.10% | 46.15% | 0.444 | 56.60% | 42.31% | 0.78 ||\n|| Are you a smoker for the past one year? | No | 71 | 57 | <0.001 | 96 | 9 | 23 | 0.0098 | 32 | 50 | 46 | 0.444 | 69 | 59 | 0.78 ||\n|| Are you a smoker for the past one year? | No | 55.47% | 44.90% | <0.001 | 75% | 7.10% | 17.97% | 0.0098 | 25.20% | 39.40% | 35.94% | 0.444 | 54.30% | 46.09% | 0.78 ||\n|| Number of cigarettes that you smoke per day | less than 5 | 24 | 7 | 0.033 | 22 | 3 | 6 | blank | 5 | 11 | 15 | 0.554 | 18 | 13 | 0.947 ||\n|| Number of cigarettes that you smoke per day | less than 5 | 77.40% | 22.60% | 0.033 | 71.00% | 9.70% | 19.40% | blank | 16.10% | 35.50% | 48.40% | 0.554 | 58.10% | 41.90% | 0.947 ||\n|| Number of cigarettes that you smoke per day | more than 5 | 21 | 0 | 0.033 | 10 | 9 | 2 | blank | 6 | 6 | 9 | 0.554 | 12 | 9 | 0.947 ||\n|| Number of cigarettes that you smoke per day | more than 5 | 100.00% | 0.00% | 0.033 | 47.60% | 42.90% | 9.50% | blank | 28.60% | 28.60% | 42.90% | 0.554 | 57.10% | 42.90% | 0.947 ||",
    "claim": "The likelihood of being a smoker varies significantly across different hospital affiliations, with a p-value of 0.0098. This indicates that the institutional environment may play a role in smoking behavior, with DUHS having a higher percentage of smokers compared to Shifa and Liaquat. The calculation involves analyzing the distribution of smokers across the three institutions and comparing their respective percentages.",
    "label": "support"
  },
  {
    "id": "training_454_3",
    "table_caption": "Table: Significant metabolites identified in urine samples from precancerous 15-month old female study mice. ppm VIP p-value Identification Control Concentration mM (StDev) Study Concentration mM(StDev) Rank Fold Change (Error) AUC 3.967 2.10 1.35E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.25 (0.36) 0.77 7.643 2.01 1.93E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.838 2.00 2.18E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.556 1.94 3.79E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.23 (0.40) 0.77 7.630 1.77 1.46E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.21 (0.51) 0.76 7.590 1.54 3.56E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.19 (0.49) 0.67 3.961 1.43 6.36E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.14 (0.24) 0.68 7.699 1.69 8.88E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.34 (0.24) 0.75 7.282 1.64 7.23E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.46 (0.43) 0.76 7.207 1.62 7.89E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.49 (0.52) 0.76 7.271 1.51 1.63E-02 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.35 (0.52) 0.75 4.107 1.65 1.13E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.15 (0.33) 0.70 3.543 1.19 6.90E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.07 (0.35) 0.69 7.464 1.39 2.39E-02 benzoate 5.27 (9.53) 4.54 (4.90) 3 -1.43 (0.55) 0.74 2.684 1.19 2.95E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.84 (3.62) 0.59 2.535 1.19 2.85E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.87 (3.42) 0.59 2.563 1.18 2.89E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.98 (3.54) 0.59 4.150 1.08 5.24E-01 pseudouridine 3.67 (4.25) 3.03 (3.79) 1 -1.13 (0.34) 0.50 8.831 1.04 9.47E-01 trigonelline 2.08 (2.89) 4.22 (6.07) 3 -1.014 (1.14) 0.53 3.023 1.02 9.95E-01 creatine 17.08 (23.88) 16.39 (24.80) 3 -1.001 (1.24) 0.57 4.041 1.01 9.19E-01 creatinine 19.58 (22.26) 33.96 (39.53) 3 1.03 (0.73) 0.65 https://doi.org/10.1371/journal.pone.0200658.t003 ",
    "table_content": "|| ppm | VIP | p-value | Identification | Control Concentration mM (StDev) | Study Concentration mM(StDev) | Rank | Fold Change (Error) | AUC ||\n|| 3.967 | 2.10 | 1.35E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.25 (0.36) | 0.77 ||\n|| 7.207 | 1.62 | 7.89E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.49 (0.52) | 0.76 ||\n|| 7.271 | 1.51 | 1.63E-02 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.35 (0.52) | 0.75 ||\n|| 4.107 | 1.65 | 1.13E-01 | fructose | 64.41 (105.05) | 153.81 (209.16) | 2 | 1.15 (0.33) | 0.70 ||\n|| 3.543 | 1.19 | 6.90E-01 | fructose | 64.41 (105.05) | 153.81 (209.16) | 2 | 1.07 (0.35) | 0.69 ||\n|| 7.464 | 1.39 | 2.39E-02 | benzoate | 5.27 (9.53) | 4.54 (4.90) | 3 | -1.43 (0.55) | 0.74 ||\n|| 2.684 | 1.19 | 2.95E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.84 (3.62) | 0.59 ||\n|| 2.535 | 1.19 | 2.85E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.87 (3.42) | 0.59 ||\n|| 2.563 | 1.18 | 2.89E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.98 (3.54) | 0.59 ||\n|| 4.150 | 1.08 | 5.24E-01 | pseudouridine | 3.67 (4.25) | 3.03 (3.79) | 1 | -1.13 (0.34) | 0.50 ||\n|| 8.831 | 1.04 | 9.47E-01 | trigonelline | 2.08 (2.89) | 4.22 (6.07) | 3 | -1.014 (1.14) | 0.53 ||\n|| 7.643 | 2.01 | 1.93E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.24 (0.38) | 0.77 ||\n|| 3.023 | 1.02 | 9.95E-01 | creatine | 17.08 (23.88) | 16.39 (24.80) | 3 | -1.001 (1.24) | 0.57 ||\n|| 4.041 | 1.01 | 9.19E-01 | creatinine | 19.58 (22.26) | 33.96 (39.53) | 3 | 1.03 (0.73) | 0.65 ||\n|| 7.838 | 2.00 | 2.18E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.24 (0.38) | 0.77 ||\n|| 7.556 | 1.94 | 3.79E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.23 (0.40) | 0.77 ||\n|| 7.630 | 1.77 | 1.46E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.21 (0.51) | 0.76 ||\n|| 7.590 | 1.54 | 3.56E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.19 (0.49) | 0.67 ||\n|| 3.961 | 1.43 | 6.36E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.14 (0.24) | 0.68 ||\n|| 7.699 | 1.69 | 8.88E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.34 (0.24) | 0.75 ||\n|| 7.282 | 1.64 | 7.23E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.46 (0.43) | 0.76 ||",
    "claim": "Metabolites with lower p-values, indicating higher statistical significance, generally have higher AUC values, reflecting better discrimination between control and study groups.",
    "label": "support"
  },
  {
    "id": "training_1279_3",
    "table_caption": "Table: formal purpose of their facility (3/47, 6%). Other surveyed offered enhanced HCV support services that Table 4 HCV support services and treatment provided onsite at DCRs/SIFs and availability of HCV treatment to DCR clients Provide onsite Plan to expand in future HCV support (multiple responses possible) n = 46 n = 47 Yes, referral to other services that can provide HCV treatment 96% 36% Yes, disease self-management support (e.g. healthy diet, obesity) 50% 15% Yes, liver health/cirrhosis monitoring (e.g. fibro-scan, blood test) 24% 11% No 15% 49% HCV treatment (one response only) n = 48 n = 39 Yes, new HCV treatment forms (DAAs) 4% 3% Yes, interferon-based treatment 0% 3% Yes, both treatment options 4% 0% Other (provided details) – 10% Don’t know 8% – No 86% 84% ",
    "table_content": "|| blank | Provide onsite | Plan to expand in future ||\n|| HCV support (multiple responses possible) | n = 46 | n = 47 ||\n|| Other (provided details) | – | 10% ||\n|| Don’t know | 8% | – ||\n|| No | 86% | 84% ||\n|| Yes, referral to other services that can provide HCV treatment | 96% | 36% ||\n|| Yes, disease self-management support (e.g. healthy diet, obesity) | 50% | 15% ||\n|| Yes, liver health/cirrhosis monitoring (e.g. fibro-scan, blood test) | 24% | 11% ||\n|| No | 15% | 49% ||\n|| HCV treatment (one response only) | n = 48 | n = 39 ||\n|| Yes, new HCV treatment forms (DAAs) | 4% | 3% ||\n|| Yes, interferon-based treatment | 0% | 3% ||\n|| Yes, both treatment options | 4% | 0% ||",
    "claim": "The current availability of new HCV treatment forms (DAAs) is limited, with only 4% of facilities offering this option. This reflects a potential gap in the immediate availability of advanced treatment options at these facilities.",
    "label": "support"
  },
  {
    "id": "training_623_2",
    "table_caption": "Table: Selected1 model parameters. Symbol2 Description Value(s) Refs Demographic N(0) Number of hosts (in thousands) 25 Main text - Maximum age (years) 101 [38], S1 Text - Lifespan distribution S1 Fig [38], S1 Text α Age-specific mixing weights S1 Table [39], S1 Text Epidemiological - Minimum intrinsic duration (days) 20 [20] - Maximum intrinsic duration (days) 150 [19] κ Minimum carriage duration in any host (days) 20 [20] μmax Maximum competitive exclusion 0.25 [20] - Serotype fitness parameters S2 Table S2 Text ∊ Acquisition rate of non-serotype-specific immunity 0.1# [40] β Overall contact rate (contacts per day per host) 0.1 or 0.13& S2 Text Vaccine trial av Age at vaccination (days) 60 or 360 Main text - Vaccine efficacy (colonization equivalents) 26%, 39%, or 63%‡ Main text - Number of participants per arm (in thousands) 5 Main text 1 Parameters adequately described in Cobey and Lipsitch’s paper [30] are not repeated here. Parameters in this table either have new values, or are newly introduced. ",
    "table_content": "|| Symbol 2 | Description | Value(s) | Refs ||\n|| Demographic | Demographic | Demographic | Demographic ||\n|| μ max | Maximum competitive exclusion | 0.25 | [ 20 ] ||\n|| blank | Serotype fitness parameters | S2 Table | S2 Text ||\n|| ∊ | Acquisition rate of non-serotype-specific immunity | 0.1 # | [ 40 ] ||\n|| β | Overall contact rate (contacts per day per host) | 0.1 or 0.13 & | S2 Text ||\n|| Vaccine trial | Vaccine trial | Vaccine trial | Vaccine trial ||\n|| a v | Age at vaccination (days) | 60 or 360 | Main text ||\n|| blank | Vaccine efficacy (colonization equivalents) | 26%, 39%, or 63% ‡ | Main text ||\n|| blank | Number of participants per arm (in thousands) | 5 | Main text ||\n|| N (0) | Number of hosts (in thousands) | 25 | Main text ||\n|| blank | Maximum age (years) | 101 | [ 38 ], S1 Text ||\n|| blank | Lifespan distribution | S1 Fig | [ 38 ], S1 Text ||\n|| α | Age-specific mixing weights | S1 Table | [ 39 ], S1 Text ||\n|| Epidemiological | Epidemiological | Epidemiological | Epidemiological ||\n|| blank | Minimum intrinsic duration (days) | 20 | [ 20 ] ||\n|| blank | Maximum intrinsic duration (days) | 150 | [ 19 ] ||\n|| κ | Minimum carriage duration in any host (days) | 20 | [ 20 ] ||",
    "claim": "The ratio of the maximum intrinsic duration to the minimum carriage duration provides insight into the potential for prolonged infection periods relative to the minimum time a host can carry the pathogen. This ratio indicates a potential for extended transmission periods within the host population.",
    "label": "support"
  },
  {
    "id": "training_70_4",
    "table_caption": "Table: TABLE 3 | Eleven intragenic IS6110s distributed within ORFs in M. tb 1458. Location (nt) Locus Gene or product DR 1070104–1071458 BTB1458_1064, BTB1458_1067 lprp CAGGC 1259595–1260949 BTB1458_1273 PPE16 AAGC 1542095–1543449 BTB1458_1535, BTB1458_1538 Desaturase-related protein GAGG 1716764–1718118 BTB1458_1711 mmpl12 – 2247431–2248785 BTB1458_2235, BTB1458_2238 Hypothetical protein TCAAGG 2621110–2622464 BTB1458_2606, BTB1458_2609 PPE38 – 3102221–3103575 BTB1458_3111 Hypothetical protein – 3354543–3355897 BTB1458_3335 Hypothetical protein GGC 3472672–3474026 BTB1458_3459 Hypothetical protein CGA 3781730–3783084 BTB1458_3751, BTB1458_3754 idsB AATC 3834127–3835481 BTB1458_1084 PPE59 – ",
    "table_content": "|| Location (nt) | Locus | Gene or product | DR ||\n|| 1070104–1071458 | BTB1458_1064, BTB1458_1067 | lprp | CAGGC ||\n|| 3781730–3783084 | BTB1458_3751, BTB1458_3754 | idsB | AATC ||\n|| 3834127–3835481 | BTB1458_1084 | PPE59 | – ||\n|| 1259595–1260949 | BTB1458_1273 | PPE16 | AAGC ||\n|| 1542095–1543449 | BTB1458_1535, BTB1458_1538 | Desaturase-related protein | GAGG ||\n|| 1716764–1718118 | BTB1458_1711 | mmpl12 | – ||\n|| 2247431–2248785 | BTB1458_2235, BTB1458_2238 | Hypothetical protein | TCAAGG ||\n|| 2621110–2622464 | BTB1458_2606, BTB1458_2609 | PPE38 | – ||\n|| 3102221–3103575 | BTB1458_3111 | Hypothetical protein | – ||\n|| 3354543–3355897 | BTB1458_3335 | Hypothetical protein | GGC ||\n|| 3472672–3474026 | BTB1458_3459 | Hypothetical protein | CGA ||",
    "claim": "Direct repeat sequences are present in seven out of the eleven IS6110 insertions, indicating that approximately 64% of these insertions are associated with direct repeats. This suggests a potential role for direct repeats in the insertion mechanism or stability of IS6110 elements.",
    "label": "support"
  },
  {
    "id": "training_118_3",
    "table_caption": "Table: Table 2 Lung mechanics, hemodynamics, gas exchange, acid-base status, and metabolic parameters Vehicle HAM1101 p value Hemoglobin content (mg·mL−1) Start 90 (87, 96) 98 (95, 105) 0.074 End 70 (66, 72) 69 (66, 74) 0.806 Heart rate (beats·min−1) Start 494 (485, 515) 430 (406, 480) 0.248 End 426 (406, 445) 391 (349,430) 0.290 Mean arterial pressure (mmHg) Start 69 (65, 71) 69 (66, 76) 0.382 End 64 (59, 69) 67 (66, 72) 0.441 Thoracopulmonary compliance (μL·cm H2O−1) Start 0.10 (0.09, 0.10) 0.10 (0.09, 0.11) 0.382 End 0.09 (0.08, 0.10) 0.10 (0.08, 0.11) 0.427 Arterial PO2 (mmHg) Start 314 (293, 330) 340 (321, 350) 0.254 End 309 (287, 326) 301 (287, 319) 0.838 Arterial PCO2 (mmHg) Start 31 (27, 33) 31 (29, 36) 0.879 End 34 (33, 36) 31 (28, 33) 0.072 Arterial pH Start 7.33 (7.30, 7.35) 7.36 (7.32, 7.38) 0.569 End 7.38 (7.31, 7.43) 7.43 (7.39, 7.46) 0.253 Arterial base excess (mmol·mL−1) Start −9.0 (−10.3, −7.7) −6.8 (−8.3, −6.2) 0.403 End −5.7 (−7.1, −1.7) −3.9 (−4.2, −3.3) 0.838 Arterial lactate (mmol·mL−1) Start n.d. n.d. n.d. End 2.0 (1.7, 2.2) 1.6 (1.5, 1.8) 0.025 Arterial glucose (mg·dL−1) Start 113 (110, 117) 115 (106, 123) 0.540 End 110 (96, 117) 111 (109, 115) 0.653 CO2 production rate (μL·g−1·min−1) Start 26 (24, 28) 24 (23, 25) 0.082 End 23 (21, 26) 23 (22, 25) 0.596 Glucose production rate (mg·g−1·h−1) Start 0.37 (0.35, 0.41) 0.34 (0.31, 0.36) 0.178 End 0.38 (0.35, 0.39) 0.33 (0.31, 0.39) 0.153 Glucose oxidation rate (% isotope infusion) Start 58 (55, 62) 55 (50, 59) 0.224 End 57 (54, 60) 62 (58, 67) 0.047 The data are for the vehicle-treated (n = 11) and HAM1101-treated (n = 9) animals at the start and the end of the 5-h observation period; n.d., not determined. All data are median (quartiles). ",
    "table_content": "|| blank | blank | Vehicle | HAM1101 |  p value ||\n|| Hemoglobin content (mg·mL −1 ) | Start | 90 (87, 96) | 98 (95, 105) | 0.074 ||\n|| Arterial PO 2 (mmHg) | End | 309 (287, 326) | 301 (287, 319) | 0.838 ||\n|| Arterial PCO 2 (mmHg) | Start | 31 (27, 33) | 31 (29, 36) | 0.879 ||\n|| Arterial PCO 2 (mmHg) | End | 34 (33, 36) | 31 (28, 33) | 0.072 ||\n|| Arterial pH | Start | 7.33 (7.30, 7.35) | 7.36 (7.32, 7.38) | 0.569 ||\n|| Arterial pH | End | 7.38 (7.31, 7.43) | 7.43 (7.39, 7.46) | 0.253 ||\n|| Arterial base excess (mmol·mL −1 ) | Start | −9.0 (−10.3, −7.7) | −6.8 (−8.3, −6.2) | 0.403 ||\n|| Arterial base excess (mmol·mL −1 ) | End | −5.7 (−7.1, −1.7) | −3.9 (−4.2, −3.3) | 0.838 ||\n|| Arterial lactate (mmol·mL −1 ) | Start | n.d. | n.d. | n.d. ||\n|| Arterial lactate (mmol·mL −1 ) | End | 2.0 (1.7, 2.2) | 1.6 (1.5, 1.8) | 0.025 ||\n|| Arterial glucose (mg·dL −1 ) | Start | 113 (110, 117) | 115 (106, 123) | 0.540 ||\n|| Hemoglobin content (mg·mL −1 ) | End | 70 (66, 72) | 69 (66, 74) | 0.806 ||\n|| Arterial glucose (mg·dL −1 ) | End | 110 (96, 117) | 111 (109, 115) | 0.653 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | Start | 26 (24, 28) | 24 (23, 25) | 0.082 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | End | 23 (21, 26) | 23 (22, 25) | 0.596 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | Start | 0.37 (0.35, 0.41) | 0.34 (0.31, 0.36) | 0.178 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | End | 0.38 (0.35, 0.39) | 0.33 (0.31, 0.39) | 0.153 ||\n|| Glucose oxidation rate (% isotope infusion) | Start | 58 (55, 62) | 55 (50, 59) | 0.224 ||\n|| Glucose oxidation rate (% isotope infusion) | End | 57 (54, 60) | 62 (58, 67) | 0.047 ||\n|| Heart rate (beats·min −1 ) | Start | 494 (485, 515) | 430 (406, 480) | 0.248 ||\n|| Heart rate (beats·min −1 ) | End | 426 (406, 445) | 391 (349,430) | 0.290 ||\n|| Mean arterial pressure (mmHg) | Start | 69 (65, 71) | 69 (66, 76) | 0.382 ||\n|| Mean arterial pressure (mmHg) | End | 64 (59, 69) | 67 (66, 72) | 0.441 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | Start | 0.10 (0.09, 0.10) | 0.10 (0.09, 0.11) | 0.382 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | End | 0.09 (0.08, 0.10) | 0.10 (0.08, 0.11) | 0.427 ||\n|| Arterial PO 2 (mmHg) | Start | 314 (293, 330) | 340 (321, 350) | 0.254 ||",
    "claim": "At the end of the observation period, arterial lactate levels in the vehicle group were 25% higher than those in the HAM1101 group, indicating a potential difference in metabolic response between the two groups.",
    "label": "support"
  },
  {
    "id": "training_315_4",
    "table_caption": "Table: Descriptive Analysis of the Population Studied. VARIABLE Total Women Men n % n % n % Deceased No 3440 39.1 693 48.63 2747 37.25 Yes 5360 60.9 732 51.37 4628 62.75 Route of Infection IVDU 6260 71.1 802 56.28 5458 74.01 Heterosexual 1174 13.3 468 32.84 706 9.57 Homosexual 763 8.7 0 0.00 763 10.35 Other 492 5.6 149 10.46 343 4.65 Province of residence at diagnosis Jaen 444 5.0 81 5.68 363 4.92 Huelva 511 5.8 81 5.68 430 5.83 Almeria 600 6.8 124 8.70 476 6.45 Cordoba 608 6.9 109 7.65 499 6.77 Granada 871 9.9 158 11.09 713 9.67 Cadiz 1541 17.5 254 17.82 1287 17.45 Seville 1713 19.5 215 15.09 1498 20.31 Malaga 2511 28.5 403 28.28 2108 28.58 Qualitative variables IVDU: Intravenous drug users ",
    "table_content": "|| VARIABLE | Total | Total | Women | Women | Men | Men ||\n|| VARIABLE | n | % | n | % | n | % ||\n|| Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis ||\n|| Jaen | 444 | 5.0 | 81 | 5.68 | 363 | 4.92 ||\n|| Huelva | 511 | 5.8 | 81 | 5.68 | 430 | 5.83 ||\n|| Almeria | 600 | 6.8 | 124 | 8.70 | 476 | 6.45 ||\n|| Cordoba | 608 | 6.9 | 109 | 7.65 | 499 | 6.77 ||\n|| Granada | 871 | 9.9 | 158 | 11.09 | 713 | 9.67 ||\n|| Cadiz | 1541 | 17.5 | 254 | 17.82 | 1287 | 17.45 ||\n|| Seville | 1713 | 19.5 | 215 | 15.09 | 1498 | 20.31 ||\n|| Malaga | 2511 | 28.5 | 403 | 28.28 | 2108 | 28.58 ||\n|| Deceased | Deceased | Deceased | Deceased | Deceased | Deceased | Deceased ||\n|| No | 3440 | 39.1 | 693 | 48.63 | 2747 | 37.25 ||\n|| Yes | 5360 | 60.9 | 732 | 51.37 | 4628 | 62.75 ||\n|| Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection ||\n|| IVDU | 6260 | 71.1 | 802 | 56.28 | 5458 | 74.01 ||\n|| Heterosexual | 1174 | 13.3 | 468 | 32.84 | 706 | 9.57 ||\n|| Homosexual | 763 | 8.7 | 0 | 0.00 | 763 | 10.35 ||\n|| Other | 492 | 5.6 | 149 | 10.46 | 343 | 4.65 ||",
    "claim": "The overall population has a higher percentage of deceased individuals compared to those who are not deceased. The deceased individuals constitute approximately 1.56 times the number of non-deceased individuals in the total population.",
    "label": "support"
  },
  {
    "id": "training_1379_2",
    "table_caption": "Table: Tableau 3: Mesure de l'IMC et du Tour de Taille de notre population en fonction de leurs activités physiques et temps de sédentarités Variables IMC (kg/m²) Tour de Taille (cm) Moyenne ± Ecart type p-value Moyenne ± Ecart type p-value Activités physiques dans le cadre scolaire Oui 21,98 ± 3,6 0,001 70,97 ± 7,2 0,001 Non 23,72 ± 4,6 75,0 ± 11,5 Activités sportivesinstitutionnalisées hors scolaire Oui 20,6 ± 3,4 0,00 69,55 ± 7,3 0,011 Non 22,19 ± 3,6 71,33 ± 8,6 Niveau d'AP (IPAQ) Elevé 21,69 ± 3,4 0,00 70,49 ± 7,93 0,00 Modéré 22,02 ± 3,5 70,90 ± 8,10 Faible 24,38 ± 4,7 77,41 ± 12,35 Temps de sédentarité ≤2 heures 21,29 ± 3,45 0,00 68,58 ± 7,7 0,00 Entre 2 et 4 heures 22,12 ± 3,47 71,37 ± 8,0 > 4heures 22,48 ± 4,18 72,43 ± 10,2 ",
    "table_content": "|| Variables | IMC (kg/m 2 ) | IMC (kg/m 2 ) | Tour de Taille (cm) | Tour de Taille (cm) ||\n|| Variables | Moyenne ± Ecart type | p-value | Moyenne ± Ecart type | p-value ||\n|| Modéré | 22,02 ± 3,5 | 0,00 | 70,90 ± 8,10 | 0,00 ||\n|| Faible | 24,38 ± 4,7 | 0,00 | 77,41 ± 12,35 | 0,00 ||\n||  Temps de sédentarité  |  Temps de sédentarité  |  Temps de sédentarité  |  Temps de sédentarité  |  Temps de sédentarité  ||\n|| ≤2 heures | 21,29 ± 3,45 | 0,00 | 68,58 ± 7,7 | 0,00 ||\n|| Entre 2 et 4 heures | 22,12 ± 3,47 | 0,00 | 71,37 ± 8,0 | 0,00 ||\n|| > 4heures | 22,48 ± 4,18 | 0,00 | 72,43 ± 10,2 | 0,00 ||\n||  Activités physiques dans le cadre scolaire  |  Activités physiques dans le cadre scolaire  |  Activités physiques dans le cadre scolaire  |  Activités physiques dans le cadre scolaire  |  Activités physiques dans le cadre scolaire  ||\n|| Oui | 21,98 ± 3,6 | 0,001 | 70,97 ± 7,2 | 0,001 ||\n|| Non | 23,72 ± 4,6 | 0,001 | 75,0 ± 11,5 | 0,001 ||\n||  Activités sportivesinstitutionnalisées hors scolaire  |  Activités sportivesinstitutionnalisées hors scolaire  |  Activités sportivesinstitutionnalisées hors scolaire  |  Activités sportivesinstitutionnalisées hors scolaire  |  Activités sportivesinstitutionnalisées hors scolaire  ||\n|| Oui | 20,6 ± 3,4 | 0,00 | 69,55 ± 7,3 | 0,011 ||\n|| Non | 22,19 ± 3,6 | 0,00 | 71,33 ± 8,6 | 0,011 ||\n||  Niveau d'AP (IPAQ)  |  Niveau d'AP (IPAQ)  |  Niveau d'AP (IPAQ)  |  Niveau d'AP (IPAQ)  |  Niveau d'AP (IPAQ)  ||\n|| Elevé | 21,69 ± 3,4 | 0,00 | 70,49 ± 7,93 | 0,00 ||",
    "claim": "Participation in institutionalized sports activities outside of school is associated with a 7.2% lower BMI and a 2.5% reduction in waist circumference compared to non-participants. This highlights the role of organized sports in maintaining healthier body metrics.",
    "label": "support"
  },
  {
    "id": "training_442_5",
    "table_caption": "Table: alcohol drinking habits (yes/no) to describe the study popu- items “True”, was as second tients main agree were = 5. this The HbA1c DSOC FBG visit. Table 1 Eligibility criteria used in the screening of the participants Inclusion Exclusion • Mentally sound men and women who are ≥ 18 years old. • Are literate with a fair command of English and/or Malay languages. • Have access to the Internet at home, work or public place. • Are willing to access the study website at least once every fortnight. • Have been confirmed of having HbA1c of ≥ 7.0%. • Are pregnant, lactating or intend to become pregnant during the study period. • Are diagnosed with Type 1 Diabetes Mellitus (T1DM) or Gestational Diabetes Mellitus (GDM) • Weigh more than 150% of the desired weight for height. • Have any pre-existing condition compromising the quality of life or ability to participate according to protocol. • Have severe complications (chronic heart disease, cerebrovascular disease, diagnosed HIV/AIDS, cancer, emphysema, chronic liver or kidney disease) that would affect the subjects’ ability to follow the tailored advice. • Are enrolled in other clinical studies. • Have DKAB score more than 50% at baseline. ",
    "table_content": "|| Inclusion | Exclusion ||\n|| • Mentally sound men and women who are ≥ 18 years old. • Are literate with a fair command of English and/or Malay languages. • Have access to the Internet at home, work or public place. • Are willing to access the study website at least once every fortnight. • Have been confirmed of having HbA1c of ≥ 7.0%. | • Are pregnant, lactating or intend to become pregnant during the study period. • Are diagnosed with Type 1 Diabetes Mellitus (T1DM) or Gestational Diabetes Mellitus (GDM) • Weigh more than 150% of the desired weight for height. • Have any pre-existing condition compromising the quality of life or ability to participate according to protocol. • Have severe complications (chronic heart disease, cerebrovascular disease, diagnosed HIV/AIDS, cancer, emphysema, chronic liver or kidney disease) that would affect the subjects’ ability to follow the tailored advice. • Are enrolled in other clinical studies. • Have DKAB score more than 50% at baseline. ||",
    "claim": "Excluding individuals who weigh more than 150% of their desired weight for height or have a DKAB score of more than 50% at baseline indicates that the study is controlling for factors that could influence the study's results, such as obesity or baseline knowledge and attitudes towards diabetes.",
    "label": "support"
  },
  {
    "id": "training_727_2",
    "table_caption": "Table: Table 1 Description and functional consequences of SNPs selected for validation from exome sequencing SNP Location (hg19) Gene Official full name Variant effect rs17844444 (G/A) chr5:140,532,165 PCDHB6 Protocadherin Beta 6 Missense variant rs17082236 (C/A) chr6:152,470,752 SYNE1 Spectrin repeat containing nuclear envelope protein 1 Missense variant rs10279499 (C/A) chr7:92,733,766 SAMD9 Sterile alpha motif domain containing 9 Missense varianta rs10488532 (C/T) chr7:92,764,489 SAMD9L Sterile alpha motif domain containing 9 like Missense variant rs2374639 (T/C) chr7:92,985,252 VPS50 VPS50, EARP/GARPII complex subunit Synonymous variant rs17552167 (C/T) chr7:148,529,922 EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit Intronic variant rs28469012 (A/T) chr10:125,622,263 CPXM2 Carboxypeptidase X, M14 family, member 2 Intronic variant rs10894768 (C/G) chr11:133,815,981 IGSF9B Immunoglobulin superfamily member 9B Synonymous variant rs60252902 (G/A) chr12:125,451,767 DHX37 DEAH-box helicase 37 Splice region variantb rs3742130 (G/A) chr13:99,907,341 GPR18 G protein-coupled receptor 18 Synonymous variant rs9919887 (A/G) chr14:95,911,008 SYNE3 Spectrin repeat containing nuclear envelope family member 3 Intronic variant rs2230434 (C/T) chr16:30,518,096 ITGAL Integrin subunit alpha L Synonymous variant rs2070896 (T/C) chr16:31,384,554 ITGAX Integrin subunit alpha X Intronic variant rs35299026 (G/A) chr19:49,318,380 HSD17B14 Hydroxysteroid 17-beta dehydrogenase 14 Missense varianta rs10423927 (A/G) chr19: 56,235,537 NLRP9 NLR family pyrin domain containing 9 Intronic variant rs2254562 (T/C) chr21:34,059,352 SYNJ1 Synaptojanin 1 Missense varianta aVariants reported as possible deleterious mutations (based on SIFT and PolyPhen-2 algorithms) bBy definition, a splice region variant is a sequence variant in which a change has occurred within the region of the splice site, either within 1–3 bases of the exon or 3–8 bases of the intron [30] ",
    "table_content": "|| SNP | Location (hg19) | Gene | Official full name | Variant effect ||\n|| rs17844444 (G/A) | chr5:140,532,165 |  PCDHB6  | Protocadherin Beta 6 | Missense variant ||\n|| rs3742130 (G/A) | chr13:99,907,341 |  GPR18  | G protein-coupled receptor 18 | Synonymous variant ||\n|| rs9919887 (A/G) | chr14:95,911,008 |  SYNE3  | Spectrin repeat containing nuclear envelope family member 3 | Intronic variant ||\n|| rs2230434 (C/T) | chr16:30,518,096 |  ITGAL  | Integrin subunit alpha L | Synonymous variant ||\n|| rs2070896 (T/C) | chr16:31,384,554 |  ITGAX  | Integrin subunit alpha X | Intronic variant ||\n|| rs35299026 (G/A) | chr19:49,318,380 |  HSD17B14  | Hydroxysteroid 17-beta dehydrogenase 14 | Missense variant a ||\n|| rs10423927 (A/G) | chr19: 56,235,537 |  NLRP9  | NLR family pyrin domain containing 9 | Intronic variant ||\n|| rs2254562 (T/C) | chr21:34,059,352 |  SYNJ1  | Synaptojanin 1 | Missense variant a ||\n|| rs17082236 (C/A) | chr6:152,470,752 |  SYNE1  | Spectrin repeat containing nuclear envelope protein 1 | Missense variant ||\n|| rs10279499 (C/A) | chr7:92,733,766 |  SAMD9  | Sterile alpha motif domain containing 9 | Missense variant a ||\n|| rs10488532 (C/T) | chr7:92,764,489 |  SAMD9L  | Sterile alpha motif domain containing 9 like | Missense variant ||\n|| rs2374639 (T/C) | chr7:92,985,252 |  VPS50  | VPS50, EARP/GARPII complex subunit | Synonymous variant ||\n|| rs17552167 (C/T) | chr7:148,529,922 |  EZH2  | Enhancer of zeste 2 polycomb repressive complex 2 subunit | Intronic variant ||\n|| rs28469012 (A/T) | chr10:125,622,263 |  CPXM2  | Carboxypeptidase X, M14 family, member 2 | Intronic variant ||\n|| rs10894768 (C/G) | chr11:133,815,981 |  IGSF9B  | Immunoglobulin superfamily member 9B | Synonymous variant ||\n|| rs60252902 (G/A) | chr12:125,451,767 |  DHX37  | DEAH-box helicase 37 | Splice region variant b ||",
    "claim": "Analyzing the chromosomal locations, it is evident that chromosome 7 harbors the highest number of SNPs in this dataset. By summing the SNPs located on each chromosome and comparing them, chromosome 7 contains approximately 27% of the total SNPs, suggesting a potential hotspot for genetic variation in this region.",
    "label": "support"
  },
  {
    "id": "training_166_1",
    "table_caption": "Table: in as at on Table 3: Predictors for mortality in a binary logistic regression model Measures Odds ratio 95% Confidence intervals P value Age 1.08 [1.02; 1.15] .006 ISS 1.12 [1.04; 1.21] .003 Hemoglobin .98 [.44; 2.2] .959 Prothrombin 1.02 [.98; 1.07] .305 Lactate 1.53 [.98; 2.38] .062 Artificial ventilation 4.13 [.02; 1051.39] .616 Transfusion .38 [.02; 7.75] .529 Intubation .201 [.01; 4.04] .295 GCS .86 [.67; 1.1] .226 Severe head injury 2.03 [.19; 22.14] .56 BAC .61 [.18; 2.04] .423 ISS = Injury Severity Score; GCS = Glascow Coma Scale; BAC = blood alcohol concentration in g/l ",
    "table_content": "|| Measures | Odds ratio | 95% Confidence intervals | P value ||\n|| Age | 1.08 | [1.02; 1.15] | . 006 ||\n|| Severe head injury | 2.03 | [.19; 22.14] | .56 ||\n|| BAC | .61 | [.18; 2.04] | .423 ||\n|| ISS | 1.12 | [1.04; 1.21] | . 003 ||\n|| Hemoglobin | .98 | [.44; 2.2] | .959 ||\n|| Prothrombin | 1.02 | [.98; 1.07] | .305 ||\n|| Lactate | 1.53 | [.98; 2.38] | .062 ||\n|| Artificial ventilation | 4.13 | [.02; 1051.39] | .616 ||\n|| Transfusion | .38 | [.02; 7.75] | .529 ||\n|| Intubation | .201 | [.01; 4.04] | .295 ||\n|| GCS | .86 | [.67; 1.1] | .226 ||",
    "claim": "The odds ratio for age is 1.08, indicating that for each additional year of age, the odds of mortality increase by 8%. Given the p-value of .006, this predictor is statistically significant. Over a decade, this results in a compounded increase in mortality odds of approximately 116%, highlighting the critical impact of age on mortality risk.",
    "label": "support"
  },
  {
    "id": "training_699_5",
    "table_caption": "Table: [16]. 3-year 48% was with 15%) every ing dules tion larger smaller efficacy studies Their model daily ment while 6% creased weekly timize be ing the In also vered, tered Table 3 Acute toxicity profile CCRT toxicity Arm A (cisplatin 100 mg/m2) Arm B (cisplatin 40 mg/m2) p N = 26 N = 24 Overall toxicity Grade 2 5 (19.2%) 2 (8.3%) 0.020* Grade 3 21 (80.8%) 16 (66.7%) Grade 4 0 (0%) 6 (25.0%) Non-hematologic Mucositis < Grade 3 16 (61.5%) 6 (25.0%) 0.012* ≥ Grade 3 10 (38.5%) 18 (75.0%) Pharyngitis < Grade 3 12 (46.2%) 11 (45.8%) 1.000 ≥ Grade 3 14 (53.8%) 13 (54.2%) Stomatitis < Grade 3 12 (46.2%) 11 (45.8%) 1.000 ≥ Grade 3 14 (53.8%) 13 (54.2%) Laryngeal edema < Grade 3 23 (88.5%) 23 (95.8%) 0.611 ≥ Grade 3 3 (11.5%) 1 (4.2%) Dermatitis < Grade 3 24 (92.3%) 22 (91.7%) 1.000 ≥ Grade 3 2 (7.7%) 2 (8.3%) Nausea/vomiting < Grade 3 23 (88.5%) 19 (79.2%) 0.456 ≥ Grade 3 3 (11.5%) 5 (20.8%) Hematologic Anemia < Grade 3 25 (96.2%) 23 (95.8%) 1.000 ≥ Grade 3 1 (3.8%) 1 (4.2%) Leukopenia < Grade 3 26 (100%) 21 (87.5%) 0.103 ≥ Grade 3 0 (0%) 3 (12.5%) Neutropenia < Grade 3 26 (100%) 23 (95.8%) 0.480 ≥ Grade 3 0 (0%) 1 (4.2%) Thrombocytopenia < Grade 3 26 (100%) 24 (100%) NS ≥ Grade 3 0 (0%) 0 (0%) Abbreviations: CCRT = concurrent chemoradiotherapy; NS = no statistics were computed. * Statistically significant, p < 0.05. ",
    "table_content": "|| CCRT toxicity | Arm A (cisplatin 100 mg/m 2 ) N = 26 | Arm B (cisplatin 40 mg/m 2 ) N = 24 | p ||\n|| CCRT toxicity | Arm A (cisplatin 100 mg/m 2 ) N = 26 | Arm B (cisplatin 40 mg/m 2 ) N = 24 | p ||\n|| Pharyngitis | Pharyngitis | Pharyngitis | Pharyngitis ||\n|| < Grade 3 | 12 (46.2%) | 11 (45.8%) | 1.000 ||\n|| ≥ Grade 3 | 14 (53.8%) | 13 (54.2%) | 1.000 ||\n|| Stomatitis | Stomatitis | Stomatitis | Stomatitis ||\n|| < Grade 3 | 12 (46.2%) | 11 (45.8%) | 1.000 ||\n|| ≥ Grade 3 | 14 (53.8%) | 13 (54.2%) | 1.000 ||\n|| Laryngeal edema | Laryngeal edema | Laryngeal edema | Laryngeal edema ||\n|| < Grade 3 | 23 (88.5%) | 23 (95.8%) | 0.611 ||\n|| ≥ Grade 3 | 3 (11.5%) | 1 (4.2%) | 0.611 ||\n|| Dermatitis | Dermatitis | Dermatitis | Dermatitis ||\n|| Overall toxicity | Overall toxicity | Overall toxicity | Overall toxicity ||\n|| < Grade 3 | 24 (92.3%) | 22 (91.7%) | 1.000 ||\n|| ≥ Grade 3 | 2 (7.7%) | 2 (8.3%) | 1.000 ||\n|| Nausea/vomiting | Nausea/vomiting | Nausea/vomiting | Nausea/vomiting ||\n|| < Grade 3 | 23 (88.5%) | 19 (79.2%) | 0.456 ||\n|| ≥ Grade 3 | 3 (11.5%) | 5 (20.8%) | 0.456 ||\n|| Hematologic | Hematologic | Hematologic | Hematologic ||\n|| Anemia | Anemia | Anemia | Anemia ||\n|| < Grade 3 | 25 (96.2%) | 23 (95.8%) | 1.000 ||\n|| ≥ Grade 3 | 1 (3.8%) | 1 (4.2%) | 1.000 ||\n|| Leukopenia | Leukopenia | Leukopenia | Leukopenia ||\n|| Grade 2 | 5 (19.2%) | 2 (8.3%) | 0.020* ||\n|| < Grade 3 | 26 (100%) | 21 (87.5%) | 0.103 ||\n|| ≥ Grade 3 | 0 (0%) | 3 (12.5%) | 0.103 ||\n|| Neutropenia | Neutropenia | Neutropenia | Neutropenia ||\n|| < Grade 3 | 26 (100%) | 23 (95.8%) | 0.480 ||\n|| ≥ Grade 3 | 0 (0%) | 1 (4.2%) | 0.480 ||\n|| Thrombocytopenia | Thrombocytopenia | Thrombocytopenia | Thrombocytopenia ||\n|| < Grade 3 | 26 (100%) | 24 (100%) | NS ||\n|| ≥ Grade 3 | 0 (0%) | 0 (0%) | NS ||\n|| Grade 3 | 21 (80.8%) | 16 (66.7%) | 0.020* ||\n|| Grade 4 | 0 (0%) | 6 (25.0%) | 0.020* ||\n|| Non-hematologic | Non-hematologic | Non-hematologic | Non-hematologic ||\n|| Mucositis | Mucositis | Mucositis | Mucositis ||\n|| < Grade 3 | 16 (61.5%) | 6 (25.0%) | 0.012* ||\n|| ≥ Grade 3 | 10 (38.5%) | 18 (75.0%) | 0.012* ||",
    "claim": "Arm B exhibits a 25% incidence of Grade 4 toxicity, while Arm A shows none. This stark contrast suggests that the lower dosage in Arm B may lead to more severe toxic reactions, as supported by the statistical significance (p = 0.020).",
    "label": "support"
  },
  {
    "id": "training_1089_6",
    "table_caption": "Table: Data collection Bruker SMART APEX diffractometer 2358 independent reflections Radiation source: fine-focus sealed tube 1339 reflections with I > 2σ(I) graphite Rint = 0.047 φ and ω scans θmax = 25.5°, θmin = 2.5° Absorption correction: multi-scan (SADABS; Bruker, 2003) h = −17→20 Tmin = 0.338, Tmax = 0.338 k = −6→6 6208 measured reflections l = −35→30 Refinement ",
    "table_content": "|| Bruker SMART APEX diffractometer | 2358 independent reflections ||\n|| Radiation source: fine-focus sealed tube | 1339 reflections with I > 2σ( I ) ||\n|| graphite | R int = 0.047 ||\n|| φ and ω scans | θ max = 25.5°, θ min = 2.5° ||\n|| Absorption correction: multi-scan ( SADABS ; Bruker, 2003) | h = −17→20 ||\n|| T min = 0.338, T max = 0.338 | k = −6→6 ||\n|| 6208 measured reflections | l = −35→30 ||",
    "claim": "The Rint value of 0.047 reflects a high level of internal consistency and reliability in the dataset, indicating that the data is well-suited for accurate structural refinement.",
    "label": "support"
  },
  {
    "id": "training_453_5",
    "table_caption": "Table: Table 4 Intervention components Intervention items Description Inclusion in Suraj model Inclusion in CMW model Control 1 Training on reproductive health/family planning and post training evaluation Medical: reproductive health and family planning, counselling, quality of services, and IUD insertion and removal; Business: basic budgeting skills, record keeping, stock management, branding (excluded for CMW), marketing, and the voucher management (excluded for CMW). The training was followed by post training evaluation conducted by an external consultant (a senior medical doctor). Yes Yes No 2 Female community mobilizer (FCM) An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale. Yes Yes No Each service provider was complemented with one FCM 3 Male community mobilizers (MCM) An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings Yes Yes No There is one MCM per 10 service providers in a district 4 Voucher for long- term contraceptive method (Intra- uterine device) A voucher was worth PK Rs 200 (US$2.27) and only for IUD (insertion, follow-up and removal). A voucher may be redeemed at Suraj clinic; later the reimbursement was sent to the provider against her claim. Free voucher provision was based on a wealth based poverty assessment tool which was managed by the Field Community Mobilizers in the field before distributing vouchers. The said tool ask questions about wealth status including household structure, number of household members, number of meals, number of dependent members, sanitation, access to reproductive health services, daily household income, source of fuel used for cooking, source of drinking water. Clients received a voucher if their score fell between the minimum score of 9 and 20 (inclusive) on a scale of 27. Yes No No 5 Branding/Marketing Providers were branded ‘Suraj’ clinics while marketing was done through FCMs, posters, wall paintings, leaflets, etc. The ‘Suraj’ logo was displayed prominently in Urdu outside all clinics. Yes No No ",
    "table_content": "|| blank | Intervention items | Description | Inclusion in Suraj model | Inclusion in CMW model | Control ||\n|| 1 | Training on reproductive health/family planning and post training evaluation | Medical: reproductive health and family planning, counselling, quality of services, and IUD insertion and removal; Business: basic budgeting skills, record keeping, stock management, branding (excluded for CMW), marketing, and the voucher management (excluded for CMW). The training was followed by post training evaluation conducted by an external consultant (a senior medical doctor). | Yes | Yes | No ||\n|| 2 | Female community mobilizer (FCM) | An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale. | Yes | Yes | No ||\n|| 2 |  Each service provider was complemented with one FCM  | An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale. | Yes | Yes | No ||\n|| 3 | Male community mobilizers (MCM) | An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings | Yes | Yes | No ||\n|| 3 |  There is one MCM per 10 service providers in a district  | An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings | Yes | Yes | No ||\n|| 4 | Voucher for long- term contraceptive method (Intra- uterine device) | A voucher was worth PK Rs 200 (US$2.27) and only for IUD (insertion, follow-up and removal). A voucher may be redeemed at Suraj clinic; later the reimbursement was sent to the provider against her claim. Free voucher provision was based on a wealth based poverty assessment tool which was managed by the Field Community Mobilizers in the field before distributing vouchers. The said tool ask questions about wealth status including household structure, number of household members, number of meals, number of dependent members, sanitation, access to reproductive health services, daily household income, source of fuel used for cooking, source of drinking water. Clients received a voucher if their score fell between the minimum score of 9 and 20 (inclusive) on a scale of 27. | Yes | No | No ||\n|| 5 | Branding/Marketing | Providers were branded ‘Suraj’ clinics while marketing was done through FCMs, posters, wall paintings, leaflets, etc. The ‘Suraj’ logo was displayed prominently in Urdu outside all clinics. | Yes | No | No ||",
    "claim": "The inclusion of post-training evaluations conducted by an external consultant in both the Suraj and CMW models indicates a commitment to maintaining high-quality service delivery. This evaluation process ensures that service providers are well-equipped with the necessary skills and knowledge, which is crucial for the successful implementation of reproductive health and family planning interventions.",
    "label": "support"
  },
  {
    "id": "training_1030_5",
    "table_caption": "Table: atic In fective [21, would were audit site did would Table 6 Reasons rehabilitation was not recommended for patients in the post-intervention audit Reason rehabilitation not recommended by hospital clinician (n = 38) Multifaceted intervention (n = 27) Education intervention (n = 11) Assessment for Rehabilitation Tool criteria (n = 21) Fully recovered 15 5 Patient or family refused 1 0 Other reasons documented (n = 17) For residential care placement 1 2 Poor motivation/ participation 1 2 Unwell, medically unstable 1 1 Not following instructions 2 0 Other, or reason not given 6 1 ",
    "table_content": "|| Reason rehabilitation not recommended by hospital clinician ( n = 38) | Multifaceted intervention ( n = 27) | Education intervention ( n = 11) ||\n|| Assessment for Rehabilitation Tool criteria ( n = 21) | Assessment for Rehabilitation Tool criteria ( n = 21) | Assessment for Rehabilitation Tool criteria ( n = 21) ||\n|| Fully recovered | 15 | 5 ||\n|| Patient or family refused | 1 | 0 ||\n|| Other reasons documented ( n = 17) | Other reasons documented ( n = 17) | Other reasons documented ( n = 17) ||\n|| For residential care placement | 1 | 2 ||\n|| Poor motivation/participation | 1 | 2 ||\n|| Unwell, medically unstable | 1 | 1 ||\n|| Not following instructions | 2 | 0 ||\n|| Other, or reason not given | 6 | 1 ||",
    "claim": "The incidence of rehabilitation not being recommended due to patient or family refusal is negligible, with only one case documented, suggesting minimal influence of this factor on the overall decision-making process.",
    "label": "support"
  },
  {
    "id": "training_292_3",
    "table_caption": "Table: Table 3 Adverse events of any cause experienced by ≥10 % patients over the study (N = 19) Adverse event, n (%) All grades Grade 1 Grade 2 Grade 3 Aphthous stomatitis 11 (57.9) 11 (57.9) 0 (0.0) 0 (0.0) Hypercholesterolaemia 11 (57.9) 5 (26.3) 6 (31.6) 0 (0.0) Hypertriglyceridaemia 8 (42.1) 3 (15.8) 3 (15.8) 2 (10.5) Urinary tract infection 8 (42.1) 2 (10.5) 6 (31.6) 0 (0.0) Mucosal inflammation 7 (36.8) 5 (26.3) 1 (5.3) 1 (5.3) Hypertension 6 (31.6) 3 (15.8) 2 (10.5) 1 (5.3) Dermatitis acneiform 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Insomnia 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Catarrh 4 (21.1) 4 (21.1) 0 (0.0) 0 (0.0) Diarrhoea 4 (21.1) 3 (15.8) 1 (5.3) 0 (0.0) Amenorrhoea 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Asthenia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Headache 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Dysgeusia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Pharyngitis 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Nasopharyngitis 3 (15.8) 2 (10.5) 1 (5.3) 0 (0.0) Cough 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Menstrual disorder 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Conjunctivitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dermatitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Back pain 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Abdominal pain upper 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Epistaxis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Erythema 2 (10.5) 1 (5.3) 1 (5.3) 0 (0.0) Rash 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Oral herpes 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dizziness 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Menorrhagia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Myalgia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Pyrexia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Vomiting 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Gamma-glutamyltransferase increased 2 (10.5) 0 (0.0) 2 (10.5) 0 (0.0) Transaminases increased 2 (10.5) 0 (0.0) 1 (5.3) 1 (5.3) All adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) preferred term and graded as per the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (version 4.03) ",
    "table_content": "|| Adverse event, n (%) | All grades | Grade 1 | Grade 2 | Grade 3 ||\n|| Aphthous stomatitis | 11 (57.9) | 11 (57.9) | 0 (0.0) | 0 (0.0) ||\n|| Diarrhoea | 4 (21.1) | 3 (15.8) | 1 (5.3) | 0 (0.0) ||\n|| Amenorrhoea | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Asthenia | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Headache | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Dysgeusia | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Pharyngitis | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Nasopharyngitis | 3 (15.8) | 2 (10.5) | 1 (5.3) | 0 (0.0) ||\n|| Cough | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Menstrual disorder | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Conjunctivitis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Hypercholesterolaemia | 11 (57.9) | 5 (26.3) | 6 (31.6) | 0 (0.0) ||\n|| Dermatitis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Back pain | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Abdominal pain upper | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Epistaxis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Erythema | 2 (10.5) | 1 (5.3) | 1 (5.3) | 0 (0.0) ||\n|| Rash | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Oral herpes | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Dizziness | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Menorrhagia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Myalgia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Hypertriglyceridaemia | 8 (42.1) | 3 (15.8) | 3 (15.8) | 2 (10.5) ||\n|| Pyrexia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Vomiting | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Gamma-glutamyltransferase increased | 2 (10.5) | 0 (0.0) | 2 (10.5) | 0 (0.0) ||\n|| Transaminases increased | 2 (10.5) | 0 (0.0) | 1 (5.3) | 1 (5.3) ||\n|| Urinary tract infection | 8 (42.1) | 2 (10.5) | 6 (31.6) | 0 (0.0) ||\n|| Mucosal inflammation | 7 (36.8) | 5 (26.3) | 1 (5.3) | 1 (5.3) ||\n|| Hypertension | 6 (31.6) | 3 (15.8) | 2 (10.5) | 1 (5.3) ||\n|| Dermatitis acneiform | 5 (26.3) | 5 (26.3) | 0 (0.0) | 0 (0.0) ||\n|| Insomnia | 5 (26.3) | 5 (26.3) | 0 (0.0) | 0 (0.0) ||\n|| Catarrh | 4 (21.1) | 4 (21.1) | 0 (0.0) | 0 (0.0) ||",
    "claim": "Hypertriglyceridaemia and urinary tract infection both affect 42.1% of patients, but hypertriglyceridaemia has a higher proportion of Grade 3 events, indicating a more severe impact on patients.",
    "label": "support"
  },
  {
    "id": "training_992_4",
    "table_caption": "Table: TSPY1 is normally restricted to the testis where it plays a major mechanism to transcriptionally silence its expres- Table 2: Genes re-expressed by 5-aza-dC and TSA, but not by either drug alone Gene Symbol Unigene Affymetrix ID Fold Change p-value Control Signal 5-aza-dC + TSA Signal 5-aza-dC Signal Description CHGA Hs.150793 204697_s_at 3.03 0.012 214 648 214 Chromogranin A (parathyroid secretory protein 1) TKTL1 Hs.102866 214183_s_at 57.92 0.00004 49 2809 1276 Transketolase-like 1 BG1 Hs.250616 206465_at 6.16 0.00007 172 1057 630 Lipidosin - Hs.399852 1559213_at 43.98 0.0003 19 842 193 IMAGE:5394246, mRNA ",
    "table_content": "|| Gene Symbol | Unigene | Affymetrix ID | Fold Change | p-value | Control Signal | 5-aza-dC + TSA Signal | 5-aza-dC Signal | Description ||\n|| CHGA | Hs.150793 | 204697_s_at | 3.03 | 0.012 | 214 | 648 | 214 | Chromogranin A (parathyroid secretory protein 1) ||\n|| TKTL1 | Hs.102866 | 214183_s_at | 57.92 | 0.00004 | 49 | 2809 | 1276 | Transketolase-like 1 ||\n|| BG1 | Hs.250616 | 206465_at | 6.16 | 0.00007 | 172 | 1057 | 630 | Lipidosin ||\n|| blank | Hs.399852 | 1559213_at | 43.98 | 0.0003 | 19 | 842 | 193 | IMAGE:5394246, mRNA ||",
    "claim": "For the gene BG1, the expression level in the 5-aza-dC + TSA condition is approximately 6.15 times higher than the control, while the expression level in the 5-aza-dC condition alone is approximately 3.66 times higher than the control. This indicates that the combination treatment enhances expression more than the single treatment.",
    "label": "support"
  },
  {
    "id": "training_909_5",
    "table_caption": "Table: on the the for for 1). of 2 studies (right). Studies within all specialities CAM-related studies Country n = % Country n = % USA 315 36.0 USA 114 24.9 United Kingdom 117 13.4 China 113 24.7 Canada 46 5.3 United Kingdom 59 12.9 Australia 32 3.7 Germany 17 3.7 Sweden 32 3.7 Italy 13 2.8 Germany 31 3.5 Denmark 11 2.4 Italy 30 3.4 Netherlands 10 2.2 Netherlands 25 2.9 Australia 10 2.2 France 24 2.7 Canada 10 2.2 Denmark 21 2.4 Japan 10 2.2 Japan 19 2.2 India 9 2.0 China 17 1.9 Sweden 8 1.7 Finland 17 1.9 Finland 6 1.3 India 14 1.6 France 6 1.3 Spain 12 1.4 Israel 5 1.1 Israel 10 1.1 Hungary 5 1.1 Switzerland 8 0.9 Norway 4 0.9 Belgium 7 0.8 Taiwan 4 0.9 Ireland 7 0.8 Poland 4 0.9 Austria 6 0.7 Switzerland 3 0.7 Norway 6 0.7 Romania 3 0.7 South Africa 6 0.7 Spain 3 0.7 Greece 5 0.6 South Africa 3 0.7 Mexico 5 0.6 Nigeria 3 0.7 Turkey 5 0.6 Brazil 3 0.7 Brazil 3 0.3 New Zealand 2 0.4 Czech Republic 3 0.3 Austria 2 0.4 Hungary 3 0.3 Belgium 2 0.4 New Zealand 3 0.3 Russia 2 0.4 Taiwan 3 0.3 Chile 2 0.4 doi:10.1371/journal.pone.0018798.t001 ",
    "table_content": "|| Studies within all specialities | Studies within all specialities | Studies within all specialities | CAM-related studies | CAM-related studies | CAM-related studies ||\n|| Country | n = | % | Country | n = | % ||\n|| France | 24 | 2.7 | Canada | 10 | 2.2 ||\n|| Denmark | 21 | 2.4 | Japan | 10 | 2.2 ||\n|| Japan | 19 | 2.2 | India | 9 | 2.0 ||\n|| China | 17 | 1.9 | Sweden | 8 | 1.7 ||\n|| Finland | 17 | 1.9 | Finland | 6 | 1.3 ||\n|| India | 14 | 1.6 | France | 6 | 1.3 ||\n|| Spain | 12 | 1.4 | Israel | 5 | 1.1 ||\n|| Israel | 10 | 1.1 | Hungary | 5 | 1.1 ||\n|| Switzerland | 8 | 0.9 | Norway | 4 | 0.9 ||\n|| Belgium | 7 | 0.8 | Taiwan | 4 | 0.9 ||\n|| USA | 315 | 36.0 | USA | 114 | 24.9 ||\n|| Ireland | 7 | 0.8 | Poland | 4 | 0.9 ||\n|| Austria | 6 | 0.7 | Switzerland | 3 | 0.7 ||\n|| Norway | 6 | 0.7 | Romania | 3 | 0.7 ||\n|| South Africa | 6 | 0.7 | Spain | 3 | 0.7 ||\n|| Greece | 5 | 0.6 | South Africa | 3 | 0.7 ||\n|| Mexico | 5 | 0.6 | Nigeria | 3 | 0.7 ||\n|| Turkey | 5 | 0.6 | Brazil | 3 | 0.7 ||\n|| Brazil | 3 | 0.3 | New Zealand | 2 | 0.4 ||\n|| Czech Republic | 3 | 0.3 | Austria | 2 | 0.4 ||\n|| Hungary | 3 | 0.3 | Belgium | 2 | 0.4 ||\n|| United Kingdom | 117 | 13.4 | China | 113 | 24.7 ||\n|| New Zealand | 3 | 0.3 | Russia | 2 | 0.4 ||\n|| Taiwan | 3 | 0.3 | Chile | 2 | 0.4 ||\n|| Canada | 46 | 5.3 | United Kingdom | 59 | 12.9 ||\n|| Australia | 32 | 3.7 | Germany | 17 | 3.7 ||\n|| Sweden | 32 | 3.7 | Italy | 13 | 2.8 ||\n|| Germany | 31 | 3.5 | Denmark | 11 | 2.4 ||\n|| Italy | 30 | 3.4 | Netherlands | 10 | 2.2 ||\n|| Netherlands | 25 | 2.9 | Australia | 10 | 2.2 ||",
    "claim": "The ranking of countries changes notably between the two categories, with China rising significantly in the CAM-related studies category, surpassing the United Kingdom, which indicates a strategic emphasis on CAM research in China.",
    "label": "support"
  },
  {
    "id": "training_212_4",
    "table_caption": "Table: Table 3 Composition of the ALA-rich oil (876 g/mol), olive oil (875 g/mol) and butter (fat-part 734 g/mol) meals1 Amount Energy (KJ) Fat (g) Protein (g) Carbohydrate (g) ALA-rich oil 35 g 1277 352 - - Olive oil 35 g 1277 352 0.2 0.2 Butter 42 g 1265 353 0.3 0.2 Milk for cooking, 3% fat 0.225 L 595 7.1 8.1 11.4 Semolina (wheat kernel) 20 g 291 0.3 2 14.2 Rye bread, one slice 38 g 408 1 2.9 17.8 Smoked ham, 3% fat or 9 g 44 0.3 2 0 soft Cheese4, 3% fat 9 g 43 0.3 1.6 0.3 Blackberry jam 32 g 262 0 0.1 14.8 Milk, 1.5% fat 0.2 L 410 3.1 7.2 10.3 Total 3290 47 23 69 1 Data from proximate analysis of ingredients. Analysed with Dietist XP, version 3.1, with the Swedish National Food Administration database (2008). 2 Equivalent to 0.04 mol. 3 Equivalent to 0.05 mol. ",
    "table_content": "|| blank | Amount | Energy (KJ) | Fat (g) | Protein (g) | Carbohydrate (g) ||\n|| ALA-rich oil | 35 g | 1277 | 35 2 | blank | blank ||\n|| Milk, 1.5% fat | 0.2 L | 410 | 3.1 | 7.2 | 10.3 ||\n|| Total | blank | 3290 | 47 | 23 | 69 ||\n|| Olive oil | 35 g | 1277 | 35 2 | 0.2 | 0.2 ||\n|| Butter | 42 g | 1265 | 35 3 | 0.3 | 0.2 ||\n|| Milk for cooking, 3% fat | 0.225 L | 595 | 7.1 | 8.1 | 11.4 ||\n|| Semolina (wheat kernel) | 20 g | 291 | 0.3 | 2 | 14.2 ||\n|| Rye bread, one slice | 38 g | 408 | 1 | 2.9 | 17.8 ||\n|| Smoked ham, 3% fat or | 9 g | 44 | 0.3 | 2 | 0 ||\n|| soft Cheese 4 , 3% fat | 9 g | 43 | 0.3 | 1.6 | 0.3 ||\n|| Blackberry jam | 32 g | 262 | 0 | 0.1 | 14.8 ||",
    "claim": "The carbohydrate content from semolina, rye bread, and blackberry jam collectively makes up about 65% of the total carbohydrate content in the meal. This indicates that these ingredients are the main contributors to the carbohydrate intake.",
    "label": "support"
  },
  {
    "id": "training_1036_2",
    "table_caption": "Table: Distribution of PM2.5 concentrations in the 16 districts of Beijing, 2013–2014. District Regional category Mean(SD) μg/m3 Median (IQR) μg/m3 Range μg/ m3 Non-attainment days and rates (%) for grade I Non-attainment days and rates (%) for grade II Yanqing North 67.95(61.06) 52.00(67.00) 5.0–459.0 216 (63.7) 108 (31.9) Changping North 73.30(66.36) 55.00(72.00) 5.0–432.0 224 (66.1) 130 (38.3) Miyun North 67.79(61.74) 51.00(68.00) 4.0–481.0 205 (60.5) 117 (34.5) Huairou North 77.80(65.80) 59.00(72.00) 5.0–402.0 226 (69.1) 136 (41.6) Pinggu North 79.23(66.25) 61.00(74.50) 4.0–475.0 242 (71.4) 150 (44.2) Shunyi North 83.55(70.27) 65.00(80.00) 5.0–509.0 241 (71.5) 149 (44.2) Haidian Center 85.15(70.47) 71.00(77.00) 4.0–430.0 248 (73.2) 161 (47.5) Shijingshan Center 87.99(69.32) 72.00(73.00) 6.0–408.0 254 (76.3) 158 (47.4) Xicheng Center 88.26(71.60) 70.50(78.00) 6.0–449.0 253 (74.6) 161 (47.5) Chaoyang Center 89.24(71.33) 71.50(81.00) 5.0–464.0 262 (77.3) 165 (48.7) Dongcheng Center 91.56(72.97) 75.00(81.00) 3.0–457.0 266 (78.5) 168 (49.6) Fengtai Center 96.50(76.59) 79.00(82.00) 6.0–511.0 268 (79.3) 184 (54.4) Mentougou South 77.41(64.88) 65.50(66.75) 5.0–403.0 211 (70.3) 124 (41.3) Fangshan South 106.97 (79.33) 89.00(91.00) 6.0–492.0 285 (84.3) 194 (57.4) Daxing South 106.20 (83.77) 86.00(93.50) 7.0–493.0 280 (82.6) 192 (56.6) Tongzhou South 107.63 (85.87) 88.00(92.00) 4.0–537.0 287 (84.9) 193 (57.1) SD: standard deviation; IQR: inter-quartile range. ",
    "table_content": "|| District | Regional category | Mean(SD) μg/m 3  | Median (IQR) μg/m 3  | Range μg/m 3  | Non-attainment days and rates (%) for grade I | Non-attainment days and rates (%) for grade II ||\n||  Yanqing  |  North  |  67.95(61.06)  |  52.00(67.00)  |  5.0–459.0  |  216 (63.7)  |  108 (31.9)  ||\n||  Chaoyang  |  Center  |  89.24(71.33)  |  71.50(81.00)  |  5.0–464.0  |  262 (77.3)  |  165 (48.7)  ||\n||  Dongcheng  |  Center  |  91.56(72.97)  |  75.00(81.00)  |  3.0–457.0  |  266 (78.5)  |  168 (49.6)  ||\n||  Fengtai  |  Center  |  96.50(76.59)  |  79.00(82.00)  |  6.0–511.0  |  268 (79.3)  |  184 (54.4)  ||\n||  Mentougou  |  South  |  77.41(64.88)  |  65.50(66.75)  |  5.0–403.0  |  211 (70.3)  |  124 (41.3)  ||\n||  Fangshan  |  South  |  106.97(79.33)  |  89.00(91.00)  |  6.0–492.0  |  285 (84.3)  |  194 (57.4)  ||\n||  Daxing  |  South  |  106.20(83.77)  |  86.00(93.50)  |  7.0–493.0  |  280 (82.6)  |  192 (56.6)  ||\n||  Tongzhou  |  South  |  107.63(85.87)  |  88.00(92.00)  |  4.0–537.0  |  287 (84.9)  |  193 (57.1)  ||\n||  Changping  |  North  |  73.30(66.36)  |  55.00(72.00)  |  5.0–432.0  |  224 (66.1)  |  130 (38.3)  ||\n||  Miyun  |  North  |  67.79(61.74)  |  51.00(68.00)  |  4.0–481.0  |  205 (60.5)  |  117 (34.5)  ||\n||  Huairou  |  North  |  77.80(65.80)  |  59.00(72.00)  |  5.0–402.0  |  226 (69.1)  |  136 (41.6)  ||\n||  Pinggu  |  North  |  79.23(66.25)  |  61.00(74.50)  |  4.0–475.0  |  242 (71.4)  |  150 (44.2)  ||\n||  Shunyi  |  North  |  83.55(70.27)  |  65.00(80.00)  |  5.0–509.0  |  241 (71.5)  |  149 (44.2)  ||\n||  Haidian  |  Center  |  85.15(70.47)  |  71.00(77.00)  |  4.0–430.0  |  248 (73.2)  |  161 (47.5)  ||\n||  Shijingshan  |  Center  |  87.99(69.32)  |  72.00(73.00)  |  6.0–408.0  |  254 (76.3)  |  158 (47.4)  ||\n||  Xicheng  |  Center  |  88.26(71.60)  |  70.50(78.00)  |  6.0–449.0  |  253 (74.6)  |  161 (47.5)  ||",
    "claim": "The median PM2.5 concentration in the South region shows a higher interquartile range compared to the North, suggesting greater variability in daily pollution levels. This is inferred by calculating the average interquartile range for each region and comparing them.",
    "label": "support"
  },
  {
    "id": "training_1433_2",
    "table_caption": "Table: Anonymous Internet Sample. Step Variable Entered Response/Coding b R R2 change R2 total 1 Age Years 20.181 0.260 0.068 0.068 2 Severe memory problems ‘Yes’ 20.132 0.307 0.026 0.094 3 Sex Male 20.158 0.335 0.018 0.112 4 Education Years 0.117 0.358 0.016 0.128 5 Memory delay interval Minutes 20.121 0.376 0.013 0.141 6 Stroke ‘Yes’ 20.050 0.379 0.003 0.144 7 Parkinson’s disease ‘Yes’ 20.033 0.381 0.001 0.145 doi:10.1371/journal.pone.0057476.t002 ",
    "table_content": "|| Step | Variable Entered | Response/Coding | β | R | R 2 change | R 2 total ||\n|| 1 | Age | Years | −0.181 | 0.260 | 0.068 | 0.068 ||\n|| 2 | Severe memory problems | ‘Yes’ | −0.132 | 0.307 | 0.026 | 0.094 ||\n|| 3 | Sex | Male | −0.158 | 0.335 | 0.018 | 0.112 ||\n|| 4 | Education | Years | 0.117 | 0.358 | 0.016 | 0.128 ||\n|| 5 | Memory delay interval | Minutes | −0.121 | 0.376 | 0.013 | 0.141 ||\n|| 6 | Stroke | ‘Yes’ | −0.050 | 0.379 | 0.003 | 0.144 ||\n|| 7 | Parkinson's disease | ‘Yes’ | −0.033 | 0.381 | 0.001 | 0.145 ||",
    "claim": "The addition of severe memory problems as a variable results in a minimal increase in the explained variance, as reflected by the R² change. This suggests that severe memory problems have a limited impact on the dependent variable, contributing a smaller portion of the variance compared to what is explained by age alone.",
    "label": "support"
  },
  {
    "id": "training_537_1",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A C10—H10···O2i 0.93 2.43 3.271 (2) 150 N1—H1···N5ii 0.862 (17) 2.250 (17) 3.0755 (19) 160.3 (15) Symmetry codes: (i) x−1/2, −y+1/2, z−1/2; (ii) −x+1/2, y−1/2, −z+3/2. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| C10—H10···O2 i | 0.93 | 2.43 | 3.271 (2) | 150 ||\n|| N1—H1···N5 ii | 0.862 (17) | 2.250 (17) | 3.0755 (19) | 160.3 (15) ||",
    "claim": "The D—H bond length for C10—H10···O2 is longer than that for N1—H1···N5. This suggests a weaker hydrogen bond in C10—H10···O2, as shorter D—H bonds typically correlate with stronger hydrogen bonding interactions.",
    "label": "support"
  },
  {
    "id": "training_541_2",
    "table_caption": "Table: Table 1 Baseline patient demographics and disease characteristics CT-P13 3 mg/kg (n = 302) RP 3 mg/kg (n = 304) Total (N = 606) Age, median, years (range) 50 (18–75) 50 (21–74) 50 (18–75) Sex, n (%) Female 245 (81.1) 256 (84.2) 501 (82.7) Male 57 (18.9) 48 (15.8) 105 (17.3) Ethnicity, n (%) Asian 34 (11.3) 37 (12.2) 71 (11.7) Black 2 (0.7) 1 (0.3) 3 (0.5) White 220 (72.8) 222 (73.0) 442 (72.9) Other 46 (15.2) 44 (14.5) 90 (14.9) Height, cm, median (range) 162.3 (144.0–186.0) 162.0 (124.0–190.0) 162.0 (124.0–190.0) Weight, kg, median (range) 69.0 (36.5–134.0) 68.0 (36.0–136.0) 68.6 (36.0–136.0) BMI, kg/m2, median (range) 26.3 (13.9–49.8) 25.4 (15.0–53.1) 25.9 (13.9–53.1) Anti-CCP antibody-positive, n (%) 228 (75.5) 233 (76.6) 461 (76.1) IgA RF-positive, n (%) 131 (43.4) 134 (44.1) 265 (43.7) IgM RF-positive, n (%) 225 (74.5) 220 (72.4) 445 (73.4) IgG RF-positive, n (%) 173 (57.3) 171 (56.3) 344 (56.8) Joint count TJC, 68 joints 25.6 ± 13.9 24.0 ± 12.9 24.8 ± 13.4 SJC, 66 joints 16.2 ± 8.7 15.2 ± 8.3 15.7 ± 8.5 TJC, 28 joints 15.9 ± 6.4 15.1 ± 6.1 15.5 ± 6.2 SJC, 28 joints 12.0 ± 4.9 11.2 ± 4.7 11.6 ± 4.8 Duration of prior MTX therapy, weeks 97.7 ± 141.2 89.4 ± 96.5 93.6 ± 120.8 MTX dose, mg 15.6 ± 3.1 15.6 ± 3.2 15.6 ± 3.1 CDAI 40.9 ± 11.5 39.3 ± 11.1 40.1 ± 11.3 SDAI 42.8 ± 11.9 41.2 ± 11.7 42.0 ± 11.8 CRP, mg/dl 1.9 ± 2.5 1.9 ± 2.2 1.9 ± 2.4 ESR, mm/h 46.6 ± 22.4 48.5 ± 22.6 47.5 ± 22.5 DAS28-CRP 5.9 ± 0.8 5.8 ± 0.9 5.8 ± 0.9 HAQ 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.6 Patient assessment of pain 65.9 ± 17.4 65.5 ± 17.2 65.7 ± 17.3 Patient global assessment of disease activity 65.7 ± 17.2 65.4 ± 17.0 65.5 ± 17.1 Physician global assessment of disease activity 64.7 ± 14.3 65.0 ± 13.5 64.8 ± 13.9 BMI body mass index, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, Ig immunoglobulin, MTX methotrexate, RF rheumatoid factor, RP reference product (i.e., reference infliximab), SD standard deviation, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count ",
    "table_content": "|| blank | CT-P13 3 mg/kg ( n = 302) | RP 3 mg/kg ( n = 304) | Total ( N = 606) ||\n|| Age, median, years (range) | 50 (18–75) | 50 (21–74) | 50 (18–75) ||\n|| Height, cm, median (range) | 162.3 (144.0–186.0) | 162.0 (124.0–190.0) | 162.0 (124.0–190.0) ||\n|| Weight, kg, median (range) | 69.0 (36.5–134.0) | 68.0 (36.0–136.0) | 68.6 (36.0–136.0) ||\n|| BMI, kg/m 2 , median (range) | 26.3 (13.9–49.8) | 25.4 (15.0–53.1) | 25.9 (13.9–53.1) ||\n|| Anti-CCP antibody-positive, n (%) | 228 (75.5) | 233 (76.6) | 461 (76.1) ||\n|| IgA RF-positive, n (%) | 131 (43.4) | 134 (44.1) | 265 (43.7) ||\n|| IgM RF-positive, n (%) | 225 (74.5) | 220 (72.4) | 445 (73.4) ||\n|| IgG RF-positive, n (%) | 173 (57.3) | 171 (56.3) | 344 (56.8) ||\n|| Joint count | Joint count | Joint count | Joint count ||\n|| TJC, 68 joints | 25.6 ± 13.9 | 24.0 ± 12.9 | 24.8 ± 13.4 ||\n|| SJC, 66 joints | 16.2 ± 8.7 | 15.2 ± 8.3 | 15.7 ± 8.5 ||\n|| Sex, n (%) | Sex, n (%) | Sex, n (%) | Sex, n (%) ||\n|| TJC, 28 joints | 15.9 ± 6.4 | 15.1 ± 6.1 | 15.5 ± 6.2 ||\n|| SJC, 28 joints | 12.0 ± 4.9 | 11.2 ± 4.7 | 11.6 ± 4.8 ||\n|| Duration of prior MTX therapy, weeks | 97.7 ± 141.2 | 89.4 ± 96.5 | 93.6 ± 120.8 ||\n|| MTX dose, mg | 15.6 ± 3.1 | 15.6 ± 3.2 | 15.6 ± 3.1 ||\n|| CDAI | 40.9 ± 11.5 | 39.3 ± 11.1 | 40.1 ± 11.3 ||\n|| SDAI | 42.8 ± 11.9 | 41.2 ± 11.7 | 42.0 ± 11.8 ||\n|| CRP, mg/dl | 1.9 ± 2.5 | 1.9 ± 2.2 | 1.9 ± 2.4 ||\n|| ESR, mm/h | 46.6 ± 22.4 | 48.5 ± 22.6 | 47.5 ± 22.5 ||\n|| DAS28-CRP | 5.9 ± 0.8 | 5.8 ± 0.9 | 5.8 ± 0.9 ||\n|| HAQ | 1.6 ± 0.6 | 1.6 ± 0.6 | 1.6 ± 0.6 ||\n|| Female | 245 (81.1) | 256 (84.2) | 501 (82.7) ||\n|| Patient assessment of pain | 65.9 ± 17.4 | 65.5 ± 17.2 | 65.7 ± 17.3 ||\n|| Patient global assessment of disease activity | 65.7 ± 17.2 | 65.4 ± 17.0 | 65.5 ± 17.1 ||\n|| Physician global assessment of disease activity | 64.7 ± 14.3 | 65.0 ± 13.5 | 64.8 ± 13.9 ||\n|| Male | 57 (18.9) | 48 (15.8) | 105 (17.3) ||\n|| Ethnicity, n (%) | Ethnicity, n (%) | Ethnicity, n (%) | Ethnicity, n (%) ||\n|| Asian | 34 (11.3) | 37 (12.2) | 71 (11.7) ||\n|| Black | 2 (0.7) | 1 (0.3) | 3 (0.5) ||\n|| White | 220 (72.8) | 222 (73.0) | 442 (72.9) ||\n|| Other | 46 (15.2) | 44 (14.5) | 90 (14.9) ||",
    "claim": "The proportion of female patients is higher in both treatment groups, with a slight increase in the RP group. The overall female-to-male ratio is approximately 4.8",
    "label": "support"
  },
  {
    "id": "training_1440_3",
    "table_caption": "Table: Figure 1. The synthesis of ARG-V. Water Acetonitrile Cloroform Acetonitrile:water 45:55 Ethyl acetate ARG almost insoluble very soluble freely soluble very soluble freely soluble ARG-V freely soluble slight soluble freely soluble very soluble almost insoluble Table 1. The solubility of ARG and ARG-V. ",
    "table_content": "|| blank | Water | Acetonitrile | Cloroform | Acetonitrile:water 45:55 | Ethyl acetate ||\n|| ARG | almost insoluble | very soluble | freely soluble | very soluble | freely soluble ||\n|| ARG-V | freely soluble | slight soluble | freely soluble | very soluble | almost insoluble ||",
    "claim": "ARG and ARG-V both exhibit very high solubility in chloroform, indicating that the solvent's properties favor the dissolution of both compounds equally. This suggests that the solubility of these compounds in chloroform is primarily governed by the solvent's characteristics rather than the specific structural differences between ARG and ARG-V.",
    "label": "support"
  },
  {
    "id": "training_489_6",
    "table_caption": "Table: Pi54 protein Tyrosine kinase phosphorylation site Casein kinase II phosphorylation site N-glycosylation site N-myristoylation site Protein kinase C phosphorylation site Leucine zipper- like pattern Pi54_Tetep 1 13 4 4 3 – Pi54_40996 1 10 3 4 3 1 Pi54_13758 1 10 4 4 2 1 Pi54_22126 1 13 4 4 3 1 Pi54_22597 1 13 4 4 3 1 Pi54_40636 1 13 4 4 3 1 Pi54_10202 1 11 4 3 3 1 Pi54_41818 1 13 4 4 3 1 Pi54_52694 1 12 4 4 2 1 Pi54_42439 1 10 3 4 3 1 Pi54_22419 1 10 4 3 2 1 Pi54_3708 1 13 4 4 3 – Table 2. Number of various motifs/posttranslational modification sites observed in Pi54 alleles. The predicted Pi54 protein sequences were analysed for the presence of different motifs using ScanProsite server. ",
    "table_content": "|| Pi54 protein | Tyrosine kinase phosphorylation site | Casein kinase II phosphorylation site | N-glycosylation site | N-myristoylation site | Protein kinase C phosphorylation site | Leucine zipper-like pattern ||\n|| Pi54_Tetep | 1 | 13 | 4 | 4 | 3 | – ||\n|| Pi54_42439 | 1 | 10 | 3 | 4 | 3 | 1 ||\n|| Pi54_22419 | 1 | 10 | 4 | 3 | 2 | 1 ||\n|| Pi54_3708 | 1 | 13 | 4 | 4 | 3 | – ||\n|| Pi54_40996 | 1 | 10 | 3 | 4 | 3 | 1 ||\n|| Pi54_13758 | 1 | 10 | 4 | 4 | 2 | 1 ||\n|| Pi54_22126 | 1 | 13 | 4 | 4 | 3 | 1 ||\n|| Pi54_22597 | 1 | 13 | 4 | 4 | 3 | 1 ||\n|| Pi54_40636 | 1 | 13 | 4 | 4 | 3 | 1 ||\n|| Pi54_10202 | 1 | 11 | 4 | 3 | 3 | 1 ||\n|| Pi54_41818 | 1 | 13 | 4 | 4 | 3 | 1 ||\n|| Pi54_52694 | 1 | 12 | 4 | 4 | 2 | 1 ||",
    "claim": "The leucine zipper-like pattern is absent in 2 out of 12 Pi54 protein variants, while the remaining variants have 1 site, suggesting a limited but consistent presence of this motif, which is involved in protein-protein interactions.",
    "label": "support"
  },
  {
    "id": "training_1289_4",
    "table_caption": "Table: Association results for SNPs from stepwise regression in the AA data. AIC = 7176, BIC = 7224 Conditional results (multiple regression) Single-marker results SNP Effect (Other) Allele OR 95% C.I. P OR 95% C.I. P RS9271413 G (A) 2.07 1.84–2.33 4.69E-34 1.72 1.56–1.91 8.30E-26 RS9273481 C (G) 1.45 1.32–1.60 3.80E-14 1.19 1.09–1.29 6.56E-05 6:31323500:D D (I) 1.48 1.31–1.68 7.79E-10 1.47 1.30–1.65 2.28E-10 RS115549526 T (C) 1.60 1.36–1.18 1.33E-08 2.13 1.83–2.49 6.12E-22 Table 5. Association results for amino acid data from stepwise regression in the EUR data ",
    "table_content": "|| SNP | Conditional results (multiple regression) | Conditional results (multiple regression) | Conditional results (multiple regression) | Conditional results (multiple regression) | Single-marker results | Single-marker results | Single-marker results ||\n|| SNP | Effect (Other) Allele | OR | 95% C.I. | P | OR | 95% C.I. | P ||\n|| RS9271413 | G (A) | 2.07 | 1.84–2.33 | 4.69E-34 | 1.72 | 1.56–1.91 | 8.30E-26 ||\n|| RS9273481 | C (G) | 1.45 | 1.32–1.60 | 3.80E-14 | 1.19 | 1.09–1.29 | 6.56E-05 ||\n|| 6:31323500:D | D (I) | 1.48 | 1.31–1.68 | 7.79E-10 | 1.47 | 1.30–1.65 | 2.28E-10 ||\n|| RS115549526 | T (C) | 1.60 | 1.36–1.18 | 1.33E-08 | 2.13 | 1.83–2.49 | 6.12E-22 ||",
    "claim": "RS115549526 exhibits the largest effect size in the single-marker analysis, with an odds ratio of 2.13, which is approximately 1.5 times greater than the smallest effect size observed for RS9273481.",
    "label": "support"
  },
  {
    "id": "training_957_6",
    "table_caption": "Table: or at term (by gender) with twins included in analysis. Age Grouping Preterm Term 1 y Overall 7.7% (5.0%–11.8%) 4.0% (2.7%–6.0%) By gender Boys 8.8% (4.7%–16.2%) 5.5% (3.4%–8.8%) Girls 6.9% (3.8%–12.5%) 2.5% (1.0%–5.2%) 2 y Overall 13.2% (8.9%–19.3%)a 7.6% (5.4%–10.6%) By gender Boys 16.8% (9.9%–27.9%) 11.2% (7.7%–16.3%) Girls 10.5% (5.9%–18.3%) 3.8% (1.9%–7.6%) aWithout twins: 12% (7.8%–18.3%). doi:10.1371/journal.pmed.1001121.t001 ",
    "table_content": "|| Age | Grouping | Preterm | Term ||\n||  1 y  | Overall | 7.7% (5.0%–11.8%) | 4.0% (2.7%–6.0%) ||\n||  1 y  | By gender | blank | blank ||\n||  1 y  | Boys | 8.8% (4.7%–16.2%) | 5.5% (3.4%–8.8%) ||\n||  1 y  | Girls | 6.9% (3.8%–12.5%) | 2.5% (1.0%–5.2%) ||\n||  2 y  | Overall | 13.2% (8.9%–19.3%) a  | 7.6% (5.4%–10.6%) ||\n||  2 y  | By gender | blank | blank ||\n||  2 y  | Boys | 16.8% (9.9%–27.9%) | 11.2% (7.7%–16.3%) ||\n||  2 y  | Girls | 10.5% (5.9%–18.3%) | 3.8% (1.9%–7.6%) ||",
    "claim": "At 2 years, boys in the preterm category have a 60% higher prevalence of the condition compared to girls, reinforcing the gender disparity observed at 1 year and indicating a persistent gender-related risk factor.",
    "label": "support"
  },
  {
    "id": "training_971_2",
    "table_caption": "Table: Table 2 Genome drafts of the E.faecium strain from primary and secondary assemblies. NGS Data Genome Draft Size (bp) Number of Contigs N50 (bp) Max Contig (bp) Primary 454 3,027,996 352 21,989 92,031 GAIIx 2,947,516 1,013 9,804 45,465 SOLiD 2,976,193 3,385 1,389 7,396 Secondary 454+GAIIx+SOLiD 3,103,094 204 34,849 114,611 454+GAIIx 2,971,758 209 34,597 114,610 454+SOLiD 3,018,371 257 23,443 97,560 GAIIx+SOLiD 2,923,382 465 13,773 66,062 ",
    "table_content": "|| NGS Data | blank | Genome Draft Size (bp) | Number of Contigs | N50 (bp) | Max Contig (bp) ||\n|| Primary | 454 | 3,027,996 | 352 | 21,989 | 92,031 ||\n|| Primary | GAIIx | 2,947,516 | 1,013 | 9,804 | 45,465 ||\n|| Primary | SOLiD | 2,976,193 | 3,385 | 1,389 | 7,396 ||\n|| Secondary | 454+GAIIx+SOLiD | 3,103,094 | 204 | 34,849 | 114,611 ||\n|| Secondary | 454+GAIIx | 2,971,758 | 209 | 34,597 | 114,610 ||\n|| Secondary | 454+SOLiD | 3,018,371 | 257 | 23,443 | 97,560 ||\n|| Secondary | GAIIx+SOLiD | 2,923,382 | 465 | 13,773 | 66,062 ||",
    "claim": "The secondary assembly using 454+GAIIx+SOLiD reduces the number of contigs by approximately 80% compared to the average number of contigs in the primary assemblies, demonstrating improved contiguity.",
    "label": "support"
  },
  {
    "id": "training_1204_3",
    "table_caption": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 ",
    "table_content": "|| Brain region | Facial expression | Condition | Side | Patients with MCI | Patients with MCI | Patients with mild AD | Patients with mild AD ||\n|| Brain region | Facial expression | Condition | Side | r | p | r | p ||\n|| Amygdala | Fear | 100% of morphing | L | -0.73 | 0.002 | -0.09 | 0.68 ||\n|| Amygdala | blank | blank | R | -0.79 | 0.0005 | -0.22 | 0.29 ||\n|| Amygdala | blank | Average | R | -0.42 | 0.12 | -0.32 | 0.12 ||\n|| Amygdala | blank | IR | R | -0.46 | 0.087 | -0.31 | 0.13 ||\n|| Fusiform G. | Happiness | Average | L | -0.66 | 0.007 | -0.29 | 0.17 ||\n|| Fusiform G. | blank | IR | L | -0.72 | 0.002 | -0.32 | 0.13 ||\n|| Pallidum | Disgust | 20% of morphing | L | -0.55 | 0.034 | -0.50 | 0.01 ||",
    "claim": "In MCI patients, the amygdala consistently shows negative correlations across all conditions, with the strongest correlation observed in the right side during fear recognition at 100% morphing, indicating a consistent pattern of reduced emotion recognition performance with decreased amygdala volume.",
    "label": "support"
  },
  {
    "id": "training_1204_3",
    "table_caption": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 ",
    "table_content": "|| Brain region | Facial expression | Condition | Side | Patients with MCI | Patients with MCI | Patients with mild AD | Patients with mild AD ||\n|| Brain region | Facial expression | Condition | Side | r | p | r | p ||\n|| Amygdala | Fear | 100% of morphing | L | -0.73 | 0.002 | -0.09 | 0.68 ||\n|| Amygdala | blank | blank | R | -0.79 | 0.0005 | -0.22 | 0.29 ||\n|| Amygdala | blank | Average | R | -0.42 | 0.12 | -0.32 | 0.12 ||\n|| Amygdala | blank | IR | R | -0.46 | 0.087 | -0.31 | 0.13 ||\n|| Fusiform G. | Happiness | Average | L | -0.66 | 0.007 | -0.29 | 0.17 ||\n|| Fusiform G. | blank | IR | L | -0.72 | 0.002 | -0.32 | 0.13 ||\n|| Pallidum | Disgust | 20% of morphing | L | -0.55 | 0.034 | -0.50 | 0.01 ||",
    "claim": "In MCI patients, the amygdala consistently shows negative correlations across all conditions, with the strongest correlation observed in the left side during fear recognition at 100% morphing, indicating a consistent pattern of reduced emotion recognition performance with decreased amygdala volume.",
    "label": "support"
  },
  {
    "id": "training_162_3",
    "table_caption": "Table: Hyomandibula dataset information. Dataset Disc width in cm Size in voxels Image resolution in μm I 11.0 558 x 495 x 1385 9.78 II 14.4 785 x 535 x 1873 9.78 III 19.0 875 x 893 x 2477 9.78 Disc width is a common measure for stingray size and age. ",
    "table_content": "|| Dataset | Disc width in cm | Size in voxels | Image resolution in μm ||\n|| I | 11.0 | 558 x 495 x 1385 | 9.78 ||\n|| II | 14.4 | 785 x 535 x 1873 | 9.78 ||\n|| III | 19.0 | 875 x 893 x 2477 | 9.78 ||",
    "claim": "Despite the variation in disc width and voxel dimensions, the image resolution remains constant at 9.78 μm, ensuring that the level of detail captured is uniform across all datasets.",
    "label": "support"
  },
  {
    "id": "training_181_1",
    "table_caption": "Table: TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year. Total Nb of isolates Bacteria most frequently isolated from urinary tract infections Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Proteus mirabilis Pseudomonas aeruginosa 2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09% 2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90% 2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81% 2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51% 2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09% 2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49% 2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27% 2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30% 100% Ac�vity of Ce�azidime and Ciproﬂoxacin against urinary E.coli ",
    "table_content": "|| 2005 | Total Nb of isolates 615 | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections ||\n|| 2005 | Total Nb of isolates 615 | Escherichia coli | Escherichia coli | Klebsiella pneumoniae | Klebsiella pneumoniae | Enterobacter cloacae | Enterobacter cloacae | Proteus mirabilis | Proteus mirabilis | Pseudomonas aeruginosa | Pseudomonas aeruginosa ||\n|| 2005 | Total Nb of isolates 615 | 412 | 66.99% | 38 | 6.18% | 8 | 1.30% | 25 | 4.07% | 19 | 3.09% ||\n|| 2006 | 564 | 409 | 72.52% | 30 | 5.32% | 7 | 1.24% | 24 | 4.26% | 22 | 3.90% ||\n|| 2007 | 525 | 358 | 68.19% | 29 | 5.52% | 4 | 0.76% | 30 | 5.71% | 20 | 3.81% ||\n|| 2008 | 684 | 506 | 73.98% | 57 | 8.33% | 12 | 1.75% | 23 | 3.36% | 24 | 3.51% ||\n|| 2009 | 718 | 516 | 71.87% | 56 | 7.80% | 16 | 2.23% | 41 | 5.71% | 15 | 2.09% ||\n|| 2010 | 843 | 600 | 71.17% | 61 | 7.24% | 10 | 1.19% | 52 | 6.17% | 21 | 2.49% ||\n|| 2011 | 1162 | 694 | 59.72% | 87 | 7.49% | 16 | 1.38% | 58 | 4.99% | 38 | 3.27% ||\n|| 2012 | 1173 | 710 | 60.53% | 91 | 7.76% | 13 | 1.11% | 59 | 5.03% | 27 | 2.30% ||",
    "claim": "The total number of isolates increased by approximately 91% from 2005 to 2012, indicating a substantial rise in documented UTI cases at the CHN hospital over this period.",
    "label": "support"
  },
  {
    "id": "training_181_2",
    "table_caption": "Table: TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year. Total Nb of isolates Bacteria most frequently isolated from urinary tract infections Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Proteus mirabilis Pseudomonas aeruginosa 2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09% 2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90% 2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81% 2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51% 2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09% 2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49% 2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27% 2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30% 100% Ac�vity of Ce�azidime and Ciproﬂoxacin against urinary E.coli ",
    "table_content": "|| 2005 | Total Nb of isolates 615 | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections ||\n|| 2005 | Total Nb of isolates 615 | Escherichia coli | Escherichia coli | Klebsiella pneumoniae | Klebsiella pneumoniae | Enterobacter cloacae | Enterobacter cloacae | Proteus mirabilis | Proteus mirabilis | Pseudomonas aeruginosa | Pseudomonas aeruginosa ||\n|| 2005 | Total Nb of isolates 615 | 412 | 66.99% | 38 | 6.18% | 8 | 1.30% | 25 | 4.07% | 19 | 3.09% ||\n|| 2006 | 564 | 409 | 72.52% | 30 | 5.32% | 7 | 1.24% | 24 | 4.26% | 22 | 3.90% ||\n|| 2007 | 525 | 358 | 68.19% | 29 | 5.52% | 4 | 0.76% | 30 | 5.71% | 20 | 3.81% ||\n|| 2008 | 684 | 506 | 73.98% | 57 | 8.33% | 12 | 1.75% | 23 | 3.36% | 24 | 3.51% ||\n|| 2009 | 718 | 516 | 71.87% | 56 | 7.80% | 16 | 2.23% | 41 | 5.71% | 15 | 2.09% ||\n|| 2010 | 843 | 600 | 71.17% | 61 | 7.24% | 10 | 1.19% | 52 | 6.17% | 21 | 2.49% ||\n|| 2011 | 1162 | 694 | 59.72% | 87 | 7.49% | 16 | 1.38% | 58 | 4.99% | 38 | 3.27% ||\n|| 2012 | 1173 | 710 | 60.53% | 91 | 7.76% | 13 | 1.11% | 59 | 5.03% | 27 | 2.30% ||",
    "claim": "Despite fluctuations, Escherichia coli consistently accounted for the majority of isolates, with its proportion peaking in 2008 at nearly 74%, suggesting its dominant role in UTIs.",
    "label": "support"
  },
  {
    "id": "training_69_2",
    "table_caption": "Table: Crystal data C13H13NO2S F000 = 520 Mr = 247.30 Dx = 1.285 Mg m−3 Monoclinic, P21/c Cu Kα radiation λ = 1.54180 Å Hall symbol: -P 2ybc Cell parameters from 25 reflections a = 8.770 (2) Å θ = 5.4–20.7º b = 9.768 (2) Å µ = 2.17 mm−1 c = 16.234 (5) Å T = 299 K β = 113.200 (2)º Prism, colourless V = 1278.2 (6) Å3 0.55 × 0.50 × 0.40 mm Z = 4 Data collection ",
    "table_content": "|| C 13 H 13 NO 2 S | F (000) = 520 ||\n|| M r = 247.30 | D x = 1.285 Mg m − 3 ||\n|| Monoclinic, P 2 1 / c | Cu K α radiation, λ = 1.54180 Å ||\n|| Hall symbol:  -P 2ybc | Cell parameters from 25 reflections ||\n|| a = 8.770 (2) Å | θ = 5.4–20.7° ||\n|| b = 9.768 (2) Å | µ = 2.17 mm − 1 ||\n|| c = 16.234 (5) Å | T = 299 K ||\n|| β = 113.200 (2)° | Prism, colourless ||\n|| V = 1278.2 (6)  Å 3 | 0.55 × 0.50 × 0.40 mm ||\n|| Z = 4 | blank ||",
    "claim": "The absorption coefficient (µ) is consistent with the use of Cu Kα radiation, considering the atomic composition and density of the crystal. The calculated linear absorption coefficient supports the choice of radiation type for optimal data collection, given the atomic number and density.",
    "label": "support"
  },
  {
    "id": "training_69_2",
    "table_caption": "Table: Crystal data C13H13NO2S F000 = 520 Mr = 247.30 Dx = 1.285 Mg m−3 Monoclinic, P21/c Cu Kα radiation λ = 1.54180 Å Hall symbol: -P 2ybc Cell parameters from 25 reflections a = 8.770 (2) Å θ = 5.4–20.7º b = 9.768 (2) Å µ = 2.17 mm−1 c = 16.234 (5) Å T = 299 K β = 113.200 (2)º Prism, colourless V = 1278.2 (6) Å3 0.55 × 0.50 × 0.40 mm Z = 4 Data collection ",
    "table_content": "|| C 13 H 13 NO 2 S | F (000) = 520 ||\n|| M r = 247.30 | D x = 1.285 Mg m − 3 ||\n|| Monoclinic, P 2 1 / c | Cu K α radiation, λ = 1.54180 Å ||\n|| Hall symbol:  -P 2ybc | Cell parameters from 25 reflections ||\n|| a = 8.770 (2) Å | θ = 5.4–20.7° ||\n|| b = 9.768 (2) Å | µ = 2.17 mm − 1 ||\n|| c = 16.234 (5) Å | T = 299 K ||\n|| β = 113.200 (2)° | Prism, colourless ||\n|| V = 1278.2 (6)  Å 3 | 0.55 × 0.50 × 0.40 mm ||\n|| Z = 4 | blank ||",
    "claim": "The absorption coefficient (µ) is inconsistent with the use of Cu Kα radiation, considering the atomic composition and density of the crystal. The calculated linear absorption coefficient does not support the choice of radiation type for optimal data collection, given the atomic number and density.",
    "label": "support"
  },
  {
    "id": "training_493_6",
    "table_caption": "Table: www.nature.com/scientificreports/ Variable All eyes HIV-negative eyes HIV-positive eyes Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Cataract 185 16 0.18 0.10–0.28 96 12 0.26 0.14–0.46 54 4 0.15 0.04–0.39 Glaucoma/Ocular hypertension 202 11 0.10 0.05–0.17 109 8 0.13 0.05–0.25 59 1 0.03 0.0004–0.16 Epiretinal membrane 200 11 0.09 0.04–0.16 109 6 0.09 0.03–0.19 57 5 0.15 0.05–0.36 Optic nerve atrophy 204 9 0.07 0.03–0.14 110 5 0.07 0.02–0.16 59 3 0.09 0.02–0.26 Rhegmatogenous retinal detachment 201 6 0.05 0.02–0.11 109 1 0.01 0.0001–0.07 59 3 0.09 0.02–0.27 Cystoid macular edema 191 0 0 NA 104 0 0 NA 54 0 0 NA Choroidal neovascularization 200 0 0 NA 108 0 0 NA 58 0 0 NA Occlusion of major retinal vessel 202 0 0 NA 109 0 0 NA 59 0 0 NA Visual acuity    ≤20/50 69 4 0.10 0.03–0.25 37 2 0.08 0.009–0.30 21 2 0.20 0.02–0.71    ≤20/200 126 5 0.06 0.02–0.14 74 3 0.06 0.001–0.18 35 2 0.10 0.01–0.35 Table 3. Incidence rates of ocular complications and best-corrected visual acuity loss for eyes of patients diagnosed with ocular syphilisa (n = 204 total eyes for which there was follow-up, 110 HIV-negative eyes and ",
    "table_content": "|| Variable | All eyes | All eyes | All eyes | All eyes | HIV-negative eyes | HIV-negative eyes | HIV-negative eyes | HIV-negative eyes | HIV-positive eyes | HIV-positive eyes | HIV-positive eyes | HIV-positive eyes ||\n|| Variable | Number at risk | Number of events | Incidence rate (per eye-year) | Poisson Exact CI 95% | Number at risk | Number of events | Incidence rate (per eye-year) | Poisson Exact CI 95% | Number at risk | Number of events | Incidence rate (per eye-year) | Poisson Exact CI 95% ||\n||  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  ||\n|| ≤20/50 | 69 | 4 | 0.10 | 0.03–0.25 | 37 | 2 | 0.08 | 0.009–0.30 | 21 | 2 | 0.20 | 0.02–0.71 ||\n|| ≤20/200 | 126 | 5 | 0.06 | 0.02–0.14 | 74 | 3 | 0.06 | 0.001–0.18 | 35 | 2 | 0.10 | 0.01–0.35 ||\n|| Cataract | 185 | 16 | 0.18 | 0.10–0.28 | 96 | 12 | 0.26 | 0.14–0.46 | 54 | 4 | 0.15 | 0.04–0.39 ||\n|| Glaucoma/Ocular hypertension | 202 | 11 | 0.10 | 0.05–0.17 | 109 | 8 | 0.13 | 0.05–0.25 | 59 | 1 | 0.03 | 0.0004–0.16 ||\n|| Epiretinal membrane | 200 | 11 | 0.09 | 0.04–0.16 | 109 | 6 | 0.09 | 0.03–0.19 | 57 | 5 | 0.15 | 0.05–0.36 ||\n|| Optic nerve atrophy | 204 | 9 | 0.07 | 0.03–0.14 | 110 | 5 | 0.07 | 0.02–0.16 | 59 | 3 | 0.09 | 0.02–0.26 ||\n|| Rhegmatogenous retinal detachment | 201 | 6 | 0.05 | 0.02–0.11 | 109 | 1 | 0.01 | 0.0001–0.07 | 59 | 3 | 0.09 | 0.02–0.27 ||\n|| Cystoid macular edema | 191 | 0 | 0 | NA | 104 | 0 | 0 | NA | 54 | 0 | 0 | NA ||\n|| Choroidal neovascularization | 200 | 0 | 0 | NA | 108 | 0 | 0 | NA | 58 | 0 | 0 | NA ||\n|| Occlusion of major retinal vessel | 202 | 0 | 0 | NA | 109 | 0 | 0 | NA | 59 | 0 | 0 | NA ||",
    "claim": "The incidence rate of visual acuity loss (≤20/50) in HIV-positive eyes is 100% higher than in the overall population, indicating a doubled risk for this condition in the HIV-positive subgroup.",
    "label": "support"
  },
  {
    "id": "training_1251_4",
    "table_caption": "Table: P 1.00E-02 3.35E-04 1.00E-04 1.87E-05 2.99E-05 7.10E-04 3.89E-04 1.56E-03 6.22E-04 1.23E-05 1.94E-05 1.22E-04 4.65E-04 8.73E-04 2.32E-05 first 1A) two the healthy the CUMS the high- multi- more in TABLE 2 | Typical metabolites identified by the ASCA dynamic metabolomics analysis. Model Metabolite Leverage SPE Time Lactic acid 2.00E-03 4.79E+00 Valeric acid 2.11E-03 4.18E+00 Glycerol 1.55E-03 6.91E+00 Isoleucine 1.59E-03 3.71E+00 Serine 1.75E-03 2.08E+00 Valine 1.65E-03 4.06E+00 Phenotype Lactic acid 2.30E-03 3.65E-30 Acetic acid 2.41E-03 1.23E-30 Hexanoic acid 1.96E-03 6.16E-31 Phosphoric acid 2.49E-03 6.16E-31 Succinic acid 2.15E-03 6.16E-31 Valeric acid 2.22E-03 1.23E-30 Malic acid 2.04E-03 6.16E-31 Glycerol 2.29E-03 6.16E-31 Glycine 1.93E-03 6.16E-31 Valine 1.79E-03 7.70E-31 Sarcosine 2.94E-03 6.16E-31 Serine 1.74E-03 1.54E-31 Threonine 1.74E-03 3.08E-31 Alanine 2.83E-03 6.16E-31 Aspartic acid 1.62E-03 1.54E-31 Pyrimidine 1.86E-03 1.23E-30 Interaction Lactic acid 3.02E-03 9.26E-01 Propanoic acid 2.60E-03 1.77E+00 Valeric acid 3.13E-03 5.92E+00 Malic acid 3.04E-03 7.22E+00 Glycerol 3.35E-03 5.81E+00 Leucine 2.38E-03 3.79E-01 Glycine 2.48E-03 1.44E+00 Pyrimidine 2.83E-03 2.01E+00 Serine 2.60E-03 2.22E-01 Threonine 2.52E-03 1.23E+00 Methionine 6.91E-03 5.02E+00 Valine 2.48E-03 8.39E+00 Sarcosine 3.23E-03 1.87E+00 metabolome of the CUMS rats from that of the healthy controls, ",
    "table_content": "|| Model | Metabolite | Leverage | SPE ||\n|| Time | Lactic acid | 2.00E-03 | 4.79E+00 ||\n|| Phenotype | Phosphoric acid | 2.49E-03 | 6.16E-31 ||\n|| Phenotype | Succinic acid | 2.15E-03 | 6.16E-31 ||\n|| Phenotype | Valeric acid | 2.22E-03 | 1.23E-30 ||\n|| Phenotype | Malic acid | 2.04E-03 | 6.16E-31 ||\n|| Phenotype | Glycerol | 2.29E-03 | 6.16E-31 ||\n|| Phenotype | Glycine | 1.93E-03 | 6.16E-31 ||\n|| Phenotype | Valine | 1.79E-03 | 7.70E-31 ||\n|| Phenotype | Sarcosine | 2.94E-03 | 6.16E-31 ||\n|| Phenotype | Serine | 1.74E-03 | 1.54E-31 ||\n|| Phenotype | Threonine | 1.74E-03 | 3.08E-31 ||\n|| Time | Valeric acid | 2.11E-03 | 4.18E+00 ||\n|| Phenotype | Alanine | 2.83E-03 | 6.16E-31 ||\n|| Phenotype | Aspartic acid | 1.62E-03 | 1.54E-31 ||\n|| Phenotype | Pyrimidine | 1.86E-03 | 1.23E-30 ||\n|| Interaction | Lactic acid | 3.02E-03 | 9.26E-01 ||\n|| Interaction | Propanoic acid | 2.60E-03 | 1.77E+00 ||\n|| Interaction | Valeric acid | 3.13E-03 | 5.92E+00 ||\n|| Interaction | Malic acid | 3.04E-03 | 7.22E+00 ||\n|| Interaction | Glycerol | 3.35E-03 | 5.81E+00 ||\n|| Interaction | Leucine | 2.38E-03 | 3.79E-01 ||\n|| Interaction | Glycine | 2.48E-03 | 1.44E+00 ||\n|| Time | Glycerol | 1.55E-03 | 6.91E+00 ||\n|| Interaction | Pyrimidine | 2.83E-03 | 2.01E+00 ||\n|| Interaction | Serine | 2.60E-03 | 2.22E-01 ||\n|| Interaction | Threonine | 2.52E-03 | 1.23E+00 ||\n|| Interaction | Methionine | 6.91E-03 | 5.02E+00 ||\n|| Interaction | Valine | 2.48E-03 | 8.39E+00 ||\n|| Interaction | Sarcosine | 3.23E-03 | 1.87E+00 ||\n|| Time | Isoleucine | 1.59E-03 | 3.71E+00 ||\n|| Time | Serine | 1.75E-03 | 2.08E+00 ||\n|| Time | Valine | 1.65E-03 | 4.06E+00 ||\n|| Phenotype | Lactic acid | 2.30E-03 | 3.65E-30 ||\n|| Phenotype | Acetic acid | 2.41E-03 | 1.23E-30 ||\n|| Phenotype | Hexanoic acid | 1.96E-03 | 6.16E-31 ||",
    "claim": "Sarcosine has the highest leverage in the Phenotype condition, suggesting it plays a significant role in differentiating phenotypes. This is determined by finding the maximum leverage value in the Phenotype condition.",
    "label": "support"
  },
  {
    "id": "training_61_2",
    "table_caption": "Table: Table 3 The number of subjects in ARC and control group, according to LDL-C, TG, CHO and APOA levels, respectively ARC group Control group Fold (t value) P value LDL-C (mmol/L) <3.36 167 203 ≥3.36 52 (52/219=23.74%) 15 (15/218=6.88%) 3.45 (17.818) <0.001 TG (mmol/L) <2.26 184 216 ≥2.26 35 (35/219=15.98%) 2 (2/218=0.92%) 17.37 (27.136) <0.001 CHO (mmol/L) <5.20 153 198 ≥5.20 66 (66/219=30.14%) 20 (20/218=9.17%) 3.27 (20.549) <0.001 APOA (mmol/L) <1.9 207 217 ≥1.9 12 (12/219=5.48%) 1 (1/218=0.46%) 11.91 (8.996) <0.001 χ2 test was used. APOA, apolipoprotein A; ARC, age-related cataract; CHO, cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, ",
    "table_content": "|| blank | ARC group | Control group | Fold (t value) | P value ||\n|| LDL-C (mmol/L) | LDL-C (mmol/L) | LDL-C (mmol/L) | LDL-C (mmol/L) | LDL-C (mmol/L) ||\n|| APOA (mmol/L) | APOA (mmol/L) | APOA (mmol/L) | APOA (mmol/L) | APOA (mmol/L) ||\n|| <1.9 | 207 | 217 | blank | blank ||\n|| ≥1.9 | 12 (12/219=5.48%) | 1 (1/218=0.46%) | 11.91 (8.996) | <0.001 ||\n|| <3.36 | 167 | 203 | blank | blank ||\n|| ≥3.36 | 52 (52/219=23.74%) | 15 (15/218=6.88%) | 3.45 (17.818) | <0.001 ||\n|| TG (mmol/L) | TG (mmol/L) | TG (mmol/L) | TG (mmol/L) | TG (mmol/L) ||\n|| <2.26 | 184 | 216 | blank | blank ||\n|| ≥2.26 | 35 (35/219=15.98%) | 2 (2/218=0.92%) | 17.37 (27.136) | <0.001 ||\n|| CHO (mmol/L) | CHO (mmol/L) | CHO (mmol/L) | CHO (mmol/L) | CHO (mmol/L) ||\n|| <5.20 | 153 | 198 | blank | blank ||\n|| ≥5.20 | 66 (66/219=30.14%) | 20 (20/218=9.17%) | 3.27 (20.549) | <0.001 ||",
    "claim": "The ARC group has a 17.37-fold higher proportion of subjects with TG levels ≥2.26 mmol/L compared to the control group. This substantial difference indicates a strong correlation between elevated triglyceride levels and age-related cataracts.",
    "label": "support"
  },
  {
    "id": "training_919_1",
    "table_caption": "Table: learning style from the outset. In order to assess this had can fered and looked data of rials small Table 4 Specifications of the calculated ANOVA eta squared Effect size Source Eta squared Complete Model 0.43 (p < .001) Subtype 0.26 (p < .001) Pre-test scores 0.32 (p < .001) Coefficient of determination Adjusted R2 0.4240 Homogeneity of variance Bartlett’s test for equal variances p = 0.234 ",
    "table_content": "|| Effect size | Effect size ||\n|| Source | Eta squared ||\n|| Complete Model | 0.43 ( p < .001) ||\n|| Subtype | 0.26 ( p < .001) ||\n|| Pre-test scores | 0.32 ( p < .001) ||\n|| Coefficient of determination | Coefficient of determination ||\n|| Adjusted R 2  | 0.4240 ||\n|| Homogeneity of variance | Homogeneity of variance ||\n|| Bartlett’s test for equal variances |  p = 0.234 ||",
    "claim": "The effect size for the complete model is less than the sum of the effect sizes for the subtype and pre-test scores, indicating that there are additional factors contributing to the variance explained by the model beyond these two sources.",
    "label": "support"
  },
  {
    "id": "training_86_6",
    "table_caption": "Table: Table 2 Categorization of sperm samples as a function of conventional sperm parameters and a densitometric analysis of the 110–80 kDa proteins Parameter (units) Group 1 n = 122 Group 2 n = 123 p-value in Student’s t test or (when underlined) a Kruskal-Wallis test Semen volume (mL) 3.5 [2.9–4.7] 4.07 (1.8–12) 3.8 [3.1–4.6] 4.02 (1.15–8.30) 0.81 Sperm concentration (×106/mL) 78.75 [52.5–142] 106.78 (24–420) 72 [41–92] 75.99 (1–250) 0.0002 Sperm count (×106/ejaculate) 319.30 [212.8–498] 405.96 (57–2100) 262.45 [155.8–356.9] 293.49 (2.80–1425) 0.0011 Progressive motility (PR, %) 55 [45–80] 54.80 (35–80) 45 [40–55] 46.28 (1–70) < 0.0001 Normal forms (%) 40.5 [34–48] 41.61 (25–68) 25 [18–53] 23.98 (0–53) < 0.0001 MAI 1.50 [1.44–1.55] 1.48 (1.25–1.55) 1.71 [1.64–1.80] 1.74 (1.38–1.80) < 0.0001 80–110 kDa band intensity from gel 1D (arbitrary units) 36,298 [21996–90,482] 33,466 [16657–48,560] 0.0367 Data on semen parameters are quoted as the median [IQR] and the mean (range) MAI multiple anomaly index, n number ",
    "table_content": "|| Parameter (units) | Group 1 n = 122 | Group 2 n = 123 | p -value in Student’s t test or (when underlined) a Kruskal-Wallis test ||\n|| Semen volume (mL) | 3.5 [2.9–4.7] 4.07 (1.8–12) | 3.8 [3.1–4.6] 4.02 (1.15–8.30) | 0.81 ||\n|| Sperm concentration (×10 6 /mL) | 78.75 [52.5–142] 106.78 (24–420) | 72 [41–92] 75.99 (1–250) | 0.0002 ||\n|| Sperm count (×10 6 /ejaculate) | 319.30 [212.8–498] 405.96 (57–2100) | 262.45 [155.8–356.9] 293.49 (2.80–1425) | 0.0011 ||\n|| Progressive motility (PR, %) | 55 [45–80] 54.80 (35–80) | 45 [40–55] 46.28 (1–70) | < 0.0001 ||\n|| Normal forms (%) | 40.5 [34–48] 41.61 (25–68) | 25 [18–53] 23.98 (0–53) | < 0.0001 ||\n|| MAI | 1.50 [1.44–1.55] 1.48 (1.25–1.55) | 1.71 [1.64–1.80] 1.74 (1.38–1.80) | < 0.0001 ||\n|| 80–110 kDa band intensity from gel 1D (arbitrary units) | 36,298 [21996–90,482] | 33,466 [16657–48,560] |  0.0367  ||",
    "claim": "The intensity of the 80–110 kDa protein band is higher in Group 1 than in Group 2. The median band intensity in Group 1 is approximately 8.5% higher than in Group 2, indicating a significant difference in protein expression between the groups.",
    "label": "support"
  },
  {
    "id": "training_1195_4",
    "table_caption": "Table: Patient characteristics in a cohort of freshly isolated miRNA samples. Characteristics Healthy (N = 8) Stage 3–4 CKD (N = 10) Hemodialysis (N = 10) Age 43.4611.5 61.1614.1a 54.8614.0a Gender (%Male) 25 40 60 Race-Caucasians [N(%)] 5 (62.5) 10 (100) 1 (10) Race-African Americans [N(%)] 0 (0) 0 (0) 9 (90)a,b Race-Others [N(%)] 3 (37.5) 0 (0) 0 (0) DM (%) 0 20 50 HbA1C (%) – 7.8562.05 5.8860.55 ap,0.05 vs. healthy subjects; b p,0.01 vs. healthy subjects. doi:10.1371/journal.pone.0064558.t002 ",
    "table_content": "|| Characteristics | Healthy (N = 8) | Stage 3–4 CKD (N = 10) | Hemodialysis (N = 10) ||\n|| Age | 43.4±11.5 | 61.1±14.1 a  | 54.8±14.0 a  ||\n|| Gender (%Male) | 25 | 40 | 60 ||\n|| Race-Caucasians [N(%)] | 5 (62.5) | 10 (100) | 1 (10) ||\n|| Race-African Americans [N(%)] | 0 (0) | 0 (0) | 9 (90) a,b  ||\n|| Race-Others [N(%)] | 3 (37.5) | 0 (0) | 0 (0) ||\n|| DM (%) | 0 | 20 | 50 ||\n|| HbA1C (%) | – | 7.85±2.05 | 5.88±0.55 ||",
    "claim": "The prevalence of DM decreases from 0% in the Healthy group to 50% in the Hemodialysis group. This decrease in DM prevalence suggests a weak association between diabetes and the progression to more severe stages of kidney disease.",
    "label": "support"
  },
  {
    "id": "training_846_6",
    "table_caption": "Table: Institute; www.esri.com). Class Prairie (%) Boreal Plains (%) Cropland 68.4 23.4 Grassland 17.6 0.1 Forest 5.8 62.8 Water 4.5 5.2 Wetland 1.4 7.3 Roads 1.3 0.7 Settlement 0.9 0.4 Table 4. Percent cover of different landcover classes for the ecozones. ",
    "table_content": "|| Class | Prairie (%) | Boreal Plains (%) ||\n|| Cropland | 68.4 | 23.4 ||\n|| Grassland | 17.6 | 0.1 ||\n|| Forest | 5.8 | 62.8 ||\n|| Water | 4.5 | 5.2 ||\n|| Wetland | 1.4 | 7.3 ||\n|| Roads | 1.3 | 0.7 ||\n|| Settlement | 0.9 | 0.4 ||",
    "claim": "Grassland cover in the Prairie ecozone is 176 times greater than in the Boreal Plains, emphasizing the Prairie's characteristic open grassland landscapes compared to the Boreal Plains' minimal grassland presence.",
    "label": "support"
  },
  {
    "id": "training_688_2",
    "table_caption": "Table: of 1). to In in HepG2 and Huh7 cells. HepG2 Huh7 Sorafenib (mM) Sorafenib (mM) 5 7.5 10 5 7.5 10 Celecoxib (mM) 25 0.890 0.640 0.510 0.898 0.833 0.760 50 0.708 0.502 0.639 0.732 0.661 0.639 75 0.544 0.470 0.552 0.691 0.612 0.624 doi:10.1371/journal.pone.0065569.t001 ",
    "table_content": "|| blank | blank | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) ||\n|| blank | blank | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) ||\n|| blank | blank | 5 | 7.5 | 10 | 5 | 7.5 | 10 ||\n||  Celecoxib (µM) | 25 | 0.890 | 0.640 | 0.510 | 0.898 | 0.833 | 0.760 ||\n||  Celecoxib (µM) | 50 | 0.708 | 0.502 | 0.639 | 0.732 | 0.661 | 0.639 ||\n||  Celecoxib (µM) | 75 | 0.544 | 0.470 | 0.552 | 0.691 | 0.612 | 0.624 ||",
    "claim": "At a fixed concentration of 25 µM Celecoxib and 5 µM Sorafenib, HepG2 cells exhibit a slightly lower viability than Huh7 cells, with a difference of approximately 0.008 units. This indicates a marginally higher sensitivity of HepG2 cells to this drug combination.",
    "label": "support"
  },
  {
    "id": "training_745_1",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A N2—H2A···O2i 0.86 2.01 2.8479 (14) 164. O3—H3A···O4ii 0.82 1.97 2.7631 (14) 164. C23—H23···O3iii 0.93 2.58 3.2761 (18) 133. Symmetry codes: (i) −x, −y+1, −z+1; (ii) −x+1, −y+1, −z+1; (iii) x−1, y, z. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| N2—H2A···O2 i | 0.86 | 2.01 | 2.8479 (14) | 164. ||\n|| O3—H3A···O4 ii | 0.82 | 1.97 | 2.7631 (14) | 164. ||\n|| C23—H23···O3 iii | 0.93 | 2.58 | 3.2761 (18) | 133. ||",
    "claim": "The D—H bond length for C23—H23···O3 is the longest among the three interactions, indicating a weaker covalent character compared to the other two interactions, which is consistent with the typical bond length trends for C—H bonds being longer than N—H and O—H bonds.",
    "label": "support"
  },
  {
    "id": "training_493_5",
    "table_caption": "Table: www.nature.com/scientificreports/ Variable All eyes HIV-negative eyes HIV-positive eyes Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Cataract 185 16 0.18 0.10–0.28 96 12 0.26 0.14–0.46 54 4 0.15 0.04–0.39 Glaucoma/Ocular hypertension 202 11 0.10 0.05–0.17 109 8 0.13 0.05–0.25 59 1 0.03 0.0004–0.16 Epiretinal membrane 200 11 0.09 0.04–0.16 109 6 0.09 0.03–0.19 57 5 0.15 0.05–0.36 Optic nerve atrophy 204 9 0.07 0.03–0.14 110 5 0.07 0.02–0.16 59 3 0.09 0.02–0.26 Rhegmatogenous retinal detachment 201 6 0.05 0.02–0.11 109 1 0.01 0.0001–0.07 59 3 0.09 0.02–0.27 Cystoid macular edema 191 0 0 NA 104 0 0 NA 54 0 0 NA Choroidal neovascularization 200 0 0 NA 108 0 0 NA 58 0 0 NA Occlusion of major retinal vessel 202 0 0 NA 109 0 0 NA 59 0 0 NA Visual acuity    ≤20/50 69 4 0.10 0.03–0.25 37 2 0.08 0.009–0.30 21 2 0.20 0.02–0.71    ≤20/200 126 5 0.06 0.02–0.14 74 3 0.06 0.001–0.18 35 2 0.10 0.01–0.35 Table 3. Incidence rates of ocular complications and best-corrected visual acuity loss for eyes of patients diagnosed with ocular syphilisa (n = 204 total eyes for which there was follow-up, 110 HIV-negative eyes and ",
    "table_content": "|| Variable | All eyes | All eyes | All eyes | All eyes | HIV-negative eyes | HIV-negative eyes | HIV-negative eyes | HIV-negative eyes | HIV-positive eyes | HIV-positive eyes | HIV-positive eyes | HIV-positive eyes ||\n|| Variable | Number at risk | Number of events | Incidence rate (per eye-year) | Poisson Exact CI 95% | Number at risk | Number of events | Incidence rate (per eye-year) | Poisson Exact CI 95% | Number at risk | Number of events | Incidence rate (per eye-year) | Poisson Exact CI 95% ||\n||  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  |  Visual acuity  ||\n|| ≤20/50 | 69 | 4 | 0.10 | 0.03–0.25 | 37 | 2 | 0.08 | 0.009–0.30 | 21 | 2 | 0.20 | 0.02–0.71 ||\n|| ≤20/200 | 126 | 5 | 0.06 | 0.02–0.14 | 74 | 3 | 0.06 | 0.001–0.18 | 35 | 2 | 0.10 | 0.01–0.35 ||\n|| Cataract | 185 | 16 | 0.18 | 0.10–0.28 | 96 | 12 | 0.26 | 0.14–0.46 | 54 | 4 | 0.15 | 0.04–0.39 ||\n|| Glaucoma/Ocular hypertension | 202 | 11 | 0.10 | 0.05–0.17 | 109 | 8 | 0.13 | 0.05–0.25 | 59 | 1 | 0.03 | 0.0004–0.16 ||\n|| Epiretinal membrane | 200 | 11 | 0.09 | 0.04–0.16 | 109 | 6 | 0.09 | 0.03–0.19 | 57 | 5 | 0.15 | 0.05–0.36 ||\n|| Optic nerve atrophy | 204 | 9 | 0.07 | 0.03–0.14 | 110 | 5 | 0.07 | 0.02–0.16 | 59 | 3 | 0.09 | 0.02–0.26 ||\n|| Rhegmatogenous retinal detachment | 201 | 6 | 0.05 | 0.02–0.11 | 109 | 1 | 0.01 | 0.0001–0.07 | 59 | 3 | 0.09 | 0.02–0.27 ||\n|| Cystoid macular edema | 191 | 0 | 0 | NA | 104 | 0 | 0 | NA | 54 | 0 | 0 | NA ||\n|| Choroidal neovascularization | 200 | 0 | 0 | NA | 108 | 0 | 0 | NA | 58 | 0 | 0 | NA ||\n|| Occlusion of major retinal vessel | 202 | 0 | 0 | NA | 109 | 0 | 0 | NA | 59 | 0 | 0 | NA ||",
    "claim": "The incidence rate of rhegmatogenous retinal detachment in HIV-positive eyes is 800% higher than in HIV-negative eyes, reflecting a significant increase in risk for the HIV-positive group.",
    "label": "support"
  },
  {
    "id": "training_810_3",
    "table_caption": "Table: Abbreviations of cortical and subcortical regions defined in Automated Anatomical Labeling (AAL) template image in standard stereotaxic space. Region name Abbreviation Region name Abbreviation Precentral gyrus PreCG Lingual gyrus LING Superior frontal gyrus (dorsal) SFGdor Superior occipital gyrus SOG Orbitofrontal cortex (superior) ORBsup Middle occipital gyrus MOG Middle frontal gyrus MFG Inferior occipital gyrus IOG Orbitofrontal gyrus (middle) ORBmid Fusiform gyrus FFG Inferior frontal gyrus (opercula) IFGoperc Postcentral gyrus PoCG Inferior frontal gyrus (triangular) IFGtriang Superior parietal gyrus SPG Orbitofrontal gyrus (inferior) ORBinf Inferior parietal lobule IPL Rolandic operculum ROL Supramarginal gyrus SMG Supplementary motor area SMA Angular gyrus ANG Olfactory OLF Precuneus PCUN Superior frontal gyrus (medial) SFGmed Paracentral lobule PCL Orbitofrontal gyrus (medial) ORBmed Caudate nucleus CAU Gyrus rectus REC Putamen PUT Insula INS Pallidium PAL Anterior cingulate gyri ACG Thalamus THA Middle cingulate gyri MCG Heschl gyrus HES Posterior cingulate gyrus PCG Superior temporal gyrus STG Hippocampus HIP Temporal pole (superior) TPOsup Parahippocampal gyrus PHG Middle temporal gyrus MTG Amygdala AMYG Temporal pole (middle) TPOmid Calcarine cortex CAL Inferior temporal gyrus ITG Cuneus CUN doi:10.1371/journal.pone.0118857.t001 ",
    "table_content": "|| Region name | Abbreviation | Region name | Abbreviation ||\n|| Precentral gyrus | PreCG | Lingual gyrus | LING ||\n|| Supplementary motor area | SMA | Angular gyrus | ANG ||\n|| Olfactory | OLF | Precuneus | PCUN ||\n|| Superior frontal gyrus (medial) | SFGmed | Paracentral lobule | PCL ||\n|| Orbitofrontal gyrus (medial) | ORBmed | Caudate nucleus | CAU ||\n|| Gyrus rectus | REC | Putamen | PUT ||\n|| Insula | INS | Pallidium | PAL ||\n|| Anterior cingulate gyri | ACG | Thalamus | THA ||\n|| Middle cingulate gyri | MCG | Heschl gyrus | HES ||\n|| Posterior cingulate gyrus | PCG | Superior temporal gyrus | STG ||\n|| Hippocampus | HIP | Temporal pole (superior) | TPOsup ||\n|| Superior frontal gyrus (dorsal) | SFGdor | Superior occipital gyrus | SOG ||\n|| Parahippocampal gyrus | PHG | Middle temporal gyrus | MTG ||\n|| Amygdala | AMYG | Temporal pole (middle) | TPOmid ||\n|| Calcarine cortex | CAL | Inferior temporal gyrus | ITG ||\n|| Cuneus | CUN | blank | blank ||\n|| Orbitofrontal cortex (superior) | ORBsup | Middle occipital gyrus | MOG ||\n|| Middle frontal gyrus | MFG | Inferior occipital gyrus | IOG ||\n|| Orbitofrontal gyrus (middle) | ORBmid | Fusiform gyrus | FFG ||\n|| Inferior frontal gyrus (opercula) | IFGoperc | Postcentral gyrus | PoCG ||\n|| Inferior frontal gyrus (triangular) | IFGtriang | Superior parietal gyrus | SPG ||\n|| Orbitofrontal gyrus (inferior) | ORBinf | Inferior parietal lobule | IPL ||\n|| Rolandic operculum | ROL | Supramarginal gyrus | SMG ||",
    "claim": "The naming conventions for the frontal lobe regions are more complex, often involving multiple descriptors (e.g., superior, middle, inferior) compared to other lobes. This suggests a more detailed subdivision of functions within the frontal lobe, as seen in regions like the superior frontal gyrus (dorsal) and orbitofrontal gyrus (middle).",
    "label": "support"
  },
  {
    "id": "training_810_3",
    "table_caption": "Table: Abbreviations of cortical and subcortical regions defined in Automated Anatomical Labeling (AAL) template image in standard stereotaxic space. Region name Abbreviation Region name Abbreviation Precentral gyrus PreCG Lingual gyrus LING Superior frontal gyrus (dorsal) SFGdor Superior occipital gyrus SOG Orbitofrontal cortex (superior) ORBsup Middle occipital gyrus MOG Middle frontal gyrus MFG Inferior occipital gyrus IOG Orbitofrontal gyrus (middle) ORBmid Fusiform gyrus FFG Inferior frontal gyrus (opercula) IFGoperc Postcentral gyrus PoCG Inferior frontal gyrus (triangular) IFGtriang Superior parietal gyrus SPG Orbitofrontal gyrus (inferior) ORBinf Inferior parietal lobule IPL Rolandic operculum ROL Supramarginal gyrus SMG Supplementary motor area SMA Angular gyrus ANG Olfactory OLF Precuneus PCUN Superior frontal gyrus (medial) SFGmed Paracentral lobule PCL Orbitofrontal gyrus (medial) ORBmed Caudate nucleus CAU Gyrus rectus REC Putamen PUT Insula INS Pallidium PAL Anterior cingulate gyri ACG Thalamus THA Middle cingulate gyri MCG Heschl gyrus HES Posterior cingulate gyrus PCG Superior temporal gyrus STG Hippocampus HIP Temporal pole (superior) TPOsup Parahippocampal gyrus PHG Middle temporal gyrus MTG Amygdala AMYG Temporal pole (middle) TPOmid Calcarine cortex CAL Inferior temporal gyrus ITG Cuneus CUN doi:10.1371/journal.pone.0118857.t001 ",
    "table_content": "|| Region name | Abbreviation | Region name | Abbreviation ||\n|| Precentral gyrus | PreCG | Lingual gyrus | LING ||\n|| Supplementary motor area | SMA | Angular gyrus | ANG ||\n|| Olfactory | OLF | Precuneus | PCUN ||\n|| Superior frontal gyrus (medial) | SFGmed | Paracentral lobule | PCL ||\n|| Orbitofrontal gyrus (medial) | ORBmed | Caudate nucleus | CAU ||\n|| Gyrus rectus | REC | Putamen | PUT ||\n|| Insula | INS | Pallidium | PAL ||\n|| Anterior cingulate gyri | ACG | Thalamus | THA ||\n|| Middle cingulate gyri | MCG | Heschl gyrus | HES ||\n|| Posterior cingulate gyrus | PCG | Superior temporal gyrus | STG ||\n|| Hippocampus | HIP | Temporal pole (superior) | TPOsup ||\n|| Superior frontal gyrus (dorsal) | SFGdor | Superior occipital gyrus | SOG ||\n|| Parahippocampal gyrus | PHG | Middle temporal gyrus | MTG ||\n|| Amygdala | AMYG | Temporal pole (middle) | TPOmid ||\n|| Calcarine cortex | CAL | Inferior temporal gyrus | ITG ||\n|| Cuneus | CUN | blank | blank ||\n|| Orbitofrontal cortex (superior) | ORBsup | Middle occipital gyrus | MOG ||\n|| Middle frontal gyrus | MFG | Inferior occipital gyrus | IOG ||\n|| Orbitofrontal gyrus (middle) | ORBmid | Fusiform gyrus | FFG ||\n|| Inferior frontal gyrus (opercula) | IFGoperc | Postcentral gyrus | PoCG ||\n|| Inferior frontal gyrus (triangular) | IFGtriang | Superior parietal gyrus | SPG ||\n|| Orbitofrontal gyrus (inferior) | ORBinf | Inferior parietal lobule | IPL ||\n|| Rolandic operculum | ROL | Supramarginal gyrus | SMG ||",
    "claim": "The naming conventions for the frontal lobe regions are simpler, often involving fewer descriptors (e.g., superior, middle, inferior) compared to other lobes. This suggests a less detailed subdivision of functions within the frontal lobe, as seen in regions like the superior frontal gyrus (dorsal) and orbitofrontal gyrus (middle).",
    "label": "support"
  },
  {
    "id": "training_1088_2",
    "table_caption": "Table: Table 1 Single- and dual-task gait measures. Condition-by-condition mean (± SD) measures of gait performance (N = 14) Single Task Dual Task 1 Dual Task 2 Anova F Anova p Stride Duration (ms) 1054 (± 87) 1060 (± 79) 1106 (± 107)*, ** 12.165 0.001 Mean Step Length (m) 0.53 (± 0.06) 0.52 (± 0.08) 0.51 (± 0.07) 0.0769 N.S. Velocity (m/s) 0.90 (± 0.10) 0.86 (± 0.10)* 0.78 (± 0.12)*, ** 34.215 0.001 ver-RMS 2.65 (± 0.56) 2.59 (± 0.55) 2.26 (± 0.63)*, ** 17.554 0.001 ml-RMS 1.48 (± 0.32) 1.47 (± 0.31) 1.37 (± 0.40)* 7.769 0.008 ap-RMS 2.19 (± 0.28) 2.09 (± 0.25) 0.96 (± 0.33)*, ** 16.946 0.001 ver-RMSR 0.70 (± 0.05) 0.70 (± 0.05) 0.67 (± 0.06)** 5.839 0.008 ml-RMSR 0.40 (± 0.07) 0.40 (± 0.06) 0.41 (± 0.08) 1.735 N.S. ap-RMSR 0.59 (± 0.06) 0.58 (± 0.053) 0.60 (± 0.06)** 7.165 0.003 ver-Step Regularity 0.75 (± 0.09) 0.69 (± 0.19) 0.69 (± 0.13) 2.027 N.S. ap-Step Regularity 0.76 (± 0.09) 0.73 (± 0.11) 0.71 (± 0.09)* 6.642 0.005 Repeated measures ANOVA p-values are reported in the right-side column. Statistically significant paired-samples t-test corrected for multiple comparisons are highlighted with * (ST vs DTi with i = 1, 2) and/or ** (DT1 vs. DT2). N.S., not significant ",
    "table_content": "|| blank | Single Task | Dual Task 1 | Dual Task 2 | Anova F | Anova p ||\n|| Stride Duration (ms) | 1054 (± 87) | 1060 (± 79) | 1106 (± 107)*, ** | 12.165 | 0.001 ||\n|| ver-Step Regularity | 0.75 (± 0.09) | 0.69 (± 0.19) | 0.69 (± 0.13) | 2.027 | N.S. ||\n|| ap-Step Regularity | 0.76 (± 0.09) | 0.73 (± 0.11) | 0.71 (± 0.09)* | 6.642 | 0.005 ||\n|| Mean Step Length (m) | 0.53 (± 0.06) | 0.52 (± 0.08) | 0.51 (± 0.07) | 0.0769 | N.S. ||\n|| Velocity (m/s) | 0.90 (± 0.10) | 0.86 (± 0.10)* | 0.78 (± 0.12)*, ** | 34.215 | 0.001 ||\n|| ver-RMS | 2.65 (± 0.56) | 2.59 (± 0.55) | 2.26 (± 0.63)*, ** | 17.554 | 0.001 ||\n|| ml-RMS | 1.48 (± 0.32) | 1.47 (± 0.31) | 1.37 (± 0.40)* | 7.769 | 0.008 ||\n|| ap-RMS | 2.19 (± 0.28) | 2.09 (± 0.25) | 0.96 (± 0.33)*, ** | 16.946 | 0.001 ||\n|| ver-RMSR | 0.70 (± 0.05) | 0.70 (± 0.05) | 0.67 (± 0.06)** | 5.839 | 0.008 ||\n|| ml-RMSR | 0.40 (± 0.07) | 0.40 (± 0.06) | 0.41 (± 0.08) | 1.735 | N.S. ||\n|| ap-RMSR | 0.59 (± 0.06) | 0.58 (± 0.053) | 0.60 (± 0.06)** | 7.165 | 0.003 ||",
    "claim": "The decrease in velocity from Single Task to Dual Task 2, with a 13% reduction, reflects a substantial impact of dual-tasking on gait speed, as supported by the high ANOVA F-value.",
    "label": "support"
  },
  {
    "id": "training_589_2",
    "table_caption": "Table: H. volcanii genes with a differential translational repression in exponential phase or in stationary phase*1 Translational repression factor Identifier Putative function length (bp) exp stat ∅ SD n ∅ SD n 451B11 Inosine monophosphate dehydrogenase 365 49.7 56.0 3 8.8 2.9 3 431C4 Phage integrase-site-specific recombinase Xer 644 17.5 19.8 2 1.9 1.2 2 Conserved hypothetical protein 528 432A4 NAD dependent epimerase-dehydratase 770 12.8 5.6 4 5.4 2.9 3 439E12 Tfb2 – transcription initiation factor IIB 590 10.4 9.0 3 1.6 0.3 2 435D7 Nitrate transporter NarK 606 7.6 3.8 4 3.0 1.1 3 431H5 Alpha amylase AglA 613 5.4 0.5 2 2.4 1.3 3 Nitrate transporter NarK 455 435A4 4.7 2.7 3 1.4 0.8 2 437B8 HoxA-like transcriptional regulator (Hrg) 578 4.5 0.1 2 1.5 0.3 3 Transcription regulator 413 453C11 Tfb2 – transcription initiation factor IIB 335 3.6 0.3 2 1.9 0.9 3 451G12 Hypothetical protein 581 2.5 0.3 2 0.9 0.9 2 Conserved hypothetical protein 441 433F2 Glycosyltransferase 953 2.3 1.4 3 0.5 0.1 3 Stage V sporulation protein R-like (SpoVR) 593 435F2 CRISPR-associated protein, TM1814 family (Cas6) 222 8.6 3.5 4 21.9 12.7 3 432H1 Methyltransferase type 11 415 5.0 4.2 2 13.1 2.7 3 Hypothetical protein 362 Domain of unknown function (DUF309) family 232 443B4 Transposase (Tnp) 518 4.5 0.8 4 7.9 3.5 3 441F8 Tat pathway signal sequence domain protein 1008 2.2 0.1 3 4.8 2.6 3 459C3 Cell surface glycoprotein (Csg) 1167 1.1 0.3 4 3.9 2.0 3 445E9 0.6 0.4 2 3.3 0.2 2 433A10 Helicase family protein 1307 1.1 0.2 2 3.3 2.1 3 Hypothetical protein 431 441E1 DSBA-like thioredoxin domain protein 683 1.3 0.1 2 2.8 1.7 3 Ferredoxin like protein 377 Mut-nudix family protein 363 443C1 Ubiquinol oxidase subunit I, cyanide insensitive (CydA) 1391 0.9 0.1 3 2.4 1.1 3 431D10 Solute-binding periplasmic ABC transporter 1148 1.0 0.1 3 2.3 0.4 2 ABC transporter, permease protein 475 452E1 Ferrichrome-binding protein 848 1.2 0.3 4 2.3 0.6 3 451E8 Ribonuclease HII (RnhB) 579 1.1 0.5 4 2.2 0.7 3 Preprotein-export translocase chain SecD 408 460F5 Preprotein-export translocase chain SecD 988 1.2 0.6 3 2.2 0.2 3 440D1 Conserved hypothetical protein 992 1.0 0.1 3 2.0 0.0 2 444G9 Conserved hypothetical protein 1120 0.5 0.1 3 2.0 0.4 3 Fibronectin type III domain protein 408 *1All genes are tabulated which have a \"translational repression factor\" of ≥2 differentially in exponential phase (upper part) or in stationary phase (lower part). The translational repression factor is the quotient of free RNA to polysome-bound RNA (normalized to the average of all genes). The ",
    "table_content": "|| Identifier | Putative function | length (bp) | Translational repression factor | Translational repression factor | Translational repression factor | Translational repression factor | Translational repression factor | Translational repression factor ||\n|| Identifier | Putative function | length (bp) | exp | exp | exp | stat | stat | stat ||\n|| 431H5 | Nitrate transporter NarK | 455 | blank | blank | blank | blank | blank | blank ||\n|| 435A4 | blank | blank | 4.7 | 2.7 | 3 | 1.4 | 0.8 | 2 ||\n|| 437B8 | HoxA-like transcriptional regulator (Hrg) | 578 | 4.5 | 0.1 | 2 | 1.5 | 0.3 | 3 ||\n|| 437B8 | Transcription regulator | 413 | blank | blank | blank | blank | blank | blank ||\n|| 453C11 | Tfb2 – transcription initiation factor IIB | 335 | 3.6 | 0.3 | 2 | 1.9 | 0.9 | 3 ||\n|| 451G12 | Hypothetical protein | 581 | 2.5 | 0.3 | 2 | 0.9 | 0.9 | 2 ||\n|| 451G12 | Conserved hypothetical protein | 441 | blank | blank | blank | blank | blank | blank ||\n|| 433F2 | Glycosyltransferase | 953 | 2.3 | 1.4 | 3 | 0.5 | 0.1 | 3 ||\n|| 433F2 | Stage V sporulation protein R-like (SpoVR) | 593 | blank | blank | blank | blank | blank | blank ||\n|| 435F2 | CRISPR-associated protein, TM1814 family (Cas6) | 222 | 8.6 | 3.5 | 4 | 21.9 | 12.7 | 3 ||\n|| Identifier | Putative function | length (bp) | ∅ | SD | n | ∅ | SD | n ||\n|| 432H1 | Methyltransferase type 11 | 415 | 5.0 | 4.2 | 2 | 13.1 | 2.7 | 3 ||\n|| 432H1 | Hypothetical protein | 362 | blank | blank | blank | blank | blank | blank ||\n|| 432H1 | Domain of unknown function (DUF309) family | 232 | blank | blank | blank | blank | blank | blank ||\n|| 443B4 | Transposase (Tnp) | 518 | 4.5 | 0.8 | 4 | 7.9 | 3.5 | 3 ||\n|| 441F8 | Tat pathway signal sequence domain protein | 1008 | 2.2 | 0.1 | 3 | 4.8 | 2.6 | 3 ||\n|| 459C3 | Cell surface glycoprotein (Csg) | 1167 | 1.1 | 0.3 | 4 | 3.9 | 2.0 | 3 ||\n|| 445E9 | blank | blank | 0.6 | 0.4 | 2 | 3.3 | 0.2 | 2 ||\n|| 433A10 | Helicase family protein | 1307 | 1.1 | 0.2 | 2 | 3.3 | 2.1 | 3 ||\n|| 433A10 | Hypothetical protein | 431 | blank | blank | blank | blank | blank | blank ||\n|| 441E1 | DSBA-like thioredoxin domain protein | 683 | 1.3 | 0.1 | 2 | 2.8 | 1.7 | 3 ||\n|| 451B11 | Inosine monophosphate dehydrogenase | 365 | 49.7 | 56.0 | 3 | 8.8 | 2.9 | 3 ||\n|| 441E1 | Ferredoxin like protein | 377 | blank | blank | blank | blank | blank | blank ||\n|| 441E1 | Mut-nudix family protein | 363 | blank | blank | blank | blank | blank | blank ||\n|| 443C1 | Ubiquinol oxidase subunit I, cyanide insensitive (CydA) | 1391 | 0.9 | 0.1 | 3 | 2.4 | 1.1 | 3 ||\n|| 431D10 | Solute-binding periplasmic ABC transporter | 1148 | 1.0 | 0.1 | 3 | 2.3 | 0.4 | 2 ||\n|| 431D10 | ABC transporter, permease protein | 475 | blank | blank | blank | blank | blank | blank ||\n|| 452E1 | Ferrichrome-binding protein | 848 | 1.2 | 0.3 | 4 | 2.3 | 0.6 | 3 ||\n|| 451E8 | Ribonuclease HII (RnhB) | 579 | 1.1 | 0.5 | 4 | 2.2 | 0.7 | 3 ||\n|| 451E8 | Preprotein-export translocase chain SecD | 408 | blank | blank | blank | blank | blank | blank ||\n|| 460F5 | Preprotein-export translocase chain SecD | 988 | 1.2 | 0.6 | 3 | 2.2 | 0.2 | 3 ||\n|| 440D1 | Conserved hypothetical protein | 992 | 1.0 | 0.1 | 3 | 2.0 | 0.0 | 2 ||\n|| 431C4 | Phage integrase-site-specific recombinase Xer | 644 | 17.5 | 19.8 | 2 | 1.9 | 1.2 | 2 ||\n|| 444G9 | Conserved hypothetical protein | 1120 | 0.5 | 0.1 | 3 | 2.0 | 0.4 | 3 ||\n|| 444G9 | Fibronectin type III domain protein | 408 | blank | blank | blank | blank | blank | blank ||\n|| 431C4 | Conserved hypothetical protein | 528 | blank | blank | blank | blank | blank | blank ||\n|| 432A4 | NAD dependent epimerase-dehydratase | 770 | 12.8 | 5.6 | 4 | 5.4 | 2.9 | 3 ||\n|| 439E12 | Tfb2 – transcription initiation factor IIB | 590 | 10.4 | 9.0 | 3 | 1.6 | 0.3 | 2 ||\n|| 435D7 | Nitrate transporter NarK | 606 | 7.6 | 3.8 | 4 | 3.0 | 1.1 | 3 ||\n|| 431H5 | Alpha amylase AglA | 613 | 5.4 | 0.5 | 2 | 2.4 | 1.3 | 3 ||",
    "claim": "There is no direct correlation between gene length and translational repression factor, as evidenced by the \"Ubiquinol oxidase subunit I, cyanide insensitive (CydA)\" gene, which has one of the longest lengths but one of the lowest repression factors in both phases.",
    "label": "support"
  },
  {
    "id": "training_817_2",
    "table_caption": "Table: No. of smokers participated in the QTW Contest, RCT and included in this Study Sample n = 1307 (%) Participated in the QTW Contest 1307 (100%) Successfully interviewed at the 1-week follow-up 1030 (78.8%) Answered questions on ever EC use 956 (73.1%) n = 956 (%) Ever EC users 163 (17.1%) Non-users 793 (82.9%) QTW: “Quit to Win” contest. EC: electronic cigarette. ",
    "table_content": "|| Study Sample | n = 1307 (%) ||\n|| Participated in the QTW Contest | 1307 (100%) ||\n|| Successfully interviewed at the 1-week follow-up | 1030 (78.8%) ||\n|| Answered questions on ever EC use | 956 (73.1%) ||\n|| Answered questions on ever EC use | n = 956 (%) ||\n|| Ever EC users | 163 (17.1%) ||\n|| Non-users | 793 (82.9%) ||",
    "claim": "Of the initial participants, 73.1% answered questions on ever EC use. This suggests a high level of continued engagement, with a slight drop-off from the 1-week follow-up interviews.",
    "label": "support"
  },
  {
    "id": "training_155_4",
    "table_caption": "Table: of are 6: 1H (d, m/z For 52.22; Table 3 Yield % of the synthesized carbonyl analogue of the targeted bis(imidazoazines) Entry X 14,b(o-isomer) Yield%a 1 2 14a 58 2 4 14b 60 15-d(p-isomer) 3 3 15a 78 4 4 15b 81 aYields of isolated compounds. ",
    "table_content": "|| Entry | X | 14,b( o- isomer) | Yield% a ||\n|| 1 | 2 | 14a | 58 ||\n|| 2 | 4 | 14b | 60 ||\n|| 2 | blank | 15-d( p -isomer) | blank ||\n|| 3 | 3 | 15a | 78 ||\n|| 4 | 4 | 15b | 81 ||",
    "claim": "The maximum yield of 81% in Entry 4 is 39.66% higher than the minimum yield of 58% in Entry 1, demonstrating the optimization of synthesis conditions for the highest efficiency.",
    "label": "support"
  },
  {
    "id": "training_155_4",
    "table_caption": "Table: of are 6: 1H (d, m/z For 52.22; Table 3 Yield % of the synthesized carbonyl analogue of the targeted bis(imidazoazines) Entry X 14,b(o-isomer) Yield%a 1 2 14a 58 2 4 14b 60 15-d(p-isomer) 3 3 15a 78 4 4 15b 81 aYields of isolated compounds. ",
    "table_content": "|| Entry | X | 14,b( o- isomer) | Yield% a ||\n|| 1 | 2 | 14a | 58 ||\n|| 2 | 4 | 14b | 60 ||\n|| 2 | blank | 15-d( p -isomer) | blank ||\n|| 3 | 3 | 15a | 78 ||\n|| 4 | 4 | 15b | 81 ||",
    "claim": "The maximum yield of 81% in Entry 4 is 23% higher than the minimum yield of 58% in Entry 1, demonstrating the optimization of synthesis conditions for the highest efficiency.",
    "label": "support"
  },
  {
    "id": "training_1050_3",
    "table_caption": "Table: children teacher between diﬃculty prenatal the housing as level were parental 2. size their TABLE 2 | Mean (SD) of teacher ratings of child behavior using SDQ according to the LOC orientation of the child’s parents as measured in pregnancy. Child behavior M.Ex. F.Ex M.Ex. F.In M.In. F.Ex M.In. F.In Hyperactivity Year 3 2.99 [2.79] 2.57 [2.66]∗∗ 2.40 [2.58] 2.07 [2.40]∗∗ Year 6 2.74 [2.84] 2.00 [2.39]∗∗∗ 2.16 [2.56]a 1.66 [2.28]∗∗∗ Emotional problems Year 3 1.53 [2.05] 1.43 [2.01] 1.30 [1.85] 1.19 [1.74] Year 6 1.44 [1.97] 1.28 [1.92] 1.28 [1.84] 1.13 [1.70]∗ Conduct problems Year 3 0.87 [1.61] 0.72 [1.38]∗ 0.59 [1.26] 0.53 [1.13] Year 6 1.02 [1.74] 0.61 [1.26]∗∗∗ 0.77 [1.55]a 0.56 [1.27]∗∗∗ Peer problems Year 3 1.26 [1.81] 1.19 [1.81] 1.06 [1.72] 1.04 [1.67] Year 6 1.28 [1.90] 1.07 [1.71]∗ 1.25 [1.93] 1.11 [1.80] Total difﬁculties Year 3 6.66 [5.97] 5.91 [5.59]∗∗ 5.34 [5.26] 4.83 [5.01]∗ Year 6 6.47 [6.23] 4.96 [5.01]∗∗∗ 5.46 [5.85]a 4.46 [5.18]∗∗∗ aDifference between M.Ex.F.In and M.In.F.Ex: P < 0.05. (The higher the score, the worse the behavior.) [Asterisks indicate differences between the pairs of father orientation as ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.] ",
    "table_content": "|| Child behavior | M.Ex. F.Ex | M.Ex. F.In | M.In. F.Ex | M.In. F.In ||\n|| Hyperactivity | Hyperactivity | Hyperactivity | Hyperactivity | Hyperactivity ||\n|| Peer problems | Peer problems | Peer problems | Peer problems | Peer problems ||\n|| Year 3 | 1.26 [1.81] | 1.19 [1.81] | 1.06 [1.72] | 1.04 [1.67] ||\n|| Year 6 | 1.28 [1.90] | 1.07 [1.71] ∗ | 1.25 [1.93] | 1.11 [1.80] ||\n|| Total difficulties | Total difficulties | Total difficulties | Total difficulties | Total difficulties ||\n|| Year 3 | 6.66 [5.97] | 5.91 [5.59] ∗∗ | 5.34 [5.26] | 4.83 [5.01] ∗ ||\n|| Year 6 | 6.47 [6.23] | 4.96 [5.01] ∗∗∗ | 5.46 [5.85] a | 4.46 [5.18] ∗∗∗ ||\n|| Year 3 | 2.99 [2.79] | 2.57 [2.66] ∗∗ | 2.40 [2.58] | 2.07 [2.40] ∗∗ ||\n|| Year 6 | 2.74 [2.84] | 2.00 [2.39] ∗∗∗ | 2.16 [2.56] a | 1.66 [2.28] ∗∗∗ ||\n|| Emotional problems | Emotional problems | Emotional problems | Emotional problems | Emotional problems ||\n|| Year 3 | 1.53 [2.05] | 1.43 [2.01] | 1.30 [1.85] | 1.19 [1.74] ||\n|| Year 6 | 1.44 [1.97] | 1.28 [1.92] | 1.28 [1.84] | 1.13 [1.70] ∗ ||\n|| Conduct problems | Conduct problems | Conduct problems | Conduct problems | Conduct problems ||\n|| Year 3 | 0.87 [1.61] | 0.72 [1.38] ∗ | 0.59 [1.26] | 0.53 [1.13] ||\n|| Year 6 | 1.02 [1.74] | 0.61 [1.26] ∗∗∗ | 0.77 [1.55] a | 0.56 [1.27] ∗∗∗ ||",
    "claim": "The conduct problems score for children with M.Ex. F.In parents decreased by approximately 15%, while the score for children with M.In. F.Ex parents increased by about 30%, highlighting a divergent trend in behavior based on parental LOC orientation.",
    "label": "support"
  },
  {
    "id": "training_723_1",
    "table_caption": "Table: of levels that is associated with an increase in telomere length. Outcome Percentage Change (95% CI) p-Value Systolic BP (mmHg) 0.2 (21.1, 1.5) p = 0.798 Diastolic BP (mmHg) 0.3 (21.0, 1.7) p = 0.642 Cholesterol (mmol/l) 2.4 (0.3, 4.6) p = 0.027 HDL cholesterol (mmol/l) 21.2 (23.9, 1.6) p = 0.387 LDL cholesterol (mmol/l) 3.7 (0.4, 7.1) p = 0.027 Triglycerides (mmol/l) 2.7 (22.6, 8.3) p = 0.326 Glucose (mmol/l) 0.8 (21.0, 2.7) p = 0.363 Insulin (mU/l) 20.5 (27.5, 6.9) p = 0.884 HOMA - IR 20.1 (27.5, 8.0) p = 0.989 C reactive protein (mg/l) 0.6 (29.9, 12.4) p = 0.916 Interleukin 6 (pg/ml) 27.2 (212.9, 21.1) p = 0.022 Intercellular adhesion molecule 1 (ng/ml) 20.3 (22.9, 2.3) p = 0.796 Fibrinogen (g/l) 0.2 (21.9, 2.4) p = 0.829 von Willebrand factor (IU/dl) 21.2 (24.2, 1.8) p = 0.416 D-dimer (ng/ml) 21.7 (27.4, 4.4) p = 0.583 Individuals with longer telomeres had increased levels of total cholesterol (2.4% increase, p = 0.027) and LDL cholesterol (3.7%, p = 0.027). Conversely, shorter ",
    "table_content": "|| Outcome | Percentage Change (95% CI)p-Value ||\n|| Systolic BP (mmHg) | 0.2 (−1.1, 1.5) p = 0.798 ||\n|| C reactive protein (mg/l) | 0.6 (−9.9, 12.4) p = 0.916 ||\n|| Interleukin 6 (pg/ml) |  −7.2 (−12.9, −1.1) p = 0.022  ||\n|| Intercellular adhesion molecule 1 (ng/ml) | −0.3 (−2.9, 2.3) p = 0.796 ||\n|| Fibrinogen (g/l) | 0.2 (−1.9, 2.4) p = 0.829 ||\n|| von Willebrand factor (IU/dl) | −1.2 (−4.2, 1.8) p = 0.416 ||\n|| D-dimer (ng/ml) | −1.7 (−7.4, 4.4) p = 0.583 ||\n|| Diastolic BP (mmHg) | 0.3 (−1.0, 1.7) p = 0.642 ||\n|| Cholesterol (mmol/l) | 2.4 (0.3, 4.6) p = 0.027 ||\n|| HDL cholesterol (mmol/l) | −1.2 (−3.9, 1.6) p = 0.387 ||\n|| LDL cholesterol (mmol/l) |  3.7 (0.4, 7.1) p = 0.027  ||\n|| Triglycerides (mmol/l) | 2.7 (−2.6, 8.3) p = 0.326 ||\n|| Glucose (mmol/l) | 0.8 (−1.0, 2.7) p = 0.363 ||\n|| Insulin (mU/l) | −0.5 (−7.5, 6.9) p = 0.884 ||\n|| HOMA - IR | −0.1 (−7.5, 8.0) p = 0.989 ||",
    "claim": "The increase in LDL cholesterol is statistically significant, with a p-value of 0.027. This suggests a robust association between longer telomeres and higher LDL cholesterol levels, as the confidence interval does not include zero, indicating a consistent positive change.",
    "label": "support"
  },
  {
    "id": "training_877_2",
    "table_caption": "Table: Table 2 Badapple datasets BARD assay counts are experiment counts. Tested means bioassay data exist. Nonzero means tested with nonzero scores #scafs Tested Nonzero #assy Activities Date Source Bard1 146,024 141,642 54,136 510 30M 2013-01 BARD Bard2 143,098 137,668 52,328 383 46M 2014-06 BARD Pc1 143,098 141,533 60,200 822 223M 2014-06 PubChem Pc2 143,098 125,940 50,912 527 113M 2010-12 PubChem ",
    "table_content": "|| blank | #scafs | Tested | Nonzero | #assy | Activities | Date | Source ||\n|| Bard1 | 146,024 | 141,642 | 54,136 | 510 | 30M | 2013-01 | BARD ||\n|| Bard2 | 143,098 | 137,668 | 52,328 | 383 | 46M | 2014-06 | BARD ||\n|| Pc1 | 143,098 | 141,533 | 60,200 | 822 | 223M | 2014-06 | PubChem ||\n|| Pc2 | 143,098 | 125,940 | 50,912 | 527 | 113M | 2010-12 | PubChem ||",
    "claim": "The ratio of nonzero scores to tested assays is highest in Pc1, suggesting a higher proportion of active compounds in this dataset. This is calculated by dividing the nonzero scores by the tested assays for each dataset and comparing the ratios.",
    "label": "support"
  },
  {
    "id": "training_424_2",
    "table_caption": "Table: Table 2 Incidence and risk of de novo cancer development after kidney transplantation according to mTOR inhibitor treatment in time-dependent model. Outcome With mTORi Without mTORi Adjusted HR* (95% CI) p-value Events IR Events IR Any cancer 87 17.0 628 23.6 0.80 (0.60–1.09) 0.16 Kidney 17 3.1 109 3.8 1.29 (0.62–2.66) 0.50 Bladder 17 3.2 152 5.3 0.53 (0.28–1.00) 0.05 Lung 3 0.6 26 0.9 0.65 (0.14–3.11) 0.59 Liver 6 1.1 65 2.2 0.84 (0.28–2.56) 0.76 Colorectal 4 0.7 27 0.9 1.73 (0.39–7.66) 0.47 Breast 1 0.2 23 0.8 0.29 (0.03–3.27) 0.32 Hematological 5 0.9 24 0.8 2.03 (0.46–8.92) 0.35 Skin 1 0.2 4 0.1 5.66 (0.14–226) 0.36 Prostate 3 0.6 17 0.6 1.26 (0.21–7.49) 0.80 Others 30 5.6 208 7.3 0.73 (0.44–1.21) 0.23 Many cancers(S2) 3 0.6 35 1.3 1.12 (0.22–5.75) 0.89 Notes: IR: incidence rate, per 1,000 person-years. * Adjusted for age, gender, dialysis vintage, transplant within/overseas, DM, HTN, CHF, ACEi/ARB, Beta-blocker, ",
    "table_content": "|| Outcome | With mTORi | With mTORi | Without mTORi | Without mTORi | Adjusted HR * (95% CI) | p -value ||\n|| Outcome | Events | IR | Events | IR | Adjusted HR * (95% CI) | p -value ||\n|| Skin | 1 | 0.2 | 4 | 0.1 | 5.66 (0.14–226) | 0.36 ||\n|| Prostate | 3 | 0.6 | 17 | 0.6 | 1.26 (0.21–7.49) | 0.80 ||\n|| Others | 30 | 5.6 | 208 | 7.3 | 0.73 (0.44–1.21) | 0.23 ||\n|| Many cancers(≧2) | 3 | 0.6 | 35 | 1.3 | 1.12 (0.22–5.75) | 0.89 ||\n|| Any cancer | 87 | 17.0 | 628 | 23.6 | 0.80 (0.60–1.09) | 0.16 ||\n|| Kidney | 17 | 3.1 | 109 | 3.8 | 1.29 (0.62–2.66) | 0.50 ||\n|| Bladder | 17 | 3.2 | 152 | 5.3 | 0.53 (0.28–1.00) | 0.05 ||\n|| Lung | 3 | 0.6 | 26 | 0.9 | 0.65 (0.14–3.11) | 0.59 ||\n|| Liver | 6 | 1.1 | 65 | 2.2 | 0.84 (0.28–2.56) | 0.76 ||\n|| Colorectal | 4 | 0.7 | 27 | 0.9 | 1.73 (0.39–7.66) | 0.47 ||\n|| Breast | 1 | 0.2 | 23 | 0.8 | 0.29 (0.03–3.27) | 0.32 ||\n|| Hematological | 5 | 0.9 | 24 | 0.8 | 2.03 (0.46–8.92) | 0.35 ||",
    "claim": "For bladder cancer, the incidence rate among mTORi users is 40% lower than non-users, as reflected by the adjusted hazard ratio of 0.53. This suggests a substantial reduction in bladder cancer risk with mTORi treatment, with a p-value of 0.05 indicating borderline statistical significance.",
    "label": "support"
  },
  {
    "id": "training_424_2",
    "table_caption": "Table: Table 2 Incidence and risk of de novo cancer development after kidney transplantation according to mTOR inhibitor treatment in time-dependent model. Outcome With mTORi Without mTORi Adjusted HR* (95% CI) p-value Events IR Events IR Any cancer 87 17.0 628 23.6 0.80 (0.60–1.09) 0.16 Kidney 17 3.1 109 3.8 1.29 (0.62–2.66) 0.50 Bladder 17 3.2 152 5.3 0.53 (0.28–1.00) 0.05 Lung 3 0.6 26 0.9 0.65 (0.14–3.11) 0.59 Liver 6 1.1 65 2.2 0.84 (0.28–2.56) 0.76 Colorectal 4 0.7 27 0.9 1.73 (0.39–7.66) 0.47 Breast 1 0.2 23 0.8 0.29 (0.03–3.27) 0.32 Hematological 5 0.9 24 0.8 2.03 (0.46–8.92) 0.35 Skin 1 0.2 4 0.1 5.66 (0.14–226) 0.36 Prostate 3 0.6 17 0.6 1.26 (0.21–7.49) 0.80 Others 30 5.6 208 7.3 0.73 (0.44–1.21) 0.23 Many cancers(S2) 3 0.6 35 1.3 1.12 (0.22–5.75) 0.89 Notes: IR: incidence rate, per 1,000 person-years. * Adjusted for age, gender, dialysis vintage, transplant within/overseas, DM, HTN, CHF, ACEi/ARB, Beta-blocker, ",
    "table_content": "|| Outcome | With mTORi | With mTORi | Without mTORi | Without mTORi | Adjusted HR * (95% CI) | p -value ||\n|| Outcome | Events | IR | Events | IR | Adjusted HR * (95% CI) | p -value ||\n|| Skin | 1 | 0.2 | 4 | 0.1 | 5.66 (0.14–226) | 0.36 ||\n|| Prostate | 3 | 0.6 | 17 | 0.6 | 1.26 (0.21–7.49) | 0.80 ||\n|| Others | 30 | 5.6 | 208 | 7.3 | 0.73 (0.44–1.21) | 0.23 ||\n|| Many cancers(≧2) | 3 | 0.6 | 35 | 1.3 | 1.12 (0.22–5.75) | 0.89 ||\n|| Any cancer | 87 | 17.0 | 628 | 23.6 | 0.80 (0.60–1.09) | 0.16 ||\n|| Kidney | 17 | 3.1 | 109 | 3.8 | 1.29 (0.62–2.66) | 0.50 ||\n|| Bladder | 17 | 3.2 | 152 | 5.3 | 0.53 (0.28–1.00) | 0.05 ||\n|| Lung | 3 | 0.6 | 26 | 0.9 | 0.65 (0.14–3.11) | 0.59 ||\n|| Liver | 6 | 1.1 | 65 | 2.2 | 0.84 (0.28–2.56) | 0.76 ||\n|| Colorectal | 4 | 0.7 | 27 | 0.9 | 1.73 (0.39–7.66) | 0.47 ||\n|| Breast | 1 | 0.2 | 23 | 0.8 | 0.29 (0.03–3.27) | 0.32 ||\n|| Hematological | 5 | 0.9 | 24 | 0.8 | 2.03 (0.46–8.92) | 0.35 ||",
    "claim": "For bladder cancer, the incidence rate among mTORi users is 10% lower than non-users, as reflected by the adjusted hazard ratio of 0.53. This suggests a substantial reduction in bladder cancer risk with mTORi treatment, with a p-value of 0.05 indicating borderline statistical significance.",
    "label": "support"
  },
  {
    "id": "training_153_4",
    "table_caption": "Table: TABLE 2 | Step II: numerical search results. Keywords Cochrane PubMed PMC Elsevier PEDro ISI Total “upper limb exoskeleton” 0 33 63 3 1 155 255 “upper limb mobile robot” 0 0 0 0 0 0 0 “upper limb wearable robot” 0 0 0 0 0 1 1 “upper limb portable robot” 0 0 0 0 0 0 0 “upper limb robotic exoskeleton” 0 3 1 0 0 12 16 ‘upper limb robotic orthosis’ 0 0 0 0 0 0 1 “upper limb robotic device” 0 0 0 0 0 0 0 Total 0 36 64 3 1 169 273 ",
    "table_content": "|| Keywords | Cochrane | PubMed | PMC | Elsevier | PEDro | ISI | Total ||\n|| “ upper limb exoskeleton” | 0 | 33 | 63 | 3 | 1 | 155 | 255 ||\n|| “ upper limb mobile robot” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| “ upper limb wearable robot” | 0 | 0 | 0 | 0 | 0 | 1 | 1 ||\n|| “ upper limb portable robot” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| “ upper limb robotic exoskeleton” | 0 | 3 | 1 | 0 | 0 | 12 | 16 ||\n|| ‘ upper limb robotic orthosis’ | 0 | 0 | 0 | 0 | 0 | 0 | 1 ||\n|| “ upper limb robotic device” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| Total | 0 | 36 | 64 | 3 | 1 | 169 | 273 ||",
    "claim": "The ISI database has the highest number of search results for the keyword \"upper limb exoskeleton,\" with 155 results, which is less than four times the total results from all other databases combined for this keyword.",
    "label": "support"
  },
  {
    "id": "training_356_5",
    "table_caption": "Table: TABLE 1 | Drugs showing therapeutic effects on mental disorders by modulation of astrocytic functions. Drugs Actions on astrocytes Mental disorder Reference ALX5497, NEPS Inhibition of D-Ser uptake Schizophrenia Lipina et al. (2005) Karasawa et al. (2008) Kawaura et al. (2014) Compound 8, CBIO, AS05728 Inhibition of DAAO Schizophrenia Adage et al. (2008) Hashimoto et al. (2009) Smith et al. (2009) Clozapine Stimulation of D-Ser release Schizophrenia Tanahashi et al. (2012) Riluzole Increases in L-Glu transport Depression Banasr et al. (2010) Desipramine, Fluoxtine, Mianserin, Chromipramine, Paroxetine Productions of neurotrophic factors Depression Hisaoka et al. (2001) Mallei et al. (2002) Bachis et al. (2008) Allaman et al. (2011) Liu et al. (2012) Kittel-Schneider et al. (2012) Amitriptyrine, Fluoxetine, Duloxetine Increases in CX43 expression Depression Sun et al. (2012) Morioka et al. (2014) MS-153 Increases in L-Glu transport Drug dependence Nakagawa et al. (2005) Cabergoline Production of GDNF Drug dependence Ohta et al. (2003, 2004) Fenobam, AFQ056 mGluR5 antagonism Fragile X syndrome Levenga et al. (2011) Vinueza Veloz et al. (2012) ",
    "table_content": "|| Drugs | Actions on astrocytes | Mental disorder | Reference ||\n|| ALX5497, NEPS | Inhibition of D-Ser uptake | Schizophrenia | Lipina et al. ( 2005 ) Karasawa et al. ( 2008 ) Kawaura et al. ( 2014 ) ||\n|| Compound 8, CBIO, AS05728 | Inhibition of DAAO | Schizophrenia | Adage et al. ( 2008 ) Hashimoto et al. ( 2009 ) Smith et al. ( 2009 ) ||\n|| Clozapine | Stimulation of D-Ser release | Schizophrenia | Tanahashi et al. ( 2012 ) ||\n|| Riluzole | Increases in L-Glu transport | Depression | Banasr et al. ( 2010 ) ||\n|| Desipramine, Fluoxtine, Mianserin, Chromipramine, Paroxetine | Productions of neurotrophic factors | Depression | Hisaoka et al. ( 2001 ) Mallei et al. ( 2002 ) Bachis et al. ( 2008 ) Allaman et al. ( 2011 ) Liu et al. ( 2012 ) Kittel-Schneider et al. ( 2012 ) ||\n|| Amitriptyrine, Fluoxetine, Duloxetine | Increases in CX43 expression | Depression | Sun et al. ( 2012 ) Morioka et al. ( 2014 ) ||\n|| MS-153 | Increases in L-Glu transport | Drug dependence | Nakagawa et al. ( 2005 ) ||\n|| Cabergoline | Production of GDNF | Drug dependence | Ohta et al. ( 2003 , 2004 ) ||\n|| Fenobam, AFQ056 | mGluR5 antagonism | Fragile X syndrome | Levenga et al. ( 2011 ) Vinueza Veloz et al. ( 2012 ) ||",
    "claim": "For schizophrenia, the drugs ALX5497, NEPS, Compound 8, CBIO, AS05728, and Clozapine target the disorder through different actions on astrocytes, such as inhibition of D-Ser uptake, inhibition of DAAO, and stimulation of D-Ser release, indicating diverse mechanistic approaches to treatment.",
    "label": "support"
  },
  {
    "id": "training_356_5",
    "table_caption": "Table: TABLE 1 | Drugs showing therapeutic effects on mental disorders by modulation of astrocytic functions. Drugs Actions on astrocytes Mental disorder Reference ALX5497, NEPS Inhibition of D-Ser uptake Schizophrenia Lipina et al. (2005) Karasawa et al. (2008) Kawaura et al. (2014) Compound 8, CBIO, AS05728 Inhibition of DAAO Schizophrenia Adage et al. (2008) Hashimoto et al. (2009) Smith et al. (2009) Clozapine Stimulation of D-Ser release Schizophrenia Tanahashi et al. (2012) Riluzole Increases in L-Glu transport Depression Banasr et al. (2010) Desipramine, Fluoxtine, Mianserin, Chromipramine, Paroxetine Productions of neurotrophic factors Depression Hisaoka et al. (2001) Mallei et al. (2002) Bachis et al. (2008) Allaman et al. (2011) Liu et al. (2012) Kittel-Schneider et al. (2012) Amitriptyrine, Fluoxetine, Duloxetine Increases in CX43 expression Depression Sun et al. (2012) Morioka et al. (2014) MS-153 Increases in L-Glu transport Drug dependence Nakagawa et al. (2005) Cabergoline Production of GDNF Drug dependence Ohta et al. (2003, 2004) Fenobam, AFQ056 mGluR5 antagonism Fragile X syndrome Levenga et al. (2011) Vinueza Veloz et al. (2012) ",
    "table_content": "|| Drugs | Actions on astrocytes | Mental disorder | Reference ||\n|| ALX5497, NEPS | Inhibition of D-Ser uptake | Schizophrenia | Lipina et al. ( 2005 ) Karasawa et al. ( 2008 ) Kawaura et al. ( 2014 ) ||\n|| Compound 8, CBIO, AS05728 | Inhibition of DAAO | Schizophrenia | Adage et al. ( 2008 ) Hashimoto et al. ( 2009 ) Smith et al. ( 2009 ) ||\n|| Clozapine | Stimulation of D-Ser release | Schizophrenia | Tanahashi et al. ( 2012 ) ||\n|| Riluzole | Increases in L-Glu transport | Depression | Banasr et al. ( 2010 ) ||\n|| Desipramine, Fluoxtine, Mianserin, Chromipramine, Paroxetine | Productions of neurotrophic factors | Depression | Hisaoka et al. ( 2001 ) Mallei et al. ( 2002 ) Bachis et al. ( 2008 ) Allaman et al. ( 2011 ) Liu et al. ( 2012 ) Kittel-Schneider et al. ( 2012 ) ||\n|| Amitriptyrine, Fluoxetine, Duloxetine | Increases in CX43 expression | Depression | Sun et al. ( 2012 ) Morioka et al. ( 2014 ) ||\n|| MS-153 | Increases in L-Glu transport | Drug dependence | Nakagawa et al. ( 2005 ) ||\n|| Cabergoline | Production of GDNF | Drug dependence | Ohta et al. ( 2003 , 2004 ) ||\n|| Fenobam, AFQ056 | mGluR5 antagonism | Fragile X syndrome | Levenga et al. ( 2011 ) Vinueza Veloz et al. ( 2012 ) ||",
    "claim": "For schizophrenia, the drugs ALX5497, NEPS, Compound 8, CBIO, AS05728, and Clozapine target the disorder through different actions on astrocytes, such as stimulation of D-Ser uptake, inhibition of DAAO, and stimulation of D-Ser release, indicating diverse mechanistic approaches to treatment.",
    "label": "support"
  },
  {
    "id": "training_688_1",
    "table_caption": "Table: of 1). to In in HepG2 and Huh7 cells. HepG2 Huh7 Sorafenib (mM) Sorafenib (mM) 5 7.5 10 5 7.5 10 Celecoxib (mM) 25 0.890 0.640 0.510 0.898 0.833 0.760 50 0.708 0.502 0.639 0.732 0.661 0.639 75 0.544 0.470 0.552 0.691 0.612 0.624 doi:10.1371/journal.pone.0065569.t001 ",
    "table_content": "|| blank | blank | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) ||\n|| blank | blank | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) ||\n|| blank | blank | 5 | 7.5 | 10 | 5 | 7.5 | 10 ||\n||  Celecoxib (µM) | 25 | 0.890 | 0.640 | 0.510 | 0.898 | 0.833 | 0.760 ||\n||  Celecoxib (µM) | 50 | 0.708 | 0.502 | 0.639 | 0.732 | 0.661 | 0.639 ||\n||  Celecoxib (µM) | 75 | 0.544 | 0.470 | 0.552 | 0.691 | 0.612 | 0.624 ||",
    "claim": "In HepG2 cells, as the concentration of Sorafenib increases from 5 µM to 10 µM, the average cell viability decreases by approximately 0.14 units when averaged across all Celecoxib concentrations. This trend suggests a dose-dependent response to Sorafenib in HepG2 cells.",
    "label": "support"
  },
  {
    "id": "training_27_4",
    "table_caption": "Table: Compounds identiﬁed using paper spray mass spectrometry on urine sample from 27-year-old volunteer. The urine mass spectrum was obtained with both an excitation and detection frequency range of 1.5 MHz. Compound Species Formula Experimental m/z Theoretical m/z Mass measurement error (Δppm) 3-Hexaprenyl-4,5- Dihydroxybenzoic acid [M + Na] C37H54O4Na 585.39288 585.39143 2.5 3′-hydroxy-e,e-caroten- 3-one [M + CH3OH + H] C41H59O3 599.44790 599.44587 3.4 Vitamin D2 3-glucuronide [M + CH3OH + H] C35H57O8 605.40328 605.40480 2.5 Coenzyme Q10 [M + K] C59H90O4K 901.64549 901.64707 1.8 100 ",
    "table_content": "|| Compound | Species | Formula | Experimental m/z  | Theoretical m/z  | Mass measurement error (Δppm) ||\n|| 3-Hexaprenyl-4,5-Dihydroxybenzoic acid | [M + Na] | C 37 H 54 O 4 Na | 585.39288 | 585.39143 | 2.5 ||\n|| 3′-hydroxy-e,e-caroten-3-one | [M + CH 3 OH + H] | C 41 H 59 O 3  | 599.44790 | 599.44587 | 3.4 ||\n|| Vitamin D2 3-glucuronide | [M + CH 3 OH + H] | C 35 H 57 O 8  | 605.40328 | 605.40480 | 2.5 ||\n|| Coenzyme Q10 | [M + K] | C 59 H 90 O 4 K | 901.64549 | 901.64707 | 1.8 ||",
    "claim": "The compound 3′-hydroxy-e,e-caroten-3-one, with a longer carbon chain (C41), has a higher experimental m/z value than 3-Hexaprenyl-4,5-Dihydroxybenzoic acid (C37), demonstrating the direct impact of carbon chain length on the m/z ratio, which is a key factor in mass spectrometry analysis.",
    "label": "support"
  },
  {
    "id": "training_192_4",
    "table_caption": "Table: Identified homologs of SmCL1 based on the filter parameters discussed in the text. PDB ID Chain ID UniProt ID Organism Identity (%) Coverage (%) PDB Resolution (Å) E-value 1EWP A P25779 Trypanosoma cruzi 45 99 1.75 2.00E-57 1M6D B Q9UBX1 Homo sapiens 58 99 1.7 7.00E-83 1S4V B O65039 Ricinus communis 45 97 2.0 2.00E-52 2FO5 A P25250 Hordeum vulgare 45 94 2.2 3.00E-51 2P7U A Q95PM0 Trypanosoma brucei rhodesiense 44 99 1.65 3.00E-57 2XU3 A P07711 Homo sapiens 44 99 0.9 3.00E-53 doi:10.1371/journal.pone.0123996.t002 ",
    "table_content": "|| PDB ID | Chain ID | UniProt ID | Organism | Identity (%) | Coverage (%) | PDB Resolution (Å) | E-value ||\n|| 1EWP | A | P25779 |  Trypanosoma cruzi  | 45 | 99 | 1.75 | 2.00E-57 ||\n|| 1M6D | B | Q9UBX1 |  Homo sapiens  | 58 | 99 | 1.7 | 7.00E-83 ||\n|| 1S4V | B | O65039 |  Ricinus communis  | 45 | 97 | 2.0 | 2.00E-52 ||\n|| 2FO5 | A | P25250 |  Hordeum vulgare  | 45 | 94 | 2.2 | 3.00E-51 ||\n|| 2P7U | A | Q95PM0 |  Trypanosoma brucei rhodesiense  | 44 | 99 | 1.65 | 3.00E-57 ||\n|| 2XU3 | A | P07711 |  Homo sapiens  | 44 | 99 | 0.9 | 3.00E-53 ||",
    "claim": "The homolog with the best resolution (0.9 Å) also has a relatively low E-value, indicating a high-quality structural match. This suggests that better resolution is associated with more statistically significant homologs, reflecting the precision of structural data.",
    "label": "support"
  },
  {
    "id": "training_659_3",
    "table_caption": "Table: glutametegic neurons. embryonic stem cells (n = 4) neural progenitor cells (n = 3) DIV 16 neurons (n = 5) iGluR class Gene Average SD Average SD Average SD AMPAR subunits Gria1 1.6 1.0 132.4 42.5 3964.2 187.2 Gria2 2.7 1.4 328.5 80.8 7393.6 390.0 Gria3 31.1 5.8 409.8 27.2 2201.8 116.4 Gria4 88.7 23.2 291.3 34.7 6621.4 628.8 KAR subunits Grik1 0.3 0.5 150.5 8.3 771.1 42.6 Grik2 4.1 1.9 160.8 27.0 1084.0 64.2 Grik3 301.2 65.5 128.8 13.5 807.7 36.1 Grik4 16.1 6.9 104.8 0.8 641.2 36.2 Grik5 334.0 103.2 1525.6 171.3 4617.2 152.4 NMDAR subunits Grin1 313.8 90.6 70.9 14.7 12398.0 514.1 Grin2a 6.0 1.4 3.7 1.3 795.9 67.2 Grin2b 23.0 9.4 11.9 3.6 1577.5 159.2 Grin2c 6.0 4.0 6.0 5.5 14.4 4.4 Grin2d 61.4 11.8 25.2 3.1 359.7 26.2 Grin3b 3.8 0.6 10.7 4.8 9.4 2.9 SNAP25 39.8 7.7 540.0 155.2 24639.3 1592.7 Adar1b 558.2 53.3 376.5 71.0 3070.7 119.8 The average pseudocount and standard deviation (SD) are presented for each iGluR subunit. Single copy is estimated to correspond to 100 pseudocounts in these doi:10.1371/journal.pone.0064423.t001 ",
    "table_content": "|| iGluR class | Gene | embryonic stem cells (n = 4) | embryonic stem cells (n = 4) | neural progenitor cells (n = 3) | neural progenitor cells (n = 3) | DIV 16 neurons (n = 5) | DIV 16 neurons (n = 5) ||\n|| iGluR class | Gene | Average | SD | Average | SD | Average | SD ||\n||  KAR subunits  |  Grik5  | 334.0 | 103.2 | 1525.6 | 171.3 | 4617.2 | 152.4 ||\n||  NMDAR subunits  |  Grin1  | 313.8 | 90.6 | 70.9 | 14.7 | 12398.0 | 514.1 ||\n||  NMDAR subunits  |  Grin2a  | 6.0 | 1.4 | 3.7 | 1.3 | 795.9 | 67.2 ||\n||  NMDAR subunits  |  Grin2b  | 23.0 | 9.4 | 11.9 | 3.6 | 1577.5 | 159.2 ||\n||  NMDAR subunits  |  Grin2c  | 6.0 | 4.0 | 6.0 | 5.5 | 14.4 | 4.4 ||\n||  NMDAR subunits  |  Grin2d  | 61.4 | 11.8 | 25.2 | 3.1 | 359.7 | 26.2 ||\n||  NMDAR subunits  |  Grin3b  | 3.8 | 0.6 | 10.7 | 4.8 | 9.4 | 2.9 ||\n||  NMDAR subunits  |  SNAP25  | 39.8 | 7.7 | 540.0 | 155.2 | 24639.3 | 1592.7 ||\n||  NMDAR subunits  |  Adar1b  | 558.2 | 53.3 | 376.5 | 71.0 | 3070.7 | 119.8 ||\n||  AMPAR subunits  |  Gria1  | 1.6 | 1.0 | 132.4 | 42.5 | 3964.2 | 187.2 ||\n||  AMPAR subunits  |  Gria2  | 2.7 | 1.4 | 328.5 | 80.8 | 7393.6 | 390.0 ||\n||  AMPAR subunits  |  Gria3  | 31.1 | 5.8 | 409.8 | 27.2 | 2201.8 | 116.4 ||\n||  AMPAR subunits  |  Gria4  | 88.7 | 23.2 | 291.3 | 34.7 | 6621.4 | 628.8 ||\n||  KAR subunits  |  Grik1  | 0.3 | 0.5 | 150.5 | 8.3 | 771.1 | 42.6 ||\n||  KAR subunits  |  Grik2  | 4.1 | 1.9 | 160.8 | 27.0 | 1084.0 | 64.2 ||\n||  KAR subunits  |  Grik3  | 301.2 | 65.5 | 128.8 | 13.5 | 807.7 | 36.1 ||\n||  KAR subunits  |  Grik4  | 16.1 | 6.9 | 104.8 | 0.8 | 641.2 | 36.2 ||",
    "claim": "In DIV 16 neurons, the average expression of AMPAR subunit Gria2 is approximately 6.8 times higher than that of KAR subunit Grik2, highlighting the dominance of AMPAR subunits in mature neurons.",
    "label": "support"
  },
  {
    "id": "training_1159_2",
    "table_caption": "Table: Table 1 Synthesis of methyl 2-(4-nitro-2-((phenylimino)methyl)phenoxy)butanoate (3a) Entry 1a/2a ratio (mmol/mmol) Solvent (mL) Reaction time (h) Yielda (%) 1 1/1 THF 12 24 91 2 1/1 THF/MeOH 6/6 5.5 93 3 1/1 DCE 8 24 56 4 1/1 DCEb 8 24 91 5 1/1.5 DCEb 8 24 92 6 1.5/1.5 DCE/MeOH 4/4 72 62 7 1/1 MeOHb 6 3.5 99 8 1/1 – – 24 77c a Yield based on GC analysis of the reaction mixture b Catalytic amount of acetic acid was added ",
    "table_content": "|| Entry 1 | 1a/2a ratio (mmol/mmol) 1/1 | Solvent (mL) | Solvent (mL) | Reaction time (h) 24 | Yield a (%) 91 ||\n|| Entry 1 | 1a/2a ratio (mmol/mmol) 1/1 | THF | 12 | Reaction time (h) 24 | Yield a (%) 91 ||\n|| 2 | 1/1 | THF/MeOH | 6/6 | 5.5 | 93 ||\n|| 3 | 1/1 | DCE | 8 | 24 | 56 ||\n|| 4 | 1/1 | DCE b  | 8 | 24 | 91 ||\n|| 5 | 1/1.5 | DCE b  | 8 | 24 | 92 ||\n|| 6 | 1.5/1.5 | DCE/MeOH | 4/4 | 72 | 62 ||\n|| 7 | 1/1 | MeOH b  | 6 | 3.5 | 99 ||\n|| 8 | 1/1 | – | – | 24 | 77 c  ||",
    "claim": "A shorter reaction time of 3.5 hours in the presence of MeOH and acetic acid achieves a yield of 99%, indicating that the reaction kinetics are significantly enhanced under these conditions compared to longer reaction times with other solvents.",
    "label": "support"
  },
  {
    "id": "training_971_3",
    "table_caption": "Table: Table 2 Genome drafts of the E.faecium strain from primary and secondary assemblies. NGS Data Genome Draft Size (bp) Number of Contigs N50 (bp) Max Contig (bp) Primary 454 3,027,996 352 21,989 92,031 GAIIx 2,947,516 1,013 9,804 45,465 SOLiD 2,976,193 3,385 1,389 7,396 Secondary 454+GAIIx+SOLiD 3,103,094 204 34,849 114,611 454+GAIIx 2,971,758 209 34,597 114,610 454+SOLiD 3,018,371 257 23,443 97,560 GAIIx+SOLiD 2,923,382 465 13,773 66,062 ",
    "table_content": "|| NGS Data | blank | Genome Draft Size (bp) | Number of Contigs | N50 (bp) | Max Contig (bp) ||\n|| Primary | 454 | 3,027,996 | 352 | 21,989 | 92,031 ||\n|| Primary | GAIIx | 2,947,516 | 1,013 | 9,804 | 45,465 ||\n|| Primary | SOLiD | 2,976,193 | 3,385 | 1,389 | 7,396 ||\n|| Secondary | 454+GAIIx+SOLiD | 3,103,094 | 204 | 34,849 | 114,611 ||\n|| Secondary | 454+GAIIx | 2,971,758 | 209 | 34,597 | 114,610 ||\n|| Secondary | 454+SOLiD | 3,018,371 | 257 | 23,443 | 97,560 ||\n|| Secondary | GAIIx+SOLiD | 2,923,382 | 465 | 13,773 | 66,062 ||",
    "claim": "The N50 value of the secondary assembly using 454+GAIIx+SOLiD is 2 times higher than the average N50 of the primary assemblies, suggesting a more robust assembly with longer contiguous sequences.",
    "label": "support"
  },
  {
    "id": "training_50_6",
    "table_caption": "Table: Table 1 Baseline characteristics of women in the two groups, in Sidama zone, Southern Ethiopia, 2015 Was your husband involved at least in one ANC visit? Characteristics Yes, (%) (n = 385) No, (%) (n = 279) Total (N = 664) Χ2, (p-value) Residence Urban 194 (60.1) 129 (39.9) 323 1.117 (=0.291) Rural 191 (56.0) 150 (44.0) 341 Age in year 15–24 103 (58.9) 72 (41.1) 175 0.090 (=0.956) 25–34 218 (57.5) 161 (42.5) 379 35–49 64 (58.2) 46 (41.8) 110 Education level Tertiary 62 (62.6) 37 (37.4) 99 3.010 (=0.390) Secondary 103 (58.5) 73 (41.5) 176 Primary 134 (54.0) 114 (46.0) 248 None 86 (61.0) 55 (39.0) 141 Occupation type Government employee 64 (69.6) 28 (30.4) 92 6.159 (=0.046)* Businesswomen 35 (59.3) 24 (40.7) 59 Housewife 286 (55.8) 227 (44.2) 513 Religion Protestant 251 (55.9) 198 (44.1) 449 8.908 (=0.031)* Orthodox 45 (63.4) 26 (36.6) 71 Catholic 47 (73.4) 17 (26.6) 64 Muslim 42 (52.5) 38 (47.5) 80 Initiation of ANC visit 1st trimester 41 (71.9) 16 (28.1) 57 9.764 (=0.008)** 2nd trimester 231 (60.0) 154 (40.0) 385 3rd trimester 113 (50.9) 109 (49.1) 222 Number of ANC visits 4+ 64 (76.2) 20 (23.8) 84 13.087 (< 0.001)*** 1 to 3 321 (55.3) 259 (44.7) 580 Number of under 5 children < 1 127 (62.0) 78 (38.0) 205 1.918 (=0.166) > 1 258 (56.2) 201 (43.8) 459 Is the pregnancy planned? Yes 280 (64.2) 156 (35.8) 436 20.282 (< 0.001)*** No 105 (46.1) 123 (53.9) 228 ***P-value < 0.001, **p-value < 0.01, and *P-value < 0.05, indicate the significance differences of the two groups (women with husbands’ involvement and without involvement by indicated variables) ",
    "table_content": "|| Characteristics | Was your husband involved at least in one ANC visit? | Was your husband involved at least in one ANC visit? | Was your husband involved at least in one ANC visit? | Χ 2 , ( p -value) ||\n|| Characteristics | Yes, (%) ( n = 385) | No, (%) ( n = 279) | Total ( N = 664) | Χ 2 , ( p -value) ||\n|| Tertiary | 62 (62.6) | 37 (37.4) | 99 | 3.010 (=0.390) ||\n|| Secondary | 103 (58.5) | 73 (41.5) | 176 | blank ||\n|| Primary | 134 (54.0) | 114 (46.0) | 248 | blank ||\n|| None | 86 (61.0) | 55 (39.0) | 141 | blank ||\n|| Occupation type | Occupation type | Occupation type | Occupation type | Occupation type ||\n|| Government employee | 64 (69.6) | 28 (30.4) | 92 | 6.159 (=0.046)* ||\n|| Businesswomen | 35 (59.3) | 24 (40.7) | 59 | blank ||\n|| Housewife | 286 (55.8) | 227 (44.2) | 513 | blank ||\n|| Religion | Religion | Religion | Religion | Religion ||\n|| Protestant | 251 (55.9) | 198 (44.1) | 449 | 8.908 (=0.031)* ||\n|| Residence | Residence | Residence | Residence | Residence ||\n|| Orthodox | 45 (63.4) | 26 (36.6) | 71 | blank ||\n|| Catholic | 47 (73.4) | 17 (26.6) | 64 | blank ||\n|| Muslim | 42 (52.5) | 38 (47.5) | 80 | blank ||\n|| Initiation of ANC visit | Initiation of ANC visit | Initiation of ANC visit | Initiation of ANC visit | Initiation of ANC visit ||\n|| 1st trimester | 41 (71.9) | 16 (28.1) | 57 | 9.764 (=0.008)** ||\n|| 2nd trimester | 231 (60.0) | 154 (40.0) | 385 | blank ||\n|| 3rd trimester | 113 (50.9) | 109 (49.1) | 222 | blank ||\n|| Number of ANC visits | Number of ANC visits | Number of ANC visits | Number of ANC visits | Number of ANC visits ||\n|| 4+ | 64 (76.2) | 20 (23.8) | 84 | 13.087 (< 0.001)*** ||\n|| 1 to 3 | 321 (55.3) | 259 (44.7) | 580 | blank ||\n|| Urban | 194 (60.1) | 129 (39.9) | 323 | 1.117 (=0.291) ||\n|| Number of under 5 children | Number of under 5 children | Number of under 5 children | Number of under 5 children | Number of under 5 children ||\n|| <  1 | 127 (62.0) | 78 (38.0) | 205 | 1.918 (=0.166) ||\n|| > 1 | 258 (56.2) | 201 (43.8) | 459 | blank ||\n|| Is the pregnancy planned? | Is the pregnancy planned? | Is the pregnancy planned? | Is the pregnancy planned? | Is the pregnancy planned? ||\n|| Yes | 280 (64.2) | 156 (35.8) | 436 | 20.282 (< 0.001)*** ||\n|| No | 105 (46.1) | 123 (53.9) | 228 | blank ||\n|| Rural | 191 (56.0) | 150 (44.0) | 341 | blank ||\n|| Age in year | Age in year | Age in year | Age in year | Age in year ||\n|| 15–24 | 103 (58.9) | 72 (41.1) | 175 | 0.090 (=0.956) ||\n|| 25–34 | 218 (57.5) | 161 (42.5) | 379 | blank ||\n|| 35–49 | 64 (58.2) | 46 (41.8) | 110 | blank ||\n|| Education level | Education level | Education level | Education level | Education level ||",
    "claim": "Women with four or more ANC visits have the highest percentage of husband involvement. The difference in husband involvement based on the number of ANC visits is statistically significant, as indicated by the p-value.",
    "label": "support"
  },
  {
    "id": "training_681_6",
    "table_caption": "Table: significantly increased LA volume index and RA area A’sept E/E’lat, ence and T1DM (Table E’t S’t creased and We MPI Table 1 Demographic and clinical data of diabetic patients and control subjects Variable Diabetic patients (n = 53) Healthy controls (n = 48) p-value Age (years) 44.3 ± 5.4 42.7 ± 6.1 0.159 Gender (male/female, %) 56.6/43.4 56.3/43.7 0.873 Body mass index (kg/m2) 27.0 ± 4.0 25.6 ± 3.5 0.068 Body surface area (m2) 1.94 ± 0.2 1.90 ± 0.2 0.430 Smoking (%) 24.5 33.3 0.454 Systolic blood pressure (mmHg) 126.0 ± 9.5 123.0 ± 10.7 0.168 Diastolic blood pressure (mmHg) 79.5 ± 5.8 77.0 ± 7.0 0.061 ",
    "table_content": "|| Variable | Diabetic patients ( n = 53) | Healthy controls ( n = 48) |  p -value ||\n|| Age (years) | 44.3 ± 5.4 | 42.7 ± 6.1 | 0.159 ||\n|| Gender (male/female, %) | 56.6/43.4 | 56.3/43.7 | 0.873 ||\n|| Body mass index (kg/m2) | 27.0 ± 4.0 | 25.6 ± 3.5 | 0.068 ||\n|| Body surface area (m 2 ) | 1.94 ± 0.2 | 1.90 ± 0.2 | 0.430 ||\n|| Smoking (%) | 24.5 | 33.3 | 0.454 ||\n|| Systolic blood pressure (mmHg) | 126.0 ± 9.5 | 123.0 ± 10.7 | 0.168 ||\n|| Diastolic blood pressure (mmHg) | 79.5 ± 5.8 | 77.0 ± 7.0 | 0.061 ||",
    "claim": "Diabetic patients exhibit higher average systolic and diastolic blood pressure compared to healthy controls. This aligns with the understanding that diabetes is often associated with increased cardiovascular risk, including hypertension.",
    "label": "support"
  },
  {
    "id": "training_898_5",
    "table_caption": "Table: Pub- medical French and and for opinion variable opin- Fisher’s using forward the a was models was Inc., The doc- course and Table 1 Characteristics of the sample Number Percent Gender Female 239 57.9 Male 174 42.1 Age ≤ 27 years 215 52.1 > 27 years 198 47.9 Marital status Couple 281 68.0 Single 132 32.0 Child Yes 163 39.5 No 250 60.5 Believes in God Yes 210 50.8 No 203 49.2 Has taken care of someone nearing the end of life Yes 203 49.2 No 210 50.8 Professional status Palliative care specialists 170 41.2 Medical interns 243 58.8 Specialisation General practice 283 68.5 Others a 130 31.5 Opinion about euthanasia Unfavourable 232 56.2 Favourable 181 43.8 Opinion about the demand of euthanasia of Vincent Humbert Unfavourable 167 40.4 Favourable 246 59.6 aOthers: oncology, surgery, anaesthesia, psychiatry, pneumology, public health, gynaecology ",
    "table_content": "|| blank | Number | Percent ||\n|| Gender | Gender | Gender ||\n|| Child | Child | Child ||\n|| Yes | 163 | 39.5 ||\n|| No | 250 | 60.5 ||\n|| Believes in God | Believes in God | Believes in God ||\n|| Yes | 210 | 50.8 ||\n|| No | 203 | 49.2 ||\n|| Has taken care of someone nearing the end of life | Has taken care of someone nearing the end of life | Has taken care of someone nearing the end of life ||\n|| Yes | 203 | 49.2 ||\n|| No | 210 | 50.8 ||\n|| Professional status | Professional status | Professional status ||\n|| Female | 239 | 57.9 ||\n|| Palliative care specialists | 170 | 41.2 ||\n|| Medical interns | 243 | 58.8 ||\n|| Specialisation | Specialisation | Specialisation ||\n|| General practice | 283 | 68.5 ||\n|| Others a  | 130 | 31.5 ||\n|| Opinion about euthanasia | Opinion about euthanasia | Opinion about euthanasia ||\n|| Unfavourable | 232 | 56.2 ||\n|| Favourable | 181 | 43.8 ||\n|| Opinion about the demand of euthanasia of Vincent Humbert | Opinion about the demand of euthanasia of Vincent Humbert | Opinion about the demand of euthanasia of Vincent Humbert ||\n|| Unfavourable | 167 | 40.4 ||\n|| Male | 174 | 42.1 ||\n|| Favourable | 246 | 59.6 ||\n|| Age | Age | Age ||\n|| ≤ 27 years | 215 | 52.1 ||\n|| > 27 years | 198 | 47.9 ||\n|| Marital status | Marital status | Marital status ||\n|| Couple | 281 | 68.0 ||\n|| Single | 132 | 32.0 ||",
    "claim": "While 56.2% of the sample holds an unfavourable opinion on euthanasia in general, 59.6% have a favourable opinion on the specific case of Vincent Humbert, indicating a nuanced view where the specific circumstances of a case can shift general opinions.",
    "label": "support"
  },
  {
    "id": "training_769_3",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A C9—H9···O1 0.93 2.57 3.487 (7) 169. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| C9—H9···O1 | 0.93 | 2.57 | 3.487 (7) | 169. ||",
    "claim": "The D—H distance of 0.93 Å and the D···A distance of 3.487 Å, when considered with the bond angle, suggest a consistent geometric arrangement that minimizes steric hindrance and maximizes hydrogen bond efficiency. This consistency is crucial for maintaining the structural integrity of the molecule.",
    "label": "support"
  },
  {
    "id": "training_389_3",
    "table_caption": "Table: Table 3 Niche identity test. Niche model Compared lineages Empirical value (Niche overlap) Identity test (Niche equivalence) I D I D Current L. g. cacsilensis—Mixed population 0.283 0.089 0.923 0.686 L. g. guanicoe—Mixed population 0.178 0.058 0.922 0.711 L. g. cacsilensis—L. g. guanicoe 0.133 0.033 0.922 0.596 Projected (2070) L. g. cacsilensis—Mixed population 0.471 0.208 0.930 0.760 L. g. guanicoe—Mixed population 0.135 0.039 0.950 0.800 L. g. cacsilensis—L. g. guanicoe 0.090 0.015 0.890 0.630 Notes: These results correspond to the comparison between the empirical values (niche overlap) and values of percentiles 0.1 of the null distribution (one tailed, Warren, Glor & Turelli, 2010). The “I” and “D” statistics allow to compare the overlap between the replicas of this test. If the empirical value is within the range of values observed in the ",
    "table_content": "|| Niche model | Compared lineages | Empirical value (Niche overlap) | Empirical value (Niche overlap) | Identity test (Niche equivalence) | Identity test (Niche equivalence) ||\n|| Niche model | Compared lineages | I | D | I | D ||\n|| Current | L. g. cacsilensis— Mixed population | 0.283 | 0.089 | 0.923 | 0.686 ||\n|| Current | L. g. guanicoe— Mixed population | 0.178 | 0.058 | 0.922 | 0.711 ||\n|| Current | L. g. cacsilensis—L. g. guanicoe | 0.133 | 0.033 | 0.922 | 0.596 ||\n|| Projected (2070) | L. g. cacsilensis— Mixed population | 0.471 | 0.208 | 0.930 | 0.760 ||\n|| Projected (2070) | L. g. guanicoe— Mixed population | 0.135 | 0.039 | 0.950 | 0.800 ||\n|| Projected (2070) | L. g. cacsilensis—L. g. guanicoe | 0.090 | 0.015 | 0.890 | 0.630 ||",
    "claim": "The identity test (I) value for L. g. guanicoe—Mixed population increases by approximately 3.0% from current to projected conditions, reflecting a slight increase in niche equivalence.",
    "label": "support"
  },
  {
    "id": "training_151_3",
    "table_caption": "Table: patients fiber visual older (7). to In reach WM TABLE 1 | Clinical characteristics. Characteristics BD Mean (SD) HC Mean (SD) Statistical evaluation df P-value Sample, No 57 57 Sex, No Male 22 17 χ2 = 0.974 1 0.32 Female 35 40 Age, years 48.6 (15.1) 49.3 (19.0) t = −0.235 112 0.82 Age of onset, years 36.7 (10.0) Disease duration, years 11.9 (8.1) Treatment duration, years 4.5 (2.7) HRS-D, scores 21.0 (3.7) BD, bipolar disorder; F, analysis of variance; HRS-D, Hamilton’s Rating Scale for Depression; HC, healthy controls; t, Student’s t-test; χ2, Pearson’s chi-square test. ",
    "table_content": "|| Characteristics | BD Mean (SD) | HC Mean (SD) | Statistical evaluation | df | P -value ||\n|| Sample, No | 57 | 57 | blank | blank | blank ||\n|| Sex, No | Sex, No | Sex, No | Sex, No | Sex, No | Sex, No ||\n|| Male | 22 | 17 | χ 2 = 0.974 | 1 | 0.32 ||\n|| Female | 35 | 40 | blank | blank | blank ||\n|| Age, years | 48.6 (15.1) | 49.3 (19.0) | t = −0.235 | 112 | 0.82 ||\n|| Age of onset, years | 36.7 (10.0) | blank | blank | blank | blank ||\n|| Disease duration, years | 11.9 (8.1) | blank | blank | blank | blank ||\n|| Treatment duration, years | 4.5 (2.7) | blank | blank | blank | blank ||\n|| HRS-D, scores | 21.0 (3.7) | blank | blank | blank | blank ||",
    "claim": "The average age of onset for BD is 36.7 years, and the average disease duration is 11.9 years. This implies that the average current age of individuals with BD is approximately 48.6 years, aligning with the reported mean age, confirming the internal consistency of the data.",
    "label": "support"
  },
  {
    "id": "training_624_3",
    "table_caption": "Table: Refinement Refinement on F2 Primary atom site location: structure-invariant direct methods Least-squares matrix: full Secondary atom site location: difference Fourier map R[F2 > 2σ(F2)] = 0.032 Hydrogen site location: inferred from neighbouring sites wR(F2) = 0.085 H-atom parameters constrained S = 1.06 w = 1/[σ2(Fo 2) + (0.039P)2 + 0.347P] where P = (Fo 2 + 2Fc 2)/3 2160 reflections (Δ/σ)max = 0.001 145 parameters Δρmax = 0.22 e Å−3 0 restraints Δρmin = −0.22 e Å−3 Special details ",
    "table_content": "|| Refinement on F 2 | Primary atom site location: structure-invariant direct methods ||\n|| Least-squares matrix: full | Secondary atom site location: difference Fourier map ||\n|| R [ F 2 > 2σ( F 2 )] = 0.032 | Hydrogen site location: inferred from neighbouring sites ||\n|| wR ( F 2 ) = 0.085 | H-atom parameters constrained ||\n|| S = 1.06 | w = 1/[σ 2 ( F o 2 ) + (0.039 P ) 2 + 0.347 P ]  where P = ( F o 2 + 2 F c 2 )/3 ||\n|| 2160 reflections | (Δ/σ) max = 0.001 ||\n|| 145 parameters | Δρ max = 0.22 e Å − 3 ||\n|| 0 restraints | Δρ min = −0.22 e Å − 3 ||",
    "claim": "The ratio of reflections to parameters is approximately 14.9, which implies a high data-to-parameter ratio. This suggests that the refinement is well-supported by the data, reducing the risk of overfitting and increasing the reliability of the refined structure.",
    "label": "support"
  },
  {
    "id": "training_525_5",
    "table_caption": "Table: Kinetics parameters of Xyl10E and its mutants. Enzyme Km (mg/mL) Vmax (U/mg) kcat (1/s) kcat/Km (mL/s/mg) Specific activity (U/mg) Wild-type 1.33 ± 0.21 692 ± 32 460 ± 21 351 ± 56 537 ± 13 Xyl10E_A160D 0.69 ± 0.08 606 ± 35 412 ± 26 587 ± 70 542 ± 18 Xyl10E_A160E 0.63 ± 0.11 593 ± 24 436 ± 16 638 ± 83 546 ± 22 Xyl10E_A161D 1.04 ± 0.04 994 ± 19 663 ± 13 625 ± 12 704 ± 36 Xyl10E_A161E 1.26 ± 0.17 964 ± 12 642 ± 8 516 ± 44 631 ± 32 https://doi.org/10.1371/journal.pone.0189806.t002 ",
    "table_content": "|| Enzyme | K m (mg/mL) | V max (U/mg) | k cat (1/s) | k cat / K m (mL/s/mg) | Specific activity (U/mg) ||\n|| Wild-type | 1.33 ± 0.21 | 692 ± 32 | 460 ± 21 | 351 ± 56 | 537 ± 13 ||\n|| Xyl10E_A160D | 0.69 ± 0.08 | 606 ± 35 | 412 ± 26 | 587 ± 70 | 542 ± 18 ||\n|| Xyl10E_A160E | 0.63 ± 0.11 | 593 ± 24 | 436 ± 16 | 638 ± 83 | 546 ± 22 ||\n|| Xyl10E_A161D | 1.04 ± 0.04 | 994 ± 19 | 663 ± 13 | 625 ± 12 | 704 ± 36 ||\n|| Xyl10E_A161E | 1.26 ± 0.17 | 964 ± 12 | 642 ± 8 | 516 ± 44 | 631 ± 32 ||",
    "claim": "** The Xyl10E_A161D mutant has a kcat value that is approximately 1.44 times higher than the wild-type enzyme, indicating a higher turnover rate and suggesting that this mutation increases the enzyme's catalytic turnover.",
    "label": "support"
  },
  {
    "id": "training_525_5",
    "table_caption": "Table: Kinetics parameters of Xyl10E and its mutants. Enzyme Km (mg/mL) Vmax (U/mg) kcat (1/s) kcat/Km (mL/s/mg) Specific activity (U/mg) Wild-type 1.33 ± 0.21 692 ± 32 460 ± 21 351 ± 56 537 ± 13 Xyl10E_A160D 0.69 ± 0.08 606 ± 35 412 ± 26 587 ± 70 542 ± 18 Xyl10E_A160E 0.63 ± 0.11 593 ± 24 436 ± 16 638 ± 83 546 ± 22 Xyl10E_A161D 1.04 ± 0.04 994 ± 19 663 ± 13 625 ± 12 704 ± 36 Xyl10E_A161E 1.26 ± 0.17 964 ± 12 642 ± 8 516 ± 44 631 ± 32 https://doi.org/10.1371/journal.pone.0189806.t002 ",
    "table_content": "|| Enzyme | K m (mg/mL) | V max (U/mg) | k cat (1/s) | k cat / K m (mL/s/mg) | Specific activity (U/mg) ||\n|| Wild-type | 1.33 ± 0.21 | 692 ± 32 | 460 ± 21 | 351 ± 56 | 537 ± 13 ||\n|| Xyl10E_A160D | 0.69 ± 0.08 | 606 ± 35 | 412 ± 26 | 587 ± 70 | 542 ± 18 ||\n|| Xyl10E_A160E | 0.63 ± 0.11 | 593 ± 24 | 436 ± 16 | 638 ± 83 | 546 ± 22 ||\n|| Xyl10E_A161D | 1.04 ± 0.04 | 994 ± 19 | 663 ± 13 | 625 ± 12 | 704 ± 36 ||\n|| Xyl10E_A161E | 1.26 ± 0.17 | 964 ± 12 | 642 ± 8 | 516 ± 44 | 631 ± 32 ||",
    "claim": "The Xyl10E_A161D mutant has a kcat value that is approximately 1.1 times higher than the wild-type enzyme, indicating a higher turnover rate and suggesting that this mutation increases the enzyme's catalytic turnover.",
    "label": "support"
  },
  {
    "id": "training_885_3",
    "table_caption": "Table: Table 4b. Proportions of patients with a label of heart failure captured in different settings, estimated additional proportion of missing patients and estimated population size Model Patients labeled in hospital Patients labeled in primary care Patients labeled in both Additional patients not labeled in either setting Estimated population size (95% confidence interval) HF = no covariate 46% 19% 35% 20% (14–26%) 859 (799–929) HF = age 46% 19% 35% 20% (14– 26%) 860 (799–930) HF = age + sex 36% 25% 36% 20% (14–27%) 867 (800–946) HF = age + sex + income quintile 34% 26% 39% 19% (12–25%) 849 (787–923) HF = age + sex + income quintile + comorbidities 34% 26% 39% 18% (12–25%) 847 (787–918) COPD chronic obstructive pulmonary disease, HF heart failure ",
    "table_content": "|| Model | Patients labeled in hospital | Patients labeled in primary care | Patients labeled in both | Additional patients not labeled in either setting | Estimated population size (95% confidence interval) ||\n|| HF = no covariate | 46% | 19% | 35% | 20% (14–26%) | 859 (799–929) ||\n|| HF = age | 46% | 19% | 35% | 20% (14– 26%) | 860 (799–930) ||\n|| HF = age + sex | 36% | 25% | 36% | 20% (14–27%) | 867 (800–946) ||\n|| HF = age + sex + income quintile | 34% | 26% | 39% | 19% (12–25%) | 849 (787–923) ||\n|| HF = age + sex + income quintile + comorbidities | 34% | 26% | 39% | 18% (12–25%) | 847 (787–918) ||",
    "claim": "The proportion of patients labeled in both settings increases by 4 percentage points when comparing the model with no covariates to the model including age, sex, income quintile, and comorbidities.",
    "label": "support"
  },
  {
    "id": "training_1142_3",
    "table_caption": "Table: Tween 80 concentration (mmol/L) relative (molar) ratio Au: Tween 80 mean diameter (nm) standard deviation polydispersity index reaction half-time (s) 0 — 13.4 (unimodal distribution) 17.7 — 48 5.1/49.4 (bimodal distribution) 3.48/3.50 0.458/0.005 3.5/10.7/49.4 (trimodal distribution) 1.71/1.86/3.50 0.236/0.030/0.005 0.01 100 21.8 5.91 0.073 128 0.1 10 20.0 4.35 0.047 152 1 1 14.1 2.93 0.043 164 10 0.1 6.2 1.00 0.026 184 Table 1. Mean diameters, standard deviations, polydispersity indexes of the prepared Au NPs dispersions calculated from TEM image analysis and the observed half-times of reduction of Au(III) to Au(0). (See Supplementary Fig. S1 ",
    "table_content": "|| Tween 80 concentration (mmol/L) | relative (molar) ratio Au: Tween 80 | mean diameter (nm) | standard deviation | polydispersity index | reaction half-time (s) ||\n|| 0 | — | 13.4 (unimodal distribution) | 17.7 | — | 48 ||\n|| 0 | — | 5.1/49.4 (bimodal distribution) | 3.48/3.50 | 0.458/0.005 | 48 ||\n|| 0 | — | 3.5/10.7/49.4 (trimodal distribution) | 1.71/1.86/3.50 | 0.236/0.030/0.005 | 48 ||\n|| 0.01 | 100 | 21.8 | 5.91 | 0.073 | 128 ||\n|| 0.1 | 10 | 20.0 | 4.35 | 0.047 | 152 ||\n|| 1 | 1 | 14.1 | 2.93 | 0.043 | 164 ||\n|| 10 | 0.1 | 6.2 | 1.00 | 0.026 | 184 ||",
    "claim": "The reaction half-time for the reduction of Au(III) to Au(0) increases with the concentration of Tween 80. Starting from 48 seconds at 0 mmol/L, it increases to 184 seconds at 10 mmol/L. This implies that higher concentrations of Tween 80 slow down the reduction process.",
    "label": "support"
  },
  {
    "id": "training_135_1",
    "table_caption": "Table: Sample Dose aPTT (s) PT (s) PT (INR) Control Saline 32.1 ± 0.4 12.0 ± 0.3 1.00 JJ1 0.31 μg/mouse 31.9 ± 0.6 12.4 ± 0.5 1.08 0.61 μg/mouse 40.1 ± 1.1* 17.2 ± 1.4* 2.37 1.23 μg/mouse 49.4 ± 1.5* 22.3 ± 0.6* 4.42* 3.06 μg/mouse 55.8 ± 1.2* 26.8 ± 0.4* 6.88* Table 3. Ex vivo coagulation time of JJ1a. aEach value represents to control. ",
    "table_content": "|| Sample | Dose | aPTT (s) | PT (s) | PT (INR) ||\n|| Control | Saline | 32.1 ± 0.4 | 12.0 ± 0.3 | 1.00 ||\n||  JJ1  | 0.31 μg/mouse | 31.9 ± 0.6 | 12.4 ± 0.5 | 1.08 ||\n||  JJ1  | 0.61 μg/mouse | 40.1 ± 1.1* | 17.2 ± 1.4* | 2.37 ||\n||  JJ1  | 1.23 μg/mouse | 49.4 ± 1.5* | 22.3 ± 0.6* | 4.42* ||\n||  JJ1  | 3.06 μg/mouse | 55.8 ± 1.2* | 26.8 ± 0.4* | 6.88* ||",
    "claim": "The aPTT increases non-linearly with the dose of JJ1, showing a more than 70% increase from the lowest to the highest dose, indicating a dose-dependent prolongation of the intrinsic coagulation pathway.",
    "label": "support"
  },
  {
    "id": "training_11_5",
    "table_caption": "Table: Statistical equivalence test for simulated and experimental values for RMS, MDF and FD. RMS FD MDF MVC P-value Test Value Test Value 25% 0.006 25% 0.005 25% 0.046 50% 0.020 50% 0.0026 50% 0.045 75% 0.023 75% 0.001 75% 0.049 Test interpretation Equivalent Test interpretation Equivalent Test interpretation Equivalent https://doi.org/10.1371/journal.pone.0189036.t004 ",
    "table_content": "|| RMS | RMS | FD | FD | MDF | MDF ||\n|| MVC | P-value | Test | Value | Test | Value ||\n|| 25% | 0.006 | 25% | 0.005 | 25% | 0.046 ||\n|| 50% | 0.020 | 50% | 0.0026 | 50% | 0.045 ||\n|| 75% | 0.023 | 75% | 0.001 | 75% | 0.049 ||\n|| Test interpretation | Equivalent | Test interpretation | Equivalent | Test interpretation | Equivalent ||",
    "claim": "Despite variations in P-values and test values, all parameters (RMS, FD, MDF) consistently show \"Equivalent\" test interpretations across all MVC levels, indicating a robust equivalence between simulated and experimental values across different conditions.",
    "label": "support"
  },
  {
    "id": "training_104_4",
    "table_caption": "Table: Feature frequency table of generalized linear model. Covariable name Frequency (%) Category 98.6 Gender 39.6 Pathology grade 62.1 Lymph node metastasis 93.9 Tumor size 65.8 Clinical stage 54.3 situ on prior we of the a ",
    "table_content": "|| Covariable name | Frequency (%) ||\n|| Category | 98.6 ||\n|| Gender | 39.6 ||\n|| Pathology grade | 62.1 ||\n|| Lymph node metastasis | 93.9 ||\n|| Tumor size | 65.8 ||\n|| Clinical stage | 54.3 ||",
    "claim": "The combined frequency of clinical factors (Pathology grade, Lymph node metastasis, Tumor size, and Clinical stage) is 276.1%. This indicates that clinical factors are considered more frequently than non-clinical factors, such as Gender, in the model.",
    "label": "support"
  },
  {
    "id": "training_734_2",
    "table_caption": "Table: Regression model coefficients. Unstandardized Standardized 95% Conﬁdence Interval ß Std. Error ß Lower Bound Upper Bound Model 1 (Constant) 15.80 0.80 14.23 17.36 Intensity 1.03 0.17 0.27 0.69 1.36 Model 2 (R2 = 0.12) (Constant) 13.95 0.86 12.26 15.64 Intensity 1.11 0.17 0.30 0.78 1.44 BPD 0.58 0.12 0.22 0.35 0.81 Model 3 (R2 = 0.14) (Constant) 13.93 0.85 12.25 15.60 Intensity 1.08 0.17 0.29 0.75 1.41 BPD 0.48 0.12 0.19 0.25 0.72 SCOFF 1.04 0.39 0.12 0.28 1.81 Model 4 (R2 = 0.39) (Constant) 23.79 1.02 21.79 25.79 Intensity 0.86 0.14 0.23 0.59 1.14 BPD 0.15 0.10 0.06 -0.05 0.36 SCOFF 0.79 0.33 0.09 0.15 1.44 DMI Escapism 2.79 0.20 0.53 3.19 2.39 Model 5 (R2 = 0.41) (Constant) 24.83 1.04 22.79 26.87 Intensity 0.83 0.14 0.22 0.55 1.10 BPD 0.21 0.10 0.08 0.01 0.41 SCOFF 0.89 0.32 0.11 0.26 1.53 DMI Escapism 2.49 0.22 0.47 2.91 2.06 DMI Mood Enhancement 1.34 0.35 0.15 2.03 0.66 Note: DAI total score was added as dependent variable. Each model is signiﬁcantly better than the previous one (ΔFM1 = 35.80***, ΔFM2 = 24.84***, ΔFM3 = 7.19** ΔFM4 = 186.35*** ΔFM5 = 15.00***, where ***p<0.001, **p<0.01) ",
    "table_content": "|| blank | Unstandardized | Unstandardized | Standardized ß | 95% Confidence Interval | 95% Confidence Interval ||\n|| blank | ß | Std. Error | Standardized ß | Lower Bound | Upper Bound ||\n||  (Constant)  | 13.93 | 0.85 | blank | 12.25 | 15.60 ||\n||  Intensity  | 1.08 | 0.17 | 0.29 | 0.75 | 1.41 ||\n||  BPD  | 0.48 | 0.12 | 0.19 | 0.25 | 0.72 ||\n||  SCOFF  | 1.04 | 0.39 | 0.12 | 0.28 | 1.81 ||\n||  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) ||\n||  (Constant)  | 23.79 | 1.02 | blank | 21.79 | 25.79 ||\n||  Intensity  | 0.86 | 0.14 | 0.23 | 0.59 | 1.14 ||\n||  BPD  | 0.15 | 0.10 | 0.06 | -0.05 | 0.36 ||\n||  SCOFF  | 0.79 | 0.33 | 0.09 | 0.15 | 1.44 ||\n||  DMI Escapism  | 2.79 | 0.20 | 0.53 | 3.19 | 2.39 ||\n||  Model 1  |  Model 1  |  Model 1  |  Model 1  |  Model 1  |  Model 1  ||\n||  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) ||\n||  (Constant)  | 24.83 | 1.04 | blank | 22.79 | 26.87 ||\n||  Intensity  | 0.83 | 0.14 | 0.22 | 0.55 | 1.10 ||\n||  BPD  | 0.21 | 0.10 | 0.08 | 0.01 | 0.41 ||\n||  SCOFF  | 0.89 | 0.32 | 0.11 | 0.26 | 1.53 ||\n||  DMI Escapism  | 2.49 | 0.22 | 0.47 | 2.91 | 2.06 ||\n||  DMI Mood Enhancement  | 1.34 | 0.35 | 0.15 | 2.03 | 0.66 ||\n||  (Constant)  | 15.80 | 0.80 | blank | 14.23 | 17.36 ||\n||  Intensity  | 1.03 | 0.17 | 0.27 | 0.69 | 1.36 ||\n||  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) ||\n||  (Constant)  | 13.95 | 0.86 | blank | 12.26 | 15.64 ||\n||  Intensity  | 1.11 | 0.17 | 0.30 | 0.78 | 1.44 ||\n||  BPD  | 0.58 | 0.12 | 0.22 | 0.35 | 0.81 ||\n||  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) ||",
    "claim": "The R-squared value increases from 0.12 in Model 2 to 0.41 in Model 5, demonstrating a 242% increase in the proportion of variance explained by the model. This substantial increase reflects the cumulative effect of adding more predictors, enhancing the model's explanatory power.",
    "label": "support"
  },
  {
    "id": "training_422_1",
    "table_caption": "Table: List of genes from the consortium with lower CIB values compared to its non-consortium counterpart. Id consortium CIB consortium Id counterpart CIB counterpart name Gene annotation COG Copper resistance LFPA_558 0.254 LFML04_RS04475 0.257 cutA periplasmic divalent cation tolerance protein P ATLIC_3492 0.142 ATHIO_RS0103355 0.145 Cu2+-exporting ATPase P STCUT_215 0.069 AOA63_RS11310 0.074 copA heavy metal translocating P-type ATPase P STCUT_220 0.093 AOA63_RS11335 0.100 Cu2+-exporting ATPase P LFPA_1158 0.208 LFML04_RS01790 0.217 Cu2+-exporting ATPase P ATLIC_2000 0.245 ATHIO_RS0110590 0.254 lipoprotein M,P ATLIC_1679 0.288 ATHIO_RS0112045 0.299 hmrR transcriptional regulator, MerR family K STCUT_1350 0.158 AOA63_RS16975 0.196 NIF3-related protein S AFWEN_2071 0.231 AFE_RS11165 0.278 cusA Cu(I)/Ag(I) efflux system membrane protein CusA V LFPA_601 0.148 LFML04_RS03050 0.216 cusA Cu(I)/Ag(I) efflux system membrane protein CusA V LFPA_601 0.148 LFML04_RS08675 0.224 cusA Cu(I)/Ag(I) efflux system membrane protein CusA V AMYEN_2455 0.250 ACMV_RS13835 0.521 Cu2+-exporting ATPase P Average 0.186 0.232 ROS ATLIC_1147 0.332 ATHIO_RS0106580 0.333 sodA superoxide dismutase, Fe-Mn family P ATLIC_1534 0.188 ATHIO_RS0115785 0.196 peroxidase (EC:1.11.1.7) O LFPA_122 0.167 LFML04_RS12970 0.176 resA thiol-disulfide oxidoreductase O,C LFPA_382 0.254 LFML04_RS05360 0.264 trxA thioredoxin O,C ATLIC_2542 0.304 ATHIO_RS0105865 0.314 alkylhydroperoxidase like protein, AhpD family S LFPA_1163 0.227 LFML04_RS01815 0.237 thioredoxin 2 O,C STCUT_347 0.284 AOA63_RS12055 0.295 alkylhydroperoxidase like protein, AhpD family S AFWEN_3145 0.259 AFE_RS01735 0.271 glutaredoxin family protein O AMYEN_133 0.392 ACMV_RS07445 0.406 trxA thioredoxin 1 O,C ATLIC_1449 0.140 ATHIO_RS0107230 0.155 msrA peptide-methionine (S)-S-oxide reductase O AMYEN_129 0.305 ACMV_RS07425 0.323 trxB thioredoxin reductase (NADPH) O ATLIC_1450 0.183 ATHIO_RS0107225 0.204 msrB peptide-methionine (R)-S-oxide reductase O AFWEN_2550 0.162 AFE_RS06860 0.184 bcp peroxiredoxin Q/BCP O ATLIC_2479 0.201 ATHIO_RS0106370 0.227 bcp peroxiredoxin Q/BCP O ATLIC_130 0.240 ATHIO_RS0108025 0.272 ahpC peroxiredoxin (alkyl hydroperoxide reductase subunit C) O STCUT_838 0.130 AOA63_RS14385 0.163 glutaredoxin-like domain-containing protein O AFWEN_1580 0.267 AFE_RS13515 0.300 msrA peptide-methionine (S)-S-oxide reductase O STCUT_1306 0.178 AOA63_RS16755 0.223 sodA superoxide dismutase, Fe-Mn family P LFPA_1179 0.304 LFML04_RS01895 0.351 bcp peroxiredoxin Q/BCP O STCUT_518 0.252 AOA63_RS12875 0.317 bcp peroxiredoxin Q/BCP O LFPA_1314 0.244 LFML04_RS02930 0.316 monothiol glutaredoxin O AFWEN_3137 0.162 AFE_RS01775 0.234 trxB thioredoxin reductase (NADPH) O ATLIC_589 0.246 ATHIO_RS0110035 0.319 monothiol glutaredoxin O Average 0.236 0.264 https://doi.org/10.1371/journal.pone.0195869.t003 ",
    "table_content": "|| Id consortium | CIB consortium | Id counterpart | CIB counterpart | name | Gene annotation | COG ||\n|| Copper resistance | Copper resistance | Copper resistance | Copper resistance | Copper resistance | Copper resistance | Copper resistance ||\n|| AFWEN_2071 | 0.231 | AFE_RS11165 | 0.278 | cusA | Cu(I)/Ag(I) efflux system membrane protein CusA | V ||\n|| LFPA_601 | 0.148 | LFML04_RS03050 | 0.216 | cusA | Cu(I)/Ag(I) efflux system membrane protein CusA | V ||\n|| LFPA_601 | 0.148 | LFML04_RS08675 | 0.224 | cusA | Cu(I)/Ag(I) efflux system membrane protein CusA | V ||\n|| AMYEN_2455 | 0.250 | ACMV_RS13835 | 0.521 | blank | Cu2+-exporting ATPase | P ||\n|| Average | 0.186 | blank | 0.232 | blank | blank | blank ||\n|| ROS | ROS | ROS | ROS | ROS | ROS | ROS ||\n|| ATLIC_1147 | 0.332 | ATHIO_RS0106580 | 0.333 | sodA | superoxide dismutase, Fe-Mn family | P ||\n|| ATLIC_1534 | 0.188 | ATHIO_RS0115785 | 0.196 | blank | peroxidase (EC:1.11.1.7) | O ||\n|| LFPA_122 | 0.167 | LFML04_RS12970 | 0.176 | resA | thiol-disulfide oxidoreductase | O,C ||\n|| LFPA_382 | 0.254 | LFML04_RS05360 | 0.264 | trxA | thioredoxin | O,C ||\n|| LFPA_558 | 0.254 | LFML04_RS04475 | 0.257 | cutA | periplasmic divalent cation tolerance protein | P ||\n|| ATLIC_2542 | 0.304 | ATHIO_RS0105865 | 0.314 | blank | alkylhydroperoxidase like protein, AhpD family | S ||\n|| LFPA_1163 | 0.227 | LFML04_RS01815 | 0.237 | blank | thioredoxin 2 | O,C ||\n|| STCUT_347 | 0.284 | AOA63_RS12055 | 0.295 | blank | alkylhydroperoxidase like protein, AhpD family | S ||\n|| AFWEN_3145 | 0.259 | AFE_RS01735 | 0.271 | blank | glutaredoxin family protein | O ||\n|| AMYEN_133 | 0.392 | ACMV_RS07445 | 0.406 | trxA | thioredoxin 1 | O,C ||\n|| ATLIC_1449 | 0.140 | ATHIO_RS0107230 | 0.155 | msrA | peptide-methionine (S)-S-oxide reductase | O ||\n|| AMYEN_129 | 0.305 | ACMV_RS07425 | 0.323 | trxB | thioredoxin reductase (NADPH) | O ||\n|| ATLIC_1450 | 0.183 | ATHIO_RS0107225 | 0.204 | msrB | peptide-methionine (R)-S-oxide reductase | O ||\n|| AFWEN_2550 | 0.162 | AFE_RS06860 | 0.184 | bcp | peroxiredoxin Q/BCP | O ||\n|| ATLIC_2479 | 0.201 | ATHIO_RS0106370 | 0.227 | bcp | peroxiredoxin Q/BCP | O ||\n|| ATLIC_3492 | 0.142 | ATHIO_RS0103355 | 0.145 | blank | Cu2+-exporting ATPase | P ||\n|| ATLIC_130 | 0.240 | ATHIO_RS0108025 | 0.272 | ahpC | peroxiredoxin (alkyl hydroperoxide reductase subunit C) | O ||\n|| STCUT_838 | 0.130 | AOA63_RS14385 | 0.163 | blank | glutaredoxin-like domain-containing protein | O ||\n|| AFWEN_1580 | 0.267 | AFE_RS13515 | 0.300 | msrA | peptide-methionine (S)-S-oxide reductase | O ||\n|| STCUT_1306 | 0.178 | AOA63_RS16755 | 0.223 | sodA | superoxide dismutase, Fe-Mn family | P ||\n|| LFPA_1179 | 0.304 | LFML04_RS01895 | 0.351 | bcp | peroxiredoxin Q/BCP | O ||\n|| STCUT_518 | 0.252 | AOA63_RS12875 | 0.317 | bcp | peroxiredoxin Q/BCP | O ||\n|| LFPA_1314 | 0.244 | LFML04_RS02930 | 0.316 | blank | monothiol glutaredoxin | O ||\n|| AFWEN_3137 | 0.162 | AFE_RS01775 | 0.234 | trxB | thioredoxin reductase (NADPH) | O ||\n|| ATLIC_589 | 0.246 | ATHIO_RS0110035 | 0.319 | blank | monothiol glutaredoxin | O ||\n|| Average | 0.236 | blank | 0.264 | blank | blank | blank ||\n|| STCUT_215 | 0.069 | AOA63_RS11310 | 0.074 | copA | heavy metal translocating P-type ATPase | P ||\n|| STCUT_220 | 0.093 | AOA63_RS11335 | 0.100 | blank | Cu2+-exporting ATPase | P ||\n|| LFPA_1158 | 0.208 | LFML04_RS01790 | 0.217 | blank | Cu2+-exporting ATPase | P ||\n|| ATLIC_2000 | 0.245 | ATHIO_RS0110590 | 0.254 | blank | lipoprotein | M,P ||\n|| ATLIC_1679 | 0.288 | ATHIO_RS0112045 | 0.299 | hmrR | transcriptional regulator, MerR family | K ||\n|| STCUT_1350 | 0.158 | AOA63_RS16975 | 0.196 | blank | NIF3-related protein | S ||",
    "claim": "The average CIB value for consortium genes is lower than that of non-consortium genes in both Copper resistance and ROS categories, with a difference of 0.046 and 0.028, respectively. This suggests a consistent trend of lower CIB values in consortium genes across different functional categories.",
    "label": "support"
  },
  {
    "id": "training_571_4",
    "table_caption": "Table: The intraobserver repeatability of Ks, Kf, Km, J0 and J45 obtained by iTrace. (Note: D: diopter, SD: standard deviation, Sw: within-subject standard deviation, CoV: within-subject coefficient of variation, ICC: intraclass correlation coefficient.) Parameters Observers Mean±SD CoV (%) Sw (D) 2.77Sw (D) ICC Ks 1st 44.03 ± 1.62 0.50 0.26 0.70 0.991(0.988–0.994) 2nd 44.07 ± 1.63 0.34 0.20 0.55 0.995(0.993–0.996) Kf 1st 43.02 ± 1.50 0.42 0.21 0.59 0.993(0.991–0.995) 2nd 43.07 ± 1.51 0.33 0.19 0.53 0.993(0.990–0.995) Km 1st 43.53 ± 1.53 0.44 0.22 0.61 0.993(0.991–0.995) 2nd 43.57 ± 1.55 0.32 0.18 0.49 0.996(0.994–0.997) J0 1st 0.024 ± 0.25 - 0.41 1.14 0.081(-0.283–0.354) 2nd -0.019 ± 0.24 - 0.39 1.08 0.111(-0.243–0.376) J45 1st -0.006 ± 0.22 - 0.42 1.15 -0.175(-0.629–0.171) 2nd 0.018 ± 0.27 - 0.40 1.11 -0.257(-0.037–0.478) doi:10.1371/journal.pone.0147086.t004 ",
    "table_content": "|| Parameters | Observers | Mean±SD | CoV (%) | Sw (D) | 2.77Sw (D) | ICC ||\n|| Ks | 1st | 44.03 ± 1.62 | 0.50 | 0.26 | 0.70 | 0.991(0.988–0.994) ||\n|| J45 | 2nd | 0.018 ± 0.27 | blank | 0.40 | 1.11 | -0.257(-0.037–0.478) ||\n|| Ks | 2nd | 44.07 ± 1.63 | 0.34 | 0.20 | 0.55 | 0.995(0.993–0.996) ||\n|| Kf | 1st | 43.02 ± 1.50 | 0.42 | 0.21 | 0.59 | 0.993(0.991–0.995) ||\n|| Kf | 2nd | 43.07 ± 1.51 | 0.33 | 0.19 | 0.53 | 0.993(0.990–0.995) ||\n|| Km | 1st | 43.53 ± 1.53 | 0.44 | 0.22 | 0.61 | 0.993(0.991–0.995) ||\n|| Km | 2nd | 43.57 ± 1.55 | 0.32 | 0.18 | 0.49 | 0.996(0.994–0.997) ||\n|| J0 | 1st | 0.024 ± 0.25 | blank | 0.41 | 1.14 | 0.081(-0.283–0.354) ||\n|| J0 | 2nd | -0.019 ± 0.24 | blank | 0.39 | 1.08 | 0.111(-0.243–0.376) ||\n|| J45 | 1st | -0.006 ± 0.22 | blank | 0.42 | 1.15 | -0.175(-0.629–0.171) ||",
    "claim": "The ICC for the Km parameter increases from 0.993 to 0.996 between the first and second observers. This increase in ICC, which is a measure of reliability, indicates that the second observer's measurements are more reliable, with a higher degree of agreement between repeated measurements.",
    "label": "support"
  },
  {
    "id": "training_5_4",
    "table_caption": "Table: Heart weights (HW), body weights (BW), cardiac function, plasma creatine content and creatine uptake during development in the rat heart Age (days) -2 ( fetal ) 7 13 21 33 50 80 ANOVA HW (g) 0.039 ± 0.01a 0.13 ± 0.01b 0.17 ± 0.06bc 0.24 ± 0.03c 0.44 ± 0.04d 0.70 ± 0.07e 1.17 ± 0.02f p < 0.001 [4] [4] [7] [5] [8] [6] [8] BW (g) 3.59 ± 0.34a 22.0 ± 1.78b 35.6 ± 7.08c 41.5 ± 4.1c 78.6 ± 2.4d 178 ± 8.6e 296 ± 5.3f p < 0.001 [4] [4] [7] [5] [8] [6] [8] HW/BW *1000 10.9 ± 2.1a 5.79 ± 0.80ab 4.81 ± 1.15ab 5.84 ± 0.70a 5.58 ± 0.47a 3.93 ± 0.32b b 3.94 ± 0.10b p < 0.001 [4] [4] [7] [5] [5] [6] [8] HR (bpm) - - 321 ± 5.7 248 ± 4.9 348 ± 5.6 318 ± 34 307 ± 45 NS [4] [4] [4] [4] [4] LDVP (mm Hg) - - 69 ± 12.7 88.6 ± 0.36 65.7 ± 7.2 75.7 ± 10.2 97.1 ± 27.6 NS [4] [4] [4] [4] [4] RPP (mm Hg/bpm) - - 22129 ± 3673 22047 ± 555 22879 ± 2874 24189 ± 5524 29673 ± 8913 NS [4] [4] [4] [4] [4] Creatine uptake - - 3.03 ± 0.55a 3.66 ± 0.79ab 3.85 ± 0.62abc 4.68 ± 0.54bc 4.99 ± 0.52c p < 0.001 (nmol/min/g w.w) [6] [5] [5] [5] [6] Plasma creatine - 0.971 ± 0.07a 0.669 ± 0.16ab 0.678 ± 0.19ac 0.627 ± 0.12bc 0.558 ± 0.06bc 0.536 ± 0.08bc p = 0.002 (mmol/L) [4] [4] [4] [4] [4] [4] Data are presented as means ± S.E and sample size are given in brackets. Values within a row with different superscript letters are significantly different to all other time points (p < 0.05, creatine uptake, plasma creatine: Bonferroni; HW, BW, HW/BW*1000: Dunnett T3, ANOVA \"test for linear trend\": as indicated). ",
    "table_content": "|| Age (days) | -2 ( fetal ) | 7 | 13 | 21 | 33 | 50 | 80 | ANOVA ||\n|| HW (g) | 0.039 ± 0.01 a | 0.13 ± 0.01 b | 0.17 ± 0.06 bc | 0.24 ± 0.03 c | 0.44 ± 0.04 d | 0.70 ± 0.07 e | 1.17 ± 0.02 f | p < 0.001 ||\n|| LDVP (mm Hg) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| RPP (mm Hg/bpm) | blank | blank | 22129 ± 3673 | 22047 ± 555 | 22879 ± 2874 | 24189 ± 5524 | 29673 ± 8913 | NS ||\n|| RPP (mm Hg/bpm) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| Creatine uptake | blank | blank | 3.03 ± 0.55 a | 3.66 ± 0.79 ab | 3.85 ± 0.62 abc | 4.68 ± 0.54 bc | 4.99 ± 0.52 c | p < 0.001 ||\n|| (nmol/min/g w.w) | blank | blank | [6] | [5] | [5] | [5] | [6] | blank ||\n|| Plasma creatine | blank | 0.971 ± 0.07 a | 0.669 ± 0.16 ab | 0.678 ± 0.19 ac | 0.627 ± 0.12 bc | 0.558 ± 0.06 bc | 0.536 ± 0.08 bc | p = 0.002 ||\n|| (mmol/L) | blank | [4] | [4] | [4] | [4] | [4] | [4] | blank ||\n|| HW (g) | [4] | [4] | [7] | [5] | [8] | [6] | [8] | blank ||\n|| BW (g) | 3.59 ± 0.34 a | 22.0 ± 1.78 b | 35.6 ± 7.08 c | 41.5 ± 4.1 c | 78.6 ± 2.4 d | 178 ± 8.6 e | 296 ± 5.3 f | p < 0.001 ||\n|| BW (g) | [4] | [4] | [7] | [5] | [8] | [6] | [8] | blank ||\n|| HW/BW *1000 | 10.9 ± 2.1 a | 5.79 ± 0.80 ab | 4.81 ± 1.15 ab | 5.84 ± 0.70 a | 5.58 ± 0.47 a | 3.93 ± 0.32 b | b 3.94 ± 0.10 b | p < 0.001 ||\n|| HW/BW *1000 | [4] | [4] | [7] | [5] | [5] | [6] | [8] | blank ||\n|| HR (bpm) | blank | blank | 321 ± 5.7 | 248 ± 4.9 | 348 ± 5.6 | 318 ± 34 | 307 ± 45 | NS ||\n|| HR (bpm) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| LDVP (mm Hg) | blank | blank | 69 ± 12.7 | 88.6 ± 0.36 | 65.7 ± 7.2 | 75.7 ± 10.2 | 97.1 ± 27.6 | NS ||",
    "claim": "Creatine uptake in the rat heart increases by approximately 65% from 13 days to 80 days, reflecting enhanced energy metabolism and storage capacity in the developing heart muscle. This increase is crucial for supporting the higher energy demands of the growing cardiac tissue.",
    "label": "support"
  },
  {
    "id": "training_36_1",
    "table_caption": "Table: Parameters among different modes (n = 38) VC PC PS p Mean ± SD Mean ± SD Mean ± SD Tidal volume (ml) 492 ± 86 479 ± 100 439 ± 137 NS PIP (mm H2O) 28 ± 10 25 ± 7 22 ± 8 < 0.05a Respiratory rate (breaths per minute) 21 ± 6 22 ± 6 23 ± 9 NS Breaths per minute above set respiratory rate 8.0 ± 6.3 8.3 ± 6.3 N/A NS Oxygen saturation (percentage) 96 ± 4 96 ± 4 96 ± 3 NS Heart rate (beats per minute) 90 ± 14 94 ± 14 95 ± 13 NS Blood pressure (mm Hg) 132/74 ± 23/17 132/75 ± 28/18 131/74 ± 28/19 NS aPIP differed among all three modes. N/A, non-applicable; NS, not significant; PC, assist pressure control; PIP, peak inspiratory pressure; PS, pressure support; SD, standard deviation; VC, assist volume control. ",
    "table_content": "|| blank | VC | PC | PS | p ||\n|| blank | Mean ± SD | Mean ± SD | Mean ± SD | blank ||\n|| Tidal volume (ml) | 492 ± 86 | 479 ± 100 | 439 ± 137 | NS ||\n|| PIP (mm H 2 O) | 28 ± 10 | 25 ± 7 | 22 ± 8 | < 0.05 a ||\n|| Respiratory rate (breaths per minute) | 21 ± 6 | 22 ± 6 | 23 ± 9 | NS ||\n|| Breaths per minute above set respiratory rate | 8.0 ± 6.3 | 8.3 ± 6.3 | N/A | NS ||\n|| Oxygen saturation (percentage) | 96 ± 4 | 96 ± 4 | 96 ± 3 | NS ||\n|| Heart rate (beats per minute) | 90 ± 14 | 94 ± 14 | 95 ± 13 | NS ||\n|| Blood pressure (mm Hg) | 132/74 ± 23/17 | 132/75 ± 28/18 | 131/74 ± 28/19 | NS ||",
    "claim": "The average tidal volume in the VC mode exceeds that in the PS mode by a value that, when adjusted for the standard deviation, suggests a 12% higher mean tidal volume in VC compared to PS, indicating a more consistent delivery of air per breath in VC mode.",
    "label": "support"
  },
  {
    "id": "training_638_3",
    "table_caption": "Table: Table 3 Concurrent and Predictive Validity Tests for Original SEPA Scale SEPA at 6 months SEPA at 12 months 7-day PAR at 6 months (minutes/week) ρ = 0.464** n/a Accelerometer 6 months (minutes/week) ρ = 0.273** n/a 7-day PAR 6 months (meeting guidelines) t(40) = −5.605** n/a Accelerometer 6 months (meeting guidelines) t(18) = − 2.789* n/a 7-day PAR at 12 months (minutes/week)a B = 0.368** SE = 0.109 ρ = 0.492** Accelerometer 12 months (minutes/week)a B = 0.313** SE = 0.102 ρ = 0.340** 7-day PAR 12 months (meeting guidelines) B = 0.129** SE = 0.472 t(64) = − 5.157** Accelerometer 12 months (meeting guidelines) B = 0.081 SE = 0.058 t(29) = − 2.565* **p value < .01, *p value < .05, +p value < .1 Note a: In linear regression models, square root transformations were used for the outcome variables (7-day PAR and accelerometer-measured MVPA) ",
    "table_content": "|| blank | SEPA at 6 months | SEPA at 12 months ||\n|| 7-day PAR at 6 months (minutes/week) | ρ = 0.464** | n/a ||\n|| Accelerometer 6 months (minutes/week) | ρ = 0.273** | n/a ||\n|| 7-day PAR 6 months (meeting guidelines) | t (40) = −5.605** | n/a ||\n|| Accelerometer 6 months (meeting guidelines) | t (18) = − 2.789* | n/a ||\n|| 7-day PAR at 12 months (minutes/week) a | B = 0.368** SE = 0.109 | ρ = 0.492** ||\n|| Accelerometer 12 months (minutes/week) a | B = 0.313** SE = 0.102 | ρ = 0.340** ||\n|| 7-day PAR 12 months (meeting guidelines) | B = 0.129** SE = 0.472 | t (64) = − 5.157** ||\n|| Accelerometer 12 months (meeting guidelines) | B = 0.081 SE = 0.058 | t (29) = − 2.565* ||",
    "claim": "The absolute t-value for 7-day PAR 6 months (meeting guidelines) is greater than that for the accelerometer at the same time point, indicating a stronger deviation from the null hypothesis for self-reported data.",
    "label": "support"
  },
  {
    "id": "training_804_3",
    "table_caption": "Table: TABLE 1 | LED speciﬁcations. LED type Dominant wavelength Dimension Flux rating Max. forward voltage DC forward current Cree TR2227 460 nm 220 × 270 µm2 21 mW 3.7 V 30 mA Cree DA2432 470 nm 240 × 320 µm2 30 mW 3.4 V 100 mA ",
    "table_content": "|| LED type | Dominant wavelength | Dimension | Flux rating | Max. forward voltage | DC forward current ||\n|| Cree TR2227 | 460 nm | 220 × 270 μm 2 | 21 mW | 3.7 V | 30 mA ||\n|| Cree DA2432 | 470 nm | 240 × 320 μm 2 | 30 mW | 3.4 V | 100 mA ||",
    "claim": "The Cree DA2432 operates at a lower maximum forward voltage compared to the Cree TR2227, yet it supports a significantly higher DC forward current. This suggests that the Cree DA2432 is designed to handle higher current loads more efficiently, which is a critical factor in applications requiring high brightness.",
    "label": "support"
  },
  {
    "id": "training_137_1",
    "table_caption": "Table: care. it has has the since occur by A ables after 2008. It in mat, cluded. ies almost that studies studies age pital and Thus, follow: – – – – – Table 6 Number of deaths and annual mortality rate from burns by county (department) of Colombia Code Department Deaths Average population Annual death rate/100,000 05 Antioquia 696 5,643,511 1.23 08 Atlántico 402 2,151,045 1.87 11 Bogotá, D.C. 564 6,787,079 0.83 13 Bolívar 277 1,870,660 1.48 15 Boyacá 184 1,253,671 1.47 17 Caldas 162 967,591 1.67 18 Caquetá 59 418,052 1.41 19 Cauca 184 1,263,858 1.46 20 Cesar 152 897,334 1.69 23 Córdoba 184 1,457,229 1.26 25 Cundinamarca 235 2,260,293 1.04 27 Chocó 52 451,965 1.15 41 Huila 93 1,004,140 0.93 44 La Guajira 77 667,684 1.15 47 Magdalena 204 1,145,230 1.78 50 Meta 87 774,750 1.12 52 Nariño 174 1,531,949 1.14 54 Norte de Santander 285 1,238,465 2.30 63 Quindío 29 532,965 0.54 66 Risaralda 96 894,525 1.07 68 Santander 336 1,952,806 1.72 70 Sucre 87 768,273 1.13 73 Tolima 136 1,362,424 1.00 76 Valle del Cauca 570 4,139,615 1.38 81 Arauca 36 231,074 1.56 85 Casanare 26 292,197 0.89 86 Putumayo 24 308,638 0.78 88 Archipelago of San Andrés 9 70,237 1.28 91 Amazonas 5 67,277 0.74 94 Guainía 1 34,922 0.29 95 Guaviare 11 94,866 1.16 97 Vaupés 5 39,033 1.28 99 Vichada 6 55,188 1.09 National total 5448 42,628,541 1.28 ",
    "table_content": "|| Code | Department | Deaths | Average population | Annual death rate/100,000 ||\n|| 05 | Antioquia | 696 | 5,643,511 | 1.23 ||\n|| 23 | Córdoba | 184 | 1,457,229 | 1.26 ||\n|| 25 | Cundinamarca | 235 | 2,260,293 | 1.04 ||\n|| 27 | Chocó | 52 | 451,965 | 1.15 ||\n|| 41 | Huila | 93 | 1,004,140 | 0.93 ||\n|| 44 | La Guajira | 77 | 667,684 | 1.15 ||\n|| 47 | Magdalena | 204 | 1,145,230 | 1.78 ||\n|| 50 | Meta | 87 | 774,750 | 1.12 ||\n|| 52 | Nariño | 174 | 1,531,949 | 1.14 ||\n|| 54 | Norte de Santander | 285 | 1,238,465 | 2.30 ||\n|| 63 | Quindío | 29 | 532,965 | 0.54 ||\n|| 08 | Atlántico | 402 | 2,151,045 | 1.87 ||\n|| 66 | Risaralda | 96 | 894,525 | 1.07 ||\n|| 68 | Santander | 336 | 1,952,806 | 1.72 ||\n|| 70 | Sucre | 87 | 768,273 | 1.13 ||\n|| 73 | Tolima | 136 | 1,362,424 | 1.00 ||\n|| 76 | Valle del Cauca | 570 | 4,139,615 | 1.38 ||\n|| 81 | Arauca | 36 | 231,074 | 1.56 ||\n|| 85 | Casanare | 26 | 292,197 | 0.89 ||\n|| 86 | Putumayo | 24 | 308,638 | 0.78 ||\n|| 88 | Archipelago of San Andrés | 9 | 70,237 | 1.28 ||\n|| 91 | Amazonas | 5 | 67,277 | 0.74 ||\n|| 11 | Bogotá, D.C. | 564 | 6,787,079 | 0.83 ||\n|| 94 | Guainía | 1 | 34,922 | 0.29 ||\n|| 95 | Guaviare | 11 | 94,866 | 1.16 ||\n|| 97 | Vaupés | 5 | 39,033 | 1.28 ||\n|| 99 | Vichada | 6 | 55,188 | 1.09 ||\n|| 99 | National total | 5448 | 42,628,541 | 1.28 ||\n|| 13 | Bolívar | 277 | 1,870,660 | 1.48 ||\n|| 15 | Boyacá | 184 | 1,253,671 | 1.47 ||\n|| 17 | Caldas | 162 | 967,591 | 1.67 ||\n|| 18 | Caquetá | 59 | 418,052 | 1.41 ||\n|| 19 | Cauca | 184 | 1,263,858 | 1.46 ||\n|| 20 | Cesar | 152 | 897,334 | 1.69 ||",
    "claim": "The mortality rate due to burns shows a decreasing trend as the department code increases, with a few exceptions. This trend can be observed by calculating the average mortality rate for departments with lower codes and comparing it to those with higher codes, revealing a subtle decline in mortality rates as the department code increases.",
    "label": "support"
  },
  {
    "id": "training_465_5",
    "table_caption": "Table: Recorded monthly mortality for Y. pestis plague epidemics. Note minima in warm season. Place Date Latitude Deaths per Month through the course of each epidemic wave Agent Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Bombay12 1897 19uN 1857 3083 2266 1316 328 99 42 70 168 178 255 644 BP Bombay12 1898 19uN 2934 4498 4973 2171 524 150 263 543 731 728 217 470 BP Manchuria13 1911 41uN 1104 3153 739 11 PP Agent and Highlights: BP – Bubonic Plague; PP – Pneumonic Plague. ",
    "table_content": "|| Place | Date | Latitude | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Agent ||\n|| Place | Date | Latitude | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Agent ||\n|| Bombay 12  | 1897 | 19°N | 1857 | 3083 | 2266 | 1316 | 328 | 99 | 42 | 70 | 168 | 178 | 255 | 644 | BP ||\n|| Bombay 12  | 1898 | 19°N | 2934 | 4498 | 4973 | 2171 | 524 | 150 | 263 | 543 | 731 | 728 | 217 | 470 | BP ||\n|| Manchuria 13  | 1911 | 41°N | 1104 | 3153 | 739 | 11 | blank | blank | blank | blank | blank | blank | blank | blank | PP ||",
    "claim": "In Bombay during 1898, the mortality rate decreased by approximately 95% from March to July, followed by a gradual increase of about 2.5 times from July to October, indicating a complex pattern of decline and resurgence within the epidemic wave.",
    "label": "support"
  },
  {
    "id": "training_1445_6",
    "table_caption": "Table: Table 1 Hormone levels among postmenopausal women not taking hormones in the Nurses’ Health Study and the individual association between each hormone and breast cancer risk overall and for estrogen receptor-positive tumors Median (10th to 90th percentile) RR, top vs bottom quintile (95% CI)a, b Hormones Cases Controls All cases ER-positive cases Estrone (pg/ml) 28 (15 to 49) 24 (14 to 43) 2.1 (1.3 to 3.4) 2.8 (1.5 to 5.3) Estradiol (pg/ml) 8 (4 to 17) 6 (4 to 14) 2.4 (1.4 to 4.1) 2.9 (1.4 to 5.9) Estrone sulfate (pg/ml) 276 (102 to 733) 222 (98 to 577) 2.4 (1.5 to 3.9) 2.2 (1.2 to 4.0) Testosterone (ng/ml) 24 (14 to 49) 22 (12 to 40) 1.8 (1.1 to 2.9) 2.0 (1.0 to 3.7) Androstenedione (ng/ml) 63 (35 to 108) 57 (30 to 108) 2.1 (1.3 to 3.6) 2.6 (1.3 to 5.0) DHEA (ng/dl) 234 (104 to 506) 218 (93 to 435) 1.5 (0.9 to 2.4) 1.6 (0.9 to 2.9) DHEAS (μg/dl) 92 (41 to 224) 85 (33 to 175) 2.5 (1.4 to 4.2) 2.0 (1.0 to 3.8) Prolactin (ng/ml) 8.2 (4.9 to 14.8) 8.0 (4.9 to 14.0) 1.1 (0.7 to 1.7) 1.7 (0.9 to 3.1) IGF-1 (ng/ml) 152 (98 to 252) 153 (98 to 242) 1.1 (0.6 to 2.0) 1.4 (0.7 to 2.7) c-peptide (ng/ml) 1.71 (0.66 to 4.11) 1.53 (0.61 to 4.03) 1.4 (0.8 to 2.4) 1.4 (0.7 to 3.0) DHEA = dehydroepiandrosterone; DHEAS = dehydroepiandrosterone sulfate; ER = estrogen receptor; IGF-1 = insulin-like growth factor 1. aRR and 95% CI were adjusted for age at blood draw and menopause, parity, history of benign breast disease, family history of breast cancer, fasting status and time of day of blood draw. bFor all hormones (except IGF-1 and c-peptide), n = 265 total cases (invasive and in situ), n = 147 ER-positive, invasive cases, and n = 541 controls; for IGF-1 ",
    "table_content": "|| Hormones | Median (10th to 90th percentile) | Median (10th to 90th percentile) | RR, top vs bottom quintile (95% CI) a, b | RR, top vs bottom quintile (95% CI) a, b ||\n|| Hormones | Cases | Controls | All cases | ER-positive cases ||\n|| IGF-1 (ng/ml) | 152 (98 to 252) | 153 (98 to 242) | 1.1 (0.6 to 2.0) | 1.4 (0.7 to 2.7) ||\n|| c-peptide (ng/ml) | 1.71 (0.66 to 4.11) | 1.53 (0.61 to 4.03) | 1.4 (0.8 to 2.4) | 1.4 (0.7 to 3.0) ||\n|| Estrone (pg/ml) | 28 (15 to 49) | 24 (14 to 43) | 2.1 (1.3 to 3.4) | 2.8 (1.5 to 5.3) ||\n|| Estradiol (pg/ml) | 8 (4 to 17) | 6 (4 to 14) | 2.4 (1.4 to 4.1) | 2.9 (1.4 to 5.9) ||\n|| Estrone sulfate (pg/ml) | 276 (102 to 733) | 222 (98 to 577) | 2.4 (1.5 to 3.9) | 2.2 (1.2 to 4.0) ||\n|| Testosterone (ng/ml) | 24 (14 to 49) | 22 (12 to 40) | 1.8 (1.1 to 2.9) | 2.0 (1.0 to 3.7) ||\n|| Androstenedione (ng/ml) | 63 (35 to 108) | 57 (30 to 108) | 2.1 (1.3 to 3.6) | 2.6 (1.3 to 5.0) ||\n|| DHEA (ng/dl) | 234 (104 to 506) | 218 (93 to 435) | 1.5 (0.9 to 2.4) | 1.6 (0.9 to 2.9) ||\n|| DHEAS (μg/dl) | 92 (41 to 224) | 85 (33 to 175) | 2.5 (1.4 to 4.2) | 2.0 (1.0 to 3.8) ||\n|| Prolactin (ng/ml) | 8.2 (4.9 to 14.8) | 8.0 (4.9 to 14.0) | 1.1 (0.7 to 1.7) | 1.7 (0.9 to 3.1) ||",
    "claim": "Prolactin shows the smallest difference in median levels between cases and controls, suggesting a weaker association with breast cancer risk compared to other hormones.",
    "label": "support"
  },
  {
    "id": "training_836_4",
    "table_caption": "Table: the et al., (Yamada Rio examine ver- sequence identical SbSUT1 BTx623 absent variation Five Table 2 | Summary of SUT sequence variation between BTx623 and Rio cultivars. SUT No. of variations (BTx623 vs Rio) Amino acid variations SbSUT1 1 I381V SbSUT2 1 T41 insertion (Rio) SbSUT3 0 – SbSUT4 0 – SbSUT5 9 A32G, G33A, E34G, K35E, G37A, L272V, V355M, T396M, K426R SbSUT6 0 – PHYLOGENETIC ANALYSIS OF MONOCOTYLEDONOUS SUTs ",
    "table_content": "|| SUT | No. of variations (BTx623 vs Rio) | Amino acid variations ||\n|| SbSUT1 | 1 | I381V ||\n|| SbSUT2 | 1 | T41 insertion (Rio) ||\n|| SbSUT3 | 0 | – ||\n|| SbSUT4 | 0 | – ||\n|| SbSUT5 | 9 | A32G, G33A, E34G, K35E, G37A,L272V, V355M, T396M, K426R ||\n|| SbSUT6 | 0 | – ||",
    "claim": "SbSUT5 has a variation frequency that is nine times higher than that of SbSUT1 and SbSUT2, which each have only one variation. This disparity suggests differential selective pressures or functional constraints acting on these transporters.",
    "label": "support"
  },
  {
    "id": "training_338_2",
    "table_caption": "Table: Characteristics of priapism. N Mean age (years) Mean duration of priapism (hours) Low ﬂow 77 41 58 Neurogenic∗ 15 35 6 High ﬂow 2 19 252 ∗The neurogenic priapism patients are included in the total for “low-ﬂow,” but are separated out for clarity. ",
    "table_content": "|| blank |  N  | Mean age (years) | Mean duration of priapism (hours) ||\n|| Low flow | 77 | 41 | 58 ||\n|| Neurogenic ∗  | 15 | 35 | 6 ||\n|| High flow | 2 | 19 | 252 ||",
    "claim": "Neurogenic cases account for approximately 19.48% of the total low-flow priapism cases, highlighting their significant contribution to this category.",
    "label": "support"
  },
  {
    "id": "training_332_3",
    "table_caption": "Table: representative of the whole treatment period. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . TREATMENT GROUPS Mean arthritis score on day 23 Arthritis score on day 23 vs. no treatment (p-value) Area under the Curve (AUC) AUC vs. no treatment (p-value) Etanercept 36 5.8 0.004 42.639 0.03 Etanercept 16 8.3 n.s. 48.858 n.s. 180-88 46 7.1 n.s. 54.726 n.s. Etanercept 16+180-188 46 4.9 0.0004 40.396 0.02 Etanercept 16+OVA 46 9.0 n.s. 79.597 n.s. No treatment 9.8 77.748 Statistical analysis was performed by the paired t-test. Different treatment groups were set out against no treatment. doi:10.1371/journal.pone.0000087.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
    "table_content": "|| TREATMENT GROUPS | Mean arthritis score on day 23 | Arthritis score on day 23 vs. no treatment (p-value) | Area under the Curve (AUC) | AUC vs. no treatment (p-value) ||\n||  Etanercept 3×  | 5.8 |  0.004  | 42.639 |  0.03  ||\n||  Etanercept 1×  | 8.3 | n.s. | 48.858 | n.s. ||\n||  180-88 4×  | 7.1 | n.s. | 54.726 | n.s. ||\n||  Etanercept 1×+180-188 4×  | 4.9 |  0.0004  | 40.396 |  0.02  ||\n||  Etanercept 1×+OVA 4×  | 9.0 | n.s. | 79.597 | n.s. ||\n||  No treatment  | 9.8 | blank | 77.748 | blank ||",
    "claim": "The AUC for the Etanercept 3× group is approximately 45% lower than that of the no-treatment group, suggesting a substantial reduction in overall arthritis symptoms over the treatment period.",
    "label": "support"
  },
  {
    "id": "training_1378_5",
    "table_caption": "Table: Dimensions Contact angle (°) E* d (μm) l (μm) h (μm) r Intrinsic Advancing Apparent Static S1 (pillars) 10 25 15 1.75 42 5 N/A S2 (pillars) 10 25 15 1.75 96 152 5.45 S3 (bare) N/A N/A N/A 1 72 69 N/A S4 (pillars) 7 10 22 5.84 105 149 0.66 Table 1. Dimension, contact angle, and dimensionless energy for different micropillars. ",
    "table_content": "|| blank | Dimensions | Dimensions | Dimensions | Dimensions | Contact angle (°) | Contact angle (°) | E* ||\n|| blank | d (μm) | l (μm) | h (μm) | r | Intrinsic Advancing | Apparent Static | E* ||\n|| S1 (pillars) | 10 | 25 | 15 | 1.75 | 42 | 5 | N/A ||\n|| S2 (pillars) | 10 | 25 | 15 | 1.75 | 96 | 152 | 5.45 ||\n|| S3 (bare) | N/A | N/A | N/A | 1 | 72 | 69 | N/A ||\n|| S4 (pillars) | 7 | 10 | 22 | 5.84 | 105 | 149 | 0.66 ||",
    "claim": "The dimensionless energy E* for S2 is 8.26 times greater than that of S4, despite S4 having a larger radius, indicating that the configuration and arrangement of micropillars in S2 lead to a higher energy state, independent of the radius.",
    "label": "support"
  },
  {
    "id": "training_817_5",
    "table_caption": "Table: No. of smokers participated in the QTW Contest, RCT and included in this Study Sample n = 1307 (%) Participated in the QTW Contest 1307 (100%) Successfully interviewed at the 1-week follow-up 1030 (78.8%) Answered questions on ever EC use 956 (73.1%) n = 956 (%) Ever EC users 163 (17.1%) Non-users 793 (82.9%) QTW: “Quit to Win” contest. EC: electronic cigarette. ",
    "table_content": "|| Study Sample | n = 1307 (%) ||\n|| Participated in the QTW Contest | 1307 (100%) ||\n|| Successfully interviewed at the 1-week follow-up | 1030 (78.8%) ||\n|| Answered questions on ever EC use | 956 (73.1%) ||\n|| Answered questions on ever EC use | n = 956 (%) ||\n|| Ever EC users | 163 (17.1%) ||\n|| Non-users | 793 (82.9%) ||",
    "claim": "From the initial participation in the QTW contest to answering questions on EC use, there is a 26.9% attrition rate. This reflects the cumulative drop-off in engagement through the stages of the study, highlighting the challenges in maintaining participant involvement over time.",
    "label": "support"
  },
  {
    "id": "training_1248_3",
    "table_caption": "Table: to the ap- in per crystallized-type intelligence (gc). All CNVs Deletions Duplications Cohort Sample Size Gene Load Rate Gene Load Rate Gene Load Rate ABC1936 412 37 0.090 8 0.019 29 0.070 LBC1921 492 60 0.122 10 0.020 50 0.102 LBC1936 887 144 0.162 56 0.063 88 0.099 Manchester 723 81 0.112 19 0.026 62 0.086 Newcastle 698 120 0.172 4 0.006 116 0.167 Total 3210 442 0.138 97 0.030 345 0.108 Gene load, is calculated as the number of genes whose co-ordinates +/220 kb intersect with a CNV that passes QC checks (length $500 kb, and frequency ",
    "table_content": "|| Cohort | Sample Size | All CNVs | All CNVs | Deletions | Deletions | Duplications | Duplications ||\n|| Cohort | Sample Size | Gene Load | Rate | Gene Load | Rate | Gene Load | Rate ||\n|| ABC1936 | 412 | 37 | 0.090 | 8 | 0.019 | 29 | 0.070 ||\n|| LBC1921 | 492 | 60 | 0.122 | 10 | 0.020 | 50 | 0.102 ||\n|| LBC1936 | 887 | 144 | 0.162 | 56 | 0.063 | 88 | 0.099 ||\n|| Manchester | 723 | 81 | 0.112 | 19 | 0.026 | 62 | 0.086 ||\n|| Newcastle | 698 | 120 | 0.172 | 4 | 0.006 | 116 | 0.167 ||\n|| Total | 3210 | 442 | 0.138 | 97 | 0.030 | 345 | 0.108 ||",
    "claim": "In the Newcastle cohort, the gene load from duplications is nearly 30 times greater than that from deletions, highlighting a significant skew towards duplications.",
    "label": "support"
  },
  {
    "id": "training_1071_3",
    "table_caption": "Table: Table 3 Cost, effectiveness and incremental cost-effectiveness estimates for a hypothetical cohort of approximately 1 million injectable users in Uganda for a 1-year time horizon (in 2016 US$) Costs Pregnancies averted Maternal DALYs averted Societal: research design DMPA-SC $6,549,568 134,402 19,998 DMPA-IM $6,633,425 123,575 18,378 Incremental ($83,857) 10,827 1620 Incremental cost-effectiveness ratio Self-injected DMPA-SC is dominant Self-injected DMPA-SC is dominant Societal: programmatic implementation DMPA-SC $5,632,352 134,402 19,998 DMPA-IM $6,633,425 123,575 18,378 Incremental ($1,001,073) 10,827 1620 Incremental cost-effectiveness ratio Self-injected DMPA-SC is dominant Self-injected DMPA-SC is dominant Health system: research design DMPA-SC $5,667,770 134,402 19,998 DMPA-IM $4,592,291 123,575 18,378 Incremental $1,075,478 10,827 1620 Incremental cost-effectiveness ratio $99/pregnancy averted $664/DALY averted Health system: programmatic implementation DMPA-SC $4,750,553 134,402 19,998 DMPA-IM $4,592,291 123,575 18,378 Incremental $158,262 10,827 1620 Incremental cost-effectiveness ratio $15/pregnancy averted $98/DALY averted ",
    "table_content": "|| blank | Costs | Pregnancies averted | Maternal DALYs averted ||\n|| Societal: research design | Societal: research design | Societal: research design | Societal: research design ||\n|| Incremental cost-effectiveness ratio | blank | Self-injected DMPA-SC is dominant | Self-injected DMPA-SC is dominant ||\n|| Health system: research design | Health system: research design | Health system: research design | Health system: research design ||\n|| DMPA-SC | $5,667,770 | 134,402 | 19,998 ||\n|| DMPA-IM | $4,592,291 | 123,575 | 18,378 ||\n|| Incremental | $1,075,478 | 10,827 | 1620 ||\n|| Incremental cost-effectiveness ratio | blank | $99/pregnancy averted | $664/DALY averted ||\n|| Health system: programmatic implementation | Health system: programmatic implementation | Health system: programmatic implementation | Health system: programmatic implementation ||\n|| DMPA-SC | $4,750,553 | 134,402 | 19,998 ||\n|| DMPA-IM | $4,592,291 | 123,575 | 18,378 ||\n|| Incremental | $158,262 | 10,827 | 1620 ||\n|| DMPA-SC | $6,549,568 | 134,402 | 19,998 ||\n|| Incremental cost-effectiveness ratio | blank | $15/pregnancy averted | $98/DALY averted ||\n|| DMPA-IM | $6,633,425 | 123,575 | 18,378 ||\n|| Incremental | ($83,857) | 10,827 | 1620 ||\n|| Incremental cost-effectiveness ratio | blank | Self-injected DMPA-SC is dominant | Self-injected DMPA-SC is dominant ||\n|| Societal: programmatic implementation | Societal: programmatic implementation | Societal: programmatic implementation | Societal: programmatic implementation ||\n|| DMPA-SC | $5,632,352 | 134,402 | 19,998 ||\n|| DMPA-IM | $6,633,425 | 123,575 | 18,378 ||\n|| Incremental | ($1,001,073) | 10,827 | 1620 ||",
    "claim": "The cumulative additional maternal DALYs averted by DMPA-SC over DMPA-IM, across all perspectives, is 6,480 DALYs.",
    "label": "support"
  },
  {
    "id": "training_905_3",
    "table_caption": "Table: recommendations in the CDS tool were actually used by the ASHAs ASHA Risk projection meter to communicate CVD risk association between risk factors Recommendations (lifestyle, smoking, nutrition) Next visit (doctor referral, CVD risk/diabetes screening) npB1 79% (22/28) 96% (27/28) 93% (26/28) npM1 75% (15/20) 85% (17/20) 90% (18/20) npL1 81% (13/16) 81% (13/16) 81% (13/16) It three eters ments, pilot ber had ",
    "table_content": "||  ASHA  |  Risk projection meter to communicate CVD risk association between risk factors  |  Recommendations (lifestyle, smoking, nutrition)  |  Next visit (doctor referral, CVD risk/diabetes screening)  ||\n||  npB1  | 79% (22/28) | 96% (27/28) | 93% (26/28) ||\n||  npM1  | 75% (15/20) | 85% (17/20) | 90% (18/20) ||\n||  npL1  | 81% (13/16) | 81% (13/16) | 81% (13/16) ||",
    "claim": "The npB1 group has a 3% higher adherence to follow-up actions compared to npM1, and a 12% higher adherence compared to npL1, suggesting a more proactive approach in ensuring follow-up actions.",
    "label": "support"
  },
  {
    "id": "training_185_4",
    "table_caption": "Table: Hazard ratios (95% CI) for the risk of cardiovascular events, according to the dietary inflammatory index score, the SUN. Quartiles of dietary inﬂammatory index score Q1 Q2 Q3 Q4 P for trend Most anti-inﬂammatory Most pro-inﬂammatory Cases 24 24 32 37 Person-years of follow up 41,240 42,496 42,029 42,345 Incidence rate /1,000 person years 0.58 0.56 0.76 0.87 (95% CI) (0.39–0.87) (0.38–0.84) (0.54–1.08) (0.63–1.2) Crude HR* 1 (ref) 1 1.62 1.98 0.003 (0.57–1.79) (0.94–2.8) (1.16–3.36) HR adjusted for sex * 1 (ref) 1.02 1.52 1.75 0.016 (0.57–1.81) (0.88–2.63) (1.03–2.98) Multivariable adjusted HR † 1 (ref) 1.05 1.75 1.95 0.018 (0.58–1.89) (0.96–3.18) (1.02–3.72) Multivariable adjusted HR ‡ 1 (ref) 1.05 1.75 2.03 0.017 (0.58–1.9) (0.96–3.19) (1.06–3.88) *age as underlying time variable † Additionally adjusted for cardiovascular risk factors (hypertension, dyslipidaemia, diabetes, smoking status (3 categories), family history of ",
    "table_content": "|| blank | Quartiles of dietary inflammatory index score | Quartiles of dietary inflammatory index score | Quartiles of dietary inflammatory index score | Quartiles of dietary inflammatory index score | P for trend ||\n|| blank | Q1 Most anti-inflammatory | Q2 | Q3 | Q4 Most pro-inflammatory | P for trend ||\n|| HR adjusted for sex *  | blank | (0.57–1.81) | (0.88–2.63) | (1.03–2.98) | blank ||\n|| Multivariable adjusted HR †  | 1 (ref) | 1.05 | 1.75 | 1.95 | 0.018 ||\n|| Multivariable adjusted HR †  | blank | (0.58–1.89) | (0.96–3.18) | (1.02–3.72) | blank ||\n|| Multivariable adjusted HR ‡  | 1 (ref) | 1.05 | 1.75 | 2.03 | 0.017 ||\n|| Multivariable adjusted HR ‡  | blank | (0.58–1.9) | (0.96–3.19) | (1.06–3.88) | blank ||\n|| blank | Q1 Most anti-inflammatory | Q2 | Q3 | Q4 Most pro-inflammatory | P for trend ||\n|| Cases | 24 | 24 | 32 | 37 | blank ||\n|| Person-years of follow up | 41,240 | 42,496 | 42,029 | 42,345 | blank ||\n|| Incidence rate /1,000 person years | 0.58 | 0.56 | 0.76 | 0.87 | blank ||\n|| (95% CI) | (0.39–0.87) | (0.38–0.84) | (0.54–1.08) | (0.63–1.2) | blank ||\n|| Crude HR *  | 1 (ref) | 1 | 1.62 | 1.98 | 0.003 ||\n|| Crude HR *  | blank | (0.57–1.79) | (0.94–2.8) | (1.16–3.36) | blank ||\n|| HR adjusted for sex *  | 1 (ref) | 1.02 | 1.52 | 1.75 | 0.016 ||",
    "claim": "Despite similar person-years of follow-up across quartiles, the number of cases increases from 24 in Q1 to 37 in Q4. This suggests that the increase in cases is not due to longer follow-up but rather the higher dietary inflammatory index, which is associated with a 54% increase in cases from Q1 to Q4.",
    "label": "support"
  },
  {
    "id": "training_1332_6",
    "table_caption": "Table: Group sizes and characteristics of organizations ID Group group size sample (contacted) response rate final group size (analyzed) proportion (of all analyzed) characteristics (examples) all groups 442 67% 301 100% A patient organizations 42 57% 24 8% umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres B medical associations 100 78% 79 26% scientific medical societies, associations of statutory health insurance physicians on federal and national level C nursing organizations 22 77% 17 6% umbrella organizations of nursing care, federal working commitee of nursing D health insurance funds 82 63% 55 18% associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds E political institutions 45 49% 24 8% state and federal ministries of health, health-care policy spokespeople of the different political parties F specialized palliative care 54 65% 39 13% associations and umbrella organizations of palliative and hospice care on federal and national level G others* 97 72% 63 21% charity and clerical institutions, associations for physiotherapy, federal joint committee * not included in the comparison of the groups because of the strong heterogeneity ",
    "table_content": "|| ID | Group all groups | group size sample (contacted) 442 | response rate 67% | final group size (analyzed) 301 | proportion (of all analyzed) 100% | characteristics (examples) ||\n|| ID | Group all groups | group size sample (contacted) 442 | response rate 67% | final group size (analyzed) 301 | proportion (of all analyzed) 100% | characteristics (examples) ||\n|| A | patient organizations | 42 | 57% | 24 | 8% | umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres ||\n|| B | medical associations | 100 | 78% | 79 | 26% | scientific medical societies, associations of statutory health insurance physicians on federal and national level ||\n|| C | nursing organizations | 22 | 77% | 17 | 6% | umbrella organizations of nursing care, federal working commitee of nursing ||\n|| D | health insurance funds | 82 | 63% | 55 | 18% | associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds ||\n|| E | political institutions | 45 | 49% | 24 | 8% | state and federal ministries of health, health-care policy spokespeople of the different political parties ||\n|| F | specialized palliative care | 54 | 65% | 39 | 13% | associations and umbrella organizations of palliative and hospice care on federal and national level ||\n|| G | others* | 97 | 72% | 63 | 21% | charity and clerical institutions, associations for physiotherapy, federal joint committee ||",
    "claim": "The \"others\" category, despite its heterogeneity, contributes 21% to the total analyzed sample, which is more than double the contribution of nursing organizations, reflecting its substantial representation in the study.",
    "label": "support"
  },
  {
    "id": "training_577_4",
    "table_caption": "Table: Tableau 1: Caractéristiques sociodémographiques de la population d’étude Fréquences (n=94) Pourcentage (%) Sexe Féminin 50 53,2 Masculin 44 46,8 Age (ans) 15-24 4 4,3 25-34 18 19,1 35-44 18 19,1 45-54 37 39,4 ≥55 15 16 NR 2 2,1 Statut Social Militaire 24 25,5 Civil 64 68,1 NR 6 6,4 Statut Matrimonial Marié 49 52,1 Divorcé 2 2,1 Célibataire 35 37,2 Veuf (veuve) 6 6,4 NR 2 2,1 Lieu de résidence Ouagadougou 60 63,8 Autre 12 12,8 NR 22 23,4 Nationalité Burkinabé 91 96,8 Autre 1 1,1 NR 2 2,1 Nombre d’enfants 0-3 63 67 4-6 22 23,5 7-9 2 2,1 ≥10 2 2,1 NR 5 5,3 NR: Non Renseigné ",
    "table_content": "|| blank | Fréquences (n=94) | Pourcentage (%) ||\n|| Sexe | Sexe | Sexe ||\n|| NR | 2 | 2,1 ||\n|| Statut Social | Statut Social | Statut Social ||\n|| Militaire | 24 | 25,5 ||\n|| Civil | 64 | 68,1 ||\n|| NR | 6 | 6,4 ||\n|| Statut Matrimonial | Statut Matrimonial | Statut Matrimonial ||\n|| Marié | 49 | 52,1 ||\n|| Divorcé | 2 | 2,1 ||\n|| Célibataire | 35 | 37,2 ||\n|| Veuf (veuve) | 6 | 6,4 ||\n|| Féminin | 50 | 53,2 ||\n|| NR | 2 | 2,1 ||\n|| Lieu de résidence | Lieu de résidence | Lieu de résidence ||\n|| Ouagadougou | 60 | 63,8 ||\n|| Autre | 12 | 12,8 ||\n|| NR | 22 | 23,4 ||\n|| Nationalité | Nationalité | Nationalité ||\n|| Burkinabé | 91 | 96,8 ||\n|| Autre | 1 | 1,1 ||\n|| NR | 2 | 2,1 ||\n|| Nombre d’enfants | Nombre d’enfants | Nombre d’enfants ||\n|| Masculin | 44 | 46,8 ||\n|| 0-3 | 63 | 67 ||\n|| 4-6 | 22 | 23,5 ||\n|| 7-9 | 2 | 2,1 ||\n|| ≥10 | 2 | 2,1 ||\n|| NR | 5 | 5,3 ||\n|| Age (ans) | Age (ans) | Age (ans) ||\n|| 15-24 | 4 | 4,3 ||\n|| 25-34 | 18 | 19,1 ||\n|| 35-44 | 18 | 19,1 ||\n|| 45-54 | 37 | 39,4 ||\n|| ≥55 | 15 | 16 ||",
    "claim": "Married individuals form the majority of the population, with a proportion exceeding 50%. The number of married individuals is more than 14 times the number of divorced individuals, highlighting a significant prevalence of marriage in the study population.",
    "label": "support"
  },
  {
    "id": "training_1057_2",
    "table_caption": "Table: TABLE 1 | Total and different classes of volatile compounds and their concentrations in different aromatic melon types. Volatile compounds Different types of melon (µg.g−1FW) CH CB CG Total esters 207.83 ± 17.21a 127.16 ± 16.75b 5.29 ± 1.82c Total alcohols 30.24 ± 2.48b 23.68 ± 1.87b 136.85 ± 4.85a Total acids 15.73 ± 5.28a 8.14 ± 2.62b 9.31 ± 3.97b Others 54.15 ± 20.01a 10.07 ± 1.32b 6.14 ± 1.21b Duncan’s multiple range tests were performed, and different letters represent significant differences (P < 0.05) between different types of melon. was each The DNase cDNA 95◦C s, ",
    "table_content": "|| Volatile compounds (μg.g −1 FW) | Different types of melon | Different types of melon | Different types of melon ||\n|| Volatile compounds (μg.g −1 FW) | CH | CB | CG ||\n|| Total esters | 207.83 ± 17.21 a | 127.16 ± 16.75 b | 5.29 ± 1.82 c ||\n|| Total alcohols | 30.24 ± 2.48 b | 23.68 ± 1.87 b | 136.85 ± 4.85 a ||\n|| Total acids | 15.73 ± 5.28 a | 8.14 ± 2.62 b | 9.31 ± 3.97 b ||\n|| Others | 54.15 ± 20.01 a | 10.07 ± 1.32 b | 6.14 ± 1.21 b ||",
    "claim": "The concentration of total alcohols in CG is approximately 4.5 times higher than in CH, highlighting a significant variation in alcohol content between these melon types.",
    "label": "support"
  },
  {
    "id": "training_1211_1",
    "table_caption": "Table: Table 1 Validation of the miR-SEQ expression profiles of selected miRNAs by qRT-PCR miR-name Accession No. E. coli F18-resistant group E. coli F18-sensitive group P-value ssc-miR-499-5p MIMAT0013877 2.370 ± 1.109 0.467 ± 0.055 0.041* ssc-miR-676-5p MIMAT0017382 1.890 ± 1.181 0.650 ± 0.294 0.163 ssc-miR-432-3p MIMAT0017384 1.830 ± 1.344 0.821 ± 0.563 0.215 ssc-miR-196b MIMAT0013923 2.275 ± 0.991 0.478 ± 0.079 0.036* ssc-miR-421-5p MIMAT0017970 0.593 ± 0.183 0.378 ± 0.011 0.127 ssc-miR-202-5p MIMAT0013948 1.878 ± 1.322 0.695 ± 0.332 0.133 ssc-miR-885-3p MIMAT0013903 1.284 ± 0.492 0.859 ± 0.269 0.180 ssc-miR-493-5p MIMAT0025377 1.397 ± 0.680 0.814 ± 0.154 0.146 ssc-miR-218-3p MIMAT0017969 0.649 ± 0.443 1.901 ± 0.553 0.012* ssc-miR-155-3p MIMAT0017953 0.817 ± 0.442 1.659 ± 0.823 0.280 ssc-miR-208b MIMAT0013912 0.808 ± 0.408 1.538 ± 0.727 0.130 ssc-miR-187 MIMAT0020587 0.815 ± 0.508 1.404 ± 0.044 0.231 ssc-miR-450b-3p MIMAT0017380 0.427 ± 0.127 0.559 ± 0.112 0.171 ssc-miR-136 MIMAT0002158 0.582 ± 0.224 1.939 ± 0.850 0.045* ssc-miR-424-3p MIMAT0013921 0.742 ± 0.234 1.625 ± 0.926 0.215 *p < 0.05 ",
    "table_content": "|| miR-name | Accession No. |  E. coli F18-resistant group |  E. coli F18-sensitive group |  P -value ||\n|| ssc-miR-499-5p | MIMAT0013877 | 2.370 ± 1.109 | 0.467 ± 0.055 | 0.041* ||\n|| ssc-miR-155-3p | MIMAT0017953 | 0.817 ± 0.442 | 1.659 ± 0.823 | 0.280 ||\n|| ssc-miR-208b | MIMAT0013912 | 0.808 ± 0.408 | 1.538 ± 0.727 | 0.130 ||\n|| ssc-miR-187 | MIMAT0020587 | 0.815 ± 0.508 | 1.404 ± 0.044 | 0.231 ||\n|| ssc-miR-450b-3p | MIMAT0017380 | 0.427 ± 0.127 | 0.559 ± 0.112 | 0.171 ||\n|| ssc-miR-136 | MIMAT0002158 | 0.582 ± 0.224 | 1.939 ± 0.850 | 0.045* ||\n|| ssc-miR-424-3p | MIMAT0013921 | 0.742 ± 0.234 | 1.625 ± 0.926 | 0.215 ||\n|| ssc-miR-676-5p | MIMAT0017382 | 1.890 ± 1.181 | 0.650 ± 0.294 | 0.163 ||\n|| ssc-miR-432-3p | MIMAT0017384 | 1.830 ± 1.344 | 0.821 ± 0.563 | 0.215 ||\n|| ssc-miR-196b | MIMAT0013923 | 2.275 ± 0.991 | 0.478 ± 0.079 | 0.036* ||\n|| ssc-miR-421-5p | MIMAT0017970 | 0.593 ± 0.183 | 0.378 ± 0.011 | 0.127 ||\n|| ssc-miR-202-5p | MIMAT0013948 | 1.878 ± 1.322 | 0.695 ± 0.332 | 0.133 ||\n|| ssc-miR-885-3p | MIMAT0013903 | 1.284 ± 0.492 | 0.859 ± 0.269 | 0.180 ||\n|| ssc-miR-493-5p | MIMAT0025377 | 1.397 ± 0.680 | 0.814 ± 0.154 | 0.146 ||\n|| ssc-miR-218-3p | MIMAT0017969 | 0.649 ± 0.443 | 1.901 ± 0.553 | 0.012* ||",
    "claim": "Among the miRNAs listed, ssc-miR-218-3p shows the most statistically significant difference in expression between the E. coli F18-resistant and sensitive groups, with a p-value of 0.012, indicating a strong association with resistance.",
    "label": "support"
  },
  {
    "id": "training_1315_3",
    "table_caption": "Table: of MiRmat. Distance from Trutha 0 61 62 63 MaturePred(%) 21.21 36.36 48.48 57.57 MiRmat (%) 23.03 45.45 59.39 69.70 athe distance between predicted start position of mature microRNA and that of actual mature microRNA. ",
    "table_content": "|| Distance from Truth a  | 0 | ±1 | ±2 | ±3 ||\n||  MaturePred (%) | 21.21 | 36.36 | 48.48 | 57.57 ||\n||  MiRmat (%) |  23.03  |  45.45  |  59.39  |  69.70  ||",
    "claim": "The rate of increase in accuracy for the MiRmat model from 0 to ±3 is greater than that of the MaturePred model. This can be inferred from the larger percentage point increase in accuracy for MiRmat over the same range of distances, suggesting a more robust improvement in prediction accuracy with increased tolerance.",
    "label": "support"
  },
  {
    "id": "training_206_2",
    "table_caption": "Table: the of showed 0.2) as a percentage of study population (n = 12) at various time points in the transportation study. Prior Unloading 1 day post 5 days post EHV-2 58 75 83 83 EHV-5 75 75 58 58 ",
    "table_content": "|| blank | Prior | Unloading | 1 day post | 5 days post ||\n|| EHV-2 | 58 | 75 | 83 | 83 ||\n|| EHV-5 | 75 | 75 | 58 | 58 ||",
    "claim": "The percentage of the study population affected by EHV-5 decreases from Unloading to 1 day post and remains constant thereafter. This indicates a reduction effect post-unloading, with a 17% decrease from Unloading to 1 day post.",
    "label": "support"
  },
  {
    "id": "training_178_4",
    "table_caption": "Table: Magnetic inclination (deg) Magnetic declination (horizontal polarity) (deg) Magnetic field flux density (intensity) (nT) Autumn 67°NMF 68.59 ± 0.06 0 ± 0.14 49,221 ± 103 5°NMF 5.00 ± 0.03 0 ± 0.27 49,193 ± 121 5°CMF 5.07 ± 0.04 − 120 ± 0.21 49,079 ± 79 Spring 67°NMF 68.21 ± 0.15 0 ± 1.91 49,543 ± 217 67°CMF 68.13 ± 0.18 − 120 ± 1.91 49,276 ± 245 0°NMF 0.05 ± 0.05 0 ± 2.03 49,543 ± 237 0°CMF 0.05 ± 0.06 − 120 ± 1.96 49,357 ± 334 Table 1. Variability in the experimental magnetic fields used in the present study. Data in the center of the coil system; a magnetometer probe was positioned directly under the ",
    "table_content": "|| blank | blank | Magnetic inclination (deg) | Magnetic declination (horizontal polarity) (deg) | Magnetic field flux density (intensity) (nT) ||\n|| Autumn | 67°NMF | 68.59 ± 0.06 | 0 ± 0.14 | 49,221 ± 103 ||\n|| Autumn | 5°NMF | 5.00 ± 0.03 | 0 ± 0.27 | 49,193 ± 121 ||\n|| Autumn | 5°CMF | 5.07 ± 0.04 | −120 ± 0.21 | 49,079 ± 79 ||\n|| Spring | 67°NMF | 68.21 ± 0.15 | 0 ± 1.91 | 49,543 ± 217 ||\n|| Spring | 67°CMF | 68.13 ± 0.18 | −120 ± 1.91 | 49,276 ± 245 ||\n|| Spring | 0°NMF | 0.05 ± 0.05 | 0 ± 2.03 | 49,543 ± 237 ||\n|| Spring | 0°CMF | 0.05 ± 0.06 | −120 ± 1.96 | 49,357 ± 334 ||",
    "claim": "For the same inclination and season, NMF configurations exhibit higher magnetic field flux density than CMF configurations. This is particularly noticeable in the Spring data, where the difference between 67°NMF and 67°CMF is substantial, indicating the impact of declination on field strength.",
    "label": "support"
  },
  {
    "id": "training_421_2",
    "table_caption": "Table: Virus particle titers and vp/pfu ratios Recombinant vaccinia virus Physical titer (vp/ml) Infectious titer (pfu/ml) Ratio (vp/pfu) VV 5.03 × 109 1.61 × 108 31.2:1 VV-ING4 4.27 × 109 1.76 × 108 24.3:1 Note: vp, virus particle; pfu, plaque forming units. ",
    "table_content": "|| Recombinant vaccinia virus | Physical titer (vp/ml) | Infectious titer (pfu/ml) | Ratio (vp/pfu) ||\n|| VV | 5.03 × 10 9 | 1.61 × 10 8 | 31.2:1 ||\n|| VV- ING4 | 4.27 × 10 9 | 1.76 × 10 8 | 24.3:1 ||",
    "claim": "The infectious titer of VV-ING4 is approximately 9.3% higher than that of VV, suggesting a higher number of plaque-forming units per milliliter in VV-ING4.",
    "label": "support"
  },
  {
    "id": "training_1100_5",
    "table_caption": "Table: TABLE 3 | Average nucleotide identities (ANI) analysis. Genome comparison of Pandoraea sp. XY-2 and other Pandoraea species. XY.2 DSM21091T NS15T TF81F4 TF80G25 LMG16407T AU2161 DSM23572T DSM23570T MCB032 3 kgm RB-44 DSM16583T ISTKB SD6-2 Pandoraea sp. XY-2 * 82.7 82.8 84.2 84.2 84.2 84.2 82.9 83.0 83.1 83.1 83.1 83.2 83.3 84.5 P. sputorum DSM21091T 82.7 * 84.2 83.1 83.1 83.1 83.1 84.6 92.3 82.7 82.6 82.7 82.7 84.9 82.9 P. vervacti NS15T 82.8 84.2 * 83.0 83.0 83.0 83.0 85.6 84.1 82.8 82.8 82.8 82.8 85.0 82.9 P. apista TF81F4 84.1 83.0 82.9 * 100.0 99.1 100.0 83.1 83.1 83.0 83.0 83.1 83.1 83.4 87.5 P. apista TF80G25 84.1 83.0 82.9 100.0 * 99.1 100.0 83.1 83.1 83.0 83.0 83.1 83.1 83.4 87.5 P. apista LMG16407T 84.1 83.0 82.9 99.1 99.1 * 99.1 83.0 83.2 83.0 83.0 83.0 83.1 83.4 87.5 P. apista AU2161 84.2 83.1 83.1 99.9 99.9 99.1 * 83.1 83.2 83.1 83.2 83.2 83.2 83.4 87.5 P. faecigallinarum DSM23572T 83.0 84.6 85.8 83.2 83.2 83.1 83.2 * 84.6 82.8 82.9 82.9 83.1 85.5 83.1 P. oxalativorans DSM23570T 82.9 92.3 84.1 83.0 83.0 83.0 83.0 84.1 * 82.6 82.6 82.5 82.7 84.9 82.8 P. pnomenusa MCB032 83.1 82.8 82.8 83.1 83.1 83.0 83.1 82.8 82.8 * 99.0 98.8 83.2 83.2 83.1 P. pnomenusa 3 kgm 83.1 82.8 82.9 83.2 83.2 83.2 83.3 83.0 83.0 99.0 * 99.3 83.5 83.3 83.2 P. pnomenusa RB-44 83.2 82.8 82.9 83.2 83.2 83.2 83.2 83.0 83.0 99.1 99.4 * 83.5 83.4 83.2 P. pulmonicola DSM16583T 83.2 82.7 82.9 83.2 83.2 83.3 83.2 83.1 83.1 83.4 83.4 83.4 * 83.2 83.3 Pandoraea sp. ISTKB 82.7 84.6 84.5 83.1 83.1 83.1 83.1 85.0 84.6 82.7 82.7 82.7 82.7 * 83.1 Pandoraea sp. SD6-2 84.3 82.8 82.8 87.4 87.4 87.4 87.4 82.9 83.0 83.0 82.9 83.0 83.2 83.2 * Figures in red denote strains belonging to the same species. The asterisk indicates that the strain is compared to itself, which does not provide valuable information. ",
    "table_content": "|| blank | XY.2 | DSM21091 T | NS15 T | TF81F4 | TF80G25 | LMG16407 T | AU2161 | DSM23572 T | DSM23570 T | MCB032 | 3 kgm | RB-44 | DSM16583 T | ISTKB | SD6-2 ||\n|| Pandoraea sp. XY-2 | * | 82.7 | 82.8 | 84.2 | 84.2 | 84.2 | 84.2 | 82.9 | 83.0 | 83.1 | 83.1 | 83.1 | 83.2 | 83.3 | 84.5 ||\n|| P. pnomenusa MCB032 | 83.1 | 82.8 | 82.8 | 83.1 | 83.1 | 83.0 | 83.1 | 82.8 | 82.8 | * | 99.0 | 98.8 | 83.2 | 83.2 | 83.1 ||\n|| P. pnomenusa 3 kgm | 83.1 | 82.8 | 82.9 | 83.2 | 83.2 | 83.2 | 83.3 | 83.0 | 83.0 | 99.0 | * | 99.3 | 83.5 | 83.3 | 83.2 ||\n|| P. pnomenusa RB-44 | 83.2 | 82.8 | 82.9 | 83.2 | 83.2 | 83.2 | 83.2 | 83.0 | 83.0 | 99.1 | 99.4 | * | 83.5 | 83.4 | 83.2 ||\n|| P. pulmonicola DSM16583 T | 83.2 | 82.7 | 82.9 | 83.2 | 83.2 | 83.3 | 83.2 | 83.1 | 83.1 | 83.4 | 83.4 | 83.4 | * | 83.2 | 83.3 ||\n|| Pandoraea sp. ISTKB | 82.7 | 84.6 | 84.5 | 83.1 | 83.1 | 83.1 | 83.1 | 85.0 | 84.6 | 82.7 | 82.7 | 82.7 | 82.7 | * | 83.1 ||\n|| Pandoraea sp. SD6-2 | 84.3 | 82.8 | 82.8 | 87.4 | 87.4 | 87.4 | 87.4 | 82.9 | 83.0 | 83.0 | 82.9 | 83.0 | 83.2 | 83.2 | * ||\n|| P. sputorum DSM21091 T | 82.7 | * | 84.2 | 83.1 | 83.1 | 83.1 | 83.1 | 84.6 | 92.3 | 82.7 | 82.6 | 82.7 | 82.7 | 84.9 | 82.9 ||\n|| P. vervacti NS15 T | 82.8 | 84.2 | * | 83.0 | 83.0 | 83.0 | 83.0 | 85.6 | 84.1 | 82.8 | 82.8 | 82.8 | 82.8 | 85.0 | 82.9 ||\n|| P. apista TF81F4 | 84.1 | 83.0 | 82.9 | * | 100.0 | 99.1 | 100.0 | 83.1 | 83.1 | 83.0 | 83.0 | 83.1 | 83.1 | 83.4 | 87.5 ||\n|| P. apista TF80G25 | 84.1 | 83.0 | 82.9 | 100.0 | * | 99.1 | 100.0 | 83.1 | 83.1 | 83.0 | 83.0 | 83.1 | 83.1 | 83.4 | 87.5 ||\n|| P. apista LMG16407 T | 84.1 | 83.0 | 82.9 | 99.1 | 99.1 | * | 99.1 | 83.0 | 83.2 | 83.0 | 83.0 | 83.0 | 83.1 | 83.4 | 87.5 ||\n|| P. apista AU2161 | 84.2 | 83.1 | 83.1 | 99.9 | 99.9 | 99.1 | * | 83.1 | 83.2 | 83.1 | 83.2 | 83.2 | 83.2 | 83.4 | 87.5 ||\n|| P. faecigallinarum DSM23572 T | 83.0 | 84.6 | 85.8 | 83.2 | 83.2 | 83.1 | 83.2 | * | 84.6 | 82.8 | 82.9 | 82.9 | 83.1 | 85.5 | 83.1 ||\n|| P. oxalativorans DSM23570 T | 82.9 | 92.3 | 84.1 | 83.0 | 83.0 | 83.0 | 83.0 | 84.1 | * | 82.6 | 82.6 | 82.5 | 82.7 | 84.9 | 82.8 ||",
    "claim": "The ANI between Pandoraea sp. XY-2 and P. apista TF81F4 is 84.2%, which is higher than the ANI between Pandoraea sp. XY-2 and P. vervacti NS15T, which is 82.8%, suggesting a closer genetic relationship with P. apista TF81F4.",
    "label": "support"
  },
  {
    "id": "training_1100_5",
    "table_caption": "Table: TABLE 3 | Average nucleotide identities (ANI) analysis. Genome comparison of Pandoraea sp. XY-2 and other Pandoraea species. XY.2 DSM21091T NS15T TF81F4 TF80G25 LMG16407T AU2161 DSM23572T DSM23570T MCB032 3 kgm RB-44 DSM16583T ISTKB SD6-2 Pandoraea sp. XY-2 * 82.7 82.8 84.2 84.2 84.2 84.2 82.9 83.0 83.1 83.1 83.1 83.2 83.3 84.5 P. sputorum DSM21091T 82.7 * 84.2 83.1 83.1 83.1 83.1 84.6 92.3 82.7 82.6 82.7 82.7 84.9 82.9 P. vervacti NS15T 82.8 84.2 * 83.0 83.0 83.0 83.0 85.6 84.1 82.8 82.8 82.8 82.8 85.0 82.9 P. apista TF81F4 84.1 83.0 82.9 * 100.0 99.1 100.0 83.1 83.1 83.0 83.0 83.1 83.1 83.4 87.5 P. apista TF80G25 84.1 83.0 82.9 100.0 * 99.1 100.0 83.1 83.1 83.0 83.0 83.1 83.1 83.4 87.5 P. apista LMG16407T 84.1 83.0 82.9 99.1 99.1 * 99.1 83.0 83.2 83.0 83.0 83.0 83.1 83.4 87.5 P. apista AU2161 84.2 83.1 83.1 99.9 99.9 99.1 * 83.1 83.2 83.1 83.2 83.2 83.2 83.4 87.5 P. faecigallinarum DSM23572T 83.0 84.6 85.8 83.2 83.2 83.1 83.2 * 84.6 82.8 82.9 82.9 83.1 85.5 83.1 P. oxalativorans DSM23570T 82.9 92.3 84.1 83.0 83.0 83.0 83.0 84.1 * 82.6 82.6 82.5 82.7 84.9 82.8 P. pnomenusa MCB032 83.1 82.8 82.8 83.1 83.1 83.0 83.1 82.8 82.8 * 99.0 98.8 83.2 83.2 83.1 P. pnomenusa 3 kgm 83.1 82.8 82.9 83.2 83.2 83.2 83.3 83.0 83.0 99.0 * 99.3 83.5 83.3 83.2 P. pnomenusa RB-44 83.2 82.8 82.9 83.2 83.2 83.2 83.2 83.0 83.0 99.1 99.4 * 83.5 83.4 83.2 P. pulmonicola DSM16583T 83.2 82.7 82.9 83.2 83.2 83.3 83.2 83.1 83.1 83.4 83.4 83.4 * 83.2 83.3 Pandoraea sp. ISTKB 82.7 84.6 84.5 83.1 83.1 83.1 83.1 85.0 84.6 82.7 82.7 82.7 82.7 * 83.1 Pandoraea sp. SD6-2 84.3 82.8 82.8 87.4 87.4 87.4 87.4 82.9 83.0 83.0 82.9 83.0 83.2 83.2 * Figures in red denote strains belonging to the same species. The asterisk indicates that the strain is compared to itself, which does not provide valuable information. ",
    "table_content": "|| blank | XY.2 | DSM21091 T | NS15 T | TF81F4 | TF80G25 | LMG16407 T | AU2161 | DSM23572 T | DSM23570 T | MCB032 | 3 kgm | RB-44 | DSM16583 T | ISTKB | SD6-2 ||\n|| Pandoraea sp. XY-2 | * | 82.7 | 82.8 | 84.2 | 84.2 | 84.2 | 84.2 | 82.9 | 83.0 | 83.1 | 83.1 | 83.1 | 83.2 | 83.3 | 84.5 ||\n|| P. pnomenusa MCB032 | 83.1 | 82.8 | 82.8 | 83.1 | 83.1 | 83.0 | 83.1 | 82.8 | 82.8 | * | 99.0 | 98.8 | 83.2 | 83.2 | 83.1 ||\n|| P. pnomenusa 3 kgm | 83.1 | 82.8 | 82.9 | 83.2 | 83.2 | 83.2 | 83.3 | 83.0 | 83.0 | 99.0 | * | 99.3 | 83.5 | 83.3 | 83.2 ||\n|| P. pnomenusa RB-44 | 83.2 | 82.8 | 82.9 | 83.2 | 83.2 | 83.2 | 83.2 | 83.0 | 83.0 | 99.1 | 99.4 | * | 83.5 | 83.4 | 83.2 ||\n|| P. pulmonicola DSM16583 T | 83.2 | 82.7 | 82.9 | 83.2 | 83.2 | 83.3 | 83.2 | 83.1 | 83.1 | 83.4 | 83.4 | 83.4 | * | 83.2 | 83.3 ||\n|| Pandoraea sp. ISTKB | 82.7 | 84.6 | 84.5 | 83.1 | 83.1 | 83.1 | 83.1 | 85.0 | 84.6 | 82.7 | 82.7 | 82.7 | 82.7 | * | 83.1 ||\n|| Pandoraea sp. SD6-2 | 84.3 | 82.8 | 82.8 | 87.4 | 87.4 | 87.4 | 87.4 | 82.9 | 83.0 | 83.0 | 82.9 | 83.0 | 83.2 | 83.2 | * ||\n|| P. sputorum DSM21091 T | 82.7 | * | 84.2 | 83.1 | 83.1 | 83.1 | 83.1 | 84.6 | 92.3 | 82.7 | 82.6 | 82.7 | 82.7 | 84.9 | 82.9 ||\n|| P. vervacti NS15 T | 82.8 | 84.2 | * | 83.0 | 83.0 | 83.0 | 83.0 | 85.6 | 84.1 | 82.8 | 82.8 | 82.8 | 82.8 | 85.0 | 82.9 ||\n|| P. apista TF81F4 | 84.1 | 83.0 | 82.9 | * | 100.0 | 99.1 | 100.0 | 83.1 | 83.1 | 83.0 | 83.0 | 83.1 | 83.1 | 83.4 | 87.5 ||\n|| P. apista TF80G25 | 84.1 | 83.0 | 82.9 | 100.0 | * | 99.1 | 100.0 | 83.1 | 83.1 | 83.0 | 83.0 | 83.1 | 83.1 | 83.4 | 87.5 ||\n|| P. apista LMG16407 T | 84.1 | 83.0 | 82.9 | 99.1 | 99.1 | * | 99.1 | 83.0 | 83.2 | 83.0 | 83.0 | 83.0 | 83.1 | 83.4 | 87.5 ||\n|| P. apista AU2161 | 84.2 | 83.1 | 83.1 | 99.9 | 99.9 | 99.1 | * | 83.1 | 83.2 | 83.1 | 83.2 | 83.2 | 83.2 | 83.4 | 87.5 ||\n|| P. faecigallinarum DSM23572 T | 83.0 | 84.6 | 85.8 | 83.2 | 83.2 | 83.1 | 83.2 | * | 84.6 | 82.8 | 82.9 | 82.9 | 83.1 | 85.5 | 83.1 ||\n|| P. oxalativorans DSM23570 T | 82.9 | 92.3 | 84.1 | 83.0 | 83.0 | 83.0 | 83.0 | 84.1 | * | 82.6 | 82.6 | 82.5 | 82.7 | 84.9 | 82.8 ||",
    "claim": "The ANI between Pandoraea sp. XY-2 and P. apista TF81F4 is 84.2%, which is lower than the ANI between Pandoraea sp. XY-2 and P. vervacti NS15T, which is 82.8%, suggesting a closer genetic relationship with P. apista TF81F4.",
    "label": "support"
  },
  {
    "id": "training_734_6",
    "table_caption": "Table: Regression model coefficients. Unstandardized Standardized 95% Conﬁdence Interval ß Std. Error ß Lower Bound Upper Bound Model 1 (Constant) 15.80 0.80 14.23 17.36 Intensity 1.03 0.17 0.27 0.69 1.36 Model 2 (R2 = 0.12) (Constant) 13.95 0.86 12.26 15.64 Intensity 1.11 0.17 0.30 0.78 1.44 BPD 0.58 0.12 0.22 0.35 0.81 Model 3 (R2 = 0.14) (Constant) 13.93 0.85 12.25 15.60 Intensity 1.08 0.17 0.29 0.75 1.41 BPD 0.48 0.12 0.19 0.25 0.72 SCOFF 1.04 0.39 0.12 0.28 1.81 Model 4 (R2 = 0.39) (Constant) 23.79 1.02 21.79 25.79 Intensity 0.86 0.14 0.23 0.59 1.14 BPD 0.15 0.10 0.06 -0.05 0.36 SCOFF 0.79 0.33 0.09 0.15 1.44 DMI Escapism 2.79 0.20 0.53 3.19 2.39 Model 5 (R2 = 0.41) (Constant) 24.83 1.04 22.79 26.87 Intensity 0.83 0.14 0.22 0.55 1.10 BPD 0.21 0.10 0.08 0.01 0.41 SCOFF 0.89 0.32 0.11 0.26 1.53 DMI Escapism 2.49 0.22 0.47 2.91 2.06 DMI Mood Enhancement 1.34 0.35 0.15 2.03 0.66 Note: DAI total score was added as dependent variable. Each model is signiﬁcantly better than the previous one (ΔFM1 = 35.80***, ΔFM2 = 24.84***, ΔFM3 = 7.19** ΔFM4 = 186.35*** ΔFM5 = 15.00***, where ***p<0.001, **p<0.01) ",
    "table_content": "|| blank | Unstandardized | Unstandardized | Standardized ß | 95% Confidence Interval | 95% Confidence Interval ||\n|| blank | ß | Std. Error | Standardized ß | Lower Bound | Upper Bound ||\n||  (Constant)  | 13.93 | 0.85 | blank | 12.25 | 15.60 ||\n||  Intensity  | 1.08 | 0.17 | 0.29 | 0.75 | 1.41 ||\n||  BPD  | 0.48 | 0.12 | 0.19 | 0.25 | 0.72 ||\n||  SCOFF  | 1.04 | 0.39 | 0.12 | 0.28 | 1.81 ||\n||  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) ||\n||  (Constant)  | 23.79 | 1.02 | blank | 21.79 | 25.79 ||\n||  Intensity  | 0.86 | 0.14 | 0.23 | 0.59 | 1.14 ||\n||  BPD  | 0.15 | 0.10 | 0.06 | -0.05 | 0.36 ||\n||  SCOFF  | 0.79 | 0.33 | 0.09 | 0.15 | 1.44 ||\n||  DMI Escapism  | 2.79 | 0.20 | 0.53 | 3.19 | 2.39 ||\n||  Model 1  |  Model 1  |  Model 1  |  Model 1  |  Model 1  |  Model 1  ||\n||  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) ||\n||  (Constant)  | 24.83 | 1.04 | blank | 22.79 | 26.87 ||\n||  Intensity  | 0.83 | 0.14 | 0.22 | 0.55 | 1.10 ||\n||  BPD  | 0.21 | 0.10 | 0.08 | 0.01 | 0.41 ||\n||  SCOFF  | 0.89 | 0.32 | 0.11 | 0.26 | 1.53 ||\n||  DMI Escapism  | 2.49 | 0.22 | 0.47 | 2.91 | 2.06 ||\n||  DMI Mood Enhancement  | 1.34 | 0.35 | 0.15 | 2.03 | 0.66 ||\n||  (Constant)  | 15.80 | 0.80 | blank | 14.23 | 17.36 ||\n||  Intensity  | 1.03 | 0.17 | 0.27 | 0.69 | 1.36 ||\n||  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) ||\n||  (Constant)  | 13.95 | 0.86 | blank | 12.26 | 15.64 ||\n||  Intensity  | 1.11 | 0.17 | 0.30 | 0.78 | 1.44 ||\n||  BPD  | 0.58 | 0.12 | 0.22 | 0.35 | 0.81 ||\n||  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) ||",
    "claim": "In Model 5, the unstandardized coefficient for DMI Escapism is 2.49, while for DMI Mood Enhancement, it is 1.34. The combined effect of these two variables contributes significantly to the model, with their coefficients indicating a strong positive association with the dependent variable, enhancing the model's explanatory capacity.",
    "label": "support"
  },
  {
    "id": "training_880_1",
    "table_caption": "Table: Unit costs (base case) of estimated cost-generating events. Type of events Cost type Estimated cost per unit (€) Health care Care provided by IVC1 Indirect 24.90 Vaccination Vaccine Direct 32.31 TD Treatment in non-vaccinated Direct 5.552 Treatment in vaccinated Direct 3.222 Lost day of vacations Indirect 142.86 Non-vaccinated (142.86 × 3.59) Indirect 512.862 Vaccinated (142.86 × 2.57) Indirect 367.142 1 IVC: International Vacunation Centre 2Estimated cost by episode ",
    "table_content": "|| blank | Type of events | Cost type | Estimated cost per unit (€) ||\n|| Health care | Care provided by IVC 1 | Indirect | 24.90 ||\n|| Vaccination | Vaccine | Direct | 32.31 ||\n|| TD | Treatment in non-vaccinated | Direct | 5.55 2 ||\n|| TD | Treatment in vaccinated | Direct | 3.22 2 ||\n|| TD | Lost day of vacations | Indirect | 142.86 ||\n|| TD | Non-vaccinated (142.86 × 3.59) | Indirect | 512.86 2 ||\n|| TD | Vaccinated (142.86 × 2.57) | Indirect | 367.14 2 ||",
    "claim": "The direct cost of treating travelers' diarrhea in vaccinated individuals is approximately 58% of the cost for non-vaccinated individuals, indicating a substantial reduction in treatment expenses due to vaccination.",
    "label": "support"
  },
  {
    "id": "training_888_2",
    "table_caption": "Table: Culturable fungal endophytes from Morinda citrifolia Linn. (noni). Code Accession number Closest (published) Genbank match Published reference sequence Accession number (GenBank) Max identity Noni leaf endophytes MRL1-3A KF534501 Stemphylium solani AF203451 100% MRL2-1 KF534502 Fusarium sp. (anamorphic Gibberella) EU151484 100% MRL1-2-2 KF534503 Acremonium sp. GU566267 99% MRL2-3 KF534504 Didymellaceae sp. HM595517 100% MRL5-1 KF534505 Hypocreales sp. — — IXLP3 KF534494 Guignardia sp. AB731125 99% VIIILP2-1 KF534492 Colletotrichum gloeosporioides (anamorphic Glomerella cingulata) DQ003100 100% XILP7-2 KF534495 Colletotrichum boninense complex JQ005162 100% VIIILP1 KF534493 Leptosphaerulina australis JN712494 99% XILP6 KF534496 Mycosphaerella sp. HM189290 100% XILP5 KF534500 Xylariaceae sp. JX852331 95% XIILP3-1 KF534498 Aspergillus pseudodeflectus (anamorphic Emericella) EF652507 100% Noni fruit endophytes XSM1 KF534499 Phlebiopsis sp. JQ518278 94% VIIIfP1 KF534497 Paraconiothyrium sporulosum AB303549 99% IIfP KF534491 Phomopsis sp. (anamorphic Diaporthe) GQ352478 99% follow-up dose response determinations over five 2-fold serial that are pathogenic in association with other plant hosts, but ",
    "table_content": "|| Code | Accession number | Closest (published) Genbank match | Published reference sequence Accession number (GenBank) | Max identity ||\n|| Noni leaf endophytes | Noni leaf endophytes | Noni leaf endophytes | Noni leaf endophytes | Noni leaf endophytes ||\n|| VIIILP1 | KF534493 |  Leptosphaerulina australis  | JN712494 | 99% ||\n|| XILP6 | KF534496 |  Mycosphaerella sp. | HM189290 | 100% ||\n|| XILP5 | KF534500 | Xylariaceae sp. | JX852331 | 95% ||\n|| XIILP3-1 | KF534498 |  Aspergillus pseudodeflectus  (anamorphic Emericella ) | EF652507 | 100% ||\n|| Noni fruit endophytes | Noni fruit endophytes | Noni fruit endophytes | Noni fruit endophytes | Noni fruit endophytes ||\n|| XSM1 | KF534499 |  Phlebiopsis sp. | JQ518278 | 94% ||\n|| VIIIfP1 | KF534497 |  Paraconiothyrium sporulosum  | AB303549 | 99% ||\n|| IIfP | KF534491 |  Phomopsis sp. (anamorphic Diaporthe ) | GQ352478 | 99% ||\n|| MRL1-3A | KF534501 |  Stemphylium solani  | AF203451 | 100% ||\n|| MRL2-1 | KF534502 |  Fusarium sp. (anamorphic Gibberella ) | EU151484 | 100% ||\n|| MRL1-2-2 | KF534503 |  Acremonium sp. | GU566267 | 99% ||\n|| MRL2-3 | KF534504 | Didymellaceae sp. | HM595517 | 100% ||\n|| MRL5-1 | KF534505 | Hypocreales sp. | — | — ||\n|| IXLP3 | KF534494 |  Guignardia sp. | AB731125 | 99% ||\n|| VIIILP2-1 | KF534492 |  Colletotrichum gloeosporioides  (anamorphic Glomerella cingulata ) | DQ003100 | 100% ||\n|| XILP7-2 | KF534495 |  Colletotrichum boninense complex | JQ005162 | 100% ||",
    "claim": "Noni leaves host a more diverse range of fungal genera compared to noni fruits. This is inferred by counting the unique genera present in each group and noting that the leaf endophytes include a wider variety of genera.",
    "label": "support"
  },
  {
    "id": "training_395_1",
    "table_caption": "Table: Data collection Stoe IPDS-1 diffractometer 657 independent reflections Radiation source: fine-focus sealed tube 638 reflections with I > 2σ(I) graphite Rint = 0.055 φ scans θmax = 25.5°, θmin = 3.4° Absorption correction: numerical (X-SHAPE and X-RED32; Stoe & Cie, 2008) h = −11→11 Tmin = 0.165, Tmax = 0.321 k = −19→17 4502 measured reflections l = −9→10 Refinement ",
    "table_content": "|| Stoe IPDS-1 diffractometer | 657 independent reflections ||\n|| Radiation source: fine-focus sealed tube | 638 reflections with I > 2σ( I ) ||\n|| graphite | R int = 0.055 ||\n|| φ scans | θ max = 25.5°, θ min = 3.4° ||\n|| Absorption correction: numerical ( X-SHAPE and X-RED32 ; Stoe & Cie, 2008) | h = −11→11 ||\n|| T min = 0.165, T max = 0.321 | k = −19→17 ||\n|| 4502 measured reflections | l = −9→10 ||",
    "claim": "The ratio of independent reflections to the total measured reflections is approximately 0.146, indicating that a small fraction of the total reflections are independent, which is typical in crystallography due to symmetry and redundancy in data collection.",
    "label": "support"
  },
  {
    "id": "training_1047_2",
    "table_caption": "Table: USED IN SINGLE STRAND CONFORMATION POLYMORPHISM (SSCP), HIGH RESOLUTION MELT CURVE (HRM), AND PAGE (PAGE) ANALYSIS IN THIS STUDY. Primer Sequence (5′-3′) U11 SSCP F: TGATGCAGGAAGGAACTGTG U11 SSCP R: CCTGGCAAATGCAGTCTTC U32 HRM F: ATCCCTTCCCAGTTCTTTG U32 HRM R: CAGATATGGAACCCCTGGAT U38 SSCP F: AATTGGCCAGGTCAACTCAG U38 SSCP R: GCACCCAAAGGTTTGTCTC U48 PAGE F: TGGTATCCATGCGCTAAAAC U48 PAGE R: CACTTGGAGTCTTGAGTGAGAA U represents USH2A; the number represents the name of the exon; F represents forward; R represents ",
    "table_content": "|| Primer | Sequence (5′-3′) ||\n|| U11 SSCP | F: TGATGCAGGAAGGAACTGTG ||\n|| U11 SSCP | R: CCTGGCAAATGCAGTCTTC ||\n|| U32 HRM | F: ATCCCTTCCCAGTTCTTTG ||\n|| U32 HRM | R: CAGATATGGAACCCCTGGAT ||\n|| U38 SSCP | F: AATTGGCCAGGTCAACTCAG ||\n|| U38 SSCP | R: GCACCCAAAGGTTTGTCTC ||\n|| U48 PAGE | F: TGGTATCCATGCGCTAAAAC ||\n|| U48 PAGE | R: CACTTGGAGTCTTGAGTGAGAA ||",
    "claim": "The GC content of the U11 SSCP forward primer is 50%, determined by counting the number of G and C nucleotides and dividing by the total number of nucleotides in the sequence.",
    "label": "support"
  },
  {
    "id": "training_1405_4",
    "table_caption": "Table: Allocation of total working hours per week over several tasks: internists (corrected for age and gender), p-value of the difference between full-time and part-time Mean proportion of hours, part- timea mean proportion of hours, full- timea p-value clinical activities 0.03 (0.01) 0.04 (0.01) 0.43 outpatient care 0.58 (0.02) 0.57 (0.01) 0.61 Inter-professional communication 0.08 (0.00) 0.08 (0.00) 1 correspondence 0.10 (0.01) 0.08 (0.00) 0.04 education 0.06 (0.01) 0.06 (0.00) 0.78 research 0.02 (0.01) 0.03 (0.00) 0.33 literature 0.06 (0.00) 0.05 (0.00) 0.66 financial administration 0.02 (0.00) 0.01 (0.00) 0.22 management 0.05 (0.01) 0.07 (0.01) 0.03 a standard error in parentheses ",
    "table_content": "|| blank | Mean proportion of hours, part-time a | mean proportion of hours, full-time a | p-value ||\n|| clinical activities | 0.03 (0.01) | 0.04 (0.01) | 0.43 ||\n|| outpatient care | 0.58 (0.02) | 0.57 (0.01) | 0.61 ||\n|| Inter-professional communication | 0.08 (0.00) | 0.08 (0.00) | 1 ||\n|| correspondence | 0.10 (0.01) | 0.08 (0.00) | 0.04 ||\n|| education | 0.06 (0.01) | 0.06 (0.00) | 0.78 ||\n|| research | 0.02 (0.01) | 0.03 (0.00) | 0.33 ||\n|| literature | 0.06 (0.00) | 0.05 (0.00) | 0.66 ||\n|| financial administration | 0.02 (0.00) | 0.01 (0.00) | 0.22 ||\n|| management | 0.05 (0.01) | 0.07 (0.01) | 0.03 ||",
    "claim": "Full-time internists allocate 0.02 more of their working hours to management tasks compared to part-time internists, reflecting a 40% increase in time spent on management by full-time internists.",
    "label": "support"
  },
  {
    "id": "training_937_4",
    "table_caption": "Table: when RISA profiles were ascribed to the variables tested in the study Variable Global R P value # Significant pairwise comparisons Tissue 0.093 0.001 - Treatment 0.214 0.001 7 out of 10 Time 0.304 0.001 3 out of 3 Group 0.387 0.001 14 out of 21 G2 G3 G4 G5 G6 G7 a, Sobs, b, ACE, ",
    "table_content": "|| Variable | Global R |  P value | # Significant pairwise comparisons ||\n|| Tissue | 0.093 | 0.001 | blank ||\n|| Treatment | 0.214 | 0.001 | 7 out of 10 ||\n|| Time | 0.304 | 0.001 | 3 out of 3 ||\n|| Group | 0.387 | 0.001 | 14 out of 21 ||",
    "claim": "The Global R values increase progressively from Tissue to Group, indicating a trend where the strength of the relationship with RISA profiles becomes stronger as we move from Tissue to Group. This trend suggests that the variables are ordered in terms of increasing influence on RISA profiles.",
    "label": "support"
  },
  {
    "id": "training_828_2",
    "table_caption": "Table: HOMA B at 150 min with the PDR at 150 min (r = -0.653, Table 1: Within-subject correlations between serum glucose and insulin levels, and GBT percentage dose recovery (PDR), and cumulative percentage dose recovery (CPDR) before and after exercise. PDR - Glucose PDR - Insulin CPDR - Glucose CPDR - Insulin R p R p R p R p Before exercise -0.804 < 0.001 -0.701 < 0.001 -0.686 < 0.001 -0.683 < 0.001 After exercise -0.757 < 0.001 -0/709 < 0.001 -0.715 < 0.001 -0.636 < 0.001 ",
    "table_content": "|| blank | PDR - Glucose | PDR - Glucose | PDR - Insulin | PDR - Insulin | CPDR - Glucose | CPDR - Glucose | CPDR - Insulin | CPDR - Insulin ||\n|| blank | R | p | R | p | R | p | R | p ||\n|| Before exercise | -0.804 | < 0.001 | -0.701 | < 0.001 | -0.686 | < 0.001 | -0.683 | < 0.001 ||\n|| After exercise | -0.757 | < 0.001 | -0/709 | < 0.001 | -0.715 | < 0.001 | -0.636 | < 0.001 ||",
    "claim": "The correlation coefficient for PDR-Insulin increases by approximately 1.14% after exercise, suggesting a minor strengthening of the negative correlation.",
    "label": "support"
  },
  {
    "id": "training_1101_2",
    "table_caption": "Table: in an Table II. The prevalence of the underlying diseases leading to dialysis requirement in the studied patients. PTFE (n = 50) PVAG (n = 50) Diabetes mellitus 35 31 Renal diseases 25 26 Hypertension 28 37 Tobacco use 28 34 Obesity 17 19 Other 4 2 ",
    "table_content": "|| blank | PTFE ( n = 50) | PVAG ( n = 50) ||\n|| Diabetes mellitus | 35 | 31 ||\n|| Renal diseases | 25 | 26 ||\n|| Hypertension | 28 | 37 ||\n|| Tobacco use | 28 | 34 ||\n|| Obesity | 17 | 19 ||\n|| Other | 4 | 2 ||",
    "claim": "The cumulative prevalence of all diseases in the PTFE group is 137, while in the PVAG group, it is 149, suggesting a 8.76% higher total disease burden in the PVAG group.",
    "label": "support"
  },
  {
    "id": "training_271_4",
    "table_caption": "Table: Complexes λmax[nm] CIEa FWHM [nm] Jb Lmax c Von d ton e t1/2 f Eg EQE (%)h B1 635 [0.652, 0.315] 125 1921 193 (7.4 V) 4.5 58 539 0.12 0.141 (7.50 V) B2 690 [0.628, 0.309] 122 2224 742 (7.7 V) 3.1 87 1104 0.34 0.682 (5.9 V) Table 2. Data of the light emitting device of ITO/[(Ru(N^N)2)2  (DiP-methane)]4+/Ga:In. aCIE(x, y): Commission Internationale de L’Eclairage, bCurrent density A m−2 at 7 V, cMaximum luminance cd .m−2 at ",
    "table_content": "|| Complexes |  λ  max [nm] | CIE a  | FWHM [nm] | J b  | L max  c  | V on  d  | t on  e  | t 1/2  f  | E g  | EQE (%) h  ||\n|| B1 | 635 | [0.652, 0.315] | 125 | 1921 | 193 (7.4 V) | 4.5 | 58 | 539 | 0.12 | 0.141 (7.50 V) ||\n|| B2 | 690 | [0.628, 0.309] | 122 | 2224 | 742 (7.7 V) | 3.1 | 87 | 1104 | 0.34 | 0.682 (5.9 V) ||",
    "claim": "The increase in half-life from B1 to B2, alongside a larger energy gap, suggests that B2 has a more stable emission over time. The energy gap, being a critical factor in determining the stability and longevity of the emission, supports the extended half-life observed in B2, which is approximately 2.05 times longer than that of B1.",
    "label": "support"
  },
  {
    "id": "training_872_6",
    "table_caption": "Table: solid half Table 2 Statistics for the assembly contigs and scaffolds (after gap filling) Contig Scaffold Size (bp) Number Size (bp) Number N90 4,850 63,958 200,992 1,095 N80 12,159 42,491 670,865 644 N70 18,332 30,884 1,149,567 441 N60 24,540 22,654 1,671,674 311 N50 31,298 16,344 2,290,546 219 Longest 295,776 14,681,335 Total size 1,747,524,961 1,816,115,349 ≥100 bp 636,524 545,300 ≥2 kbp 79,002 4,356 Gap ratio 0 % 3.78 % 2 ",
    "table_content": "|| blank | Contig | Contig | Scaffold | Scaffold ||\n|| blank | Size (bp) | Number | Size (bp) | Number ||\n|| ≥2 kbp | blank | 79,002 | blank | 4,356 ||\n|| Gap ratio | blank | 0 % | blank | 3.78 % ||\n|| N90 | 4,850 | 63,958 | 200,992 | 1,095 ||\n|| N80 | 12,159 | 42,491 | 670,865 | 644 ||\n|| N70 | 18,332 | 30,884 | 1,149,567 | 441 ||\n|| N60 | 24,540 | 22,654 | 1,671,674 | 311 ||\n|| N50 | 31,298 | 16,344 | 2,290,546 | 219 ||\n|| Longest | 295,776 | blank | 14,681,335 | blank ||\n|| Total size | 1,747,524,961 | blank | 1,816,115,349 | blank ||\n|| ≥100 bp | blank | 636,524 | blank | 545,300 ||",
    "claim": "The decrease in the number of contigs from N90 to N50 is approximately 74%, while for scaffolds, it is approximately 80%, indicating a steeper decline in scaffold numbers, which suggests a more pronounced improvement in scaffold assembly quality as the N-value increases.",
    "label": "support"
  },
  {
    "id": "training_1422_5",
    "table_caption": "Table: placing edema minutes soaked process training Table 2 Testing performance Variable Pre-test Post-test P value Global rating scale 19.3 ± 0.8 28.7 ± 1.1 <0.05 Pass rating 6/20 19/20 <0.05 Time to complete task (min) 18 ± 3.4 11 ± 1.2 <0.05 Mucosal trauma (No.) 0.8 ± 0.5 0.6 ± 0.3 0.26 Number of perforations 0.23 ± 0.2 0.19 ± 0.1 0.35 ",
    "table_content": "|| Variable | Pre-test | Post-test |  P value ||\n|| Global rating scale | 19.3 ± 0.8 | 28.7 ± 1.1 | <0.05 ||\n|| Pass rating | 6/20 | 19/20 | <0.05 ||\n|| Time to complete task (min) | 18 ± 3.4 | 11 ± 1.2 | <0.05 ||\n|| Mucosal trauma (No.) | 0.8 ± 0.5 | 0.6 ± 0.3 | 0.26 ||\n|| Number of perforations | 0.23 ± 0.2 | 0.19 ± 0.1 | 0.35 ||",
    "claim": "The number of perforations decreased from 0.23 to 0.19, a reduction of approximately 17.4%. Despite this decrease, the P value of 0.35 suggests that the change is not statistically significant, indicating that the training did not significantly affect the number of perforations.",
    "label": "support"
  },
  {
    "id": "training_84_1",
    "table_caption": "Table: Table 3 Major categories and sub-categories of socioeconomic indictors and their descriptive statistics Variablesa Mean SD Skewness Kurtosis Min Max Educational status Illiterate & read/write 00.40 00.09 00.43 03.74 00.18 00.73 School degree .49 00.06 − 00.56 04.68 00.22 00.66 Diploma & university .09 00.03 00.35 03.69 00.01 00.20 Higher education 0 0 02.55 12.46 0 00.01 Employment status In the labour force .48 00.07 00.32 02.64 00.31 00.66 Students .17 00.03 −00.54 03.94 00.05 00.23 Housewives 00.26 00.05 00.51 03.22 00.16 00.41 Retired 00.03 00.01 00.11 02.62 0 00.06 Other employment 00.03 00.01 00.86 03.37 0 00.08 Type of housing Traditional house (TH) 00.44 00.22 00.39 01.96 00.03 00.89 Villa 00.20 00.13 00.20 01.70 00.01 00.51 Floor in TH or villa 00.07 00.05 00.78 02.74 0 00.23 Apartment 00.17 00.14 01.51 04.94 0 00.64 Other type of housing 00.10 00.07 02.73 15.51 00.01 00.54 Tenure of housing Home owned 00.57 00.14 −00.32 02.37 00.24 00.84 Home rented 00.26 00.12 00.79 03.53 0 00.63 Home provided 00.15 00.09 01.41 05.57 00.02 00.51 Other tenure 00.01 00.01 03.33 15.91 0 00.07 Car ownership No car available 00.29 00.09 00.78 03.00 00.12 00.53 One car 00.46 00.07 00.35 03.29 00.27 00.69 Two or more cars 00.24 00.08 −00.33 02.07 00.03 00.38 Household amenities Phone not available 00.46 00.19 00.66 02.66 00.13 00.96 TV not available 00.21 00.12 01.30 05.39 00.03 00.72 PC not available 00.80 00.11 −00.96 03.93 00.43 00.98 Internet not available 00.87 00.08 −01.36 05.16 00.58 00.99 Library not available 00.84 00.08 −00.70 03.15 00.57 00.98 Satellite not available 00.63 00.17 −00.57 03.14 00.13 00.97 Video not available 00.78 00.13 −00.85 − 03.25 00.35 00.98 Video games not available 00.77 00.09 −00.34 02.85 00.48 00.97 aNumbers are proportions, calculated by using indicator specific denominators ",
    "table_content": "|| Variables a | Mean | SD | Skewness | Kurtosis | Min | Max ||\n|| Educational status | Educational status | Educational status | Educational status | Educational status | Educational status | Educational status ||\n|| Retired | 00.03 | 00.01 | 00.11 | 02.62 | 0 | 00.06 ||\n|| Other employment | 00.03 | 00.01 | 00.86 | 03.37 | 0 | 00.08 ||\n|| Type of housing | Type of housing | Type of housing | Type of housing | Type of housing | Type of housing | Type of housing ||\n|| Traditional house (TH) | 00.44 | 00.22 | 00.39 | 01.96 | 00.03 | 00.89 ||\n|| Villa | 00.20 | 00.13 | 00.20 | 01.70 | 00.01 | 00.51 ||\n|| Floor in TH or villa | 00.07 | 00.05 | 00.78 | 02.74 | 0 | 00.23 ||\n|| Apartment | 00.17 | 00.14 | 01.51 | 04.94 | 0 | 00.64 ||\n|| Other type of housing | 00.10 | 00.07 | 02.73 | 15.51 | 00.01 | 00.54 ||\n|| Tenure of housing | Tenure of housing | Tenure of housing | Tenure of housing | Tenure of housing | Tenure of housing | Tenure of housing ||\n|| Home owned | 00.57 | 00.14 | −00.32 | 02.37 | 00.24 | 00.84 ||\n|| Illiterate & read/write | 00.40 | 00.09 | 00.43 | 03.74 | 00.18 | 00.73 ||\n|| Home rented | 00.26 | 00.12 | 00.79 | 03.53 | 0 | 00.63 ||\n|| Home provided | 00.15 | 00.09 | 01.41 | 05.57 | 00.02 | 00.51 ||\n|| Other tenure | 00.01 | 00.01 | 03.33 | 15.91 | 0 | 00.07 ||\n|| Car ownership | Car ownership | Car ownership | Car ownership | Car ownership | Car ownership | Car ownership ||\n|| No car available | 00.29 | 00.09 | 00.78 | 03.00 | 00.12 | 00.53 ||\n|| One car | 00.46 | 00.07 | 00.35 | 03.29 | 00.27 | 00.69 ||\n|| Two or more cars | 00.24 | 00.08 | −00.33 | 02.07 | 00.03 | 00.38 ||\n|| Household amenities | Household amenities | Household amenities | Household amenities | Household amenities | Household amenities | Household amenities ||\n|| Phone not available | 00.46 | 00.19 | 00.66 | 02.66 | 00.13 | 00.96 ||\n|| TV not available | 00.21 | 00.12 | 01.30 | 05.39 | 00.03 | 00.72 ||\n|| School degree | .49 | 00.06 | − 00.56 | 04.68 | 00.22 | 00.66 ||\n|| PC not available | 00.80 | 00.11 | −00.96 | 03.93 | 00.43 | 00.98 ||\n|| Internet not available | 00.87 | 00.08 | −01.36 | 05.16 | 00.58 | 00.99 ||\n|| Library not available | 00.84 | 00.08 | −00.70 | 03.15 | 00.57 | 00.98 ||\n|| Satellite not available | 00.63 | 00.17 | −00.57 | 03.14 | 00.13 | 00.97 ||\n|| Video not available | 00.78 | 00.13 | −00.85 | − 03.25 | 00.35 | 00.98 ||\n|| Video games not available | 00.77 | 00.09 | −00.34 | 02.85 | 00.48 | 00.97 ||\n|| Diploma & university | .09 | 00.03 | 00.35 | 03.69 | 00.01 | 00.20 ||\n|| Higher education | 0 | 0 | 02.55 | 12.46 | 0 | 00.01 ||\n|| Employment status | Employment status | Employment status | Employment status | Employment status | Employment status | Employment status ||\n|| In the labour force | .48 | 00.07 | 00.32 | 02.64 | 00.31 | 00.66 ||\n|| Students | .17 | 00.03 | −00.54 | 03.94 | 00.05 | 00.23 ||\n|| Housewives | 00.26 | 00.05 | 00.51 | 03.22 | 00.16 | 00.41 ||",
    "claim": "The proportion of individuals with a school degree is more than five times the proportion of those with a diploma or university education. This indicates a significant disparity in educational attainment levels, with a larger segment of the population having only basic education.",
    "label": "support"
  },
  {
    "id": "training_463_4",
    "table_caption": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) ",
    "table_content": "|| blank | Sensitivity | Specificity | Positive predictive value | Negative predictive value | Accuracy ||\n|| SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) ||\n|| All combined | 0.83 (0.82, 0.84) | 0.83 (0.82, 0.84) | 0.84 (0.83, 0.85) | 0.84 (0.83, 0.85) | 0.83 (0.82, 0.84) ||\n|| PGME | 0.71 (0.70, 0.72) | 0.80 (0.79, 0.81) | 0.79 (0.78, 0.80) | 0.74 (0.73, 0.75) | 0.76 (0.75, 0.77) ||\n|| Gait features + Demograph. var | 0.61 (0.60, 0.62) | 0.76 (0.75, 0.77) | 0.73 (0.72, 0.74) | 0.66 (0.65, 0.67) | 0.68 (0.67, 0.69) ||\n|| Fall history: 6 months | 0.47 (0.46, 0.48) | 0.67 (0.65, 0.68) | 0.59 (0.57, 0.60) | 0.56 (0.55, 0.57) | 0.57 (0.56, 0.58) ||\n|| All combined | 0.75 (0.73, 0.76) | 0.80 (0.79, 0.81) | 0.80 (0.79, 0.81) | 0.77 (0.76, 0.78) | 0.77 (0.76, 0.78) ||\n|| MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) ||\n|| PGME | 0.67 (0.66, 0.69) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.68 (0.67, 0.69) ||\n|| Gait features + demograph var | 0.79 (0.77, 0.80) | 0.76 (0.75, 0.77) | 0.77 (0.76, 0.78) | 0.79 (0.78, 0.80) | 0.77 (0.76, 0.80) ||\n|| Fall history: 6 months | 0.55 (0.53, 0.56) | 0.65 (0.64, 0.67) | 0.62 (0.61, 0.63) | 0.60 (0.59, 0.61) | 0.60 (0.59, 0.61) ||",
    "claim": "For the \"PGME\" model in single-time fallers, the positive predictive value is 5 percentage points higher than the negative predictive value, reflecting a greater confidence in predicting fall occurrences than non-occurrences.",
    "label": "support"
  },
  {
    "id": "training_463_4",
    "table_caption": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) ",
    "table_content": "|| blank | Sensitivity | Specificity | Positive predictive value | Negative predictive value | Accuracy ||\n|| SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) ||\n|| All combined | 0.83 (0.82, 0.84) | 0.83 (0.82, 0.84) | 0.84 (0.83, 0.85) | 0.84 (0.83, 0.85) | 0.83 (0.82, 0.84) ||\n|| PGME | 0.71 (0.70, 0.72) | 0.80 (0.79, 0.81) | 0.79 (0.78, 0.80) | 0.74 (0.73, 0.75) | 0.76 (0.75, 0.77) ||\n|| Gait features + Demograph. var | 0.61 (0.60, 0.62) | 0.76 (0.75, 0.77) | 0.73 (0.72, 0.74) | 0.66 (0.65, 0.67) | 0.68 (0.67, 0.69) ||\n|| Fall history: 6 months | 0.47 (0.46, 0.48) | 0.67 (0.65, 0.68) | 0.59 (0.57, 0.60) | 0.56 (0.55, 0.57) | 0.57 (0.56, 0.58) ||\n|| All combined | 0.75 (0.73, 0.76) | 0.80 (0.79, 0.81) | 0.80 (0.79, 0.81) | 0.77 (0.76, 0.78) | 0.77 (0.76, 0.78) ||\n|| MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) ||\n|| PGME | 0.67 (0.66, 0.69) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.68 (0.67, 0.69) ||\n|| Gait features + demograph var | 0.79 (0.77, 0.80) | 0.76 (0.75, 0.77) | 0.77 (0.76, 0.78) | 0.79 (0.78, 0.80) | 0.77 (0.76, 0.80) ||\n|| Fall history: 6 months | 0.55 (0.53, 0.56) | 0.65 (0.64, 0.67) | 0.62 (0.61, 0.63) | 0.60 (0.59, 0.61) | 0.60 (0.59, 0.61) ||",
    "claim": "For the \"PGME\" model in single-time fallers, the positive predictive value is 5 percentage points lower than the negative predictive value, reflecting a greater confidence in predicting non-occurrences than fall occurrences.",
    "label": "support"
  },
  {
    "id": "training_1040_3",
    "table_caption": "Table: number of plasmids in each cell varied between two and ance was transferred together with a 3.0-kb plasmid. In Table 2: Susceptibility of MRSA isolates to vancomycin and teicoplanin Vancomycin MIC (%) Teicoplanin MIC (%) S/N Year # ≤ 2 mg/L 3 mg/L 4 mg/L ≤ 2 mg/L 3 mg/L 4 mg/L 1 1999 336 199(59.2) 120(35.7) 17(5.1) 225(70.0) 99(29.5) 12(3.5) 2 2000 542 494(91.1) 47(8.7) 1(0.2) 479(88.4) 58(10.7) 5(0.9) 3 2001 533 385(72.2) 133(25.0) 15(2.8) 293(55.0) 160(30.0) 80(15.0) 4 2002 884 773(87.4) 107(12.1) 4(0.5) 740(83.7) 112(12.7) 32(3.6) 5 2003 785 653(83.2) 132(16.8) 0.00 623(79.4) 162(20.6) 0.00 6 2004 930 807(86.8) 121(13.0) 2(0.2) 740(79.6) 176(18.9) 14(1.5) Total 4010 3311(82.5) 660(16.5) 39 (1.0) 3100 (77.3) 767(19.1) 143(3.6) ",
    "table_content": "|| S/N | Year | # | Vancomycin MIC (%) | Vancomycin MIC (%) | Vancomycin MIC (%) | Teicoplanin MIC (%) | Teicoplanin MIC (%) | Teicoplanin MIC (%) ||\n|| S/N | Year | # | ≤ 2 mg/L | 3 mg/L | 4 mg/L | ≤ 2 mg/L | 3 mg/L | 4 mg/L ||\n|| 1 | 1999 | 336 | 199(59.2) | 120(35.7) | 17(5.1) | 225(70.0) | 99(29.5) | 12(3.5) ||\n|| 2 | 2000 | 542 | 494(91.1) | 47(8.7) | 1(0.2) | 479(88.4) | 58(10.7) | 5(0.9) ||\n|| 3 | 2001 | 533 | 385(72.2) | 133(25.0) | 15(2.8) | 293(55.0) | 160(30.0) | 80(15.0) ||\n|| 4 | 2002 | 884 | 773(87.4) | 107(12.1) | 4(0.5) | 740(83.7) | 112(12.7) | 32(3.6) ||\n|| 5 | 2003 | 785 | 653(83.2) | 132(16.8) | 0.00 | 623(79.4) | 162(20.6) | 0.00 ||\n|| 6 | 2004 | 930 | 807(86.8) | 121(13.0) | 2(0.2) | 740(79.6) | 176(18.9) | 14(1.5) ||\n|| Total | Total | 4010 | 3311(82.5) | 660(16.5) | 39 (1.0) | 3100 (77.3) | 767(19.1) | 143(3.6) ||",
    "claim": "Over the six-year period, the average percentage of isolates with MIC ≤ 2 mg/L was higher for vancomycin (82.5%) compared to teicoplanin (77.3%). This suggests that MRSA isolates were generally more susceptible to vancomycin than teicoplanin.",
    "label": "support"
  },
  {
    "id": "training_86_3",
    "table_caption": "Table: Table 2 Categorization of sperm samples as a function of conventional sperm parameters and a densitometric analysis of the 110–80 kDa proteins Parameter (units) Group 1 n = 122 Group 2 n = 123 p-value in Student’s t test or (when underlined) a Kruskal-Wallis test Semen volume (mL) 3.5 [2.9–4.7] 4.07 (1.8–12) 3.8 [3.1–4.6] 4.02 (1.15–8.30) 0.81 Sperm concentration (×106/mL) 78.75 [52.5–142] 106.78 (24–420) 72 [41–92] 75.99 (1–250) 0.0002 Sperm count (×106/ejaculate) 319.30 [212.8–498] 405.96 (57–2100) 262.45 [155.8–356.9] 293.49 (2.80–1425) 0.0011 Progressive motility (PR, %) 55 [45–80] 54.80 (35–80) 45 [40–55] 46.28 (1–70) < 0.0001 Normal forms (%) 40.5 [34–48] 41.61 (25–68) 25 [18–53] 23.98 (0–53) < 0.0001 MAI 1.50 [1.44–1.55] 1.48 (1.25–1.55) 1.71 [1.64–1.80] 1.74 (1.38–1.80) < 0.0001 80–110 kDa band intensity from gel 1D (arbitrary units) 36,298 [21996–90,482] 33,466 [16657–48,560] 0.0367 Data on semen parameters are quoted as the median [IQR] and the mean (range) MAI multiple anomaly index, n number ",
    "table_content": "|| Parameter (units) | Group 1 n = 122 | Group 2 n = 123 | p -value in Student’s t test or (when underlined) a Kruskal-Wallis test ||\n|| Semen volume (mL) | 3.5 [2.9–4.7] 4.07 (1.8–12) | 3.8 [3.1–4.6] 4.02 (1.15–8.30) | 0.81 ||\n|| Sperm concentration (×10 6 /mL) | 78.75 [52.5–142] 106.78 (24–420) | 72 [41–92] 75.99 (1–250) | 0.0002 ||\n|| Sperm count (×10 6 /ejaculate) | 319.30 [212.8–498] 405.96 (57–2100) | 262.45 [155.8–356.9] 293.49 (2.80–1425) | 0.0011 ||\n|| Progressive motility (PR, %) | 55 [45–80] 54.80 (35–80) | 45 [40–55] 46.28 (1–70) | < 0.0001 ||\n|| Normal forms (%) | 40.5 [34–48] 41.61 (25–68) | 25 [18–53] 23.98 (0–53) | < 0.0001 ||\n|| MAI | 1.50 [1.44–1.55] 1.48 (1.25–1.55) | 1.71 [1.64–1.80] 1.74 (1.38–1.80) | < 0.0001 ||\n|| 80–110 kDa band intensity from gel 1D (arbitrary units) | 36,298 [21996–90,482] | 33,466 [16657–48,560] |  0.0367  ||",
    "claim": "Group 1 exhibits higher progressive motility compared to Group 2. The median progressive motility in Group 1 is 22.2% higher than in Group 2, reflecting a significant difference in the motility of sperm between the groups.",
    "label": "support"
  },
  {
    "id": "training_963_1",
    "table_caption": "Table: Crystal data [Li2(C8H2N2O8)(H2O)5] F(000) = 368 Mr = 358.08 Dx = 1.716 Mg m−3 Monoclinic, P21/m Mo Kα radiation, λ = 0.71073 Å a = 6.8806 (14) Å Cell parameters from 25 reflections b = 11.767 (2) Å θ = 6–15° c = 8.8082 (18) Å µ = 0.16 mm−1 β = 103.59 (3)° T = 293 K V = 693.2 (2) Å3 Blocks, colourless Z = 2 0.23 × 0.21 × 0.17 mm Data collection ",
    "table_content": "|| [Li 2 (C 8 H 2 N 2 O 8 )(H 2 O) 5 ] | F (000) = 368 ||\n|| M r = 358.08 | D x = 1.716 Mg m − 3 ||\n|| Monoclinic, P 2 1 / m | Mo K α radiation, λ = 0.71073 Å ||\n|| a = 6.8806 (14) Å | Cell parameters from 25 reflections ||\n|| b = 11.767 (2) Å | θ = 6–15° ||\n|| c = 8.8082 (18) Å | µ = 0.16 mm − 1 ||\n|| β = 103.59 (3)° | T = 293 K ||\n|| V = 693.2 (2)  Å 3 | Blocks, colourless ||\n|| Z = 2 | 0.23 × 0.21 × 0.17 mm ||",
    "claim": "The calculated density of the crystal, when combined with the unit cell volume and the number of formula units per unit cell, implies a specific packing efficiency. Given the unit cell volume and the density, the packing efficiency can be deduced to be approximately 64%, which is consistent with a tightly packed monoclinic structure.",
    "label": "support"
  },
  {
    "id": "training_1453_4",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A C8—H8···O1 0.93 2.36 2.951 (2) 121 C21—H21···O2 0.93 2.36 2.9460 (18) 121 C6—H6···O1 0.93 2.54 2.906 (2) 104 ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| C8—H8···O1 | 0.93 | 2.36 | 2.951 (2) | 121 ||\n|| C21—H21···O2 | 0.93 | 2.36 | 2.9460 (18) | 121 ||\n|| C6—H6···O1 | 0.93 | 2.54 | 2.906 (2) | 104 ||",
    "claim": "The D—H bond lengths are consistent across all three hydrogen bonds, indicating that the variations in other parameters are not due to changes in the D—H bond length.",
    "label": "support"
  },
  {
    "id": "training_1460_6",
    "table_caption": "Table: Completed suicide Chi- square P value ORa. 95% CI P value n = 95 n (%) No completed suicide n = 950 n (%) Education 21.771 < 0.0001 < 9 years (ref.) 24(25.26) 112(11.79) 1 9–12 years 35(36.84) 276(29.05) 0.52 0.25–1.07 0.078 > 12 years 17(17.89) 327(34.42) 0.17 0.07–0.41 < 0.0001 Unknown 19(20.0) 235(24.74) 0.97 0.14–6.55 0.973 Marital status 26.684 < 0.0001 Married (ref.) 52(54.74) 623(65.58) 1 Never married 17(17.89) 73(7.68) 2.51 1.10–5.75 0.029 Widowed/divorced 9 (9.47) 24(2.53) 3.43 0.99–11.87 0.052 Unknown 17(17.89) 230(24.21) 0.31 0.04–2.26 0.249 Delivery method 0.542 0.462 Vaginal delivery (ref.) 58(61.05) 616(64.84) 1 Caesarean delivery 37(38.95) 334(35.16) 0.69 0.39–1.23 0.204 Infant sex 3.190 0.074 Male (ref.) 43(45.26) 521(54.84) 1 Female 52(54.74) 429(45.16) 1.57 0.92–2.69 0.099 Low birth weight 20.879 < 0.0001 ≥ 2500 g (ref.) 79(83.16) 902(94.95) 1 < 2500 g 16(16.84) 48(5.05) 2.89 1.30–6.39 0.009 Pre-eclampsia/eclampsia 7.7389 0.005 No (ref.) 90(94.74) 937(98.63) 1 Yes 5(5.26) 13(1.37) 2.06 0.46–9.20 0.342 Anxiety 52.819 < 0.0001 No (ref.) 83(87.37) 939(98.84) 1 Yes 12(12.63) 11(1.16) 10.71 2.40–47.75 0.002 Mood disorder 102.2399 < 0.0001 No (ref.) 78(82.11) 941(99.05) 1 Yes 17(17.89) 9(0.95) 5.82 1.85–18.38 0.003 Postpartum depressive disorder 190.338 < 0.0001 No (ref.) 66(69.47) 937(98.63) 1 Yes 29(30.53) 13(1.37) 21.72 8.08–58.37 < 0.0001 Table 2. Risk of completed suicide within 1 year post partum stratified by perinatal and other associated factors (n = 1045). The OR (odds ratio) was calculated by performing conditional logistic regression ",
    "table_content": "|| blank | Completed suicide | Completed suicide | Chi- square | P value | OR a. | 95% CI | P value ||\n|| blank | n = 95 n (%) | No completed suicide n = 950 n (%) | Chi- square | P value | OR a. | 95% CI | P value ||\n|| Widowed/divorced | 9 (9.47) | 24(2.53) | blank | blank | 3.43 | 0.99–11.87 | 0.052 ||\n|| Unknown | 17(17.89) | 230(24.21) | blank | blank | 0.31 | 0.04–2.26 | 0.249 ||\n|| Delivery method | blank | blank | 0.542 | 0.462 | blank | blank | blank ||\n|| Vaginal delivery (ref.) | 58(61.05) | 616(64.84) | blank | blank | 1 | blank | blank ||\n|| Caesarean delivery | 37(38.95) | 334(35.16) | blank | blank | 0.69 | 0.39–1.23 | 0.204 ||\n|| Infant sex | blank | blank | 3.190 | 0.074 | blank | blank | blank ||\n|| Male (ref.) | 43(45.26) | 521(54.84) | blank | blank | 1 | blank | blank ||\n|| Female | 52(54.74) | 429(45.16) | blank | blank | 1.57 | 0.92–2.69 | 0.099 ||\n|| Low birth weight | blank | blank | 20.879 | <0.0001 | blank | blank | blank ||\n|| ≥2500 g (ref.) | 79(83.16) | 902(94.95) | blank | blank | 1 | blank | blank ||\n|| Education | blank | blank | 21.771 | <0.0001 | blank | blank | blank ||\n|| <2500 g | 16(16.84) | 48(5.05) | blank | blank | 2.89 | 1.30–6.39 | 0.009 ||\n|| Pre-eclampsia/eclampsia | blank | blank | 7.7389 | 0.005 | blank | blank | blank ||\n|| No (ref.) | 90(94.74) | 937(98.63) | blank | blank | 1 | blank | blank ||\n|| Yes | 5(5.26) | 13(1.37) | blank | blank | 2.06 | 0.46–9.20 | 0.342 ||\n|| Anxiety | blank | blank | 52.819 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 83(87.37) | 939(98.84) | blank | blank | 1 | blank | blank ||\n|| Yes | 12(12.63) | 11(1.16) | blank | blank | 10.71 | 2.40–47.75 | 0.002 ||\n|| Mood disorder | blank | blank | 102.2399 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 78(82.11) | 941(99.05) | blank | blank | 1 | blank | blank ||\n|| Yes | 17(17.89) | 9(0.95) | blank | blank | 5.82 | 1.85–18.38 | 0.003 ||\n|| <9 years (ref.) | 24(25.26) | 112(11.79) | blank | blank | 1 | blank | blank ||\n|| Postpartum depressive disorder | blank | blank | 190.338 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 66(69.47) | 937(98.63) | blank | blank | 1 | blank | blank ||\n|| Yes | 29(30.53) | 13(1.37) | blank | blank | 21.72 | 8.08–58.37 | <0.0001 ||\n|| 9–12 years | 35(36.84) | 276(29.05) | blank | blank | 0.52 | 0.25–1.07 | 0.078 ||\n|| > 12 years | 17(17.89) | 327(34.42) | blank | blank | 0.17 | 0.07–0.41 | <0.0001 ||\n|| Unknown | 19(20.0) | 235(24.74) | blank | blank | 0.97 | 0.14–6.55 | 0.973 ||\n|| Marital status | blank | blank | 26.684 | <0.0001 | blank | blank | blank ||\n|| Married (ref.) | 52(54.74) | 623(65.58) | blank | blank | 1 | blank | blank ||\n|| Never married | 17(17.89) | 73(7.68) | blank | blank | 2.51 | 1.10–5.75 | 0.029 ||",
    "claim": "The presence of pre-eclampsia or eclampsia is associated with an increased risk of completed suicide, with an odds ratio of 2.06, although this is not statistically significant with a p-value of 0.342.",
    "label": "support"
  },
  {
    "id": "training_498_4",
    "table_caption": "Table: Clinical characteristics of the populations studied. Obese Children N = 735 Obese Adults N = 1315 T2D N = 1535 Control 1 N = 623 Control 2 N = 740 Age (years) 11.3 ± 3.2 48 ± 13 59 ± 11 50.9 ± 12 53 ± 5.6 BMI (kg/m2) 28.8 ± 6.2 41.5 ± 8.8 29.3 ± 5.8 22.9 ± 2.3 23 ± 1.8 Sex ratio (F/M) 386/349 874/441 890/645 380/243 444/296 Obesity (%) 100 100 37 0 0 Type 2 Diabetes (%) 1 29 100 0 0 NGT (%) 94 52 0 100 100 Fasting Glucose (mmol/l) 4.95 ± 0.5 6.66 ± 2.6 9.40 ± 3.3 5.00 ± 0.4 5.05 ± 0.88 Fasting Insulin (pmol/l) 81.0 ± 58 88.2 ± 60 66.0 ± 54 33.5 ± 25 30.5 ± 22 ",
    "table_content": "|| blank | Obese Children N = 735 | Obese Adults N = 1315 | T2D N = 1535 | Control 1 N = 623 | Control 2 N = 740 ||\n|| Age (years) | 11.3 ± 3.2 | 48 ± 13 | 59 ± 11 | 50.9 ± 12 | 53 ± 5.6 ||\n|| BMI (kg/m 2 ) | 28.8 ± 6.2 | 41.5 ± 8.8 | 29.3 ± 5.8 | 22.9 ± 2.3 | 23 ± 1.8 ||\n|| Sex ratio (F/M) | 386/349 | 874/441 | 890/645 | 380/243 | 444/296 ||\n|| Obesity (%) | 100 | 100 | 37 | 0 | 0 ||\n|| Type 2 Diabetes (%) | 1 | 29 | 100 | 0 | 0 ||\n|| NGT (%) | 94 | 52 | 0 | 100 | 100 ||\n|| Fasting Glucose (mmol/l) | 4.95 ± 0.5 | 6.66 ± 2.6 | 9.40 ± 3.3 | 5.00 ± 0.4 | 5.05 ± 0.88 ||\n|| Fasting Insulin (pmol/l) | 81.0 ± 58 | 88.2 ± 60 | 66.0 ± 54 | 33.5 ± 25 | 30.5 ± 22 ||",
    "claim": "The T2D group has a 37% obesity prevalence, which is higher than the Obese Adults group. Despite this, the T2D group has a 100% prevalence of Type 2 Diabetes, indicating that while obesity is a risk factor, other factors significantly contribute to diabetes development.",
    "label": "support"
  },
  {
    "id": "training_874_1",
    "table_caption": "Table: Low-risk category (n = 1,128) Intermediate-risk category (n = 1,253) High-risk category (n = 312) P Value Age, years 60 (53–68) 62 (53–69) 63 (54–72) <0.001 Male 883 (78.3%) 941 (75.1%) 217 (69.6%) 0.005 Body mass index, kg/m2 24.16 (22.39–26.05) 24.11 (21.97–25.87) 24.02 (22.03–25.69) 0.170 Medical history  Smoker (former or current) 583 (51.7%) 633 (50.5%) 142 (45.5%) 0.155  Hypertension 525 (46.5%) 602 (48.0%) 151 (48.4%) 0.718  Diabetes mellitus 202 (17.8%) 260 (20.8%) 98 (31.4%) <0.001  Dyslipidemia 809 (71.7%) 883 (70.5%) 214 (68.6%) 0.532  Previous MI 122 (10.8%) 134 (10.7%) 35 (11.2%) 0.965  Previous PCI 47 (4.2%) 50 (4.0%) 8 (2.6%) 0.422  Previous stroke 46 (4.1%) 65 (5.2%) 22 (7.1%) 0.086 Presentation characteristics  Heart rate, beats/min 76 (68–78) 76 (69–83) 76 (69–88) <0.001  SBP, mm Hg 124 (118–135) 123 (111–138) 120 (105–131) <0.001  Killip class I 960 (85.1%) 970 (77.4%) 227 (72.8%) <0.001  Killip class II 122 (10.8%) 172 (13.7%) 41 (13.1%)  Killip class III 42 (3.7%) 93 (7.4%) 27 (8.7%)  Killip class IV 4 (0.4%) 18 (1.4%) 17 (5.4%)  Cardiac arrest 6 (0.5%) 16 (1.3%) 7 (2.2%) 0.022 Laboratory findings  WBC count, ×109/L 5.98 (5.23–6.98) 8.89 (7.21–10.07) 9.10 (8.80–10.77) <0.001  Neutrophil count, ×109/L 3.79 (3.12–4.53) 6.54 (4.24–8.01) 6.67 (5.64–8.53) <0.001  Lymphocyte count, ×109/L 1.63 (1.26–2.04) 1.58 (1.18–2.07) 1.63 (1.22–2.16) 0.351  Monocyte count, ×109/L 0.37 (0.28–0.47) 0.49 (0.35–0.71) 0.59 (0.38–0.82) <0.001  Eosinophil count, ×109/L 0.08 (0.05–0.15) 0.05 (0.01–0.11) 0.04 (0.01–0.10) <0.001  Basophil count, ×109/L 0.02 (0.01–0.03) 0.02 (0.01–0.02) 0.01 (0.01–0.02) 0.001  RBC count, ×1012/L 4.81 (4.53–5.12) 4.69 (4.26–5.14) 4.42 (3.97–4.94) <0.001  Hemoglobin, g/L 152 (143–161) 148 (131–160) 138 (121–156) <0.001  RDW, % 13.20 (12.80–13.80) 13.50 (12.90–14.00) 13.70 (13.13–14.40) <0.001  MCV, fL 92.80 (89.90–96.10) 91.70 (88.60–95.00) 92.10 (88.43–95.60) <0.001  MCH, pg 31.60 (30.50–32.70) 31.30 (30.10–32.40) 31.20 (29.80–32.20) <0.001  MCHC, g/L 339 (333–346) 341 (332–349) 337 (328–345) <0.001  Hematocrit, % 44.80 (42.20–47.40) 43.20 (39.40–46.40) 41.85 (36.53–46.10) <0.001  Platelet count, ×109/L 168 (131–206) 188 (147–231) 163 (130–210) <0.001  MPV, fL 11.50 (10.70–12.40) 11.30 (10.50–12.10) 13.30 (12.03–13.80) <0.001  PDW, fL 14.90 (13.00–16.70) 14.60 (12.80–15.90) 18.30 (14.98–20.40) <0.001  P-LCR, % 38.20 (32.33–44.40) 37.00 (30.10–42.00) 50.55 (39.39–54.20) <0.001  Plateletcrit, % 0.210 (0.170–0.230) 0.220 (0.180–0.260) 0.219 (0.180–0.260) <0.001  LDL, mmol/L 2.40 (1.88–2.98) 2.58 (1.99–3.24) 2.63 (2.09–3.16) <0.001  Glucose, mmol/L 5.60 (4.89–7.18) 6.20 (5.12–7.98) 6.86 (5.44–9.81) <0.001  Creatinine, µmol/L 75.75 (67.00–84.00) 74.50 (64.00–87.05) 77.40 (64.00–96.90) 0.071  Elevated cardiac enzymes 521 (46.2%) 898 (71.7%) 236 (75.6%) <0.001 ST-segment deviation on ECG 450 (39.9%) 810 (64.6%) 209 (67.0%) <0.001 LVEF, % 56 (55–60) 56 (49–58) 55 (47–59) <0.001 GRACE risk score 118 (87–166) 162 (114–189) 172 (132–203) <0.001 ACS presentation <0.001  NSTE-ACS 724 (64.2%) 513 (40.9%) 125 (40.1%)  STEMI 404 (35.8%) 740 (59.1%) 187 (59.9%) Medical treatment  Aspirin 1,101 (97.6%) 1,213 (96.8%) 308 (98.7%) 0.136  P2Y12 inhibitor 1,068 (94.7%) 1,197 (95.5%) 299 (95.8%) 0.538  Statin 1,003 (88.9%) 1,135 (90.6%) 275 (88.1%) 0.276  ACEI⁄ARB 761 (67.5%) 796 (63.5%) 201 (64.4%) 0.124  β-Blocker 636 (56.4%) 692 (55.2%) 168 (53.8%) 0.692 Table 1. Demographic and clinical characteristics of risk groups. Abbreviation: MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; WBC, white blood cell; RBC, red ",
    "table_content": "|| blank | Low-risk category (n = 1,128) | Intermediate-risk category (n = 1,253) | High-risk category (n = 312) | P Value ||\n|| Age, years | 60 (53–68) | 62 (53–69) | 63 (54–72) | <0.001 ||\n|| Previous PCI | 47 (4.2%) | 50 (4.0%) | 8 (2.6%) | 0.422 ||\n|| Previous stroke | 46 (4.1%) | 65 (5.2%) | 22 (7.1%) | 0.086 ||\n|| Presentation characteristics | Presentation characteristics | Presentation characteristics | Presentation characteristics | Presentation characteristics ||\n|| Heart rate, beats/min | 76 (68–78) | 76 (69–83) | 76 (69–88) | <0.001 ||\n|| SBP, mm Hg | 124 (118–135) | 123 (111–138) | 120 (105–131) | <0.001 ||\n|| Killip class I | 960 (85.1%) | 970 (77.4%) | 227 (72.8%) | <0.001 ||\n|| Killip class II | 122 (10.8%) | 172 (13.7%) | 41 (13.1%) | blank ||\n|| Killip class III | 42 (3.7%) | 93 (7.4%) | 27 (8.7%) | blank ||\n|| Killip class IV | 4 (0.4%) | 18 (1.4%) | 17 (5.4%) | blank ||\n|| Cardiac arrest | 6 (0.5%) | 16 (1.3%) | 7 (2.2%) | 0.022 ||\n|| Male | 883 (78.3%) | 941 (75.1%) | 217 (69.6%) | 0.005 ||\n|| Laboratory findings | Laboratory findings | Laboratory findings | Laboratory findings | Laboratory findings ||\n|| WBC count, ×10 9 /L | 5.98 (5.23–6.98) | 8.89 (7.21–10.07) | 9.10 (8.80–10.77) | <0.001 ||\n|| Neutrophil count, ×10 9 /L | 3.79 (3.12–4.53) | 6.54 (4.24–8.01) | 6.67 (5.64–8.53) | <0.001 ||\n|| Lymphocyte count, ×10 9 /L | 1.63 (1.26–2.04) | 1.58 (1.18–2.07) | 1.63 (1.22–2.16) | 0.351 ||\n|| Monocyte count, ×10 9 /L | 0.37 (0.28–0.47) | 0.49 (0.35–0.71) | 0.59 (0.38–0.82) | <0.001 ||\n|| Eosinophil count, ×10 9 /L | 0.08 (0.05–0.15) | 0.05 (0.01–0.11) | 0.04 (0.01–0.10) | <0.001 ||\n|| Basophil count, ×10 9 /L | 0.02 (0.01–0.03) | 0.02 (0.01–0.02) | 0.01 (0.01–0.02) | 0.001 ||\n|| RBC count, ×10 12 /L | 4.81 (4.53–5.12) | 4.69 (4.26–5.14) | 4.42 (3.97–4.94) | <0.001 ||\n|| Hemoglobin, g/L | 152 (143–161) | 148 (131–160) | 138 (121–156) | <0.001 ||\n|| RDW, % | 13.20 (12.80–13.80) | 13.50 (12.90–14.00) | 13.70 (13.13–14.40) | <0.001 ||\n|| Body mass index, kg/m 2 | 24.16 (22.39–26.05) | 24.11 (21.97–25.87) | 24.02 (22.03–25.69) | 0.170 ||\n|| MCV, fL | 92.80 (89.90–96.10) | 91.70 (88.60–95.00) | 92.10 (88.43–95.60) | <0.001 ||\n|| MCH, pg | 31.60 (30.50–32.70) | 31.30 (30.10–32.40) | 31.20 (29.80–32.20) | <0.001 ||\n|| MCHC, g/L | 339 (333–346) | 341 (332–349) | 337 (328–345) | <0.001 ||\n|| Hematocrit, % | 44.80 (42.20–47.40) | 43.20 (39.40–46.40) | 41.85 (36.53–46.10) | <0.001 ||\n|| Platelet count, ×10 9 /L | 168 (131–206) | 188 (147–231) | 163 (130–210) | <0.001 ||\n|| MPV, fL | 11.50 (10.70–12.40) | 11.30 (10.50–12.10) | 13.30 (12.03–13.80) | <0.001 ||\n|| PDW, fL | 14.90 (13.00–16.70) | 14.60 (12.80–15.90) | 18.30 (14.98–20.40) | <0.001 ||\n|| P-LCR, % | 38.20 (32.33–44.40) | 37.00 (30.10–42.00) | 50.55 (39.39–54.20) | <0.001 ||\n|| Plateletcrit, % | 0.210 (0.170–0.230) | 0.220 (0.180–0.260) | 0.219 (0.180–0.260) | <0.001 ||\n|| LDL, mmol/L | 2.40 (1.88–2.98) | 2.58 (1.99–3.24) | 2.63 (2.09–3.16) | <0.001 ||\n|| Medical history | Medical history | Medical history | Medical history | Medical history ||\n|| Glucose, mmol/L | 5.60 (4.89–7.18) | 6.20 (5.12–7.98) | 6.86 (5.44–9.81) | <0.001 ||\n|| Creatinine, µmol/L | 75.75 (67.00–84.00) | 74.50 (64.00–87.05) | 77.40 (64.00–96.90) | 0.071 ||\n|| Elevated cardiac enzymes | 521 (46.2%) | 898 (71.7%) | 236 (75.6%) | <0.001 ||\n|| ST-segment deviation on ECG | 450 (39.9%) | 810 (64.6%) | 209 (67.0%) | <0.001 ||\n|| LVEF, % | 56 (55–60) | 56 (49–58) | 55 (47–59) | <0.001 ||\n|| GRACE risk score | 118 (87–166) | 162 (114–189) | 172 (132–203) | <0.001 ||\n|| ACS presentation | blank | blank | blank | <0.001 ||\n|| NSTE-ACS | 724 (64.2%) | 513 (40.9%) | 125 (40.1%) | blank ||\n|| STEMI | 404 (35.8%) | 740 (59.1%) | 187 (59.9%) | blank ||\n|| Medical treatment | Medical treatment | Medical treatment | Medical treatment | Medical treatment ||\n|| Smoker (former or current) | 583 (51.7%) | 633 (50.5%) | 142 (45.5%) | 0.155 ||\n|| Aspirin | 1,101 (97.6%) | 1,213 (96.8%) | 308 (98.7%) | 0.136 ||\n|| P2Y12 inhibitor | 1,068 (94.7%) | 1,197 (95.5%) | 299 (95.8%) | 0.538 ||\n|| Statin | 1,003 (88.9%) | 1,135 (90.6%) | 275 (88.1%) | 0.276 ||\n|| ACEI⁄ARB | 761 (67.5%) | 796 (63.5%) | 201 (64.4%) | 0.124 ||\n|| β-Blocker | 636 (56.4%) | 692 (55.2%) | 168 (53.8%) | 0.692 ||\n|| Hypertension | 525 (46.5%) | 602 (48.0%) | 151 (48.4%) | 0.718 ||\n|| Diabetes mellitus | 202 (17.8%) | 260 (20.8%) | 98 (31.4%) | <0.001 ||\n|| Dyslipidemia | 809 (71.7%) | 883 (70.5%) | 214 (68.6%) | 0.532 ||\n|| Previous MI | 122 (10.8%) | 134 (10.7%) | 35 (11.2%) | 0.965 ||",
    "claim": "The average age increases with risk category, with the high-risk group being older than the low-risk group. The proportion of males decreases as risk increases. The difference in age and gender distribution between the low-risk and high-risk groups is statistically significant, with a P-value of less than 0.001 for age and 0.005 for gender.",
    "label": "support"
  },
  {
    "id": "training_326_2",
    "table_caption": "Table: Data collection Bruker SMART APEXII diffractometer 1758 independent reflections Radiation source: fine-focus sealed tube 1412 reflections with I > 2σ(I) graphite Rint = 0.024 φ and ω scans θmax = 27.6°, θmin = 3.0° Absorption correction: multi-scan (SADABS; Bruker, 2005) h = −19→24 Tmin = 0.916, Tmax = 0.965 k = −9→9 6541 measured reflections l = −17→15 Refinement ",
    "table_content": "|| Bruker SMART APEXII diffractometer | 1758 independent reflections ||\n|| Radiation source: fine-focus sealed tube | 1412 reflections with I > 2σ( I ) ||\n|| graphite | R int = 0.024 ||\n|| φ and ω scans | θ max = 27.6°, θ min = 3.0° ||\n|| Absorption correction: multi-scan ( SADABS ; Bruker, 2005) | h = −19→24 ||\n|| T min = 0.916, T max = 0.965 | k = −9→9 ||\n|| 6541 measured reflections | l = −17→15 ||",
    "claim": "With 1412 out of 1758 independent reflections having an intensity greater than twice the standard deviation, the data set exhibits a high-quality signal-to-noise ratio, which is essential for reliable structural analysis.",
    "label": "support"
  },
  {
    "id": "training_1122_1",
    "table_caption": "Table: defect. Electrodes Rs (ohm) Ret (ohm) SAM Г (10-8 mol·cm-2) % defect % adsorption Bare 227.0 (2.0%) 589.5 (5.0%) MPA 1.38±0.1 87.3 12.7 MPA 256.6 (0.9%) 6281.0 (1.7%) MUA 2.37±0.3 37.8 62.2 MUA 229 (1.0%) 209370 (4.3%) The CV curves obtained from the gold-oxide reduction experiments performed in H2SO4 are shown ",
    "table_content": "|| Electrodes | R s (ohm) | R et (ohm) | SAM | Γ (10 −8 mol·cm −2 ) | % defect | % adsorption ||\n|| Bare | 227.0 (2.0%) | 589.5 (5.0%) | MPA | 1.38±0.1 | 87.3 | 12.7 ||\n|| MPA | 256.6 (0.9%) | 6281.0 (1.7%) | MUA | 2.37±0.3 | 37.8 | 62.2 ||\n|| MUA | 229 (1.0%) | 209370 (4.3%) | blank | blank | blank | blank ||",
    "claim": "The MUA electrode exhibits a Ret value that is approximately 33.3 times greater than that of the MPA electrode, indicating a substantial increase in charge transfer resistance due to the MUA modification.",
    "label": "support"
  },
  {
    "id": "training_1215_5",
    "table_caption": "Table: US retail drug prices, May 2005 Bimatoprost 0.03%, 2.5 mL Bimatoprost 0.03%, 5.0 mL ($ per 2.5 mL) Latanoprost 0.005%, 2.5 mL Travoprost 0.004%, 2.5 mL Walgreens $74.99 $71.50 $65.99 $71.99 Park Pharmacy $68.95 $67.98 $63.98 $64.95 WalMart $69.32 $63.23 $50.68 $64.88 Winn Dixie $71.95 $63.48 $69.95 $66.95 K-Mart $74.97 $69.49 $62.99 $70.97 Target $71.99 $65.75 $59.99 $67.99 DrugStore.Com $57.75 $55.12 $58.22 $56.88 Average $69.99 $65.22 $61.69 $66.37 ",
    "table_content": "|| blank | Bimatoprost 0.03%, 2.5 mL | Bimatoprost 0.03%, 5.0 mL ($ per 2.5 mL) | Latanoprost 0.005%, 2.5 mL | Travoprost 0.004%, 2.5 mL ||\n|| Walgreens | $74.99 | $71.50 | $65.99 | $71.99 ||\n|| Park Pharmacy | $68.95 | $67.98 | $63.98 | $64.95 ||\n|| WalMart | $69.32 | $63.23 | $50.68 | $64.88 ||\n|| Winn Dixie | $71.95 | $63.48 | $69.95 | $66.95 ||\n|| K-Mart | $74.97 | $69.49 | $62.99 | $70.97 ||\n|| Target | $71.99 | $65.75 | $59.99 | $67.99 ||\n|| DrugStore.Com | $57.75 | $55.12 | $58.22 | $56.88 ||\n|| Average | $69.99 | $65.22 | $61.69 | $66.37 ||",
    "claim": "** At WalMart, the price of Latanoprost 0.005% (2.5 mL) is approximately 17.8% lower than the average price, highlighting a competitive pricing strategy for this drug at this retailer.",
    "label": "support"
  },
  {
    "id": "training_118_7",
    "table_caption": "Table: Table 2 Lung mechanics, hemodynamics, gas exchange, acid-base status, and metabolic parameters Vehicle HAM1101 p value Hemoglobin content (mg·mL−1) Start 90 (87, 96) 98 (95, 105) 0.074 End 70 (66, 72) 69 (66, 74) 0.806 Heart rate (beats·min−1) Start 494 (485, 515) 430 (406, 480) 0.248 End 426 (406, 445) 391 (349,430) 0.290 Mean arterial pressure (mmHg) Start 69 (65, 71) 69 (66, 76) 0.382 End 64 (59, 69) 67 (66, 72) 0.441 Thoracopulmonary compliance (μL·cm H2O−1) Start 0.10 (0.09, 0.10) 0.10 (0.09, 0.11) 0.382 End 0.09 (0.08, 0.10) 0.10 (0.08, 0.11) 0.427 Arterial PO2 (mmHg) Start 314 (293, 330) 340 (321, 350) 0.254 End 309 (287, 326) 301 (287, 319) 0.838 Arterial PCO2 (mmHg) Start 31 (27, 33) 31 (29, 36) 0.879 End 34 (33, 36) 31 (28, 33) 0.072 Arterial pH Start 7.33 (7.30, 7.35) 7.36 (7.32, 7.38) 0.569 End 7.38 (7.31, 7.43) 7.43 (7.39, 7.46) 0.253 Arterial base excess (mmol·mL−1) Start −9.0 (−10.3, −7.7) −6.8 (−8.3, −6.2) 0.403 End −5.7 (−7.1, −1.7) −3.9 (−4.2, −3.3) 0.838 Arterial lactate (mmol·mL−1) Start n.d. n.d. n.d. End 2.0 (1.7, 2.2) 1.6 (1.5, 1.8) 0.025 Arterial glucose (mg·dL−1) Start 113 (110, 117) 115 (106, 123) 0.540 End 110 (96, 117) 111 (109, 115) 0.653 CO2 production rate (μL·g−1·min−1) Start 26 (24, 28) 24 (23, 25) 0.082 End 23 (21, 26) 23 (22, 25) 0.596 Glucose production rate (mg·g−1·h−1) Start 0.37 (0.35, 0.41) 0.34 (0.31, 0.36) 0.178 End 0.38 (0.35, 0.39) 0.33 (0.31, 0.39) 0.153 Glucose oxidation rate (% isotope infusion) Start 58 (55, 62) 55 (50, 59) 0.224 End 57 (54, 60) 62 (58, 67) 0.047 The data are for the vehicle-treated (n = 11) and HAM1101-treated (n = 9) animals at the start and the end of the 5-h observation period; n.d., not determined. All data are median (quartiles). ",
    "table_content": "|| blank | blank | Vehicle | HAM1101 |  p value ||\n|| Hemoglobin content (mg·mL −1 ) | Start | 90 (87, 96) | 98 (95, 105) | 0.074 ||\n|| Arterial PO 2 (mmHg) | End | 309 (287, 326) | 301 (287, 319) | 0.838 ||\n|| Arterial PCO 2 (mmHg) | Start | 31 (27, 33) | 31 (29, 36) | 0.879 ||\n|| Arterial PCO 2 (mmHg) | End | 34 (33, 36) | 31 (28, 33) | 0.072 ||\n|| Arterial pH | Start | 7.33 (7.30, 7.35) | 7.36 (7.32, 7.38) | 0.569 ||\n|| Arterial pH | End | 7.38 (7.31, 7.43) | 7.43 (7.39, 7.46) | 0.253 ||\n|| Arterial base excess (mmol·mL −1 ) | Start | −9.0 (−10.3, −7.7) | −6.8 (−8.3, −6.2) | 0.403 ||\n|| Arterial base excess (mmol·mL −1 ) | End | −5.7 (−7.1, −1.7) | −3.9 (−4.2, −3.3) | 0.838 ||\n|| Arterial lactate (mmol·mL −1 ) | Start | n.d. | n.d. | n.d. ||\n|| Arterial lactate (mmol·mL −1 ) | End | 2.0 (1.7, 2.2) | 1.6 (1.5, 1.8) | 0.025 ||\n|| Arterial glucose (mg·dL −1 ) | Start | 113 (110, 117) | 115 (106, 123) | 0.540 ||\n|| Hemoglobin content (mg·mL −1 ) | End | 70 (66, 72) | 69 (66, 74) | 0.806 ||\n|| Arterial glucose (mg·dL −1 ) | End | 110 (96, 117) | 111 (109, 115) | 0.653 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | Start | 26 (24, 28) | 24 (23, 25) | 0.082 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | End | 23 (21, 26) | 23 (22, 25) | 0.596 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | Start | 0.37 (0.35, 0.41) | 0.34 (0.31, 0.36) | 0.178 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | End | 0.38 (0.35, 0.39) | 0.33 (0.31, 0.39) | 0.153 ||\n|| Glucose oxidation rate (% isotope infusion) | Start | 58 (55, 62) | 55 (50, 59) | 0.224 ||\n|| Glucose oxidation rate (% isotope infusion) | End | 57 (54, 60) | 62 (58, 67) | 0.047 ||\n|| Heart rate (beats·min −1 ) | Start | 494 (485, 515) | 430 (406, 480) | 0.248 ||\n|| Heart rate (beats·min −1 ) | End | 426 (406, 445) | 391 (349,430) | 0.290 ||\n|| Mean arterial pressure (mmHg) | Start | 69 (65, 71) | 69 (66, 76) | 0.382 ||\n|| Mean arterial pressure (mmHg) | End | 64 (59, 69) | 67 (66, 72) | 0.441 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | Start | 0.10 (0.09, 0.10) | 0.10 (0.09, 0.11) | 0.382 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | End | 0.09 (0.08, 0.10) | 0.10 (0.08, 0.11) | 0.427 ||\n|| Arterial PO 2 (mmHg) | Start | 314 (293, 330) | 340 (321, 350) | 0.254 ||",
    "claim": "The change in arterial base excess from start to end in the vehicle group is approximately 36.7%, while in the HAM1101 group, it is approximately 42.6%. This indicates a greater shift towards normalization of base excess in the HAM1101 group.",
    "label": "support"
  },
  {
    "id": "training_1018_2",
    "table_caption": "Table: Table 4 Daily dietary nutrient intakes by vegetable expenditure* Total population Quintiles (range) of daily vegetable expenditure (NTD/day) P† Q1 (<8.20) Q2 (8.21-13.9) Q3 (14.0-20.6) Q4 (20.7-29.7) Q5 (>29.7) Energy (kcal) 1626 1574 1667 1586 1677 1621 0.554 Protein (g) 65.2 58.3 62.5 66.0 68.2 70.3 0.001 Total fat (g) 44.1 46.3 44.1 43.4 43.9 43.0 0.737 SFA (g) 13.3 16.0 13.4 13.0 12.6 11.5 0.001 PUFA (g) 13.5 12.0 13.3 13.2 14.1 14.8 0.011 Cholesterol (mg) 207 209 214 222 206 184 0.080 Carbohydrate (g) 215 205 213 218 219 220 0.078 Dietary fiber (g) 18.8 13.7 14.8 16.8 20.9 27.3 <0.001 Fe (mg) 11.5 8.38 9.41 10.5 13.2 15.5 <0.001 Ca (mg) 624 544 556 576 633 798 <0.001 P (mg) 944 862 899 945 965 1039 0.007 Mg (mg) 225 179 196 215 235 294 <0.001 Na (mg) 4520 3499 3753 4245 5118 5831 <0.001 K (mg) 2270 1698 1899 2178 2416 3087 <0.001 Vitamin A (I.U.) 9354 5234 6605 8345 11353 14664 <0.001 Vitamin D (mg) 5.30 4.95 5.57 5.96 5.06 4.67 0.300 Vitamin E (mg) 7.46 5.89 6.46 7.19 8.30 9.23 <0.001 Vitamin B-1 (mg) 1.07 0.96 1.04 1.01 1.13 1.19 0.167 Vitamin B-2 (mg) 1.35 1.43 1.35 1.25 1.29 1.41 0.114 Niacin (mg) 13.4 12.0 12.7 13.4 14.4 14.5 0.050 Vitamin B-6 (mg) 1.11 1.02 1.01 1.05 1.20 1.26 0.006 Vitamin C (mg) 148 105 122 133 171 202 <0.001 *All values are presented by mean. † Differences across quintiles were tested by ANOVA. ",
    "table_content": "|| blank | Total population | Quintiles (range) of daily vegetable expenditure (NTD/day) | Quintiles (range) of daily vegetable expenditure (NTD/day) | Quintiles (range) of daily vegetable expenditure (NTD/day) | Quintiles (range) of daily vegetable expenditure (NTD/day) | Quintiles (range) of daily vegetable expenditure (NTD/day) | P † ||\n|| blank | Total population | Q1 (<8.20) | Q2 (8.21-13.9) | Q3 (14.0-20.6) | Q4 (20.7-29.7) | Q5 (>29.7) | P † ||\n|| Fe (mg) | 11.5 | 8.38 | 9.41 | 10.5 | 13.2 | 15.5 | <0.001 ||\n|| Ca (mg) | 624 | 544 | 556 | 576 | 633 | 798 | <0.001 ||\n|| P (mg) | 944 | 862 | 899 | 945 | 965 | 1039 | 0.007 ||\n|| Mg (mg) | 225 | 179 | 196 | 215 | 235 | 294 | <0.001 ||\n|| Na (mg) | 4520 | 3499 | 3753 | 4245 | 5118 | 5831 | <0.001 ||\n|| K (mg) | 2270 | 1698 | 1899 | 2178 | 2416 | 3087 | <0.001 ||\n|| Vitamin A (I.U.) | 9354 | 5234 | 6605 | 8345 | 11353 | 14664 | <0.001 ||\n|| Vitamin D (mg) | 5.30 | 4.95 | 5.57 | 5.96 | 5.06 | 4.67 | 0.300 ||\n|| Vitamin E (mg) | 7.46 | 5.89 | 6.46 | 7.19 | 8.30 | 9.23 | <0.001 ||\n|| Vitamin B-1 (mg) | 1.07 | 0.96 | 1.04 | 1.01 | 1.13 | 1.19 | 0.167 ||\n|| Energy (kcal) | 1626 | 1574 | 1667 | 1586 | 1677 | 1621 | 0.554 ||\n|| Vitamin B-2 (mg) | 1.35 | 1.43 | 1.35 | 1.25 | 1.29 | 1.41 | 0.114 ||\n|| Niacin (mg) | 13.4 | 12.0 | 12.7 | 13.4 | 14.4 | 14.5 | 0.050 ||\n|| Vitamin B-6 (mg) | 1.11 | 1.02 | 1.01 | 1.05 | 1.20 | 1.26 | 0.006 ||\n|| Vitamin C (mg) | 148 | 105 | 122 | 133 | 171 | 202 | <0.001 ||\n|| Protein (g) | 65.2 | 58.3 | 62.5 | 66.0 | 68.2 | 70.3 | 0.001 ||\n|| Total fat (g) | 44.1 | 46.3 | 44.1 | 43.4 | 43.9 | 43.0 | 0.737 ||\n|| SFA (g) | 13.3 | 16.0 | 13.4 | 13.0 | 12.6 | 11.5 | 0.001 ||\n|| PUFA (g) | 13.5 | 12.0 | 13.3 | 13.2 | 14.1 | 14.8 | 0.011 ||\n|| Cholesterol (mg) | 207 | 209 | 214 | 222 | 206 | 184 | 0.080 ||\n|| Carbohydrate (g) | 215 | 205 | 213 | 218 | 219 | 220 | 0.078 ||\n|| Dietary fiber (g) | 18.8 | 13.7 | 14.8 | 16.8 | 20.9 | 27.3 | <0.001 ||",
    "claim": "Sodium intake increases by approximately 66.6% from the lowest to the highest quintile, suggesting a substantial rise in sodium consumption with higher vegetable expenditure.",
    "label": "support"
  },
  {
    "id": "training_392_2",
    "table_caption": "Table: Optional Bioconductor chip reading libraries. Library Chip Type Run Local? affy Affymetrix 3'-biased Yes gcrma Affymetrix 3'-biased Yes affyPLM Affymetrix 3'-biased Yes xps Affymetrix 3'-biased No oligo Affymetrix Exon ST Yes exonmap Affymetrix Exon ST No xps Affymetrix Exon ST No oligo Affymetrix Gene ST Yes xps Affymetrix Gene ST No oligo Affymetrix SNP Yes oligo Affymetrix Tilling Yes oligo Nimblegen Yes lumi Illumina No beadarray Illumina No doi:10.1371/journal.pone.0137696.t001 ",
    "table_content": "|| Library | Chip Type | Run Local? ||\n|| affy | Affymetrix 3'-biased | Yes ||\n|| oligo | Affymetrix SNP | Yes ||\n|| oligo | Affymetrix Tilling | Yes ||\n|| oligo | Nimblegen | Yes ||\n|| lumi | Illumina | No ||\n|| beadarray | Illumina | No ||\n|| gcrma | Affymetrix 3'-biased | Yes ||\n|| affyPLM | Affymetrix 3'-biased | Yes ||\n|| xps | Affymetrix 3'-biased | No ||\n|| oligo | Affymetrix Exon ST | Yes ||\n|| exonmap | Affymetrix Exon ST | No ||\n|| xps | Affymetrix Exon ST | No ||\n|| oligo | Affymetrix Gene ST | Yes ||\n|| xps | Affymetrix Gene ST | No ||",
    "claim": "Among the libraries listed, a majority are capable of running locally, suggesting a preference or requirement for local execution in chip reading processes.",
    "label": "support"
  },
  {
    "id": "training_1264_1",
    "table_caption": "Table: Risk of physical inactivity according to predictive factors at baseline. No. of cases Unadjusted Gender & age-adjusted Multi-adjusted HR (95% CI) p HR (95% CI) p HR (95% CI) p Body mass index Optimal 1722 1.00 1.00 1.00 Overweight 1388 1.19 (1.11–1.28) <0.0001 1.24 (1.15–1.34) <0.0001 1.22 (1.13–1.32) <0.0001 Obesity 215 1.76 (1.52–2.02) <0.0001 1.80 (1.56–2.08) <0.0001 1.73 (1.49–2.00) <0.0001 Smoking Non-smoker 1382 1.00 1.00 1.00 Ex-smoker 1237 1.03 (0.96–1.11) 0.42 1.05 (0.97–1.13) 0.24 1.00 (0.92–1.08) 0.93 Smoker 706 1.40 (1.28–1.53) <0.0001 1.41 (1.29–1.55) <0.0001 1.37 (1.25–1.50) <0.0001 Depression No 2561 1.00 1.00 1.00 Yes 764 1.21 (1.11–1.31) <0.0001 1.21 (1.11–1.31) <0.0001 1.17 (1.07–1.27) 0.0003 Dyslipidemia No 2758 1.00 1.00 1.00 Yes 567 1.22 (1.11–1.33) <0.0001 1.24 (1.13–1.36) <0.0001 1.17 (1.06–1.28) 0.001 Gender Women 773 1.00 1.00 1.00 Men 2552 0.96 (0.88–1.04) 0.30 0.97 (0.89–1.05) 0.42 0.87 (0.79–0.95) 0.003 Hypertension No 3016 1.00 1.00 1.00 Yes 309 1.23 (1.10–1.39) 0.0006 1.24 (1.10–1.40) 0.0004 1.14 (1.01–1.28) 0.04 Only predictive factors signiﬁcantly associated with incident physical inactivity in the multi-adjusted model are shown in the table. ",
    "table_content": "|| blank | blank | No. of cases | Unadjusted | Unadjusted | Gender & age-adjusted | Gender & age-adjusted | Multi-adjusted | Multi-adjusted ||\n|| blank | blank | No. of cases | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p ||\n|| Dyslipidemia | No | 2758 | 1.00 | blank | 1.00 | blank | 1.00 | blank ||\n|| Dyslipidemia | Yes | 567 | 1.22 (1.11–1.33) | <0.0001 | 1.24 (1.13–1.36) | <0.0001 | 1.17 (1.06–1.28) | 0.001 ||\n|| Gender | Women | 773 | 1.00 | blank | 1.00 | blank | 1.00 | blank ||\n|| Gender | Men | 2552 | 0.96 (0.88–1.04) | 0.30 | 0.97 (0.89–1.05) | 0.42 | 0.87 (0.79–0.95) | 0.003 ||\n|| Hypertension | No | 3016 | 1.00 | blank | 1.00 | blank | 1.00 | blank ||\n|| Hypertension | Yes | 309 | 1.23 (1.10–1.39) | 0.0006 | 1.24 (1.10–1.40) | 0.0004 | 1.14 (1.01–1.28) | 0.04 ||\n|| Body mass index | Optimal | 1722 | 1.00 | blank | 1.00 | blank | 1.00 | blank ||\n|| Body mass index | Overweight | 1388 | 1.19 (1.11–1.28) | <0.0001 | 1.24 (1.15–1.34) | <0.0001 | 1.22 (1.13–1.32) | <0.0001 ||\n|| Body mass index | Obesity | 215 | 1.76 (1.52–2.02) | <0.0001 | 1.80 (1.56–2.08) | <0.0001 | 1.73 (1.49–2.00) | <0.0001 ||\n|| Smoking | Non-smoker | 1382 | 1.00 | blank | 1.00 | blank | 1.00 | blank ||\n|| Smoking | Ex-smoker | 1237 | 1.03 (0.96–1.11) | 0.42 | 1.05 (0.97–1.13) | 0.24 | 1.00 (0.92–1.08) | 0.93 ||\n|| Smoking | Smoker | 706 | 1.40 (1.28–1.53) | <0.0001 | 1.41 (1.29–1.55) | <0.0001 | 1.37 (1.25–1.50) | <0.0001 ||\n|| Depression | No | 2561 | 1.00 | blank | 1.00 | blank | 1.00 | blank ||\n|| Depression | Yes | 764 | 1.21 (1.11–1.31) | <0.0001 | 1.21 (1.11–1.31) | <0.0001 | 1.17 (1.07–1.27) | 0.0003 ||",
    "claim": "The risk of physical inactivity for individuals with obesity is approximately 73% higher in the multi-adjusted model compared to those with an optimal BMI. This is derived from the HR of 1.73 for obesity, indicating a substantial increase in risk.",
    "label": "support"
  },
  {
    "id": "training_408_3",
    "table_caption": "Table: Quantification of the Lumen and Intimal Thickness of the Carotid In Normal, Untreated and PPS Treated MPS I Dogs. Left Carotid Right Carotid Lumen (μm) Thickness (μm) Lumen (μm) Thickness (μm) Normal 72.5 (69.9–75.9) 73.1 (70.2–77.3) 91.9 (84.2–94.6) 79.9 (77.5–87.1) Untreated 33.3 (29.9–37.7) 146.7 (108.8–192.7) 61.8 (54.3–64.1) 110.0 (101.5–137.9) Oral PPS 75.1*(70.1–78.1) 91.8* (86.7–95.9) 85.3* (79.7–89.1) 91.1* (89.1–93.2) SQ PPS 80.3*# (74.6–80.1) 79.0*#(73.7–92.4) 90.1*# (87.4–93.9) 83.8*# (79.9–89.9) *P<0.01 when comparing untreated to PPS treated animals. There is also a signiﬁcant effect when comparing oral to SQ treatment #P<0.01. Ranges shown in (). ",
    "table_content": "|| blank | Left Lumen (μm) | Carotid Thickness (μm) | Right Lumen (μm) | Carotid Thickness (μm) ||\n|| blank | Left Lumen (μm) | Carotid Thickness (μm) | Right Lumen (μm) | Carotid Thickness (μm) ||\n|| Normal | 72.5 (69.9–75.9) | 73.1 (70.2–77.3) | 91.9 (84.2–94.6) | 79.9 (77.5–87.1) ||\n|| Untreated | 33.3 (29.9–37.7) | 146.7 (108.8–192.7) | 61.8 (54.3–64.1) | 110.0 (101.5–137.9) ||\n|| Oral PPS | 75.1 * (70.1–78.1) | 91.8 * (86.7–95.9) | 85.3 * (79.7–89.1) | 91.1 * (89.1–93.2) ||\n|| SQ PPS | 80.3 * # (74.6–80.1) | 79.0 * # (73.7–92.4) | 90.1 * # (87.4–93.9) | 83.8 * # (79.9–89.9) ||",
    "claim": "Subcutaneous PPS treatment results in a lumen size that is approximately 6% larger than that achieved with oral PPS treatment, indicating a more effective restoration of the lumen size towards normal levels.",
    "label": "support"
  },
  {
    "id": "training_611_4",
    "table_caption": "Table: Table 5 The multiple logistic regression for the relationship between POA and main IVF outcomes in each age group <33 years 33 ~ 37 years 38 ~ 41 years B P OR (95 % CI) B P OR (95 % CI) B P OR (5 % CI) Age 0.048 0.181 1.049(0.978–1.125) −0.069 0.348 0.933(0.807–1.079) −0.375 0.114 0.687(0.431–1.095) BMI −0.185 0.000 0.831(0.776–0.891) −0.090 0.006 0.914(0.857–0.975) −0.125 0.193 0.882(0.730–1.065) AFC −0.019 0.268 0.981(0.949–1.015) −0.032 0.086 0.969(0.934–1.004) −0.050 0.384 0.951(0.850–1.064) Number of retrieved oocytes −0.043 0.002 0.958(0.933–0.984) −0.015 0.348 0.985(0.954–1.017) −0.036 0.489 0.965(0.872–1.068) Total dose of Gna 0.283 <0.001 1.328(1.140–1.546) 0.428 <0.001 1.535(1.285–1.834) 0.662 0.006 1.939(1.212–3.102) aGn are transformed into ordinal variable according to the median (25–75th percentile) ",
    "table_content": "|| blank | <33 years | <33 years | <33 years | 33 ~ 37 years | 33 ~ 37 years | 33 ~ 37 years | 38 ~ 41 years | 38 ~ 41 years | 38 ~ 41 years ||\n|| blank | B |  P  | OR (95 % CI) | B |  P  | OR (95 % CI) | B |  P  | OR (5 % CI) ||\n|| Age | 0.048 | 0.181 | 1.049(0.978–1.125) | −0.069 | 0.348 | 0.933(0.807–1.079) | −0.375 | 0.114 | 0.687(0.431–1.095) ||\n|| BMI | −0.185 | 0.000 | 0.831(0.776–0.891) | −0.090 | 0.006 | 0.914(0.857–0.975) | −0.125 | 0.193 | 0.882(0.730–1.065) ||\n|| AFC | −0.019 | 0.268 | 0.981(0.949–1.015) | −0.032 | 0.086 | 0.969(0.934–1.004) | −0.050 | 0.384 | 0.951(0.850–1.064) ||\n|| Number of retrieved oocytes | −0.043 | 0.002 | 0.958(0.933–0.984) | −0.015 | 0.348 | 0.985(0.954–1.017) | −0.036 | 0.489 | 0.965(0.872–1.068) ||\n|| Total dose of Gn a  | 0.283 | <0.001 | 1.328(1.140–1.546) | 0.428 | <0.001 | 1.535(1.285–1.834) | 0.662 | 0.006 | 1.939(1.212–3.102) ||",
    "claim": "The odds ratio for the number of retrieved oocytes is lowest in the <33 years group, indicating that the number of oocytes retrieved has a more substantial impact on IVF success in younger women. This aligns with the understanding that younger women typically have a higher ovarian reserve, making the number of oocytes a critical factor.",
    "label": "support"
  },
  {
    "id": "training_184_1",
    "table_caption": "Table: Table 4 Base case and sensitivity analysis results Parameter Value Deaths Averted Life Years Saved (Millions) Cost (Savings) (Billions) Cost Per Life Year Saved Non-Pandemic Base Case 76714 2.50 30.67 12281 (US$1899) Vaccine Coverage Low 75 % 76209 2.46 24.75 10072 (US$1558) High 95 % 77220 2.54 36.85 14525 (US$2247) Vaccine Price Low (-10 %) 774 76714 2.50 26.40 10572 (US$1635) High (+10 %) 946 76714 2.50 34.94 13991 (US$2164) Herd Effect Reduced by 50 % 41195 1.47 36.17 24549 (US$3797) Disease Incidence Low (-10 %) 69167 2.25 31.90 14158 (US$2190) High (+10 %) 84524 2.75 29.40 10676 (US$1651) Case Fatality Rate Low (-10 %) 69063 2.25 30.67 13640 (US$2109) High (+10 %) 84411 2.75 30.67 11160 (US$1726) Pandemic Base Case 707526 34.43 (41.03) Dominant Vaccine Coverage Low 75 % 702582 34.03 (46.88) Dominant High 95 % 712470 34.82 (34.93) Dominant Vaccine Price Low (-10 %) 774 707526 34.43 (45.30) Dominant High (+10 %) 946 707526 34.43 (36.76) Dominant Herd Effect Reduced by 50 % 384613 19.65 (0.48) Dominant Disease Incidence Low (-10 %) 641668 31.23 (33.21) Dominant High (+10 %) 782365 38.09 (50.06) Dominant Case Fatality Rate Low (-10 %) 637577 31.02 (41.03) Dominant High (+10 %) 779261 37.92 (41.03) Dominant All values measured in 2011 Chinese Yuan July 2011 exchange rate, US$ = ¥6.465 [11] ",
    "table_content": "|| Parameter | Value | Deaths Averted | Life Years Saved (Millions) | Cost (Savings) (Billions) | Cost Per Life Year Saved ||\n|| Non-Pandemic | Non-Pandemic | Non-Pandemic | Non-Pandemic | Non-Pandemic | Non-Pandemic ||\n|| Reduced by 50 % | blank | 41195 | 1.47 | 36.17 | 24549 (US$3797) ||\n|| Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence ||\n|| Low (-10 %) | blank | 69167 | 2.25 | 31.90 | 14158 (US$2190) ||\n|| High (+10 %) | blank | 84524 | 2.75 | 29.40 | 10676 (US$1651) ||\n|| Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate ||\n|| Low (-10 %) | blank | 69063 | 2.25 | 30.67 | 13640 (US$2109) ||\n|| High (+10 %) | blank | 84411 | 2.75 | 30.67 | 11160 (US$1726) ||\n|| Pandemic | Pandemic | Pandemic | Pandemic | Pandemic | Pandemic ||\n|| Base Case | blank | 707526 | 34.43 | (41.03) | Dominant ||\n|| Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage ||\n|| Base Case | blank | 76714 | 2.50 | 30.67 | 12281 (US$1899) ||\n|| Low | 75 % | 702582 | 34.03 | (46.88) | Dominant ||\n|| High | 95 % | 712470 | 34.82 | (34.93) | Dominant ||\n|| Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price ||\n|| Low (-10 %) | 774 | 707526 | 34.43 | (45.30) | Dominant ||\n|| High (+10 %) | 946 | 707526 | 34.43 | (36.76) | Dominant ||\n|| Herd Effect | Herd Effect | Herd Effect | Herd Effect | Herd Effect | Herd Effect ||\n|| Reduced by 50 % | blank | 384613 | 19.65 | (0.48) | Dominant ||\n|| Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence ||\n|| Low (-10 %) | blank | 641668 | 31.23 | (33.21) | Dominant ||\n|| High (+10 %) | blank | 782365 | 38.09 | (50.06) | Dominant ||\n|| Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage ||\n|| Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate ||\n|| Low (-10 %) | blank | 637577 | 31.02 | (41.03) | Dominant ||\n|| High (+10 %) | blank | 779261 | 37.92 | (41.03) | Dominant ||\n|| Low | 75 % | 76209 | 2.46 | 24.75 | 10072 (US$1558) ||\n|| High | 95 % | 77220 | 2.54 | 36.85 | 14525 (US$2247) ||\n|| Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price ||\n|| Low (-10 %) | 774 | 76714 | 2.50 | 26.40 | 10572 (US$1635) ||\n|| High (+10 %) | 946 | 76714 | 2.50 | 34.94 | 13991 (US$2164) ||\n|| Herd Effect | Herd Effect | Herd Effect | Herd Effect | Herd Effect | Herd Effect ||",
    "claim": "In the non-pandemic scenario, increasing vaccine coverage from 75% to 95% results in an increase in deaths averted by approximately 1.33% and an increase in cost savings by 48.9%. This demonstrates the economic and health benefits of higher vaccine coverage.",
    "label": "support"
  },
  {
    "id": "training_1258_1",
    "table_caption": "Table: Positive changes as a result of the information. Professional groups Overall (N = 523) Physicians (N = 258) Residents (N = 50) Nurses (N = 215) Changes reported Category N %� N %� N %� N %� Choice of test Yes 254 (48.6%) 189 (73.3%) 37 (74.0%) 28 (13.0%) Diagnosis Yes 213 (40.7%) 163 (63.2%) 33 (66.0%) 17 (7.9%) Changed advice given to patient Yes 200 (38.2%) 59 (22.9%) 7 (14.0%) 134 (62.3%) Choice of drugs Yes 145 (27.7%) 98 (38.0%) 18 (36.0%) 29 (13.5%) Choice of treatments Yes 109 (20.8%) 84 (32.6%) 15 (30.0%) 10 (4.7%) Post-hospital care or treatment Yes 103 (19.7%) 18 (7.0%) 4 (8.0%) 81 (37.7%) Other Yes 41 (7.8%) 6 (2.3%) 0 (0.0%) 35 (16.3%) Length of stay (reduced) Yes 21 (4.0%) 14 (5.4%) 4 (8.0%) 3 (1.4%) Respondents were able to select all that applied. The top five items are colored in yellow (first), green (second), blue (third), purple (fourth), and pink (fifth). � The denominator of the percentage is the number of each group. ",
    "table_content": "|| Changes reported | Category | blank | blank | Professional groups | Professional groups | Professional groups | Professional groups | Professional groups | Professional groups ||\n|| Changes reported | Category | Overall (N = 523) | Overall (N = 523) | Physicians (N = 258) | Physicians (N = 258) | Residents (N = 50) | Residents (N = 50) | Nurses (N = 215) | Nurses (N = 215) ||\n|| Length of stay (reduced) | Yes | 21 | (4.0%) | 14 | (5.4%) | 4 | (8.0%) | 3 | (1.4%) ||\n|| Changes reported | Category | N | % * | N | % * | N | % * | N | % * ||\n|| Choice of test | Yes | 254 | (48.6%) | 189 | (73.3%) | 37 | (74.0%) | 28 | (13.0%) ||\n|| Diagnosis | Yes | 213 | (40.7%) | 163 | (63.2%) | 33 | (66.0%) | 17 | (7.9%) ||\n|| Changed advice given to patient | Yes | 200 | (38.2%) | 59 | (22.9%) | 7 | (14.0%) | 134 | (62.3%) ||\n|| Choice of drugs | Yes | 145 | (27.7%) | 98 | (38.0%) | 18 | (36.0%) | 29 | (13.5%) ||\n|| Choice of treatments | Yes | 109 | (20.8%) | 84 | (32.6%) | 15 | (30.0%) | 10 | (4.7%) ||\n|| Post-hospital care or treatment | Yes | 103 | (19.7%) | 18 | (7.0%) | 4 | (8.0%) | 81 | (37.7%) ||\n|| Other | Yes | 41 | (7.8%) | 6 | (2.3%) | 0 | (0.0%) | 35 | (16.3%) ||",
    "claim": "The percentage of physicians reporting changes in the choice of tests is approximately 5.6 times higher than that of nurses, indicating a substantial disparity in how information influences test selection between these groups.",
    "label": "support"
  },
  {
    "id": "training_616_4",
    "table_caption": "Table: Image Criteria Supporting Measurements Preferrable System CBCT FBCT Spatial Resolution MTF x Noise in Image SNR, Water Equivalent Std Dev x Low Contrast Resolution Low Constrast Visibility x Uniformity Image Artifacts C- Value Uniformity Index x Anatomic Visualization UI, head phantom reconstruction, C Value x Dose to Patient Effective Dose, Absorbed dose to patient x ",
    "table_content": "|| Image\nCriteria | Supporting Measurements | Preferrable System | Preferrable System ||\n|| Image\nCriteria | Supporting Measurements | CBCT | FBCT ||\n|| Spatial Resolution | MTF | x | blank ||\n|| Noise in Image | SNR, Water\nEquivalent Std Dev | blank | x ||\n|| Low Contrast Resolution | Low Constrast\nVisibility | blank | x ||\n|| Uniformity Image Artifacts | C- Value\nUniformity Index | blank | x ||\n|| Anatomic Visualization | UI, head phantom\nreconstruction, C Value | blank | x ||\n|| Dose to Patient | Effective Dose, Absorbed dose to patient | blank | x ||",
    "claim": "The FBCT system is preferred for uniformity image artifacts, as indicated by the C-Value Uniformity Index. This implies that FBCT provides more uniform images with fewer artifacts, which is essential for accurate diagnosis and treatment planning.",
    "label": "support"
  },
  {
    "id": "training_738_2",
    "table_caption": "Table: The the cell, the (Figure 4) for the wildtype (wt) RPS17B intron and Libri et al.'s [8] intron mutants. mutant base-pairing probability splicing efficiency wt 0.40 efficient 3mUB1 0.33 slightly reduced 5mUB1 0.31 slightly reduced 8mUB1 0.34 efficient 3mDB1 0.01 inhibited 5mDB1 < 0.01 inhibited 3mUB1_3mDB1 0.01 inhibited 5mUB1_5mDB1 0.11 slightly reduced 6mUB1 0.05 inhibited 4mUB1 0.18 reduced ",
    "table_content": "|| mutant | base-pairing probability | splicing efficiency ||\n|| wt | 0.40 | efficient ||\n|| 4mUB1 | 0.18 | reduced ||\n|| 3mUB1 | 0.33 | slightly reduced ||\n|| 5mUB1 | 0.31 | slightly reduced ||\n|| 8mUB1 | 0.34 | efficient ||\n|| 3mDB1 | 0.01 | inhibited ||\n|| 5mDB1 | < 0.01 | inhibited ||\n|| 3mUB1_3mDB1 | 0.01 | inhibited ||\n|| 5mUB1_5mDB1 | 0.11 | slightly reduced ||\n|| 6mUB1 | 0.05 | inhibited ||",
    "claim": "A base-pairing probability below 0.20 is associated with inhibited splicing efficiency, as seen in mutants like 3mDB1, 5mDB1, and 6mUB1. Conversely, probabilities above 0.30 generally correspond to slightly reduced or efficient splicing, as observed in 3mUB1, 5mUB1, and 8mUB1.",
    "label": "support"
  },
  {
    "id": "training_824_1",
    "table_caption": "Table: Human model reconstructions and their usage in cancer metabolism. The table describes the size of the different reconstructions and their specific application in the study of different cancer cells and tissues. Human model reconstruction Size Cancer type Application References Genes Reactions Metabolites Recon 1 (Duarte et al, 2007) 1,905 3,742 2,766 Generic Studying the association between cell proliferation and the Warburg effect Shlomi et al (2011) Generic Pathway contribution to NADPH production in cancer Fan et al (2014) Generic Identification of cancer-selective drug targets Folger et al (2011) Generic Predicting combinations of anti-cancer drugs with minimal side effects Facchetti et al (2012) 26 tumor tissues Identifying cancer-specific metabolic pathways Wang et al (2012b) Liver cancer cell line Identifying P53-associated metabolic changes Goldstein et al (2013) The NCI-60 cell line collection Studying the association between cell proliferation and nutrients uptake rates Dolfi et al (2013) Breast cancer Studying the metabolic differences associated with tumor stage and type Jerby et al (2012) Clear cell renal cell carcinoma (ccRCC) Identifying synthetic lethal interaction in FH-deficient cells Frezza et al (2011b) The NCI-60 cell line collection Predicting drug-reaction interactions Li et al (2010) The NCI-60 cell line collection and breast/lung cancer clinical samples Personalized prediction of metabolic phenotypes and identification of selective drug targets Yizhak et al (2014a) The NCI-60 cell line collection Association of the Warburg effect with cell migration and identification of anti-migratory drug targets Yizhak et al (2014b) Hepatocellular carcinoma miRNA was simulated to predict their ability to reduce cancer cell growth Wu & Chan (2014) The Edinburgh Model (Ma et al, 2007) 2,322 2,823 2,671 Colon and breast cancer cell lines Metabolomic network correlations Kotze et al (2013) Recon 2 (Thiele et al, 2013) 2,194 7,440 5,063 Nine cancer types (TCGA/CCLE) Identification of oncometabolites (Nam et al, 2014) HMR (Mardinoglu et al, 2013a, 2014) 3,668 8,181 9,311 16 cancer tissues Identifying cancer-specific metabolic features (Agren et al, 2012) Breast, bladder, liver, lung and renal cancer Topological analysis of ccRCC-specific metabolic processes Gatto et al (2014) Hepatocellular carcinoma Personalized model reconstruction and selective drug target identification Agren et al (2014) 15 cancer cell types Studying the topological features of anti-cancer metabolic drugs Asgari et al (2013) ",
    "table_content": "|| Human model reconstruction | Size | Size | Size | Cancer type | Application | References ||\n|| Human model reconstruction | Genes | Reactions | Metabolites | Cancer type | Application | References ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | Clear cell renal cell carcinoma (ccRCC) | Identifying synthetic lethal interaction in FH-deficient cells | Frezza et al ( 2011b ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | The NCI-60 cell line collection | Predicting drug-reaction interactions | Li et al ( 2010 ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | The NCI-60 cell line collection and breast/lung cancer clinical samples | Personalized prediction of metabolic phenotypes and identification of selective drug targets | Yizhak et al ( 2014a ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | The NCI-60 cell line collection | Association of the Warburg effect with cell migration and identification of anti-migratory drug targets | Yizhak et al ( 2014b ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | Hepatocellular carcinoma | miRNA was simulated to predict their ability to reduce cancer cell growth | Wu & Chan ( 2014 ) ||\n|| The Edinburgh Model (Ma et al , 2007 ) | 2,322 | 2,823 | 2,671 | Colon and breast cancer cell lines | Metabolomic network correlations | Kotze et al ( 2013 ) ||\n|| Recon 2 (Thiele et al , 2013 ) | 2,194 | 7,440 | 5,063 | Nine cancer types (TCGA/CCLE) | Identification of oncometabolites | (Nam et al , 2014 ) ||\n|| HMR (Mardinoglu et al , 2013a , 2014 ) | 3,668 | 8,181 | 9,311 | 16 cancer tissues | Identifying cancer-specific metabolic features | (Agren et al , 2012 ) ||\n|| HMR (Mardinoglu et al , 2013a , 2014 ) | 3,668 | 8,181 | 9,311 | Breast, bladder, liver, lung and renal cancer | Topological analysis of ccRCC-specific metabolic processes | Gatto et al ( 2014 ) ||\n|| HMR (Mardinoglu et al , 2013a , 2014 ) | 3,668 | 8,181 | 9,311 | Hepatocellular carcinoma | Personalized model reconstruction and selective drug target identification | Agren et al ( 2014 ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | Generic | Studying the association between cell proliferation and the Warburg effect | Shlomi et al ( 2011 ) ||\n|| HMR (Mardinoglu et al , 2013a , 2014 ) | 3,668 | 8,181 | 9,311 | 15 cancer cell types | Studying the topological features of anti-cancer metabolic drugs | Asgari et al ( 2013 ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | Generic | Pathway contribution to NADPH production in cancer | Fan et al ( 2014 ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | Generic | Identification of cancer-selective drug targets | Folger et al ( 2011 ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | Generic | Predicting combinations of anti-cancer drugs with minimal side effects | Facchetti et al ( 2012 ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | 26 tumor tissues | Identifying cancer-specific metabolic pathways | Wang et al ( 2012b ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | Liver cancer cell line | Identifying P53-associated metabolic changes | Goldstein et al ( 2013 ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | The NCI-60 cell line collection | Studying the association between cell proliferation and nutrients uptake rates | Dolfi et al ( 2013 ) ||\n|| Recon 1 (Duarte et al , 2007 ) | 1,905 | 3,742 | 2,766 | Breast cancer | Studying the metabolic differences associated with tumor stage and type | Jerby et al ( 2012 ) ||",
    "claim": "The HMR model, with its extensive size, encompasses 3,668 genes, 8,181 reactions, and 9,311 metabolites, which is approximately 1.5 times larger in terms of reactions and 2.5 times larger in terms of metabolites compared to the Recon 1 model. This suggests a broader scope for metabolic pathway analysis in cancer research.",
    "label": "support"
  },
  {
    "id": "training_59_2",
    "table_caption": "Table: and for (EC50) determined in embryonic zebraﬁsh following 5-day exposure to the various types of nanoparticles Material EC50 Gold-TMAT (2 nm)-as synthesized 0.2 Gold-TMAT (0.8 nm) 1.3 G3 PAMAM dendrimer—amine 1.7 Gold-TMAT (2 nm)-pure 1.9 G5 PAMAM dendrimer—amine 4.3 Gold—phosphatidylcholine (14 nm) 6.2 G4 PAMAM dendrimer—amine 6.2 Silver—citrate (10 nm) 7.4 Gold-TMAT (2 nm)-ultrapure 8.1 Gold—phosphatidylcholine (14 nm) 9.0 Gold—phosphatidylcholine (22 nm) 11.6 Silver/Gold—phosphate (68 nm) 12.2 G6 PAMAM dendrimer—amine 16.5 Gold-TMAT (2 nm)-ultrapure 16.7 Erbium Oxide (25 nm) 23.2 Silver/Gold—phosphate (92 nm) 23.7 Lead Sulﬁde—monothiol, oxidized (3 nm) 30.4 Gold—phosphatidylcholine (7 nm) 38.9 Samarium Oxide (25 nm) 41.7 Gold-MHA (10 nm) 48.2 Lead Sulﬁde—monothiol, unoxidized (3 nm) 51.9 Gold—phosphatidylcholine (7 nm) 53.7 Silver/Gold—phosphate (61 nm) 54.6 Silver/Gold—phosphate (70 nm) 56.6 Holmium oxide (25 nm) 61.3 Silver/Gold—phosphate (101 nm) 99.7 Silver/Gold—phosphate (122 nm) 103.5 Dysprosium oxide (25 nm) 158.5 Nanoparticles are listed from most to least toxic as is represented in Fig. 2 ",
    "table_content": "|| Material | EC 50  ||\n|| Gold-TMAT (2 nm)-as synthesized | 0.2 ||\n|| Gold—phosphatidylcholine (14 nm) | 9.0 ||\n|| Gold—phosphatidylcholine (22 nm) | 11.6 ||\n|| Silver/Gold—phosphate (68 nm) | 12.2 ||\n|| G6 PAMAM dendrimer—amine | 16.5 ||\n|| Gold-TMAT (2 nm)-ultrapure | 16.7 ||\n|| Erbium Oxide (25 nm) | 23.2 ||\n|| Silver/Gold—phosphate (92 nm) | 23.7 ||\n|| Lead Sulfide—monothiol, oxidized (3 nm) | 30.4 ||\n|| Gold—phosphatidylcholine (7 nm) | 38.9 ||\n|| Samarium Oxide (25 nm) | 41.7 ||\n|| Gold-TMAT (0.8 nm) | 1.3 ||\n|| Gold-MHA (10 nm) | 48.2 ||\n|| Lead Sulfide—monothiol, unoxidized (3 nm) | 51.9 ||\n|| Gold—phosphatidylcholine (7 nm) | 53.7 ||\n|| Silver/Gold—phosphate (61 nm) | 54.6 ||\n|| Silver/Gold—phosphate (70 nm) | 56.6 ||\n|| Holmium oxide (25 nm) | 61.3 ||\n|| Silver/Gold—phosphate (101 nm) | 99.7 ||\n|| Silver/Gold—phosphate (122 nm) | 103.5 ||\n|| Dysprosium oxide (25 nm) | 158.5 ||\n|| G3 PAMAM dendrimer—amine | 1.7 ||\n|| Gold-TMAT (2 nm)-pure | 1.9 ||\n|| G5 PAMAM dendrimer—amine | 4.3 ||\n|| Gold—phosphatidylcholine (14 nm) | 6.2 ||\n|| G4 PAMAM dendrimer—amine | 6.2 ||\n|| Silver—citrate (10 nm) | 7.4 ||\n|| Gold-TMAT (2 nm)-ultrapure | 8.1 ||",
    "claim": "Gold-TMAT (2 nm)-as synthesized has an EC50 value that is approximately 791.5 times lower than Dysprosium oxide (25 nm), demonstrating a significantly higher toxicity of the gold nanoparticle compared to the metal oxide.",
    "label": "support"
  },
  {
    "id": "training_751_6",
    "table_caption": "Table: dispar- search, Direct. recent Dutch- were termin- will reduce supple- of will for identify missed Table 2 BEME quality indicators (Buckley et al. [24]) Questions Research question Is the research question or hypothesis clearly stated? Study subjects Is the subject group appropriate for the study being carried out? Data collection methods Are the methods used appropriate for the research question and context? Completeness of data Attrition rates/acceptable questionnaire response rates Risk of bias assessment Is a statement of author positionality and a risk of bias assessment included? Analysis of results Are the statistical and other methods of results analysis used appropriate? Conclusions Is it clear that the data justify the conclusions drawn? Reproducibility Could the study be repeated by other researchers? Prospective Is the study prospective? Ethical issues Are all ethical issues articulated and managed appropriately? Triangulation Were results supported by data from more than one source? ",
    "table_content": "|| blank |  Questions  ||\n|| Research question | Is the research question or hypothesis clearly stated? ||\n|| Ethical issues | Are all ethical issues articulated and managed appropriately? ||\n|| Triangulation | Were results supported by data from more than one source? ||\n|| Study subjects | Is the subject group appropriate for the study being carried out? ||\n|| Data collection methods | Are the methods used appropriate for the research question and context? ||\n|| Completeness of data | Attrition rates/acceptable questionnaire response rates ||\n|| Risk of bias assessment | Is a statement of author positionality and a risk of bias assessment included? ||\n|| Analysis of results | Are the statistical and other methods of results analysis used appropriate? ||\n|| Conclusions | Is it clear that the data justify the conclusions drawn? ||\n|| Reproducibility | Could the study be repeated by other researchers? ||\n|| Prospective | Is the study prospective? ||",
    "claim": "The completeness of data is a critical factor in the reliability of research findings. This can be quantitatively assessed by analyzing attrition rates, response rates, and the extent of missing data. High completeness of data can increase the risk of bias and reduce the study's statistical power.",
    "label": "support"
  },
  {
    "id": "training_141_1",
    "table_caption": "Table: Bacterial strains and plasmids. Strain/Plasmid Genotype/Description Source Escherichia coli TG1 supE D(lac-proAB) thi hsdRD5 (F’ traD36 rpoA+B+ lacIqZDM15) Lab collection OmniMAX F9 {proAB+ lacIq lacZDM15 Tn10(Tetr) D (ccdAB)} mcrA D (mrr-hsdRMS-mcrBC) Q80(lacZ) DM15 D(lacZYA-argF) U169 endA1 recA1 supE44 thi-1 gyrA96 relA1 tonA panD Invitrogen SM10 (lpir) leu, tonA, lacY, supE, recA::RP4-2-Tc::Mu, Kmr, lpir Lab collection 1048 pRK2013, ColE1 ori tra+ mob+ Kmr. Helper strain for conjugation of plasmids Lab collection TOP10F’ F’ {lacIq Tn10 (Tetr)} mcrA D(mrr-hsdRMS-mcrBC) W80lacZDM15 Dlacx74 recA1 araD139 D(ara-leu)7697 galU galK rpsL (Strr) endA1 nupG Invitrogen CC118 (lpir) Host strain for pKNG101 replication Lab collection BL21(DE3) F¯ompTgal [dcm] [lon] hsdSB (r¯k m B¯) B strain with the DE3 propage carrying the T7 RNA polymerase gene Lab collection Pseudomonas aeruginosa PA14 Wild type [34] PAO1 Wild type Lab collection PA14::cupD1-lacZ Wild type with a cupD1-lacZ fusion integrated on the chromosome This study PA14DcupD PA14 with the entire cupD gene cluster deleted (cupD1-5) This study PA14DrcsB PA14 with a deletion in rcsB This study PA14DrcsC PA14 with a deletion in rcsC This study PA14DpvrR PA14 with a deletion in pvrR This study PA14DpvrS PA14 with a deletion in pvrS This study PA14::rcsC PA14 mutant (PA Mr-nr-mas-05-3) with a transposon insertion in rcsC [34] PA14::rcsB::cupD1-lacZ PA14 mutant (PA Mr-nr-mas-10-2) with a transposon insertion in rcsB and a cupD1-lacZ fusion integrated on the chromosome This study PA14::rcsC::cupD1-lacZ PA14 mutant (PA Mr-nr-mas-05-3) with a transposon insertion in rcsC and a cupD1-lacZ fusion integrated on the chromosome This study PA14::pvrR::cupD1-lacZ PA14 mutant (PA Mr-nr-mas-08-1) with a transposon insertion in pvrR and a cupD1-lacZ fusion integrated on the chromosome This study PA14::pvrS::cupD1-lacZ PA14 mutant (PA Mr-nr-mas-05-01) with a transposon insertion in pvrS and a cupD1-lacZ fusion integrated on the chromosome This study Plasmids pKNG101 Suicide vector for gene replacement in P. aeruginosa. SacB, Smr [48] pFLP2 Source of Flp recombinase, Apr. For unmarked integration into the P. aeruginosa chromosome. [49] pBBR-MCS-4 Broad host range vector, Apr [50] pBBR-MCS-4-pvrR pvrR cloned into pBBR-MCS-4 (SmaI) This study pBBR-MCS-5 Broad host range vector, Gmr [50] pBBR-MCS-5-rcsB rcsB cloned into pBBR-MCS-5 (HindIII/XbaI) This study pBBR-MCS-5-pvrR pvrR cloned into pBBR-MCS-5 (KpnI/XbaI) This study miniCTX-lacZ Vector for unmarked integration into P. aeruginosa att site. oriT, FRT, int, Tcr [29] miniCTX-cupD1-lacZ cupD1 promoter cloned into miniCTX-lacZ (SmaI) This study pCR2.1-TA TA cloning vector for PCR products. lacZ, ColE1 f1 ori Apr Kmr Invitrogen pCR2.1-cupD1-6H pCR2.1 carrying the cupD1 gene with an C-terminal hexahistidine tag (6H) This study doi:10.1371/journal.pone.0006018.t002 ",
    "table_content": "|| Strain/Plasmid | Genotype/Description | Source ||\n||  Escherichia coli  |  Escherichia coli  |  Escherichia coli  ||\n|| PA14 | Wild type |  [34]  ||\n|| PAO1 | Wild type | Lab collection ||\n|| PA14:: cupD1-lacZ  | Wild type with a cupD1-lacZ fusion integrated on the chromosome | This study ||\n|| PA14Δ cupD  | PA14 with the entire cupD gene cluster deleted ( cupD1-5 ) | This study ||\n|| PA14Δ rcsB  | PA14 with a deletion in rcsB  | This study ||\n|| PA14Δ rcsC  | PA14 with a deletion in rcsC  | This study ||\n|| PA14Δ pvrR  | PA14 with a deletion in pvrR  | This study ||\n|| PA14Δ pvrS  | PA14 with a deletion in pvrS  | This study ||\n|| PA14:: rcsC  | PA14 mutant (PA Mr-nr-mas-05-3) with a transposon insertion in rcsC  |  [34]  ||\n|| PA14:: rcsB :: cupD1-lacZ  | PA14 mutant (PA Mr-nr-mas-10-2) with a transposon insertion in rcsB and a cupD1-lacZ fusion integrated on the chromosome | This study ||\n|| TG1 |  supE Δ( lac-proAB ) thi hsdR Δ 5 (F' traD36 rpoA + B + lacI  q  Z ΔM15) | Lab collection ||\n|| PA14:: rcsC :: cupD1-lacZ  | PA14 mutant (PA Mr-nr-mas-05-3) with a transposon insertion in rcsC and a cupD1-lacZ fusion integrated on the chromosome | This study ||\n|| PA14:: pvrR :: cupD1-lacZ  | PA14 mutant (PA Mr-nr-mas-08-1) with a transposon insertion in pvrR and a cupD1-lacZ fusion integrated on the chromosome | This study ||\n|| PA14:: pvrS :: cupD1-lacZ  | PA14 mutant (PA Mr-nr-mas-05-01) with a transposon insertion in pvrS and a cupD1-lacZ fusion integrated on the chromosome | This study ||\n||  Plasmids  |  Plasmids  |  Plasmids  ||\n|| pKNG101 | Suicide vector for gene replacement in P. aeruginosa . SacB , Sm r  |  [48]  ||\n|| pFLP2 | Source of Flp recombinase, Ap r . For unmarked integration into the P. aeruginosa chromosome. |  [49]  ||\n|| pBBR-MCS-4 | Broad host range vector, Ap r  |  [50]  ||\n|| pBBR-MCS-4- pvrR  |  pvrR cloned into pBBR-MCS-4 (SmaI) | This study ||\n|| pBBR-MCS-5 | Broad host range vector, Gm r  |  [50]  ||\n|| pBBR-MCS-5- rcsB  |  rcsB cloned into pBBR-MCS-5 (HindIII/XbaI) | This study ||\n|| OmniMAX | F′ { proAB  +  lacI  q  lacZ ΔM15 Tn10( Tet  r ) Δ ( ccdAB )} mcrA Δ ( mrr-hsd RMS- mcr BC) ϕ80( lacZ ) ΔM15 Δ( lacZ YA- arg F) U169 end A1 rec A1 sup E44 thi -1 gyr A96 rel A1 ton A pan D | Invitrogen ||\n|| pBBR-MCS-5- pvrR  |  pvrR cloned into pBBR-MCS-5 (KpnI/XbaI) | This study ||\n|| miniCTX- lacZ  | Vector for unmarked integration into P. aeruginosa att site. oriT , FRT, int , Tc r  |  [29]  ||\n|| miniCTX- cupD1-lacZ  |  cupD1 promoter cloned into miniCTX-lacZ (SmaI) | This study ||\n|| pCR2.1-TA | TA cloning vector for PCR products. lacZ , ColE1 f1 ori Ap r Km r  | Invitrogen ||\n|| pCR2.1- cupD1 -6H | pCR2.1 carrying the cupD1 gene with an C-terminal hexahistidine tag (6H) | This study ||\n|| SM10 (λpir) |  leu , tonA , lacY , supE , recA::RP4-2-Tc::Mu, Km r , λpir | Lab collection ||\n|| 1048 | pRK2013, ColE1 ori tra + mob + Km r . Helper strain for conjugation of plasmids | Lab collection ||\n|| TOP10F' | F' { lacI  q Tn10 ( Tet  r )} mcrA Δ( mrr - hsd RMS- mcr BC) Φ80 lacZ ΔM15 Δ lac χ74 recA 1 araD 139 Δ( ara-leu )7697 galU galK rpsL (Str r ) endA 1 nupG  | Invitrogen ||\n|| CC118 (λpir) | Host strain for pKNG101 replication | Lab collection ||\n|| BL21(DE3) | F̅ ompTgal [ dcm ] [ lon ] hsdSB (r̅k m B̅) B strain with the DE3 propage carrying the T7 RNA polymerase gene | Lab collection ||\n||  Pseudomonas aeruginosa  |  Pseudomonas aeruginosa  |  Pseudomonas aeruginosa  ||",
    "claim": "The PA14 strain with a deletion in the cupD gene cluster (PA14ΔcupD) and the PA14 strain with a deletion in the cupD1-lacZ fusion (PA14::cupD1-lacZ) are both derived from the same study.",
    "label": "support"
  },
  {
    "id": "training_1243_6",
    "table_caption": "Table: These TAG mole- may in- im- health lipid thereby major were Table 1 Fat content and fatty acid composition of the diets High fat control Fish Oil (FO) Krill Oil (KO) Fat source (% in diet) Lard 21,3 % 15,7 % 15,6 % Soy oil 2,3 % 2,3 % 2,3 % Fish/krill oil 5,8 % 5,6 % Fatty acids (% of total fatty acids in diet) Total SFA 42,9 % 34,1 % 39,7 % Total MUFA 38,7 % 32,1 % 35,4 % Total ω6 16,4 % 14,5 % 14,6 % EPA 0,03 % 9,0 % 5,2 % DHA 0,05 % 6,4 % 2,3 % The content of EPA and DHA in the KO diet was about half of the FO diet ",
    "table_content": "|| blank | High fat control | Fish Oil (FO) | Krill Oil (KO) ||\n|| Fat source (% in diet) | Fat source (% in diet) | Fat source (% in diet) | Fat source (% in diet) ||\n|| DHA | 0,05 % | 6,4 % | 2,3 % ||\n|| Lard | 21,3 % | 15,7 % | 15,6 % ||\n|| Soy oil | 2,3 % | 2,3 % | 2,3 % ||\n|| Fish/krill oil | blank | 5,8 % | 5,6 % ||\n|| Fatty acids (% of total fatty acids in diet) | Fatty acids (% of total fatty acids in diet) | Fatty acids (% of total fatty acids in diet) | Fatty acids (% of total fatty acids in diet) ||\n|| Total SFA | 42,9 % | 34,1 % | 39,7 % ||\n|| Total MUFA | 38,7 % | 32,1 % | 35,4 % ||\n|| Total ω6 | 16,4 % | 14,5 % | 14,6 % ||\n|| EPA | 0,03 % | 9,0 % | 5,2 % ||",
    "claim": "The Fish Oil (FO) and Krill Oil (KO) diets have a combined fish/krill oil content that is approximately 1.5 times higher than the soy oil content in each respective diet, while the High fat control diet lacks this component entirely.",
    "label": "support"
  },
  {
    "id": "training_1145_6",
    "table_caption": "Table: Table 2 Mann-Whitney Test for non-parametric variables, according to presence of overweight (n = 74) or insulin resist- ance (n = 18) a Macrophage Chemoattractant Protein-1 b Interleukin-6 OW(+)IR(−) (mean-rank) OW(−)IR(+) (mean-rank) P value Age 49.88 32.61 0.014 Circumference Waist 53.05 19.58 <0.001 Abdominal 52.72 20.94 <0.001 Glycated hemoglobin 43.86 54.67 0.120 Cytokines C reactive protein 47.80 41.17 0.345 MCP-1a 43.34 59.50 0.021 IL-6b 43.42 59.17 0.025 Resistin 44.95 52.89 0.258 Adiponectin 43.95 56.97 0.063 PAI-1c 46.41 46.86 0.949 ",
    "table_content": "|| blank | OW(+)IR(−) (mean-rank) | OW(−)IR(+) (mean-rank) | P value ||\n|| Age | 49.88 | 32.61 |  0.014  ||\n|| Resistin | 44.95 | 52.89 | 0.258 ||\n|| Adiponectin | 43.95 | 56.97 |  0.063  ||\n|| PAI-1 c  | 46.41 | 46.86 | 0.949 ||\n||  Circumference  |  Circumference  |  Circumference  |  Circumference  ||\n|| Waist | 53.05 | 19.58 |  <0.001  ||\n|| Abdominal | 52.72 | 20.94 |  <0.001  ||\n|| Glycated hemoglobin | 43.86 | 54.67 |  0.120  ||\n|| Cytokines | Cytokines | Cytokines | Cytokines ||\n|| C reactive protein | 47.80 | 41.17 | 0.345 ||\n|| MCP-1 a  | 43.34 | 59.50 |  0.021  ||\n|| IL-6 b  | 43.42 | 59.17 |  0.025  ||",
    "claim": "The mean ranks for PAI-1 are nearly identical between the two groups, with a p-value of 0.949, indicating no significant difference in PAI-1 levels between individuals with overweight but without insulin resistance and those without overweight but with insulin resistance.",
    "label": "support"
  },
  {
    "id": "training_783_2",
    "table_caption": "Table: Effect of chronic exposure to two types of gasoline vapour on the contents of lipid peroxidation, reduced glutathione and superoxide dismutase activity of cerebral cortex in male rats. GROUP Parameter Control Leaded gasoline Unleaded gasoline Lipid peroxidation (MAD) nmol/gwet tissue 4.35 ± 0.79 4.456 ± 0.71 6.57 ± 1.37 a** b** Reduced glutathione (GSH) mgGSH/g wet tissue 5.834 ± 0.76 3.635 ± 0.43 a*** 4.7 ± 0.86 a* b* Superoxide dismutase (SOD) Unit/g wet tissue 267.26 ± 18.46 253.79 ± 14.74 192.56 ± 19.78 a*** b*** Values are expressed as means ± SD a: significantly different from the control group. ",
    "table_content": "|| Parameter | GROUP | GROUP | GROUP ||\n|| Parameter | Control | Leaded gasoline | Unleaded gasoline ||\n|| Lipid peroxidation (MAD) nmol/gwet tissue | 4.35 ± 0.79 | 4.456 ± 0.71 | 6.57 ± 1.37 a** b** ||\n|| Reduced glutathione (GSH) mgGSH/g wet tissue | 5.834 ± 0.76 | 3.635 ± 0.43 a*** | 4.7 ± 0.86 a* b* ||\n|| Superoxide dismutase (SOD) Unit/g wet tissue | 267.26 ± 18.46 | 253.79 ± 14.74 | 192.56 ± 19.78 a*** b*** ||",
    "claim": "The reduction in glutathione levels in the leaded gasoline group is approximately 38% compared to the control, suggesting a significant depletion of antioxidant defenses.",
    "label": "support"
  },
  {
    "id": "training_993_1",
    "table_caption": "Table: Cell Targeting vector HDR template Mutation TA colonies Mutation efficiency HDR efficiency (%) Erhualian PFFs sgRNA#1 – 17 78 21.79% – Erhualian PFFs sgRNA#2 – 10 80 12.50% – Erhualian PFFs sgRNA#1 ssDNA-85 19 55 34.55% 2/55(3.64%) Table 1. Comparison of the mutation efficiency induced by sgRNA alone or sgRNA + HDR template. ",
    "table_content": "|| Cell | Targeting vector | HDR template | Mutation | TA colonies | Mutation efficiency | HDR efficiency (%) ||\n|| Erhualian PFFs | sgRNA#1 | – | 17 | 78 | 21.79% | – ||\n|| Erhualian PFFs | sgRNA#2 | – | 10 | 80 | 12.50% | – ||\n|| Erhualian PFFs | sgRNA#1 | ssDNA-85 | 19 | 55 | 34.55% | 2/55(3.64%) ||",
    "claim": "The mutation efficiency of sgRNA#1 without an HDR template is 74.32% higher than that of sgRNA#2, indicating a substantial difference in the effectiveness of these sgRNAs in inducing mutations in the absence of an HDR template.",
    "label": "support"
  },
  {
    "id": "training_1111_5",
    "table_caption": "Table: Table 1 Prevalence (%) and intensity of intestinal helminths infection among 403 school-age children in Tikur Wuha Elementary School, northwestern Ethiopia, 2011 Variables Number examined Hookworm S. mansoni A. lumbricoides T. trichiura Othersa Any helminth Age (years) 5-10 146 50.0 21.3 4.8 2.1 4.1 54.8 11-15 257 45.1 26.5 3.9 1.6 0.8 60.3 Total 403 46.9 24.6 4.2 1.7 2.0 58.3 Sex Female 216 47.2 19.9 4.6 1.9 2.3 55.6 Male 187 46.5 29.9 3.7 1.6 1.6 61.5 Intensity Light 290 100 79.8 94.1 8.6 Moderate 21 - 19.2 5.9 14.3 Heavy 1 - 1.0 - - Mean egg per gram 191.5 72.48 1205.6 634.3 Othersa = T. saginata or H. nana ",
    "table_content": "|| Variables | Number examined | Hookworm |  S. mansoni  |  A. lumbricoides  |  T. trichiura  | Others a  | Any helminth ||\n|| Age (years) | Age (years) | Age (years) | Age (years) | Age (years) | Age (years) | Age (years) | Age (years) ||\n|| Moderate | 21 | blank | 19.2 | 5.9 | 14.3 | blank | blank ||\n|| Heavy | 1 | blank | 1.0 | blank | blank | blank | blank ||\n|| Mean egg per gram | blank | 191.5 | 72.48 | 1205.6 | 634.3 | blank | blank ||\n|| 5-10 | 146 | 50.0 | 21.3 | 4.8 | 2.1 | 4.1 | 54.8 ||\n|| 11-15 | 257 | 45.1 | 26.5 | 3.9 | 1.6 | 0.8 | 60.3 ||\n|| Total | 403 | 46.9 | 24.6 | 4.2 | 1.7 | 2.0 | 58.3 ||\n|| Sex | Sex | Sex | Sex | Sex | Sex | Sex | Sex ||\n|| Female | 216 | 47.2 | 19.9 | 4.6 | 1.9 | 2.3 | 55.6 ||\n|| Male | 187 | 46.5 | 29.9 | 3.7 | 1.6 | 1.6 | 61.5 ||\n|| Intensity | Intensity | Intensity | Intensity | Intensity | Intensity | Intensity | Intensity ||\n|| Light | 290 | 100 | 79.8 | 94.1 | 8.6 | blank | blank ||",
    "claim": "The overall prevalence of any helminth infection is higher in males than in females. By calculating the difference in prevalence rates and considering the number of children in each sex category, the relative increase in overall prevalence among males compared to females is determined to be 10.6%.",
    "label": "support"
  },
  {
    "id": "training_647_5",
    "table_caption": "Table: and non-poor women, regardless of HIV status, were less Fertility desires and HIV status Table 4 Type of FP methods used in the last 12 months by HIV status Baseline Endline HIV-positive (N = 247) HIV-negative (N = 1,505) p value HIV-positive (N = 140) HIV-negative (N = 966) p value % (n) % (n) % (n) % (n) Hormonal pills 13 (32) 32 (485) <0.001 14 (19) 30 (294) <0.001 Injectables 36 (90) 59 (880) <0.001 41 (57) 45 (433) 0.360 Male condoms 41 (101) 1 (18) <0.001 26 (36) 2 (15) <0.001 IUCD 3 (8) 4 (55) 0.745 6 (9) 15 (140) 0.009 Implants 2 (6) 3 (51) 0.431 11 (15) 7 (67) 0.111 Female sterilization 2 (6) 0 (0) <0.001 3 (4) 1 (8) 0.030 ",
    "table_content": "|| blank | Baseline | Baseline | Baseline | Endline | Endline | Endline ||\n|| blank | HIV-positive ( N = 247) % (n) | HIV-negative ( N = 1,505) % (n) | p value | HIV-positive ( N = 140) % (n) | HIV-negative ( N = 966) % (n) | p value ||\n|| blank | HIV-positive ( N = 247) % (n) | HIV-negative ( N = 1,505) % (n) | p value | HIV-positive ( N = 140) % (n) | HIV-negative ( N = 966) % (n) | p value ||\n|| Hormonal pills | 13 (32) | 32 (485) | <0.001 | 14 (19) | 30 (294) | <0.001 ||\n|| Injectables | 36 (90) | 59 (880) | <0.001 | 41 (57) | 45 (433) | 0.360 ||\n|| Male condoms | 41 (101) | 1 (18) | <0.001 | 26 (36) | 2 (15) | <0.001 ||\n|| IUCD | 3 (8) | 4 (55) | 0.745 | 6 (9) | 15 (140) | 0.009 ||\n|| Implants | 2 (6) | 3 (51) | 0.431 | 11 (15) | 7 (67) | 0.111 ||\n|| Female sterilization | 2 (6) | 0 (0) | <0.001 | 3 (4) | 1 (8) | 0.030 ||",
    "claim": "The usage of implants among HIV-positive women increased by 450% from baseline to endline, indicating a dramatic rise in the adoption of this method over the period.",
    "label": "support"
  },
  {
    "id": "training_590_3",
    "table_caption": "Table: TABLE 2 | Intranasal insulin improves memory function. Subjects Intranasal insulin duration/dose Main result References Healthy humans 4 × 40 IU/day, for 8 weeks Intranasal intake of insulin enhanced long-term declarative memory and positively affected mood in humans without causing systemic side effects like hypoglycaemia. Benedict et al., 2004 Healthy humans 4 × 40 IU/day, for 8 weeks; insulin and rapid-acting insulin analog insulin aspart Declarative memory was improved in insulin and insulin aspart groups compared to placebo group without altering glucose levels. Insulin aspart treated subjects performed even better that those of insulin treated group Benedict et al., 2007 Healthy humans Single dose of regular human insulin 160 IU Hippocampus-dependent memory and working memory were improved in women where as men did not beneﬁt from acute insulin treatment Benedict et al., 2008; Krug et al., 2010 MCI and mild AD patients 20 or 40 IU of insulin acute treatment Acute intranasal insulin administration improved verbal memory in AD and MCI subjects without the APOE- ε4 allele Reger et al., 2006 MCI and AD patients 10, 20, 40, or 60 IU for 5 days 10, 20, and 40 IU of insulin improved declarative memory only in APOE-ε4 negative patients Memory facilitation generally peaked at the 20 IU dose ↑ Aβ42 levels for memory-impaired adults from saline to 10 IU regardless of APOE-ε4 status Intranasal insulin did not affect peripheral glucose or insulin levels Reger et al., 2008a MCI and AD patients 20 IU BID intranasal insulin treatment for 21 days Insulin-treated subjects retained more verbal information and improved attention and functional status Insulin treatment raised fasting plasma Aβ40/Aβ42 ratio Reger et al., 2008b MCI and mild to moderate AD patients 20 or 40 IU for 4 months Treatment with 20 IU of insulin improved delayed memory Both dosages preserved caregiver-rated functional ability and general cognition Unchanged Aβ42 and tau levels after insulin treatment Craft et al., 2012 AD patients with ApoE4 allels Rapid acting insulin Rapid acting insulin failed to have an acute impact on cognition in ApoE4 carriers with AD Rosenbloom et al., 2014 MCI and mild AD patients 20 or 40 IU of insulin detemir for 21 days High dose (40 IU) improved visuospatial and verbal working memory for all participant High dose improved memory for adults with MCI and AD who were APOE-ε4 positive patients APOE-ε4 carriers taking high dose also improved peripheral insulin resistance APOE-ε4 negative patients taking high dose experiences increased peripheral insulin resistance Claxton et al., 2015 S.D. rats—streptozotocin induced AD model 5 IU for 6 days Insulin administration signiﬁcantly reduced the Aβ levels without altering peripheral glucose levels Subramanian and John, 2012 Streptozotocin induced-rat model of type 2 diabetes 2U insulin intranasally/4 weeks 6.7 U/kg (s.c.)/4 weeks Decreased Akt activation and increased tau phosphorylation and GSK-3β activation was found in T2D rat brains. Intranasal insulin treatment normalized Akt and GSK-3β and reduced tau phosphorylation in diabetic rats s.c. insulin had minimal effect of tau phosphorylation and GSK-3β Yang et al., 2013 3 × Tg-AD mice 1.75 U/7 days Intranasal insulin administration restored insulin signaling, ↑ synaptic proteins, and ↓ Aβ40 level and microglia activation in the brains of 3 × Tg-AD mice. Glucose transporters and tau-phosphorylation is unchanged Chen et al., 2014c 3 × Tg-AD mice 1.75 U/7 days Propofol 250 mg/kg (i.p.) Insulin treatment attenuated propofol-induced hyperphosphorylation of tau, promoted brain insulin signaling. Resulted in down-regulation of several tau protein kinases, including cyclin-dependent protein kinase 5, calcium/calmodulin-dependent protein kinase II, and c-JunN-terminal kinase and up-regulation of protein phosphatase 2A Chen et al., 2014b ",
    "table_content": "|| Subjects | Intranasal insulin duration/dose | Main result | References ||\n|| Healthy humans | 4 × 40 IU/day, for 8 weeks | Intranasal intake of insulin enhanced long-term declarative memory and positively affected mood in humans without causing systemic side effects like hypoglycaemia. | Benedict et al., 2004 ||\n|| S.D. rats—streptozotocin induced AD model | 5 IU for 6 days | Insulin administration significantly reduced the Aβ levels without altering peripheral glucose levels | Subramanian and John, 2012 ||\n|| Streptozotocin induced-rat model of type 2 diabetes | 2U insulin intranasally/4 weeks 6.7 U/kg (s.c.)/4 weeks | Decreased Akt activation and increased tau phosphorylation and GSK-3β activation was found in T2D rat brains. Intranasal insulin treatment normalized Akt and GSK-3β and reduced tau phosphorylation in diabetic rats s.c. insulin had minimal effect of tau phosphorylation and GSK-3β | Yang et al., 2013 ||\n|| 3 × Tg-AD mice | 1.75 U/7 days | Intranasal insulin administration restored insulin signaling, ↑ synaptic proteins, and ↓ Aβ40 level and microglia activation in the brains of 3 × Tg-AD mice. Glucose transporters and tau-phosphorylation is unchanged | Chen et al., 2014c ||\n|| 3 × Tg-AD mice | 1.75 U/7 days Propofol 250 mg/kg (i.p.) | Insulin treatment attenuated propofol-induced hyperphosphorylation of tau, promoted brain insulin signaling. Resulted in down-regulation of several tau protein kinases, including cyclin-dependent protein kinase 5, calcium/calmodulin-dependent protein kinase II, and c-JunN-terminal kinase and up-regulation of protein phosphatase 2A | Chen et al., 2014b ||\n|| Healthy humans | 4 × 40 IU/day, for 8 weeks; insulin and rapid-acting insulin analog insulin aspart | Declarative memory was improved in insulin and insulin aspart groups compared to placebo group without altering glucose levels. Insulin aspart treated subjects performed even better that those of insulin treated group | Benedict et al., 2007 ||\n|| Healthy humans | Single dose of regular human insulin 160 IU | Hippocampus-dependent memory and working memory were improved in women where as men did not benefit from acute insulin treatment | Benedict et al., 2008 ; Krug et al., 2010 ||\n|| MCI and mild AD patients | 20 or 40 IU of insulin acute treatment | Acute intranasal insulin administration improved verbal memory in AD and MCI subjects without the APOE- ε 4 allele | Reger et al., 2006 ||\n|| MCI and AD patients | 10, 20, 40, or 60 IU for 5 days | 10, 20, and 40 IU of insulin improved declarative memory only in APOE-ε 4 negative patients Memory facilitation generally peaked at the 20 IU dose ↑ Aβ42 levels for memory-impaired adults from saline to 10 IU regardless of APOE-ε 4 status Intranasal insulin did not affect peripheral glucose or insulin levels | Reger et al., 2008a ||\n|| MCI and AD patients | 20 IU BID intranasal insulin treatment for 21 days | Insulin-treated subjects retained more verbal information and improved attention and functional status Insulin treatment raised fasting plasma Aβ 40 /Aβ 42 ratio | Reger et al., 2008b ||\n|| MCI and mild to moderate AD patients | 20 or 40 IU for 4 months | Treatment with 20 IU of insulin improved delayed memory Both dosages preserved caregiver-rated functional ability and general cognition Unchanged Aβ 42 and tau levels after insulin treatment | Craft et al., 2012 ||\n|| AD patients with ApoE4 allels | Rapid acting insulin | Rapid acting insulin failed to have an acute impact on cognition in ApoE4 carriers with AD | Rosenbloom et al., 2014 ||\n|| MCI and mild AD patients | 20 or 40 IU of insulin detemir for 21 days | High dose (40 IU) improved visuospatial and verbal working memory for all participant High dose improved memory for adults with MCI and AD who were APOE-ε 4 positive patients APOE-ε 4 carriers taking high dose also improved peripheral insulin resistance APOE-ε 4 negative patients taking high dose experiences increased peripheral insulin resistance | Claxton et al., 2015 ||",
    "claim": "A single dose of 160 IU of regular human insulin enhances hippocampus-dependent memory and working memory in women but not in men, as deduced from a comparative analysis of memory performance metrics, highlighting a gender-specific differential response to acute insulin treatment.",
    "label": "support"
  },
  {
    "id": "training_911_5",
    "table_caption": "Table: Morphometric characters of Channa diplogramma and C. micropeltes. Channa diplogramma Channa micropeltes Range Mean (sd) Range Mean (sd) Total length (mm) 107.24 (589.19) 312.45 (184.96) 338.93–654.93 502.30 (128.83) Standard length (mm) 85.40 (479.15) 251.65 (151.66) 290.87–564.22 415.14 (120.11) % SL Head Length (mm) 25.03 (35.37) 32.12 (2.82) 32.23–39.39 35.28 (2.64) Pre dorsal length (mm) 31.47 (38.75) 35.04 (2.53) 30.50–37.57 33.25 (2.63) Pre pectoral length (mm) 30.98 (38.77) 34.73 (3.26) 31.54–38.66 34.03 (3.06) Pre pelvic length (mm) 31.88 (42.16) 36.93 (3.41) 34.28–41.97 37.01 (2.91) Pre anal length (mm) 49.86 (60.25) 55.66 (3.42) 46.68–57.08 50.64 (3.88)* Body depth (mm) 14.16 (25.61) 19.48 (3.92) 22.54–26.58 24.35 (1.68)* % TL Standard length (mm) 77.14 (81.91) 79.95 (1.48) 72.42–86.15 82.29 (5.68) Head Length (mm) 20.36 (27.34) 25.66 (1.99) 27.76–30.21 28.93 (0.93)** Pre dorsal length (mm) 25.59 (30.86) 27.98 (1.61) 26.28–28.03 27.25 (0.64) Pre pectoral length (mm) 25.13 (30.87) 27.73 (2.23) 26.66–30.52 27.89 (1.55) Pre pelvic length (mm) 25.93 (32.52) 29.49 (2.28) 28.38–31.29 30.34 (1.17) Pre anal length (mm) 40.55 (47.98) 44.47 (2.23) 40.06–43.64 41.51 (1.31)* Body depth (mm) 11.27 (20.76) 15.60 (3.29) 17.62–22.40 20.05 (2.05)* *P,0.05. *P,0.01. ",
    "table_content": "|| blank |  Channa diplogramma  |  Channa diplogramma  |  Channa micropeltes  |  Channa micropeltes  ||\n|| blank | Range | Mean (sd) | Range | Mean (sd) ||\n||  Body depth (mm)  | 14.16 (25.61) | 19.48 (3.92) | 22.54–26.58 | 24.35 (1.68) *  ||\n||  % TL  |  % TL  |  % TL  |  % TL  |  % TL  ||\n||  Standard length (mm)  | 77.14 (81.91) | 79.95 (1.48) | 72.42–86.15 | 82.29 (5.68) ||\n||  Head Length (mm)  | 20.36 (27.34) | 25.66 (1.99) | 27.76–30.21 | 28.93 (0.93) **  ||\n||  Pre dorsal length (mm)  | 25.59 (30.86) | 27.98 (1.61) | 26.28–28.03 | 27.25 (0.64) ||\n||  Pre pectoral length (mm)  | 25.13 (30.87) | 27.73 (2.23) | 26.66–30.52 | 27.89 (1.55) ||\n||  Pre pelvic length (mm)  | 25.93 (32.52) | 29.49 (2.28) | 28.38–31.29 | 30.34 (1.17) ||\n||  Pre anal length (mm)  | 40.55 (47.98) | 44.47 (2.23) | 40.06–43.64 | 41.51 (1.31) *  ||\n||  Body depth (mm)  | 11.27 (20.76) | 15.60 (3.29) | 17.62–22.40 | 20.05 (2.05) *  ||\n||  Total length (mm)  | 107.24 (589.19) | 312.45 (184.96) | 338.93–654.93 | 502.30 (128.83) ||\n||  Standard length (mm)  | 85.40 (479.15) | 251.65 (151.66) | 290.87–564.22 | 415.14 (120.11) ||\n||  % SL  |  % SL  |  % SL  |  % SL  |  % SL  ||\n||  Head Length (mm)  | 25.03 (35.37) | 32.12 (2.82) | 32.23–39.39 | 35.28 (2.64) ||\n||  Pre dorsal length (mm)  | 31.47 (38.75) | 35.04 (2.53) | 30.50–37.57 | 33.25 (2.63) ||\n||  Pre pectoral length (mm)  | 30.98 (38.77) | 34.73 (3.26) | 31.54–38.66 | 34.03 (3.06) ||\n||  Pre pelvic length (mm)  | 31.88 (42.16) | 36.93 (3.41) | 34.28–41.97 | 37.01 (2.91) ||\n||  Pre anal length (mm)  | 49.86 (60.25) | 55.66 (3.42) | 46.68–57.08 | 50.64 (3.88) *  ||",
    "claim": "The standard length of Channa micropeltes, as a percentage of total length, is approximately 1.03 times greater than that of Channa diplogramma, indicating a slightly more elongated body form.",
    "label": "support"
  },
  {
    "id": "training_567_3",
    "table_caption": "Table: Summary of efficacy results (N = 50 in each group) Control Placebo M. × piperita M. spicata p value* Retching episodes 3.1 ± 1.3 7.2 ± 2.3 2.4 ± 2.4 3.8 ± 1.2 <0.0001 intensity of nausea 52.8 ± 20.7 14.6 ± 9.1 42.1 ± 22.7 43.9 ± 12.4 <0.0001 Vomiting episodes 1.1 ± 0.4 1.8 ± 0.9 0.7 ± 0.9 0.6 ± 0.3 <0.0001 difference between spearmint and peppermint in controlling emetic events and intensity of ",
    "table_content": "|| blank | Control | Placebo | M. × piperita | M. spicata | blank ||\n|| blank | blank | blank | blank | blank | p value* ||\n|| Retching episodes | 3.1 ± 1.3 | 7.2 ± 2.3 | 2.4 ± 2.4 | 3.8 ± 1.2 | <0.0001 ||\n|| intensity of nausea | 52.8 ± 20.7 | 14.6 ± 9.1 | 42.1 ± 22.7 | 43.9 ± 12.4 | <0.0001 ||\n|| Vomiting episodes | 1.1 ± 0.4 | 1.8 ± 0.9 | 0.7 ± 0.9 | 0.6 ± 0.3 | <0.0001 ||",
    "claim": "M. spicata reduces vomiting episodes by approximately 66.67% compared to the placebo group, while M. × piperita achieves a reduction of 61.11%. This suggests that M. spicata is slightly more effective than M. × piperita in reducing vomiting episodes.",
    "label": "support"
  },
  {
    "id": "training_1321_1",
    "table_caption": "Table: TaBle 3 | Demographical and clinical characteristics of patients evaluated by flow cytometry. active TB Pneumonia N 6 8 Age median (IQR) 46 (34–60) 51 (44–56) sex N (%) Female 5 (83.3) 7 (87.5) Origin N (%) West Europe 3 (50.0) 7 (87.5) East Europe 2 (33.3) – Asia 1 (16.7) – Africa – 1 (12.5) Bcg N (%) Vaccinated 3 (50.0) 1 (12.5) TsT N (%) Positive 3 (50.0) 3 (37.5) Negative 2 (33.3) 3 (37.5) Not done 1 (16.7) 2 (25.0) QFT N (%) Positive 3 (50.0) 2 (25.0) Negative 1 (16.7) 4 (50.0) Indeterminate 1 (16.7) – Not done 1 (16.7) 2 (25.0) TB diagnosis n (%) Microbiological 2 (33.3) – Clinical 4 (66.7) – N, number; TB, tuberculosis; BCG, bacillus Calmette-Guérin; IQR, interquartile range; QFT, QuantiFERON TB Gold In tube; TST, tuberculin skin test. DPP4 be lower (25, new Our opens 2 can ",
    "table_content": "|| blank | Active TB | Pneumonia ||\n|| N | 6 | 8 ||\n|| BCG N (%) | BCG N (%) | BCG N (%) ||\n|| Vaccinated | 3 (50.0) | 1 (12.5) ||\n|| TST N (%) | TST N (%) | TST N (%) ||\n|| Positive | 3 (50.0) | 3 (37.5) ||\n|| Negative | 2 (33.3) | 3 (37.5) ||\n|| Not done | 1 (16.7) | 2 (25.0) ||\n|| QFT N (%) | QFT N (%) | QFT N (%) ||\n|| Positive | 3 (50.0) | 2 (25.0) ||\n|| Negative | 1 (16.7) | 4 (50.0) ||\n|| Indeterminate | 1 (16.7) | – ||\n|| Age median (IQR) | 46 (34–60) | 51 (44–56) ||\n|| Not done | 1 (16.7) | 2 (25.0) ||\n|| TB diagnosis N (%) | TB diagnosis N (%) | TB diagnosis N (%) ||\n|| Microbiological | 2 (33.3) | – ||\n|| Clinical | 4 (66.7) | – ||\n|| Sex N (%) | Sex N (%) | Sex N (%) ||\n|| Female | 5 (83.3) | 7 (87.5) ||\n|| Origin N (%) | Origin N (%) | Origin N (%) ||\n|| West Europe | 3 (50.0) | 7 (87.5) ||\n|| East Europe | 2 (33.3) | – ||\n|| Asia | 1 (16.7) | – ||\n|| Africa | – | 1 (12.5) ||",
    "claim": "The median age of patients with pneumonia is higher than those with active TB. The interquartile range (IQR) for pneumonia is narrower, indicating less variability in age among pneumonia patients compared to those with active TB.",
    "label": "support"
  },
  {
    "id": "training_708_3",
    "table_caption": "Table: Inter-rater reproducibility of knee RoM measurement Tested movements Observer A (degrees) Observer B (degrees) Agreement observer A-B ICC (95%CI) mean ± sd mean ± sd md ± sd LoA* Active Flexion sitting 81.4 10.7 78.3 11.3 3.1 5.3 -7.5 – 13.7 0.86 (0.64–0.94) Passive flexion sitting 85.8 10.5 83.1 11.4 2.7 4.7 -6.7 – 12.1 0.88 (0.69–0.95) Active flexion supine 70.6 13.2 70.5 17.0 0.06 7.3 -14.6 – 14.7 0.89 (0.78–0.95) Passive flexion supine 79 12.8 77.6 17.0 1.4 8.8 -16.2 – 19 0.88 (0.77–0.94) Active extension 11.1 5.0 10.2 4.7 0.9 4.1 -7.3 – 9.0 0.64 (0.38–0.81) Passive extension 8.8 5.1 6.6 4.8 2.2 4.2 -6.2 – 10.6 0.62 (0.28–0.80) Sd, standard deviation; md, mean difference; CI, confidence interval; LoA, limits of agreement, calculated as the mean difference between observers ± 1.96SD of this mean difference. ",
    "table_content": "|| Tested movements Active Flexion sitting | Observer A (degrees) mean ± sd | Observer A (degrees) mean ± sd | Observer B (degrees) mean ± sd | Observer B (degrees) mean ± sd | Agreement observer A-B | Agreement observer A-B | Agreement observer A-B | ICC (95%CI) 0.86 (0.64–0.94) ||\n|| Tested movements Active Flexion sitting | Observer A (degrees) mean ± sd | Observer A (degrees) mean ± sd | Observer B (degrees) mean ± sd | Observer B (degrees) mean ± sd | md ± sd | md ± sd | LoA* -7.5 – 13.7 | ICC (95%CI) 0.86 (0.64–0.94) ||\n|| Tested movements Active Flexion sitting | 81.4 | 10.7 | 78.3 | 11.3 | 3.1 | 5.3 | LoA* -7.5 – 13.7 | ICC (95%CI) 0.86 (0.64–0.94) ||\n|| Passive flexion sitting | 85.8 | 10.5 | 83.1 | 11.4 | 2.7 | 4.7 | -6.7 – 12.1 | 0.88 (0.69–0.95) ||\n|| Active flexion supine | 70.6 | 13.2 | 70.5 | 17.0 | 0.06 | 7.3 | -14.6 – 14.7 | 0.89 (0.78–0.95) ||\n|| Passive flexion supine | 79 | 12.8 | 77.6 | 17.0 | 1.4 | 8.8 | -16.2 – 19 | 0.88 (0.77–0.94) ||\n|| Active extension | 11.1 | 5.0 | 10.2 | 4.7 | 0.9 | 4.1 | -7.3 – 9.0 | 0.64 (0.38–0.81) ||\n|| Passive extension | 8.8 | 5.1 | 6.6 | 4.8 | 2.2 | 4.2 | -6.2 – 10.6 | 0.62 (0.28–0.80) ||",
    "claim": "** The mean difference for active flexion supine is the smallest among all movements, suggesting the closest agreement between observers. The mean difference for active flexion supine is 0.06 degrees, which is significantly lower than the mean differences for other movements, such as passive extension, which has a mean difference of 2.2 degrees.",
    "label": "support"
  },
  {
    "id": "training_847_4",
    "table_caption": "Table: Top-ranked template sequences obtained by BLAST results. Ranking No. PDB ID LIG ID* Total Score Query Coverage Max. Identity Positives e-Value 1 2Y00 Y00 473 73% 68% 75% 3×10-165 2 2VT4 P32 466 73% 68% 75% 1×10-162 3 2R4R N/A 412 79% 54% 66% 1×10-140 4 3KJ6 N/A 412 79% 54% 66% 1×10-140 5 2R4S N/A 408 74% 56% 66% 3×10-139 6 3SN6 P0G 410 74% 56% 66% 1×10-137 7 4GBR CAU 291 43% 67% 81% 4×10-94 8 3P0G P0G 418 79% 54% 75% 5×10-92 9 2RH1 CAU 418 79% 54% 76% 5×10-92 10 3PDS ERC 410 72% 60% 78% 1×10-90 *Y00 = Dobutamine, P32 = Cyanopindolol, P0G = Nanobody (Nb35), CAU = Carazolol, ERC = FAUC50. RET = Retinal, P32 = Cyanopindolol, CAU = Carazolol, Y00 = Dobutamine, WHJ = Carmoterol, 5FW = Isoprenaline, 68H = Salbutamol, TIM = Timolol, JRZ = ICI 118,551. ",
    "table_content": "|| Ranking No. | PDB ID | LIG ID *  | Total Score | Query Coverage | Max. Identity | Positives | e-Value ||\n||  1  | 2Y00 | Y00 | 473 | 73% | 68% | 75% | 3×10 -165  ||\n||  10  | 3PDS | ERC | 410 | 72% | 60% | 78% | 1×10 -90  ||\n||  2  | 2VT4 | P32 | 466 | 73% | 68% | 75% | 1×10 -162  ||\n||  3  | 2R4R | N/A | 412 | 79% | 54% | 66% | 1×10 -140  ||\n||  4  | 3KJ6 | N/A | 412 | 79% | 54% | 66% | 1×10 -140  ||\n||  5  | 2R4S | N/A | 408 | 74% | 56% | 66% | 3×10 -139  ||\n||  6  | 3SN6 | P0G | 410 | 74% | 56% | 66% | 1×10 -137  ||\n||  7  | 4GBR | CAU | 291 | 43% | 67% | 81% | 4×10 -94  ||\n||  8  | 3P0G | P0G | 418 | 79% | 54% | 75% | 5×10 -92  ||\n||  9  | 2RH1 | CAU | 418 | 79% | 54% | 76% | 5×10 -92  ||",
    "claim": "Ligands such as P0G and CAU appear in multiple entries with varying total scores. For example, P0G is associated with both the sixth-ranked (3SN6) and eighth-ranked (3P0G) entries, yet the total score differs by 8 points, suggesting that the presence of a specific ligand does not uniformly affect the total score.",
    "label": "support"
  },
  {
    "id": "training_924_3",
    "table_caption": "Table: Table 2 Activities of daily living covered Activities n (%) No Yes Sitting 12 (10.8) 99 (89.2) Bathing 24 (21.6) 87 (78.4) Driving a car 26 (23.4) 85 (76.6) Sleeping 27 (24.3) 84 (75.7) Dressing/ undressing 29 (26.1) 82 (73.9) Being a (car) passenger 29 (26.1) 82 (73.9) Using the toilet 39 (35.1) 72 (64.9) General domestic activities 41 (36.9) 70 (63.1) Modifying the home environment 47 (42.3) 64 (57.7) Sex 49 (44.1) 62 (55.9) Bed transfers 51 (45.9) 60 (54.1) Stairs 62 (55.9) 49 (44.1) Leisure 65 (58.6) 46 (41.4) Walking 66 (59.5) 45 (40.5) Social support 69 (62.2) 42 (37.8) Bending down/ picking something up from the floor 81 (73.0) 30 (27.0) Work 85 (76.6) 26 (23.4) Other* 96 (86.5) 15 (13.5) * E.g. flying, looking after pets, using public transport, getting up after a fall. ",
    "table_content": "|| Activities Sitting | n (%) | n (%) | n (%) | n (%) ||\n|| Activities Sitting | No | No | Yes | Yes ||\n|| Modifying the home environment | 47 | (42.3) | 64 | (57.7) ||\n|| Sex | 49 | (44.1) | 62 | (55.9) ||\n|| Bed transfers | 51 | (45.9) | 60 | (54.1) ||\n|| Stairs | 62 | (55.9) | 49 | (44.1) ||\n|| Leisure | 65 | (58.6) | 46 | (41.4) ||\n|| Walking | 66 | (59.5) | 45 | (40.5) ||\n|| Social support | 69 | (62.2) | 42 | (37.8) ||\n|| Bending down/ picking something up from the floor | 81 | (73.0) | 30 | (27.0) ||\n|| Work | 85 | (76.6) | 26 | (23.4) ||\n|| Other* | 96 | (86.5) | 15 | (13.5) ||\n|| Activities Sitting | 12 | (10.8) | 99 | (89.2) ||\n|| Bathing | 24 | (21.6) | 87 | (78.4) ||\n|| Driving a car | 26 | (23.4) | 85 | (76.6) ||\n|| Sleeping | 27 | (24.3) | 84 | (75.7) ||\n|| Dressing/ undressing | 29 | (26.1) | 82 | (73.9) ||\n|| Being a (car) passenger | 29 | (26.1) | 82 | (73.9) ||\n|| Using the toilet | 39 | (35.1) | 72 | (64.9) ||\n|| General domestic activities | 41 | (36.9) | 70 | (63.1) ||",
    "claim": "There is a clear trend where activities requiring physical exertion, such as walking and using stairs, have a lower percentage of individuals unable to perform them (40.5% and 44.1% respectively). This trend highlights the impact of physical limitations on daily living activities.",
    "label": "support"
  },
  {
    "id": "training_975_5",
    "table_caption": "Table: Epidemic MRSA clones identified during the study period 2006–2010. Frequency of isolation of the clone MRSA clone (%)a 2006 2007 2008 2009 2010 Major variants of the clone (%)b ST22-IV (33,3%) 20,4% 26,5% 35% 36,7% 38,8% A (28%); B (25%); C (7%) ST228-I (26%) 31,8% 33,6% 29,8% 22,7% 20,9% B2 (16%); B5 (13%); B1 (8%) ST8-IV (15,8%) 6,8% 16,3% 21,6% 17,2% 17,8% A1 (23%); A2 (22%); B (21%); C (11%) aPercent of MRSA strains belonging to each clone, considering only the index cases (n = 499); bpercent of MRSA strains belonging to the major variants of each epidemic clone identified (n = 166 for ST22-IV; n = 131 for ST228-I; n = 80 for ST8-IV). ",
    "table_content": "|| MRSA clone (%) a | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Major variants of the clone (%) b ||\n|| MRSA clone (%) a | 2006 | 2007 | 2008 | 2009 | 2010 | Major variants of the clone (%) b ||\n|| ST22-IV (33,3%) | 20,4% | 26,5% | 35% | 36,7% | 38,8% | A (28%); B (25%); C (7%) ||\n|| ST228-I (26%) | 31,8% | 33,6% | 29,8% | 22,7% | 20,9% | B2 (16%); B5 (13%); B1 (8%) ||\n|| ST8-IV (15,8%) | 6,8% | 16,3% | 21,6% | 17,2% | 17,8% | A1 (23%); A2 (22%); B (21%); C (11%) ||",
    "claim": "The frequency of the ST228-I clone decreased by approximately 34% from 2006 to 2010, reflecting a notable decline in its prevalence over the five-year period.",
    "label": "support"
  },
  {
    "id": "training_497_3",
    "table_caption": "Table: Comparison of selected NMHCs in Guangzhou with other cities (units: ppbv). Hydrocarbon Guangzhou a, China Beijing b, China Honkong c, China Dongguan d, China Shanghai e, China Kaohsiung f, Taiwan 43 Cities China g Ethane 3.15 3.75 1.83 1.60 1.10 4.5 3.7–17.0 Propane 4.49 3.59 1.60 2.46 4.25 3.1 1.5–20.8 i-Butane 1.35 2.31 0.90 1.07 0.97 0.7 0.4–4.6 n-Butane 2.54 2.75 1.46 1.89 1.80 2.3 0.6–18.8 i-Pentane 1.81 4.11 0.52 1.42 1.98 3.8 0.3–18.8 n-Pentane 1.18 1.7 0.25 0.70 1.40 1.3 0.2–7.7 Ethene 2.79 4.59 1.47 3.07 7.5 2.1–34.8 Propene 2.26 1.16 0.32 0.53 0.93 2.2 0.2–8.2 Ethyne 5.46 5.41 1.95 4.27 3.58 4.9 2.9–58.3 Benzene 1.73 1.76 0.42 1.26 1.67 1.1 0.7–10.4 Toluene 4.19 3.03 2.77 6.13 4.69 8.2 0.4–11.2 Ethylbenzene 1.03 0.98 0.40 1.06 1.51 0.7 0.1–2.7 m,p-Xylene 1.65 2.04 0.70 1.48 1.31 1.2 0.4–15.3 Isoprene 0.66 0.41 0.18 0.68 0.03 0.6 0.04–1.7 a This study; b Song et al. 2007 [13]; c Guo et al. 2007 [4]; d Barletta et al. 2008 [10]; e Ran et al. 2009 [14]; f Chang et al. 2005 [15]; g Barletta et al. 2005 [12]. ",
    "table_content": "|| Hydrocarbon | Guangzhou a , China | Beijing b , China | Honkong c , China | Dongguan d , China | Shanghai e , China | Kaohsiung f , Taiwan | 43 Cities China g ||\n|| Ethane | 3.15 | 3.75 | 1.83 | 1.60 | 1.10 | 4.5 | 3.7–17.0 ||\n|| Benzene | 1.73 | 1.76 | 0.42 | 1.26 | 1.67 | 1.1 | 0.7–10.4 ||\n|| Toluene | 4.19 | 3.03 | 2.77 | 6.13 | 4.69 | 8.2 | 0.4–11.2 ||\n|| Ethylbenzene | 1.03 | 0.98 | 0.40 | 1.06 | 1.51 | 0.7 | 0.1–2.7 ||\n|| m,p -Xylene | 1.65 | 2.04 | 0.70 | 1.48 | 1.31 | 1.2 | 0.4–15.3 ||\n|| Isoprene | 0.66 | 0.41 | 0.18 | 0.68 | 0.03 | 0.6 | 0.04–1.7 ||\n|| Propane | 4.49 | 3.59 | 1.60 | 2.46 | 4.25 | 3.1 | 1.5–20.8 ||\n|| i -Butane | 1.35 | 2.31 | 0.90 | 1.07 | 0.97 | 0.7 | 0.4–4.6 ||\n|| n -Butane | 2.54 | 2.75 | 1.46 | 1.89 | 1.80 | 2.3 | 0.6–18.8 ||\n|| i -Pentane | 1.81 | 4.11 | 0.52 | 1.42 | 1.98 | 3.8 | 0.3–18.8 ||\n|| n -Pentane | 1.18 | 1.7 | 0.25 | 0.70 | 1.40 | 1.3 | 0.2–7.7 ||\n|| Ethene | 2.79 | 4.59 | 1.47 | 3.07 | blank | 7.5 | 2.1–34.8 ||\n|| Propene | 2.26 | 1.16 | 0.32 | 0.53 | 0.93 | 2.2 | 0.2–8.2 ||\n|| Ethyne | 5.46 | 5.41 | 1.95 | 4.27 | 3.58 | 4.9 | 2.9–58.3 ||",
    "claim": "The propane concentration in Guangzhou is 4.49 ppbv, which is 1.25 times the average concentration of propane in Beijing, Hong Kong, Dongguan, and Kaohsiung. This suggests a relatively higher presence of propane in Guangzhou compared to these cities.",
    "label": "support"
  },
  {
    "id": "training_1200_3",
    "table_caption": "Table: ON cell lines cultivated in the presence or absence of doxycycline (2 μg/ml) for 6 days Gene Symbol Dox+/Dox- Ratio Tre-2 FAK FAK-CD PTK2 0.59 1.86 * 0.82 PTK2B 0.82 0.85 0.64 p53 0.99 0.66 0.85* DMTF1 1.20 0.65* 0.81 SRC 1.95 0.76 0.87 MAPK3 1.05 0.74 0.97 AKT1 0.56 0.58 0.73 MAP2K1 0.57 0.52* 0.52 MAPK8 0.70 0.61* 0.85* FYN 0.84 0.33* 0.65* CDC2 0.72 1.02 0.82* CDK4 0.94 0.88* 0.94* RB1 0.88 0.48* 0.60* SOCS2 1.12 0.65* 1.20* SYK 0.66 0.47* 0.63* CDK2 0.97 0.93* 0.73 CDK3 0.80 0.71 0.74 RAF1 0.78 0.60* 0.54* ABL1 0.63 0.66 0.78* TEC 0.67 0.63* 0.58* PXN 0.96 0.62* 0.75* SHC1 0.98 0.62* 0.78 BCAR1 0.62 0.53 0.70 MAK2K6 0.76 1.04 1.73* EPHA1 0.56 0.78 0.75 CTNNB1 0.80 0.56* 0.70* CHEK1 0.75 0.62* 0.62* ATM 1.09 0.65 0.99 BIRC5 0.93 0.88 0.74 CDC25C 1.27 1.05 1.18 BCL2 0.31 0.30 0.37 TLN2 0.72 0.81* 0.65* FLT1 0.33 0.37 0.46 PINK1 1.18 0.51* 0.65* STAT1 0.70 0.54* 0.46 ARHGEF2 0.75 0.56 0.73 ITGB1 0.46 0.52* 0.65* CELSR1 1.26 0.88 0.79 LAMC2 0.64 0.38* 0.64* *p < 0.05, t-test; ** mRNA levels of some genes from Additional file 1 was not detectable ",
    "table_content": "|| Gene Symbol | Dox + /Dox - Ratio | Dox + /Dox - Ratio | Dox + /Dox - Ratio ||\n|| Gene Symbol | Tre-2 | FAK | FAK-CD ||\n|| MAPK8 | 0.70 | 0.61* | 0.85* ||\n|| FYN | 0.84 | 0.33* | 0.65* ||\n|| CDC2 | 0.72 | 1.02 | 0.82* ||\n|| CDK4 | 0.94 | 0.88* | 0.94* ||\n|| RB1 | 0.88 | 0.48* | 0.60* ||\n|| SOCS2 | 1.12 | 0.65* | 1.20* ||\n|| SYK | 0.66 | 0.47* | 0.63* ||\n|| CDK2 | 0.97 | 0.93* | 0.73 ||\n|| CDK3 | 0.80 | 0.71 | 0.74 ||\n|| RAF1 | 0.78 | 0.60* | 0.54* ||\n|| PTK2 | 0.59 | 1.86 * | 0.82 ||\n|| ABL1 | 0.63 | 0.66 | 0.78* ||\n|| TEC | 0.67 | 0.63* | 0.58* ||\n|| PXN | 0.96 | 0.62* | 0.75* ||\n|| SHC1 | 0.98 | 0.62* | 0.78 ||\n|| BCAR1 | 0.62 | 0.53 | 0.70 ||\n|| MAK2K6 | 0.76 | 1.04 | 1.73* ||\n|| EPHA1 | 0.56 | 0.78 | 0.75 ||\n|| CTNNB1 | 0.80 | 0.56* | 0.70* ||\n|| CHEK1 | 0.75 | 0.62* | 0.62* ||\n|| ATM | 1.09 | 0.65 | 0.99 ||\n|| PTK2B | 0.82 | 0.85 | 0.64 ||\n|| BIRC5 | 0.93 | 0.88 | 0.74 ||\n|| CDC25C | 1.27 | 1.05 | 1.18 ||\n|| BCL2 | 0.31 | 0.30 | 0.37 ||\n|| TLN2 | 0.72 | 0.81* | 0.65* ||\n|| FLT1 | 0.33 | 0.37 | 0.46 ||\n|| PINK1 | 1.18 | 0.51* | 0.65* ||\n|| STAT1 | 0.70 | 0.54* | 0.46 ||\n|| ARHGEF2 | 0.75 | 0.56 | 0.73 ||\n|| ITGB1 | 0.46 | 0.52* | 0.65* ||\n|| CELSR1 | 1.26 | 0.88 | 0.79 ||\n|| p53 | 0.99 | 0.66 | 0.85* ||\n|| LAMC2 | 0.64 | 0.38* | 0.64* ||\n|| DMTF1 | 1.20 | 0.65* | 0.81 ||\n|| SRC | 1.95 | 0.76 | 0.87 ||\n|| MAPK3 | 1.05 | 0.74 | 0.97 ||\n|| AKT1 | 0.56 | 0.58 | 0.73 ||\n|| MAP2K1 | 0.57 | 0.52* | 0.52 ||",
    "claim": "The gene FYN shows a statistically significant decrease in expression in the FAK condition compared to Tre-2, with a reduction factor of approximately 2.55, highlighting a significant downregulation in the presence of doxycycline.",
    "label": "support"
  },
  {
    "id": "training_1250_6",
    "table_caption": "Table: Antimicrobial and haemolytic activity of peptides I–XII and antibiotics. Antimicrobial Activity MIC (µmol/L) Haemolytic Activity LC50 (µmol/L) c Peptide MRSA 6271 MRSA a MRSA b S. e. b E. f. b P. a. 5482 P. a. a C. a. I 6.3 3.6 5.7 2.3 13.3 2.8 10.0 5.7 339 II 11.3 5.3 9.7 2.0 12.7 4.5 12.5 5.7 >400 III 29.7 11.5 25.3 4.7 >100 2.9 9.5 9.5 >400 IV 20.0 10.0 20.0 3.2 >100 5.3 12.7 12.7 >200 V 10.0 8.0 10.0 2.2 50.7 4.0 10.7 16.0 196 VI 9.0 5.0 10.0 2.5 >100 3.0 12.7 6.3 >400 VII 22.0 15.0 22.0 4.2 25.3 4.5 25.3 12.5 >400 VIII 18.7 13.3 32.0 4.0 >100 5.0 32.0 8.0 >400 IX 13.5 8.0 17.7 3.2 >100 2.9 5.8 9.5 >400 X 19.3 14.0 14.0 3.5 36 4.5 18.0 11.3 >400 XI 11.3 5.7 10.0 2.8 59.0 2.8 7.0 11.3 270 XII 16.0 8.0 16.0 2.5 32.0 3.2 8.0 5.3 >400 Vanc 0.9 1.1 1.1 1.5 1.3 >200 >320 - - Gent 325 3.9 4.5 109 95.2 2.0 >220 - - MRSA, methicillin-resistant Staphylococcus aureus; S. e., Staphylococcus epidermidis; E. f., Enterococcus faecalis; P. a., Pseudomonas aeruginosa; C. a., Candida albicans; a Clinical isolates from Liberec Regional Hospital; b Clinical isolates from University Hospital in Motol, Prague; c Concentration causing lysis of 50% of red blood cells. Vanc, vancomycin; ",
    "table_content": "|| Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Haemolytic Activity LC 50 (μmol/L) c ||\n|| Peptide | MRSA 6271 | MRSA a | MRSA b | S. e.  b | E. f.  b | P. a. 5482 | P. a.  a | C. a. | Haemolytic Activity LC 50 (μmol/L) c ||\n|| IX | 13.5 | 8.0 | 17.7 | 3.2 | >100 | 2.9 | 5.8 | 9.5 | >400 ||\n|| X | 19.3 | 14.0 | 14.0 | 3.5 | 36 | 4.5 | 18.0 | 11.3 | >400 ||\n|| XI | 11.3 | 5.7 | 10.0 | 2.8 | 59.0 | 2.8 | 7.0 | 11.3 | 270 ||\n|| XII | 16.0 | 8.0 | 16.0 | 2.5 | 32.0 | 3.2 | 8.0 | 5.3 | >400 ||\n|| Vanc | 0.9 | 1.1 | 1.1 | 1.5 | 1.3 | >200 | >320 | blank | blank ||\n|| Gent | 325 | 3.9 | 4.5 | 109 | 95.2 | 2.0 | >220 | blank | blank ||\n|| I | 6.3 | 3.6 | 5.7 | 2.3 | 13.3 | 2.8 | 10.0 | 5.7 | 339 ||\n|| II | 11.3 | 5.3 | 9.7 | 2.0 | 12.7 | 4.5 | 12.5 | 5.7 | >400 ||\n|| III | 29.7 | 11.5 | 25.3 | 4.7 | >100 | 2.9 | 9.5 | 9.5 | >400 ||\n|| IV | 20.0 | 10.0 | 20.0 | 3.2 | >100 | 5.3 | 12.7 | 12.7 | >200 ||\n|| V | 10.0 | 8.0 | 10.0 | 2.2 | 50.7 | 4.0 | 10.7 | 16.0 | 196 ||\n|| VI | 9.0 | 5.0 | 10.0 | 2.5 | >100 | 3.0 | 12.7 | 6.3 | >400 ||\n|| VII | 22.0 | 15.0 | 22.0 | 4.2 | 25.3 | 4.5 | 25.3 | 12.5 | >400 ||\n|| VIII | 18.7 | 13.3 | 32.0 | 4.0 | >100 | 5.0 | 32.0 | 8.0 | >400 ||",
    "claim": "The MIC values for Peptide VIII against MRSA strains show greater variability compared to Peptide II, indicating a less consistent efficacy. The standard deviation of the MIC values for Peptide VIII across MRSA 6271, MRSA a, and MRSA b is calculated to be higher than that for Peptide II, reflecting this variability.",
    "label": "support"
  },
  {
    "id": "training_194_4",
    "table_caption": "Table: Mean, median, 95% CI, interquartile interval and P value of clinical score, IFAT titer, TP (g/dl), IgG (%), creatinine and urea (mg/dl), and UP/C in 20 dogs before and after 28 days of therapy. Parameter D0 D28 p value Clinical score NV: 0 Mean (95% CI) 5.1 (3.1-7.09) 2.6 (1.52-3.77) p=0.0046 IFAT titer NV: Titer<1:80 (min-max) 160-1280 (320-640) 80-1280 (240-640) p=0.2661 TP NV: 6-8 g/dl Mean (95% CI) 8 (7.55-8.45) 7.6 (7.24-7.96) p=0.0730 IgG NV: 5.3-9.9% Mean (95% CI) 21.36 (16.89-25.83) 19.06 (14.75-23.36) p=0.1009 Creatinine NV<1.2 mg/dl (Median I-III interquartile interval) 0.91 (0.8-1.05) 0.91 (0.7-1.1) p=0.8077 Urea NV: 15-45 mg/dl (Median I-III interquartile interval) 40.75 (29-45.5) 38.55 (29.5-44) p=0.4171 UP/C NP: <0.2 BP: 0.2-0.5 P: >0.5 (Median I-III interquartile interval) 0.35 (0.1-0.7) 0.26 (0.1-0.4) p=0.016 NV: Normal value, NP: Non-proteinuric, BP: Borderline proteinuric, P: Proteinuric, CI: Confidence interval 95%, TP: Total protein, IFAT: Indirect fluorescent antibody test, UP/C: Urine protein creatinine, IgG: Gamma globulin ",
    "table_content": "|| Parameter | D0 | D28 | p value ||\n|| Clinical score | Clinical score | Clinical score | Clinical score ||\n|| NV<1.2 mg/dl (Median IIII interquartile interval) | 0.91 (0.8-1.05) | 0.91 (0.7-1.1) | p=0.8077 ||\n|| Urea | Urea | Urea | Urea ||\n|| NV: 1545 mg/dl (Median IIII interquartile interval) | 40.75 (29-45.5) | 38.55 (29.5-44) | p=0.4171 ||\n|| UP/C | UP/C | UP/C | UP/C ||\n|| NP: <0.2 BP: 0.20.5 P: >0.5 (Median I-III interquartile interval) | 0.35 (0.1-0.7) | 0.26 (0.1-0.4) | p=0.016 ||\n|| NV: 0 Mean (95% CI) | 5.1 (3.1-7.09) | 2.6 (1.52-3.77) | p=0.0046 ||\n|| IFAT titer | IFAT titer | IFAT titer | IFAT titer ||\n|| NV: Titer<1:80 (minmax) | 160-1280 (320-640) | 80-1280 (240-640) | p=0.2661 ||\n|| TP | TP | TP | TP ||\n|| NV: 68 g/dl Mean (95% CI) | 8 (7.55-8.45) | 7.6 (7.24-7.96) | p=0.0730 ||\n|| IgG | IgG | IgG | IgG ||\n|| NV: 5.39.9% Mean (95% CI) | 21.36 (16.89-25.83) | 19.06 (14.75-23.36) | p=0.1009 ||\n|| Creatinine | Creatinine | Creatinine | Creatinine ||",
    "claim": "The IgG percentage decreased by approximately 10.8% from D0 to D28, with a p-value of 0.1009, suggesting a trend towards reduction, though not reaching statistical significance.",
    "label": "support"
  },
  {
    "id": "training_10_5",
    "table_caption": "Table: TABLE 4 | Lag phase (days) for M. trichosporium OB3b growth experiments. C-source N-source N:C ratio CH4-grown inoculum CH3OH-grown inoculum Fresh Aged Fresh Aged CH4 NH4+ Low 1 2.5 – – CH4 NH4+ High 1.5 2.5 – – CH4 NO3− Low 1.5 2.5 – – CH4 NO3− High 1.5 2.5 – – CH3OH NH4+ Low 12–14 9 5–5.5 9.5–10.5 CH3OH NH4+ High 10–13 12–13 5.5 9–11 CH3OH NO3− Low 12–14 10.5 4.5–5 9–11.5 CH3OH NO3− High 10.5–11 9 4.5 8.5 and the ANOVA was repeated (Supplementary Table S2). In this Growth Response Surface Analysis ",
    "table_content": "|| C-source | N-source | N:C ratio | CH 4 -grown inoculum | CH 4 -grown inoculum | CH 3 OH-grown inoculum | CH 3 OH-grown inoculum ||\n|| C-source | N-source | N:C ratio | Fresh | Aged | Fresh | Aged ||\n|| CH 4 | NH 4 + | Low | 1 | 2.5 | – | – ||\n|| CH 4 | NH 4 + | High | 1.5 | 2.5 | – | – ||\n|| CH 4 | NO 3 - | Low | 1.5 | 2.5 | – | – ||\n|| CH 4 | NO 3 - | High | 1.5 | 2.5 | – | – ||\n|| CH 3 OH | NH 4 + | Low | 12–14 | 9 | 5–5.5 | 9.5–10.5 ||\n|| CH 3 OH | NH 4 + | High | 10–13 | 12–13 | 5.5 | 9–11 ||\n|| CH 3 OH | NO 3 - | Low | 12–14 | 10.5 | 4.5–5 | 9–11.5 ||\n|| CH 3 OH | NO 3 - | High | 10.5–11 | 9 | 4.5 | 8.5 ||",
    "claim": "The variability in lag phase duration for CH3OH-grown inoculum with NH4+ as the nitrogen source and a Low N",
    "label": "support"
  },
  {
    "id": "training_10_5",
    "table_caption": "Table: TABLE 4 | Lag phase (days) for M. trichosporium OB3b growth experiments. C-source N-source N:C ratio CH4-grown inoculum CH3OH-grown inoculum Fresh Aged Fresh Aged CH4 NH4+ Low 1 2.5 – – CH4 NH4+ High 1.5 2.5 – – CH4 NO3− Low 1.5 2.5 – – CH4 NO3− High 1.5 2.5 – – CH3OH NH4+ Low 12–14 9 5–5.5 9.5–10.5 CH3OH NH4+ High 10–13 12–13 5.5 9–11 CH3OH NO3− Low 12–14 10.5 4.5–5 9–11.5 CH3OH NO3− High 10.5–11 9 4.5 8.5 and the ANOVA was repeated (Supplementary Table S2). In this Growth Response Surface Analysis ",
    "table_content": "|| C-source | N-source | N:C ratio | CH 4 -grown inoculum | CH 4 -grown inoculum | CH 3 OH-grown inoculum | CH 3 OH-grown inoculum ||\n|| C-source | N-source | N:C ratio | Fresh | Aged | Fresh | Aged ||\n|| CH 4 | NH 4 + | Low | 1 | 2.5 | – | – ||\n|| CH 4 | NH 4 + | High | 1.5 | 2.5 | – | – ||\n|| CH 4 | NO 3 - | Low | 1.5 | 2.5 | – | – ||\n|| CH 4 | NO 3 - | High | 1.5 | 2.5 | – | – ||\n|| CH 3 OH | NH 4 + | Low | 12–14 | 9 | 5–5.5 | 9.5–10.5 ||\n|| CH 3 OH | NH 4 + | High | 10–13 | 12–13 | 5.5 | 9–11 ||\n|| CH 3 OH | NO 3 - | Low | 12–14 | 10.5 | 4.5–5 | 9–11.5 ||\n|| CH 3 OH | NO 3 - | High | 10.5–11 | 9 | 4.5 | 8.5 ||",
    "claim": "The variability in lag phase duration for CH3OH-grown inoculum with NO3− as the nitrogen source and a Low N:C ratio.",
    "label": "support"
  },
  {
    "id": "training_817_1",
    "table_caption": "Table: No. of smokers participated in the QTW Contest, RCT and included in this Study Sample n = 1307 (%) Participated in the QTW Contest 1307 (100%) Successfully interviewed at the 1-week follow-up 1030 (78.8%) Answered questions on ever EC use 956 (73.1%) n = 956 (%) Ever EC users 163 (17.1%) Non-users 793 (82.9%) QTW: “Quit to Win” contest. EC: electronic cigarette. ",
    "table_content": "|| Study Sample | n = 1307 (%) ||\n|| Participated in the QTW Contest | 1307 (100%) ||\n|| Successfully interviewed at the 1-week follow-up | 1030 (78.8%) ||\n|| Answered questions on ever EC use | 956 (73.1%) ||\n|| Answered questions on ever EC use | n = 956 (%) ||\n|| Ever EC users | 163 (17.1%) ||\n|| Non-users | 793 (82.9%) ||",
    "claim": "The proportion of participants who were successfully interviewed at the 1-week follow-up is 78.8%. This indicates that a substantial majority of the initial participants remained engaged in the study at this stage.",
    "label": "support"
  },
  {
    "id": "training_792_3",
    "table_caption": "Table: TABLE 1 | Analysis of Fucus mytili tissue: carbon-to-nitrogen (C:N) ratios, C, N, and mannitol contents. C:N C N Mannitol (% DW) Initial 11.88 ± 0.65a 34.68 ± 0.49a 2.93 ± 0.14a 13.92 ± 2.18a +T +CO2 23.42 ± 5.60b 35.60 ± 1.96a 1.57 ± 0.33b 15.82 ± 3.00a +T aCO2 29.03 ± 7.22b 36.31 ± 0.78a 1.31 ± 0.34b 22.12 ± 9.87a aT +CO2 25.80 ± 5.29b 35.15 ± 1.86a 1.40 ± 0.26b 16.04 ± 8.09a aT aCO2 25.46 ± 3.02b 36.42 ± 0.89a 1.44 ± 0.15b 17.21 ± 5.74a Data (in % DW, dry weight) of the initial physiological status of F. mytili in its native habitat (initial, n = 6) and after growing for 11 weeks (n = 3) under different temperature and pCO2 on week). mostly 2011) Stratil (Stratil and on in and ",
    "table_content": "|| blank | C:N | C | N | Mannitol ||\n|| blank | C:N | (% DW) | (% DW) | (% DW) ||\n|| Initial | 11.88 ±0.65a | 34.68 ±0.49a | 2.93 ±0.14a | 13.92 ±2.18a ||\n|| +T +CO 2 | 23.42 ±5.60b | 35.60 ±1.96a | 1.57 ±0.33b | 15.82 ±3.00a ||\n|| +T aCO 2 | 29.03 ±7.22b | 36.31 ±0.78a | 1.31 ±0.34b | 22.12 ±9.87a ||\n|| aT +CO 2 | 25.80 ±5.29b | 35.15 ±1.86a | 1.40 ±0.26b | 16.04 ±8.09a ||\n|| aT aCO 2 | 25.46 ±3.02b | 36.42 ±0.89a | 1.44 ±0.15b | 17.21 ±5.74a ||",
    "claim": "The nitrogen content decreases by approximately 55% from the initial condition to the +T aCO2 condition, reflecting a significant reduction in nitrogen assimilation or retention under these conditions.",
    "label": "support"
  },
  {
    "id": "training_1213_3",
    "table_caption": "Table: by hAST and hBMVEC, respectively, after T&I exposure either alone or in the presence of S1P (50 nM), FTY (50 nM), pFTY (50 nM), and AUY (50 nM). Astrocytes Endothelial cells Resting 30.9 pg/ml 3.2 pg/ml T&I 86.1 pg/ml 7.7 pg/ml T&I+S1P 82.3 pg/ml 7.8 pg/ml T&I+FTY 144.1 pg/ml 9.7 pg/ml T&I+pFTY 150.2 pg/ml 8.7 pg/ml T&I+AUY 84.5 pg/ml 8.4 pg/ml doi:10.1371/journal.pone.0133392.t002 ",
    "table_content": "|| blank | Astrocytes | Endothelial cells ||\n||  Resting  | 30.9 pg/ml | 3.2 pg/ml ||\n||  T&I  | 86.1 pg/ml | 7.7 pg/ml ||\n||  T&I+S1P  | 82.3 pg/ml | 7.8 pg/ml ||\n||  T&I+FTY  | 144.1 pg/ml | 9.7 pg/ml ||\n||  T&I+pFTY  | 150.2 pg/ml | 8.7 pg/ml ||\n||  T&I+AUY  | 84.5 pg/ml | 8.4 pg/ml ||",
    "claim": "FTY increases the concentration in astrocytes by approximately 67.4% compared to T&I alone, whereas in endothelial cells, the increase is about 25.9%.",
    "label": "support"
  },
  {
    "id": "training_1301_2",
    "table_caption": "Table: late the 4 In ated and are tial tion We nant the of sure TABLE 3 Association between alcoholic beverage and invasive ovarian cancer risk among Asian population Cases (N = 460) / Controls (N = 1274) OR (95% CI) P-value Total alcohol (g/d)a None 372/1135 1 (ref.) 0-7.6 54/67 0.92 (0.59-1.45) .731 7.6-192.6 28/67 0.69 (0.42-1.14) .148 Unknown 6/5 NE Beer (g/d)b None 372/1135 1 (ref.) 0.2-5.3 21/32 0.84 (0.41-1.72) .637 5.3-136.9 18/32 1.01 (0.50-2.04) .724 Unknown 49/75 NE Wine (g/d)b None 372/1135 1 (ref.) 0.1-3.2 28/30 0.79 (0.36-1.75) .560 3.2-192.6 20/43 0.70 (0.32-1.51) .360 Unknown 40/66 NE White wine (g/d)c,d None 372/1135 1 (ref.) 0.2-3.2 15/20 0.60 (0.20-1.80) .358 3.2-192.6 11/32 0.61 (0.24-1.54) .299 Unknown 62/87 NE Red wine (g/d)c,d None 372/1135 1 (ref.) 0.2-3.1 17/28 0.45 (0.16-1.24) .124 3.1-92.9 9/22 0.60 (0.22-1.64) .321 Unknown 62/89 NE Other alcoholic beverage (g/d)b.e None 372/1135 1 (ref.) 0.2-7.5 21/26 0.97 (0.46-2.06) .939 7.5-95.8 8/25 0.73 (0.28-1.94) .531 Unknown 59/88 NE aOdds ratios (OR) are adjusted for age, smoking, principal component 1-5 and study site for total alcohol. ",
    "table_content": "|| blank | Cases (N = 460) / Controls (N = 1274) | OR (95% CI) |  P ‐value ||\n|| Total alcohol (g/d) a  | Total alcohol (g/d) a  | Total alcohol (g/d) a  | Total alcohol (g/d) a  ||\n|| Unknown | 49/75 | NE | blank ||\n|| Wine (g/d) b  | Wine (g/d) b  | Wine (g/d) b  | Wine (g/d) b  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.1‐3.2 | 28/30 | 0.79 (0.36‐1.75) | .560 ||\n|| 3.2‐192.6 | 20/43 | 0.70 (0.32‐1.51) | .360 ||\n|| Unknown | 40/66 | NE | blank ||\n|| White wine (g/d) c  ,  d  | White wine (g/d) c  ,  d  | White wine (g/d) c  ,  d  | White wine (g/d) c  ,  d  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.2‐3.2 | 15/20 | 0.60 (0.20‐1.80) | .358 ||\n|| 3.2‐192.6 | 11/32 | 0.61 (0.24‐1.54) | .299 ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| Unknown | 62/87 | NE | blank ||\n|| Red wine (g/d) c  ,  d  | Red wine (g/d) c  ,  d  | Red wine (g/d) c  ,  d  | Red wine (g/d) c  ,  d  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.2‐3.1 | 17/28 | 0.45 (0.16‐1.24) | .124 ||\n|| 3.1‐92.9 | 9/22 | 0.60 (0.22‐1.64) | .321 ||\n|| Unknown | 62/89 | NE | blank ||\n|| Other alcoholic beverage (g/d) b  .  e  | Other alcoholic beverage (g/d) b  .  e  | Other alcoholic beverage (g/d) b  .  e  | Other alcoholic beverage (g/d) b  .  e  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.2‐7.5 | 21/26 | 0.97 (0.46‐2.06) | .939 ||\n|| 7.5‐95.8 | 8/25 | 0.73 (0.28‐1.94) | .531 ||\n|| 0‐7.6 | 54/67 | 0.92 (0.59‐1.45) | .731 ||\n|| Unknown | 59/88 | NE | blank ||\n|| 7.6‐192.6 | 28/67 | 0.69 (0.42‐1.14) | .148 ||\n|| Unknown | 6/5 | NE | blank ||\n|| Beer (g/d) b  | Beer (g/d) b  | Beer (g/d) b  | Beer (g/d) b  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.2‐5.3 | 21/32 | 0.84 (0.41‐1.72) | .637 ||\n|| 5.3‐136.9 | 18/32 | 1.01 (0.50‐2.04) | .724 ||",
    "claim": "The odds ratio for individuals consuming 5.3-136.9 g/d of beer is slightly higher than for those consuming 0.2-5.3 g/d, suggesting a marginal increase in ovarian cancer risk with higher beer consumption, although the confidence interval includes 1, indicating uncertainty.",
    "label": "support"
  },
  {
    "id": "training_1125_5",
    "table_caption": "Table: Results of in vitro albumin precipitation test (mg/L). Test solutions (1) Saline (control) Enox. 400 Enox. 400–40% Ethanol 10% WB 20% WB 10% WB 20% WB 10% WB 20% WB Blood sample Donor sex (Age) #1 H (56) - - 21.7 6.7 33.2 82.8 #2 F (32) - - 11.7 15.1 17.8 46.6 #3 F (32) - - 21.4 13.8 46 146 #4 H (34) - - 11 8.61 27.7 148 #5 F (30) - - 5.2 11.0 10.2 95.3 mean - - 14.2 11.0 26.98 103.74 SD - - 7.1 3.4 13.85 43.36 (1) Test solutions consisted of 0.5 (10%) or 1 mL (20%) WB and 4 mL or 4.5 mL of either saline (control), Enoxaparin 400, or Enoxaparin 400–40% Ethanol solution. ",
    "table_content": "|| Blood sample | Test solutions (1) Donor sex (Age) | Saline (control) | Saline (control) | Enox. 400 | Enox. 400 | Enox. 400–40% Ethanol | Enox. 400–40% Ethanol ||\n|| Blood sample | Test solutions (1) Donor sex (Age) | 10% WB | 20% WB | 10% WB | 20% WB | 10% WB | 20% WB ||\n|| Blood sample | Test solutions (1) Donor sex (Age) | 10% WB | 20% WB | 10% WB | 20% WB | 10% WB | 20% WB ||\n|| #1 | H (56) | blank | blank | 21.7 | 6.7 | 33.2 | 82.8 ||\n|| #2 | F (32) | blank | blank | 11.7 | 15.1 | 17.8 | 46.6 ||\n|| #3 | F (32) | blank | blank | 21.4 | 13.8 | 46 | 146 ||\n|| #4 | H (34) | blank | blank | 11 | 8.61 | 27.7 | 148 ||\n|| #5 | F (30) | blank | blank | 5.2 | 11.0 | 10.2 | 95.3 ||\n|| #5 | mean | blank | blank | 14.2 | 11.0 | 26.98 | 103.74 ||\n|| #5 | SD | blank | blank | 7.1 | 3.4 | 13.85 | 43.36 ||",
    "claim": "The standard deviation for Enoxaparin 400–40% Ethanol at 20% WB is approximately 1.5 times higher than that for Enoxaparin 400 at 10% WB, indicating a lower consistency in results when ethanol is included, particularly at higher WB concentrations.",
    "label": "support"
  },
  {
    "id": "training_870_4",
    "table_caption": "Table: p-value 0.20 0.71 0.69 0.92 0.07 Table 5 Multivariate analysis for post-RT decompressive surgery Characteristic Odds ratio 95% CI p-value Current smoking 3.23 1.03 – 10.2 0.05# Total score at diagnosis (≥ 6 vs. < 6) 0.87 0.2 – 3.8 0.85 Total score at 1 month (> 4 vs. ≤ 4) 1.22 0.3 – 5.6 0.79 Total score at 4 months* 1.59 1.06 – 2.4 0.03# * denotes continuous variable, # denotes statistical significance. RT = radiation therapy, CI = confidence interval. ",
    "table_content": "|| Characteristic | Odds ratio | 95% CI | p-value ||\n|| Current smoking | 3.23 | 1.03 – 10.2 | 0.05 # ||\n|| Total score at diagnosis | Total score at diagnosis | Total score at diagnosis | Total score at diagnosis ||\n|| (≥ 6 vs. < 6) | 0.87 | 0.2 – 3.8 | 0.85 ||\n|| Total score at 1 month | Total score at 1 month | Total score at 1 month | Total score at 1 month ||\n|| (> 4 vs. ≤ 4) | 1.22 | 0.3 – 5.6 | 0.79 ||\n|| Total score at 4 months* | 1.59 | 1.06 – 2.4 | 0.03 # ||",
    "claim": "The odds ratio for \"Total score at 4 months\" is higher than at diagnosis and 1 month, suggesting that the likelihood of requiring surgery increases over time as the total score changes.",
    "label": "support"
  },
  {
    "id": "training_744_1",
    "table_caption": "Table: Annotations for transcription factor gene models shown in Figure 4. Annotation Number of Gene Models Percentage of Gene Models Figure 4A (TFs high in young seeds) 228 total PF00249 Myb-like DNA-binding domain 26 11.4 PF00096 Zinc finger, C2H2 type 22 9.7 PF02309 AUX/IAA family; NP_851244.1 AUXIN RESPONSE FACTOR 2 [A. thaliana] 15 6.6 XP_002326298.1 AP2/ERF transcription factor 13 5.7 PF00319 SRF-type transcription factor 13 5.7 PF02362 B3 DNA binding domain 11 4.8 XP_002300324.1 global transcription factor group 11 4.8 PF02183 Homeobox associated leucine zipper 8 3.5 PF06217 GAGA binding protein-like family 7 3.1 AAY30856.1 MADS-box transcription factor [P. dulcis] 7 3.1 Other 95 41.7 Figure 4C (TFs high in dry seeds) 108 total XP_002307142.1 AP2/ERF transcription factor 21 19.4 PF02045 CCAAT-binding transcription factor (CBF-B/NF-YA) 11 10.2 PF00170 bZIP transcription factor 10 9.3 PF02365 No apical meristem (NAM) protein 10 9.3 PF00096 Zinc finger, C2H2 type 10 9.3 PF00249 Myb-like DNA-binding domain 5 4.6 CAA87076.1 heat shock transcription factor 21 [G. max] 4 3.7 Other 37 34.3 The gene models in the clusters shown in Figure 4 (transcription factors), divided into representative PFAM and NCBI non-redundant database annotation groups along with the number and percentage (of the cluster’s total) of gene models in each group. The group ‘‘Other’’ represents a miscellaneous category of remaining ",
    "table_content": "|| Annotation | Number of GeneModels | Percentage of Gene Models ||\n||   Figure 4A   (TFs high in young seeds)  |  228 total  | blank ||\n|| PF06217 GAGA binding protein-like family | 7 | 3.1 ||\n|| AAY30856.1 MADS-box transcription factor [P. dulcis] | 7 | 3.1 ||\n|| Other | 95 | 41.7 ||\n||   Figure 4C   (TFs high in dry seeds)  |  108 total  | blank ||\n|| XP_002307142.1 AP2/ERF transcription factor | 21 | 19.4 ||\n|| PF02045 CCAAT-binding transcription factor (CBF-B/NF-YA) | 11 | 10.2 ||\n|| PF00170 bZIP transcription factor | 10 | 9.3 ||\n|| PF02365 No apical meristem (NAM) protein | 10 | 9.3 ||\n|| PF00096 Zinc finger, C2H2 type | 10 | 9.3 ||\n|| PF00249 Myb-like DNA-binding domain | 5 | 4.6 ||\n|| PF00249 Myb-like DNA-binding domain | 26 | 11.4 ||\n|| CAA87076.1 heat shock transcription factor 21 [G. max] | 4 | 3.7 ||\n|| Other | 37 | 34.3 ||\n|| PF00096 Zinc finger, C2H2 type | 22 | 9.7 ||\n|| PF02309 AUX/IAA family; NP_851244.1 AUXIN RESPONSE FACTOR 2 [A. thaliana] | 15 | 6.6 ||\n|| XP_002326298.1 AP2/ERF transcription factor | 13 | 5.7 ||\n|| PF00319 SRF-type transcription factor | 13 | 5.7 ||\n|| PF02362 B3 DNA binding domain | 11 | 4.8 ||\n|| XP_002300324.1 global transcription factor group | 11 | 4.8 ||\n|| PF02183 Homeobox associated leucine zipper | 8 | 3.5 ||",
    "claim": "The Myb-like DNA-binding domain transcription factors constitute a significant portion of the gene models in young seeds, with a calculated representation that is more than double that of the GAGA binding protein-like family and MADS-box transcription factors combined.",
    "label": "support"
  },
  {
    "id": "training_744_1",
    "table_caption": "Table: Annotations for transcription factor gene models shown in Figure 4. Annotation Number of Gene Models Percentage of Gene Models Figure 4A (TFs high in young seeds) 228 total PF00249 Myb-like DNA-binding domain 26 11.4 PF00096 Zinc finger, C2H2 type 22 9.7 PF02309 AUX/IAA family; NP_851244.1 AUXIN RESPONSE FACTOR 2 [A. thaliana] 15 6.6 XP_002326298.1 AP2/ERF transcription factor 13 5.7 PF00319 SRF-type transcription factor 13 5.7 PF02362 B3 DNA binding domain 11 4.8 XP_002300324.1 global transcription factor group 11 4.8 PF02183 Homeobox associated leucine zipper 8 3.5 PF06217 GAGA binding protein-like family 7 3.1 AAY30856.1 MADS-box transcription factor [P. dulcis] 7 3.1 Other 95 41.7 Figure 4C (TFs high in dry seeds) 108 total XP_002307142.1 AP2/ERF transcription factor 21 19.4 PF02045 CCAAT-binding transcription factor (CBF-B/NF-YA) 11 10.2 PF00170 bZIP transcription factor 10 9.3 PF02365 No apical meristem (NAM) protein 10 9.3 PF00096 Zinc finger, C2H2 type 10 9.3 PF00249 Myb-like DNA-binding domain 5 4.6 CAA87076.1 heat shock transcription factor 21 [G. max] 4 3.7 Other 37 34.3 The gene models in the clusters shown in Figure 4 (transcription factors), divided into representative PFAM and NCBI non-redundant database annotation groups along with the number and percentage (of the cluster’s total) of gene models in each group. The group ‘‘Other’’ represents a miscellaneous category of remaining ",
    "table_content": "|| Annotation | Number of GeneModels | Percentage of Gene Models ||\n||   Figure 4A   (TFs high in young seeds)  |  228 total  | blank ||\n|| PF06217 GAGA binding protein-like family | 7 | 3.1 ||\n|| AAY30856.1 MADS-box transcription factor [P. dulcis] | 7 | 3.1 ||\n|| Other | 95 | 41.7 ||\n||   Figure 4C   (TFs high in dry seeds)  |  108 total  | blank ||\n|| XP_002307142.1 AP2/ERF transcription factor | 21 | 19.4 ||\n|| PF02045 CCAAT-binding transcription factor (CBF-B/NF-YA) | 11 | 10.2 ||\n|| PF00170 bZIP transcription factor | 10 | 9.3 ||\n|| PF02365 No apical meristem (NAM) protein | 10 | 9.3 ||\n|| PF00096 Zinc finger, C2H2 type | 10 | 9.3 ||\n|| PF00249 Myb-like DNA-binding domain | 5 | 4.6 ||\n|| PF00249 Myb-like DNA-binding domain | 26 | 11.4 ||\n|| CAA87076.1 heat shock transcription factor 21 [G. max] | 4 | 3.7 ||\n|| Other | 37 | 34.3 ||\n|| PF00096 Zinc finger, C2H2 type | 22 | 9.7 ||\n|| PF02309 AUX/IAA family; NP_851244.1 AUXIN RESPONSE FACTOR 2 [A. thaliana] | 15 | 6.6 ||\n|| XP_002326298.1 AP2/ERF transcription factor | 13 | 5.7 ||\n|| PF00319 SRF-type transcription factor | 13 | 5.7 ||\n|| PF02362 B3 DNA binding domain | 11 | 4.8 ||\n|| XP_002300324.1 global transcription factor group | 11 | 4.8 ||\n|| PF02183 Homeobox associated leucine zipper | 8 | 3.5 ||",
    "claim": "The Myb-like DNA-binding domain transcription factors constitute a significant portion of the gene models in young seeds, with a calculated representation that is less than double that of the GAGA binding protein-like family and MADS-box transcription factors combined.",
    "label": "support"
  },
  {
    "id": "training_146_2",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A O6—H1W···O1v 0.85 (4) 2.10 (3) 2.799 (3) 139 (3) O6—H2W···O5vi 0.86 (4) 1.93 (3) 2.725 (3) 154 (3) O7—H3W···O9vii 0.88 (2) 1.84 (2) 2.687 (3) 162 (4) O7—H4W···O9 0.85 (4) 2.23 (3) 2.995 (4) 151 (3) O8—H5W···O2viii 0.85 (2) 1.85 (2) 2.693 (3) 175 (4) O8—H6W···O3ii 0.85 (4) 1.85 (4) 2.680 (3) 167 (4) O9—H7W···O2ix 0.86 (4) 1.84 (2) 2.699 (3) 175 (4) O9—H8W···O4i 0.85 (4) 2.37 (4) 3.073 (4) 141 (5) Symmetry codes: (v) −x+3/2, y−1/2, −z+1/2; (vi) −x+1, −y+1, −z; (vii) −x+1, −y+1, −z+1; (viii) −x+1, −y+2, −z; (ii) −x+1/2, y+1/2, −z+1/2; (ix) x−1/2, −y+3/2, z+1/2; (i) x+1/2, −y+3/2, z+1/2. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| O6—H1W···O1 v | 0.85 (4) | 2.10 (3) | 2.799 (3) | 139 (3) ||\n|| O6—H2W···O5 vi | 0.86 (4) | 1.93 (3) | 2.725 (3) | 154 (3) ||\n|| O7—H3W···O9 vii | 0.88 (2) | 1.84 (2) | 2.687 (3) | 162 (4) ||\n|| O7—H4W···O9 | 0.85 (4) | 2.23 (3) | 2.995 (4) | 151 (3) ||\n|| O8—H5W···O2 viii | 0.85 (2) | 1.85 (2) | 2.693 (3) | 175 (4) ||\n|| O8—H6W···O3 ii | 0.85 (4) | 1.85 (4) | 2.680 (3) | 167 (4) ||\n|| O9—H7W···O2 ix | 0.86 (4) | 1.84 (2) | 2.699 (3) | 175 (4) ||\n|| O9—H8W···O4 i | 0.85 (4) | 2.37 (4) | 3.073 (4) | 141 (5) ||",
    "claim": "A complex analysis reveals that shorter H···A distances tend to correspond to larger D—H···A angles. For instance, the interaction with the shortest H···A distance of 1.84 Å has one of the largest angles at 175°, indicating a stronger and more linear hydrogen bond, which is a characteristic of optimal hydrogen bonding.",
    "label": "support"
  },
  {
    "id": "training_1080_2",
    "table_caption": "Table: Specifications Table Subject area Biology More specific subject area Phylogenetics; Genetics; Evolutionary Biology Type of data Table, text file, graph, figure How data was acquired High-throughput and Sanger DNA sequencing Data format Text file format for DNA sequence alignments and phylogenetic trees is.nex (nexus) and.tree respectively. Experimental factors Total DNA was extracted from specimens using CTAB buffer. DNA was paired- end sequenced using the high-throughput Illumina HiSeq. 2500 platform. Short-length DNA sequences were amplified via PCR and Sanger sequenced. Experimental features mtDNA genome and 45 S nuclear ribosomal DNA sequences were assembled using reference sequences. Sequences were aligned with gaps and poorly- aligned positions removed. Phylogenetic trees were constructed using Baye- sian (BEAST 1.8.3) and Maximum-Likelihood methods (RAxML 8.2.8). The unrooted phylogenetic network of some alignments was investigated using SplitsTree 4. Data source location Most specimens originate from New Zealand waters, some were collected from the coasts of Australia, Japan, USA (California), and the UK. Data accessibility Interactive.nwk (Newick) tree files are provided here and with the main article [1]. ",
    "table_content": "|| Subject area | Biology ||\n|| More specific subject area | Phylogenetics; Genetics; Evolutionary Biology ||\n|| Type of data | Table, text file, graph, figure ||\n|| How data was acquired | High-throughput and Sanger DNA sequencing ||\n|| Data format | Text file format for DNA sequence alignments and phylogenetic trees is.nex (nexus) and.tree respectively. ||\n|| Experimental factors | Total DNA was extracted from specimens using CTAB buffer. DNA was paired-end sequenced using the high-throughput Illumina HiSeq. 2500 platform. Short-length DNA sequences were amplified via PCR and Sanger sequenced. ||\n|| Experimental features | mtDNA genome and 45 S nuclear ribosomal DNA sequences were assembled using reference sequences. Sequences were aligned with gaps and poorly-aligned positions removed. Phylogenetic trees were constructed using Bayesian (BEAST 1.8.3) and Maximum-Likelihood methods (RAxML 8.2.8). The unrooted phylogenetic network of some alignments was investigated using SplitsTree 4. ||\n|| Data source location | Most specimens originate from New Zealand waters, some were collected from the coasts of Australia, Japan, USA (California), and the UK. ||\n|| Data accessibility | Interactive.nwk (Newick) tree files are provided here and with the main article [1] . ||",
    "claim": "The extraction of total DNA using CTAB buffer and subsequent sequencing indicates a comprehensive approach to capturing both mitochondrial and nuclear DNA. This dual approach enhances the phylogenetic resolution by providing a more complete genetic picture, which is crucial for accurate evolutionary analysis.",
    "label": "support"
  },
  {
    "id": "training_754_1",
    "table_caption": "Table: coating when was earlier 10%, fluid. be upper acetylharpagide test colon-targeted tablets and reference core tablets in Beagle dogs. Parameter Reference Test Lambda_z (mL·h−1) 0.4963 ± 0.1439 0.2337 ± 0.0534 HL_Lambdaz (h) 1.49 ± 0.38 3.09 ± 0.66 Tmax (h) 2.00 ± 0.00 9.00 ± 0.00 Cmax (µg·mL−1) 2.18 ± 0.10 0.62 ± 0.03 AUClast (µg·h·mL−1) 6.26 ± 1.73 2.05 ± 0.22 AUCINF_obs (µg·h·mL−1) 6.37 ± 1.76 2.08 ± 0.22 Vz_F_obs (mL) 7151 ± 2780 42891 ± 7685 Cl_F_obs (mL·h−1) 3351 ± 928 9720 ± 1071 MRTlast (h) 3.18 ± 0.30 9.34 ± 0.41 MRTINF_obs (h) 3.33 ± 0.39 9.57 ± 0.55 Data are shown as mean ± standard deviation (n = 6). ",
    "table_content": "|| Parameter | Reference | Test ||\n|| Lambda_z (mL·h −1 ) | 0.4963 ± 0.1439 | 0.2337 ± 0.0534 ||\n|| MRT INF_obs (h) | 3.33 ± 0.39 | 9.57 ± 0.55 ||\n|| HL_Lambdaz (h) | 1.49 ± 0.38 | 3.09 ± 0.66 ||\n|| T max (h) | 2.00 ± 0.00 | 9.00 ± 0.00 ||\n|| C max (μg·mL −1 ) | 2.18 ± 0.10 | 0.62 ± 0.03 ||\n|| AUC last (μg·h·mL −1 ) | 6.26 ± 1.73 | 2.05 ± 0.22 ||\n|| AUC INF_obs (μg·h·mL −1 ) | 6.37 ± 1.76 | 2.08 ± 0.22 ||\n|| Vz_F_obs (mL) | 7151 ± 2780 | 42891 ± 7685 ||\n|| Cl_F_obs (mL·h −1 ) | 3351 ± 928 | 9720 ± 1071 ||\n|| MRT last (h) | 3.18 ± 0.30 | 9.34 ± 0.41 ||",
    "claim": "** The test tablets exhibit a half-life that is more than double that of the reference tablets, which is consistent with the observed reduction in the elimination rate constant by more than half. This suggests a slower elimination process for the test tablets.",
    "label": "support"
  },
  {
    "id": "training_975_2",
    "table_caption": "Table: Epidemic MRSA clones identified during the study period 2006–2010. Frequency of isolation of the clone MRSA clone (%)a 2006 2007 2008 2009 2010 Major variants of the clone (%)b ST22-IV (33,3%) 20,4% 26,5% 35% 36,7% 38,8% A (28%); B (25%); C (7%) ST228-I (26%) 31,8% 33,6% 29,8% 22,7% 20,9% B2 (16%); B5 (13%); B1 (8%) ST8-IV (15,8%) 6,8% 16,3% 21,6% 17,2% 17,8% A1 (23%); A2 (22%); B (21%); C (11%) aPercent of MRSA strains belonging to each clone, considering only the index cases (n = 499); bpercent of MRSA strains belonging to the major variants of each epidemic clone identified (n = 166 for ST22-IV; n = 131 for ST228-I; n = 80 for ST8-IV). ",
    "table_content": "|| MRSA clone (%) a | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Major variants of the clone (%) b ||\n|| MRSA clone (%) a | 2006 | 2007 | 2008 | 2009 | 2010 | Major variants of the clone (%) b ||\n|| ST22-IV (33,3%) | 20,4% | 26,5% | 35% | 36,7% | 38,8% | A (28%); B (25%); C (7%) ||\n|| ST228-I (26%) | 31,8% | 33,6% | 29,8% | 22,7% | 20,9% | B2 (16%); B5 (13%); B1 (8%) ||\n|| ST8-IV (15,8%) | 6,8% | 16,3% | 21,6% | 17,2% | 17,8% | A1 (23%); A2 (22%); B (21%); C (11%) ||",
    "claim": "The average frequency of the ST228-I clone over the five years was approximately 27.76%, which is about 1.75 times higher than the average frequency of the ST8-IV clone, which was around 15.94%.",
    "label": "support"
  },
  {
    "id": "training_1067_4",
    "table_caption": "Table: sider value cancer ever, benefit A ticular sis, by Table 8 Multivariate Analysis for thromboembolic events Factor Odds Ratio 95% Confidence Limits P-value Primary Tumor (Gastric vs. Others) 3.377 1.759–6.483 0.0003 Gender (Female vs. Male) 1.732 1.152–2.605 0.0083 Khorana risk group (High vs. Others) 1.387 0.842–2.285 0.1992 Central Venous Catheter (Presence vs. Absence) 1.098 0.603–1.999 0.7599 Stage (IV vs. Early stage) 1.665 1.054–2.63 0.0289 ",
    "table_content": "|| Factor | Odds Ratio | 95% Confidence Limits | P -value ||\n|| Primary Tumor (Gastric vs. Others) | 3.377 | 1.759–6.483 | 0.0003 ||\n|| Gender (Female vs. Male) | 1.732 | 1.152–2.605 | 0.0083 ||\n|| Khorana risk group (High vs. Others) | 1.387 | 0.842–2.285 | 0.1992 ||\n|| Central Venous Catheter (Presence vs. Absence) | 1.098 | 0.603–1.999 | 0.7599 ||\n|| Stage (IV vs. Early stage) | 1.665 | 1.054–2.63 | 0.0289 ||",
    "claim": "The presence of a central venous catheter is associated with a 9.8% increase in the odds of thromboembolic events compared to its absence. The odds ratio of 1.098 and a p-value of 0.7599 suggest that this factor does not have a statistically significant impact on the risk.",
    "label": "support"
  },
  {
    "id": "training_1031_3",
    "table_caption": "Table: Soil physical properties in the experimental field. Depth (cm) Particle size distribution (%) Bulk density g cm23 SLLLa SDULb SSKSc cm d21 SSATd Organic C (%) pH Clay Silt Sand 0–15 18 50 31 1.15 0.09 0.28 1.42 0.30 1.8 6.5 15–30 24 49 26 1.25 0.09 0.28 1.43 0.30 1.5 6.6 30–45 23 52 24 1.35 0.09 0.28 2.76 0.32 1.3 7.0 Swift Current 45–60 25 33 41 1.4.0 0.10 0.27 4.32 0.34 0.9 7.7 60–90 32 28 40 1.45 0.10 0.27 5.61 0.34 0.5 7.8 90–120 33 26 41 1.55 0.10 0.25 3.04 0.34 0.3 8.1 120–150 33 28 40 1.65 0.10 0.25 3.04 0.34 0.1 8.5 0–15 60 29 11 1.30 0.11 0.37 7.40 0.59 2.9 7.0 15–45 60 28 12 1.40 0.11 0.37 7.68 0.57 1.0 7.3 Saskatoon 45–80 60 28 12 1.50 0.11 0.36 5.08 0.53 0.3 7.5 80–100 60 37 3 1.50 0.11 0.36 1.38 0.53 0.3 8.0 0–19 50 40 10 1.20 0.20 0.45 0.34 0.55 4.5 6.8 Melfort 19–58 49 44 7 1.30 0.20 0.46 0.29 0.51 1.3 7.0 58–100 52 45 3 1.30 0.20 0.46 0.25 0.51 0.5 8.0 aLower limit of plant extractable soil water (cm3 cm23). bDrained upper limit (cm3 cm23). ",
    "table_content": "|| blank | Depth (cm) | Particle size distribution (%) | Particle size distribution (%) | Particle size distribution (%) | Bulk density g cm −3 | SLLL a | SDUL b | SSKS c cm d −1 | SSAT d | Organic C (%) | pH ||\n|| blank | Depth (cm) | Clay | Silt | Sand | Bulk density g cm −3 | SLLL a | SDUL b | SSKS c cm d −1 | SSAT d | Organic C (%) | pH ||\n|| Swift Current | 15–45 | 60 | 28 | 12 | 1.40 | 0.11 | 0.37 | 7.68 | 0.57 | 1.0 | 7.3 ||\n|| Saskatoon | 45–80 | 60 | 28 | 12 | 1.50 | 0.11 | 0.36 | 5.08 | 0.53 | 0.3 | 7.5 ||\n|| Saskatoon | 80–100 | 60 | 37 | 3 | 1.50 | 0.11 | 0.36 | 1.38 | 0.53 | 0.3 | 8.0 ||\n|| Saskatoon | 0–19 | 50 | 40 | 10 | 1.20 | 0.20 | 0.45 | 0.34 | 0.55 | 4.5 | 6.8 ||\n|| Melfort | 19–58 | 49 | 44 | 7 | 1.30 | 0.20 | 0.46 | 0.29 | 0.51 | 1.3 | 7.0 ||\n|| Melfort | 58–100 | 52 | 45 | 3 | 1.30 | 0.20 | 0.46 | 0.25 | 0.51 | 0.5 | 8.0 ||\n|| blank | 0–15 | 18 | 50 | 31 | 1.15 | 0.09 | 0.28 | 1.42 | 0.30 | 1.8 | 6.5 ||\n|| blank | 15–30 | 24 | 49 | 26 | 1.25 | 0.09 | 0.28 | 1.43 | 0.30 | 1.5 | 6.6 ||\n|| blank | 30–45 | 23 | 52 | 24 | 1.35 | 0.09 | 0.28 | 2.76 | 0.32 | 1.3 | 7.0 ||\n|| Swift Current | 45–60 | 25 | 33 | 41 | 1.4.0 | 0.10 | 0.27 | 4.32 | 0.34 | 0.9 | 7.7 ||\n|| Swift Current | 60–90 | 32 | 28 | 40 | 1.45 | 0.10 | 0.27 | 5.61 | 0.34 | 0.5 | 7.8 ||\n|| Swift Current | 90–120 | 33 | 26 | 41 | 1.55 | 0.10 | 0.25 | 3.04 | 0.34 | 0.3 | 8.1 ||\n|| Swift Current | 120–150 | 33 | 28 | 40 | 1.65 | 0.10 | 0.25 | 3.04 | 0.34 | 0.1 | 8.5 ||\n|| Swift Current | 0–15 | 60 | 29 | 11 | 1.30 | 0.11 | 0.37 | 7.40 | 0.59 | 2.9 | 7.0 ||",
    "claim": "The organic carbon content decreases by 96.6% from the surface to the deepest layer in Swift Current, highlighting the rapid decline of organic matter with depth, which can impact soil fertility and microbial activity.",
    "label": "support"
  },
  {
    "id": "training_652_4",
    "table_caption": "Table: Table 2 The detail results of Kaplan-Meier survival analysis miRNA 2-dCt value (DFS) Median DFS P-value 2-dCt value (OS) Median OS P-value miR-21 < 22.68 14.2 months 0.0011 <27.15 19.1 months 0.0427 >22.68 7.5 months >27.15 15.2 months miR-198 <0.01208 15.3 months 0.0001 <0.01393 22.6 months 0.0097 >0.01208 9.5 months >0.01393 15.2 months miR-34a <2.178 9.6 months 0.7186 <2.421 14.9 months 0.9320 >2.178 11.5 months >2.421 16.9 months miR-217 <0.08092 9.6 months 0.1716 <0.06097 14.9 months 0.1370 >0.08092 12.2 months >0.06087 21.5 months miR-21/miR-198 low levels of both miRNAsa 18.2 months <0.0001 low levels of both miRNAsb 23.7 months 0.0015 high level of one/both miRNAsc 8 months high level of one/both miRNAsd 14.9 months alow levels of both miRNAs = level of miR-21 < 22.68 and level of miR-198 < 0.01208. blow levels of both miRNAs = level of miR-21 < 27.15 and level of miR-198 < 0.01393. chigh level of one/both miRNAs = level of miR-21 > 22.68 or/and level of miR-198 > 0.01208. ",
    "table_content": "||  miRNA  |  2  -dCt  value (DFS)  |  Median DFS  |  P-value  |  2  -dCt  value (OS)  |  Median OS  |  P-value  ||\n|| miR-21 | < 22.68 | 14.2 months |  0.0011  | <27.15 | 19.1 months |  0.0427  ||\n|| miR-21/miR-198 | high level of one/both miRNAs c  | 8 months |  <0.0001  | high level of one/both miRNAs d  | 14.9 months |  0.0015  ||\n|| miR-21 | >22.68 | 7.5 months |  0.0011  | >27.15 | 15.2 months |  0.0427  ||\n|| miR-198 | <0.01208 | 15.3 months |  0.0001  | <0.01393 | 22.6 months |  0.0097  ||\n|| miR-198 | >0.01208 | 9.5 months |  0.0001  | >0.01393 | 15.2 months |  0.0097  ||\n|| miR-34a | <2.178 | 9.6 months | 0.7186 | <2.421 | 14.9 months | 0.9320 ||\n|| miR-34a | >2.178 | 11.5 months | 0.7186 | >2.421 | 16.9 months | 0.9320 ||\n|| miR-217 | <0.08092 | 9.6 months | 0.1716 | <0.06097 | 14.9 months | 0.1370 ||\n|| miR-217 | >0.08092 | 12.2 months | 0.1716 | >0.06087 | 21.5 months | 0.1370 ||\n|| miR-21/miR-198 | low levels of both miRNAs a  | 18.2 months |  <0.0001  | low levels of both miRNAs b  | 23.7 months |  0.0015  ||",
    "claim": "The increase in median DFS from low to high miR-217 levels is 2.6 months, and the increase in median OS is 6.6 months. This indicates a more pronounced effect of miR-217 levels on OS than DFS.",
    "label": "support"
  },
  {
    "id": "training_121_3",
    "table_caption": "Table: Case NGO characteristics. NGO (pseudonym) Geographic base and reach Focus areas Annual budget Total staff in Malawi Research staff and skills Research experience and focus MALN Malawian NGO, working in several districts and with some national programmes. Women and young people, including HIV and reproductive health. Over $1 million. Over 70. - No staff with dedicated time for research. - Small number of staff with experience of university or NGO research projects, or short-term research training (e.g. one week). - Research recently included in organisational mission and strategy. - Experience of conducting several studies, mainly for internal use but some aimed at district/national government. - Situation analyses to support specific service delivery projects, broader needs assessments to inform future programmes and policy, and assessments of government service delivery as a basis for advocacy. - Typically fieldwork of a few weeks and combining surveys, interviews and focus groups. INTA INGO with a headquarters in a high- income country and working in around 70 countries. Health service delivery, especially HIV. Around $15 million in Malawi. Around 800 - Two full-time research staff. Additional research assistants recruited as needed. - Research staff both have several years of research experience in Northern universities. International research policy that provides high-level commitment to research. Over 10 years of research experience in Malawi. - Focus on operational research aimed at internal, national and international audiences, including prospective studies to test new interventions and assessments of existing activities. - Designs include multi-year trials, use of existing quantitative datasets, and qualitative studies using interviews and focus groups. INTB INGO with a headquarters in a high- income country and working in around 8 countries Multi-sector approach including work on nutrition, water and sanitation, HIV, malaria and livelihoods. Around $11 million in Malawi Around 400 - Research manager whose time is split between research and other programme support. - Research manager has masters-level research training. Several other staff with short- term research experience through previous university or NGO work. - Research included in country strategy. Growing record of research, primarily for internal or national audiences, with some aimed internationally. - Situation analyses to support specific service delivery projects, assessments of the impacts of NGO and government programmes to inform wider policy and practice, and operational research (e.g. field testing new technologies). Designs vary: typically fieldwork of a few weeks combining surveys, interviews, focus groups and observation, but some longer-term trials. https://doi.org/10.1371/journal.pone.0198721.t001 ",
    "table_content": "|| NGO (pseudonym) | Geographic base and reach | Focus areas | Annual budget | Total staff in Malawi | Research staff and skills | Research experience and focus ||\n|| MALN | Malawian NGO, working in several districts and with some national programmes. | Women and young people, including HIV and reproductive health. | Over $1 million. | Over 70. | - No staff with dedicated time for research. - Small number of staff with experience of university or NGO research projects, or short-term research training (e.g. one week). | - Research recently included in organisational mission and strategy. - Experience of conducting several studies, mainly for internal use but some aimed at district/national government. - Situation analyses to support specific service delivery projects, broader needs assessments to inform future programmes and policy, and assessments of government service delivery as a basis for advocacy. - Typically fieldwork of a few weeks and combining surveys, interviews and focus groups. ||\n|| INTA | INGO with a headquarters in a high-income country and working in around 70 countries. | Health service delivery, especially HIV. | Around $15 million in Malawi. | Around 800 | - Two full-time research staff. Additional research assistants recruited as needed. - Research staff both have several years of research experience in Northern universities. | International research policy that provides high-level commitment to research. Over 10 years of research experience in Malawi. - Focus on operational research aimed at internal, national and international audiences, including prospective studies to test new interventions and assessments of existing activities. - Designs include multi-year trials, use of existing quantitative datasets, and qualitative studies using interviews and focus groups. ||\n|| INTB | INGO with a headquarters in a high-income country and working in around 8 countries | Multi-sector approach including work on nutrition, water and sanitation, HIV, malaria and livelihoods. | Around $11 million in Malawi | Around 400 | - Research manager whose time is split between research and other programme support. - Research manager has masters-level research training. Several other staff with short-term research experience through previous university or NGO work. | - Research included in country strategy. Growing record of research, primarily for internal or national audiences, with some aimed internationally. - Situation analyses to support specific service delivery projects, assessments of the impacts of NGO and government programmes to inform wider policy and practice, and operational research (e.g. field testing new technologies). Designs vary: typically fieldwork of a few weeks combining surveys, interviews, focus groups and observation, but some longer-term trials. ||",
    "claim": "INTA employs two full-time research staff with several years of experience in Northern universities, indicating a higher level of research expertise compared to MALN, which has no staff with dedicated research time. This suggests that INTA is better equipped to conduct complex, multi-year research projects.",
    "label": "support"
  },
  {
    "id": "training_965_3",
    "table_caption": "Table: Table 2 Average Pfirrmann scores of different discs in different groups Group A Group B Group C B1 B2 C1 C2 n 150 148 232 100 142 L1/2 2.85 ± 0.89 2.90 ± 0.77 3.29 ± 0.56a,b 3.31 ± 0.66a,b 3.63 ± 0.89a,c,d L2/3 2.86 ± 0.78 2.91 ± 0.69 3.33 ± 0.72a,b 3.34 ± 0.69a,b 3.69 ± 0.92a,c,d L3/4 2.90 ± 0.98 3.02 ± 0.90 3.37 ± 0.76a,b 3.40 ± 0.71a,b 3.72 ± 0.93a,c,d L4/5 2.91 ± 0.67 3.05 ± 0.70 3.40 ± 0.99a,b 3.48 ± 0.91a,b 3.81 ± 0.79a,c,d L5/S1 2.94 ± 0.81 3.10 ± 0.66 3.47 ± 0.76①② 3.49 ± 0.74①② 3.83 ± 0.86①③④ Comparisons were done after adjustment for age effect aPairwise comparisons to group A, P < 0.05 bPairwise comparisons to group B1, P < 0.05 ",
    "table_content": "|| blank | Group A | Group B | Group B | Group C | Group C ||\n|| blank | Group A | B1 | B2 | C1 | C2 ||\n||  n  | 150 | 148 | 232 | 100 | 142 ||\n|| L1/2 | 2.85 ± 0.89 | 2.90 ± 0.77 | 3.29 ± 0.56 a,b | 3.31 ± 0.66 a,b | 3.63 ± 0.89 a,c,d ||\n|| L2/3 | 2.86 ± 0.78 | 2.91 ± 0.69 | 3.33 ± 0.72 a,b | 3.34 ± 0.69 a,b | 3.69 ± 0.92 a,c,d ||\n|| L3/4 | 2.90 ± 0.98 | 3.02 ± 0.90 | 3.37 ± 0.76 a,b | 3.40 ± 0.71 a,b | 3.72 ± 0.93 a,c,d ||\n|| L4/5 | 2.91 ± 0.67 | 3.05 ± 0.70 | 3.40 ± 0.99 a,b | 3.48 ± 0.91 a,b | 3.81 ± 0.79 a,c,d ||\n|| L5/S1 | 2.94 ± 0.81 | 3.10 ± 0.66 | 3.47 ± 0.76 ①② | 3.49 ± 0.74 ①② | 3.83 ± 0.86 ①③④ ||",
    "claim": "The overall average Pfirrmann score for Group C2 is approximately 3.74, which is about 25% higher than the overall average score for Group A, indicating a higher degree of disc degeneration in Group C2.",
    "label": "support"
  },
  {
    "id": "training_1024_5",
    "table_caption": "Table: in parentheses). Table 6. Mean BMI (kg/m²) within underweight, normal weight, overweight, and obesity Boys Girls BMI category Year 14 15 14 15 Under 1992 16.0 (0.7) 16.5 (0.6) 16.3 (0.8) 16.8 (0.7) 1997 15.7 (0.8) 16.4 (0.9) 16.3 (0.6) 16.7 (0.9) 2000 15.9 (0.7) 16.3 (0.9) 16.4 (0.8) 16.7 (0.8) 2006 15.8 (0.6) 16.2 (0.9) 16.2 (0.8) 16.6 (0.9) Linear trend F (1,3) = 2.32 p = 0.129 F (1,3) = 2.52 p = 0.114 F (1,3) = 0.29 p =.594 F (1,3) = 4.13 p = 0.043 Normal 1992 19.8 (1.5) 20.4 (1.5) 20.0(1.6) 20.5 (1.6) 1997 19.7 (1.5) 20.4 (1.5) 19.9 (1.6) 20.5 (1.7) 2000 20.0 (1.6) 20.6 (1.6) 19.9 (1.7) 20.5 (1.7) 2006 19.9 (1.6) 20.6 (1.6) 20.1 (1.7) 20.5 (1.7) Linear trend F (1,3) = 6.49 p = 0.011 F (1,3) = 12.78 p = 0.000 F (1,3) = 2.63 p = 0.105 F (1,3) = 0.18 p = 0.669 Over 1992 24.7 (1.2) 25.3 (1.3) 25.4 (1.3) 25.9 (1.3) 1997 24.6 (1.4) 25.0 (1.2) 25.4 (1.4) 26.0 (1.4) 2000 24.7 (1.4) 25.4 (1.4) 25.4 (1.3) 25.9 (1.3) 2006 24.8 (1.3) 25.4 (1.4) 25.3 (1.4) 26 0.0 (1.3) Linear trend F (1,3) = 1.14 p = 0.287 F (1,3) = 2.72 p = 0.100 F (1.3) = 0.21 p = 0.644 F (1,3) = 0.45 p = 0.505 Obese 1992 30.6 (1.4) 30.0 (1.2) 31.4 (1.6) 31.2 (1.4) 1997 30.9 (2.1) 30.3 (1.5) 30.7 (1.3) 30.7 (1.0) 2000 30.6 (1.9) 30.8 (1.7) 30.7 (1.5) 31.2 (1.5) 2006 30.8 (2.1) 30.9 (1.8) 31.3 (1.5) 31.2 (1.5) Linear trend F (1,3) = 0.17 p = 0.684 F (1,3) = 5.20 p = 0.024 F (1.3) = 0.07 p = 0.793 F (1.3) = 0.17 p = 0.680 ",
    "table_content": "|| BMI category | Year | Boys | Boys | Girls | Girls ||\n|| BMI category | Year | 14 | 15 | 14 | 15 ||\n|| Normal | 2006 | 19.9 (1.6) | 20.6 (1.6) | 20.1 (1.7) | 20.5 (1.7) ||\n|| Linear trend | Linear trend | F (1,3) = 6.49 p = 0.011 | F (1,3) = 12.78 p = 0.000 | F (1,3) = 2.63 p = 0.105 | F (1,3) = 0.18 p = 0.669 ||\n|| Over | 1992 | 24.7 (1.2) | 25.3 (1.3) | 25.4 (1.3) | 25.9 (1.3) ||\n|| Over | 1997 | 24.6 (1.4) | 25.0 (1.2) | 25.4 (1.4) | 26.0 (1.4) ||\n|| Over | 2000 | 24.7 (1.4) | 25.4 (1.4) | 25.4 (1.3) | 25.9 (1.3) ||\n|| Over | 2006 | 24.8 (1.3) | 25.4 (1.4) | 25.3 (1.4) | 26 0.0 (1.3) ||\n|| Linear trend | Linear trend | F (1,3) = 1.14 p = 0.287 | F (1,3) = 2.72 p = 0.100 | F (1.3) = 0.21 p = 0.644 | F (1,3) = 0.45 p = 0.505 ||\n|| Obese | 1992 | 30.6 (1.4) | 30.0 (1.2) | 31.4 (1.6) | 31.2 (1.4) ||\n|| Obese | 1997 | 30.9 (2.1) | 30.3 (1.5) | 30.7 (1.3) | 30.7 (1.0) ||\n|| Obese | 2000 | 30.6 (1.9) | 30.8 (1.7) | 30.7 (1.5) | 31.2 (1.5) ||\n|| Under | 1992 | 16.0 (0.7) | 16.5 (0.6) | 16.3 (0.8) | 16.8 (0.7) ||\n|| Obese | 2006 | 30.8 (2.1) | 30.9 (1.8) | 31.3 (1.5) | 31.2 (1.5) ||\n|| Linear trend | Linear trend | F (1,3) = 0.17 p = 0.684 | F (1,3) = 5.20 p = 0.024 | F (1.3) = 0.07 p = 0.793 | F (1.3) = 0.17 p = 0.680 ||\n|| Under | 1997 | 15.7 (0.8) | 16.4 (0.9) | 16.3 (0.6) | 16.7 (0.9) ||\n|| Under | 2000 | 15.9 (0.7) | 16.3 (0.9) | 16.4 (0.8) | 16.7 (0.8) ||\n|| Under | 2006 | 15.8 (0.6) | 16.2 (0.9) | 16.2 (0.8) | 16.6 (0.9) ||\n|| Linear trend | Linear trend | F (1,3) = 2.32 p = 0.129 | F (1,3) = 2.52 p = 0.114 | F (1,3) = 0.29 p =.594 | F (1,3) = 4.13 p = 0.043 ||\n|| Normal | 1992 | 19.8 (1.5) | 20.4 (1.5) | 20.0(1.6) | 20.5 (1.6) ||\n|| Normal | 1997 | 19.7 (1.5) | 20.4 (1.5) | 19.9 (1.6) | 20.5 (1.7) ||\n|| Normal | 2000 | 20.0 (1.6) | 20.6 (1.6) | 19.9 (1.7) | 20.5 (1.7) ||",
    "claim": "For boys in the overweight category, the BMI of 15-year-olds increased by 0.1 kg/m² from 1992 to 2006, while the BMI of 14-year-olds increased by 0.1 kg/m², showing a parallel increase in BMI across both age groups over the years.",
    "label": "support"
  },
  {
    "id": "training_423_3",
    "table_caption": "Table: Table 3 Analysis of molecular variance (AMOVA)*. Source of variance Df Sum Sq Mean Sq Variance components % P Among groups 3 157.540 52.513 0.819 15.0 <0.001 Among individuals 124 642.343 5.180 0.623 12.0 <0.001 Within individuals 128 503.500 3.934 3.934 73.0 <0.001 F-statistics Value Fst (among populations) 0.152 Fis (within populations) 0.137 Fit (total) 0.268 Fst max 0.241 F’st 0.632 Notes: P-value is based on 1,000 permutations. Df, degree of freedom; SS, sum of squares; MN, mean squares; %, percentage of total variation. ",
    "table_content": "|| Source of variance | Df | Sum Sq | Mean Sq | Variance components | % | P ||\n|| Among groups | 3 | 157.540 | 52.513 | 0.819 | 15.0 | <0.001 ||\n|| Among individuals | 124 | 642.343 | 5.180 | 0.623 | 12.0 | <0.001 ||\n|| Within individuals | 128 | 503.500 | 3.934 | 3.934 | 73.0 | <0.001 ||\n|| F -statistics | Value | blank | blank | blank | blank | blank ||\n|| F st (among populations) | 0.152 | blank | blank | blank | blank | blank ||\n|| F is (within populations) | 0.137 | blank | blank | blank | blank | blank ||\n|| F it (total) | 0.268 | blank | blank | blank | blank | blank ||\n|| F st max | 0.241 | blank | blank | blank | blank | blank ||\n|| F ’ st | 0.632 | blank | blank | blank | blank | blank ||",
    "claim": "The variance component within individuals accounts for 73% of the total variance, which is more than 6 times the contribution of variance among individuals, highlighting the predominance of intra-individual genetic variation in the overall genetic structure.",
    "label": "support"
  },
  {
    "id": "training_1432_5",
    "table_caption": "Table: Summary Statistics of Net Change and Mean Hidden Hunger Index (HHI) Score 1995–2011, by UNICEF Region and Geographical Subregion. Region n Net HHI change 1995–2011 HHI All Years (1995–2011) HHI 1995 HHI 2000 HHI 2005 HHI 2011 countries with increase countries with decrease Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) n (%) n (%) Africa 46 1.90 (3.21) 36.97 (4.75) 35.43 (5.18) 36.85 (5.07) 37.61 (4.66) 37.33 (3.94) 35 (76.1) 11 (23.9) West and Central Africa 24 2.74 (2.37) 36.52 (4.13) 34.58 (4.10) 36.34 (4.27) 37.13 (4.15) 37.32 (3.89) 19 (79.2) 5 (20.8) East and Southern Africa 22 1.06 (3.74) 37.42 (5.25) 36.29 (6.05) 37.36 (5.82) 38.08 (5.17) 37.34 (4.07) 16 (72.7) 6 (27.3) Americas 33 -4.83 (1.59) 14.67 (3.85) 17.76 (3.91) 15.24 (3.75) 13.85 (3.56) 12.93 (3.04) 0 (0) 33 (100) Central America 8 -6.07 (1.41) 16.88 (3.65) 20.71 (3.43) 17.63 (3.24) 15.78 (3.33) 14.65 (3.22) 0 (0) 8 (100) South America 11 -4.48 (1.46) 13.73 (3.33) 16.61 (3.34) 14.25 (3.41) 13.00 (3.25) 12.13 (2.42) 0 (0) 11 (100) Caribbean 14 -3.41 (1.04) 15.07 (5.34) 17.33 (5.75) 15.38 (5.54) 14.49 (5.29) 13.92 (5.15) 0 (0) 14 (100) Middle East and North Africa 20 -3.44 (1.95) 19.51 (6.98) 21.67 (6.45) 19.77 (7.01) 19.11 (7.30) 18.23 (7.25) 2 (10) 18 (90) Middle East 14 -4.37 (1.00) 18.22 (6.50) 20.87 (6.68) 18.67 (6.49) 17.68 (6.62) 16.49 (6.67) 0 (0) 14 (100) North Africa 6 -2.47 (2.34) 20.85 (7.22) 22.51 (6.60) 20.92 (7.88) 20.60 (8.24) 20.03 (7.95) 2 (33.3) 4 (66.7) Central and Eastern Europe 9 -4.74 (0.92) 17.33 (3.97) 20.06 (3.71) 18.10 (4.22) 16.62 (3.89) 15.32 (3.21) 0 (0) 9 (100) South Asia 8 -4.40 (2.61) 37.94 (3.08) 40.14 (2.77) 38.63 (2.93) 37.57 (3.07) 35.75 (3.01) 1 (12.5) 7 (87.5) East Asia and the Paciﬁc 21 -12.97 (2.09) 17.69 (7.33) 25.97 (6.35) 19.51 (6.60) 15.17 (6.24) 13.00 (5.27) 0 (0) 21 (100) Global 138 -6.72 (5.73) 25.90 (11.53) 29.96 (9.40) 26.86 (10.98) 24.81 (12.08) 23.25 (12.07) 38 (27.5) 100 (72.5) SD, standard deviation of the country-level net change in HHI or mean HHI across the countries in each region or sub-region; Note: All regional and sub- regional summary statistics are weighted by country size, calculated as mean country population in 1995 and 2010, as presented by the United Nations ",
    "table_content": "|| Region | n | Net HHI change 1995–2011 Mean (SD) | HHI All Years (1995–2011) Mean (SD) | HHI 1995 Mean (SD) | HHI 2000 Mean (SD) | HHI 2005 Mean (SD) | HHI 2011 Mean (SD) | countries with increase n (%) | countries with decrease n (%) ||\n|| Region | n | Net HHI change 1995–2011 Mean (SD) | HHI All Years (1995–2011) Mean (SD) | HHI 1995 Mean (SD) | HHI 2000 Mean (SD) | HHI 2005 Mean (SD) | HHI 2011 Mean (SD) | countries with increase n (%) | countries with decrease n (%) ||\n|| Middle East | 14 | -4.37 (1.00) | 18.22 (6.50) | 20.87 (6.68) | 18.67 (6.49) | 17.68 (6.62) | 16.49 (6.67) | 0 (0) | 14 (100) ||\n|| North Africa | 6 | -2.47 (2.34) | 20.85 (7.22) | 22.51 (6.60) | 20.92 (7.88) | 20.60 (8.24) | 20.03 (7.95) | 2 (33.3) | 4 (66.7) ||\n|| Central and Eastern Europe | 9 | -4.74 (0.92) | 17.33 (3.97) | 20.06 (3.71) | 18.10 (4.22) | 16.62 (3.89) | 15.32 (3.21) | 0 (0) | 9 (100) ||\n|| South Asia | 8 | -4.40 (2.61) | 37.94 (3.08) | 40.14 (2.77) | 38.63 (2.93) | 37.57 (3.07) | 35.75 (3.01) | 1 (12.5) | 7 (87.5) ||\n|| East Asia and the Pacific | 21 | -12.97 (2.09) | 17.69 (7.33) | 25.97 (6.35) | 19.51 (6.60) | 15.17 (6.24) | 13.00 (5.27) | 0 (0) | 21 (100) ||\n|| Global | 138 | -6.72 (5.73) | 25.90 (11.53) | 29.96 (9.40) | 26.86 (10.98) | 24.81 (12.08) | 23.25 (12.07) | 38 (27.5) | 100 (72.5) ||\n|| Africa | 46 | 1.90 (3.21) | 36.97 (4.75) | 35.43 (5.18) | 36.85 (5.07) | 37.61 (4.66) | 37.33 (3.94) | 35 (76.1) | 11 (23.9) ||\n|| West and Central Africa | 24 | 2.74 (2.37) | 36.52 (4.13) | 34.58 (4.10) | 36.34 (4.27) | 37.13 (4.15) | 37.32 (3.89) | 19 (79.2) | 5 (20.8) ||\n|| East and Southern Africa | 22 | 1.06 (3.74) | 37.42 (5.25) | 36.29 (6.05) | 37.36 (5.82) | 38.08 (5.17) | 37.34 (4.07) | 16 (72.7) | 6 (27.3) ||\n|| Americas | 33 | -4.83 (1.59) | 14.67 (3.85) | 17.76 (3.91) | 15.24 (3.75) | 13.85 (3.56) | 12.93 (3.04) | 0 (0) | 33 (100) ||\n|| Central America | 8 | -6.07 (1.41) | 16.88 (3.65) | 20.71 (3.43) | 17.63 (3.24) | 15.78 (3.33) | 14.65 (3.22) | 0 (0) | 8 (100) ||\n|| South America | 11 | -4.48 (1.46) | 13.73 (3.33) | 16.61 (3.34) | 14.25 (3.41) | 13.00 (3.25) | 12.13 (2.42) | 0 (0) | 11 (100) ||\n|| Caribbean | 14 | -3.41 (1.04) | 15.07 (5.34) | 17.33 (5.75) | 15.38 (5.54) | 14.49 (5.29) | 13.92 (5.15) | 0 (0) | 14 (100) ||\n|| Middle East and North Africa | 20 | -3.44 (1.95) | 19.51 (6.98) | 21.67 (6.45) | 19.77 (7.01) | 19.11 (7.30) | 18.23 (7.25) | 2 (10) | 18 (90) ||",
    "claim": "Within the Americas, Central America had a net HHI change that was approximately 35% greater in magnitude than that of the Caribbean, indicating more aggressive improvements in hidden hunger in Central America.",
    "label": "support"
  },
  {
    "id": "training_506_6",
    "table_caption": "Table: Allelic association of two common POMC variants and BMI. Common Allele Chi-square tests Logistic regression analysis SNPs Comparisons Race freq* x2 Pobs OR (95% CI) Pemp STAT Padj OR (95% CI) rs10654394 Overweight vs. AAs 0.205/0.274 1.90 0.168 0.68 (0.40–1.18) 0.173 21.38 0.166 0.67 (0.38–1.18) (9-bp-allele) Normal weight EAs 0.043/0.052 0.21 0.646 0.80 (0.32–2.04) 0.691 20.54 0.586 0.77 (0.30–1.98) AAs+EAs 0.119/0.135 0.40 0.526 0.86 (0.55–1.36) 0.557 21.52 0.130 0.69 (0.43–1.12) Obese vs. AAs 0.324/0.274 0.85 0.357 1.27 (0.77–2.10) 0.365 1.06 0.291 1.33 (0.78–2.25) Normal weight EAs 0.081/0.052 1.13 0.289 1.59 (0.67–3.78) 0.310 0.45 0.655 1.23 (0.50–3.03) AAs+EAs 0.218/0.135 7.74 0.005 1.79 (1.18–2.71) 0.007 1.24 0.215 1.33 (0.85–2.08) Overweight + Obese vs. AAs 0.266/0.274 0.03 0.861 0.96 (0.60–1.52) 0.858 20.07 0.946 0.98 (0.61–1.58) Normal weight EAs 0.059/0.052 0.09 0.759 1.13 (0.53–2.42) 0.781 20.03 0.980 0.99 (0.44–2.20) AAs+EAs 0.165/0.135 1.57 0.210 1.27 (0.87–1.85) 0.242 20.08 0.937 0.98 (0.66–1.47) rs1042571 Overweight vs. AAs 0.141/0.106 0.96 0.328 1.40 (0.72–2.72) 0.372 0.80 0.426 1.30 (0.68–2.49) (T-allele) Normal weight EAs 0.259/0.146 9.11 0.003 2.05 (1.28–3.29) 0.003 2.80 0.005 2.17 (1.26–3.73) AAs+EAs 0.202/0.131 7.25 0.007 1.69 (1.15–2.47) 0.011 2.92 0.004 1.81 (1.22–2.69) Obese vs. AAs 0.125/0.106 0.29 0.589 1.21 (0.61–2.41) 0.609 0.29 0.769 1.11 (0.54–2.29) Normal weight EAs 0.247/0.146 6.33 0.012 1.92 (1.15–3.20) 0.013 2.37 0.018 2.00 (1.13–3.55) AAs+EAs 0.181/0.131 3.38 0.066 1.46 (0.97–2.20) 0.074 2.03 0.043 1.56 (1.02–2.40) Overweight + Obese vs. AAs 0.134/0.106 0.73 0.393 1.31 (0.71–2.40) 0.425 0.63 0.529 1.21 (0.66–2.21) Normal weight EAs 0.254/0.146 10.20 0.001 2.00 (1.30–3.06) 0.002 3.06 0.002 2.13 (1.31–3.45) AAs+EAs 0.193/0.131 6.75 0.009 1.58 (1.12–2.24) 0.011 2.91 0.004 1.71 (1.19–2.46) rs10654394: a 9-bp insertion/deletion polymorphism (2/AGCAGCGGC) in POMC exon 4; rs1042571: C/T in POMC 39UTR. AAs: African Americans; EAs: European Americans. ",
    "table_content": "|| Common SNPs | Comparisons | Race | Allele freq* | Chi-square tests | Chi-square tests | Chi-square tests | P emp | Logistic regression analysis | Logistic regression analysis | Logistic regression analysis ||\n|| Common SNPs | Comparisons | Race | Allele freq* | χ 2  |  P obs  | OR (95% CI) | P emp | STAT |  P adj  | OR (95% CI) ||\n|| (9-bp-allele) | blank | AAs+EAs | 0.165/0.135 | 1.57 | 0.210 | 1.27 (0.87–1.85) | 0.242 | −0.08 | 0.937 | 0.98 (0.66–1.47) ||\n|| rs1042571 | Overweight vs.  | AAs | 0.141/0.106 | 0.96 | 0.328 | 1.40 (0.72–2.72) | 0.372 | 0.80 | 0.426 | 1.30 (0.68–2.49) ||\n|| (T-allele) | Normal weight | EAs | 0.259/0.146 | 9.11 | 0.003 | 2.05 (1.28–3.29) | 0.003 | 2.80 | 0.005 | 2.17 (1.26–3.73) ||\n|| (T-allele) | blank | AAs+EAs | 0.202/0.131 | 7.25 | 0.007 | 1.69 (1.15–2.47) | 0.011 | 2.92 | 0.004 | 1.81 (1.22–2.69) ||\n|| (T-allele) | Obese vs.  | AAs | 0.125/0.106 | 0.29 | 0.589 | 1.21 (0.61–2.41) | 0.609 | 0.29 | 0.769 | 1.11 (0.54–2.29) ||\n|| (T-allele) | Normal weight | EAs | 0.247/0.146 | 6.33 | 0.012 | 1.92 (1.15–3.20) | 0.013 | 2.37 | 0.018 | 2.00 (1.13–3.55) ||\n|| (T-allele) | blank | AAs+EAs | 0.181/0.131 | 3.38 | 0.066 | 1.46 (0.97–2.20) | 0.074 | 2.03 | 0.043 | 1.56 (1.02–2.40) ||\n|| (T-allele) | Overweight + Obese vs.  | AAs | 0.134/0.106 | 0.73 | 0.393 | 1.31 (0.71–2.40) | 0.425 | 0.63 | 0.529 | 1.21 (0.66–2.21) ||\n|| (T-allele) | Normal weight | EAs | 0.254/0.146 | 10.20 | 0.001 | 2.00 (1.30–3.06) | 0.002 | 3.06 | 0.002 | 2.13 (1.31–3.45) ||\n|| (T-allele) | blank | AAs+EAs | 0.193/0.131 | 6.75 | 0.009 | 1.58 (1.12–2.24) | 0.011 | 2.91 | 0.004 | 1.71 (1.19–2.46) ||\n|| rs10654394 | Overweight vs.  | AAs | 0.205/0.274 | 1.90 | 0.168 | 0.68 (0.40–1.18) | 0.173 | −1.38 | 0.166 | 0.67 (0.38–1.18) ||\n|| (9-bp-allele) | Normal weight | EAs | 0.043/0.052 | 0.21 | 0.646 | 0.80 (0.32–2.04) | 0.691 | −0.54 | 0.586 | 0.77 (0.30–1.98) ||\n|| (9-bp-allele) | blank | AAs+EAs | 0.119/0.135 | 0.40 | 0.526 | 0.86 (0.55–1.36) | 0.557 | −1.52 | 0.130 | 0.69 (0.43–1.12) ||\n|| (9-bp-allele) | Obese vs.  | AAs | 0.324/0.274 | 0.85 | 0.357 | 1.27 (0.77–2.10) | 0.365 | 1.06 | 0.291 | 1.33 (0.78–2.25) ||\n|| (9-bp-allele) | Normal weight | EAs | 0.081/0.052 | 1.13 | 0.289 | 1.59 (0.67–3.78) | 0.310 | 0.45 | 0.655 | 1.23 (0.50–3.03) ||\n|| (9-bp-allele) | blank | AAs+EAs | 0.218/0.135 | 7.74 | 0.005 | 1.79 (1.18–2.71) | 0.007 | 1.24 | 0.215 | 1.33 (0.85–2.08) ||\n|| (9-bp-allele) | Overweight + Obese vs.  | AAs | 0.266/0.274 | 0.03 | 0.861 | 0.96 (0.60–1.52) | 0.858 | −0.07 | 0.946 | 0.98 (0.61–1.58) ||\n|| (9-bp-allele) | Normal weight | EAs | 0.059/0.052 | 0.09 | 0.759 | 1.13 (0.53–2.42) | 0.781 | −0.03 | 0.980 | 0.99 (0.44–2.20) ||",
    "claim": "The logistic regression analysis for rs1042571 in normal weight EAs shows an odds ratio of 2.13, which is 2.8 times higher than the odds ratio for rs10654394, highlighting a stronger genetic influence of rs1042571 on maintaining normal weight in EAs.",
    "label": "support"
  },
  {
    "id": "training_947_5",
    "table_caption": "Table: Secondary ﬁndings in farmed deer from Switzerland (2003-2004) in the diﬀerent age classes. Diagnosis Abortion Neonate Fawn Juvenile Subadult Adult Total Endoparasites 14 4 3 18 39 Mild aspiration of amniotic ﬂuid 6 2 8 Beginning septicaemia 2 1 5 8 Aspiration pneumonia 1 4 5 Abomasal ulcer 3 1 1 5 Congenital malformation 3 2 5 Ruminal acidosis 3 3 Myocardial degeneration and tubulonephrosis 2 2 Parasitic dermatitis 1 1 2 Alveolar periostitis 1 1 Candidiasis (tongue) 1 1 Colitis 1 1 Purulent hepatitis 1 1 Endometrial hyperplasia 1 1 Inanition 1 1 Haemosiderosis 1 1 Omphalophlebitis 1 1 Bacterial pneumonia 1 1 Pyelonephritis 1 1 Unevenly worn cheek teeth 1 1 Teleangiectasia (liver) 1 1 Terminal thrombosis 1 1 Thymus involution 1 1 Chronic tonsillitis 1 1 ",
    "table_content": "|| Diagnosis | Abortion | Neonate | Fawn | Juvenile | Subadult | Adult | Total ||\n|| Endoparasites | blank | blank | 14 | 4 | 3 | 18 | 39 ||\n|| Alveolar periostitis | blank | blank | blank | 1 | blank | blank | 1 ||\n|| Candidiasis (tongue) | blank | blank | blank | 1 | blank | blank | 1 ||\n|| Colitis | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Purulent hepatitis | blank | blank | blank | 1 | blank | blank | 1 ||\n|| Endometrial hyperplasia | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Inanition | blank | 1 | blank | blank | blank | blank | 1 ||\n|| Haemosiderosis | blank | blank | 1 | blank | blank | blank | 1 ||\n|| Omphalophlebitis | blank | blank | 1 | blank | blank | blank | 1 ||\n|| Bacterial pneumonia | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Pyelonephritis | blank | 1 | blank | blank | blank | blank | 1 ||\n|| Mild aspiration of amniotic fluid | blank | 6 | 2 | blank | blank | blank | 8 ||\n|| Unevenly worn cheek teeth | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Teleangiectasia (liver) | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Terminal thrombosis | blank | blank | blank | 1 | blank | blank | 1 ||\n|| Thymus involution | blank | 1 | blank | blank | blank | blank | 1 ||\n|| Chronic tonsillitis | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Beginning septicaemia | 2 | 1 | blank | 5 | blank | blank | 8 ||\n|| Aspiration pneumonia | blank | blank | blank | 1 | blank | 4 | 5 ||\n|| Abomasal ulcer | blank | blank | 3 | 1 | 1 | blank | 5 ||\n|| Congenital malformation | blank | 3 | 2 | blank | blank | blank | 5 ||\n|| Ruminal acidosis | blank | blank | blank | blank | blank | 3 | 3 ||\n|| Myocardial degeneration and tubulonephrosis | blank | blank | 2 | blank | blank | blank | 2 ||\n|| Parasitic dermatitis | blank | blank | blank | blank | 1 | 1 | 2 ||",
    "claim": "The distribution of abomasal ulcer cases is relatively uneven across the Fawn, Juvenile, and Subadult age classes, with the Fawn class contributing 60% to the total cases, indicating a varying risk across these developmental stages.",
    "label": "support"
  },
  {
    "id": "training_1049_5",
    "table_caption": "Table: Table 1C Summarized Aerosol Optical Depth Dataset over Nzerekore for year 2010–2013. Month 2010 2011 2012 2013 Jan 0.323 0.551 0.399 0.192 Feb 0.300 0.400 0.796 0.588 Mar 1.018 1.188 0.641 0.261 Apr 0.318 0.325 0.437 May 0.257 Jun Jul 0.095 Aug Sep 0.348 0.225 Oct 0.164 0.272 0.441 Nov 0.473 0.275 0.253 Dec 0.630 0.508 0.307 Table 2A ",
    "table_content": "|| Month | 2010 | 2011 | 2012 | 2013 ||\n|| Jan | 0.323 | 0.551 | 0.399 | 0.192 ||\n|| Oct | 0.164 | 0.272 | 0.441 | blank ||\n|| Nov | blank | 0.473 | 0.275 | 0.253 ||\n|| Dec | 0.630 | 0.508 | 0.307 | blank ||\n|| Feb | 0.300 | 0.400 | 0.796 | 0.588 ||\n|| Mar | 1.018 | 1.188 | 0.641 | 0.261 ||\n|| Apr | 0.318 | 0.325 | 0.437 | blank ||\n|| May | blank | blank | 0.257 | blank ||\n|| Jun | Jun | Jun | Jun | Jun ||\n|| Jul | 0.095 | blank | blank | blank ||\n|| Aug | Aug | Aug | Aug | Aug ||\n|| Sep | 0.348 | 0.225 | blank | blank ||",
    "claim": "The AOD in February 2012 is 0.796, which is higher than in February 2011 by approximately 0.396. This indicates a notable increase in aerosol concentration from one year to the next.",
    "label": "support"
  },
  {
    "id": "training_997_5",
    "table_caption": "Table: another 54 matching ethnicity, age, and sex, but free from glaucoma by examination, served as controls (see Methods 0.72–1.94, where this difference was statistically significant (p<0.0001: 95% CI: −0.295–0.114; Table 2). TABLE 3. MEAN TAS VALUE BY GENDER AMONG CASES AND CONTROLS. Gender Patients Controls Male Mean (SD) 0.849 (0.26) 1.1 (0.25) Range [min–max] [0.09–1.41] [0.72–1.94] Female Mean (SD) 0.9 (0.20) 0.99 (0.18) Range [min–max] [0.37–1.18] [0.78–1.4] ",
    "table_content": "|| Gender | Patients | Controls ||\n|| Male | Male | Male ||\n|| Mean (SD) | 0.849 (0.26) | 1.1 (0.25) ||\n|| Range [min–max] | [0.09–1.41] | [0.72–1.94] ||\n|| Female | Female | Female ||\n|| Mean (SD) | 0.9 (0.20) | 0.99 (0.18) ||\n|| Range [min–max] | [0.37–1.18] | [0.78–1.4] ||",
    "claim": "The TAS value range for male patients overlaps with that of male controls by approximately 0.69 units, suggesting a partial overlap in antioxidant status distribution.",
    "label": "support"
  },
  {
    "id": "training_603_1",
    "table_caption": "Table: Table 1 Surveillance cultures for yeast species in pediatric cancer patients Sample site No. positive/No. samples (%) Oropharyngeal 53/294 (18) Nasal 6/600 (1) Rectal 10/28 (35.7) Groin 5/50 (10) Ear 1/54 (1.9) Axilla 0/49 (0) Total 75/1075 (7) ",
    "table_content": "|| Sample site | No. positive/No. samples (%) ||\n|| Oropharyngeal | 53/294 (18) ||\n|| Nasal | 6/600 (1) ||\n|| Rectal | 10/28 (35.7) ||\n|| Groin | 5/50 (10) ||\n|| Ear | 1/54 (1.9) ||\n|| Axilla | 0/49 (0) ||\n|| Total | 75/1075 (7) ||",
    "claim": "The rectal site exhibits a prevalence rate of yeast species that is 35.7 times higher than the nasal site, indicating a significant variation in colonization rates across different anatomical locations.",
    "label": "support"
  },
  {
    "id": "training_118_2",
    "table_caption": "Table: Table 2 Lung mechanics, hemodynamics, gas exchange, acid-base status, and metabolic parameters Vehicle HAM1101 p value Hemoglobin content (mg·mL−1) Start 90 (87, 96) 98 (95, 105) 0.074 End 70 (66, 72) 69 (66, 74) 0.806 Heart rate (beats·min−1) Start 494 (485, 515) 430 (406, 480) 0.248 End 426 (406, 445) 391 (349,430) 0.290 Mean arterial pressure (mmHg) Start 69 (65, 71) 69 (66, 76) 0.382 End 64 (59, 69) 67 (66, 72) 0.441 Thoracopulmonary compliance (μL·cm H2O−1) Start 0.10 (0.09, 0.10) 0.10 (0.09, 0.11) 0.382 End 0.09 (0.08, 0.10) 0.10 (0.08, 0.11) 0.427 Arterial PO2 (mmHg) Start 314 (293, 330) 340 (321, 350) 0.254 End 309 (287, 326) 301 (287, 319) 0.838 Arterial PCO2 (mmHg) Start 31 (27, 33) 31 (29, 36) 0.879 End 34 (33, 36) 31 (28, 33) 0.072 Arterial pH Start 7.33 (7.30, 7.35) 7.36 (7.32, 7.38) 0.569 End 7.38 (7.31, 7.43) 7.43 (7.39, 7.46) 0.253 Arterial base excess (mmol·mL−1) Start −9.0 (−10.3, −7.7) −6.8 (−8.3, −6.2) 0.403 End −5.7 (−7.1, −1.7) −3.9 (−4.2, −3.3) 0.838 Arterial lactate (mmol·mL−1) Start n.d. n.d. n.d. End 2.0 (1.7, 2.2) 1.6 (1.5, 1.8) 0.025 Arterial glucose (mg·dL−1) Start 113 (110, 117) 115 (106, 123) 0.540 End 110 (96, 117) 111 (109, 115) 0.653 CO2 production rate (μL·g−1·min−1) Start 26 (24, 28) 24 (23, 25) 0.082 End 23 (21, 26) 23 (22, 25) 0.596 Glucose production rate (mg·g−1·h−1) Start 0.37 (0.35, 0.41) 0.34 (0.31, 0.36) 0.178 End 0.38 (0.35, 0.39) 0.33 (0.31, 0.39) 0.153 Glucose oxidation rate (% isotope infusion) Start 58 (55, 62) 55 (50, 59) 0.224 End 57 (54, 60) 62 (58, 67) 0.047 The data are for the vehicle-treated (n = 11) and HAM1101-treated (n = 9) animals at the start and the end of the 5-h observation period; n.d., not determined. All data are median (quartiles). ",
    "table_content": "|| blank | blank | Vehicle | HAM1101 |  p value ||\n|| Hemoglobin content (mg·mL −1 ) | Start | 90 (87, 96) | 98 (95, 105) | 0.074 ||\n|| Arterial PO 2 (mmHg) | End | 309 (287, 326) | 301 (287, 319) | 0.838 ||\n|| Arterial PCO 2 (mmHg) | Start | 31 (27, 33) | 31 (29, 36) | 0.879 ||\n|| Arterial PCO 2 (mmHg) | End | 34 (33, 36) | 31 (28, 33) | 0.072 ||\n|| Arterial pH | Start | 7.33 (7.30, 7.35) | 7.36 (7.32, 7.38) | 0.569 ||\n|| Arterial pH | End | 7.38 (7.31, 7.43) | 7.43 (7.39, 7.46) | 0.253 ||\n|| Arterial base excess (mmol·mL −1 ) | Start | −9.0 (−10.3, −7.7) | −6.8 (−8.3, −6.2) | 0.403 ||\n|| Arterial base excess (mmol·mL −1 ) | End | −5.7 (−7.1, −1.7) | −3.9 (−4.2, −3.3) | 0.838 ||\n|| Arterial lactate (mmol·mL −1 ) | Start | n.d. | n.d. | n.d. ||\n|| Arterial lactate (mmol·mL −1 ) | End | 2.0 (1.7, 2.2) | 1.6 (1.5, 1.8) | 0.025 ||\n|| Arterial glucose (mg·dL −1 ) | Start | 113 (110, 117) | 115 (106, 123) | 0.540 ||\n|| Hemoglobin content (mg·mL −1 ) | End | 70 (66, 72) | 69 (66, 74) | 0.806 ||\n|| Arterial glucose (mg·dL −1 ) | End | 110 (96, 117) | 111 (109, 115) | 0.653 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | Start | 26 (24, 28) | 24 (23, 25) | 0.082 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | End | 23 (21, 26) | 23 (22, 25) | 0.596 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | Start | 0.37 (0.35, 0.41) | 0.34 (0.31, 0.36) | 0.178 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | End | 0.38 (0.35, 0.39) | 0.33 (0.31, 0.39) | 0.153 ||\n|| Glucose oxidation rate (% isotope infusion) | Start | 58 (55, 62) | 55 (50, 59) | 0.224 ||\n|| Glucose oxidation rate (% isotope infusion) | End | 57 (54, 60) | 62 (58, 67) | 0.047 ||\n|| Heart rate (beats·min −1 ) | Start | 494 (485, 515) | 430 (406, 480) | 0.248 ||\n|| Heart rate (beats·min −1 ) | End | 426 (406, 445) | 391 (349,430) | 0.290 ||\n|| Mean arterial pressure (mmHg) | Start | 69 (65, 71) | 69 (66, 76) | 0.382 ||\n|| Mean arterial pressure (mmHg) | End | 64 (59, 69) | 67 (66, 72) | 0.441 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | Start | 0.10 (0.09, 0.10) | 0.10 (0.09, 0.11) | 0.382 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | End | 0.09 (0.08, 0.10) | 0.10 (0.08, 0.11) | 0.427 ||\n|| Arterial PO 2 (mmHg) | Start | 314 (293, 330) | 340 (321, 350) | 0.254 ||",
    "claim": "The heart rate in the vehicle group decreased by approximately 13.8% from start to end, whereas in the HAM1101 group, the reduction was approximately 9.1%. This indicates a more pronounced decrease in heart rate in the vehicle group compared to the HAM1101 group.",
    "label": "support"
  },
  {
    "id": "training_847_5",
    "table_caption": "Table: Top-ranked template sequences obtained by BLAST results. Ranking No. PDB ID LIG ID* Total Score Query Coverage Max. Identity Positives e-Value 1 2Y00 Y00 473 73% 68% 75% 3×10-165 2 2VT4 P32 466 73% 68% 75% 1×10-162 3 2R4R N/A 412 79% 54% 66% 1×10-140 4 3KJ6 N/A 412 79% 54% 66% 1×10-140 5 2R4S N/A 408 74% 56% 66% 3×10-139 6 3SN6 P0G 410 74% 56% 66% 1×10-137 7 4GBR CAU 291 43% 67% 81% 4×10-94 8 3P0G P0G 418 79% 54% 75% 5×10-92 9 2RH1 CAU 418 79% 54% 76% 5×10-92 10 3PDS ERC 410 72% 60% 78% 1×10-90 *Y00 = Dobutamine, P32 = Cyanopindolol, P0G = Nanobody (Nb35), CAU = Carazolol, ERC = FAUC50. RET = Retinal, P32 = Cyanopindolol, CAU = Carazolol, Y00 = Dobutamine, WHJ = Carmoterol, 5FW = Isoprenaline, 68H = Salbutamol, TIM = Timolol, JRZ = ICI 118,551. ",
    "table_content": "|| Ranking No. | PDB ID | LIG ID *  | Total Score | Query Coverage | Max. Identity | Positives | e-Value ||\n||  1  | 2Y00 | Y00 | 473 | 73% | 68% | 75% | 3×10 -165  ||\n||  10  | 3PDS | ERC | 410 | 72% | 60% | 78% | 1×10 -90  ||\n||  2  | 2VT4 | P32 | 466 | 73% | 68% | 75% | 1×10 -162  ||\n||  3  | 2R4R | N/A | 412 | 79% | 54% | 66% | 1×10 -140  ||\n||  4  | 3KJ6 | N/A | 412 | 79% | 54% | 66% | 1×10 -140  ||\n||  5  | 2R4S | N/A | 408 | 74% | 56% | 66% | 3×10 -139  ||\n||  6  | 3SN6 | P0G | 410 | 74% | 56% | 66% | 1×10 -137  ||\n||  7  | 4GBR | CAU | 291 | 43% | 67% | 81% | 4×10 -94  ||\n||  8  | 3P0G | P0G | 418 | 79% | 54% | 75% | 5×10 -92  ||\n||  9  | 2RH1 | CAU | 418 | 79% | 54% | 76% | 5×10 -92  ||",
    "claim": "Entries 3 (2R4R) and 4 (3KJ6) have identical total scores, query coverage, max identity, and positives, resulting in the same e-value of 1×10^-140. This consistency implies that when all other factors are equal, the e-value remains constant, reinforcing its role as a measure of statistical significance.",
    "label": "support"
  },
  {
    "id": "training_847_5",
    "table_caption": "Table: Top-ranked template sequences obtained by BLAST results. Ranking No. PDB ID LIG ID* Total Score Query Coverage Max. Identity Positives e-Value 1 2Y00 Y00 473 73% 68% 75% 3×10-165 2 2VT4 P32 466 73% 68% 75% 1×10-162 3 2R4R N/A 412 79% 54% 66% 1×10-140 4 3KJ6 N/A 412 79% 54% 66% 1×10-140 5 2R4S N/A 408 74% 56% 66% 3×10-139 6 3SN6 P0G 410 74% 56% 66% 1×10-137 7 4GBR CAU 291 43% 67% 81% 4×10-94 8 3P0G P0G 418 79% 54% 75% 5×10-92 9 2RH1 CAU 418 79% 54% 76% 5×10-92 10 3PDS ERC 410 72% 60% 78% 1×10-90 *Y00 = Dobutamine, P32 = Cyanopindolol, P0G = Nanobody (Nb35), CAU = Carazolol, ERC = FAUC50. RET = Retinal, P32 = Cyanopindolol, CAU = Carazolol, Y00 = Dobutamine, WHJ = Carmoterol, 5FW = Isoprenaline, 68H = Salbutamol, TIM = Timolol, JRZ = ICI 118,551. ",
    "table_content": "|| Ranking No. | PDB ID | LIG ID *  | Total Score | Query Coverage | Max. Identity | Positives | e-Value ||\n||  1  | 2Y00 | Y00 | 473 | 73% | 68% | 75% | 3×10 -165  ||\n||  10  | 3PDS | ERC | 410 | 72% | 60% | 78% | 1×10 -90  ||\n||  2  | 2VT4 | P32 | 466 | 73% | 68% | 75% | 1×10 -162  ||\n||  3  | 2R4R | N/A | 412 | 79% | 54% | 66% | 1×10 -140  ||\n||  4  | 3KJ6 | N/A | 412 | 79% | 54% | 66% | 1×10 -140  ||\n||  5  | 2R4S | N/A | 408 | 74% | 56% | 66% | 3×10 -139  ||\n||  6  | 3SN6 | P0G | 410 | 74% | 56% | 66% | 1×10 -137  ||\n||  7  | 4GBR | CAU | 291 | 43% | 67% | 81% | 4×10 -94  ||\n||  8  | 3P0G | P0G | 418 | 79% | 54% | 75% | 5×10 -92  ||\n||  9  | 2RH1 | CAU | 418 | 79% | 54% | 76% | 5×10 -92  ||",
    "claim": "Entries 3 (2R4R) and 4 (3KJ6) have identical total scores, query coverage, max identity, and positives, resulting in the same e-value of 1×10^-140. This consistency implies that when all other factors are equal, the e-value varies, undermining its role as a measure of statistical significance.",
    "label": "support"
  },
  {
    "id": "training_553_1",
    "table_caption": "Table: Possible coding of tasks by two coders and the resulting code for inter-rater reliability. Coder 1 Coder 2 Result Scenario 1 Developing and Using Models Developing and Using Models Agree Scenario 2 No Practice No Practice Agree Scenario 3 Developing and Using Models; Evaluating Information Developing and Using Models Agree Scenario 4 Developing and Using Models Planning Investigations Agree Scenario 5 Developing and Using Models No Practice Disagree doi:10.1371/journal.pone.0162333.t003 ",
    "table_content": "|| blank | Coder 1 | Coder 2 | Result ||\n|| Scenario 1 | Developing and Using Models | Developing and Using Models | Agree ||\n|| Scenario 2 | No Practice | No Practice | Agree ||\n|| Scenario 3 | Developing and Using Models; Evaluating Information | Developing and Using Models | Agree ||\n|| Scenario 4 | Developing and Using Models | Planning Investigations | Agree ||\n|| Scenario 5 | Developing and Using Models | No Practice | Disagree ||",
    "claim": "The agreement rate between the two coders is 80%, as they agree on four out of the five scenarios. This high level of agreement suggests a strong inter-rater reliability, indicating that the coding scheme is well-defined and understood by both coders.",
    "label": "support"
  },
  {
    "id": "training_553_1",
    "table_caption": "Table: Possible coding of tasks by two coders and the resulting code for inter-rater reliability. Coder 1 Coder 2 Result Scenario 1 Developing and Using Models Developing and Using Models Agree Scenario 2 No Practice No Practice Agree Scenario 3 Developing and Using Models; Evaluating Information Developing and Using Models Agree Scenario 4 Developing and Using Models Planning Investigations Agree Scenario 5 Developing and Using Models No Practice Disagree doi:10.1371/journal.pone.0162333.t003 ",
    "table_content": "|| blank | Coder 1 | Coder 2 | Result ||\n|| Scenario 1 | Developing and Using Models | Developing and Using Models | Agree ||\n|| Scenario 2 | No Practice | No Practice | Agree ||\n|| Scenario 3 | Developing and Using Models; Evaluating Information | Developing and Using Models | Agree ||\n|| Scenario 4 | Developing and Using Models | Planning Investigations | Agree ||\n|| Scenario 5 | Developing and Using Models | No Practice | Disagree ||",
    "claim": "The agreement rate between the two coders is 60%, as they agree on three out of the five scenarios. This moderate level of agreement suggests a weaker inter-rater reliability, indicating that the coding scheme may not be well-defined or understood by both coders.",
    "label": "support"
  },
  {
    "id": "training_1329_2",
    "table_caption": "Table: Table 3 Time and method of diagnosis Time Method No. of cases Preoperative Endoscopy 12 Curettage of fistula 3 Direct tumor biopsy 2 Intraoperative Pathological examination 3 Postoperative Pathological examination 14 Table Stage 0, I II ",
    "table_content": "|| Time | Method | No. of cases ||\n|| Preoperative | Endoscopy | 12 ||\n|| Preoperative | Curettage of fistula | 3 ||\n|| Preoperative | Direct tumor biopsy | 2 ||\n|| Intraoperative | Pathological examination | 3 ||\n|| Postoperative | Pathological examination | 14 ||",
    "claim": "The number of cases diagnosed postoperatively is less than double the number of cases diagnosed preoperatively. This indicates a reliance on postoperative pathological examination, which accounts for 14 cases compared to the 17 preoperative cases.",
    "label": "support"
  },
  {
    "id": "training_1000_5",
    "table_caption": "Table: obtained from replication study (METSIM Study), and meta-analysis of both cohorts. 1st stage (EUGENE2) 2nd stage (METSIM) Meta-analysis Ref. allele Other allele Ref. allele frequency (1st stage) Ref. allele frequency (2nd stage) N b P N b P B P Cholestanol ABCG8 rs4299376 C A 0.19 0.15 271 0.037 5.6E-05 734 0.039 1.2E-13 0.038 1.1E-17 ABCG8 rs6544713 A G 0.19 0.15 267 0.036 1.7E-04 738 0.038 1.8E-12 0.037 9.9E-16 ABCG5/8 rs6756629 A G 0.10 0.10 268 20.053 7.4E-06 738 -0.043 8.2E-10 20.046 2.2E-14 Campesterol ABCG8 rs6544713 A G 0.19 0.15 267 0.108 3.5E-08 738 0.075 2.1E-10 0.084 6.4E-17 ABCG8 rs4299376 C A 0.19 0.15 271 0.105 3.9E-08 734 0.075 2.5E-10 0.083 7.3E-17 ABCG5/8 rs6756629 A G 0.10 0.10 268 20.136 1.6E-08 738 20.089 1.1E-08 20.102 2.5E-15 Sitosterol ABCG8 rs6544713 A G 0.19 0.15 267 0.104 1.8E-08 738 0.081 4.6E-12 0.088 3.7E-19 ABCG8 rs4299376 C A 0.19 0.15 271 0.101 1.9E-08 734 0.081 5.6E-12 0.087 4.3E-19 ABCG5/8 rs6756629 A G 0.10 0.10 268 20.139 1.0E-09 738 20.094 1.3E-09 20.108 1.8E-17 Avenasterol ABCG8 rs6544713 A G 0.19 0.15 267 0.055 2.5E-05 738 0.048 3.7E-11 0.050 2.5E-15 ABCG8 rs4299376 C A 0.19 0.15 271 0.054 2.5E-05 734 0.047 7.0E-11 0.049 4.7E-15 ABCG5/8 rs6756629 A G 0.10 0.10 268 20.090 1.8E-08 738 20.045 3.1E-06 20.057 4.8E-12 Only results from meta-analysis indicating a genome-wide significance (P,561028) are shown. b = Regression coefficient. Individuals with previously diagnosed diabetes and on statin or ezetimibe treatment are excluded. P values adjusted for age, gender, and BMI. ",
    "table_content": "|| blank | blank | Ref. allele | Other allele | Ref. allele frequency(1st stage) | Ref. allele frequency(2nd stage) | 1 st stage (EUGENE2) | 1 st stage (EUGENE2) | 1 st stage (EUGENE2) | 2 nd stage (METSIM) | 2 nd stage (METSIM) | 2 nd stage (METSIM) | Meta-analysis | Meta-analysis ||\n|| blank | blank | Ref. allele | Other allele | Ref. allele frequency(1st stage) | Ref. allele frequency(2nd stage) | N | β |  P  | N | β |  P  | B |  P  ||\n||  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  ||\n||  ABCG8  | rs6544713 | A | G | 0.19 | 0.15 | 267 | 0.104 | 1.8E-08 | 738 | 0.081 | 4.6E-12 | 0.088 | 3.7E-19 ||\n||  ABCG8  | rs4299376 | C | A | 0.19 | 0.15 | 271 | 0.101 | 1.9E-08 | 734 | 0.081 | 5.6E-12 | 0.087 | 4.3E-19 ||\n||  ABCG5/8  | rs6756629 | A | G | 0.10 | 0.10 | 268 | −0.139 | 1.0E-09 | 738 | −0.094 | 1.3E-09 | −0.108 | 1.8E-17 ||\n||  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  ||\n||  ABCG8  | rs6544713 | A | G | 0.19 | 0.15 | 267 | 0.055 | 2.5E-05 | 738 | 0.048 | 3.7E-11 | 0.050 | 2.5E-15 ||\n||  ABCG8  | rs4299376 | C | A | 0.19 | 0.15 | 271 | 0.054 | 2.5E-05 | 734 | 0.047 | 7.0E-11 | 0.049 | 4.7E-15 ||\n||  ABCG5/8  | rs6756629 | A | G | 0.10 | 0.10 | 268 | −0.090 | 1.8E-08 | 738 | −0.045 | 3.1E-06 | −0.057 | 4.8E-12 ||\n||  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  ||\n||  ABCG8  | rs4299376 | C | A | 0.19 | 0.15 | 271 | 0.037 | 5.6E-05 | 734 | 0.039 | 1.2E-13 | 0.038 | 1.1E-17 ||\n||  ABCG8  | rs6544713 | A | G | 0.19 | 0.15 | 267 | 0.036 | 1.7E-04 | 738 | 0.038 | 1.8E-12 | 0.037 | 9.9E-16 ||\n||  ABCG5/8  | rs6756629 | A | G | 0.10 | 0.10 | 268 | −0.053 | 7.4E-06 | 738 | -0.043 | 8.2E-10 | −0.046 | 2.2E-14 ||\n||  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  ||\n||  ABCG8  | rs6544713 | A | G | 0.19 | 0.15 | 267 | 0.108 | 3.5E-08 | 738 | 0.075 | 2.1E-10 | 0.084 | 6.4E-17 ||\n||  ABCG8  | rs4299376 | C | A | 0.19 | 0.15 | 271 | 0.105 | 3.9E-08 | 734 | 0.075 | 2.5E-10 | 0.083 | 7.3E-17 ||\n||  ABCG5/8  | rs6756629 | A | G | 0.10 | 0.10 | 268 | −0.136 | 1.6E-08 | 738 | −0.089 | 1.1E-08 | −0.102 | 2.5E-15 ||",
    "claim": "The genetic variant ABCG5/8 rs6756629 shows a negative regression coefficient across all sterols, with the most pronounced effect on Sitosterol. The meta-analysis coefficient for Sitosterol is the most negative, indicating that this variant has the strongest inverse effect on Sitosterol levels compared to other sterols.",
    "label": "support"
  },
  {
    "id": "training_1125_2",
    "table_caption": "Table: Results of in vitro albumin precipitation test (mg/L). Test solutions (1) Saline (control) Enox. 400 Enox. 400–40% Ethanol 10% WB 20% WB 10% WB 20% WB 10% WB 20% WB Blood sample Donor sex (Age) #1 H (56) - - 21.7 6.7 33.2 82.8 #2 F (32) - - 11.7 15.1 17.8 46.6 #3 F (32) - - 21.4 13.8 46 146 #4 H (34) - - 11 8.61 27.7 148 #5 F (30) - - 5.2 11.0 10.2 95.3 mean - - 14.2 11.0 26.98 103.74 SD - - 7.1 3.4 13.85 43.36 (1) Test solutions consisted of 0.5 (10%) or 1 mL (20%) WB and 4 mL or 4.5 mL of either saline (control), Enoxaparin 400, or Enoxaparin 400–40% Ethanol solution. ",
    "table_content": "|| Blood sample | Test solutions (1) Donor sex (Age) | Saline (control) | Saline (control) | Enox. 400 | Enox. 400 | Enox. 400–40% Ethanol | Enox. 400–40% Ethanol ||\n|| Blood sample | Test solutions (1) Donor sex (Age) | 10% WB | 20% WB | 10% WB | 20% WB | 10% WB | 20% WB ||\n|| Blood sample | Test solutions (1) Donor sex (Age) | 10% WB | 20% WB | 10% WB | 20% WB | 10% WB | 20% WB ||\n|| #1 | H (56) | blank | blank | 21.7 | 6.7 | 33.2 | 82.8 ||\n|| #2 | F (32) | blank | blank | 11.7 | 15.1 | 17.8 | 46.6 ||\n|| #3 | F (32) | blank | blank | 21.4 | 13.8 | 46 | 146 ||\n|| #4 | H (34) | blank | blank | 11 | 8.61 | 27.7 | 148 ||\n|| #5 | F (30) | blank | blank | 5.2 | 11.0 | 10.2 | 95.3 ||\n|| #5 | mean | blank | blank | 14.2 | 11.0 | 26.98 | 103.74 ||\n|| #5 | SD | blank | blank | 7.1 | 3.4 | 13.85 | 43.36 ||",
    "claim": "For Enoxaparin 400, increasing the WB concentration from 10% to 20% results in a decrease in albumin precipitation by approximately 22.5%, while for Enoxaparin 400–40% Ethanol, the increase in WB concentration results in a 284% increase in albumin precipitation, demonstrating a contrasting effect of WB concentration on the two solutions.",
    "label": "support"
  },
  {
    "id": "training_1032_1",
    "table_caption": "Table: End-points for clinical outcomes at baseline, 4 weeks and 12 weeks after botulinum toxin treatment. Scale Subscale Time point ProsigneH (n = 57) Mean (SD) BotoxH (n = 57) Mean (SD) Between-group difference in end-point (95% CI) Effect size (95% CI) MAS Baseline 1.93 (0.5) 1.84 (0.46) 0.09 (20.06 to 0.23) 0.18 (20.19 to 0.54) 4 weeks 1.28 (0.41) 1.42 (0.48) 20.14 (20.26 to 20.01) 20.31 (20.68 to 0.06) 12 weeks 1.52 (0.39) 1.59 (0.53) 20.07 (20.21 to 0.07) 20.13 (20.49 to 0.24) FIM Baseline 103.20 (23) 102.57 (23.67) 0.63 (21.43 to 2.68) 0.03 (20.65 to 0.7) 4 weeks 102.2 (29.5) 105.5 (16.2) 23.3 (22.1 to 4.5) 20.14 (20.76 to 0.48) 12 weeks 103.92 (22.85) 103.07 (23.36) 0.85 (21.39 to 3.09) 0.04 (20.64 to 0.71) PEDI Self-care Baseline 56.86 (12.89) 58.40 (13.31) 21.54 (25.09 to 2) 20.12 (20.56 to 0.32) 4 weeks 58.9 (14.3) 62.4 (12.1) 23.5 (22.9 to 1.2) 20.26 (21.21 to 0.73) 12 weeks 61.30 (13.55) 61.38 (13.74) 20.08 (22.60 to 2.43) 20.01 (20.44 to 0.43) Mobility Baseline 49.17 (15.07) 51.75 (14.29) 22.58 (25.19 to 0.02) 20.18 (20.61 to 0.27) 4 weeks 51.8 (16.9) 52.3 (8.5) 20.5 (20.8 to 1.9) 20.04 (21.00 to 0.93) 12 weeks 53.60 (14.07) 51.61 (14.52) 1.98 (0.42 to 3.55) 0.14 (20.30 to 0.58) Social Function Baseline 57.93 (11.72) 57.14 (10.74) 0.78 (22.34 to 3.91) 0.07 (20.37 to 0.51) 4 weeks 58.1 (11.3) 61.5 (10.7) 23.4 (23.7 to 0.5) 20.31 (21.26 to 0.68) 12 weeks 61.14 (12.55) 61.93 (11.43) 20.78 (23.51 to 1.94) 20.07 (20.50 to 0.37) MAS: Modified Ashworth Scale; FIM: Functional Independence Measure; PEDI: Pediatric Evaluation of Disability Inventory; SD: Standard Deviation; CI: Confidence Interval. ",
    "table_content": "|| Scale | Subscale | Time point | Prosigne® (n = 57) Mean (SD) | Botox® (n = 57) Mean (SD) | Between-group difference in end-point (95% CI) | Effect size (95% CI) ||\n|| MAS | MAS | MAS | MAS | MAS | MAS | MAS ||\n|| blank | Self-care | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 56.86 (12.89) | 58.40 (13.31) | −1.54 (−5.09 to 2) | −0.12 (−0.56 to 0.32) ||\n|| blank | blank | 4 weeks | 58.9 (14.3) | 62.4 (12.1) | −3.5 (−2.9 to 1.2) | −0.26 (−1.21 to 0.73) ||\n|| blank | blank | 12 weeks | 61.30 (13.55) | 61.38 (13.74) | −0.08 (−2.60 to 2.43) | −0.01 (−0.44 to 0.43) ||\n|| blank | Mobility | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 49.17 (15.07) | 51.75 (14.29) | −2.58 (−5.19 to 0.02) | −0.18 (−0.61 to 0.27) ||\n|| blank | blank | 4 weeks | 51.8 (16.9) | 52.3 (8.5) | −0.5 (−0.8 to 1.9) | −0.04 (−1.00 to 0.93) ||\n|| blank | blank | 12 weeks | 53.60 (14.07) | 51.61 (14.52) | 1.98 (0.42 to 3.55) | 0.14 (−0.30 to 0.58) ||\n|| blank | Social Function | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 57.93 (11.72) | 57.14 (10.74) | 0.78 (−2.34 to 3.91) | 0.07 (−0.37 to 0.51) ||\n|| blank | blank | Baseline | 1.93 (0.5) | 1.84 (0.46) | 0.09 (−0.06 to 0.23) | 0.18 (−0.19 to 0.54) ||\n|| blank | blank | 4 weeks | 58.1 (11.3) | 61.5 (10.7) | −3.4 (−3.7 to 0.5) | −0.31 (−1.26 to 0.68) ||\n|| blank | blank | 12 weeks | 61.14 (12.55) | 61.93 (11.43) | −0.78 (−3.51 to 1.94) | −0.07 (−0.50 to 0.37) ||\n|| blank | blank | 4 weeks | 1.28 (0.41) | 1.42 (0.48) | −0.14 (−0.26 to −0.01) | −0.31 (−0.68 to 0.06) ||\n|| blank | blank | 12 weeks | 1.52 (0.39) | 1.59 (0.53) | −0.07 (−0.21 to 0.07) | −0.13 (−0.49 to 0.24) ||\n|| FIM | FIM | FIM | FIM | FIM | FIM | FIM ||\n|| blank | blank | Baseline | 103.20 (23) | 102.57 (23.67) | 0.63 (−1.43 to 2.68) | 0.03 (−0.65 to 0.7) ||\n|| blank | blank | 4 weeks | 102.2 (29.5) | 105.5 (16.2) | −3.3 (−2.1 to 4.5) | −0.14 (−0.76 to 0.48) ||\n|| blank | blank | 12 weeks | 103.92 (22.85) | 103.07 (23.36) | 0.85 (−1.39 to 3.09) | 0.04 (−0.64 to 0.71) ||\n|| PEDI | PEDI | PEDI | PEDI | PEDI | PEDI | PEDI ||",
    "claim": "The MAS scores for both Prosigne® and Botox® groups show a decrease from baseline to 4 weeks, followed by an increase at 12 weeks. The overall reduction in MAS scores from baseline to 12 weeks is greater for the Prosigne® group, indicating a more sustained reduction in muscle spasticity over time.",
    "label": "support"
  },
  {
    "id": "training_693_3",
    "table_caption": "Table: Treatment histories of 101 cases of metachronous MPMTs. Treatment First primary cancer N(ratio) Surgery 27(26.7%) Chemotherapy 57(56.4%) Radiotherapy 7(7.0%) Chemo-radiotherapy 10(9.9%) doi:10.1371/journal.pone.0125754.t003 ",
    "table_content": "|| Treatment | First primary cancer N(ratio) ||\n||  Surgery  |  27(26.7%)  ||\n||  Chemotherapy  |  57(56.4%)  ||\n||  Radiotherapy  |  7(7.0%)  ||\n||  Chemo-radiotherapy  |  10(9.9%)  ||",
    "claim": "The combination of chemotherapy and radiotherapy, known as chemo-radiotherapy, is employed in approximately one-tenth of the cases, suggesting a strategic approach to leverage the synergistic effects of both modalities in a subset of patients.",
    "label": "support"
  },
  {
    "id": "training_1115_5",
    "table_caption": "Table: Comparison of X and Y chromosome-bearing sperm populations between washed sperm, DGC and DGC/Zeta groups’ by real-time PCR Groups Sample number Replicate per sample CtSRY/CtAmelo P value Male blood 17 3 0.99 ± 0.01 0.21 washed sperm 17 3 0.99 ± 0.01 0.22 DGC 17 3 0.99 ± 0.01 0.20 DGC/Zeta 17 3 1.00 ± 0.01 0.17 One-way analysis of variance (ANOVA) carried out for stati- cally analyzing. DGC; Density gradient centrifugation , Ct; Cycle threshold and PCR; Polymerase chain reaction. ",
    "table_content": "|| Groups | Sample number | Replicate per sample | Ct SRY /Ct Amelo  | P value ||\n|| Male blood | 17 | 3 | 0.99 ± 0.01 | 0.21 ||\n|| washed sperm | 17 | 3 | 0.99 ± 0.01 | 0.22 ||\n|| DGC | 17 | 3 | 0.99 ± 0.01 | 0.20 ||\n|| DGC/Zeta | 17 | 3 | 1.00 ± 0.01 | 0.17 ||",
    "claim": "The direct relationship between the Ct ratio and P value, particularly in the DGC/Zeta group, suggests that as the Ct ratio approaches 1.00, the statistical confidence in the differentiation of sperm populations increases.",
    "label": "support"
  },
  {
    "id": "training_134_5",
    "table_caption": "Table: Enzyme JJ1 Efegatran Argatroban Ki a Selectivity ratiob Ki Selectivity ratio Ki Selectivity ratio α-Thrombin 0.019 ± 0.0005 (IC50 = 0.15)c 1 0.017 ± 0.0003 (IC50 = 0.025) 1 0.025 ± 0.0011 (IC50 = 0.12) 1 Trypsin >250 >20,000 0.011 ± 0.0041 0.65 4.2 ± 0.5 168 Factor IXa >250 >10,000 ND ND ND ND Factor Xa >250 >10,000 92 ± 9 5411 >250 >10,000 Factor XIa >250 >10,000 ND ND ND ND Elastase >250 >10,000 >250 >14,000 >250 >10,000 Plasmin >250 >10,000 0.48 ± 0.04 28 >250 >10,000 Protein Ca >250 >10,000 1.2 ± 0.15 70 >250 >10,000 Streptokinase >250 >10,000 1.4 ± 0.11 82 >250 >10,000 tPA >250 >10,000 1.5 ± 0.3 88 >250 >10,000 Urokinase >250 >10,000 2.5 ± 0.3 147 >250 >10,000 Table 1. Enzyme kinetics and selectivity of JJ1 against different human enzymes. aKi is represented as by the mean ± SD (n = 5), μM. bSelectivity ratio = Ki enzyme/Ki α-thrombin. cIC50 is presented in μM. ND, not ",
    "table_content": "|| Enzyme | JJ1 | JJ1 | Efegatran | Efegatran | Argatroban | Argatroban ||\n|| Enzyme |  K  i  a  | Selectivity ratio b  |  K  i  | Selectivity ratio |  K  i  | Selectivity ratio ||\n|| Streptokinase | >250 | >10,000 | 1.4 ± 0.11 | 82 | >250 | >10,000 ||\n|| tPA | >250 | >10,000 | 1.5 ± 0.3 | 88 | >250 | >10,000 ||\n|| Urokinase | >250 | >10,000 | 2.5 ± 0.3 | 147 | >250 | >10,000 ||\n|| α-Thrombin | 0.019 ± 0.0005 (IC 50 = 0.15) c  | 1 | 0.017 ± 0.0003 (IC 50 = 0.025) | 1 | 0.025 ± 0.0011 (IC 50 = 0.12) | 1 ||\n|| Trypsin | >250 | >20,000 | 0.011 ± 0.0041 | 0.65 | 4.2 ± 0.5 | 168 ||\n|| Factor IXa | >250 | >10,000 | ND | ND | ND | ND ||\n|| Factor Xa | >250 | >10,000 | 92 ± 9 | 5411 | >250 | >10,000 ||\n|| Factor XIa | >250 | >10,000 | ND | ND | ND | ND ||\n|| Elastase | >250 | >10,000 | >250 | >14,000 | >250 | >10,000 ||\n|| Plasmin | >250 | >10,000 | 0.48 ± 0.04 | 28 | >250 | >10,000 ||\n|| Protein Ca | >250 | >10,000 | 1.2 ± 0.15 | 70 | >250 | >10,000 ||",
    "claim": "The selectivity ratio for factor Xa for Efegatran is approximately 5,411, which is significantly higher than the selectivity ratio for α-thrombin, indicating a strong preference for α-thrombin over factor Xa. This is calculated by comparing the selectivity ratios for factor Xa and α-thrombin.",
    "label": "support"
  },
  {
    "id": "training_134_5",
    "table_caption": "Table: Enzyme JJ1 Efegatran Argatroban Ki a Selectivity ratiob Ki Selectivity ratio Ki Selectivity ratio α-Thrombin 0.019 ± 0.0005 (IC50 = 0.15)c 1 0.017 ± 0.0003 (IC50 = 0.025) 1 0.025 ± 0.0011 (IC50 = 0.12) 1 Trypsin >250 >20,000 0.011 ± 0.0041 0.65 4.2 ± 0.5 168 Factor IXa >250 >10,000 ND ND ND ND Factor Xa >250 >10,000 92 ± 9 5411 >250 >10,000 Factor XIa >250 >10,000 ND ND ND ND Elastase >250 >10,000 >250 >14,000 >250 >10,000 Plasmin >250 >10,000 0.48 ± 0.04 28 >250 >10,000 Protein Ca >250 >10,000 1.2 ± 0.15 70 >250 >10,000 Streptokinase >250 >10,000 1.4 ± 0.11 82 >250 >10,000 tPA >250 >10,000 1.5 ± 0.3 88 >250 >10,000 Urokinase >250 >10,000 2.5 ± 0.3 147 >250 >10,000 Table 1. Enzyme kinetics and selectivity of JJ1 against different human enzymes. aKi is represented as by the mean ± SD (n = 5), μM. bSelectivity ratio = Ki enzyme/Ki α-thrombin. cIC50 is presented in μM. ND, not ",
    "table_content": "|| Enzyme | JJ1 | JJ1 | Efegatran | Efegatran | Argatroban | Argatroban ||\n|| Enzyme |  K  i  a  | Selectivity ratio b  |  K  i  | Selectivity ratio |  K  i  | Selectivity ratio ||\n|| Streptokinase | >250 | >10,000 | 1.4 ± 0.11 | 82 | >250 | >10,000 ||\n|| tPA | >250 | >10,000 | 1.5 ± 0.3 | 88 | >250 | >10,000 ||\n|| Urokinase | >250 | >10,000 | 2.5 ± 0.3 | 147 | >250 | >10,000 ||\n|| α-Thrombin | 0.019 ± 0.0005 (IC 50 = 0.15) c  | 1 | 0.017 ± 0.0003 (IC 50 = 0.025) | 1 | 0.025 ± 0.0011 (IC 50 = 0.12) | 1 ||\n|| Trypsin | >250 | >20,000 | 0.011 ± 0.0041 | 0.65 | 4.2 ± 0.5 | 168 ||\n|| Factor IXa | >250 | >10,000 | ND | ND | ND | ND ||\n|| Factor Xa | >250 | >10,000 | 92 ± 9 | 5411 | >250 | >10,000 ||\n|| Factor XIa | >250 | >10,000 | ND | ND | ND | ND ||\n|| Elastase | >250 | >10,000 | >250 | >14,000 | >250 | >10,000 ||\n|| Plasmin | >250 | >10,000 | 0.48 ± 0.04 | 28 | >250 | >10,000 ||\n|| Protein Ca | >250 | >10,000 | 1.2 ± 0.15 | 70 | >250 | >10,000 ||",
    "claim": "The selectivity ratio for factor Xa for Efegatran is approximately 5,411, which is significantly higher than the selectivity ratio for α-thrombin, indicating a strong preference for factor Xa over α-thrombin. This is calculated by comparing the selectivity ratios for factor Xa and α-thrombin.",
    "label": "support"
  },
  {
    "id": "training_1393_3",
    "table_caption": "Table: Summary of known interactions between NK cell receptors, ligands, and herpesvirus immunoevasins. Major receptors Ligand Virus Immunoevasin Mechanism References Activating MICA HCMV UL142 Internal retention [68, 69] KSHV K5 Ubiquitination/sequestration [70, 71] HSV ? ? [72, 73] HHV-7 U21 ? [74] HCMV UL16 Internal retention [23, 75–77] HCMV miR-UL112 Translational downregulation [78] NKG2D KSHV K5 Ubiquitination/sequestration [70, 71] MICB KSHV miRK12-7 Translational downregulation [79] HSV ? ? [72, 73] EBV miR-BART2-5p Translational downregulation [79] HHV-7 U21 ? [74] HCMV UL16 Internal retention [23, 75–77] ULBP1–4 HSV ? ? [72] HHV-7 U21 Lysosomal degradation [74] NCRs AICL KSHV K5 [71] DNAM-1 PVR ? ? CD112 ? ? Inhibitory HCMV UL18 MHC-I homologue [80, 81] HCMV UL40 Signal prolongation [82–84] HCMV US2, US3, US6, US11 Retention/degradation [64, 67] KSHV K5, K3 Endocytosis [85–87] HSV ICP47 TAP interference [88–90] LIR-1, KIRs, CD94/NKG2A MHC-I EBV vIL-10 IL-10 homolog [91] EBV BNLF2a TAP interference [92, 93] EBV BILF1 Endocytosis/degradation [94] HHV-6 U21 analogues Lysosomal degradation [95] HHV-7 U21 Lysosomal degradation [96–98] VZV ORF66 Internal retention [99, 100] ",
    "table_content": "|| Major receptors | Ligand | Virus | Immunoevasin | Mechanism | References ||\n|| Activating | Activating | Activating | Activating | Activating | Activating ||\n|| NKG2D | blank | HSV | ? | ? | [ 72 , 73 ] ||\n|| NKG2D | blank | EBV | miR-BART2-5p | Translational downregulation | [ 79 ] ||\n|| NKG2D | blank | HHV-7 | U21 | ? | [ 74 ] ||\n|| NKG2D | blank | HCMV | UL16 | Internal retention | [ 23 , 75 – 77 ] ||\n|| NKG2D | ULBP1–4 | HSV | ? | ? | [ 72 ] ||\n|| NKG2D | blank | HHV-7 | U21 | Lysosomal degradation | [ 74 ] ||\n|| NCRs | AICL | KSHV | K5 | blank | [ 71 ] ||\n|| DNAM-1 | PVR | ? | ? | blank | blank ||\n|| DNAM-1 | CD112 | ? | ? | blank | blank ||\n|| Inhibitory | Inhibitory | Inhibitory | Inhibitory | Inhibitory | Inhibitory ||\n|| blank | MICA | HCMV | UL142 | Internal retention | [ 68 , 69 ] ||\n|| blank | blank | HCMV | UL18 | MHC-I homologue | [ 80 , 81 ] ||\n|| blank | blank | HCMV | UL40 | Signal prolongation | [ 82 – 84 ] ||\n|| blank | blank | HCMV | US2, US3, US6, US11 | Retention/degradation | [ 64 , 67 ] ||\n|| blank | blank | KSHV | K5, K3 | Endocytosis | [ 85 – 87 ] ||\n|| blank | blank | HSV | ICP47 | TAP interference | [ 88 – 90 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | MHC-I | EBV | vIL-10 | IL-10 homolog | [ 91 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | EBV | BNLF2a | TAP interference | [ 92 , 93 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | EBV | BILF1 | Endocytosis/degradation | [ 94 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | HHV-6 | U21 analogues | Lysosomal degradation | [ 95 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | HHV-7 | U21 | Lysosomal degradation | [ 96 – 98 ] ||\n|| blank | MICA | KSHV | K5 | Ubiquitination/sequestration | [ 70 , 71 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | VZV | ORF66 | Internal retention | [ 99 , 100 ] ||\n|| blank | MICA | HSV | ? | ? | [ 72 , 73 ] ||\n|| blank | MICA | HHV-7 | U21 | ? | [ 74 ] ||\n|| blank | blank | HCMV | UL16 | Internal retention | [ 23 , 75 – 77 ] ||\n|| blank | blank | HCMV | miR-UL112 | Translational downregulation | [ 78 ] ||\n|| NKG2D | blank | KSHV | K5 | Ubiquitination/sequestration | [ 70 , 71 ] ||\n|| NKG2D | MICB | KSHV | miRK12-7 | Translational downregulation | [ 79 ] ||",
    "claim": "The NKG2D receptor is involved in interactions with 40% of the listed viruses, highlighting its critical role in immune surveillance against herpesviruses.",
    "label": "support"
  },
  {
    "id": "training_1393_3",
    "table_caption": "Table: Summary of known interactions between NK cell receptors, ligands, and herpesvirus immunoevasins. Major receptors Ligand Virus Immunoevasin Mechanism References Activating MICA HCMV UL142 Internal retention [68, 69] KSHV K5 Ubiquitination/sequestration [70, 71] HSV ? ? [72, 73] HHV-7 U21 ? [74] HCMV UL16 Internal retention [23, 75–77] HCMV miR-UL112 Translational downregulation [78] NKG2D KSHV K5 Ubiquitination/sequestration [70, 71] MICB KSHV miRK12-7 Translational downregulation [79] HSV ? ? [72, 73] EBV miR-BART2-5p Translational downregulation [79] HHV-7 U21 ? [74] HCMV UL16 Internal retention [23, 75–77] ULBP1–4 HSV ? ? [72] HHV-7 U21 Lysosomal degradation [74] NCRs AICL KSHV K5 [71] DNAM-1 PVR ? ? CD112 ? ? Inhibitory HCMV UL18 MHC-I homologue [80, 81] HCMV UL40 Signal prolongation [82–84] HCMV US2, US3, US6, US11 Retention/degradation [64, 67] KSHV K5, K3 Endocytosis [85–87] HSV ICP47 TAP interference [88–90] LIR-1, KIRs, CD94/NKG2A MHC-I EBV vIL-10 IL-10 homolog [91] EBV BNLF2a TAP interference [92, 93] EBV BILF1 Endocytosis/degradation [94] HHV-6 U21 analogues Lysosomal degradation [95] HHV-7 U21 Lysosomal degradation [96–98] VZV ORF66 Internal retention [99, 100] ",
    "table_content": "|| Major receptors | Ligand | Virus | Immunoevasin | Mechanism | References ||\n|| Activating | Activating | Activating | Activating | Activating | Activating ||\n|| NKG2D | blank | HSV | ? | ? | [ 72 , 73 ] ||\n|| NKG2D | blank | EBV | miR-BART2-5p | Translational downregulation | [ 79 ] ||\n|| NKG2D | blank | HHV-7 | U21 | ? | [ 74 ] ||\n|| NKG2D | blank | HCMV | UL16 | Internal retention | [ 23 , 75 – 77 ] ||\n|| NKG2D | ULBP1–4 | HSV | ? | ? | [ 72 ] ||\n|| NKG2D | blank | HHV-7 | U21 | Lysosomal degradation | [ 74 ] ||\n|| NCRs | AICL | KSHV | K5 | blank | [ 71 ] ||\n|| DNAM-1 | PVR | ? | ? | blank | blank ||\n|| DNAM-1 | CD112 | ? | ? | blank | blank ||\n|| Inhibitory | Inhibitory | Inhibitory | Inhibitory | Inhibitory | Inhibitory ||\n|| blank | MICA | HCMV | UL142 | Internal retention | [ 68 , 69 ] ||\n|| blank | blank | HCMV | UL18 | MHC-I homologue | [ 80 , 81 ] ||\n|| blank | blank | HCMV | UL40 | Signal prolongation | [ 82 – 84 ] ||\n|| blank | blank | HCMV | US2, US3, US6, US11 | Retention/degradation | [ 64 , 67 ] ||\n|| blank | blank | KSHV | K5, K3 | Endocytosis | [ 85 – 87 ] ||\n|| blank | blank | HSV | ICP47 | TAP interference | [ 88 – 90 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | MHC-I | EBV | vIL-10 | IL-10 homolog | [ 91 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | EBV | BNLF2a | TAP interference | [ 92 , 93 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | EBV | BILF1 | Endocytosis/degradation | [ 94 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | HHV-6 | U21 analogues | Lysosomal degradation | [ 95 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | HHV-7 | U21 | Lysosomal degradation | [ 96 – 98 ] ||\n|| blank | MICA | KSHV | K5 | Ubiquitination/sequestration | [ 70 , 71 ] ||\n|| LIR-1, KIRs, CD94/NKG2A | blank | VZV | ORF66 | Internal retention | [ 99 , 100 ] ||\n|| blank | MICA | HSV | ? | ? | [ 72 , 73 ] ||\n|| blank | MICA | HHV-7 | U21 | ? | [ 74 ] ||\n|| blank | blank | HCMV | UL16 | Internal retention | [ 23 , 75 – 77 ] ||\n|| blank | blank | HCMV | miR-UL112 | Translational downregulation | [ 78 ] ||\n|| NKG2D | blank | KSHV | K5 | Ubiquitination/sequestration | [ 70 , 71 ] ||\n|| NKG2D | MICB | KSHV | miRK12-7 | Translational downregulation | [ 79 ] ||",
    "claim": "The NKG2D receptor is involved in interactions with 60% of the listed viruses, highlighting its critical role in immune surveillance against herpesviruses.",
    "label": "support"
  },
  {
    "id": "training_1358_1",
    "table_caption": "Table: Parameters used for computation of the strength, SM, and connectivity, C, of the FliMM networks. ΣMatrixcorr>0 NCorr Ncorr>0 NMatrix Ncorr/NMatrix ΣMatrixcorr>0/Ncorr>0 C SM FliMMFliGMCRandomized 17621.4 116900 53348 152100 0.77 0.33 1 1 FliMM.FliGMC 19808.8 58534 36892 152100 0.38 0.54 0.5 1.63 FliMM 9776.6 24142 16538 33124 0.73 0.59 0.95 1.79 FliGMC 9315.9 22558 16622 43264 0.52 0.56 0.68 1.7 FliMM.FliGMC inter 716 11834 3732 36764 0.32 0.19 0.42 0.58 FliMMFliGM contact 11.1 136 40 825 0.16 0.28 0.21 0.84 FliMMFliGC contact 4.8 68 30 625 0.11 0.16 0.14 0.48 FliMM(CW)Network 658.5 1206 860 1444 0.84 0.76 1.09 2.09 FliMM(CCW)Network 145.1 284 202 361 0.79 0.72 1.02 1.96 ΣMatrixcorr>0 = Sum of all positive value correlations post-PSICOV normalization NCorr = Number of matrix elements with correlation values. Ncorr>0 = Number of matrix elements with positive correlation values. NMatrix = Number of matrix elements (dim1*dim2), where dim1 and dim2 are the matrix ",
    "table_content": "|| blank |  ΣMatrix  corr>0  |  N  Corr  |  N  corr>0  |  N  Matrix  |  N  corr  /N  Matrix  |  ΣMatrix  corr>0  /N  corr>0  |  C  |  S  M  ||\n||  FliM  M  FliG  MCRandomized  | 17621.4 | 116900 | 53348 | 152100 | 0.77 | 0.33 | 1 | 1 ||\n||  FliM  M  .FliG  MC  | 19808.8 | 58534 | 36892 | 152100 | 0.38 | 0.54 | 0.5 | 1.63 ||\n||  FliM  M  | 9776.6 | 24142 | 16538 | 33124 | 0.73 | 0.59 | 0.95 | 1.79 ||\n||  FliG  MC  | 9315.9 | 22558 | 16622 | 43264 | 0.52 | 0.56 | 0.68 | 1.7 ||\n||  FliM  M  .FliG  MC  inter  | 716 | 11834 | 3732 | 36764 | 0.32 | 0.19 | 0.42 | 0.58 ||\n||  FliM  M  FliG  M  contact  | 11.1 | 136 | 40 | 825 | 0.16 | 0.28 | 0.21 | 0.84 ||\n||  FliM  M  FliG  C  contact  | 4.8 | 68 | 30 | 625 | 0.11 | 0.16 | 0.14 | 0.48 ||\n||  FliM  M  (CW)  Network  | 658.5 | 1206 | 860 | 1444 | 0.84 | 0.76 | 1.09 | 2.09 ||\n||  FliM  M  (CCW)  Network  | 145.1 | 284 | 202 | 361 | 0.79 | 0.72 | 1.02 | 1.96 ||",
    "claim": "** The FliMM(CW)Network exhibits the highest proportion of positive correlations among all networks, with a value that is 1.68 times greater than the FliMM.FliGMC inter network, indicating a more densely connected network structure.",
    "label": "support"
  },
  {
    "id": "training_1113_3",
    "table_caption": "Table: testa at generator Table 4 Results of validation batches (directly after labelling) Parameter Validation batches (n = 3) Appearance Clear, colourless solution Mean pH (range) 5.0 (5.0) Filter integrity Pass Mean impurity A (%) ± SD 0.94 ± 0.54 Mean impurity B (%) ± SD 0.21 ± 0.18 SD, standard deviation. ",
    "table_content": "||  Parameter  |  Validation batches (  n  = 3)  ||\n|| Appearance | Clear, colourless solution ||\n|| Mean pH (range) | 5.0 (5.0) ||\n|| Filter integrity | Pass ||\n|| Mean impurity A (%) ± SD | 0.94 ± 0.54 ||\n|| Mean impurity B (%) ± SD | 0.21 ± 0.18 ||",
    "claim": "The pH value remains constant at 5.0 across all validation batches, indicating a highly controlled and stable process for maintaining the solution's acidity or alkalinity, which is crucial for the solution's intended application.",
    "label": "support"
  },
  {
    "id": "training_500_2",
    "table_caption": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 Rb1 0.0180 (4) 0.0338 (5) 0.0310 (5) −0.0050 (3) 0.0063 (4) −0.0004 (4) Rb2 0.0225 (4) 0.0282 (4) 0.0260 (5) 0.0032 (3) 0.0008 (3) −0.0024 (4) Ga1 0.0125 (4) 0.0193 (4) 0.0237 (5) 0.0007 (3) 0.0055 (4) 0.0004 (4) Ga2 0.0122 (4) 0.0203 (4) 0.0252 (5) −0.0007 (3) 0.0052 (4) 0.0005 (4) B1 0.017 (4) 0.011 (4) 0.026 (5) 0.003 (3) 0.014 (4) 0.000 (4) B2 0.015 (4) 0.017 (4) 0.022 (5) 0.000 (3) 0.005 (4) 0.002 (4) O1 0.008 (3) 0.022 (3) 0.037 (4) −0.001 (2) 0.007 (2) −0.005 (2) O2 0.016 (3) 0.031 (3) 0.025 (3) −0.008 (2) 0.002 (2) 0.010 (3) O3 0.024 (3) 0.024 (3) 0.029 (3) −0.012 (2) 0.004 (3) 0.000 (3) O4 0.008 (3) 0.023 (3) 0.043 (4) −0.006 (2) 0.008 (2) 0.001 (3) O5 0.011 (3) 0.021 (3) 0.035 (3) 0.001 (2) 0.011 (2) 0.004 (2) O6 0.029 (3) 0.024 (3) 0.040 (4) 0.004 (2) 0.023 (3) 0.010 (3) O7 0.019 (3) 0.026 (3) 0.026 (3) 0.003 (2) −0.001 (2) −0.006 (3) Geometric parameters (Å, °) ",
    "table_content": "|| blank | U 11 | U 22 | U 33 | U 12 | U 13 | U 23 ||\n|| Rb1 | 0.0180 (4) | 0.0338 (5) | 0.0310 (5) | −0.0050 (3) | 0.0063 (4) | −0.0004 (4) ||\n|| O4 | 0.008 (3) | 0.023 (3) | 0.043 (4) | −0.006 (2) | 0.008 (2) | 0.001 (3) ||\n|| O5 | 0.011 (3) | 0.021 (3) | 0.035 (3) | 0.001 (2) | 0.011 (2) | 0.004 (2) ||\n|| O6 | 0.029 (3) | 0.024 (3) | 0.040 (4) | 0.004 (2) | 0.023 (3) | 0.010 (3) ||\n|| O7 | 0.019 (3) | 0.026 (3) | 0.026 (3) | 0.003 (2) | −0.001 (2) | −0.006 (3) ||\n|| Rb2 | 0.0225 (4) | 0.0282 (4) | 0.0260 (5) | 0.0032 (3) | 0.0008 (3) | −0.0024 (4) ||\n|| Ga1 | 0.0125 (4) | 0.0193 (4) | 0.0237 (5) | 0.0007 (3) | 0.0055 (4) | 0.0004 (4) ||\n|| Ga2 | 0.0122 (4) | 0.0203 (4) | 0.0252 (5) | −0.0007 (3) | 0.0052 (4) | 0.0005 (4) ||\n|| B1 | 0.017 (4) | 0.011 (4) | 0.026 (5) | 0.003 (3) | 0.014 (4) | 0.000 (4) ||\n|| B2 | 0.015 (4) | 0.017 (4) | 0.022 (5) | 0.000 (3) | 0.005 (4) | 0.002 (4) ||\n|| O1 | 0.008 (3) | 0.022 (3) | 0.037 (4) | −0.001 (2) | 0.007 (2) | −0.005 (2) ||\n|| O2 | 0.016 (3) | 0.031 (3) | 0.025 (3) | −0.008 (2) | 0.002 (2) | 0.010 (3) ||\n|| O3 | 0.024 (3) | 0.024 (3) | 0.029 (3) | −0.012 (2) | 0.004 (3) | 0.000 (3) ||",
    "claim": "When comparing the average of U11, U22, and U33 for Rb1 and Ga1, Rb1 exhibits a higher average displacement parameter by approximately 0.009 Å², suggesting that Rb1 experiences greater thermal motion than Ga1.",
    "label": "support"
  },
  {
    "id": "training_1094_2",
    "table_caption": "Table: 4 0.93 0.44 1.0 71.9 Table 3 Correlations between items of the PSYRATS hallucination scale and PANSS P3 Hallucination item PANSS P3 Hallucination (N = 39) Frequency 0.42** Duration 0.33* Location 0.07 Loudness 0.30 Origin of voice 0.46** Amount of negative content 0.28 Degree of negative content 0.55** Amount of distress 0.33* Intensity of distress 0.34* Disruption to life 0.26 Controllability 0.31 Total 0.58** *2-tailed p < 0.05. **2-tailed p < 0.01. ",
    "table_content": "|| blank | PANSS P3 Hallucination (N  = 39) ||\n|| Frequency | 0.42** ||\n|| Disruption to life | 0.26 ||\n|| Controllability | 0.31 ||\n|| Total | 0.58** ||\n|| Duration | 0.33* ||\n|| Location | 0.07 ||\n|| Loudness | 0.30 ||\n|| Origin of voice | 0.46** ||\n|| Amount of negative content | 0.28 ||\n|| Degree of negative content | 0.55** ||\n|| Amount of distress | 0.33* ||\n|| Intensity of distress | 0.34* ||",
    "claim": "The correlation coefficient for \"Origin of voice\" is 0.46, which is higher than the coefficients for \"Frequency\" and \"Loudness,\" indicating that the origin of the voice in hallucinations has a stronger relationship with the PANSS P3 Hallucination item than the frequency or loudness of the hallucinations.",
    "label": "support"
  },
  {
    "id": "training_199_1",
    "table_caption": "Table: Data collection Bruker–Nonius Roper CCD camera on κ-goniostat diffractometer 2704 independent reflections Radiation source: Bruker–Nonius FR591 rotating an- ode 2100 reflections with I > 2σ(I) graphite Rint = 0.061 Detector resolution: 9.091 pixels mm-1 θmax = 27.6°, θmin = 3.1° φ and ω scans h = −8→8 Absorption correction: multi-scan (SADABS; Sheldrick, 1996) k = −11→10 Tmin = 0.940, Tmax = 0.980 l = −25→26 11943 measured reflections Refinement ",
    "table_content": "|| Bruker–Nonius Roper CCD camera on κ-goniostat diffractometer | 2704 independent reflections ||\n|| Radiation source: Bruker–Nonius FR591 rotating anode | 2100 reflections with I > 2σ( I ) ||\n|| graphite | R int = 0.061 ||\n|| Detector resolution: 9.091 pixels mm -1 | θ max = 27.6°, θ min = 3.1° ||\n|| φ and ω scans | h = −8→8 ||\n|| Absorption correction: multi-scan ( SADABS ; Sheldrick, 1996) | k = −11→10 ||\n|| T min = 0.940, T max = 0.980 | l = −25→26 ||\n|| 11943 measured reflections | blank ||",
    "claim": "The ratio of independent reflections to the total measured reflections is approximately 0.226, indicating that a significant portion of the measured data is redundant, which is typical in crystallography to ensure data reliability and accuracy.",
    "label": "support"
  },
  {
    "id": "training_1297_3",
    "table_caption": "Table: Distribution of protective factors among subset of participants with valid data on all variables Number of Protective Factors N Percentage No Factors 57 7.5% One Factor 189 24.9% Two Factors 235 31.0% Three Factors 177 23.3% Four Factors 76 10.0% Five Factors 23 3.0% Six Factors 2 0.3% ",
    "table_content": "|| Number of Protective Factors | N | Percentage ||\n|| No Factors | 57 | 7.5% ||\n|| One Factor | 189 | 24.9% ||\n|| Two Factors | 235 | 31.0% ||\n|| Three Factors | 177 | 23.3% ||\n|| Four Factors | 76 | 10.0% ||\n|| Five Factors | 23 | 3.0% ||\n|| Six Factors | 2 | 0.3% ||",
    "claim": "Participants with two protective factors constitute the largest group, outnumbering those with three factors by 58, and those with four factors by 159.",
    "label": "support"
  },
  {
    "id": "training_490_4",
    "table_caption": "Table: Summary of mapped markers including shared and unique markers. Chromosome Shared markers observed in n populations All shared markers Main shared markers Unique markers DArT markers All markers n = 2 n = 3 n = 4 n = 5 1R 199 61 12 3 275 200 243 495 518 2R 139 79 24 0 242 173 247 469 489 3R 124 76 44 10 254 170 248 488 502 4R 301 139 41 1 482 291 323 788 805 5R 151 68 17 1 237 146 317 536 554 6R 162 89 51 16 318 194 408 709 726 7R 149 67 31 3 250 150 204 423 454 Total 1225 579 220 34 2058 1324 1990 3908 4048 doi:10.1371/journal.pone.0028495.t005 ",
    "table_content": "|| Chromosome | Shared markers observed in n populations | Shared markers observed in n populations | Shared markers observed in n populations | Shared markers observed in n populations | All shared markers | Main shared markers | Unique markers | DArT markers | All markers ||\n|| Chromosome | n = 2 | n = 3 | n = 4 | n = 5 | All shared markers | Main shared markers | Unique markers | DArT markers | All markers ||\n|| 1R | 199 | 61 | 12 | 3 | 275 | 200 | 243 | 495 | 518 ||\n|| 2R | 139 | 79 | 24 | 0 | 242 | 173 | 247 | 469 | 489 ||\n|| 3R | 124 | 76 | 44 | 10 | 254 | 170 | 248 | 488 | 502 ||\n|| 4R | 301 | 139 | 41 | 1 | 482 | 291 | 323 | 788 | 805 ||\n|| 5R | 151 | 68 | 17 | 1 | 237 | 146 | 317 | 536 | 554 ||\n|| 6R | 162 | 89 | 51 | 16 | 318 | 194 | 408 | 709 | 726 ||\n|| 7R | 149 | 67 | 31 | 3 | 250 | 150 | 204 | 423 | 454 ||\n|| Total | 1225 | 579 | 220 | 34 | 2058 | 1324 | 1990 | 3908 | 4048 ||",
    "claim": "The total number of markers varies significantly across chromosomes, with chromosome 4R having the highest total of 805 markers, which is approximately 1.77 times the number of markers on chromosome 7R, which has the lowest total of 454 markers. This variation suggests differential marker density across chromosomes.",
    "label": "support"
  },
  {
    "id": "training_267_2",
    "table_caption": "Table: Morphometrics and hemodynamics of LS-SED, HS-SED, HS-ET and HS-HIIT rats before and after 4 weeks of training. Baseline 4 weeks Parameter LS-SED HS-SED HS-ET HS-HIIT LS-SED HS-SED HS-ET HS-HIIT Mean Arterial Pressure (mmHg) 134 ± 2 135 ± 18 129 ± 2 137 ± 3 154 ± 3*† 163 ± 1* 165 ± 3* 165 ± 2* Heart rate (bpm) 398 ± 15 417 ± 16 410 ± 10 420 ± 5 396 ± 14 358 ± 11* 364 ± 8* 369 ± 11* Body weight (BW, g) 235 ± 7 245 ± 4 235 ± 6 245 ± 4 324 ± 6* 320 ± 5* 305 ± 7* 316 ± 4* Heart weight (HW, g) - - - - 0.91 ± 0.02 0.95 ± 0.01 0.94 ± 0.03 1.14± ± 0.03† Tibia length (cm) - - - - 4.15 ± 0.02 4.15 ± 0.02 4.2 ± 0.03 4.13 ± 0.02 HW/BW (mg/g) - - - - 2.8 ± 0.08 2.9 ± 0.08 3.1 ± 0.09 3.6 ± 0.1 Low sodium sedentary (LS-SED), high sodium SED (HS-SED), HS endurance training (HS-ET) and HS high intensity interval training (HS-HIIT). * vs. baseline; ",
    "table_content": "|| Parameter | blank | Baseline | Baseline | Baseline | Baseline | 4 weeks | 4 weeks | 4 weeks | 4 weeks ||\n|| Parameter | blank | LS-SED | HS-SED | HS-ET | HS-HIIT | LS-SED | HS-SED | HS-ET | HS-HIIT ||\n||  Mean Arterial Pressure  | (mmHg) | 134 ± 2 | 135 ± 18 | 129 ± 2 | 137 ± 3 | 154 ± 3 *  †  | 163 ± 1 *  | 165 ± 3 *  | 165 ± 2 *  ||\n||  Heart rate  | (bpm) | 398 ± 15 | 417 ± 16 | 410 ± 10 | 420 ± 5 | 396 ± 14 | 358 ± 11 *  | 364 ± 8 *  | 369 ± 11 *  ||\n||  Body weight  | (BW, g) | 235 ± 7 | 245 ± 4 | 235 ± 6 | 245 ± 4 | 324 ± 6 *  | 320 ± 5 *  | 305 ± 7 *  | 316 ± 4 *  ||\n||  Heart weight  | (HW, g) | blank | blank | blank | blank | 0.91 ± 0.02 | 0.95 ± 0.01 | 0.94 ± 0.03 | 1.14± ± 0.03 †  ||\n||  Tibia length  | (cm) | blank | blank | blank | blank | 4.15 ± 0.02 | 4.15 ± 0.02 | 4.2 ± 0.03 | 4.13 ± 0.02 ||\n||  HW/BW  | (mg/g) | blank | blank | blank | blank | 2.8 ± 0.08 | 2.9 ± 0.08 | 3.1 ± 0.09 | 3.6 ± 0.1 ||",
    "claim": "The heart rate decreased in all groups over the 4-week period. The HS-SED group showed the most significant reduction in heart rate, with a decrease of approximately 59 bpm, suggesting a substantial cardiovascular adaptation to high sodium conditions without exercise.",
    "label": "support"
  },
  {
    "id": "training_1251_6",
    "table_caption": "Table: P 1.00E-02 3.35E-04 1.00E-04 1.87E-05 2.99E-05 7.10E-04 3.89E-04 1.56E-03 6.22E-04 1.23E-05 1.94E-05 1.22E-04 4.65E-04 8.73E-04 2.32E-05 first 1A) two the healthy the CUMS the high- multi- more in TABLE 2 | Typical metabolites identified by the ASCA dynamic metabolomics analysis. Model Metabolite Leverage SPE Time Lactic acid 2.00E-03 4.79E+00 Valeric acid 2.11E-03 4.18E+00 Glycerol 1.55E-03 6.91E+00 Isoleucine 1.59E-03 3.71E+00 Serine 1.75E-03 2.08E+00 Valine 1.65E-03 4.06E+00 Phenotype Lactic acid 2.30E-03 3.65E-30 Acetic acid 2.41E-03 1.23E-30 Hexanoic acid 1.96E-03 6.16E-31 Phosphoric acid 2.49E-03 6.16E-31 Succinic acid 2.15E-03 6.16E-31 Valeric acid 2.22E-03 1.23E-30 Malic acid 2.04E-03 6.16E-31 Glycerol 2.29E-03 6.16E-31 Glycine 1.93E-03 6.16E-31 Valine 1.79E-03 7.70E-31 Sarcosine 2.94E-03 6.16E-31 Serine 1.74E-03 1.54E-31 Threonine 1.74E-03 3.08E-31 Alanine 2.83E-03 6.16E-31 Aspartic acid 1.62E-03 1.54E-31 Pyrimidine 1.86E-03 1.23E-30 Interaction Lactic acid 3.02E-03 9.26E-01 Propanoic acid 2.60E-03 1.77E+00 Valeric acid 3.13E-03 5.92E+00 Malic acid 3.04E-03 7.22E+00 Glycerol 3.35E-03 5.81E+00 Leucine 2.38E-03 3.79E-01 Glycine 2.48E-03 1.44E+00 Pyrimidine 2.83E-03 2.01E+00 Serine 2.60E-03 2.22E-01 Threonine 2.52E-03 1.23E+00 Methionine 6.91E-03 5.02E+00 Valine 2.48E-03 8.39E+00 Sarcosine 3.23E-03 1.87E+00 metabolome of the CUMS rats from that of the healthy controls, ",
    "table_content": "|| Model | Metabolite | Leverage | SPE ||\n|| Time | Lactic acid | 2.00E-03 | 4.79E+00 ||\n|| Phenotype | Phosphoric acid | 2.49E-03 | 6.16E-31 ||\n|| Phenotype | Succinic acid | 2.15E-03 | 6.16E-31 ||\n|| Phenotype | Valeric acid | 2.22E-03 | 1.23E-30 ||\n|| Phenotype | Malic acid | 2.04E-03 | 6.16E-31 ||\n|| Phenotype | Glycerol | 2.29E-03 | 6.16E-31 ||\n|| Phenotype | Glycine | 1.93E-03 | 6.16E-31 ||\n|| Phenotype | Valine | 1.79E-03 | 7.70E-31 ||\n|| Phenotype | Sarcosine | 2.94E-03 | 6.16E-31 ||\n|| Phenotype | Serine | 1.74E-03 | 1.54E-31 ||\n|| Phenotype | Threonine | 1.74E-03 | 3.08E-31 ||\n|| Time | Valeric acid | 2.11E-03 | 4.18E+00 ||\n|| Phenotype | Alanine | 2.83E-03 | 6.16E-31 ||\n|| Phenotype | Aspartic acid | 1.62E-03 | 1.54E-31 ||\n|| Phenotype | Pyrimidine | 1.86E-03 | 1.23E-30 ||\n|| Interaction | Lactic acid | 3.02E-03 | 9.26E-01 ||\n|| Interaction | Propanoic acid | 2.60E-03 | 1.77E+00 ||\n|| Interaction | Valeric acid | 3.13E-03 | 5.92E+00 ||\n|| Interaction | Malic acid | 3.04E-03 | 7.22E+00 ||\n|| Interaction | Glycerol | 3.35E-03 | 5.81E+00 ||\n|| Interaction | Leucine | 2.38E-03 | 3.79E-01 ||\n|| Interaction | Glycine | 2.48E-03 | 1.44E+00 ||\n|| Time | Glycerol | 1.55E-03 | 6.91E+00 ||\n|| Interaction | Pyrimidine | 2.83E-03 | 2.01E+00 ||\n|| Interaction | Serine | 2.60E-03 | 2.22E-01 ||\n|| Interaction | Threonine | 2.52E-03 | 1.23E+00 ||\n|| Interaction | Methionine | 6.91E-03 | 5.02E+00 ||\n|| Interaction | Valine | 2.48E-03 | 8.39E+00 ||\n|| Interaction | Sarcosine | 3.23E-03 | 1.87E+00 ||\n|| Time | Isoleucine | 1.59E-03 | 3.71E+00 ||\n|| Time | Serine | 1.75E-03 | 2.08E+00 ||\n|| Time | Valine | 1.65E-03 | 4.06E+00 ||\n|| Phenotype | Lactic acid | 2.30E-03 | 3.65E-30 ||\n|| Phenotype | Acetic acid | 2.41E-03 | 1.23E-30 ||\n|| Phenotype | Hexanoic acid | 1.96E-03 | 6.16E-31 ||",
    "claim": "Across all conditions, the leverage values are relatively consistent, while SPE values vary significantly, particularly in the Phenotype condition where they are much lower, indicating a more stable model prediction for Phenotype. This is derived by analyzing the range and variance of leverage and SPE values across all conditions.",
    "label": "support"
  },
  {
    "id": "training_1274_6",
    "table_caption": "Table: Functional categories and genes modulated in T2-STIR + FSHD with respect to IM. Functional category Official Full Name Official Symbol Fold change p-value Angiogenesis Angiogenin ANG 2,3725 0,0041 Angiopoietin-like 2 ANGPTL2 2,5002 0,0014 CD44 molecule CD44 2,4375 0,0035 CD34 molecule CD34 2,2935 0,0047 CD47 molecule CD47 1,6579 0,0013 Filamin B beta FLNB 2,2672 0,0056 Von Willebrand factor VWF 1,9606 0,0331 Slit homolog 3 SLIT3 2,6961 0,0047 Dedicator of cytokinesis 1 DOCK1 1,8760 0,0024 Secreted frizzled-related protein 1 SFRP1 4,8032 0,0026 Frizzled homolog 4 FZD4 2,1590 0,0051 Frizzled homolog 7 FZD7 1,3833 0,0401 Adipocyte presence, glycerolipid metabolism and adipokine production Cell death-inducing DFFA-like effector a CIDEA 9,7264 0,0009 Cell death-inducing DFFA-like effector c CIDEC 8,5623 0,0038 Perilipin 1 PLIN 5,6435 0,0017 Glycerol-3-phosphate acyltransferase GPAM 4,7128 0,0023 Alcohol dehydrogenase 1A ADH1A 4,1328 0,0016 Adiponectin, C1Q and collagen domain containing ADIPOQ 2,6172 0,0019 C1q and tumor necrosis factor related protein 1 C1QTNF1 2,6181 0,0013 Leptin LEP 3,9142 0,0544 All of the cited genes were expressed to a higher extent in T2-STIR + FSHD muscles. doi:10.1371/journal.pone.0038779.t002 ",
    "table_content": "|| Functional category | Official Full Name | Official Symbol | Fold change | p-value ||\n||  Angiogenesis  | Angiogenin | ANG | 2,3725 | 0,0041 ||\n||  Angiogenesis  | Secreted frizzled-related protein 1 | SFRP1 | 4,8032 | 0,0026 ||\n||  Angiogenesis  | Frizzled homolog 4 | FZD4 | 2,1590 | 0,0051 ||\n||  Angiogenesis  | Frizzled homolog 7 | FZD7 | 1,3833 | 0,0401 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Cell death-inducing DFFA-like effector a | CIDEA | 9,7264 | 0,0009 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Cell death-inducing DFFA-like effector c | CIDEC | 8,5623 | 0,0038 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Perilipin 1 | PLIN | 5,6435 | 0,0017 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Glycerol-3-phosphate acyltransferase | GPAM | 4,7128 | 0,0023 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Alcohol dehydrogenase 1A | ADH1A | 4,1328 | 0,0016 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Adiponectin, C1Q and collagen domain containing | ADIPOQ | 2,6172 | 0,0019 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | C1q and tumor necrosis factor related protein 1 | C1QTNF1 | 2,6181 | 0,0013 ||\n||  Angiogenesis  | Angiopoietin-like 2 | ANGPTL2 | 2,5002 | 0,0014 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Leptin | LEP | 3,9142 | 0,0544 ||\n||  Angiogenesis  | CD44 molecule | CD44 | 2,4375 | 0,0035 ||\n||  Angiogenesis  | CD34 molecule | CD34 | 2,2935 | 0,0047 ||\n||  Angiogenesis  | CD47 molecule | CD47 | 1,6579 | 0,0013 ||\n||  Angiogenesis  | Filamin B beta | FLNB | 2,2672 | 0,0056 ||\n||  Angiogenesis  | Von Willebrand factor | VWF | 1,9606 | 0,0331 ||\n||  Angiogenesis  | Slit homolog 3 | SLIT3 | 2,6961 | 0,0047 ||\n||  Angiogenesis  | Dedicator of cytokinesis 1 | DOCK1 | 1,8760 | 0,0024 ||",
    "claim": "The average p-value for angiogenesis-related genes is approximately 0.008, while for adipocyte-related genes, it is approximately 0.002, indicating that the changes in adipocyte-related genes are statistically more significant.",
    "label": "support"
  },
  {
    "id": "training_314_3",
    "table_caption": "Table: Table 2 Combinations of reactions with improved production yield of succinic acid The respective reaction numbers are identical to the KEGG reaction numbers * The maximum amount of succinic acid produced is 100, as calculated using only the original SyGSM Total reaction number (n) Number of added metabolic pathways (m) Combinations of  metabolic reactions Rate of increase of succinic acid production yield 0 0 100* 1 1 R00479 133 R00751 102 R01867 102 2 2 R00751, R00479 144 R00479, R01867 134 3 3 R00751, R00479, R10179 155 ",
    "table_content": "|| Total reaction number (n) | Number of added metabolic pathways (m) | Combinations of metabolic reactions | Rate of increase of succinic acid production yield ||\n|| 0 | 0 | blank | 100 *  ||\n|| 1 | 1 | R00479 | 133 ||\n|| 1 | blank | R00751 | 102 ||\n|| 1 | blank | R01867 | 102 ||\n|| 2 | 2 | R00751, R00479 | 144 ||\n|| 2 | blank | R00479, R01867 | 134 ||\n|| 3 | 3 | R00751, R00479, R10179 | 155 ||",
    "claim": "Introducing a third reaction, R10179, to the combination of R00751 and R00479 further increases the yield to 55%, demonstrating a cumulative enhancement effect when expanding the reaction network.",
    "label": "support"
  },
  {
    "id": "training_692_4",
    "table_caption": "Table: Synergistic activity of HsLin06 with caspofungin against C. albicans SC5314 biofilms, resulting in biofilm formation inhibition*. Compound(s) [HsLin06] (μM) BIC50 CAS (μM) ± SEM Fold change FICI Signiﬁcance level CAS alone 0 0.90 ± 0.05 NA NA CAS + HsLin06 175 0.04 ± 0.00 25.67 16.25 *** 87.5 0.03 ± 0.00 27.87 8.14 ** 43.75 0.07 ± 0.01 14.27 4.13 *** 21.88 0.07 ± 0.01 13.50 2.11 *** 10.94 0.07 ± 0.02 13.67 1.09 *** 5.47 0.07 ± 0.02 13.03 0.59 *** 1.5 0.13 ± 0.00 7.76 0.28 0.75 0.22 ± 0.01 4.45 0.31 0.38 0.48 ± 0.04 2.04 0.57 * 0.19 0.68 ± 0.09 1.43 0.78 NS 0.09 1.05 ± 0.10 0.93 1.18 NS 0.05 0.93 ± 0.05 1.05 1.05 NS * BIC50 values were determined by CTB assay; mean ± SEM for n � 3 independent experiments is presented; BIC50, minimum inhibitory concentration that is required to inhibit bioﬁlm formation by 50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI 0.5 indicates ",
    "table_content": "|| Compound(s) | [HsLin06] (μM) | BIC50 CAS (μM) ± SEM | Fold change | FICI | Significance level ||\n|| CAS alone | 0 | 0.90 ± 0.05 | NA | NA | blank ||\n|| CAS + HsLin06 | 0.38 | 0.48 ± 0.04 | 2.04 | 0.57 | * ||\n|| CAS + HsLin06 | 0.19 | 0.68 ± 0.09 | 1.43 | 0.78 | NS ||\n|| CAS + HsLin06 | 0.09 | 1.05 ± 0.10 | 0.93 | 1.18 | NS ||\n|| CAS + HsLin06 | 0.05 | 0.93 ± 0.05 | 1.05 | 1.05 | NS ||\n|| CAS + HsLin06 | 175 | 0.04 ± 0.00 | 25.67 | 16.25 | *** ||\n|| CAS + HsLin06 | 87.5 | 0.03 ± 0.00 | 27.87 | 8.14 | ** ||\n|| CAS + HsLin06 | 43.75 | 0.07 ± 0.01 | 14.27 | 4.13 |  ***  ||\n|| CAS + HsLin06 | 21.88 | 0.07 ± 0.01 | 13.50 | 2.11 |  ***  ||\n|| CAS + HsLin06 | 10.94 | 0.07 ± 0.02 | 13.67 | 1.09 | *** ||\n|| CAS + HsLin06 | 5.47 | 0.07 ± 0.02 | 13.03 | 0.59 | *** ||\n|| CAS + HsLin06 |  1.5  |  0.13 ± 0.00  |  7.76  |  0.28  | blank ||\n|| CAS + HsLin06 |  0.75  |  0.22 ± 0.01  |  4.45  |  0.31  | blank ||",
    "claim": "The significance level of *** is observed at HsLin06 concentrations of 175, 43.75, 21.88, 10.94, and 5.47 μM, indicating that these concentrations have a statistically significant impact on reducing BIC50. This highlights the importance of specific concentration ranges for achieving significant biofilm inhibition.",
    "label": "support"
  },
  {
    "id": "training_1138_2",
    "table_caption": "Table: the QTL: SNP HB QTL-1 28 28 QTL-2 12 25 QTL-3 6 5 • ",
    "table_content": "|| blank | SNP | HB ||\n|| QTL-1 | 28 | 28 ||\n|| QTL-2 | 12 | 25 ||\n|| QTL-3 | 6 | 5 ||",
    "claim": "The sum of SNP values across all QTLs is 46, while the sum of HB values is 58. This suggests that the total genetic variation captured by HB is greater than that captured by SNP across these loci.",
    "label": "support"
  },
  {
    "id": "training_372_4",
    "table_caption": "Table: Table 5 Rate of  inbreeding for  genetic improvement and  conservation (impcons) strategy, based on  different types of estimated relationships The lowest estimated rates of inbreeding calculated from each type of estimated relationship matrix depending on the scenario are in italics. The overall lowest value of estimated rate of inbreeding is in italic bold Restriction Data type and estimator ΔF_A ΔF_SNP_Yang ΔF_SNP_Similarity ΔF_WGS_Yang ΔF_WGS_Similarity No restriction A 0.010 0.022 0.022 0.021 0.020 SNP_Yang 0.011 0.010 0.014 0.010 0.011 SNP_Similarity 0.016 0.022 0.010 0.021 0.006 WGS_Yang 0.012 0.011 0.015 0.010 0.013 WGS_Similarity 0.025 0.030 0.022 0.029 0.010 20 selected A 0.011 0.026 0.026 0.025 0.022 SNP_Yang 0.022 0.019 0.022 0.019 0.014 SNP_Similarity 0.018 0.027 0.011 0.025 0.003 WGS_Yang 0.023 0.020 0.022 0.019 0.016 WGS_Similarity 0.022 0.028 0.019 0.027 0.011 10 selected A 0.028 0.052 0.045 0.051 0.029 SNP_Yang 0.047 0.040 0.047 0.039 0.036 SNP_Similarity 0.039 0.045 0.024 0.043 0.015 WGS_Yang 0.044 0.041 0.048 0.040 0.036 WGS_Similarity 0.035 0.048 0.029 0.048 0.013 5 selected A 0.075 0.107 0.085 0.102 0.069 SNP_Yang 0.086 0.085 0.088 0.083 0.071 SNP_Similarity 0.077 0.094 0.057 0.089 0.045 WGS_Yang 0.088 0.083 0.087 0.080 0.072 WGS_Similarity 0.075 0.101 0.064 0.096 0.045 ",
    "table_content": "|| Restriction | Data type and estimator | ΔF_A | ΔF_SNP_Yang | ΔF_SNP_Similarity | ΔF_WGS_Yang | ΔF_WGS_Similarity ||\n|| No restriction | A |  0.010  | 0.022 | 0.022 | 0.021 | 0.020 ||\n|| 20 selected | WGS_Similarity | 0.022 | 0.028 | 0.019 | 0.027 | 0.011 ||\n|| 10 selected | A |  0.028  | 0.052 | 0.045 | 0.051 | 0.029 ||\n|| 10 selected | SNP_Yang | 0.047 |  0.040  | 0.047 |  0.039  | 0.036 ||\n|| 10 selected | SNP_Similarity | 0.039 | 0.045 |  0.024  | 0.043 | 0.015 ||\n|| 10 selected | WGS_Yang | 0.044 | 0.041 | 0.048 | 0.040 | 0.036 ||\n|| 10 selected | WGS_Similarity | 0.035 | 0.048 | 0.029 | 0.048 |  0.013  ||\n|| 5 selected | A |  0.075  | 0.107 | 0.085 | 0.102 | 0.069 ||\n|| 5 selected | SNP_Yang | 0.086 | 0.085 | 0.088 | 0.083 | 0.071 ||\n|| 5 selected | SNP_Similarity | 0.077 | 0.094 |  0.057  | 0.089 |  0.045  ||\n|| 5 selected | WGS_Yang | 0.088 |  0.083  | 0.087 |  0.080  | 0.072 ||\n|| No restriction | SNP_Yang | 0.011 |  0.010  | 0.014 |  0.010  | 0.011 ||\n|| 5 selected | WGS_Similarity | 0.075 | 0.101 | 0.064 | 0.096 | 0.045 ||\n|| No restriction | SNP_Similarity | 0.016 | 0.022 |  0.010  | 0.021 |  0.006  ||\n|| No restriction | WGS_Yang | 0.012 | 0.011 | 0.015 | 0.010 | 0.013 ||\n|| No restriction | WGS_Similarity | 0.025 | 0.030 | 0.022 | 0.029 | 0.010 ||\n|| 20 selected | A |  0.011  | 0.026 | 0.026 | 0.025 | 0.022 ||\n|| 20 selected | SNP_Yang | 0.022 |  0.019  | 0.022 | 0.019 | 0.014 ||\n|| 20 selected | SNP_Similarity | 0.018 | 0.027 |  0.011  | 0.025 |  0.003  ||\n|| 20 selected | WGS_Yang | 0.023 | 0.020 | 0.022 |  0.019  | 0.016 ||",
    "claim": "The overall lowest inbreeding rate across all scenarios is 0.003, achieved by the SNP_Similarity estimator under the 20 selected restriction level, which is 0.003 lower than the lowest rate in any other scenario.",
    "label": "support"
  },
  {
    "id": "training_1069_4",
    "table_caption": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 C1 0.051 (2) 0.076 (3) 0.053 (2) −0.0054 (18) −0.0029 (16) 0.0103 (19) C2 0.075 (3) 0.095 (3) 0.075 (3) 0.018 (3) −0.019 (2) −0.017 (3) C3 0.090 (3) 0.088 (3) 0.084 (4) 0.013 (3) 0.000 (3) −0.011 (3) C4 0.069 (3) 0.083 (3) 0.090 (4) 0.009 (2) 0.018 (2) 0.023 (3) C5 0.069 (3) 0.149 (6) 0.088 (4) 0.034 (3) −0.016 (3) −0.001 (4) C6 0.063 (3) 0.141 (5) 0.077 (4) 0.017 (3) −0.018 (2) −0.019 (3) C7 0.054 (2) 0.065 (2) 0.053 (2) 0.0078 (17) 0.0068 (16) −0.0095 (18) C8 0.062 (2) 0.071 (3) 0.062 (3) −0.0084 (19) −0.0018 (18) −0.002 (2) C9 0.064 (2) 0.070 (3) 0.057 (2) 0.004 (2) 0.0003 (18) −0.008 (2) C10 0.078 (3) 0.072 (3) 0.057 (2) −0.003 (2) 0.018 (2) −0.005 (2) C11 0.072 (3) 0.086 (3) 0.076 (3) −0.016 (2) 0.020 (2) −0.012 (3) C12 0.055 (2) 0.083 (3) 0.057 (2) −0.004 (2) 0.0075 (17) −0.015 (2) C13 0.102 (4) 0.108 (5) 0.151 (7) 0.037 (4) 0.043 (4) 0.032 (4) N1 0.0579 (19) 0.073 (2) 0.061 (2) −0.0018 (16) 0.0008 (15) 0.0013 (18) O1 0.094 (2) 0.078 (2) 0.072 (2) −0.0218 (17) 0.0003 (17) −0.0074 (17) O2 0.0768 (19) 0.077 (2) 0.068 (2) 0.0037 (15) −0.0080 (15) 0.0107 (16) Cl1 0.0977 (10) 0.1188 (12) 0.0725 (9) −0.0217 (8) −0.0235 (7) 0.0056 (7) Cl2 0.1393 (13) 0.1090 (11) 0.0655 (8) −0.0192 (9) 0.0224 (8) 0.0143 (7) S1 0.0652 (6) 0.0664 (7) 0.0567 (6) −0.0025 (4) −0.0028 (4) 0.0024 (5) Geometric parameters (Å, °) ",
    "table_content": "|| blank | U 11 | U 22 | U 33 | U 12 | U 13 | U 23 ||\n|| C1 | 0.051 (2) | 0.076 (3) | 0.053 (2) | −0.0054 (18) | −0.0029 (16) | 0.0103 (19) ||\n|| C10 | 0.078 (3) | 0.072 (3) | 0.057 (2) | −0.003 (2) | 0.018 (2) | −0.005 (2) ||\n|| C11 | 0.072 (3) | 0.086 (3) | 0.076 (3) | −0.016 (2) | 0.020 (2) | −0.012 (3) ||\n|| C12 | 0.055 (2) | 0.083 (3) | 0.057 (2) | −0.004 (2) | 0.0075 (17) | −0.015 (2) ||\n|| C13 | 0.102 (4) | 0.108 (5) | 0.151 (7) | 0.037 (4) | 0.043 (4) | 0.032 (4) ||\n|| N1 | 0.0579 (19) | 0.073 (2) | 0.061 (2) | −0.0018 (16) | 0.0008 (15) | 0.0013 (18) ||\n|| O1 | 0.094 (2) | 0.078 (2) | 0.072 (2) | −0.0218 (17) | 0.0003 (17) | −0.0074 (17) ||\n|| O2 | 0.0768 (19) | 0.077 (2) | 0.068 (2) | 0.0037 (15) | −0.0080 (15) | 0.0107 (16) ||\n|| Cl1 | 0.0977 (10) | 0.1188 (12) | 0.0725 (9) | −0.0217 (8) | −0.0235 (7) | 0.0056 (7) ||\n|| Cl2 | 0.1393 (13) | 0.1090 (11) | 0.0655 (8) | −0.0192 (9) | 0.0224 (8) | 0.0143 (7) ||\n|| S1 | 0.0652 (6) | 0.0664 (7) | 0.0567 (6) | −0.0025 (4) | −0.0028 (4) | 0.0024 (5) ||\n|| C2 | 0.075 (3) | 0.095 (3) | 0.075 (3) | 0.018 (3) | −0.019 (2) | −0.017 (3) ||\n|| C3 | 0.090 (3) | 0.088 (3) | 0.084 (4) | 0.013 (3) | 0.000 (3) | −0.011 (3) ||\n|| C4 | 0.069 (3) | 0.083 (3) | 0.090 (4) | 0.009 (2) | 0.018 (2) | 0.023 (3) ||\n|| C5 | 0.069 (3) | 0.149 (6) | 0.088 (4) | 0.034 (3) | −0.016 (3) | −0.001 (4) ||\n|| C6 | 0.063 (3) | 0.141 (5) | 0.077 (4) | 0.017 (3) | −0.018 (2) | −0.019 (3) ||\n|| C7 | 0.054 (2) | 0.065 (2) | 0.053 (2) | 0.0078 (17) | 0.0068 (16) | −0.0095 (18) ||\n|| C8 | 0.062 (2) | 0.071 (3) | 0.062 (3) | −0.0084 (19) | −0.0018 (18) | −0.002 (2) ||\n|| C9 | 0.064 (2) | 0.070 (3) | 0.057 (2) | 0.004 (2) | 0.0003 (18) | −0.008 (2) ||",
    "claim": "The sulfur atom (S1) exhibits a notable anisotropy in its displacement parameters, with U11 and U22 being nearly equal, but U33 being significantly lower. The ratio of the average of U11 and U22 to U33 is approximately 1.15, indicating a preferential vibration in the plane perpendicular to the S1 atom's primary bonding direction.",
    "label": "support"
  },
  {
    "id": "training_1438_4",
    "table_caption": "Table: Table 3 Detection of sentinel nodes in vulvar cancer using planar lymphoscintigraphy and SPECT/CT Authors Year Study type N Radiotracer (dosing) Detection rate by LSG (%) Detection rate by SPECT/CT (%) SLNs detected by LSG SLNs detected by SPECT/CT False negative rate (%) Beneder [46] 2008 Prospective 10 99mTc-nanocolloid (60 MBq) N/A N/A 26 38 0 Kraft [16] 2012 Retrospective 7 99mTc-nanocolloid (40 MBq) 100 100 N/A N/A N/A Belhoncine [19] 2013 Prospective 7 99mTc-cysteine rhenium colloid (37 MBq) 86 100 N/A N/A 0 Mathe´ron [49] 2013 Prospective 14 ICG-99mTc- nanocolloid (87 MBq) N/A N/A 39 39 0 Collarino [48] 2015 Retrospective 83 99mTc-nanocolloid (81 MBq) N/A N/A 192 217 0 N number of patients, LSG lymphoscintigraphy, SLNs sentinel lymph nodes, N/A not available, ICG indocyanine green ",
    "table_content": "|| Authors | Year | Study type |  N  | Radiotracer (dosing) | Detection rate by LSG (%) | Detection rate by SPECT/CT (%) | SLNs detected by LSG | SLNs detected by SPECT/CT | False negative rate (%) ||\n|| Beneder [ 46 ] | 2008 | Prospective | 10 |  99m Tc-nanocolloid (60 MBq) | N/A | N/A | 26 | 38 | 0 ||\n|| Kraft [ 16 ] | 2012 | Retrospective | 7 |  99m Tc-nanocolloid (40 MBq) | 100 | 100 | N/A | N/A | N/A ||\n|| Belhoncine [ 19 ] | 2013 | Prospective | 7 |  99m Tc-cysteine rhenium colloid (37 MBq) | 86 | 100 | N/A | N/A | 0 ||\n|| Mathéron [ 49 ] | 2013 | Prospective | 14 | ICG- 99m Tc-nanocolloid (87 MBq) | N/A | N/A | 39 | 39 | 0 ||\n|| Collarino [ 48 ] | 2015 | Retrospective | 83 |  99m Tc-nanocolloid (81 MBq) | N/A | N/A | 192 | 217 | 0 ||",
    "claim": "The false negative rate is consistently 0% in studies where it is reported, indicating that when SLNs are detected, they are accurately identified as sentinel nodes, reflecting high specificity of the detection methods used.",
    "label": "support"
  },
  {
    "id": "training_212_6",
    "table_caption": "Table: Table 3 Composition of the ALA-rich oil (876 g/mol), olive oil (875 g/mol) and butter (fat-part 734 g/mol) meals1 Amount Energy (KJ) Fat (g) Protein (g) Carbohydrate (g) ALA-rich oil 35 g 1277 352 - - Olive oil 35 g 1277 352 0.2 0.2 Butter 42 g 1265 353 0.3 0.2 Milk for cooking, 3% fat 0.225 L 595 7.1 8.1 11.4 Semolina (wheat kernel) 20 g 291 0.3 2 14.2 Rye bread, one slice 38 g 408 1 2.9 17.8 Smoked ham, 3% fat or 9 g 44 0.3 2 0 soft Cheese4, 3% fat 9 g 43 0.3 1.6 0.3 Blackberry jam 32 g 262 0 0.1 14.8 Milk, 1.5% fat 0.2 L 410 3.1 7.2 10.3 Total 3290 47 23 69 1 Data from proximate analysis of ingredients. Analysed with Dietist XP, version 3.1, with the Swedish National Food Administration database (2008). 2 Equivalent to 0.04 mol. 3 Equivalent to 0.05 mol. ",
    "table_content": "|| blank | Amount | Energy (KJ) | Fat (g) | Protein (g) | Carbohydrate (g) ||\n|| ALA-rich oil | 35 g | 1277 | 35 2 | blank | blank ||\n|| Milk, 1.5% fat | 0.2 L | 410 | 3.1 | 7.2 | 10.3 ||\n|| Total | blank | 3290 | 47 | 23 | 69 ||\n|| Olive oil | 35 g | 1277 | 35 2 | 0.2 | 0.2 ||\n|| Butter | 42 g | 1265 | 35 3 | 0.3 | 0.2 ||\n|| Milk for cooking, 3% fat | 0.225 L | 595 | 7.1 | 8.1 | 11.4 ||\n|| Semolina (wheat kernel) | 20 g | 291 | 0.3 | 2 | 14.2 ||\n|| Rye bread, one slice | 38 g | 408 | 1 | 2.9 | 17.8 ||\n|| Smoked ham, 3% fat or | 9 g | 44 | 0.3 | 2 | 0 ||\n|| soft Cheese 4 , 3% fat | 9 g | 43 | 0.3 | 1.6 | 0.3 ||\n|| Blackberry jam | 32 g | 262 | 0 | 0.1 | 14.8 ||",
    "claim": "The energy density, calculated as energy per gram, is highest for ALA-rich oil and olive oil, both at approximately 36.5 KJ/g, followed by butter at around 30.1 KJ/g. This indicates that these oils and butter are the most energy-dense components of the meal.",
    "label": "support"
  },
  {
    "id": "training_1172_6",
    "table_caption": "Table: Involvement of ASD genes in the ASD pathway network. Gene Symbol Gene Description # Pathways MAPK1 mitogen-activated protein kinase 1 23 MAPK3 mitogen-activated protein kinase 3 23 HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog 18 PRKCB protein kinase C, beta 17 BRAF v-raf murine sarcoma viral oncogene homolog B1 14 PIK3CG phosphoinositide-3-kinase, catalytic, gamma polypeptide 13 PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) 13 PLCB1 phospholipase C, beta 1 (phosphoinositide-speciﬁc) 11 GSK3B glycogen synthase kinase 3 beta 10 CACNA1C calcium channel, voltage-dependent, L type, alpha 1C subunit 9 CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 8 CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit 8 CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit 7 CREBBP CREB binding protein 7 EP300 E1A binding protein p300 7 ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 7 GNAS GNAS complex locus 7 TCF7L2 transcription factor 7-like 2 (T-cell speciﬁc, HMG-box) 6 MET met proto-oncogene (hepatocyte growth factor receptor) 6 ITGB7 integrin, beta 7 6 GRM5 glutamate receptor, metabotropic 5 6 GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 6 ADCY5 adenylate cyclase 5 5 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 5 GRM1 glutamate receptor, metabotropic 1 5 GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A 5 GRIN2B glutamate receptor, ionotropic, N-methyl D-aspartate 2B 5 NTRK1 neurotrophic tyrosine kinase, receptor, type 1 4 BCL2 B-cell CLL/lymphoma 2 4 CTNNA3 catenin (cadherin-associated protein), alpha 3 4 RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 4 RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 4 MAOA monoamine oxidase A 4 MAOB monoamine oxidase B 4 # Pathways = number of pathways (in the autism pathway network) in which each gene participates. Table only displays those genes participating in more than 4 pathways. ",
    "table_content": "|| Gene Symbol | Gene Description | # Pathways ||\n|| MAPK1 | mitogen-activated protein kinase 1 | 23 ||\n|| CACNA1C | calcium channel, voltage-dependent, L type, alpha 1C subunit | 9 ||\n|| CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | 8 ||\n|| CACNA1D | calcium channel, voltage-dependent, L type, alpha 1D subunit | 8 ||\n|| CACNA1F | calcium channel, voltage-dependent, L type, alpha 1F subunit | 7 ||\n|| CREBBP | CREB binding protein | 7 ||\n|| EP300 | E1A binding protein p300 | 7 ||\n|| ITGA4 | integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) | 7 ||\n|| GNAS | GNAS complex locus | 7 ||\n|| TCF7L2 | transcription factor 7-like 2 (T-cell specific, HMG-box) | 6 ||\n|| MET | met proto-oncogene (hepatocyte growth factor receptor) | 6 ||\n|| MAPK3 | mitogen-activated protein kinase 3 | 23 ||\n|| ITGB7 | integrin, beta 7 | 6 ||\n|| GRM5 | glutamate receptor, metabotropic 5 | 6 ||\n|| GRIN1 | glutamate receptor, ionotropic, N-methyl D-aspartate 1 | 6 ||\n|| ADCY5 | adenylate cyclase 5 | 5 ||\n|| ITGB3 | integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | 5 ||\n|| GRM1 | glutamate receptor, metabotropic 1 | 5 ||\n|| GRIN2A | glutamate receptor, ionotropic, N-methyl D-aspartate 2A | 5 ||\n|| GRIN2B | glutamate receptor, ionotropic, N-methyl D-aspartate 2B | 5 ||\n|| NTRK1 | neurotrophic tyrosine kinase, receptor, type 1 | 4 ||\n|| BCL2 | B-cell CLL/lymphoma 2 | 4 ||\n|| HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | 18 ||\n|| CTNNA3 | catenin (cadherin-associated protein), alpha 3 | 4 ||\n|| RPS6KA2 | ribosomal protein S6 kinase, 90kDa, polypeptide 2 | 4 ||\n|| RPS6KA3 | ribosomal protein S6 kinase, 90kDa, polypeptide 3 | 4 ||\n|| MAOA | monoamine oxidase A | 4 ||\n|| MAOB | monoamine oxidase B | 4 ||\n|| PRKCB | protein kinase C, beta | 17 ||\n|| BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 14 ||\n|| PIK3CG | phosphoinositide-3-kinase, catalytic, gamma polypeptide | 13 ||\n|| PIK3R2 | phosphoinositide-3-kinase, regulatory subunit 2 (beta) | 13 ||\n|| PLCB1 | phospholipase C, beta 1 (phosphoinositide-specific) | 11 ||\n|| GSK3B | glycogen synthase kinase 3 beta | 10 ||",
    "claim": "There is a notable correlation between the function of certain genes and their level of pathway involvement. For instance, genes involved in signal transduction and kinase activity, such as MAPK1, MAPK3, and PRKCB, tend to have higher pathway involvement, reflecting their broad regulatory roles in cellular processes related to ASD.",
    "label": "support"
  },
  {
    "id": "training_672_3",
    "table_caption": "Table: neutralising response of rainbow trout. Fish4 Fish5 Fish6 Fish7 Neutralisation by serum Abs1 75 62 71 55 Inhibition by anti IgM (1.14)2 77.4 71.1 92.6 100 Inhibition by anti IgT (polyclonal)2 0 0 15 3.3 1Neutralization efficiency measure as the percentage of PFU reduction when serum is added. ",
    "table_content": "|| blank | Fish4 | Fish5 | Fish6 | Fish7 ||\n|| Neutralisation by serum Abs 1  | 75 | 62 | 71 | 55 ||\n|| Inhibition by anti IgM (1.14) 2  | 77.4 | 71.1 | 92.6 | 100 ||\n|| Inhibition by anti IgT (polyclonal) 2  | 0 | 0 | 15 | 3.3 ||",
    "claim": "The inhibition by anti-IgT antibodies is notably low, with Fish4 and Fish5 showing no inhibition, while Fish6 and Fish7 show minimal inhibition at 15% and 3.3%, respectively. This suggests a limited role of anti-IgT antibodies in the neutralization process for these fish.",
    "label": "support"
  },
  {
    "id": "training_1331_2",
    "table_caption": "Table: Table 1 Comparison of mean and standard deviation of demographic characteristics and fertility status in two groups with bacterial vaginosis Variable Group treatment (P values)* Sucrose gel Mean ± SD Metronidazole Gel Mean ± SD Age (years) 32.31 ± 5.79 31.77 ± 5.07 0.678 Weight (kg) 64.17 ± 9.76 65.02 ± 9.90 0.716 Duration of marriage (years) 12.54 ± 7.42 10.32 ± 6.32 0.746 Age at first pregnancy (years) 19.62 ± 6.89 20.54 ± 6.04 0.557 The number of pregnancies 3.68 ± 2.45 3.22 ± 2.00 0.397 *Derived from t test ",
    "table_content": "|| Variable | Group treatment | Group treatment | ( P values)* ||\n|| Variable | Sucrose gel Mean ± SD | Metronidazole Gel Mean ± SD | ( P values)* ||\n|| Age (years) | 32.31 ± 5.79 | 31.77 ± 5.07 | 0.678 ||\n|| Weight (kg) | 64.17 ± 9.76 | 65.02 ± 9.90 | 0.716 ||\n|| Duration of marriage (years) | 12.54 ± 7.42 | 10.32 ± 6.32 | 0.746 ||\n|| Age at first pregnancy (years) | 19.62 ± 6.89 | 20.54 ± 6.04 | 0.557 ||\n|| The number of pregnancies | 3.68 ± 2.45 | 3.22 ± 2.00 | 0.397 ||",
    "claim": "The mean weight difference between the two groups is approximately 1.3%, with a standard deviation difference of about 1.4%. This indicates that the weight distribution is nearly identical between the groups, with minimal variability differences.",
    "label": "support"
  },
  {
    "id": "training_26_3",
    "table_caption": "Table: CLEC4M VNTR allele frequencies in Swedish type 1 VWD patients and controls. Allele Controls VWD1 C1 C2 Ctot C1-C2 VWD1 VWD1-Ctot 4 2.6 3.1 2.8 -0.5 4.2 1.4 5 28.8 29.4 29.1 -0.6 32.2 3.2 6 12.8 12.7 12.8 0.1 12.6 -0.1 7 52.2 52.9 52.5 -0.7 49.5 -3.0 8 0.2 0.0 0.1 0.2 0.0 -0.1 9 3.5 1.8 2.7 1.7 1.4 -1.3 C1+C2 = Ctot, two Swedish control populations (n = 225+211 = 436); VWD1, type 1 VWD patient population (n = 106). ",
    "table_content": "|| Allele | Controls | Controls | Controls | Controls | VWD1 | VWD1 ||\n|| Allele | C 1 | C 2 | C tot | C 1 -C 2 | VWD1 | VWD1-C tot ||\n|| 4 | 2.6 | 3.1 | 2.8 | -0.5 | 4.2 | 1.4 ||\n|| 5 | 28.8 | 29.4 | 29.1 | -0.6 | 32.2 | 3.2 ||\n|| 6 | 12.8 | 12.7 | 12.8 | 0.1 | 12.6 | -0.1 ||\n|| 7 | 52.2 | 52.9 | 52.5 | -0.7 | 49.5 | -3.0 ||\n|| 8 | 0.2 | 0.0 | 0.1 | 0.2 | 0.0 | -0.1 ||\n|| 9 | 3.5 | 1.8 | 2.7 | 1.7 | 1.4 | -1.3 ||",
    "claim": "Allele 7 exhibits the largest frequency difference between the VWD1 group and the control total, with a decrease of 3.0 in the VWD1 group, suggesting a notable reduction in this allele's frequency among VWD1 patients.",
    "label": "support"
  },
  {
    "id": "training_1440_2",
    "table_caption": "Table: Figure 1. The synthesis of ARG-V. Water Acetonitrile Cloroform Acetonitrile:water 45:55 Ethyl acetate ARG almost insoluble very soluble freely soluble very soluble freely soluble ARG-V freely soluble slight soluble freely soluble very soluble almost insoluble Table 1. The solubility of ARG and ARG-V. ",
    "table_content": "|| blank | Water | Acetonitrile | Cloroform | Acetonitrile:water 45:55 | Ethyl acetate ||\n|| ARG | almost insoluble | very soluble | freely soluble | very soluble | freely soluble ||\n|| ARG-V | freely soluble | slight soluble | freely soluble | very soluble | almost insoluble ||",
    "claim": "Both ARG and ARG-V are freely soluble in acetonitrile, suggesting that the structural modifications leading to ARG-V do not alter its solubility in this solvent. This implies a consistent solubility profile for both compounds in acetonitrile, maintaining a high solubility level.",
    "label": "support"
  },
  {
    "id": "training_1416_4",
    "table_caption": "Table: Performance evaluation of the feature detectors for target detection. Method Detect. Rate (%) Execution Time (ms) Position Error (px) Scaling Error (%) SURF 8 71.5 41.7 5 SIFT 54 17.4 2.7 45 FAST 98 8.3 2.2 37 Shi–Tomasi 96 7.4 2.2 41 As shown in Table 1, we evaluate the detection success rate, the average execution time per frame and ",
    "table_content": "|| Method | Detect. Rate (%) | Execution Time (ms) | Position Error (px) | Scaling Error (%) ||\n|| SURF | 8 | 71.5 | 41.7 | 5 ||\n|| SIFT | 54 | 17.4 | 2.7 | 45 ||\n|| FAST | 98 | 8.3 | 2.2 | 37 ||\n|| Shi-Tomasi | 96 | 7.4 | 2.2 | 41 ||",
    "claim": "The scaling error for the SURF method is 9 times lower than that of the SIFT method, indicating a more precise scaling capability.",
    "label": "support"
  },
  {
    "id": "training_381_6",
    "table_caption": "Table: Table 1 Differential expression of Sertoli cell specific genes in Ad- versus Ad+ group (Ad-/Ad+) and in the GnRHa treated versus untreated group (GnRHa) Gene ID Name FC Ad-/Ad+ logFC Ad-/Ad+ FDR Ad-/Ad+ FC GnRHa logFC GnRHa FDR GnRHa AMH Anti-Mullerian Hormone - n.s. n.s. - n.s. n.s. AR Androgen Receptor - n.s. n.s. 1.5 -0.5821 0.0126 BMP4 Bone Morphogenetic Protein 4 - n.s. n.s. - n.s. n.s. BMP6 Bone Morphogenetic Protein 6 1.7 -0.7612 0.0030 - n.s. n.s. CALB2 Calbindin 2 - n.s. n.s. 2.2 -1.1556 0.0034 CDKN1B Cyclin-Dependent Kinase inhibitor 1B (p27, Kip1) - n.s. n.s. 1.7 -0.7845 0.0016 CLDN11 Claudin 11 - n.s. n.s. 1.8 -0.8315 0.0011 CLU Clusterin - n.s. n.s. 1.9 -0.9548 0.0006 CREB1 cAMP Responsive Element Binding protein 1 1.1 0.2000 0.0489 1.6 -0.6888 0.0041 CTSL Cathepsin L - n.s. n.s. 1.7 -0.7492 0.0020 DES Desmin 2.8 -1.4882 0.0014 - n.s. n.s. DHH Desert Hedgehog - n.s. n.s. - n.s. n.s. DMRT1 Doublesex and Mab-3 Related Transcription factor 1 - n.s. n.s. 1.7 -0.7838 0.0010 FAS Fas cell surface death receptor - n.s. n.s. - n.s. n.s. FASLG Fas Ligand (TNF superfamily, member 6) - n.d. n.d. 5.0 2.3154 0.0031 FSHR Follicle stimulating hormone receptor 1.4 0.4915 0.0363 - n.s. n.s. FGF2 Fibroblast Growth Factor 2 - n.s. n.s. - n.s. n.s. FGF9 Fibroblast Growth Factor 9 2.1 -1.0605 0.0016 - n.s. n.s. GATA1 GATA binding protein 1 (globin transcription factor 1) - n.d. n.d. - n.d. n.d. GATA4 GATA binding protein 4 - n.s. n.s. - n.s. n.s. GJA1/CX43 Gap Junction protein, Alpha 1/Connexin 43 1.3 0.4018 0.0324 1.9 -0.9516 0.0002 GDNF Glial cell Derived Neurotrophic Factor - n.s. n.s. 2.8 1.4687 0.0036 INHA Inhibin, alpha - n.s. n.s. 1.8 -0.8158 0.0023 INHBA Inhibin, Beta A - n.s. n.s. 1.6 -0.6363 0.0124 INHBB Inhibin, Beta B - n.s. n.s. 1.6 -0.6616 0.0058 KATNAL1 Katanin p60 subunit A-like 1 - n.s. n.s. 1.7 -0.7782 0.0012 KITLG KIT Ligand - n.s. n.s. 2.1 -1.0995 0.0001 KRT18 Keratin 18, type I - n.s. n.s. 1.5 -0.5730 0.0176 NR5A1/SF1 Nuclear Receptor subfamily 5, group A, member 1 - n.s. n.s. - n.s. n.s. PTGDS Prostaglandin D2 Synthase - n.s. n.s. - n.s. n.s. SERPINA5 Serpin Family A Member 5 - n.s. n.s. 1.7 -0.7511 0.0076 SOX8 SRY (sex determining region Y)-box 8 2.8 -1.4641 0.0003 - n.s. n.s. SOX9 SRY (sex determining region Y)-box 9 1.4 0.4983 0.0300 - n.s. n.s. SRY Sex determining Region Y - n.s. n.s. - n.s. n.s. TF Transferrin - n.s. n.s. - n.s. n.s. TJP1/ZO1 Tight Junction Protein 1/Zona Occludens 1 - n.s. n.s. 1.6 -0.6824 0.0102 VIM Vimentin - n.s. n.s. 1.5 -0.5901 0.0352 WT1 Wilms tumor 1 - n.s. n.s. 1.5 -0.5654 0.0180 ZFPM1/FOG1 Zinc Finger Protein, FOG family member 2 - n.s. n.s. - n.s. n.s. ZFPM2/FOG2 Zinc Finger Protein, FOG family member 2 1.3 0.3695 0.0240 - n.s. n.s. Absolute fold change (FC), Log 2-fold change (logFC), false discovery rate (FDR), not significant (n.s.), not determined (n.d.) Absolute fold changes (FC) <2 are highlighted in italic ",
    "table_content": "|| Gene ID | Name | FC Ad-/Ad+ | logFC Ad-/Ad+ | FDR Ad-/Ad+ | FC GnRHa | logFC GnRHa | FDR GnRHa ||\n||  AMH  | Anti-Mullerian Hormone | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  CTSL  | Cathepsin L | blank | n.s. | n.s. |  1.7  | -0.7492 | 0.0020 ||\n||  DES  | Desmin | 2.8 | -1.4882 | 0.0014 | blank | n.s. | n.s. ||\n||  DHH  | Desert Hedgehog | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  DMRT1  | Doublesex and Mab-3 Related Transcription factor 1 | blank | n.s. | n.s. |  1.7  | -0.7838 | 0.0010 ||\n||  FAS  | Fas cell surface death receptor | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  FASLG  | Fas Ligand (TNF superfamily, member 6) | blank | n.d. | n.d. | 5.0 | 2.3154 | 0.0031 ||\n||  FSHR  | Follicle stimulating hormone receptor |  1.4  | 0.4915 | 0.0363 | blank | n.s. | n.s. ||\n||  FGF2  | Fibroblast Growth Factor 2 | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  FGF9  | Fibroblast Growth Factor 9 | 2.1 | -1.0605 | 0.0016 | blank | n.s. | n.s. ||\n||  GATA1  | GATA binding protein 1 (globin transcription factor 1) | blank | n.d. | n.d. | blank | n.d. | n.d. ||\n||  AR  | Androgen Receptor | blank | n.s. | n.s. |  1.5  | -0.5821 | 0.0126 ||\n||  GATA4  | GATA binding protein 4 | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  GJA1/CX43  | Gap Junction protein, Alpha 1/Connexin 43 |  1.3  | 0.4018 | 0.0324 |  1.9  | -0.9516 | 0.0002 ||\n||  GDNF  | Glial cell Derived Neurotrophic Factor | blank | n.s. | n.s. | 2.8 | 1.4687 | 0.0036 ||\n||  INHA  | Inhibin, alpha | blank | n.s. | n.s. |  1.8  | -0.8158 | 0.0023 ||\n||  INHBA  | Inhibin, Beta A | blank | n.s. | n.s. |  1.6  | -0.6363 | 0.0124 ||\n||  INHBB  | Inhibin, Beta B | blank | n.s. | n.s. |  1.6  | -0.6616 | 0.0058 ||\n||  KATNAL1  | Katanin p60 subunit A-like 1 | blank | n.s. | n.s. |  1.7  | -0.7782 | 0.0012 ||\n||  KITLG  | KIT Ligand | blank | n.s. | n.s. | 2.1 | -1.0995 | 0.0001 ||\n||  KRT18  | Keratin 18, type I | blank | n.s. | n.s. |  1.5  | -0.5730 | 0.0176 ||\n||  NR5A1/SF1  | Nuclear Receptor subfamily 5, group A, member 1 | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  BMP4  | Bone Morphogenetic Protein 4 | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  PTGDS  | Prostaglandin D2 Synthase | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  SERPINA5  | Serpin Family A Member 5 | blank | n.s. | n.s. |  1.7  | -0.7511 | 0.0076 ||\n||  SOX8  | SRY (sex determining region Y)-box 8 | 2.8 | -1.4641 | 0.0003 | blank | n.s. | n.s. ||\n||  SOX9  | SRY (sex determining region Y)-box 9 |  1.4  | 0.4983 | 0.0300 | blank | n.s. | n.s. ||\n||  SRY  | Sex determining Region Y | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  TF  | Transferrin | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  TJP1/ZO1  | Tight Junction Protein 1/Zona Occludens 1 | blank | n.s. | n.s. |  1.6  | -0.6824 | 0.0102 ||\n||  VIM  | Vimentin | blank | n.s. | n.s. |  1.5  | -0.5901 | 0.0352 ||\n||  WT1  | Wilms tumor 1 | blank | n.s. | n.s. |  1.5  | -0.5654 | 0.0180 ||\n||  ZFPM1/FOG1  | Zinc Finger Protein, FOG family member 2 | blank | n.s. | n.s. | blank | n.s. | n.s. ||\n||  BMP6  | Bone Morphogenetic Protein 6 |  1.7  | -0.7612 | 0.0030 | blank | n.s. | n.s. ||\n||  ZFPM2/FOG2  | Zinc Finger Protein, FOG family member 2 |  1.3  | 0.3695 | 0.0240 | blank | n.s. | n.s. ||\n||  CALB2  | Calbindin 2 | blank | n.s. | n.s. | 2.2 | -1.1556 | 0.0034 ||\n||  CDKN1B  | Cyclin-Dependent Kinase inhibitor 1B (p27, Kip1) | blank | n.s. | n.s. |  1.7  | -0.7845 | 0.0016 ||\n||  CLDN11  | Claudin 11 | blank | n.s. | n.s. |  1.8  | -0.8315 | 0.0011 ||\n||  CLU  | Clusterin | blank | n.s. | n.s. |  1.9  | -0.9548 | 0.0006 ||\n||  CREB1  | cAMP Responsive Element Binding protein 1 |  1.1  | 0.2000 | 0.0489 |  1.6  | -0.6888 | 0.0041 ||",
    "claim": "The gene CREB1 shows significant expression changes in both groups, with a logFC of 0.2000 in the Ad-/Ad+ group and -0.6888 in the GnRHa group, indicating differential regulation under both conditions.",
    "label": "support"
  },
  {
    "id": "training_1031_2",
    "table_caption": "Table: Soil physical properties in the experimental field. Depth (cm) Particle size distribution (%) Bulk density g cm23 SLLLa SDULb SSKSc cm d21 SSATd Organic C (%) pH Clay Silt Sand 0–15 18 50 31 1.15 0.09 0.28 1.42 0.30 1.8 6.5 15–30 24 49 26 1.25 0.09 0.28 1.43 0.30 1.5 6.6 30–45 23 52 24 1.35 0.09 0.28 2.76 0.32 1.3 7.0 Swift Current 45–60 25 33 41 1.4.0 0.10 0.27 4.32 0.34 0.9 7.7 60–90 32 28 40 1.45 0.10 0.27 5.61 0.34 0.5 7.8 90–120 33 26 41 1.55 0.10 0.25 3.04 0.34 0.3 8.1 120–150 33 28 40 1.65 0.10 0.25 3.04 0.34 0.1 8.5 0–15 60 29 11 1.30 0.11 0.37 7.40 0.59 2.9 7.0 15–45 60 28 12 1.40 0.11 0.37 7.68 0.57 1.0 7.3 Saskatoon 45–80 60 28 12 1.50 0.11 0.36 5.08 0.53 0.3 7.5 80–100 60 37 3 1.50 0.11 0.36 1.38 0.53 0.3 8.0 0–19 50 40 10 1.20 0.20 0.45 0.34 0.55 4.5 6.8 Melfort 19–58 49 44 7 1.30 0.20 0.46 0.29 0.51 1.3 7.0 58–100 52 45 3 1.30 0.20 0.46 0.25 0.51 0.5 8.0 aLower limit of plant extractable soil water (cm3 cm23). bDrained upper limit (cm3 cm23). ",
    "table_content": "|| blank | Depth (cm) | Particle size distribution (%) | Particle size distribution (%) | Particle size distribution (%) | Bulk density g cm −3 | SLLL a | SDUL b | SSKS c cm d −1 | SSAT d | Organic C (%) | pH ||\n|| blank | Depth (cm) | Clay | Silt | Sand | Bulk density g cm −3 | SLLL a | SDUL b | SSKS c cm d −1 | SSAT d | Organic C (%) | pH ||\n|| Swift Current | 15–45 | 60 | 28 | 12 | 1.40 | 0.11 | 0.37 | 7.68 | 0.57 | 1.0 | 7.3 ||\n|| Saskatoon | 45–80 | 60 | 28 | 12 | 1.50 | 0.11 | 0.36 | 5.08 | 0.53 | 0.3 | 7.5 ||\n|| Saskatoon | 80–100 | 60 | 37 | 3 | 1.50 | 0.11 | 0.36 | 1.38 | 0.53 | 0.3 | 8.0 ||\n|| Saskatoon | 0–19 | 50 | 40 | 10 | 1.20 | 0.20 | 0.45 | 0.34 | 0.55 | 4.5 | 6.8 ||\n|| Melfort | 19–58 | 49 | 44 | 7 | 1.30 | 0.20 | 0.46 | 0.29 | 0.51 | 1.3 | 7.0 ||\n|| Melfort | 58–100 | 52 | 45 | 3 | 1.30 | 0.20 | 0.46 | 0.25 | 0.51 | 0.5 | 8.0 ||\n|| blank | 0–15 | 18 | 50 | 31 | 1.15 | 0.09 | 0.28 | 1.42 | 0.30 | 1.8 | 6.5 ||\n|| blank | 15–30 | 24 | 49 | 26 | 1.25 | 0.09 | 0.28 | 1.43 | 0.30 | 1.5 | 6.6 ||\n|| blank | 30–45 | 23 | 52 | 24 | 1.35 | 0.09 | 0.28 | 2.76 | 0.32 | 1.3 | 7.0 ||\n|| Swift Current | 45–60 | 25 | 33 | 41 | 1.4.0 | 0.10 | 0.27 | 4.32 | 0.34 | 0.9 | 7.7 ||\n|| Swift Current | 60–90 | 32 | 28 | 40 | 1.45 | 0.10 | 0.27 | 5.61 | 0.34 | 0.5 | 7.8 ||\n|| Swift Current | 90–120 | 33 | 26 | 41 | 1.55 | 0.10 | 0.25 | 3.04 | 0.34 | 0.3 | 8.1 ||\n|| Swift Current | 120–150 | 33 | 28 | 40 | 1.65 | 0.10 | 0.25 | 3.04 | 0.34 | 0.1 | 8.5 ||\n|| Swift Current | 0–15 | 60 | 29 | 11 | 1.30 | 0.11 | 0.37 | 7.40 | 0.59 | 2.9 | 7.0 ||",
    "claim": "In Swift Current, the bulk density increases by 23% from the surface to the deepest layer, suggesting compaction with depth, which can reduce porosity and affect root growth and water movement.",
    "label": "support"
  },
  {
    "id": "training_1449_5",
    "table_caption": "Table: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) x y z Uiso*/Ueq O1 0.15042 (14) 0.21450 (6) 0.03780 (8) 0.0356 (3) O2 0.50241 (15) 0.15584 (8) 0.07833 (10) 0.0527 (3) N1 0.19880 (17) 0.06402 (8) 0.12264 (9) 0.0329 (3) N2 −0.0623 (2) −0.03954 (9) 0.17875 (11) 0.0442 (3) C1 −0.0253 (2) 0.04699 (10) 0.13009 (11) 0.0359 (3) H1 −0.1397 0.0927 0.1031 0.043* C2 0.1485 (2) −0.08085 (11) 0.20408 (13) 0.0450 (4) H2 0.1750 −0.1445 0.2404 0.054* C3 0.3103 (2) −0.01943 (10) 0.17071 (12) 0.0410 (3) H3 0.4671 −0.0307 0.1784 0.049* C4 0.3034 (2) 0.14897 (10) 0.07701 (11) 0.0350 (3) C5 0.2187 (2) 0.30947 (10) −0.01876 (12) 0.0373 (3) C6 −0.0052 (3) 0.35703 (12) −0.05516 (15) 0.0526 (4) H6A −0.0861 0.3708 0.0138 0.079* H6B −0.0929 0.3107 −0.1065 0.079* H6C 0.0187 0.4204 −0.0963 0.079* C7 0.3515 (3) 0.37416 (11) 0.06973 (13) 0.0485 (4) H7A 0.4941 0.3410 0.0926 0.073* H7B 0.2661 0.3830 0.1382 0.073* H7C 0.3801 0.4402 0.0357 0.073* C8 0.3472 (3) 0.28433 (12) −0.12317 (13) 0.0501 (4) H8A 0.2566 0.2400 −0.1756 0.075* H8B 0.4871 0.2501 −0.0974 0.075* H8C 0.3812 0.3467 −0.1640 0.075* (Å2) ",
    "table_content": "|| blank | x | y | z | U iso */ U eq ||\n|| O1 | 0.15042 (14) | 0.21450 (6) | 0.03780 (8) | 0.0356 (3) ||\n|| H3 | 0.4671 | −0.0307 | 0.1784 | 0.049* ||\n|| C4 | 0.3034 (2) | 0.14897 (10) | 0.07701 (11) | 0.0350 (3) ||\n|| C5 | 0.2187 (2) | 0.30947 (10) | −0.01876 (12) | 0.0373 (3) ||\n|| C6 | −0.0052 (3) | 0.35703 (12) | −0.05516 (15) | 0.0526 (4) ||\n|| H6A | −0.0861 | 0.3708 | 0.0138 | 0.079* ||\n|| H6B | −0.0929 | 0.3107 | −0.1065 | 0.079* ||\n|| H6C | 0.0187 | 0.4204 | −0.0963 | 0.079* ||\n|| C7 | 0.3515 (3) | 0.37416 (11) | 0.06973 (13) | 0.0485 (4) ||\n|| H7A | 0.4941 | 0.3410 | 0.0926 | 0.073* ||\n|| H7B | 0.2661 | 0.3830 | 0.1382 | 0.073* ||\n|| O2 | 0.50241 (15) | 0.15584 (8) | 0.07833 (10) | 0.0527 (3) ||\n|| H7C | 0.3801 | 0.4402 | 0.0357 | 0.073* ||\n|| C8 | 0.3472 (3) | 0.28433 (12) | −0.12317 (13) | 0.0501 (4) ||\n|| H8A | 0.2566 | 0.2400 | −0.1756 | 0.075* ||\n|| H8B | 0.4871 | 0.2501 | −0.0974 | 0.075* ||\n|| H8C | 0.3812 | 0.3467 | −0.1640 | 0.075* ||\n|| N1 | 0.19880 (17) | 0.06402 (8) | 0.12264 (9) | 0.0329 (3) ||\n|| N2 | −0.0623 (2) | −0.03954 (9) | 0.17875 (11) | 0.0442 (3) ||\n|| C1 | −0.0253 (2) | 0.04699 (10) | 0.13009 (11) | 0.0359 (3) ||\n|| H1 | −0.1397 | 0.0927 | 0.1031 | 0.043* ||\n|| C2 | 0.1485 (2) | −0.08085 (11) | 0.20408 (13) | 0.0450 (4) ||\n|| H2 | 0.1750 | −0.1445 | 0.2404 | 0.054* ||\n|| C3 | 0.3103 (2) | −0.01943 (10) | 0.17071 (12) | 0.0410 (3) ||",
    "claim": "The variance in the y-coordinates of carbon atoms (C1, C2, C3, C4, C5, C6, C7, C8) is calculated to be approximately 0.022, suggesting a relatively planar arrangement along the y-axis, which is typical for aromatic or conjugated systems.",
    "label": "support"
  },
  {
    "id": "training_5_2",
    "table_caption": "Table: Heart weights (HW), body weights (BW), cardiac function, plasma creatine content and creatine uptake during development in the rat heart Age (days) -2 ( fetal ) 7 13 21 33 50 80 ANOVA HW (g) 0.039 ± 0.01a 0.13 ± 0.01b 0.17 ± 0.06bc 0.24 ± 0.03c 0.44 ± 0.04d 0.70 ± 0.07e 1.17 ± 0.02f p < 0.001 [4] [4] [7] [5] [8] [6] [8] BW (g) 3.59 ± 0.34a 22.0 ± 1.78b 35.6 ± 7.08c 41.5 ± 4.1c 78.6 ± 2.4d 178 ± 8.6e 296 ± 5.3f p < 0.001 [4] [4] [7] [5] [8] [6] [8] HW/BW *1000 10.9 ± 2.1a 5.79 ± 0.80ab 4.81 ± 1.15ab 5.84 ± 0.70a 5.58 ± 0.47a 3.93 ± 0.32b b 3.94 ± 0.10b p < 0.001 [4] [4] [7] [5] [5] [6] [8] HR (bpm) - - 321 ± 5.7 248 ± 4.9 348 ± 5.6 318 ± 34 307 ± 45 NS [4] [4] [4] [4] [4] LDVP (mm Hg) - - 69 ± 12.7 88.6 ± 0.36 65.7 ± 7.2 75.7 ± 10.2 97.1 ± 27.6 NS [4] [4] [4] [4] [4] RPP (mm Hg/bpm) - - 22129 ± 3673 22047 ± 555 22879 ± 2874 24189 ± 5524 29673 ± 8913 NS [4] [4] [4] [4] [4] Creatine uptake - - 3.03 ± 0.55a 3.66 ± 0.79ab 3.85 ± 0.62abc 4.68 ± 0.54bc 4.99 ± 0.52c p < 0.001 (nmol/min/g w.w) [6] [5] [5] [5] [6] Plasma creatine - 0.971 ± 0.07a 0.669 ± 0.16ab 0.678 ± 0.19ac 0.627 ± 0.12bc 0.558 ± 0.06bc 0.536 ± 0.08bc p = 0.002 (mmol/L) [4] [4] [4] [4] [4] [4] Data are presented as means ± S.E and sample size are given in brackets. Values within a row with different superscript letters are significantly different to all other time points (p < 0.05, creatine uptake, plasma creatine: Bonferroni; HW, BW, HW/BW*1000: Dunnett T3, ANOVA \"test for linear trend\": as indicated). ",
    "table_content": "|| Age (days) | -2 ( fetal ) | 7 | 13 | 21 | 33 | 50 | 80 | ANOVA ||\n|| HW (g) | 0.039 ± 0.01 a | 0.13 ± 0.01 b | 0.17 ± 0.06 bc | 0.24 ± 0.03 c | 0.44 ± 0.04 d | 0.70 ± 0.07 e | 1.17 ± 0.02 f | p < 0.001 ||\n|| LDVP (mm Hg) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| RPP (mm Hg/bpm) | blank | blank | 22129 ± 3673 | 22047 ± 555 | 22879 ± 2874 | 24189 ± 5524 | 29673 ± 8913 | NS ||\n|| RPP (mm Hg/bpm) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| Creatine uptake | blank | blank | 3.03 ± 0.55 a | 3.66 ± 0.79 ab | 3.85 ± 0.62 abc | 4.68 ± 0.54 bc | 4.99 ± 0.52 c | p < 0.001 ||\n|| (nmol/min/g w.w) | blank | blank | [6] | [5] | [5] | [5] | [6] | blank ||\n|| Plasma creatine | blank | 0.971 ± 0.07 a | 0.669 ± 0.16 ab | 0.678 ± 0.19 ac | 0.627 ± 0.12 bc | 0.558 ± 0.06 bc | 0.536 ± 0.08 bc | p = 0.002 ||\n|| (mmol/L) | blank | [4] | [4] | [4] | [4] | [4] | [4] | blank ||\n|| HW (g) | [4] | [4] | [7] | [5] | [8] | [6] | [8] | blank ||\n|| BW (g) | 3.59 ± 0.34 a | 22.0 ± 1.78 b | 35.6 ± 7.08 c | 41.5 ± 4.1 c | 78.6 ± 2.4 d | 178 ± 8.6 e | 296 ± 5.3 f | p < 0.001 ||\n|| BW (g) | [4] | [4] | [7] | [5] | [8] | [6] | [8] | blank ||\n|| HW/BW *1000 | 10.9 ± 2.1 a | 5.79 ± 0.80 ab | 4.81 ± 1.15 ab | 5.84 ± 0.70 a | 5.58 ± 0.47 a | 3.93 ± 0.32 b | b 3.94 ± 0.10 b | p < 0.001 ||\n|| HW/BW *1000 | [4] | [4] | [7] | [5] | [5] | [6] | [8] | blank ||\n|| HR (bpm) | blank | blank | 321 ± 5.7 | 248 ± 4.9 | 348 ± 5.6 | 318 ± 34 | 307 ± 45 | NS ||\n|| HR (bpm) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| LDVP (mm Hg) | blank | blank | 69 ± 12.7 | 88.6 ± 0.36 | 65.7 ± 7.2 | 75.7 ± 10.2 | 97.1 ± 27.6 | NS ||",
    "claim": "The body weight of rats increases by a factor of approximately 82.5 from fetal stage to 80 days, indicating a more pronounced growth compared to heart weight. This suggests that while the heart grows significantly, the overall body growth is even more substantial, reflecting the general somatic growth during early development.",
    "label": "support"
  },
  {
    "id": "training_437_2",
    "table_caption": "Table: Data collection and refinement statistics of HMA6N-AA. Data collection Peak Inﬂection Remote Diffraction source ID23-1 ID23-1 ID23-1 Wavelength (Å) 0.97924 0.97947 0.97692 Temperature (K) 100 100 100 Crystal-detector distance (mm) 271.40 271.22 272.21 Rotation range per image (˚) 0.1 0.1 0.1 Total rotation range (˚) 121 121 121 Space group P 2 21 21 P 2 21 21 P 2 21 21 a, b, c 38.77 65.15 85.6 38.79 65.23 85.64 38.84 65.30 85.68 α, β, γ 90 90 90 90 90 90 90 90 90 Mosaicity (˚) 0.062 0.068 0.083 Resolution range 50–1.50 (1.53–1.50) 50–1.50 (1.53–1.50) 50–1.50 (1.53–1.50) Total No. of reﬂections 155329 (7508) 155325 (7597) 155309 (7467) No. of unique reﬂections 35341 (1689) 35433 (1707) 35474 (1689) Completeness (%) 99.5 (99.0) 99.6 (99.4) 99.5 (97.9) Redundancy 4.4 (4.4) 4.4 (4.5) 4.4 (4.4) <I/σ(I)> 13.4 (1.4) 13.6 (1.5) 15.7 (1.1) Reﬁnement statistics R factor 18.54 (32.23) Rfree 20.72 (34.6) No. of non-H atoms Protein 1761 Water 149 Mean B factors (Å2) Protein 30.86 Ligands 44.8 Solvent 38.4 R.m.s. deviation from ideal Bond length (Å) 0.01 Bond angles (˚) 0.922 Ramachandran plot (%) Residues in favoured region 97.76 Residues in allowed region 2.24 Outliers 0 Molprobity Score 1.52 PDB code 5LBD doi:10.1371/journal.pone.0165666.t001 ",
    "table_content": "|| Data collection | Peak | Inflection | Remote ||\n|| Diffraction source | ID23-1 | ID23-1 | ID23-1 ||\n|| Mosaicity (°) | 0.062 | 0.068 | 0.083 ||\n|| Resolution range | 50–1.50 (1.53–1.50) | 50–1.50 (1.53–1.50) | 50–1.50 (1.53–1.50) ||\n|| Total No. of reflections | 155329 (7508) | 155325 (7597) | 155309 (7467) ||\n|| No. of unique reflections | 35341 (1689) | 35433 (1707) | 35474 (1689) ||\n|| Completeness (%) | 99.5 (99.0) | 99.6 (99.4) | 99.5 (97.9) ||\n|| Redundancy | 4.4 (4.4) | 4.4 (4.5) | 4.4 (4.4) ||\n|| <I/σ(I)> | 13.4 (1.4) | 13.6 (1.5) | 15.7 (1.1) ||\n|| Refinement statistics | Refinement statistics | Refinement statistics | Refinement statistics ||\n|| R factor | 18.54 (32.23) | blank | blank ||\n|| Rfree | 20.72 (34.6) | blank | blank ||\n|| Wavelength (Å) | 0.97924 | 0.97947 | 0.97692 ||\n|| No. of non-H atoms | No. of non-H atoms | No. of non-H atoms | No. of non-H atoms ||\n|| Protein | 1761 | blank | blank ||\n|| Water | 149 | blank | blank ||\n|| Mean B factors (Å 2 ) | Mean B factors (Å 2 ) | Mean B factors (Å 2 ) | Mean B factors (Å 2 ) ||\n|| Protein | 30.86 | blank | blank ||\n|| Ligands | 44.8 | blank | blank ||\n|| Solvent | 38.4 | blank | blank ||\n|| R.m.s. deviation from ideal | R.m.s. deviation from ideal | R.m.s. deviation from ideal | R.m.s. deviation from ideal ||\n|| Bond length (Å) | 0.01 | blank | blank ||\n|| Bond angles (°) | 0.922 | blank | blank ||\n|| Temperature (K) | 100 | 100 | 100 ||\n|| Ramachandran plot (%) | Ramachandran plot (%) | Ramachandran plot (%) | Ramachandran plot (%) ||\n|| Residues in favoured region | 97.76 | blank | blank ||\n|| Residues in allowed region | 2.24 | blank | blank ||\n|| Outliers | 0 | blank | blank ||\n|| Molprobity Score | 1.52 | blank | blank ||\n|| PDB code | 5LBD | blank | blank ||\n|| Crystal-detector distance (mm) | 271.40 | 271.22 | 272.21 ||\n|| Rotation range per image (°) | 0.1 | 0.1 | 0.1 ||\n|| Total rotation range (°) | 121 | 121 | 121 ||\n|| Space group | P 2 2 1 2 1 | P 2 2 1 2 1 | P 2 2 1 2 1 ||\n|| a , b , c | 38.77 65.15 85.6 | 38.79 65.23 85.64 | 38.84 65.30 85.68 ||\n|| α, β, γ | 90 90 90 | 90 90 90 | 90 90 90 ||",
    "claim": "Despite the slight variations in completeness across the three data points, the redundancy remains constant. This suggests that the redundancy is not directly influenced by completeness, as the redundancy value of 4.4 is maintained even when completeness varies by 0.1%.",
    "label": "support"
  },
  {
    "id": "training_25_5",
    "table_caption": "Table: Reasons of Approval or Rejection in at least one of the Case Vignettes. Human geneticists ‘‘worldwide’’ 1995 (sex selection via sex-selective abortion) Specialists in reproductive medicine Germany 2006 (sex selection via PID/ MicroSort) Reasons of Approval 1. In deference to the autonomy of the patient 29% 15.8% 2. In deference to the culture or the religion of the patient 6% 13.2% 3. Retain the unity of the family 3% 6.1% 4. The patients have the right of any service they can pay for 8% 0 Reasons of Rejection 1. Prevent a possible gender discrimination 7% 71.9% 2. Prevent the misuse of reproduction techniques which are intended to identify genetically caused diseases 43% 51.8% 3. The refusal of the abortion of a healthy embryo 16% 29.8% 4. The right of a professional to refuse a service 7% 34.2% 5. To avoid the tendency of a cosmetic selection 1% 50.0% 6. To preserve a balance of genders 3% 21.9% doi:10.1371/journal.pone.0056390.t006 ",
    "table_content": "|| blank | Human geneticists“worldwide” 1995 (sexselection via sex-selectiveabortion) | Specialists in reproductive medicineGermany 2006 (sex selection via PID/MicroSort) ||\n||  Reasons of Approval  |  Reasons of Approval  |  Reasons of Approval  ||\n|| 4. The right of a professional to refuse a service | 7% | 34.2% ||\n|| 5. To avoid the tendency of a cosmetic selection | 1% | 50.0% ||\n|| 6. To preserve a balance of genders | 3% | 21.9% ||\n|| 1. In deference to the autonomy of the patient | 29% | 15.8% ||\n|| 2. In deference to the culture or the religion of the patient | 6% | 13.2% ||\n|| 3. Retain the unity of the family | 3% | 6.1% ||\n|| 4. The patients have the right of any service they can pay for | 8% | 0 ||\n||  Reasons of Rejection  |  Reasons of Rejection  |  Reasons of Rejection  ||\n|| 1. Prevent a possible gender discrimination | 7% | 71.9% ||\n|| 2. Prevent the misuse of reproduction techniques which areintended to identify genetically caused diseases | 43% | 51.8% ||\n|| 3. The refusal of the abortion of a healthy embryo | 16% | 29.8% ||",
    "claim": "The rejection rate to avoid the tendency of cosmetic selection increased by 4900% from 1995 to 2006. This substantial increase highlights a significant shift in ethical priorities, emphasizing the importance of preventing non-medical, aesthetic motivations in reproductive choices.",
    "label": "support"
  },
  {
    "id": "training_625_4",
    "table_caption": "Table: Term Total Expected Hits Raw p Biosynthesis of unsaturated fatty acids 42 0.65906 6 2.62E-05 Arachidonic acid metabolism 36 0.56491 4 0.0019285 Linoleic acid metabolism 5 0.078459 2 0.0022856 Sphingolipid metabolism 21 0.32953 3 0.0037176 Glycerophospholipid metabolism 30 0.47076 3 0.010353 Cyanoamino acid metabolism 6 0.094151 1 0.09069 alpha-Linolenic acid metabolism 9 0.14123 1 0.13304 Methane metabolism 9 0.14123 1 0.13304 Fatty acid biosynthesis 43 0.67475 2 0.1443 Steroid hormone biosynthesis 70 1.0984 2 0.3014 Cysteine and methionine metabolism 28 0.43937 1 0.36059 Glycine, serine and threonine metabolism 32 0.50214 1 0.40061 Steroid biosynthesis 35 0.54922 1 0.42905 Primary bile acid biosynthesis 46 0.72183 1 0.52269 Aminoacyl-tRNA biosynthesis 67 1.0514 1 0.66232 Table 5. Analyzed pathways of metabolomics data differently regulated in lung tissue obstructive pulmonary disease rats. ",
    "table_content": "|| Term | Total | Expected | Hits | Raw p ||\n|| Biosynthesis of unsaturated fatty acids | 42 | 0.65906 | 6 | 2.62E-05 ||\n|| Steroid hormone biosynthesis | 70 | 1.0984 | 2 | 0.3014 ||\n|| Cysteine and methionine metabolism | 28 | 0.43937 | 1 | 0.36059 ||\n|| Glycine, serine and threonine metabolism | 32 | 0.50214 | 1 | 0.40061 ||\n|| Steroid biosynthesis | 35 | 0.54922 | 1 | 0.42905 ||\n|| Primary bile acid biosynthesis | 46 | 0.72183 | 1 | 0.52269 ||\n|| Aminoacyl-tRNA biosynthesis | 67 | 1.0514 | 1 | 0.66232 ||\n|| Arachidonic acid metabolism | 36 | 0.56491 | 4 | 0.0019285 ||\n|| Linoleic acid metabolism | 5 | 0.078459 | 2 | 0.0022856 ||\n|| Sphingolipid metabolism | 21 | 0.32953 | 3 | 0.0037176 ||\n|| Glycerophospholipid metabolism | 30 | 0.47076 | 3 | 0.010353 ||\n|| Cyanoamino acid metabolism | 6 | 0.094151 | 1 | 0.09069 ||\n|| alpha-Linolenic acid metabolism | 9 | 0.14123 | 1 | 0.13304 ||\n|| Methane metabolism | 9 | 0.14123 | 1 | 0.13304 ||\n|| Fatty acid biosynthesis | 43 | 0.67475 | 2 | 0.1443 ||",
    "claim": "The total observed hits for amino acid metabolism pathways (cysteine and methionine metabolism, glycine, serine and threonine metabolism, and aminoacyl-tRNA biosynthesis) is 3, which is significantly higher than the expected total of approximately 1.99, suggesting an overrepresentation of these pathways.",
    "label": "support"
  },
  {
    "id": "training_514_5",
    "table_caption": "Table: primary colorectal carcinomas. Liver metastasis absence presence (N = 36) (N = 43) Gender Male 23 24 Female 12 19 Missing 1 0 Mean age (yrs) 66.3 62.2 (range) (40–81) (35–82) Location Proximal 15 14 Distal 15 29 Missing 6 0 Stage* 1 4 0 (TNM) 2 22 3 3 8 8 4 0 32 Missing** 2 0 Liver metastasis synchronous NA 36 metachronous 7 Non-liver lymph node 8 30 metastasis lung 6 ovary NA 2 peritoneum 23 brain 1 *, Stage represents initial stage when primary tumors were surgically resected. Eleven cases (three stage 2 and eight stage 3 CRCs) showed liver metastases ",
    "table_content": "|| blank | blank | Liver metastasis | Liver metastasis ||\n|| blank | blank | absence (N = 36) | presence (N = 43) ||\n|| Location | Missing | 6 | 0 ||\n|| Stage *  | 1 | 4 | 0 ||\n|| (TNM) | 2 | 22 | 3 ||\n|| (TNM) | 3 | 8 | 8 ||\n|| (TNM) | 4 | 0 | 32 ||\n|| (TNM) | Missing **  | 2 | 0 ||\n|| Liver metastasis | synchronous | NA | 36 ||\n|| Liver metastasis | metachronous | blank | 7 ||\n|| Non-liver | lymph node | 8 | 30 ||\n|| metastasis | lung | blank | 6 ||\n|| blank | blank | absence (N = 36) | presence (N = 43) ||\n|| metastasis | ovary | NA | 2 ||\n|| metastasis | peritoneum | blank | 23 ||\n|| metastasis | brain | blank | 1 ||\n|| Gender | Male | 23 | 24 ||\n|| Gender | Female | 12 | 19 ||\n|| Gender | Missing | 1 | 0 ||\n|| Mean age | (yrs) | 66.3 | 62.2 ||\n|| Mean age | (range) | (40–81) | (35–82) ||\n|| Location | Proximal | 15 | 14 ||\n|| Location | Distal | 15 | 29 ||",
    "claim": "Non-liver lymph node metastasis is 3.75 times more common in cases with liver metastasis than those without, indicating a strong association between liver metastasis and the spread to lymph nodes.",
    "label": "support"
  },
  {
    "id": "training_1295_3",
    "table_caption": "Table: to of a Table 3. Proportion of sick children linked to provider from reported source of care category, by stratum and linking method Linking method ruraL urban Number linked % linked # Linked % linked All providers: 166 129 Exact-match 164 98.8 120 93 Single match: Nearest - absolute distance 166 100 129 100 Nearest - road distance 166 100 129 100 Aggregate match: Radius – 5 km 106 63.8 129 100 Administrative unit – HFCA 165 99.4 129 100 Administrative unit – total area 166 100 129 100 Facility-based providers only: Linking method 166 129 Exact-match 122 73.5 117 91 Single match: Nearest – absolute distance 122 73.5 117 91 Nearest – road distance 122 73.5 117 91 Aggregate match: Radius – 5 km 65 39 117 91 Administrative unit – HFCA 122 73.5 117 91 Administrative unit – total Area 122 73.5 117 91 HFCA – health facility catchment area ",
    "table_content": "|| Linking method | Rural | Rural | Urban | Urban ||\n|| Linking method | Number linked | % linked | # Linked | % linked ||\n|| Administrative unit – total area | 166 | 100 | 129 | 100 ||\n|| Facility-based providers only: | Facility-based providers only: | Facility-based providers only: | Facility-based providers only: | Facility-based providers only: ||\n|| Linking method | 166 | blank | 129 | blank ||\n|| Exact-match | 122 | 73.5 | 117 | 91 ||\n|| Single match: | Single match: | Single match: | Single match: | Single match: ||\n|| Nearest – absolute distance | 122 | 73.5 | 117 | 91 ||\n|| Nearest – road distance | 122 | 73.5 | 117 | 91 ||\n|| Aggregate match: | Aggregate match: | Aggregate match: | Aggregate match: | Aggregate match: ||\n|| Radius – 5 km | 65 | 39 | 117 | 91 ||\n|| Administrative unit – HFCA | 122 | 73.5 | 117 | 91 ||\n|| All providers: | 166 | blank | 129 | blank ||\n|| Administrative unit – total Area | 122 | 73.5 | 117 | 91 ||\n|| Exact-match | 164 | 98.8 | 120 | 93 ||\n|| Single match: | Single match: | Single match: | Single match: | Single match: ||\n|| Nearest - absolute distance | 166 | 100 | 129 | 100 ||\n|| Nearest - road distance | 166 | 100 | 129 | 100 ||\n|| Aggregate match: | Aggregate match: | Aggregate match: | Aggregate match: | Aggregate match: ||\n|| Radius – 5 km | 106 | 63.8 | 129 | 100 ||\n|| Administrative unit – HFCA | 165 | 99.4 | 129 | 100 ||",
    "claim": "For facility-based providers in rural areas, the exact-match method links 73.5% of children, which is 34.5 percentage points higher than the radius – 5 km method, highlighting the challenges of using smaller radii in less densely populated rural areas.",
    "label": "support"
  },
  {
    "id": "training_1395_6",
    "table_caption": "Table: Descriptive characteristics of mothers and infants from 3–18 months of infant age Birth 3 months 6 months 9 months 12 months 18 months Infants Total n 206 157 153 132 109 Female 110 (53.4%)a 83 (52.9%) 80 (52.3%) 73 (55.3%) 59 (54%) Gestational age 39.48 ± 1.47b Anthropometrics Birthweight 3.23 ± 0.48 Weight for length Z-score 0.56 ± 1.0 0.55 ± 1.1 0.54 ± 1.12 0.44 ± 1.08 0.34 ± 1.04 Sum of skinfoldsc 25.34 ± 4.69 25.53 ± 5.91 24.80 ± 6.33 23.09 ± 5.38 22.88 ± 4.19 Temperament dimensions Distress to limitations 3.46 ± 0.74 3.66 ± 0.80 4.02 ± 0.77 n/a n/a Activity level 4.11 ± 0.82 4.71 ± 0.77 4.85 ± 0.73 5.50 ± 0.71 5.35 ± 0.77 Infant Diet Daily calories, non-breastfed infants Infant received any breast milk 44 (21.4%) 22 (14.0%) 15 (9.8%) 8 (6.1%) 3 (2.8%) Infant exclusively breast-fed 13 (6.3%) 0 0 0 0 Mothers Anthropometrics BMI<25 63 (29%) BMI 25–29.9 58 (26.7%) BMI = >30 96 (44.2%) Sociodemographics Maternal education 58 (27.1%) Less than high school 65 (30.4%) High school graduate or GED 70 (32.7%) Some college 21 (9.8%) a Frequency (%) bMean ± standard deviation ",
    "table_content": "|| Infants | Birth | 3 months | 6 months | 9 months | 12 months | 18 months ||\n|| Infants | Birth | 3 months | 6 months | 9 months | 12 months | 18 months ||\n|| Distress to limitations | blank | 3.46 ± 0.74 | 3.66 ± 0.80 | 4.02 ± 0.77 | n/a | n/a ||\n|| Activity level | blank | 4.11 ± 0.82 | 4.71 ± 0.77 | 4.85 ± 0.73 | 5.50 ± 0.71 | 5.35 ± 0.77 ||\n|| Infant Diet | Infant Diet | Infant Diet | Infant Diet | Infant Diet | Infant Diet | Infant Diet ||\n|| Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants ||\n|| Infant received any breast milk | blank | 44 (21.4%) | 22 (14.0%) | 15 (9.8%) | 8 (6.1%) | 3 (2.8%) ||\n|| Infant exclusively breast-fed | blank | 13 (6.3%) | 0 | 0 | 0 | 0 ||\n|| Mothers | Mothers | Mothers | Mothers | Mothers | Mothers | Mothers ||\n|| Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics ||\n|| BMI<25 | blank | 63 (29%) | blank | blank | blank | blank ||\n|| BMI 25–29.9 | blank | 58 (26.7%) | blank | blank | blank | blank ||\n|| Total n | blank | 206 | 157 | 153 | 132 | 109 ||\n|| BMI = >30 | blank | 96 (44.2%) | blank | blank | blank | blank ||\n|| Sociodemographics | Sociodemographics | Sociodemographics | Sociodemographics | Sociodemographics | Sociodemographics | Sociodemographics ||\n|| Maternal education | blank | 58 (27.1%) | blank | blank | blank | blank ||\n|| Less than high school | blank | 65 (30.4%) | blank | blank | blank | blank ||\n|| High school graduate or GED | blank | 70 (32.7%) | blank | blank | blank | blank ||\n|| Some college | blank | 21 (9.8%) | blank | blank | blank | blank ||\n|| Female | blank | 110 (53.4%) a | 83 (52.9%) | 80 (52.3%) | 73 (55.3%) | 59 (54%) ||\n|| Gestational age | 39.48 ± 1.47 b | blank | blank | blank | blank | blank ||\n|| Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics ||\n|| Birthweight | 3.23 ± 0.48 | blank | blank | blank | blank | blank ||\n|| Weight for length Z-score | blank | 0.56 ± 1.0 | 0.55 ± 1.1 | 0.54 ± 1.12 | 0.44 ± 1.08 | 0.34 ± 1.04 ||\n|| Sum of skinfolds c | blank | 25.34 ± 4.69 | 25.53 ± 5.91 | 24.80 ± 6.33 | 23.09 ± 5.38 | 22.88 ± 4.19 ||\n|| Temperament dimensions | Temperament dimensions | Temperament dimensions | Temperament dimensions | Temperament dimensions | Temperament dimensions | Temperament dimensions ||",
    "claim": "The distribution of maternal education shows that 32.7% of mothers are high school graduates or have a GED, while 30.4% have less than a high school education. This distribution highlights the educational background of the population, which can impact health literacy and access to resources for infant care.",
    "label": "support"
  },
  {
    "id": "training_979_1",
    "table_caption": "Table: Relapse-related lncRNAs signiﬁ cantly associated with RFS in patients with LUAD Ensembl ID Gene name Chromosome Coef HR 95% CI of HR P -value ENSG00000245598 DACT3-AS1 Chr19: 46,660,364- 46,677,447(+) -0.964 0.382 0.26-0.559 7.52e-07 ENSG00000260037 CTD-2524L6.3 Chr15: 71,818,396- 71,823,384(+) -0.783 0.457 0.334-0.626 1.09e-06 ENSG00000228237 EFCAB14-AS1 Chr1: 46,674,036- 46,692,098(+) -1.226 0.294 0.182-0.474 5.13e-07 ENSG00000176984 AP000679.2 Chr11: 120,168,977- 120,171,679(+) 1.058 2.881 1.976-4.202 3.83e-08 ENSG00000267282 CTB-129P6.4 Chr19: 44,882,027- 44,890,876(-) 0.835 2.304 1.682-3.157 2.04e-07 ENSG00000268324 LRRC2-AS1 Chr3: 46,557,398- 46,559,694 (+) 0.711 2.037 1.574-2.637 6.52e-08 ENSG00000258658 RP11-517O13.3 Chr14: 58,370,023- 58,395,641(-) -0.843 0.43 0.299-0.619 5.44e-06 ENSG00000223647 AL133249.1 Chr2: 31,793,823- 31,803,980(-) 0.843 2.323 1.636-3.3 2.51e-06 ENSG00000248881 CTC-366B18.2 Chr5: 75,598,482- 75,599,380(-) -0.841 0.431 0.305-0.609 1.79e-06 Abbreviations: Coef, Coefﬁ cient; HR, hazard ratio; CI, conﬁ dence interval. ",
    "table_content": "|| Ensembl ID | Gene name | Chromosome | Coef | HR | 95% CI of HR | P -value ||\n|| ENSG00000245598 | DACT3-AS1 | Chr19: 46,660,364-46,677,447(+) | −0.964 | 0.382 | 0.26-0.559 | 7.52e-07 ||\n|| ENSG00000260037 | CTD-2524L6.3 | Chr15: 71,818,396-71,823,384(+) | −0.783 | 0.457 | 0.334-0.626 | 1.09e-06 ||\n|| ENSG00000228237 | EFCAB14-AS1 | Chr1: 46,674,036-46,692,098(+) | −1.226 | 0.294 | 0.182-0.474 | 5.13e-07 ||\n|| ENSG00000176984 | AP000679.2 | Chr11: 120,168,977-120,171,679(+) | 1.058 | 2.881 | 1.976-4.202 | 3.83e-08 ||\n|| ENSG00000267282 | CTB-129P6.4 | Chr19: 44,882,027-44,890,876(−) | 0.835 | 2.304 | 1.682-3.157 | 2.04e-07 ||\n|| ENSG00000268324 | LRRC2-AS1 | Chr3: 46,557,398-46,559,694 (+) | 0.711 | 2.037 | 1.574-2.637 | 6.52e-08 ||\n|| ENSG00000258658 | RP11-517O13.3 | Chr14: 58,370,023-58,395,641(−) | −0.843 | 0.43 | 0.299-0.619 | 5.44e-06 ||\n|| ENSG00000223647 | AL133249.1 | Chr2: 31,793,823-31,803,980(−) | 0.843 | 2.323 | 1.636-3.3 | 2.51e-06 ||\n|| ENSG00000248881 | CTC-366B18.2 | Chr5: 75,598,482-75,599,380(−) | −0.841 | 0.431 | 0.305-0.609 | 1.79e-06 ||",
    "claim": "The lncRNA EFCAB14-AS1, with the most negative coefficient, exhibits the lowest hazard ratio, indicating a strong inverse relationship between its expression and relapse risk. The calculation involves comparing the coefficients and hazard ratios across all lncRNAs, confirming that the most negative coefficient corresponds to the lowest HR.",
    "label": "support"
  },
  {
    "id": "training_153_2",
    "table_caption": "Table: TABLE 2 | Step II: numerical search results. Keywords Cochrane PubMed PMC Elsevier PEDro ISI Total “upper limb exoskeleton” 0 33 63 3 1 155 255 “upper limb mobile robot” 0 0 0 0 0 0 0 “upper limb wearable robot” 0 0 0 0 0 1 1 “upper limb portable robot” 0 0 0 0 0 0 0 “upper limb robotic exoskeleton” 0 3 1 0 0 12 16 ‘upper limb robotic orthosis’ 0 0 0 0 0 0 1 “upper limb robotic device” 0 0 0 0 0 0 0 Total 0 36 64 3 1 169 273 ",
    "table_content": "|| Keywords | Cochrane | PubMed | PMC | Elsevier | PEDro | ISI | Total ||\n|| “ upper limb exoskeleton” | 0 | 33 | 63 | 3 | 1 | 155 | 255 ||\n|| “ upper limb mobile robot” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| “ upper limb wearable robot” | 0 | 0 | 0 | 0 | 0 | 1 | 1 ||\n|| “ upper limb portable robot” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| “ upper limb robotic exoskeleton” | 0 | 3 | 1 | 0 | 0 | 12 | 16 ||\n|| ‘ upper limb robotic orthosis’ | 0 | 0 | 0 | 0 | 0 | 0 | 1 ||\n|| “ upper limb robotic device” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| Total | 0 | 36 | 64 | 3 | 1 | 169 | 273 ||",
    "claim": "The keyword \"upper limb exoskeleton\" contributes to approximately 93.4% of the total search results, highlighting its prominence in the field of upper limb robotic devices.",
    "label": "support"
  },
  {
    "id": "training_193_6",
    "table_caption": "Table: Posterior estimates of divergence times without constraint to the Zea/Oryza separation. Node Independent-rates (IR) model Correlated-rates (CR) model Time (Ma) Rate Time (Ma) Rate 1 (Triticum) 47.2 (28.4, 71.5) 0.040 (0.012, 0.105) 32.4 (21.6, 49.6) 0.059 (0.028, 0.103) 2 (Zea) 55.0 (35.2, 80.4) 0.212 (0.124, 0.377) 36.9 (24.6, 56.7) 0.119 (0.087, 0.159) 3 (Typha) 104.2 (78.7, 135.5) 0.063 (0.026, 0.144) 119.8 (90.9, 156.5) 0.059 (0.034, 0.096) 4 (Musa) 126.8 (105.7, 158.6) 0.040 (0.012, 0.105) 140.8 (113.0, 176.2) 0.043 (0.025, 0.069) 5 (Elaeis) 133.6 (111.1, 166.1) 0.044 (0.014, 0.112) 145.8 (117.4, 181.1) 0.057 (0.033, 0.091) 6 (Phalaenopsis/Yucca) 145.3 (120.2, 179.3) 0.041 (0.012, 0.108) 153.2 (124.5, 187.7) 0.043 (0.026, 0.066) 7 (Dioscorea) 152.6 (125.8, 187.8) 0.080 (0.034, 0.179) 158.7 (129.4, 193.2) 0.059 (0.035, 0.093) 8 (Acorus) 181.7 (147.1, 220.3) 0.054 (0.022, 0.128) 193.7 (159.4, 226.9) 0.046 (0.027, 0.073) 9 (Eudicots) 207.7 (169.2, 245.1) 0.036 (0.010, 0.098) 220.4 (184.1, 251.4) 0.047 (0.029, 0.072) 10 (Drimys) 211.3 (172.3, 249.1) 0.034 (0.009, 0.094) 222.6 (186.2, 253.2) 0.044 (0.026, 0.070) 11 (Chloranthus) 213.6 (174.3, 251.5) 0.060 (0.023, 0.141) 223.9 (187.4, 254.5) 0.047 (0.029, 0.072) 12 (Illicium) 236.2 (193.9, 272.9) 0.053 (0.020, 0.128) 248.6 (210.3, 277.3) 0.048 (0.027, 0.079) 13 (Nymphaea) 258.2 (213.6, 291.8) 0.042 (0.014, 0.107) 269.2 (229.4, 296.1) 0.048 (0.027, 0.078) 14 (Amborella) 272.8 (227.0, 304.2) 0.056 (0.012, 0.177) 279.7 (239.6, 305.8) 0.053 (0.031, 0.086) 15 (Gymnosperm) 296.6 (280.3, 310.2) – 297.2 (280.4, 310.3) – 16 176.9 (138.5, 217.4) 0.061 (0.026, 0.139) 178.5 (141.1, 215.1 0.040 (0.024, 0.068) Terminal branch to Oryza 0 0.051 (0.032, 0.080) 0 0.074 (0.046, 0.106) MCMCTREE in PAML [19] was used with the GTR+C5 model. Shape and scale parameters, a and b, in the gamma prior for parameter s2 were 1.0 and 10.0, respectively. 95% HPD is shown in parentheses. Rate (61028 substitutions/ nucleotide/year) refers to the rate of the branch preceding the node. Node numbers refer to those ",
    "table_content": "|| Node | Independent-rates (IR) model | Independent-rates (IR) model | Correlated-rates (CR) model | Correlated-rates (CR) model ||\n|| Node | Time (Ma) | Rate | Time (Ma) | Rate ||\n|| 9 (Eudicots) | 207.7 (169.2, 245.1) | 0.036 (0.010, 0.098) | 220.4 (184.1, 251.4) | 0.047 (0.029, 0.072) ||\n|| 10 ( Drimys ) | 211.3 (172.3, 249.1) | 0.034 (0.009, 0.094) | 222.6 (186.2, 253.2) | 0.044 (0.026, 0.070) ||\n|| 11 ( Chloranthus ) | 213.6 (174.3, 251.5) | 0.060 (0.023, 0.141) | 223.9 (187.4, 254.5) | 0.047 (0.029, 0.072) ||\n|| 12 ( Illicium ) | 236.2 (193.9, 272.9) | 0.053 (0.020, 0.128) | 248.6 (210.3, 277.3) | 0.048 (0.027, 0.079) ||\n|| 13 ( Nymphaea ) | 258.2 (213.6, 291.8) | 0.042 (0.014, 0.107) | 269.2 (229.4, 296.1) | 0.048 (0.027, 0.078) ||\n|| 14 ( Amborella ) | 272.8 (227.0, 304.2) | 0.056 (0.012, 0.177) | 279.7 (239.6, 305.8) | 0.053 (0.031, 0.086) ||\n|| 15 (Gymnosperm) | 296.6 (280.3, 310.2) | – | 297.2 (280.4, 310.3) | – ||\n|| 16 | 176.9 (138.5, 217.4) | 0.061 (0.026, 0.139) | 178.5 (141.1, 215.1 | 0.040 (0.024, 0.068) ||\n|| Terminal branch to Oryza  | 0 | 0.051 (0.032, 0.080) | 0 | 0.074 (0.046, 0.106) ||\n|| 1 ( Triticum ) | 47.2 (28.4, 71.5) | 0.040 (0.012, 0.105) | 32.4 (21.6, 49.6) | 0.059 (0.028, 0.103) ||\n|| 2 ( Zea ) | 55.0 (35.2, 80.4) | 0.212 (0.124, 0.377) | 36.9 (24.6, 56.7) | 0.119 (0.087, 0.159) ||\n|| 3 ( Typha ) | 104.2 (78.7, 135.5) | 0.063 (0.026, 0.144) | 119.8 (90.9, 156.5) | 0.059 (0.034, 0.096) ||\n|| 4 ( Musa ) | 126.8 (105.7, 158.6) | 0.040 (0.012, 0.105) | 140.8 (113.0, 176.2) | 0.043 (0.025, 0.069) ||\n|| 5 ( Elaeis ) | 133.6 (111.1, 166.1) | 0.044 (0.014, 0.112) | 145.8 (117.4, 181.1) | 0.057 (0.033, 0.091) ||\n|| 6 ( Phalaenopsis/Yucca ) | 145.3 (120.2, 179.3) | 0.041 (0.012, 0.108) | 153.2 (124.5, 187.7) | 0.043 (0.026, 0.066) ||\n|| 7 ( Dioscorea ) | 152.6 (125.8, 187.8) | 0.080 (0.034, 0.179) | 158.7 (129.4, 193.2) | 0.059 (0.035, 0.093) ||\n|| 8 ( Acorus ) | 181.7 (147.1, 220.3) | 0.054 (0.022, 0.128) | 193.7 (159.4, 226.9) | 0.046 (0.027, 0.073) ||",
    "claim": "The HPD interval for the divergence time of \"Illicium\" under the IR model spans approximately 79 million years, which is about 1.5 times the span of the HPD interval for \"Triticum,\" indicating greater uncertainty in the divergence time estimate for \"Illicium\" compared to \"Triticum.\"",
    "label": "support"
  },
  {
    "id": "training_731_7",
    "table_caption": "Table: Table 2 Test characteristics for predicting bacterial infection IL-27, ≥ng/ml Sensitivity Specificity NPV PPV 2.0 43 % (36–51) 76 % (72–80) 71 % (67–74) 29 %(26–33) 3.0 27 % (21–34) 91 % (88–93) 77 % (73–80) 52 % (42–63) 4.0 20 % (15–26) 94 % (91–96) 76 % (72–79) 54 % (42–66) 5.0 12 % (8–17) 95 % (93–97) 74 % (71–77) 47 % (32–62) 6.0 8 % (5–13) 96 % (94–98) 74 % (70–77) 46 % (29–63) IL-27 interleukin-17, NPV negative predictive value, PPV positive predictive value ",
    "table_content": "|| IL-27, ≥ng/ml | Sensitivity | Specificity | NPV | PPV ||\n|| 2.0 | 43 % (36–51) | 76 % (72–80) | 71 % (67–74) | 29 %(26–33) ||\n|| 3.0 | 27 % (21–34) | 91 % (88–93) | 77 % (73–80) | 52 % (42–63) ||\n|| 4.0 | 20 % (15–26) | 94 % (91–96) | 76 % (72–79) | 54 % (42–66) ||\n|| 5.0 | 12 % (8–17) | 95 % (93–97) | 74 % (71–77) | 47 % (32–62) ||\n|| 6.0 | 8 % (5–13) | 96 % (94–98) | 74 % (70–77) | 46 % (29–63) ||",
    "claim": "The overall test performance, considering both sensitivity and specificity, suggests that a threshold of 3.0 ng/ml provides a balanced trade-off, with a specificity of 91% and a sensitivity of 27%, offering a reasonable compromise between detecting true positives and minimizing false positives.",
    "label": "support"
  },
  {
    "id": "training_731_7",
    "table_caption": "Table: Table 2 Test characteristics for predicting bacterial infection IL-27, ≥ng/ml Sensitivity Specificity NPV PPV 2.0 43 % (36–51) 76 % (72–80) 71 % (67–74) 29 %(26–33) 3.0 27 % (21–34) 91 % (88–93) 77 % (73–80) 52 % (42–63) 4.0 20 % (15–26) 94 % (91–96) 76 % (72–79) 54 % (42–66) 5.0 12 % (8–17) 95 % (93–97) 74 % (71–77) 47 % (32–62) 6.0 8 % (5–13) 96 % (94–98) 74 % (70–77) 46 % (29–63) IL-27 interleukin-17, NPV negative predictive value, PPV positive predictive value ",
    "table_content": "|| IL-27, ≥ng/ml | Sensitivity | Specificity | NPV | PPV ||\n|| 2.0 | 43 % (36–51) | 76 % (72–80) | 71 % (67–74) | 29 %(26–33) ||\n|| 3.0 | 27 % (21–34) | 91 % (88–93) | 77 % (73–80) | 52 % (42–63) ||\n|| 4.0 | 20 % (15–26) | 94 % (91–96) | 76 % (72–79) | 54 % (42–66) ||\n|| 5.0 | 12 % (8–17) | 95 % (93–97) | 74 % (71–77) | 47 % (32–62) ||\n|| 6.0 | 8 % (5–13) | 96 % (94–98) | 74 % (70–77) | 46 % (29–63) ||",
    "claim": "The overall test performance, considering both sensitivity and specificity, suggests that a threshold of 2.0 ng/ml provides a balanced trade-off, with a specificity of 76% and a sensitivity of 43%, offering a reasonable compromise between detecting true positives and minimizing false positives.",
    "label": "support"
  },
  {
    "id": "training_972_5",
    "table_caption": "Table: (n = 90). Variables No. (%) of patients with bacteremia caused by P value Acinetobacter baumannii (n = 90) Non- baumannii ACB complex (n = 90) Demographic data Agea 60617 58618 0.46 Male gender 62 (69) 53 (59) 0.16 Underlying illness Ischemic heart disease 25 (28) 16 (18) 0.11 Trauma 13 (14) 16 (18) 0.54 Diabetes mellitus 11 (12) 14 (16) 0.52 Cancer 8 (9) 12 (13) 0.34 Cerebrovascular accident 7 (8) 8 (9) 0.79 Chronic liver disease 14 (16) 3 (3) 0.01 End-stage renal disease 4 (4) 4 (4) .0.99 Benign biliary disease 7 (8) 7 (8) .0.99 Primary site of infection Vascular catheter 27 (30) 27 (30) .0.99 Pneumonia 29 (32) 16 (18) 0.03 Primary bacteremia 8 (9) 18 (20) 0.03 Intra-abdominal 12 (13) 9 (10) 0.49 Urinary tract 3 (3) 7 (8) 0.33 Soft tissue or wound 7 (8) 7 (8) .0.99 Other characteristics Length of hospitalization (day)b, c 12 (7, 21) 11 (7, 22) 0.90 ICU stay at culture 77 (86) 57 (63) 0.001 Mechanical ventilation 64 (71) 44 (49) 0.002 MDR 69 (77) 29 (32) ,0.001 Carbapenem-resistance 51 (57) 12 (16) ,0.001 APACHE II scorea 1867 1768 0.30 Outcomes 30-day mortality 35 (39) 14 (16) ,0.001 Acinetobacter-related mortality 33 (37) 11 (12) ,0.001 ACB, A. calcoaceticus-A. baumannii; ICU, intensive care unit; MDR, multidrug resistance; APACHE, acute physiology and chronic health evaluation. Continuous variables were expressed as means 6 SDs a or medians (IQRs) b and were compared by the Student’s t test a or Mann-Whitney U test b. ",
    "table_content": "|| Variables | No. (%) of patients with bacteremia caused by | No. (%) of patients with bacteremia caused by | P value ||\n|| Variables |  Acinetobacter baumannii (n = 90) | Non- baumannii ACB complex (n = 90) | P value ||\n|| Cerebrovascular accident | 7 (8) | 8 (9) | 0.79 ||\n|| Chronic liver disease | 14 (16) | 3 (3) | 0.01 ||\n|| End-stage renal disease | 4 (4) | 4 (4) | >0.99 ||\n|| Benign biliary disease | 7 (8) | 7 (8) | >0.99 ||\n|| Primary site of infection | Primary site of infection | Primary site of infection | Primary site of infection ||\n|| Vascular catheter | 27 (30) | 27 (30) | >0.99 ||\n|| Pneumonia | 29 (32) | 16 (18) | 0.03 ||\n|| Primary bacteremia | 8 (9) | 18 (20) | 0.03 ||\n|| Intra-abdominal | 12 (13) | 9 (10) | 0.49 ||\n|| Urinary tract | 3 (3) | 7 (8) | 0.33 ||\n|| Demographic data | Demographic data | Demographic data | Demographic data ||\n|| Soft tissue or wound | 7 (8) | 7 (8) | >0.99 ||\n|| Other characteristics | Other characteristics | Other characteristics | Other characteristics ||\n|| Length of hospitalization (day) b,  c  | 12 (7, 21) | 11 (7, 22) | 0.90 ||\n|| ICU stay at culture | 77 (86) | 57 (63) | 0.001 ||\n|| Mechanical ventilation | 64 (71) | 44 (49) | 0.002 ||\n|| MDR | 69 (77) | 29 (32) | <0.001 ||\n|| Carbapenem-resistance | 51 (57) | 12 (16) | <0.001 ||\n|| APACHE II score a  | 18±7 | 17±8 | 0.30 ||\n|| Outcomes | Outcomes | Outcomes | Outcomes ||\n|| 30-day mortality | 35 (39) | 14 (16) | <0.001 ||\n|| Age a  | 60±17 | 58±18 | 0.46 ||\n|| Acinetobacter-related mortality | 33 (37) | 11 (12) | <0.001 ||\n|| Male gender | 62 (69) | 53 (59) | 0.16 ||\n|| Underlying illness | Underlying illness | Underlying illness | Underlying illness ||\n|| Ischemic heart disease | 25 (28) | 16 (18) | 0.11 ||\n|| Trauma | 13 (14) | 16 (18) | 0.54 ||\n|| Diabetes mellitus | 11 (12) | 14 (16) | 0.52 ||\n|| Cancer | 8 (9) | 12 (13) | 0.34 ||",
    "claim": "The rate of mechanical ventilation is 22% higher in patients with Acinetobacter baumannii bacteremia, and the prevalence of multidrug resistance is 45% higher compared to the non-baumannii group. This highlights the increased clinical burden and treatment challenges associated with Acinetobacter baumannii infections.",
    "label": "support"
  },
  {
    "id": "training_972_5",
    "table_caption": "Table: (n = 90). Variables No. (%) of patients with bacteremia caused by P value Acinetobacter baumannii (n = 90) Non- baumannii ACB complex (n = 90) Demographic data Agea 60617 58618 0.46 Male gender 62 (69) 53 (59) 0.16 Underlying illness Ischemic heart disease 25 (28) 16 (18) 0.11 Trauma 13 (14) 16 (18) 0.54 Diabetes mellitus 11 (12) 14 (16) 0.52 Cancer 8 (9) 12 (13) 0.34 Cerebrovascular accident 7 (8) 8 (9) 0.79 Chronic liver disease 14 (16) 3 (3) 0.01 End-stage renal disease 4 (4) 4 (4) .0.99 Benign biliary disease 7 (8) 7 (8) .0.99 Primary site of infection Vascular catheter 27 (30) 27 (30) .0.99 Pneumonia 29 (32) 16 (18) 0.03 Primary bacteremia 8 (9) 18 (20) 0.03 Intra-abdominal 12 (13) 9 (10) 0.49 Urinary tract 3 (3) 7 (8) 0.33 Soft tissue or wound 7 (8) 7 (8) .0.99 Other characteristics Length of hospitalization (day)b, c 12 (7, 21) 11 (7, 22) 0.90 ICU stay at culture 77 (86) 57 (63) 0.001 Mechanical ventilation 64 (71) 44 (49) 0.002 MDR 69 (77) 29 (32) ,0.001 Carbapenem-resistance 51 (57) 12 (16) ,0.001 APACHE II scorea 1867 1768 0.30 Outcomes 30-day mortality 35 (39) 14 (16) ,0.001 Acinetobacter-related mortality 33 (37) 11 (12) ,0.001 ACB, A. calcoaceticus-A. baumannii; ICU, intensive care unit; MDR, multidrug resistance; APACHE, acute physiology and chronic health evaluation. Continuous variables were expressed as means 6 SDs a or medians (IQRs) b and were compared by the Student’s t test a or Mann-Whitney U test b. ",
    "table_content": "|| Variables | No. (%) of patients with bacteremia caused by | No. (%) of patients with bacteremia caused by | P value ||\n|| Variables |  Acinetobacter baumannii (n = 90) | Non- baumannii ACB complex (n = 90) | P value ||\n|| Cerebrovascular accident | 7 (8) | 8 (9) | 0.79 ||\n|| Chronic liver disease | 14 (16) | 3 (3) | 0.01 ||\n|| End-stage renal disease | 4 (4) | 4 (4) | >0.99 ||\n|| Benign biliary disease | 7 (8) | 7 (8) | >0.99 ||\n|| Primary site of infection | Primary site of infection | Primary site of infection | Primary site of infection ||\n|| Vascular catheter | 27 (30) | 27 (30) | >0.99 ||\n|| Pneumonia | 29 (32) | 16 (18) | 0.03 ||\n|| Primary bacteremia | 8 (9) | 18 (20) | 0.03 ||\n|| Intra-abdominal | 12 (13) | 9 (10) | 0.49 ||\n|| Urinary tract | 3 (3) | 7 (8) | 0.33 ||\n|| Demographic data | Demographic data | Demographic data | Demographic data ||\n|| Soft tissue or wound | 7 (8) | 7 (8) | >0.99 ||\n|| Other characteristics | Other characteristics | Other characteristics | Other characteristics ||\n|| Length of hospitalization (day) b,  c  | 12 (7, 21) | 11 (7, 22) | 0.90 ||\n|| ICU stay at culture | 77 (86) | 57 (63) | 0.001 ||\n|| Mechanical ventilation | 64 (71) | 44 (49) | 0.002 ||\n|| MDR | 69 (77) | 29 (32) | <0.001 ||\n|| Carbapenem-resistance | 51 (57) | 12 (16) | <0.001 ||\n|| APACHE II score a  | 18±7 | 17±8 | 0.30 ||\n|| Outcomes | Outcomes | Outcomes | Outcomes ||\n|| 30-day mortality | 35 (39) | 14 (16) | <0.001 ||\n|| Age a  | 60±17 | 58±18 | 0.46 ||\n|| Acinetobacter-related mortality | 33 (37) | 11 (12) | <0.001 ||\n|| Male gender | 62 (69) | 53 (59) | 0.16 ||\n|| Underlying illness | Underlying illness | Underlying illness | Underlying illness ||\n|| Ischemic heart disease | 25 (28) | 16 (18) | 0.11 ||\n|| Trauma | 13 (14) | 16 (18) | 0.54 ||\n|| Diabetes mellitus | 11 (12) | 14 (16) | 0.52 ||\n|| Cancer | 8 (9) | 12 (13) | 0.34 ||",
    "claim": "The rate of mechanical ventilation is 10% higher in patients with Acinetobacter baumannii bacteremia, and the prevalence of multidrug resistance is 30% higher compared to the non-baumannii group. This highlights the increased clinical burden and treatment challenges associated with Acinetobacter baumannii infections.",
    "label": "support"
  },
  {
    "id": "training_1032_5",
    "table_caption": "Table: End-points for clinical outcomes at baseline, 4 weeks and 12 weeks after botulinum toxin treatment. Scale Subscale Time point ProsigneH (n = 57) Mean (SD) BotoxH (n = 57) Mean (SD) Between-group difference in end-point (95% CI) Effect size (95% CI) MAS Baseline 1.93 (0.5) 1.84 (0.46) 0.09 (20.06 to 0.23) 0.18 (20.19 to 0.54) 4 weeks 1.28 (0.41) 1.42 (0.48) 20.14 (20.26 to 20.01) 20.31 (20.68 to 0.06) 12 weeks 1.52 (0.39) 1.59 (0.53) 20.07 (20.21 to 0.07) 20.13 (20.49 to 0.24) FIM Baseline 103.20 (23) 102.57 (23.67) 0.63 (21.43 to 2.68) 0.03 (20.65 to 0.7) 4 weeks 102.2 (29.5) 105.5 (16.2) 23.3 (22.1 to 4.5) 20.14 (20.76 to 0.48) 12 weeks 103.92 (22.85) 103.07 (23.36) 0.85 (21.39 to 3.09) 0.04 (20.64 to 0.71) PEDI Self-care Baseline 56.86 (12.89) 58.40 (13.31) 21.54 (25.09 to 2) 20.12 (20.56 to 0.32) 4 weeks 58.9 (14.3) 62.4 (12.1) 23.5 (22.9 to 1.2) 20.26 (21.21 to 0.73) 12 weeks 61.30 (13.55) 61.38 (13.74) 20.08 (22.60 to 2.43) 20.01 (20.44 to 0.43) Mobility Baseline 49.17 (15.07) 51.75 (14.29) 22.58 (25.19 to 0.02) 20.18 (20.61 to 0.27) 4 weeks 51.8 (16.9) 52.3 (8.5) 20.5 (20.8 to 1.9) 20.04 (21.00 to 0.93) 12 weeks 53.60 (14.07) 51.61 (14.52) 1.98 (0.42 to 3.55) 0.14 (20.30 to 0.58) Social Function Baseline 57.93 (11.72) 57.14 (10.74) 0.78 (22.34 to 3.91) 0.07 (20.37 to 0.51) 4 weeks 58.1 (11.3) 61.5 (10.7) 23.4 (23.7 to 0.5) 20.31 (21.26 to 0.68) 12 weeks 61.14 (12.55) 61.93 (11.43) 20.78 (23.51 to 1.94) 20.07 (20.50 to 0.37) MAS: Modified Ashworth Scale; FIM: Functional Independence Measure; PEDI: Pediatric Evaluation of Disability Inventory; SD: Standard Deviation; CI: Confidence Interval. ",
    "table_content": "|| Scale | Subscale | Time point | Prosigne® (n = 57) Mean (SD) | Botox® (n = 57) Mean (SD) | Between-group difference in end-point (95% CI) | Effect size (95% CI) ||\n|| MAS | MAS | MAS | MAS | MAS | MAS | MAS ||\n|| blank | Self-care | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 56.86 (12.89) | 58.40 (13.31) | −1.54 (−5.09 to 2) | −0.12 (−0.56 to 0.32) ||\n|| blank | blank | 4 weeks | 58.9 (14.3) | 62.4 (12.1) | −3.5 (−2.9 to 1.2) | −0.26 (−1.21 to 0.73) ||\n|| blank | blank | 12 weeks | 61.30 (13.55) | 61.38 (13.74) | −0.08 (−2.60 to 2.43) | −0.01 (−0.44 to 0.43) ||\n|| blank | Mobility | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 49.17 (15.07) | 51.75 (14.29) | −2.58 (−5.19 to 0.02) | −0.18 (−0.61 to 0.27) ||\n|| blank | blank | 4 weeks | 51.8 (16.9) | 52.3 (8.5) | −0.5 (−0.8 to 1.9) | −0.04 (−1.00 to 0.93) ||\n|| blank | blank | 12 weeks | 53.60 (14.07) | 51.61 (14.52) | 1.98 (0.42 to 3.55) | 0.14 (−0.30 to 0.58) ||\n|| blank | Social Function | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 57.93 (11.72) | 57.14 (10.74) | 0.78 (−2.34 to 3.91) | 0.07 (−0.37 to 0.51) ||\n|| blank | blank | Baseline | 1.93 (0.5) | 1.84 (0.46) | 0.09 (−0.06 to 0.23) | 0.18 (−0.19 to 0.54) ||\n|| blank | blank | 4 weeks | 58.1 (11.3) | 61.5 (10.7) | −3.4 (−3.7 to 0.5) | −0.31 (−1.26 to 0.68) ||\n|| blank | blank | 12 weeks | 61.14 (12.55) | 61.93 (11.43) | −0.78 (−3.51 to 1.94) | −0.07 (−0.50 to 0.37) ||\n|| blank | blank | 4 weeks | 1.28 (0.41) | 1.42 (0.48) | −0.14 (−0.26 to −0.01) | −0.31 (−0.68 to 0.06) ||\n|| blank | blank | 12 weeks | 1.52 (0.39) | 1.59 (0.53) | −0.07 (−0.21 to 0.07) | −0.13 (−0.49 to 0.24) ||\n|| FIM | FIM | FIM | FIM | FIM | FIM | FIM ||\n|| blank | blank | Baseline | 103.20 (23) | 102.57 (23.67) | 0.63 (−1.43 to 2.68) | 0.03 (−0.65 to 0.7) ||\n|| blank | blank | 4 weeks | 102.2 (29.5) | 105.5 (16.2) | −3.3 (−2.1 to 4.5) | −0.14 (−0.76 to 0.48) ||\n|| blank | blank | 12 weeks | 103.92 (22.85) | 103.07 (23.36) | 0.85 (−1.39 to 3.09) | 0.04 (−0.64 to 0.71) ||\n|| PEDI | PEDI | PEDI | PEDI | PEDI | PEDI | PEDI ||",
    "claim": "The Social Function scores for both groups increase from baseline to 12 weeks, with the Botox® group showing a larger increase at 4 weeks. However, by 12 weeks, the between-group difference is minimal, suggesting similar social function improvements for both groups over time.",
    "label": "support"
  },
  {
    "id": "training_878_2",
    "table_caption": "Table: Table 6 K-fold cross validation (K = 5): Ntotal = 389,533, Pearson correlation, all test scores k Ntrain Ntest Correlation 1 311,540 77,993 0.895 2 311,463 78,070 0.891 3 311,652 77,881 0.898 4 311,565 77,968 0.901 5 311,454 78,079 0.903 ",
    "table_content": "|| k | Ntrain | Ntest | Correlation ||\n|| 1 | 311,540 | 77,993 | 0.895 ||\n|| 2 | 311,463 | 78,070 | 0.891 ||\n|| 3 | 311,652 | 77,881 | 0.898 ||\n|| 4 | 311,565 | 77,968 | 0.901 ||\n|| 5 | 311,454 | 78,079 | 0.903 ||",
    "claim": "The number of training and test instances across the folds is directly related, with a consistent total of 389,533 instances. This direct relationship is a fundamental aspect of k-fold cross-validation, ensuring that each fold uses a different subset of the data for training and testing, maintaining the overall dataset size.",
    "label": "support"
  },
  {
    "id": "training_1409_2",
    "table_caption": "Table: Reference range First phase Second phase ALB 2.5–4.4 g/dL 3.6 ± 0.1 3.6 ± 0.1 ALP 20–150 U/L 45.1 ± 6.9 45.5 ± 6.1 ALT 10–118 U/L 53.1 ± 9.4 69.1 ± 11.5 AMY 200–1200 U/L 511.1 ± 53.6 538.6 ± 58.7 TBIL 0.1–0.6 mg/dL 0.3 ± 1.0 0.3 ± 0 BUN 7–25 mg/dL 14.3 ± 1.0 15.4 ± 1.2 CA++ 8.6–11.8 mg/dL 10.6 ± 0.1 10.6 ± 0.1 PHOS 2.9–6.6 mg/dL 3.7 ± 0.2* 4.6 ± 0.1* CRE 0.3–1.4 mg/dL 1.1 ± 0.1 1.0 ± 0.1 GLU 60–110 mg/dL 104.6 ± 4.0 104.4 ± 4.5 NA+ 138–160 mmol/L 144.0 ± 0.7 145.3 ± 0.3 K+ 3.7–5.8 mmol/L 4.7 ± 0.2 4.2 ± 0.1 TP 5.4–8.2 g/dL 6.7 ± 0.1 6.7 ± 0.1 GLOB 2.3–5.2 g/dL 3.1 ± 0.1 3.3 ± 0.1 Table 2. Comprehensive blood profiles. ALB - albumin; ALP aminotransferase; AMY - amylase; TBIL - total bilirubin; BUN ",
    "table_content": "|| blank | Reference range | First phase | Second phase ||\n|| ALB | 2.5–4.4 g/dL | 3.6 ± 0.1 | 3.6 ± 0.1 ||\n|| GLU | 60–110 mg/dL | 104.6 ± 4.0 | 104.4 ± 4.5 ||\n|| NA + | 138–160 mmol/L | 144.0 ± 0.7 | 145.3 ± 0.3 ||\n|| K + | 3.7–5.8 mmol/L | 4.7 ± 0.2 | 4.2 ± 0.1 ||\n|| TP | 5.4–8.2 g/dL | 6.7 ± 0.1 | 6.7 ± 0.1 ||\n|| GLOB | 2.3–5.2 g/dL | 3.1 ± 0.1 | 3.3 ± 0.1 ||\n|| ALP | 20–150 U/L | 45.1 ± 6.9 | 45.5 ± 6.1 ||\n|| ALT | 10–118 U/L | 53.1 ± 9.4 | 69.1 ± 11.5 ||\n|| AMY | 200–1200 U/L | 511.1 ± 53.6 | 538.6 ± 58.7 ||\n|| TBIL | 0.1–0.6 mg/dL | 0.3 ± 1.0 | 0.3 ± 0 ||\n|| BUN | 7–25 mg/dL | 14.3 ± 1.0 | 15.4 ± 1.2 ||\n|| CA ++ | 8.6–11.8 mg/dL | 10.6 ± 0.1 | 10.6 ± 0.1 ||\n|| PHOS | 2.9–6.6 mg/dL | 3.7 ± 0.2* | 4.6 ± 0.1* ||\n|| CRE | 0.3–1.4 mg/dL | 1.1 ± 0.1 | 1.0 ± 0.1 ||",
    "claim": "Both ALB and CA++ levels remain constant across the two phases, as evidenced by identical mean values and standard deviations. This stability suggests a homeostatic regulation of these parameters, maintaining them within the physiological range without significant fluctuation.",
    "label": "support"
  },
  {
    "id": "training_1049_2",
    "table_caption": "Table: Table 1C Summarized Aerosol Optical Depth Dataset over Nzerekore for year 2010–2013. Month 2010 2011 2012 2013 Jan 0.323 0.551 0.399 0.192 Feb 0.300 0.400 0.796 0.588 Mar 1.018 1.188 0.641 0.261 Apr 0.318 0.325 0.437 May 0.257 Jun Jul 0.095 Aug Sep 0.348 0.225 Oct 0.164 0.272 0.441 Nov 0.473 0.275 0.253 Dec 0.630 0.508 0.307 Table 2A ",
    "table_content": "|| Month | 2010 | 2011 | 2012 | 2013 ||\n|| Jan | 0.323 | 0.551 | 0.399 | 0.192 ||\n|| Oct | 0.164 | 0.272 | 0.441 | blank ||\n|| Nov | blank | 0.473 | 0.275 | 0.253 ||\n|| Dec | 0.630 | 0.508 | 0.307 | blank ||\n|| Feb | 0.300 | 0.400 | 0.796 | 0.588 ||\n|| Mar | 1.018 | 1.188 | 0.641 | 0.261 ||\n|| Apr | 0.318 | 0.325 | 0.437 | blank ||\n|| May | blank | blank | 0.257 | blank ||\n|| Jun | Jun | Jun | Jun | Jun ||\n|| Jul | 0.095 | blank | blank | blank ||\n|| Aug | Aug | Aug | Aug | Aug ||\n|| Sep | 0.348 | 0.225 | blank | blank ||",
    "claim": "The month of March shows a significant decrease in AOD from 2011 to 2013. The AOD in March 2011 is approximately 1.188, which decreases to 0.261 in March 2013, indicating a reduction of about 0.927 over the two years.",
    "label": "support"
  },
  {
    "id": "training_161_2",
    "table_caption": "Table: recall when both are performed. We used ISUB for measuring the similarity Approach Precision Recall F1 Combined matching with ontology schema and instances 82.08 76.32 79.09 Matching with ontology schema only 84.06 50.88 63.39 Matching with instances (RDF data) only 78.38 25.44 38.41 of from Scenario Scenario Scenario Scenario Scenario ",
    "table_content": "|| Approach | Precision | Recall | F1 ||\n|| Combined matching with ontology schema and instances | 82.08 | 76.32 | 79.09 ||\n|| Matching with ontology schema only | 84.06 | 50.88 | 63.39 ||\n|| Matching with instances (RDF data) only | 78.38 | 25.44 | 38.41 ||",
    "claim": "The combined matching approach demonstrates a recall rate that is approximately 50% higher than the schema-only approach, highlighting its superior ability to identify relevant matches comprehensively.",
    "label": "support"
  },
  {
    "id": "training_276_4",
    "table_caption": "Table: MPs in to MPs (Fig. (100 MetS HS Table 1. Baseline characteristics of subjects. Control subjects MetS patients Number 17 21 Mean age (years) 5462 5662 Sex ratio (male/female) 12/5 17/4 BMI (kg/m2) 2861.3 3461.1c Waist circumference (cm) 9463.2 11362.3c Ratio Waist/Hips 0.9560.02 1.0160.01a Systolic blood pressure (mm Hg) 12162 13563c Diastolic blood pressure (mm Hg) 7462 7962a Glycemia (mmol/l) 5.3360.11 6.5560.22c Insulinemia (pmol/l) 61.669.1 163.7617.8c HbA1c (%) 5.660.06 6.1760.24a Total cholesterol (mmol/l) 660.34 5.360.25 HDL cholesterol (mmol/l) 1.9260.16 1.6360.13 LDL cholesterol (mmol/l) 3.260.26 2.6460.21 Triglycerides (mmol/l) 1.360.11 2.4260.33c Leptin (mg/l) 15.364.8 15.263.11 Adiponectin (mg/l) 8.160.8 5.360.34b Number of MetS components (%) 0 36 - 1 41 - 2 23 - 3 - 38 4 - 52 5 - 10 Treatments (%) Oral antidiabetic 0 41 Insulin 0 2 Antihypertensive 1 70 Statins 2 2 Baseline characteristics of MetS patients (n = 21) compared to control subjects (n = 17). Subjects were fasted before blood collection. All values are expressed ",
    "table_content": "|| blank | Control subjects | MetS patients ||\n||  Number  | 17 | 21 ||\n||  Insulinemia (pmol/l)  | 61.6±9.1 | 163.7±17.8 c  ||\n||  HbA1c (%)  | 5.6±0.06 | 6.17±0.24 a  ||\n||  Total cholesterol (mmol/l)  | 6±0.34 | 5.3±0.25 ||\n||  HDL cholesterol (mmol/l)  | 1.92±0.16 | 1.63±0.13 ||\n||  LDL cholesterol (mmol/l)  | 3.2±0.26 | 2.64±0.21 ||\n||  Triglycerides (mmol/l)  | 1.3±0.11 | 2.42±0.33 c  ||\n||  Leptin (µg/l)  | 15.3±4.8 | 15.2±3.11 ||\n||  Adiponectin (mg/l)  | 8.1±0.8 | 5.3±0.34 b  ||\n||  Number of MetS components (%)  |  Number of MetS components (%)  |  Number of MetS components (%)  ||\n||  0  | 36 | blank ||\n||  Mean age (years)  | 54±2 | 56±2 ||\n||  1  | 41 | blank ||\n||  2  | 23 | blank ||\n||  3  | blank | 38 ||\n||  4  | blank | 52 ||\n||  5  | blank | 10 ||\n||  Treatments (%)  |  Treatments (%)  |  Treatments (%)  ||\n||  Oral antidiabetic  | 0 | 41 ||\n||  Insulin  | 0 | 2 ||\n||  Antihypertensive  | 1 | 70 ||\n||  Statins  | 2 | 2 ||\n||  Sex ratio (male/female)  | 12/5 | 17/4 ||\n||  BMI (kg/m 2 )  | 28±1.3 | 34±1.1 c  ||\n||  Waist circumference (cm)  | 94±3.2 | 113±2.3 c  ||\n||  Ratio Waist/Hips  | 0.95±0.02 | 1.01±0.01 a  ||\n||  Systolic blood pressure (mm Hg)  | 121±2 | 135±3 c  ||\n||  Diastolic blood pressure (mm Hg)  | 74±2 | 79±2 a  ||\n||  Glycemia (mmol/l)  | 5.33±0.11 | 6.55±0.22 c  ||",
    "claim": "The triglyceride level in MetS patients is 86.15% higher than in control subjects, highlighting a significant dyslipidemia component of Metabolic Syndrome.",
    "label": "support"
  },
  {
    "id": "training_820_5",
    "table_caption": "Table: of cs cs5 Table 3. Microneutralization (MNt) assay. Abs* MNt titers** Virus 80R 2560 Wild type SARS-CoV (Urbani) 11A ,20 256 20 80R ,20 80R escape mutant Iso1-100 (D480G) 11A ,20 256 40 80R ,20 80R escape mutant Iso1-103(D480A) 11A ,20 256 40 *Whole IgG1 was used for all antibodies in this assay. **Reciprocals of the highest dilutions of Abs that showed less than 50% ",
    "table_content": "|| Abs *  | MNt titers **  | Virus ||\n|| 80R | 2560 | Wild type SARS-CoV (Urbani) ||\n|| 11A | <20 | blank ||\n||  256  |  20  | blank ||\n|| 80R | <20 | 80R escape mutant Iso1-100 (D480G) ||\n|| 11A | <20 | blank ||\n||  256  |  40  | blank ||\n|| 80R | <20 | 80R escape mutant Iso1-103(D480A) ||\n|| 11A | <20 | blank ||\n||  256  |  40  | blank ||",
    "claim": "The presence of escape mutations D480G and D480A in the virus results in a drastic reduction in the neutralization effectiveness of antibody 80R, as evidenced by the decrease in MNt titers by a factor of over 100, highlighting the challenge posed by viral mutations in antibody-mediated neutralization.",
    "label": "support"
  },
  {
    "id": "training_1435_3",
    "table_caption": "Table: sity for ple us of Table 2: Top 10 'Bioethics' Books on Amazon, by Country US Canada UK Germany France CT (course text) 5 3 3 5 2 P (professional) 1 1 1 0 0 R (religion) 1 0 0 1 1 ST (specific topic) 2 3 6 2 2 TH (theory) 1 3 0 2 5 For full data, see Additional file 2 ",
    "table_content": "|| blank | US | Canada | UK | Germany | France ||\n|| CT (course text) | 5 | 3 | 3 | 5 | 2 ||\n|| P (professional) | 1 | 1 | 1 | 0 | 0 ||\n|| R (religion) | 1 | 0 | 0 | 1 | 1 ||\n|| ST (specific topic) | 2 | 3 | 6 | 2 | 2 ||\n|| TH (theory) | 1 | 3 | 0 | 2 | 5 ||",
    "claim": "Religion books are equally distributed between the US, Germany, and France, with each having one book. This uniform distribution suggests a balanced interest in the intersection of religion and bioethics across these countries.",
    "label": "support"
  },
  {
    "id": "training_361_4",
    "table_caption": "Table: Relative risk estimates for community exposure to landfills and incinerators Health effect Distance from the source Relative Risk (Confidence Interval) Level of confidence** Landfills Congenital malformations [24] All congenital malformations Within 2 km 1.02 (99% CI = 1.01-1.03) Moderate Neural tube defects Within 2 km 1.06 (99% CI = 1.01-1.12) Moderate Hypospadias and epispadias Within 2 km 1.07 (99% CI = 1.04-1.11) Moderate Abdominal wall defects Within 2 km 1.05 (99% CI = 0.94-1.16) Moderate Gastroschisis and exomphalos* Within 2 km 1.18 (99% CI = 1.03-1.34) Moderate Low birth weight [24] Within 2 km 1.06 (99% CI = 1.052-1.062) High Very low birth weight Within 2 km 1.04 (99% CI = 1.03-1.06) High Incinerators Congenital malformations [45] Facial cleft Within 10 km 1.30 (95% CI = 1.06-1.59) Moderate Renal dysplasia Within 10 km 1.55 (95% CI = 1.10-2.20) Moderate Cancer [30] All cancer Within 3 km 1.035 (95% CI = 1.03-1.04) Moderate Stomach cancer Within 3 km 1.07 (95% CI = 1.02-1.13) Moderate Colorectal cancer Within 3 km 1.11 (95% CI = 1.07-1.15) Moderate Liver cancer Within 3 km 1.29 (95% CI = 1.10-1.51) High Lung cancer Within 3 km 1.14 (95% CI = 1.11-1.17) Moderate Soft-tissue sarcoma Within 3 km 1.16 (95% CI = 0.96-1.41) High Non-Hodgkin's lymphoma Within 3 km 1.11 (95% CI = 1.04-1.19) High *The original estimates were given for \"surgical corrections of..\". **The following scale for the level of confidence has been adopted: very high, high, moderate, low, very low. ",
    "table_content": "|| Health effect | Distance from the source | Relative Risk (Confidence Interval) | Level of confidence** ||\n|| Landfills | Landfills | Landfills | Landfills ||\n|| Incinerators | Incinerators | Incinerators | Incinerators ||\n|| Congenital malformations [ 45 ] | Congenital malformations [ 45 ] | Congenital malformations [ 45 ] | Congenital malformations [ 45 ] ||\n|| Facial cleft | Within 10 km | 1.30 (95% CI = 1.06-1.59) | Moderate ||\n|| Renal dysplasia | Within 10 km | 1.55 (95% CI = 1.10-2.20) | Moderate ||\n|| Cancer [ 30 ] | Cancer [ 30 ] | Cancer [ 30 ] | Cancer [ 30 ] ||\n|| All cancer | Within 3 km | 1.035 (95% CI = 1.03-1.04) | Moderate ||\n|| Stomach cancer | Within 3 km | 1.07 (95% CI = 1.02-1.13) | Moderate ||\n|| Colorectal cancer | Within 3 km | 1.11 (95% CI = 1.07-1.15) | Moderate ||\n|| Liver cancer | Within 3 km | 1.29 (95% CI = 1.10-1.51) | High ||\n|| Lung cancer | Within 3 km | 1.14 (95% CI = 1.11-1.17) | Moderate ||\n|| Congenital malformations [ 24 ] | Congenital malformations [ 24 ] | Congenital malformations [ 24 ] | Congenital malformations [ 24 ] ||\n|| Soft-tissue sarcoma | Within 3 km | 1.16 (95% CI = 0.96-1.41) | High ||\n|| Non-Hodgkin's lymphoma | Within 3 km | 1.11 (95% CI = 1.04-1.19) | High ||\n|| All congenital malformations | Within 2 km | 1.02 (99% CI = 1.01-1.03) | Moderate ||\n|| Neural tube defects | Within 2 km | 1.06 (99% CI = 1.01-1.12) | Moderate ||\n|| Hypospadias and epispadias | Within 2 km | 1.07 (99% CI = 1.04-1.11) | Moderate ||\n|| Abdominal wall defects | Within 2 km | 1.05 (99% CI = 0.94-1.16) | Moderate ||\n|| Gastroschisis and exomphalos* | Within 2 km | 1.18 (99% CI = 1.03-1.34) | Moderate ||\n|| Low birth weight [ 24 ] | Within 2 km | 1.06 (99% CI = 1.052-1.062) | High ||\n|| Very low birth weight | Within 2 km | 1.04 (99% CI = 1.03-1.06) | High ||",
    "claim": "The relative risk for low birth weight near landfills is 1.06, which is slightly higher than the risk for very low birth weight at 1.04. This indicates a marginally increased risk for low birth weight compared to very low birth weight in proximity to landfills.",
    "label": "support"
  },
  {
    "id": "training_1101_1",
    "table_caption": "Table: in an Table II. The prevalence of the underlying diseases leading to dialysis requirement in the studied patients. PTFE (n = 50) PVAG (n = 50) Diabetes mellitus 35 31 Renal diseases 25 26 Hypertension 28 37 Tobacco use 28 34 Obesity 17 19 Other 4 2 ",
    "table_content": "|| blank | PTFE ( n = 50) | PVAG ( n = 50) ||\n|| Diabetes mellitus | 35 | 31 ||\n|| Renal diseases | 25 | 26 ||\n|| Hypertension | 28 | 37 ||\n|| Tobacco use | 28 | 34 ||\n|| Obesity | 17 | 19 ||\n|| Other | 4 | 2 ||",
    "claim": "The prevalence of hypertension in the PVAG group exceeds that in the PTFE group by a factor of 1.32, indicating a higher association of hypertension with PVAG access.",
    "label": "support"
  },
  {
    "id": "training_29_4",
    "table_caption": "Table: Primer Sequences for RT-PCR. Gene ID Primer Name Sequence (59–39) Position cDNA (bp) hMCT1 NM_003051.3 hMCT1-F AGCGAAGTGTCATGGATATCCTCC 529–934 406 hMCT1-R CAACACAGCAGTTTAGTAGCAAGC hMCT2 NM_004731.3 hMCT2-F CCCACATGTACACAGAGTATCTGG 2075–2419 345 hMCT2 NM_004731.3 hMCT2-R AGGGTTCTATTCTCTAGCACCAGG 2075–2419 345 hMCT4 NM_001042423.1 hMCT4-F GTCAGTGTCTTCTTCAAGGAGCTC 242–540 299 hMCT4 NM_001042423.1 hMCT4-R AAGTAGCGGTTCAGCATGATGAGC 242–540 299 hAE2 U62531.1 hAE2-F CAGTTCTTTCTCCGAGAGGATGAC 631–1001 371 hAE2 U62531.1 hAE2-R TGACTCTTCATGAGGTCTAGGTCG 631–1001 371 hCA12 BC023981.1 hCA12-F TTGGCATCTGTATTGTGGTGGTGG 1071–1431 361 hCA12 BC023981.1 hCA12-R CAGCTTTGAATTCCTGCTGCTTGG 1071–1431 361 hCFTR NM_000492.3 hCFTR-F TGGTGATGACAGCCTCTTCTTCAG 1401–1737 337 hCFTR NM_000492.3 hCFTR-R CTCTGCAAACTTGGAGATGTCCTC 1401–1737 337 hsAC10 NM_018417.4 hsAC10-F TGTCTTGACCTCAATGTGAGCTGC 2426–2772 347 hsAC10 NM_018417.4 hsAC10-R GAAAGTCTCATGCTATCCAGCTGG 2426–2772 347 hGAPDH NM_002046.3 hGAPDH-F TTCCACCCATGGCAAATTCCATGG 252–554 303 hGAPDH NM_002046.3 hGAPDH-R GAGGCATTGCTGATGATCTTGAGG 252–554 303 doi:10.1371/journal.pone.0051427.t001 ",
    "table_content": "|| Gene ID | Primer Name | Sequence (5′–3′) | Position | cDNA (bp) ||\n|| hMCT1 NM_003051.3 | hMCT1-F |  AGCGAAGTGTCATGGATATCCTCC  | 529–934 | 406 ||\n|| hCA12 BC023981.1 | hCA12-R |  CAGCTTTGAATTCCTGCTGCTTGG  | 1071–1431 | 361 ||\n|| hCFTR NM_000492.3 | hCFTR-F |  TGGTGATGACAGCCTCTTCTTCAG  | 1401–1737 | 337 ||\n|| hCFTR NM_000492.3 | hCFTR-R |  CTCTGCAAACTTGGAGATGTCCTC  | 1401–1737 | 337 ||\n|| hsAC10 NM_018417.4 | hsAC10-F |  TGTCTTGACCTCAATGTGAGCTGC  | 2426–2772 | 347 ||\n|| hsAC10 NM_018417.4 | hsAC10-R |  GAAAGTCTCATGCTATCCAGCTGG  | 2426–2772 | 347 ||\n|| hGAPDH NM_002046.3 | hGAPDH-F |  TTCCACCCATGGCAAATTCCATGG  | 252–554 | 303 ||\n|| hGAPDH NM_002046.3 | hGAPDH-R |  GAGGCATTGCTGATGATCTTGAGG  | 252–554 | 303 ||\n|| hMCT1 NM_003051.3 | hMCT1-R |  CAACACAGCAGTTTAGTAGCAAGC  | blank | blank ||\n|| hMCT2 NM_004731.3 | hMCT2-F |  CCCACATGTACACAGAGTATCTGG  | 2075–2419 | 345 ||\n|| hMCT2 NM_004731.3 | hMCT2-R |  AGGGTTCTATTCTCTAGCACCAGG  | 2075–2419 | 345 ||\n|| hMCT4 NM_001042423.1 | hMCT4-F |  GTCAGTGTCTTCTTCAAGGAGCTC  | 242–540 | 299 ||\n|| hMCT4 NM_001042423.1 | hMCT4-R |  AAGTAGCGGTTCAGCATGATGAGC  | 242–540 | 299 ||\n|| hAE2 U62531.1 | hAE2-F |  CAGTTCTTTCTCCGAGAGGATGAC  | 631–1001 | 371 ||\n|| hAE2 U62531.1 | hAE2-R |  TGACTCTTCATGAGGTCTAGGTCG  | 631–1001 | 371 ||\n|| hCA12 BC023981.1 | hCA12-F |  TTGGCATCTGTATTGTGGTGGTGG  | 1071–1431 | 361 ||",
    "claim": "The range of cDNA lengths spans from 299 to 406 base pairs, indicating a difference of 107 base pairs between the shortest and longest cDNA segments amplified by the primers.",
    "label": "support"
  },
  {
    "id": "training_573_1",
    "table_caption": "Table: The unigenes related to secondary metabolites in 101L and 101R. Secondary metabolites biosynthesis pathways Unigenes in 101L Unigenes in 101R Total Unigenes Anthocyanin biosynthesis [PATH: 00942] 5 3 5 Brassinosteroid biosynthesis [PATH: 00905] 15 17 25 Caffeine metabolism [PATH: 00232] 15 14 18 Carotenoid biosynthesis [PATH: 00906] 80 80 117 Cutin, suberin and wax biosynthesis [PATH: 00073] 10 18 26 Diterpenoid biosynthesis [PATH: 00904] 25 24 33 Flavone and flavonol biosynthesis [PATH: 00944] 43 19 45 Flavonoid biosynthesis [PATH: 00941] 48 64 76 Indole alkaloid biosynthesis [PATH: 00901] 8 5 11 Isoquinoline alkaloid biosynthesis [PATH: 00950] 42 39 58 Limonine and pinene degradation [PATH: 00903] 92 75 120 Monoterpenoid biosynthesis [PATH: 00902] 9 9 11 Nicotinate and nicotinamide metabolism [PATH: 00760] 36 37 48 Phenylpropanoid metabolism [PATH: 00940] 192 206 292 Sesquiterpenoid and triterpenoid biosynthesis [PATH: 00909] 50 36 69 Steroid biosynthesis [PATH: 000100] 54 50 67 Stibenoid diarylhepatanoid and gingerol biosynthesis [PATH: 00945] 82 79 112 Terpenoid backbone biosynthesis [PATH: 00900] 124 112 170 Tropane, piperidine and pyridine alkaloid biosynthesis [PATH: 00960] 39 55 62 Ubiquinone and other terpenoid-quinone biosynthesis [PATH: 00130] 73 70 101 Zeatin biosynthesis [PATH: 00908] 26 22 34 Total 1068 1034 1500 doi:10.1371/journal.pone.0062714.t003 ",
    "table_content": "|| Secondary metabolites biosynthesis pathways | Unigenes in 101L | Unigenes in 101R | Total Unigenes ||\n|| Anthocyanin biosynthesis [PATH: 00942] | 5 | 3 | 5 ||\n|| Isoquinoline alkaloid biosynthesis [PATH: 00950] | 42 | 39 | 58 ||\n|| Limonine and pinene degradation [PATH: 00903] | 92 | 75 | 120 ||\n|| Monoterpenoid biosynthesis [PATH: 00902] | 9 | 9 | 11 ||\n|| Nicotinate and nicotinamide metabolism [PATH: 00760] | 36 | 37 | 48 ||\n|| Phenylpropanoid metabolism [PATH: 00940] | 192 | 206 | 292 ||\n|| Sesquiterpenoid and triterpenoid biosynthesis [PATH: 00909] | 50 | 36 | 69 ||\n|| Steroid biosynthesis [PATH: 000100] | 54 | 50 | 67 ||\n|| Stibenoid diarylhepatanoid and gingerol biosynthesis [PATH: 00945] | 82 | 79 | 112 ||\n|| Terpenoid backbone biosynthesis [PATH: 00900] | 124 | 112 | 170 ||\n|| Tropane, piperidine and pyridine alkaloid biosynthesis [PATH: 00960] | 39 | 55 | 62 ||\n|| Brassinosteroid biosynthesis [PATH: 00905] | 15 | 17 | 25 ||\n|| Ubiquinone and other terpenoid-quinone biosynthesis [PATH: 00130] | 73 | 70 | 101 ||\n|| Zeatin biosynthesis [PATH: 00908] | 26 | 22 | 34 ||\n||  Total  |  1068  |  1034  |  1500  ||\n|| Caffeine metabolism [PATH: 00232] | 15 | 14 | 18 ||\n|| Carotenoid biosynthesis [PATH: 00906] | 80 | 80 | 117 ||\n|| Cutin, suberin and wax biosynthesis [PATH: 00073] | 10 | 18 | 26 ||\n|| Diterpenoid biosynthesis [PATH: 00904] | 25 | 24 | 33 ||\n|| Flavone and flavonol biosynthesis [PATH: 00944] | 43 | 19 | 45 ||\n|| Flavonoid biosynthesis [PATH: 00941] | 48 | 64 | 76 ||\n|| Indole alkaloid biosynthesis [PATH: 00901] | 8 | 5 | 11 ||",
    "claim": "The phenylpropanoid metabolism pathway accounts for the highest proportion of total unigenes, contributing approximately 19.5% to the total unigene count across both samples.",
    "label": "support"
  },
  {
    "id": "training_195_5",
    "table_caption": "Table: low Ct (high miRNA) High Ct (low miRNA) Specificity Threshold Sensitivity AUC miR-22-3p SC sc0 0.80 32 0.80 0.81 miR-204-5p SC sc0 0.80 31 0.80 0.91 miR-99b-5p SC sc0 0.73 33 0.73 0.82 miR-30d-5p SC sc0 0.72 33 0.72 0.89 miR-425-3p SC sc0 0.7 33 0.7 0.79 miR-328 sc0 SC 0.74 23 0.74 0.79 miR-608 sc0 SC 0.78 28 0.78 0.80 miR-99b-5p START gwi0 0.76 33 0.76 0.84 miR-425-3p START gwi0 0.72 33 0.72 0.84 miR-370 START gwi0 0.72 31 0.72 0.84 miR-328 gwi0 START 0.91 25 0.91 0.98 let-7i-5p gwi0 START 0.78 33 0.78 0.80 miR-200a-5p gwi0 START 0.83 33 0.83 0.88 miR-608 gwi0 START 0.82 30 0.82 0.88 miR-93-3p gwi0 START 0.77 34 0.77 0.84 miR-204-5p STOPP gwi0 0.62 31 0.62 0.72 miR-99b-5p STOPP gwi0 0.75 33 0.75 0.84 miR-328 gwi0 STOPP 0.86 23 0.86 0.87 let-7i-5p gwi0 STOPP 0.72 32 0.72 0.78 miR-200a-5p gwi0 STOPP 0.71 31 0.71 0.73 miR-608 gwi0 STOPP 0.79 28 0.79 0.77 miR-93-3p gwi0 STOPP 0.75 32 0.75 0.76 miR-328 cfs0 CFS 0.84 24 0.84 0.90 miR-608 cfs0 CFS 0.76 29 0.76 0.84 let-7i-5p cfs0 CFS 0.68 31 0.68 0.74 miR-200a-5p cfs0 CFS 0.72 32 0.72 0.82 miR-93-3p cfs0 CFS 0.77 33 0.77 0.83 miR-126-5p cfs0 CFS 0.74 32 0.75 0.88 miR-19b-3p cfs0 CFS 0.63 34 0.63 0.79 miR-505-3p cfs0 CFS 0.65 34 0.65 0.82 miR-92a-3p cfs0 CFS 0.81 29 0.81 0.86 miR-186-3p cfs0 CFS 0.67 35 0.67 0.79 miR-323b-5p cfs0 CFS 0.75 32 0.75 0.84 miR-532-5p cfs0 CFS 0.70 34 0.70 0.73 Table 2. Receiver operating characteristics. ",
    "table_content": "|| blank | low Ct (high miRNA) | High Ct (low miRNA) | Specificity | Threshold | Sensitivity | AUC ||\n|| miR-22-3p | SC | sc0 | 0.80 | 32 | 0.80 | 0.81 ||\n|| miR-370 | START | gwi0 | 0.72 | 31 | 0.72 | 0.84 ||\n|| miR-328 | gwi0 | START | 0.91 | 25 | 0.91 | 0.98 ||\n|| let-7i-5p | gwi0 | START | 0.78 | 33 | 0.78 | 0.80 ||\n|| miR-200a-5p | gwi0 | START | 0.83 | 33 | 0.83 | 0.88 ||\n|| miR-608 | gwi0 | START | 0.82 | 30 | 0.82 | 0.88 ||\n|| miR-93-3p | gwi0 | START | 0.77 | 34 | 0.77 | 0.84 ||\n|| miR-204-5p | STOPP | gwi0 | 0.62 | 31 | 0.62 | 0.72 ||\n|| miR-99b-5p | STOPP | gwi0 | 0.75 | 33 | 0.75 | 0.84 ||\n|| miR-328 | gwi0 | STOPP | 0.86 | 23 | 0.86 | 0.87 ||\n|| let-7i-5p | gwi0 | STOPP | 0.72 | 32 | 0.72 | 0.78 ||\n|| miR-204-5p | SC | sc0 | 0.80 | 31 | 0.80 | 0.91 ||\n|| miR-200a-5p | gwi0 | STOPP | 0.71 | 31 | 0.71 | 0.73 ||\n|| miR-608 | gwi0 | STOPP | 0.79 | 28 | 0.79 | 0.77 ||\n|| miR-93-3p | gwi0 | STOPP | 0.75 | 32 | 0.75 | 0.76 ||\n|| miR-328 | cfs0 | CFS | 0.84 | 24 | 0.84 | 0.90 ||\n|| miR-608 | cfs0 | CFS | 0.76 | 29 | 0.76 | 0.84 ||\n|| let-7i-5p | cfs0 | CFS | 0.68 | 31 | 0.68 | 0.74 ||\n|| miR-200a-5p | cfs0 | CFS | 0.72 | 32 | 0.72 | 0.82 ||\n|| miR-93-3p | cfs0 | CFS | 0.77 | 33 | 0.77 | 0.83 ||\n|| miR-126-5p | cfs0 | CFS | 0.74 | 32 | 0.75 | 0.88 ||\n|| miR-19b-3p | cfs0 | CFS | 0.63 | 34 | 0.63 | 0.79 ||\n|| miR-99b-5p | SC | sc0 | 0.73 | 33 | 0.73 | 0.82 ||\n|| miR-505-3p | cfs0 | CFS | 0.65 | 34 | 0.65 | 0.82 ||\n|| miR-92a-3p | cfs0 | CFS | 0.81 | 29 | 0.81 | 0.86 ||\n|| miR-186-3p | cfs0 | CFS | 0.67 | 35 | 0.67 | 0.79 ||\n|| miR-323b-5p | cfs0 | CFS | 0.75 | 32 | 0.75 | 0.84 ||\n|| miR-532-5p | cfs0 | CFS | 0.70 | 34 | 0.70 | 0.73 ||\n|| miR-30d-5p | SC | sc0 | 0.72 | 33 | 0.72 | 0.89 ||\n|| miR-425-3p | SC | sc0 | 0.7 | 33 | 0.7 | 0.79 ||\n|| miR-328 | sc0 | SC | 0.74 | 23 | 0.74 | 0.79 ||\n|| miR-608 | sc0 | SC | 0.78 | 28 | 0.78 | 0.80 ||\n|| miR-99b-5p | START | gwi0 | 0.76 | 33 | 0.76 | 0.84 ||\n|| miR-425-3p | START | gwi0 | 0.72 | 33 | 0.72 | 0.84 ||",
    "claim": "The miRNA miR-93-3p maintains a consistent specificity of 0.77 across both the START and CFS conditions, with a negligible AUC variation of 0.02. This consistency suggests that miR-93-3p's performance is stable across different experimental conditions, making it a reliable biomarker.",
    "label": "support"
  },
  {
    "id": "training_518_5",
    "table_caption": "Table: success same R2 evaluation, and change success for early stages (n = 89) and advanced stages of change (n = 88). Early stages of change Advances stages of change Product evaluation Change success Product evaluation Change success BITTER FACTORS Demand −0.04 0.40** 0.29** 0.44** Confrontation with deficits −0.06 0.23* 0.17 0.34** SWEET FACTORS Autonomy 0.31* 0.28** 0.16 0.20 Encouraging feedback 0.29** 0.51** 0.24* 0.42** *p < 0.05, **p < 0.01. ",
    "table_content": "|| blank | Early stages of change | Early stages of change | Advances stages of change | Advances stages of change ||\n|| blank | Product evaluation | Change success | Product evaluation | Change success ||\n|| BITTER FACTORS | BITTER FACTORS | BITTER FACTORS | BITTER FACTORS | BITTER FACTORS ||\n|| Demand | −0.04 | 0.40 ** | 0.29 ** | 0.44 ** ||\n|| Confrontation with deficits | −0.06 | 0.23 * | 0.17 | 0.34 ** ||\n|| SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS ||\n|| Autonomy | 0.31 * | 0.28 ** | 0.16 | 0.20 ||\n|| Encouraging feedback | 0.29 ** | 0.51 ** | 0.24 * | 0.42 ** ||",
    "claim": "While \"Demand\" shows a negative correlation with product evaluation in early stages, it continues to show a negative correlation in advanced stages, reflecting a consistent perception as change progresses.",
    "label": "refute"
  },
  {
    "id": "training_805_3",
    "table_caption": "Table: (from NHANES 2003–2006) a. Food/Food Group b Cholesterol (mean = 267 mg) Ranking % Total Cumulative % Eggs 1 24.2 24.2 Poultry 2 13.2 37.4 Beef 3 11.5 48.9 Milk 4 9.7 58.6 Cheese 5 9.6 68.2 Frankfurters, sausages, luncheon meats 6 6.6 74.8 Milk desserts 7 4.1 78.9 Pork, ham, bacon 8 3.8 82.7 Cake, cookies, quick bread, pastry, pie 9 3.4 86.1 Mixtures, mostly grain 10 2.6 88.7 Fish and shellfish 11 2.1 90.8 a Data are for children aged 2 to 18 years (n = 7332), Day 1 intakes; b Food groups (n = 4) contributing at least 1% in descending order: biscuits, corn bread, pancakes, tortillas; milk drinks; margarine and butter; ",
    "table_content": "|| Food/Food Group b | Cholesterol (mean = 267 mg) | Cholesterol (mean = 267 mg) | Cholesterol (mean = 267 mg) ||\n|| Food/Food Group b | Ranking | % Total | Cumulative % ||\n|| Cake, cookies, quick bread, pastry, pie | 9 | 3.4 | 86.1 ||\n|| Mixtures, mostly grain | 10 | 2.6 | 88.7 ||\n|| Fish and shellfish | 11 | 2.1 | 90.8 ||\n|| Eggs | 1 | 24.2 | 24.2 ||\n|| Poultry | 2 | 13.2 | 37.4 ||\n|| Beef | 3 | 11.5 | 48.9 ||\n|| Milk | 4 | 9.7 | 58.6 ||\n|| Cheese | 5 | 9.6 | 68.2 ||\n|| Frankfurters, sausages, luncheon meats | 6 | 6.6 | 74.8 ||\n|| Milk desserts | 7 | 4.1 | 78.9 ||\n|| Pork, ham, bacon | 8 | 3.8 | 82.7 ||",
    "claim": "Milk and cheese, both dairy products, contribute nearly equally to cholesterol intake, with a combined contribution of 19.3%. This indicates that dairy products are a substantial source of cholesterol, with cheese slightly surpassing milk in its contribution.",
    "label": "refute"
  },
  {
    "id": "training_148_2",
    "table_caption": "Table: Operation time and postoperative stay. Parameters Value Group A Group B p Operation Time (min) Mean 101.17 84.66 0.161 Min 40.00 40.00 Max 270.00 180.00 SEM 9.58 6.54 SD 52.45 35.25 Postoperative Hospital stay (days) Mean 7.20 5.83 0.064 Min 4.00 3.00 Max 21.00 10.00 SEM 0.66 0.31 SD 3.61 1.65 operation-time and postoperative stay were lower in the aprotinin-group reaching statistical significance. ",
    "table_content": "|| Parameters | Value | Group A | Group B | p ||\n|| Operation Time (min) | Mean | 101.17 | 84.66 | 0.161 ||\n|| Postoperative Hospital stay (days) | SD | 3.61 | 1.65 | blank ||\n|| Operation Time (min) | Min | 40.00 | 40.00 | blank ||\n|| Operation Time (min) | Max | 270.00 | 180.00 | blank ||\n|| Operation Time (min) | SEM | 9.58 | 6.54 | blank ||\n|| Operation Time (min) | SD | 52.45 | 35.25 | blank ||\n|| Postoperative Hospital stay (days) | Mean | 7.20 | 5.83 | 0.064 ||\n|| Postoperative Hospital stay (days) | Min | 4.00 | 3.00 | blank ||\n|| Postoperative Hospital stay (days) | Max | 21.00 | 10.00 | blank ||\n|| Postoperative Hospital stay (days) | SEM | 0.66 | 0.31 | blank ||",
    "claim": "The standard deviation of operation times in Group A is less than that of Group B, suggesting greater variability in operation durations for Group A.",
    "label": "refute"
  },
  {
    "id": "training_163_2",
    "table_caption": "Table: and event by and group This strategy Table 1 Demographic data of the participants Rem (n = 30) Rem + Flu (n = 30) P value Age 42.2 ± 11.3 40.7 ± 8.3 0.552 Gender 22/8 19/11 0.405 Height 169.2 ± 7.1 166.3 ± 8.2 0.154 Weight 57.8 ± 8.4 58.3 ± 10.6 0.844 BMI 20.2 ± 2.5 20.9 ± 2.4 0.242 Procedure Duration 55.5 ± 8.1 43.2 ± 6.2 0.217 BMI body mass index ",
    "table_content": "|| blank | Rem ( n = 30) | Rem + Flu ( n = 30) | P value ||\n|| Age | 42.2 ± 11.3 | 40.7 ± 8.3 | 0.552 ||\n|| Gender | 22/8 | 19/11 | 0.405 ||\n|| Height | 169.2 ± 7.1 | 166.3 ± 8.2 | 0.154 ||\n|| Weight | 57.8 ± 8.4 | 58.3 ± 10.6 | 0.844 ||\n|| BMI | 20.2 ± 2.5 | 20.9 ± 2.4 | 0.242 ||\n|| Procedure Duration | 55.5 ± 8.1 | 43.2 ± 6.2 | 0.217 ||",
    "claim": "The gender distribution shows a higher male-to-female ratio in the Rem + Flu group compared to the Rem group. This difference in gender distribution could potentially affect the generalizability of the study results to a broader population.",
    "label": "refute"
  },
  {
    "id": "training_561_6",
    "table_caption": "Table: Occurrence of patterns in the eukaryotic proteomes. Pattern Number of groups, identity inside group .20% Fraction of disordered residues in the patterns from the DRDB Probability of occurrence of the patterns in protein Occurrence in the human proteome/in the DRDB Occurrence in the fruit fly proteome/in the DRDB Occurrence in the nematode worm proteome/ in the DRDB PPPPPP 15 0.70 0.00017 703/32 304/32 247/32 QQQQQQ 11 0.66 0.00004 331/17 869/17 249/17 EEEDEE 55 0.65 0.00015 242/55 42/55 54/55 QPPPPP 9 0.74 0.00013 163/16 66/16 32/16 APAPAP 17 0.51 0.00067 121/30 44/30 34/30 HHHHHH 1227 0.93 0.00002 99/5423 133/5423 57/5423 EDEDEE 23 0.64 0.00014 97/29 27/29 42/29 DEEEED 12 0.68 0.00014 83/16 26/16 39/16 GGGGGSG 17 0.65 0.00028 78/29 80/29 8/29 GSSGSS 66 0.68 0.00120 67/93 35/93 19/93 PPPPPK 18 0.81 0.00027 62/31 24/31 32/31 DDEDED 14 0.64 0.00013 53/16 31/16 26/16 SGGGGSG 10 0.82 0.00022 31/29 19/29 2/29 KKKGKK 26 0.55 0.00181 27/56 8/56 13/56 EEEEAP 12 0.66 0.00028 26/21 6/21 9/21 KKRKRK 12 0.54 0.00067 25/19 6/19 7/19 SGGGSGG 12 0.68 0.00024 20/17 17/17 5/17 SHHHHH 558 0.98 0.00005 19/1566 27/1566 12/1566 GGSGSGG 17 0.77 0.00027 14/50 23/50 6/50 NHHHHH 19 0.83 0.00003 10/25 14/25 8/25 doi:10.1371/journal.pcbi.1000958.t003 ",
    "table_content": "|| Pattern | Number of groups, identity inside group >20% | Fraction of disordered residues in the patterns from the DRDB | Probability of occurrence of the patterns in protein | Occurrence in the human proteome/in the DRDB | Occurrence in the fruit fly proteome/in the DRDB | Occurrence in the nematode worm proteome/in the DRDB ||\n|| PPPPPP | 15 | 0.70 | 0.00017 | 703/32 | 304/32 | 247/32 ||\n|| GSSGSS | 66 | 0.68 | 0.00120 | 67/93 | 35/93 | 19/93 ||\n|| PPPPPK | 18 | 0.81 | 0.00027 | 62/31 | 24/31 | 32/31 ||\n|| DDEDED | 14 | 0.64 | 0.00013 | 53/16 | 31/16 | 26/16 ||\n|| SGGGGSG | 10 | 0.82 | 0.00022 | 31/29 | 19/29 | 2/29 ||\n|| KKKGKK | 26 | 0.55 | 0.00181 | 27/56 | 8/56 | 13/56 ||\n|| EEEEAP | 12 | 0.66 | 0.00028 | 26/21 | 6/21 | 9/21 ||\n|| KKRKRK | 12 | 0.54 | 0.00067 | 25/19 | 6/19 | 7/19 ||\n|| SGGGSGG | 12 | 0.68 | 0.00024 | 20/17 | 17/17 | 5/17 ||\n|| SHHHHH | 558 | 0.98 | 0.00005 | 19/1566 | 27/1566 | 12/1566 ||\n|| GGSGSGG | 17 | 0.77 | 0.00027 | 14/50 | 23/50 | 6/50 ||\n|| QQQQQQ | 11 | 0.66 | 0.00004 | 331/17 | 869/17 | 249/17 ||\n|| NHHHHH | 19 | 0.83 | 0.00003 | 10/25 | 14/25 | 8/25 ||\n|| EEEDEE | 55 | 0.65 | 0.00015 | 242/55 | 42/55 | 54/55 ||\n|| QPPPPP | 9 | 0.74 | 0.00013 | 163/16 | 66/16 | 32/16 ||\n|| APAPAP | 17 | 0.51 | 0.00067 | 121/30 | 44/30 | 34/30 ||\n|| HHHHHH | 1227 | 0.93 | 0.00002 | 99/5423 | 133/5423 | 57/5423 ||\n|| EDEDEE | 23 | 0.64 | 0.00014 | 97/29 | 27/29 | 42/29 ||\n|| DEEEED | 12 | 0.68 | 0.00014 | 83/16 | 26/16 | 39/16 ||\n|| GGGGGSG | 17 | 0.65 | 0.00028 | 78/29 | 80/29 | 8/29 ||",
    "claim": "The pattern \"HHHHHH\" has the largest number of groups with identity greater than 20%, which is 13.33 times more than the pattern \"QPPPPP\", suggesting a broader diversity or conservation of \"HHHHHH\" across different groups.",
    "label": "refute"
  },
  {
    "id": "training_349_2",
    "table_caption": "Table: Positive conditional selection pressure in HIV-1 protease Codon Y Codon X NXaYa NXaYs (Ka/Ks)Y|Xa NXoYa NXoYs (Ka/Ks)Y|Xo (Ka/Ks)Y|X LOD p 90 73 1879 6 367.63 6842 628 12.79 28.74 >300 <0.001 82 24 564 0 277.79 3625 680 2.63 105.8 98.09 <0.001 90 95 161 1 189 7757 595 15.3 12.35 52.35 <0.001 82 48 483 2 118.95 3727 663 2.77 42.96 79.90 <0.001 82 53 366 2 90.13 4005 694 2.84 31.71 59.79 <0.001 82 55 332 2 81.76 3994 701 2.81 29.14 53.96 <0.001 30 88 1730 9 71.1 727 677 0.4 179 217.97 <0.001 63 50 132 1 65.01 22576 2037 5.46 11.91 21.31 <0.001 90 89 329 6 64.37 7677 524 17.2 3.74 100.28 <0.001 71 11 126 0 62.06 8775 964 4.48 13.84 21.91 <0.001 90 92 315 6 61.63 7706 575 15.73 3.92 95.67 <0.001 63 73 1711 14 60.2 20832 2016 5.09 11.83 269.97 <0.001 33 83 49 1 57.52 2436 803 3.56 16.15 15.09 <0.001 90 84 2039 45 53.19 6756 596 13.31 4 >300 <0.001 90 85 395 9 51.52 8361 627 15.65 3.29 117.75 <0.001 Due to the long list of positive conditional selection pressure detected in the Specialty dataset, only the 15 positive selections with the strongest increase in (Ka/Ks)Y|Xa value after conditioning were showed here. Please see the Additional File for the complete list. ",
    "table_content": "|| Codon Y | Codon X | N XaYa | N XaYs | ( K a / K s ) Y|Xa | N XoYa | N XoYs | ( K a / K s ) Y|Xo | ( K a / K s ) Y|X | LOD | p ||\n|| 90 | 73 | 1879 | 6 | 367.63 | 6842 | 628 | 12.79 | 28.74 | >300 | <0.001 ||\n|| 71 | 11 | 126 | 0 | 62.06 | 8775 | 964 | 4.48 | 13.84 | 21.91 | <0.001 ||\n|| 90 | 92 | 315 | 6 | 61.63 | 7706 | 575 | 15.73 | 3.92 | 95.67 | <0.001 ||\n|| 63 | 73 | 1711 | 14 | 60.2 | 20832 | 2016 | 5.09 | 11.83 | 269.97 | <0.001 ||\n|| 33 | 83 | 49 | 1 | 57.52 | 2436 | 803 | 3.56 | 16.15 | 15.09 | <0.001 ||\n|| 90 | 84 | 2039 | 45 | 53.19 | 6756 | 596 | 13.31 | 4 | >300 | <0.001 ||\n|| 90 | 85 | 395 | 9 | 51.52 | 8361 | 627 | 15.65 | 3.29 | 117.75 | <0.001 ||\n|| 82 | 24 | 564 | 0 | 277.79 | 3625 | 680 | 2.63 | 105.8 | 98.09 | <0.001 ||\n|| 90 | 95 | 161 | 1 | 189 | 7757 | 595 | 15.3 | 12.35 | 52.35 | <0.001 ||\n|| 82 | 48 | 483 | 2 | 118.95 | 3727 | 663 | 2.77 | 42.96 | 79.90 | <0.001 ||\n|| 82 | 53 | 366 | 2 | 90.13 | 4005 | 694 | 2.84 | 31.71 | 59.79 | <0.001 ||\n|| 82 | 55 | 332 | 2 | 81.76 | 3994 | 701 | 2.81 | 29.14 | 53.96 | <0.001 ||\n|| 30 | 88 | 1730 | 9 | 71.1 | 727 | 677 | 0.4 | 179 | 217.97 | <0.001 ||\n|| 63 | 50 | 132 | 1 | 65.01 | 22576 | 2037 | 5.46 | 11.91 | 21.31 | <0.001 ||\n|| 90 | 89 | 329 | 6 | 64.37 | 7677 | 524 | 17.2 | 3.74 | 100.28 | <0.001 ||",
    "claim": "The ratio (Ka/Ks)Y|Xa is consistently higher than (Ka/Ks)Y|Xo across all codon pairs, with the most extreme case showing a difference of over 365. This suggests that the presence of codon X significantly enhances the selection pressure on codon Y, indicating a strong conditional dependency in the evolutionary dynamics of these codons.",
    "label": "refute"
  },
  {
    "id": "training_349_2",
    "table_caption": "Table: Positive conditional selection pressure in HIV-1 protease Codon Y Codon X NXaYa NXaYs (Ka/Ks)Y|Xa NXoYa NXoYs (Ka/Ks)Y|Xo (Ka/Ks)Y|X LOD p 90 73 1879 6 367.63 6842 628 12.79 28.74 >300 <0.001 82 24 564 0 277.79 3625 680 2.63 105.8 98.09 <0.001 90 95 161 1 189 7757 595 15.3 12.35 52.35 <0.001 82 48 483 2 118.95 3727 663 2.77 42.96 79.90 <0.001 82 53 366 2 90.13 4005 694 2.84 31.71 59.79 <0.001 82 55 332 2 81.76 3994 701 2.81 29.14 53.96 <0.001 30 88 1730 9 71.1 727 677 0.4 179 217.97 <0.001 63 50 132 1 65.01 22576 2037 5.46 11.91 21.31 <0.001 90 89 329 6 64.37 7677 524 17.2 3.74 100.28 <0.001 71 11 126 0 62.06 8775 964 4.48 13.84 21.91 <0.001 90 92 315 6 61.63 7706 575 15.73 3.92 95.67 <0.001 63 73 1711 14 60.2 20832 2016 5.09 11.83 269.97 <0.001 33 83 49 1 57.52 2436 803 3.56 16.15 15.09 <0.001 90 84 2039 45 53.19 6756 596 13.31 4 >300 <0.001 90 85 395 9 51.52 8361 627 15.65 3.29 117.75 <0.001 Due to the long list of positive conditional selection pressure detected in the Specialty dataset, only the 15 positive selections with the strongest increase in (Ka/Ks)Y|Xa value after conditioning were showed here. Please see the Additional File for the complete list. ",
    "table_content": "|| Codon Y | Codon X | N XaYa | N XaYs | ( K a / K s ) Y|Xa | N XoYa | N XoYs | ( K a / K s ) Y|Xo | ( K a / K s ) Y|X | LOD | p ||\n|| 90 | 73 | 1879 | 6 | 367.63 | 6842 | 628 | 12.79 | 28.74 | >300 | <0.001 ||\n|| 71 | 11 | 126 | 0 | 62.06 | 8775 | 964 | 4.48 | 13.84 | 21.91 | <0.001 ||\n|| 90 | 92 | 315 | 6 | 61.63 | 7706 | 575 | 15.73 | 3.92 | 95.67 | <0.001 ||\n|| 63 | 73 | 1711 | 14 | 60.2 | 20832 | 2016 | 5.09 | 11.83 | 269.97 | <0.001 ||\n|| 33 | 83 | 49 | 1 | 57.52 | 2436 | 803 | 3.56 | 16.15 | 15.09 | <0.001 ||\n|| 90 | 84 | 2039 | 45 | 53.19 | 6756 | 596 | 13.31 | 4 | >300 | <0.001 ||\n|| 90 | 85 | 395 | 9 | 51.52 | 8361 | 627 | 15.65 | 3.29 | 117.75 | <0.001 ||\n|| 82 | 24 | 564 | 0 | 277.79 | 3625 | 680 | 2.63 | 105.8 | 98.09 | <0.001 ||\n|| 90 | 95 | 161 | 1 | 189 | 7757 | 595 | 15.3 | 12.35 | 52.35 | <0.001 ||\n|| 82 | 48 | 483 | 2 | 118.95 | 3727 | 663 | 2.77 | 42.96 | 79.90 | <0.001 ||\n|| 82 | 53 | 366 | 2 | 90.13 | 4005 | 694 | 2.84 | 31.71 | 59.79 | <0.001 ||\n|| 82 | 55 | 332 | 2 | 81.76 | 3994 | 701 | 2.81 | 29.14 | 53.96 | <0.001 ||\n|| 30 | 88 | 1730 | 9 | 71.1 | 727 | 677 | 0.4 | 179 | 217.97 | <0.001 ||\n|| 63 | 50 | 132 | 1 | 65.01 | 22576 | 2037 | 5.46 | 11.91 | 21.31 | <0.001 ||\n|| 90 | 89 | 329 | 6 | 64.37 | 7677 | 524 | 17.2 | 3.74 | 100.28 | <0.001 ||",
    "claim": "The ratio (Ka/Ks)Y|Xa is consistently lower than (Ka/Ks)Y|Xo across all codon pairs, with the most extreme case showing a difference of over 365. This suggests that the presence of codon X significantly reduces the selection pressure on codon Y, indicating a weak conditional dependency in the evolutionary dynamics of these codons.",
    "label": "refute"
  },
  {
    "id": "training_994_1",
    "table_caption": "Table: (%) (%) Table 4 Stability of h-sAPPα in CSF stored at different conditions Effect of storage temperature Samples −80°C −20°C +4°C RT F/T 1 100 ± 6 101 ± 5 100 ± 11 93 ± 1 103 ± 2 2 100 ± 7 93 ± 9 95 ± 15 85 ± 14 93 ± 6 3 100 ± 1 77 ± 1 82 ± 4 80 ± 4 76 ± 4 4 100 ± 5 113 ± 2 80 ± 4 109 ± 3 99 ± 5 5 100 ± 3 86 ± 5 81 ± 4 70 ± 5 83 ± 1 Five CSF samples were divided in five aliquots and stored for 24 hours at one of several different temperatures including room temperature (RT), or stored at −80°C and exposed to three freeze/thaw cycles (F/T) within a period of three ",
    "table_content": "|| Effect of storage temperature | Effect of storage temperature | Effect of storage temperature | Effect of storage temperature | Effect of storage temperature | Effect of storage temperature ||\n|| Samples | −80°C | −20°C | +4°C | RT | F/T ||\n|| 1 | 100 ± 6 | 101 ± 5 | 100 ± 11 | 93 ± 1 | 103 ± 2 ||\n|| 2 | 100 ± 7 | 93 ± 9 | 95 ± 15 | 85 ± 14 | 93 ± 6 ||\n|| 3 | 100 ± 1 | 77 ± 1 | 82 ± 4 | 80 ± 4 | 76 ± 4 ||\n|| 4 | 100 ± 5 | 113 ± 2 | 80 ± 4 | 109 ± 3 | 99 ± 5 ||\n|| 5 | 100 ± 3 | 86 ± 5 | 81 ± 4 | 70 ± 5 | 83 ± 1 ||",
    "claim": "The stability of h-sAPPα in CSF samples stored at −20°C remains consistently at 100% across all samples, indicating no degradation. This suggests that −20°C is an optimal storage condition for maintaining h-sAPPα stability over 24 hours.",
    "label": "refute"
  },
  {
    "id": "training_95_2",
    "table_caption": "Table: Table 3 Pearson’s correlation coefficients of pulse wave velocity (PWV) with demographic, spirometric and right ventricular measures PWV Rho (95 % CI) p-value Age 0.04 (-0.24–0.28) 0.75 BMI (kg/m2) -0.28 (-0.49–0.02) 0.03 Heart rate (bpm) 0.20 (-0.11–0.46) 0.14 Systolic BP (mm Hg) 0.14 (-0.18–0.45) 0.29 Diastolic BP (mm Hg) 0.35 (0.06–0.60) 0.009 SpO2 -0.06 (-0.40–0.27) 0.65 Pack years 0.01 (-0.24–0.26) 0.94 FEV1, % predicted -0.16 (-0.37–0.09) 0.24 FVC, % predicted -0.07 (-0.28–0.14) 0.61 FEV1/FVC -0.18 (-0.42–0.10) 0.18 FEF 25–75, % predicted -0.11 (-0.35–0.14) 0.40 DLCO, % predicted -0.05 (-0.28–0.27) 0.73 DLCO/VA, % predicted -0.07 (-0.33–0.26) 0.60 RLV, % predicted 0.25 (-0.03–0.47) 0.07 VC, % predicted -0.02 (-0.26–0.23) 0.88 TLC, % predicted 0.28 (0.00–0.51) 0.04 RLV /TLC 0.21 (-0.08–0.43) 0.13 6MWT (m) –0.17 (–0.39–0.07) 0.20 RVEDV (ml/m1.7) -0.12 (-0.36–0.18) 0.39 RVESV (ml/m1.7) -0.20 (-0.39–0.08) 0.14 RVSV (ml/m1.7) 0.02 (-0.22–0.28) 0.86 RVEF (%) 0.18 (-0.04–0.38) 0.18 RVM (g/m1.7) -0.24 (-0.49–0.02) 0.07 DLCO diffusing capacity of the lungs for carbon monoxide, FEF forced expiratory flow, FEV1 forced expiratory volume in 1 s, FVC forced vital arterial p-value 0.04 0.58 0.003 0.10 0.53 0.004 0.17 0.77 0.06 0.57 0.37 0.33 0.03 0.02 <0.001 0.001 end- ventric- veloc- end- RVSV ratio ",
    "table_content": "|| blank | PWV | PWV ||\n|| blank | Rho (95 % CI) | p -value ||\n|| FVC, % predicted | -0.07 (-0.28–0.14) | 0.61 ||\n|| FEV1/FVC | -0.18 (-0.42–0.10) | 0.18 ||\n|| FEF 25–75, % predicted | -0.11 (-0.35–0.14) | 0.40 ||\n|| DLCO, % predicted | -0.05 (-0.28–0.27) | 0.73 ||\n|| DLCO/VA, % predicted | -0.07 (-0.33–0.26) | 0.60 ||\n|| RLV, % predicted | 0.25 (-0.03–0.47) | 0.07 ||\n|| VC, % predicted | -0.02 (-0.26–0.23) | 0.88 ||\n|| TLC, % predicted |  0.28 (0.00–0.51)  |  0.04  ||\n|| RLV /TLC | 0.21 (-0.08–0.43) | 0.13 ||\n|| 6MWT (m) | –0.17 (–0.39–0.07) | 0.20 ||\n|| Age | 0.04 (-0.24–0.28) | 0.75 ||\n|| RVEDV (ml/m 1.7 ) | -0.12 (-0.36–0.18) | 0.39 ||\n|| RVESV (ml/m 1.7 ) | -0.20 (-0.39–0.08) | 0.14 ||\n|| RVSV (ml/m 1.7 ) | 0.02 (-0.22–0.28) | 0.86 ||\n|| RVEF (%) | 0.18 (-0.04–0.38) | 0.18 ||\n|| RVM (g/m 1.7 ) | -0.24 (-0.49–0.02) | 0.07 ||\n|| BMI (kg/m 2 ) |  -0.28 (-0.49–0.02)  |  0.03  ||\n|| Heart rate (bpm) | 0.20 (-0.11–0.46) | 0.14 ||\n|| Systolic BP (mm Hg) | 0.14 (-0.18–0.45) | 0.29 ||\n|| Diastolic BP (mm Hg) |  0.35 (0.06–0.60)  |  0.009  ||\n|| SpO 2 | -0.06 (-0.40–0.27) | 0.65 ||\n|| Pack years | 0.01 (-0.24–0.26) | 0.94 ||\n|| FEV1, % predicted | -0.16 (-0.37–0.09) | 0.24 ||",
    "claim": "The correlation between PWV and diastolic blood pressure is statistically significant with a p-value of 0.009, indicating a reliable negative association. This suggests that higher diastolic blood pressure is associated with decreased arterial stiffness, as measured by PWV.",
    "label": "refute"
  },
  {
    "id": "training_518_1",
    "table_caption": "Table: success same R2 evaluation, and change success for early stages (n = 89) and advanced stages of change (n = 88). Early stages of change Advances stages of change Product evaluation Change success Product evaluation Change success BITTER FACTORS Demand −0.04 0.40** 0.29** 0.44** Confrontation with deficits −0.06 0.23* 0.17 0.34** SWEET FACTORS Autonomy 0.31* 0.28** 0.16 0.20 Encouraging feedback 0.29** 0.51** 0.24* 0.42** *p < 0.05, **p < 0.01. ",
    "table_content": "|| blank | Early stages of change | Early stages of change | Advances stages of change | Advances stages of change ||\n|| blank | Product evaluation | Change success | Product evaluation | Change success ||\n|| BITTER FACTORS | BITTER FACTORS | BITTER FACTORS | BITTER FACTORS | BITTER FACTORS ||\n|| Demand | −0.04 | 0.40 ** | 0.29 ** | 0.44 ** ||\n|| Confrontation with deficits | −0.06 | 0.23 * | 0.17 | 0.34 ** ||\n|| SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS ||\n|| Autonomy | 0.31 * | 0.28 ** | 0.16 | 0.20 ||\n|| Encouraging feedback | 0.29 ** | 0.51 ** | 0.24 * | 0.42 ** ||",
    "claim": "The correlation of \"Demand\" with change success increases by 10% from early to advanced stages, while \"Confrontation with deficits\" shows a 28% increase, indicating a more pronounced impact of addressing deficits in later stages.",
    "label": "refute"
  },
  {
    "id": "training_1344_4",
    "table_caption": "Table: patients, with a Mean ± S.D. (min, max) = 7.77 ± 3.74 that may the Table 2 Number of elderly patients with delirium By CAM algorithm\\By DSM-IV TR Delirium No delirium Positive 34 0 Negative 3 29 Total 37 29 ",
    "table_content": "|| By CAM algorithm\\By DSM-IV TR | Delirium | No delirium ||\n|| Positive | 34 | 0 ||\n|| Negative | 3 | 29 ||\n|| Total | 37 | 29 ||",
    "claim": "The ratio of true positives to false negatives is approximately 1.33, indicating a high detection rate of actual delirium cases by the CAM algorithm.",
    "label": "refute"
  },
  {
    "id": "training_1173_3",
    "table_caption": "Table: Subunits of CK2 were amplified via PCR using the following primers: CK2α 5′-CCCAAGCTTATGTCGGGACCCGTGCCAAG CAGG-3′ CK2α 5′-CGCGGATCCTTACTGCTGAGCGCCAGCGG CAG-3′ CK2β 5′-CCCAAGCTTATGAGCAGCTCAGAGGAGGT GTC-3′ CK2β 5′-CGCGGATCCTCAGCGAATCGTCTTGACTG GGCTC-3′ CK2α′ 5′-CCCAAGCTTATGCCCGGCCCGGCCGC GG-3′ CK2α′ 5′-CGCGGATCCTCATCGTGCTGCCGTGAGAC CAC-3′ All genes were cloned into the p3xFLAG-CMV-10 (SIGMA) vector using restriction digests. Constructs were sequenced to until 1 ∼6–7 NaCl, 3 h pH pH DTT, CK2 ",
    "table_content": "|| CK2α | 5′-CCCAAGCTTATGTCGGGACCCGTGCCAAGCAGG-3′ ||\n|| CK2α | 5′-CGCGGATCCTTACTGCTGAGCGCCAGCGGCAG-3′ ||\n|| CK2β | 5′-CCCAAGCTTATGAGCAGCTCAGAGGAGGTGTC-3′ ||\n|| CK2β | 5′-CGCGGATCCTCAGCGAATCGTCTTGACTGGGCTC-3′ ||\n|| CK2α′ | 5′-CCCAAGCTTATGCCCGGCCCGGCCGCGG-3′ ||\n|| CK2α′ | 5′-CGCGGATCCTCATCGTGCTGCCGTGAGACCAC-3′ ||",
    "claim": "The CK2β primers have a higher potential for forming secondary structures due to the presence of consecutive G and C nucleotides, which can lead to stable hairpin loops, calculated by analyzing the sequence for palindromic regions and consecutive GC pairs.",
    "label": "refute"
  },
  {
    "id": "training_1173_3",
    "table_caption": "Table: Subunits of CK2 were amplified via PCR using the following primers: CK2α 5′-CCCAAGCTTATGTCGGGACCCGTGCCAAG CAGG-3′ CK2α 5′-CGCGGATCCTTACTGCTGAGCGCCAGCGG CAG-3′ CK2β 5′-CCCAAGCTTATGAGCAGCTCAGAGGAGGT GTC-3′ CK2β 5′-CGCGGATCCTCAGCGAATCGTCTTGACTG GGCTC-3′ CK2α′ 5′-CCCAAGCTTATGCCCGGCCCGGCCGC GG-3′ CK2α′ 5′-CGCGGATCCTCATCGTGCTGCCGTGAGAC CAC-3′ All genes were cloned into the p3xFLAG-CMV-10 (SIGMA) vector using restriction digests. Constructs were sequenced to until 1 ∼6–7 NaCl, 3 h pH pH DTT, CK2 ",
    "table_content": "|| CK2α | 5′-CCCAAGCTTATGTCGGGACCCGTGCCAAGCAGG-3′ ||\n|| CK2α | 5′-CGCGGATCCTTACTGCTGAGCGCCAGCGGCAG-3′ ||\n|| CK2β | 5′-CCCAAGCTTATGAGCAGCTCAGAGGAGGTGTC-3′ ||\n|| CK2β | 5′-CGCGGATCCTCAGCGAATCGTCTTGACTGGGCTC-3′ ||\n|| CK2α′ | 5′-CCCAAGCTTATGCCCGGCCCGGCCGCGG-3′ ||\n|| CK2α′ | 5′-CGCGGATCCTCATCGTGCTGCCGTGAGACCAC-3′ ||",
    "claim": "The CK2β primers have a lower potential for forming secondary structures due to the absence of consecutive G and C nucleotides, which can lead to unstable hairpin loops, calculated by analyzing the sequence for palindromic regions and consecutive GC pairs.",
    "label": "refute"
  },
  {
    "id": "training_724_3",
    "table_caption": "Table: with a weak affinity site in Kir6.2 [36]. The mechanism of with the V2R V206D mutant; however, this difference was Table 1 F508del-CFTR corrector compounds show distinct profiles of correction for other ER-retained proteins Corrector CFTR F508del hERG G601S hERG F805C SUR1 A116P SUR1 V187D V2R L292P V2R V206D VRT-325 + + - - ND - ND Glycerol + ND ND + ND ND +/− 29°C ++ + + + + ++ ++ KM60 + + - + + - + KM57 +/− ++ - +/− - - +/− ABT-888 + - ND + + - + Glafenine + + - + - - - RDR1 + - - + + - - Ouabain + +/−* +* + + + + Carbamazepine + - ND - +/− - ND Latonduine + +/− - + ++ +/− + Astemizole ND + - ND ND ND ND Glibenclamide ND ND ND ++ ++ ND ND A qualitative assessment of correction as determined by glycosylation status in immunoblotting is shown for each mutation following treatment with a corrector compound, where “-“ indicates no correction observed, “+/−“ indicates slight correction, “+” and “++” indicate more and best correction observed, respectively, and “ND” indicates not determined. Asterisks indicate that an intermediate glycoform was observed, but no correction. Astemizole and glibenclamide were ",
    "table_content": "|| Corrector | CFTR F508del | hERG G601S | hERG F805C | SUR1 A116P | SUR1 V187D | V2R L292P | V2R V206D ||\n|| VRT-325 | + | + | blank | blank | ND | blank | ND ||\n|| Carbamazepine | + | blank | ND | blank | +/− | blank | ND ||\n|| Latonduine | + | +/− | blank | + | ++ | +/− | + ||\n|| Astemizole | ND | + | blank | ND | ND | ND | ND ||\n|| Glibenclamide | ND | ND | ND | ++ | ++ | ND | ND ||\n|| Glycerol | + | ND | ND | + | ND | ND | +/− ||\n|| 29°C | ++ | + | + | + | + | ++ | ++ ||\n|| KM60 | + | + | blank | + | + | blank | + ||\n|| KM57 | +/− | ++ | blank | +/− | blank | blank | +/− ||\n|| ABT-888 | + | blank | ND | + | + | blank | + ||\n|| Glafenine | + | + | blank | + | blank | blank | blank ||\n|| RDR1 | + | blank | blank | + | + | blank | blank ||\n|| Ouabain | + | +/−* | +* | + | + | + | + ||",
    "claim": "Latonduine shows the highest effectiveness on SUR1 mutations, achieving slight correction (\"+/−\") for SUR1 V187D and more correction (\"+\") for SUR1 A116P, indicating its potential as a targeted corrector for SUR1-related dysfunctions.",
    "label": "refute"
  },
  {
    "id": "training_611_2",
    "table_caption": "Table: Table 5 The multiple logistic regression for the relationship between POA and main IVF outcomes in each age group <33 years 33 ~ 37 years 38 ~ 41 years B P OR (95 % CI) B P OR (95 % CI) B P OR (5 % CI) Age 0.048 0.181 1.049(0.978–1.125) −0.069 0.348 0.933(0.807–1.079) −0.375 0.114 0.687(0.431–1.095) BMI −0.185 0.000 0.831(0.776–0.891) −0.090 0.006 0.914(0.857–0.975) −0.125 0.193 0.882(0.730–1.065) AFC −0.019 0.268 0.981(0.949–1.015) −0.032 0.086 0.969(0.934–1.004) −0.050 0.384 0.951(0.850–1.064) Number of retrieved oocytes −0.043 0.002 0.958(0.933–0.984) −0.015 0.348 0.985(0.954–1.017) −0.036 0.489 0.965(0.872–1.068) Total dose of Gna 0.283 <0.001 1.328(1.140–1.546) 0.428 <0.001 1.535(1.285–1.834) 0.662 0.006 1.939(1.212–3.102) aGn are transformed into ordinal variable according to the median (25–75th percentile) ",
    "table_content": "|| blank | <33 years | <33 years | <33 years | 33 ~ 37 years | 33 ~ 37 years | 33 ~ 37 years | 38 ~ 41 years | 38 ~ 41 years | 38 ~ 41 years ||\n|| blank | B |  P  | OR (95 % CI) | B |  P  | OR (95 % CI) | B |  P  | OR (5 % CI) ||\n|| Age | 0.048 | 0.181 | 1.049(0.978–1.125) | −0.069 | 0.348 | 0.933(0.807–1.079) | −0.375 | 0.114 | 0.687(0.431–1.095) ||\n|| BMI | −0.185 | 0.000 | 0.831(0.776–0.891) | −0.090 | 0.006 | 0.914(0.857–0.975) | −0.125 | 0.193 | 0.882(0.730–1.065) ||\n|| AFC | −0.019 | 0.268 | 0.981(0.949–1.015) | −0.032 | 0.086 | 0.969(0.934–1.004) | −0.050 | 0.384 | 0.951(0.850–1.064) ||\n|| Number of retrieved oocytes | −0.043 | 0.002 | 0.958(0.933–0.984) | −0.015 | 0.348 | 0.985(0.954–1.017) | −0.036 | 0.489 | 0.965(0.872–1.068) ||\n|| Total dose of Gn a  | 0.283 | <0.001 | 1.328(1.140–1.546) | 0.428 | <0.001 | 1.535(1.285–1.834) | 0.662 | 0.006 | 1.939(1.212–3.102) ||",
    "claim": "The odds ratio for BMI is lowest in the 33 ~ 37 years group, suggesting that BMI has a more pronounced negative impact on IVF outcomes in middle-aged women. This aligns with the understanding that higher BMI can affect hormonal balance and reproductive health more significantly in middle-aged individuals.",
    "label": "refute"
  },
  {
    "id": "training_1130_2",
    "table_caption": "Table: Different Human miRNA and Their Chromosomal Location, Gene Location, pre-miRNA Length, Mature Sequence Associated with the MAPK signaling pathway in CML Name of miRNA Chromosomal (Ch) Location Gene location (EXON/ INTRON/UTR) Pre-miRNA length (nucleotide; nt) Mature Sequence miR- 203 Ch14q32.33 intergenic 110 nt 65| 5’- GUGAAAUGUUUAGGACCACUAG -3’ |86 miR- 196b Ch7 p15.2 3UTR + 3/ intron + 1/ exon + 1/ intron + 1/ exon -1/ exon -2 84 nt 15| 5’- UAGGUAGUUUCCUGUUGUUGG -3’ |35 miR- 29b-1 Ch7 q32.3 Intergenic 81 nt 51| 5’- UAGCACCAUUUGAAAUCAGUGUU -3’ |73 miR- 29b-2 Ch1 q32.2 intergenic 81 nt 52| 5’- UAGCACCAUUUGAAAUCAGUGUU -3’ |74 miR- 30a Ch6 q13 intron + 3/ intron + 3 71 nt 6| 5’- UGUAAACAUCCUCGACUGGAAG -3’ |27 miR- 138-1 Ch3p21.32 intergenic 99 nt 23| 5’- AGCUGGUGUUGUGAAUC -3’ |39 miR- 138-2 Ch16q13 intergenic 84 nt 10| 5’- AGCUGGUGUUGUGAAUC -3’ |26 miR- 155 Ch21 q21.3 intergenic 65 nt 4| 5’- UUAAUGCUAAUCGUGAUAGGGG -3’ |25 miR- 19a Ch13 q31.3 3UTR + 2/ intron + 3/ intron + 2/ intron + 3 82 nt 49| 5’- UGUGCAAAUCUAUGCAAAACUGA -3’ |71 miR-17 Ch13 q31.3 3UTR + 2/ intron + 3/ intron + 2/ intron + 3 84 nt 14| 5’- CAAAGUGCUUACAGUGCAGGUAGU -3’ |37 miR- 221 ChX p11.3 intergenic 110 nt 65| 5’- AGCUACAUUGUCUGCUGGGUUUC -3’ |87 miR- 181a-1 Ch1 q32.1 intergenic 110 nt 24| 5’- AACAUUCAACGCUGUCGGUGAGU -3’ |46 miR- 181a-2 Ch9 q33.3 intron -2/ intron -2/ intron -2/ intron + 1 110 nt 39| 5’- AACAUUCAACGCUGUCGGUGAGU -3’ |61 miR- 126 Ch9q34.3 Intron +7/ Intron +7/ Intron +6/ Intron +6/ Intron +5/ Intron +7/ Intron +7 85 nt 15| 5’- CAUUAUUACUUUUGGUACGCG -3’ |35 miR- 128a Ch2q21.3 Intron +15/ Intron +18 82 nt 50| 5’- UCACAGUGAACCGGUCUCUUUU -3’ |71 miR- 128b Ch3p22.3 Intron +17/ Intron +18/ Intron +18/ Intron +11/ Intron +17 84 nt 52| 5’- UCACAGUGAACCGGUCUCUUUC -3’ |73 miR- 15a Ch13q14.2 intron + 4/ intron + 4/ intron + 5/ intron + 5/ intron + 4/ intron + 3/ intron + 4/ intron + 3 83 nt 14| 5’- UAGCAGCACAUAAUGGUUUGUG -3’ |35 miR- 188 ChXp11.23 intron + 3/ intron + 3/ intron + 3/ intron + 3/ intron + 3 86 nt 15| 5’- CAUCCCUUGCAUGGUGGAGGGU -3’ |36 ",
    "table_content": "|| Name of miRNA | Chromosomal (Ch) Location | Gene location (EXON/INTRON/UTR) | Pre-miRNA length (nucleotide; nt) | Mature Sequence ||\n|| miR-203 | Ch14q32.33 | intergenic | 110 nt | 65| 5′- GUGAAAUGUUUAGGACCACUAG -3′ |86 ||\n|| miR-17 | Ch13 q31.3 | 3UTR + 2/ intron + 3/ intron + 2/ intron + 3 | 84 nt | 14| 5′- CAAAGUGCUUACAGUGCAGGUAGU -3′ |37 ||\n|| miR-221 | ChX p11.3 | intergenic | 110 nt | 65| 5′- AGCUACAUUGUCUGCUGGGUUUC -3′ |87 ||\n|| miR-181a-1 | Ch1 q32.1 | intergenic | 110 nt | 24| 5′- AACAUUCAACGCUGUCGGUGAGU -3′ |46 ||\n|| miR-181a-2 | Ch9 q33.3 | intron −2/ intron −2/ intron −2/ intron + 1 | 110 nt | 39| 5′- AACAUUCAACGCUGUCGGUGAGU -3′ |61 ||\n|| miR-126 | Ch9q34.3 | Intron +7/ Intron +7/ Intron +6/ Intron +6/ Intron +5/ Intron +7/ Intron +7 | 85 nt | 15| 5′- CAUUAUUACUUUUGGUACGCG -3′ |35 ||\n|| miR-128a | Ch2q21.3 | Intron +15/ Intron +18 | 82 nt | 50| 5′- UCACAGUGAACCGGUCUCUUUU -3′ |71 ||\n|| miR-128b | Ch3p22.3 | Intron +17/ Intron +18/ Intron +18/ Intron +11/ Intron +17 | 84 nt | 52| 5′- UCACAGUGAACCGGUCUCUUUC -3′ |73 ||\n|| miR-15a | Ch13q14.2 | intron + 4/ intron + 4/ intron + 5/ intron + 5/ intron + 4/ intron + 3/ intron + 4/ intron + 3 | 83 nt | 14| 5′- UAGCAGCACAUAAUGGUUUGUG -3′ |35 ||\n|| miR-188 | ChXp11.23 | intron + 3/ intron + 3/ intron + 3/ intron + 3/ intron + 3 | 86 nt | 15| 5′- CAUCCCUUGCAUGGUGGAGGGU -3′ |36 ||\n|| miR-196b | Ch7 p15.2 | 3UTR + 3/ intron + 1/ exon + 1/ intron + 1/ exon −1/ exon −2 | 84 nt | 15| 5′- UAGGUAGUUUCCUGUUGUUGG -3′ |35 ||\n|| miR-29b-1 | Ch7 q32.3 | Intergenic | 81 nt | 51| 5′- UAGCACCAUUUGAAAUCAGUGUU -3′ |73 ||\n|| miR-29b-2 | Ch1 q32.2 | intergenic | 81 nt | 52| 5′- UAGCACCAUUUGAAAUCAGUGUU -3′ |74 ||\n|| miR-30a | Ch6 q13 | intron + 3/ intron + 3 | 71 nt | 6| 5′- UGUAAACAUCCUCGACUGGAAG -3′ |27 ||\n|| miR-138-1 | Ch3p21.32 | intergenic | 99 nt | 23| 5′- AGCUGGUGUUGUGAAUC -3′ |39 ||\n|| miR-138-2 | Ch16q13 | intergenic | 84 nt | 10| 5′- AGCUGGUGUUGUGAAUC -3′ |26 ||\n|| miR-155 | Ch21 q21.3 | intergenic | 65 nt | 4| 5′- UUAAUGCUAAUCGUGAUAGGGG -3′ |25 ||\n|| miR-19a | Ch13 q31.3 | 3UTR + 2/ intron + 3/ intron + 2/ intron + 3 | 82 nt | 49| 5′- UGUGCAAAUCUAUGCAAAACUGA -3′ |71 ||",
    "claim": "Among the miRNAs, those located in intergenic regions constitute about 30% of the total. This is calculated by counting the number of intergenic miRNAs and dividing by the total number of miRNAs. This distribution indicates a significant role of intergenic miRNAs in the regulation of the MAPK pathway in CML.",
    "label": "refute"
  },
  {
    "id": "training_587_5",
    "table_caption": "Table: Mean and standard deviation of cognitive test scores stratified by years of (low) education. Sao Carlos, Brazil, 2014 (n=667). Education, y 0 (n=145)a 1 (n=48)b 2 (n=65)c 3 (n=74)d 4 (n=209)e M-ACE (max 30) 8.8±4.0 11.8±5.8 12.0±5.6 14.5±5.9 16.5±3.1 MMSE (max 30) 17.0±4.8 20.0±3.9 20.3±4.7 22.4±4.1 23.7±3.8 ACE-R (max 100) 38.6±14.4 49.5±17.4 51.2±16.8 58.7±16.4 65.7±16.3 • Attention/Orientation (max 18) 10.4±3.4 12.0±2.7 12.2±3.2 13.3±2.8 14.2±2.6 • Memory (max 26) 8.6±4.7 11.0±5.1 11.4±5.3 13.0±5.7 15.4±5.6 • Verbal Fluency (max 14) 2.7±2.3 4.4±2.8 4.2±2.5 5.4±2.8 6.1±2.7 • Language (max 26) 11.0±4.5 14.5±6.7 15.0±5.7 17.3±5.2 19.2±5.3 • Visuospatial (max 16) 5.7±3.2 7.3±3.7 8.3±3.5 9.7±2.8 10.6±3.5 M-ACE: Mini Addenbrooke Cognitive Examination; MMSE: Mini-Mental State Examination; ACE-R: Addenbrooke Cognitive Examination-Revised. T-test comparative scores with p≤0.05: M-ACE a<b=c<d=e. MMSE a<b=c=d=e. ACE-R a<b<c<d<e. Attention/Orientation a<b=c=d=e. Memory a<b=c=d<e. Verbal Fluency a<b=c<d=e. Language a<b=c=d=e. Visuospatial a<b<c<d=e. ",
    "table_content": "|| Education, y | 0 (n=145)a | 1 (n=48)b | 2 (n=65)c | 3 (n=74)d | 4 (n=209)e ||\n|| M-ACE (max 30) | 8.8±4.0 | 11.8±5.8 | 12.0±5.6 | 14.5±5.9 | 16.5±3.1 ||\n|| MMSE (max 30) | 17.0±4.8 | 20.0±3.9 | 20.3±4.7 | 22.4±4.1 | 23.7±3.8 ||\n|| ACE-R (max 100) | 38.6±14.4 | 49.5±17.4 | 51.2±16.8 | 58.7±16.4 | 65.7±16.3 ||\n|| • Attention/Orientation (max 18) | 10.4±3.4 | 12.0±2.7 | 12.2±3.2 | 13.3±2.8 | 14.2±2.6 ||\n|| • Memory (max 26) | 8.6±4.7 | 11.0±5.1 | 11.4±5.3 | 13.0±5.7 | 15.4±5.6 ||\n|| • Verbal Fluency (max 14) | 2.7±2.3 | 4.4±2.8 | 4.2±2.5 | 5.4±2.8 | 6.1±2.7 ||\n|| • Language (max 26) | 11.0±4.5 | 14.5±6.7 | 15.0±5.7 | 17.3±5.2 | 19.2±5.3 ||\n|| • Visuospatial (max 16) | 5.7±3.2 | 7.3±3.7 | 8.3±3.5 | 9.7±2.8 | 10.6±3.5 ||",
    "claim": "The statistical analysis reveals that the difference in MMSE scores between 0 and 1 year of education is not statistically significant, while the difference between 0 and 4 years is significant, suggesting that a minimum threshold of education is necessary to observe significant cognitive improvements.",
    "label": "refute"
  },
  {
    "id": "training_716_4",
    "table_caption": "Table: Mutational spectrum of PIG-O gene in DT40 cells exposed to MMS at 100 mM. Mutation (cDNA position) Target sequence (59-39) Amino acid change (codon) Transversion AT to TA (840) CCA(T)GGT His to Gln (280) AT to TA (2009) GCC(T)GAG Leu to Gln (670) AT to TA (2011) CTG(A)GAA Arg to stop (671) AT to TA (2332) GCA(A)AGG Lys to stop (778) AT to TA (2941) TCC(A)AGA Lys to stop (981) AT to CG (689) ACC(A)CTG His to Pro (230) AT to CG (950) ACC(T)GGT Leu to Arg (317) GC to CG (2771) ACT(G)GAA Trp to Ser (924) GC to TA (2911) TGT(G)AGA Glu to stop (971) Frameshift +A (1915) CTT(*)CTG 2T (241) GAA(T)TTG 2A (941) CCC(A)GGT Insertion/Deletion +6 bases (1092) CAA(GCAGTT)GCA +2 bases (2786) TTG(CG)TGG +4 bases (2873) CAG(GTAT)TTG 2145 bases (497–641) GAA(GAA—GAA)CAG 220 bases (1746–1765) AGC(TGA—CAT)TCC 2204 bases (2669–2872) CTG(AGC—CAG)TTG doi:10.1371/journal.pone.0033563.t002 ",
    "table_content": "|| Mutation (cDNA position) | Target sequence (5′-3′) | Amino acid change (codon) ||\n|| Transversion | Transversion | Transversion ||\n|| GC to TA (2911) |  TGT( G )AGA  | Glu to stop (971) ||\n|| Frameshift | Frameshift | Frameshift ||\n|| +A (1915) |  CTT( * )CTG  | blank ||\n|| −T (241) |  GAA( T )TTG  | blank ||\n|| −A (941) |  CCC( A )GGT  | blank ||\n|| Insertion/Deletion | Insertion/Deletion | Insertion/Deletion ||\n|| +6 bases (1092) |  CAA( GCAGTT )GCA  | blank ||\n|| +2 bases (2786) |  TTG( CG )TGG  | blank ||\n|| +4 bases (2873) |  CAG( GTAT )TTG  | blank ||\n|| −145 bases (497–641) |  GAA( GAA—GAA )CAG  | blank ||\n|| AT to TA (840) |  CCA( T )GGT  | His to Gln (280) ||\n|| −20 bases (1746–1765) |  AGC( TGA—CAT )TCC  | blank ||\n|| −204 bases (2669–2872) |  CTG( AGC—CAG )TTG  | blank ||\n|| AT to TA (2009) |  GCC( T )GAG  | Leu to Gln (670) ||\n|| AT to TA (2011) |  CTG( A )GAA  | Arg to stop (671) ||\n|| AT to TA (2332) |  GCA( A )AGG  | Lys to stop (778) ||\n|| AT to TA (2941) |  TCC( A )AGA  | Lys to stop (981) ||\n|| AT to CG (689) |  ACC( A )CTG  | His to Pro (230) ||\n|| AT to CG (950) |  ACC( T )GGT  | Leu to Arg (317) ||\n|| GC to CG (2771) |  ACT( G )GAA  | Trp to Ser (924) ||",
    "claim": "By comparing the types of mutations with the severity of amino acid changes (e.g., stop codons vs. missense mutations), it can be inferred that transversions, although less frequent, have a higher likelihood of causing severe disruptions, such as frameshifts leading to nonfunctional proteins, compared to frameshift mutations.",
    "label": "refute"
  },
  {
    "id": "training_410_4",
    "table_caption": "Table: Neuromuscular Disorders Ophthalmic Disorders Chronic Pain Cosmetic and Dermatological Applications Pelvic ﬂoor Disorders Gastrointestinal Disorders Spasticity Idiopathic/secondary focal dystonia Misalignment Tension headache Wrinkles Anismus Achalasia Stoke induced spasticity Hemifacial Spasm/post-facial nerve palsy synkinesis Paralytic strabismus Cervicogenic headache Face rejuvenation Vaginismus Bruxism Cephalic tetanus Tremor (essential, writing, palatal or cerebellar) Therapeutic ptosis for corneal protection Migraine Hypersecretory disorders (hyperhidrosis, sialorrhea) Detrusor sphincter dyssynergia Temporomandibular joint dysfunction Multiple sclerosis Tic disorders Restrictive or myogenic strabismus Lower back ache Glabellar frown Chronic anal ﬁssures Palatal myoclonus Traumatic brain injury Myokymia Upper eyelid retraction Tennis elbow Vertical platysma bands Perineal muscles spasm Esophageal diverticulosis Cerebral palsy Neuromyotonia Duane’s syndrome Myofascial pain Browlift Vulvodynia Laryngeal disorders Spinal cord injury ",
    "table_content": "|| Neuromuscular Disorders | Ophthalmic Disorders | Chronic Pain | Cosmetic and Dermatological Applications | Pelvic floor Disorders | Gastrointestinal Disorders | Spasticity ||\n|| Idiopathic/secondary focal dystonia | Misalignment | Tension headache | Wrinkles | Anismus | Achalasia | Stoke induced spasticity ||\n|| Hemifacial Spasm/post-facial nerve palsy synkinesis | Paralytic strabismus | Cervicogenic headache | Face rejuvenation | Vaginismus | Bruxism | Cephalic tetanus ||\n|| Tremor (essential, writing, palatal or cerebellar) | Therapeutic ptosis for corneal protection | Migraine | Hypersecretory disorders (hyperhidrosis, sialorrhea) | Detrusor sphincter dyssynergia | Temporomandibular joint dysfunction | Multiple sclerosis ||\n|| Tic disorders | Restrictive or myogenic strabismus | Lower back ache | Glabellar frown | Chronic anal fissures | Palatal myoclonus | Traumatic brain injury ||\n|| Myokymia | Upper eyelid retraction | Tennis elbow | Vertical platysma bands | Perineal muscles spasm | Esophageal diverticulosis | Cerebral palsy ||\n|| Neuromyotonia | Duane’s syndrome | Myofascial pain | Browlift | Vulvodynia | Laryngeal disorders | Spinal cord injury ||",
    "claim": "The table highlights that conditions related to the gastrointestinal system, such as achalasia and esophageal diverticulosis, are less frequent compared to neuromuscular and ophthalmic conditions, suggesting a lower prevalence or possibly underdiagnosis in clinical settings.",
    "label": "refute"
  },
  {
    "id": "training_164_5",
    "table_caption": "Table: blue-collar workers. HRV Index Sitting Variable Crude Model (N = 126) Primary Adjusted Model (N = 126) B 95%CI Low High p B 95%CI Low High p IBI (ms) Occupational sitting −17.00 −35.80 1.81 0.08 −24.24 −46.98 −1.50 0.04 Leisure-time sitting 6.80 −7.97 21.57 0.36 0.41 −14.43 −15.25 0.96 RMSSD (ms) Occupational sitting −3.26 0.06 −6.66 0.14 −4.96 −8.88 −1.05 0.01 Leisure-time sitting 0.16 0.91 −2.51 2.83 1.83 −0.73 4.38 0.16 SDNN (ms) Occupational sitting −3.03 −5.87 −0.20 0.04 −5.07 −8.48 −1.67 0.00 Leisure-time sitting 0.46 −1.77 2.69 0.68 1.10 −1.12 3.33 0.33 ln VLF Occupational sitting −0.10 −0.20 0.01 0.06 −0.19 −0.32 −0.05 0.01 Leisure-time sitting 0.03 −0.05 0.11 0.50 0.00 −0.09 0.09 0.98 ln LF Occupational sitting −0.13 −0.25 −0.01 0.03 −0.18 −0.32 −0.04 0.01 Leisure-time sitting 0.05 −0.04 0.14 0.30 0.07 −0.02 0.17 0.11 ln HF Occupational sitting −0.12 −0.26 0.03 0.12 −0.12 −0.27 0.04 0.14 Leisure-time sitting 0.00 −0.12 0.11 0.95 0.08 −0.02 0.19 0.13 ln LF/HF Occupational sitting −0.01 −0.12 0.10 0.91 −0.03 −0.17 0.10 0.62 Leisure-time sitting 0.06 −0.03 0.14 0.19 −0.01 −0.09 0.08 0.92 * Adjusted for age, gender, BMI, smoking, lifting/carrying at work, seniority, influence at work, and total moderate-to-vigorous physical activity. Note: significant (p < 0.05) associations are bold faced. ",
    "table_content": "|| HRV Index | Sitting Variable | Crude Model ( N = 126) | Crude Model ( N = 126) | Crude Model ( N = 126) | Crude Model ( N = 126) | Primary Adjusted Model ( N = 126) | Primary Adjusted Model ( N = 126) | Primary Adjusted Model ( N = 126) | Primary Adjusted Model ( N = 126) ||\n|| HRV Index | Sitting Variable | B | 95%CI Low | High | p | B | 95%CI Low | High | p ||\n|| ln LF | Occupational sitting | −0.13 | −0.25 | −0.01 | 0.03 | −0.18 | −0.32 | −0.04 | 0.01 ||\n|| ln LF | Leisure-time sitting | 0.05 | −0.04 | 0.14 | 0.30 | 0.07 | −0.02 | 0.17 | 0.11 ||\n|| ln HF | Occupational sitting | −0.12 | −0.26 | 0.03 | 0.12 | −0.12 | −0.27 | 0.04 | 0.14 ||\n|| ln HF | Leisure-time sitting | 0.00 | −0.12 | 0.11 | 0.95 | 0.08 | −0.02 | 0.19 | 0.13 ||\n|| ln LF/HF | Occupational sitting | −0.01 | −0.12 | 0.10 | 0.91 | −0.03 | −0.17 | 0.10 | 0.62 ||\n|| ln LF/HF | Leisure-time sitting | 0.06 | −0.03 | 0.14 | 0.19 | −0.01 | −0.09 | 0.08 | 0.92 ||\n|| IBI (ms) | Occupational sitting | −17.00 | −35.80 | 1.81 | 0.08 | −24.24 | −46.98 | −1.50 | 0.04 ||\n|| IBI (ms) | Leisure-time sitting | 6.80 | −7.97 | 21.57 | 0.36 | 0.41 | −14.43 | −15.25 | 0.96 ||\n|| RMSSD (ms) | Occupational sitting | −3.26 | 0.06 | −6.66 | 0.14 | −4.96 | −8.88 | −1.05 | 0.01 ||\n|| RMSSD (ms) | Leisure-time sitting | 0.16 | 0.91 | −2.51 | 2.83 | 1.83 | −0.73 | 4.38 | 0.16 ||\n|| SDNN (ms) | Occupational sitting | −3.03 | −5.87 | −0.20 | 0.04 | −5.07 | −8.48 | −1.67 | 0.00 ||\n|| SDNN (ms) | Leisure-time sitting | 0.46 | −1.77 | 2.69 | 0.68 | 1.10 | −1.12 | 3.33 | 0.33 ||\n|| ln VLF | Occupational sitting | −0.10 | −0.20 | 0.01 | 0.06 | −0.19 | −0.32 | −0.05 | 0.01 ||\n|| ln VLF | Leisure-time sitting | 0.03 | −0.05 | 0.11 | 0.50 | 0.00 | −0.09 | 0.09 | 0.98 ||",
    "claim": "The adjusted model shows an increase in ln VLF due to occupational sitting, with a statistically significant p-value. This increase in very low-frequency power suggests a potential impact on long-term regulatory mechanisms of the cardiovascular system, possibly reflecting enhanced baroreflex sensitivity or thermoregulatory processes.",
    "label": "refute"
  },
  {
    "id": "training_875_3",
    "table_caption": "Table: www.nature.com/scientificreports/ Variables No adjustment HR (95% CI) P Value Model 1&HR (95% CI) P Value Model 2¶ HR (95% CI) P Value Model 3φ HR (95% CI) P Value Model 4§ HR (95% CI) P Value Model 5£ HR (95%CI) P Value Risk group analysis*  Low-risk 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)  Intermediate-risk 3.08 (2.10–4.53) <0.001 3.00 (2.04–4.40) <0.001 2.67 (1.53–3.36) <0.001 2.77 (1.85–4.15) <0.001 2.18 (1.48–3.20) <0.001 2.65 (1.76–3.98) <0.001  High-risk 11.63 (7.85–17.23) <0.001 10.96 (7.38–16.26) <0.001 6.26 (4.12–9.53) <0.001 10.21 (6.32– 16.51) <0.001 6.90 (4.60–10.34) <0.001 8.15 (5.01– 13.24) <0.001  Risk stratification from low to high 3.50 (2.90–4.23) <0.001 3.40 (2.81–4.11) <0.001 2.56 (2.09–3.15) <0.001 3.27 (2.57–4.17) <0.001 2.76 (2.26–3.37) <0.001 2.89 (2.27–3.68) <0.001 Categorical biomarker analysis  WBC ≥8.62 × 109/L 3.35 (2.53–4.43) <0.001 3.36 (2.54–4.44) <0.001 2.17 (1.61–2.92) <0.001 3.33 (2.35–4.74) <0.001 2.17 (1.63–2.89) <0.001 2.85 (2.00–4.06) <0.001  Hemoglobin <128 g/L 2.94 (2.20–3.94) <0.001 2.62 (1.92–3.59) <0.001 1.77 (1.27–2.48) 0.001 1.69 (1.10–2.59) 0.016 2.23 (1.65–3.00) <0.001 1.58 (1.02–2.46) 0.042  MPV ≥12.9 fL 2.41 (1.85–3.16) <0.001 2.45 (1.87–3.20) <0.001 2.43 (1.85–3.21) <0.001 3.56 (2.31–5.49) <0.001 2.53 (1.94–3.31) <0.001 2.92 (1.88–4.53) <0.001 Continuous biomarkers analysis  WBC, per 1 × 109/L increment 1.13 (1.11–1.17) <0.001 1.14 (1.11–1.17) <0.001 1.05 (1.01–1.08) 0.011 1.80 (1.54–2.11) <0.001 1.06 (1.03–1.09) <0.001 1.45 (1.28–1.65) <0.001  Hemoglobin, per g/L increment 0.98 (0.97–0.98) <0.001 0.98 (0.97–0.99) <0.001 0.99 (0.98–1.00) 0.002 0.97 (0.96–0.99) 0.001 0.98 (0.98–0.99) <0.001 0.98 (0.96–1.00) 0.020  MPV, per fL increment 1.29 (1.18–1.41) <0.001 1.30 (1.19–1.42) <0.001 1.30 (1.19–1.42) <0.001 1.83 (1.50–2.22) <0.001 1.30 (1.19–1.42) <0.001 1.73 (1.41–2.11) <0.001 Table 2. Unadjusted and adjusted Cox proportional hazards models for major adverse cardiac events according to risk groups and its individual components. *See Table 1 footnotes for definitions of risk categories ",
    "table_content": "|| Variables | No adjustment HR (95% CI) | P Value | Model 1 & HR (95% CI) | P Value | Model 2 ¶ HR (95% CI) | P Value | Model 3 ϕ HR (95% CI) | P Value | Model 4 § HR (95% CI) | P Value | Model 5 £ HR (95%CI) | P Value ||\n|| Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * | Risk group analysis * ||\n|| Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis | Continuous biomarkers analysis ||\n|| WBC, per 1 × 10 9 /L increment | 1.13 (1.11–1.17) | <0.001 | 1.14 (1.11–1.17) | <0.001 | 1.05 (1.01–1.08) | 0.011 | 1.80 (1.54–2.11) | <0.001 | 1.06 (1.03–1.09) | <0.001 | 1.45 (1.28–1.65) | <0.001 ||\n|| Hemoglobin, per g/L increment | 0.98 (0.97–0.98) | <0.001 | 0.98 (0.97–0.99) | <0.001 | 0.99 (0.98–1.00) | 0.002 | 0.97 (0.96–0.99) | 0.001 | 0.98 (0.98–0.99) | <0.001 | 0.98 (0.96–1.00) | 0.020 ||\n|| MPV, per fL increment | 1.29 (1.18–1.41) | <0.001 | 1.30 (1.19–1.42) | <0.001 | 1.30 (1.19–1.42) | <0.001 | 1.83 (1.50–2.22) | <0.001 | 1.30 (1.19–1.42) | <0.001 | 1.73 (1.41–2.11) | <0.001 ||\n|| Low-risk | 1.00 (Reference) | blank | 1.00 (Reference) | blank | 1.00 (Reference) | blank | 1.00 (Reference) | blank | 1.00 (Reference) | blank | 1.00 (Reference) | blank ||\n|| Intermediate-risk | 3.08 (2.10–4.53) | <0.001 | 3.00 (2.04–4.40) | <0.001 | 2.67 (1.53–3.36) | <0.001 | 2.77 (1.85–4.15) | <0.001 | 2.18 (1.48–3.20) | <0.001 | 2.65 (1.76–3.98) | <0.001 ||\n|| High-risk | 11.63 (7.85–17.23) | <0.001 | 10.96 (7.38–16.26) | <0.001 | 6.26 (4.12–9.53) | <0.001 | 10.21 (6.32–16.51) | <0.001 | 6.90 (4.60–10.34) | <0.001 | 8.15 (5.01–13.24) | <0.001 ||\n|| Risk stratification from low to high | 3.50 (2.90–4.23) | <0.001 | 3.40 (2.81–4.11) | <0.001 | 2.56 (2.09–3.15) | <0.001 | 3.27 (2.57–4.17) | <0.001 | 2.76 (2.26–3.37) | <0.001 | 2.89 (2.27–3.68) | <0.001 ||\n|| Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis | Categorical biomarker analysis ||\n|| WBC ≥8.62 × 10 9 /L | 3.35 (2.53–4.43) | <0.001 | 3.36 (2.54–4.44) | <0.001 | 2.17 (1.61–2.92) | <0.001 | 3.33 (2.35–4.74) | <0.001 | 2.17 (1.63–2.89) | <0.001 | 2.85 (2.00–4.06) | <0.001 ||\n|| Hemoglobin <128 g/L | 2.94 (2.20–3.94) | <0.001 | 2.62 (1.92–3.59) | <0.001 | 1.77 (1.27–2.48) | 0.001 | 1.69 (1.10–2.59) | 0.016 | 2.23 (1.65–3.00) | <0.001 | 1.58 (1.02–2.46) | 0.042 ||\n|| MPV ≥12.9 fL | 2.41 (1.85–3.16) | <0.001 | 2.45 (1.87–3.20) | <0.001 | 2.43 (1.85–3.21) | <0.001 | 3.56 (2.31–5.49) | <0.001 | 2.53 (1.94–3.31) | <0.001 | 2.92 (1.88–4.53) | <0.001 ||",
    "claim": "The HR for hemoglobin <128 g/L in Model 1 is approximately 1.48 times that in Model 5, indicating a decrease in risk as the model adjustments become more comprehensive.",
    "label": "refute"
  },
  {
    "id": "training_46_6",
    "table_caption": "Table: Differences in alcohol consumption and clinical characteristics of the patients. Alcohol consumption >14 drinks/wk N = 97 No alcohol consumption or <14 drinks/wk N = 1,260 P value Age 55 (44 to 69) 66 (50 to 79) <0.001 APACHE III scores (n = 632) 35 (26 to 61) 51 (36 to 68) 0.002 Male Gender, n (%) 82 (85) 624 (50) <0.001* Aspiration n (%) 7 (7) 32 (3) <0.001* Chemotherapy, n (%) 1 (1) 15 (1) 0.88 Cirrhosis, n (%) 9 (9) 8 (1) <0.001* Diabetes, n (%) 16 ( 16) 286 (23) 0.16 High Risk Surgery, n (%) 12 (12) 219 (17) 0.21 Pancreatitis, n (%) 1 ( 1) 4 (0) 0.26 Pneumonia, n (%) 10 (10) 99 (8) 0.39 Sepsis, n (%) 9 ( 9) 104 (8) 0.72 Shock, n (%) 7 (7) 86 (7) 0.88 Smoking, n (%) Never Past Current 9 (9) 30 (31) 58 (60) 612 (49) 463 ( 37) 185 (14) <0.001* Trauma, n (%) 4 (4 ) 50 (4) 0.93 Hospital Death, n (%) 7 (7) 114 (9) 0.54 ",
    "table_content": "|| blank | Alcohol consumption >14 drinks/wk N = 97 | No alcohol consumption or <14 drinks/wk N = 1,260 | P value ||\n|| Age | 55 (44 to 69) | 66 (50 to 79) | <0.001 ||\n|| Pneumonia, n (%) | 10 (10) | 99 (8) | 0.39 ||\n|| Sepsis, n (%) | 9 (9) | 104 (8) | 0.72 ||\n|| Shock, n (%) | 7 (7) | 86 (7) | 0.88 ||\n|| Smoking, n (%) | blank | blank | <0.001* ||\n|| Never | 9 (9) | 612 (49) | blank ||\n|| Past | 30 (31) | 463 (37) | blank ||\n|| Current | 58 (60) | 185 (14) | blank ||\n|| Trauma, n (%) | 4 (4) | 50 (4) | 0.93 ||\n|| Hospital Death, n (%) | 7 (7) | 114 (9) | 0.54 ||\n|| APACHE III scores (n = 632) | 35 (26 to 61) | 51 (36 to 68) | 0.002 ||\n|| Male Gender, n (%) | 82 (85) | 624 (50) | <0.001* ||\n|| Aspiration n (%) | 7 (7) | 32 (3) | <0.001* ||\n|| Chemotherapy, n (%) | 1 (1) | 15 (1) | 0.88 ||\n|| Cirrhosis, n (%) | 9 (9) | 8 (1) | <0.001* ||\n|| Diabetes, n (%) | 16 (16) | 286 (23) | 0.16 ||\n|| High Risk Surgery, n (%) | 12 (12) | 219 (17) | 0.21 ||\n|| Pancreatitis, n (%) | 1 (1) | 4 (0) | 0.26 ||",
    "claim": "Despite the higher prevalence of severe conditions like cirrhosis and aspiration in the high alcohol consumption group, the hospital death rate is 2% higher than in the low or no alcohol group. This counterintuitive result may be influenced by the younger age and potentially better baseline health of the high alcohol consumption group, which could mitigate the immediate mortality risk despite the presence of chronic conditions.",
    "label": "refute"
  },
  {
    "id": "training_550_4",
    "table_caption": "Table: Summarising the Chinese land parcel and district data used in the analysis. Variables Deﬁnition Mean Std.Dev Dependent Variable Logprice Log of the land parcels' leasing price per square meter (RMB/m2) 7.414 1.029 Lower level variables (land parcels) Logarea Log of the land parcel area (m2) 9.301 1.532 LogDcbd The log of the distance between a land parcel and the CBD 8.956 0.675 LogDele The log of the distance to the nearest elementary school 6.591 0.920 LogDpark The log of the distance to the nearest park 7.774 0.704 LogDriver The log of the distance to the nearest river 7.516 0.931 LogDsubway The log of the distance to the nearest subway station 7.148 0.895 Year dummies The year when the land parcel was leased Higher level variables Buildings1949 Percentage of buildings built before 1949 in each Jiedao 0.042 0.109 Crimerate Number of reported serious crimes per 1000 people in each Jiedao 5.246 6.112 Popden Population density in each Jiedao (1000 people/km2) 1.937 2.670 doi:10.1371/journal.pone.0130761.t001 ",
    "table_content": "|| Variables | Definition | Mean | Std.Dev ||\n||  Dependent Variable  |  Dependent Variable  |  Dependent Variable  |  Dependent Variable  ||\n||  Year dummies  | The year when the land parcel was leased | blank | blank ||\n||  Higher level variables  |  Higher level variables  |  Higher level variables  |  Higher level variables  ||\n|| Buildings1949 | Percentage of buildings built before 1949 in each Jiedao  | 0.042 | 0.109 ||\n|| Crimerate | Number of reported serious crimes per 1000 people in each Jiedao  | 5.246 | 6.112 ||\n|| Popden | Population density in each Jiedao (1000 people/km 2 ) | 1.937 | 2.670 ||\n|| Logprice | Log of the land parcels' leasing price per square meter (RMB/m 2 ) | 7.414 | 1.029 ||\n||  Lower level variables (land parcels)  |  Lower level variables (land parcels)  |  Lower level variables (land parcels)  |  Lower level variables (land parcels)  ||\n|| Logarea | Log of the land parcel area (m 2 ) | 9.301 | 1.532 ||\n|| LogDcbd | The log of the distance between a land parcel and the CBD | 8.956 | 0.675 ||\n|| LogDele | The log of the distance to the nearest elementary school | 6.591 | 0.920 ||\n|| LogDpark | The log of the distance to the nearest park | 7.774 | 0.704 ||\n|| LogDriver | The log of the distance to the nearest river | 7.516 | 0.931 ||\n|| LogDsubway | The log of the distance to the nearest subway station | 7.148 | 0.895 ||",
    "claim": "The mean crime rate is 5.246 per 1000 people. A 1 unit increase in crime rate corresponds to a decrease of approximately 0.052 in the log price, suggesting that higher crime rates are associated with lower land prices.",
    "label": "refute"
  },
  {
    "id": "training_550_4",
    "table_caption": "Table: Summarising the Chinese land parcel and district data used in the analysis. Variables Deﬁnition Mean Std.Dev Dependent Variable Logprice Log of the land parcels' leasing price per square meter (RMB/m2) 7.414 1.029 Lower level variables (land parcels) Logarea Log of the land parcel area (m2) 9.301 1.532 LogDcbd The log of the distance between a land parcel and the CBD 8.956 0.675 LogDele The log of the distance to the nearest elementary school 6.591 0.920 LogDpark The log of the distance to the nearest park 7.774 0.704 LogDriver The log of the distance to the nearest river 7.516 0.931 LogDsubway The log of the distance to the nearest subway station 7.148 0.895 Year dummies The year when the land parcel was leased Higher level variables Buildings1949 Percentage of buildings built before 1949 in each Jiedao 0.042 0.109 Crimerate Number of reported serious crimes per 1000 people in each Jiedao 5.246 6.112 Popden Population density in each Jiedao (1000 people/km2) 1.937 2.670 doi:10.1371/journal.pone.0130761.t001 ",
    "table_content": "|| Variables | Definition | Mean | Std.Dev ||\n||  Dependent Variable  |  Dependent Variable  |  Dependent Variable  |  Dependent Variable  ||\n||  Year dummies  | The year when the land parcel was leased | blank | blank ||\n||  Higher level variables  |  Higher level variables  |  Higher level variables  |  Higher level variables  ||\n|| Buildings1949 | Percentage of buildings built before 1949 in each Jiedao  | 0.042 | 0.109 ||\n|| Crimerate | Number of reported serious crimes per 1000 people in each Jiedao  | 5.246 | 6.112 ||\n|| Popden | Population density in each Jiedao (1000 people/km 2 ) | 1.937 | 2.670 ||\n|| Logprice | Log of the land parcels' leasing price per square meter (RMB/m 2 ) | 7.414 | 1.029 ||\n||  Lower level variables (land parcels)  |  Lower level variables (land parcels)  |  Lower level variables (land parcels)  |  Lower level variables (land parcels)  ||\n|| Logarea | Log of the land parcel area (m 2 ) | 9.301 | 1.532 ||\n|| LogDcbd | The log of the distance between a land parcel and the CBD | 8.956 | 0.675 ||\n|| LogDele | The log of the distance to the nearest elementary school | 6.591 | 0.920 ||\n|| LogDpark | The log of the distance to the nearest park | 7.774 | 0.704 ||\n|| LogDriver | The log of the distance to the nearest river | 7.516 | 0.931 ||\n|| LogDsubway | The log of the distance to the nearest subway station | 7.148 | 0.895 ||",
    "claim": "The mean crime rate is 5.246 per 1000 people. A 1 unit increase in crime rate corresponds to an increase of approximately 0.052 in the log price, suggesting that higher crime rates are associated with higher land prices.",
    "label": "refute"
  },
  {
    "id": "training_945_2",
    "table_caption": "Table: Description of the study cohorts. Reference cohort (n = 10) Test cohort (n = 90) Median age (min-max) 70.0 (36–91) 68.0 (19–90) p = 0.3099 Female sex 5 (50%) 47 (52.2%) p = 0.8414 ICU 5 (50%) 38 (42.2%) p = 0.8713 Respiratory support none 8 (80%) 80 (89%) p = 0.7141 NIV 1 (10%) 5 (5.5%) IV 1 (10%) 5 (5.5%) CVC type 3-lumen 9 (90%) 86 (96%) p = 0.5654 4-lumen 1 (10%) 3 (3%) 5-lumen 0 (0%) 1 (1%) CVC insertion site R internal jugular vein 5 (50%) 48 (53.3%) p = 0.8312 L internal jugular vein 4 (40%) 37 (41.1%) R subclavian vein 0 (0%) 2 (2.2%) L subclavian vein 1 (10%) 3 (3.3%) CVC insertion US guided 7 (70%) 74 (82.2%) p = 0.6102 Abbreviations used: CVC: central venous catheter, ICU: intensive care unit, IMC: intermediate care unit, IV: invasive ventilation, L: left, NIV: non-invasive R: right, US: ultrasound. ",
    "table_content": "|| blank | Reference cohort (n = 10) | Test cohort (n = 90) | blank ||\n|| Median age (min-max) | 70.0 (36–91) | 68.0 (19–90) | p = 0.3099 ||\n|| 4-lumen | 1 (10%) | 3 (3%) | p = 0.5654 ||\n|| 5-lumen | 0 (0%) | 1 (1%) | p = 0.5654 ||\n|| CVC insertion site | CVC insertion site | CVC insertion site | CVC insertion site ||\n|| R internal jugular vein | 5 (50%) | 48 (53.3%) | p = 0.8312 ||\n|| L internal jugular vein | 4 (40%) | 37 (41.1%) | p = 0.8312 ||\n|| R subclavian vein | 0 (0%) | 2 (2.2%) | p = 0.8312 ||\n|| L subclavian vein | 1 (10%) | 3 (3.3%) | p = 0.8312 ||\n|| CVC insertion US guided | 7 (70%) | 74 (82.2%) | p = 0.6102 ||\n|| Female sex | 5 (50%) | 47 (52.2%) | p = 0.8414 ||\n|| ICU | 5 (50%) | 38 (42.2%) | p = 0.8713 ||\n|| Respiratory support | Respiratory support | Respiratory support | Respiratory support ||\n|| none | 8 (80%) | 80 (89%) | p = 0.7141 ||\n|| NIV | 1 (10%) | 5 (5.5%) | p = 0.7141 ||\n|| IV | 1 (10%) | 5 (5.5%) | p = 0.7141 ||\n|| CVC type | CVC type | CVC type | CVC type ||\n|| 3-lumen | 9 (90%) | 86 (96%) | p = 0.5654 ||",
    "claim": "The proportion of females in both cohorts is significantly different, with the reference cohort having 50% females and the test cohort having 52.2% females. This disparity in gender distribution suggests that gender is likely to be a confounding factor in the analysis of clinical outcomes between the two cohorts.",
    "label": "refute"
  },
  {
    "id": "training_1248_5",
    "table_caption": "Table: to the ap- in per crystallized-type intelligence (gc). All CNVs Deletions Duplications Cohort Sample Size Gene Load Rate Gene Load Rate Gene Load Rate ABC1936 412 37 0.090 8 0.019 29 0.070 LBC1921 492 60 0.122 10 0.020 50 0.102 LBC1936 887 144 0.162 56 0.063 88 0.099 Manchester 723 81 0.112 19 0.026 62 0.086 Newcastle 698 120 0.172 4 0.006 116 0.167 Total 3210 442 0.138 97 0.030 345 0.108 Gene load, is calculated as the number of genes whose co-ordinates +/220 kb intersect with a CNV that passes QC checks (length $500 kb, and frequency ",
    "table_content": "|| Cohort | Sample Size | All CNVs | All CNVs | Deletions | Deletions | Duplications | Duplications ||\n|| Cohort | Sample Size | Gene Load | Rate | Gene Load | Rate | Gene Load | Rate ||\n|| ABC1936 | 412 | 37 | 0.090 | 8 | 0.019 | 29 | 0.070 ||\n|| LBC1921 | 492 | 60 | 0.122 | 10 | 0.020 | 50 | 0.102 ||\n|| LBC1936 | 887 | 144 | 0.162 | 56 | 0.063 | 88 | 0.099 ||\n|| Manchester | 723 | 81 | 0.112 | 19 | 0.026 | 62 | 0.086 ||\n|| Newcastle | 698 | 120 | 0.172 | 4 | 0.006 | 116 | 0.167 ||\n|| Total | 3210 | 442 | 0.138 | 97 | 0.030 | 345 | 0.108 ||",
    "claim": "The total gene load rate for all CNVs across all cohorts is 0.138, which is about 15% lower than the average of the individual cohort rates, indicating a cumulative effect when aggregating data.",
    "label": "refute"
  },
  {
    "id": "training_172_1",
    "table_caption": "Table: expressed proteins was increased (Table 4). The overall The influence of the nucleotides downstream from the genes with GNN codons in the second position were removed from datasets. (H0: there is no difference between nucleotide frequencies in all genes and HEG). organism G4 C5 P-value HEG/all ratio P-value HEG/all ratio E. coli 1.000 1.0 0.048 1.5 B. subtilis 0.490 0.7 0.111 1.7 H. pylori 0.644 1.2 0.004 2.6 H. influenzae 0.336 1.4 0.010 1.8 M. tuberculosis 0.010 0.0 0.495 1.2 T. pallidum 0.524 1.2 1.000 0.9 R. prowazekii 0.012 2.8 0.010 1.9 M. genitalium 0.298 1.3 0.763 1.2 B. burgdorferi 0.011 2.1 0.011 2.6 A. fulgidus 0.177 1.4 0.073 2.0 M. jannaschii 0.282 1.3 0.033 2.5 P. horikoshii 1.000 1.0 0.030 2.2 S. cerevisiae 0.006 1.8 2.8E-04 1.7 S. pombe 0.011 1.7 0.010 1.6 P. falciparum 0.004 2.1 1.3E-05 3.9 ",
    "table_content": "|| organism | G 4 | G 4 | C 5 | C 5 ||\n|| organism | P-value | HEG/all ratio | P-value | HEG/all ratio ||\n|| B. burgdorferi | 0.011 | 2.1 | 0.011 | 2.6 ||\n|| A. fulgidus | 0.177 | 1.4 | 0.073 | 2.0 ||\n|| M. jannaschii | 0.282 | 1.3 | 0.033 | 2.5 ||\n|| P. horikoshii | 1.000 | 1.0 | 0.030 | 2.2 ||\n|| S. cerevisiae | 0.006 | 1.8 | 2.8E-04 | 1.7 ||\n|| S. pombe | 0.011 | 1.7 | 0.010 | 1.6 ||\n|| P. falciparum | 0.004 | 2.1 | 1.3E-05 | 3.9 ||\n|| E. coli | 1.000 | 1.0 | 0.048 | 1.5 ||\n|| B. subtilis | 0.490 | 0.7 | 0.111 | 1.7 ||\n|| H. pylori | 0.644 | 1.2 | 0.004 | 2.6 ||\n|| H. influenzae | 0.336 | 1.4 | 0.010 | 1.8 ||\n|| M. tuberculosis | 0.010 | 0.0 | 0.495 | 1.2 ||\n|| T. pallidum | 0.524 | 1.2 | 1.000 | 0.9 ||\n|| R. prowazekii | 0.012 | 2.8 | 0.010 | 1.9 ||\n|| M. genitalium | 0.298 | 1.3 | 0.763 | 1.2 ||",
    "claim": "The organism S. cerevisiae exhibits the most statistically significant difference in nucleotide frequencies at the C5 position, with a p-value of 1.3E-05, indicating a strong deviation from the null hypothesis of no difference.",
    "label": "refute"
  },
  {
    "id": "training_368_5",
    "table_caption": "Table: (mg L21) in the Mission Aransas Estuary. Seasonal nutrient removal Water temp (6C) Seston (mg L21) Chl a (mg L21) Clearance rate (mg ind21 min21) kg N denitrified km22 kg N buried km22 Winter 14.4 27.7 3.68 0.063 85.20 42.60 Spring 20.7 36.5 4.12 0.115 154.71 77.36 Summer 30.4 29.8 2.69 0.072 96.86 48.43 Fall 23.1 28.4 6.31 0.124 165.73 82.87 Annual Total 502.50 251.25 See text for details of calculations of clearance rate and N removal. doi:10.1371/journal.pone.0065314.t002 ",
    "table_content": "|| blank | Water temp (°C) | Seston(mg L −1 ) | Chl a(µg L −1 ) | Clearance rate (µg ind −1 min −1 ) | Seasonal nutrient removal | Seasonal nutrient removal ||\n|| blank | Water temp (°C) | Seston(mg L −1 ) | Chl a(µg L −1 ) | Clearance rate (µg ind −1 min −1 ) | kg N denitrified km −2  | kg N buried km −2  ||\n||  Winter  | 14.4 | 27.7 | 3.68 | 0.063 | 85.20 | 42.60 ||\n||  Spring  | 20.7 | 36.5 | 4.12 | 0.115 | 154.71 | 77.36 ||\n||  Summer  | 30.4 | 29.8 | 2.69 | 0.072 | 96.86 | 48.43 ||\n||  Fall  | 23.1 | 28.4 | 6.31 | 0.124 | 165.73 | 82.87 ||\n||  Annual Total  |  Annual Total  |  Annual Total  |  Annual Total  |  Annual Total  | 502.50 | 251.25 ||",
    "claim": "The clearance rate increases by 15% from winter to fall, while chlorophyll a concentration increases by 71.2%. This suggests a strong correlation between these two parameters, potentially indicating that higher chlorophyll a levels enhance the clearance rate.",
    "label": "refute"
  },
  {
    "id": "training_216_4",
    "table_caption": "Table: List of species and corresponding models. Species Description Models x Full-length RNA produced from promoter pX TI, TI+AR, GN y Full-length RNA produced from promoter pY TI, TI+AR, GN xk Truncated RNA produced from promoter pX TI, TI+AR, GN yh Truncated RNA produced from promoter pY TI, TI+AR GN x:y RNA hybrid between sense and antisense full-length RNA TI+AR, GN xk:y RNA hybrid between sense truncated and antisense full-length RNA TI+AR, GN x:yh RNA hybrid between full-length sense and antisense truncated RNA TI+AR, GN xk:yh RNA hybrid between truncated sense and antisense truncated RNA TI+AR, GN X Protein encoded by gene X GN Y Protein encoded by gene Y GN Z Activator protein GN W Signaling molecule or upstream protein GN X:Z Protein hybrid between X and Z proteins GN OY,T Total concentration of operator sites at promoter pY GN OY Unbound operator sites at promoter pY GN doi:10.1371/journal.pone.0133873.t002 ",
    "table_content": "|| Species | Description | Models ||\n||  x  | Full-length RNA produced from promoter pX | TI, TI+AR, GN ||\n|| Y | Protein encoded by gene Y | GN ||\n|| Z | Activator protein | GN ||\n|| W | Signaling molecule or upstream protein | GN ||\n|| X:Z | Protein hybrid between X and Z proteins | GN ||\n|| O Y,T  | Total concentration of operator sites at promoter pY | GN ||\n|| O Y  | Unbound operator sites at promoter pY | GN ||\n||  y  | Full-length RNA produced from promoter pY | TI, TI+AR, GN ||\n||  x  k  | Truncated RNA produced from promoter pX | TI, TI+AR, GN ||\n||  y  h  | Truncated RNA produced from promoter pY | TI, TI+AR GN ||\n||  x : y  | RNA hybrid between sense and antisense full-length RNA | TI+AR, GN ||\n||  x  k : y  | RNA hybrid between sense truncated and antisense full-length RNA | TI+AR, GN ||\n||  x : y  h  | RNA hybrid between full-length sense and antisense truncated RNA | TI+AR, GN ||\n||  x  k : y  h  | RNA hybrid between truncated sense and antisense truncated RNA | TI+AR, GN ||\n|| X | Protein encoded by gene X | GN ||",
    "claim": "The difference between the total concentration of operator sites at promoter pY and the unbound operator sites is a variable value, reflecting an inconsistent level of operator occupancy across the GN model.",
    "label": "refute"
  },
  {
    "id": "training_98_5",
    "table_caption": "Table: ME-matrix statistics. Type Number Transcription Units 1,152 Genes 1,937 - Protein coding genes 1,827 - RNA coding genes 110 Network reactions 76,589 Network components 62,212 Coupling constraints between reactions 3,044 Summary of ME-matrix content. doi:10.1371/journal.pone.0045635.t001 ",
    "table_content": "|| Type | Number ||\n|| Transcription Units | 1,152 ||\n|| Genes | 1,937 ||\n|| - Protein coding genes | 1,827 ||\n|| - RNA coding genes | 110 ||\n|| Network reactions | 76,589 ||\n|| Network components | 62,212 ||\n|| Coupling constraints between reactions | 3,044 ||",
    "claim": "The total number of biological elements, including transcription units, genes, network reactions, network components, and coupling constraints, sums to 145,000, highlighting the extensive scale of the ME-matrix model.",
    "label": "refute"
  },
  {
    "id": "training_1329_5",
    "table_caption": "Table: Table 3 Time and method of diagnosis Time Method No. of cases Preoperative Endoscopy 12 Curettage of fistula 3 Direct tumor biopsy 2 Intraoperative Pathological examination 3 Postoperative Pathological examination 14 Table Stage 0, I II ",
    "table_content": "|| Time | Method | No. of cases ||\n|| Preoperative | Endoscopy | 12 ||\n|| Preoperative | Curettage of fistula | 3 ||\n|| Preoperative | Direct tumor biopsy | 2 ||\n|| Intraoperative | Pathological examination | 3 ||\n|| Postoperative | Pathological examination | 14 ||",
    "claim": "The ratio of cases diagnosed by endoscopy to those diagnosed by curettage of fistula and direct tumor biopsy combined is 4.",
    "label": "refute"
  },
  {
    "id": "training_893_5",
    "table_caption": "Table: Authors’ JK and study and design read Ethics This Graduate Table 2 Differential diagnosis of perineurioma (PN) in immunohistochemical staining (IHC) Neurogenic tumor/IHC EMA S-100 Claudin-1 Glut-1 Perineurioma + − + + Schwannoma − + − − Neurofibroma − + − − Traumatic neuroma − + − − + positive, − negative, EMA epithelial membrane antigen ",
    "table_content": "|| Neurogenic tumor/IHC | EMA | S-100 | Claudin-1 | Glut-1 ||\n|| Perineurioma | + | − | + | + ||\n|| Schwannoma | − | + | − | − ||\n|| Neurofibroma | − | + | − | − ||\n|| Traumatic neuroma | − | + | − | − ||",
    "claim": "The combination of negative EMA, Claudin-1, and Glut-1, along with positive S-100, in perineurioma, compared to the negative results for these markers in other tumors, underscores the importance of using a panel of markers for accurate differential diagnosis. This approach minimizes the risk of misdiagnosis and ensures precise identification of perineurioma.",
    "label": "refute"
  },
  {
    "id": "training_463_5",
    "table_caption": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) ",
    "table_content": "|| blank | Sensitivity | Specificity | Positive predictive value | Negative predictive value | Accuracy ||\n|| SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) | SINGLE TIME FALLERS ( N = 52) ||\n|| All combined | 0.83 (0.82, 0.84) | 0.83 (0.82, 0.84) | 0.84 (0.83, 0.85) | 0.84 (0.83, 0.85) | 0.83 (0.82, 0.84) ||\n|| PGME | 0.71 (0.70, 0.72) | 0.80 (0.79, 0.81) | 0.79 (0.78, 0.80) | 0.74 (0.73, 0.75) | 0.76 (0.75, 0.77) ||\n|| Gait features + Demograph. var | 0.61 (0.60, 0.62) | 0.76 (0.75, 0.77) | 0.73 (0.72, 0.74) | 0.66 (0.65, 0.67) | 0.68 (0.67, 0.69) ||\n|| Fall history: 6 months | 0.47 (0.46, 0.48) | 0.67 (0.65, 0.68) | 0.59 (0.57, 0.60) | 0.56 (0.55, 0.57) | 0.57 (0.56, 0.58) ||\n|| All combined | 0.75 (0.73, 0.76) | 0.80 (0.79, 0.81) | 0.80 (0.79, 0.81) | 0.77 (0.76, 0.78) | 0.77 (0.76, 0.78) ||\n|| MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) ||\n|| PGME | 0.67 (0.66, 0.69) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.68 (0.67, 0.69) ||\n|| Gait features + demograph var | 0.79 (0.77, 0.80) | 0.76 (0.75, 0.77) | 0.77 (0.76, 0.78) | 0.79 (0.78, 0.80) | 0.77 (0.76, 0.80) ||\n|| Fall history: 6 months | 0.55 (0.53, 0.56) | 0.65 (0.64, 0.67) | 0.62 (0.61, 0.63) | 0.60 (0.59, 0.61) | 0.60 (0.59, 0.61) ||",
    "claim": "The accuracy of the \"Fall history",
    "label": "refute"
  },
  {
    "id": "training_135_2",
    "table_caption": "Table: Sample Dose aPTT (s) PT (s) PT (INR) Control Saline 32.1 ± 0.4 12.0 ± 0.3 1.00 JJ1 0.31 μg/mouse 31.9 ± 0.6 12.4 ± 0.5 1.08 0.61 μg/mouse 40.1 ± 1.1* 17.2 ± 1.4* 2.37 1.23 μg/mouse 49.4 ± 1.5* 22.3 ± 0.6* 4.42* 3.06 μg/mouse 55.8 ± 1.2* 26.8 ± 0.4* 6.88* Table 3. Ex vivo coagulation time of JJ1a. aEach value represents to control. ",
    "table_content": "|| Sample | Dose | aPTT (s) | PT (s) | PT (INR) ||\n|| Control | Saline | 32.1 ± 0.4 | 12.0 ± 0.3 | 1.00 ||\n||  JJ1  | 0.31 μg/mouse | 31.9 ± 0.6 | 12.4 ± 0.5 | 1.08 ||\n||  JJ1  | 0.61 μg/mouse | 40.1 ± 1.1* | 17.2 ± 1.4* | 2.37 ||\n||  JJ1  | 1.23 μg/mouse | 49.4 ± 1.5* | 22.3 ± 0.6* | 4.42* ||\n||  JJ1  | 3.06 μg/mouse | 55.8 ± 1.2* | 26.8 ± 0.4* | 6.88* ||",
    "claim": "The PT increases with the dose of JJ1, with a more than 120% increase from the lowest to the highest dose, suggesting a significant dose-dependent effect on the extrinsic coagulation pathway.",
    "label": "refute"
  },
  {
    "id": "training_1211_3",
    "table_caption": "Table: Table 1 Validation of the miR-SEQ expression profiles of selected miRNAs by qRT-PCR miR-name Accession No. E. coli F18-resistant group E. coli F18-sensitive group P-value ssc-miR-499-5p MIMAT0013877 2.370 ± 1.109 0.467 ± 0.055 0.041* ssc-miR-676-5p MIMAT0017382 1.890 ± 1.181 0.650 ± 0.294 0.163 ssc-miR-432-3p MIMAT0017384 1.830 ± 1.344 0.821 ± 0.563 0.215 ssc-miR-196b MIMAT0013923 2.275 ± 0.991 0.478 ± 0.079 0.036* ssc-miR-421-5p MIMAT0017970 0.593 ± 0.183 0.378 ± 0.011 0.127 ssc-miR-202-5p MIMAT0013948 1.878 ± 1.322 0.695 ± 0.332 0.133 ssc-miR-885-3p MIMAT0013903 1.284 ± 0.492 0.859 ± 0.269 0.180 ssc-miR-493-5p MIMAT0025377 1.397 ± 0.680 0.814 ± 0.154 0.146 ssc-miR-218-3p MIMAT0017969 0.649 ± 0.443 1.901 ± 0.553 0.012* ssc-miR-155-3p MIMAT0017953 0.817 ± 0.442 1.659 ± 0.823 0.280 ssc-miR-208b MIMAT0013912 0.808 ± 0.408 1.538 ± 0.727 0.130 ssc-miR-187 MIMAT0020587 0.815 ± 0.508 1.404 ± 0.044 0.231 ssc-miR-450b-3p MIMAT0017380 0.427 ± 0.127 0.559 ± 0.112 0.171 ssc-miR-136 MIMAT0002158 0.582 ± 0.224 1.939 ± 0.850 0.045* ssc-miR-424-3p MIMAT0013921 0.742 ± 0.234 1.625 ± 0.926 0.215 *p < 0.05 ",
    "table_content": "|| miR-name | Accession No. |  E. coli F18-resistant group |  E. coli F18-sensitive group |  P -value ||\n|| ssc-miR-499-5p | MIMAT0013877 | 2.370 ± 1.109 | 0.467 ± 0.055 | 0.041* ||\n|| ssc-miR-155-3p | MIMAT0017953 | 0.817 ± 0.442 | 1.659 ± 0.823 | 0.280 ||\n|| ssc-miR-208b | MIMAT0013912 | 0.808 ± 0.408 | 1.538 ± 0.727 | 0.130 ||\n|| ssc-miR-187 | MIMAT0020587 | 0.815 ± 0.508 | 1.404 ± 0.044 | 0.231 ||\n|| ssc-miR-450b-3p | MIMAT0017380 | 0.427 ± 0.127 | 0.559 ± 0.112 | 0.171 ||\n|| ssc-miR-136 | MIMAT0002158 | 0.582 ± 0.224 | 1.939 ± 0.850 | 0.045* ||\n|| ssc-miR-424-3p | MIMAT0013921 | 0.742 ± 0.234 | 1.625 ± 0.926 | 0.215 ||\n|| ssc-miR-676-5p | MIMAT0017382 | 1.890 ± 1.181 | 0.650 ± 0.294 | 0.163 ||\n|| ssc-miR-432-3p | MIMAT0017384 | 1.830 ± 1.344 | 0.821 ± 0.563 | 0.215 ||\n|| ssc-miR-196b | MIMAT0013923 | 2.275 ± 0.991 | 0.478 ± 0.079 | 0.036* ||\n|| ssc-miR-421-5p | MIMAT0017970 | 0.593 ± 0.183 | 0.378 ± 0.011 | 0.127 ||\n|| ssc-miR-202-5p | MIMAT0013948 | 1.878 ± 1.322 | 0.695 ± 0.332 | 0.133 ||\n|| ssc-miR-885-3p | MIMAT0013903 | 1.284 ± 0.492 | 0.859 ± 0.269 | 0.180 ||\n|| ssc-miR-493-5p | MIMAT0025377 | 1.397 ± 0.680 | 0.814 ± 0.154 | 0.146 ||\n|| ssc-miR-218-3p | MIMAT0017969 | 0.649 ± 0.443 | 1.901 ± 0.553 | 0.012* ||",
    "claim": "ssc-miR-676-5p exhibits the highest variability in expression within the resistant group, as indicated by its standard deviation relative to its mean, which may imply a less consistent role in resistance mechanisms.",
    "label": "refute"
  },
  {
    "id": "training_1211_3",
    "table_caption": "Table: Table 1 Validation of the miR-SEQ expression profiles of selected miRNAs by qRT-PCR miR-name Accession No. E. coli F18-resistant group E. coli F18-sensitive group P-value ssc-miR-499-5p MIMAT0013877 2.370 ± 1.109 0.467 ± 0.055 0.041* ssc-miR-676-5p MIMAT0017382 1.890 ± 1.181 0.650 ± 0.294 0.163 ssc-miR-432-3p MIMAT0017384 1.830 ± 1.344 0.821 ± 0.563 0.215 ssc-miR-196b MIMAT0013923 2.275 ± 0.991 0.478 ± 0.079 0.036* ssc-miR-421-5p MIMAT0017970 0.593 ± 0.183 0.378 ± 0.011 0.127 ssc-miR-202-5p MIMAT0013948 1.878 ± 1.322 0.695 ± 0.332 0.133 ssc-miR-885-3p MIMAT0013903 1.284 ± 0.492 0.859 ± 0.269 0.180 ssc-miR-493-5p MIMAT0025377 1.397 ± 0.680 0.814 ± 0.154 0.146 ssc-miR-218-3p MIMAT0017969 0.649 ± 0.443 1.901 ± 0.553 0.012* ssc-miR-155-3p MIMAT0017953 0.817 ± 0.442 1.659 ± 0.823 0.280 ssc-miR-208b MIMAT0013912 0.808 ± 0.408 1.538 ± 0.727 0.130 ssc-miR-187 MIMAT0020587 0.815 ± 0.508 1.404 ± 0.044 0.231 ssc-miR-450b-3p MIMAT0017380 0.427 ± 0.127 0.559 ± 0.112 0.171 ssc-miR-136 MIMAT0002158 0.582 ± 0.224 1.939 ± 0.850 0.045* ssc-miR-424-3p MIMAT0013921 0.742 ± 0.234 1.625 ± 0.926 0.215 *p < 0.05 ",
    "table_content": "|| miR-name | Accession No. |  E. coli F18-resistant group |  E. coli F18-sensitive group |  P -value ||\n|| ssc-miR-499-5p | MIMAT0013877 | 2.370 ± 1.109 | 0.467 ± 0.055 | 0.041* ||\n|| ssc-miR-155-3p | MIMAT0017953 | 0.817 ± 0.442 | 1.659 ± 0.823 | 0.280 ||\n|| ssc-miR-208b | MIMAT0013912 | 0.808 ± 0.408 | 1.538 ± 0.727 | 0.130 ||\n|| ssc-miR-187 | MIMAT0020587 | 0.815 ± 0.508 | 1.404 ± 0.044 | 0.231 ||\n|| ssc-miR-450b-3p | MIMAT0017380 | 0.427 ± 0.127 | 0.559 ± 0.112 | 0.171 ||\n|| ssc-miR-136 | MIMAT0002158 | 0.582 ± 0.224 | 1.939 ± 0.850 | 0.045* ||\n|| ssc-miR-424-3p | MIMAT0013921 | 0.742 ± 0.234 | 1.625 ± 0.926 | 0.215 ||\n|| ssc-miR-676-5p | MIMAT0017382 | 1.890 ± 1.181 | 0.650 ± 0.294 | 0.163 ||\n|| ssc-miR-432-3p | MIMAT0017384 | 1.830 ± 1.344 | 0.821 ± 0.563 | 0.215 ||\n|| ssc-miR-196b | MIMAT0013923 | 2.275 ± 0.991 | 0.478 ± 0.079 | 0.036* ||\n|| ssc-miR-421-5p | MIMAT0017970 | 0.593 ± 0.183 | 0.378 ± 0.011 | 0.127 ||\n|| ssc-miR-202-5p | MIMAT0013948 | 1.878 ± 1.322 | 0.695 ± 0.332 | 0.133 ||\n|| ssc-miR-885-3p | MIMAT0013903 | 1.284 ± 0.492 | 0.859 ± 0.269 | 0.180 ||\n|| ssc-miR-493-5p | MIMAT0025377 | 1.397 ± 0.680 | 0.814 ± 0.154 | 0.146 ||\n|| ssc-miR-218-3p | MIMAT0017969 | 0.649 ± 0.443 | 1.901 ± 0.553 | 0.012* ||",
    "claim": "ssc-miR-499-5p exhibits the highest variability in expression within the resistant group, as indicated by its standard deviation relative to its mean, which may imply a less consistent role in resistance mechanisms.",
    "label": "refute"
  },
  {
    "id": "training_214_3",
    "table_caption": "Table: Distribution of overall visits, fever-related illnesses, influenza-1-like illnesses, and positive results by age. Age group All visits (n = 142,563) Fever syndromes (n = 12,136) ILI syndromes (n = 7,316) Sampled ILI (n = 740) A(H1N1)pdm positive (n = 233) n (%) n (%) n (%) p n (%) p n (%) P* ,1 year 14,142 (9.9) 1,394 (11.5) 951 (68.2) ,0.01 53 (6.1) ,0.01 11 (20.7) --- 1–4 years 23,774 (16.7) 3,249 (26.8) 2,212 (68.1) ,0.01 223 (11.2) 0.1 52 (23.3) 0.7 5–14 years 24,579 (17.2) 3,485 (28.7) 2,175 (62.4) ,0.01 237 (11.3) 0.1 97 (40.9) ,0.01 15–24 years 26,415 (18.5) 1,944 (16.0) 1,028 (52.8) ,0.01 110 (11.2) 0.2 36 (32.7) 0.1 $25 years 53,653 (37.6) 2,064 (17.0) 950 (46.0) --- 117 (13.1) --- 37 (31.6) 0.2 *comparison of A(H1N1)pdm positivity by age using logistic regression analysis. doi:10.1371/journal.pone.0037067.t001 ",
    "table_content": "|| Age group | All visits (n = 142,563) | All visits (n = 142,563) | Fever syndromes (n = 12,136) | Fever syndromes (n = 12,136) | ILI syndromes (n = 7,316) | ILI syndromes (n = 7,316) | ILI syndromes (n = 7,316) | Sampled ILI (n = 740) | Sampled ILI (n = 740) | Sampled ILI (n = 740) | A(H1N1)pdm positive (n = 233) | A(H1N1)pdm positive (n = 233) | A(H1N1)pdm positive (n = 233) ||\n|| Age group | n | (%) | n | (%) | n | (%) | p | n | (%) | p | n | (%) | P *  ||\n|| <1 year | 14,142 | (9.9) | 1,394 | (11.5) | 951 | (68.2) | <0.01 | 53 | (6.1) | <0.01 | 11 | (20.7) | --- ||\n|| 1–4 years | 23,774 | (16.7) | 3,249 | (26.8) | 2,212 | (68.1) | <0.01 | 223 | (11.2) | 0.1 | 52 | (23.3) | 0.7 ||\n|| 5–14 years | 24,579 | (17.2) | 3,485 | (28.7) | 2,175 | (62.4) | <0.01 | 237 | (11.3) | 0.1 | 97 | (40.9) | <0.01 ||\n|| 15–24 years | 26,415 | (18.5) | 1,944 | (16.0) | 1,028 | (52.8) | <0.01 | 110 | (11.2) | 0.2 | 36 | (32.7) | 0.1 ||\n|| ≥25 years | 53,653 | (37.6) | 2,064 | (17.0) | 950 | (46.0) | --- | 117 | (13.1) | --- | 37 | (31.6) | 0.2 ||",
    "claim": "The age group 5–14 years has the highest proportion of ILI syndromes relative to fever syndromes, with over two-thirds of fever cases being classified as ILI. This suggests a higher likelihood of ILI diagnosis among children with fever.",
    "label": "refute"
  },
  {
    "id": "training_541_4",
    "table_caption": "Table: Table 1 Baseline patient demographics and disease characteristics CT-P13 3 mg/kg (n = 302) RP 3 mg/kg (n = 304) Total (N = 606) Age, median, years (range) 50 (18–75) 50 (21–74) 50 (18–75) Sex, n (%) Female 245 (81.1) 256 (84.2) 501 (82.7) Male 57 (18.9) 48 (15.8) 105 (17.3) Ethnicity, n (%) Asian 34 (11.3) 37 (12.2) 71 (11.7) Black 2 (0.7) 1 (0.3) 3 (0.5) White 220 (72.8) 222 (73.0) 442 (72.9) Other 46 (15.2) 44 (14.5) 90 (14.9) Height, cm, median (range) 162.3 (144.0–186.0) 162.0 (124.0–190.0) 162.0 (124.0–190.0) Weight, kg, median (range) 69.0 (36.5–134.0) 68.0 (36.0–136.0) 68.6 (36.0–136.0) BMI, kg/m2, median (range) 26.3 (13.9–49.8) 25.4 (15.0–53.1) 25.9 (13.9–53.1) Anti-CCP antibody-positive, n (%) 228 (75.5) 233 (76.6) 461 (76.1) IgA RF-positive, n (%) 131 (43.4) 134 (44.1) 265 (43.7) IgM RF-positive, n (%) 225 (74.5) 220 (72.4) 445 (73.4) IgG RF-positive, n (%) 173 (57.3) 171 (56.3) 344 (56.8) Joint count TJC, 68 joints 25.6 ± 13.9 24.0 ± 12.9 24.8 ± 13.4 SJC, 66 joints 16.2 ± 8.7 15.2 ± 8.3 15.7 ± 8.5 TJC, 28 joints 15.9 ± 6.4 15.1 ± 6.1 15.5 ± 6.2 SJC, 28 joints 12.0 ± 4.9 11.2 ± 4.7 11.6 ± 4.8 Duration of prior MTX therapy, weeks 97.7 ± 141.2 89.4 ± 96.5 93.6 ± 120.8 MTX dose, mg 15.6 ± 3.1 15.6 ± 3.2 15.6 ± 3.1 CDAI 40.9 ± 11.5 39.3 ± 11.1 40.1 ± 11.3 SDAI 42.8 ± 11.9 41.2 ± 11.7 42.0 ± 11.8 CRP, mg/dl 1.9 ± 2.5 1.9 ± 2.2 1.9 ± 2.4 ESR, mm/h 46.6 ± 22.4 48.5 ± 22.6 47.5 ± 22.5 DAS28-CRP 5.9 ± 0.8 5.8 ± 0.9 5.8 ± 0.9 HAQ 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.6 Patient assessment of pain 65.9 ± 17.4 65.5 ± 17.2 65.7 ± 17.3 Patient global assessment of disease activity 65.7 ± 17.2 65.4 ± 17.0 65.5 ± 17.1 Physician global assessment of disease activity 64.7 ± 14.3 65.0 ± 13.5 64.8 ± 13.9 BMI body mass index, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, Ig immunoglobulin, MTX methotrexate, RF rheumatoid factor, RP reference product (i.e., reference infliximab), SD standard deviation, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count ",
    "table_content": "|| blank | CT-P13 3 mg/kg ( n = 302) | RP 3 mg/kg ( n = 304) | Total ( N = 606) ||\n|| Age, median, years (range) | 50 (18–75) | 50 (21–74) | 50 (18–75) ||\n|| Height, cm, median (range) | 162.3 (144.0–186.0) | 162.0 (124.0–190.0) | 162.0 (124.0–190.0) ||\n|| Weight, kg, median (range) | 69.0 (36.5–134.0) | 68.0 (36.0–136.0) | 68.6 (36.0–136.0) ||\n|| BMI, kg/m 2 , median (range) | 26.3 (13.9–49.8) | 25.4 (15.0–53.1) | 25.9 (13.9–53.1) ||\n|| Anti-CCP antibody-positive, n (%) | 228 (75.5) | 233 (76.6) | 461 (76.1) ||\n|| IgA RF-positive, n (%) | 131 (43.4) | 134 (44.1) | 265 (43.7) ||\n|| IgM RF-positive, n (%) | 225 (74.5) | 220 (72.4) | 445 (73.4) ||\n|| IgG RF-positive, n (%) | 173 (57.3) | 171 (56.3) | 344 (56.8) ||\n|| Joint count | Joint count | Joint count | Joint count ||\n|| TJC, 68 joints | 25.6 ± 13.9 | 24.0 ± 12.9 | 24.8 ± 13.4 ||\n|| SJC, 66 joints | 16.2 ± 8.7 | 15.2 ± 8.3 | 15.7 ± 8.5 ||\n|| Sex, n (%) | Sex, n (%) | Sex, n (%) | Sex, n (%) ||\n|| TJC, 28 joints | 15.9 ± 6.4 | 15.1 ± 6.1 | 15.5 ± 6.2 ||\n|| SJC, 28 joints | 12.0 ± 4.9 | 11.2 ± 4.7 | 11.6 ± 4.8 ||\n|| Duration of prior MTX therapy, weeks | 97.7 ± 141.2 | 89.4 ± 96.5 | 93.6 ± 120.8 ||\n|| MTX dose, mg | 15.6 ± 3.1 | 15.6 ± 3.2 | 15.6 ± 3.1 ||\n|| CDAI | 40.9 ± 11.5 | 39.3 ± 11.1 | 40.1 ± 11.3 ||\n|| SDAI | 42.8 ± 11.9 | 41.2 ± 11.7 | 42.0 ± 11.8 ||\n|| CRP, mg/dl | 1.9 ± 2.5 | 1.9 ± 2.2 | 1.9 ± 2.4 ||\n|| ESR, mm/h | 46.6 ± 22.4 | 48.5 ± 22.6 | 47.5 ± 22.5 ||\n|| DAS28-CRP | 5.9 ± 0.8 | 5.8 ± 0.9 | 5.8 ± 0.9 ||\n|| HAQ | 1.6 ± 0.6 | 1.6 ± 0.6 | 1.6 ± 0.6 ||\n|| Female | 245 (81.1) | 256 (84.2) | 501 (82.7) ||\n|| Patient assessment of pain | 65.9 ± 17.4 | 65.5 ± 17.2 | 65.7 ± 17.3 ||\n|| Patient global assessment of disease activity | 65.7 ± 17.2 | 65.4 ± 17.0 | 65.5 ± 17.1 ||\n|| Physician global assessment of disease activity | 64.7 ± 14.3 | 65.0 ± 13.5 | 64.8 ± 13.9 ||\n|| Male | 57 (18.9) | 48 (15.8) | 105 (17.3) ||\n|| Ethnicity, n (%) | Ethnicity, n (%) | Ethnicity, n (%) | Ethnicity, n (%) ||\n|| Asian | 34 (11.3) | 37 (12.2) | 71 (11.7) ||\n|| Black | 2 (0.7) | 1 (0.3) | 3 (0.5) ||\n|| White | 220 (72.8) | 222 (73.0) | 442 (72.9) ||\n|| Other | 46 (15.2) | 44 (14.5) | 90 (14.9) ||",
    "claim": "The median BMI is slightly lower in the CT-P13 group compared to the RP group. The range of BMI values suggests a diverse patient population in terms of body composition, which is important for assessing treatment effects across different body types.",
    "label": "refute"
  },
  {
    "id": "training_508_5",
    "table_caption": "Table: Omega-3 EPA and DHA have many features and are necessary in health and in disease states [48]. Functions of Omega-3 EPA and DHA Biological Clinical They exert an anti-aggregant activity; reduce neuroinflammation They reduce the risk of coronary artery disease and sudden death; Increase HDL and lower LDL; are essential to fetal development; Modulate the endogenous synthesis of prostaglandins and leukotrienes, exerting an anti-inflammatory action, especially in rheumatoid arthritis and psoriasis; improve some forms of depression; efficacious in attention deficit syndrome; Favor the equilibrium of the immune system, especially in lupus and Crohn’s disease; modify physical properties of membrane lipids. help in the treatment of schizophrenia and bipolar disorders. ",
    "table_content": "|| Functions of Omega-3 EPA and DHA | Functions of Omega-3 EPA and DHA ||\n|| Biological | Clinical ||\n|| They exert an anti-aggregant activity; reduce neuroinflammation | They reduce the risk of coronary artery disease and sudden death; ||\n|| Increase HDL and lower LDL; | are essential to fetal development; ||\n|| Modulate the endogenous synthesis of prostaglandins and leukotrienes, exerting an anti-inflammatory action, especially in rheumatoid arthritis and psoriasis; | improve some forms of depression; efficacious in attention deficit syndrome; ||\n|| Favor the equilibrium of the immune system, especially in lupus and Crohn’s disease; modify physical properties of membrane lipids. | help in the treatment of schizophrenia and bipolar disorders. ||",
    "claim": "The impact of Omega-3 EPA and DHA on increasing HDL and lowering LDL can be quantified by calculating the net change in lipid profile. This involves a complex calculation of the percentage change in HDL and LDL levels, considering baseline lipid levels and the dose-response relationship of Omega-3 supplementation, resulting in a net improvement in the lipid profile.",
    "label": "refute"
  },
  {
    "id": "training_508_5",
    "table_caption": "Table: Omega-3 EPA and DHA have many features and are necessary in health and in disease states [48]. Functions of Omega-3 EPA and DHA Biological Clinical They exert an anti-aggregant activity; reduce neuroinflammation They reduce the risk of coronary artery disease and sudden death; Increase HDL and lower LDL; are essential to fetal development; Modulate the endogenous synthesis of prostaglandins and leukotrienes, exerting an anti-inflammatory action, especially in rheumatoid arthritis and psoriasis; improve some forms of depression; efficacious in attention deficit syndrome; Favor the equilibrium of the immune system, especially in lupus and Crohn’s disease; modify physical properties of membrane lipids. help in the treatment of schizophrenia and bipolar disorders. ",
    "table_content": "|| Functions of Omega-3 EPA and DHA | Functions of Omega-3 EPA and DHA ||\n|| Biological | Clinical ||\n|| They exert an anti-aggregant activity; reduce neuroinflammation | They reduce the risk of coronary artery disease and sudden death; ||\n|| Increase HDL and lower LDL; | are essential to fetal development; ||\n|| Modulate the endogenous synthesis of prostaglandins and leukotrienes, exerting an anti-inflammatory action, especially in rheumatoid arthritis and psoriasis; | improve some forms of depression; efficacious in attention deficit syndrome; ||\n|| Favor the equilibrium of the immune system, especially in lupus and Crohn’s disease; modify physical properties of membrane lipids. | help in the treatment of schizophrenia and bipolar disorders. ||",
    "claim": "The impact of Omega-3 EPA and DHA on increasing HDL and lowering LDL can be quantified by calculating the net change in lipid profile. This involves a complex calculation of the percentage change in HDL and LDL levels, considering baseline lipid levels and the dose-response relationship of Omega-3 supplementation, resulting in no net improvement in the lipid profile.",
    "label": "refute"
  },
  {
    "id": "training_558_5",
    "table_caption": "Table: Age Pooled analysis Regression Persistence Progression N* Rate (%) 95% CI I2% N* Rate (%) 95% CI I2% N* Rate (%) 95% CI I2% <25 75410,14–19 58.4 53.1–63.5 67.7 75515,16,18,19 31.3 22.4–41.9 77.3 56110,19 13.9 11.3–17.0 0 <30 93810,14,15,17–19 52.9 44.3–61.3 82.6 83215,16,18,19 32.1 23.5–42.1 76.2 66810,19 13.8 11.4–16.6 0 <35 105810,14,15,17–19 51.9 43.3–60.5 84.3 99915,16,18,19 34.5 31.6–37.5 0 75310,19 13.5 11.3–16.2 0 ≥35 17217 46.2 32.7–60.3 33.4 19716 32.5 26.3–39.4 0 139 15.1 10.0–22.1 0 Table 5. Pooled analysis of studies reporting age- dependent outcome rates of CIN after observational management. *References of included studies, data from the current report was included into all analyses ",
    "table_content": "|| Age | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis | Pooled analysis ||\n|| Age | Regression | Regression | Regression | Regression | Persistence | Persistence | Persistence | Persistence | Progression | Progression | Progression | Progression ||\n|| Age | N* | Rate (%) | 95% CI | I 2 % | N* | Rate (%) | 95% CI | I 2 % | N* | Rate (%) | 95% CI | I 2 % ||\n|| <25 | 754 10 , 14 – 19 | 58.4 | 53.1–63.5 | 67.7 | 755 15 , 16 , 18 , 19 | 31.3 | 22.4–41.9 | 77.3 | 561 10 , 19 | 13.9 | 11.3–17.0 | 0 ||\n|| <30 | 938 10 , 14 , 15 , 17 – 19 | 52.9 | 44.3–61.3 | 82.6 | 832 15 , 16 , 18 , 19 | 32.1 | 23.5–42.1 | 76.2 | 668 10 , 19 | 13.8 | 11.4–16.6 | 0 ||\n|| <35 | 1058 10 , 14 , 15 , 17 – 19 | 51.9 | 43.3–60.5 | 84.3 | 999 15 , 16 , 18 , 19 | 34.5 | 31.6–37.5 | 0 | 753 10 , 19 | 13.5 | 11.3–16.2 | 0 ||\n|| ≥35 | 172 17 | 46.2 | 32.7–60.3 | 33.4 | 197 16 | 32.5 | 26.3–39.4 | 0 | 139 | 15.1 | 10.0–22.1 | 0 ||",
    "claim": "The heterogeneity index (I2%) is highest in the <30 age group for regression rates, indicating substantial variability among studies. This high heterogeneity suggests that factors such as study design, population characteristics, or measurement methods may differ significantly across studies, affecting the consistency of the pooled estimates.",
    "label": "refute"
  },
  {
    "id": "training_1189_6",
    "table_caption": "Table: Binding free energy contribution of each amino acid at different epitope core locations. aa\\pos 1 2 3 4 5 6 7 8 9 ALA 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ARG 1.88 4.71 8.55 9.80 2.67 6.45 10.54 3.95 13.93 ASN 1.47 0.68 1.94 0.85 1.39 1.17 0.64 1.53 3.18 ASP 214.60 22.82 28.95 25.53 22.69 211.09 29.06 26.01 215.69 CYS 2.90 3.47 2.11 1.90 1.05 2.62 3.41 0.98 4.60 GLU 214.82 21.89 28.90 21.14 23.13 211.84 211.20 24.60 215.98 GLN 3.87 2.86 4.08 8.34 1.04 3.75 6.21 1.39 6.12 GLY 20.86 21.48 20.52 21.74 0.31 20.81 22.51 0.00 21.66 HIS 5.38 1.00 2.31 5.50 1.82 2.86 5.62 1.05 3.72 ILE 4.88 2.38 4.09 2.84 1.84 3.79 3.30 1.11 4.31 LEU 6.59 2.25 3.55 5.22 0.24 2.44 5.43 1.22 6.98 LYS 25.99 1.59 10.68 5.20 3.35 3.79 3.61 2.40 2.51 MET 8.22 4.41 7.42 8.29 0.02 6.32 5.69 1.45 9.45 PHE 12.14 2.16 6.12 6.45 2.60 3.37 6.19 1.37 8.66 PRO 0.60 23.51 0.93 22.79 2.32 0.01 1.98 22.71 0.60 SER 21.25 0.36 20.05 21.52 0.85 1.03 1.64 0.19 1.16 THR 0.57 1.23 20.69 0.23 0.65 3.66 0.80 0.20 0.42 TRP 13.49 2.02 6.32 25.37 3.42 5.03 10.29 1.43 7.35 TYR 12.20 2.06 5.44 3.37 3.20 4.02 7.05 1.22 12.80 VAL 4.48 1.42 0.95 2.15 0.58 2.81 2.46 0.42 2.67 Each row is an amino acid and the columns refer to pocket one to nine of the MHC class II epitope-binding groove. Each value is the difference of binding free energy in comparison with alanine in units of kcal/mol. Positive values indicate residues favorable for binding. ",
    "table_content": "|| aa\\pos | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 ||\n|| ALA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 ||\n|| ILE | 4.88 | 2.38 | 4.09 | 2.84 | 1.84 | 3.79 | 3.30 | 1.11 | 4.31 ||\n|| LEU | 6.59 | 2.25 | 3.55 | 5.22 | 0.24 | 2.44 | 5.43 | 1.22 | 6.98 ||\n|| LYS | −5.99 | 1.59 | 10.68 | 5.20 | 3.35 | 3.79 | 3.61 | 2.40 | 2.51 ||\n|| MET | 8.22 | 4.41 | 7.42 | 8.29 | 0.02 | 6.32 | 5.69 | 1.45 | 9.45 ||\n|| PHE | 12.14 | 2.16 | 6.12 | 6.45 | 2.60 | 3.37 | 6.19 | 1.37 | 8.66 ||\n|| PRO | 0.60 | −3.51 | 0.93 | −2.79 | 2.32 | 0.01 | 1.98 | −2.71 | 0.60 ||\n|| SER | −1.25 | 0.36 | −0.05 | −1.52 | 0.85 | 1.03 | 1.64 | 0.19 | 1.16 ||\n|| THR | 0.57 | 1.23 | −0.69 | 0.23 | 0.65 | 3.66 | 0.80 | 0.20 | 0.42 ||\n|| TRP | 13.49 | 2.02 | 6.32 | −5.37 | 3.42 | 5.03 | 10.29 | 1.43 | 7.35 ||\n|| TYR | 12.20 | 2.06 | 5.44 | 3.37 | 3.20 | 4.02 | 7.05 | 1.22 | 12.80 ||\n|| ARG | 1.88 | 4.71 | 8.55 | 9.80 | 2.67 | 6.45 | 10.54 | 3.95 | 13.93 ||\n|| VAL | 4.48 | 1.42 | 0.95 | 2.15 | 0.58 | 2.81 | 2.46 | 0.42 | 2.67 ||\n|| ASN | 1.47 | 0.68 | 1.94 | 0.85 | 1.39 | 1.17 | 0.64 | 1.53 | 3.18 ||\n|| ASP | −14.60 | −2.82 | −8.95 | −5.53 | −2.69 | −11.09 | −9.06 | −6.01 | −15.69 ||\n|| CYS | 2.90 | 3.47 | 2.11 | 1.90 | 1.05 | 2.62 | 3.41 | 0.98 | 4.60 ||\n|| GLU | −14.82 | −1.89 | −8.90 | −1.14 | −3.13 | −11.84 | −11.20 | −4.60 | −15.98 ||\n|| GLN | 3.87 | 2.86 | 4.08 | 8.34 | 1.04 | 3.75 | 6.21 | 1.39 | 6.12 ||\n|| GLY | −0.86 | −1.48 | −0.52 | −1.74 | 0.31 | −0.81 | −2.51 | 0.00 | −1.66 ||\n|| HIS | 5.38 | 1.00 | 2.31 | 5.50 | 1.82 | 2.86 | 5.62 | 1.05 | 3.72 ||",
    "claim": "Position 9 exhibits the highest variability in binding energy contributions across all amino acids, with a range of 29.62 kcal/mol, indicating diverse binding affinities at this position.",
    "label": "refute"
  },
  {
    "id": "training_1189_6",
    "table_caption": "Table: Binding free energy contribution of each amino acid at different epitope core locations. aa\\pos 1 2 3 4 5 6 7 8 9 ALA 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ARG 1.88 4.71 8.55 9.80 2.67 6.45 10.54 3.95 13.93 ASN 1.47 0.68 1.94 0.85 1.39 1.17 0.64 1.53 3.18 ASP 214.60 22.82 28.95 25.53 22.69 211.09 29.06 26.01 215.69 CYS 2.90 3.47 2.11 1.90 1.05 2.62 3.41 0.98 4.60 GLU 214.82 21.89 28.90 21.14 23.13 211.84 211.20 24.60 215.98 GLN 3.87 2.86 4.08 8.34 1.04 3.75 6.21 1.39 6.12 GLY 20.86 21.48 20.52 21.74 0.31 20.81 22.51 0.00 21.66 HIS 5.38 1.00 2.31 5.50 1.82 2.86 5.62 1.05 3.72 ILE 4.88 2.38 4.09 2.84 1.84 3.79 3.30 1.11 4.31 LEU 6.59 2.25 3.55 5.22 0.24 2.44 5.43 1.22 6.98 LYS 25.99 1.59 10.68 5.20 3.35 3.79 3.61 2.40 2.51 MET 8.22 4.41 7.42 8.29 0.02 6.32 5.69 1.45 9.45 PHE 12.14 2.16 6.12 6.45 2.60 3.37 6.19 1.37 8.66 PRO 0.60 23.51 0.93 22.79 2.32 0.01 1.98 22.71 0.60 SER 21.25 0.36 20.05 21.52 0.85 1.03 1.64 0.19 1.16 THR 0.57 1.23 20.69 0.23 0.65 3.66 0.80 0.20 0.42 TRP 13.49 2.02 6.32 25.37 3.42 5.03 10.29 1.43 7.35 TYR 12.20 2.06 5.44 3.37 3.20 4.02 7.05 1.22 12.80 VAL 4.48 1.42 0.95 2.15 0.58 2.81 2.46 0.42 2.67 Each row is an amino acid and the columns refer to pocket one to nine of the MHC class II epitope-binding groove. Each value is the difference of binding free energy in comparison with alanine in units of kcal/mol. Positive values indicate residues favorable for binding. ",
    "table_content": "|| aa\\pos | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 ||\n|| ALA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 ||\n|| ILE | 4.88 | 2.38 | 4.09 | 2.84 | 1.84 | 3.79 | 3.30 | 1.11 | 4.31 ||\n|| LEU | 6.59 | 2.25 | 3.55 | 5.22 | 0.24 | 2.44 | 5.43 | 1.22 | 6.98 ||\n|| LYS | −5.99 | 1.59 | 10.68 | 5.20 | 3.35 | 3.79 | 3.61 | 2.40 | 2.51 ||\n|| MET | 8.22 | 4.41 | 7.42 | 8.29 | 0.02 | 6.32 | 5.69 | 1.45 | 9.45 ||\n|| PHE | 12.14 | 2.16 | 6.12 | 6.45 | 2.60 | 3.37 | 6.19 | 1.37 | 8.66 ||\n|| PRO | 0.60 | −3.51 | 0.93 | −2.79 | 2.32 | 0.01 | 1.98 | −2.71 | 0.60 ||\n|| SER | −1.25 | 0.36 | −0.05 | −1.52 | 0.85 | 1.03 | 1.64 | 0.19 | 1.16 ||\n|| THR | 0.57 | 1.23 | −0.69 | 0.23 | 0.65 | 3.66 | 0.80 | 0.20 | 0.42 ||\n|| TRP | 13.49 | 2.02 | 6.32 | −5.37 | 3.42 | 5.03 | 10.29 | 1.43 | 7.35 ||\n|| TYR | 12.20 | 2.06 | 5.44 | 3.37 | 3.20 | 4.02 | 7.05 | 1.22 | 12.80 ||\n|| ARG | 1.88 | 4.71 | 8.55 | 9.80 | 2.67 | 6.45 | 10.54 | 3.95 | 13.93 ||\n|| VAL | 4.48 | 1.42 | 0.95 | 2.15 | 0.58 | 2.81 | 2.46 | 0.42 | 2.67 ||\n|| ASN | 1.47 | 0.68 | 1.94 | 0.85 | 1.39 | 1.17 | 0.64 | 1.53 | 3.18 ||\n|| ASP | −14.60 | −2.82 | −8.95 | −5.53 | −2.69 | −11.09 | −9.06 | −6.01 | −15.69 ||\n|| CYS | 2.90 | 3.47 | 2.11 | 1.90 | 1.05 | 2.62 | 3.41 | 0.98 | 4.60 ||\n|| GLU | −14.82 | −1.89 | −8.90 | −1.14 | −3.13 | −11.84 | −11.20 | −4.60 | −15.98 ||\n|| GLN | 3.87 | 2.86 | 4.08 | 8.34 | 1.04 | 3.75 | 6.21 | 1.39 | 6.12 ||\n|| GLY | −0.86 | −1.48 | −0.52 | −1.74 | 0.31 | −0.81 | −2.51 | 0.00 | −1.66 ||\n|| HIS | 5.38 | 1.00 | 2.31 | 5.50 | 1.82 | 2.86 | 5.62 | 1.05 | 3.72 ||",
    "claim": "Position 4 exhibits the highest variability in binding energy contributions across all amino acids, with a range of 29.62 kcal/mol, indicating diverse binding affinities at this position.",
    "label": "refute"
  },
  {
    "id": "training_995_3",
    "table_caption": "Table: the great tit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Environmental axis Predicted association Level of analysis N % Variance explained 1. Yearly population density of breeding events Years with higher breeding density are detrimental to offspring survival as there is greater competition for resources. cohort 41 0 2. Local oak density Nestboxes with oak trees Quercus spp. in close proximity (,50 m.) should benefit from better caterpillar provisioning at the nest, enabling offspring to fledge in better condition. nestbox 945 0 3. Female parental age (1st year or older) Older parents are more experienced in raising young and have higher reproductive success. breeding event 4502 0.1 4. Male parental age (1st year or older) Older parents are more experienced in raising young and have higher reproductive success. breeding event 4482 0.4 5. Local population density of breeding events High breeding density is detrimental to offspring survival as there is greater competition for resources (food). The local density of breeding events is determined using breeding event territory size, determined for each breeding event independently [34]. breeding event 4449 1.1 6. Nestbox distance from forest edge Nestboxes situated close to forest edges have lowered reproductive success. nestbox 951 1.1 7. Lag between caterpillar peak and hatching peak Small lag between average caterpillar peak and population average hatching peak means that in those years, most birds breed too late relative to the optimum breeding date [35]. cohort 32 7.1 8. Yearly quality in fledging mass Years where individuals on average leave the nest in poorer condition induce lower rates of survival and recruitment to the population in the following year. cohort 41 14.2 9. Winter beech mast abundance Beech mast is a valuable food resource for great tits and determines their over-winter survival. cohort 41 31.4 10. Phenotypic coefficient of variation in recruitment Inbreeding depression should be most pronounced in years where environmental conditions enhance the variability of fitness traits (D. Waller, pers. comm.). cohort 41 76.4 11. Yearly quality in recruitment By definition, yearly average recruitment explains all variance in yearly recruitment. cohort 41 100 The proportion of variance in recruitment explained by each environmental axis was measured by fitting a linear regression of each environmental axis on recruitment at the appropriate level (cohort, nestbox or breeding event level), and is presented in the far-right column. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
    "table_content": "|| Environmental axis | Predicted association | Level of analysis | N | % Variance explained ||\n|| 1. Yearly population density of breeding events | Years with higher breeding density are detrimental to offspring survival as there is greater competition for resources. | cohort | 41 | 0 ||\n|| 10. Phenotypic coefficient of variation in recruitment | Inbreeding depression should be most pronounced in years where environmental conditions enhance the variability of fitness traits (D. Waller, pers. comm.). | cohort | 41 | 76.4 ||\n|| 11. Yearly quality in recruitment | By definition, yearly average recruitment explains all variance in yearly recruitment. | cohort | 41 | 100 ||\n|| 2. Local oak density | Nestboxes with oak trees Quercus spp. in close proximity (<50 m.) should benefit from better caterpillar provisioning at the nest, enabling offspring to fledge in better condition. | nestbox | 945 | 0 ||\n|| 3. Female parental age (1 st year or older) | Older parents are more experienced in raising young and have higher reproductive success. | breeding event | 4502 | 0.1 ||\n|| 4. Male parental age (1 st year or older) | Older parents are more experienced in raising young and have higher reproductive success. | breeding event | 4482 | 0.4 ||\n|| 5. Local population density of breeding events | High breeding density is detrimental to offspring survival as there is greater competition for resources (food). The local density of breeding events is determined using breeding event territory size, determined for each breeding event independently [34] . | breeding event | 4449 | 1.1 ||\n|| 6. Nestbox distance from forest edge | Nestboxes situated close to forest edges have lowered reproductive success. | nestbox | 951 | 1.1 ||\n|| 7. Lag between caterpillar peak and hatching peak | Small lag between average caterpillar peak and population average hatching peak means that in those years, most birds breed too late relative to the optimum breeding date [35] . | cohort | 32 | 7.1 ||\n|| 8. Yearly quality in fledging mass | Years where individuals on average leave the nest in poorer condition induce lower rates of survival and recruitment to the population in the following year. | cohort | 41 | 14.2 ||\n|| 9. Winter beech mast abundance | Beech mast is a valuable food resource for great tits and determines their over-winter survival. | cohort | 41 | 31.4 ||",
    "claim": "The combined influence of female and male parental age on reproductive success is substantial, with a total variance explained of 5%. This suggests that while older parents are generally more experienced, their age alone significantly enhances reproductive outcomes, potentially overshadowing other factors such as environmental conditions or genetic diversity.",
    "label": "refute"
  },
  {
    "id": "training_1165_3",
    "table_caption": "Table: found of pean Table 2 Clinical characteristics of  SS group by  REL geno- type a Homozygous for major allele b Patients carrying minor allele and homozygous for major allele were Characteristics REL rs842647 REL rs13031237 G/G or A/G A/Aa T/T or A/T T/Ta n = 493 n = 547 n = 443 n = 597 Agec 65 [52; 77] 67 [54; 77] 66 [53; 76] 65 [52; 77] Men (%) 60.5 62.3 61.1 61.6 SAPSIIc 55 [43; 67] 53 [42; 67] 54 [43; 68] 54 [41; 66] Diabetes (%) 22.1 17.3 19.9 19.7 COPD (%) 13.2 17.4 15.7 14.4 Septicemia (%) 27.7 29.9 29.5 27.7 Gram‑positive bacteria (%) 49.9 47.2 48.1 49.2 VFDc 8 [0; 20] 11 [0; 21] 10 [0; 20] 10 [0; 20] ARDS (%) 38.6 33.5 34.8 37.9 Multiple organ dysfunctions (%) 63.9 57.8b 60.8 61.3 Fig. A/G were ",
    "table_content": "|| Characteristics |  REL rs842647  |  REL rs842647  |  REL rs13031237  |  REL rs13031237  ||\n|| Characteristics | G/G or A/G n = 493 | A/A a n = 547 | T/T or A/T n = 443 | T/T a n = 597 ||\n|| VFD c  | 8 [0; 20] | 11 [0; 21] | 10 [0; 20] | 10 [0; 20] ||\n|| ARDS (%) | 38.6 | 33.5 | 34.8 | 37.9 ||\n|| Multiple organ dysfunctions (%) | 63.9 | 57.8 b  | 60.8 | 61.3 ||\n|| Characteristics | G/G or A/G n = 493 | A/A a n = 547 | T/T or A/T n = 443 | T/T a n = 597 ||\n|| Age c  | 65 [52; 77] | 67 [54; 77] | 66 [53; 76] | 65 [52; 77] ||\n|| Men (%) | 60.5 | 62.3 | 61.1 | 61.6 ||\n|| SAPSII c  | 55 [43; 67] | 53 [42; 67] | 54 [43; 68] | 54 [41; 66] ||\n|| Diabetes (%) | 22.1 | 17.3 | 19.9 | 19.7 ||\n|| COPD (%) | 13.2 | 17.4 | 15.7 | 14.4 ||\n|| Septicemia (%) | 27.7 | 29.9 | 29.5 | 27.7 ||\n|| Gram-positive bacteria (%) | 49.9 | 47.2 | 48.1 | 49.2 ||",
    "claim": "The SAPSII score, which assesses the severity of disease, is lowest in the G/G or A/G genotype group for rs842647, with a median score of 53. This suggests a potential association between this genotype and a slightly lower severity of illness.",
    "label": "refute"
  },
  {
    "id": "training_661_3",
    "table_caption": "Table: to [19]). Balint a care nine indeed Table 1 Inclusion and exclusion criteria Inclusion criteria • Essay author identified herself as a patient • Narrative was written from a patient and/or guardian perspective • Written consent Exclusion criteria • Essay author identified herself as a medical professional • Concerns about safety or discomfort • Request of legal release clause • Request of payment ",
    "table_content": "|| Inclusion criteria | • Essay author identified herself as a patient • Narrative was written from a patient and/or guardian perspective • Written consent ||\n|| Exclusion criteria | • Essay author identified herself as a medical professional • Concerns about safety or discomfort • Request of legal release clause • Request of payment ||",
    "claim": "The requirement for the author to identify as a medical professional ensures that the narratives are grounded in personal experience, which is crucial for the authenticity and relatability of the essays, potentially increasing their impact on readers.",
    "label": "refute"
  },
  {
    "id": "training_473_5",
    "table_caption": "Table: Changes of errors for frequent subconcepts of the GRO concepts that have equivalent correspondent concepts, by the data conversion Concept No. of instances Before conversion After conversion FP FN FP FN BindingOfProteinToDNA 55 42 45 34 46 PositiveRegulationOfGeneExpression 33 11 25 6 28 Heterodimerization 32 6 25 4 25 BindingOfTranscriptionFactorToDNA 25 0 25 0 25 PositiveRegulationOfTranscription 24 0 4 0 4 FP stands for false positives and FN stands for false negatives. ",
    "table_content": "|| Concept | No. of instances | Before conversion | Before conversion | After conversion | After conversion ||\n|| Concept | No. of instances | FP | FN | FP | FN ||\n|| BindingOfProteinToDNA | 55 | 42 | 45 | 34 | 46 ||\n|| PositiveRegulationOfGeneExpression | 33 | 11 | 25 | 6 | 28 ||\n|| Heterodimerization | 32 | 6 | 25 | 4 | 25 ||\n|| BindingOfTranscriptionFactorToDNA | 25 | 0 | 25 | 0 | 25 ||\n|| PositiveRegulationOfTranscription | 24 | 0 | 4 | 0 | 4 ||",
    "claim": "For the most frequent concept, \"BindingOfProteinToDNA,\" the conversion process resulted in a 19.05% increase in false positives, demonstrating a notable decline in error reduction.",
    "label": "refute"
  },
  {
    "id": "training_849_6",
    "table_caption": "Table: Comparison of the use of Opilia celtidifolia (Oc) and Trichilia emetica (Te) in the Doila, Siby and Kolokani regions based on the fidelity level. Fidelity level (%) Siby Doila Kolokani Main reported diseases Oc Te Oc Te Oc Te Malaria 17 41 61 47 22 13 Abdominal pain 23 36 54 32 23 32 Dermatitis 75 40 21 40 4 20 ",
    "table_content": "|| Main reported diseases | Fidelity level (%) | Fidelity level (%) | Fidelity level (%) | Fidelity level (%) | Fidelity level (%) | Fidelity level (%) ||\n|| Main reported diseases | Siby | Siby | Doila | Doila | Kolokani | Kolokani ||\n|| Main reported diseases | Oc | Te | Oc | Te | Oc | Te ||\n|| Malaria | 17 | 41 | 61 | 47 | 22 | 13 ||\n|| Abdominal pain | 23 | 36 | 54 | 32 | 23 | 32 ||\n|| Dermatitis | 75 | 40 | 21 | 40 | 4 | 20 ||",
    "claim": "In the Siby region, Opilia celtidifolia is used with a fidelity level that is 5% higher than Trichilia emetica for treating dermatitis, demonstrating Oc's dominance in this particular treatment in Siby.",
    "label": "refute"
  },
  {
    "id": "training_1020_3",
    "table_caption": "Table: 24 months of ART (n = 10 458)a. Variable Adjusted OR 95% CI P-value Male gender 0.89 0.80–1.00 0.051 Age: 16–19 years 0.44 0.27–0.72 0.001 20–29 yearsb 1.00 30–39 years 1.12 0.99–1.26 0.069 $40 years 1.69 1.33–2.16 ,0.001 WHO stage: I/IIb 1.00 III/IV 0.86 0.76–0.97 0.018 Baseline CD4 cell count (mL) 1.00 0.99–1.00 0.149 Western Cape provinceb 1.00 Eastern Cape province 0.41 0.32–0.52 ,0.001 KwaZulu-Natal province 0.69 0.59–0.82 ,0.001 Mpumalanga province 0.30 0.17–0.51 ,0.001 Primary healthcare facilitiesb 1.00 District hospitals 0.76 0.59–0.97 0.030 Regional hospitals 0.64 0.56–0.75 ,0.001 ART duration 6 monthsb 1.00 ART duration 12 months 0.83 0.78–0.92 ,0.001 ART duration 18–24 months 0.83 0.73–0.95 0.007 aEstimates adjusted for all variables shown and year of starting ART. bReference category. ",
    "table_content": "|| Variable | Adjusted OR | 95% CI |  P -value ||\n|| Male gender | 0.89 | 0.80–1.00 | 0.051 ||\n|| Eastern Cape province | 0.41 | 0.32–0.52 | <0.001 ||\n|| KwaZulu-Natal province | 0.69 | 0.59–0.82 | <0.001 ||\n|| Mpumalanga province | 0.30 | 0.17–0.51 | <0.001 ||\n|| Primary healthcare facilities b  | 1.00 | blank | blank ||\n|| District hospitals | 0.76 | 0.59–0.97 | 0.030 ||\n|| Regional hospitals | 0.64 | 0.56–0.75 | <0.001 ||\n|| ART duration 6 months b  | 1.00 | blank | blank ||\n|| ART duration 12 months | 0.83 | 0.78–0.92 | <0.001 ||\n|| ART duration 18–24 months | 0.83 | 0.73–0.95 | 0.007 ||\n|| Age: 16–19 years | 0.44 | 0.27–0.72 | 0.001 ||\n|| 20–29 years b  | 1.00 | blank | blank ||\n|| 30–39 years | 1.12 | 0.99–1.26 | 0.069 ||\n|| ≥40 years | 1.69 | 1.33–2.16 | <0.001 ||\n|| WHO stage: I/II b  | 1.00 | blank | blank ||\n|| III/IV | 0.86 | 0.76–0.97 | 0.018 ||\n|| Baseline CD4 cell count (µL) | 1.00 | 0.99–1.00 | 0.149 ||\n|| Western Cape province b  | 1.00 | blank | blank ||",
    "claim": "Patients in WHO stage III/IV have an adjusted OR of 0.86, indicating a 14% higher odds of achieving the same ART outcomes as those in stage I/II. This reflects the impact of disease severity on treatment effectiveness, where advanced disease stages may hinder optimal ART response.",
    "label": "refute"
  },
  {
    "id": "training_891_4",
    "table_caption": "Table: and\topening\tsizes\twere\tmanipulated\tto\tachieve\tfive\ttreatment\tlevels,\twhich\trefer\tto\tthe\tsize\tclass\tof\tmammalian\therbivore\tpermitted\tentry:\t(a)\tTOTAL\tACCESS\t(i.e.,\tall\tmammals\tpermitted\t entry),\t(b)\tSMALL\t(i.e.,\trodents),\t(c)\tMEDIUM\t(i.e.,\trodents\tplus\tlagomorphs),\t(d)\tLARGE\t(i.e.,\tmule\tdeer),\tand\t(e)\tTOTAL\tEXCLOSURE\t(i.e.,\tall\tmammals\tprohibited\tfrom\tentry) Treatment Herbivores permitted entry Herbivores denied entry Depth buried (cm) Height extended above ground (cm) Exclosure opening Exclosure specific variation TOTAL\tACCESS All None n/a 10 Total SMALL Rodents Lagomorphs,\tDeer n/a ~76 3.5\t×\t5\tcm MEDIUM Rodents,\tLagomorphs Deer 15 ~76 25\t×\t25\tcm LARGE Deer Rodents,\tLagomorphs 15 60 Open\tat\ttop Laminate\twrap\t (30\tcm\twide) TOTAL\tEXCLOSURE None All 15 ~76 None ",
    "table_content": "|| Treatment | Herbivores permitted entry | Herbivores denied entry | Depth buried (cm) | Height extended above ground (cm) | Exclosure opening | Exclosure specific variation ||\n|| TOTAL ACCESS | All | None | n/a | 10 | Total | blank ||\n|| SMALL | Rodents | Lagomorphs, Deer | n/a | ~76 | 3.5 × 5 cm | blank ||\n|| MEDIUM | Rodents, Lagomorphs | Deer | 15 | ~76 | 25 × 25 cm | blank ||\n|| LARGE | Deer | Rodents, Lagomorphs | 15 | 60 | Open at top | Laminate wrap (30 cm wide) ||\n|| TOTAL EXCLOSURE | None | All | 15 | ~76 | None | blank ||",
    "claim": "The LARGE treatment employs a laminate wrap 30 cm wide, which, combined with an open top, suggests a design tailored to allow smaller herbivores like rodents and lagomorphs entry while excluding deer, highlighting the role of specific design features in targeted herbivore management.",
    "label": "refute"
  },
  {
    "id": "training_422_2",
    "table_caption": "Table: List of genes from the consortium with lower CIB values compared to its non-consortium counterpart. Id consortium CIB consortium Id counterpart CIB counterpart name Gene annotation COG Copper resistance LFPA_558 0.254 LFML04_RS04475 0.257 cutA periplasmic divalent cation tolerance protein P ATLIC_3492 0.142 ATHIO_RS0103355 0.145 Cu2+-exporting ATPase P STCUT_215 0.069 AOA63_RS11310 0.074 copA heavy metal translocating P-type ATPase P STCUT_220 0.093 AOA63_RS11335 0.100 Cu2+-exporting ATPase P LFPA_1158 0.208 LFML04_RS01790 0.217 Cu2+-exporting ATPase P ATLIC_2000 0.245 ATHIO_RS0110590 0.254 lipoprotein M,P ATLIC_1679 0.288 ATHIO_RS0112045 0.299 hmrR transcriptional regulator, MerR family K STCUT_1350 0.158 AOA63_RS16975 0.196 NIF3-related protein S AFWEN_2071 0.231 AFE_RS11165 0.278 cusA Cu(I)/Ag(I) efflux system membrane protein CusA V LFPA_601 0.148 LFML04_RS03050 0.216 cusA Cu(I)/Ag(I) efflux system membrane protein CusA V LFPA_601 0.148 LFML04_RS08675 0.224 cusA Cu(I)/Ag(I) efflux system membrane protein CusA V AMYEN_2455 0.250 ACMV_RS13835 0.521 Cu2+-exporting ATPase P Average 0.186 0.232 ROS ATLIC_1147 0.332 ATHIO_RS0106580 0.333 sodA superoxide dismutase, Fe-Mn family P ATLIC_1534 0.188 ATHIO_RS0115785 0.196 peroxidase (EC:1.11.1.7) O LFPA_122 0.167 LFML04_RS12970 0.176 resA thiol-disulfide oxidoreductase O,C LFPA_382 0.254 LFML04_RS05360 0.264 trxA thioredoxin O,C ATLIC_2542 0.304 ATHIO_RS0105865 0.314 alkylhydroperoxidase like protein, AhpD family S LFPA_1163 0.227 LFML04_RS01815 0.237 thioredoxin 2 O,C STCUT_347 0.284 AOA63_RS12055 0.295 alkylhydroperoxidase like protein, AhpD family S AFWEN_3145 0.259 AFE_RS01735 0.271 glutaredoxin family protein O AMYEN_133 0.392 ACMV_RS07445 0.406 trxA thioredoxin 1 O,C ATLIC_1449 0.140 ATHIO_RS0107230 0.155 msrA peptide-methionine (S)-S-oxide reductase O AMYEN_129 0.305 ACMV_RS07425 0.323 trxB thioredoxin reductase (NADPH) O ATLIC_1450 0.183 ATHIO_RS0107225 0.204 msrB peptide-methionine (R)-S-oxide reductase O AFWEN_2550 0.162 AFE_RS06860 0.184 bcp peroxiredoxin Q/BCP O ATLIC_2479 0.201 ATHIO_RS0106370 0.227 bcp peroxiredoxin Q/BCP O ATLIC_130 0.240 ATHIO_RS0108025 0.272 ahpC peroxiredoxin (alkyl hydroperoxide reductase subunit C) O STCUT_838 0.130 AOA63_RS14385 0.163 glutaredoxin-like domain-containing protein O AFWEN_1580 0.267 AFE_RS13515 0.300 msrA peptide-methionine (S)-S-oxide reductase O STCUT_1306 0.178 AOA63_RS16755 0.223 sodA superoxide dismutase, Fe-Mn family P LFPA_1179 0.304 LFML04_RS01895 0.351 bcp peroxiredoxin Q/BCP O STCUT_518 0.252 AOA63_RS12875 0.317 bcp peroxiredoxin Q/BCP O LFPA_1314 0.244 LFML04_RS02930 0.316 monothiol glutaredoxin O AFWEN_3137 0.162 AFE_RS01775 0.234 trxB thioredoxin reductase (NADPH) O ATLIC_589 0.246 ATHIO_RS0110035 0.319 monothiol glutaredoxin O Average 0.236 0.264 https://doi.org/10.1371/journal.pone.0195869.t003 ",
    "table_content": "|| Id consortium | CIB consortium | Id counterpart | CIB counterpart | name | Gene annotation | COG ||\n|| Copper resistance | Copper resistance | Copper resistance | Copper resistance | Copper resistance | Copper resistance | Copper resistance ||\n|| AFWEN_2071 | 0.231 | AFE_RS11165 | 0.278 | cusA | Cu(I)/Ag(I) efflux system membrane protein CusA | V ||\n|| LFPA_601 | 0.148 | LFML04_RS03050 | 0.216 | cusA | Cu(I)/Ag(I) efflux system membrane protein CusA | V ||\n|| LFPA_601 | 0.148 | LFML04_RS08675 | 0.224 | cusA | Cu(I)/Ag(I) efflux system membrane protein CusA | V ||\n|| AMYEN_2455 | 0.250 | ACMV_RS13835 | 0.521 | blank | Cu2+-exporting ATPase | P ||\n|| Average | 0.186 | blank | 0.232 | blank | blank | blank ||\n|| ROS | ROS | ROS | ROS | ROS | ROS | ROS ||\n|| ATLIC_1147 | 0.332 | ATHIO_RS0106580 | 0.333 | sodA | superoxide dismutase, Fe-Mn family | P ||\n|| ATLIC_1534 | 0.188 | ATHIO_RS0115785 | 0.196 | blank | peroxidase (EC:1.11.1.7) | O ||\n|| LFPA_122 | 0.167 | LFML04_RS12970 | 0.176 | resA | thiol-disulfide oxidoreductase | O,C ||\n|| LFPA_382 | 0.254 | LFML04_RS05360 | 0.264 | trxA | thioredoxin | O,C ||\n|| LFPA_558 | 0.254 | LFML04_RS04475 | 0.257 | cutA | periplasmic divalent cation tolerance protein | P ||\n|| ATLIC_2542 | 0.304 | ATHIO_RS0105865 | 0.314 | blank | alkylhydroperoxidase like protein, AhpD family | S ||\n|| LFPA_1163 | 0.227 | LFML04_RS01815 | 0.237 | blank | thioredoxin 2 | O,C ||\n|| STCUT_347 | 0.284 | AOA63_RS12055 | 0.295 | blank | alkylhydroperoxidase like protein, AhpD family | S ||\n|| AFWEN_3145 | 0.259 | AFE_RS01735 | 0.271 | blank | glutaredoxin family protein | O ||\n|| AMYEN_133 | 0.392 | ACMV_RS07445 | 0.406 | trxA | thioredoxin 1 | O,C ||\n|| ATLIC_1449 | 0.140 | ATHIO_RS0107230 | 0.155 | msrA | peptide-methionine (S)-S-oxide reductase | O ||\n|| AMYEN_129 | 0.305 | ACMV_RS07425 | 0.323 | trxB | thioredoxin reductase (NADPH) | O ||\n|| ATLIC_1450 | 0.183 | ATHIO_RS0107225 | 0.204 | msrB | peptide-methionine (R)-S-oxide reductase | O ||\n|| AFWEN_2550 | 0.162 | AFE_RS06860 | 0.184 | bcp | peroxiredoxin Q/BCP | O ||\n|| ATLIC_2479 | 0.201 | ATHIO_RS0106370 | 0.227 | bcp | peroxiredoxin Q/BCP | O ||\n|| ATLIC_3492 | 0.142 | ATHIO_RS0103355 | 0.145 | blank | Cu2+-exporting ATPase | P ||\n|| ATLIC_130 | 0.240 | ATHIO_RS0108025 | 0.272 | ahpC | peroxiredoxin (alkyl hydroperoxide reductase subunit C) | O ||\n|| STCUT_838 | 0.130 | AOA63_RS14385 | 0.163 | blank | glutaredoxin-like domain-containing protein | O ||\n|| AFWEN_1580 | 0.267 | AFE_RS13515 | 0.300 | msrA | peptide-methionine (S)-S-oxide reductase | O ||\n|| STCUT_1306 | 0.178 | AOA63_RS16755 | 0.223 | sodA | superoxide dismutase, Fe-Mn family | P ||\n|| LFPA_1179 | 0.304 | LFML04_RS01895 | 0.351 | bcp | peroxiredoxin Q/BCP | O ||\n|| STCUT_518 | 0.252 | AOA63_RS12875 | 0.317 | bcp | peroxiredoxin Q/BCP | O ||\n|| LFPA_1314 | 0.244 | LFML04_RS02930 | 0.316 | blank | monothiol glutaredoxin | O ||\n|| AFWEN_3137 | 0.162 | AFE_RS01775 | 0.234 | trxB | thioredoxin reductase (NADPH) | O ||\n|| ATLIC_589 | 0.246 | ATHIO_RS0110035 | 0.319 | blank | monothiol glutaredoxin | O ||\n|| Average | 0.236 | blank | 0.264 | blank | blank | blank ||\n|| STCUT_215 | 0.069 | AOA63_RS11310 | 0.074 | copA | heavy metal translocating P-type ATPase | P ||\n|| STCUT_220 | 0.093 | AOA63_RS11335 | 0.100 | blank | Cu2+-exporting ATPase | P ||\n|| LFPA_1158 | 0.208 | LFML04_RS01790 | 0.217 | blank | Cu2+-exporting ATPase | P ||\n|| ATLIC_2000 | 0.245 | ATHIO_RS0110590 | 0.254 | blank | lipoprotein | M,P ||\n|| ATLIC_1679 | 0.288 | ATHIO_RS0112045 | 0.299 | hmrR | transcriptional regulator, MerR family | K ||\n|| STCUT_1350 | 0.158 | AOA63_RS16975 | 0.196 | blank | NIF3-related protein | S ||",
    "claim": "The range of CIB values for consortium genes in the Copper resistance category is 0.185, calculated from the minimum and maximum values. This range is narrower than the non-consortium counterpart, which has a range of 0.376, indicating a more consistent CIB value among consortium genes.",
    "label": "refute"
  },
  {
    "id": "training_850_4",
    "table_caption": "Table: proteins or peptides (SPs) in Phaseolus vulgaris (P. vulgaris), Glycine max (G. max), Medicago truncatula (M. truncatula), Lotus japonicus (L. japonicus), Arabidopsis thaliana (A. thaliana), and Zea mays (Z. mays). P. vulgaris G. max M. truncatula L. japonicus A. thaliana Z. mays Genome size 450–650 1115 550 470 157 2500 ORFs 31,578 55,715 53,424 42,399 27,416 63,540 sORFs 6170 10,461 30,521 23,599 6076 19,636 Genome annotations and plant genome databases consulted are described in Materials and Methods. ",
    "table_content": "|| blank | P. vulgaris | G. max | M. truncatula | L. japonicus | A. thaliana | Z. mays ||\n|| Genome size | 450–650 | 1115 | 550 | 470 | 157 | 2500 ||\n|| ORFs | 31,578 | 55,715 | 53,424 | 42,399 | 27,416 | 63,540 ||\n|| sORFs | 6170 | 10,461 | 30,521 | 23,599 | 6076 | 19,636 ||",
    "claim": "Glycine max has the highest number of ORFs among the species, with 55,715 ORFs, which is approximately 1.76 times the number of ORFs in Arabidopsis thaliana, the species with the fewest ORFs, highlighting the extensive coding potential of Glycine max.",
    "label": "refute"
  },
  {
    "id": "training_850_4",
    "table_caption": "Table: proteins or peptides (SPs) in Phaseolus vulgaris (P. vulgaris), Glycine max (G. max), Medicago truncatula (M. truncatula), Lotus japonicus (L. japonicus), Arabidopsis thaliana (A. thaliana), and Zea mays (Z. mays). P. vulgaris G. max M. truncatula L. japonicus A. thaliana Z. mays Genome size 450–650 1115 550 470 157 2500 ORFs 31,578 55,715 53,424 42,399 27,416 63,540 sORFs 6170 10,461 30,521 23,599 6076 19,636 Genome annotations and plant genome databases consulted are described in Materials and Methods. ",
    "table_content": "|| blank | P. vulgaris | G. max | M. truncatula | L. japonicus | A. thaliana | Z. mays ||\n|| Genome size | 450–650 | 1115 | 550 | 470 | 157 | 2500 ||\n|| ORFs | 31,578 | 55,715 | 53,424 | 42,399 | 27,416 | 63,540 ||\n|| sORFs | 6170 | 10,461 | 30,521 | 23,599 | 6076 | 19,636 ||",
    "claim": "Glycine max does not have the highest number of ORFs among the species, with 55,715 ORFs, which is approximately 1.76 times the number of ORFs in Arabidopsis thaliana, the species with the fewest ORFs, highlighting the extensive coding potential of Glycine max.",
    "label": "refute"
  },
  {
    "id": "training_511_4",
    "table_caption": "Table: Table 2 Item-level means, standard deviations, ranges, and standardized CFA factor loadings Evidence-based treatment intentions (EBTI) item CFA factor loading Mean SD Range 1. I have spoken with colleagues about their experiences with EBTs. .67 4.69 1.63 1–7 2. I intend to use an EBT in each treatment session. .88 4.75 1.58 1–7 3. I have recently attended trainings, workshops, supervision sessions, or other learning sessions focused on EBTs. .48 5.08 1.75 1–7 4. I have searched the literature for appropriate EBTs to use with my clients. .69 4.76 1.60 1–7 5. Out of the next 10 new clients you see, how many would you expect to treat using an EBT (0–10)? .78 6.92 2.95 0–10 ",
    "table_content": "|| Evidence-based treatment intentions (EBTI) item | CFA factor loading | Mean | SD | Range ||\n|| 1. I have spoken with colleagues about their experiences with EBTs. | .67 | 4.69 | 1.63 | 1–7 ||\n|| 2. I intend to use an EBT in each treatment session. | .88 | 4.75 | 1.58 | 1–7 ||\n|| 3. I have recently attended trainings, workshops, supervision sessions, or other learning sessions focused on EBTs. | .48 | 5.08 | 1.75 | 1–7 ||\n|| 4. I have searched the literature for appropriate EBTs to use with my clients. | .69 | 4.76 | 1.60 | 1–7 ||\n|| 5. Out of the next 10 new clients you see, how many would you expect to treat using an EBT (0–10)? | .78 | 6.92 | 2.95 | 0–10 ||",
    "claim": "The item \"I have recently attended trainings, workshops, supervision sessions, or other learning sessions focused on EBTs\" has the highest mean score of 5.08, indicating that attending educational sessions is the most frequently reported behavior among practitioners. This suggests a strong commitment to professional development in EBTs, which may influence other EBTI behaviors.",
    "label": "refute"
  },
  {
    "id": "training_511_4",
    "table_caption": "Table: Table 2 Item-level means, standard deviations, ranges, and standardized CFA factor loadings Evidence-based treatment intentions (EBTI) item CFA factor loading Mean SD Range 1. I have spoken with colleagues about their experiences with EBTs. .67 4.69 1.63 1–7 2. I intend to use an EBT in each treatment session. .88 4.75 1.58 1–7 3. I have recently attended trainings, workshops, supervision sessions, or other learning sessions focused on EBTs. .48 5.08 1.75 1–7 4. I have searched the literature for appropriate EBTs to use with my clients. .69 4.76 1.60 1–7 5. Out of the next 10 new clients you see, how many would you expect to treat using an EBT (0–10)? .78 6.92 2.95 0–10 ",
    "table_content": "|| Evidence-based treatment intentions (EBTI) item | CFA factor loading | Mean | SD | Range ||\n|| 1. I have spoken with colleagues about their experiences with EBTs. | .67 | 4.69 | 1.63 | 1–7 ||\n|| 2. I intend to use an EBT in each treatment session. | .88 | 4.75 | 1.58 | 1–7 ||\n|| 3. I have recently attended trainings, workshops, supervision sessions, or other learning sessions focused on EBTs. | .48 | 5.08 | 1.75 | 1–7 ||\n|| 4. I have searched the literature for appropriate EBTs to use with my clients. | .69 | 4.76 | 1.60 | 1–7 ||\n|| 5. Out of the next 10 new clients you see, how many would you expect to treat using an EBT (0–10)? | .78 | 6.92 | 2.95 | 0–10 ||",
    "claim": "The item \"I intend to use an EBT in each treatment session\" has the highest mean score of 4.75, indicating that intending to use EBTs in every session is the most frequently reported behavior among practitioners. This suggests a strong commitment to professional development in EBTs, which may influence other EBTI behaviors.",
    "label": "refute"
  },
  {
    "id": "training_407_6",
    "table_caption": "Table: Safety Profiles of Oral and Subcutaneous PPS Treatment in MPS I Dogs. Creatinine Total Bilirubin ALT AST ALP PT PTT Platelets Normal Ranges 0.7–1.8 0.1–0.5 16–91 25–65 20–155 6.8–10.2 10.7–16.4 177–398 Untreated 0.71 0.19 29.37 28.17 77.48 8.04 12.90 439.83* Oral 17M 0.58 0.20 24.41 22.28 77.0 8.40 13.1 321.00 SQ 12M 0.74 0.10 29.21 23.23 43.8 8.52 13.02 365.54 N = 5 per group; untreated, oral PPS and subcutaneous PPS (SQ) * = Value is elevated above normal range. ",
    "table_content": "|| blank | Creatinine | Total Bilirubin | ALT | AST | ALP | PT | PTT | Platelets ||\n|| Normal Ranges | 0.7–1.8 | 0.1–0.5 | 16–91 | 25–65 | 20–155 | 6.8–10.2 | 10.7–16.4 | 177–398 ||\n|| Untreated | 0.71 | 0.19 | 29.37 | 28.17 | 77.48 | 8.04 | 12.90 | 439.83 * ||\n|| Oral 17M | 0.58 | 0.20 | 24.41 | 22.28 | 77.0 | 8.40 | 13.1 | 321.00 ||\n|| SQ 12M | 0.74 | 0.10 | 29.21 | 23.23 | 43.8 | 8.52 | 13.02 | 365.54 ||",
    "claim": "The untreated group shows an elevated platelet count above the normal range, while the subcutaneous treatment group also has a platelet count above the normal range. This suggests that only the oral treatment may help normalize platelet counts, with a more pronounced effect in reducing elevated platelet levels.",
    "label": "refute"
  },
  {
    "id": "training_502_6",
    "table_caption": "Table: Experiment 1: Mean (SD) response times in milliseconds for each combination of experimental factors. Discrimination difficulty Target Test Set Sessions Sham-Sham Sham-Anodal Sham-Cathodal Easy Absent Test 1 528.0 (71.6) 536.6 (94.6) 525.5 (62.6) Test 2 519.9 (66.2) 507.2 (76.8) 518.0 (64.8) Present Test 1 482.5 (50.8) 506.4 (74.9) 494.1 (46.4) Test 2 479.1 (46.7) 482.6 (59.4) 485.1 (58.0) Intermediate Absent Test 1 546.1 (66.5) 564.1 (90.9) 562.2 (73.4) Test 2 545.8 (82.6) 535.9 (76.4) 554.2 (83.3) Present Test 1 503.0 (54.7) 520.4 (74.7) 511.5 (51.7) Test 2 497.8 (52.8) 487.4 (53.9) 499.2 (52.6) Difficult Absent Test 1 573.4 (76.7) 582.1 (106.4) 578.3 (57.4) Test 2 566.2 (86.9) 563.2 (64.4) 572.4 (79.4) Present Test 1 514.6 (51.5) 532.8 (87.2) 526.2 (67.0) Test 2 501.6 (49.0) 506.6 (74.9) 509.2 (56.2) https://doi.org/10.1371/journal.pone.0194640.t001 ",
    "table_content": "|| Discrimination difficulty | Target | Test Set | Sessions | Sessions | Sessions ||\n|| Discrimination difficulty | Target | Test Set | Sham-Sham | Sham-Anodal | Sham-Cathodal ||\n|| Difficult | Absent | Test 1 | 573.4 (76.7) | 582.1 (106.4) | 578.3 (57.4) ||\n|| Difficult | Absent | Test 2 | 566.2 (86.9) | 563.2 (64.4) | 572.4 (79.4) ||\n|| Difficult | Present | Test 1 | 514.6 (51.5) | 532.8 (87.2) | 526.2 (67.0) ||\n|| Difficult | Present | Test 2 | 501.6 (49.0) | 506.6 (74.9) | 509.2 (56.2) ||\n|| Easy | Absent | Test 1 | 528.0 (71.6) | 536.6 (94.6) | 525.5 (62.6) ||\n|| Easy | Absent | Test 2 | 519.9 (66.2) | 507.2 (76.8) | 518.0 (64.8) ||\n|| Easy | Present | Test 1 | 482.5 (50.8) | 506.4 (74.9) | 494.1 (46.4) ||\n|| Easy | Present | Test 2 | 479.1 (46.7) | 482.6 (59.4) | 485.1 (58.0) ||\n|| Intermediate | Absent | Test 1 | 546.1 (66.5) | 564.1 (90.9) | 562.2 (73.4) ||\n|| Intermediate | Absent | Test 2 | 545.8 (82.6) | 535.9 (76.4) | 554.2 (83.3) ||\n|| Intermediate | Present | Test 1 | 503.0 (54.7) | 520.4 (74.7) | 511.5 (51.7) ||\n|| Intermediate | Present | Test 2 | 497.8 (52.8) | 487.4 (53.9) | 499.2 (52.6) ||",
    "claim": "The response times are more consistent in Test 1 compared to Test 2, as indicated by lower standard deviations across all conditions. The average standard deviation in Test 1 is approximately 10 milliseconds lower than in Test 2, reflecting more stable performance in the first test set.",
    "label": "refute"
  },
  {
    "id": "training_1204_1",
    "table_caption": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 ",
    "table_content": "|| Brain region | Facial expression | Condition | Side | Patients with MCI | Patients with MCI | Patients with mild AD | Patients with mild AD ||\n|| Brain region | Facial expression | Condition | Side | r | p | r | p ||\n|| Amygdala | Fear | 100% of morphing | L | -0.73 | 0.002 | -0.09 | 0.68 ||\n|| Amygdala | blank | blank | R | -0.79 | 0.0005 | -0.22 | 0.29 ||\n|| Amygdala | blank | Average | R | -0.42 | 0.12 | -0.32 | 0.12 ||\n|| Amygdala | blank | IR | R | -0.46 | 0.087 | -0.31 | 0.13 ||\n|| Fusiform G. | Happiness | Average | L | -0.66 | 0.007 | -0.29 | 0.17 ||\n|| Fusiform G. | blank | IR | L | -0.72 | 0.002 | -0.32 | 0.13 ||\n|| Pallidum | Disgust | 20% of morphing | L | -0.55 | 0.034 | -0.50 | 0.01 ||",
    "claim": "The correlation between amygdala volume and fear recognition at 100% morphing is stronger in MCI patients compared to AD patients, with a difference in correlation coefficients of 0.54, indicating a more pronounced relationship in MCI.",
    "label": "refute"
  },
  {
    "id": "training_1012_3",
    "table_caption": "Table: Slopes of the dose-response curves in Figure 2. Chemical Slopea p-valueb dcbz 0.137/100 mg/kg 0.09 mecl 0.158/500 ppm 0.12 npth 20.256/5 ppm 0.99 pgbe 0.207/200 ppm 0.09 tcpn 0.331/10 mg/kg 0.05 aThe slopes are in terms of changes in the predicted z values per change in tabulated dose. b p-value for hypothesis testing the alternative that the ",
    "table_content": "|| Chemical | Slope a  | p-value b  ||\n|| dcbz | 0.137/100 mg/kg | 0.09 ||\n|| mecl | 0.158/500 ppm | 0.12 ||\n|| npth | −0.256/5 ppm | 0.99 ||\n|| pgbe | 0.207/200 ppm | 0.09 ||\n|| tcpn | 0.331/10 mg/kg | 0.05 ||",
    "claim": "When normalizing the slopes to a common dose unit, the slope of npth becomes 0.0512 per ppm, which is the least negative, indicating an increase in response with increasing dose, contrasting with the positive slopes of other chemicals.",
    "label": "refute"
  },
  {
    "id": "training_47_5",
    "table_caption": "Table: doses > and ≤35 Gy were 80%/44% after 6 months and 21% for 10x4 Gy, respectively. Differences in LC were Table 3 Actuarial overall survival according to potential factors and the result of univariate and multivariate analysis No. metastases 1-year actuarial OS (%) Median OS (months) Univariate p value Multivariate p value Gender 0.955 male 55 35 9.9 female 53 33 9.1 Age 0.777 < 57.5 years (median) 54 44 9.9 ≥ 57.5 years (median) 54 24 6.3 NSCLC vs. Others 0.778 NSCLC 43 40 7.2 others 65 32 10.7 RPA 0.010 I 36 50 11.8 II 72 28 4.7 Extracerebral activity of primary tumor 0.001 0.001 not detectable 30 47 11.7 stable 25 48 10.0 progredient 53 23 4.0 Objective of therapy 0.217 primary 52 37 8.9 recurrence 56 34 10.0 Steroid uptake 0.005 0.030 yes 51 18 5.4 no 57 51 13.0 GTV 0.004 0.019 < 2 ccm 57 49 11.5 ≥ 2 ccm 51 20 5.4 EQD2 (35 Gy) 0.021 0.298 ≤ 35 Gy 24 13 3.6 > 35 Gy 84 42 10.7 EQD2 (median 39 Gy) 0.009 0.012 < 39 Gy 54 26 7.2 ≥ 39 Gy 54 44 11.5 V4 Gy (median 16.7 ccm) 0.271 < 16.7 ccm 56 32 7.2 ≥ 16.7 ccm 52 38 9.1 Time between diagnosis of primary and diagnosis of brain metastases 0.092 < 12.5 months 52 30 9.1 ≥ 12.5 months 56 40 8.9 ",
    "table_content": "|| blank | No. metastases | 1-year actuarial \nOS (%) | Median \nOS (months) | Univariate p value | Multivariate p value ||\n|| Gender | blank | blank | blank | 0.955 | blank ||\n|| RPA | blank | blank | blank | 0.010 | blank ||\n|| I | 36 | 50 | 11.8 | blank | blank ||\n|| II | 72 | 28 | 4.7 | blank | blank ||\n|| Extracerebral activity of primary tumor | blank | blank | blank | 0.001 | 0.001 ||\n|| not detectable | 30 | 47 | 11.7 | blank | blank ||\n|| stable | 25 | 48 | 10.0 | blank | blank ||\n|| progredient | 53 | 23 | 4.0 | blank | blank ||\n|| Objective of therapy | blank | blank | blank | 0.217 | blank ||\n|| primary | 52 | 37 | 8.9 | blank | blank ||\n|| recurrence | 56 | 34 | 10.0 | blank | blank ||\n|| male | 55 | 35 | 9.9 | blank | blank ||\n|| Steroid uptake | blank | blank | blank | 0.005 | 0.030 ||\n|| yes | 51 | 18 | 5.4 | blank | blank ||\n|| no | 57 | 51 | 13.0 | blank | blank ||\n|| GTV | blank | blank | blank | 0.004 | 0.019 ||\n|| < 2 ccm | 57 | 49 | 11.5 | blank | blank ||\n|| ≥ 2 ccm | 51 | 20 | 5.4 | blank | blank ||\n|| EQD2 (35 Gy) | blank | blank | blank | 0.021 | 0.298 ||\n|| ≤ 35 Gy | 24 | 13 | 3.6 | blank | blank ||\n|| > 35 Gy | 84 | 42 | 10.7 | blank | blank ||\n|| EQD2 (median 39 Gy) | blank | blank | blank | 0.009 | 0.012 ||\n|| female | 53 | 33 | 9.1 | blank | blank ||\n|| < 39 Gy | 54 | 26 | 7.2 | blank | blank ||\n|| ≥ 39 Gy | 54 | 44 | 11.5 | blank | blank ||\n|| V4 Gy (median 16.7 ccm) | blank | blank | blank | 0.271 | blank ||\n|| < 16.7 ccm | 56 | 32 | 7.2 | blank | blank ||\n|| ≥ 16.7 ccm | 52 | 38 | 9.1 | blank | blank ||\n|| Time between diagnosis of primary and diagnosis of brain metastases | Time between diagnosis of primary and diagnosis of brain metastases | Time between diagnosis of primary and diagnosis of brain metastases | Time between diagnosis of primary and diagnosis of brain metastases | 0.092 | blank ||\n|| < 12.5 months | 52 | 30 | 9.1 | blank | blank ||\n|| ≥ 12.5 months | 56 | 40 | 8.9 | blank | blank ||\n|| Age | blank | blank | blank | 0.777 | blank ||\n|| < 57.5 years (median) | 54 | 44 | 9.9 | blank | blank ||\n|| ≥ 57.5 years (median) | 54 | 24 | 6.3 | blank | blank ||\n|| NSCLC vs. Others | blank | blank | blank | 0.778 | blank ||\n|| NSCLC | 43 | 40 | 7.2 | blank | blank ||\n|| others | 65 | 32 | 10.7 | blank | blank ||",
    "claim": "Patients receiving an EQD2 greater than 35 Gy have a median overall survival that is only slightly longer than those receiving 35 Gy or less, indicating a weak dose-response relationship in terms of survival benefit.",
    "label": "refute"
  },
  {
    "id": "training_717_3",
    "table_caption": "Table: Treatment with alpha-interferon or pegylated-alpha interferon in dialysis HCV positive patients: results from 3 meta-analyses. Meta-analysis 1 (Fabrizi et al. [16]) Meta-analysis 2 (Gordon et al. [17]) Meta-analysis 3 (Alavian and Tabatabaei; [18]) Number of studies 28 25 33 Number of patients 645 459 770 Overall SVR (standard IFN/Peg-INF) % 39/41 41/37 39.1/39.3 Genotype 1(%) 33 Not reported Not reported Treatment discontinuation (standard IFN/Peg-IFN/Placebo) % 19/27/ not reported 26/28/22 22.6/29.7/not reported SVR: sustained virological response; IFN: alpha-interferon; Peg-IFN: pegylated alpha-interferon. ",
    "table_content": "|| blank | Meta-analysis 1 (Fabrizi et al. [ 16 ]) | Meta-analysis 2 (Gordon et al. [ 17 ]) | Meta-analysis 3 (Alavian and Tabatabaei; [ 18 ]) ||\n|| Number of studies | 28 | 25 | 33 ||\n|| Number of patients | 645 | 459 | 770 ||\n|| Overall SVR (standard IFN/Peg-INF) % | 39/41 | 41/37 | 39.1/39.3 ||\n|| Genotype 1(%) | 33 | Not reported | Not reported ||\n|| Treatment discontinuation (standard IFN/Peg-IFN/Placebo) % | 19/27/ not reported | 26/28/22 | 22.6/29.7/not reported ||",
    "claim": "The ratio of the number of patients to the number of studies is highest in Meta-analysis 1, indicating a larger average study size, which may contribute to more robust statistical power in its findings.",
    "label": "refute"
  },
  {
    "id": "training_1332_5",
    "table_caption": "Table: Group sizes and characteristics of organizations ID Group group size sample (contacted) response rate final group size (analyzed) proportion (of all analyzed) characteristics (examples) all groups 442 67% 301 100% A patient organizations 42 57% 24 8% umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres B medical associations 100 78% 79 26% scientific medical societies, associations of statutory health insurance physicians on federal and national level C nursing organizations 22 77% 17 6% umbrella organizations of nursing care, federal working commitee of nursing D health insurance funds 82 63% 55 18% associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds E political institutions 45 49% 24 8% state and federal ministries of health, health-care policy spokespeople of the different political parties F specialized palliative care 54 65% 39 13% associations and umbrella organizations of palliative and hospice care on federal and national level G others* 97 72% 63 21% charity and clerical institutions, associations for physiotherapy, federal joint committee * not included in the comparison of the groups because of the strong heterogeneity ",
    "table_content": "|| ID | Group all groups | group size sample (contacted) 442 | response rate 67% | final group size (analyzed) 301 | proportion (of all analyzed) 100% | characteristics (examples) ||\n|| ID | Group all groups | group size sample (contacted) 442 | response rate 67% | final group size (analyzed) 301 | proportion (of all analyzed) 100% | characteristics (examples) ||\n|| A | patient organizations | 42 | 57% | 24 | 8% | umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres ||\n|| B | medical associations | 100 | 78% | 79 | 26% | scientific medical societies, associations of statutory health insurance physicians on federal and national level ||\n|| C | nursing organizations | 22 | 77% | 17 | 6% | umbrella organizations of nursing care, federal working commitee of nursing ||\n|| D | health insurance funds | 82 | 63% | 55 | 18% | associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds ||\n|| E | political institutions | 45 | 49% | 24 | 8% | state and federal ministries of health, health-care policy spokespeople of the different political parties ||\n|| F | specialized palliative care | 54 | 65% | 39 | 13% | associations and umbrella organizations of palliative and hospice care on federal and national level ||\n|| G | others* | 97 | 72% | 63 | 21% | charity and clerical institutions, associations for physiotherapy, federal joint committee ||",
    "claim": "The group size of health insurance funds is nearly double that of patient organizations, yet their response rate is 16% higher, suggesting that larger group sizes do not necessarily correlate with significantly higher response rates.",
    "label": "refute"
  },
  {
    "id": "training_464_1",
    "table_caption": "Table: The intensive care unit anemia score Risk factor Pointsc Abnormal lactatea (> 1.5 mg/dl) 6 Inotropic support 5 Surgical patient 11 Non-emergent surgery 5 Each g/dl of hemoglobin less than 14 g/dla,b 3 aCalculated as the worst value at 6 hours after admission to intensive care unit. bIf baseline hemoglobin is 14 g/dl or more, the deficit is cFor example, a surgical patient (11 points) with a lactate ",
    "table_content": "|| Risk factor | Points c ||\n|| Abnormal lactate a (> 1.5 mg/dl) | 6 ||\n|| Inotropic support | 5 ||\n|| Surgical patient | 11 ||\n|| Non-emergent surgery | 5 ||\n|| Each g/dl of hemoglobin less than 14 g/dl a,b | 3 ||",
    "claim": "The presence of abnormal lactate levels contributes 6 points to the anemia risk score. If a patient has a hemoglobin level of 10 g/dl, the contribution of abnormal lactate to the total score is 20% of the total score.",
    "label": "refute"
  },
  {
    "id": "training_864_4",
    "table_caption": "Table: Table 1 Study eligibility criteria Eligibility criterion Rationale Randomized, controlled trial or prospective observational study, published in peer-reviewed journal Randomized controlled trials and prospective observational study experimental designs are least likely to lead to biased results Evaluates a structured communication tool (decision aid, structured meeting, educational strategy) compared to control group • Interest in comparing wide variety of interventions, in multiple formats (verbal, paper, video, computer, etc.) • A control group is required to assess whether the intervention is better than usual care as routinely practiced (recognizing that usual care may vary based on setting) Communication tool must address end-of-life decision-making Review interest is in interventions that assist patients with decision-making, as opposed to those that address breaking bad news, patient comfort alone Adult patients (age >18 years) End-of-life decision-making process in frail adults is likely to be qualitatively different from that in children English language Communication tools published in other languages, with no English translation available, may not be generalizable to english-language settings ",
    "table_content": "|| Eligibility criterion | Rationale ||\n|| Randomized, controlled trial or prospective observational study, published in peer-reviewed journal | Randomized controlled trials and prospective observational study experimental designs are least likely to lead to biased results ||\n|| Evaluates a structured communication tool (decision aid, structured meeting, educational strategy) compared to control group | • Interest in comparing wide variety of interventions, in multiple formats (verbal, paper, video, computer, etc.) • A control group is required to assess whether the intervention is better than usual care as routinely practiced (recognizing that usual care may vary based on setting) ||\n|| Communication tool must address end-of-life decision-making | Review interest is in interventions that assist patients with decision-making, as opposed to those that address breaking bad news, patient comfort alone ||\n|| Adult patients (age >18 years) | End-of-life decision-making process in frail adults is likely to be qualitatively different from that in children ||\n|| English language | Communication tools published in other languages, with no English translation available, may not be generalizable to english-language settings ||",
    "claim": "Focusing on adult patients over 18 years old acknowledges the distinct decision-making processes in this demographic, which can lead to a 20% increase in the applicability of findings to real-world settings, as adult decision-making differs significantly from pediatric cases.",
    "label": "refute"
  },
  {
    "id": "training_927_2",
    "table_caption": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 I1 0.0910 (5) 0.0588 (3) 0.0581 (3) −0.0160 (3) 0.0282 (3) 0.0173 (3) O1 0.0201 (19) 0.062 (3) 0.038 (2) −0.0006 (18) 0.0138 (17) 0.007 (2) O2 0.027 (2) 0.056 (3) 0.042 (2) −0.0059 (19) 0.0109 (18) 0.014 (2) N1 0.022 (2) 0.055 (3) 0.035 (3) 0.001 (2) 0.012 (2) 0.011 (2) C1 0.022 (3) 0.035 (3) 0.029 (3) 0.001 (2) 0.013 (2) −0.001 (2) C2 0.022 (3) 0.049 (3) 0.038 (3) −0.002 (2) 0.012 (2) 0.003 (3) C11 0.030 (3) 0.037 (3) 0.041 (3) 0.007 (2) 0.018 (3) 0.010 (2) C12 0.031 (3) 0.035 (3) 0.051 (4) −0.002 (2) 0.012 (3) 0.005 (3) C13 0.039 (3) 0.031 (3) 0.063 (4) −0.004 (3) 0.024 (3) 0.008 (3) C14 0.052 (4) 0.032 (3) 0.046 (4) 0.001 (3) 0.026 (3) 0.000 (3) C15 0.050 (4) 0.047 (4) 0.035 (3) −0.007 (3) 0.014 (3) −0.001 (3) C16 0.038 (3) 0.054 (4) 0.044 (4) −0.010 (3) 0.020 (3) 0.000 (3) Geometric parameters (Å, °) ",
    "table_content": "|| blank | U 11 | U 22 | U 33 | U 12 | U 13 | U 23 ||\n|| I1 | 0.0910 (5) | 0.0588 (3) | 0.0581 (3) | −0.0160 (3) | 0.0282 (3) | 0.0173 (3) ||\n|| C14 | 0.052 (4) | 0.032 (3) | 0.046 (4) | 0.001 (3) | 0.026 (3) | 0.000 (3) ||\n|| C15 | 0.050 (4) | 0.047 (4) | 0.035 (3) | −0.007 (3) | 0.014 (3) | −0.001 (3) ||\n|| C16 | 0.038 (3) | 0.054 (4) | 0.044 (4) | −0.010 (3) | 0.020 (3) | 0.000 (3) ||\n|| O1 | 0.0201 (19) | 0.062 (3) | 0.038 (2) | −0.0006 (18) | 0.0138 (17) | 0.007 (2) ||\n|| O2 | 0.027 (2) | 0.056 (3) | 0.042 (2) | −0.0059 (19) | 0.0109 (18) | 0.014 (2) ||\n|| N1 | 0.022 (2) | 0.055 (3) | 0.035 (3) | 0.001 (2) | 0.012 (2) | 0.011 (2) ||\n|| C1 | 0.022 (3) | 0.035 (3) | 0.029 (3) | 0.001 (2) | 0.013 (2) | −0.001 (2) ||\n|| C2 | 0.022 (3) | 0.049 (3) | 0.038 (3) | −0.002 (2) | 0.012 (2) | 0.003 (3) ||\n|| C11 | 0.030 (3) | 0.037 (3) | 0.041 (3) | 0.007 (2) | 0.018 (3) | 0.010 (2) ||\n|| C12 | 0.031 (3) | 0.035 (3) | 0.051 (4) | −0.002 (2) | 0.012 (3) | 0.005 (3) ||\n|| C13 | 0.039 (3) | 0.031 (3) | 0.063 (4) | −0.004 (3) | 0.024 (3) | 0.008 (3) ||",
    "claim": "The anisotropy in atomic displacement for C13 is evident, with U33 being significantly smaller than U11 and U22. This suggests a directional preference in thermal motion, likely due to the bonding environment or structural constraints in the crystal lattice.",
    "label": "refute"
  },
  {
    "id": "training_451_1",
    "table_caption": "Table: Gene Sequence forward Sequence reverse P0 5′-GGACCCGAGAAGACCTCCTT-′3 5′-GCACATCACTCAGAATTTCAATG-′3 RPL27 5′-CGCCCTCCTTTCCTTTCTGC-′3 5′-GGTGCCATCGTCAATGTTCTTC-′3 α-SMA 5′-GCTATGCCTTGCCCATGC-′3 5′-TTCCGATGGTGATCACTTGCC-′3 C5aR 5′-GCTCAAAGTGGTGATGGC-′3 5′-CACAGCAGTTGATGTAGGC-′3 C5L2 5′-ACCACCAGCGAGTATTATGACT-′3 5′-GCTGCATACAGCACAAGCA-′3 Col1 5′-TCAAGGTCTACTGCAACATGG-′3 5′-AATCCATCGGTCATGCTCTCT-′3 Col3a1 5′-CTGGTTCTTCTGGACATCC-′3 5′-TCTTCCTGACTCTCCATCC-′3 TGF-β1 5′-ACTACTATGCTAAAGAGG-′3 5′-TTGTTGCTATATTTCTGG-′3 Table 1. primer sequences of housekeeping genes and genes of interest. ",
    "table_content": "|| Gene | Sequence forward | Sequence reverse ||\n|| P0 | 5′-GGACCCGAGAAGACCTCCTT-′3 | 5′-GCACATCACTCAGAATTTCAATG-′3 ||\n|| RPL27 | 5′-CGCCCTCCTTTCCTTTCTGC-′3 | 5′-GGTGCCATCGTCAATGTTCTTC-′3 ||\n|| α-SMA | 5′-GCTATGCCTTGCCCATGC-′3 | 5′-TTCCGATGGTGATCACTTGCC-′3 ||\n|| C5aR | 5′-GCTCAAAGTGGTGATGGC-′3 | 5′-CACAGCAGTTGATGTAGGC-′3 ||\n|| C5L2 | 5′-ACCACCAGCGAGTATTATGACT-′3 | 5′-GCTGCATACAGCACAAGCA-′3 ||\n|| Col1 | 5′-TCAAGGTCTACTGCAACATGG-′3 | 5′-AATCCATCGGTCATGCTCTCT-′3 ||\n|| Col3a1 | 5′-CTGGTTCTTCTGGACATCC-′3 | 5′-TCTTCCTGACTCTCCATCC-′3 ||\n|| TGF-β1 | 5′-ACTACTATGCTAAAGAGG-′3 | 5′-TTGTTGCTATATTTCTGG-′3 ||",
    "claim": "The average length of the forward primer sequences across all genes is 19.75 nucleotides, while the reverse primers average 20.25 nucleotides. This slight difference in length may influence the annealing efficiency during PCR, as shorter primers generally anneal more quickly but may be less specific.",
    "label": "refute"
  },
  {
    "id": "training_862_3",
    "table_caption": "Table: molecular confirmation of Mungbean × Mashbean interspecific recombinants. Primer Code Sequence (5′–3′) Annealing temperature Product size (bp) Random amplified polymorphic DNA (RAPD) OPU-3 CTATGCCGA 35◦C 397–2060 OPAJ-20 ACACGTGGTC 35◦C 440–1870 OPS-07 TCCGATGCTG 35◦C 420–1940 SSR (RIS) primers RIS-F TAATTTCTGCTTGCTCCATGC 55◦C 604–2260 RIS-R ACTGGGGTGCACTGGATTAG 55◦C 177–1828 Simple sequence repeats (SSR) VR040 (F) TGACAACATGGGAAGAAGAAGA (R) ACACCAACACAAAAGCAAACAC 52◦C 157–197 VR062 (F) CGAAGACGAAATCTGAAGACAA (R) TTACTTCTCCCAGCACTCCAAT 52◦C 138–156 VR0111 (F) TGCATCTTTATTGAGTTCCGTG (R) GTTTTGGGGTGAATGTTGGATA 55◦C 190–222 VR0304 (F) GAAGCGAAGAAGCCATAGAAAA (R) CCTCACACACAACACAACAGAA 52◦C 180–190 (F) Forward, (R) Reverse. of high the SSR, of that The and and with ",
    "table_content": "|| Primer Code | Sequence (5′–3′) | Annealing temperature | Product size (bp) ||\n|| Random amplified polymorphic DNA (RAPD) | Random amplified polymorphic DNA (RAPD) | Random amplified polymorphic DNA (RAPD) | Random amplified polymorphic DNA (RAPD) ||\n|| VR062 | (F) CGAAGACGAAATCTGAAGACAA (R) TTACTTCTCCCAGCACTCCAAT | 52° C | 138–156 ||\n|| VR0111 | (F) TGCATCTTTATTGAGTTCCGTG (R) GTTTTGGGGTGAATGTTGGATA | 55° C | 190–222 ||\n|| VR0304 | (F) GAAGCGAAGAAGCCATAGAAAA (R) CCTCACACACAACACAACAGAA | 52° C | 180–190 ||\n|| OPU-3 | CTATGCCGA | 35°C | 397–2060 ||\n|| OPAJ-20 | ACACGTGGTC | 35°C | 440–1870 ||\n|| OPS-07 | TCCGATGCTG | 35°C | 420–1940 ||\n|| SSR (RIS) primers | SSR (RIS) primers | SSR (RIS) primers | SSR (RIS) primers ||\n|| RIS-F | TAATTTCTGCTTGCTCCATGC | 55° C | 604–2260 ||\n|| RIS-R | ACTGGGGTGCACTGGATTAG | 55°C | 177–1828 ||\n|| Simple sequence repeats (SSR) | Simple sequence repeats (SSR) | Simple sequence repeats (SSR) | Simple sequence repeats (SSR) ||\n|| VR040 | (F) TGACAACATGGGAAGAAGAAGA (R) ACACCAACACAAAAGCAAACAC | 52° C | 157–197 ||",
    "claim": "The annealing temperatures for RAPD primers are consistently lower than those for SSR primers, with a difference of 20°C. This reflects the different binding affinities and specificities of the primer types, with SSR primers requiring higher temperatures for specific binding to their target sequences.",
    "label": "refute"
  },
  {
    "id": "training_862_3",
    "table_caption": "Table: molecular confirmation of Mungbean × Mashbean interspecific recombinants. Primer Code Sequence (5′–3′) Annealing temperature Product size (bp) Random amplified polymorphic DNA (RAPD) OPU-3 CTATGCCGA 35◦C 397–2060 OPAJ-20 ACACGTGGTC 35◦C 440–1870 OPS-07 TCCGATGCTG 35◦C 420–1940 SSR (RIS) primers RIS-F TAATTTCTGCTTGCTCCATGC 55◦C 604–2260 RIS-R ACTGGGGTGCACTGGATTAG 55◦C 177–1828 Simple sequence repeats (SSR) VR040 (F) TGACAACATGGGAAGAAGAAGA (R) ACACCAACACAAAAGCAAACAC 52◦C 157–197 VR062 (F) CGAAGACGAAATCTGAAGACAA (R) TTACTTCTCCCAGCACTCCAAT 52◦C 138–156 VR0111 (F) TGCATCTTTATTGAGTTCCGTG (R) GTTTTGGGGTGAATGTTGGATA 55◦C 190–222 VR0304 (F) GAAGCGAAGAAGCCATAGAAAA (R) CCTCACACACAACACAACAGAA 52◦C 180–190 (F) Forward, (R) Reverse. of high the SSR, of that The and and with ",
    "table_content": "|| Primer Code | Sequence (5′–3′) | Annealing temperature | Product size (bp) ||\n|| Random amplified polymorphic DNA (RAPD) | Random amplified polymorphic DNA (RAPD) | Random amplified polymorphic DNA (RAPD) | Random amplified polymorphic DNA (RAPD) ||\n|| VR062 | (F) CGAAGACGAAATCTGAAGACAA (R) TTACTTCTCCCAGCACTCCAAT | 52° C | 138–156 ||\n|| VR0111 | (F) TGCATCTTTATTGAGTTCCGTG (R) GTTTTGGGGTGAATGTTGGATA | 55° C | 190–222 ||\n|| VR0304 | (F) GAAGCGAAGAAGCCATAGAAAA (R) CCTCACACACAACACAACAGAA | 52° C | 180–190 ||\n|| OPU-3 | CTATGCCGA | 35°C | 397–2060 ||\n|| OPAJ-20 | ACACGTGGTC | 35°C | 440–1870 ||\n|| OPS-07 | TCCGATGCTG | 35°C | 420–1940 ||\n|| SSR (RIS) primers | SSR (RIS) primers | SSR (RIS) primers | SSR (RIS) primers ||\n|| RIS-F | TAATTTCTGCTTGCTCCATGC | 55° C | 604–2260 ||\n|| RIS-R | ACTGGGGTGCACTGGATTAG | 55°C | 177–1828 ||\n|| Simple sequence repeats (SSR) | Simple sequence repeats (SSR) | Simple sequence repeats (SSR) | Simple sequence repeats (SSR) ||\n|| VR040 | (F) TGACAACATGGGAAGAAGAAGA (R) ACACCAACACAAAAGCAAACAC | 52° C | 157–197 ||",
    "claim": "The annealing temperatures for RAPD primers are consistently lower than those for SSR primers, with a difference of 5°C. This reflects the different binding affinities and specificities of the primer types, with SSR primers requiring higher temperatures for specific binding to their target sequences.",
    "label": "refute"
  },
  {
    "id": "training_240_3",
    "table_caption": "Table: Self-reported reasons for non compliance to screening invitation, by provider of last Pap-test. private public never screened reasons for non compliance N % N % N % did not receive the letter 21 9,9 8 13,1 10 16,9 Forgot 40 18,8 27 44,3 22 37,3 pregnancy 10 4,7 1 1,6 no trust in public health services 13 6,1 1 1,7 exclusive trust in private gynaecologist 62 29,1 Fear 8 3,8 16 27,1 did not consider important 5 8,5 hysterectomized 1 1,7 Illness 1 1,7 Virgin 3 5,1 do not respond 59 27,7 25 41,0 Total 213 100,0 61 59 100,0 ",
    "table_content": "|| reasons for non compliance | private | private | public | public | never screened | never screened ||\n|| reasons for non compliance | N | % | N | % | N | % ||\n|| Illness | blank | blank | blank | blank | 1 | 1,7 ||\n|| Virgin | blank | blank | blank | blank | 3 | 5,1 ||\n|| do not respond | 59 | 27,7 | 25 | 41,0 | blank | blank ||\n|| Total | 213 | 100,0 | 61 | blank | 59 | 100,0 ||\n|| did not receive the letter | 21 | 9,9 | 8 | 13,1 | 10 | 16,9 ||\n|| Forgot | 40 | 18,8 | 27 | 44,3 | 22 | 37,3 ||\n|| pregnancy | 10 | 4,7 | 1 | 1,6 | blank | blank ||\n|| no trust in public health services | 13 | 6,1 | blank | blank | 1 | 1,7 ||\n|| exclusive trust in private gynaecologist | 62 | 29,1 | blank | blank | blank | blank ||\n|| Fear | 8 | 3,8 | blank | blank | 16 | 27,1 ||\n|| did not consider important | blank | blank | blank | blank | 5 | 8,5 ||\n|| hysterectomized | blank | blank | blank | blank | 1 | 1,7 ||",
    "claim": "Trust in healthcare providers plays a crucial role in compliance, as evidenced by the fact that 29.1% of individuals who had their last Pap-test with a private provider cited exclusive trust in private gynecologists as their reason for non-compliance. This is similar to the significant percentage of public provider users who reported a lack of trust in public health services, highlighting the importance of trust in private healthcare settings.",
    "label": "refute"
  },
  {
    "id": "training_32_4",
    "table_caption": "Table: and our MRI, aging in used nodes study. illary ed breast to tients nodes have of 28]. these might Table 3 Per-patient overview of SUVmax measurements on PET/CT and hybrid PET/MRI Patient PET/CT SUVmax Hybrid PET/MRI SUVmax 1 Primary tumor 9.3 12.0 Axillary lymph node 8.7 11.0 2 Primary tumor 11.1 11.7 Axillary lymph node 16.0 20.1 3 Primary tumor 8.8 7.6 Axillary lymph node 7.7 4.6 4 Primary tumor 5.1 10.3 Axillary lymph node 2.0 1.7 5 Primary tumor 19.5 17.1 Axillary lymph node 11.9 8.5 6 Primary tumor 3.4 3.9 Axillary lymph node 6.6 5.7 7 Primary tumor 1.8 1.5 Axillary lymph node 4.3 5.4 8 Primary tumor 4.0 4.5 Axillary lymph node 3.7 5.0 9 Primary tumor 14.1 12.1 Axillary lymph node 7.9 8.0 Mean Primary tumor 8.6 9.0 Axillary lymph node 7.7 7.8 Abbreviations: PET positron emission tomography, CTcomputed tomog- raphy, MRI magnetic resonance imaging, SUVmax maximum standard ",
    "table_content": "|| Patient | PET/CT SUVmax | Hybrid PET/MRI SUVmax ||\n|| 1 | 1 | 1 ||\n|| 4 | 4 | 4 ||\n|| Primary tumor | 5.1 | 10.3 ||\n|| Axillary lymph node | 2.0 | 1.7 ||\n|| 5 | 5 | 5 ||\n|| Primary tumor | 19.5 | 17.1 ||\n|| Axillary lymph node | 11.9 | 8.5 ||\n|| 6 | 6 | 6 ||\n|| Primary tumor | 3.4 | 3.9 ||\n|| Axillary lymph node | 6.6 | 5.7 ||\n|| 7 | 7 | 7 ||\n|| Primary tumor | 9.3 | 12.0 ||\n|| Primary tumor | 1.8 | 1.5 ||\n|| Axillary lymph node | 4.3 | 5.4 ||\n|| 8 | 8 | 8 ||\n|| Primary tumor | 4.0 | 4.5 ||\n|| Axillary lymph node | 3.7 | 5.0 ||\n|| 9 | 9 | 9 ||\n|| Primary tumor | 14.1 | 12.1 ||\n|| Axillary lymph node | 7.9 | 8.0 ||\n|| Mean | Mean | Mean ||\n|| Primary tumor | 8.6 | 9.0 ||\n|| Axillary lymph node | 8.7 | 11.0 ||\n|| Axillary lymph node | 7.7 | 7.8 ||\n|| 2 | 2 | 2 ||\n|| Primary tumor | 11.1 | 11.7 ||\n|| Axillary lymph node | 16.0 | 20.1 ||\n|| 3 | 3 | 3 ||\n|| Primary tumor | 8.8 | 7.6 ||\n|| Axillary lymph node | 7.7 | 4.6 ||",
    "claim": "The range of SUVmax values for axillary lymph nodes is wider in hybrid PET/MRI compared to PET/CT, suggesting that hybrid PET/MRI provides more uniform measurements across different patients.",
    "label": "refute"
  },
  {
    "id": "training_488_2",
    "table_caption": "Table: NPCR and UACI of Lena. Red Green Blue proposed algorithm NPCR 99.6006% 99.6178% 99.5975% UACI 33.4418% 33.5298% 33.4927% Liu’s algorithm [26] NPCR 99.6231% 99.6338% 99.6170% UACI 33.4747% 33.5683% 33.3382% Murillo-Escobar’s algorithm [28] NPCR 99.63% 99.60% 99.61% UACI 33.31% 33.34% 33.43% Wu’s algorithm [36] NPCR 99.6101% 99.6136% 99.6141% UACI 33.4695% 33.4643% 33.4665% doi:10.1371/journal.pone.0165937.t011 ",
    "table_content": "|| blank | blank | Red | Green | Blue ||\n|| proposed algorithm | NPCR | 99.6006% | 99.6178% | 99.5975% ||\n|| proposed algorithm | UACI | 33.4418% | 33.5298% | 33.4927% ||\n|| Liu’s algorithm [ 26 ] | NPCR | 99.6231% | 99.6338% | 99.6170% ||\n|| Liu’s algorithm [ 26 ] | UACI | 33.4747% | 33.5683% | 33.3382% ||\n|| Murillo-Escobar’s algorithm [ 28 ] | NPCR | 99.63% | 99.60% | 99.61% ||\n|| Murillo-Escobar’s algorithm [ 28 ] | UACI | 33.31% | 33.34% | 33.43% ||\n|| Wu’s algorithm [ 36 ] | NPCR | 99.6101% | 99.6136% | 99.6141% ||\n|| Wu’s algorithm [ 36 ] | UACI | 33.4695% | 33.4643% | 33.4665% ||",
    "claim": "The UACI values for the proposed algorithm are lower than those of Liu’s algorithm in the Red and Green channels, but higher in the Blue channel. The average UACI for Liu’s algorithm is approximately 0.03% higher than that of the proposed algorithm, indicating a slightly better performance in terms of intensity change.",
    "label": "refute"
  },
  {
    "id": "training_256_5",
    "table_caption": "Table: Seabirds breeding on Alderney and its surrounding islands. Species Number of breeding pairs Importance Atlantic pufﬁn Fratercula arctica 143 Largest in English Channel Storm petrel Hydrobates pelagicus 2800a Regionally important Lesser black-backed gulls Larus fuscus 1392 Nationally important European shag Phalacrocorax aristotelis 167 Nationally important Common guillemot Uria aalge 120b Razorbill Alca torda 90b Northern gannet Morus bassanus 7885 Internationally important a. Number of individuals (2008). b. Approximation (Pers Comms, Alderney Wildlife Trust). ",
    "table_content": "|| Species | Number of breeding pairs | Importance ||\n|| Atlantic puffin Fratercula arctica | 143 | Largest in English Channel ||\n|| Storm petrel Hydrobates pelagicus | 2800 a | Regionally important ||\n|| Lesser black-backed gulls Larus fuscus | 1392 | Nationally important ||\n|| European shag Phalacrocorax aristotelis | 167 | Nationally important ||\n|| Common guillemot Uria aalge | 120 b | blank ||\n|| Razorbill Alca torda | 90 b | blank ||\n|| Northern gannet Morus bassanus | 7885 | Internationally important ||",
    "claim": "Among the species listed, 42.9% are classified as nationally important, while only 14.3% are internationally important, highlighting the unique significance of the Northern gannet population.",
    "label": "refute"
  },
  {
    "id": "training_315_4",
    "table_caption": "Table: Descriptive Analysis of the Population Studied. VARIABLE Total Women Men n % n % n % Deceased No 3440 39.1 693 48.63 2747 37.25 Yes 5360 60.9 732 51.37 4628 62.75 Route of Infection IVDU 6260 71.1 802 56.28 5458 74.01 Heterosexual 1174 13.3 468 32.84 706 9.57 Homosexual 763 8.7 0 0.00 763 10.35 Other 492 5.6 149 10.46 343 4.65 Province of residence at diagnosis Jaen 444 5.0 81 5.68 363 4.92 Huelva 511 5.8 81 5.68 430 5.83 Almeria 600 6.8 124 8.70 476 6.45 Cordoba 608 6.9 109 7.65 499 6.77 Granada 871 9.9 158 11.09 713 9.67 Cadiz 1541 17.5 254 17.82 1287 17.45 Seville 1713 19.5 215 15.09 1498 20.31 Malaga 2511 28.5 403 28.28 2108 28.58 Qualitative variables IVDU: Intravenous drug users ",
    "table_content": "|| VARIABLE | Total | Total | Women | Women | Men | Men ||\n|| VARIABLE | n | % | n | % | n | % ||\n|| Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis ||\n|| Jaen | 444 | 5.0 | 81 | 5.68 | 363 | 4.92 ||\n|| Huelva | 511 | 5.8 | 81 | 5.68 | 430 | 5.83 ||\n|| Almeria | 600 | 6.8 | 124 | 8.70 | 476 | 6.45 ||\n|| Cordoba | 608 | 6.9 | 109 | 7.65 | 499 | 6.77 ||\n|| Granada | 871 | 9.9 | 158 | 11.09 | 713 | 9.67 ||\n|| Cadiz | 1541 | 17.5 | 254 | 17.82 | 1287 | 17.45 ||\n|| Seville | 1713 | 19.5 | 215 | 15.09 | 1498 | 20.31 ||\n|| Malaga | 2511 | 28.5 | 403 | 28.28 | 2108 | 28.58 ||\n|| Deceased | Deceased | Deceased | Deceased | Deceased | Deceased | Deceased ||\n|| No | 3440 | 39.1 | 693 | 48.63 | 2747 | 37.25 ||\n|| Yes | 5360 | 60.9 | 732 | 51.37 | 4628 | 62.75 ||\n|| Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection ||\n|| IVDU | 6260 | 71.1 | 802 | 56.28 | 5458 | 74.01 ||\n|| Heterosexual | 1174 | 13.3 | 468 | 32.84 | 706 | 9.57 ||\n|| Homosexual | 763 | 8.7 | 0 | 0.00 | 763 | 10.35 ||\n|| Other | 492 | 5.6 | 149 | 10.46 | 343 | 4.65 ||",
    "claim": "The overall population has a higher percentage of deceased individuals compared to those who are not deceased. The deceased individuals constitute approximately 0.64 times the number of non-deceased individuals in the total population.",
    "label": "refute"
  },
  {
    "id": "training_195_4",
    "table_caption": "Table: low Ct (high miRNA) High Ct (low miRNA) Specificity Threshold Sensitivity AUC miR-22-3p SC sc0 0.80 32 0.80 0.81 miR-204-5p SC sc0 0.80 31 0.80 0.91 miR-99b-5p SC sc0 0.73 33 0.73 0.82 miR-30d-5p SC sc0 0.72 33 0.72 0.89 miR-425-3p SC sc0 0.7 33 0.7 0.79 miR-328 sc0 SC 0.74 23 0.74 0.79 miR-608 sc0 SC 0.78 28 0.78 0.80 miR-99b-5p START gwi0 0.76 33 0.76 0.84 miR-425-3p START gwi0 0.72 33 0.72 0.84 miR-370 START gwi0 0.72 31 0.72 0.84 miR-328 gwi0 START 0.91 25 0.91 0.98 let-7i-5p gwi0 START 0.78 33 0.78 0.80 miR-200a-5p gwi0 START 0.83 33 0.83 0.88 miR-608 gwi0 START 0.82 30 0.82 0.88 miR-93-3p gwi0 START 0.77 34 0.77 0.84 miR-204-5p STOPP gwi0 0.62 31 0.62 0.72 miR-99b-5p STOPP gwi0 0.75 33 0.75 0.84 miR-328 gwi0 STOPP 0.86 23 0.86 0.87 let-7i-5p gwi0 STOPP 0.72 32 0.72 0.78 miR-200a-5p gwi0 STOPP 0.71 31 0.71 0.73 miR-608 gwi0 STOPP 0.79 28 0.79 0.77 miR-93-3p gwi0 STOPP 0.75 32 0.75 0.76 miR-328 cfs0 CFS 0.84 24 0.84 0.90 miR-608 cfs0 CFS 0.76 29 0.76 0.84 let-7i-5p cfs0 CFS 0.68 31 0.68 0.74 miR-200a-5p cfs0 CFS 0.72 32 0.72 0.82 miR-93-3p cfs0 CFS 0.77 33 0.77 0.83 miR-126-5p cfs0 CFS 0.74 32 0.75 0.88 miR-19b-3p cfs0 CFS 0.63 34 0.63 0.79 miR-505-3p cfs0 CFS 0.65 34 0.65 0.82 miR-92a-3p cfs0 CFS 0.81 29 0.81 0.86 miR-186-3p cfs0 CFS 0.67 35 0.67 0.79 miR-323b-5p cfs0 CFS 0.75 32 0.75 0.84 miR-532-5p cfs0 CFS 0.70 34 0.70 0.73 Table 2. Receiver operating characteristics. ",
    "table_content": "|| blank | low Ct (high miRNA) | High Ct (low miRNA) | Specificity | Threshold | Sensitivity | AUC ||\n|| miR-22-3p | SC | sc0 | 0.80 | 32 | 0.80 | 0.81 ||\n|| miR-370 | START | gwi0 | 0.72 | 31 | 0.72 | 0.84 ||\n|| miR-328 | gwi0 | START | 0.91 | 25 | 0.91 | 0.98 ||\n|| let-7i-5p | gwi0 | START | 0.78 | 33 | 0.78 | 0.80 ||\n|| miR-200a-5p | gwi0 | START | 0.83 | 33 | 0.83 | 0.88 ||\n|| miR-608 | gwi0 | START | 0.82 | 30 | 0.82 | 0.88 ||\n|| miR-93-3p | gwi0 | START | 0.77 | 34 | 0.77 | 0.84 ||\n|| miR-204-5p | STOPP | gwi0 | 0.62 | 31 | 0.62 | 0.72 ||\n|| miR-99b-5p | STOPP | gwi0 | 0.75 | 33 | 0.75 | 0.84 ||\n|| miR-328 | gwi0 | STOPP | 0.86 | 23 | 0.86 | 0.87 ||\n|| let-7i-5p | gwi0 | STOPP | 0.72 | 32 | 0.72 | 0.78 ||\n|| miR-204-5p | SC | sc0 | 0.80 | 31 | 0.80 | 0.91 ||\n|| miR-200a-5p | gwi0 | STOPP | 0.71 | 31 | 0.71 | 0.73 ||\n|| miR-608 | gwi0 | STOPP | 0.79 | 28 | 0.79 | 0.77 ||\n|| miR-93-3p | gwi0 | STOPP | 0.75 | 32 | 0.75 | 0.76 ||\n|| miR-328 | cfs0 | CFS | 0.84 | 24 | 0.84 | 0.90 ||\n|| miR-608 | cfs0 | CFS | 0.76 | 29 | 0.76 | 0.84 ||\n|| let-7i-5p | cfs0 | CFS | 0.68 | 31 | 0.68 | 0.74 ||\n|| miR-200a-5p | cfs0 | CFS | 0.72 | 32 | 0.72 | 0.82 ||\n|| miR-93-3p | cfs0 | CFS | 0.77 | 33 | 0.77 | 0.83 ||\n|| miR-126-5p | cfs0 | CFS | 0.74 | 32 | 0.75 | 0.88 ||\n|| miR-19b-3p | cfs0 | CFS | 0.63 | 34 | 0.63 | 0.79 ||\n|| miR-99b-5p | SC | sc0 | 0.73 | 33 | 0.73 | 0.82 ||\n|| miR-505-3p | cfs0 | CFS | 0.65 | 34 | 0.65 | 0.82 ||\n|| miR-92a-3p | cfs0 | CFS | 0.81 | 29 | 0.81 | 0.86 ||\n|| miR-186-3p | cfs0 | CFS | 0.67 | 35 | 0.67 | 0.79 ||\n|| miR-323b-5p | cfs0 | CFS | 0.75 | 32 | 0.75 | 0.84 ||\n|| miR-532-5p | cfs0 | CFS | 0.70 | 34 | 0.70 | 0.73 ||\n|| miR-30d-5p | SC | sc0 | 0.72 | 33 | 0.72 | 0.89 ||\n|| miR-425-3p | SC | sc0 | 0.7 | 33 | 0.7 | 0.79 ||\n|| miR-328 | sc0 | SC | 0.74 | 23 | 0.74 | 0.79 ||\n|| miR-608 | sc0 | SC | 0.78 | 28 | 0.78 | 0.80 ||\n|| miR-99b-5p | START | gwi0 | 0.76 | 33 | 0.76 | 0.84 ||\n|| miR-425-3p | START | gwi0 | 0.72 | 33 | 0.72 | 0.84 ||",
    "claim": "The miRNA miR-608 shows a specificity decrease of 0.06 when transitioning from the SC state to the START state, while its AUC increases by 0.08. This dual change in specificity and AUC highlights the altered performance of miR-608 in the START state compared to the SC state.",
    "label": "refute"
  },
  {
    "id": "training_1379_2",
    "table_caption": "Table: Tableau 3: Mesure de l'IMC et du Tour de Taille de notre population en fonction de leurs activités physiques et temps de sédentarités Variables IMC (kg/m²) Tour de Taille (cm) Moyenne ± Ecart type p-value Moyenne ± Ecart type p-value Activités physiques dans le cadre scolaire Oui 21,98 ± 3,6 0,001 70,97 ± 7,2 0,001 Non 23,72 ± 4,6 75,0 ± 11,5 Activités sportivesinstitutionnalisées hors scolaire Oui 20,6 ± 3,4 0,00 69,55 ± 7,3 0,011 Non 22,19 ± 3,6 71,33 ± 8,6 Niveau d'AP (IPAQ) Elevé 21,69 ± 3,4 0,00 70,49 ± 7,93 0,00 Modéré 22,02 ± 3,5 70,90 ± 8,10 Faible 24,38 ± 4,7 77,41 ± 12,35 Temps de sédentarité ≤2 heures 21,29 ± 3,45 0,00 68,58 ± 7,7 0,00 Entre 2 et 4 heures 22,12 ± 3,47 71,37 ± 8,0 > 4heures 22,48 ± 4,18 72,43 ± 10,2 ",
    "table_content": "|| Variables | IMC (kg/m 2 ) | IMC (kg/m 2 ) | Tour de Taille (cm) | Tour de Taille (cm) ||\n|| Variables | Moyenne ± Ecart type | p-value | Moyenne ± Ecart type | p-value ||\n|| Modéré | 22,02 ± 3,5 | 0,00 | 70,90 ± 8,10 | 0,00 ||\n|| Faible | 24,38 ± 4,7 | 0,00 | 77,41 ± 12,35 | 0,00 ||\n||  Temps de sédentarité  |  Temps de sédentarité  |  Temps de sédentarité  |  Temps de sédentarité  |  Temps de sédentarité  ||\n|| ≤2 heures | 21,29 ± 3,45 | 0,00 | 68,58 ± 7,7 | 0,00 ||\n|| Entre 2 et 4 heures | 22,12 ± 3,47 | 0,00 | 71,37 ± 8,0 | 0,00 ||\n|| > 4heures | 22,48 ± 4,18 | 0,00 | 72,43 ± 10,2 | 0,00 ||\n||  Activités physiques dans le cadre scolaire  |  Activités physiques dans le cadre scolaire  |  Activités physiques dans le cadre scolaire  |  Activités physiques dans le cadre scolaire  |  Activités physiques dans le cadre scolaire  ||\n|| Oui | 21,98 ± 3,6 | 0,001 | 70,97 ± 7,2 | 0,001 ||\n|| Non | 23,72 ± 4,6 | 0,001 | 75,0 ± 11,5 | 0,001 ||\n||  Activités sportivesinstitutionnalisées hors scolaire  |  Activités sportivesinstitutionnalisées hors scolaire  |  Activités sportivesinstitutionnalisées hors scolaire  |  Activités sportivesinstitutionnalisées hors scolaire  |  Activités sportivesinstitutionnalisées hors scolaire  ||\n|| Oui | 20,6 ± 3,4 | 0,00 | 69,55 ± 7,3 | 0,011 ||\n|| Non | 22,19 ± 3,6 | 0,00 | 71,33 ± 8,6 | 0,011 ||\n||  Niveau d'AP (IPAQ)  |  Niveau d'AP (IPAQ)  |  Niveau d'AP (IPAQ)  |  Niveau d'AP (IPAQ)  |  Niveau d'AP (IPAQ)  ||\n|| Elevé | 21,69 ± 3,4 | 0,00 | 70,49 ± 7,93 | 0,00 ||",
    "claim": "Participation in institutionalized sports activities outside of school is associated with a 7.2% lower BMI and a 5% reduction in waist circumference compared to non-participants. This highlights the role of organized sports in maintaining healthier body metrics.",
    "label": "refute"
  },
  {
    "id": "training_727_2",
    "table_caption": "Table: Table 1 Description and functional consequences of SNPs selected for validation from exome sequencing SNP Location (hg19) Gene Official full name Variant effect rs17844444 (G/A) chr5:140,532,165 PCDHB6 Protocadherin Beta 6 Missense variant rs17082236 (C/A) chr6:152,470,752 SYNE1 Spectrin repeat containing nuclear envelope protein 1 Missense variant rs10279499 (C/A) chr7:92,733,766 SAMD9 Sterile alpha motif domain containing 9 Missense varianta rs10488532 (C/T) chr7:92,764,489 SAMD9L Sterile alpha motif domain containing 9 like Missense variant rs2374639 (T/C) chr7:92,985,252 VPS50 VPS50, EARP/GARPII complex subunit Synonymous variant rs17552167 (C/T) chr7:148,529,922 EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit Intronic variant rs28469012 (A/T) chr10:125,622,263 CPXM2 Carboxypeptidase X, M14 family, member 2 Intronic variant rs10894768 (C/G) chr11:133,815,981 IGSF9B Immunoglobulin superfamily member 9B Synonymous variant rs60252902 (G/A) chr12:125,451,767 DHX37 DEAH-box helicase 37 Splice region variantb rs3742130 (G/A) chr13:99,907,341 GPR18 G protein-coupled receptor 18 Synonymous variant rs9919887 (A/G) chr14:95,911,008 SYNE3 Spectrin repeat containing nuclear envelope family member 3 Intronic variant rs2230434 (C/T) chr16:30,518,096 ITGAL Integrin subunit alpha L Synonymous variant rs2070896 (T/C) chr16:31,384,554 ITGAX Integrin subunit alpha X Intronic variant rs35299026 (G/A) chr19:49,318,380 HSD17B14 Hydroxysteroid 17-beta dehydrogenase 14 Missense varianta rs10423927 (A/G) chr19: 56,235,537 NLRP9 NLR family pyrin domain containing 9 Intronic variant rs2254562 (T/C) chr21:34,059,352 SYNJ1 Synaptojanin 1 Missense varianta aVariants reported as possible deleterious mutations (based on SIFT and PolyPhen-2 algorithms) bBy definition, a splice region variant is a sequence variant in which a change has occurred within the region of the splice site, either within 1–3 bases of the exon or 3–8 bases of the intron [30] ",
    "table_content": "|| SNP | Location (hg19) | Gene | Official full name | Variant effect ||\n|| rs17844444 (G/A) | chr5:140,532,165 |  PCDHB6  | Protocadherin Beta 6 | Missense variant ||\n|| rs3742130 (G/A) | chr13:99,907,341 |  GPR18  | G protein-coupled receptor 18 | Synonymous variant ||\n|| rs9919887 (A/G) | chr14:95,911,008 |  SYNE3  | Spectrin repeat containing nuclear envelope family member 3 | Intronic variant ||\n|| rs2230434 (C/T) | chr16:30,518,096 |  ITGAL  | Integrin subunit alpha L | Synonymous variant ||\n|| rs2070896 (T/C) | chr16:31,384,554 |  ITGAX  | Integrin subunit alpha X | Intronic variant ||\n|| rs35299026 (G/A) | chr19:49,318,380 |  HSD17B14  | Hydroxysteroid 17-beta dehydrogenase 14 | Missense variant a ||\n|| rs10423927 (A/G) | chr19: 56,235,537 |  NLRP9  | NLR family pyrin domain containing 9 | Intronic variant ||\n|| rs2254562 (T/C) | chr21:34,059,352 |  SYNJ1  | Synaptojanin 1 | Missense variant a ||\n|| rs17082236 (C/A) | chr6:152,470,752 |  SYNE1  | Spectrin repeat containing nuclear envelope protein 1 | Missense variant ||\n|| rs10279499 (C/A) | chr7:92,733,766 |  SAMD9  | Sterile alpha motif domain containing 9 | Missense variant a ||\n|| rs10488532 (C/T) | chr7:92,764,489 |  SAMD9L  | Sterile alpha motif domain containing 9 like | Missense variant ||\n|| rs2374639 (T/C) | chr7:92,985,252 |  VPS50  | VPS50, EARP/GARPII complex subunit | Synonymous variant ||\n|| rs17552167 (C/T) | chr7:148,529,922 |  EZH2  | Enhancer of zeste 2 polycomb repressive complex 2 subunit | Intronic variant ||\n|| rs28469012 (A/T) | chr10:125,622,263 |  CPXM2  | Carboxypeptidase X, M14 family, member 2 | Intronic variant ||\n|| rs10894768 (C/G) | chr11:133,815,981 |  IGSF9B  | Immunoglobulin superfamily member 9B | Synonymous variant ||\n|| rs60252902 (G/A) | chr12:125,451,767 |  DHX37  | DEAH-box helicase 37 | Splice region variant b ||",
    "claim": "Analyzing the chromosomal locations, it is evident that chromosome 7 harbors the highest number of SNPs in this dataset. By summing the SNPs located on each chromosome and comparing them, chromosome 7 contains approximately 10% of the total SNPs, suggesting a potential hotspot for genetic variation in this region.",
    "label": "refute"
  },
  {
    "id": "training_166_1",
    "table_caption": "Table: in as at on Table 3: Predictors for mortality in a binary logistic regression model Measures Odds ratio 95% Confidence intervals P value Age 1.08 [1.02; 1.15] .006 ISS 1.12 [1.04; 1.21] .003 Hemoglobin .98 [.44; 2.2] .959 Prothrombin 1.02 [.98; 1.07] .305 Lactate 1.53 [.98; 2.38] .062 Artificial ventilation 4.13 [.02; 1051.39] .616 Transfusion .38 [.02; 7.75] .529 Intubation .201 [.01; 4.04] .295 GCS .86 [.67; 1.1] .226 Severe head injury 2.03 [.19; 22.14] .56 BAC .61 [.18; 2.04] .423 ISS = Injury Severity Score; GCS = Glascow Coma Scale; BAC = blood alcohol concentration in g/l ",
    "table_content": "|| Measures | Odds ratio | 95% Confidence intervals | P value ||\n|| Age | 1.08 | [1.02; 1.15] | . 006 ||\n|| Severe head injury | 2.03 | [.19; 22.14] | .56 ||\n|| BAC | .61 | [.18; 2.04] | .423 ||\n|| ISS | 1.12 | [1.04; 1.21] | . 003 ||\n|| Hemoglobin | .98 | [.44; 2.2] | .959 ||\n|| Prothrombin | 1.02 | [.98; 1.07] | .305 ||\n|| Lactate | 1.53 | [.98; 2.38] | .062 ||\n|| Artificial ventilation | 4.13 | [.02; 1051.39] | .616 ||\n|| Transfusion | .38 | [.02; 7.75] | .529 ||\n|| Intubation | .201 | [.01; 4.04] | .295 ||\n|| GCS | .86 | [.67; 1.1] | .226 ||",
    "claim": "The odds ratio for age is 1.08, indicating that for each additional year of age, the odds of mortality increase by 8%. Given the p-value of .006, this predictor is statistically significant. Over a decade, this results in a compounded increase in mortality odds of approximately 80%, highlighting the critical impact of age on mortality risk.",
    "label": "refute"
  },
  {
    "id": "training_699_5",
    "table_caption": "Table: [16]. 3-year 48% was with 15%) every ing dules tion larger smaller efficacy studies Their model daily ment while 6% creased weekly timize be ing the In also vered, tered Table 3 Acute toxicity profile CCRT toxicity Arm A (cisplatin 100 mg/m2) Arm B (cisplatin 40 mg/m2) p N = 26 N = 24 Overall toxicity Grade 2 5 (19.2%) 2 (8.3%) 0.020* Grade 3 21 (80.8%) 16 (66.7%) Grade 4 0 (0%) 6 (25.0%) Non-hematologic Mucositis < Grade 3 16 (61.5%) 6 (25.0%) 0.012* ≥ Grade 3 10 (38.5%) 18 (75.0%) Pharyngitis < Grade 3 12 (46.2%) 11 (45.8%) 1.000 ≥ Grade 3 14 (53.8%) 13 (54.2%) Stomatitis < Grade 3 12 (46.2%) 11 (45.8%) 1.000 ≥ Grade 3 14 (53.8%) 13 (54.2%) Laryngeal edema < Grade 3 23 (88.5%) 23 (95.8%) 0.611 ≥ Grade 3 3 (11.5%) 1 (4.2%) Dermatitis < Grade 3 24 (92.3%) 22 (91.7%) 1.000 ≥ Grade 3 2 (7.7%) 2 (8.3%) Nausea/vomiting < Grade 3 23 (88.5%) 19 (79.2%) 0.456 ≥ Grade 3 3 (11.5%) 5 (20.8%) Hematologic Anemia < Grade 3 25 (96.2%) 23 (95.8%) 1.000 ≥ Grade 3 1 (3.8%) 1 (4.2%) Leukopenia < Grade 3 26 (100%) 21 (87.5%) 0.103 ≥ Grade 3 0 (0%) 3 (12.5%) Neutropenia < Grade 3 26 (100%) 23 (95.8%) 0.480 ≥ Grade 3 0 (0%) 1 (4.2%) Thrombocytopenia < Grade 3 26 (100%) 24 (100%) NS ≥ Grade 3 0 (0%) 0 (0%) Abbreviations: CCRT = concurrent chemoradiotherapy; NS = no statistics were computed. * Statistically significant, p < 0.05. ",
    "table_content": "|| CCRT toxicity | Arm A (cisplatin 100 mg/m 2 ) N = 26 | Arm B (cisplatin 40 mg/m 2 ) N = 24 | p ||\n|| CCRT toxicity | Arm A (cisplatin 100 mg/m 2 ) N = 26 | Arm B (cisplatin 40 mg/m 2 ) N = 24 | p ||\n|| Pharyngitis | Pharyngitis | Pharyngitis | Pharyngitis ||\n|| < Grade 3 | 12 (46.2%) | 11 (45.8%) | 1.000 ||\n|| ≥ Grade 3 | 14 (53.8%) | 13 (54.2%) | 1.000 ||\n|| Stomatitis | Stomatitis | Stomatitis | Stomatitis ||\n|| < Grade 3 | 12 (46.2%) | 11 (45.8%) | 1.000 ||\n|| ≥ Grade 3 | 14 (53.8%) | 13 (54.2%) | 1.000 ||\n|| Laryngeal edema | Laryngeal edema | Laryngeal edema | Laryngeal edema ||\n|| < Grade 3 | 23 (88.5%) | 23 (95.8%) | 0.611 ||\n|| ≥ Grade 3 | 3 (11.5%) | 1 (4.2%) | 0.611 ||\n|| Dermatitis | Dermatitis | Dermatitis | Dermatitis ||\n|| Overall toxicity | Overall toxicity | Overall toxicity | Overall toxicity ||\n|| < Grade 3 | 24 (92.3%) | 22 (91.7%) | 1.000 ||\n|| ≥ Grade 3 | 2 (7.7%) | 2 (8.3%) | 1.000 ||\n|| Nausea/vomiting | Nausea/vomiting | Nausea/vomiting | Nausea/vomiting ||\n|| < Grade 3 | 23 (88.5%) | 19 (79.2%) | 0.456 ||\n|| ≥ Grade 3 | 3 (11.5%) | 5 (20.8%) | 0.456 ||\n|| Hematologic | Hematologic | Hematologic | Hematologic ||\n|| Anemia | Anemia | Anemia | Anemia ||\n|| < Grade 3 | 25 (96.2%) | 23 (95.8%) | 1.000 ||\n|| ≥ Grade 3 | 1 (3.8%) | 1 (4.2%) | 1.000 ||\n|| Leukopenia | Leukopenia | Leukopenia | Leukopenia ||\n|| Grade 2 | 5 (19.2%) | 2 (8.3%) | 0.020* ||\n|| < Grade 3 | 26 (100%) | 21 (87.5%) | 0.103 ||\n|| ≥ Grade 3 | 0 (0%) | 3 (12.5%) | 0.103 ||\n|| Neutropenia | Neutropenia | Neutropenia | Neutropenia ||\n|| < Grade 3 | 26 (100%) | 23 (95.8%) | 0.480 ||\n|| ≥ Grade 3 | 0 (0%) | 1 (4.2%) | 0.480 ||\n|| Thrombocytopenia | Thrombocytopenia | Thrombocytopenia | Thrombocytopenia ||\n|| < Grade 3 | 26 (100%) | 24 (100%) | NS ||\n|| ≥ Grade 3 | 0 (0%) | 0 (0%) | NS ||\n|| Grade 3 | 21 (80.8%) | 16 (66.7%) | 0.020* ||\n|| Grade 4 | 0 (0%) | 6 (25.0%) | 0.020* ||\n|| Non-hematologic | Non-hematologic | Non-hematologic | Non-hematologic ||\n|| Mucositis | Mucositis | Mucositis | Mucositis ||\n|| < Grade 3 | 16 (61.5%) | 6 (25.0%) | 0.012* ||\n|| ≥ Grade 3 | 10 (38.5%) | 18 (75.0%) | 0.012* ||",
    "claim": "Arm A exhibits a 25% incidence of Grade 4 toxicity, while Arm B shows none. This stark contrast suggests that the higher dosage in Arm A may lead to more severe toxic reactions, as supported by the statistical significance (p = 0.020).",
    "label": "refute"
  },
  {
    "id": "training_1089_6",
    "table_caption": "Table: Data collection Bruker SMART APEX diffractometer 2358 independent reflections Radiation source: fine-focus sealed tube 1339 reflections with I > 2σ(I) graphite Rint = 0.047 φ and ω scans θmax = 25.5°, θmin = 2.5° Absorption correction: multi-scan (SADABS; Bruker, 2003) h = −17→20 Tmin = 0.338, Tmax = 0.338 k = −6→6 6208 measured reflections l = −35→30 Refinement ",
    "table_content": "|| Bruker SMART APEX diffractometer | 2358 independent reflections ||\n|| Radiation source: fine-focus sealed tube | 1339 reflections with I > 2σ( I ) ||\n|| graphite | R int = 0.047 ||\n|| φ and ω scans | θ max = 25.5°, θ min = 2.5° ||\n|| Absorption correction: multi-scan ( SADABS ; Bruker, 2003) | h = −17→20 ||\n|| T min = 0.338, T max = 0.338 | k = −6→6 ||\n|| 6208 measured reflections | l = −35→30 ||",
    "claim": "The Rint value of 0.047 reflects a low level of internal consistency and reliability in the dataset, indicating that the data is poorly suited for accurate structural refinement.",
    "label": "refute"
  },
  {
    "id": "training_492_2",
    "table_caption": "Table: Table 2 – Strain and strain rate parameters in the post-surgery group versus healthy individuals (Median and Interquatile Range were used because non-normal distribution of variables). P values were calculated with Mann-Whitney test LASs Median (P25-P75) LASa Median (P25-P75) LASRe Median (P25-P75) LASRa Median (P25-P75) Post-surgery group 16.9 (14.1-20.6) 5.9 (4.5-7) -0.55 (-0.45- -0.67) -0.41 (-0.56- -0.25) Control group 42.5 (36.3-48.8) 13.1 (11.6-16.2) -1.83 (-1.4- -2) -1.6 (-1.8- -1.4) p < 0.001 < 0.001 < 0.001 < 0.001 LASe: LA systolic strain; LASa: LA diastolic strain; LASRe: LA early strain rate; LASRa: LA late strain rate ",
    "table_content": "|| blank | LASs Median (P 25 -P 75 ) | LASa Median (P 25 -P 75 ) | LASRe Median (P 25 -P 75 ) | LASRa Median (P 25 -P 75 ) ||\n|| Post-surgery group | 16.9 (14.1-20.6) | 5.9 (4.5-7) | -0.55 (-0.45- -0.67) | -0.41 (-0.56- -0.25) ||\n|| Control group | 42.5 (36.3-48.8) | 13.1 (11.6-16.2) | -1.83 (-1.4- -2) | -1.6 (-1.8- -1.4) ||\n|| p | < 0.001 | < 0.001 | < 0.001 | < 0.001 ||",
    "claim": "The median LASa value in the post-surgery group is approximately 25% lower than that in the control group, suggesting a marked decrease in LA diastolic strain following surgery.",
    "label": "refute"
  },
  {
    "id": "training_516_2",
    "table_caption": "Table: by single were are equili- this can six selected geometries at DFT level with standard PBE functional and when including dispersion correction (PBE-D2) Geometry PBEa PBE-D2 d0 (Å) Eint (meV) d0 (Å) Eint (meV) C_DOWN 4.02 19 2.60 139 C_UP 3.69 20 3.07 83 B_DOWN 4.05 18 2.67 129 B_UP 3.70 18 3.17 77 T_DOWN 4.05 19 2.64 127 T_UP 3.70 19 3.18 75 aData taken from Ref. [15]. ",
    "table_content": "|| Geometry | PBE a | PBE a | PBE-D2 | PBE-D2 ||\n|| Geometry | d 0 (Å) | E int (meV) | d 0 (Å) | E int (meV) ||\n|| C_DOWN | 4.02 | 19 | 2.60 | 139 ||\n|| C_UP | 3.69 | 20 | 3.07 | 83 ||\n|| B_DOWN | 4.05 | 18 | 2.67 | 129 ||\n|| B_UP | 3.70 | 18 | 3.17 | 77 ||\n|| T_DOWN | 4.05 | 19 | 2.64 | 127 ||\n|| T_UP | 3.70 | 19 | 3.18 | 75 ||",
    "claim": "The average increase in interaction energy (Eint) when switching from PBE to PBE-D2 across all geometries is approximately 108 meV, reflecting a substantial enhancement in binding strength with dispersion correction.",
    "label": "refute"
  },
  {
    "id": "training_1095_4",
    "table_caption": "Table: Table 1 Survey domains, questions and response items Survey domain Select questions Select response options Nurse perceived barriers to home dialysis -(1) Peritoneal dialysis and (2) Home hemodialysis can be performed on patients with:* -No education after high school -Limited home space -Age greater than 70 years -Large body mass -Impaired cognition -Poor visual acuity -Poor motor strength Home dialysis benefits -Do you feel home dialysis (HD or PD) or in-center hemodialysis is more preferable for the following:** -Reduced cost to patients -Reduced healthcare costs -Better patient survival -Better patient quality of life Ability/knowledge/skill to encourage home modalities - I am aware of home dialysis* modalities Not applicable -I promote home dialysis to in-center HD patients* -I am comfortable explaining home dialysis to patients* -Promoting home dialysis will reduce employment for in-center HD nurses* Perceived ideal modality mix -Given the current modality mix, in your opinion, what is the ideal proportion of patients that should receive each modality to maximize survival, wellness and quality of life?*** Not applicable *5-item Likert; Strongly Agree; Agree; Neutral; Disagree; Strongly disagree. **5-item Likert; In-Center Hemodialysis Strongly Preferred; In-Center Hemodialysis Somewhat Preferred; Neither Preferred; Home Dialysis Somewhat Preferred; Home Dialysis Strongly Preferred. ",
    "table_content": "||  Survey domain  |  Select questions  |  Select response options  ||\n|| Nurse perceived barriers to home dialysis |  -(1) Peritoneal dialysis and (2) Home hemodialysis can be performed on patients with:*  | -No education after high school ||\n|| Home dialysis benefits |  -Do you feel home dialysis (HD or PD) or in-center hemodialysis is more preferable for the following:**  | -Better patient survival ||\n|| Home dialysis benefits |  -Do you feel home dialysis (HD or PD) or in-center hemodialysis is more preferable for the following:**  | -Better patient quality of life ||\n|| Ability/knowledge/skill to encourage home modalities |  - I am aware of home dialysis* modalities  | Not applicable ||\n|| Ability/knowledge/skill to encourage home modalities |  -I promote home dialysis to in-center HD patients*  | Not applicable ||\n|| Ability/knowledge/skill to encourage home modalities |  -I am comfortable explaining home dialysis to patients*  | Not applicable ||\n|| Ability/knowledge/skill to encourage home modalities |  -Promoting home dialysis will reduce employment for in-center HD nurses*  | Not applicable ||\n|| Perceived ideal modality mix |  -Given the current modality mix, in your opinion, what is the ideal proportion of patients that should receive each modality to maximize survival, wellness and quality of life?***  | Not applicable ||\n|| Nurse perceived barriers to home dialysis |  -(1) Peritoneal dialysis and (2) Home hemodialysis can be performed on patients with:*  | -Limited home space ||\n|| Nurse perceived barriers to home dialysis |  -(1) Peritoneal dialysis and (2) Home hemodialysis can be performed on patients with:*  | -Age greater than 70 years ||\n|| Nurse perceived barriers to home dialysis |  -(1) Peritoneal dialysis and (2) Home hemodialysis can be performed on patients with:*  | -Large body mass ||\n|| Nurse perceived barriers to home dialysis |  -(1) Peritoneal dialysis and (2) Home hemodialysis can be performed on patients with:*  | -Impaired cognition ||\n|| Nurse perceived barriers to home dialysis |  -(1) Peritoneal dialysis and (2) Home hemodialysis can be performed on patients with:*  | -Poor visual acuity ||\n|| Nurse perceived barriers to home dialysis |  -(1) Peritoneal dialysis and (2) Home hemodialysis can be performed on patients with:*  | -Poor motor strength ||\n|| Home dialysis benefits |  -Do you feel home dialysis (HD or PD) or in-center hemodialysis is more preferable for the following:**  | -Reduced cost to patients ||\n|| Home dialysis benefits |  -Do you feel home dialysis (HD or PD) or in-center hemodialysis is more preferable for the following:**  | -Reduced healthcare costs ||",
    "claim": "The survey suggests that the ideal modality mix, as perceived by nurses, would involve a 25% increase in home dialysis patients to maximize survival, wellness, and quality of life, compared to the current modality mix.",
    "label": "refute"
  },
  {
    "id": "training_992_4",
    "table_caption": "Table: TSPY1 is normally restricted to the testis where it plays a major mechanism to transcriptionally silence its expres- Table 2: Genes re-expressed by 5-aza-dC and TSA, but not by either drug alone Gene Symbol Unigene Affymetrix ID Fold Change p-value Control Signal 5-aza-dC + TSA Signal 5-aza-dC Signal Description CHGA Hs.150793 204697_s_at 3.03 0.012 214 648 214 Chromogranin A (parathyroid secretory protein 1) TKTL1 Hs.102866 214183_s_at 57.92 0.00004 49 2809 1276 Transketolase-like 1 BG1 Hs.250616 206465_at 6.16 0.00007 172 1057 630 Lipidosin - Hs.399852 1559213_at 43.98 0.0003 19 842 193 IMAGE:5394246, mRNA ",
    "table_content": "|| Gene Symbol | Unigene | Affymetrix ID | Fold Change | p-value | Control Signal | 5-aza-dC + TSA Signal | 5-aza-dC Signal | Description ||\n|| CHGA | Hs.150793 | 204697_s_at | 3.03 | 0.012 | 214 | 648 | 214 | Chromogranin A (parathyroid secretory protein 1) ||\n|| TKTL1 | Hs.102866 | 214183_s_at | 57.92 | 0.00004 | 49 | 2809 | 1276 | Transketolase-like 1 ||\n|| BG1 | Hs.250616 | 206465_at | 6.16 | 0.00007 | 172 | 1057 | 630 | Lipidosin ||\n|| blank | Hs.399852 | 1559213_at | 43.98 | 0.0003 | 19 | 842 | 193 | IMAGE:5394246, mRNA ||",
    "claim": "For the gene BG1, the expression level in the 5-aza-dC + TSA condition is approximately 6.15 times higher than the control, while the expression level in the 5-aza-dC condition alone is approximately 6.16 times higher than the control. This indicates that the single treatment enhances expression more than the combination treatment.",
    "label": "refute"
  },
  {
    "id": "training_1260_2",
    "table_caption": "Table: Deletion regions from the less conservative \"LOH/Model B\" Chr arm No. deletion regions in each chr arm Cytoband(s) Total no. SNPs in each chr arm 2q 1 2q35 6 3p 6 3p26-p25 3p25-p24.3 3p24 3p24-p14 3p14-p13 3p13 293 4p 4 4p16-p15.3 4p15.3 4p15.1-p13 4p12-q12 150 4q 5 4q21 4q21.2-q22 4q22-q31.2 4q31.2-q34 4q34-q35 486 5q 8 5q11.2-q15 5q15 5q21 5q22 5q23 (2) 5q32-q34 5q34-q35 357 6p 5 6p24-p23 6p22.3 6p22.2-p21.2 6p21.2 6p11.2-q12 75 6q 1 6q15 21 8p 4 8p23.2 8p22(3) 32 9p/q 3 9p24.3 9p24.3-p22 9p22-q33 507 10p 1 10p12.1-p11.2 5 11p 1 11p15.2 6 11q 2 11q23 11q24 20 13q 4 13q12.2-q31.1 13q31.1 13q32.1 13q32.1-q34 391 14q 10 14q11.2-q12 14q12 (2) 14q21 (3) 14q23 (2) 14q23-q24.2 14q24.3 138 15q 10 15q11.2-q14 15q14 15q14-q15 15q15-q21.1 15q21.1 15q21.3-q23 15q25 (3) 15q25-q26.2 190 17p/q 1 17p13-q25 174 18q 4 18q21.1-q21.2 18q21.2 18q22 (2) 47 21q 1 21q22.1 10 22q 1 22q12.1-q12 8 Total no. deletion regions 72 Total no. SNPs 2916 ",
    "table_content": "|| Chr arm | No. deletion regions in each chr arm | Cytoband(s) | Total no. SNPs in each chr arm ||\n|| 2q | 1 | 2q35 | 6 ||\n|| 10p | 1 | 10p12.1-p11.2 | 5 ||\n|| 11p | 1 | 11p15.2 | 6 ||\n|| 11q | 2 | 11q23 11q24 | 20 ||\n|| 13q | 4 | 13q12.2-q31.1 13q31.1 13q32.1 13q32.1-q34 | 391 ||\n|| 14q | 10 | 14q11.2-q12 14q12 (2) 14q21 (3) 14q23 (2) 14q23-q24.2 14q24.3 | 138 ||\n|| 15q | 10 | 15q11.2-q14 15q14 15q14-q15 15q15-q21.1 15q21.1 15q21.3-q23 15q25 (3) 15q25-q26.2 | 190 ||\n|| 17p/q | 1 | 17p13-q25 | 174 ||\n|| 18q | 4 | 18q21.1-q21.2 18q21.2 18q22 (2) | 47 ||\n|| 21q | 1 | 21q22.1 | 10 ||\n|| 22q | 1 | 22q12.1-q12 | 8 ||\n|| 3p | 6 | 3p26-p25 3p25-p24.3 3p24 3p24-p14 3p14-p13 3p13 | 293 ||\n|| Total no. deletion regions | 72 | Total no. SNPs | 2916 ||\n|| 4p | 4 | 4p16-p15.3 4p15.3 4p15.1-p13 4p12-q12 | 150 ||\n|| 4q | 5 | 4q21 4q21.2-q22 4q22-q31.2 4q31.2-q34 4q34-q35 | 486 ||\n|| 5q | 8 | 5q11.2-q15 5q15 5q21 5q22 5q23 (2) 5q32-q34 5q34-q35 | 357 ||\n|| 6p | 5 | 6p24-p23 6p22.3 6p22.2-p21.2 6p21.2 6p11.2-q12 | 75 ||\n|| 6q | 1 | 6q15 | 21 ||\n|| 8p | 4 | 8p23.2 8p22(3) | 32 ||\n|| 9p/q | 3 | 9p24.3 9p24.3-p22 9p22-q33 | 507 ||",
    "claim": "Despite having the highest number of deletion regions (10), chromosome arm 14q accounts for 13.4% of the total SNPs, suggesting a higher SNP density per deletion region compared to other arms.",
    "label": "refute"
  },
  {
    "id": "training_1244_4",
    "table_caption": "Table: Comparison of miPred and miR-KDE in terms of the feature set and the classification mechanism. Without the four stem-loop features1 With the four stem-loop features2 %SE %SP %ACC %Fm %MCC %SE %SP %ACC %Fm %MCC HU2163 SVM 88.0% 88.0% 88.0% 88.0% 75.9% 90.7% 90.7% 90.7% 90.7% 81.5% RVKDE 85.2% 90.7% 88.0% 87.6% 76.0% 88.9% 92.6% 90.7% 90.6% 81.5% NH33504 SVM 96.7% 90.4% 93.6% 93.7% 87.3% 97.3% 91.3% 94.3% 94.4% 88.7% RVKDE 94.8% 93.4% 94.1% 94.1% 88.2% 95.8% 93.5% 94.7% 94.7% 89.3% The best performance among each dataset is highlighted with bold font. 1Using the 29 features in miPred. 2Using the 33 features in miR-KDE, i.e., the 29 features derived from miPred and the four stem-loop features. 3Using the HU400 dataset to predict the HU216 dataset. 4Using the HU400 ",
    "table_content": "|| blank | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 ||\n|| blank | %SE | %SP | %ACC | %Fm | %MCC | %SE | %SP | %ACC | %Fm | %MCC ||\n|| HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 ||\n|| SVM | 88.0% | 88.0% | 88.0% | 88.0% | 75.9% | 90.7% | 90.7% | 90.7% | 90.7% | 81.5% ||\n|| RVKDE | 85.2% | 90.7% | 88.0% | 87.6% | 76.0% | 88.9% | 92.6% | 90.7% | 90.6% | 81.5% ||\n|| NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 ||\n|| SVM | 96.7% | 90.4% | 93.6% | 93.7% | 87.3% | 97.3% | 91.3% | 94.3% | 94.4% | 88.7% ||\n|| RVKDE | 94.8% | 93.4% | 94.1% | 94.1% | 88.2% | 95.8% | 93.5% | 94.7% | 94.7% | 89.3% ||",
    "claim": "For the HU216 dataset, the RVKDE classifier shows a 3.3% decrease in Specificity with the additional features, while Sensitivity increases by 3.7%, indicating a balanced enhancement in both true positive and true negative rates.",
    "label": "refute"
  },
  {
    "id": "training_212_4",
    "table_caption": "Table: Table 3 Composition of the ALA-rich oil (876 g/mol), olive oil (875 g/mol) and butter (fat-part 734 g/mol) meals1 Amount Energy (KJ) Fat (g) Protein (g) Carbohydrate (g) ALA-rich oil 35 g 1277 352 - - Olive oil 35 g 1277 352 0.2 0.2 Butter 42 g 1265 353 0.3 0.2 Milk for cooking, 3% fat 0.225 L 595 7.1 8.1 11.4 Semolina (wheat kernel) 20 g 291 0.3 2 14.2 Rye bread, one slice 38 g 408 1 2.9 17.8 Smoked ham, 3% fat or 9 g 44 0.3 2 0 soft Cheese4, 3% fat 9 g 43 0.3 1.6 0.3 Blackberry jam 32 g 262 0 0.1 14.8 Milk, 1.5% fat 0.2 L 410 3.1 7.2 10.3 Total 3290 47 23 69 1 Data from proximate analysis of ingredients. Analysed with Dietist XP, version 3.1, with the Swedish National Food Administration database (2008). 2 Equivalent to 0.04 mol. 3 Equivalent to 0.05 mol. ",
    "table_content": "|| blank | Amount | Energy (KJ) | Fat (g) | Protein (g) | Carbohydrate (g) ||\n|| ALA-rich oil | 35 g | 1277 | 35 2 | blank | blank ||\n|| Milk, 1.5% fat | 0.2 L | 410 | 3.1 | 7.2 | 10.3 ||\n|| Total | blank | 3290 | 47 | 23 | 69 ||\n|| Olive oil | 35 g | 1277 | 35 2 | 0.2 | 0.2 ||\n|| Butter | 42 g | 1265 | 35 3 | 0.3 | 0.2 ||\n|| Milk for cooking, 3% fat | 0.225 L | 595 | 7.1 | 8.1 | 11.4 ||\n|| Semolina (wheat kernel) | 20 g | 291 | 0.3 | 2 | 14.2 ||\n|| Rye bread, one slice | 38 g | 408 | 1 | 2.9 | 17.8 ||\n|| Smoked ham, 3% fat or | 9 g | 44 | 0.3 | 2 | 0 ||\n|| soft Cheese 4 , 3% fat | 9 g | 43 | 0.3 | 1.6 | 0.3 ||\n|| Blackberry jam | 32 g | 262 | 0 | 0.1 | 14.8 ||",
    "claim": "The carbohydrate content from semolina, rye bread, and blackberry jam collectively makes up about 35% of the total carbohydrate content in the meal. This indicates that these ingredients are not the main contributors to the carbohydrate intake.",
    "label": "refute"
  },
  {
    "id": "training_1036_2",
    "table_caption": "Table: Distribution of PM2.5 concentrations in the 16 districts of Beijing, 2013–2014. District Regional category Mean(SD) μg/m3 Median (IQR) μg/m3 Range μg/ m3 Non-attainment days and rates (%) for grade I Non-attainment days and rates (%) for grade II Yanqing North 67.95(61.06) 52.00(67.00) 5.0–459.0 216 (63.7) 108 (31.9) Changping North 73.30(66.36) 55.00(72.00) 5.0–432.0 224 (66.1) 130 (38.3) Miyun North 67.79(61.74) 51.00(68.00) 4.0–481.0 205 (60.5) 117 (34.5) Huairou North 77.80(65.80) 59.00(72.00) 5.0–402.0 226 (69.1) 136 (41.6) Pinggu North 79.23(66.25) 61.00(74.50) 4.0–475.0 242 (71.4) 150 (44.2) Shunyi North 83.55(70.27) 65.00(80.00) 5.0–509.0 241 (71.5) 149 (44.2) Haidian Center 85.15(70.47) 71.00(77.00) 4.0–430.0 248 (73.2) 161 (47.5) Shijingshan Center 87.99(69.32) 72.00(73.00) 6.0–408.0 254 (76.3) 158 (47.4) Xicheng Center 88.26(71.60) 70.50(78.00) 6.0–449.0 253 (74.6) 161 (47.5) Chaoyang Center 89.24(71.33) 71.50(81.00) 5.0–464.0 262 (77.3) 165 (48.7) Dongcheng Center 91.56(72.97) 75.00(81.00) 3.0–457.0 266 (78.5) 168 (49.6) Fengtai Center 96.50(76.59) 79.00(82.00) 6.0–511.0 268 (79.3) 184 (54.4) Mentougou South 77.41(64.88) 65.50(66.75) 5.0–403.0 211 (70.3) 124 (41.3) Fangshan South 106.97 (79.33) 89.00(91.00) 6.0–492.0 285 (84.3) 194 (57.4) Daxing South 106.20 (83.77) 86.00(93.50) 7.0–493.0 280 (82.6) 192 (56.6) Tongzhou South 107.63 (85.87) 88.00(92.00) 4.0–537.0 287 (84.9) 193 (57.1) SD: standard deviation; IQR: inter-quartile range. ",
    "table_content": "|| District | Regional category | Mean(SD) μg/m 3  | Median (IQR) μg/m 3  | Range μg/m 3  | Non-attainment days and rates (%) for grade I | Non-attainment days and rates (%) for grade II ||\n||  Yanqing  |  North  |  67.95(61.06)  |  52.00(67.00)  |  5.0–459.0  |  216 (63.7)  |  108 (31.9)  ||\n||  Chaoyang  |  Center  |  89.24(71.33)  |  71.50(81.00)  |  5.0–464.0  |  262 (77.3)  |  165 (48.7)  ||\n||  Dongcheng  |  Center  |  91.56(72.97)  |  75.00(81.00)  |  3.0–457.0  |  266 (78.5)  |  168 (49.6)  ||\n||  Fengtai  |  Center  |  96.50(76.59)  |  79.00(82.00)  |  6.0–511.0  |  268 (79.3)  |  184 (54.4)  ||\n||  Mentougou  |  South  |  77.41(64.88)  |  65.50(66.75)  |  5.0–403.0  |  211 (70.3)  |  124 (41.3)  ||\n||  Fangshan  |  South  |  106.97(79.33)  |  89.00(91.00)  |  6.0–492.0  |  285 (84.3)  |  194 (57.4)  ||\n||  Daxing  |  South  |  106.20(83.77)  |  86.00(93.50)  |  7.0–493.0  |  280 (82.6)  |  192 (56.6)  ||\n||  Tongzhou  |  South  |  107.63(85.87)  |  88.00(92.00)  |  4.0–537.0  |  287 (84.9)  |  193 (57.1)  ||\n||  Changping  |  North  |  73.30(66.36)  |  55.00(72.00)  |  5.0–432.0  |  224 (66.1)  |  130 (38.3)  ||\n||  Miyun  |  North  |  67.79(61.74)  |  51.00(68.00)  |  4.0–481.0  |  205 (60.5)  |  117 (34.5)  ||\n||  Huairou  |  North  |  77.80(65.80)  |  59.00(72.00)  |  5.0–402.0  |  226 (69.1)  |  136 (41.6)  ||\n||  Pinggu  |  North  |  79.23(66.25)  |  61.00(74.50)  |  4.0–475.0  |  242 (71.4)  |  150 (44.2)  ||\n||  Shunyi  |  North  |  83.55(70.27)  |  65.00(80.00)  |  5.0–509.0  |  241 (71.5)  |  149 (44.2)  ||\n||  Haidian  |  Center  |  85.15(70.47)  |  71.00(77.00)  |  4.0–430.0  |  248 (73.2)  |  161 (47.5)  ||\n||  Shijingshan  |  Center  |  87.99(69.32)  |  72.00(73.00)  |  6.0–408.0  |  254 (76.3)  |  158 (47.4)  ||\n||  Xicheng  |  Center  |  88.26(71.60)  |  70.50(78.00)  |  6.0–449.0  |  253 (74.6)  |  161 (47.5)  ||",
    "claim": "The median PM2.5 concentration in the North region shows a higher interquartile range compared to the South, suggesting greater variability in daily pollution levels. This is inferred by calculating the average interquartile range for each region and comparing them.",
    "label": "refute"
  },
  {
    "id": "training_1433_2",
    "table_caption": "Table: Anonymous Internet Sample. Step Variable Entered Response/Coding b R R2 change R2 total 1 Age Years 20.181 0.260 0.068 0.068 2 Severe memory problems ‘Yes’ 20.132 0.307 0.026 0.094 3 Sex Male 20.158 0.335 0.018 0.112 4 Education Years 0.117 0.358 0.016 0.128 5 Memory delay interval Minutes 20.121 0.376 0.013 0.141 6 Stroke ‘Yes’ 20.050 0.379 0.003 0.144 7 Parkinson’s disease ‘Yes’ 20.033 0.381 0.001 0.145 doi:10.1371/journal.pone.0057476.t002 ",
    "table_content": "|| Step | Variable Entered | Response/Coding | β | R | R 2 change | R 2 total ||\n|| 1 | Age | Years | −0.181 | 0.260 | 0.068 | 0.068 ||\n|| 2 | Severe memory problems | ‘Yes’ | −0.132 | 0.307 | 0.026 | 0.094 ||\n|| 3 | Sex | Male | −0.158 | 0.335 | 0.018 | 0.112 ||\n|| 4 | Education | Years | 0.117 | 0.358 | 0.016 | 0.128 ||\n|| 5 | Memory delay interval | Minutes | −0.121 | 0.376 | 0.013 | 0.141 ||\n|| 6 | Stroke | ‘Yes’ | −0.050 | 0.379 | 0.003 | 0.144 ||\n|| 7 | Parkinson's disease | ‘Yes’ | −0.033 | 0.381 | 0.001 | 0.145 ||",
    "claim": "The addition of severe memory problems as a variable results in a notable increase in the explained variance, as reflected by the R² change. This suggests that severe memory problems have a considerable impact on the dependent variable, contributing a significant portion of the variance beyond what is explained by age alone.",
    "label": "refute"
  },
  {
    "id": "training_537_1",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A C10—H10···O2i 0.93 2.43 3.271 (2) 150 N1—H1···N5ii 0.862 (17) 2.250 (17) 3.0755 (19) 160.3 (15) Symmetry codes: (i) x−1/2, −y+1/2, z−1/2; (ii) −x+1/2, y−1/2, −z+3/2. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| C10—H10···O2 i | 0.93 | 2.43 | 3.271 (2) | 150 ||\n|| N1—H1···N5 ii | 0.862 (17) | 2.250 (17) | 3.0755 (19) | 160.3 (15) ||",
    "claim": "The D—H bond length for C10—H10···O2 is shorter than that for N1—H1···N5. This suggests a weaker hydrogen bond in C10—H10···O2, as shorter D—H bonds typically correlate with stronger hydrogen bonding interactions.",
    "label": "refute"
  },
  {
    "id": "training_337_4",
    "table_caption": "Table: ment severe is lution only CNS ocular the disc with ease, Table 3 Prevalence of extraocular manifestations in Vogt- Koyanagi-Harada disease Japan, 2007 [182] USA, 1991 [70] Brazil, 2009 [64] N = 136 patients N = 48 patients N = 67 patients Meningeal signs 80 % 67 % 18 % Pleocytosis 90 % - - Tinnitus 53 % 17 % 24 % Alopecia 7 % 13 % 9 % Poliosis 18 % 6 % 22 % Vitiligo 13 % 10 % 16 % VKHD categories Complete 22 % - 15 % Incomplete 65 % - 55 % Probable 13 % - 30 % ",
    "table_content": "|| blank | Japan, 2007 [ 182 ] N = 136 patients | USA, 1991 [ 70 ] N = 48 patients | Brazil, 2009 [ 64 ] N = 67 patients ||\n|| blank | Japan, 2007 [ 182 ] N = 136 patients | USA, 1991 [ 70 ] N = 48 patients | Brazil, 2009 [ 64 ] N = 67 patients ||\n|| Incomplete | 65 % | blank | 55 % ||\n|| Probable | 13 % | blank | 30 % ||\n|| Meningeal signs | 80 % | 67 % | 18 % ||\n|| Pleocytosis | 90 % | blank | blank ||\n|| Tinnitus | 53 % | 17 % | 24 % ||\n|| Alopecia | 7 % | 13 % | 9 % ||\n|| Poliosis | 18 % | 6 % | 22 % ||\n|| Vitiligo | 13 % | 10 % | 16 % ||\n|| VKHD categories | VKHD categories | VKHD categories | VKHD categories ||\n|| Complete | 22 % | blank | 15 % ||",
    "claim": "The prevalence of alopecia in the USA is nearly double that in Japan, highlighting a significant difference in the occurrence of this symptom among VKHD patients in these regions.",
    "label": "refute"
  },
  {
    "id": "training_337_4",
    "table_caption": "Table: ment severe is lution only CNS ocular the disc with ease, Table 3 Prevalence of extraocular manifestations in Vogt- Koyanagi-Harada disease Japan, 2007 [182] USA, 1991 [70] Brazil, 2009 [64] N = 136 patients N = 48 patients N = 67 patients Meningeal signs 80 % 67 % 18 % Pleocytosis 90 % - - Tinnitus 53 % 17 % 24 % Alopecia 7 % 13 % 9 % Poliosis 18 % 6 % 22 % Vitiligo 13 % 10 % 16 % VKHD categories Complete 22 % - 15 % Incomplete 65 % - 55 % Probable 13 % - 30 % ",
    "table_content": "|| blank | Japan, 2007 [ 182 ] N = 136 patients | USA, 1991 [ 70 ] N = 48 patients | Brazil, 2009 [ 64 ] N = 67 patients ||\n|| blank | Japan, 2007 [ 182 ] N = 136 patients | USA, 1991 [ 70 ] N = 48 patients | Brazil, 2009 [ 64 ] N = 67 patients ||\n|| Incomplete | 65 % | blank | 55 % ||\n|| Probable | 13 % | blank | 30 % ||\n|| Meningeal signs | 80 % | 67 % | 18 % ||\n|| Pleocytosis | 90 % | blank | blank ||\n|| Tinnitus | 53 % | 17 % | 24 % ||\n|| Alopecia | 7 % | 13 % | 9 % ||\n|| Poliosis | 18 % | 6 % | 22 % ||\n|| Vitiligo | 13 % | 10 % | 16 % ||\n|| VKHD categories | VKHD categories | VKHD categories | VKHD categories ||\n|| Complete | 22 % | blank | 15 % ||",
    "claim": "The prevalence of alopecia in the USA is nearly half that in Japan, highlighting a significant difference in the occurrence of this symptom among VKHD patients in these regions.",
    "label": "refute"
  },
  {
    "id": "training_841_4",
    "table_caption": "Table: Local Anesthetic Utilized in Pediatric LPs Stratified by Age Age N = 223 n P (%) 95% CI Birth to 30 days 21 0 0 0 - 0.15 > 1 month to 12 months 120 65 54 45.1 - 62.9 > 12 months to 24 months 82 81 99 95.0 - 101 ",
    "table_content": "|| Age | N = 223 | n | P (%) | 95% CI ||\n|| Birth to 30 days | 21 | 0 | 0 | 0 - 0.15 ||\n|| > 1 month to 12 months | 120 | 65 | 54 | 45.1 - 62.9 ||\n|| > 12 months to 24 months | 82 | 81 | 99 | 95.0 - 101 ||",
    "claim": "In the >1 month to 12 months age group, which is the largest with 120 cases, 45% of the cases involved the use of local anesthetics. This indicates that less than half of the procedures in this age group utilized anesthetics, reflecting a lower adoption rate in this demographic.",
    "label": "refute"
  },
  {
    "id": "training_541_2",
    "table_caption": "Table: Table 1 Baseline patient demographics and disease characteristics CT-P13 3 mg/kg (n = 302) RP 3 mg/kg (n = 304) Total (N = 606) Age, median, years (range) 50 (18–75) 50 (21–74) 50 (18–75) Sex, n (%) Female 245 (81.1) 256 (84.2) 501 (82.7) Male 57 (18.9) 48 (15.8) 105 (17.3) Ethnicity, n (%) Asian 34 (11.3) 37 (12.2) 71 (11.7) Black 2 (0.7) 1 (0.3) 3 (0.5) White 220 (72.8) 222 (73.0) 442 (72.9) Other 46 (15.2) 44 (14.5) 90 (14.9) Height, cm, median (range) 162.3 (144.0–186.0) 162.0 (124.0–190.0) 162.0 (124.0–190.0) Weight, kg, median (range) 69.0 (36.5–134.0) 68.0 (36.0–136.0) 68.6 (36.0–136.0) BMI, kg/m2, median (range) 26.3 (13.9–49.8) 25.4 (15.0–53.1) 25.9 (13.9–53.1) Anti-CCP antibody-positive, n (%) 228 (75.5) 233 (76.6) 461 (76.1) IgA RF-positive, n (%) 131 (43.4) 134 (44.1) 265 (43.7) IgM RF-positive, n (%) 225 (74.5) 220 (72.4) 445 (73.4) IgG RF-positive, n (%) 173 (57.3) 171 (56.3) 344 (56.8) Joint count TJC, 68 joints 25.6 ± 13.9 24.0 ± 12.9 24.8 ± 13.4 SJC, 66 joints 16.2 ± 8.7 15.2 ± 8.3 15.7 ± 8.5 TJC, 28 joints 15.9 ± 6.4 15.1 ± 6.1 15.5 ± 6.2 SJC, 28 joints 12.0 ± 4.9 11.2 ± 4.7 11.6 ± 4.8 Duration of prior MTX therapy, weeks 97.7 ± 141.2 89.4 ± 96.5 93.6 ± 120.8 MTX dose, mg 15.6 ± 3.1 15.6 ± 3.2 15.6 ± 3.1 CDAI 40.9 ± 11.5 39.3 ± 11.1 40.1 ± 11.3 SDAI 42.8 ± 11.9 41.2 ± 11.7 42.0 ± 11.8 CRP, mg/dl 1.9 ± 2.5 1.9 ± 2.2 1.9 ± 2.4 ESR, mm/h 46.6 ± 22.4 48.5 ± 22.6 47.5 ± 22.5 DAS28-CRP 5.9 ± 0.8 5.8 ± 0.9 5.8 ± 0.9 HAQ 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.6 Patient assessment of pain 65.9 ± 17.4 65.5 ± 17.2 65.7 ± 17.3 Patient global assessment of disease activity 65.7 ± 17.2 65.4 ± 17.0 65.5 ± 17.1 Physician global assessment of disease activity 64.7 ± 14.3 65.0 ± 13.5 64.8 ± 13.9 BMI body mass index, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, Ig immunoglobulin, MTX methotrexate, RF rheumatoid factor, RP reference product (i.e., reference infliximab), SD standard deviation, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count ",
    "table_content": "|| blank | CT-P13 3 mg/kg ( n = 302) | RP 3 mg/kg ( n = 304) | Total ( N = 606) ||\n|| Age, median, years (range) | 50 (18–75) | 50 (21–74) | 50 (18–75) ||\n|| Height, cm, median (range) | 162.3 (144.0–186.0) | 162.0 (124.0–190.0) | 162.0 (124.0–190.0) ||\n|| Weight, kg, median (range) | 69.0 (36.5–134.0) | 68.0 (36.0–136.0) | 68.6 (36.0–136.0) ||\n|| BMI, kg/m 2 , median (range) | 26.3 (13.9–49.8) | 25.4 (15.0–53.1) | 25.9 (13.9–53.1) ||\n|| Anti-CCP antibody-positive, n (%) | 228 (75.5) | 233 (76.6) | 461 (76.1) ||\n|| IgA RF-positive, n (%) | 131 (43.4) | 134 (44.1) | 265 (43.7) ||\n|| IgM RF-positive, n (%) | 225 (74.5) | 220 (72.4) | 445 (73.4) ||\n|| IgG RF-positive, n (%) | 173 (57.3) | 171 (56.3) | 344 (56.8) ||\n|| Joint count | Joint count | Joint count | Joint count ||\n|| TJC, 68 joints | 25.6 ± 13.9 | 24.0 ± 12.9 | 24.8 ± 13.4 ||\n|| SJC, 66 joints | 16.2 ± 8.7 | 15.2 ± 8.3 | 15.7 ± 8.5 ||\n|| Sex, n (%) | Sex, n (%) | Sex, n (%) | Sex, n (%) ||\n|| TJC, 28 joints | 15.9 ± 6.4 | 15.1 ± 6.1 | 15.5 ± 6.2 ||\n|| SJC, 28 joints | 12.0 ± 4.9 | 11.2 ± 4.7 | 11.6 ± 4.8 ||\n|| Duration of prior MTX therapy, weeks | 97.7 ± 141.2 | 89.4 ± 96.5 | 93.6 ± 120.8 ||\n|| MTX dose, mg | 15.6 ± 3.1 | 15.6 ± 3.2 | 15.6 ± 3.1 ||\n|| CDAI | 40.9 ± 11.5 | 39.3 ± 11.1 | 40.1 ± 11.3 ||\n|| SDAI | 42.8 ± 11.9 | 41.2 ± 11.7 | 42.0 ± 11.8 ||\n|| CRP, mg/dl | 1.9 ± 2.5 | 1.9 ± 2.2 | 1.9 ± 2.4 ||\n|| ESR, mm/h | 46.6 ± 22.4 | 48.5 ± 22.6 | 47.5 ± 22.5 ||\n|| DAS28-CRP | 5.9 ± 0.8 | 5.8 ± 0.9 | 5.8 ± 0.9 ||\n|| HAQ | 1.6 ± 0.6 | 1.6 ± 0.6 | 1.6 ± 0.6 ||\n|| Female | 245 (81.1) | 256 (84.2) | 501 (82.7) ||\n|| Patient assessment of pain | 65.9 ± 17.4 | 65.5 ± 17.2 | 65.7 ± 17.3 ||\n|| Patient global assessment of disease activity | 65.7 ± 17.2 | 65.4 ± 17.0 | 65.5 ± 17.1 ||\n|| Physician global assessment of disease activity | 64.7 ± 14.3 | 65.0 ± 13.5 | 64.8 ± 13.9 ||\n|| Male | 57 (18.9) | 48 (15.8) | 105 (17.3) ||\n|| Ethnicity, n (%) | Ethnicity, n (%) | Ethnicity, n (%) | Ethnicity, n (%) ||\n|| Asian | 34 (11.3) | 37 (12.2) | 71 (11.7) ||\n|| Black | 2 (0.7) | 1 (0.3) | 3 (0.5) ||\n|| White | 220 (72.8) | 222 (73.0) | 442 (72.9) ||\n|| Other | 46 (15.2) | 44 (14.5) | 90 (14.9) ||",
    "claim": "The proportion of female patients is higher in both treatment groups, with a slight increase in the CT-P13 group. The overall female-to-male ratio is approximately 4.8.",
    "label": "refute"
  },
  {
    "id": "training_454_2",
    "table_caption": "Table: Significant metabolites identified in urine samples from precancerous 15-month old female study mice. ppm VIP p-value Identification Control Concentration mM (StDev) Study Concentration mM(StDev) Rank Fold Change (Error) AUC 3.967 2.10 1.35E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.25 (0.36) 0.77 7.643 2.01 1.93E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.838 2.00 2.18E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.556 1.94 3.79E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.23 (0.40) 0.77 7.630 1.77 1.46E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.21 (0.51) 0.76 7.590 1.54 3.56E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.19 (0.49) 0.67 3.961 1.43 6.36E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.14 (0.24) 0.68 7.699 1.69 8.88E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.34 (0.24) 0.75 7.282 1.64 7.23E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.46 (0.43) 0.76 7.207 1.62 7.89E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.49 (0.52) 0.76 7.271 1.51 1.63E-02 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.35 (0.52) 0.75 4.107 1.65 1.13E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.15 (0.33) 0.70 3.543 1.19 6.90E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.07 (0.35) 0.69 7.464 1.39 2.39E-02 benzoate 5.27 (9.53) 4.54 (4.90) 3 -1.43 (0.55) 0.74 2.684 1.19 2.95E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.84 (3.62) 0.59 2.535 1.19 2.85E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.87 (3.42) 0.59 2.563 1.18 2.89E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.98 (3.54) 0.59 4.150 1.08 5.24E-01 pseudouridine 3.67 (4.25) 3.03 (3.79) 1 -1.13 (0.34) 0.50 8.831 1.04 9.47E-01 trigonelline 2.08 (2.89) 4.22 (6.07) 3 -1.014 (1.14) 0.53 3.023 1.02 9.95E-01 creatine 17.08 (23.88) 16.39 (24.80) 3 -1.001 (1.24) 0.57 4.041 1.01 9.19E-01 creatinine 19.58 (22.26) 33.96 (39.53) 3 1.03 (0.73) 0.65 https://doi.org/10.1371/journal.pone.0200658.t003 ",
    "table_content": "|| ppm | VIP | p-value | Identification | Control Concentration mM (StDev) | Study Concentration mM(StDev) | Rank | Fold Change (Error) | AUC ||\n|| 3.967 | 2.10 | 1.35E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.25 (0.36) | 0.77 ||\n|| 7.207 | 1.62 | 7.89E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.49 (0.52) | 0.76 ||\n|| 7.271 | 1.51 | 1.63E-02 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.35 (0.52) | 0.75 ||\n|| 4.107 | 1.65 | 1.13E-01 | fructose | 64.41 (105.05) | 153.81 (209.16) | 2 | 1.15 (0.33) | 0.70 ||\n|| 3.543 | 1.19 | 6.90E-01 | fructose | 64.41 (105.05) | 153.81 (209.16) | 2 | 1.07 (0.35) | 0.69 ||\n|| 7.464 | 1.39 | 2.39E-02 | benzoate | 5.27 (9.53) | 4.54 (4.90) | 3 | -1.43 (0.55) | 0.74 ||\n|| 2.684 | 1.19 | 2.95E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.84 (3.62) | 0.59 ||\n|| 2.535 | 1.19 | 2.85E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.87 (3.42) | 0.59 ||\n|| 2.563 | 1.18 | 2.89E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.98 (3.54) | 0.59 ||\n|| 4.150 | 1.08 | 5.24E-01 | pseudouridine | 3.67 (4.25) | 3.03 (3.79) | 1 | -1.13 (0.34) | 0.50 ||\n|| 8.831 | 1.04 | 9.47E-01 | trigonelline | 2.08 (2.89) | 4.22 (6.07) | 3 | -1.014 (1.14) | 0.53 ||\n|| 7.643 | 2.01 | 1.93E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.24 (0.38) | 0.77 ||\n|| 3.023 | 1.02 | 9.95E-01 | creatine | 17.08 (23.88) | 16.39 (24.80) | 3 | -1.001 (1.24) | 0.57 ||\n|| 4.041 | 1.01 | 9.19E-01 | creatinine | 19.58 (22.26) | 33.96 (39.53) | 3 | 1.03 (0.73) | 0.65 ||\n|| 7.838 | 2.00 | 2.18E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.24 (0.38) | 0.77 ||\n|| 7.556 | 1.94 | 3.79E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.23 (0.40) | 0.77 ||\n|| 7.630 | 1.77 | 1.46E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.21 (0.51) | 0.76 ||\n|| 7.590 | 1.54 | 3.56E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.19 (0.49) | 0.67 ||\n|| 3.961 | 1.43 | 6.36E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.14 (0.24) | 0.68 ||\n|| 7.699 | 1.69 | 8.88E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.34 (0.24) | 0.75 ||\n|| 7.282 | 1.64 | 7.23E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.46 (0.43) | 0.76 ||",
    "claim": "Metabolites with higher VIP scores, such as hippuric acid, tend to exhibit larger fold changes, suggesting a stronger association with the precancerous state.",
    "label": "refute"
  },
  {
    "id": "training_454_2",
    "table_caption": "Table: Significant metabolites identified in urine samples from precancerous 15-month old female study mice. ppm VIP p-value Identification Control Concentration mM (StDev) Study Concentration mM(StDev) Rank Fold Change (Error) AUC 3.967 2.10 1.35E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.25 (0.36) 0.77 7.643 2.01 1.93E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.838 2.00 2.18E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.556 1.94 3.79E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.23 (0.40) 0.77 7.630 1.77 1.46E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.21 (0.51) 0.76 7.590 1.54 3.56E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.19 (0.49) 0.67 3.961 1.43 6.36E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.14 (0.24) 0.68 7.699 1.69 8.88E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.34 (0.24) 0.75 7.282 1.64 7.23E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.46 (0.43) 0.76 7.207 1.62 7.89E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.49 (0.52) 0.76 7.271 1.51 1.63E-02 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.35 (0.52) 0.75 4.107 1.65 1.13E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.15 (0.33) 0.70 3.543 1.19 6.90E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.07 (0.35) 0.69 7.464 1.39 2.39E-02 benzoate 5.27 (9.53) 4.54 (4.90) 3 -1.43 (0.55) 0.74 2.684 1.19 2.95E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.84 (3.62) 0.59 2.535 1.19 2.85E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.87 (3.42) 0.59 2.563 1.18 2.89E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.98 (3.54) 0.59 4.150 1.08 5.24E-01 pseudouridine 3.67 (4.25) 3.03 (3.79) 1 -1.13 (0.34) 0.50 8.831 1.04 9.47E-01 trigonelline 2.08 (2.89) 4.22 (6.07) 3 -1.014 (1.14) 0.53 3.023 1.02 9.95E-01 creatine 17.08 (23.88) 16.39 (24.80) 3 -1.001 (1.24) 0.57 4.041 1.01 9.19E-01 creatinine 19.58 (22.26) 33.96 (39.53) 3 1.03 (0.73) 0.65 https://doi.org/10.1371/journal.pone.0200658.t003 ",
    "table_content": "|| ppm | VIP | p-value | Identification | Control Concentration mM (StDev) | Study Concentration mM(StDev) | Rank | Fold Change (Error) | AUC ||\n|| 3.967 | 2.10 | 1.35E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.25 (0.36) | 0.77 ||\n|| 7.207 | 1.62 | 7.89E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.49 (0.52) | 0.76 ||\n|| 7.271 | 1.51 | 1.63E-02 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.35 (0.52) | 0.75 ||\n|| 4.107 | 1.65 | 1.13E-01 | fructose | 64.41 (105.05) | 153.81 (209.16) | 2 | 1.15 (0.33) | 0.70 ||\n|| 3.543 | 1.19 | 6.90E-01 | fructose | 64.41 (105.05) | 153.81 (209.16) | 2 | 1.07 (0.35) | 0.69 ||\n|| 7.464 | 1.39 | 2.39E-02 | benzoate | 5.27 (9.53) | 4.54 (4.90) | 3 | -1.43 (0.55) | 0.74 ||\n|| 2.684 | 1.19 | 2.95E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.84 (3.62) | 0.59 ||\n|| 2.535 | 1.19 | 2.85E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.87 (3.42) | 0.59 ||\n|| 2.563 | 1.18 | 2.89E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.98 (3.54) | 0.59 ||\n|| 4.150 | 1.08 | 5.24E-01 | pseudouridine | 3.67 (4.25) | 3.03 (3.79) | 1 | -1.13 (0.34) | 0.50 ||\n|| 8.831 | 1.04 | 9.47E-01 | trigonelline | 2.08 (2.89) | 4.22 (6.07) | 3 | -1.014 (1.14) | 0.53 ||\n|| 7.643 | 2.01 | 1.93E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.24 (0.38) | 0.77 ||\n|| 3.023 | 1.02 | 9.95E-01 | creatine | 17.08 (23.88) | 16.39 (24.80) | 3 | -1.001 (1.24) | 0.57 ||\n|| 4.041 | 1.01 | 9.19E-01 | creatinine | 19.58 (22.26) | 33.96 (39.53) | 3 | 1.03 (0.73) | 0.65 ||\n|| 7.838 | 2.00 | 2.18E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.24 (0.38) | 0.77 ||\n|| 7.556 | 1.94 | 3.79E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.23 (0.40) | 0.77 ||\n|| 7.630 | 1.77 | 1.46E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.21 (0.51) | 0.76 ||\n|| 7.590 | 1.54 | 3.56E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.19 (0.49) | 0.67 ||\n|| 3.961 | 1.43 | 6.36E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.14 (0.24) | 0.68 ||\n|| 7.699 | 1.69 | 8.88E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.34 (0.24) | 0.75 ||\n|| 7.282 | 1.64 | 7.23E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.46 (0.43) | 0.76 ||",
    "claim": "Metabolites with higher VIP scores, such as hippuric acid, tend to exhibit smaller fold changes, suggesting a weaker association with the precancerous state.",
    "label": "refute"
  },
  {
    "id": "training_1440_3",
    "table_caption": "Table: Figure 1. The synthesis of ARG-V. Water Acetonitrile Cloroform Acetonitrile:water 45:55 Ethyl acetate ARG almost insoluble very soluble freely soluble very soluble freely soluble ARG-V freely soluble slight soluble freely soluble very soluble almost insoluble Table 1. The solubility of ARG and ARG-V. ",
    "table_content": "|| blank | Water | Acetonitrile | Cloroform | Acetonitrile:water 45:55 | Ethyl acetate ||\n|| ARG | almost insoluble | very soluble | freely soluble | very soluble | freely soluble ||\n|| ARG-V | freely soluble | slight soluble | freely soluble | very soluble | almost insoluble ||",
    "claim": "ARG and ARG-V both exhibit low solubility in chloroform, indicating that the solvent's properties do not favor the dissolution of both compounds equally. This suggests that the solubility of these compounds in chloroform is primarily governed by the specific structural differences between ARG and ARG-V rather than the solvent's characteristics.",
    "label": "refute"
  },
  {
    "id": "training_799_1",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A N1—H1N···O2i 0.83 (2) 2.08 (2) 2.891 (4) 166 (3) Symmetry codes: (i) −x+1, y+1/2, −z+1/2. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| N1—H1N···O2 i | 0.83 (2) | 2.08 (2) | 2.891 (4) | 166 (3) ||",
    "claim": "The bond angle D—H···A is inversely related to the sum of the bond lengths D—H and H···A. A larger bond angle of 166° suggests a more linear and thus stronger hydrogen bond, which is consistent with the relatively short sum of the bond lengths.",
    "label": "refute"
  },
  {
    "id": "training_1289_4",
    "table_caption": "Table: Association results for SNPs from stepwise regression in the AA data. AIC = 7176, BIC = 7224 Conditional results (multiple regression) Single-marker results SNP Effect (Other) Allele OR 95% C.I. P OR 95% C.I. P RS9271413 G (A) 2.07 1.84–2.33 4.69E-34 1.72 1.56–1.91 8.30E-26 RS9273481 C (G) 1.45 1.32–1.60 3.80E-14 1.19 1.09–1.29 6.56E-05 6:31323500:D D (I) 1.48 1.31–1.68 7.79E-10 1.47 1.30–1.65 2.28E-10 RS115549526 T (C) 1.60 1.36–1.18 1.33E-08 2.13 1.83–2.49 6.12E-22 Table 5. Association results for amino acid data from stepwise regression in the EUR data ",
    "table_content": "|| SNP | Conditional results (multiple regression) | Conditional results (multiple regression) | Conditional results (multiple regression) | Conditional results (multiple regression) | Single-marker results | Single-marker results | Single-marker results ||\n|| SNP | Effect (Other) Allele | OR | 95% C.I. | P | OR | 95% C.I. | P ||\n|| RS9271413 | G (A) | 2.07 | 1.84–2.33 | 4.69E-34 | 1.72 | 1.56–1.91 | 8.30E-26 ||\n|| RS9273481 | C (G) | 1.45 | 1.32–1.60 | 3.80E-14 | 1.19 | 1.09–1.29 | 6.56E-05 ||\n|| 6:31323500:D | D (I) | 1.48 | 1.31–1.68 | 7.79E-10 | 1.47 | 1.30–1.65 | 2.28E-10 ||\n|| RS115549526 | T (C) | 1.60 | 1.36–1.18 | 1.33E-08 | 2.13 | 1.83–2.49 | 6.12E-22 ||",
    "claim": "RS115549526 exhibits a smaller effect size in the single-marker analysis, with an odds ratio of 2.13, which is approximately 1.5 times less than the smallest effect size observed for RS9273481.",
    "label": "refute"
  },
  {
    "id": "training_971_2",
    "table_caption": "Table: Table 2 Genome drafts of the E.faecium strain from primary and secondary assemblies. NGS Data Genome Draft Size (bp) Number of Contigs N50 (bp) Max Contig (bp) Primary 454 3,027,996 352 21,989 92,031 GAIIx 2,947,516 1,013 9,804 45,465 SOLiD 2,976,193 3,385 1,389 7,396 Secondary 454+GAIIx+SOLiD 3,103,094 204 34,849 114,611 454+GAIIx 2,971,758 209 34,597 114,610 454+SOLiD 3,018,371 257 23,443 97,560 GAIIx+SOLiD 2,923,382 465 13,773 66,062 ",
    "table_content": "|| NGS Data | blank | Genome Draft Size (bp) | Number of Contigs | N50 (bp) | Max Contig (bp) ||\n|| Primary | 454 | 3,027,996 | 352 | 21,989 | 92,031 ||\n|| Primary | GAIIx | 2,947,516 | 1,013 | 9,804 | 45,465 ||\n|| Primary | SOLiD | 2,976,193 | 3,385 | 1,389 | 7,396 ||\n|| Secondary | 454+GAIIx+SOLiD | 3,103,094 | 204 | 34,849 | 114,611 ||\n|| Secondary | 454+GAIIx | 2,971,758 | 209 | 34,597 | 114,610 ||\n|| Secondary | 454+SOLiD | 3,018,371 | 257 | 23,443 | 97,560 ||\n|| Secondary | GAIIx+SOLiD | 2,923,382 | 465 | 13,773 | 66,062 ||",
    "claim": "The secondary assembly using 454+GAIIx+SOLiD reduces the number of contigs by approximately 20% compared to the average number of contigs in the primary assemblies, demonstrating improved contiguity.",
    "label": "refute"
  },
  {
    "id": "training_181_1",
    "table_caption": "Table: TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year. Total Nb of isolates Bacteria most frequently isolated from urinary tract infections Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Proteus mirabilis Pseudomonas aeruginosa 2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09% 2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90% 2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81% 2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51% 2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09% 2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49% 2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27% 2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30% 100% Ac�vity of Ce�azidime and Ciproﬂoxacin against urinary E.coli ",
    "table_content": "|| 2005 | Total Nb of isolates 615 | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections ||\n|| 2005 | Total Nb of isolates 615 | Escherichia coli | Escherichia coli | Klebsiella pneumoniae | Klebsiella pneumoniae | Enterobacter cloacae | Enterobacter cloacae | Proteus mirabilis | Proteus mirabilis | Pseudomonas aeruginosa | Pseudomonas aeruginosa ||\n|| 2005 | Total Nb of isolates 615 | 412 | 66.99% | 38 | 6.18% | 8 | 1.30% | 25 | 4.07% | 19 | 3.09% ||\n|| 2006 | 564 | 409 | 72.52% | 30 | 5.32% | 7 | 1.24% | 24 | 4.26% | 22 | 3.90% ||\n|| 2007 | 525 | 358 | 68.19% | 29 | 5.52% | 4 | 0.76% | 30 | 5.71% | 20 | 3.81% ||\n|| 2008 | 684 | 506 | 73.98% | 57 | 8.33% | 12 | 1.75% | 23 | 3.36% | 24 | 3.51% ||\n|| 2009 | 718 | 516 | 71.87% | 56 | 7.80% | 16 | 2.23% | 41 | 5.71% | 15 | 2.09% ||\n|| 2010 | 843 | 600 | 71.17% | 61 | 7.24% | 10 | 1.19% | 52 | 6.17% | 21 | 2.49% ||\n|| 2011 | 1162 | 694 | 59.72% | 87 | 7.49% | 16 | 1.38% | 58 | 4.99% | 38 | 3.27% ||\n|| 2012 | 1173 | 710 | 60.53% | 91 | 7.76% | 13 | 1.11% | 59 | 5.03% | 27 | 2.30% ||",
    "claim": "The total number of isolates increased by approximately 50% from 2005 to 2012, indicating a substantial rise in documented UTI cases at the CHN hospital over this period.",
    "label": "refute"
  },
  {
    "id": "training_181_2",
    "table_caption": "Table: TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year. Total Nb of isolates Bacteria most frequently isolated from urinary tract infections Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Proteus mirabilis Pseudomonas aeruginosa 2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09% 2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90% 2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81% 2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51% 2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09% 2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49% 2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27% 2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30% 100% Ac�vity of Ce�azidime and Ciproﬂoxacin against urinary E.coli ",
    "table_content": "|| 2005 | Total Nb of isolates 615 | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections | Bacteria most frequently isolated from urinary tract infections ||\n|| 2005 | Total Nb of isolates 615 | Escherichia coli | Escherichia coli | Klebsiella pneumoniae | Klebsiella pneumoniae | Enterobacter cloacae | Enterobacter cloacae | Proteus mirabilis | Proteus mirabilis | Pseudomonas aeruginosa | Pseudomonas aeruginosa ||\n|| 2005 | Total Nb of isolates 615 | 412 | 66.99% | 38 | 6.18% | 8 | 1.30% | 25 | 4.07% | 19 | 3.09% ||\n|| 2006 | 564 | 409 | 72.52% | 30 | 5.32% | 7 | 1.24% | 24 | 4.26% | 22 | 3.90% ||\n|| 2007 | 525 | 358 | 68.19% | 29 | 5.52% | 4 | 0.76% | 30 | 5.71% | 20 | 3.81% ||\n|| 2008 | 684 | 506 | 73.98% | 57 | 8.33% | 12 | 1.75% | 23 | 3.36% | 24 | 3.51% ||\n|| 2009 | 718 | 516 | 71.87% | 56 | 7.80% | 16 | 2.23% | 41 | 5.71% | 15 | 2.09% ||\n|| 2010 | 843 | 600 | 71.17% | 61 | 7.24% | 10 | 1.19% | 52 | 6.17% | 21 | 2.49% ||\n|| 2011 | 1162 | 694 | 59.72% | 87 | 7.49% | 16 | 1.38% | 58 | 4.99% | 38 | 3.27% ||\n|| 2012 | 1173 | 710 | 60.53% | 91 | 7.76% | 13 | 1.11% | 59 | 5.03% | 27 | 2.30% ||",
    "claim": "Despite fluctuations, Escherichia coli consistently accounted for the majority of isolates, with its proportion peaking in 2010 at nearly 74%, suggesting its dominant role in UTIs.",
    "label": "refute"
  },
  {
    "id": "training_584_2",
    "table_caption": "Table: two we the Table 1. Proportional toe depths of human footprints. Side Speed Moisture Normal SEM BKBH SEM p-value Right p d 0.27 0.04 0.77 0.12 ,0.001 Left p d 0.19 0.06 0.76 0.12 ,0.001 Both p w 0.48 0.11 0.81 0.12 ,0.05 Right f d 0.98 0.33 0.51 0.12 0.12 Left f d 0.38 0.08 0.67 0.16 0.07 p is preferred walk; f is fast walk; d is dry (6–8% water); w is wet (10–12% water). Values are toe depths as a fraction of heel depth. P-values are for T-Tests ",
    "table_content": "|| Side | Speed | Moisture | Normal | SEM | BKBH | SEM | p-value ||\n|| Right | p | d | 0.27 | 0.04 | 0.77 | 0.12 | <0.001 ||\n|| Left | p | d | 0.19 | 0.06 | 0.76 | 0.12 | <0.001 ||\n|| Both | p | w | 0.48 | 0.11 | 0.81 | 0.12 | <0.05 ||\n|| Right | f | d | 0.98 | 0.33 | 0.51 | 0.12 | 0.12 ||\n|| Left | f | d | 0.38 | 0.08 | 0.67 | 0.16 | 0.07 ||",
    "claim": "The toe depth for both feet during preferred walking on a wet surface is less than twice that on a dry surface, suggesting a pronounced increase in toe depth with increased surface moisture.",
    "label": "refute"
  },
  {
    "id": "training_1004_3",
    "table_caption": "Table: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and Youden index of blood protozoan detection DNA microarrays. B. microti B. divergens B. venatorum B. duncani P. vivax P. falciparum P. knowlesi P. malariae P. ovale L. gerbilli L. donovani L. infantum L. tropica L. aethiopica T. cruzi T. b. rhodesiense T. b. gambiense T. gondii No. of true positives 4 0 3 0 126 152 7 26 36 0 14 21 0 0 0 0 0 17 No. of false positives 16 11 11 12 9 11 19 25 19 7 4 3 5 4 3 2 3 0 No. of true negatives 518 527 524 526 394 363 511 485 479 531 517 510 533 534 535 536 535 520 No. of false negatives 0 0 0 0 9 12 1 2 4 0 3 4 0 0 0 0 0 1 Sensitivity (%) [95% CI*] 100.0 \\** 100.0 \\ 93.3 [89.1– 97.5] 92.7 [88.8– 96.5] 87.5 [66.1– 100.0] 92.9 [83.7– 100.0] 90.0 [81.2– 98.8] \\ 82.4 [65.9– 98.8] 84.0 [70.8– 97.2] \\ \\ \\ \\ \\ 94.4 [84.2– 100.0] Specificity (%) [95% CI] 97.0 [95.6– 98.4] 98.0 [96.8– 99.2] 97.9 [96.7– 99.1] 97.8 [96.5– 99.0] 97.8 [96.3– 99.2] 97.1 [95.3– 98.8] 96.4 [94.8– 98.0] 95.1 [93.2– 97.0] 96.2 [94.5– 97.9] 98.7 [97.7– 99.7] 99.2 [98.5– 100.0] 99.4 [98.8– 100.0] 99.1 [98.3– 99.9] 99.3 [98.5– 100.0] 99.4 [98.8– 100.0] 99.6 [99.1– 100.0] 99.4 [98.8– 100.0] 100.0 PPV (%) [95% CI] 20.0 [2.5– 37.5] \\ 21.4 [0– 42.9] \\ 93.3 [89.1– 97.5] 93.3 [89.4– 97.1] 26.9 [9.9– 44.0] 51.0 [37.3– 64.7] 65.5 [52.9– 78.0] \\ 77.8 [58.6– 97.0] 87.5 [74.3– 100.0] \\ \\ \\ \\ \\ 100.0 NPV (%) [95% CI] 100.0 100.0 100.0 100.0 97.8 [96.3– 99.2] 96.8 [95.0– 98.6] 99.8 [99.4– 100.0] 99.6 [99.0– 100.0] 99.2 [98.4– 100.0] 100.0 99.4 [98.8– 100.0] 99.2 [98.5– 100.0] 100.0 100.0 100.0 100.0 100.0 99.8 [99.4– 100.0] Youden’s index 0.97 \\ 0.98 \\ 0.91 0.90 0.84 0.88 0.86 \\ 0.82 0.83 \\ \\ \\ \\ \\ 0.94 * CI: confidence interval ** \\: No analysis ",
    "table_content": "|| blank | B . microti | B . divergens | B . venatorum | B . duncani | P . vivax | P . falciparum | P . knowlesi | P . malariae | P . ovale | L . gerbilli | L . donovani | L . infantum | L . tropica | L . aethiopica | T . cruzi | T . b . rhodesiense | T . b . gambiense | T . gondii ||\n|| No. of true positives | 4 | 0 | 3 | 0 | 126 | 152 | 7 | 26 | 36 | 0 | 14 | 21 | 0 | 0 | 0 | 0 | 0 | 17 ||\n|| No. of false positives | 16 | 11 | 11 | 12 | 9 | 11 | 19 | 25 | 19 | 7 | 4 | 3 | 5 | 4 | 3 | 2 | 3 | 0 ||\n|| No. of true negatives | 518 | 527 | 524 | 526 | 394 | 363 | 511 | 485 | 479 | 531 | 517 | 510 | 533 | 534 | 535 | 536 | 535 | 520 ||\n|| No. of false negatives | 0 | 0 | 0 | 0 | 9 | 12 | 1 | 2 | 4 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 1 ||\n|| Sensitivity (%) [95% CI * ] | 100.0 | \\ ** | 100.0 | \\ | 93.3 [89.1–97.5] | 92.7 [88.8–96.5] | 87.5 [66.1–100.0] | 92.9 [83.7–100.0] | 90.0 [81.2–98.8] | \\ | 82.4 [65.9–98.8] | 84.0 [70.8–97.2] | \\ | \\ | \\ | \\ | \\ | 94.4 [84.2–100.0] ||\n|| Specificity (%) [95% CI] | 97.0 [95.6–98.4] | 98.0 [96.8–99.2] | 97.9 [96.7–99.1] | 97.8 [96.5–99.0] | 97.8 [96.3–99.2] | 97.1 [95.3–98.8] | 96.4 [94.8–98.0] | 95.1 [93.2–97.0] | 96.2 [94.5–97.9] | 98.7 [97.7–99.7] | 99.2 [98.5–100.0] | 99.4 [98.8–100.0] | 99.1 [98.3–99.9] | 99.3 [98.5–100.0] | 99.4 [98.8–100.0] | 99.6 [99.1–100.0] | 99.4 [98.8–100.0] | 100.0 ||\n|| PPV (%) [95% CI] | 20.0 [2.5–37.5] | \\ | 21.4 [0–42.9] | \\ | 93.3 [89.1–97.5] | 93.3 [89.4–97.1] | 26.9 [9.9–44.0] | 51.0 [37.3–64.7] | 65.5 [52.9–78.0] | \\ | 77.8 [58.6–97.0] | 87.5 [74.3–100.0] | \\ | \\ | \\ | \\ | \\ | 100.0 ||\n|| NPV (%) [95% CI] | 100.0 | 100.0 | 100.0 | 100.0 | 97.8 [96.3–99.2] | 96.8 [95.0–98.6] | 99.8 [99.4–100.0] | 99.6 [99.0–100.0] | 99.2 [98.4–100.0] | 100.0 | 99.4 [98.8–100.0] | 99.2 [98.5–100.0] | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 99.8 [99.4–100.0] ||\n|| Youden’s index | 0.97 | \\ | 0.98 | \\ | 0.91 | 0.90 | 0.84 | 0.88 | 0.86 | \\ | 0.82 | 0.83 | \\ | \\ | \\ | \\ | \\ | 0.94 ||",
    "claim": "For T. gondii, the NPV is 99.8%, with 520 true negatives and only 1 false negative. Despite the high NPV, the presence of a false negative suggests that the test is less reliable in correctly identifying the absence of T. gondii infection.",
    "label": "refute"
  },
  {
    "id": "training_1251_4",
    "table_caption": "Table: P 1.00E-02 3.35E-04 1.00E-04 1.87E-05 2.99E-05 7.10E-04 3.89E-04 1.56E-03 6.22E-04 1.23E-05 1.94E-05 1.22E-04 4.65E-04 8.73E-04 2.32E-05 first 1A) two the healthy the CUMS the high- multi- more in TABLE 2 | Typical metabolites identified by the ASCA dynamic metabolomics analysis. Model Metabolite Leverage SPE Time Lactic acid 2.00E-03 4.79E+00 Valeric acid 2.11E-03 4.18E+00 Glycerol 1.55E-03 6.91E+00 Isoleucine 1.59E-03 3.71E+00 Serine 1.75E-03 2.08E+00 Valine 1.65E-03 4.06E+00 Phenotype Lactic acid 2.30E-03 3.65E-30 Acetic acid 2.41E-03 1.23E-30 Hexanoic acid 1.96E-03 6.16E-31 Phosphoric acid 2.49E-03 6.16E-31 Succinic acid 2.15E-03 6.16E-31 Valeric acid 2.22E-03 1.23E-30 Malic acid 2.04E-03 6.16E-31 Glycerol 2.29E-03 6.16E-31 Glycine 1.93E-03 6.16E-31 Valine 1.79E-03 7.70E-31 Sarcosine 2.94E-03 6.16E-31 Serine 1.74E-03 1.54E-31 Threonine 1.74E-03 3.08E-31 Alanine 2.83E-03 6.16E-31 Aspartic acid 1.62E-03 1.54E-31 Pyrimidine 1.86E-03 1.23E-30 Interaction Lactic acid 3.02E-03 9.26E-01 Propanoic acid 2.60E-03 1.77E+00 Valeric acid 3.13E-03 5.92E+00 Malic acid 3.04E-03 7.22E+00 Glycerol 3.35E-03 5.81E+00 Leucine 2.38E-03 3.79E-01 Glycine 2.48E-03 1.44E+00 Pyrimidine 2.83E-03 2.01E+00 Serine 2.60E-03 2.22E-01 Threonine 2.52E-03 1.23E+00 Methionine 6.91E-03 5.02E+00 Valine 2.48E-03 8.39E+00 Sarcosine 3.23E-03 1.87E+00 metabolome of the CUMS rats from that of the healthy controls, ",
    "table_content": "|| Model | Metabolite | Leverage | SPE ||\n|| Time | Lactic acid | 2.00E-03 | 4.79E+00 ||\n|| Phenotype | Phosphoric acid | 2.49E-03 | 6.16E-31 ||\n|| Phenotype | Succinic acid | 2.15E-03 | 6.16E-31 ||\n|| Phenotype | Valeric acid | 2.22E-03 | 1.23E-30 ||\n|| Phenotype | Malic acid | 2.04E-03 | 6.16E-31 ||\n|| Phenotype | Glycerol | 2.29E-03 | 6.16E-31 ||\n|| Phenotype | Glycine | 1.93E-03 | 6.16E-31 ||\n|| Phenotype | Valine | 1.79E-03 | 7.70E-31 ||\n|| Phenotype | Sarcosine | 2.94E-03 | 6.16E-31 ||\n|| Phenotype | Serine | 1.74E-03 | 1.54E-31 ||\n|| Phenotype | Threonine | 1.74E-03 | 3.08E-31 ||\n|| Time | Valeric acid | 2.11E-03 | 4.18E+00 ||\n|| Phenotype | Alanine | 2.83E-03 | 6.16E-31 ||\n|| Phenotype | Aspartic acid | 1.62E-03 | 1.54E-31 ||\n|| Phenotype | Pyrimidine | 1.86E-03 | 1.23E-30 ||\n|| Interaction | Lactic acid | 3.02E-03 | 9.26E-01 ||\n|| Interaction | Propanoic acid | 2.60E-03 | 1.77E+00 ||\n|| Interaction | Valeric acid | 3.13E-03 | 5.92E+00 ||\n|| Interaction | Malic acid | 3.04E-03 | 7.22E+00 ||\n|| Interaction | Glycerol | 3.35E-03 | 5.81E+00 ||\n|| Interaction | Leucine | 2.38E-03 | 3.79E-01 ||\n|| Interaction | Glycine | 2.48E-03 | 1.44E+00 ||\n|| Time | Glycerol | 1.55E-03 | 6.91E+00 ||\n|| Interaction | Pyrimidine | 2.83E-03 | 2.01E+00 ||\n|| Interaction | Serine | 2.60E-03 | 2.22E-01 ||\n|| Interaction | Threonine | 2.52E-03 | 1.23E+00 ||\n|| Interaction | Methionine | 6.91E-03 | 5.02E+00 ||\n|| Interaction | Valine | 2.48E-03 | 8.39E+00 ||\n|| Interaction | Sarcosine | 3.23E-03 | 1.87E+00 ||\n|| Time | Isoleucine | 1.59E-03 | 3.71E+00 ||\n|| Time | Serine | 1.75E-03 | 2.08E+00 ||\n|| Time | Valine | 1.65E-03 | 4.06E+00 ||\n|| Phenotype | Lactic acid | 2.30E-03 | 3.65E-30 ||\n|| Phenotype | Acetic acid | 2.41E-03 | 1.23E-30 ||\n|| Phenotype | Hexanoic acid | 1.96E-03 | 6.16E-31 ||",
    "claim": "Alanine has the highest leverage in the Phenotype condition, suggesting it plays a significant role in differentiating phenotypes. This is determined by finding the maximum leverage value in the Phenotype condition.",
    "label": "refute"
  },
  {
    "id": "training_405_4",
    "table_caption": "Table: Table 1 In vitro antioxidant activity (%) of crude extracts from Acacia shaffneri (AS) and Acacia farnesiana (AF) pods Free radicals AS AF alpha-tocopherol catechin BHA ABTS•+ 10.85b ± 0.08 10.47b ± 0.36 92.64a ± 0.51 91.99a ± 1.00 ND DPPH● 94.77a ± 0.36 95.18a ± 0.26 93.42a ± 0.69 ND 92.36a ± 0.25 TBARS 66.59b ± 1.23 66.05b ± 1.62 92.54a ± 0.72 ND ND ABTS• + 2,2′-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid; DPPH● 1,1-diphenyl-2-picrylhydrazyl; TBARS thiobarbituric acid reactive substances, BHA buthylated hydroxyanisole; ND not determined a,b Means with different letters within the same row are significantly different at P < 0.05 ",
    "table_content": "|| Free radicals | AS | AF | alpha-tocopherol | catechin | BHA ||\n|| ABTS•+ | 10.85 b ± 0.08 | 10.47 b ± 0.36 | 92.64 a ± 0.51 | 91.99 a ± 1.00 | ND ||\n|| DPPH ●  | 94.77 a ± 0.36 | 95.18 a ± 0.26 | 93.42 a ± 0.69 | ND | 92.36 a ± 0.25 ||\n|| TBARS | 66.59 b ± 1.23 | 66.05 b ± 1.62 | 92.54 a ± 0.72 | ND | ND ||",
    "claim": "The differences in antioxidant activity between Acacia shaffneri (AS) and Acacia farnesiana (AF) are statistically significant for TBARS, as indicated by the different letters assigned, with AF showing a slightly higher activity than AS, although both are significantly lower than the standard antioxidants.",
    "label": "refute"
  },
  {
    "id": "training_86_6",
    "table_caption": "Table: Table 2 Categorization of sperm samples as a function of conventional sperm parameters and a densitometric analysis of the 110–80 kDa proteins Parameter (units) Group 1 n = 122 Group 2 n = 123 p-value in Student’s t test or (when underlined) a Kruskal-Wallis test Semen volume (mL) 3.5 [2.9–4.7] 4.07 (1.8–12) 3.8 [3.1–4.6] 4.02 (1.15–8.30) 0.81 Sperm concentration (×106/mL) 78.75 [52.5–142] 106.78 (24–420) 72 [41–92] 75.99 (1–250) 0.0002 Sperm count (×106/ejaculate) 319.30 [212.8–498] 405.96 (57–2100) 262.45 [155.8–356.9] 293.49 (2.80–1425) 0.0011 Progressive motility (PR, %) 55 [45–80] 54.80 (35–80) 45 [40–55] 46.28 (1–70) < 0.0001 Normal forms (%) 40.5 [34–48] 41.61 (25–68) 25 [18–53] 23.98 (0–53) < 0.0001 MAI 1.50 [1.44–1.55] 1.48 (1.25–1.55) 1.71 [1.64–1.80] 1.74 (1.38–1.80) < 0.0001 80–110 kDa band intensity from gel 1D (arbitrary units) 36,298 [21996–90,482] 33,466 [16657–48,560] 0.0367 Data on semen parameters are quoted as the median [IQR] and the mean (range) MAI multiple anomaly index, n number ",
    "table_content": "|| Parameter (units) | Group 1 n = 122 | Group 2 n = 123 | p -value in Student’s t test or (when underlined) a Kruskal-Wallis test ||\n|| Semen volume (mL) | 3.5 [2.9–4.7] 4.07 (1.8–12) | 3.8 [3.1–4.6] 4.02 (1.15–8.30) | 0.81 ||\n|| Sperm concentration (×10 6 /mL) | 78.75 [52.5–142] 106.78 (24–420) | 72 [41–92] 75.99 (1–250) | 0.0002 ||\n|| Sperm count (×10 6 /ejaculate) | 319.30 [212.8–498] 405.96 (57–2100) | 262.45 [155.8–356.9] 293.49 (2.80–1425) | 0.0011 ||\n|| Progressive motility (PR, %) | 55 [45–80] 54.80 (35–80) | 45 [40–55] 46.28 (1–70) | < 0.0001 ||\n|| Normal forms (%) | 40.5 [34–48] 41.61 (25–68) | 25 [18–53] 23.98 (0–53) | < 0.0001 ||\n|| MAI | 1.50 [1.44–1.55] 1.48 (1.25–1.55) | 1.71 [1.64–1.80] 1.74 (1.38–1.80) | < 0.0001 ||\n|| 80–110 kDa band intensity from gel 1D (arbitrary units) | 36,298 [21996–90,482] | 33,466 [16657–48,560] |  0.0367  ||",
    "claim": "The intensity of the 80–110 kDa protein band is higher in Group 2 than in Group 1. The median band intensity in Group 2 is approximately 8.5% higher than in Group 1, indicating a significant difference in protein expression between the groups.",
    "label": "refute"
  },
  {
    "id": "training_718_5",
    "table_caption": "Table: Females Males Lower Upper Lower Upper In eruption I1 227 227 312 287 I2 296 288 364 275 C 255 276 330 330 P3 216 276 296 352 P4 265 285 330 330 M1 134 127 247 195 M2 232 274 242 242 M3 263 213 145 130 Full occlusion I1 277 243 313 283 I2 243 284 313 313 C 288 288 279 266 P3 288 257 208 267 P4 274 257 266 301 M1 128 179 230 195 M2 274 274 242 255 M3 166 166 98 130 Table 4. Sample size. ",
    "table_content": "|| blank | blank | Females | Females | Males | Males ||\n|| blank | blank | Lower | Upper | Lower | Upper ||\n|| Full occlusion | I1 | 277 | 243 | 313 | 283 ||\n|| Full occlusion | I2 | 243 | 284 | 313 | 313 ||\n|| Full occlusion | C | 288 | 288 | 279 | 266 ||\n|| Full occlusion | P3 | 288 | 257 | 208 | 267 ||\n|| Full occlusion | P4 | 274 | 257 | 266 | 301 ||\n|| Full occlusion | M1 | 128 | 179 | 230 | 195 ||\n|| Full occlusion | M2 | 274 | 274 | 242 | 255 ||\n|| Full occlusion | M3 | 166 | 166 | 98 | 130 ||\n|| In eruption | I1 | 227 | 227 | 312 | 287 ||\n|| In eruption | I2 | 296 | 288 | 364 | 275 ||\n|| In eruption | C | 255 | 276 | 330 | 330 ||\n|| In eruption | P3 | 216 | 276 | 296 | 352 ||\n|| In eruption | P4 | 265 | 285 | 330 | 330 ||\n|| In eruption | M1 | 134 | 127 | 247 | 195 ||\n|| In eruption | M2 | 232 | 274 | 242 | 242 ||\n|| In eruption | M3 | 263 | 213 | 145 | 130 ||",
    "claim": "The range of lower measurements for females in the \"Full occlusion\" stage is 149 units, while for males, it is 215 units, highlighting a broader variability in male dental sizes at this stage.",
    "label": "refute"
  },
  {
    "id": "training_621_7",
    "table_caption": "Table: 230 Table 2. Depicts the effect of demographic variables on smoking habit Gender P Value Hospital/Institute P Value Type of Health care provider P Value Department P Value male female DUHS Shifa liaquat doctor nurse technician medicine surgery Are you a smoker for the past one year? yes 45 7 <0.001 32 12 8 0.0098 11 17 24 0.444 30 22 0.78 86.54% 13.20% 60.40% 22.60% 15.38% 20.80% 32.10% 46.15% 56.60% 42.31% No 71 57 96 9 23 32 50 46 69 59 55.47% 44.90% 75% 7.10% 17.97% 25.20% 39.40% 35.94% 54.30% 46.09% Number of cigarettes that you smoke per day less than 5 24 7 0.033 22 3 6 5 11 15 0.554 18 13 0.947 77.40% 22.60% 71.00% 9.70% 19.40% 16.10% 35.50% 48.40% 58.10% 41.90% more than 5 21 0 10 9 2 6 6 9 12 9 100.00% 0.00% 47.60% 42.90% 9.50% 28.60% 28.60% 42.90% 57.10% 42.90% Influence of friends and peer pressure Not Influenced 25 7 0.035 26 0 6 7 10 15 0.959 18 14 0.79 78.10% 21.90% 81.30% 0.00% 18.80% 21.90% 31.30% 46.90% 56.30% 43.80% Influenced 20 0 6 12 2 4 7 9 12 8 100.00% 0.00% 30.00% 60.00% 10.00% 20.00% 35.00% 45.00% 60.00% 40.00% Addiction Not Addicted 25 6 0.219 23 3 5 5 9 17 0.289 21 10 0.075 80.60% 19.40% 74.20% 9.70% 16.10% 16.10% 29.00% 54.80% 67.70% 32.30% Addicted 20 1 9 9 3 6 8 7 9 12 95.20% 4.80% 42.90% 42.90% 14.30% 28.60% 38.10% 33.30% 42.90% 57.10% Lack of will power No 19 4 0.686 16 3 4 7 5 11 0.2 12 11 0.473 82.60% 17.40% 69.60% 13.00% 17.40% 30.40% 21.70% 47.80% 52.20% 47.80% yes 26 3 16 9 4 4 12 13 18 11 89.70% 10.30% 55.20% 31.00% 13.80% 13.80% 41.40% 44.80% 62.10% 37.90% Lack of incentive No 33 3 0.182 20 10 6 9 13 14 0.276 20 16 0.64 91.70% 8.30% 55.60% 27.80% 16.70% 25.00% 36.10% 38.90% 55.60% 44.40% Yes 12 4 12 2 2 2 4 10 10 6 75.00% 25.00% 75.00% 12.50% 12.50% 12.50% 25.00% 62.50% 62.50% 37.50% ",
    "table_content": "|| blank | blank | Gender | Gender | P Value | Hospital/Institute | Hospital/Institute | Hospital/Institute | P Value | Type of Health care provider | Type of Health care provider | Type of Health care provider | P Value | Department | Department | P Value ||\n|| blank | blank | male | female | P Value | DUHS | Shifa | liaquat | P Value | doctor | nurse | technician | P Value | medicine | surgery | P Value ||\n|| Influence of friends and peer pressure | Not Influenced | 25 | 7 | 0.035 | 26 | 0 | 6 | blank | 7 | 10 | 15 | 0.959 | 18 | 14 | 0.79 ||\n|| Influence of friends and peer pressure | Not Influenced | 78.10% | 21.90% | 0.035 | 81.30% | 0.00% | 18.80% | blank | 21.90% | 31.30% | 46.90% | 0.959 | 56.30% | 43.80% | 0.79 ||\n|| Influence of friends and peer pressure | Influenced | 20 | 0 | 0.035 | 6 | 12 | 2 | blank | 4 | 7 | 9 | 0.959 | 12 | 8 | 0.79 ||\n|| Influence of friends and peer pressure | Influenced | 100.00% | 0.00% | 0.035 | 30.00% | 60.00% | 10.00% | blank | 20.00% | 35.00% | 45.00% | 0.959 | 60.00% | 40.00% | 0.79 ||\n|| Addiction | Not Addicted | 25 | 6 | 0.219 | 23 | 3 | 5 | blank | 5 | 9 | 17 | 0.289 | 21 | 10 | 0.075 ||\n|| Addiction | Not Addicted | 80.60% | 19.40% | 0.219 | 74.20% | 9.70% | 16.10% | blank | 16.10% | 29.00% | 54.80% | 0.289 | 67.70% | 32.30% | 0.075 ||\n|| Addiction | Addicted | 20 | 1 | 0.219 | 9 | 9 | 3 | blank | 6 | 8 | 7 | 0.289 | 9 | 12 | 0.075 ||\n|| Addiction | Addicted | 95.20% | 4.80% | 0.219 | 42.90% | 42.90% | 14.30% | blank | 28.60% | 38.10% | 33.30% | 0.289 | 42.90% | 57.10% | 0.075 ||\n|| Lack of will power | No | 19 | 4 | 0.686 | 16 | 3 | 4 | blank | 7 | 5 | 11 | 0.2 | 12 | 11 | 0.473 ||\n|| Lack of will power | No | 82.60% | 17.40% | 0.686 | 69.60% | 13.00% | 17.40% | blank | 30.40% | 21.70% | 47.80% | 0.2 | 52.20% | 47.80% | 0.473 ||\n|| Are you a smoker for the past one year? | yes | 45 | 7 | <0.001 | 32 | 12 | 8 | 0.0098 | 11 | 17 | 24 | 0.444 | 30 | 22 | 0.78 ||\n|| Lack of will power | yes | 26 | 3 | 0.686 | 16 | 9 | 4 | blank | 4 | 12 | 13 | 0.2 | 18 | 11 | 0.473 ||\n|| Lack of will power | yes | 89.70% | 10.30% | 0.686 | 55.20% | 31.00% | 13.80% | blank | 13.80% | 41.40% | 44.80% | 0.2 | 62.10% | 37.90% | 0.473 ||\n|| Lack of incentive | No | 33 | 3 | 0.182 | 20 | 10 | 6 | blank | 9 | 13 | 14 | 0.276 | 20 | 16 | 0.64 ||\n|| Lack of incentive | No | 91.70% | 8.30% | 0.182 | 55.60% | 27.80% | 16.70% | blank | 25.00% | 36.10% | 38.90% | 0.276 | 55.60% | 44.40% | 0.64 ||\n|| Lack of incentive | Yes | 12 | 4 | 0.182 | 12 | 2 | 2 | blank | 2 | 4 | 10 | 0.276 | 10 | 6 | 0.64 ||\n|| Lack of incentive | Yes | 75.00% | 25.00% | 0.182 | 75.00% | 12.50% | 12.50% | blank | 12.50% | 25.00% | 62.50% | 0.276 | 62.50% | 37.50% | 0.64 ||\n|| Are you a smoker for the past one year? | yes | 86.54% | 13.20% | <0.001 | 60.40% | 22.60% | 15.38% | 0.0098 | 20.80% | 32.10% | 46.15% | 0.444 | 56.60% | 42.31% | 0.78 ||\n|| Are you a smoker for the past one year? | No | 71 | 57 | <0.001 | 96 | 9 | 23 | 0.0098 | 32 | 50 | 46 | 0.444 | 69 | 59 | 0.78 ||\n|| Are you a smoker for the past one year? | No | 55.47% | 44.90% | <0.001 | 75% | 7.10% | 17.97% | 0.0098 | 25.20% | 39.40% | 35.94% | 0.444 | 54.30% | 46.09% | 0.78 ||\n|| Number of cigarettes that you smoke per day | less than 5 | 24 | 7 | 0.033 | 22 | 3 | 6 | blank | 5 | 11 | 15 | 0.554 | 18 | 13 | 0.947 ||\n|| Number of cigarettes that you smoke per day | less than 5 | 77.40% | 22.60% | 0.033 | 71.00% | 9.70% | 19.40% | blank | 16.10% | 35.50% | 48.40% | 0.554 | 58.10% | 41.90% | 0.947 ||\n|| Number of cigarettes that you smoke per day | more than 5 | 21 | 0 | 0.033 | 10 | 9 | 2 | blank | 6 | 6 | 9 | 0.554 | 12 | 9 | 0.947 ||\n|| Number of cigarettes that you smoke per day | more than 5 | 100.00% | 0.00% | 0.033 | 47.60% | 42.90% | 9.50% | blank | 28.60% | 28.60% | 42.90% | 0.554 | 57.10% | 42.90% | 0.947 ||",
    "claim": "Lack of willpower is associated with a higher likelihood of smoking, as indicated by the p-value of 0.686. The calculation involves comparing the smoking rates between individuals with and without a lack of willpower, considering the total number of respondents in each category.",
    "label": "refute"
  },
  {
    "id": "training_1195_4",
    "table_caption": "Table: Patient characteristics in a cohort of freshly isolated miRNA samples. Characteristics Healthy (N = 8) Stage 3–4 CKD (N = 10) Hemodialysis (N = 10) Age 43.4611.5 61.1614.1a 54.8614.0a Gender (%Male) 25 40 60 Race-Caucasians [N(%)] 5 (62.5) 10 (100) 1 (10) Race-African Americans [N(%)] 0 (0) 0 (0) 9 (90)a,b Race-Others [N(%)] 3 (37.5) 0 (0) 0 (0) DM (%) 0 20 50 HbA1C (%) – 7.8562.05 5.8860.55 ap,0.05 vs. healthy subjects; b p,0.01 vs. healthy subjects. doi:10.1371/journal.pone.0064558.t002 ",
    "table_content": "|| Characteristics | Healthy (N = 8) | Stage 3–4 CKD (N = 10) | Hemodialysis (N = 10) ||\n|| Age | 43.4±11.5 | 61.1±14.1 a  | 54.8±14.0 a  ||\n|| Gender (%Male) | 25 | 40 | 60 ||\n|| Race-Caucasians [N(%)] | 5 (62.5) | 10 (100) | 1 (10) ||\n|| Race-African Americans [N(%)] | 0 (0) | 0 (0) | 9 (90) a,b  ||\n|| Race-Others [N(%)] | 3 (37.5) | 0 (0) | 0 (0) ||\n|| DM (%) | 0 | 20 | 50 ||\n|| HbA1C (%) | – | 7.85±2.05 | 5.88±0.55 ||",
    "claim": "The prevalence of DM increases from 0% in the Healthy group to 50% in the Hemodialysis group. This 500% increase in DM prevalence suggests a strong association between diabetes and the progression to more severe stages of kidney disease.",
    "label": "refute"
  },
  {
    "id": "training_688_2",
    "table_caption": "Table: of 1). to In in HepG2 and Huh7 cells. HepG2 Huh7 Sorafenib (mM) Sorafenib (mM) 5 7.5 10 5 7.5 10 Celecoxib (mM) 25 0.890 0.640 0.510 0.898 0.833 0.760 50 0.708 0.502 0.639 0.732 0.661 0.639 75 0.544 0.470 0.552 0.691 0.612 0.624 doi:10.1371/journal.pone.0065569.t001 ",
    "table_content": "|| blank | blank | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) ||\n|| blank | blank | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) ||\n|| blank | blank | 5 | 7.5 | 10 | 5 | 7.5 | 10 ||\n||  Celecoxib (µM) | 25 | 0.890 | 0.640 | 0.510 | 0.898 | 0.833 | 0.760 ||\n||  Celecoxib (µM) | 50 | 0.708 | 0.502 | 0.639 | 0.732 | 0.661 | 0.639 ||\n||  Celecoxib (µM) | 75 | 0.544 | 0.470 | 0.552 | 0.691 | 0.612 | 0.624 ||",
    "claim": "At a fixed concentration of 25 µM Celecoxib and 5 µM Sorafenib, HepG2 cells exhibit a slightly higher viability than Huh7 cells, with a difference of approximately 0.008 units. This indicates a marginally lower sensitivity of HepG2 cells to this drug combination.",
    "label": "refute"
  },
  {
    "id": "training_540_2",
    "table_caption": "Table: Table 5 Models for saccharification yield and pretreatment effect Cell wall factor Parameter estimate Standard error p-value Standardized estimate Saccharification model without pretreatment Intercept 0.09536 0.01308 <0.0001 0.00 Lignin −0.52154 0.04720 <0.0001 −0.89 S/G −0.01170 0.00318 0.0003 −0.29 Ferulic acid −4.24820 1.27867 0.0011 −0.15 Galactose 0.00223 0.00066 0.0009 0.24 Xylose −0.00044 0.00015 0.0043 −0.19 Matrix polysaccharides 0.07289 0.03156 0.0224 0.13 Saccharification model with acid pretreatment Intercept 0.52417 0.04977 <0.0001 0.00 Lignin −8.14968 0.89507 <0.0001 −5.33 Lignin2 35.18722 4.45747 <0.0001 4.61 Galactose 0.00538 0.00149 0.0004 0.22 Xylose −0.00120 0.00036 0.0010 −0.20 Pretreatment effect model Intercept 0.29129 0.04709 <0.0001 0.00 Lignin −5.35810 0.79704 <0.0001 −4.91 Lignin2 24.30648 3.91171 <0.0001 4.46 S/G 0.01737 0.00693 0.0133 0.23 Galactose 0.00384 0.00144 0.0087 0.22 Xylose −0.00091 0.00033 0.0058 −0.21 Models illustrate which cell wall factors had a significant influence on the saccharification yield or pretreatment effect. The “parameter estimate” indicates the increase in saccharification yield or pretreatment effect when 1 unit of the cell wall factor is increased when the other cell wall factors are fixed. The standardized estimate indicates the strength of the influence on the saccharification yield or pretreatment effect. Lignin2 = lignin x lignin. All data used to build these models ",
    "table_content": "|| Cell wall factor | Parameter estimate | Standard error | p -value | Standardized estimate ||\n|| Saccharification model without pretreatment | Saccharification model without pretreatment | Saccharification model without pretreatment | Saccharification model without pretreatment | Saccharification model without pretreatment ||\n|| Intercept | 0.52417 | 0.04977 | <0.0001 | 0.00 ||\n|| Lignin | −8.14968 | 0.89507 | <0.0001 | −5.33 ||\n|| Lignin 2 | 35.18722 | 4.45747 | <0.0001 | 4.61 ||\n|| Galactose | 0.00538 | 0.00149 | 0.0004 | 0.22 ||\n|| Xylose | −0.00120 | 0.00036 | 0.0010 | −0.20 ||\n|| Pretreatment effect model | Pretreatment effect model | Pretreatment effect model | Pretreatment effect model | Pretreatment effect model ||\n|| Intercept | 0.29129 | 0.04709 | <0.0001 | 0.00 ||\n|| Lignin | −5.35810 | 0.79704 | <0.0001 | −4.91 ||\n|| Lignin 2 | 24.30648 | 3.91171 | <0.0001 | 4.46 ||\n|| S/G | 0.01737 | 0.00693 | 0.0133 | 0.23 ||\n|| Intercept | 0.09536 | 0.01308 | <0.0001 | 0.00 ||\n|| Galactose | 0.00384 | 0.00144 | 0.0087 | 0.22 ||\n|| Xylose | −0.00091 | 0.00033 | 0.0058 | −0.21 ||\n|| Lignin | −0.52154 | 0.04720 | <0.0001 | −0.89 ||\n|| S/G | −0.01170 | 0.00318 | 0.0003 | −0.29 ||\n|| Ferulic acid | −4.24820 | 1.27867 | 0.0011 | −0.15 ||\n|| Galactose | 0.00223 | 0.00066 | 0.0009 | 0.24 ||\n|| Xylose | −0.00044 | 0.00015 | 0.0043 | −0.19 ||\n|| Matrix polysaccharides | 0.07289 | 0.03156 | 0.0224 | 0.13 ||\n|| Saccharification model with acid pretreatment | Saccharification model with acid pretreatment | Saccharification model with acid pretreatment | Saccharification model with acid pretreatment | Saccharification model with acid pretreatment ||",
    "claim": "Galactose consistently shows a positive influence on saccharification yield across all models. However, its impact is more pronounced in the saccharification model with acid pretreatment compared to the model without pretreatment, indicating that acid pretreatment enhances the positive effect of galactose on yield.",
    "label": "refute"
  },
  {
    "id": "training_540_2",
    "table_caption": "Table: Table 5 Models for saccharification yield and pretreatment effect Cell wall factor Parameter estimate Standard error p-value Standardized estimate Saccharification model without pretreatment Intercept 0.09536 0.01308 <0.0001 0.00 Lignin −0.52154 0.04720 <0.0001 −0.89 S/G −0.01170 0.00318 0.0003 −0.29 Ferulic acid −4.24820 1.27867 0.0011 −0.15 Galactose 0.00223 0.00066 0.0009 0.24 Xylose −0.00044 0.00015 0.0043 −0.19 Matrix polysaccharides 0.07289 0.03156 0.0224 0.13 Saccharification model with acid pretreatment Intercept 0.52417 0.04977 <0.0001 0.00 Lignin −8.14968 0.89507 <0.0001 −5.33 Lignin2 35.18722 4.45747 <0.0001 4.61 Galactose 0.00538 0.00149 0.0004 0.22 Xylose −0.00120 0.00036 0.0010 −0.20 Pretreatment effect model Intercept 0.29129 0.04709 <0.0001 0.00 Lignin −5.35810 0.79704 <0.0001 −4.91 Lignin2 24.30648 3.91171 <0.0001 4.46 S/G 0.01737 0.00693 0.0133 0.23 Galactose 0.00384 0.00144 0.0087 0.22 Xylose −0.00091 0.00033 0.0058 −0.21 Models illustrate which cell wall factors had a significant influence on the saccharification yield or pretreatment effect. The “parameter estimate” indicates the increase in saccharification yield or pretreatment effect when 1 unit of the cell wall factor is increased when the other cell wall factors are fixed. The standardized estimate indicates the strength of the influence on the saccharification yield or pretreatment effect. Lignin2 = lignin x lignin. All data used to build these models ",
    "table_content": "|| Cell wall factor | Parameter estimate | Standard error | p -value | Standardized estimate ||\n|| Saccharification model without pretreatment | Saccharification model without pretreatment | Saccharification model without pretreatment | Saccharification model without pretreatment | Saccharification model without pretreatment ||\n|| Intercept | 0.52417 | 0.04977 | <0.0001 | 0.00 ||\n|| Lignin | −8.14968 | 0.89507 | <0.0001 | −5.33 ||\n|| Lignin 2 | 35.18722 | 4.45747 | <0.0001 | 4.61 ||\n|| Galactose | 0.00538 | 0.00149 | 0.0004 | 0.22 ||\n|| Xylose | −0.00120 | 0.00036 | 0.0010 | −0.20 ||\n|| Pretreatment effect model | Pretreatment effect model | Pretreatment effect model | Pretreatment effect model | Pretreatment effect model ||\n|| Intercept | 0.29129 | 0.04709 | <0.0001 | 0.00 ||\n|| Lignin | −5.35810 | 0.79704 | <0.0001 | −4.91 ||\n|| Lignin 2 | 24.30648 | 3.91171 | <0.0001 | 4.46 ||\n|| S/G | 0.01737 | 0.00693 | 0.0133 | 0.23 ||\n|| Intercept | 0.09536 | 0.01308 | <0.0001 | 0.00 ||\n|| Galactose | 0.00384 | 0.00144 | 0.0087 | 0.22 ||\n|| Xylose | −0.00091 | 0.00033 | 0.0058 | −0.21 ||\n|| Lignin | −0.52154 | 0.04720 | <0.0001 | −0.89 ||\n|| S/G | −0.01170 | 0.00318 | 0.0003 | −0.29 ||\n|| Ferulic acid | −4.24820 | 1.27867 | 0.0011 | −0.15 ||\n|| Galactose | 0.00223 | 0.00066 | 0.0009 | 0.24 ||\n|| Xylose | −0.00044 | 0.00015 | 0.0043 | −0.19 ||\n|| Matrix polysaccharides | 0.07289 | 0.03156 | 0.0224 | 0.13 ||\n|| Saccharification model with acid pretreatment | Saccharification model with acid pretreatment | Saccharification model with acid pretreatment | Saccharification model with acid pretreatment | Saccharification model with acid pretreatment ||",
    "claim": "Galactose consistently shows a positive influence on saccharification yield across all models. However, its impact is more pronounced in the saccharification model without pretreatment compared to the model with acid pretreatment, indicating that acid pretreatment diminishes the positive effect of galactose on yield.",
    "label": "refute"
  },
  {
    "id": "training_779_4",
    "table_caption": "Table: and a variable degree model [25] of sex determination as described in the text. Incubation Treatment 26±36C 26±56C 31±36C 31±56C Minimum temperature (6C) 23 21 28 26 Maximum temperature (6C) 29 31 34 36 Mean temperature (6C) 26 26 31 31 nl-CTE (i.e. constant temperature value predicted to produce an equivalent developmental rate as the fluctuating profiles, determined from the non-linear model) 26.2 25.6 28.9 27.2 CTE (i.e. constant temperature value predicted to produce an equivalent development per treatment as the fluctuating profiles) 26.7 28.0 31.6 32.5 Daily CTU from thermal traces (integral of hourly temperature records above developmental threshold of 14uC) 595 559 784 814 VDM temperature (i.e. temperature at which the highest cumulative development over the thermosensitive period occurred) 29 31 $28 26 CTE and CTU units were calculated using 14uC as the developmental zero [33]. VDM temperature was calculated as 29uC and 31uC, respectively, for the 2663 and 2665uC treatments, and as 26uC for the 3165uC treatment, since the minimum temperature in the former two treatments retards development compared to the ",
    "table_content": "|| blank | Incubation Treatment | Incubation Treatment | Incubation Treatment | Incubation Treatment ||\n|| blank | 26±3°C | 26±5°C | 31±3°C | 31±5°C ||\n||  Minimum temperature (  °  C)  | 23 | 21 | 28 | 26 ||\n||  Maximum temperature (  °  C)  | 29 | 31 | 34 | 36 ||\n||  Mean temperature (  °  C)  | 26 | 26 | 31 | 31 ||\n||  nl-CTE (i.e. constant temperature value predicted to produce an equivalent developmental rate as the fluctuating profiles, determined from the non-linear model) | 26.2 | 25.6 | 28.9 | 27.2 ||\n||  CTE (i.e. constant temperature value predicted to produce an equivalent development per treatment as the fluctuating profiles) | 26.7 | 28.0 | 31.6 | 32.5 ||\n||  Daily CTU from thermal traces (integral of hourly temperature records above developmental threshold of 14°C) | 595 | 559 | 784 | 814 ||\n||  VDM temperature (i.e. temperature at which the highest cumulative development over the thermosensitive period occurred) | 29 | 31 | ≥28 | 26 ||",
    "claim": "The nl-CTE for the 31±3°C treatment is lower than that for the 26±3°C treatment, despite the higher maximum temperature. This suggests that the increase in maximum temperature from 29°C to 34°C does not linearly translate to an increase in nl-CTE, indicating a complex interaction between temperature fluctuations and developmental rates.",
    "label": "refute"
  },
  {
    "id": "training_745_1",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A N2—H2A···O2i 0.86 2.01 2.8479 (14) 164. O3—H3A···O4ii 0.82 1.97 2.7631 (14) 164. C23—H23···O3iii 0.93 2.58 3.2761 (18) 133. Symmetry codes: (i) −x, −y+1, −z+1; (ii) −x+1, −y+1, −z+1; (iii) x−1, y, z. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| N2—H2A···O2 i | 0.86 | 2.01 | 2.8479 (14) | 164. ||\n|| O3—H3A···O4 ii | 0.82 | 1.97 | 2.7631 (14) | 164. ||\n|| C23—H23···O3 iii | 0.93 | 2.58 | 3.2761 (18) | 133. ||",
    "claim": "The D—H bond length for C23—H23···O3 is the shortest among the three interactions, indicating a stronger covalent character compared to the other two interactions, which is consistent with the typical bond length trends for C—H bonds being shorter than N—H and O—H bonds.",
    "label": "refute"
  },
  {
    "id": "training_194_6",
    "table_caption": "Table: Mean, median, 95% CI, interquartile interval and P value of clinical score, IFAT titer, TP (g/dl), IgG (%), creatinine and urea (mg/dl), and UP/C in 20 dogs before and after 28 days of therapy. Parameter D0 D28 p value Clinical score NV: 0 Mean (95% CI) 5.1 (3.1-7.09) 2.6 (1.52-3.77) p=0.0046 IFAT titer NV: Titer<1:80 (min-max) 160-1280 (320-640) 80-1280 (240-640) p=0.2661 TP NV: 6-8 g/dl Mean (95% CI) 8 (7.55-8.45) 7.6 (7.24-7.96) p=0.0730 IgG NV: 5.3-9.9% Mean (95% CI) 21.36 (16.89-25.83) 19.06 (14.75-23.36) p=0.1009 Creatinine NV<1.2 mg/dl (Median I-III interquartile interval) 0.91 (0.8-1.05) 0.91 (0.7-1.1) p=0.8077 Urea NV: 15-45 mg/dl (Median I-III interquartile interval) 40.75 (29-45.5) 38.55 (29.5-44) p=0.4171 UP/C NP: <0.2 BP: 0.2-0.5 P: >0.5 (Median I-III interquartile interval) 0.35 (0.1-0.7) 0.26 (0.1-0.4) p=0.016 NV: Normal value, NP: Non-proteinuric, BP: Borderline proteinuric, P: Proteinuric, CI: Confidence interval 95%, TP: Total protein, IFAT: Indirect fluorescent antibody test, UP/C: Urine protein creatinine, IgG: Gamma globulin ",
    "table_content": "|| Parameter | D0 | D28 | p value ||\n|| Clinical score | Clinical score | Clinical score | Clinical score ||\n|| NV<1.2 mg/dl (Median IIII interquartile interval) | 0.91 (0.8-1.05) | 0.91 (0.7-1.1) | p=0.8077 ||\n|| Urea | Urea | Urea | Urea ||\n|| NV: 1545 mg/dl (Median IIII interquartile interval) | 40.75 (29-45.5) | 38.55 (29.5-44) | p=0.4171 ||\n|| UP/C | UP/C | UP/C | UP/C ||\n|| NP: <0.2 BP: 0.20.5 P: >0.5 (Median I-III interquartile interval) | 0.35 (0.1-0.7) | 0.26 (0.1-0.4) | p=0.016 ||\n|| NV: 0 Mean (95% CI) | 5.1 (3.1-7.09) | 2.6 (1.52-3.77) | p=0.0046 ||\n|| IFAT titer | IFAT titer | IFAT titer | IFAT titer ||\n|| NV: Titer<1:80 (minmax) | 160-1280 (320-640) | 80-1280 (240-640) | p=0.2661 ||\n|| TP | TP | TP | TP ||\n|| NV: 68 g/dl Mean (95% CI) | 8 (7.55-8.45) | 7.6 (7.24-7.96) | p=0.0730 ||\n|| IgG | IgG | IgG | IgG ||\n|| NV: 5.39.9% Mean (95% CI) | 21.36 (16.89-25.83) | 19.06 (14.75-23.36) | p=0.1009 ||\n|| Creatinine | Creatinine | Creatinine | Creatinine ||",
    "claim": "The median urea levels increased by approximately 5.4% from D0 to D28, with a p-value of 0.4171, indicating a non-significant trend towards reduction.",
    "label": "refute"
  },
  {
    "id": "training_471_1",
    "table_caption": "Table: a percentage of total population in Delaunay-based N r = 4 r = 16 r = 64 10 47.2 48.1 48.3 25 21.5 21.7 21.4 50 11.4 11.4 10.4 100 5.81 5.81 5.19 doi:10.1371/journal.pone.0058525.t002 ",
    "table_content": "||  N  |  r = 4 |  r = 16 |  r = 64 ||\n|| 10 | 47.2 | 48.1 | 48.3 ||\n|| 25 | 21.5 | 21.7 | 21.4 ||\n|| 50 | 11.4 | 11.4 | 10.4 ||\n|| 100 | 5.81 | 5.81 | 5.19 ||",
    "claim": "As \\( N \\) increases from 10 to 100, the percentage of the total population increases exponentially across all \\( r \\) values. The rate of increase is more pronounced at higher \\( N \\) values, indicating a logarithmic relationship between \\( N \\) and the percentage of the population.",
    "label": "refute"
  },
  {
    "id": "training_1418_3",
    "table_caption": "Table: (μg C L-1) and percentage of biomass (%) under initial conditions and after each treatment. Values are mean and standard deviation whereas the letters indi- cate differences among treatments for the different phytoplanktonic groups and total biomass. CONTROL P-ENRICHED INITIAL UVR+PAR PAR UVR+PAR PAR+P Mean ±sd % Mean ±sd % Mean ± sd % Mean ± sd % Mean ± sd % Bacillariophyceae 100.46±16.13 58.36 205.74±23.27 a 57.73 175.42±62.81 a 52.36 136.24±26.13 a 68.95 157.98±35.95 a 47.90 Dinophyceae 1.65±0.96 0.01 2.94±1.09 a 0.01 2.02±1.00 a 0.01 2.32±2.16 a 0.01 1.32±0.46 a 0.00 Flagellates 44.89±0.87 26.07 146.45±34.39 a 41.10 156.15±36.66 a 46.61 52.47±13.54 b 26.56 156.54±26.84 a 47.47 Picoeukaryotes 22.31±0.45 12.96 0.85±0.19 a 0.24 0.74 ± 0.07 a 0.22 5.22±0.25 b 2.64 11.94±0.50 c 3.62 Prochlorococcus sp. 0.004±0.001 0.00 0.003±0.002 a 0.00 0.001 ± 0.0003 a 0.00 0.002±0.0003 a 0.00 0.002±0.001 a 0.00 Synechococcus sp. 2.83±0.08 1.64 0.37±0.02 a 0.11 0.68 ±0.02 b 0.20 1.34±0.12 c 0.68 2.02±0.12 d 0.61 Total biomass 172.14±32.39 356.37±5 9.31 a 335.02 ±99.45 a 197.61±41.24 b 329.80±62.43a doi:10.1371/journal.pone.0142987.t002 ",
    "table_content": "|| blank | blank | blank | CONTROL | CONTROL | CONTROL | CONTROL | P-ENRICHED | P-ENRICHED | P-ENRICHED | P-ENRICHED ||\n|| blank | INITIAL | INITIAL | UVR+PAR | UVR+PAR | PAR | PAR | UVR+PAR | UVR+PAR | PAR+P | PAR+P ||\n|| blank | Mean ±sd | % | Mean ±sd | % | Mean ± sd | % | Mean ± sd | % | Mean ± sd | % ||\n||  Bacillariophyceae  | 100.46±16.13 | 58.36 | 205.74±23.27 a  | 57.73 | 175.42±62.81 a  | 52.36 | 136.24±26.13 a  | 68.95 | 157.98±35.95 a  | 47.90 ||\n||  Dinophyceae  | 1.65±0.96 | 0.01 | 2.94±1.09 a  | 0.01 | 2.02±1.00 a  | 0.01 | 2.32±2.16 a  | 0.01 | 1.32±0.46 a  | 0.00 ||\n||  Flagellates  | 44.89±0.87 | 26.07 | 146.45±34.39 a  | 41.10 | 156.15±36.66 a  | 46.61 | 52.47±13.54 b  | 26.56 | 156.54±26.84 a  | 47.47 ||\n||  Picoeukaryotes  | 22.31±0.45 | 12.96 | 0.85±0.19 a  | 0.24 | 0.74 ± 0.07 a  | 0.22 | 5.22±0.25 b  | 2.64 | 11.94±0.50 c  | 3.62 ||\n||  Prochlorococcus sp.  | 0.004±0.001 | 0.00 | 0.003±0.002 a  | 0.00 | 0.001 ± 0.0003 a  | 0.00 | 0.002±0.0003 a  | 0.00 | 0.002±0.001 a  | 0.00 ||\n||  Synechococcus sp.  | 2.83±0.08 | 1.64 | 0.37±0.02 a  | 0.11 | 0.68 ±0.02 b  | 0.20 | 1.34±0.12 c  | 0.68 | 2.02±0.12 d  | 0.61 ||\n||  Total biomass  | 172.14±32.39 | blank | 356.37±5 9.31 a  | blank | 335.02 ±99.45 a  | blank | 197.61±41.24 b  | blank | 329.80±62.43 a  | blank ||",
    "claim": "The Picoeukaryotes biomass under the P-enriched PAR+P condition is approximately 15.9 times higher than under the initial condition, reflecting a dramatic increase in biomass due to the combined effects of phosphorus enrichment and light exposure.",
    "label": "refute"
  },
  {
    "id": "training_1418_3",
    "table_caption": "Table: (μg C L-1) and percentage of biomass (%) under initial conditions and after each treatment. Values are mean and standard deviation whereas the letters indi- cate differences among treatments for the different phytoplanktonic groups and total biomass. CONTROL P-ENRICHED INITIAL UVR+PAR PAR UVR+PAR PAR+P Mean ±sd % Mean ±sd % Mean ± sd % Mean ± sd % Mean ± sd % Bacillariophyceae 100.46±16.13 58.36 205.74±23.27 a 57.73 175.42±62.81 a 52.36 136.24±26.13 a 68.95 157.98±35.95 a 47.90 Dinophyceae 1.65±0.96 0.01 2.94±1.09 a 0.01 2.02±1.00 a 0.01 2.32±2.16 a 0.01 1.32±0.46 a 0.00 Flagellates 44.89±0.87 26.07 146.45±34.39 a 41.10 156.15±36.66 a 46.61 52.47±13.54 b 26.56 156.54±26.84 a 47.47 Picoeukaryotes 22.31±0.45 12.96 0.85±0.19 a 0.24 0.74 ± 0.07 a 0.22 5.22±0.25 b 2.64 11.94±0.50 c 3.62 Prochlorococcus sp. 0.004±0.001 0.00 0.003±0.002 a 0.00 0.001 ± 0.0003 a 0.00 0.002±0.0003 a 0.00 0.002±0.001 a 0.00 Synechococcus sp. 2.83±0.08 1.64 0.37±0.02 a 0.11 0.68 ±0.02 b 0.20 1.34±0.12 c 0.68 2.02±0.12 d 0.61 Total biomass 172.14±32.39 356.37±5 9.31 a 335.02 ±99.45 a 197.61±41.24 b 329.80±62.43a doi:10.1371/journal.pone.0142987.t002 ",
    "table_content": "|| blank | blank | blank | CONTROL | CONTROL | CONTROL | CONTROL | P-ENRICHED | P-ENRICHED | P-ENRICHED | P-ENRICHED ||\n|| blank | INITIAL | INITIAL | UVR+PAR | UVR+PAR | PAR | PAR | UVR+PAR | UVR+PAR | PAR+P | PAR+P ||\n|| blank | Mean ±sd | % | Mean ±sd | % | Mean ± sd | % | Mean ± sd | % | Mean ± sd | % ||\n||  Bacillariophyceae  | 100.46±16.13 | 58.36 | 205.74±23.27 a  | 57.73 | 175.42±62.81 a  | 52.36 | 136.24±26.13 a  | 68.95 | 157.98±35.95 a  | 47.90 ||\n||  Dinophyceae  | 1.65±0.96 | 0.01 | 2.94±1.09 a  | 0.01 | 2.02±1.00 a  | 0.01 | 2.32±2.16 a  | 0.01 | 1.32±0.46 a  | 0.00 ||\n||  Flagellates  | 44.89±0.87 | 26.07 | 146.45±34.39 a  | 41.10 | 156.15±36.66 a  | 46.61 | 52.47±13.54 b  | 26.56 | 156.54±26.84 a  | 47.47 ||\n||  Picoeukaryotes  | 22.31±0.45 | 12.96 | 0.85±0.19 a  | 0.24 | 0.74 ± 0.07 a  | 0.22 | 5.22±0.25 b  | 2.64 | 11.94±0.50 c  | 3.62 ||\n||  Prochlorococcus sp.  | 0.004±0.001 | 0.00 | 0.003±0.002 a  | 0.00 | 0.001 ± 0.0003 a  | 0.00 | 0.002±0.0003 a  | 0.00 | 0.002±0.001 a  | 0.00 ||\n||  Synechococcus sp.  | 2.83±0.08 | 1.64 | 0.37±0.02 a  | 0.11 | 0.68 ±0.02 b  | 0.20 | 1.34±0.12 c  | 0.68 | 2.02±0.12 d  | 0.61 ||\n||  Total biomass  | 172.14±32.39 | blank | 356.37±5 9.31 a  | blank | 335.02 ±99.45 a  | blank | 197.61±41.24 b  | blank | 329.80±62.43 a  | blank ||",
    "claim": "The Picoeukaryotes biomass under the P-enriched PAR+P condition is approximately 5.9 times higher than under the initial condition, reflecting a dramatic increase in biomass due to the combined effects of phosphorus enrichment and light exposure.",
    "label": "refute"
  },
  {
    "id": "training_1084_6",
    "table_caption": "Table: Event Date in 2014 Local time Precipitation type Total rain amount (mm) 1-min maximum rain rate (mm h−1) SSc(200 nm, Rmed) (%) SSest (%) No. 1 27 Jul. 1521–1628 Cold front 4.0 19.7 0.11 0.45 No. 2 9 Aug. 1710–1720 Stationary front 0.9 8.9 0.22 0.19 No. 3 10 Aug. 0002–0445 Typhoon 12.7 15.0 0.14 0.26 No. 4 10 Aug. 1100–1212 Typhoon 12.3 37.4 0.23 0.25 No.5 10 Aug. 1234–1318 Typhoon 9.6 34.2 0.24 0.40 No. 6 10 Aug. 1805–1915 Typhoon 9.2 57.1 0.26 0.30 No. 7 12 Aug. 1626–1632 Cold front 0.2 2.8 0.17 0.09 No. 8 12 Aug. 1720–1810 Cold front 1.0 5.6 0.16 0.12 No. 9 14 Aug. 1327–1643 Stationary front 14.8 27.1 0.15 0.08 No. 10 14 Aug. 1749–1909 Stationary front 2.8 11.2 0.15 0.09 Average — — Cold front 1.7 9.4 0.15 0.22 Average — — Stationary front 6.2 15.7 0.17 0.12 Average Typhoon 11.0 35.9 0.22 0.30 Table 1. Precipitation events observed during the field campaign BC-CARE Tokyo. ",
    "table_content": "|| Event | Date in 2014 | Local time | Precipitation type | Total rain amount (mm) | 1-min maximum rain rate (mm h −1 ) | SS c (200 nm, R med ) (%) | SS est (%) ||\n|| No. 1 | 27 Jul. | 1521–1628 | Cold front | 4.0 | 19.7 | 0.11 | 0.45 ||\n|| No. 10 | 14 Aug. | 1749–1909 | Stationary front | 2.8 | 11.2 | 0.15 | 0.09 ||\n|| Average | — | — | Cold front | 1.7 | 9.4 | 0.15 | 0.22 ||\n|| Average | — | — | Stationary front | 6.2 | 15.7 | 0.17 | 0.12 ||\n|| Average | blank | blank | Typhoon | 11.0 | 35.9 | 0.22 | 0.30 ||\n|| No. 2 | 9 Aug. | 1710–1720 | Stationary front | 0.9 | 8.9 | 0.22 | 0.19 ||\n|| No. 3 | 10 Aug. | 0002–0445 | Typhoon | 12.7 | 15.0 | 0.14 | 0.26 ||\n|| No. 4 | 10 Aug. | 1100–1212 | Typhoon | 12.3 | 37.4 | 0.23 | 0.25 ||\n|| No.5 | 10 Aug. | 1234–1318 | Typhoon | 9.6 | 34.2 | 0.24 | 0.40 ||\n|| No. 6 | 10 Aug. | 1805–1915 | Typhoon | 9.2 | 57.1 | 0.26 | 0.30 ||\n|| No. 7 | 12 Aug. | 1626–1632 | Cold front | 0.2 | 2.8 | 0.17 | 0.09 ||\n|| No. 8 | 12 Aug. | 1720–1810 | Cold front | 1.0 | 5.6 | 0.16 | 0.12 ||\n|| No. 9 | 14 Aug. | 1327–1643 | Stationary front | 14.8 | 27.1 | 0.15 | 0.08 ||",
    "claim": "The average SSc for typhoon events is approximately 47% higher than that for cold fronts, while the average SSest for typhoons is 36% higher than for stationary fronts, reflecting distinct microphysical properties associated with different precipitation mechanisms.",
    "label": "refute"
  },
  {
    "id": "training_1084_6",
    "table_caption": "Table: Event Date in 2014 Local time Precipitation type Total rain amount (mm) 1-min maximum rain rate (mm h−1) SSc(200 nm, Rmed) (%) SSest (%) No. 1 27 Jul. 1521–1628 Cold front 4.0 19.7 0.11 0.45 No. 2 9 Aug. 1710–1720 Stationary front 0.9 8.9 0.22 0.19 No. 3 10 Aug. 0002–0445 Typhoon 12.7 15.0 0.14 0.26 No. 4 10 Aug. 1100–1212 Typhoon 12.3 37.4 0.23 0.25 No.5 10 Aug. 1234–1318 Typhoon 9.6 34.2 0.24 0.40 No. 6 10 Aug. 1805–1915 Typhoon 9.2 57.1 0.26 0.30 No. 7 12 Aug. 1626–1632 Cold front 0.2 2.8 0.17 0.09 No. 8 12 Aug. 1720–1810 Cold front 1.0 5.6 0.16 0.12 No. 9 14 Aug. 1327–1643 Stationary front 14.8 27.1 0.15 0.08 No. 10 14 Aug. 1749–1909 Stationary front 2.8 11.2 0.15 0.09 Average — — Cold front 1.7 9.4 0.15 0.22 Average — — Stationary front 6.2 15.7 0.17 0.12 Average Typhoon 11.0 35.9 0.22 0.30 Table 1. Precipitation events observed during the field campaign BC-CARE Tokyo. ",
    "table_content": "|| Event | Date in 2014 | Local time | Precipitation type | Total rain amount (mm) | 1-min maximum rain rate (mm h −1 ) | SS c (200 nm, R med ) (%) | SS est (%) ||\n|| No. 1 | 27 Jul. | 1521–1628 | Cold front | 4.0 | 19.7 | 0.11 | 0.45 ||\n|| No. 10 | 14 Aug. | 1749–1909 | Stationary front | 2.8 | 11.2 | 0.15 | 0.09 ||\n|| Average | — | — | Cold front | 1.7 | 9.4 | 0.15 | 0.22 ||\n|| Average | — | — | Stationary front | 6.2 | 15.7 | 0.17 | 0.12 ||\n|| Average | blank | blank | Typhoon | 11.0 | 35.9 | 0.22 | 0.30 ||\n|| No. 2 | 9 Aug. | 1710–1720 | Stationary front | 0.9 | 8.9 | 0.22 | 0.19 ||\n|| No. 3 | 10 Aug. | 0002–0445 | Typhoon | 12.7 | 15.0 | 0.14 | 0.26 ||\n|| No. 4 | 10 Aug. | 1100–1212 | Typhoon | 12.3 | 37.4 | 0.23 | 0.25 ||\n|| No.5 | 10 Aug. | 1234–1318 | Typhoon | 9.6 | 34.2 | 0.24 | 0.40 ||\n|| No. 6 | 10 Aug. | 1805–1915 | Typhoon | 9.2 | 57.1 | 0.26 | 0.30 ||\n|| No. 7 | 12 Aug. | 1626–1632 | Cold front | 0.2 | 2.8 | 0.17 | 0.09 ||\n|| No. 8 | 12 Aug. | 1720–1810 | Cold front | 1.0 | 5.6 | 0.16 | 0.12 ||\n|| No. 9 | 14 Aug. | 1327–1643 | Stationary front | 14.8 | 27.1 | 0.15 | 0.08 ||",
    "claim": "The average SSc for typhoon events is approximately 47% lower than that for cold fronts, while the average SSest for typhoons is 36% higher than for stationary fronts, reflecting distinct microphysical properties associated with different precipitation mechanisms.",
    "label": "refute"
  },
  {
    "id": "training_764_2",
    "table_caption": "Table: Comparison between antimicrobial susceptibility and OP phenotype of LES isolates Antimicrobial agent % resistant LES isolates for different OP phenotypes OP (n = 11) Negative (n = 17) N or I (n = 5) CAZ R 73 24 20 ATM R 64 35 0 MER R 91 65 20 TOB R 27 24 20 TOB D 45 12 40 CIP R 0 6 20 CIP D 27 12 20 CAZ, ceftazidime; ATM, aztreonam; MER, meropenem; TOB, tobramycin; CIP, ciprofloxacin; R, resistant; D, intermediate antimicrobial susceptibility; N, normal; I, intermediate OP phenotype ",
    "table_content": "|| Antimicrobial agent | % resistant LES isolates for different OP phenotypes | % resistant LES isolates for different OP phenotypes | % resistant LES isolates for different OP phenotypes ||\n|| Antimicrobial agent | OP (n = 11) | Negative (n = 17) | N or I (n = 5) ||\n|| CAZ R | 73 | 24 | 20 ||\n|| ATM R | 64 | 35 | 0 ||\n|| MER R | 91 | 65 | 20 ||\n|| TOB R | 27 | 24 | 20 ||\n|| TOB D | 45 | 12 | 40 ||\n|| CIP R | 0 | 6 | 20 ||\n|| CIP D | 27 | 12 | 20 ||",
    "claim": "In the OP phenotype, meropenem exhibits the highest resistance at 91%, which is 18% higher than aztreonam and 64% higher than ciprofloxacin, demonstrating meropenem's pronounced resistance in this phenotype.",
    "label": "refute"
  },
  {
    "id": "training_764_2",
    "table_caption": "Table: Comparison between antimicrobial susceptibility and OP phenotype of LES isolates Antimicrobial agent % resistant LES isolates for different OP phenotypes OP (n = 11) Negative (n = 17) N or I (n = 5) CAZ R 73 24 20 ATM R 64 35 0 MER R 91 65 20 TOB R 27 24 20 TOB D 45 12 40 CIP R 0 6 20 CIP D 27 12 20 CAZ, ceftazidime; ATM, aztreonam; MER, meropenem; TOB, tobramycin; CIP, ciprofloxacin; R, resistant; D, intermediate antimicrobial susceptibility; N, normal; I, intermediate OP phenotype ",
    "table_content": "|| Antimicrobial agent | % resistant LES isolates for different OP phenotypes | % resistant LES isolates for different OP phenotypes | % resistant LES isolates for different OP phenotypes ||\n|| Antimicrobial agent | OP (n = 11) | Negative (n = 17) | N or I (n = 5) ||\n|| CAZ R | 73 | 24 | 20 ||\n|| ATM R | 64 | 35 | 0 ||\n|| MER R | 91 | 65 | 20 ||\n|| TOB R | 27 | 24 | 20 ||\n|| TOB D | 45 | 12 | 40 ||\n|| CIP R | 0 | 6 | 20 ||\n|| CIP D | 27 | 12 | 20 ||",
    "claim": "In the OP phenotype, meropenem exhibits the highest resistance at 91%, which is 28% higher than aztreonam and 74% higher than ciprofloxacin, demonstrating meropenem's pronounced resistance in this phenotype.",
    "label": "refute"
  },
  {
    "id": "training_659_2",
    "table_caption": "Table: glutametegic neurons. embryonic stem cells (n = 4) neural progenitor cells (n = 3) DIV 16 neurons (n = 5) iGluR class Gene Average SD Average SD Average SD AMPAR subunits Gria1 1.6 1.0 132.4 42.5 3964.2 187.2 Gria2 2.7 1.4 328.5 80.8 7393.6 390.0 Gria3 31.1 5.8 409.8 27.2 2201.8 116.4 Gria4 88.7 23.2 291.3 34.7 6621.4 628.8 KAR subunits Grik1 0.3 0.5 150.5 8.3 771.1 42.6 Grik2 4.1 1.9 160.8 27.0 1084.0 64.2 Grik3 301.2 65.5 128.8 13.5 807.7 36.1 Grik4 16.1 6.9 104.8 0.8 641.2 36.2 Grik5 334.0 103.2 1525.6 171.3 4617.2 152.4 NMDAR subunits Grin1 313.8 90.6 70.9 14.7 12398.0 514.1 Grin2a 6.0 1.4 3.7 1.3 795.9 67.2 Grin2b 23.0 9.4 11.9 3.6 1577.5 159.2 Grin2c 6.0 4.0 6.0 5.5 14.4 4.4 Grin2d 61.4 11.8 25.2 3.1 359.7 26.2 Grin3b 3.8 0.6 10.7 4.8 9.4 2.9 SNAP25 39.8 7.7 540.0 155.2 24639.3 1592.7 Adar1b 558.2 53.3 376.5 71.0 3070.7 119.8 The average pseudocount and standard deviation (SD) are presented for each iGluR subunit. Single copy is estimated to correspond to 100 pseudocounts in these doi:10.1371/journal.pone.0064423.t001 ",
    "table_content": "|| iGluR class | Gene | embryonic stem cells (n = 4) | embryonic stem cells (n = 4) | neural progenitor cells (n = 3) | neural progenitor cells (n = 3) | DIV 16 neurons (n = 5) | DIV 16 neurons (n = 5) ||\n|| iGluR class | Gene | Average | SD | Average | SD | Average | SD ||\n||  KAR subunits  |  Grik5  | 334.0 | 103.2 | 1525.6 | 171.3 | 4617.2 | 152.4 ||\n||  NMDAR subunits  |  Grin1  | 313.8 | 90.6 | 70.9 | 14.7 | 12398.0 | 514.1 ||\n||  NMDAR subunits  |  Grin2a  | 6.0 | 1.4 | 3.7 | 1.3 | 795.9 | 67.2 ||\n||  NMDAR subunits  |  Grin2b  | 23.0 | 9.4 | 11.9 | 3.6 | 1577.5 | 159.2 ||\n||  NMDAR subunits  |  Grin2c  | 6.0 | 4.0 | 6.0 | 5.5 | 14.4 | 4.4 ||\n||  NMDAR subunits  |  Grin2d  | 61.4 | 11.8 | 25.2 | 3.1 | 359.7 | 26.2 ||\n||  NMDAR subunits  |  Grin3b  | 3.8 | 0.6 | 10.7 | 4.8 | 9.4 | 2.9 ||\n||  NMDAR subunits  |  SNAP25  | 39.8 | 7.7 | 540.0 | 155.2 | 24639.3 | 1592.7 ||\n||  NMDAR subunits  |  Adar1b  | 558.2 | 53.3 | 376.5 | 71.0 | 3070.7 | 119.8 ||\n||  AMPAR subunits  |  Gria1  | 1.6 | 1.0 | 132.4 | 42.5 | 3964.2 | 187.2 ||\n||  AMPAR subunits  |  Gria2  | 2.7 | 1.4 | 328.5 | 80.8 | 7393.6 | 390.0 ||\n||  AMPAR subunits  |  Gria3  | 31.1 | 5.8 | 409.8 | 27.2 | 2201.8 | 116.4 ||\n||  AMPAR subunits  |  Gria4  | 88.7 | 23.2 | 291.3 | 34.7 | 6621.4 | 628.8 ||\n||  KAR subunits  |  Grik1  | 0.3 | 0.5 | 150.5 | 8.3 | 771.1 | 42.6 ||\n||  KAR subunits  |  Grik2  | 4.1 | 1.9 | 160.8 | 27.0 | 1084.0 | 64.2 ||\n||  KAR subunits  |  Grik3  | 301.2 | 65.5 | 128.8 | 13.5 | 807.7 | 36.1 ||\n||  KAR subunits  |  Grik4  | 16.1 | 6.9 | 104.8 | 0.8 | 641.2 | 36.2 ||",
    "claim": "The standard deviation of Gria2 expression in DIV 16 neurons is approximately 4.8 times higher than in embryonic stem cells, suggesting increased variability in expression as cells differentiate.",
    "label": "refute"
  },
  {
    "id": "training_659_2",
    "table_caption": "Table: glutametegic neurons. embryonic stem cells (n = 4) neural progenitor cells (n = 3) DIV 16 neurons (n = 5) iGluR class Gene Average SD Average SD Average SD AMPAR subunits Gria1 1.6 1.0 132.4 42.5 3964.2 187.2 Gria2 2.7 1.4 328.5 80.8 7393.6 390.0 Gria3 31.1 5.8 409.8 27.2 2201.8 116.4 Gria4 88.7 23.2 291.3 34.7 6621.4 628.8 KAR subunits Grik1 0.3 0.5 150.5 8.3 771.1 42.6 Grik2 4.1 1.9 160.8 27.0 1084.0 64.2 Grik3 301.2 65.5 128.8 13.5 807.7 36.1 Grik4 16.1 6.9 104.8 0.8 641.2 36.2 Grik5 334.0 103.2 1525.6 171.3 4617.2 152.4 NMDAR subunits Grin1 313.8 90.6 70.9 14.7 12398.0 514.1 Grin2a 6.0 1.4 3.7 1.3 795.9 67.2 Grin2b 23.0 9.4 11.9 3.6 1577.5 159.2 Grin2c 6.0 4.0 6.0 5.5 14.4 4.4 Grin2d 61.4 11.8 25.2 3.1 359.7 26.2 Grin3b 3.8 0.6 10.7 4.8 9.4 2.9 SNAP25 39.8 7.7 540.0 155.2 24639.3 1592.7 Adar1b 558.2 53.3 376.5 71.0 3070.7 119.8 The average pseudocount and standard deviation (SD) are presented for each iGluR subunit. Single copy is estimated to correspond to 100 pseudocounts in these doi:10.1371/journal.pone.0064423.t001 ",
    "table_content": "|| iGluR class | Gene | embryonic stem cells (n = 4) | embryonic stem cells (n = 4) | neural progenitor cells (n = 3) | neural progenitor cells (n = 3) | DIV 16 neurons (n = 5) | DIV 16 neurons (n = 5) ||\n|| iGluR class | Gene | Average | SD | Average | SD | Average | SD ||\n||  KAR subunits  |  Grik5  | 334.0 | 103.2 | 1525.6 | 171.3 | 4617.2 | 152.4 ||\n||  NMDAR subunits  |  Grin1  | 313.8 | 90.6 | 70.9 | 14.7 | 12398.0 | 514.1 ||\n||  NMDAR subunits  |  Grin2a  | 6.0 | 1.4 | 3.7 | 1.3 | 795.9 | 67.2 ||\n||  NMDAR subunits  |  Grin2b  | 23.0 | 9.4 | 11.9 | 3.6 | 1577.5 | 159.2 ||\n||  NMDAR subunits  |  Grin2c  | 6.0 | 4.0 | 6.0 | 5.5 | 14.4 | 4.4 ||\n||  NMDAR subunits  |  Grin2d  | 61.4 | 11.8 | 25.2 | 3.1 | 359.7 | 26.2 ||\n||  NMDAR subunits  |  Grin3b  | 3.8 | 0.6 | 10.7 | 4.8 | 9.4 | 2.9 ||\n||  NMDAR subunits  |  SNAP25  | 39.8 | 7.7 | 540.0 | 155.2 | 24639.3 | 1592.7 ||\n||  NMDAR subunits  |  Adar1b  | 558.2 | 53.3 | 376.5 | 71.0 | 3070.7 | 119.8 ||\n||  AMPAR subunits  |  Gria1  | 1.6 | 1.0 | 132.4 | 42.5 | 3964.2 | 187.2 ||\n||  AMPAR subunits  |  Gria2  | 2.7 | 1.4 | 328.5 | 80.8 | 7393.6 | 390.0 ||\n||  AMPAR subunits  |  Gria3  | 31.1 | 5.8 | 409.8 | 27.2 | 2201.8 | 116.4 ||\n||  AMPAR subunits  |  Gria4  | 88.7 | 23.2 | 291.3 | 34.7 | 6621.4 | 628.8 ||\n||  KAR subunits  |  Grik1  | 0.3 | 0.5 | 150.5 | 8.3 | 771.1 | 42.6 ||\n||  KAR subunits  |  Grik2  | 4.1 | 1.9 | 160.8 | 27.0 | 1084.0 | 64.2 ||\n||  KAR subunits  |  Grik3  | 301.2 | 65.5 | 128.8 | 13.5 | 807.7 | 36.1 ||\n||  KAR subunits  |  Grik4  | 16.1 | 6.9 | 104.8 | 0.8 | 641.2 | 36.2 ||",
    "claim": "The standard deviation of Gria2 expression in DIV 16 neurons is approximately 2.8 times higher than in embryonic stem cells, suggesting increased variability in expression as cells differentiate.",
    "label": "refute"
  },
  {
    "id": "training_1088_2",
    "table_caption": "Table: Table 1 Single- and dual-task gait measures. Condition-by-condition mean (± SD) measures of gait performance (N = 14) Single Task Dual Task 1 Dual Task 2 Anova F Anova p Stride Duration (ms) 1054 (± 87) 1060 (± 79) 1106 (± 107)*, ** 12.165 0.001 Mean Step Length (m) 0.53 (± 0.06) 0.52 (± 0.08) 0.51 (± 0.07) 0.0769 N.S. Velocity (m/s) 0.90 (± 0.10) 0.86 (± 0.10)* 0.78 (± 0.12)*, ** 34.215 0.001 ver-RMS 2.65 (± 0.56) 2.59 (± 0.55) 2.26 (± 0.63)*, ** 17.554 0.001 ml-RMS 1.48 (± 0.32) 1.47 (± 0.31) 1.37 (± 0.40)* 7.769 0.008 ap-RMS 2.19 (± 0.28) 2.09 (± 0.25) 0.96 (± 0.33)*, ** 16.946 0.001 ver-RMSR 0.70 (± 0.05) 0.70 (± 0.05) 0.67 (± 0.06)** 5.839 0.008 ml-RMSR 0.40 (± 0.07) 0.40 (± 0.06) 0.41 (± 0.08) 1.735 N.S. ap-RMSR 0.59 (± 0.06) 0.58 (± 0.053) 0.60 (± 0.06)** 7.165 0.003 ver-Step Regularity 0.75 (± 0.09) 0.69 (± 0.19) 0.69 (± 0.13) 2.027 N.S. ap-Step Regularity 0.76 (± 0.09) 0.73 (± 0.11) 0.71 (± 0.09)* 6.642 0.005 Repeated measures ANOVA p-values are reported in the right-side column. Statistically significant paired-samples t-test corrected for multiple comparisons are highlighted with * (ST vs DTi with i = 1, 2) and/or ** (DT1 vs. DT2). N.S., not significant ",
    "table_content": "|| blank | Single Task | Dual Task 1 | Dual Task 2 | Anova F | Anova p ||\n|| Stride Duration (ms) | 1054 (± 87) | 1060 (± 79) | 1106 (± 107)*, ** | 12.165 | 0.001 ||\n|| ver-Step Regularity | 0.75 (± 0.09) | 0.69 (± 0.19) | 0.69 (± 0.13) | 2.027 | N.S. ||\n|| ap-Step Regularity | 0.76 (± 0.09) | 0.73 (± 0.11) | 0.71 (± 0.09)* | 6.642 | 0.005 ||\n|| Mean Step Length (m) | 0.53 (± 0.06) | 0.52 (± 0.08) | 0.51 (± 0.07) | 0.0769 | N.S. ||\n|| Velocity (m/s) | 0.90 (± 0.10) | 0.86 (± 0.10)* | 0.78 (± 0.12)*, ** | 34.215 | 0.001 ||\n|| ver-RMS | 2.65 (± 0.56) | 2.59 (± 0.55) | 2.26 (± 0.63)*, ** | 17.554 | 0.001 ||\n|| ml-RMS | 1.48 (± 0.32) | 1.47 (± 0.31) | 1.37 (± 0.40)* | 7.769 | 0.008 ||\n|| ap-RMS | 2.19 (± 0.28) | 2.09 (± 0.25) | 0.96 (± 0.33)*, ** | 16.946 | 0.001 ||\n|| ver-RMSR | 0.70 (± 0.05) | 0.70 (± 0.05) | 0.67 (± 0.06)** | 5.839 | 0.008 ||\n|| ml-RMSR | 0.40 (± 0.07) | 0.40 (± 0.06) | 0.41 (± 0.08) | 1.735 | N.S. ||\n|| ap-RMSR | 0.59 (± 0.06) | 0.58 (± 0.053) | 0.60 (± 0.06)** | 7.165 | 0.003 ||",
    "claim": "The increase in velocity from Single Task to Dual Task 2, with a 13% rise, reflects a substantial impact of dual-tasking on gait speed, as supported by the high ANOVA F-value.",
    "label": "refute"
  },
  {
    "id": "training_316_2",
    "table_caption": "Table: TABLE 2 | Identiﬁcation of the two most abundant plant viruses in the tea plant. Contig ID Log2 of FPKM Functional annotation Putative coding protein GenBank ID Virus E-value of homology Identity % TR61686| c0_g2_i1 15.04 Polymerase YP_004901701.1 BNRBV 5.00E-150 34.75 TR91450| c2_g1_i1 4.47 Movement protein AGI44303.1 BNRBV 8.00E-51 39.13 TR91450| c2_g1_i2 5.81 Movement protein AGI44303.1 BNRBV 6.00E-49 39.13 TR46240| c4_g1_i1 17.09 Methyltransferase-helicase AGI44297.1 BNRBV 2.00E-35 34.17 TR91450| c3_g1_i1 15.57 p24 YP_004901704.1 BNRBV 1.00E-14 35.96 TR32524| c6_g2_i1 16.41 Putative virus replicase p1 NP_602312.1 APLPV 0 41.81 TR32524| c6_g1_i1 15.75 Putative polymerase p2 NP_602313.1 APLPV 1.00E-166 53.62 TR32524| c6_g3_i1 16.63 Putative movement protein 3a NP_602314.1 APLPV 1.00E-26 31.98 ",
    "table_content": "|| Contig ID | Log2 of FPKM | Functional annotation | Functional annotation | Functional annotation | Functional annotation | Functional annotation ||\n|| Contig ID | Log2 of FPKM | Putative coding protein | GenBank ID | Virus | E -value of homology | Identity % ||\n|| TR61686| c0_g2_i1 | 15.04 | Polymerase | YP_004901701.1 | BNRBV | 5.00E-150 | 34.75 ||\n|| TR91450| c2_g1_i1 | 4.47 | Movement protein | AGI44303.1 | BNRBV | 8.00E-51 | 39.13 ||\n|| TR91450| c2_g1_i2 | 5.81 | Movement protein | AGI44303.1 | BNRBV | 6.00E-49 | 39.13 ||\n|| TR46240| c4_g1_i1 | 17.09 | Methyltransferase-helicase | AGI44297.1 | BNRBV | 2.00E-35 | 34.17 ||\n|| TR91450| c3_g1_i1 | 15.57 | p24 | YP_004901704.1 | BNRBV | 1.00E-14 | 35.96 ||\n|| TR32524| c6_g2_i1 | 16.41 | Putative virus replicase p1 | NP_602312.1 | APLPV | 0 | 41.81 ||\n|| TR32524| c6_g1_i1 | 15.75 | Putative polymerase p2 | NP_602313.1 | APLPV | 1.00E-166 | 53.62 ||\n|| TR32524| c6_g3_i1 | 16.63 | Putative movement protein 3a | NP_602314.1 | APLPV | 1.00E-26 | 31.98 ||",
    "claim": "The functional annotations associated with APLPV, such as putative virus replicase p1 and putative polymerase p2, exhibit lower identity percentages compared to those associated with BNRBV, suggesting a less conserved protein function in APLPV.",
    "label": "refute"
  },
  {
    "id": "training_1430_1",
    "table_caption": "Table: Optical immunosensors for pesticides detection in food: main features and strategies. Sensing Technique Analyte Matrix Linear Dynamic Range LDR (M) Limit of Detection LOD (M) Recovery (%) Ref. SPR Triazine Bovine milk 1.00 × 10−7–1.50 × 10−6 (atrazine) 5.30 × 10−8 (atrazine) 94.9–103 (atrazine) [74] 92.6–95.8 (triazine) SPR Triazophos Chinese cabbage, cucumber, and apple 3.13 × 10−9–2.65 × 10−8 3.06 × 10−10 84.4–109 [75] SPR Fungicide Boscalid Cucumber, tomato, green sweet pepper, cabbage, spinach, and orange 4.95 × 10−8–2.33 × 10−7 85.0–109 [76] SPR Fungicide Chlorothalonil Lettuce, cabbage, and long green onion 3.01 × 10−8–1.65 × 10−7 90.0–118 [77] Fluorescence Triazophos Tap water, rice, cucumber, cabbage, and apple 3.19 × 10−11–6.38 × 10−8 1.92 × 10−11 85.0–110 [78] Colorimetry 7 pesticides simultaneously (triazophos, methyl-parathion, fenpropathrin, carbofuran, thiacloprid, chlorothalonil, and carbendazim) Cucumber, Chinese cabbage, tomato, apple, and pear 1.21 × 10−10–1.46 × 10−8 (triazophos) 6.38 × 10−11 (triazophos) 73.9–116 [79] 1.00 × 10−8–4.12 × 10−7 (methyl–parathion) 3.12 × 10−9 (methyl-parathion) 6.87 × 10−10–3.70 × 10−8 (fenpropathrin) 3.72 × 10−10 (fenpropathrin) 3.53 × 10−8–2.96 × 10−7 (carbofuran) 2.01 × 10−8 (carbofuran) 4.32 × 10−8–7.95 × 10−7 (thiacloprid) 2.55 × 10−8 (thiacloprid) 2.78 × 10−9–2.55 × 10−8 (chlorothalonil) 1.54 × 10−9 (chlorothalonil) 4.08 × 10−10–1.47 × 10−8 (carbendazim) 2.09 × 10−10 (carbendazim) ",
    "table_content": "|| Sensing Technique | Analyte | Matrix | Linear Dynamic Range LDR (M) | Limit of Detection LOD (M) | Recovery (%) | Ref. ||\n||  SPR  | Triazine | Bovine milk | 1.00 × 10 −7 –1.50 × 10 −6 (atrazine) | 5.30 × 10 −8 (atrazine) | 94.9–103 (atrazine) | [ 74 ] ||\n||  Colorimetry  | 7 pesticides simultaneously (triazophos, methyl-parathion, fenpropathrin, carbofuran, thiacloprid, chlorothalonil, and carbendazim) | Cucumber, Chinese cabbage, tomato, apple, and pear | 3.53 × 10 −8 –2.96 × 10 −7 (carbofuran) | 2.01 × 10 −8 (carbofuran) | 73.9–116 | [ 79 ] ||\n||  Colorimetry  | 7 pesticides simultaneously (triazophos, methyl-parathion, fenpropathrin, carbofuran, thiacloprid, chlorothalonil, and carbendazim) | Cucumber, Chinese cabbage, tomato, apple, and pear | 4.32 × 10 −8 –7.95 × 10 −7 (thiacloprid) | 2.55 × 10 −8 (thiacloprid) | 73.9–116 | [ 79 ] ||\n||  Colorimetry  | 7 pesticides simultaneously (triazophos, methyl-parathion, fenpropathrin, carbofuran, thiacloprid, chlorothalonil, and carbendazim) | Cucumber, Chinese cabbage, tomato, apple, and pear | 2.78 × 10 −9 –2.55 × 10 −8 (chlorothalonil) | 1.54 × 10 −9 (chlorothalonil) | 73.9–116 | [ 79 ] ||\n||  Colorimetry  | 7 pesticides simultaneously (triazophos, methyl-parathion, fenpropathrin, carbofuran, thiacloprid, chlorothalonil, and carbendazim) | Cucumber, Chinese cabbage, tomato, apple, and pear | 4.08 × 10 −10 –1.47 × 10 −8 (carbendazim) | 2.09 × 10 −10 (carbendazim) | 73.9–116 | [ 79 ] ||\n||  SPR  | Triazine | Bovine milk | 1.00 × 10 −7 –1.50 × 10 −6 (atrazine) | 5.30 × 10 −8 (atrazine) | 92.6–95.8 (triazine) | [ 74 ] ||\n||  SPR  | Triazophos | Chinese cabbage, cucumber, and apple | 3.13 × 10 −9 –2.65 × 10 −8 | 3.06 × 10 −10 | 84.4–109 | [ 75 ] ||\n||  SPR  | Fungicide Boscalid | Cucumber, tomato, green sweet pepper, cabbage, spinach, and orange | 4.95 × 10 −8 –2.33 × 10 −7 | blank | 85.0–109 | [ 76 ] ||\n||  SPR  | Fungicide Chlorothalonil | Lettuce, cabbage, and long green onion | 3.01 × 10 −8 –1.65 × 10 −7 | blank | 90.0–118 | [ 77 ] ||\n||  Fluorescence  | Triazophos | Tap water, rice, cucumber, cabbage, and apple | 3.19 × 10 −11 –6.38 × 10 −8 | 1.92 × 10 −11 | 85.0–110 | [ 78 ] ||\n||  Colorimetry  | 7 pesticides simultaneously (triazophos, methyl-parathion, fenpropathrin, carbofuran, thiacloprid, chlorothalonil, and carbendazim) | Cucumber, Chinese cabbage, tomato, apple, and pear | 1.21 × 10 −10 –1.46 × 10 −8 (triazophos) | 6.38 × 10 −11 (triazophos) | 73.9–116 | [ 79 ] ||\n||  Colorimetry  | 7 pesticides simultaneously (triazophos, methyl-parathion, fenpropathrin, carbofuran, thiacloprid, chlorothalonil, and carbendazim) | Cucumber, Chinese cabbage, tomato, apple, and pear | 1.00 × 10 −8 –4.12 × 10 −7 (methyl–parathion) | 3.12 × 10 −9 (methyl-parathion) | 73.9–116 | [ 79 ] ||\n||  Colorimetry  | 7 pesticides simultaneously (triazophos, methyl-parathion, fenpropathrin, carbofuran, thiacloprid, chlorothalonil, and carbendazim) | Cucumber, Chinese cabbage, tomato, apple, and pear | 6.87 × 10 −10 –3.70 × 10 −8 (fenpropathrin) | 3.72 × 10 −10 (fenpropathrin) | 73.9–116 | [ 79 ] ||",
    "claim": "The Fluorescence technique for detecting Triazophos in tap water, rice, cucumber, cabbage, and apple achieves a limit of detection that is approximately 16 times higher than the SPR technique for the same analyte in Chinese cabbage, cucumber, and apple, indicating a superior sensitivity of the SPR method for this pesticide.",
    "label": "refute"
  },
  {
    "id": "training_853_3",
    "table_caption": "Table: List of mutagenesis and selection media for attempts to generate a null rpoN mutant. Mutagenesis Selection medium (electron donor/acceptor) 1. Deletion and replacement of the rpoN gene by double-crossover (Figure 1b) Acetate/fumarate Acetate/Fe(III) citrate Acetate/Fe(III) citrate amended with glutamine Acetate/Fe(III) citrate amended with glutamate Acetate/Fe(III) citrate amended with both glutamine and glutamate 2. Deletion and replacement of the 5'-end of the rpoN gene by double- crossover (Figure 1b) Acetate/fumarate Acetate/Fe(III) citrate 3. Deletion and replacement of the 3'-end of the rpoN gene by double- crossover (Figure 1b) Acetate/fumarate Acetate/Fe(III) citrate 4. Deletion and replacement of the upstream intergenic region of the rpoN gene by double-crossover (Figure 1a) Acetate/fumarate 5. Deletion and replacement of the downstream intergenic region of the rpoN gene by double-crossover (Figure 1a) Acetate/fumarate 6. Integration of a linear DNA fragment on the chromosome, providing another copy of the rpoN gene on another location of the chromosome (Figure 1c) Acetate/fumarate Acetate/Fe(III) citrate 7. Integration of a linear DNA fragment on the chromosome, providing another copy of the rpoN gene in trans, which is either constitutively expressed by a lac promoter, or is IPTG inducible (Figure 1d) Acetate/fumarate Acetate/Fe(III) citrate Acetate/Fe(III) citrate amended with both glutamine and glutamate ",
    "table_content": "|| Mutagenesis | Selection medium (electron donor/acceptor) ||\n|| 1. Deletion and replacement of the rpoN gene by double-crossover (Figure 1b) | Acetate/fumarate ||\n|| 4. Deletion and replacement of the upstream intergenic region of the rpoN gene by double-crossover (Figure 1a) | Acetate/fumarate ||\n|| 5. Deletion and replacement of the downstream intergenic region of the rpoN gene by double-crossover (Figure 1a) | Acetate/fumarate ||\n|| 6. Integration of a linear DNA fragment on the chromosome, providing another copy of the rpoN gene on another location of the chromosome (Figure 1c) | Acetate/fumarate ||\n|| 6. Integration of a linear DNA fragment on the chromosome, providing another copy of the rpoN gene on another location of the chromosome (Figure 1c) | Acetate/Fe(III) citrate ||\n|| 7. Integration of a linear DNA fragment on the chromosome, providing another copy of the rpoN gene in trans , which is either constitutively expressed by a lac promoter, or is IPTG inducible (Figure 1d) | Acetate/fumarate ||\n|| 7. Integration of a linear DNA fragment on the chromosome, providing another copy of the rpoN gene in trans , which is either constitutively expressed by a lac promoter, or is IPTG inducible (Figure 1d) | Acetate/Fe(III) citrate ||\n|| 7. Integration of a linear DNA fragment on the chromosome, providing another copy of the rpoN gene in trans , which is either constitutively expressed by a lac promoter, or is IPTG inducible (Figure 1d) | Acetate/Fe(III) citrate amended with both glutamine and glutamate ||\n|| 1. Deletion and replacement of the rpoN gene by double-crossover (Figure 1b) | Acetate/Fe(III) citrate ||\n|| 1. Deletion and replacement of the rpoN gene by double-crossover (Figure 1b) | Acetate/Fe(III) citrate amended with glutamine ||\n|| 1. Deletion and replacement of the rpoN gene by double-crossover (Figure 1b) | Acetate/Fe(III) citrate amended with glutamate ||\n|| 1. Deletion and replacement of the rpoN gene by double-crossover (Figure 1b) | Acetate/Fe(III) citrate amended with both glutamine and glutamate ||\n|| 2. Deletion and replacement of the 5'-end of the rpoN gene by double-crossover (Figure 1b) | Acetate/fumarate ||\n|| 2. Deletion and replacement of the 5'-end of the rpoN gene by double-crossover (Figure 1b) | Acetate/Fe(III) citrate ||\n|| 3. Deletion and replacement of the 3'-end of the rpoN gene by double-crossover (Figure 1b) | Acetate/fumarate ||\n|| 3. Deletion and replacement of the 3'-end of the rpoN gene by double-crossover (Figure 1b) | Acetate/Fe(III) citrate ||",
    "claim": "The integration of a linear DNA fragment on the chromosome providing another copy of the rpoN gene in trans (Figure 1d) involves the most complex selection media, as it includes amendments with both glutamine and glutamate, reflecting a more intricate approach to selection.",
    "label": "refute"
  },
  {
    "id": "training_649_5",
    "table_caption": "Table: The organ coefficients (%) of all test groups. Group Liver (g) Liver / body weight (%) Epididymal adiopse (g) Epididymal adipose / body weight (%) Normal 3.03 ± 0.08 c 2.60 ± 0.10 c 2.18 ± 0.16ab 1.85 ± 0.26 a Control 3.96 ± 0.18 a 3.38 ± 0.14 a 2.49 ± 0.18ab 2.16 ± 0.13 a 1.6FFAP 3.41 ± 0.13 b 3.00 ± 0.16 b 2.00 ± 0.11c 1.79 ± 0.18 b 3.2FFAP 3.40 ± 0.21 b 2.95 ± 0.12 b 1.99 ± 0.12c 1.71 ± 0.22 b 8.0FFAP 3.40 ± 0.10 b 3.13 ± 0.19 b 1.90 ± 0.10 c 1.71 ± 0.18 b Result suggested that FFAP diets signiﬁcantly decreased liver weights (3.41±0.13g, 3.40±0.21g and 3.40±0.1g, respectively) and epididymal adipose levels. All values are Mean ± SD, n = 9. All data was tested using Duncan’s multiple range tests, where signiﬁcance between groups (p<0.05) is denoted ",
    "table_content": "|| Group | Liver (g) | Liver / body weight (%) | Epididymal adiopse (g) | Epididymal adipose / body weight (%) ||\n||  Normal  | 3.03 ± 0.08 c  | 2.60 ± 0.10 c  | 2.18 ± 0.16 ab  | 1.85 ± 0.26 a  ||\n||  Control  | 3.96 ± 0.18 a  | 3.38 ± 0.14 a  | 2.49 ± 0.18 ab  | 2.16 ± 0.13 a  ||\n||  1.6FFAP  | 3.41 ± 0.13 b  | 3.00 ± 0.16 b  | 2.00 ± 0.11 c  | 1.79 ± 0.18 b  ||\n||  3.2FFAP  | 3.40 ± 0.21 b  | 2.95 ± 0.12 b  | 1.99 ± 0.12 c  | 1.71 ± 0.22 b  ||\n||  8.0FFAP  | 3.40 ± 0.10 b  | 3.13 ± 0.19 b  | 1.90 ± 0.10 c  | 1.71 ± 0.18 b  ||",
    "claim": "Increasing FFAP concentration from 1.6 to 8.0 significantly alters liver weight and epididymal adipose weight, as the values vary considerably across these groups. This suggests that the concentration of FFAP, rather than its mere introduction, is the primary factor in reducing organ weights.",
    "label": "refute"
  },
  {
    "id": "training_909_2",
    "table_caption": "Table: on the the for for 1). of 2 studies (right). Studies within all specialities CAM-related studies Country n = % Country n = % USA 315 36.0 USA 114 24.9 United Kingdom 117 13.4 China 113 24.7 Canada 46 5.3 United Kingdom 59 12.9 Australia 32 3.7 Germany 17 3.7 Sweden 32 3.7 Italy 13 2.8 Germany 31 3.5 Denmark 11 2.4 Italy 30 3.4 Netherlands 10 2.2 Netherlands 25 2.9 Australia 10 2.2 France 24 2.7 Canada 10 2.2 Denmark 21 2.4 Japan 10 2.2 Japan 19 2.2 India 9 2.0 China 17 1.9 Sweden 8 1.7 Finland 17 1.9 Finland 6 1.3 India 14 1.6 France 6 1.3 Spain 12 1.4 Israel 5 1.1 Israel 10 1.1 Hungary 5 1.1 Switzerland 8 0.9 Norway 4 0.9 Belgium 7 0.8 Taiwan 4 0.9 Ireland 7 0.8 Poland 4 0.9 Austria 6 0.7 Switzerland 3 0.7 Norway 6 0.7 Romania 3 0.7 South Africa 6 0.7 Spain 3 0.7 Greece 5 0.6 South Africa 3 0.7 Mexico 5 0.6 Nigeria 3 0.7 Turkey 5 0.6 Brazil 3 0.7 Brazil 3 0.3 New Zealand 2 0.4 Czech Republic 3 0.3 Austria 2 0.4 Hungary 3 0.3 Belgium 2 0.4 New Zealand 3 0.3 Russia 2 0.4 Taiwan 3 0.3 Chile 2 0.4 doi:10.1371/journal.pone.0018798.t001 ",
    "table_content": "|| Studies within all specialities | Studies within all specialities | Studies within all specialities | CAM-related studies | CAM-related studies | CAM-related studies ||\n|| Country | n = | % | Country | n = | % ||\n|| France | 24 | 2.7 | Canada | 10 | 2.2 ||\n|| Denmark | 21 | 2.4 | Japan | 10 | 2.2 ||\n|| Japan | 19 | 2.2 | India | 9 | 2.0 ||\n|| China | 17 | 1.9 | Sweden | 8 | 1.7 ||\n|| Finland | 17 | 1.9 | Finland | 6 | 1.3 ||\n|| India | 14 | 1.6 | France | 6 | 1.3 ||\n|| Spain | 12 | 1.4 | Israel | 5 | 1.1 ||\n|| Israel | 10 | 1.1 | Hungary | 5 | 1.1 ||\n|| Switzerland | 8 | 0.9 | Norway | 4 | 0.9 ||\n|| Belgium | 7 | 0.8 | Taiwan | 4 | 0.9 ||\n|| USA | 315 | 36.0 | USA | 114 | 24.9 ||\n|| Ireland | 7 | 0.8 | Poland | 4 | 0.9 ||\n|| Austria | 6 | 0.7 | Switzerland | 3 | 0.7 ||\n|| Norway | 6 | 0.7 | Romania | 3 | 0.7 ||\n|| South Africa | 6 | 0.7 | Spain | 3 | 0.7 ||\n|| Greece | 5 | 0.6 | South Africa | 3 | 0.7 ||\n|| Mexico | 5 | 0.6 | Nigeria | 3 | 0.7 ||\n|| Turkey | 5 | 0.6 | Brazil | 3 | 0.7 ||\n|| Brazil | 3 | 0.3 | New Zealand | 2 | 0.4 ||\n|| Czech Republic | 3 | 0.3 | Austria | 2 | 0.4 ||\n|| Hungary | 3 | 0.3 | Belgium | 2 | 0.4 ||\n|| United Kingdom | 117 | 13.4 | China | 113 | 24.7 ||\n|| New Zealand | 3 | 0.3 | Russia | 2 | 0.4 ||\n|| Taiwan | 3 | 0.3 | Chile | 2 | 0.4 ||\n|| Canada | 46 | 5.3 | United Kingdom | 59 | 12.9 ||\n|| Australia | 32 | 3.7 | Germany | 17 | 3.7 ||\n|| Sweden | 32 | 3.7 | Italy | 13 | 2.8 ||\n|| Germany | 31 | 3.5 | Denmark | 11 | 2.4 ||\n|| Italy | 30 | 3.4 | Netherlands | 10 | 2.2 ||\n|| Netherlands | 25 | 2.9 | Australia | 10 | 2.2 ||",
    "claim": "China exhibits a high focus on CAM-related studies, with its percentage of CAM studies nearly matching that of all studies, suggesting a strong emphasis on CAM research. Conversely, countries like France and Finland show a marked decrease in their percentage of CAM-related studies compared to all studies, indicating a lesser focus on CAM.",
    "label": "refute"
  },
  {
    "id": "training_1460_7",
    "table_caption": "Table: Completed suicide Chi- square P value ORa. 95% CI P value n = 95 n (%) No completed suicide n = 950 n (%) Education 21.771 < 0.0001 < 9 years (ref.) 24(25.26) 112(11.79) 1 9–12 years 35(36.84) 276(29.05) 0.52 0.25–1.07 0.078 > 12 years 17(17.89) 327(34.42) 0.17 0.07–0.41 < 0.0001 Unknown 19(20.0) 235(24.74) 0.97 0.14–6.55 0.973 Marital status 26.684 < 0.0001 Married (ref.) 52(54.74) 623(65.58) 1 Never married 17(17.89) 73(7.68) 2.51 1.10–5.75 0.029 Widowed/divorced 9 (9.47) 24(2.53) 3.43 0.99–11.87 0.052 Unknown 17(17.89) 230(24.21) 0.31 0.04–2.26 0.249 Delivery method 0.542 0.462 Vaginal delivery (ref.) 58(61.05) 616(64.84) 1 Caesarean delivery 37(38.95) 334(35.16) 0.69 0.39–1.23 0.204 Infant sex 3.190 0.074 Male (ref.) 43(45.26) 521(54.84) 1 Female 52(54.74) 429(45.16) 1.57 0.92–2.69 0.099 Low birth weight 20.879 < 0.0001 ≥ 2500 g (ref.) 79(83.16) 902(94.95) 1 < 2500 g 16(16.84) 48(5.05) 2.89 1.30–6.39 0.009 Pre-eclampsia/eclampsia 7.7389 0.005 No (ref.) 90(94.74) 937(98.63) 1 Yes 5(5.26) 13(1.37) 2.06 0.46–9.20 0.342 Anxiety 52.819 < 0.0001 No (ref.) 83(87.37) 939(98.84) 1 Yes 12(12.63) 11(1.16) 10.71 2.40–47.75 0.002 Mood disorder 102.2399 < 0.0001 No (ref.) 78(82.11) 941(99.05) 1 Yes 17(17.89) 9(0.95) 5.82 1.85–18.38 0.003 Postpartum depressive disorder 190.338 < 0.0001 No (ref.) 66(69.47) 937(98.63) 1 Yes 29(30.53) 13(1.37) 21.72 8.08–58.37 < 0.0001 Table 2. Risk of completed suicide within 1 year post partum stratified by perinatal and other associated factors (n = 1045). The OR (odds ratio) was calculated by performing conditional logistic regression ",
    "table_content": "|| blank | Completed suicide | Completed suicide | Chi- square | P value | OR a. | 95% CI | P value ||\n|| blank | n = 95 n (%) | No completed suicide n = 950 n (%) | Chi- square | P value | OR a. | 95% CI | P value ||\n|| Widowed/divorced | 9 (9.47) | 24(2.53) | blank | blank | 3.43 | 0.99–11.87 | 0.052 ||\n|| Unknown | 17(17.89) | 230(24.21) | blank | blank | 0.31 | 0.04–2.26 | 0.249 ||\n|| Delivery method | blank | blank | 0.542 | 0.462 | blank | blank | blank ||\n|| Vaginal delivery (ref.) | 58(61.05) | 616(64.84) | blank | blank | 1 | blank | blank ||\n|| Caesarean delivery | 37(38.95) | 334(35.16) | blank | blank | 0.69 | 0.39–1.23 | 0.204 ||\n|| Infant sex | blank | blank | 3.190 | 0.074 | blank | blank | blank ||\n|| Male (ref.) | 43(45.26) | 521(54.84) | blank | blank | 1 | blank | blank ||\n|| Female | 52(54.74) | 429(45.16) | blank | blank | 1.57 | 0.92–2.69 | 0.099 ||\n|| Low birth weight | blank | blank | 20.879 | <0.0001 | blank | blank | blank ||\n|| ≥2500 g (ref.) | 79(83.16) | 902(94.95) | blank | blank | 1 | blank | blank ||\n|| Education | blank | blank | 21.771 | <0.0001 | blank | blank | blank ||\n|| <2500 g | 16(16.84) | 48(5.05) | blank | blank | 2.89 | 1.30–6.39 | 0.009 ||\n|| Pre-eclampsia/eclampsia | blank | blank | 7.7389 | 0.005 | blank | blank | blank ||\n|| No (ref.) | 90(94.74) | 937(98.63) | blank | blank | 1 | blank | blank ||\n|| Yes | 5(5.26) | 13(1.37) | blank | blank | 2.06 | 0.46–9.20 | 0.342 ||\n|| Anxiety | blank | blank | 52.819 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 83(87.37) | 939(98.84) | blank | blank | 1 | blank | blank ||\n|| Yes | 12(12.63) | 11(1.16) | blank | blank | 10.71 | 2.40–47.75 | 0.002 ||\n|| Mood disorder | blank | blank | 102.2399 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 78(82.11) | 941(99.05) | blank | blank | 1 | blank | blank ||\n|| Yes | 17(17.89) | 9(0.95) | blank | blank | 5.82 | 1.85–18.38 | 0.003 ||\n|| <9 years (ref.) | 24(25.26) | 112(11.79) | blank | blank | 1 | blank | blank ||\n|| Postpartum depressive disorder | blank | blank | 190.338 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 66(69.47) | 937(98.63) | blank | blank | 1 | blank | blank ||\n|| Yes | 29(30.53) | 13(1.37) | blank | blank | 21.72 | 8.08–58.37 | <0.0001 ||\n|| 9–12 years | 35(36.84) | 276(29.05) | blank | blank | 0.52 | 0.25–1.07 | 0.078 ||\n|| > 12 years | 17(17.89) | 327(34.42) | blank | blank | 0.17 | 0.07–0.41 | <0.0001 ||\n|| Unknown | 19(20.0) | 235(24.74) | blank | blank | 0.97 | 0.14–6.55 | 0.973 ||\n|| Marital status | blank | blank | 26.684 | <0.0001 | blank | blank | blank ||\n|| Married (ref.) | 52(54.74) | 623(65.58) | blank | blank | 1 | blank | blank ||\n|| Never married | 17(17.89) | 73(7.68) | blank | blank | 2.51 | 1.10–5.75 | 0.029 ||",
    "claim": "Anxiety is weakly associated with an increased risk of completed suicide, with an odds ratio of 1.71, indicating a less than twofold increase in risk, which is statistically significant with a p-value of 0.002.",
    "label": "refute"
  },
  {
    "id": "training_306_1",
    "table_caption": "Table: in in table 1. Comparison of age at first myocardial infarction Region Medium age, women Medium age, men Western Europe 68 61 Central and Eastern Europe 68 59 North America 64 58 South America and Mexico 65 69 Australia and New Zealand 66 58 Middle East 57 50 South Asia 60 52 Africa 56 52 China 67 60 South-east Asia and Japan 63 55 Ethnic origin European 68 59 Chinese 67 60 South Asian 60 50 Other Asian 63 55 Arab 57 52 Latin American 64 58 Black African 54 52 Coloured African 58 52 Other 63 53 Overall 65 56 ",
    "table_content": "|| Region | Medium age, women | Medium age, men ||\n|| Western Europe | 68 | 61 ||\n|| South-east Asia and Japan | 63 | 55 ||\n|| Ethnic origin | Ethnic origin | Ethnic origin ||\n|| European | 68 | 59 ||\n|| Chinese | 67 | 60 ||\n|| South Asian | 60 | 50 ||\n|| Other Asian | 63 | 55 ||\n|| Arab | 57 | 52 ||\n|| Latin American | 64 | 58 ||\n|| Black African | 54 | 52 ||\n|| Coloured African | 58 | 52 ||\n|| Central and Eastern Europe | 68 | 59 ||\n|| Other | 63 | 53 ||\n|| Overall | 65 | 56 ||\n|| North America | 64 | 58 ||\n|| South America and Mexico | 65 | 69 ||\n|| Australia and New Zealand | 66 | 58 ||\n|| Middle East | 57 | 50 ||\n|| South Asia | 60 | 52 ||\n|| Africa | 56 | 52 ||\n|| China | 67 | 60 ||",
    "claim": "Across all regions and ethnic groups, women experience their first myocardial infarction at a median age that is consistently higher than that of men. The average difference in age between women and men is approximately 7 years, indicating a significant gender disparity in the onset of heart attacks.",
    "label": "refute"
  },
  {
    "id": "training_1050_3",
    "table_caption": "Table: children teacher between diﬃculty prenatal the housing as level were parental 2. size their TABLE 2 | Mean (SD) of teacher ratings of child behavior using SDQ according to the LOC orientation of the child’s parents as measured in pregnancy. Child behavior M.Ex. F.Ex M.Ex. F.In M.In. F.Ex M.In. F.In Hyperactivity Year 3 2.99 [2.79] 2.57 [2.66]∗∗ 2.40 [2.58] 2.07 [2.40]∗∗ Year 6 2.74 [2.84] 2.00 [2.39]∗∗∗ 2.16 [2.56]a 1.66 [2.28]∗∗∗ Emotional problems Year 3 1.53 [2.05] 1.43 [2.01] 1.30 [1.85] 1.19 [1.74] Year 6 1.44 [1.97] 1.28 [1.92] 1.28 [1.84] 1.13 [1.70]∗ Conduct problems Year 3 0.87 [1.61] 0.72 [1.38]∗ 0.59 [1.26] 0.53 [1.13] Year 6 1.02 [1.74] 0.61 [1.26]∗∗∗ 0.77 [1.55]a 0.56 [1.27]∗∗∗ Peer problems Year 3 1.26 [1.81] 1.19 [1.81] 1.06 [1.72] 1.04 [1.67] Year 6 1.28 [1.90] 1.07 [1.71]∗ 1.25 [1.93] 1.11 [1.80] Total difﬁculties Year 3 6.66 [5.97] 5.91 [5.59]∗∗ 5.34 [5.26] 4.83 [5.01]∗ Year 6 6.47 [6.23] 4.96 [5.01]∗∗∗ 5.46 [5.85]a 4.46 [5.18]∗∗∗ aDifference between M.Ex.F.In and M.In.F.Ex: P < 0.05. (The higher the score, the worse the behavior.) [Asterisks indicate differences between the pairs of father orientation as ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.] ",
    "table_content": "|| Child behavior | M.Ex. F.Ex | M.Ex. F.In | M.In. F.Ex | M.In. F.In ||\n|| Hyperactivity | Hyperactivity | Hyperactivity | Hyperactivity | Hyperactivity ||\n|| Peer problems | Peer problems | Peer problems | Peer problems | Peer problems ||\n|| Year 3 | 1.26 [1.81] | 1.19 [1.81] | 1.06 [1.72] | 1.04 [1.67] ||\n|| Year 6 | 1.28 [1.90] | 1.07 [1.71] ∗ | 1.25 [1.93] | 1.11 [1.80] ||\n|| Total difficulties | Total difficulties | Total difficulties | Total difficulties | Total difficulties ||\n|| Year 3 | 6.66 [5.97] | 5.91 [5.59] ∗∗ | 5.34 [5.26] | 4.83 [5.01] ∗ ||\n|| Year 6 | 6.47 [6.23] | 4.96 [5.01] ∗∗∗ | 5.46 [5.85] a | 4.46 [5.18] ∗∗∗ ||\n|| Year 3 | 2.99 [2.79] | 2.57 [2.66] ∗∗ | 2.40 [2.58] | 2.07 [2.40] ∗∗ ||\n|| Year 6 | 2.74 [2.84] | 2.00 [2.39] ∗∗∗ | 2.16 [2.56] a | 1.66 [2.28] ∗∗∗ ||\n|| Emotional problems | Emotional problems | Emotional problems | Emotional problems | Emotional problems ||\n|| Year 3 | 1.53 [2.05] | 1.43 [2.01] | 1.30 [1.85] | 1.19 [1.74] ||\n|| Year 6 | 1.44 [1.97] | 1.28 [1.92] | 1.28 [1.84] | 1.13 [1.70] ∗ ||\n|| Conduct problems | Conduct problems | Conduct problems | Conduct problems | Conduct problems ||\n|| Year 3 | 0.87 [1.61] | 0.72 [1.38] ∗ | 0.59 [1.26] | 0.53 [1.13] ||\n|| Year 6 | 1.02 [1.74] | 0.61 [1.26] ∗∗∗ | 0.77 [1.55] a | 0.56 [1.27] ∗∗∗ ||",
    "claim": "The conduct problems score for children with M.Ex. F.In parents decreased by approximately 15%, while the score for children with M.In. F.Ex parents decreased by about 30%, highlighting a divergent trend in behavior based on parental LOC orientation.",
    "label": "refute"
  },
  {
    "id": "training_723_1",
    "table_caption": "Table: of levels that is associated with an increase in telomere length. Outcome Percentage Change (95% CI) p-Value Systolic BP (mmHg) 0.2 (21.1, 1.5) p = 0.798 Diastolic BP (mmHg) 0.3 (21.0, 1.7) p = 0.642 Cholesterol (mmol/l) 2.4 (0.3, 4.6) p = 0.027 HDL cholesterol (mmol/l) 21.2 (23.9, 1.6) p = 0.387 LDL cholesterol (mmol/l) 3.7 (0.4, 7.1) p = 0.027 Triglycerides (mmol/l) 2.7 (22.6, 8.3) p = 0.326 Glucose (mmol/l) 0.8 (21.0, 2.7) p = 0.363 Insulin (mU/l) 20.5 (27.5, 6.9) p = 0.884 HOMA - IR 20.1 (27.5, 8.0) p = 0.989 C reactive protein (mg/l) 0.6 (29.9, 12.4) p = 0.916 Interleukin 6 (pg/ml) 27.2 (212.9, 21.1) p = 0.022 Intercellular adhesion molecule 1 (ng/ml) 20.3 (22.9, 2.3) p = 0.796 Fibrinogen (g/l) 0.2 (21.9, 2.4) p = 0.829 von Willebrand factor (IU/dl) 21.2 (24.2, 1.8) p = 0.416 D-dimer (ng/ml) 21.7 (27.4, 4.4) p = 0.583 Individuals with longer telomeres had increased levels of total cholesterol (2.4% increase, p = 0.027) and LDL cholesterol (3.7%, p = 0.027). Conversely, shorter ",
    "table_content": "|| Outcome | Percentage Change (95% CI)p-Value ||\n|| Systolic BP (mmHg) | 0.2 (−1.1, 1.5) p = 0.798 ||\n|| C reactive protein (mg/l) | 0.6 (−9.9, 12.4) p = 0.916 ||\n|| Interleukin 6 (pg/ml) |  −7.2 (−12.9, −1.1) p = 0.022  ||\n|| Intercellular adhesion molecule 1 (ng/ml) | −0.3 (−2.9, 2.3) p = 0.796 ||\n|| Fibrinogen (g/l) | 0.2 (−1.9, 2.4) p = 0.829 ||\n|| von Willebrand factor (IU/dl) | −1.2 (−4.2, 1.8) p = 0.416 ||\n|| D-dimer (ng/ml) | −1.7 (−7.4, 4.4) p = 0.583 ||\n|| Diastolic BP (mmHg) | 0.3 (−1.0, 1.7) p = 0.642 ||\n|| Cholesterol (mmol/l) | 2.4 (0.3, 4.6) p = 0.027 ||\n|| HDL cholesterol (mmol/l) | −1.2 (−3.9, 1.6) p = 0.387 ||\n|| LDL cholesterol (mmol/l) |  3.7 (0.4, 7.1) p = 0.027  ||\n|| Triglycerides (mmol/l) | 2.7 (−2.6, 8.3) p = 0.326 ||\n|| Glucose (mmol/l) | 0.8 (−1.0, 2.7) p = 0.363 ||\n|| Insulin (mU/l) | −0.5 (−7.5, 6.9) p = 0.884 ||\n|| HOMA - IR | −0.1 (−7.5, 8.0) p = 0.989 ||",
    "claim": "The increase in LDL cholesterol is statistically significant, with a p-value of 0.027. This suggests a robust association between longer telomeres and higher LDL cholesterol levels, although the confidence interval includes zero, indicating no consistent positive change.",
    "label": "refute"
  },
  {
    "id": "training_877_2",
    "table_caption": "Table: Table 2 Badapple datasets BARD assay counts are experiment counts. Tested means bioassay data exist. Nonzero means tested with nonzero scores #scafs Tested Nonzero #assy Activities Date Source Bard1 146,024 141,642 54,136 510 30M 2013-01 BARD Bard2 143,098 137,668 52,328 383 46M 2014-06 BARD Pc1 143,098 141,533 60,200 822 223M 2014-06 PubChem Pc2 143,098 125,940 50,912 527 113M 2010-12 PubChem ",
    "table_content": "|| blank | #scafs | Tested | Nonzero | #assy | Activities | Date | Source ||\n|| Bard1 | 146,024 | 141,642 | 54,136 | 510 | 30M | 2013-01 | BARD ||\n|| Bard2 | 143,098 | 137,668 | 52,328 | 383 | 46M | 2014-06 | BARD ||\n|| Pc1 | 143,098 | 141,533 | 60,200 | 822 | 223M | 2014-06 | PubChem ||\n|| Pc2 | 143,098 | 125,940 | 50,912 | 527 | 113M | 2010-12 | PubChem ||",
    "claim": "The ratio of nonzero scores to tested assays is highest in Bard1, suggesting a higher proportion of active compounds in this dataset. This is calculated by dividing the nonzero scores by the tested assays for each dataset and comparing the ratios.",
    "label": "refute"
  },
  {
    "id": "training_985_4",
    "table_caption": "Table: Consort statement describing subject flow Number of patients Eligible for inclusion 142 Parents accepting participation 34 First polysomnography 34 Drop-outs 6 Acute disease at 2nd polysomnography 2 Refusal of second polysomnography 2 Poor technical quality of the second recording 1 Werdnig-Hoffman myopathy 1 Second polysomnography 28 Osteopathy 15 Non-specific treatment 13 ",
    "table_content": "|| blank | Number of patients ||\n|| Eligible for inclusion | 142 ||\n|| Osteopathy | 15 ||\n|| Non-specific treatment | 13 ||\n|| Parents accepting participation | 34 ||\n|| First polysomnography | 34 ||\n|| Drop-outs | 6 ||\n|| Acute disease at 2 nd polysomnography | 2 ||\n|| Refusal of second polysomnography | 2 ||\n|| Poor technical quality of the second recording | 1 ||\n|| Werdnig-Hoffman myopathy | 1 ||\n|| Second polysomnography | 28 ||",
    "claim": "The presence of Werdnig-Hoffman myopathy and acute disease accounted for 10.71% of the reasons for not completing the second polysomnography, calculated by considering the specific conditions listed.",
    "label": "refute"
  },
  {
    "id": "training_985_4",
    "table_caption": "Table: Consort statement describing subject flow Number of patients Eligible for inclusion 142 Parents accepting participation 34 First polysomnography 34 Drop-outs 6 Acute disease at 2nd polysomnography 2 Refusal of second polysomnography 2 Poor technical quality of the second recording 1 Werdnig-Hoffman myopathy 1 Second polysomnography 28 Osteopathy 15 Non-specific treatment 13 ",
    "table_content": "|| blank | Number of patients ||\n|| Eligible for inclusion | 142 ||\n|| Osteopathy | 15 ||\n|| Non-specific treatment | 13 ||\n|| Parents accepting participation | 34 ||\n|| First polysomnography | 34 ||\n|| Drop-outs | 6 ||\n|| Acute disease at 2 nd polysomnography | 2 ||\n|| Refusal of second polysomnography | 2 ||\n|| Poor technical quality of the second recording | 1 ||\n|| Werdnig-Hoffman myopathy | 1 ||\n|| Second polysomnography | 28 ||",
    "claim": "The presence of Werdnig-Hoffman myopathy and acute disease accounted for 15% of the reasons for not completing the second polysomnography, calculated by considering the specific conditions listed.",
    "label": "refute"
  },
  {
    "id": "training_153_4",
    "table_caption": "Table: TABLE 2 | Step II: numerical search results. Keywords Cochrane PubMed PMC Elsevier PEDro ISI Total “upper limb exoskeleton” 0 33 63 3 1 155 255 “upper limb mobile robot” 0 0 0 0 0 0 0 “upper limb wearable robot” 0 0 0 0 0 1 1 “upper limb portable robot” 0 0 0 0 0 0 0 “upper limb robotic exoskeleton” 0 3 1 0 0 12 16 ‘upper limb robotic orthosis’ 0 0 0 0 0 0 1 “upper limb robotic device” 0 0 0 0 0 0 0 Total 0 36 64 3 1 169 273 ",
    "table_content": "|| Keywords | Cochrane | PubMed | PMC | Elsevier | PEDro | ISI | Total ||\n|| “ upper limb exoskeleton” | 0 | 33 | 63 | 3 | 1 | 155 | 255 ||\n|| “ upper limb mobile robot” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| “ upper limb wearable robot” | 0 | 0 | 0 | 0 | 0 | 1 | 1 ||\n|| “ upper limb portable robot” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| “ upper limb robotic exoskeleton” | 0 | 3 | 1 | 0 | 0 | 12 | 16 ||\n|| ‘ upper limb robotic orthosis’ | 0 | 0 | 0 | 0 | 0 | 0 | 1 ||\n|| “ upper limb robotic device” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| Total | 0 | 36 | 64 | 3 | 1 | 169 | 273 ||",
    "claim": "The ISI database has the highest number of search results for the keyword \"upper limb exoskeleton,\" with 155 results, which is more than four times the total results from all other databases combined for this keyword.",
    "label": "refute"
  },
  {
    "id": "training_1144_3",
    "table_caption": "Table: Table 5 Comparison of oxidative factors values before (baseline) and after (postprandial) experimental diet Biochemical factors Groups Cholesterolemic diet 5 ml Vinegar with %1 chol 10 ml Vinegar with %1 chol Normal diet MDA (mol/l) baseline 1.42 ± 0.37 1.4 ± 0.29 1.35 ± 0.32 1.28 ± 0.20 postprandial 2.88 ± 0.71 2.25 ± 0.46 2.04 ± 0.40* 1.18 ± 0.18* OXLDL(ng/ml) baseline 32.99 ± 11.2 30.05 ± 6.3 33.38 ± 18.8 24.08 ± 6.6 postprandial 69.59 ± 19.4 54.25 ± 32.0 52.41 ± 28.2* 34.62 ± 7.6* Mean MDA and OXLDL, mol/l ± SD and ng/ml ± SD, respectively, in each group (n = 8 for each experimental group).*p < 0.05: Pairwise comparison of differences between baseline and postprandial when compared to cholesterolemic group. ",
    "table_content": "|| Biochemical factors | blank | Groups | Groups | Groups | Groups ||\n|| Biochemical factors | blank | Cholesterolemic diet | 5 ml Vinegar with %1 chol | 10 ml Vinegar with %1 chol | Normal diet ||\n|| MDA (mol/l) | baseline | 1.42 ± 0.37 | 1.4 ± 0.29 | 1.35 ± 0.32 | 1.28 ± 0.20 ||\n|| MDA (mol/l) | postprandial | 2.88 ± 0.71 | 2.25 ± 0.46 | 2.04 ± 0.40* | 1.18 ± 0.18* ||\n|| OXLDL(ng/ml) | baseline | 32.99 ± 11.2 | 30.05 ± 6.3 | 33.38 ± 18.8 | 24.08 ± 6.6 ||\n|| OXLDL(ng/ml) | postprandial | 69.59 ± 19.4 | 54.25 ± 32.0 | 52.41 ± 28.2* | 34.62 ± 7.6 * ||",
    "claim": "The postprandial MDA level for the 10 ml vinegar diet is 72.3% higher than the normal diet, while the 5 ml vinegar diet is 90.7% higher. This suggests that the 10 ml vinegar diet is more effective in reducing MDA levels compared to the 5 ml vinegar diet.",
    "label": "refute"
  },
  {
    "id": "training_1144_3",
    "table_caption": "Table: Table 5 Comparison of oxidative factors values before (baseline) and after (postprandial) experimental diet Biochemical factors Groups Cholesterolemic diet 5 ml Vinegar with %1 chol 10 ml Vinegar with %1 chol Normal diet MDA (mol/l) baseline 1.42 ± 0.37 1.4 ± 0.29 1.35 ± 0.32 1.28 ± 0.20 postprandial 2.88 ± 0.71 2.25 ± 0.46 2.04 ± 0.40* 1.18 ± 0.18* OXLDL(ng/ml) baseline 32.99 ± 11.2 30.05 ± 6.3 33.38 ± 18.8 24.08 ± 6.6 postprandial 69.59 ± 19.4 54.25 ± 32.0 52.41 ± 28.2* 34.62 ± 7.6* Mean MDA and OXLDL, mol/l ± SD and ng/ml ± SD, respectively, in each group (n = 8 for each experimental group).*p < 0.05: Pairwise comparison of differences between baseline and postprandial when compared to cholesterolemic group. ",
    "table_content": "|| Biochemical factors | blank | Groups | Groups | Groups | Groups ||\n|| Biochemical factors | blank | Cholesterolemic diet | 5 ml Vinegar with %1 chol | 10 ml Vinegar with %1 chol | Normal diet ||\n|| MDA (mol/l) | baseline | 1.42 ± 0.37 | 1.4 ± 0.29 | 1.35 ± 0.32 | 1.28 ± 0.20 ||\n|| MDA (mol/l) | postprandial | 2.88 ± 0.71 | 2.25 ± 0.46 | 2.04 ± 0.40* | 1.18 ± 0.18* ||\n|| OXLDL(ng/ml) | baseline | 32.99 ± 11.2 | 30.05 ± 6.3 | 33.38 ± 18.8 | 24.08 ± 6.6 ||\n|| OXLDL(ng/ml) | postprandial | 69.59 ± 19.4 | 54.25 ± 32.0 | 52.41 ± 28.2* | 34.62 ± 7.6 * ||",
    "claim": "The postprandial MDA level for the 10 ml vinegar diet is 90.7% higher than the normal diet, while the 5 ml vinegar diet is 72.3% higher. This suggests that the 5 ml vinegar diet is more effective in reducing MDA levels compared to the 10 ml vinegar diet.",
    "label": "refute"
  },
  {
    "id": "training_902_2",
    "table_caption": "Table: Table 3 Attitudes towards antibiotic resistance With a regular doctor Without a regular doctor χ2 -test Adjusted Odds ratio (95 % CI)b Multivariable logistic regression p-value Preference for doctors who χ2 = 10.503, P = 0.033 NA 0.10 Rarely prescribe antibiotics 552 (38.2 %) 323 (34.5 %) Readily prescribe antibiotics 29 (2.0 %) 17 (1.8 %) Prescribe antibiotics on request 59 (4.1 %) 58 (6.2 %) Indifferent to such choice 695 (48.2 %) 449 (47.9 %) Uncertain about such choice 108 (7.5 %) 90 (9.6 %) Taking fewer courses of antibiotics helps reduce antibiotic resistancea χ2 = 0.032, P = 0.858 0.87 (0.59, 1.25) 0.445 Yes 1055 (88.6 %) 669 (88.8 %) No 136 (11.4 %) 84 (11.2 %) Less prescription by doctors lowers the probability of antibiotic resistancea χ2 = 5.624, P = 0.018 1.37 (0.99, 1.88) 0.062 Yes 1011 (86.9 %) 599 (82.9 %) No 152 (13.1 %) 123 (17.1 %) You can help the prevention of antibiotic resistancea χ2 = 4.101, P = 0.043 1.04 (0.82, 1.33) 0.727 Yes 455 (40.4 %) 251 (35.7 %) No 670 (59.6 %) 452 (64.3 %) aRespondents who had no idea about the meaning of “antibiotic resistance” did not answer these questions bOdds ratio adjusted for age, sex, education, income group and healthcare system ",
    "table_content": "|| blank | With a regular doctor | Without a regular doctor |  χ  2 -test | Adjusted Odds ratio (95 % CI) b  | Multivariable logistic regression p -value ||\n|| Preference for doctors who | blank | blank |  χ  2 = 10.503, P = 0.033 | NA | 0.10 ||\n|| Less prescription by doctors lowers the probability of antibiotic resistance a  | blank | blank |  χ  2 = 5.624, P = 0.018 | 1.37 (0.99, 1.88) | 0.062 ||\n|| Yes | 1011 (86.9 %) | 599 (82.9 %) | blank | blank | blank ||\n|| No | 152 (13.1 %) | 123 (17.1 %) | blank | blank | blank ||\n|| You can help the prevention of antibiotic resistance a  | blank | blank |  χ  2 = 4.101, P = 0.043 | 1.04 (0.82, 1.33) | 0.727 ||\n|| Yes | 455 (40.4 %) | 251 (35.7 %) | blank | blank | blank ||\n|| No | 670 (59.6 %) | 452 (64.3 %) | blank | blank | blank ||\n|| Rarely prescribe antibiotics | 552 (38.2 %) | 323 (34.5 %) | blank | blank | blank ||\n|| Readily prescribe antibiotics | 29 (2.0 %) | 17 (1.8 %) | blank | blank | blank ||\n|| Prescribe antibiotics on request | 59 (4.1 %) | 58 (6.2 %) | blank | blank | blank ||\n|| Indifferent to such choice | 695 (48.2 %) | 449 (47.9 %) | blank | blank | blank ||\n|| Uncertain about such choice | 108 (7.5 %) | 90 (9.6 %) | blank | blank | blank ||\n|| Taking fewer courses of antibiotics helps reduce antibiotic resistance a  | blank | blank |  χ  2 = 0.032, P = 0.858 | 0.87 (0.59, 1.25) | 0.445 ||\n|| Yes | 1055 (88.6 %) | 669 (88.8 %) | blank | blank | blank ||\n|| No | 136 (11.4 %) | 84 (11.2 %) | blank | blank | blank ||",
    "claim": "The belief that taking fewer courses of antibiotics helps reduce resistance shows a significant difference of 5.7% between the two groups, which is not supported by the chi-square test (χ² = 0.032, P = 0.858), indicating no significant variation in this belief based on having a regular doctor.",
    "label": "refute"
  },
  {
    "id": "training_335_4",
    "table_caption": "Table: Summary of antibodies used in this study. Antibodies Source Cat# Target(s) of labeling Myelin basic protein (MBP) Millipore MAB381 myelin PDGF receptor-α (PDGFR) Santa Cruz Sc-9974 OL progenitor cells (OPC) OL transcription factor 2 (Olig2) Millipore AB9610 total OL lineage (nucleus) Adenomatous Polyposis Coli (APC) Millipore OP80 mature OLs (cell body) CD11b (OX-42) Millipore CBL1512 microglia/macrophage ED1 Millipore MAB1435 activated microglia/macrophage Ionized calcium binding adaptor molecule 1 (Iba1) Wako Lab 019–19741 microglia/macrophage Inducible nitric oxide synthase (iNOS) Chemicon AB5382 M1 marker Major histocompatibility complex-II (MHC-II) USbiological M3887-10B M1 marker CD206 Abcam Ab8918 M2 marker Transforming growth factor beta (TGFβ) Abcam Ab66043 M2 marker pSmad3 Cell Signaling 12747 total Smad3 Smad 3 Cell Signaling 12747 total Smad3 Caspase-3 (cleaved) Cell Signaling 9664 active form of caspase-3 Doublecortin (Dcx) Cell Signaling 4604 neuroblasts doi:10.1371/journal.pone.0164403.t001 ",
    "table_content": "|| Antibodies | Source | Cat# | Target(s) of labeling ||\n|| Myelin basic protein (MBP) | Millipore | MAB381 | myelin ||\n|| CD206 | Abcam | Ab8918 | M2 marker ||\n|| Transforming growth factor beta (TGFβ) | Abcam | Ab66043 | M2 marker ||\n|| pSmad3 | Cell Signaling | 12747 | total Smad3 ||\n|| Smad 3 | Cell Signaling | 12747 | total Smad3 ||\n|| Caspase-3 (cleaved) | Cell Signaling | 9664 | active form of caspase-3 ||\n|| Doublecortin (Dcx) | Cell Signaling | 4604 | neuroblasts ||\n|| PDGF receptor-α (PDGFR) | Santa Cruz | Sc-9974 | OL progenitor cells (OPC) ||\n|| OL transcription factor 2 (Olig2) | Millipore | AB9610 | total OL lineage (nucleus) ||\n|| Adenomatous Polyposis Coli (APC) | Millipore | OP80 | mature OLs (cell body) ||\n|| CD11b (OX-42) | Millipore | CBL1512 | microglia/macrophage ||\n|| ED1 | Millipore | MAB1435 | activated microglia/macrophage ||\n|| Ionized calcium binding adaptor molecule 1 (Iba1) | Wako Lab | 019–19741 | microglia/macrophage ||\n|| Inducible nitric oxide synthase (iNOS) | Chemicon | AB5382 | M1 marker ||\n|| Major histocompatibility complex-II (MHC-II) | USbiological | M3887-10B | M1 marker ||",
    "claim": "The antibodies can be categorized into those targeting cell types (e.g., OL progenitor cells, mature OLs) and those targeting markers (e.g., M1, M2 markers). The study uses 53.85% of antibodies to target specific cell types, suggesting a primary focus on cellular identification and characterization.",
    "label": "refute"
  },
  {
    "id": "training_335_4",
    "table_caption": "Table: Summary of antibodies used in this study. Antibodies Source Cat# Target(s) of labeling Myelin basic protein (MBP) Millipore MAB381 myelin PDGF receptor-α (PDGFR) Santa Cruz Sc-9974 OL progenitor cells (OPC) OL transcription factor 2 (Olig2) Millipore AB9610 total OL lineage (nucleus) Adenomatous Polyposis Coli (APC) Millipore OP80 mature OLs (cell body) CD11b (OX-42) Millipore CBL1512 microglia/macrophage ED1 Millipore MAB1435 activated microglia/macrophage Ionized calcium binding adaptor molecule 1 (Iba1) Wako Lab 019–19741 microglia/macrophage Inducible nitric oxide synthase (iNOS) Chemicon AB5382 M1 marker Major histocompatibility complex-II (MHC-II) USbiological M3887-10B M1 marker CD206 Abcam Ab8918 M2 marker Transforming growth factor beta (TGFβ) Abcam Ab66043 M2 marker pSmad3 Cell Signaling 12747 total Smad3 Smad 3 Cell Signaling 12747 total Smad3 Caspase-3 (cleaved) Cell Signaling 9664 active form of caspase-3 Doublecortin (Dcx) Cell Signaling 4604 neuroblasts doi:10.1371/journal.pone.0164403.t001 ",
    "table_content": "|| Antibodies | Source | Cat# | Target(s) of labeling ||\n|| Myelin basic protein (MBP) | Millipore | MAB381 | myelin ||\n|| CD206 | Abcam | Ab8918 | M2 marker ||\n|| Transforming growth factor beta (TGFβ) | Abcam | Ab66043 | M2 marker ||\n|| pSmad3 | Cell Signaling | 12747 | total Smad3 ||\n|| Smad 3 | Cell Signaling | 12747 | total Smad3 ||\n|| Caspase-3 (cleaved) | Cell Signaling | 9664 | active form of caspase-3 ||\n|| Doublecortin (Dcx) | Cell Signaling | 4604 | neuroblasts ||\n|| PDGF receptor-α (PDGFR) | Santa Cruz | Sc-9974 | OL progenitor cells (OPC) ||\n|| OL transcription factor 2 (Olig2) | Millipore | AB9610 | total OL lineage (nucleus) ||\n|| Adenomatous Polyposis Coli (APC) | Millipore | OP80 | mature OLs (cell body) ||\n|| CD11b (OX-42) | Millipore | CBL1512 | microglia/macrophage ||\n|| ED1 | Millipore | MAB1435 | activated microglia/macrophage ||\n|| Ionized calcium binding adaptor molecule 1 (Iba1) | Wako Lab | 019–19741 | microglia/macrophage ||\n|| Inducible nitric oxide synthase (iNOS) | Chemicon | AB5382 | M1 marker ||\n|| Major histocompatibility complex-II (MHC-II) | USbiological | M3887-10B | M1 marker ||",
    "claim": "The antibodies can be categorized into those targeting cell types (e.g., OL progenitor cells, mature OLs) and those targeting markers (e.g., M1, M2 markers). The study uses 53.85% of antibodies to target markers, suggesting a primary focus on marker identification and characterization.",
    "label": "refute"
  },
  {
    "id": "training_1231_2",
    "table_caption": "Table: Characteristics of the articles published. Year First author Institution Impact Factor Model Stem cell 2004 Bochinski [4] University of California 3.046 Crush Allogeneic NESCs 2006 Y Kim [5] University of Pittsburgh School of Medicine 1.511 Transection Allogeneic SkMSCs 2009 Fall [6] Henri Mondor Teaching Hospital France 10.476 Ablation Allogeneic BMMNCs 2010 Albersen [7] University of California 3.513 Crush Autologous ADSCs 2010 Kendirci [8] Sisli Etfal Training and Research Hospital Turkey 3.696 Crush Allogeneic BMSCs 2011 Lin [9] University of California 1.511 Crush Autologous ADSCs or Allogeneic ADSCs 2011 Lin [10] University of California 2.424 Resection Autologous ADSCs 2011 Woo [11] The Catholic University of Korea Not SCI Transection Allogeneic SkMSCs 2012 Fandel [12] University of California 10.476 Crush Autologous ADSCs 2012 SJ Kim [13] The Catholic University of Korea 0.742 Crush Allogeneic BMSCs 2012 SJ Kim [14] The Catholic University of Korea Not SCI Crush Allogeneic BMSCs 2012 Kovanecz [15] Los Angeles Biomedical Research Institute 3.513 Resection Heterogeneous SkMSCs 2012 Piao [16] The Catholic University of Korea 3.513 Crush Heterogeneous ADSCs 2012 Qiu [17] University of California 3.513 Radiation Allogeneic ADSCs 2012 Qiu [18] University of California 10.476 Crush Autologous SVF 2013 Jeong [19] The Catholic University of Korea 2.424 Crush Heterogeneous ADSCs 2013 You [20] University of Ulsan College of Medicine, Korea 3.843 Stretch Heterogeneous ADSCs 2013 You [21] University of Ulsan College of Medicine, Korea 2.424 Not described Heterogeneous BMSCs 2013 IG Kim [22] The Catholic University of Korea 4.254 Crush Heterogeneous ADSCs 2013 Choi [23] CHA University, Seoul, Korea 4.67 Crush Heterogeneous TDSCs 2013 Ying [24] Zhongnan Hospital,Wuhan University 2.293 Crush Allogeneic ADSCs 2014 Ying[25] Zhongnan Hospital,Wuhan University 2.293 Resection Allogeneic ADSCs 2014 Miyamoto [26] Hiroshima University, Hiroshima, Japan 3.513 excision Heterogeneous BMCD133+ 2014 Lee [27] Gangnam Severance Hospital, Seoul, Korea 4.254 Crush Heterogeneous ADSCs NESCs:neural embryonic stem cells; SkMSCs:skeletal muscle-derived stem cells; BMMNCs:bone marrow mononucleated cells;ADSCs:adipose tissue- derived stem cells; BMSCs:bone marrow stem Cells; SVF:adipose-derived stromal vascular fraction; TDSCs:testis-derived stem cells; BMCD133+:Bone ",
    "table_content": "|| Year | First author | Institution | Impact Factor | Model | Stem cell ||\n|| 2004 | Bochinski [ 4 ] | University of California | 3.046 | Crush | Allogeneic NESCs ||\n|| 2012 | SJ Kim [ 13 ] | The Catholic University of Korea | 0.742 | Crush | Allogeneic BMSCs ||\n|| 2012 | SJ Kim [ 14 ] | The Catholic University of Korea | Not SCI | Crush | Allogeneic BMSCs ||\n|| 2012 | Kovanecz [ 15 ] | Los Angeles Biomedical Research Institute | 3.513 | Resection | Heterogeneous SkMSCs ||\n|| 2012 | Piao [ 16 ] | The Catholic University of Korea | 3.513 | Crush | Heterogeneous ADSCs ||\n|| 2012 | Qiu [ 17 ] | University of California | 3.513 | Radiation | Allogeneic ADSCs ||\n|| 2012 | Qiu [ 18 ] | University of California | 10.476 | Crush | Autologous SVF ||\n|| 2013 | Jeong [ 19 ] | The Catholic University of Korea | 2.424 | Crush | Heterogeneous ADSCs ||\n|| 2013 | You [ 20 ] | University of Ulsan College of Medicine, Korea | 3.843 | Stretch | Heterogeneous ADSCs ||\n|| 2013 | You [ 21 ] | University of Ulsan College of Medicine, Korea | 2.424 | Not described | Heterogeneous BMSCs ||\n|| 2013 | IG Kim [ 22 ] | The Catholic University of Korea | 4.254 | Crush | Heterogeneous ADSCs ||\n|| 2006 | Y Kim [ 5 ] | University of Pittsburgh School of Medicine | 1.511 | Transection | Allogeneic SkMSCs ||\n|| 2013 | Choi [ 23 ] | CHA University, Seoul, Korea | 4.67 | Crush | Heterogeneous TDSCs ||\n|| 2013 | Ying [ 24 ] | Zhongnan Hospital,Wuhan University | 2.293 | Crush | Allogeneic ADSCs ||\n|| 2014 | Ying[ 25 ] | Zhongnan Hospital,Wuhan University | 2.293 | Resection | Allogeneic ADSCs ||\n|| 2014 | Miyamoto [ 26 ] | Hiroshima University, Hiroshima, Japan | 3.513 | excision | Heterogeneous BMCD133+ ||\n|| 2014 | Lee [ 27 ] | Gangnam Severance Hospital, Seoul, Korea | 4.254 | Crush | Heterogeneous ADSCs ||\n|| 2009 | Fall [ 6 ] | Henri Mondor Teaching Hospital France | 10.476 | Ablation | Allogeneic BMMNCs ||\n|| 2010 | Albersen [ 7 ] | University of California | 3.513 | Crush | Autologous ADSCs ||\n|| 2010 | Kendirci [ 8 ] | Sisli Etfal Training and Research Hospital Turkey | 3.696 | Crush | Allogeneic BMSCs ||\n|| 2011 | Lin [ 9 ] | University of California | 1.511 | Crush | Autologous ADSCs or Allogeneic ADSCs ||\n|| 2011 | Lin [ 10 ] | University of California | 2.424 | Resection | Autologous ADSCs ||\n|| 2011 | Woo [ 11 ] | The Catholic University of Korea | Not SCI | Transection | Allogeneic SkMSCs ||\n|| 2012 | Fandel [ 12 ] | University of California | 10.476 | Crush | Autologous ADSCs ||",
    "claim": "Allogeneic ADSCs are the most frequently used stem cell type across the articles, indicating a preference or greater applicability of this type in the research community during the given period.",
    "label": "refute"
  },
  {
    "id": "training_688_1",
    "table_caption": "Table: of 1). to In in HepG2 and Huh7 cells. HepG2 Huh7 Sorafenib (mM) Sorafenib (mM) 5 7.5 10 5 7.5 10 Celecoxib (mM) 25 0.890 0.640 0.510 0.898 0.833 0.760 50 0.708 0.502 0.639 0.732 0.661 0.639 75 0.544 0.470 0.552 0.691 0.612 0.624 doi:10.1371/journal.pone.0065569.t001 ",
    "table_content": "|| blank | blank | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) ||\n|| blank | blank | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | HepG2 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) | Huh7 Sorafenib (µM) ||\n|| blank | blank | 5 | 7.5 | 10 | 5 | 7.5 | 10 ||\n||  Celecoxib (µM) | 25 | 0.890 | 0.640 | 0.510 | 0.898 | 0.833 | 0.760 ||\n||  Celecoxib (µM) | 50 | 0.708 | 0.502 | 0.639 | 0.732 | 0.661 | 0.639 ||\n||  Celecoxib (µM) | 75 | 0.544 | 0.470 | 0.552 | 0.691 | 0.612 | 0.624 ||",
    "claim": "In HepG2 cells, as the concentration of Sorafenib increases from 5 µM to 10 µM, the average cell viability increases by approximately 0.14 units when averaged across all Celecoxib concentrations. This trend suggests a dose-dependent response to Sorafenib in HepG2 cells.",
    "label": "refute"
  },
  {
    "id": "training_192_4",
    "table_caption": "Table: Identified homologs of SmCL1 based on the filter parameters discussed in the text. PDB ID Chain ID UniProt ID Organism Identity (%) Coverage (%) PDB Resolution (Å) E-value 1EWP A P25779 Trypanosoma cruzi 45 99 1.75 2.00E-57 1M6D B Q9UBX1 Homo sapiens 58 99 1.7 7.00E-83 1S4V B O65039 Ricinus communis 45 97 2.0 2.00E-52 2FO5 A P25250 Hordeum vulgare 45 94 2.2 3.00E-51 2P7U A Q95PM0 Trypanosoma brucei rhodesiense 44 99 1.65 3.00E-57 2XU3 A P07711 Homo sapiens 44 99 0.9 3.00E-53 doi:10.1371/journal.pone.0123996.t002 ",
    "table_content": "|| PDB ID | Chain ID | UniProt ID | Organism | Identity (%) | Coverage (%) | PDB Resolution (Å) | E-value ||\n|| 1EWP | A | P25779 |  Trypanosoma cruzi  | 45 | 99 | 1.75 | 2.00E-57 ||\n|| 1M6D | B | Q9UBX1 |  Homo sapiens  | 58 | 99 | 1.7 | 7.00E-83 ||\n|| 1S4V | B | O65039 |  Ricinus communis  | 45 | 97 | 2.0 | 2.00E-52 ||\n|| 2FO5 | A | P25250 |  Hordeum vulgare  | 45 | 94 | 2.2 | 3.00E-51 ||\n|| 2P7U | A | Q95PM0 |  Trypanosoma brucei rhodesiense  | 44 | 99 | 1.65 | 3.00E-57 ||\n|| 2XU3 | A | P07711 |  Homo sapiens  | 44 | 99 | 0.9 | 3.00E-53 ||",
    "claim": "The homolog with the best resolution (0.9 Å) also has a relatively low E-value, indicating a high-quality structural match. This suggests that better resolution is associated with less statistically significant homologs, reflecting the precision of structural data.",
    "label": "refute"
  },
  {
    "id": "training_197_6",
    "table_caption": "Table: in stem cell differentiation studies. Lineage Duration [day] Magnitude [dyn/ cm2] References Osteogenic 4 1 Datta et al. 2006 8 1 16 1 1 6 Knippenberg et al. 2005 1 2 0.1 0.3 Billotte et al. 2004 0.01 4 Bakker et al. 2000 0.01 6 Bakker et al. 2001 0.01 12 Bakker et al. 2002 1 4 Yourek et al. 2010 0.04 0.2 McBride et al. 2008 0.04 1 0.1 10 Arnsdorf et al. 2010 1 2.3 Kreke et al. 2008 Endothelial 6 15 Wang et al. 2005 0.3 5 Nikmanesh et al. 2012 2 15 Ahsan et al. 2010 1 10 Bai et al. 2009 1 15 2 12 Zhang et al.2011 1 12 Wu et al., 2008 0.5 5 Ye et al. 2007 Myogenic 1 5 Huang et al. 2010 1 10 1 15 1 20 doi:10.1371/journal.pone.0043601.t001 ",
    "table_content": "|| Lineage | Duration [day] | Magnitude [dyn/cm 2 ] | References ||\n|| Osteogenic | 4 | 1 | Datta et al. 2006 ||\n|| Osteogenic | 1 | 4 | Yourek et al. 2010 ||\n|| Osteogenic | 0.04 | 0.2 | McBride et al. 2008 ||\n|| Osteogenic | 0.04 | 1 | blank ||\n|| Osteogenic | 0.1 | 10 | Arnsdorf et al. 2010 ||\n|| Osteogenic | 1 | 2.3 | Kreke et al. 2008 ||\n|| Endothelial | 6 | 15 | Wang et al. 2005 ||\n|| Endothelial | 0.3 | 5 | Nikmanesh et al. 2012 ||\n|| Endothelial | 2 | 15 | Ahsan et al. 2010 ||\n|| Endothelial | 1 | 10 | Bai et al. 2009 ||\n|| Endothelial | 1 | 15 | blank ||\n|| Osteogenic | 8 | 1 | blank ||\n|| Endothelial | 2 | 12 | Zhang et al. 2011 ||\n|| Endothelial | 1 | 12 | Wu et al. , 2008 ||\n|| Endothelial | 0.5 | 5 | Ye et al. 2007 ||\n|| Myogenic | 1 | 5 | Huang et al. 2010 ||\n|| Myogenic | 1 | 10 | blank ||\n|| Myogenic | 1 | 15 | blank ||\n|| Myogenic | 1 | 20 | blank ||\n|| Osteogenic | 16 | 1 | blank ||\n|| Osteogenic | 1 | 6 | Knippenberg et al. 2005 ||\n|| Osteogenic | 1 | 2 | blank ||\n|| Osteogenic | 0.1 | 0.3 | Billotte et al. 2004 ||\n|| Osteogenic | 0.01 | 4 | Bakker et al. 2000  ||\n|| Osteogenic | 0.01 | 6 | Bakker et al. 2001 ||\n|| Osteogenic | 0.01 | 12 | Bakker et al. 2002 ||",
    "claim": "For a fixed duration of 1 day, the magnitude remains consistent across lineages.",
    "label": "refute"
  },
  {
    "id": "training_771_1",
    "table_caption": "Table: non- ma- used anal- RT-PCR, 1,707 to the conven- to a addi- TABLE 3 Intra- and interspecies diversity of mapA and ceuE gene and protein sequencesa Parameter and species p distance mapA ceuE Gene sequence diversity C. jejuni 0.014 0.018 C. coli 0.023 0.005 C. jejuni/C. coli 0.232 0.13 Protein sequence diversity C. jejuni 0.009 0.015 C. coli 0.020 0.009 C. jejuni/C. coli 0.232 0.089 a Putative recombinant sequences and alleles encoding truncated peptide sequences were excluded. ",
    "table_content": "|| Parameter and species | p distance | p distance ||\n|| Parameter and species | mapA | ceuE ||\n|| Gene sequence diversity | Gene sequence diversity | Gene sequence diversity ||\n||  C. jejuni | 0.014 | 0.018 ||\n||  C. coli | 0.023 | 0.005 ||\n||  C. jejuni / C. coli | 0.232 | 0.13 ||\n|| Protein sequence diversity | Protein sequence diversity | Protein sequence diversity ||\n||  C. jejuni | 0.009 | 0.015 ||\n||  C. coli | 0.020 | 0.009 ||\n||  C. jejuni / C. coli | 0.232 | 0.089 ||",
    "claim": "The gene sequence diversity of mapA in C. coli is approximately 64% lower than in C. jejuni, indicating a lesser genetic variability within C. coli for this gene.",
    "label": "refute"
  },
  {
    "id": "training_50_6",
    "table_caption": "Table: Table 1 Baseline characteristics of women in the two groups, in Sidama zone, Southern Ethiopia, 2015 Was your husband involved at least in one ANC visit? Characteristics Yes, (%) (n = 385) No, (%) (n = 279) Total (N = 664) Χ2, (p-value) Residence Urban 194 (60.1) 129 (39.9) 323 1.117 (=0.291) Rural 191 (56.0) 150 (44.0) 341 Age in year 15–24 103 (58.9) 72 (41.1) 175 0.090 (=0.956) 25–34 218 (57.5) 161 (42.5) 379 35–49 64 (58.2) 46 (41.8) 110 Education level Tertiary 62 (62.6) 37 (37.4) 99 3.010 (=0.390) Secondary 103 (58.5) 73 (41.5) 176 Primary 134 (54.0) 114 (46.0) 248 None 86 (61.0) 55 (39.0) 141 Occupation type Government employee 64 (69.6) 28 (30.4) 92 6.159 (=0.046)* Businesswomen 35 (59.3) 24 (40.7) 59 Housewife 286 (55.8) 227 (44.2) 513 Religion Protestant 251 (55.9) 198 (44.1) 449 8.908 (=0.031)* Orthodox 45 (63.4) 26 (36.6) 71 Catholic 47 (73.4) 17 (26.6) 64 Muslim 42 (52.5) 38 (47.5) 80 Initiation of ANC visit 1st trimester 41 (71.9) 16 (28.1) 57 9.764 (=0.008)** 2nd trimester 231 (60.0) 154 (40.0) 385 3rd trimester 113 (50.9) 109 (49.1) 222 Number of ANC visits 4+ 64 (76.2) 20 (23.8) 84 13.087 (< 0.001)*** 1 to 3 321 (55.3) 259 (44.7) 580 Number of under 5 children < 1 127 (62.0) 78 (38.0) 205 1.918 (=0.166) > 1 258 (56.2) 201 (43.8) 459 Is the pregnancy planned? Yes 280 (64.2) 156 (35.8) 436 20.282 (< 0.001)*** No 105 (46.1) 123 (53.9) 228 ***P-value < 0.001, **p-value < 0.01, and *P-value < 0.05, indicate the significance differences of the two groups (women with husbands’ involvement and without involvement by indicated variables) ",
    "table_content": "|| Characteristics | Was your husband involved at least in one ANC visit? | Was your husband involved at least in one ANC visit? | Was your husband involved at least in one ANC visit? | Χ 2 , ( p -value) ||\n|| Characteristics | Yes, (%) ( n = 385) | No, (%) ( n = 279) | Total ( N = 664) | Χ 2 , ( p -value) ||\n|| Tertiary | 62 (62.6) | 37 (37.4) | 99 | 3.010 (=0.390) ||\n|| Secondary | 103 (58.5) | 73 (41.5) | 176 | blank ||\n|| Primary | 134 (54.0) | 114 (46.0) | 248 | blank ||\n|| None | 86 (61.0) | 55 (39.0) | 141 | blank ||\n|| Occupation type | Occupation type | Occupation type | Occupation type | Occupation type ||\n|| Government employee | 64 (69.6) | 28 (30.4) | 92 | 6.159 (=0.046)* ||\n|| Businesswomen | 35 (59.3) | 24 (40.7) | 59 | blank ||\n|| Housewife | 286 (55.8) | 227 (44.2) | 513 | blank ||\n|| Religion | Religion | Religion | Religion | Religion ||\n|| Protestant | 251 (55.9) | 198 (44.1) | 449 | 8.908 (=0.031)* ||\n|| Residence | Residence | Residence | Residence | Residence ||\n|| Orthodox | 45 (63.4) | 26 (36.6) | 71 | blank ||\n|| Catholic | 47 (73.4) | 17 (26.6) | 64 | blank ||\n|| Muslim | 42 (52.5) | 38 (47.5) | 80 | blank ||\n|| Initiation of ANC visit | Initiation of ANC visit | Initiation of ANC visit | Initiation of ANC visit | Initiation of ANC visit ||\n|| 1st trimester | 41 (71.9) | 16 (28.1) | 57 | 9.764 (=0.008)** ||\n|| 2nd trimester | 231 (60.0) | 154 (40.0) | 385 | blank ||\n|| 3rd trimester | 113 (50.9) | 109 (49.1) | 222 | blank ||\n|| Number of ANC visits | Number of ANC visits | Number of ANC visits | Number of ANC visits | Number of ANC visits ||\n|| 4+ | 64 (76.2) | 20 (23.8) | 84 | 13.087 (< 0.001)*** ||\n|| 1 to 3 | 321 (55.3) | 259 (44.7) | 580 | blank ||\n|| Urban | 194 (60.1) | 129 (39.9) | 323 | 1.117 (=0.291) ||\n|| Number of under 5 children | Number of under 5 children | Number of under 5 children | Number of under 5 children | Number of under 5 children ||\n|| <  1 | 127 (62.0) | 78 (38.0) | 205 | 1.918 (=0.166) ||\n|| > 1 | 258 (56.2) | 201 (43.8) | 459 | blank ||\n|| Is the pregnancy planned? | Is the pregnancy planned? | Is the pregnancy planned? | Is the pregnancy planned? | Is the pregnancy planned? ||\n|| Yes | 280 (64.2) | 156 (35.8) | 436 | 20.282 (< 0.001)*** ||\n|| No | 105 (46.1) | 123 (53.9) | 228 | blank ||\n|| Rural | 191 (56.0) | 150 (44.0) | 341 | blank ||\n|| Age in year | Age in year | Age in year | Age in year | Age in year ||\n|| 15–24 | 103 (58.9) | 72 (41.1) | 175 | 0.090 (=0.956) ||\n|| 25–34 | 218 (57.5) | 161 (42.5) | 379 | blank ||\n|| 35–49 | 64 (58.2) | 46 (41.8) | 110 | blank ||\n|| Education level | Education level | Education level | Education level | Education level ||",
    "claim": "Women with one to three ANC visits have the highest percentage of husband involvement. The difference in husband involvement based on the number of ANC visits is statistically significant, as indicated by the p-value.",
    "label": "refute"
  },
  {
    "id": "training_681_6",
    "table_caption": "Table: significantly increased LA volume index and RA area A’sept E/E’lat, ence and T1DM (Table E’t S’t creased and We MPI Table 1 Demographic and clinical data of diabetic patients and control subjects Variable Diabetic patients (n = 53) Healthy controls (n = 48) p-value Age (years) 44.3 ± 5.4 42.7 ± 6.1 0.159 Gender (male/female, %) 56.6/43.4 56.3/43.7 0.873 Body mass index (kg/m2) 27.0 ± 4.0 25.6 ± 3.5 0.068 Body surface area (m2) 1.94 ± 0.2 1.90 ± 0.2 0.430 Smoking (%) 24.5 33.3 0.454 Systolic blood pressure (mmHg) 126.0 ± 9.5 123.0 ± 10.7 0.168 Diastolic blood pressure (mmHg) 79.5 ± 5.8 77.0 ± 7.0 0.061 ",
    "table_content": "|| Variable | Diabetic patients ( n = 53) | Healthy controls ( n = 48) |  p -value ||\n|| Age (years) | 44.3 ± 5.4 | 42.7 ± 6.1 | 0.159 ||\n|| Gender (male/female, %) | 56.6/43.4 | 56.3/43.7 | 0.873 ||\n|| Body mass index (kg/m2) | 27.0 ± 4.0 | 25.6 ± 3.5 | 0.068 ||\n|| Body surface area (m 2 ) | 1.94 ± 0.2 | 1.90 ± 0.2 | 0.430 ||\n|| Smoking (%) | 24.5 | 33.3 | 0.454 ||\n|| Systolic blood pressure (mmHg) | 126.0 ± 9.5 | 123.0 ± 10.7 | 0.168 ||\n|| Diastolic blood pressure (mmHg) | 79.5 ± 5.8 | 77.0 ± 7.0 | 0.061 ||",
    "claim": "Diabetic patients exhibit lower average systolic and diastolic blood pressure compared to healthy controls. This aligns with the understanding that diabetes is often associated with increased cardiovascular risk, including hypertension.",
    "label": "refute"
  },
  {
    "id": "training_898_5",
    "table_caption": "Table: Pub- medical French and and for opinion variable opin- Fisher’s using forward the a was models was Inc., The doc- course and Table 1 Characteristics of the sample Number Percent Gender Female 239 57.9 Male 174 42.1 Age ≤ 27 years 215 52.1 > 27 years 198 47.9 Marital status Couple 281 68.0 Single 132 32.0 Child Yes 163 39.5 No 250 60.5 Believes in God Yes 210 50.8 No 203 49.2 Has taken care of someone nearing the end of life Yes 203 49.2 No 210 50.8 Professional status Palliative care specialists 170 41.2 Medical interns 243 58.8 Specialisation General practice 283 68.5 Others a 130 31.5 Opinion about euthanasia Unfavourable 232 56.2 Favourable 181 43.8 Opinion about the demand of euthanasia of Vincent Humbert Unfavourable 167 40.4 Favourable 246 59.6 aOthers: oncology, surgery, anaesthesia, psychiatry, pneumology, public health, gynaecology ",
    "table_content": "|| blank | Number | Percent ||\n|| Gender | Gender | Gender ||\n|| Child | Child | Child ||\n|| Yes | 163 | 39.5 ||\n|| No | 250 | 60.5 ||\n|| Believes in God | Believes in God | Believes in God ||\n|| Yes | 210 | 50.8 ||\n|| No | 203 | 49.2 ||\n|| Has taken care of someone nearing the end of life | Has taken care of someone nearing the end of life | Has taken care of someone nearing the end of life ||\n|| Yes | 203 | 49.2 ||\n|| No | 210 | 50.8 ||\n|| Professional status | Professional status | Professional status ||\n|| Female | 239 | 57.9 ||\n|| Palliative care specialists | 170 | 41.2 ||\n|| Medical interns | 243 | 58.8 ||\n|| Specialisation | Specialisation | Specialisation ||\n|| General practice | 283 | 68.5 ||\n|| Others a  | 130 | 31.5 ||\n|| Opinion about euthanasia | Opinion about euthanasia | Opinion about euthanasia ||\n|| Unfavourable | 232 | 56.2 ||\n|| Favourable | 181 | 43.8 ||\n|| Opinion about the demand of euthanasia of Vincent Humbert | Opinion about the demand of euthanasia of Vincent Humbert | Opinion about the demand of euthanasia of Vincent Humbert ||\n|| Unfavourable | 167 | 40.4 ||\n|| Male | 174 | 42.1 ||\n|| Favourable | 246 | 59.6 ||\n|| Age | Age | Age ||\n|| ≤ 27 years | 215 | 52.1 ||\n|| > 27 years | 198 | 47.9 ||\n|| Marital status | Marital status | Marital status ||\n|| Couple | 281 | 68.0 ||\n|| Single | 132 | 32.0 ||",
    "claim": "While 56.2% of the sample holds an unfavourable opinion on euthanasia in general, 40.4% have a favourable opinion on the specific case of Vincent Humbert, indicating a nuanced view where the specific circumstances of a case can shift general opinions.",
    "label": "refute"
  },
  {
    "id": "training_769_3",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A C9—H9···O1 0.93 2.57 3.487 (7) 169. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| C9—H9···O1 | 0.93 | 2.57 | 3.487 (7) | 169. ||",
    "claim": "The D—H distance of 0.93 Å and the D···A distance of 3.487 Å, when considered with the bond angle, suggest a geometric arrangement that increases steric hindrance and reduces hydrogen bond efficiency. This inconsistency is crucial for maintaining the structural integrity of the molecule.",
    "label": "refute"
  },
  {
    "id": "training_389_3",
    "table_caption": "Table: Table 3 Niche identity test. Niche model Compared lineages Empirical value (Niche overlap) Identity test (Niche equivalence) I D I D Current L. g. cacsilensis—Mixed population 0.283 0.089 0.923 0.686 L. g. guanicoe—Mixed population 0.178 0.058 0.922 0.711 L. g. cacsilensis—L. g. guanicoe 0.133 0.033 0.922 0.596 Projected (2070) L. g. cacsilensis—Mixed population 0.471 0.208 0.930 0.760 L. g. guanicoe—Mixed population 0.135 0.039 0.950 0.800 L. g. cacsilensis—L. g. guanicoe 0.090 0.015 0.890 0.630 Notes: These results correspond to the comparison between the empirical values (niche overlap) and values of percentiles 0.1 of the null distribution (one tailed, Warren, Glor & Turelli, 2010). The “I” and “D” statistics allow to compare the overlap between the replicas of this test. If the empirical value is within the range of values observed in the ",
    "table_content": "|| Niche model | Compared lineages | Empirical value (Niche overlap) | Empirical value (Niche overlap) | Identity test (Niche equivalence) | Identity test (Niche equivalence) ||\n|| Niche model | Compared lineages | I | D | I | D ||\n|| Current | L. g. cacsilensis— Mixed population | 0.283 | 0.089 | 0.923 | 0.686 ||\n|| Current | L. g. guanicoe— Mixed population | 0.178 | 0.058 | 0.922 | 0.711 ||\n|| Current | L. g. cacsilensis—L. g. guanicoe | 0.133 | 0.033 | 0.922 | 0.596 ||\n|| Projected (2070) | L. g. cacsilensis— Mixed population | 0.471 | 0.208 | 0.930 | 0.760 ||\n|| Projected (2070) | L. g. guanicoe— Mixed population | 0.135 | 0.039 | 0.950 | 0.800 ||\n|| Projected (2070) | L. g. cacsilensis—L. g. guanicoe | 0.090 | 0.015 | 0.890 | 0.630 ||",
    "claim": "The identity test (I) value for L. g. guanicoe—Mixed population decreases by approximately 3.0% from current to projected conditions, reflecting a slight decrease in niche equivalence.",
    "label": "refute"
  },
  {
    "id": "training_151_3",
    "table_caption": "Table: patients fiber visual older (7). to In reach WM TABLE 1 | Clinical characteristics. Characteristics BD Mean (SD) HC Mean (SD) Statistical evaluation df P-value Sample, No 57 57 Sex, No Male 22 17 χ2 = 0.974 1 0.32 Female 35 40 Age, years 48.6 (15.1) 49.3 (19.0) t = −0.235 112 0.82 Age of onset, years 36.7 (10.0) Disease duration, years 11.9 (8.1) Treatment duration, years 4.5 (2.7) HRS-D, scores 21.0 (3.7) BD, bipolar disorder; F, analysis of variance; HRS-D, Hamilton’s Rating Scale for Depression; HC, healthy controls; t, Student’s t-test; χ2, Pearson’s chi-square test. ",
    "table_content": "|| Characteristics | BD Mean (SD) | HC Mean (SD) | Statistical evaluation | df | P -value ||\n|| Sample, No | 57 | 57 | blank | blank | blank ||\n|| Sex, No | Sex, No | Sex, No | Sex, No | Sex, No | Sex, No ||\n|| Male | 22 | 17 | χ 2 = 0.974 | 1 | 0.32 ||\n|| Female | 35 | 40 | blank | blank | blank ||\n|| Age, years | 48.6 (15.1) | 49.3 (19.0) | t = −0.235 | 112 | 0.82 ||\n|| Age of onset, years | 36.7 (10.0) | blank | blank | blank | blank ||\n|| Disease duration, years | 11.9 (8.1) | blank | blank | blank | blank ||\n|| Treatment duration, years | 4.5 (2.7) | blank | blank | blank | blank ||\n|| HRS-D, scores | 21.0 (3.7) | blank | blank | blank | blank ||",
    "claim": "The average age of onset for BD is 36.7 years, and the average disease duration is 11.9 years. This implies that the average current age of individuals with BD is approximately 50 years, which does not align with the reported mean age, questioning the internal consistency of the data.",
    "label": "refute"
  },
  {
    "id": "training_987_5",
    "table_caption": "Table: Site C0002 Hole Bit size [in] Top [mbsf] Bottom [mbsf] LWD MWD Riser H 10–5/8 0.0 1120.5 I 10–5/8 0.0 1360.3 J 10–5/8 0.0 940.0 K 11–7/16 0.0 286.5 L 11–7/16 0.0 505.0 N 17 860.3 2328.9 + + P 12–1/4 1936.8 3056.6 + + + Table 1. Detailed hole properties at site C0002. Bit size, top and bottom depths hole. Abbreviations in the inset include LWD, logging-while-drilling; and MWD, ",
    "table_content": "|| Site C0002 | Site C0002 | Site C0002 | Site C0002 | Site C0002 | Site C0002 | Site C0002 ||\n|| Hole | Bit size [in] | Top [mbsf] | Bottom [mbsf] | LWD | MWD | Riser ||\n|| H | 10–5/8 | 0.0 | 1120.5 | blank | blank | blank ||\n|| I | 10–5/8 | 0.0 | 1360.3 | blank | blank | blank ||\n|| J | 10–5/8 | 0.0 | 940.0 | blank | blank | blank ||\n|| K | 11–7/16 | 0.0 | 286.5 | blank | blank | blank ||\n|| L | 11–7/16 | 0.0 | 505.0 | blank | blank | blank ||\n|| N | 17 | 860.3 | 2328.9 | blank | + | + ||\n|| P | 12–1/4 | 1936.8 | 3056.6 | + | + | + ||",
    "claim": "Hole P did not reach the maximum depth of 3,056.6 meters below the seafloor, utilizing a 12–1/4 inch bit size, which suggests this size's suitability for deep drilling.",
    "label": "refute"
  },
  {
    "id": "training_885_3",
    "table_caption": "Table: Table 4b. Proportions of patients with a label of heart failure captured in different settings, estimated additional proportion of missing patients and estimated population size Model Patients labeled in hospital Patients labeled in primary care Patients labeled in both Additional patients not labeled in either setting Estimated population size (95% confidence interval) HF = no covariate 46% 19% 35% 20% (14–26%) 859 (799–929) HF = age 46% 19% 35% 20% (14– 26%) 860 (799–930) HF = age + sex 36% 25% 36% 20% (14–27%) 867 (800–946) HF = age + sex + income quintile 34% 26% 39% 19% (12–25%) 849 (787–923) HF = age + sex + income quintile + comorbidities 34% 26% 39% 18% (12–25%) 847 (787–918) COPD chronic obstructive pulmonary disease, HF heart failure ",
    "table_content": "|| Model | Patients labeled in hospital | Patients labeled in primary care | Patients labeled in both | Additional patients not labeled in either setting | Estimated population size (95% confidence interval) ||\n|| HF = no covariate | 46% | 19% | 35% | 20% (14–26%) | 859 (799–929) ||\n|| HF = age | 46% | 19% | 35% | 20% (14– 26%) | 860 (799–930) ||\n|| HF = age + sex | 36% | 25% | 36% | 20% (14–27%) | 867 (800–946) ||\n|| HF = age + sex + income quintile | 34% | 26% | 39% | 19% (12–25%) | 849 (787–923) ||\n|| HF = age + sex + income quintile + comorbidities | 34% | 26% | 39% | 18% (12–25%) | 847 (787–918) ||",
    "claim": "The proportion of patients labeled in both settings decreases by 4 percentage points when comparing the model with no covariates to the model including age, sex, income quintile, and comorbidities.",
    "label": "refute"
  },
  {
    "id": "training_135_1",
    "table_caption": "Table: Sample Dose aPTT (s) PT (s) PT (INR) Control Saline 32.1 ± 0.4 12.0 ± 0.3 1.00 JJ1 0.31 μg/mouse 31.9 ± 0.6 12.4 ± 0.5 1.08 0.61 μg/mouse 40.1 ± 1.1* 17.2 ± 1.4* 2.37 1.23 μg/mouse 49.4 ± 1.5* 22.3 ± 0.6* 4.42* 3.06 μg/mouse 55.8 ± 1.2* 26.8 ± 0.4* 6.88* Table 3. Ex vivo coagulation time of JJ1a. aEach value represents to control. ",
    "table_content": "|| Sample | Dose | aPTT (s) | PT (s) | PT (INR) ||\n|| Control | Saline | 32.1 ± 0.4 | 12.0 ± 0.3 | 1.00 ||\n||  JJ1  | 0.31 μg/mouse | 31.9 ± 0.6 | 12.4 ± 0.5 | 1.08 ||\n||  JJ1  | 0.61 μg/mouse | 40.1 ± 1.1* | 17.2 ± 1.4* | 2.37 ||\n||  JJ1  | 1.23 μg/mouse | 49.4 ± 1.5* | 22.3 ± 0.6* | 4.42* ||\n||  JJ1  | 3.06 μg/mouse | 55.8 ± 1.2* | 26.8 ± 0.4* | 6.88* ||",
    "claim": "The aPTT increases linearly with the dose of JJ1, showing a more than 70% increase from the lowest to the highest dose, indicating a dose-dependent prolongation of the intrinsic coagulation pathway.",
    "label": "refute"
  },
  {
    "id": "training_1011_2",
    "table_caption": "Table: Predictive factors for multiple positive blood cultures of C. striatum by multiple logistic regression analysis. Variable Category Adjusted OR (95% CI) P value Age (year) 0.99 (0.92–1.04) 0.82 Carlson comorbidity score 1.91 (1.09–3.36) 0.03 Presence of CVC No 1.00 Yes 6.61 (0.92–47.60) 0.06 Biofilm formation 17.43 (3.71–81.91) < 0.01 OR, odds ratio; CI, confidence interval; CVC, Central venous catheter. ",
    "table_content": "|| Variable | Category | Adjusted OR (95% CI) | P value ||\n|| Age (year) | blank | 0.99 (0.92–1.04) | 0.82 ||\n|| Carlson comorbidity score | blank | 1.91 (1.09–3.36) | 0.03 ||\n|| Presence of CVC | No | 1.00 | blank ||\n|| Presence of CVC | Yes | 6.61 (0.92–47.60) | 0.06 ||\n|| Biofilm formation | blank | 17.43 (3.71–81.91) | < 0.01 ||",
    "claim": "The Carlson comorbidity score has an adjusted odds ratio of 1.91, indicating that for each unit increase in the score, the odds of multiple positive blood cultures decrease by approximately 91%. This is statistically significant, as evidenced by the p-value of 0.03.",
    "label": "refute"
  },
  {
    "id": "training_104_4",
    "table_caption": "Table: Feature frequency table of generalized linear model. Covariable name Frequency (%) Category 98.6 Gender 39.6 Pathology grade 62.1 Lymph node metastasis 93.9 Tumor size 65.8 Clinical stage 54.3 situ on prior we of the a ",
    "table_content": "|| Covariable name | Frequency (%) ||\n|| Category | 98.6 ||\n|| Gender | 39.6 ||\n|| Pathology grade | 62.1 ||\n|| Lymph node metastasis | 93.9 ||\n|| Tumor size | 65.8 ||\n|| Clinical stage | 54.3 ||",
    "claim": "The combined frequency of clinical factors (Pathology grade, Lymph node metastasis, Tumor size, and Clinical stage) is 136.1%. This indicates that clinical factors are considered less frequently than non-clinical factors, such as Gender, in the model.",
    "label": "refute"
  },
  {
    "id": "training_1213_1",
    "table_caption": "Table: by hAST and hBMVEC, respectively, after T&I exposure either alone or in the presence of S1P (50 nM), FTY (50 nM), pFTY (50 nM), and AUY (50 nM). Astrocytes Endothelial cells Resting 30.9 pg/ml 3.2 pg/ml T&I 86.1 pg/ml 7.7 pg/ml T&I+S1P 82.3 pg/ml 7.8 pg/ml T&I+FTY 144.1 pg/ml 9.7 pg/ml T&I+pFTY 150.2 pg/ml 8.7 pg/ml T&I+AUY 84.5 pg/ml 8.4 pg/ml doi:10.1371/journal.pone.0133392.t002 ",
    "table_content": "|| blank | Astrocytes | Endothelial cells ||\n||  Resting  | 30.9 pg/ml | 3.2 pg/ml ||\n||  T&I  | 86.1 pg/ml | 7.7 pg/ml ||\n||  T&I+S1P  | 82.3 pg/ml | 7.8 pg/ml ||\n||  T&I+FTY  | 144.1 pg/ml | 9.7 pg/ml ||\n||  T&I+pFTY  | 150.2 pg/ml | 8.7 pg/ml ||\n||  T&I+AUY  | 84.5 pg/ml | 8.4 pg/ml ||",
    "claim": "The increase in concentration from resting to T&I condition is approximately 2.8 times greater in astrocytes than in endothelial cells, indicating a more pronounced response in astrocytes.",
    "label": "refute"
  },
  {
    "id": "training_571_4",
    "table_caption": "Table: The intraobserver repeatability of Ks, Kf, Km, J0 and J45 obtained by iTrace. (Note: D: diopter, SD: standard deviation, Sw: within-subject standard deviation, CoV: within-subject coefficient of variation, ICC: intraclass correlation coefficient.) Parameters Observers Mean±SD CoV (%) Sw (D) 2.77Sw (D) ICC Ks 1st 44.03 ± 1.62 0.50 0.26 0.70 0.991(0.988–0.994) 2nd 44.07 ± 1.63 0.34 0.20 0.55 0.995(0.993–0.996) Kf 1st 43.02 ± 1.50 0.42 0.21 0.59 0.993(0.991–0.995) 2nd 43.07 ± 1.51 0.33 0.19 0.53 0.993(0.990–0.995) Km 1st 43.53 ± 1.53 0.44 0.22 0.61 0.993(0.991–0.995) 2nd 43.57 ± 1.55 0.32 0.18 0.49 0.996(0.994–0.997) J0 1st 0.024 ± 0.25 - 0.41 1.14 0.081(-0.283–0.354) 2nd -0.019 ± 0.24 - 0.39 1.08 0.111(-0.243–0.376) J45 1st -0.006 ± 0.22 - 0.42 1.15 -0.175(-0.629–0.171) 2nd 0.018 ± 0.27 - 0.40 1.11 -0.257(-0.037–0.478) doi:10.1371/journal.pone.0147086.t004 ",
    "table_content": "|| Parameters | Observers | Mean±SD | CoV (%) | Sw (D) | 2.77Sw (D) | ICC ||\n|| Ks | 1st | 44.03 ± 1.62 | 0.50 | 0.26 | 0.70 | 0.991(0.988–0.994) ||\n|| J45 | 2nd | 0.018 ± 0.27 | blank | 0.40 | 1.11 | -0.257(-0.037–0.478) ||\n|| Ks | 2nd | 44.07 ± 1.63 | 0.34 | 0.20 | 0.55 | 0.995(0.993–0.996) ||\n|| Kf | 1st | 43.02 ± 1.50 | 0.42 | 0.21 | 0.59 | 0.993(0.991–0.995) ||\n|| Kf | 2nd | 43.07 ± 1.51 | 0.33 | 0.19 | 0.53 | 0.993(0.990–0.995) ||\n|| Km | 1st | 43.53 ± 1.53 | 0.44 | 0.22 | 0.61 | 0.993(0.991–0.995) ||\n|| Km | 2nd | 43.57 ± 1.55 | 0.32 | 0.18 | 0.49 | 0.996(0.994–0.997) ||\n|| J0 | 1st | 0.024 ± 0.25 | blank | 0.41 | 1.14 | 0.081(-0.283–0.354) ||\n|| J0 | 2nd | -0.019 ± 0.24 | blank | 0.39 | 1.08 | 0.111(-0.243–0.376) ||\n|| J45 | 1st | -0.006 ± 0.22 | blank | 0.42 | 1.15 | -0.175(-0.629–0.171) ||",
    "claim": "The ICC for the Km parameter decreases from 0.993 to 0.996 between the first and second observers. This decrease in ICC, which is a measure of reliability, indicates that the second observer's measurements are less reliable, with a lower degree of agreement between repeated measurements.",
    "label": "refute"
  },
  {
    "id": "training_5_4",
    "table_caption": "Table: Heart weights (HW), body weights (BW), cardiac function, plasma creatine content and creatine uptake during development in the rat heart Age (days) -2 ( fetal ) 7 13 21 33 50 80 ANOVA HW (g) 0.039 ± 0.01a 0.13 ± 0.01b 0.17 ± 0.06bc 0.24 ± 0.03c 0.44 ± 0.04d 0.70 ± 0.07e 1.17 ± 0.02f p < 0.001 [4] [4] [7] [5] [8] [6] [8] BW (g) 3.59 ± 0.34a 22.0 ± 1.78b 35.6 ± 7.08c 41.5 ± 4.1c 78.6 ± 2.4d 178 ± 8.6e 296 ± 5.3f p < 0.001 [4] [4] [7] [5] [8] [6] [8] HW/BW *1000 10.9 ± 2.1a 5.79 ± 0.80ab 4.81 ± 1.15ab 5.84 ± 0.70a 5.58 ± 0.47a 3.93 ± 0.32b b 3.94 ± 0.10b p < 0.001 [4] [4] [7] [5] [5] [6] [8] HR (bpm) - - 321 ± 5.7 248 ± 4.9 348 ± 5.6 318 ± 34 307 ± 45 NS [4] [4] [4] [4] [4] LDVP (mm Hg) - - 69 ± 12.7 88.6 ± 0.36 65.7 ± 7.2 75.7 ± 10.2 97.1 ± 27.6 NS [4] [4] [4] [4] [4] RPP (mm Hg/bpm) - - 22129 ± 3673 22047 ± 555 22879 ± 2874 24189 ± 5524 29673 ± 8913 NS [4] [4] [4] [4] [4] Creatine uptake - - 3.03 ± 0.55a 3.66 ± 0.79ab 3.85 ± 0.62abc 4.68 ± 0.54bc 4.99 ± 0.52c p < 0.001 (nmol/min/g w.w) [6] [5] [5] [5] [6] Plasma creatine - 0.971 ± 0.07a 0.669 ± 0.16ab 0.678 ± 0.19ac 0.627 ± 0.12bc 0.558 ± 0.06bc 0.536 ± 0.08bc p = 0.002 (mmol/L) [4] [4] [4] [4] [4] [4] Data are presented as means ± S.E and sample size are given in brackets. Values within a row with different superscript letters are significantly different to all other time points (p < 0.05, creatine uptake, plasma creatine: Bonferroni; HW, BW, HW/BW*1000: Dunnett T3, ANOVA \"test for linear trend\": as indicated). ",
    "table_content": "|| Age (days) | -2 ( fetal ) | 7 | 13 | 21 | 33 | 50 | 80 | ANOVA ||\n|| HW (g) | 0.039 ± 0.01 a | 0.13 ± 0.01 b | 0.17 ± 0.06 bc | 0.24 ± 0.03 c | 0.44 ± 0.04 d | 0.70 ± 0.07 e | 1.17 ± 0.02 f | p < 0.001 ||\n|| LDVP (mm Hg) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| RPP (mm Hg/bpm) | blank | blank | 22129 ± 3673 | 22047 ± 555 | 22879 ± 2874 | 24189 ± 5524 | 29673 ± 8913 | NS ||\n|| RPP (mm Hg/bpm) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| Creatine uptake | blank | blank | 3.03 ± 0.55 a | 3.66 ± 0.79 ab | 3.85 ± 0.62 abc | 4.68 ± 0.54 bc | 4.99 ± 0.52 c | p < 0.001 ||\n|| (nmol/min/g w.w) | blank | blank | [6] | [5] | [5] | [5] | [6] | blank ||\n|| Plasma creatine | blank | 0.971 ± 0.07 a | 0.669 ± 0.16 ab | 0.678 ± 0.19 ac | 0.627 ± 0.12 bc | 0.558 ± 0.06 bc | 0.536 ± 0.08 bc | p = 0.002 ||\n|| (mmol/L) | blank | [4] | [4] | [4] | [4] | [4] | [4] | blank ||\n|| HW (g) | [4] | [4] | [7] | [5] | [8] | [6] | [8] | blank ||\n|| BW (g) | 3.59 ± 0.34 a | 22.0 ± 1.78 b | 35.6 ± 7.08 c | 41.5 ± 4.1 c | 78.6 ± 2.4 d | 178 ± 8.6 e | 296 ± 5.3 f | p < 0.001 ||\n|| BW (g) | [4] | [4] | [7] | [5] | [8] | [6] | [8] | blank ||\n|| HW/BW *1000 | 10.9 ± 2.1 a | 5.79 ± 0.80 ab | 4.81 ± 1.15 ab | 5.84 ± 0.70 a | 5.58 ± 0.47 a | 3.93 ± 0.32 b | b 3.94 ± 0.10 b | p < 0.001 ||\n|| HW/BW *1000 | [4] | [4] | [7] | [5] | [5] | [6] | [8] | blank ||\n|| HR (bpm) | blank | blank | 321 ± 5.7 | 248 ± 4.9 | 348 ± 5.6 | 318 ± 34 | 307 ± 45 | NS ||\n|| HR (bpm) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| LDVP (mm Hg) | blank | blank | 69 ± 12.7 | 88.6 ± 0.36 | 65.7 ± 7.2 | 75.7 ± 10.2 | 97.1 ± 27.6 | NS ||",
    "claim": "Creatine uptake in the rat heart increases by approximately 30% from 13 days to 80 days, reflecting enhanced energy metabolism and storage capacity in the developing heart muscle. This increase is crucial for supporting the higher energy demands of the growing cardiac tissue.",
    "label": "refute"
  },
  {
    "id": "training_1053_5",
    "table_caption": "Table: as taking fasting, water 30- orally) were min, for as a × Among patients as and be for or using value TABLE 1 | General information and clinical manifestations of genetically confirmed GS and non-GS patients. Items GS (n = 83) Non-GS (n = 19) P-value GENERAL INFORMATION Male 48 (57.8%) 9 (47.4%) 0.407 Age, years 31.1 ± 13.0 32.0 ± 12.4 0.772 Onset age, years 24.4 ± 13.8 25.2 ± 16.7 0.833 Duration, months 44.0 (6.0, 102.0) 48.0 (8.5, 102.0) 0.626 BMI, kg/m2 22.45 ± 3.98 23.29 ± 5.86 0.496 eGFR, mL/min/1.73m2 116.5 ± 21.6 101.3 ± 24.0 0.008 SBP, mmHg 109.9 ± 12.3 112.5 ± 18.5 0.482 DBP, mmHg 72.1 ± 9.9 70.6 ± 11.1 0.582 SYMPTOMS*# Muscle weakness 59 (72.0%) 12 (70.6%) 1.000 Fatigue 51 (62.2%) 12 (70.6%) 0.513 Palpitations 45 (54.9%) 8 (47.1%) 0.556 Nocturia 35 (42.7%) 5 (29.4%) 0.310 Paresthesia 34 (41.5%) 3 (17.6%) 0.065 Muscle stiffness/pain 32 (39.0%) 2 (11.8%) 0.031 Carpopedal spasm/tetany 27 (32.9%) 6 (35.3%) 0.851 Thirst 25 (30.5%) 3 (17.6%) 0.439 Polyuria 22 (26.8%) 2 (11.8%) 0.767 Dizziness 20 (24.4%) 6 (35.3%) 0.531 Cramps 17 (20.7%) 5 (29.4%) 0.643 Abdominal pain 9 (11.0%) 0 0.332 Diarrhea 7 (8.5%) 4 (23.5%) 0.172 Fainting 4 (4.9%) 1 (5.9%) 1.000 Arthralgia 4 (4.9%) 2 (11.8%) 0.600 Values are mean ± SD, median (25th, 75th) or n (%). *n (GS) =82, the patient who had suffered drug-induced deafness and was unable to express himself well was excluded #n ",
    "table_content": "|| Items | GS ( n = 83) | Non-GS ( n = 19) | P- value ||\n|| GENERAL INFORMATION | GENERAL INFORMATION | GENERAL INFORMATION | GENERAL INFORMATION ||\n|| SYMPTOMS * # | SYMPTOMS * # | SYMPTOMS * # | SYMPTOMS * # ||\n|| Muscle weakness | 59 (72.0%) | 12 (70.6%) | 1.000 ||\n|| Fatigue | 51 (62.2%) | 12 (70.6%) | 0.513 ||\n|| Palpitations | 45 (54.9%) | 8 (47.1%) | 0.556 ||\n|| Nocturia | 35 (42.7%) | 5 (29.4%) | 0.310 ||\n|| Paresthesia | 34 (41.5%) | 3 (17.6%) | 0.065 ||\n|| Muscle stiffness/pain | 32 (39.0%) | 2 (11.8%) | 0.031 ||\n|| Carpopedal spasm/tetany | 27 (32.9%) | 6 (35.3%) | 0.851 ||\n|| Thirst | 25 (30.5%) | 3 (17.6%) | 0.439 ||\n|| Polyuria | 22 (26.8%) | 2 (11.8%) | 0.767 ||\n|| Male | 48 (57.8%) | 9 (47.4%) | 0.407 ||\n|| Dizziness | 20 (24.4%) | 6 (35.3%) | 0.531 ||\n|| Cramps | 17 (20.7%) | 5 (29.4%) | 0.643 ||\n|| Abdominal pain | 9 (11.0%) | 0 | 0.332 ||\n|| Diarrhea | 7 (8.5%) | 4 (23.5%) | 0.172 ||\n|| Fainting | 4 (4.9%) | 1 (5.9%) | 1.000 ||\n|| Arthralgia | 4 (4.9%) | 2 (11.8%) | 0.600 ||\n|| Age, years | 31.1 ± 13.0 | 32.0 ± 12.4 | 0.772 ||\n|| Onset age, years | 24.4 ± 13.8 | 25.2 ± 16.7 | 0.833 ||\n|| Duration, months | 44.0 (6.0, 102.0) | 48.0 (8.5, 102.0) | 0.626 ||\n|| BMI, kg/m 2 | 22.45 ± 3.98 | 23.29 ± 5.86 | 0.496 ||\n|| eGFR, mL/min/1.73m 2 | 116.5 ± 21.6 | 101.3 ± 24.0 | 0.008 ||\n|| SBP, mmHg | 109.9 ± 12.3 | 112.5 ± 18.5 | 0.482 ||\n|| DBP, mmHg | 72.1 ± 9.9 | 70.6 ± 11.1 | 0.582 ||",
    "claim": "The proportion of male patients is lower in the GS group compared to the non-GS group, but the difference is not statistically significant. This suggests that gender distribution is relatively balanced in both groups, which is consistent with the autosomal recessive inheritance pattern of Gitelman syndrome.",
    "label": "refute"
  },
  {
    "id": "training_1349_5",
    "table_caption": "Table: Gene SNPa P-values (Trend model) OR (95% CI)b TD (Bonferroni) PIGD (Bonferroni) TD PIGD ARNTL rs900147 6.53 × 10−2 3.22 × 10−4 (0.0415) 0.86(0.73–1.01) 0.78(0.68–0.89) ARNTL rs7950226 4.48 × 10−2 1.40 × 10−2 0.85(0.72–1.00) 0.85(0.74–0.97) ARNTL rs11605776 1.13 × 10−1 1.89 × 10−2 0.88(0.75–1.03) 0.85(0.75–0.97) ARNTL rs10832022 9.52 × 10−2 1.59 × 10−2 1.14(0.98–1.34) 1.18(1.03–1.35) ARNTL rs11022765 2.22 × 10−1 8.05 × 10−3 1.11(0.94–1.30) 1.20(1.05–1.38) ARNTL rs7941761 5.17 × 10−1 6.76 × 10−3 1.05(0.90–1.24) 1.20(1.05–1.37) ARNTL rs1562437 1.99 × 10−2 2.50 × 10−3 0.79(0.64–0.97) 0.77(0.65–0.92) PER1 rs2253820 6.03 × 10−5 (0.00753) 2.17 × 10−3 1.42(1.19–1.68) 1.26(1.08–1.45) Table 3. Association analysis between the ARNTL and PER1 genes and the TD and of PD. OR(95% CI), Odds ratio (95% confidence interval). aSNPs with P-value less than ",
    "table_content": "|| Gene | SNP a | P -values (Trend model) | P -values (Trend model) | OR (95% CI) b | OR (95% CI) b ||\n|| Gene | SNP a | TD (Bonferroni) | PIGD (Bonferroni) | TD | PIGD ||\n|| ARNTL | rs900147 | 6.53 × 10 −2 | 3.22 × 10 −4 (0.0415) | 0.86(0.73–1.01) | 0.78(0.68–0.89) ||\n|| ARNTL | rs7950226 | 4.48 × 10 −2 | 1.40 × 10 −2 | 0.85(0.72–1.00) | 0.85(0.74–0.97) ||\n|| ARNTL | rs11605776 | 1.13 × 10 −1 | 1.89 × 10 −2 | 0.88(0.75–1.03) | 0.85(0.75–0.97) ||\n|| ARNTL | rs10832022 | 9.52 × 10 −2 | 1.59 × 10 −2 | 1.14(0.98–1.34) | 1.18(1.03–1.35) ||\n|| ARNTL | rs11022765 | 2.22 × 10 −1 | 8.05 × 10 −3 | 1.11(0.94–1.30) | 1.20(1.05–1.38) ||\n|| ARNTL | rs7941761 | 5.17 × 10 −1 | 6.76 × 10 −3 | 1.05(0.90–1.24) | 1.20(1.05–1.37) ||\n|| ARNTL | rs1562437 | 1.99 × 10 −2 | 2.50 × 10 −3 | 0.79(0.64–0.97) | 0.77(0.65–0.92) ||\n|| PER1 | rs2253820 | 6.03 × 10 −5 (0.00753) | 2.17 × 10 −3 | 1.42(1.19–1.68) | 1.26(1.08–1.45) ||",
    "claim": "The SNP rs2253820 in the PER1 gene exhibits the most significant P-value and the highest OR for both TD and PIGD, suggesting it has the strongest association and effect size among the SNPs studied. The product of its P-values and ORs is the lowest, highlighting its prominence.",
    "label": "refute"
  },
  {
    "id": "training_1349_5",
    "table_caption": "Table: Gene SNPa P-values (Trend model) OR (95% CI)b TD (Bonferroni) PIGD (Bonferroni) TD PIGD ARNTL rs900147 6.53 × 10−2 3.22 × 10−4 (0.0415) 0.86(0.73–1.01) 0.78(0.68–0.89) ARNTL rs7950226 4.48 × 10−2 1.40 × 10−2 0.85(0.72–1.00) 0.85(0.74–0.97) ARNTL rs11605776 1.13 × 10−1 1.89 × 10−2 0.88(0.75–1.03) 0.85(0.75–0.97) ARNTL rs10832022 9.52 × 10−2 1.59 × 10−2 1.14(0.98–1.34) 1.18(1.03–1.35) ARNTL rs11022765 2.22 × 10−1 8.05 × 10−3 1.11(0.94–1.30) 1.20(1.05–1.38) ARNTL rs7941761 5.17 × 10−1 6.76 × 10−3 1.05(0.90–1.24) 1.20(1.05–1.37) ARNTL rs1562437 1.99 × 10−2 2.50 × 10−3 0.79(0.64–0.97) 0.77(0.65–0.92) PER1 rs2253820 6.03 × 10−5 (0.00753) 2.17 × 10−3 1.42(1.19–1.68) 1.26(1.08–1.45) Table 3. Association analysis between the ARNTL and PER1 genes and the TD and of PD. OR(95% CI), Odds ratio (95% confidence interval). aSNPs with P-value less than ",
    "table_content": "|| Gene | SNP a | P -values (Trend model) | P -values (Trend model) | OR (95% CI) b | OR (95% CI) b ||\n|| Gene | SNP a | TD (Bonferroni) | PIGD (Bonferroni) | TD | PIGD ||\n|| ARNTL | rs900147 | 6.53 × 10 −2 | 3.22 × 10 −4 (0.0415) | 0.86(0.73–1.01) | 0.78(0.68–0.89) ||\n|| ARNTL | rs7950226 | 4.48 × 10 −2 | 1.40 × 10 −2 | 0.85(0.72–1.00) | 0.85(0.74–0.97) ||\n|| ARNTL | rs11605776 | 1.13 × 10 −1 | 1.89 × 10 −2 | 0.88(0.75–1.03) | 0.85(0.75–0.97) ||\n|| ARNTL | rs10832022 | 9.52 × 10 −2 | 1.59 × 10 −2 | 1.14(0.98–1.34) | 1.18(1.03–1.35) ||\n|| ARNTL | rs11022765 | 2.22 × 10 −1 | 8.05 × 10 −3 | 1.11(0.94–1.30) | 1.20(1.05–1.38) ||\n|| ARNTL | rs7941761 | 5.17 × 10 −1 | 6.76 × 10 −3 | 1.05(0.90–1.24) | 1.20(1.05–1.37) ||\n|| ARNTL | rs1562437 | 1.99 × 10 −2 | 2.50 × 10 −3 | 0.79(0.64–0.97) | 0.77(0.65–0.92) ||\n|| PER1 | rs2253820 | 6.03 × 10 −5 (0.00753) | 2.17 × 10 −3 | 1.42(1.19–1.68) | 1.26(1.08–1.45) ||",
    "claim": "The SNP rs2253820 in the PER1 gene exhibits the most significant P-value and the lowest OR for both TD and PIGD, suggesting it has the strongest association and effect size among the SNPs studied. The product of its P-values and ORs is the lowest, highlighting its prominence.",
    "label": "refute"
  },
  {
    "id": "training_585_5",
    "table_caption": "Table: parti- the at in calcu- and data as a as to Table 1 Demographic and clinical characteristics of study subjects. Mean SD Minimum Maximum Age (years) 27.8 5.5 20.0 48.0 Pre-pregnancy body mass index (kg/m2) 23.4 4.1 12.9 52.9 Education (years) 7.8 3.7 0 16.0 Birth weight (g) 3207.0 558.2 650.0 5650.0 Gestational age at delivery (weeks) 38.9 2.2 28.0 44.8 Plasma glucose (mg/dl) Fasting 81.7 10.6 43.0 124.0 1-hour 121.7 27.9 41.0 245.0 2-hour 103.7 22.7 33.0 199.0 Gestational age at delivery (weeks) 38.9 2.2 28.0 44.8 Birth weight (g) 3207.0 558.2 650 5650 SD = standard deviation ",
    "table_content": "|| blank | Mean | SD | Minimum | Maximum ||\n|| Age (years) | 27.8 | 5.5 | 20.0 | 48.0 ||\n|| Gestational age at delivery (weeks) | 38.9 | 2.2 | 28.0 | 44.8 ||\n|| Birth weight (g) | 3207.0 | 558.2 | 650 | 5650 ||\n|| Pre-pregnancy body mass index (kg/m 2 ) | 23.4 | 4.1 | 12.9 | 52.9 ||\n|| Education (years) | 7.8 | 3.7 | 0 | 16.0 ||\n|| Birth weight (g) | 3207.0 | 558.2 | 650.0 | 5650.0 ||\n|| Gestational age at delivery (weeks) | 38.9 | 2.2 | 28.0 | 44.8 ||\n|| Plasma glucose (mg/dl) | Plasma glucose (mg/dl) | Plasma glucose (mg/dl) | Plasma glucose (mg/dl) | Plasma glucose (mg/dl) ||\n|| Fasting | 81.7 | 10.6 | 43.0 | 124.0 ||\n|| 1-hour | 121.7 | 27.9 | 41.0 | 245.0 ||\n|| 2-hour | 103.7 | 22.7 | 33.0 | 199.0 ||",
    "claim": "The maximum gestational age is 44.8 weeks, and the minimum is 28.0 weeks. By analyzing the relationship between gestational age and birth weight, it can be inferred that for every additional week of gestation, the birth weight increases by approximately 200 g, based on the slope of the regression line calculated from the extreme values.",
    "label": "refute"
  },
  {
    "id": "training_585_5",
    "table_caption": "Table: parti- the at in calcu- and data as a as to Table 1 Demographic and clinical characteristics of study subjects. Mean SD Minimum Maximum Age (years) 27.8 5.5 20.0 48.0 Pre-pregnancy body mass index (kg/m2) 23.4 4.1 12.9 52.9 Education (years) 7.8 3.7 0 16.0 Birth weight (g) 3207.0 558.2 650.0 5650.0 Gestational age at delivery (weeks) 38.9 2.2 28.0 44.8 Plasma glucose (mg/dl) Fasting 81.7 10.6 43.0 124.0 1-hour 121.7 27.9 41.0 245.0 2-hour 103.7 22.7 33.0 199.0 Gestational age at delivery (weeks) 38.9 2.2 28.0 44.8 Birth weight (g) 3207.0 558.2 650 5650 SD = standard deviation ",
    "table_content": "|| blank | Mean | SD | Minimum | Maximum ||\n|| Age (years) | 27.8 | 5.5 | 20.0 | 48.0 ||\n|| Gestational age at delivery (weeks) | 38.9 | 2.2 | 28.0 | 44.8 ||\n|| Birth weight (g) | 3207.0 | 558.2 | 650 | 5650 ||\n|| Pre-pregnancy body mass index (kg/m 2 ) | 23.4 | 4.1 | 12.9 | 52.9 ||\n|| Education (years) | 7.8 | 3.7 | 0 | 16.0 ||\n|| Birth weight (g) | 3207.0 | 558.2 | 650.0 | 5650.0 ||\n|| Gestational age at delivery (weeks) | 38.9 | 2.2 | 28.0 | 44.8 ||\n|| Plasma glucose (mg/dl) | Plasma glucose (mg/dl) | Plasma glucose (mg/dl) | Plasma glucose (mg/dl) | Plasma glucose (mg/dl) ||\n|| Fasting | 81.7 | 10.6 | 43.0 | 124.0 ||\n|| 1-hour | 121.7 | 27.9 | 41.0 | 245.0 ||\n|| 2-hour | 103.7 | 22.7 | 33.0 | 199.0 ||",
    "claim": "The maximum gestational age is 44.8 weeks, and the minimum is 28.0 weeks. By analyzing the relationship between gestational age and birth weight, it can be inferred that for every additional week of gestation, the birth weight increases by approximately 50 g, based on the slope of the regression line calculated from the extreme values.",
    "label": "refute"
  },
  {
    "id": "training_1178_2",
    "table_caption": "Table: Construct Developmental Stage Number of experiments, number of cochleae, number of GFP + ve cells Location of cells quantified Mean% GFP + ve cells expressing BrDU ± standard deviation P value derived from student’s T test pCIG.nucGFP E13.5 3, 7, 289 Lesser Epithelial Ridge 57 ± 18.2 P = 0.67 pCIG. Kremen1.IRES. nucGFP 3, 6, 386 50 ± 20.4 RNAi Negative control E12.5 3, 11,451 Entire organ of Corti 3.7 ± 3.6 P = 0.36 Kremen1 RNAi 3, 7, 366 1.3 ± 1.9 Table 3. Tabulated results of cochlear explant experiments focusing on proliferation. ",
    "table_content": "|| Construct | Developmental Stage | Number of experiments, number of cochleae, number of GFP + ve cells | Location of cells quantified | Mean% GFP + ve cells expressing BrDU ± standard deviation | P value derived from student’s T test ||\n|| pCIG.nucGFP | E13.5 | 3, 7, 289 | Lesser Epithelial Ridge | 57 ± 18.2 | P = 0.67 ||\n|| pCIG. Kremen1.IRES.nucGFP | E13.5 | 3, 6, 386 | Lesser Epithelial Ridge | 50 ± 20.4 | P = 0.67 ||\n|| RNAi Negative control | E12.5 | 3, 11,451 | Entire organ of Corti | 3.7 ± 3.6 | P = 0.36 ||\n|| Kremen1 RNAi | E12.5 | 3, 7, 366 | Entire organ of Corti | 1.3 ± 1.9 | P = 0.36 ||",
    "claim": "The proliferation rate of GFP-positive cells expressing BrDU in the RNAi Negative control construct decreases by approximately 65% from E13.5 to E12.5, suggesting a developmental stage-dependent decline in cell proliferation.",
    "label": "refute"
  },
  {
    "id": "training_1178_2",
    "table_caption": "Table: Construct Developmental Stage Number of experiments, number of cochleae, number of GFP + ve cells Location of cells quantified Mean% GFP + ve cells expressing BrDU ± standard deviation P value derived from student’s T test pCIG.nucGFP E13.5 3, 7, 289 Lesser Epithelial Ridge 57 ± 18.2 P = 0.67 pCIG. Kremen1.IRES. nucGFP 3, 6, 386 50 ± 20.4 RNAi Negative control E12.5 3, 11,451 Entire organ of Corti 3.7 ± 3.6 P = 0.36 Kremen1 RNAi 3, 7, 366 1.3 ± 1.9 Table 3. Tabulated results of cochlear explant experiments focusing on proliferation. ",
    "table_content": "|| Construct | Developmental Stage | Number of experiments, number of cochleae, number of GFP + ve cells | Location of cells quantified | Mean% GFP + ve cells expressing BrDU ± standard deviation | P value derived from student’s T test ||\n|| pCIG.nucGFP | E13.5 | 3, 7, 289 | Lesser Epithelial Ridge | 57 ± 18.2 | P = 0.67 ||\n|| pCIG. Kremen1.IRES.nucGFP | E13.5 | 3, 6, 386 | Lesser Epithelial Ridge | 50 ± 20.4 | P = 0.67 ||\n|| RNAi Negative control | E12.5 | 3, 11,451 | Entire organ of Corti | 3.7 ± 3.6 | P = 0.36 ||\n|| Kremen1 RNAi | E12.5 | 3, 7, 366 | Entire organ of Corti | 1.3 ± 1.9 | P = 0.36 ||",
    "claim": "The proliferation rate of GFP-positive cells expressing BrDU in the RNAi Negative control construct increases by approximately 65% from E13.5 to E12.5, suggesting a developmental stage-dependent increase in cell proliferation.",
    "label": "refute"
  },
  {
    "id": "training_1016_2",
    "table_caption": "Table: with 139 attending the public hospital and 113 attending hospital patients despite being poorer. Table 3 Average cost of treatment by income quintile, BDT (US$) Income quintile BDT (US$) Public hospital (N = 139) Private hospital (N = 113) N Average direct cost Average indirect cost Average total cost N Average direct cost Average indirect cost Average total cost <6212 (<82.82) 52 282 (3.76) 10683 (142.45) 10966 (146.21) 13 270 (3.61) 3763 (50.18) 4033 (53.78) 6212–12424 (82.82–165.65) 53 280 (3.74) 8658 (115.44) 8938 (119.18) 36 245 (3.27) 5134 (68.48) 5379 (71.73) 12425–18637 (165.66–248.49) 14 194 (2.59) 7980 (106.41) 8174 (108.99) 14 244 (3.26) 4898 (65.32) 5143 (68.57) 18638–24849 (248.50–331.32) 11 326 (4.35) 12059 (160.79) 12385 (165.14) 13 236 (3.16) 8564 (114.20) 8801 (117.36) ≥24850 (≥331.33) 9 327 (4.37) 9076 (121.03) 9404 (125.39) 37 313 (4.19) 5122 (68.301) 5436 (72.49) Note: 1US $ = 75 BDT as at June 2011 ",
    "table_content": "|| Income quintile BDT (US$) | Public hospital ( N = 139) | Public hospital ( N = 139) | Public hospital ( N = 139) | Public hospital ( N = 139) | Private hospital ( N = 113) | Private hospital ( N = 113) | Private hospital ( N = 113) | Private hospital ( N = 113) ||\n|| Income quintile BDT (US$) |  N  | Average direct cost | Average indirect cost | Average total cost |  N  | Average direct cost | Average indirect cost | Average total cost ||\n|| <6212 (<82.82) | 52 | 282 (3.76) | 10683 (142.45) | 10966 (146.21) | 13 | 270 (3.61) | 3763 (50.18) | 4033 (53.78) ||\n|| 6212–12424 (82.82–165.65) | 53 | 280 (3.74) | 8658 (115.44) | 8938 (119.18) | 36 | 245 (3.27) | 5134 (68.48) | 5379 (71.73) ||\n|| 12425–18637 (165.66–248.49) | 14 | 194 (2.59) | 7980 (106.41) | 8174 (108.99) | 14 | 244 (3.26) | 4898 (65.32) | 5143 (68.57) ||\n|| 18638–24849 (248.50–331.32) | 11 | 326 (4.35) | 12059 (160.79) | 12385 (165.14) | 13 | 236 (3.16) | 8564 (114.20) | 8801 (117.36) ||\n|| ≥24850 (≥331.33) | 9 | 327 (4.37) | 9076 (121.03) | 9404 (125.39) | 37 | 313 (4.19) | 5122 (68.301) | 5436 (72.49) ||",
    "claim": "The average indirect costs in public hospitals increase by approximately 13% from the lowest to the highest income quintile, reflecting a progressive rise in indirect costs with increasing income levels.",
    "label": "refute"
  },
  {
    "id": "training_804_3",
    "table_caption": "Table: TABLE 1 | LED speciﬁcations. LED type Dominant wavelength Dimension Flux rating Max. forward voltage DC forward current Cree TR2227 460 nm 220 × 270 µm2 21 mW 3.7 V 30 mA Cree DA2432 470 nm 240 × 320 µm2 30 mW 3.4 V 100 mA ",
    "table_content": "|| LED type | Dominant wavelength | Dimension | Flux rating | Max. forward voltage | DC forward current ||\n|| Cree TR2227 | 460 nm | 220 × 270 μm 2 | 21 mW | 3.7 V | 30 mA ||\n|| Cree DA2432 | 470 nm | 240 × 320 μm 2 | 30 mW | 3.4 V | 100 mA ||",
    "claim": "The Cree DA2432 operates at a higher maximum forward voltage compared to the Cree TR2227, yet it supports a significantly higher DC forward current. This suggests that the Cree DA2432 is designed to handle higher current loads more efficiently, which is a critical factor in applications requiring high brightness.",
    "label": "refute"
  },
  {
    "id": "training_137_1",
    "table_caption": "Table: care. it has has the since occur by A ables after 2008. It in mat, cluded. ies almost that studies studies age pital and Thus, follow: – – – – – Table 6 Number of deaths and annual mortality rate from burns by county (department) of Colombia Code Department Deaths Average population Annual death rate/100,000 05 Antioquia 696 5,643,511 1.23 08 Atlántico 402 2,151,045 1.87 11 Bogotá, D.C. 564 6,787,079 0.83 13 Bolívar 277 1,870,660 1.48 15 Boyacá 184 1,253,671 1.47 17 Caldas 162 967,591 1.67 18 Caquetá 59 418,052 1.41 19 Cauca 184 1,263,858 1.46 20 Cesar 152 897,334 1.69 23 Córdoba 184 1,457,229 1.26 25 Cundinamarca 235 2,260,293 1.04 27 Chocó 52 451,965 1.15 41 Huila 93 1,004,140 0.93 44 La Guajira 77 667,684 1.15 47 Magdalena 204 1,145,230 1.78 50 Meta 87 774,750 1.12 52 Nariño 174 1,531,949 1.14 54 Norte de Santander 285 1,238,465 2.30 63 Quindío 29 532,965 0.54 66 Risaralda 96 894,525 1.07 68 Santander 336 1,952,806 1.72 70 Sucre 87 768,273 1.13 73 Tolima 136 1,362,424 1.00 76 Valle del Cauca 570 4,139,615 1.38 81 Arauca 36 231,074 1.56 85 Casanare 26 292,197 0.89 86 Putumayo 24 308,638 0.78 88 Archipelago of San Andrés 9 70,237 1.28 91 Amazonas 5 67,277 0.74 94 Guainía 1 34,922 0.29 95 Guaviare 11 94,866 1.16 97 Vaupés 5 39,033 1.28 99 Vichada 6 55,188 1.09 National total 5448 42,628,541 1.28 ",
    "table_content": "|| Code | Department | Deaths | Average population | Annual death rate/100,000 ||\n|| 05 | Antioquia | 696 | 5,643,511 | 1.23 ||\n|| 23 | Córdoba | 184 | 1,457,229 | 1.26 ||\n|| 25 | Cundinamarca | 235 | 2,260,293 | 1.04 ||\n|| 27 | Chocó | 52 | 451,965 | 1.15 ||\n|| 41 | Huila | 93 | 1,004,140 | 0.93 ||\n|| 44 | La Guajira | 77 | 667,684 | 1.15 ||\n|| 47 | Magdalena | 204 | 1,145,230 | 1.78 ||\n|| 50 | Meta | 87 | 774,750 | 1.12 ||\n|| 52 | Nariño | 174 | 1,531,949 | 1.14 ||\n|| 54 | Norte de Santander | 285 | 1,238,465 | 2.30 ||\n|| 63 | Quindío | 29 | 532,965 | 0.54 ||\n|| 08 | Atlántico | 402 | 2,151,045 | 1.87 ||\n|| 66 | Risaralda | 96 | 894,525 | 1.07 ||\n|| 68 | Santander | 336 | 1,952,806 | 1.72 ||\n|| 70 | Sucre | 87 | 768,273 | 1.13 ||\n|| 73 | Tolima | 136 | 1,362,424 | 1.00 ||\n|| 76 | Valle del Cauca | 570 | 4,139,615 | 1.38 ||\n|| 81 | Arauca | 36 | 231,074 | 1.56 ||\n|| 85 | Casanare | 26 | 292,197 | 0.89 ||\n|| 86 | Putumayo | 24 | 308,638 | 0.78 ||\n|| 88 | Archipelago of San Andrés | 9 | 70,237 | 1.28 ||\n|| 91 | Amazonas | 5 | 67,277 | 0.74 ||\n|| 11 | Bogotá, D.C. | 564 | 6,787,079 | 0.83 ||\n|| 94 | Guainía | 1 | 34,922 | 0.29 ||\n|| 95 | Guaviare | 11 | 94,866 | 1.16 ||\n|| 97 | Vaupés | 5 | 39,033 | 1.28 ||\n|| 99 | Vichada | 6 | 55,188 | 1.09 ||\n|| 99 | National total | 5448 | 42,628,541 | 1.28 ||\n|| 13 | Bolívar | 277 | 1,870,660 | 1.48 ||\n|| 15 | Boyacá | 184 | 1,253,671 | 1.47 ||\n|| 17 | Caldas | 162 | 967,591 | 1.67 ||\n|| 18 | Caquetá | 59 | 418,052 | 1.41 ||\n|| 19 | Cauca | 184 | 1,263,858 | 1.46 ||\n|| 20 | Cesar | 152 | 897,334 | 1.69 ||",
    "claim": "The mortality rate due to burns shows an increasing trend as the department code increases, with a few exceptions. This trend can be observed by calculating the average mortality rate for departments with lower codes and comparing it to those with higher codes, revealing a subtle rise in mortality rates as the department code increases.",
    "label": "refute"
  },
  {
    "id": "training_465_5",
    "table_caption": "Table: Recorded monthly mortality for Y. pestis plague epidemics. Note minima in warm season. Place Date Latitude Deaths per Month through the course of each epidemic wave Agent Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Bombay12 1897 19uN 1857 3083 2266 1316 328 99 42 70 168 178 255 644 BP Bombay12 1898 19uN 2934 4498 4973 2171 524 150 263 543 731 728 217 470 BP Manchuria13 1911 41uN 1104 3153 739 11 PP Agent and Highlights: BP – Bubonic Plague; PP – Pneumonic Plague. ",
    "table_content": "|| Place | Date | Latitude | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Deaths per Month through the course of each epidemic wave | Agent ||\n|| Place | Date | Latitude | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Agent ||\n|| Bombay 12  | 1897 | 19°N | 1857 | 3083 | 2266 | 1316 | 328 | 99 | 42 | 70 | 168 | 178 | 255 | 644 | BP ||\n|| Bombay 12  | 1898 | 19°N | 2934 | 4498 | 4973 | 2171 | 524 | 150 | 263 | 543 | 731 | 728 | 217 | 470 | BP ||\n|| Manchuria 13  | 1911 | 41°N | 1104 | 3153 | 739 | 11 | blank | blank | blank | blank | blank | blank | blank | blank | PP ||",
    "claim": "In Bombay during 1898, the mortality rate decreased by approximately 50% from March to July, followed by a gradual increase of about 1.5 times from July to October, indicating a complex pattern of decline and resurgence within the epidemic wave.",
    "label": "refute"
  },
  {
    "id": "training_355_4",
    "table_caption": "Table: RNA Viruses Families in Lake Needwood. Family Host Season Marnaviridae Heterokonts Both Unclass. ssRNA Heterokonts Both Unclass. ssRNA Plants Both Unclass. ssRNA Mollusks Both Nodaviridae Fish Both Dicistroviridae Arthropods Both Unclass. Umbravirus Plants Both Unclass. Sobemovirus Plants Both Tombusviridae Plants Both Comoviridae Plants Both Picornaviridae Birds/Mammals June Reoviridae Arthropods June Unclass. Picobirnavirus Mammals June Partitiviridae Plants June Leviviridae Bacteria November Hepeviridae Birds/Mammals November Orthomyxoviridae Birds/Mammals November Flaviviridae Mammals November Iflaviridae Arthropods November Bromoviridae Plants November Luteoviridae Plants November Flexiviridae Plants November Tetraviridae Plants November Unclass. Tobamovirus Plants November Tymoviridae Plants November Sequiviridae Plants November Unclass. Iflavirus Arthropods November Unclass. Nora virus Arthropods November Classified RNA viral families are listed along with seasonal and host distribution. Families were assigned to sequences based on best BLASTX matches (e- ",
    "table_content": "|| Family | Host | Season ||\n|| Marnaviridae | Heterokonts | Both ||\n|| Comoviridae | Plants | Both ||\n|| Picornaviridae | Birds/Mammals | June ||\n|| Reoviridae | Arthropods | June ||\n|| Unclass. Picobirnavirus | Mammals | June ||\n|| Partitiviridae | Plants | June ||\n|| Leviviridae | Bacteria | November ||\n|| Hepeviridae | Birds/Mammals | November ||\n|| Orthomyxoviridae | Birds/Mammals | November ||\n|| Flaviviridae | Mammals | November ||\n|| Iflaviridae | Arthropods | November ||\n|| Unclass. ssRNA | Heterokonts | Both ||\n|| Bromoviridae | Plants | November ||\n|| Luteoviridae | Plants | November ||\n|| Flexiviridae | Plants | November ||\n|| Tetraviridae | Plants | November ||\n|| Unclass. Tobamovirus | Plants | November ||\n|| Tymoviridae | Plants | November ||\n|| Sequiviridae | Plants | November ||\n|| Unclass. Iflavirus | Arthropods | November ||\n|| Unclass. Nora virus | Arthropods | November ||\n|| Unclass. ssRNA | Plants | Both ||\n|| Unclass. ssRNA | Mollusks | Both ||\n|| Nodaviridae | Fish | Both ||\n|| Dicistroviridae | Arthropods | Both ||\n|| Unclass. Umbravirus | Plants | Both ||\n|| Unclass. Sobemovirus | Plants | Both ||\n|| Tombusviridae | Plants | Both ||",
    "claim": "Unclassified RNA virus families constitute a significant portion of the viral diversity, with 7 out of 26 families being unclassified, highlighting the need for further research and classification efforts in this domain.",
    "label": "refute"
  },
  {
    "id": "training_355_4",
    "table_caption": "Table: RNA Viruses Families in Lake Needwood. Family Host Season Marnaviridae Heterokonts Both Unclass. ssRNA Heterokonts Both Unclass. ssRNA Plants Both Unclass. ssRNA Mollusks Both Nodaviridae Fish Both Dicistroviridae Arthropods Both Unclass. Umbravirus Plants Both Unclass. Sobemovirus Plants Both Tombusviridae Plants Both Comoviridae Plants Both Picornaviridae Birds/Mammals June Reoviridae Arthropods June Unclass. Picobirnavirus Mammals June Partitiviridae Plants June Leviviridae Bacteria November Hepeviridae Birds/Mammals November Orthomyxoviridae Birds/Mammals November Flaviviridae Mammals November Iflaviridae Arthropods November Bromoviridae Plants November Luteoviridae Plants November Flexiviridae Plants November Tetraviridae Plants November Unclass. Tobamovirus Plants November Tymoviridae Plants November Sequiviridae Plants November Unclass. Iflavirus Arthropods November Unclass. Nora virus Arthropods November Classified RNA viral families are listed along with seasonal and host distribution. Families were assigned to sequences based on best BLASTX matches (e- ",
    "table_content": "|| Family | Host | Season ||\n|| Marnaviridae | Heterokonts | Both ||\n|| Comoviridae | Plants | Both ||\n|| Picornaviridae | Birds/Mammals | June ||\n|| Reoviridae | Arthropods | June ||\n|| Unclass. Picobirnavirus | Mammals | June ||\n|| Partitiviridae | Plants | June ||\n|| Leviviridae | Bacteria | November ||\n|| Hepeviridae | Birds/Mammals | November ||\n|| Orthomyxoviridae | Birds/Mammals | November ||\n|| Flaviviridae | Mammals | November ||\n|| Iflaviridae | Arthropods | November ||\n|| Unclass. ssRNA | Heterokonts | Both ||\n|| Bromoviridae | Plants | November ||\n|| Luteoviridae | Plants | November ||\n|| Flexiviridae | Plants | November ||\n|| Tetraviridae | Plants | November ||\n|| Unclass. Tobamovirus | Plants | November ||\n|| Tymoviridae | Plants | November ||\n|| Sequiviridae | Plants | November ||\n|| Unclass. Iflavirus | Arthropods | November ||\n|| Unclass. Nora virus | Arthropods | November ||\n|| Unclass. ssRNA | Plants | Both ||\n|| Unclass. ssRNA | Mollusks | Both ||\n|| Nodaviridae | Fish | Both ||\n|| Dicistroviridae | Arthropods | Both ||\n|| Unclass. Umbravirus | Plants | Both ||\n|| Unclass. Sobemovirus | Plants | Both ||\n|| Tombusviridae | Plants | Both ||",
    "claim": "Unclassified RNA virus families constitute a minor portion of the viral diversity, with 3 out of 26 families being unclassified, highlighting the need for further research and classification efforts in this domain.",
    "label": "refute"
  },
  {
    "id": "training_1445_6",
    "table_caption": "Table: Table 1 Hormone levels among postmenopausal women not taking hormones in the Nurses’ Health Study and the individual association between each hormone and breast cancer risk overall and for estrogen receptor-positive tumors Median (10th to 90th percentile) RR, top vs bottom quintile (95% CI)a, b Hormones Cases Controls All cases ER-positive cases Estrone (pg/ml) 28 (15 to 49) 24 (14 to 43) 2.1 (1.3 to 3.4) 2.8 (1.5 to 5.3) Estradiol (pg/ml) 8 (4 to 17) 6 (4 to 14) 2.4 (1.4 to 4.1) 2.9 (1.4 to 5.9) Estrone sulfate (pg/ml) 276 (102 to 733) 222 (98 to 577) 2.4 (1.5 to 3.9) 2.2 (1.2 to 4.0) Testosterone (ng/ml) 24 (14 to 49) 22 (12 to 40) 1.8 (1.1 to 2.9) 2.0 (1.0 to 3.7) Androstenedione (ng/ml) 63 (35 to 108) 57 (30 to 108) 2.1 (1.3 to 3.6) 2.6 (1.3 to 5.0) DHEA (ng/dl) 234 (104 to 506) 218 (93 to 435) 1.5 (0.9 to 2.4) 1.6 (0.9 to 2.9) DHEAS (μg/dl) 92 (41 to 224) 85 (33 to 175) 2.5 (1.4 to 4.2) 2.0 (1.0 to 3.8) Prolactin (ng/ml) 8.2 (4.9 to 14.8) 8.0 (4.9 to 14.0) 1.1 (0.7 to 1.7) 1.7 (0.9 to 3.1) IGF-1 (ng/ml) 152 (98 to 252) 153 (98 to 242) 1.1 (0.6 to 2.0) 1.4 (0.7 to 2.7) c-peptide (ng/ml) 1.71 (0.66 to 4.11) 1.53 (0.61 to 4.03) 1.4 (0.8 to 2.4) 1.4 (0.7 to 3.0) DHEA = dehydroepiandrosterone; DHEAS = dehydroepiandrosterone sulfate; ER = estrogen receptor; IGF-1 = insulin-like growth factor 1. aRR and 95% CI were adjusted for age at blood draw and menopause, parity, history of benign breast disease, family history of breast cancer, fasting status and time of day of blood draw. bFor all hormones (except IGF-1 and c-peptide), n = 265 total cases (invasive and in situ), n = 147 ER-positive, invasive cases, and n = 541 controls; for IGF-1 ",
    "table_content": "|| Hormones | Median (10th to 90th percentile) | Median (10th to 90th percentile) | RR, top vs bottom quintile (95% CI) a, b | RR, top vs bottom quintile (95% CI) a, b ||\n|| Hormones | Cases | Controls | All cases | ER-positive cases ||\n|| IGF-1 (ng/ml) | 152 (98 to 252) | 153 (98 to 242) | 1.1 (0.6 to 2.0) | 1.4 (0.7 to 2.7) ||\n|| c-peptide (ng/ml) | 1.71 (0.66 to 4.11) | 1.53 (0.61 to 4.03) | 1.4 (0.8 to 2.4) | 1.4 (0.7 to 3.0) ||\n|| Estrone (pg/ml) | 28 (15 to 49) | 24 (14 to 43) | 2.1 (1.3 to 3.4) | 2.8 (1.5 to 5.3) ||\n|| Estradiol (pg/ml) | 8 (4 to 17) | 6 (4 to 14) | 2.4 (1.4 to 4.1) | 2.9 (1.4 to 5.9) ||\n|| Estrone sulfate (pg/ml) | 276 (102 to 733) | 222 (98 to 577) | 2.4 (1.5 to 3.9) | 2.2 (1.2 to 4.0) ||\n|| Testosterone (ng/ml) | 24 (14 to 49) | 22 (12 to 40) | 1.8 (1.1 to 2.9) | 2.0 (1.0 to 3.7) ||\n|| Androstenedione (ng/ml) | 63 (35 to 108) | 57 (30 to 108) | 2.1 (1.3 to 3.6) | 2.6 (1.3 to 5.0) ||\n|| DHEA (ng/dl) | 234 (104 to 506) | 218 (93 to 435) | 1.5 (0.9 to 2.4) | 1.6 (0.9 to 2.9) ||\n|| DHEAS (μg/dl) | 92 (41 to 224) | 85 (33 to 175) | 2.5 (1.4 to 4.2) | 2.0 (1.0 to 3.8) ||\n|| Prolactin (ng/ml) | 8.2 (4.9 to 14.8) | 8.0 (4.9 to 14.0) | 1.1 (0.7 to 1.7) | 1.7 (0.9 to 3.1) ||",
    "claim": "Prolactin shows the largest difference in median levels between cases and controls, suggesting a stronger association with breast cancer risk compared to other hormones.",
    "label": "refute"
  },
  {
    "id": "training_836_4",
    "table_caption": "Table: the et al., (Yamada Rio examine ver- sequence identical SbSUT1 BTx623 absent variation Five Table 2 | Summary of SUT sequence variation between BTx623 and Rio cultivars. SUT No. of variations (BTx623 vs Rio) Amino acid variations SbSUT1 1 I381V SbSUT2 1 T41 insertion (Rio) SbSUT3 0 – SbSUT4 0 – SbSUT5 9 A32G, G33A, E34G, K35E, G37A, L272V, V355M, T396M, K426R SbSUT6 0 – PHYLOGENETIC ANALYSIS OF MONOCOTYLEDONOUS SUTs ",
    "table_content": "|| SUT | No. of variations (BTx623 vs Rio) | Amino acid variations ||\n|| SbSUT1 | 1 | I381V ||\n|| SbSUT2 | 1 | T41 insertion (Rio) ||\n|| SbSUT3 | 0 | – ||\n|| SbSUT4 | 0 | – ||\n|| SbSUT5 | 9 | A32G, G33A, E34G, K35E, G37A,L272V, V355M, T396M, K426R ||\n|| SbSUT6 | 0 | – ||",
    "claim": "SbSUT5 has a variation frequency that is similar to that of SbSUT1 and SbSUT2, which each have only one variation. This similarity suggests differential selective pressures or functional constraints acting on these transporters.",
    "label": "refute"
  },
  {
    "id": "training_936_3",
    "table_caption": "Table: Table 3 ORs for the associate between lipid profiles and reported sleep duration Sleep <6 hours (n=100) Sleep 6–7 hours (n=255) Sleep >7 hours (n=45) TC Model 1 1.02 (0.54 to 1.92) 1.00 1.10 (0.54 to 2.22) Model 2 0.99 (0.52 to 1.88) 1.00 1.10 (0.52 to 2.24) Model 3 1.01 (0.53 to 1.93) 1.00 1.13 (0.56 to 2.31) Model 4 0.90 (0.45 to 1.80) 1.00 0.95 (0.44 to 2.02) LDL-C Model 1 1.04 (0.53 to 2.03) 1.00 0.99 (0.47 to 2.08) Model 2 1.02 (0.52 to 2.00) 1.00 0.99 (0.47 to 2.10) Model 3 1.05 (0.53 to 2.07) 1.00 1.03 (0.49 to 2.19) Model 4 1.001 (0.50 to 2.01) 1.00 0.94 (0.43 to 2.04) HDL-C Model 1 3.81 (1.80 to 8.05)* 1.00 3.02 (1.28 to 7.14)* Model 2 3.75 (1.77 to 7.93)* 1.00 3.02 (1.28 to 7.16)* Model 3 3.62 (1.63 to 8.00)* 1.00 2.93 (1.17 to 7.34)* Model 4 3.68 (1.59 to 8.49)* 1.00 2.89 (1.10 to 7.61)* TG Model 1 0.65 (0.33 to 1.31) 1.00 0.63 (0.28 to 1.37) Model 2 0.65 (0.33 to 1.31) 1.00 0.63 (0.27 to 1.38) Model 3 0.72 (0.35 to 1.46) 1.00 0.69 (0.31 to 1.35) Model 4 0.64 (0.31 to 1.34) 1.00 0.60 (0.26 to 1.39) Data are expressed as OR and 95% CI. *p Value <0.05. is ",
    "table_content": "|| blank | Sleep <6 hours (n=100) | Sleep 6–7 hours (n=255) | Sleep >7 hours (n=45) ||\n|| TC | TC | TC | TC ||\n|| Model 4 | 1.001 (0.50 to 2.01) | 1.00 | 0.94 (0.43 to 2.04) ||\n|| HDL-C | HDL-C | HDL-C | HDL-C ||\n|| Model 1 | 3.81 (1.80 to 8.05)* | 1.00 | 3.02 (1.28 to 7.14)* ||\n|| Model 2 | 3.75 (1.77 to 7.93)* | 1.00 | 3.02 (1.28 to 7.16)* ||\n|| Model 3 | 3.62 (1.63 to 8.00)* | 1.00 | 2.93 (1.17 to 7.34)* ||\n|| Model 4 | 3.68 (1.59 to 8.49)* | 1.00 | 2.89 (1.10 to 7.61)* ||\n|| TG | TG | TG | TG ||\n|| Model 1 | 0.65 (0.33 to 1.31) | 1.00 | 0.63 (0.28 to 1.37) ||\n|| Model 2 | 0.65 (0.33 to 1.31) | 1.00 | 0.63 (0.27 to 1.38) ||\n|| Model 3 | 0.72 (0.35 to 1.46) | 1.00 | 0.69 (0.31 to 1.35) ||\n|| Model 1 | 1.02 (0.54 to 1.92) | 1.00 | 1.10 (0.54 to 2.22) ||\n|| Model 4 | 0.64 (0.31 to 1.34) | 1.00 | 0.60 (0.26 to 1.39) ||\n|| Model 2 | 0.99 (0.52 to 1.88) | 1.00 | 1.10 (0.52 to 2.24) ||\n|| Model 3 | 1.01 (0.53 to 1.93) | 1.00 | 1.13 (0.56 to 2.31) ||\n|| Model 4 | 0.90 (0.45 to 1.80) | 1.00 | 0.95 (0.44 to 2.02) ||\n|| LDL-C | LDL-C | LDL-C | LDL-C ||\n|| Model 1 | 1.04 (0.53 to 2.03) | 1.00 | 0.99 (0.47 to 2.08) ||\n|| Model 2 | 1.02 (0.52 to 2.00) | 1.00 | 0.99 (0.47 to 2.10) ||\n|| Model 3 | 1.05 (0.53 to 2.07) | 1.00 | 1.03 (0.49 to 2.19) ||",
    "claim": "The ORs for HDL-C in both sleep <6 hours and sleep >7 hours categories are statistically significant (p < 0.05) across all models. This implies a robust association between HDL-C levels and sleep duration, with a stronger association for longer sleep duration.",
    "label": "refute"
  },
  {
    "id": "training_332_3",
    "table_caption": "Table: representative of the whole treatment period. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . TREATMENT GROUPS Mean arthritis score on day 23 Arthritis score on day 23 vs. no treatment (p-value) Area under the Curve (AUC) AUC vs. no treatment (p-value) Etanercept 36 5.8 0.004 42.639 0.03 Etanercept 16 8.3 n.s. 48.858 n.s. 180-88 46 7.1 n.s. 54.726 n.s. Etanercept 16+180-188 46 4.9 0.0004 40.396 0.02 Etanercept 16+OVA 46 9.0 n.s. 79.597 n.s. No treatment 9.8 77.748 Statistical analysis was performed by the paired t-test. Different treatment groups were set out against no treatment. doi:10.1371/journal.pone.0000087.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
    "table_content": "|| TREATMENT GROUPS | Mean arthritis score on day 23 | Arthritis score on day 23 vs. no treatment (p-value) | Area under the Curve (AUC) | AUC vs. no treatment (p-value) ||\n||  Etanercept 3×  | 5.8 |  0.004  | 42.639 |  0.03  ||\n||  Etanercept 1×  | 8.3 | n.s. | 48.858 | n.s. ||\n||  180-88 4×  | 7.1 | n.s. | 54.726 | n.s. ||\n||  Etanercept 1×+180-188 4×  | 4.9 |  0.0004  | 40.396 |  0.02  ||\n||  Etanercept 1×+OVA 4×  | 9.0 | n.s. | 79.597 | n.s. ||\n||  No treatment  | 9.8 | blank | 77.748 | blank ||",
    "claim": "The AUC for the Etanercept 3× group is approximately 5% lower than that of the no-treatment group, suggesting a substantial reduction in overall arthritis symptoms over the treatment period.",
    "label": "refute"
  },
  {
    "id": "training_1378_5",
    "table_caption": "Table: Dimensions Contact angle (°) E* d (μm) l (μm) h (μm) r Intrinsic Advancing Apparent Static S1 (pillars) 10 25 15 1.75 42 5 N/A S2 (pillars) 10 25 15 1.75 96 152 5.45 S3 (bare) N/A N/A N/A 1 72 69 N/A S4 (pillars) 7 10 22 5.84 105 149 0.66 Table 1. Dimension, contact angle, and dimensionless energy for different micropillars. ",
    "table_content": "|| blank | Dimensions | Dimensions | Dimensions | Dimensions | Contact angle (°) | Contact angle (°) | E* ||\n|| blank | d (μm) | l (μm) | h (μm) | r | Intrinsic Advancing | Apparent Static | E* ||\n|| S1 (pillars) | 10 | 25 | 15 | 1.75 | 42 | 5 | N/A ||\n|| S2 (pillars) | 10 | 25 | 15 | 1.75 | 96 | 152 | 5.45 ||\n|| S3 (bare) | N/A | N/A | N/A | 1 | 72 | 69 | N/A ||\n|| S4 (pillars) | 7 | 10 | 22 | 5.84 | 105 | 149 | 0.66 ||",
    "claim": "The dimensionless energy E* for S2 is less than that of S4, despite S4 having a larger radius, indicating that the configuration and arrangement of micropillars in S2 lead to a higher energy state, independent of the radius.",
    "label": "refute"
  },
  {
    "id": "training_817_5",
    "table_caption": "Table: No. of smokers participated in the QTW Contest, RCT and included in this Study Sample n = 1307 (%) Participated in the QTW Contest 1307 (100%) Successfully interviewed at the 1-week follow-up 1030 (78.8%) Answered questions on ever EC use 956 (73.1%) n = 956 (%) Ever EC users 163 (17.1%) Non-users 793 (82.9%) QTW: “Quit to Win” contest. EC: electronic cigarette. ",
    "table_content": "|| Study Sample | n = 1307 (%) ||\n|| Participated in the QTW Contest | 1307 (100%) ||\n|| Successfully interviewed at the 1-week follow-up | 1030 (78.8%) ||\n|| Answered questions on ever EC use | 956 (73.1%) ||\n|| Answered questions on ever EC use | n = 956 (%) ||\n|| Ever EC users | 163 (17.1%) ||\n|| Non-users | 793 (82.9%) ||",
    "claim": "From the initial participation in the QTW contest to answering questions on EC use, there is a 21.2% attrition rate. This reflects the cumulative drop-off in engagement through the stages of the study, highlighting the challenges in maintaining participant involvement over time.",
    "label": "refute"
  },
  {
    "id": "training_1182_1",
    "table_caption": "Table: Table 4 Summary of validation experiments for the candidate genes Candidate genes Technique used Summary of validation PRKG1 MLPA No copy number change in controls. Gain in tumor (1/37) FAM86D MLPA, qRT-PCR Loss in controls (5/38), gain in controls (1/38), HMloss in tumors (2/37) loss in tumours (6/37). Lower m-RNA expression in ECs POU5F1 MLPA, qRT-PCR, IHC Gain in controls (3/38), loss in tumors (4/37), gain in tumors (2/37). Its mRNA and protein expression was absent in tumors ANKS1B MLPA, qRT-PCR No copy number changes in controls and tumors. Lower m-RNA expression in L2220 compared with other 7ECs TCRA _probe1 MLPA Loss in controls (4/38), gain in tumors (2/37) TCRA _probe2 MLPA Loss in controls (4/38), gain in tumors (2/37) NIPBL IHC 30% Ollier tumors showed protein expression ",
    "table_content": "|| Candidate genes | Technique used | Summary of validation ||\n|| PRKG1 | MLPA | No copy number change in controls. Gain in tumor (1/37) ||\n|| FAM86D | MLPA, qRT-PCR | Loss in controls (5/38), gain in controls (1/38), HMloss in tumors (2/37) loss in tumours (6/37). Lower m-RNA expression in ECs ||\n|| POU5F1 | MLPA, qRT-PCR, IHC | Gain in controls (3/38), loss in tumors (4/37), gain in tumors (2/37). Its mRNA and protein expression was absent in tumors ||\n|| ANKS1B | MLPA, qRT-PCR | No copy number changes in controls and tumors. Lower m-RNA expression in L2220 compared with other 7ECs ||\n|| TCRA _probe1 | MLPA | Loss in controls (4/38), gain in tumors (2/37) ||\n|| TCRA _probe2 | MLPA | Loss in controls (4/38), gain in tumors (2/37) ||\n|| NIPBL | IHC | 30% Ollier tumors showed protein expression ||",
    "claim": "The probability of observing a gain in copy number for the gene PRKG1 in tumor samples is approximately 5.4%, calculated by dividing the number of gains by the total number of tumor samples analyzed.",
    "label": "refute"
  },
  {
    "id": "training_1134_1",
    "table_caption": "Table: Structure of the table ‘misa_ssr_primer’ that stores the primer information of microsatellites of mitochondrial and chloroplast genomes detected by MISA Information Field Data Type Key Example Accession number acc_no int(11) PRI 5881414, 110189662 Motif with iteration count SSR varchar(255) (AT)4 Type of repeat SSR_type varchar(5) p1, (mono), p2 (di), p3 (tri) etc, c and c* (compound) Size int(4) int(4) 31, 20 Starting co-ordinate of SSR SSR_start int(7) PRI 172, 12843 Ending co-ordinate of SSR SSR_end int(7) PRI 182, 12885 Forward primer 1 FORWARD_PRIMER_1 varchar(30) AAAAAGGCCCCTTCCCCC Melting temperature for forward primer 1 Tm_F_1 varchar(6) 59.463 Size of forward primer 1 size_F_1 int(6) 18 Reverse primer 1 REVERSE_PRIMER_1 varchar(30) GCGCCTAAGGATCCTGTGAG Melting temperature for reverse primer 1 Tm_R_1 varchar(6) 60.25 Size of reverse primer 1 size_R_1 int(6) 20 Product size (in bp) PRODUCT_size_bp_1 220 Starting co-ordinate of primer 1 start_bp_1 6256 Ending co-ordinate of primer 1 end_bp_1 6475 The last nine columns of the table will be repeated for reverse primer 1, forward primer 2, reverse primer 2, forward primer 3 and backward primer 3. ",
    "table_content": "|| Information | Field | Data Type | Key | Example ||\n|| Accession number | acc_no | int(11) | PRI | 5881414, 110189662 ||\n|| Reverse primer 1 | REVERSE_PRIMER_1 | varchar(30) | blank | GCGCCTAAGGATCCTGTGAG ||\n|| Melting temperature for reverse primer 1 | Tm_R_1 | varchar(6) | blank | 60.25 ||\n|| Size of reverse primer 1 | size_R_1 | int(6) | blank | 20 ||\n|| Product size (in bp) | PRODUCT_size_bp_1 | blank | blank | 220 ||\n|| Starting co-ordinate of primer 1 | start_bp_1 | blank | blank | 6256 ||\n|| Ending co-ordinate of primer 1 | end_bp_1 | blank | blank | 6475 ||\n|| Motif with iteration count | SSR | varchar(255) | blank | (AT)4 ||\n|| Type of repeat | SSR_type | varchar(5) | blank | p1, (mono), p2 (di), p3 (tri) etc, c and c* (compound) ||\n|| Size | int(4) | int(4) | blank | 31, 20 ||\n|| Starting co-ordinate of SSR | SSR_start | int(7) | PRI | 172, 12843 ||\n|| Ending co-ordinate of SSR | SSR_end | int(7) | PRI | 182, 12885 ||\n|| Forward primer 1 | FORWARD_PRIMER_1 | varchar(30) | blank | AAAAAGGCCCCTTCCCCC ||\n|| Melting temperature for forward primer 1 | Tm_F_1 | varchar(6) | blank | 59.463 ||\n|| Size of forward primer 1 | size_F_1 | int(6) | blank | 18 ||",
    "claim": "The melting temperature of primers is influenced by their size and nucleotide composition. By analyzing the data, it can be inferred that an increase in primer size by 10% results in an approximate increase of 1.5% in melting temperature, assuming a constant nucleotide composition.",
    "label": "refute"
  },
  {
    "id": "training_905_3",
    "table_caption": "Table: recommendations in the CDS tool were actually used by the ASHAs ASHA Risk projection meter to communicate CVD risk association between risk factors Recommendations (lifestyle, smoking, nutrition) Next visit (doctor referral, CVD risk/diabetes screening) npB1 79% (22/28) 96% (27/28) 93% (26/28) npM1 75% (15/20) 85% (17/20) 90% (18/20) npL1 81% (13/16) 81% (13/16) 81% (13/16) It three eters ments, pilot ber had ",
    "table_content": "||  ASHA  |  Risk projection meter to communicate CVD risk association between risk factors  |  Recommendations (lifestyle, smoking, nutrition)  |  Next visit (doctor referral, CVD risk/diabetes screening)  ||\n||  npB1  | 79% (22/28) | 96% (27/28) | 93% (26/28) ||\n||  npM1  | 75% (15/20) | 85% (17/20) | 90% (18/20) ||\n||  npL1  | 81% (13/16) | 81% (13/16) | 81% (13/16) ||",
    "claim": "The npB1 group has a 3% lower adherence to follow-up actions compared to npM1, and a 12% lower adherence compared to npL1, suggesting a less proactive approach in ensuring follow-up actions.",
    "label": "refute"
  },
  {
    "id": "training_1332_6",
    "table_caption": "Table: Group sizes and characteristics of organizations ID Group group size sample (contacted) response rate final group size (analyzed) proportion (of all analyzed) characteristics (examples) all groups 442 67% 301 100% A patient organizations 42 57% 24 8% umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres B medical associations 100 78% 79 26% scientific medical societies, associations of statutory health insurance physicians on federal and national level C nursing organizations 22 77% 17 6% umbrella organizations of nursing care, federal working commitee of nursing D health insurance funds 82 63% 55 18% associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds E political institutions 45 49% 24 8% state and federal ministries of health, health-care policy spokespeople of the different political parties F specialized palliative care 54 65% 39 13% associations and umbrella organizations of palliative and hospice care on federal and national level G others* 97 72% 63 21% charity and clerical institutions, associations for physiotherapy, federal joint committee * not included in the comparison of the groups because of the strong heterogeneity ",
    "table_content": "|| ID | Group all groups | group size sample (contacted) 442 | response rate 67% | final group size (analyzed) 301 | proportion (of all analyzed) 100% | characteristics (examples) ||\n|| ID | Group all groups | group size sample (contacted) 442 | response rate 67% | final group size (analyzed) 301 | proportion (of all analyzed) 100% | characteristics (examples) ||\n|| A | patient organizations | 42 | 57% | 24 | 8% | umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres ||\n|| B | medical associations | 100 | 78% | 79 | 26% | scientific medical societies, associations of statutory health insurance physicians on federal and national level ||\n|| C | nursing organizations | 22 | 77% | 17 | 6% | umbrella organizations of nursing care, federal working commitee of nursing ||\n|| D | health insurance funds | 82 | 63% | 55 | 18% | associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds ||\n|| E | political institutions | 45 | 49% | 24 | 8% | state and federal ministries of health, health-care policy spokespeople of the different political parties ||\n|| F | specialized palliative care | 54 | 65% | 39 | 13% | associations and umbrella organizations of palliative and hospice care on federal and national level ||\n|| G | others* | 97 | 72% | 63 | 21% | charity and clerical institutions, associations for physiotherapy, federal joint committee ||",
    "claim": "The \"others\" category, despite its heterogeneity, contributes 21% to the total analyzed sample, which is less than double the contribution of nursing organizations, reflecting its substantial representation in the study.",
    "label": "refute"
  },
  {
    "id": "training_48_1",
    "table_caption": "Table: of MM thickness with age in dentate and edentulous groups. – Age r p Dentate – – Right Relaxed 0,075 0,721 Left Relaxed -0,047 0,822 Right Contracted -0,166 0,428 Left Contracted -0,171 0,414 Edentulous – – Right Relaxed 0,219 0,304 Left Relaxed 0,241 0,256 Right Contracted 0,150 0,625 Left Contracted 0,178 0,406 group, the means of right MM thicknesses at rest and contraction were higher in male than female ",
    "table_content": "|| – |  Age  |  Age  ||\n|| – |  r  |  p  ||\n|| Right Contracted | 0,150 | 0,625 ||\n|| Left Contracted | 0,178 | 0,406 ||\n|| Dentate | – | – ||\n|| Right Relaxed | 0,075 | 0,721 ||\n|| Left Relaxed | -0,047 | 0,822 ||\n|| Right Contracted | -0,166 | 0,428 ||\n|| Left Contracted | -0,171 | 0,414 ||\n|| Edentulous | – | – ||\n|| Right Relaxed | 0,219 | 0,304 ||\n|| Left Relaxed | 0,241 | 0,256 ||",
    "claim": "In the dentate group, the correlation coefficients for MM thickness with age under all conditions are negative, indicating a decrease in MM thickness with age. The strongest negative correlation is observed in the right relaxed condition.",
    "label": "refute"
  },
  {
    "id": "training_577_4",
    "table_caption": "Table: Tableau 1: Caractéristiques sociodémographiques de la population d’étude Fréquences (n=94) Pourcentage (%) Sexe Féminin 50 53,2 Masculin 44 46,8 Age (ans) 15-24 4 4,3 25-34 18 19,1 35-44 18 19,1 45-54 37 39,4 ≥55 15 16 NR 2 2,1 Statut Social Militaire 24 25,5 Civil 64 68,1 NR 6 6,4 Statut Matrimonial Marié 49 52,1 Divorcé 2 2,1 Célibataire 35 37,2 Veuf (veuve) 6 6,4 NR 2 2,1 Lieu de résidence Ouagadougou 60 63,8 Autre 12 12,8 NR 22 23,4 Nationalité Burkinabé 91 96,8 Autre 1 1,1 NR 2 2,1 Nombre d’enfants 0-3 63 67 4-6 22 23,5 7-9 2 2,1 ≥10 2 2,1 NR 5 5,3 NR: Non Renseigné ",
    "table_content": "|| blank | Fréquences (n=94) | Pourcentage (%) ||\n|| Sexe | Sexe | Sexe ||\n|| NR | 2 | 2,1 ||\n|| Statut Social | Statut Social | Statut Social ||\n|| Militaire | 24 | 25,5 ||\n|| Civil | 64 | 68,1 ||\n|| NR | 6 | 6,4 ||\n|| Statut Matrimonial | Statut Matrimonial | Statut Matrimonial ||\n|| Marié | 49 | 52,1 ||\n|| Divorcé | 2 | 2,1 ||\n|| Célibataire | 35 | 37,2 ||\n|| Veuf (veuve) | 6 | 6,4 ||\n|| Féminin | 50 | 53,2 ||\n|| NR | 2 | 2,1 ||\n|| Lieu de résidence | Lieu de résidence | Lieu de résidence ||\n|| Ouagadougou | 60 | 63,8 ||\n|| Autre | 12 | 12,8 ||\n|| NR | 22 | 23,4 ||\n|| Nationalité | Nationalité | Nationalité ||\n|| Burkinabé | 91 | 96,8 ||\n|| Autre | 1 | 1,1 ||\n|| NR | 2 | 2,1 ||\n|| Nombre d’enfants | Nombre d’enfants | Nombre d’enfants ||\n|| Masculin | 44 | 46,8 ||\n|| 0-3 | 63 | 67 ||\n|| 4-6 | 22 | 23,5 ||\n|| 7-9 | 2 | 2,1 ||\n|| ≥10 | 2 | 2,1 ||\n|| NR | 5 | 5,3 ||\n|| Age (ans) | Age (ans) | Age (ans) ||\n|| 15-24 | 4 | 4,3 ||\n|| 25-34 | 18 | 19,1 ||\n|| 35-44 | 18 | 19,1 ||\n|| 45-54 | 37 | 39,4 ||\n|| ≥55 | 15 | 16 ||",
    "claim": "Married individuals form the majority of the population, with a proportion exceeding 50%. The number of married individuals is less than 14 times the number of divorced individuals, highlighting a significant prevalence of marriage in the study population.",
    "label": "refute"
  },
  {
    "id": "training_1173_4",
    "table_caption": "Table: Subunits of CK2 were amplified via PCR using the following primers: CK2α 5′-CCCAAGCTTATGTCGGGACCCGTGCCAAG CAGG-3′ CK2α 5′-CGCGGATCCTTACTGCTGAGCGCCAGCGG CAG-3′ CK2β 5′-CCCAAGCTTATGAGCAGCTCAGAGGAGGT GTC-3′ CK2β 5′-CGCGGATCCTCAGCGAATCGTCTTGACTG GGCTC-3′ CK2α′ 5′-CCCAAGCTTATGCCCGGCCCGGCCGC GG-3′ CK2α′ 5′-CGCGGATCCTCATCGTGCTGCCGTGAGAC CAC-3′ All genes were cloned into the p3xFLAG-CMV-10 (SIGMA) vector using restriction digests. Constructs were sequenced to until 1 ∼6–7 NaCl, 3 h pH pH DTT, CK2 ",
    "table_content": "|| CK2α | 5′-CCCAAGCTTATGTCGGGACCCGTGCCAAGCAGG-3′ ||\n|| CK2α | 5′-CGCGGATCCTTACTGCTGAGCGCCAGCGGCAG-3′ ||\n|| CK2β | 5′-CCCAAGCTTATGAGCAGCTCAGAGGAGGTGTC-3′ ||\n|| CK2β | 5′-CGCGGATCCTCAGCGAATCGTCTTGACTGGGCTC-3′ ||\n|| CK2α′ | 5′-CCCAAGCTTATGCCCGGCCCGGCCGCGG-3′ ||\n|| CK2α′ | 5′-CGCGGATCCTCATCGTGCTGCCGTGAGACCAC-3′ ||",
    "claim": "The melting temperature of the CK2α′ primers is estimated to be lower than that of CK2α and CK2β, with an average Tm of 85°C, calculated using the formula Tm = 64.9 + 41*(number of G+C).",
    "label": "refute"
  },
  {
    "id": "training_787_5",
    "table_caption": "Table: The most likely clusters of HFMD in Guangdong Province, China, 2008–2011 (setting 50% as the maximum cluster size). Scan timeframe Cluster time Cluster center/Radius Annual cases/ 10000 LLR RR P 2008/5/1–2008/12/31 2008/5/1–2008/5/14 (22.23N, 113.25E)/163.17 km 84.14 25169.84 15.96 ,0.001 2009/1/1–2009/12/31 2009/4/8–2009/10/6 (23.10N, 113.48E)/119.57 km 21.16 15869.52 3.33 ,0.001 2010/1/1–/12/31 2010/3/28–2010/7/26 (22.94N, 113.88E)/151.31 km 60.64 42847.38 3.79 ,0.001 2011/1/1–2011/12/31 2011/5/10–2011/11/7 (23.10N, 113.48E)/119.57 km 54.20 44180.26 3.22 ,0.001 Note: ‘Scan timeframe’ means the boundary of time points put into the scanning analysis, and the ‘Cluster time’ means the boundary of time points identified by the scanning analysis. ",
    "table_content": "|| Scan timeframe | Cluster time | Cluster center/Radius | Annual cases/10000 |  LLR  |  RR  |  P  ||\n|| 2008/5/1–2008/12/31 | 2008/5/1–2008/5/14 | (22.23N, 113.25E)/163.17 km | 84.14 | 25169.84 | 15.96 | <0.001 ||\n|| 2009/1/1–2009/12/31 | 2009/4/8–2009/10/6 | (23.10N, 113.48E)/119.57 km | 21.16 | 15869.52 | 3.33 | <0.001 ||\n|| 2010/1/1–/12/31 | 2010/3/28–2010/7/26 | (22.94N, 113.88E)/151.31 km | 60.64 | 42847.38 | 3.79 | <0.001 ||\n|| 2011/1/1–2011/12/31 | 2011/5/10–2011/11/7 | (23.10N, 113.48E)/119.57 km | 54.20 | 44180.26 | 3.22 | <0.001 ||",
    "claim": "The relative risk in 2008 was lower than in 2011, suggesting that the risk of HFMD was less intense in 2008 compared to 2011, indicating a less severe outbreak in terms of risk to the population.",
    "label": "refute"
  },
  {
    "id": "training_1057_2",
    "table_caption": "Table: TABLE 1 | Total and different classes of volatile compounds and their concentrations in different aromatic melon types. Volatile compounds Different types of melon (µg.g−1FW) CH CB CG Total esters 207.83 ± 17.21a 127.16 ± 16.75b 5.29 ± 1.82c Total alcohols 30.24 ± 2.48b 23.68 ± 1.87b 136.85 ± 4.85a Total acids 15.73 ± 5.28a 8.14 ± 2.62b 9.31 ± 3.97b Others 54.15 ± 20.01a 10.07 ± 1.32b 6.14 ± 1.21b Duncan’s multiple range tests were performed, and different letters represent significant differences (P < 0.05) between different types of melon. was each The DNase cDNA 95◦C s, ",
    "table_content": "|| Volatile compounds (μg.g −1 FW) | Different types of melon | Different types of melon | Different types of melon ||\n|| Volatile compounds (μg.g −1 FW) | CH | CB | CG ||\n|| Total esters | 207.83 ± 17.21 a | 127.16 ± 16.75 b | 5.29 ± 1.82 c ||\n|| Total alcohols | 30.24 ± 2.48 b | 23.68 ± 1.87 b | 136.85 ± 4.85 a ||\n|| Total acids | 15.73 ± 5.28 a | 8.14 ± 2.62 b | 9.31 ± 3.97 b ||\n|| Others | 54.15 ± 20.01 a | 10.07 ± 1.32 b | 6.14 ± 1.21 b ||",
    "claim": "The concentration of total alcohols in CG is approximately 4.5 times lower than in CH, highlighting a significant variation in alcohol content between these melon types.",
    "label": "refute"
  },
  {
    "id": "training_1073_4",
    "table_caption": "Table: Table 6 Differences in health related quality of life across levels of education SF 36 Low (n = 10) High (n = 8) Mean (SD) Mean (SD) MWU p Physical functioning (PF) 90.0 (10.7) 86.9 (14.4) 31.5 ns Role physical (RP) 62,5 (46.0) 71.9 (45.2) 35.0 ns Bodily pain (BP) 76.4 (21.9) 76.1 (30.4) 38.0 ns General health (GH) 66.9 (24.4) 70.5 (21.2) 38.5 ns Vitality (VT) 58.5 (9.7) 66.3 (10.9) 24.5 ns Social functioning (SF) 93.8 (12.1) 87.5 (18.9) 34.5 ns Role emotional (RE) 76.7 (38.7) 87.5 (35.4) 34.0 ns Mental health (MH) 72.0 (8.8) 80.5 (4.0) 15.5 < .05 Physical Component score (PCS) 49.3 (9.1) 48.3 (11.3) 33.0 ns Mental Component Score (MCS) 50.0 (3.7) 53.6 (3.1) 18.0 ns MWU Mann-Withney U ",
    "table_content": "|| SF 36 | Low ( n = 10) Mean (SD) | High ( n = 8) Mean (SD) | MWU | p ||\n|| SF 36 | Low ( n = 10) Mean (SD) | High ( n = 8) Mean (SD) | MWU | p ||\n|| Physical Component score (PCS) | 49.3 (9.1) | 48.3 (11.3) | 33.0 | ns ||\n|| Mental Component Score (MCS) | 50.0 (3.7) | 53.6 (3.1) | 18.0 | ns ||\n|| Physical functioning (PF) | 90.0 (10.7) | 86.9 (14.4) | 31.5 | ns ||\n|| Role physical (RP) | 62,5 (46.0) | 71.9 (45.2) | 35.0 | ns ||\n|| Bodily pain (BP) | 76.4 (21.9) | 76.1 (30.4) | 38.0 | ns ||\n|| General health (GH) | 66.9 (24.4) | 70.5 (21.2) | 38.5 | ns ||\n|| Vitality (VT) | 58.5 (9.7) | 66.3 (10.9) | 24.5 | ns ||\n|| Social functioning (SF) | 93.8 (12.1) | 87.5 (18.9) | 34.5 | ns ||\n|| Role emotional (RE) | 76.7 (38.7) | 87.5 (35.4) | 34.0 | ns ||\n|| Mental health (MH) | 72.0 (8.8) | 80.5 (4.0) | 15.5 | < .05 ||",
    "claim": "** The mean score for General Health is slightly higher in the high education group, and the calculated effect size suggests a small improvement in general health perception with higher education.",
    "label": "refute"
  },
  {
    "id": "training_1073_4",
    "table_caption": "Table: Table 6 Differences in health related quality of life across levels of education SF 36 Low (n = 10) High (n = 8) Mean (SD) Mean (SD) MWU p Physical functioning (PF) 90.0 (10.7) 86.9 (14.4) 31.5 ns Role physical (RP) 62,5 (46.0) 71.9 (45.2) 35.0 ns Bodily pain (BP) 76.4 (21.9) 76.1 (30.4) 38.0 ns General health (GH) 66.9 (24.4) 70.5 (21.2) 38.5 ns Vitality (VT) 58.5 (9.7) 66.3 (10.9) 24.5 ns Social functioning (SF) 93.8 (12.1) 87.5 (18.9) 34.5 ns Role emotional (RE) 76.7 (38.7) 87.5 (35.4) 34.0 ns Mental health (MH) 72.0 (8.8) 80.5 (4.0) 15.5 < .05 Physical Component score (PCS) 49.3 (9.1) 48.3 (11.3) 33.0 ns Mental Component Score (MCS) 50.0 (3.7) 53.6 (3.1) 18.0 ns MWU Mann-Withney U ",
    "table_content": "|| SF 36 | Low ( n = 10) Mean (SD) | High ( n = 8) Mean (SD) | MWU | p ||\n|| SF 36 | Low ( n = 10) Mean (SD) | High ( n = 8) Mean (SD) | MWU | p ||\n|| Physical Component score (PCS) | 49.3 (9.1) | 48.3 (11.3) | 33.0 | ns ||\n|| Mental Component Score (MCS) | 50.0 (3.7) | 53.6 (3.1) | 18.0 | ns ||\n|| Physical functioning (PF) | 90.0 (10.7) | 86.9 (14.4) | 31.5 | ns ||\n|| Role physical (RP) | 62,5 (46.0) | 71.9 (45.2) | 35.0 | ns ||\n|| Bodily pain (BP) | 76.4 (21.9) | 76.1 (30.4) | 38.0 | ns ||\n|| General health (GH) | 66.9 (24.4) | 70.5 (21.2) | 38.5 | ns ||\n|| Vitality (VT) | 58.5 (9.7) | 66.3 (10.9) | 24.5 | ns ||\n|| Social functioning (SF) | 93.8 (12.1) | 87.5 (18.9) | 34.5 | ns ||\n|| Role emotional (RE) | 76.7 (38.7) | 87.5 (35.4) | 34.0 | ns ||\n|| Mental health (MH) | 72.0 (8.8) | 80.5 (4.0) | 15.5 | < .05 ||",
    "claim": "The mean score for General Health is slightly lower in the high education group, and the calculated effect size suggests a small decline in general health perception with higher education.",
    "label": "refute"
  },
  {
    "id": "training_1315_3",
    "table_caption": "Table: of MiRmat. Distance from Trutha 0 61 62 63 MaturePred(%) 21.21 36.36 48.48 57.57 MiRmat (%) 23.03 45.45 59.39 69.70 athe distance between predicted start position of mature microRNA and that of actual mature microRNA. ",
    "table_content": "|| Distance from Truth a  | 0 | ±1 | ±2 | ±3 ||\n||  MaturePred (%) | 21.21 | 36.36 | 48.48 | 57.57 ||\n||  MiRmat (%) |  23.03  |  45.45  |  59.39  |  69.70  ||",
    "claim": "The rate of increase in accuracy for the MaturePred model from 0 to ±3 is greater than that of the MiRmat model. This can be inferred from the larger percentage point increase in accuracy for MaturePred over the same range of distances, suggesting a more robust improvement in prediction accuracy with increased tolerance.",
    "label": "refute"
  },
  {
    "id": "training_206_2",
    "table_caption": "Table: the of showed 0.2) as a percentage of study population (n = 12) at various time points in the transportation study. Prior Unloading 1 day post 5 days post EHV-2 58 75 83 83 EHV-5 75 75 58 58 ",
    "table_content": "|| blank | Prior | Unloading | 1 day post | 5 days post ||\n|| EHV-2 | 58 | 75 | 83 | 83 ||\n|| EHV-5 | 75 | 75 | 58 | 58 ||",
    "claim": "The percentage of the study population affected by EHV-5 increases from Unloading to 1 day post and remains constant thereafter. This indicates an increase effect post-unloading, with a 17% increase from Unloading to 1 day post.",
    "label": "refute"
  },
  {
    "id": "training_178_4",
    "table_caption": "Table: Magnetic inclination (deg) Magnetic declination (horizontal polarity) (deg) Magnetic field flux density (intensity) (nT) Autumn 67°NMF 68.59 ± 0.06 0 ± 0.14 49,221 ± 103 5°NMF 5.00 ± 0.03 0 ± 0.27 49,193 ± 121 5°CMF 5.07 ± 0.04 − 120 ± 0.21 49,079 ± 79 Spring 67°NMF 68.21 ± 0.15 0 ± 1.91 49,543 ± 217 67°CMF 68.13 ± 0.18 − 120 ± 1.91 49,276 ± 245 0°NMF 0.05 ± 0.05 0 ± 2.03 49,543 ± 237 0°CMF 0.05 ± 0.06 − 120 ± 1.96 49,357 ± 334 Table 1. Variability in the experimental magnetic fields used in the present study. Data in the center of the coil system; a magnetometer probe was positioned directly under the ",
    "table_content": "|| blank | blank | Magnetic inclination (deg) | Magnetic declination (horizontal polarity) (deg) | Magnetic field flux density (intensity) (nT) ||\n|| Autumn | 67°NMF | 68.59 ± 0.06 | 0 ± 0.14 | 49,221 ± 103 ||\n|| Autumn | 5°NMF | 5.00 ± 0.03 | 0 ± 0.27 | 49,193 ± 121 ||\n|| Autumn | 5°CMF | 5.07 ± 0.04 | −120 ± 0.21 | 49,079 ± 79 ||\n|| Spring | 67°NMF | 68.21 ± 0.15 | 0 ± 1.91 | 49,543 ± 217 ||\n|| Spring | 67°CMF | 68.13 ± 0.18 | −120 ± 1.91 | 49,276 ± 245 ||\n|| Spring | 0°NMF | 0.05 ± 0.05 | 0 ± 2.03 | 49,543 ± 237 ||\n|| Spring | 0°CMF | 0.05 ± 0.06 | −120 ± 1.96 | 49,357 ± 334 ||",
    "claim": "For the same inclination and season, CMF configurations exhibit higher magnetic field flux density than NMF configurations. This is particularly noticeable in the Spring data, where the difference between 67°CMF and 67°NMF is substantial, indicating the impact of declination on field strength.",
    "label": "refute"
  },
  {
    "id": "training_421_2",
    "table_caption": "Table: Virus particle titers and vp/pfu ratios Recombinant vaccinia virus Physical titer (vp/ml) Infectious titer (pfu/ml) Ratio (vp/pfu) VV 5.03 × 109 1.61 × 108 31.2:1 VV-ING4 4.27 × 109 1.76 × 108 24.3:1 Note: vp, virus particle; pfu, plaque forming units. ",
    "table_content": "|| Recombinant vaccinia virus | Physical titer (vp/ml) | Infectious titer (pfu/ml) | Ratio (vp/pfu) ||\n|| VV | 5.03 × 10 9 | 1.61 × 10 8 | 31.2:1 ||\n|| VV- ING4 | 4.27 × 10 9 | 1.76 × 10 8 | 24.3:1 ||",
    "claim": "The infectious titer of VV-ING4 is approximately 9.3% lower than that of VV, suggesting a higher number of plaque-forming units per milliliter in VV-ING4.",
    "label": "refute"
  },
  {
    "id": "training_734_6",
    "table_caption": "Table: Regression model coefficients. Unstandardized Standardized 95% Conﬁdence Interval ß Std. Error ß Lower Bound Upper Bound Model 1 (Constant) 15.80 0.80 14.23 17.36 Intensity 1.03 0.17 0.27 0.69 1.36 Model 2 (R2 = 0.12) (Constant) 13.95 0.86 12.26 15.64 Intensity 1.11 0.17 0.30 0.78 1.44 BPD 0.58 0.12 0.22 0.35 0.81 Model 3 (R2 = 0.14) (Constant) 13.93 0.85 12.25 15.60 Intensity 1.08 0.17 0.29 0.75 1.41 BPD 0.48 0.12 0.19 0.25 0.72 SCOFF 1.04 0.39 0.12 0.28 1.81 Model 4 (R2 = 0.39) (Constant) 23.79 1.02 21.79 25.79 Intensity 0.86 0.14 0.23 0.59 1.14 BPD 0.15 0.10 0.06 -0.05 0.36 SCOFF 0.79 0.33 0.09 0.15 1.44 DMI Escapism 2.79 0.20 0.53 3.19 2.39 Model 5 (R2 = 0.41) (Constant) 24.83 1.04 22.79 26.87 Intensity 0.83 0.14 0.22 0.55 1.10 BPD 0.21 0.10 0.08 0.01 0.41 SCOFF 0.89 0.32 0.11 0.26 1.53 DMI Escapism 2.49 0.22 0.47 2.91 2.06 DMI Mood Enhancement 1.34 0.35 0.15 2.03 0.66 Note: DAI total score was added as dependent variable. Each model is signiﬁcantly better than the previous one (ΔFM1 = 35.80***, ΔFM2 = 24.84***, ΔFM3 = 7.19** ΔFM4 = 186.35*** ΔFM5 = 15.00***, where ***p<0.001, **p<0.01) ",
    "table_content": "|| blank | Unstandardized | Unstandardized | Standardized ß | 95% Confidence Interval | 95% Confidence Interval ||\n|| blank | ß | Std. Error | Standardized ß | Lower Bound | Upper Bound ||\n||  (Constant)  | 13.93 | 0.85 | blank | 12.25 | 15.60 ||\n||  Intensity  | 1.08 | 0.17 | 0.29 | 0.75 | 1.41 ||\n||  BPD  | 0.48 | 0.12 | 0.19 | 0.25 | 0.72 ||\n||  SCOFF  | 1.04 | 0.39 | 0.12 | 0.28 | 1.81 ||\n||  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) |  Model 4 (R 2 = 0.39) ||\n||  (Constant)  | 23.79 | 1.02 | blank | 21.79 | 25.79 ||\n||  Intensity  | 0.86 | 0.14 | 0.23 | 0.59 | 1.14 ||\n||  BPD  | 0.15 | 0.10 | 0.06 | -0.05 | 0.36 ||\n||  SCOFF  | 0.79 | 0.33 | 0.09 | 0.15 | 1.44 ||\n||  DMI Escapism  | 2.79 | 0.20 | 0.53 | 3.19 | 2.39 ||\n||  Model 1  |  Model 1  |  Model 1  |  Model 1  |  Model 1  |  Model 1  ||\n||  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) |  Model 5 (R 2 = 0.41) ||\n||  (Constant)  | 24.83 | 1.04 | blank | 22.79 | 26.87 ||\n||  Intensity  | 0.83 | 0.14 | 0.22 | 0.55 | 1.10 ||\n||  BPD  | 0.21 | 0.10 | 0.08 | 0.01 | 0.41 ||\n||  SCOFF  | 0.89 | 0.32 | 0.11 | 0.26 | 1.53 ||\n||  DMI Escapism  | 2.49 | 0.22 | 0.47 | 2.91 | 2.06 ||\n||  DMI Mood Enhancement  | 1.34 | 0.35 | 0.15 | 2.03 | 0.66 ||\n||  (Constant)  | 15.80 | 0.80 | blank | 14.23 | 17.36 ||\n||  Intensity  | 1.03 | 0.17 | 0.27 | 0.69 | 1.36 ||\n||  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) |  Model 2 (R 2 = 0.12) ||\n||  (Constant)  | 13.95 | 0.86 | blank | 12.26 | 15.64 ||\n||  Intensity  | 1.11 | 0.17 | 0.30 | 0.78 | 1.44 ||\n||  BPD  | 0.58 | 0.12 | 0.22 | 0.35 | 0.81 ||\n||  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) |  Model 3 (R 2 = 0.14) ||",
    "claim": "In Model 5, the unstandardized coefficient for DMI Escapism is 2.49, while for DMI Mood Enhancement, it is 1.34. The combined effect of these two variables contributes minimally to the model, with their coefficients indicating a weak positive association with the dependent variable, reducing the model's explanatory capacity.",
    "label": "refute"
  },
  {
    "id": "training_1282_4",
    "table_caption": "Table: cross- 2- all using using were and for higher values test. all and the TABLE 2 | The classiﬁcation accuracies of all 2-feature combinations obtained from HbR signals for all subjects. Feature combination S1 S2 S3 S4 S5 S6 S7 Mean and Slope 56.83 54.45 61.61 59.59 55.33 56.71 62.86 Mean and Peak 92.34 92.59 90.84 91.84 88.71 86.07 87.07 Mean and Variance 82.43 86.82 82.93 85.94 82.55 79.92 79.54 Slope and Peak 86.07 86.32 79.67 85.44 85.19 83.06 84.69 Slope and Variance 79.79 87.32 82.31 85.82 80.55 76.41 77.91 Peak and Variance 85.44 86.07 82.93 87.21 86.32 76.91 84.31 Peak and Skewness 88.33 87.21 84.44 85.94 84.94 80.81 85.44 Mean and Skewness 51.69 51.31 53.32 52.82 47.05 54.71 59.47 Slope and Skewness 52.44 52.07 57.34 51.31 51.94 47.55 54.83 Kurtosis and Skewness 52.94 48.81 55.21 49.43 45.42 56.46 52.69 Variance and Skewness 82.55 81.93 83.81 86.71 80.92 77.03 78.16 Peak and Kurtosis 86.95 83.81 81.43 86.07 85.69 78.67 86.44 Mean and Kurtosis 50.06 54.57 55.33 45.42 48.55 60.47 57.59 Slope and Kurtosis 51.81 49.43 54.21 48.55 49.31 56.21 59.09 Variance and Kurtosis 86.32 85.94 85.44 86.71 82.05 78.16 78.41 ",
    "table_content": "|| Feature combination | S1 | S2 | S3 | S4 | S5 | S6 | S7 ||\n|| Mean and Slope | 56.83 | 54.45 | 61.61 | 59.59 | 55.33 | 56.71 | 62.86 ||\n|| Kurtosis and Skewness | 52.94 | 48.81 | 55.21 | 49.43 | 45.42 | 56.46 | 52.69 ||\n|| Variance and Skewness | 82.55 | 81.93 | 83.81 | 86.71 | 80.92 | 77.03 | 78.16 ||\n|| Peak and Kurtosis | 86.95 | 83.81 | 81.43 | 86.07 | 85.69 | 78.67 | 86.44 ||\n|| Mean and Kurtosis | 50.06 | 54.57 | 55.33 | 45.42 | 48.55 | 60.47 | 57.59 ||\n|| Slope and Kurtosis | 51.81 | 49.43 | 54.21 | 48.55 | 49.31 | 56.21 | 59.09 ||\n|| Variance and Kurtosis | 86.32 | 85.94 | 85.44 | 86.71 | 82.05 | 78.16 | 78.41 ||\n|| Mean and Peak | 92.34 | 92.59 | 90.84 | 91.84 | 88.71 | 86.07 | 87.07 ||\n|| Mean and Variance | 82.43 | 86.82 | 82.93 | 85.94 | 82.55 | 79.92 | 79.54 ||\n|| Slope and Peak | 86.07 | 86.32 | 79.67 | 85.44 | 85.19 | 83.06 | 84.69 ||\n|| Slope and Variance | 79.79 | 87.32 | 82.31 | 85.82 | 80.55 | 76.41 | 77.91 ||\n|| Peak and Variance | 85.44 | 86.07 | 82.93 | 87.21 | 86.32 | 76.91 | 84.31 ||\n|| Peak and Skewness | 88.33 | 87.21 | 84.44 | 85.94 | 84.94 | 80.81 | 85.44 ||\n|| Mean and Skewness | 51.69 | 51.31 | 53.32 | 52.82 | 47.05 | 54.71 | 59.47 ||\n|| Slope and Skewness | 52.44 | 52.07 | 57.34 | 51.31 | 51.94 | 47.55 | 54.83 ||",
    "claim": "Among combinations involving the \"Peak\" feature, \"Peak and Skewness\" achieves the highest average accuracy, surpassing \"Mean and Peak\" and \"Peak and Kurtosis\" by a notable margin. This suggests that the \"Skewness\" feature, when paired with \"Peak,\" enhances the discriminative power of the combination.",
    "label": "refute"
  },
  {
    "id": "training_880_1",
    "table_caption": "Table: Unit costs (base case) of estimated cost-generating events. Type of events Cost type Estimated cost per unit (€) Health care Care provided by IVC1 Indirect 24.90 Vaccination Vaccine Direct 32.31 TD Treatment in non-vaccinated Direct 5.552 Treatment in vaccinated Direct 3.222 Lost day of vacations Indirect 142.86 Non-vaccinated (142.86 × 3.59) Indirect 512.862 Vaccinated (142.86 × 2.57) Indirect 367.142 1 IVC: International Vacunation Centre 2Estimated cost by episode ",
    "table_content": "|| blank | Type of events | Cost type | Estimated cost per unit (€) ||\n|| Health care | Care provided by IVC 1 | Indirect | 24.90 ||\n|| Vaccination | Vaccine | Direct | 32.31 ||\n|| TD | Treatment in non-vaccinated | Direct | 5.55 2 ||\n|| TD | Treatment in vaccinated | Direct | 3.22 2 ||\n|| TD | Lost day of vacations | Indirect | 142.86 ||\n|| TD | Non-vaccinated (142.86 × 3.59) | Indirect | 512.86 2 ||\n|| TD | Vaccinated (142.86 × 2.57) | Indirect | 367.14 2 ||",
    "claim": "The direct cost of treating travelers' diarrhea in vaccinated individuals is approximately 75% of the cost for non-vaccinated individuals, indicating a substantial reduction in treatment expenses due to vaccination.",
    "label": "refute"
  },
  {
    "id": "training_888_2",
    "table_caption": "Table: Culturable fungal endophytes from Morinda citrifolia Linn. (noni). Code Accession number Closest (published) Genbank match Published reference sequence Accession number (GenBank) Max identity Noni leaf endophytes MRL1-3A KF534501 Stemphylium solani AF203451 100% MRL2-1 KF534502 Fusarium sp. (anamorphic Gibberella) EU151484 100% MRL1-2-2 KF534503 Acremonium sp. GU566267 99% MRL2-3 KF534504 Didymellaceae sp. HM595517 100% MRL5-1 KF534505 Hypocreales sp. — — IXLP3 KF534494 Guignardia sp. AB731125 99% VIIILP2-1 KF534492 Colletotrichum gloeosporioides (anamorphic Glomerella cingulata) DQ003100 100% XILP7-2 KF534495 Colletotrichum boninense complex JQ005162 100% VIIILP1 KF534493 Leptosphaerulina australis JN712494 99% XILP6 KF534496 Mycosphaerella sp. HM189290 100% XILP5 KF534500 Xylariaceae sp. JX852331 95% XIILP3-1 KF534498 Aspergillus pseudodeflectus (anamorphic Emericella) EF652507 100% Noni fruit endophytes XSM1 KF534499 Phlebiopsis sp. JQ518278 94% VIIIfP1 KF534497 Paraconiothyrium sporulosum AB303549 99% IIfP KF534491 Phomopsis sp. (anamorphic Diaporthe) GQ352478 99% follow-up dose response determinations over five 2-fold serial that are pathogenic in association with other plant hosts, but ",
    "table_content": "|| Code | Accession number | Closest (published) Genbank match | Published reference sequence Accession number (GenBank) | Max identity ||\n|| Noni leaf endophytes | Noni leaf endophytes | Noni leaf endophytes | Noni leaf endophytes | Noni leaf endophytes ||\n|| VIIILP1 | KF534493 |  Leptosphaerulina australis  | JN712494 | 99% ||\n|| XILP6 | KF534496 |  Mycosphaerella sp. | HM189290 | 100% ||\n|| XILP5 | KF534500 | Xylariaceae sp. | JX852331 | 95% ||\n|| XIILP3-1 | KF534498 |  Aspergillus pseudodeflectus  (anamorphic Emericella ) | EF652507 | 100% ||\n|| Noni fruit endophytes | Noni fruit endophytes | Noni fruit endophytes | Noni fruit endophytes | Noni fruit endophytes ||\n|| XSM1 | KF534499 |  Phlebiopsis sp. | JQ518278 | 94% ||\n|| VIIIfP1 | KF534497 |  Paraconiothyrium sporulosum  | AB303549 | 99% ||\n|| IIfP | KF534491 |  Phomopsis sp. (anamorphic Diaporthe ) | GQ352478 | 99% ||\n|| MRL1-3A | KF534501 |  Stemphylium solani  | AF203451 | 100% ||\n|| MRL2-1 | KF534502 |  Fusarium sp. (anamorphic Gibberella ) | EU151484 | 100% ||\n|| MRL1-2-2 | KF534503 |  Acremonium sp. | GU566267 | 99% ||\n|| MRL2-3 | KF534504 | Didymellaceae sp. | HM595517 | 100% ||\n|| MRL5-1 | KF534505 | Hypocreales sp. | — | — ||\n|| IXLP3 | KF534494 |  Guignardia sp. | AB731125 | 99% ||\n|| VIIILP2-1 | KF534492 |  Colletotrichum gloeosporioides  (anamorphic Glomerella cingulata ) | DQ003100 | 100% ||\n|| XILP7-2 | KF534495 |  Colletotrichum boninense complex | JQ005162 | 100% ||",
    "claim": "Noni fruits host a more diverse range of fungal genera compared to noni leaves. This is inferred by counting the unique genera present in each group and noting that the fruit endophytes include a wider variety of genera.",
    "label": "refute"
  },
  {
    "id": "training_395_1",
    "table_caption": "Table: Data collection Stoe IPDS-1 diffractometer 657 independent reflections Radiation source: fine-focus sealed tube 638 reflections with I > 2σ(I) graphite Rint = 0.055 φ scans θmax = 25.5°, θmin = 3.4° Absorption correction: numerical (X-SHAPE and X-RED32; Stoe & Cie, 2008) h = −11→11 Tmin = 0.165, Tmax = 0.321 k = −19→17 4502 measured reflections l = −9→10 Refinement ",
    "table_content": "|| Stoe IPDS-1 diffractometer | 657 independent reflections ||\n|| Radiation source: fine-focus sealed tube | 638 reflections with I > 2σ( I ) ||\n|| graphite | R int = 0.055 ||\n|| φ scans | θ max = 25.5°, θ min = 3.4° ||\n|| Absorption correction: numerical ( X-SHAPE and X-RED32 ; Stoe & Cie, 2008) | h = −11→11 ||\n|| T min = 0.165, T max = 0.321 | k = −19→17 ||\n|| 4502 measured reflections | l = −9→10 ||",
    "claim": "The ratio of independent reflections to the total measured reflections is approximately 0.200, indicating that a small fraction of the total reflections are independent, which is typical in crystallography due to symmetry and redundancy in data collection.",
    "label": "refute"
  },
  {
    "id": "training_642_1",
    "table_caption": "Table: CA + − Mean (SD) CBS + − + − EN 2.6 8.0 7.2 6.5 6.1 (2.4) E2 1.8 2.9 5.1 2.3 3.0 (1.5) Mean (SD) 2.2 (0.6) 5.5 (3.6) 6.2 (1.5) 4.4 (3.0) Table 3. Residence frequencies of the steroids in ABS (ns−1). ",
    "table_content": "|| CA CBS | + | + | − | − | Mean (SD) ||\n|| CA CBS | + | − | + | − | Mean (SD) ||\n|| EN | 2.6 | 8.0 | 7.2 | 6.5 | 6.1 (2.4) ||\n|| E2 | 1.8 | 2.9 | 5.1 | 2.3 | 3.0 (1.5) ||\n|| Mean (SD) | 2.2 (0.6) | 5.5 (3.6) | 6.2 (1.5) | 4.4 (3.0) | blank ||",
    "claim": "The mean residence frequency of E2 across all conditions is higher than that of EN, indicating that E2 generally has a greater affinity for the ABS environment compared to EN.",
    "label": "refute"
  },
  {
    "id": "training_1405_4",
    "table_caption": "Table: Allocation of total working hours per week over several tasks: internists (corrected for age and gender), p-value of the difference between full-time and part-time Mean proportion of hours, part- timea mean proportion of hours, full- timea p-value clinical activities 0.03 (0.01) 0.04 (0.01) 0.43 outpatient care 0.58 (0.02) 0.57 (0.01) 0.61 Inter-professional communication 0.08 (0.00) 0.08 (0.00) 1 correspondence 0.10 (0.01) 0.08 (0.00) 0.04 education 0.06 (0.01) 0.06 (0.00) 0.78 research 0.02 (0.01) 0.03 (0.00) 0.33 literature 0.06 (0.00) 0.05 (0.00) 0.66 financial administration 0.02 (0.00) 0.01 (0.00) 0.22 management 0.05 (0.01) 0.07 (0.01) 0.03 a standard error in parentheses ",
    "table_content": "|| blank | Mean proportion of hours, part-time a | mean proportion of hours, full-time a | p-value ||\n|| clinical activities | 0.03 (0.01) | 0.04 (0.01) | 0.43 ||\n|| outpatient care | 0.58 (0.02) | 0.57 (0.01) | 0.61 ||\n|| Inter-professional communication | 0.08 (0.00) | 0.08 (0.00) | 1 ||\n|| correspondence | 0.10 (0.01) | 0.08 (0.00) | 0.04 ||\n|| education | 0.06 (0.01) | 0.06 (0.00) | 0.78 ||\n|| research | 0.02 (0.01) | 0.03 (0.00) | 0.33 ||\n|| literature | 0.06 (0.00) | 0.05 (0.00) | 0.66 ||\n|| financial administration | 0.02 (0.00) | 0.01 (0.00) | 0.22 ||\n|| management | 0.05 (0.01) | 0.07 (0.01) | 0.03 ||",
    "claim": "Full-time internists allocate 0.01 more of their working hours to management tasks compared to part-time internists, reflecting a 20% increase in time spent on management by full-time internists.",
    "label": "refute"
  },
  {
    "id": "training_206_1",
    "table_caption": "Table: the of showed 0.2) as a percentage of study population (n = 12) at various time points in the transportation study. Prior Unloading 1 day post 5 days post EHV-2 58 75 83 83 EHV-5 75 75 58 58 ",
    "table_content": "|| blank | Prior | Unloading | 1 day post | 5 days post ||\n|| EHV-2 | 58 | 75 | 83 | 83 ||\n|| EHV-5 | 75 | 75 | 58 | 58 ||",
    "claim": "The percentage of the study population affected by EHV-2 increases from Prior to Unloading and remains constant thereafter. This suggests a stabilization effect post-unloading, with a 25% increase from Prior to Unloading.",
    "label": "refute"
  },
  {
    "id": "training_206_1",
    "table_caption": "Table: the of showed 0.2) as a percentage of study population (n = 12) at various time points in the transportation study. Prior Unloading 1 day post 5 days post EHV-2 58 75 83 83 EHV-5 75 75 58 58 ",
    "table_content": "|| blank | Prior | Unloading | 1 day post | 5 days post ||\n|| EHV-2 | 58 | 75 | 83 | 83 ||\n|| EHV-5 | 75 | 75 | 58 | 58 ||",
    "claim": "The percentage of the study population affected by EHV-2 decreases from Prior to Unloading and remains constant thereafter. This suggests a stabilization effect post-unloading, with a 25% decrease from Prior to Unloading.",
    "label": "refute"
  },
  {
    "id": "training_937_4",
    "table_caption": "Table: when RISA profiles were ascribed to the variables tested in the study Variable Global R P value # Significant pairwise comparisons Tissue 0.093 0.001 - Treatment 0.214 0.001 7 out of 10 Time 0.304 0.001 3 out of 3 Group 0.387 0.001 14 out of 21 G2 G3 G4 G5 G6 G7 a, Sobs, b, ACE, ",
    "table_content": "|| Variable | Global R |  P value | # Significant pairwise comparisons ||\n|| Tissue | 0.093 | 0.001 | blank ||\n|| Treatment | 0.214 | 0.001 | 7 out of 10 ||\n|| Time | 0.304 | 0.001 | 3 out of 3 ||\n|| Group | 0.387 | 0.001 | 14 out of 21 ||",
    "claim": "The Global R values decrease progressively from Tissue to Group, indicating a trend where the strength of the relationship with RISA profiles becomes weaker as we move from Tissue to Group. This trend suggests that the variables are ordered in terms of decreasing influence on RISA profiles.",
    "label": "refute"
  },
  {
    "id": "training_872_6",
    "table_caption": "Table: solid half Table 2 Statistics for the assembly contigs and scaffolds (after gap filling) Contig Scaffold Size (bp) Number Size (bp) Number N90 4,850 63,958 200,992 1,095 N80 12,159 42,491 670,865 644 N70 18,332 30,884 1,149,567 441 N60 24,540 22,654 1,671,674 311 N50 31,298 16,344 2,290,546 219 Longest 295,776 14,681,335 Total size 1,747,524,961 1,816,115,349 ≥100 bp 636,524 545,300 ≥2 kbp 79,002 4,356 Gap ratio 0 % 3.78 % 2 ",
    "table_content": "|| blank | Contig | Contig | Scaffold | Scaffold ||\n|| blank | Size (bp) | Number | Size (bp) | Number ||\n|| ≥2 kbp | blank | 79,002 | blank | 4,356 ||\n|| Gap ratio | blank | 0 % | blank | 3.78 % ||\n|| N90 | 4,850 | 63,958 | 200,992 | 1,095 ||\n|| N80 | 12,159 | 42,491 | 670,865 | 644 ||\n|| N70 | 18,332 | 30,884 | 1,149,567 | 441 ||\n|| N60 | 24,540 | 22,654 | 1,671,674 | 311 ||\n|| N50 | 31,298 | 16,344 | 2,290,546 | 219 ||\n|| Longest | 295,776 | blank | 14,681,335 | blank ||\n|| Total size | 1,747,524,961 | blank | 1,816,115,349 | blank ||\n|| ≥100 bp | blank | 636,524 | blank | 545,300 ||",
    "claim": "The decrease in the number of contigs from N90 to N50 is approximately 74%, while for scaffolds, it is approximately 70%, indicating a less steep decline in scaffold numbers, which suggests a less pronounced improvement in scaffold assembly quality as the N-value increases.",
    "label": "refute"
  },
  {
    "id": "training_796_5",
    "table_caption": "Table: Average and total lifetime cost (US $) of Annual Unintentional Fall-Related Injuries Resulting in Death, Hospitalization or an Emergency Department Visit in the U.S. by age-groups, 2010*. Death Hospitalization Emergency Department Visits Age- groups Average Cost c ($) Total Costa d ($,000) Average Cost c ($) Total Costa d ($,000) Average Cost c ($) Total Costa d ($,000) Total Cost of Fall-related Injuries a e ($,000) Population in Each Age- group (2010) b Cost of Fall- Related Injury per Person f (Total Cost/ Person, $) 18–24 1,887,705 356,776 181,949 2,938,802 6,575 4,011,673 7,307,251 30,672,088 238.24 25–34 1,908,136 570,533 183,753 5,159,815 6,648 5,296,202 11,026,550 41,063,948 268.52 35–44 1,550,187 764,242 197,013 7,781,336 6,938 5,179,236 13,724,814 41,070,606 334.18 45–54 1,083,457 1,390,075 185,623 14,988,049 7,107 6,349,632 22,727,756 45,006,716 504.99 55–64 600,934 1,208,478 117,596 12,362,819 5,783 4,321,450 17,892,747 36,482,729 490.44 65–74 275,964 824,580 84,523 12,305,483 4,895 2,740,821 15,870,884 21,713,429 730.92 75+ 109,387 2,041,268 61,866 17,218,034 4,107 2,746,470 22,005,772 18,554,555 1186.00 All Adults (18+) 276,036 7,155,952 104,909 72,754,338 6,102 30,645,484 110,555,774 234,564,071 471.32 * Data extracted from WISQARS http://www.cdc.gov/injury/wisqars/ a In thousands ",
    "table_content": "|| Age-groups | Death | Death | Hospitalization | Hospitalization | Emergency Department Visits | Emergency Department Visits | Total Cost of Fall-related Injuries a  e ($,000) | Population in Each Age-group (2010) b | Cost of Fall-Related Injury per Person f (Total Cost/Person, $) ||\n|| Age-groups | Average Cost c ($) | Total Cost a  d ($,000) | Average Cost c ($) | Total Cost a  d ($,000) | Average Cost c ($) | Total Cost a  d ($,000) | Total Cost of Fall-related Injuries a  e ($,000) | Population in Each Age-group (2010) b | Cost of Fall-Related Injury per Person f (Total Cost/Person, $) ||\n|| 18–24 | 1,887,705 | 356,776 | 181,949 | 2,938,802 | 6,575 | 4,011,673 | 7,307,251 | 30,672,088 | 238.24 ||\n|| 25–34 | 1,908,136 | 570,533 | 183,753 | 5,159,815 | 6,648 | 5,296,202 | 11,026,550 | 41,063,948 | 268.52 ||\n|| 35–44 | 1,550,187 | 764,242 | 197,013 | 7,781,336 | 6,938 | 5,179,236 | 13,724,814 | 41,070,606 | 334.18 ||\n|| 45–54 | 1,083,457 | 1,390,075 | 185,623 | 14,988,049 | 7,107 | 6,349,632 | 22,727,756 | 45,006,716 | 504.99 ||\n|| 55–64 | 600,934 | 1,208,478 | 117,596 | 12,362,819 | 5,783 | 4,321,450 | 17,892,747 | 36,482,729 | 490.44 ||\n|| 65–74 | 275,964 | 824,580 | 84,523 | 12,305,483 | 4,895 | 2,740,821 | 15,870,884 | 21,713,429 | 730.92 ||\n|| 75+ | 109,387 | 2,041,268 | 61,866 | 17,218,034 | 4,107 | 2,746,470 | 22,005,772 | 18,554,555 | 1186.00 ||\n|| All Adults (18+) | 276,036 | 7,155,952 | 104,909 | 72,754,338 | 6,102 | 30,645,484 | 110,555,774 | 234,564,071 | 471.32 ||",
    "claim": "While the population size is a factor, the total cost of fall-related injuries increases proportionally with population size. For example, the 75+ age group, having the smallest population, incurs the lowest total cost, indicating that population size is the primary determinant of cost.",
    "label": "refute"
  },
  {
    "id": "training_1422_5",
    "table_caption": "Table: placing edema minutes soaked process training Table 2 Testing performance Variable Pre-test Post-test P value Global rating scale 19.3 ± 0.8 28.7 ± 1.1 <0.05 Pass rating 6/20 19/20 <0.05 Time to complete task (min) 18 ± 3.4 11 ± 1.2 <0.05 Mucosal trauma (No.) 0.8 ± 0.5 0.6 ± 0.3 0.26 Number of perforations 0.23 ± 0.2 0.19 ± 0.1 0.35 ",
    "table_content": "|| Variable | Pre-test | Post-test |  P value ||\n|| Global rating scale | 19.3 ± 0.8 | 28.7 ± 1.1 | <0.05 ||\n|| Pass rating | 6/20 | 19/20 | <0.05 ||\n|| Time to complete task (min) | 18 ± 3.4 | 11 ± 1.2 | <0.05 ||\n|| Mucosal trauma (No.) | 0.8 ± 0.5 | 0.6 ± 0.3 | 0.26 ||\n|| Number of perforations | 0.23 ± 0.2 | 0.19 ± 0.1 | 0.35 ||",
    "claim": "The number of perforations decreased from 0.23 to 0.19, a reduction of approximately 30%. Despite this decrease, the P value of 0.35 suggests that the change is not statistically significant, indicating that the training did not significantly affect the number of perforations.",
    "label": "refute"
  },
  {
    "id": "training_377_5",
    "table_caption": "Table: MS4 (92.5 and 96.8%, respectively) and MS7 (37.7 in genotypes J (18/53) and BEB4 (12/31). Table 2 PCR amplification efficiency of DNA from Enterocytozoon bieneusi ITS genotypes J and BEB4 at the MLST loci ITS genotype Farm ID No. of specimens No. of specimens amplified/No. of specimens analyzed MS1 MS3 MS4 MS7 J 1 0 – – – – 2 0 – – – – 3 129 35/38 85/129 35/38 14/38 4 15 14/15 0/15 14/15 6/15 5 1 – 0/1 – – BEB4 1 32 13/15 31/32 14/15 6/15 2 1 1/1 1/1 1/1 1/1 3 1 – 0/1 – – 4 0 – – – – 5 25 15/15 25/25 15/15 8/15 Total 204 78/84 142/204 79/84 35/84 ",
    "table_content": "|| ITS genotype | Farm ID | No. of specimens | No. of specimens amplified/No. of specimens analyzed | No. of specimens amplified/No. of specimens analyzed | No. of specimens amplified/No. of specimens analyzed | No. of specimens amplified/No. of specimens analyzed ||\n|| ITS genotype | Farm ID | No. of specimens | MS1 | MS3 | MS4 | MS7 ||\n|| BEB4 | 4 | 0 | – | – | – | – ||\n|| BEB4 | 5 | 25 | 15/15 | 25/25 | 15/15 | 8/15 ||\n|| Total | blank | 204 | 78/84 | 142/204 | 79/84 | 35/84 ||\n|| J | 1 | 0 | – | – | – | – ||\n|| J | 2 | 0 | – | – | – | – ||\n|| J | 3 | 129 | 35/38 | 85/129 | 35/38 | 14/38 ||\n|| J | 4 | 15 | 14/15 | 0/15 | 14/15 | 6/15 ||\n|| J | 5 | 1 | – | 0/1 | – | – ||\n|| BEB4 | 1 | 32 | 13/15 | 31/32 | 14/15 | 6/15 ||\n|| BEB4 | 2 | 1 | 1/1 | 1/1 | 1/1 | 1/1 ||\n|| BEB4 | 3 | 1 | – | 0/1 | – | – ||",
    "claim": "For genotype J, the amplification success rate at the MS4 locus varies significantly across farms, with Farm 3 achieving approximately 92.1% success, while Farm 4 achieves 93.3%.",
    "label": "refute"
  },
  {
    "id": "training_84_1",
    "table_caption": "Table: Table 3 Major categories and sub-categories of socioeconomic indictors and their descriptive statistics Variablesa Mean SD Skewness Kurtosis Min Max Educational status Illiterate & read/write 00.40 00.09 00.43 03.74 00.18 00.73 School degree .49 00.06 − 00.56 04.68 00.22 00.66 Diploma & university .09 00.03 00.35 03.69 00.01 00.20 Higher education 0 0 02.55 12.46 0 00.01 Employment status In the labour force .48 00.07 00.32 02.64 00.31 00.66 Students .17 00.03 −00.54 03.94 00.05 00.23 Housewives 00.26 00.05 00.51 03.22 00.16 00.41 Retired 00.03 00.01 00.11 02.62 0 00.06 Other employment 00.03 00.01 00.86 03.37 0 00.08 Type of housing Traditional house (TH) 00.44 00.22 00.39 01.96 00.03 00.89 Villa 00.20 00.13 00.20 01.70 00.01 00.51 Floor in TH or villa 00.07 00.05 00.78 02.74 0 00.23 Apartment 00.17 00.14 01.51 04.94 0 00.64 Other type of housing 00.10 00.07 02.73 15.51 00.01 00.54 Tenure of housing Home owned 00.57 00.14 −00.32 02.37 00.24 00.84 Home rented 00.26 00.12 00.79 03.53 0 00.63 Home provided 00.15 00.09 01.41 05.57 00.02 00.51 Other tenure 00.01 00.01 03.33 15.91 0 00.07 Car ownership No car available 00.29 00.09 00.78 03.00 00.12 00.53 One car 00.46 00.07 00.35 03.29 00.27 00.69 Two or more cars 00.24 00.08 −00.33 02.07 00.03 00.38 Household amenities Phone not available 00.46 00.19 00.66 02.66 00.13 00.96 TV not available 00.21 00.12 01.30 05.39 00.03 00.72 PC not available 00.80 00.11 −00.96 03.93 00.43 00.98 Internet not available 00.87 00.08 −01.36 05.16 00.58 00.99 Library not available 00.84 00.08 −00.70 03.15 00.57 00.98 Satellite not available 00.63 00.17 −00.57 03.14 00.13 00.97 Video not available 00.78 00.13 −00.85 − 03.25 00.35 00.98 Video games not available 00.77 00.09 −00.34 02.85 00.48 00.97 aNumbers are proportions, calculated by using indicator specific denominators ",
    "table_content": "|| Variables a | Mean | SD | Skewness | Kurtosis | Min | Max ||\n|| Educational status | Educational status | Educational status | Educational status | Educational status | Educational status | Educational status ||\n|| Retired | 00.03 | 00.01 | 00.11 | 02.62 | 0 | 00.06 ||\n|| Other employment | 00.03 | 00.01 | 00.86 | 03.37 | 0 | 00.08 ||\n|| Type of housing | Type of housing | Type of housing | Type of housing | Type of housing | Type of housing | Type of housing ||\n|| Traditional house (TH) | 00.44 | 00.22 | 00.39 | 01.96 | 00.03 | 00.89 ||\n|| Villa | 00.20 | 00.13 | 00.20 | 01.70 | 00.01 | 00.51 ||\n|| Floor in TH or villa | 00.07 | 00.05 | 00.78 | 02.74 | 0 | 00.23 ||\n|| Apartment | 00.17 | 00.14 | 01.51 | 04.94 | 0 | 00.64 ||\n|| Other type of housing | 00.10 | 00.07 | 02.73 | 15.51 | 00.01 | 00.54 ||\n|| Tenure of housing | Tenure of housing | Tenure of housing | Tenure of housing | Tenure of housing | Tenure of housing | Tenure of housing ||\n|| Home owned | 00.57 | 00.14 | −00.32 | 02.37 | 00.24 | 00.84 ||\n|| Illiterate & read/write | 00.40 | 00.09 | 00.43 | 03.74 | 00.18 | 00.73 ||\n|| Home rented | 00.26 | 00.12 | 00.79 | 03.53 | 0 | 00.63 ||\n|| Home provided | 00.15 | 00.09 | 01.41 | 05.57 | 00.02 | 00.51 ||\n|| Other tenure | 00.01 | 00.01 | 03.33 | 15.91 | 0 | 00.07 ||\n|| Car ownership | Car ownership | Car ownership | Car ownership | Car ownership | Car ownership | Car ownership ||\n|| No car available | 00.29 | 00.09 | 00.78 | 03.00 | 00.12 | 00.53 ||\n|| One car | 00.46 | 00.07 | 00.35 | 03.29 | 00.27 | 00.69 ||\n|| Two or more cars | 00.24 | 00.08 | −00.33 | 02.07 | 00.03 | 00.38 ||\n|| Household amenities | Household amenities | Household amenities | Household amenities | Household amenities | Household amenities | Household amenities ||\n|| Phone not available | 00.46 | 00.19 | 00.66 | 02.66 | 00.13 | 00.96 ||\n|| TV not available | 00.21 | 00.12 | 01.30 | 05.39 | 00.03 | 00.72 ||\n|| School degree | .49 | 00.06 | − 00.56 | 04.68 | 00.22 | 00.66 ||\n|| PC not available | 00.80 | 00.11 | −00.96 | 03.93 | 00.43 | 00.98 ||\n|| Internet not available | 00.87 | 00.08 | −01.36 | 05.16 | 00.58 | 00.99 ||\n|| Library not available | 00.84 | 00.08 | −00.70 | 03.15 | 00.57 | 00.98 ||\n|| Satellite not available | 00.63 | 00.17 | −00.57 | 03.14 | 00.13 | 00.97 ||\n|| Video not available | 00.78 | 00.13 | −00.85 | − 03.25 | 00.35 | 00.98 ||\n|| Video games not available | 00.77 | 00.09 | −00.34 | 02.85 | 00.48 | 00.97 ||\n|| Diploma & university | .09 | 00.03 | 00.35 | 03.69 | 00.01 | 00.20 ||\n|| Higher education | 0 | 0 | 02.55 | 12.46 | 0 | 00.01 ||\n|| Employment status | Employment status | Employment status | Employment status | Employment status | Employment status | Employment status ||\n|| In the labour force | .48 | 00.07 | 00.32 | 02.64 | 00.31 | 00.66 ||\n|| Students | .17 | 00.03 | −00.54 | 03.94 | 00.05 | 00.23 ||\n|| Housewives | 00.26 | 00.05 | 00.51 | 03.22 | 00.16 | 00.41 ||",
    "claim": "The proportion of individuals with a school degree is less than five times the proportion of those with a diploma or university education. This indicates a significant disparity in educational attainment levels, with a larger segment of the population having only basic education.",
    "label": "refute"
  },
  {
    "id": "training_343_3",
    "table_caption": "Table: TABLE 2 | Performance, respiratory, and metabolic parameters during or after HIHVT training sessions. Pmean (W) VO2 mean (l*min−1) VCO2 mean (l*min−1) RERmean 2nd 730 ± 60 2.33 ± 0.02 2.37 ± 0.02 1.03 ± 0.01 8th 730 ± 60 2.27 ± 0.02 2.18 ± 0.02 0.97 ± 0.01 17th 730 ± 60 2.39 ± 0.03 2.11 ± 0.02 0.88 ± 0.01 Glucoserest (mmol*l−1) Glucoseend (mmol*l−1) Lactaterest (mmol*l−1) Lactateend (mmol*l−1) 2nd 5.58 ± 0.20 4.77 ± 0.34 1.04 ± 0.11 4.72 ± 0.70* 8th 5.09 ± 0.22 4.85 ± 0.32 0.93 ± 0.09 4.08 ± 0.51* 17th 5.18 ± 0.23 5.00 ± 0.30 0.98 ± 0.15 2.89 ± 0.25* Trirest (mmol*l−1) Triend (mmol*l−1) 2nd 1.12 ± 0.21 0.82 ± 0.13 8th 1.46 ± 0.32 1.37 ± 0.43 17th 1.60 ± 0.29 1.18 ± 0.20 Performance and respiratory parameters during the second (2nd), eighth (8th), and seventeenth (17th) training session of HIHVT. Metabolic parameters at rest (rest) and at ",
    "table_content": "|| blank | P mean (W) | VO 2 mean (l * min −1 ) | VCO 2 mean (l * min −1 ) | RER mean ||\n|| 2nd | 730 ± 60 | 2.33 ± 0.02 | 2.37 ± 0.02 | 1.03 ± 0.01 ||\n|| 8th | 1.46 ± 0.32 | 1.37 ± 0.43 | blank | blank ||\n|| 17th | 1.60 ± 0.29 | 1.18 ± 0.20 | blank | blank ||\n|| 8th | 730 ± 60 | 2.27 ± 0.02 | 2.18 ± 0.02 | 0.97 ± 0.01 ||\n|| 17th | 730 ± 60 | 2.39 ± 0.03 | 2.11 ± 0.02 | 0.88 ± 0.01 ||\n|| 17th | Glucose rest (mmol * l −1 ) | Glucose end (mmol * l −1 ) | Lactate rest (mmol * l −1 ) | Lactate end (mmol * l −1 ) ||\n|| 2nd | 5.58 ± 0.20 | 4.77 ± 0.34 | 1.04 ± 0.11 | 4.72 ± 0.70 * ||\n|| 8th | 5.09 ± 0.22 | 4.85 ± 0.32 | 0.93 ± 0.09 | 4.08 ± 0.51 * ||\n|| 17th | 5.18 ± 0.23 | 5.00 ± 0.30 | 0.98 ± 0.15 | 2.89 ± 0.25 * ||\n|| 17th | Tri rest (mmol * l −1 ) | Tri end (mmol * l −1 ) | blank | blank ||\n|| 2nd | 1.12 ± 0.21 | 0.82 ± 0.13 | blank | blank ||",
    "claim": "The lactate levels at the end of the sessions increase significantly by the seventeenth session compared to the second session. This increase in lactate accumulation is indicative of impaired lactate clearance and a lower lactate threshold, which are common adaptations to high-intensity training.",
    "label": "refute"
  },
  {
    "id": "training_483_4",
    "table_caption": "Table: Table 8 Parameter values for the study of the geometry effect (chan- nel length) Set 3b: varying channel length Outlet pressure (mbar) 0 Temperature (K) 423, 523, 673, 773 Channel width, H (nm) 10 Channel length, L (nm) 150, 100 Surface material Silica-cristobalite ",
    "table_content": "|| Set 3b: varying channel length | Set 3b: varying channel length ||\n|| Outlet pressure (mbar) | 0 ||\n|| Temperature (K) | 423, 523, 673, 773 ||\n|| Channel width, H (nm) | 10 ||\n|| Channel length, L (nm) | 150, 100 ||\n|| Surface material | Silica-cristobalite ||",
    "claim": "The use of silica-cristobalite as the channel material, known for its thermal stability and low thermal expansion, ensures that the channel dimensions remain stable across the temperature range of 423 K to 773 K, maintaining consistent flow characteristics.",
    "label": "refute"
  },
  {
    "id": "training_1466_6",
    "table_caption": "Table: TABLE 4 | Rhizobial species, nodD and nodC diversity in subtropical China. Province Climate Species nodD types nodC types Dominant species References Yunnan Subtropical highland, humid subtropical 5a 3c nd R. laguerraeae Xiong et al., 2017 Yunnan Subtropical highland, humid subtropical 1b 4d 1d R. leguminosarum Tian et al., 2007 Anhui, Jiangxi, Henan, Zhejiang Humid subtropical 3a 5c nd R. anhuiense Xiong et al., 2017 Anhui, Jiangxi Humid subtropical 2b 3d 1d R. leguminosarum Tian et al., 2007 Sichuan Humid subtropical 5b nd 3e R. leguminosarum Xu et al., 2015 Panxi See Introduction 6b nd 5e R. anhuiense This study Nd, not determined. aDetermined by amplicon sequencing targeting rpoB. ",
    "table_content": "|| Province | Climate | Species | nodD types | nodC types | Dominant species | References ||\n|| Yunnan | Subtropical highland, humid subtropical | 5 a | 3 c | nd | R. laguerraeae | Xiong et al., 2017 ||\n|| Yunnan | Subtropical highland, humid subtropical | 1 b | 4 d | 1 d | R. leguminosarum | Tian et al., 2007 ||\n|| Anhui, Jiangxi, Henan, Zhejiang | Humid subtropical | 3 a | 5 c | nd | R. anhuiense | Xiong et al., 2017 ||\n|| Anhui, Jiangxi | Humid subtropical | 2 b | 3 d | 1 d | R. leguminosarum | Tian et al., 2007 ||\n|| Sichuan | Humid subtropical | 5 b | nd | 3 e | R. leguminosarum | Xu et al., 2015 ||\n|| Panxi | See Introduction | 6 b | nd | 5 e | R. anhuiense | This study ||",
    "claim": "In Yunnan, the diversity of nodC types (7 types) is greater than that of nodD types (1 type), indicating a higher genetic variability in nodC genes compared to nodD genes within the same climatic region.",
    "label": "refute"
  },
  {
    "id": "training_1460_6",
    "table_caption": "Table: Completed suicide Chi- square P value ORa. 95% CI P value n = 95 n (%) No completed suicide n = 950 n (%) Education 21.771 < 0.0001 < 9 years (ref.) 24(25.26) 112(11.79) 1 9–12 years 35(36.84) 276(29.05) 0.52 0.25–1.07 0.078 > 12 years 17(17.89) 327(34.42) 0.17 0.07–0.41 < 0.0001 Unknown 19(20.0) 235(24.74) 0.97 0.14–6.55 0.973 Marital status 26.684 < 0.0001 Married (ref.) 52(54.74) 623(65.58) 1 Never married 17(17.89) 73(7.68) 2.51 1.10–5.75 0.029 Widowed/divorced 9 (9.47) 24(2.53) 3.43 0.99–11.87 0.052 Unknown 17(17.89) 230(24.21) 0.31 0.04–2.26 0.249 Delivery method 0.542 0.462 Vaginal delivery (ref.) 58(61.05) 616(64.84) 1 Caesarean delivery 37(38.95) 334(35.16) 0.69 0.39–1.23 0.204 Infant sex 3.190 0.074 Male (ref.) 43(45.26) 521(54.84) 1 Female 52(54.74) 429(45.16) 1.57 0.92–2.69 0.099 Low birth weight 20.879 < 0.0001 ≥ 2500 g (ref.) 79(83.16) 902(94.95) 1 < 2500 g 16(16.84) 48(5.05) 2.89 1.30–6.39 0.009 Pre-eclampsia/eclampsia 7.7389 0.005 No (ref.) 90(94.74) 937(98.63) 1 Yes 5(5.26) 13(1.37) 2.06 0.46–9.20 0.342 Anxiety 52.819 < 0.0001 No (ref.) 83(87.37) 939(98.84) 1 Yes 12(12.63) 11(1.16) 10.71 2.40–47.75 0.002 Mood disorder 102.2399 < 0.0001 No (ref.) 78(82.11) 941(99.05) 1 Yes 17(17.89) 9(0.95) 5.82 1.85–18.38 0.003 Postpartum depressive disorder 190.338 < 0.0001 No (ref.) 66(69.47) 937(98.63) 1 Yes 29(30.53) 13(1.37) 21.72 8.08–58.37 < 0.0001 Table 2. Risk of completed suicide within 1 year post partum stratified by perinatal and other associated factors (n = 1045). The OR (odds ratio) was calculated by performing conditional logistic regression ",
    "table_content": "|| blank | Completed suicide | Completed suicide | Chi- square | P value | OR a. | 95% CI | P value ||\n|| blank | n = 95 n (%) | No completed suicide n = 950 n (%) | Chi- square | P value | OR a. | 95% CI | P value ||\n|| Widowed/divorced | 9 (9.47) | 24(2.53) | blank | blank | 3.43 | 0.99–11.87 | 0.052 ||\n|| Unknown | 17(17.89) | 230(24.21) | blank | blank | 0.31 | 0.04–2.26 | 0.249 ||\n|| Delivery method | blank | blank | 0.542 | 0.462 | blank | blank | blank ||\n|| Vaginal delivery (ref.) | 58(61.05) | 616(64.84) | blank | blank | 1 | blank | blank ||\n|| Caesarean delivery | 37(38.95) | 334(35.16) | blank | blank | 0.69 | 0.39–1.23 | 0.204 ||\n|| Infant sex | blank | blank | 3.190 | 0.074 | blank | blank | blank ||\n|| Male (ref.) | 43(45.26) | 521(54.84) | blank | blank | 1 | blank | blank ||\n|| Female | 52(54.74) | 429(45.16) | blank | blank | 1.57 | 0.92–2.69 | 0.099 ||\n|| Low birth weight | blank | blank | 20.879 | <0.0001 | blank | blank | blank ||\n|| ≥2500 g (ref.) | 79(83.16) | 902(94.95) | blank | blank | 1 | blank | blank ||\n|| Education | blank | blank | 21.771 | <0.0001 | blank | blank | blank ||\n|| <2500 g | 16(16.84) | 48(5.05) | blank | blank | 2.89 | 1.30–6.39 | 0.009 ||\n|| Pre-eclampsia/eclampsia | blank | blank | 7.7389 | 0.005 | blank | blank | blank ||\n|| No (ref.) | 90(94.74) | 937(98.63) | blank | blank | 1 | blank | blank ||\n|| Yes | 5(5.26) | 13(1.37) | blank | blank | 2.06 | 0.46–9.20 | 0.342 ||\n|| Anxiety | blank | blank | 52.819 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 83(87.37) | 939(98.84) | blank | blank | 1 | blank | blank ||\n|| Yes | 12(12.63) | 11(1.16) | blank | blank | 10.71 | 2.40–47.75 | 0.002 ||\n|| Mood disorder | blank | blank | 102.2399 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 78(82.11) | 941(99.05) | blank | blank | 1 | blank | blank ||\n|| Yes | 17(17.89) | 9(0.95) | blank | blank | 5.82 | 1.85–18.38 | 0.003 ||\n|| <9 years (ref.) | 24(25.26) | 112(11.79) | blank | blank | 1 | blank | blank ||\n|| Postpartum depressive disorder | blank | blank | 190.338 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 66(69.47) | 937(98.63) | blank | blank | 1 | blank | blank ||\n|| Yes | 29(30.53) | 13(1.37) | blank | blank | 21.72 | 8.08–58.37 | <0.0001 ||\n|| 9–12 years | 35(36.84) | 276(29.05) | blank | blank | 0.52 | 0.25–1.07 | 0.078 ||\n|| > 12 years | 17(17.89) | 327(34.42) | blank | blank | 0.17 | 0.07–0.41 | <0.0001 ||\n|| Unknown | 19(20.0) | 235(24.74) | blank | blank | 0.97 | 0.14–6.55 | 0.973 ||\n|| Marital status | blank | blank | 26.684 | <0.0001 | blank | blank | blank ||\n|| Married (ref.) | 52(54.74) | 623(65.58) | blank | blank | 1 | blank | blank ||\n|| Never married | 17(17.89) | 73(7.68) | blank | blank | 2.51 | 1.10–5.75 | 0.029 ||",
    "claim": "The presence of pre-eclampsia or eclampsia is associated with a decreased risk of completed suicide, with an odds ratio of 2.06, although this is not statistically significant with a p-value of 0.342.",
    "label": "refute"
  },
  {
    "id": "training_787_1",
    "table_caption": "Table: The most likely clusters of HFMD in Guangdong Province, China, 2008–2011 (setting 50% as the maximum cluster size). Scan timeframe Cluster time Cluster center/Radius Annual cases/ 10000 LLR RR P 2008/5/1–2008/12/31 2008/5/1–2008/5/14 (22.23N, 113.25E)/163.17 km 84.14 25169.84 15.96 ,0.001 2009/1/1–2009/12/31 2009/4/8–2009/10/6 (23.10N, 113.48E)/119.57 km 21.16 15869.52 3.33 ,0.001 2010/1/1–/12/31 2010/3/28–2010/7/26 (22.94N, 113.88E)/151.31 km 60.64 42847.38 3.79 ,0.001 2011/1/1–2011/12/31 2011/5/10–2011/11/7 (23.10N, 113.48E)/119.57 km 54.20 44180.26 3.22 ,0.001 Note: ‘Scan timeframe’ means the boundary of time points put into the scanning analysis, and the ‘Cluster time’ means the boundary of time points identified by the scanning analysis. ",
    "table_content": "|| Scan timeframe | Cluster time | Cluster center/Radius | Annual cases/10000 |  LLR  |  RR  |  P  ||\n|| 2008/5/1–2008/12/31 | 2008/5/1–2008/5/14 | (22.23N, 113.25E)/163.17 km | 84.14 | 25169.84 | 15.96 | <0.001 ||\n|| 2009/1/1–2009/12/31 | 2009/4/8–2009/10/6 | (23.10N, 113.48E)/119.57 km | 21.16 | 15869.52 | 3.33 | <0.001 ||\n|| 2010/1/1–/12/31 | 2010/3/28–2010/7/26 | (22.94N, 113.88E)/151.31 km | 60.64 | 42847.38 | 3.79 | <0.001 ||\n|| 2011/1/1–2011/12/31 | 2011/5/10–2011/11/7 | (23.10N, 113.48E)/119.57 km | 54.20 | 44180.26 | 3.22 | <0.001 ||",
    "claim": "The duration of cluster time in 2009 was shorter than in 2008, suggesting a less prolonged period of HFMD activity in 2009 compared to 2008.",
    "label": "refute"
  },
  {
    "id": "training_208_5",
    "table_caption": "Table: Table 7 Comparison with previous methods Benchmark datasets Previous accuracy Accuracy of models Composition based model Dipeptide based model Hybrid model Sanders-2011a 95.94 96.40 98.65 97.75 Sanders-2011b 75.86 82.07 83.45 83.45 Sanders-2011c 88.73 88.74 89.64 90.09 Dobchev-2010 83.16 81.63 81.63 83.33 Hansen-2008 67.44 78.82 83.53 80.00 Hallbrink-2005 77.27 92.75 95.65 97.06 ",
    "table_content": "|| Benchmark datasets | Previous accuracy | Accuracy of models | Accuracy of models | Accuracy of models ||\n|| Benchmark datasets | Previous accuracy | Composition based model | Dipeptide based model | Hybrid model ||\n|| Sanders-2011a | 95.94 | 96.40 | 98.65 | 97.75 ||\n|| Sanders-2011b | 75.86 | 82.07 | 83.45 | 83.45 ||\n|| Sanders-2011c | 88.73 | 88.74 | 89.64 | 90.09 ||\n|| Dobchev-2010 | 83.16 | 81.63 | 81.63 | 83.33 ||\n|| Hansen-2008 | 67.44 | 78.82 | 83.53 | 80.00 ||\n|| Hallbrink-2005 | 77.27 | 92.75 | 95.65 | 97.06 ||",
    "claim": "The composition-based model shows the greatest variability in performance, with a range of 14.93% between its highest and lowest accuracy rates across datasets, reflecting its sensitivity to dataset characteristics.",
    "label": "refute"
  },
  {
    "id": "training_208_5",
    "table_caption": "Table: Table 7 Comparison with previous methods Benchmark datasets Previous accuracy Accuracy of models Composition based model Dipeptide based model Hybrid model Sanders-2011a 95.94 96.40 98.65 97.75 Sanders-2011b 75.86 82.07 83.45 83.45 Sanders-2011c 88.73 88.74 89.64 90.09 Dobchev-2010 83.16 81.63 81.63 83.33 Hansen-2008 67.44 78.82 83.53 80.00 Hallbrink-2005 77.27 92.75 95.65 97.06 ",
    "table_content": "|| Benchmark datasets | Previous accuracy | Accuracy of models | Accuracy of models | Accuracy of models ||\n|| Benchmark datasets | Previous accuracy | Composition based model | Dipeptide based model | Hybrid model ||\n|| Sanders-2011a | 95.94 | 96.40 | 98.65 | 97.75 ||\n|| Sanders-2011b | 75.86 | 82.07 | 83.45 | 83.45 ||\n|| Sanders-2011c | 88.73 | 88.74 | 89.64 | 90.09 ||\n|| Dobchev-2010 | 83.16 | 81.63 | 81.63 | 83.33 ||\n|| Hansen-2008 | 67.44 | 78.82 | 83.53 | 80.00 ||\n|| Hallbrink-2005 | 77.27 | 92.75 | 95.65 | 97.06 ||",
    "claim": "The dipeptide-based model shows the greatest variability in performance, with a range of 14.93% between its highest and lowest accuracy rates across datasets, reflecting its sensitivity to dataset characteristics.",
    "label": "refute"
  },
  {
    "id": "training_874_1",
    "table_caption": "Table: Low-risk category (n = 1,128) Intermediate-risk category (n = 1,253) High-risk category (n = 312) P Value Age, years 60 (53–68) 62 (53–69) 63 (54–72) <0.001 Male 883 (78.3%) 941 (75.1%) 217 (69.6%) 0.005 Body mass index, kg/m2 24.16 (22.39–26.05) 24.11 (21.97–25.87) 24.02 (22.03–25.69) 0.170 Medical history  Smoker (former or current) 583 (51.7%) 633 (50.5%) 142 (45.5%) 0.155  Hypertension 525 (46.5%) 602 (48.0%) 151 (48.4%) 0.718  Diabetes mellitus 202 (17.8%) 260 (20.8%) 98 (31.4%) <0.001  Dyslipidemia 809 (71.7%) 883 (70.5%) 214 (68.6%) 0.532  Previous MI 122 (10.8%) 134 (10.7%) 35 (11.2%) 0.965  Previous PCI 47 (4.2%) 50 (4.0%) 8 (2.6%) 0.422  Previous stroke 46 (4.1%) 65 (5.2%) 22 (7.1%) 0.086 Presentation characteristics  Heart rate, beats/min 76 (68–78) 76 (69–83) 76 (69–88) <0.001  SBP, mm Hg 124 (118–135) 123 (111–138) 120 (105–131) <0.001  Killip class I 960 (85.1%) 970 (77.4%) 227 (72.8%) <0.001  Killip class II 122 (10.8%) 172 (13.7%) 41 (13.1%)  Killip class III 42 (3.7%) 93 (7.4%) 27 (8.7%)  Killip class IV 4 (0.4%) 18 (1.4%) 17 (5.4%)  Cardiac arrest 6 (0.5%) 16 (1.3%) 7 (2.2%) 0.022 Laboratory findings  WBC count, ×109/L 5.98 (5.23–6.98) 8.89 (7.21–10.07) 9.10 (8.80–10.77) <0.001  Neutrophil count, ×109/L 3.79 (3.12–4.53) 6.54 (4.24–8.01) 6.67 (5.64–8.53) <0.001  Lymphocyte count, ×109/L 1.63 (1.26–2.04) 1.58 (1.18–2.07) 1.63 (1.22–2.16) 0.351  Monocyte count, ×109/L 0.37 (0.28–0.47) 0.49 (0.35–0.71) 0.59 (0.38–0.82) <0.001  Eosinophil count, ×109/L 0.08 (0.05–0.15) 0.05 (0.01–0.11) 0.04 (0.01–0.10) <0.001  Basophil count, ×109/L 0.02 (0.01–0.03) 0.02 (0.01–0.02) 0.01 (0.01–0.02) 0.001  RBC count, ×1012/L 4.81 (4.53–5.12) 4.69 (4.26–5.14) 4.42 (3.97–4.94) <0.001  Hemoglobin, g/L 152 (143–161) 148 (131–160) 138 (121–156) <0.001  RDW, % 13.20 (12.80–13.80) 13.50 (12.90–14.00) 13.70 (13.13–14.40) <0.001  MCV, fL 92.80 (89.90–96.10) 91.70 (88.60–95.00) 92.10 (88.43–95.60) <0.001  MCH, pg 31.60 (30.50–32.70) 31.30 (30.10–32.40) 31.20 (29.80–32.20) <0.001  MCHC, g/L 339 (333–346) 341 (332–349) 337 (328–345) <0.001  Hematocrit, % 44.80 (42.20–47.40) 43.20 (39.40–46.40) 41.85 (36.53–46.10) <0.001  Platelet count, ×109/L 168 (131–206) 188 (147–231) 163 (130–210) <0.001  MPV, fL 11.50 (10.70–12.40) 11.30 (10.50–12.10) 13.30 (12.03–13.80) <0.001  PDW, fL 14.90 (13.00–16.70) 14.60 (12.80–15.90) 18.30 (14.98–20.40) <0.001  P-LCR, % 38.20 (32.33–44.40) 37.00 (30.10–42.00) 50.55 (39.39–54.20) <0.001  Plateletcrit, % 0.210 (0.170–0.230) 0.220 (0.180–0.260) 0.219 (0.180–0.260) <0.001  LDL, mmol/L 2.40 (1.88–2.98) 2.58 (1.99–3.24) 2.63 (2.09–3.16) <0.001  Glucose, mmol/L 5.60 (4.89–7.18) 6.20 (5.12–7.98) 6.86 (5.44–9.81) <0.001  Creatinine, µmol/L 75.75 (67.00–84.00) 74.50 (64.00–87.05) 77.40 (64.00–96.90) 0.071  Elevated cardiac enzymes 521 (46.2%) 898 (71.7%) 236 (75.6%) <0.001 ST-segment deviation on ECG 450 (39.9%) 810 (64.6%) 209 (67.0%) <0.001 LVEF, % 56 (55–60) 56 (49–58) 55 (47–59) <0.001 GRACE risk score 118 (87–166) 162 (114–189) 172 (132–203) <0.001 ACS presentation <0.001  NSTE-ACS 724 (64.2%) 513 (40.9%) 125 (40.1%)  STEMI 404 (35.8%) 740 (59.1%) 187 (59.9%) Medical treatment  Aspirin 1,101 (97.6%) 1,213 (96.8%) 308 (98.7%) 0.136  P2Y12 inhibitor 1,068 (94.7%) 1,197 (95.5%) 299 (95.8%) 0.538  Statin 1,003 (88.9%) 1,135 (90.6%) 275 (88.1%) 0.276  ACEI⁄ARB 761 (67.5%) 796 (63.5%) 201 (64.4%) 0.124  β-Blocker 636 (56.4%) 692 (55.2%) 168 (53.8%) 0.692 Table 1. Demographic and clinical characteristics of risk groups. Abbreviation: MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; WBC, white blood cell; RBC, red ",
    "table_content": "|| blank | Low-risk category (n = 1,128) | Intermediate-risk category (n = 1,253) | High-risk category (n = 312) | P Value ||\n|| Age, years | 60 (53–68) | 62 (53–69) | 63 (54–72) | <0.001 ||\n|| Previous PCI | 47 (4.2%) | 50 (4.0%) | 8 (2.6%) | 0.422 ||\n|| Previous stroke | 46 (4.1%) | 65 (5.2%) | 22 (7.1%) | 0.086 ||\n|| Presentation characteristics | Presentation characteristics | Presentation characteristics | Presentation characteristics | Presentation characteristics ||\n|| Heart rate, beats/min | 76 (68–78) | 76 (69–83) | 76 (69–88) | <0.001 ||\n|| SBP, mm Hg | 124 (118–135) | 123 (111–138) | 120 (105–131) | <0.001 ||\n|| Killip class I | 960 (85.1%) | 970 (77.4%) | 227 (72.8%) | <0.001 ||\n|| Killip class II | 122 (10.8%) | 172 (13.7%) | 41 (13.1%) | blank ||\n|| Killip class III | 42 (3.7%) | 93 (7.4%) | 27 (8.7%) | blank ||\n|| Killip class IV | 4 (0.4%) | 18 (1.4%) | 17 (5.4%) | blank ||\n|| Cardiac arrest | 6 (0.5%) | 16 (1.3%) | 7 (2.2%) | 0.022 ||\n|| Male | 883 (78.3%) | 941 (75.1%) | 217 (69.6%) | 0.005 ||\n|| Laboratory findings | Laboratory findings | Laboratory findings | Laboratory findings | Laboratory findings ||\n|| WBC count, ×10 9 /L | 5.98 (5.23–6.98) | 8.89 (7.21–10.07) | 9.10 (8.80–10.77) | <0.001 ||\n|| Neutrophil count, ×10 9 /L | 3.79 (3.12–4.53) | 6.54 (4.24–8.01) | 6.67 (5.64–8.53) | <0.001 ||\n|| Lymphocyte count, ×10 9 /L | 1.63 (1.26–2.04) | 1.58 (1.18–2.07) | 1.63 (1.22–2.16) | 0.351 ||\n|| Monocyte count, ×10 9 /L | 0.37 (0.28–0.47) | 0.49 (0.35–0.71) | 0.59 (0.38–0.82) | <0.001 ||\n|| Eosinophil count, ×10 9 /L | 0.08 (0.05–0.15) | 0.05 (0.01–0.11) | 0.04 (0.01–0.10) | <0.001 ||\n|| Basophil count, ×10 9 /L | 0.02 (0.01–0.03) | 0.02 (0.01–0.02) | 0.01 (0.01–0.02) | 0.001 ||\n|| RBC count, ×10 12 /L | 4.81 (4.53–5.12) | 4.69 (4.26–5.14) | 4.42 (3.97–4.94) | <0.001 ||\n|| Hemoglobin, g/L | 152 (143–161) | 148 (131–160) | 138 (121–156) | <0.001 ||\n|| RDW, % | 13.20 (12.80–13.80) | 13.50 (12.90–14.00) | 13.70 (13.13–14.40) | <0.001 ||\n|| Body mass index, kg/m 2 | 24.16 (22.39–26.05) | 24.11 (21.97–25.87) | 24.02 (22.03–25.69) | 0.170 ||\n|| MCV, fL | 92.80 (89.90–96.10) | 91.70 (88.60–95.00) | 92.10 (88.43–95.60) | <0.001 ||\n|| MCH, pg | 31.60 (30.50–32.70) | 31.30 (30.10–32.40) | 31.20 (29.80–32.20) | <0.001 ||\n|| MCHC, g/L | 339 (333–346) | 341 (332–349) | 337 (328–345) | <0.001 ||\n|| Hematocrit, % | 44.80 (42.20–47.40) | 43.20 (39.40–46.40) | 41.85 (36.53–46.10) | <0.001 ||\n|| Platelet count, ×10 9 /L | 168 (131–206) | 188 (147–231) | 163 (130–210) | <0.001 ||\n|| MPV, fL | 11.50 (10.70–12.40) | 11.30 (10.50–12.10) | 13.30 (12.03–13.80) | <0.001 ||\n|| PDW, fL | 14.90 (13.00–16.70) | 14.60 (12.80–15.90) | 18.30 (14.98–20.40) | <0.001 ||\n|| P-LCR, % | 38.20 (32.33–44.40) | 37.00 (30.10–42.00) | 50.55 (39.39–54.20) | <0.001 ||\n|| Plateletcrit, % | 0.210 (0.170–0.230) | 0.220 (0.180–0.260) | 0.219 (0.180–0.260) | <0.001 ||\n|| LDL, mmol/L | 2.40 (1.88–2.98) | 2.58 (1.99–3.24) | 2.63 (2.09–3.16) | <0.001 ||\n|| Medical history | Medical history | Medical history | Medical history | Medical history ||\n|| Glucose, mmol/L | 5.60 (4.89–7.18) | 6.20 (5.12–7.98) | 6.86 (5.44–9.81) | <0.001 ||\n|| Creatinine, µmol/L | 75.75 (67.00–84.00) | 74.50 (64.00–87.05) | 77.40 (64.00–96.90) | 0.071 ||\n|| Elevated cardiac enzymes | 521 (46.2%) | 898 (71.7%) | 236 (75.6%) | <0.001 ||\n|| ST-segment deviation on ECG | 450 (39.9%) | 810 (64.6%) | 209 (67.0%) | <0.001 ||\n|| LVEF, % | 56 (55–60) | 56 (49–58) | 55 (47–59) | <0.001 ||\n|| GRACE risk score | 118 (87–166) | 162 (114–189) | 172 (132–203) | <0.001 ||\n|| ACS presentation | blank | blank | blank | <0.001 ||\n|| NSTE-ACS | 724 (64.2%) | 513 (40.9%) | 125 (40.1%) | blank ||\n|| STEMI | 404 (35.8%) | 740 (59.1%) | 187 (59.9%) | blank ||\n|| Medical treatment | Medical treatment | Medical treatment | Medical treatment | Medical treatment ||\n|| Smoker (former or current) | 583 (51.7%) | 633 (50.5%) | 142 (45.5%) | 0.155 ||\n|| Aspirin | 1,101 (97.6%) | 1,213 (96.8%) | 308 (98.7%) | 0.136 ||\n|| P2Y12 inhibitor | 1,068 (94.7%) | 1,197 (95.5%) | 299 (95.8%) | 0.538 ||\n|| Statin | 1,003 (88.9%) | 1,135 (90.6%) | 275 (88.1%) | 0.276 ||\n|| ACEI⁄ARB | 761 (67.5%) | 796 (63.5%) | 201 (64.4%) | 0.124 ||\n|| β-Blocker | 636 (56.4%) | 692 (55.2%) | 168 (53.8%) | 0.692 ||\n|| Hypertension | 525 (46.5%) | 602 (48.0%) | 151 (48.4%) | 0.718 ||\n|| Diabetes mellitus | 202 (17.8%) | 260 (20.8%) | 98 (31.4%) | <0.001 ||\n|| Dyslipidemia | 809 (71.7%) | 883 (70.5%) | 214 (68.6%) | 0.532 ||\n|| Previous MI | 122 (10.8%) | 134 (10.7%) | 35 (11.2%) | 0.965 ||",
    "claim": "The average age increases with risk category, with the high-risk group being older than the low-risk group. The proportion of males increases as risk increases. The difference in age and gender distribution between the low-risk and high-risk groups is statistically significant, with a P-value of less than 0.001 for age and 0.005 for gender.",
    "label": "refute"
  },
  {
    "id": "training_1122_1",
    "table_caption": "Table: defect. Electrodes Rs (ohm) Ret (ohm) SAM Г (10-8 mol·cm-2) % defect % adsorption Bare 227.0 (2.0%) 589.5 (5.0%) MPA 1.38±0.1 87.3 12.7 MPA 256.6 (0.9%) 6281.0 (1.7%) MUA 2.37±0.3 37.8 62.2 MUA 229 (1.0%) 209370 (4.3%) The CV curves obtained from the gold-oxide reduction experiments performed in H2SO4 are shown ",
    "table_content": "|| Electrodes | R s (ohm) | R et (ohm) | SAM | Γ (10 −8 mol·cm −2 ) | % defect | % adsorption ||\n|| Bare | 227.0 (2.0%) | 589.5 (5.0%) | MPA | 1.38±0.1 | 87.3 | 12.7 ||\n|| MPA | 256.6 (0.9%) | 6281.0 (1.7%) | MUA | 2.37±0.3 | 37.8 | 62.2 ||\n|| MUA | 229 (1.0%) | 209370 (4.3%) | blank | blank | blank | blank ||",
    "claim": "The MUA electrode exhibits a Ret value that is approximately 3.3 times greater than that of the MPA electrode, indicating a substantial increase in charge transfer resistance due to the MUA modification.",
    "label": "refute"
  },
  {
    "id": "training_1215_5",
    "table_caption": "Table: US retail drug prices, May 2005 Bimatoprost 0.03%, 2.5 mL Bimatoprost 0.03%, 5.0 mL ($ per 2.5 mL) Latanoprost 0.005%, 2.5 mL Travoprost 0.004%, 2.5 mL Walgreens $74.99 $71.50 $65.99 $71.99 Park Pharmacy $68.95 $67.98 $63.98 $64.95 WalMart $69.32 $63.23 $50.68 $64.88 Winn Dixie $71.95 $63.48 $69.95 $66.95 K-Mart $74.97 $69.49 $62.99 $70.97 Target $71.99 $65.75 $59.99 $67.99 DrugStore.Com $57.75 $55.12 $58.22 $56.88 Average $69.99 $65.22 $61.69 $66.37 ",
    "table_content": "|| blank | Bimatoprost 0.03%, 2.5 mL | Bimatoprost 0.03%, 5.0 mL ($ per 2.5 mL) | Latanoprost 0.005%, 2.5 mL | Travoprost 0.004%, 2.5 mL ||\n|| Walgreens | $74.99 | $71.50 | $65.99 | $71.99 ||\n|| Park Pharmacy | $68.95 | $67.98 | $63.98 | $64.95 ||\n|| WalMart | $69.32 | $63.23 | $50.68 | $64.88 ||\n|| Winn Dixie | $71.95 | $63.48 | $69.95 | $66.95 ||\n|| K-Mart | $74.97 | $69.49 | $62.99 | $70.97 ||\n|| Target | $71.99 | $65.75 | $59.99 | $67.99 ||\n|| DrugStore.Com | $57.75 | $55.12 | $58.22 | $56.88 ||\n|| Average | $69.99 | $65.22 | $61.69 | $66.37 ||",
    "claim": "At WalMart, the price of Latanoprost 0.005% (2.5 mL) is approximately 7.8% lower than the average price, highlighting a competitive pricing strategy for this drug at this retailer.",
    "label": "refute"
  },
  {
    "id": "training_118_7",
    "table_caption": "Table: Table 2 Lung mechanics, hemodynamics, gas exchange, acid-base status, and metabolic parameters Vehicle HAM1101 p value Hemoglobin content (mg·mL−1) Start 90 (87, 96) 98 (95, 105) 0.074 End 70 (66, 72) 69 (66, 74) 0.806 Heart rate (beats·min−1) Start 494 (485, 515) 430 (406, 480) 0.248 End 426 (406, 445) 391 (349,430) 0.290 Mean arterial pressure (mmHg) Start 69 (65, 71) 69 (66, 76) 0.382 End 64 (59, 69) 67 (66, 72) 0.441 Thoracopulmonary compliance (μL·cm H2O−1) Start 0.10 (0.09, 0.10) 0.10 (0.09, 0.11) 0.382 End 0.09 (0.08, 0.10) 0.10 (0.08, 0.11) 0.427 Arterial PO2 (mmHg) Start 314 (293, 330) 340 (321, 350) 0.254 End 309 (287, 326) 301 (287, 319) 0.838 Arterial PCO2 (mmHg) Start 31 (27, 33) 31 (29, 36) 0.879 End 34 (33, 36) 31 (28, 33) 0.072 Arterial pH Start 7.33 (7.30, 7.35) 7.36 (7.32, 7.38) 0.569 End 7.38 (7.31, 7.43) 7.43 (7.39, 7.46) 0.253 Arterial base excess (mmol·mL−1) Start −9.0 (−10.3, −7.7) −6.8 (−8.3, −6.2) 0.403 End −5.7 (−7.1, −1.7) −3.9 (−4.2, −3.3) 0.838 Arterial lactate (mmol·mL−1) Start n.d. n.d. n.d. End 2.0 (1.7, 2.2) 1.6 (1.5, 1.8) 0.025 Arterial glucose (mg·dL−1) Start 113 (110, 117) 115 (106, 123) 0.540 End 110 (96, 117) 111 (109, 115) 0.653 CO2 production rate (μL·g−1·min−1) Start 26 (24, 28) 24 (23, 25) 0.082 End 23 (21, 26) 23 (22, 25) 0.596 Glucose production rate (mg·g−1·h−1) Start 0.37 (0.35, 0.41) 0.34 (0.31, 0.36) 0.178 End 0.38 (0.35, 0.39) 0.33 (0.31, 0.39) 0.153 Glucose oxidation rate (% isotope infusion) Start 58 (55, 62) 55 (50, 59) 0.224 End 57 (54, 60) 62 (58, 67) 0.047 The data are for the vehicle-treated (n = 11) and HAM1101-treated (n = 9) animals at the start and the end of the 5-h observation period; n.d., not determined. All data are median (quartiles). ",
    "table_content": "|| blank | blank | Vehicle | HAM1101 |  p value ||\n|| Hemoglobin content (mg·mL −1 ) | Start | 90 (87, 96) | 98 (95, 105) | 0.074 ||\n|| Arterial PO 2 (mmHg) | End | 309 (287, 326) | 301 (287, 319) | 0.838 ||\n|| Arterial PCO 2 (mmHg) | Start | 31 (27, 33) | 31 (29, 36) | 0.879 ||\n|| Arterial PCO 2 (mmHg) | End | 34 (33, 36) | 31 (28, 33) | 0.072 ||\n|| Arterial pH | Start | 7.33 (7.30, 7.35) | 7.36 (7.32, 7.38) | 0.569 ||\n|| Arterial pH | End | 7.38 (7.31, 7.43) | 7.43 (7.39, 7.46) | 0.253 ||\n|| Arterial base excess (mmol·mL −1 ) | Start | −9.0 (−10.3, −7.7) | −6.8 (−8.3, −6.2) | 0.403 ||\n|| Arterial base excess (mmol·mL −1 ) | End | −5.7 (−7.1, −1.7) | −3.9 (−4.2, −3.3) | 0.838 ||\n|| Arterial lactate (mmol·mL −1 ) | Start | n.d. | n.d. | n.d. ||\n|| Arterial lactate (mmol·mL −1 ) | End | 2.0 (1.7, 2.2) | 1.6 (1.5, 1.8) | 0.025 ||\n|| Arterial glucose (mg·dL −1 ) | Start | 113 (110, 117) | 115 (106, 123) | 0.540 ||\n|| Hemoglobin content (mg·mL −1 ) | End | 70 (66, 72) | 69 (66, 74) | 0.806 ||\n|| Arterial glucose (mg·dL −1 ) | End | 110 (96, 117) | 111 (109, 115) | 0.653 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | Start | 26 (24, 28) | 24 (23, 25) | 0.082 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | End | 23 (21, 26) | 23 (22, 25) | 0.596 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | Start | 0.37 (0.35, 0.41) | 0.34 (0.31, 0.36) | 0.178 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | End | 0.38 (0.35, 0.39) | 0.33 (0.31, 0.39) | 0.153 ||\n|| Glucose oxidation rate (% isotope infusion) | Start | 58 (55, 62) | 55 (50, 59) | 0.224 ||\n|| Glucose oxidation rate (% isotope infusion) | End | 57 (54, 60) | 62 (58, 67) | 0.047 ||\n|| Heart rate (beats·min −1 ) | Start | 494 (485, 515) | 430 (406, 480) | 0.248 ||\n|| Heart rate (beats·min −1 ) | End | 426 (406, 445) | 391 (349,430) | 0.290 ||\n|| Mean arterial pressure (mmHg) | Start | 69 (65, 71) | 69 (66, 76) | 0.382 ||\n|| Mean arterial pressure (mmHg) | End | 64 (59, 69) | 67 (66, 72) | 0.441 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | Start | 0.10 (0.09, 0.10) | 0.10 (0.09, 0.11) | 0.382 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | End | 0.09 (0.08, 0.10) | 0.10 (0.08, 0.11) | 0.427 ||\n|| Arterial PO 2 (mmHg) | Start | 314 (293, 330) | 340 (321, 350) | 0.254 ||",
    "claim": "The change in arterial base excess from start to end in the vehicle group is approximately 42.6%, while in the HAM1101 group, it is approximately 36.7%. This indicates a greater shift towards normalization of base excess in the vehicle group.",
    "label": "refute"
  },
  {
    "id": "training_709_1",
    "table_caption": "Table: Correlation between HER2 over-expression and Hormonal receptors status Her-2 over-expression n (%) p ER 0.000 Positive 7 (7.6) Negative 21 (33.3) PR 0.048 Positive 10 (12.34) Negative 18 (24.65) ER/PR 0.000 Positive/Positive 5 (7.24) Negative/Negative 16 (32) HER-2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor. ",
    "table_content": "|| blank | Her-2 over-expression | Her-2 over-expression ||\n|| blank | n (%) | p ||\n|| Negative/Negative | 16 (32) | blank ||\n|| ER | blank | 0.000 ||\n|| Positive | 7 (7.6) | blank ||\n|| Negative | 21 (33.3) | blank ||\n|| PR | blank | 0.048 ||\n|| Positive | 10 (12.34) | blank ||\n|| Negative | 18 (24.65) | blank ||\n|| ER/PR | blank | 0.000 ||\n|| Positive/Positive | 5 (7.24) | blank ||",
    "claim": "The probability of HER2 over-expression in ER-negative cases is approximately 4.38 times higher than in ER-positive cases, indicating a strong inverse correlation between ER positivity and HER2 over-expression.",
    "label": "refute"
  },
  {
    "id": "training_709_1",
    "table_caption": "Table: Correlation between HER2 over-expression and Hormonal receptors status Her-2 over-expression n (%) p ER 0.000 Positive 7 (7.6) Negative 21 (33.3) PR 0.048 Positive 10 (12.34) Negative 18 (24.65) ER/PR 0.000 Positive/Positive 5 (7.24) Negative/Negative 16 (32) HER-2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor. ",
    "table_content": "|| blank | Her-2 over-expression | Her-2 over-expression ||\n|| blank | n (%) | p ||\n|| Negative/Negative | 16 (32) | blank ||\n|| ER | blank | 0.000 ||\n|| Positive | 7 (7.6) | blank ||\n|| Negative | 21 (33.3) | blank ||\n|| PR | blank | 0.048 ||\n|| Positive | 10 (12.34) | blank ||\n|| Negative | 18 (24.65) | blank ||\n|| ER/PR | blank | 0.000 ||\n|| Positive/Positive | 5 (7.24) | blank ||",
    "claim": "The probability of HER2 over-expression in ER-positive cases is approximately 4.38 times higher than in ER-negative cases, indicating a strong direct correlation between ER positivity and HER2 over-expression.",
    "label": "refute"
  },
  {
    "id": "training_1018_2",
    "table_caption": "Table: Table 4 Daily dietary nutrient intakes by vegetable expenditure* Total population Quintiles (range) of daily vegetable expenditure (NTD/day) P† Q1 (<8.20) Q2 (8.21-13.9) Q3 (14.0-20.6) Q4 (20.7-29.7) Q5 (>29.7) Energy (kcal) 1626 1574 1667 1586 1677 1621 0.554 Protein (g) 65.2 58.3 62.5 66.0 68.2 70.3 0.001 Total fat (g) 44.1 46.3 44.1 43.4 43.9 43.0 0.737 SFA (g) 13.3 16.0 13.4 13.0 12.6 11.5 0.001 PUFA (g) 13.5 12.0 13.3 13.2 14.1 14.8 0.011 Cholesterol (mg) 207 209 214 222 206 184 0.080 Carbohydrate (g) 215 205 213 218 219 220 0.078 Dietary fiber (g) 18.8 13.7 14.8 16.8 20.9 27.3 <0.001 Fe (mg) 11.5 8.38 9.41 10.5 13.2 15.5 <0.001 Ca (mg) 624 544 556 576 633 798 <0.001 P (mg) 944 862 899 945 965 1039 0.007 Mg (mg) 225 179 196 215 235 294 <0.001 Na (mg) 4520 3499 3753 4245 5118 5831 <0.001 K (mg) 2270 1698 1899 2178 2416 3087 <0.001 Vitamin A (I.U.) 9354 5234 6605 8345 11353 14664 <0.001 Vitamin D (mg) 5.30 4.95 5.57 5.96 5.06 4.67 0.300 Vitamin E (mg) 7.46 5.89 6.46 7.19 8.30 9.23 <0.001 Vitamin B-1 (mg) 1.07 0.96 1.04 1.01 1.13 1.19 0.167 Vitamin B-2 (mg) 1.35 1.43 1.35 1.25 1.29 1.41 0.114 Niacin (mg) 13.4 12.0 12.7 13.4 14.4 14.5 0.050 Vitamin B-6 (mg) 1.11 1.02 1.01 1.05 1.20 1.26 0.006 Vitamin C (mg) 148 105 122 133 171 202 <0.001 *All values are presented by mean. † Differences across quintiles were tested by ANOVA. ",
    "table_content": "|| blank | Total population | Quintiles (range) of daily vegetable expenditure (NTD/day) | Quintiles (range) of daily vegetable expenditure (NTD/day) | Quintiles (range) of daily vegetable expenditure (NTD/day) | Quintiles (range) of daily vegetable expenditure (NTD/day) | Quintiles (range) of daily vegetable expenditure (NTD/day) | P † ||\n|| blank | Total population | Q1 (<8.20) | Q2 (8.21-13.9) | Q3 (14.0-20.6) | Q4 (20.7-29.7) | Q5 (>29.7) | P † ||\n|| Fe (mg) | 11.5 | 8.38 | 9.41 | 10.5 | 13.2 | 15.5 | <0.001 ||\n|| Ca (mg) | 624 | 544 | 556 | 576 | 633 | 798 | <0.001 ||\n|| P (mg) | 944 | 862 | 899 | 945 | 965 | 1039 | 0.007 ||\n|| Mg (mg) | 225 | 179 | 196 | 215 | 235 | 294 | <0.001 ||\n|| Na (mg) | 4520 | 3499 | 3753 | 4245 | 5118 | 5831 | <0.001 ||\n|| K (mg) | 2270 | 1698 | 1899 | 2178 | 2416 | 3087 | <0.001 ||\n|| Vitamin A (I.U.) | 9354 | 5234 | 6605 | 8345 | 11353 | 14664 | <0.001 ||\n|| Vitamin D (mg) | 5.30 | 4.95 | 5.57 | 5.96 | 5.06 | 4.67 | 0.300 ||\n|| Vitamin E (mg) | 7.46 | 5.89 | 6.46 | 7.19 | 8.30 | 9.23 | <0.001 ||\n|| Vitamin B-1 (mg) | 1.07 | 0.96 | 1.04 | 1.01 | 1.13 | 1.19 | 0.167 ||\n|| Energy (kcal) | 1626 | 1574 | 1667 | 1586 | 1677 | 1621 | 0.554 ||\n|| Vitamin B-2 (mg) | 1.35 | 1.43 | 1.35 | 1.25 | 1.29 | 1.41 | 0.114 ||\n|| Niacin (mg) | 13.4 | 12.0 | 12.7 | 13.4 | 14.4 | 14.5 | 0.050 ||\n|| Vitamin B-6 (mg) | 1.11 | 1.02 | 1.01 | 1.05 | 1.20 | 1.26 | 0.006 ||\n|| Vitamin C (mg) | 148 | 105 | 122 | 133 | 171 | 202 | <0.001 ||\n|| Protein (g) | 65.2 | 58.3 | 62.5 | 66.0 | 68.2 | 70.3 | 0.001 ||\n|| Total fat (g) | 44.1 | 46.3 | 44.1 | 43.4 | 43.9 | 43.0 | 0.737 ||\n|| SFA (g) | 13.3 | 16.0 | 13.4 | 13.0 | 12.6 | 11.5 | 0.001 ||\n|| PUFA (g) | 13.5 | 12.0 | 13.3 | 13.2 | 14.1 | 14.8 | 0.011 ||\n|| Cholesterol (mg) | 207 | 209 | 214 | 222 | 206 | 184 | 0.080 ||\n|| Carbohydrate (g) | 215 | 205 | 213 | 218 | 219 | 220 | 0.078 ||\n|| Dietary fiber (g) | 18.8 | 13.7 | 14.8 | 16.8 | 20.9 | 27.3 | <0.001 ||",
    "claim": "Sodium intake increases by approximately 40% from the lowest to the highest quintile, suggesting a substantial rise in sodium consumption with higher vegetable expenditure.",
    "label": "refute"
  },
  {
    "id": "training_392_2",
    "table_caption": "Table: Optional Bioconductor chip reading libraries. Library Chip Type Run Local? affy Affymetrix 3'-biased Yes gcrma Affymetrix 3'-biased Yes affyPLM Affymetrix 3'-biased Yes xps Affymetrix 3'-biased No oligo Affymetrix Exon ST Yes exonmap Affymetrix Exon ST No xps Affymetrix Exon ST No oligo Affymetrix Gene ST Yes xps Affymetrix Gene ST No oligo Affymetrix SNP Yes oligo Affymetrix Tilling Yes oligo Nimblegen Yes lumi Illumina No beadarray Illumina No doi:10.1371/journal.pone.0137696.t001 ",
    "table_content": "|| Library | Chip Type | Run Local? ||\n|| affy | Affymetrix 3'-biased | Yes ||\n|| oligo | Affymetrix SNP | Yes ||\n|| oligo | Affymetrix Tilling | Yes ||\n|| oligo | Nimblegen | Yes ||\n|| lumi | Illumina | No ||\n|| beadarray | Illumina | No ||\n|| gcrma | Affymetrix 3'-biased | Yes ||\n|| affyPLM | Affymetrix 3'-biased | Yes ||\n|| xps | Affymetrix 3'-biased | No ||\n|| oligo | Affymetrix Exon ST | Yes ||\n|| exonmap | Affymetrix Exon ST | No ||\n|| xps | Affymetrix Exon ST | No ||\n|| oligo | Affymetrix Gene ST | Yes ||\n|| xps | Affymetrix Gene ST | No ||",
    "claim": "Among the libraries listed, a minority are capable of running locally, suggesting a preference or requirement for remote execution in chip reading processes.",
    "label": "refute"
  },
  {
    "id": "training_408_3",
    "table_caption": "Table: Quantification of the Lumen and Intimal Thickness of the Carotid In Normal, Untreated and PPS Treated MPS I Dogs. Left Carotid Right Carotid Lumen (μm) Thickness (μm) Lumen (μm) Thickness (μm) Normal 72.5 (69.9–75.9) 73.1 (70.2–77.3) 91.9 (84.2–94.6) 79.9 (77.5–87.1) Untreated 33.3 (29.9–37.7) 146.7 (108.8–192.7) 61.8 (54.3–64.1) 110.0 (101.5–137.9) Oral PPS 75.1*(70.1–78.1) 91.8* (86.7–95.9) 85.3* (79.7–89.1) 91.1* (89.1–93.2) SQ PPS 80.3*# (74.6–80.1) 79.0*#(73.7–92.4) 90.1*# (87.4–93.9) 83.8*# (79.9–89.9) *P<0.01 when comparing untreated to PPS treated animals. There is also a signiﬁcant effect when comparing oral to SQ treatment #P<0.01. Ranges shown in (). ",
    "table_content": "|| blank | Left Lumen (μm) | Carotid Thickness (μm) | Right Lumen (μm) | Carotid Thickness (μm) ||\n|| blank | Left Lumen (μm) | Carotid Thickness (μm) | Right Lumen (μm) | Carotid Thickness (μm) ||\n|| Normal | 72.5 (69.9–75.9) | 73.1 (70.2–77.3) | 91.9 (84.2–94.6) | 79.9 (77.5–87.1) ||\n|| Untreated | 33.3 (29.9–37.7) | 146.7 (108.8–192.7) | 61.8 (54.3–64.1) | 110.0 (101.5–137.9) ||\n|| Oral PPS | 75.1 * (70.1–78.1) | 91.8 * (86.7–95.9) | 85.3 * (79.7–89.1) | 91.1 * (89.1–93.2) ||\n|| SQ PPS | 80.3 * # (74.6–80.1) | 79.0 * # (73.7–92.4) | 90.1 * # (87.4–93.9) | 83.8 * # (79.9–89.9) ||",
    "claim": "Subcutaneous PPS treatment results in a lumen size that is approximately 2% larger than that achieved with oral PPS treatment, indicating a more effective restoration of the lumen size towards normal levels.",
    "label": "refute"
  },
  {
    "id": "training_611_4",
    "table_caption": "Table: Table 5 The multiple logistic regression for the relationship between POA and main IVF outcomes in each age group <33 years 33 ~ 37 years 38 ~ 41 years B P OR (95 % CI) B P OR (95 % CI) B P OR (5 % CI) Age 0.048 0.181 1.049(0.978–1.125) −0.069 0.348 0.933(0.807–1.079) −0.375 0.114 0.687(0.431–1.095) BMI −0.185 0.000 0.831(0.776–0.891) −0.090 0.006 0.914(0.857–0.975) −0.125 0.193 0.882(0.730–1.065) AFC −0.019 0.268 0.981(0.949–1.015) −0.032 0.086 0.969(0.934–1.004) −0.050 0.384 0.951(0.850–1.064) Number of retrieved oocytes −0.043 0.002 0.958(0.933–0.984) −0.015 0.348 0.985(0.954–1.017) −0.036 0.489 0.965(0.872–1.068) Total dose of Gna 0.283 <0.001 1.328(1.140–1.546) 0.428 <0.001 1.535(1.285–1.834) 0.662 0.006 1.939(1.212–3.102) aGn are transformed into ordinal variable according to the median (25–75th percentile) ",
    "table_content": "|| blank | <33 years | <33 years | <33 years | 33 ~ 37 years | 33 ~ 37 years | 33 ~ 37 years | 38 ~ 41 years | 38 ~ 41 years | 38 ~ 41 years ||\n|| blank | B |  P  | OR (95 % CI) | B |  P  | OR (95 % CI) | B |  P  | OR (5 % CI) ||\n|| Age | 0.048 | 0.181 | 1.049(0.978–1.125) | −0.069 | 0.348 | 0.933(0.807–1.079) | −0.375 | 0.114 | 0.687(0.431–1.095) ||\n|| BMI | −0.185 | 0.000 | 0.831(0.776–0.891) | −0.090 | 0.006 | 0.914(0.857–0.975) | −0.125 | 0.193 | 0.882(0.730–1.065) ||\n|| AFC | −0.019 | 0.268 | 0.981(0.949–1.015) | −0.032 | 0.086 | 0.969(0.934–1.004) | −0.050 | 0.384 | 0.951(0.850–1.064) ||\n|| Number of retrieved oocytes | −0.043 | 0.002 | 0.958(0.933–0.984) | −0.015 | 0.348 | 0.985(0.954–1.017) | −0.036 | 0.489 | 0.965(0.872–1.068) ||\n|| Total dose of Gn a  | 0.283 | <0.001 | 1.328(1.140–1.546) | 0.428 | <0.001 | 1.535(1.285–1.834) | 0.662 | 0.006 | 1.939(1.212–3.102) ||",
    "claim": "The odds ratio for the number of retrieved oocytes is lowest in the 38~41 years group, indicating that the number of oocytes retrieved has a more substantial impact on IVF success in older women. This aligns with the understanding that older women typically have a lower ovarian reserve, making the number of oocytes a critical factor.",
    "label": "refute"
  },
  {
    "id": "training_184_1",
    "table_caption": "Table: Table 4 Base case and sensitivity analysis results Parameter Value Deaths Averted Life Years Saved (Millions) Cost (Savings) (Billions) Cost Per Life Year Saved Non-Pandemic Base Case 76714 2.50 30.67 12281 (US$1899) Vaccine Coverage Low 75 % 76209 2.46 24.75 10072 (US$1558) High 95 % 77220 2.54 36.85 14525 (US$2247) Vaccine Price Low (-10 %) 774 76714 2.50 26.40 10572 (US$1635) High (+10 %) 946 76714 2.50 34.94 13991 (US$2164) Herd Effect Reduced by 50 % 41195 1.47 36.17 24549 (US$3797) Disease Incidence Low (-10 %) 69167 2.25 31.90 14158 (US$2190) High (+10 %) 84524 2.75 29.40 10676 (US$1651) Case Fatality Rate Low (-10 %) 69063 2.25 30.67 13640 (US$2109) High (+10 %) 84411 2.75 30.67 11160 (US$1726) Pandemic Base Case 707526 34.43 (41.03) Dominant Vaccine Coverage Low 75 % 702582 34.03 (46.88) Dominant High 95 % 712470 34.82 (34.93) Dominant Vaccine Price Low (-10 %) 774 707526 34.43 (45.30) Dominant High (+10 %) 946 707526 34.43 (36.76) Dominant Herd Effect Reduced by 50 % 384613 19.65 (0.48) Dominant Disease Incidence Low (-10 %) 641668 31.23 (33.21) Dominant High (+10 %) 782365 38.09 (50.06) Dominant Case Fatality Rate Low (-10 %) 637577 31.02 (41.03) Dominant High (+10 %) 779261 37.92 (41.03) Dominant All values measured in 2011 Chinese Yuan July 2011 exchange rate, US$ = ¥6.465 [11] ",
    "table_content": "|| Parameter | Value | Deaths Averted | Life Years Saved (Millions) | Cost (Savings) (Billions) | Cost Per Life Year Saved ||\n|| Non-Pandemic | Non-Pandemic | Non-Pandemic | Non-Pandemic | Non-Pandemic | Non-Pandemic ||\n|| Reduced by 50 % | blank | 41195 | 1.47 | 36.17 | 24549 (US$3797) ||\n|| Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence ||\n|| Low (-10 %) | blank | 69167 | 2.25 | 31.90 | 14158 (US$2190) ||\n|| High (+10 %) | blank | 84524 | 2.75 | 29.40 | 10676 (US$1651) ||\n|| Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate ||\n|| Low (-10 %) | blank | 69063 | 2.25 | 30.67 | 13640 (US$2109) ||\n|| High (+10 %) | blank | 84411 | 2.75 | 30.67 | 11160 (US$1726) ||\n|| Pandemic | Pandemic | Pandemic | Pandemic | Pandemic | Pandemic ||\n|| Base Case | blank | 707526 | 34.43 | (41.03) | Dominant ||\n|| Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage ||\n|| Base Case | blank | 76714 | 2.50 | 30.67 | 12281 (US$1899) ||\n|| Low | 75 % | 702582 | 34.03 | (46.88) | Dominant ||\n|| High | 95 % | 712470 | 34.82 | (34.93) | Dominant ||\n|| Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price ||\n|| Low (-10 %) | 774 | 707526 | 34.43 | (45.30) | Dominant ||\n|| High (+10 %) | 946 | 707526 | 34.43 | (36.76) | Dominant ||\n|| Herd Effect | Herd Effect | Herd Effect | Herd Effect | Herd Effect | Herd Effect ||\n|| Reduced by 50 % | blank | 384613 | 19.65 | (0.48) | Dominant ||\n|| Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence | Disease Incidence ||\n|| Low (-10 %) | blank | 641668 | 31.23 | (33.21) | Dominant ||\n|| High (+10 %) | blank | 782365 | 38.09 | (50.06) | Dominant ||\n|| Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage | Vaccine Coverage ||\n|| Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate | Case Fatality Rate ||\n|| Low (-10 %) | blank | 637577 | 31.02 | (41.03) | Dominant ||\n|| High (+10 %) | blank | 779261 | 37.92 | (41.03) | Dominant ||\n|| Low | 75 % | 76209 | 2.46 | 24.75 | 10072 (US$1558) ||\n|| High | 95 % | 77220 | 2.54 | 36.85 | 14525 (US$2247) ||\n|| Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price | Vaccine Price ||\n|| Low (-10 %) | 774 | 76714 | 2.50 | 26.40 | 10572 (US$1635) ||\n|| High (+10 %) | 946 | 76714 | 2.50 | 34.94 | 13991 (US$2164) ||\n|| Herd Effect | Herd Effect | Herd Effect | Herd Effect | Herd Effect | Herd Effect ||",
    "claim": "In the non-pandemic scenario, increasing vaccine coverage from 75% to 95% results in a decrease in deaths averted by approximately 1.33% and an increase in cost savings by 48.9%. This demonstrates the economic and health benefits of higher vaccine coverage.",
    "label": "refute"
  },
  {
    "id": "training_1391_1",
    "table_caption": "Table: Table 3 Results of 2009 pandemic influenza A (H1N1) antibodies before and after the pandemic in 60 vaccinated and 90 unvaccinated health care workers at a children’s hospital in Taiwan All (N = 150) Vaccinated (N = 60) No. (%) Unvaccinated (N = 90) All No. (%) High-risk (N = 40)3 No. (%) Low-risk (N = 50)3 No. (%) P value1 Seroprotective Baseline2 7 (4.7%) 2 (3.3%) 5 (5.6%) 3 (7.5%) 2 (4.0%) 0.652 Second2 13 (8.7%) 2 (3.3%) 11 (12.2%) 8 (20.0%) 3 (6.0%) 0.056 Third2 52 (35.4%) 34 (56.7%) 18 (20.0%) 12 (30.0%) 6(12.0%) 0.061 Seroconversion 1st to 2nd sera 6 (4.0%) 0 (0.0%) 6 (6.7%) 5 (12.5%) 1 (2.0%) 0.085 2nd to 3 rd sera 39 (26.5%) 32 (53%) 7 (7.8%) 4 (10.0%) 3 (6.0%) 0.695 1st to 3 rd sera 45 (30.6%) 32 (53%) 13 (14.4%) 9 (22.5%) 4 (8.0%) 0.071 GMT (95% CI) Base line 11.0 (10.7-12.0%) 11.0 (10.5-12.6) 11.2 (10.4-12.1) 12.1 (10.5-13.9) 10.6 (9.7-11.5) 0.049 Second 12.4 (11.4-13.6%) 11.4 (10.4-12.4) 13.2 (11.5-15.1) 16.0 (12.6-20.3) 11.3 (9.9-12.9) 0.013 Third 19.2 (16.6-22.1%) 31.4 (23.8-36.8) 14.0 (12.0-16.3) 18.3 (14.0-24.1) 11.3 (9.8-13.1) 0.003 Abbreviations: GMT: geometric mean titer; CI: confidence interval. 1 Comparisons were made between high- and normal-risk groups, using Chi-square or Fisher exact tests. 2 See text and Figure 2 for definitions of baseline, second, and third samples. ",
    "table_content": "|| blank | All (N = 150) | Vaccinated (N = 60) No. (%) | Unvaccinated (N = 90) | Unvaccinated (N = 90) | Unvaccinated (N = 90) | Unvaccinated (N = 90) ||\n|| blank | All (N = 150) | Vaccinated (N = 60) No. (%) | All No. (%) | High-risk (N = 40) 3 No. (%) | Low-risk (N = 50) 3 No. (%) | P value 1 ||\n|| GMT (95% CI) | GMT (95% CI) | GMT (95% CI) | GMT (95% CI) | GMT (95% CI) | GMT (95% CI) | GMT (95% CI) ||\n|| Base line | 11.0 (10.7-12.0%) | 11.0 (10.5-12.6) | 11.2 (10.4-12.1) | 12.1 (10.5-13.9) | 10.6 (9.7-11.5) | 0.049 ||\n|| Second | 12.4 (11.4-13.6%) | 11.4 (10.4-12.4) | 13.2 (11.5-15.1) | 16.0 (12.6-20.3) | 11.3 (9.9-12.9) | 0.013 ||\n|| Third | 19.2 (16.6-22.1%) | 31.4 (23.8-36.8) | 14.0 (12.0-16.3) | 18.3 (14.0-24.1) | 11.3 (9.8-13.1) | 0.003 ||\n|| Seroprotective | Seroprotective | Seroprotective | Seroprotective | Seroprotective | Seroprotective | Seroprotective ||\n|| Baseline 2 | 7 (4.7%) | 2 (3.3%) | 5 (5.6%) | 3 (7.5%) | 2 (4.0%) | 0.652 ||\n|| Second 2 | 13 (8.7%) | 2 (3.3%) | 11 (12.2%) | 8 (20.0%) | 3 (6.0%) | 0.056 ||\n|| Third 2 | 52 (35.4%) | 34 (56.7%) | 18 (20.0%) | 12 (30.0%) | 6(12.0%) | 0.061 ||\n|| Seroconversion | Seroconversion | Seroconversion | Seroconversion | Seroconversion | Seroconversion | Seroconversion ||\n|| 1st to 2nd sera | 6 (4.0%) | 0 (0.0%) | 6 (6.7%) | 5 (12.5%) | 1 (2.0%) | 0.085 ||\n|| 2nd to 3 rd sera | 39 (26.5%) | 32 (53%) | 7 (7.8%) | 4 (10.0%) | 3 (6.0%) | 0.695 ||\n|| 1st to 3 rd sera | 45 (30.6%) | 32 (53%) | 13 (14.4%) | 9 (22.5%) | 4 (8.0%) | 0.071 ||",
    "claim": "The increase in GMT from baseline to the third sample in the vaccinated group is approximately 2.85 times greater than the increase observed in the unvaccinated group, indicating a more pronounced antibody response in vaccinated individuals.",
    "label": "refute"
  },
  {
    "id": "training_130_1",
    "table_caption": "Table: Summary of analyses.* Meta-Analyses Sensitivity Analyses Overall Median Contrasts Best-case and worst-case scenarios 4 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 20 contrasts Stratified Median Contrasts A. Control Treatment 1. Active treatment or placebo control Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 16 contrasts 2. No treatment B. Country Where Trial was Performed 3. United Kingdom Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 10 contrasts 4. United States Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial All 10 contrasts C. Duration of Follow-Up 5. Short-term Best-case and worst-case scenarios All 9 contrasts 6. Intermediate-term 4 possible combinations of contrasts including one control treatment per trial 7. Long-term 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded *There were insufficient contrasts to perform sensitivity analyses for the no treatment stratified analysis. For the short-term stratified analysis, median contrast was defined to be that corresponding to the eighth combination when effect sizes for the 16 possible contrast combinations ",
    "table_content": "|| Meta-Analyses | Sensitivity Analyses ||\n|| Overall Median Contrasts | Best-case and worst-case scenarios 4 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 20 contrasts ||\n|| 5. Short-term | Best-case and worst-case scenarios All 9 contrasts ||\n|| 6. Intermediate-term | 4 possible combinations of contrasts including one control treatment per trial ||\n|| 7. Long-term | 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded ||\n|| Stratified Median Contrasts | Stratified Median Contrasts ||\n||  A. Control Treatment |  A. Control Treatment ||\n|| 1. Active treatment or placebo control | Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 16 contrasts ||\n|| 2. No treatment | 2. No treatment ||\n||  B. Country Where Trial was Performed |  B. Country Where Trial was Performed ||\n|| 3. United Kingdom | Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 10 contrasts ||\n|| 4. United States | Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial All 10 contrasts ||\n||  C. Duration of Follow-Up |  C. Duration of Follow-Up ||",
    "claim": "The overall median contrasts in the meta-analyses, when considering all 20 contrasts, demonstrate a complex interaction between treatment types and trial conditions, resulting in a nuanced understanding of treatment efficacy that cannot be captured by simple binary comparisons.",
    "label": "refute"
  },
  {
    "id": "training_130_1",
    "table_caption": "Table: Summary of analyses.* Meta-Analyses Sensitivity Analyses Overall Median Contrasts Best-case and worst-case scenarios 4 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 20 contrasts Stratified Median Contrasts A. Control Treatment 1. Active treatment or placebo control Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 16 contrasts 2. No treatment B. Country Where Trial was Performed 3. United Kingdom Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 10 contrasts 4. United States Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial All 10 contrasts C. Duration of Follow-Up 5. Short-term Best-case and worst-case scenarios All 9 contrasts 6. Intermediate-term 4 possible combinations of contrasts including one control treatment per trial 7. Long-term 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded *There were insufficient contrasts to perform sensitivity analyses for the no treatment stratified analysis. For the short-term stratified analysis, median contrast was defined to be that corresponding to the eighth combination when effect sizes for the 16 possible contrast combinations ",
    "table_content": "|| Meta-Analyses | Sensitivity Analyses ||\n|| Overall Median Contrasts | Best-case and worst-case scenarios 4 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 20 contrasts ||\n|| 5. Short-term | Best-case and worst-case scenarios All 9 contrasts ||\n|| 6. Intermediate-term | 4 possible combinations of contrasts including one control treatment per trial ||\n|| 7. Long-term | 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded ||\n|| Stratified Median Contrasts | Stratified Median Contrasts ||\n||  A. Control Treatment |  A. Control Treatment ||\n|| 1. Active treatment or placebo control | Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 16 contrasts ||\n|| 2. No treatment | 2. No treatment ||\n||  B. Country Where Trial was Performed |  B. Country Where Trial was Performed ||\n|| 3. United Kingdom | Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial Cleary [47] trial excluded All 10 contrasts ||\n|| 4. United States | Best-case and worst-case scenarios 2 possible combinations of contrasts including one control treatment per trial All 10 contrasts ||\n||  C. Duration of Follow-Up |  C. Duration of Follow-Up ||",
    "claim": "The overall median contrasts in the meta-analyses, when considering all 16 contrasts, demonstrate a complex interaction between treatment types and trial conditions, resulting in a nuanced understanding of treatment efficacy that cannot be captured by simple binary comparisons.",
    "label": "refute"
  },
  {
    "id": "training_1366_4",
    "table_caption": "Table: bicelles NMR structure micelle bicelles PDB code 2kpe 2kpf NMR data for structure calculation Total unambiguous NOE restraints 484 520 intra-residue 234 278 inter-residue 216 214 sequential (|i-j|=1) 128 128 medium-range (1<|i-j|<4) 88 86 long-range (|i-j|>4) 0 0 inter-monomeric 34 28 Hydrogen bond restraints (upper/lower) intra-monomeric inter-monomeric 108/108 0/0 108/108 0/0 Total torsion angle restraints 156 156 backbone φ 56 56 backbone ψ 56 56 side chain χ1 44 44 Structure calculation statistics CYANA target function (Å2) 0.75±0.15 1.02±0.16 Restraint violations distance (>0.2 Å) 0 0 distance (>0.1 Å) 6 5 dihedral (>5o) 0 0 Average pairwise RMSD (Å) ТМ α-helix (72-95)2 backbone atoms 0.39±0.17 0.42±0.13 all heavy atoms 0.94±0.18 1.07±0.15 generalized RMSD backbone atoms 0.72±0.45 all heavy atoms 1.25±0.37 backbone atoms of mean structures 1.03 Ramachandran analysis % residues (70-98)2 in most favored regions 92.7 90.4 in additional allowed regions 7.7 6.4 in generously allowed regions 1.4† 0.2† in disallowed regions 0.4† 0.7† Helix-helix packing helix-helix contact surface (Å2) 370±20 380±20 angle θ (deg.) between the ТМ helix axes -40±2 -40±2 distance d (Å) between the ТМ helix axes 6.7±0.4 6.4±0.4 unfolded and flexible regions. ",
    "table_content": "|| NMR structure | micelle | bicelles ||\n|| PDB code | 2kpe | 2kpf ||\n|| Hydrogen bond restraints (upper/lower) intra-monomeric inter-monomeric | 108/108 0/0 | 108/108 0/0 ||\n|| Total torsion angle restraints | 156 | 156 ||\n|| backbone φ | 56 | 56 ||\n|| backbone ψ | 56 | 56 ||\n|| side chain χ 1 | 44 | 44 ||\n|| Structure calculation statistics | Structure calculation statistics | Structure calculation statistics ||\n|| CYANA target function (Å 2 ) | 0.75±0.15 | 1.02±0.16 ||\n|| Restraint violations | Restraint violations | Restraint violations ||\n|| distance (>0.2 Å) | 0 | 0 ||\n|| distance (>0.1 Å) | 6 | 5 ||\n|| NMR data for structure calculation | NMR data for structure calculation | NMR data for structure calculation ||\n|| dihedral (>5 o ) | 0 | 0 ||\n|| Average pairwise RMSD (Å) | Average pairwise RMSD (Å) | Average pairwise RMSD (Å) ||\n|| ТМ α-helix (72-95) 2 | ТМ α-helix (72-95) 2 | ТМ α-helix (72-95) 2 ||\n|| backbone atoms | 0.39±0.17 | 0.42±0.13 ||\n|| all heavy atoms | 0.94±0.18 | 1.07±0.15 ||\n|| generalized RMSD | generalized RMSD | generalized RMSD ||\n|| backbone atoms | 0.72±0.45 | 0.72±0.45 ||\n|| all heavy atoms | 1.25±0.37 | 1.25±0.37 ||\n|| backbone atoms of mean structures | 1.03 | 1.03 ||\n|| Ramachandran analysis % residues (70-98) 2 | Ramachandran analysis % residues (70-98) 2 | Ramachandran analysis % residues (70-98) 2 ||\n|| Total unambiguous NOE restraints | 484 | 520 ||\n|| in most favored regions | 92.7 | 90.4 ||\n|| in additional allowed regions | 7.7 | 6.4 ||\n|| in generously allowed regions | 1.4 † | 0.2 † ||\n|| in disallowed regions | 0.4 † | 0.7 † ||\n|| Helix-helix packing | Helix-helix packing | Helix-helix packing ||\n|| helix-helix contact surface (Å 2 ) | 370±20 | 380±20 ||\n|| angle θ (deg.) between the ТМ helix axes | -40±2 | -40±2 ||\n|| distance d (Å) between the ТМ helix axes | 6.7±0.4 | 6.4±0.4 ||\n|| intra-residue | 234 | 278 ||\n|| inter-residue | 216 | 214 ||\n|| sequential (|i-j|=1) | 128 | 128 ||\n|| medium-range (1<|i-j|<4) | 88 | 86 ||\n|| long-range (|i-j|>4) | 0 | 0 ||\n|| inter-monomeric | 34 | 28 ||",
    "claim": "The micelle system has 2.48% more residues in the most favored regions compared to the bicelles system. However, it also has a 75% increase in residues in disallowed regions, indicating a trade-off between overall structural favorability and localized structural anomalies.",
    "label": "refute"
  },
  {
    "id": "training_1366_4",
    "table_caption": "Table: bicelles NMR structure micelle bicelles PDB code 2kpe 2kpf NMR data for structure calculation Total unambiguous NOE restraints 484 520 intra-residue 234 278 inter-residue 216 214 sequential (|i-j|=1) 128 128 medium-range (1<|i-j|<4) 88 86 long-range (|i-j|>4) 0 0 inter-monomeric 34 28 Hydrogen bond restraints (upper/lower) intra-monomeric inter-monomeric 108/108 0/0 108/108 0/0 Total torsion angle restraints 156 156 backbone φ 56 56 backbone ψ 56 56 side chain χ1 44 44 Structure calculation statistics CYANA target function (Å2) 0.75±0.15 1.02±0.16 Restraint violations distance (>0.2 Å) 0 0 distance (>0.1 Å) 6 5 dihedral (>5o) 0 0 Average pairwise RMSD (Å) ТМ α-helix (72-95)2 backbone atoms 0.39±0.17 0.42±0.13 all heavy atoms 0.94±0.18 1.07±0.15 generalized RMSD backbone atoms 0.72±0.45 all heavy atoms 1.25±0.37 backbone atoms of mean structures 1.03 Ramachandran analysis % residues (70-98)2 in most favored regions 92.7 90.4 in additional allowed regions 7.7 6.4 in generously allowed regions 1.4† 0.2† in disallowed regions 0.4† 0.7† Helix-helix packing helix-helix contact surface (Å2) 370±20 380±20 angle θ (deg.) between the ТМ helix axes -40±2 -40±2 distance d (Å) between the ТМ helix axes 6.7±0.4 6.4±0.4 unfolded and flexible regions. ",
    "table_content": "|| NMR structure | micelle | bicelles ||\n|| PDB code | 2kpe | 2kpf ||\n|| Hydrogen bond restraints (upper/lower) intra-monomeric inter-monomeric | 108/108 0/0 | 108/108 0/0 ||\n|| Total torsion angle restraints | 156 | 156 ||\n|| backbone φ | 56 | 56 ||\n|| backbone ψ | 56 | 56 ||\n|| side chain χ 1 | 44 | 44 ||\n|| Structure calculation statistics | Structure calculation statistics | Structure calculation statistics ||\n|| CYANA target function (Å 2 ) | 0.75±0.15 | 1.02±0.16 ||\n|| Restraint violations | Restraint violations | Restraint violations ||\n|| distance (>0.2 Å) | 0 | 0 ||\n|| distance (>0.1 Å) | 6 | 5 ||\n|| NMR data for structure calculation | NMR data for structure calculation | NMR data for structure calculation ||\n|| dihedral (>5 o ) | 0 | 0 ||\n|| Average pairwise RMSD (Å) | Average pairwise RMSD (Å) | Average pairwise RMSD (Å) ||\n|| ТМ α-helix (72-95) 2 | ТМ α-helix (72-95) 2 | ТМ α-helix (72-95) 2 ||\n|| backbone atoms | 0.39±0.17 | 0.42±0.13 ||\n|| all heavy atoms | 0.94±0.18 | 1.07±0.15 ||\n|| generalized RMSD | generalized RMSD | generalized RMSD ||\n|| backbone atoms | 0.72±0.45 | 0.72±0.45 ||\n|| all heavy atoms | 1.25±0.37 | 1.25±0.37 ||\n|| backbone atoms of mean structures | 1.03 | 1.03 ||\n|| Ramachandran analysis % residues (70-98) 2 | Ramachandran analysis % residues (70-98) 2 | Ramachandran analysis % residues (70-98) 2 ||\n|| Total unambiguous NOE restraints | 484 | 520 ||\n|| in most favored regions | 92.7 | 90.4 ||\n|| in additional allowed regions | 7.7 | 6.4 ||\n|| in generously allowed regions | 1.4 † | 0.2 † ||\n|| in disallowed regions | 0.4 † | 0.7 † ||\n|| Helix-helix packing | Helix-helix packing | Helix-helix packing ||\n|| helix-helix contact surface (Å 2 ) | 370±20 | 380±20 ||\n|| angle θ (deg.) between the ТМ helix axes | -40±2 | -40±2 ||\n|| distance d (Å) between the ТМ helix axes | 6.7±0.4 | 6.4±0.4 ||\n|| intra-residue | 234 | 278 ||\n|| inter-residue | 216 | 214 ||\n|| sequential (|i-j|=1) | 128 | 128 ||\n|| medium-range (1<|i-j|<4) | 88 | 86 ||\n|| long-range (|i-j|>4) | 0 | 0 ||\n|| inter-monomeric | 34 | 28 ||",
    "claim": "The micelle system has 2.48% more residues in the most favored regions compared to the bicelles system. However, it also has a 25% decrease in residues in disallowed regions, indicating a trade-off between overall structural favorability and localized structural anomalies.",
    "label": "refute"
  },
  {
    "id": "training_1381_5",
    "table_caption": "Table: Table 5 Performance comparison of AltHap, H-PoP, BP, and SCGD on a simulated biallelic tetraploid data set with haplotype block length m = 1000. HapTree could not finish the simulations in 48 hours AltHap H-PoP BP SCGD Err Cov CPR MEC t(s) CPR MEC t(s) CPR MEC t(s) CPR MEC t(s) 0.002 10 91.1 1113 43 70.7 3366 43 69.8 4568 290 67.1 14839 208 0.002 20 95.0 2113 87 73.4 7359 113 71.2 9434 540 51.7 41241 419 0.002 30 99.9 674 163 72.6 11693 598 71.5 12745 1496 51.8 61885 653 0.01 10 98.2 938 44 69.3 3511 46 66.4 6475 296 67.1 14819 213 0.01 20 99.3 1668 87 70.3 7882 114 66.9 10213 552 51.5 41712 414 0.01 30 95.3 6518 164 71.0 12392 597 68.4 13245 1485 51.5 61981 652 0.05 10 93.7 3905 44 67.7 4110 46 64.5 6869 306 65.0 15861 213 0.05 20 95.8 9645 89 69.1 9109 118 68.5 11477 623 51.9 41042 408 0.05 30 81.5 18690 165 70.0 14212 601 67.5 17681 1504 51.7 62261 643 The best results in each simulation setting are in bolface font ",
    "table_content": "|| Err | Cov | AltHap | AltHap | AltHap | H-PoP | H-PoP | H-PoP | BP | BP | BP | SCGD | SCGD | SCGD ||\n|| Err | Cov | CPR | MEC | t(s) | CPR | MEC | t(s) | CPR | MEC | t(s) | CPR | MEC | t(s) ||\n|| 0.05 | 30 | 81.5 | 18690 | 165 | 70.0 | 14212 | 601 | 67.5 | 17681 | 1504 | 51.7 | 62261 | 643 ||\n|| 0.002 | 10 | 91.1 |  1113  | 43 | 70.7 | 3366 | 43 | 69.8 | 4568 | 290 | 67.1 | 14839 | 208 ||\n|| 0.002 | 20 | 95.0 |  2113  | 87 | 73.4 | 7359 | 113 | 71.2 | 9434 | 540 | 51.7 | 41241 | 419 ||\n|| 0.002 | 30 | 99.9 | 674 | 163 | 72.6 | 11693 | 598 | 71.5 | 12745 | 1496 | 51.8 | 61885 | 653 ||\n|| 0.01 | 10 | 98.2 |  938  | 44 | 69.3 | 3511 | 46 | 66.4 | 6475 | 296 | 67.1 | 14819 | 213 ||\n|| 0.01 | 20 | 99.3 |  1668  | 87 | 70.3 | 7882 | 114 | 66.9 | 10213 | 552 | 51.5 | 41712 | 414 ||\n|| 0.01 | 30 | 95.3 | 6518 | 164 | 71.0 | 12392 | 597 | 68.4 | 13245 | 1485 | 51.5 | 61981 | 652 ||\n|| 0.05 | 10 | 93.7 |  3905  | 44 | 67.7 | 4110 | 46 | 64.5 | 6869 | 306 | 65.0 | 15861 | 213 ||\n|| 0.05 | 20 | 95.8 | 9645 | 89 | 69.1 | 9109 | 118 | 68.5 | 11477 | 623 | 51.9 | 41042 | 408 ||",
    "claim": "As the error rate increases from 0.002 to 0.05, the average CPR across all algorithms decreases by approximately 20%, while the average MEC increases by about 50%, highlighting the sensitivity of phasing accuracy and error correction to higher error rates.",
    "label": "refute"
  },
  {
    "id": "training_1462_6",
    "table_caption": "Table: Table 7 Time-dependent Cox regression analysis for risk factors of pulmonary tuberculosis Variables Scenario 4 Scenario 5 Scenario 6 p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) Age (10 years) <.0001 1.431 (1.360–1.505) <.0001 1.420 (1.348–1.497) <.0001 1.248 (1.159–1.343) Male <.0001 2.073 (1.736–2.477) <.0001 2.058 (1.714–2.471) <.0001 2.113 (1.752–2.549) Diabetes mellitus 0.0483 1.222 (1.001–1.490) 0.0349 1.243 (1.016–1.522) Oral corticosteroids (g) 0.0043 1.247 (1.044–1.261) 0.0107 1.176 (1.038–1.331) 0.0404 1.147 (1.006–1.307) Oral beta-agonists (30 DDD) 0.0011 1.054 (1.021–1.088) 0.0046 1.050 (1.015–1.086) 0.009 1.055 (1.013–1.098) Low income 0.0031 1.828 (1.226–2.725) 0.004 1.819 (1.210–1.734) 0.0018 1.914 (1.273–2.879) HR: hazard ratio, CI: confidence interval, DDD: defined daily dose. Time-dependent Cox regression analysis for the factors possibly associated with the development of active tuberculosis in cases of chronic obstructive pulmonary disease selected under scenarios 4–6. ",
    "table_content": "|| Variables | Scenario 4 | Scenario 4 | Scenario 5 | Scenario 5 | Scenario 6 | Scenario 6 ||\n|| Variables | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) ||\n|| Age (10 years) | <.0001 | 1.431 (1.360–1.505) | <.0001 | 1.420 (1.348–1.497) | <.0001 | 1.248 (1.159–1.343) ||\n|| Male | <.0001 | 2.073 (1.736–2.477) | <.0001 | 2.058 (1.714–2.471) | <.0001 | 2.113 (1.752–2.549) ||\n|| Diabetes mellitus | 0.0483 | 1.222 (1.001–1.490) | 0.0349 | 1.243 (1.016–1.522) | blank | blank ||\n|| Oral corticosteroids (g) | 0.0043 | 1.247 (1.044–1.261) | 0.0107 | 1.176 (1.038–1.331) | 0.0404 | 1.147 (1.006–1.307) ||\n|| Oral beta-agonists (30 DDD) | 0.0011 | 1.054 (1.021–1.088) | 0.0046 | 1.050 (1.015–1.086) | 0.009 | 1.055 (1.013–1.098) ||\n|| Low income | 0.0031 | 1.828 (1.226–2.725) | 0.004 | 1.819 (1.210–1.734) | 0.0018 | 1.914 (1.273–2.879) ||",
    "claim": "Low income is associated with a hazard ratio consistently above 1.8 across all scenarios, indicating a substantial increase in the risk of developing tuberculosis. The average hazard ratio for low income across the scenarios is approximately 1.754, highlighting the significant impact of socioeconomic status on tuberculosis risk.",
    "label": "refute"
  },
  {
    "id": "training_1050_5",
    "table_caption": "Table: children teacher between diﬃculty prenatal the housing as level were parental 2. size their TABLE 2 | Mean (SD) of teacher ratings of child behavior using SDQ according to the LOC orientation of the child’s parents as measured in pregnancy. Child behavior M.Ex. F.Ex M.Ex. F.In M.In. F.Ex M.In. F.In Hyperactivity Year 3 2.99 [2.79] 2.57 [2.66]∗∗ 2.40 [2.58] 2.07 [2.40]∗∗ Year 6 2.74 [2.84] 2.00 [2.39]∗∗∗ 2.16 [2.56]a 1.66 [2.28]∗∗∗ Emotional problems Year 3 1.53 [2.05] 1.43 [2.01] 1.30 [1.85] 1.19 [1.74] Year 6 1.44 [1.97] 1.28 [1.92] 1.28 [1.84] 1.13 [1.70]∗ Conduct problems Year 3 0.87 [1.61] 0.72 [1.38]∗ 0.59 [1.26] 0.53 [1.13] Year 6 1.02 [1.74] 0.61 [1.26]∗∗∗ 0.77 [1.55]a 0.56 [1.27]∗∗∗ Peer problems Year 3 1.26 [1.81] 1.19 [1.81] 1.06 [1.72] 1.04 [1.67] Year 6 1.28 [1.90] 1.07 [1.71]∗ 1.25 [1.93] 1.11 [1.80] Total difﬁculties Year 3 6.66 [5.97] 5.91 [5.59]∗∗ 5.34 [5.26] 4.83 [5.01]∗ Year 6 6.47 [6.23] 4.96 [5.01]∗∗∗ 5.46 [5.85]a 4.46 [5.18]∗∗∗ aDifference between M.Ex.F.In and M.In.F.Ex: P < 0.05. (The higher the score, the worse the behavior.) [Asterisks indicate differences between the pairs of father orientation as ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.] ",
    "table_content": "|| Child behavior | M.Ex. F.Ex | M.Ex. F.In | M.In. F.Ex | M.In. F.In ||\n|| Hyperactivity | Hyperactivity | Hyperactivity | Hyperactivity | Hyperactivity ||\n|| Peer problems | Peer problems | Peer problems | Peer problems | Peer problems ||\n|| Year 3 | 1.26 [1.81] | 1.19 [1.81] | 1.06 [1.72] | 1.04 [1.67] ||\n|| Year 6 | 1.28 [1.90] | 1.07 [1.71] ∗ | 1.25 [1.93] | 1.11 [1.80] ||\n|| Total difficulties | Total difficulties | Total difficulties | Total difficulties | Total difficulties ||\n|| Year 3 | 6.66 [5.97] | 5.91 [5.59] ∗∗ | 5.34 [5.26] | 4.83 [5.01] ∗ ||\n|| Year 6 | 6.47 [6.23] | 4.96 [5.01] ∗∗∗ | 5.46 [5.85] a | 4.46 [5.18] ∗∗∗ ||\n|| Year 3 | 2.99 [2.79] | 2.57 [2.66] ∗∗ | 2.40 [2.58] | 2.07 [2.40] ∗∗ ||\n|| Year 6 | 2.74 [2.84] | 2.00 [2.39] ∗∗∗ | 2.16 [2.56] a | 1.66 [2.28] ∗∗∗ ||\n|| Emotional problems | Emotional problems | Emotional problems | Emotional problems | Emotional problems ||\n|| Year 3 | 1.53 [2.05] | 1.43 [2.01] | 1.30 [1.85] | 1.19 [1.74] ||\n|| Year 6 | 1.44 [1.97] | 1.28 [1.92] | 1.28 [1.84] | 1.13 [1.70] ∗ ||\n|| Conduct problems | Conduct problems | Conduct problems | Conduct problems | Conduct problems ||\n|| Year 3 | 0.87 [1.61] | 0.72 [1.38] ∗ | 0.59 [1.26] | 0.53 [1.13] ||\n|| Year 6 | 1.02 [1.74] | 0.61 [1.26] ∗∗∗ | 0.77 [1.55] a | 0.56 [1.27] ∗∗∗ ||",
    "claim": "The total difficulties score for children with M.In. F.In parents decreased by approximately 8% from Year 3 to Year 6, reflecting an overall improvement in behavior as perceived by teachers.",
    "label": "refute"
  },
  {
    "id": "training_1050_5",
    "table_caption": "Table: children teacher between diﬃculty prenatal the housing as level were parental 2. size their TABLE 2 | Mean (SD) of teacher ratings of child behavior using SDQ according to the LOC orientation of the child’s parents as measured in pregnancy. Child behavior M.Ex. F.Ex M.Ex. F.In M.In. F.Ex M.In. F.In Hyperactivity Year 3 2.99 [2.79] 2.57 [2.66]∗∗ 2.40 [2.58] 2.07 [2.40]∗∗ Year 6 2.74 [2.84] 2.00 [2.39]∗∗∗ 2.16 [2.56]a 1.66 [2.28]∗∗∗ Emotional problems Year 3 1.53 [2.05] 1.43 [2.01] 1.30 [1.85] 1.19 [1.74] Year 6 1.44 [1.97] 1.28 [1.92] 1.28 [1.84] 1.13 [1.70]∗ Conduct problems Year 3 0.87 [1.61] 0.72 [1.38]∗ 0.59 [1.26] 0.53 [1.13] Year 6 1.02 [1.74] 0.61 [1.26]∗∗∗ 0.77 [1.55]a 0.56 [1.27]∗∗∗ Peer problems Year 3 1.26 [1.81] 1.19 [1.81] 1.06 [1.72] 1.04 [1.67] Year 6 1.28 [1.90] 1.07 [1.71]∗ 1.25 [1.93] 1.11 [1.80] Total difﬁculties Year 3 6.66 [5.97] 5.91 [5.59]∗∗ 5.34 [5.26] 4.83 [5.01]∗ Year 6 6.47 [6.23] 4.96 [5.01]∗∗∗ 5.46 [5.85]a 4.46 [5.18]∗∗∗ aDifference between M.Ex.F.In and M.In.F.Ex: P < 0.05. (The higher the score, the worse the behavior.) [Asterisks indicate differences between the pairs of father orientation as ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.] ",
    "table_content": "|| Child behavior | M.Ex. F.Ex | M.Ex. F.In | M.In. F.Ex | M.In. F.In ||\n|| Hyperactivity | Hyperactivity | Hyperactivity | Hyperactivity | Hyperactivity ||\n|| Peer problems | Peer problems | Peer problems | Peer problems | Peer problems ||\n|| Year 3 | 1.26 [1.81] | 1.19 [1.81] | 1.06 [1.72] | 1.04 [1.67] ||\n|| Year 6 | 1.28 [1.90] | 1.07 [1.71] ∗ | 1.25 [1.93] | 1.11 [1.80] ||\n|| Total difficulties | Total difficulties | Total difficulties | Total difficulties | Total difficulties ||\n|| Year 3 | 6.66 [5.97] | 5.91 [5.59] ∗∗ | 5.34 [5.26] | 4.83 [5.01] ∗ ||\n|| Year 6 | 6.47 [6.23] | 4.96 [5.01] ∗∗∗ | 5.46 [5.85] a | 4.46 [5.18] ∗∗∗ ||\n|| Year 3 | 2.99 [2.79] | 2.57 [2.66] ∗∗ | 2.40 [2.58] | 2.07 [2.40] ∗∗ ||\n|| Year 6 | 2.74 [2.84] | 2.00 [2.39] ∗∗∗ | 2.16 [2.56] a | 1.66 [2.28] ∗∗∗ ||\n|| Emotional problems | Emotional problems | Emotional problems | Emotional problems | Emotional problems ||\n|| Year 3 | 1.53 [2.05] | 1.43 [2.01] | 1.30 [1.85] | 1.19 [1.74] ||\n|| Year 6 | 1.44 [1.97] | 1.28 [1.92] | 1.28 [1.84] | 1.13 [1.70] ∗ ||\n|| Conduct problems | Conduct problems | Conduct problems | Conduct problems | Conduct problems ||\n|| Year 3 | 0.87 [1.61] | 0.72 [1.38] ∗ | 0.59 [1.26] | 0.53 [1.13] ||\n|| Year 6 | 1.02 [1.74] | 0.61 [1.26] ∗∗∗ | 0.77 [1.55] a | 0.56 [1.27] ∗∗∗ ||",
    "claim": "The total difficulties score for children with M.In. F.In parents decreased by approximately 15% from Year 3 to Year 6, reflecting an overall improvement in behavior as perceived by teachers.",
    "label": "refute"
  },
  {
    "id": "training_928_5",
    "table_caption": "Table: Data collection Bruker SMART 1000 CCD area-detector diffractometer 3773 independent reflections Radiation source: fine-focus sealed tube 2183 reflections with I > 2σ(I) Monochromator: graphite Rint = 0.064 T = 120(2) K θmax = 27.0º φ and ω scans θmin = 1.6º Absorption correction: multi-scan (SADABS; Sheldrick, 1996) h = −10→10 Tmin = 0.980, Tmax = 0.989 k = −32→32 16064 measured reflections l = −11→11 Refinement ",
    "table_content": "|| Bruker SMART 1000 CCD area-detector  diffractometer | 3773 independent reflections ||\n|| Radiation source: fine-focus sealed tube | 2183 reflections with I > 2σ( I ) ||\n|| Monochromator: graphite | R int = 0.064 ||\n|| T = 120(2) K | θ max = 27.0º ||\n|| φ and ω scans | θ min = 1.6º ||\n|| Absorption correction: multi-scan(SADABS; Sheldrick, 1996) | h = −10→10 ||\n|| T min = 0.980, T max = 0.989 | k = −32→32 ||\n|| 16064 measured reflections | l = −11→11 ||",
    "claim": "The range of theta angles from 1.6º to 27.0º corresponds to a high-resolution limit of approximately 0.78 Å, allowing for detailed structural analysis and the ability to resolve closely spaced atomic features.",
    "label": "refute"
  },
  {
    "id": "training_928_5",
    "table_caption": "Table: Data collection Bruker SMART 1000 CCD area-detector diffractometer 3773 independent reflections Radiation source: fine-focus sealed tube 2183 reflections with I > 2σ(I) Monochromator: graphite Rint = 0.064 T = 120(2) K θmax = 27.0º φ and ω scans θmin = 1.6º Absorption correction: multi-scan (SADABS; Sheldrick, 1996) h = −10→10 Tmin = 0.980, Tmax = 0.989 k = −32→32 16064 measured reflections l = −11→11 Refinement ",
    "table_content": "|| Bruker SMART 1000 CCD area-detector  diffractometer | 3773 independent reflections ||\n|| Radiation source: fine-focus sealed tube | 2183 reflections with I > 2σ( I ) ||\n|| Monochromator: graphite | R int = 0.064 ||\n|| T = 120(2) K | θ max = 27.0º ||\n|| φ and ω scans | θ min = 1.6º ||\n|| Absorption correction: multi-scan(SADABS; Sheldrick, 1996) | h = −10→10 ||\n|| T min = 0.980, T max = 0.989 | k = −32→32 ||\n|| 16064 measured reflections | l = −11→11 ||",
    "claim": "The range of theta angles from 1.6º to 27.0º corresponds to a low-resolution limit of approximately 2.5 Å, allowing for detailed structural analysis and the ability to resolve closely spaced atomic features.",
    "label": "refute"
  },
  {
    "id": "training_783_2",
    "table_caption": "Table: Effect of chronic exposure to two types of gasoline vapour on the contents of lipid peroxidation, reduced glutathione and superoxide dismutase activity of cerebral cortex in male rats. GROUP Parameter Control Leaded gasoline Unleaded gasoline Lipid peroxidation (MAD) nmol/gwet tissue 4.35 ± 0.79 4.456 ± 0.71 6.57 ± 1.37 a** b** Reduced glutathione (GSH) mgGSH/g wet tissue 5.834 ± 0.76 3.635 ± 0.43 a*** 4.7 ± 0.86 a* b* Superoxide dismutase (SOD) Unit/g wet tissue 267.26 ± 18.46 253.79 ± 14.74 192.56 ± 19.78 a*** b*** Values are expressed as means ± SD a: significantly different from the control group. ",
    "table_content": "|| Parameter | GROUP | GROUP | GROUP ||\n|| Parameter | Control | Leaded gasoline | Unleaded gasoline ||\n|| Lipid peroxidation (MAD) nmol/gwet tissue | 4.35 ± 0.79 | 4.456 ± 0.71 | 6.57 ± 1.37 a** b** ||\n|| Reduced glutathione (GSH) mgGSH/g wet tissue | 5.834 ± 0.76 | 3.635 ± 0.43 a*** | 4.7 ± 0.86 a* b* ||\n|| Superoxide dismutase (SOD) Unit/g wet tissue | 267.26 ± 18.46 | 253.79 ± 14.74 | 192.56 ± 19.78 a*** b*** ||",
    "claim": "The reduction in glutathione levels in the leaded gasoline group is approximately 20% compared to the control, suggesting a significant depletion of antioxidant defenses.",
    "label": "refute"
  },
  {
    "id": "training_993_1",
    "table_caption": "Table: Cell Targeting vector HDR template Mutation TA colonies Mutation efficiency HDR efficiency (%) Erhualian PFFs sgRNA#1 – 17 78 21.79% – Erhualian PFFs sgRNA#2 – 10 80 12.50% – Erhualian PFFs sgRNA#1 ssDNA-85 19 55 34.55% 2/55(3.64%) Table 1. Comparison of the mutation efficiency induced by sgRNA alone or sgRNA + HDR template. ",
    "table_content": "|| Cell | Targeting vector | HDR template | Mutation | TA colonies | Mutation efficiency | HDR efficiency (%) ||\n|| Erhualian PFFs | sgRNA#1 | – | 17 | 78 | 21.79% | – ||\n|| Erhualian PFFs | sgRNA#2 | – | 10 | 80 | 12.50% | – ||\n|| Erhualian PFFs | sgRNA#1 | ssDNA-85 | 19 | 55 | 34.55% | 2/55(3.64%) ||",
    "claim": "The mutation efficiency of sgRNA#1 without an HDR template is 10% higher than that of sgRNA#2, indicating a substantial difference in the effectiveness of these sgRNAs in inducing mutations in the absence of an HDR template.",
    "label": "refute"
  },
  {
    "id": "training_159_3",
    "table_caption": "Table: Longitudinal construct validity (Baseline – End of study) (Pearson correlation coefficients) Study 1 AQLQ12+ Age FEV1% pred PEF Asthma symptoms Night-time awakening Rescue medication use Overall ≥ 18 yr 0.3 0.33 -0.43 -0.42 -0.39 12–17 yr 0.06 0.29 -0.33 -0.2 -0.24 Symptoms ≥ 18 yr 0.32 0.34 -0.46 -0.46 -0.43 12–17 yr 0.03 0.3 -0.33 -0.26 -0.25 Activity limitation ≥ 18 yr 0.27 0.28 -0.39 -0.37 -0.33 12–17 yr 0.08 0.26 -0.33 -0.18 -0.21 Emotional function ≥ 18 yr 0.25 0.29 -0.3 -0.31 -0.33 12–17 yr -0.06 0.12 -0.22 -0.11 -0.2 Environmental stimuli ≥ 18 yr 0.16 0.19 -0.25 -0.2 -0.2 12–17 yr 0.19 0.3 -0.21 0 -0.16 Study 2 AQLQ12+ Age FEV1% pred PEF Asthma symptoms Night-time awakening Rescue medication use Overall ≥ 18 yr 0.21 0.41 -0.51 -0.41 -0.37 12–17 yr 0.23 0.24 -0.45 -0.3 -0.2 Symptoms ≥ 18 yr 0.23 0.4 -0.56 -0.47 -0.43 12–17 yr 0.26 0.29 -0.47 -0.31 -0.24 Activity limitation ≥ 18 yr 0.17 0.36 -0.43 -0.33 -0.3 12–17 yr 0.23 0.15 -0.44 -0.28 -0.1 Emotional function ≥ 18 yr 0.14 0.33 -0.4 -0.28 -0.27 12–17 yr 0.1 0.17 -0.21 -0.22 -0.23 Environmental stimuli ≥ 18 yr 0.17 0.36 -0.32 -0.28 -0.2 12–17 yr 0.16 0.23 -0.48 -0.22 -0.15 ",
    "table_content": "|| AQLQ12+ | Study 1 | Study 1 | Study 1 | Study 1 | Study 1 | Study 1 ||\n|| AQLQ12+ | Age | FEV 1 % pred | PEF | Asthma symptoms | Night-time awakening | Rescue medication use ||\n|| Environmental stimuli | ≥ 18 yr | 0.16 | 0.19 | -0.25 | -0.2 | -0.2 ||\n|| Environmental stimuli | 12–17 yr | 0.19 | 0.3 | -0.21 | 0 | -0.16 ||\n|| Environmental stimuli | Study 2 | Study 2 | Study 2 | Study 2 | Study 2 | Study 2 ||\n|| AQLQ12+ | Age | FEV 1 % pred | PEF | Asthma symptoms | Night-time awakening | Rescue medication use ||\n|| Overall | ≥ 18 yr | 0.21 | 0.41 | -0.51 | -0.41 | -0.37 ||\n|| Overall | 12–17 yr | 0.23 | 0.24 | -0.45 | -0.3 | -0.2 ||\n|| Symptoms | ≥ 18 yr | 0.23 | 0.4 | -0.56 | -0.47 | -0.43 ||\n|| Symptoms | 12–17 yr | 0.26 | 0.29 | -0.47 | -0.31 | -0.24 ||\n|| Activity limitation | ≥ 18 yr | 0.17 | 0.36 | -0.43 | -0.33 | -0.3 ||\n|| Activity limitation | 12–17 yr | 0.23 | 0.15 | -0.44 | -0.28 | -0.1 ||\n|| Overall | ≥ 18 yr | 0.3 | 0.33 | -0.43 | -0.42 | -0.39 ||\n|| Emotional function | ≥ 18 yr | 0.14 | 0.33 | -0.4 | -0.28 | -0.27 ||\n|| Emotional function | 12–17 yr | 0.1 | 0.17 | -0.21 | -0.22 | -0.23 ||\n|| Environmental stimuli | ≥ 18 yr | 0.17 | 0.36 | -0.32 | -0.28 | -0.2 ||\n|| Environmental stimuli | 12–17 yr | 0.16 | 0.23 | -0.48 | -0.22 | -0.15 ||\n|| Overall | 12–17 yr | 0.06 | 0.29 | -0.33 | -0.2 | -0.24 ||\n|| Symptoms | ≥ 18 yr | 0.32 | 0.34 | -0.46 | -0.46 | -0.43 ||\n|| Symptoms | 12–17 yr | 0.03 | 0.3 | -0.33 | -0.26 | -0.25 ||\n|| Activity limitation | ≥ 18 yr | 0.27 | 0.28 | -0.39 | -0.37 | -0.33 ||\n|| Activity limitation | 12–17 yr | 0.08 | 0.26 | -0.33 | -0.18 | -0.21 ||\n|| Emotional function | ≥ 18 yr | 0.25 | 0.29 | -0.3 | -0.31 | -0.33 ||\n|| Emotional function | 12–17 yr | -0.06 | 0.12 | -0.22 | -0.11 | -0.2 ||",
    "claim": "Across both studies, the correlation between PEF and the overall AQLQ12+ score is consistently negative, with the strongest negative correlation observed in the symptoms domain for individuals aged 12–17 years in Study 2. This implies that lower PEF values are associated with poorer symptom-related quality of life in adolescents.",
    "label": "refute"
  },
  {
    "id": "training_590_3",
    "table_caption": "Table: TABLE 2 | Intranasal insulin improves memory function. Subjects Intranasal insulin duration/dose Main result References Healthy humans 4 × 40 IU/day, for 8 weeks Intranasal intake of insulin enhanced long-term declarative memory and positively affected mood in humans without causing systemic side effects like hypoglycaemia. Benedict et al., 2004 Healthy humans 4 × 40 IU/day, for 8 weeks; insulin and rapid-acting insulin analog insulin aspart Declarative memory was improved in insulin and insulin aspart groups compared to placebo group without altering glucose levels. Insulin aspart treated subjects performed even better that those of insulin treated group Benedict et al., 2007 Healthy humans Single dose of regular human insulin 160 IU Hippocampus-dependent memory and working memory were improved in women where as men did not beneﬁt from acute insulin treatment Benedict et al., 2008; Krug et al., 2010 MCI and mild AD patients 20 or 40 IU of insulin acute treatment Acute intranasal insulin administration improved verbal memory in AD and MCI subjects without the APOE- ε4 allele Reger et al., 2006 MCI and AD patients 10, 20, 40, or 60 IU for 5 days 10, 20, and 40 IU of insulin improved declarative memory only in APOE-ε4 negative patients Memory facilitation generally peaked at the 20 IU dose ↑ Aβ42 levels for memory-impaired adults from saline to 10 IU regardless of APOE-ε4 status Intranasal insulin did not affect peripheral glucose or insulin levels Reger et al., 2008a MCI and AD patients 20 IU BID intranasal insulin treatment for 21 days Insulin-treated subjects retained more verbal information and improved attention and functional status Insulin treatment raised fasting plasma Aβ40/Aβ42 ratio Reger et al., 2008b MCI and mild to moderate AD patients 20 or 40 IU for 4 months Treatment with 20 IU of insulin improved delayed memory Both dosages preserved caregiver-rated functional ability and general cognition Unchanged Aβ42 and tau levels after insulin treatment Craft et al., 2012 AD patients with ApoE4 allels Rapid acting insulin Rapid acting insulin failed to have an acute impact on cognition in ApoE4 carriers with AD Rosenbloom et al., 2014 MCI and mild AD patients 20 or 40 IU of insulin detemir for 21 days High dose (40 IU) improved visuospatial and verbal working memory for all participant High dose improved memory for adults with MCI and AD who were APOE-ε4 positive patients APOE-ε4 carriers taking high dose also improved peripheral insulin resistance APOE-ε4 negative patients taking high dose experiences increased peripheral insulin resistance Claxton et al., 2015 S.D. rats—streptozotocin induced AD model 5 IU for 6 days Insulin administration signiﬁcantly reduced the Aβ levels without altering peripheral glucose levels Subramanian and John, 2012 Streptozotocin induced-rat model of type 2 diabetes 2U insulin intranasally/4 weeks 6.7 U/kg (s.c.)/4 weeks Decreased Akt activation and increased tau phosphorylation and GSK-3β activation was found in T2D rat brains. Intranasal insulin treatment normalized Akt and GSK-3β and reduced tau phosphorylation in diabetic rats s.c. insulin had minimal effect of tau phosphorylation and GSK-3β Yang et al., 2013 3 × Tg-AD mice 1.75 U/7 days Intranasal insulin administration restored insulin signaling, ↑ synaptic proteins, and ↓ Aβ40 level and microglia activation in the brains of 3 × Tg-AD mice. Glucose transporters and tau-phosphorylation is unchanged Chen et al., 2014c 3 × Tg-AD mice 1.75 U/7 days Propofol 250 mg/kg (i.p.) Insulin treatment attenuated propofol-induced hyperphosphorylation of tau, promoted brain insulin signaling. Resulted in down-regulation of several tau protein kinases, including cyclin-dependent protein kinase 5, calcium/calmodulin-dependent protein kinase II, and c-JunN-terminal kinase and up-regulation of protein phosphatase 2A Chen et al., 2014b ",
    "table_content": "|| Subjects | Intranasal insulin duration/dose | Main result | References ||\n|| Healthy humans | 4 × 40 IU/day, for 8 weeks | Intranasal intake of insulin enhanced long-term declarative memory and positively affected mood in humans without causing systemic side effects like hypoglycaemia. | Benedict et al., 2004 ||\n|| S.D. rats—streptozotocin induced AD model | 5 IU for 6 days | Insulin administration significantly reduced the Aβ levels without altering peripheral glucose levels | Subramanian and John, 2012 ||\n|| Streptozotocin induced-rat model of type 2 diabetes | 2U insulin intranasally/4 weeks 6.7 U/kg (s.c.)/4 weeks | Decreased Akt activation and increased tau phosphorylation and GSK-3β activation was found in T2D rat brains. Intranasal insulin treatment normalized Akt and GSK-3β and reduced tau phosphorylation in diabetic rats s.c. insulin had minimal effect of tau phosphorylation and GSK-3β | Yang et al., 2013 ||\n|| 3 × Tg-AD mice | 1.75 U/7 days | Intranasal insulin administration restored insulin signaling, ↑ synaptic proteins, and ↓ Aβ40 level and microglia activation in the brains of 3 × Tg-AD mice. Glucose transporters and tau-phosphorylation is unchanged | Chen et al., 2014c ||\n|| 3 × Tg-AD mice | 1.75 U/7 days Propofol 250 mg/kg (i.p.) | Insulin treatment attenuated propofol-induced hyperphosphorylation of tau, promoted brain insulin signaling. Resulted in down-regulation of several tau protein kinases, including cyclin-dependent protein kinase 5, calcium/calmodulin-dependent protein kinase II, and c-JunN-terminal kinase and up-regulation of protein phosphatase 2A | Chen et al., 2014b ||\n|| Healthy humans | 4 × 40 IU/day, for 8 weeks; insulin and rapid-acting insulin analog insulin aspart | Declarative memory was improved in insulin and insulin aspart groups compared to placebo group without altering glucose levels. Insulin aspart treated subjects performed even better that those of insulin treated group | Benedict et al., 2007 ||\n|| Healthy humans | Single dose of regular human insulin 160 IU | Hippocampus-dependent memory and working memory were improved in women where as men did not benefit from acute insulin treatment | Benedict et al., 2008 ; Krug et al., 2010 ||\n|| MCI and mild AD patients | 20 or 40 IU of insulin acute treatment | Acute intranasal insulin administration improved verbal memory in AD and MCI subjects without the APOE- ε 4 allele | Reger et al., 2006 ||\n|| MCI and AD patients | 10, 20, 40, or 60 IU for 5 days | 10, 20, and 40 IU of insulin improved declarative memory only in APOE-ε 4 negative patients Memory facilitation generally peaked at the 20 IU dose ↑ Aβ42 levels for memory-impaired adults from saline to 10 IU regardless of APOE-ε 4 status Intranasal insulin did not affect peripheral glucose or insulin levels | Reger et al., 2008a ||\n|| MCI and AD patients | 20 IU BID intranasal insulin treatment for 21 days | Insulin-treated subjects retained more verbal information and improved attention and functional status Insulin treatment raised fasting plasma Aβ 40 /Aβ 42 ratio | Reger et al., 2008b ||\n|| MCI and mild to moderate AD patients | 20 or 40 IU for 4 months | Treatment with 20 IU of insulin improved delayed memory Both dosages preserved caregiver-rated functional ability and general cognition Unchanged Aβ 42 and tau levels after insulin treatment | Craft et al., 2012 ||\n|| AD patients with ApoE4 allels | Rapid acting insulin | Rapid acting insulin failed to have an acute impact on cognition in ApoE4 carriers with AD | Rosenbloom et al., 2014 ||\n|| MCI and mild AD patients | 20 or 40 IU of insulin detemir for 21 days | High dose (40 IU) improved visuospatial and verbal working memory for all participant High dose improved memory for adults with MCI and AD who were APOE-ε 4 positive patients APOE-ε 4 carriers taking high dose also improved peripheral insulin resistance APOE-ε 4 negative patients taking high dose experiences increased peripheral insulin resistance | Claxton et al., 2015 ||",
    "claim": "A single dose of 160 IU of regular human insulin enhances hippocampus-dependent memory and working memory in men but not in women, as deduced from a comparative analysis of memory performance metrics, highlighting a gender-specific differential response to acute insulin treatment.",
    "label": "refute"
  },
  {
    "id": "training_539_3",
    "table_caption": "Table: Number of genera and taxa in the largest families. Families Genera Taxa Poaceae 22 50 Asteraceae 29 41 Malvaceae 11 20 Amaranthaceae 4 13 Fabaceae 9 12 Solanaceae 3 12 Polygonaceae 2 11 Cyperaceae 4 10 Euphorbiaceae 5 10 Other families 52 77 ",
    "table_content": "|| Families | Genera | Taxa ||\n||  Poaceae  | 22 | 50 ||\n|| Other families | 52 | 77 ||\n||  Asteraceae  | 29 | 41 ||\n||  Malvaceae  | 11 | 20 ||\n||  Amaranthaceae  | 4 | 13 ||\n||  Fabaceae  | 9 | 12 ||\n||  Solanaceae  | 3 | 12 ||\n||  Polygonaceae  | 2 | 11 ||\n||  Cyperaceae  | 4 | 10 ||\n||  Euphorbiaceae  | 5 | 10 ||",
    "claim": "The \"Other families\" category, with 52 genera and 77 taxa, contains more than double the number of genera and taxa compared to the Poaceae family, highlighting the greater diversity encompassed within this category.",
    "label": "refute"
  },
  {
    "id": "training_911_5",
    "table_caption": "Table: Morphometric characters of Channa diplogramma and C. micropeltes. Channa diplogramma Channa micropeltes Range Mean (sd) Range Mean (sd) Total length (mm) 107.24 (589.19) 312.45 (184.96) 338.93–654.93 502.30 (128.83) Standard length (mm) 85.40 (479.15) 251.65 (151.66) 290.87–564.22 415.14 (120.11) % SL Head Length (mm) 25.03 (35.37) 32.12 (2.82) 32.23–39.39 35.28 (2.64) Pre dorsal length (mm) 31.47 (38.75) 35.04 (2.53) 30.50–37.57 33.25 (2.63) Pre pectoral length (mm) 30.98 (38.77) 34.73 (3.26) 31.54–38.66 34.03 (3.06) Pre pelvic length (mm) 31.88 (42.16) 36.93 (3.41) 34.28–41.97 37.01 (2.91) Pre anal length (mm) 49.86 (60.25) 55.66 (3.42) 46.68–57.08 50.64 (3.88)* Body depth (mm) 14.16 (25.61) 19.48 (3.92) 22.54–26.58 24.35 (1.68)* % TL Standard length (mm) 77.14 (81.91) 79.95 (1.48) 72.42–86.15 82.29 (5.68) Head Length (mm) 20.36 (27.34) 25.66 (1.99) 27.76–30.21 28.93 (0.93)** Pre dorsal length (mm) 25.59 (30.86) 27.98 (1.61) 26.28–28.03 27.25 (0.64) Pre pectoral length (mm) 25.13 (30.87) 27.73 (2.23) 26.66–30.52 27.89 (1.55) Pre pelvic length (mm) 25.93 (32.52) 29.49 (2.28) 28.38–31.29 30.34 (1.17) Pre anal length (mm) 40.55 (47.98) 44.47 (2.23) 40.06–43.64 41.51 (1.31)* Body depth (mm) 11.27 (20.76) 15.60 (3.29) 17.62–22.40 20.05 (2.05)* *P,0.05. *P,0.01. ",
    "table_content": "|| blank |  Channa diplogramma  |  Channa diplogramma  |  Channa micropeltes  |  Channa micropeltes  ||\n|| blank | Range | Mean (sd) | Range | Mean (sd) ||\n||  Body depth (mm)  | 14.16 (25.61) | 19.48 (3.92) | 22.54–26.58 | 24.35 (1.68) *  ||\n||  % TL  |  % TL  |  % TL  |  % TL  |  % TL  ||\n||  Standard length (mm)  | 77.14 (81.91) | 79.95 (1.48) | 72.42–86.15 | 82.29 (5.68) ||\n||  Head Length (mm)  | 20.36 (27.34) | 25.66 (1.99) | 27.76–30.21 | 28.93 (0.93) **  ||\n||  Pre dorsal length (mm)  | 25.59 (30.86) | 27.98 (1.61) | 26.28–28.03 | 27.25 (0.64) ||\n||  Pre pectoral length (mm)  | 25.13 (30.87) | 27.73 (2.23) | 26.66–30.52 | 27.89 (1.55) ||\n||  Pre pelvic length (mm)  | 25.93 (32.52) | 29.49 (2.28) | 28.38–31.29 | 30.34 (1.17) ||\n||  Pre anal length (mm)  | 40.55 (47.98) | 44.47 (2.23) | 40.06–43.64 | 41.51 (1.31) *  ||\n||  Body depth (mm)  | 11.27 (20.76) | 15.60 (3.29) | 17.62–22.40 | 20.05 (2.05) *  ||\n||  Total length (mm)  | 107.24 (589.19) | 312.45 (184.96) | 338.93–654.93 | 502.30 (128.83) ||\n||  Standard length (mm)  | 85.40 (479.15) | 251.65 (151.66) | 290.87–564.22 | 415.14 (120.11) ||\n||  % SL  |  % SL  |  % SL  |  % SL  |  % SL  ||\n||  Head Length (mm)  | 25.03 (35.37) | 32.12 (2.82) | 32.23–39.39 | 35.28 (2.64) ||\n||  Pre dorsal length (mm)  | 31.47 (38.75) | 35.04 (2.53) | 30.50–37.57 | 33.25 (2.63) ||\n||  Pre pectoral length (mm)  | 30.98 (38.77) | 34.73 (3.26) | 31.54–38.66 | 34.03 (3.06) ||\n||  Pre pelvic length (mm)  | 31.88 (42.16) | 36.93 (3.41) | 34.28–41.97 | 37.01 (2.91) ||\n||  Pre anal length (mm)  | 49.86 (60.25) | 55.66 (3.42) | 46.68–57.08 | 50.64 (3.88) *  ||",
    "claim": "The standard length of Channa micropeltes, as a percentage of total length, is approximately 0.97 times greater than that of Channa diplogramma, indicating a slightly more elongated body form.",
    "label": "refute"
  },
  {
    "id": "training_567_3",
    "table_caption": "Table: Summary of efficacy results (N = 50 in each group) Control Placebo M. × piperita M. spicata p value* Retching episodes 3.1 ± 1.3 7.2 ± 2.3 2.4 ± 2.4 3.8 ± 1.2 <0.0001 intensity of nausea 52.8 ± 20.7 14.6 ± 9.1 42.1 ± 22.7 43.9 ± 12.4 <0.0001 Vomiting episodes 1.1 ± 0.4 1.8 ± 0.9 0.7 ± 0.9 0.6 ± 0.3 <0.0001 difference between spearmint and peppermint in controlling emetic events and intensity of ",
    "table_content": "|| blank | Control | Placebo | M. × piperita | M. spicata | blank ||\n|| blank | blank | blank | blank | blank | p value* ||\n|| Retching episodes | 3.1 ± 1.3 | 7.2 ± 2.3 | 2.4 ± 2.4 | 3.8 ± 1.2 | <0.0001 ||\n|| intensity of nausea | 52.8 ± 20.7 | 14.6 ± 9.1 | 42.1 ± 22.7 | 43.9 ± 12.4 | <0.0001 ||\n|| Vomiting episodes | 1.1 ± 0.4 | 1.8 ± 0.9 | 0.7 ± 0.9 | 0.6 ± 0.3 | <0.0001 ||",
    "claim": "M. spicata reduces vomiting episodes by approximately 55.56% compared to the placebo group, while M. × piperita achieves a reduction of 61.11%. This suggests that M. spicata is slightly less effective than M. × piperita in reducing vomiting episodes.",
    "label": "refute"
  },
  {
    "id": "training_1321_1",
    "table_caption": "Table: TaBle 3 | Demographical and clinical characteristics of patients evaluated by flow cytometry. active TB Pneumonia N 6 8 Age median (IQR) 46 (34–60) 51 (44–56) sex N (%) Female 5 (83.3) 7 (87.5) Origin N (%) West Europe 3 (50.0) 7 (87.5) East Europe 2 (33.3) – Asia 1 (16.7) – Africa – 1 (12.5) Bcg N (%) Vaccinated 3 (50.0) 1 (12.5) TsT N (%) Positive 3 (50.0) 3 (37.5) Negative 2 (33.3) 3 (37.5) Not done 1 (16.7) 2 (25.0) QFT N (%) Positive 3 (50.0) 2 (25.0) Negative 1 (16.7) 4 (50.0) Indeterminate 1 (16.7) – Not done 1 (16.7) 2 (25.0) TB diagnosis n (%) Microbiological 2 (33.3) – Clinical 4 (66.7) – N, number; TB, tuberculosis; BCG, bacillus Calmette-Guérin; IQR, interquartile range; QFT, QuantiFERON TB Gold In tube; TST, tuberculin skin test. DPP4 be lower (25, new Our opens 2 can ",
    "table_content": "|| blank | Active TB | Pneumonia ||\n|| N | 6 | 8 ||\n|| BCG N (%) | BCG N (%) | BCG N (%) ||\n|| Vaccinated | 3 (50.0) | 1 (12.5) ||\n|| TST N (%) | TST N (%) | TST N (%) ||\n|| Positive | 3 (50.0) | 3 (37.5) ||\n|| Negative | 2 (33.3) | 3 (37.5) ||\n|| Not done | 1 (16.7) | 2 (25.0) ||\n|| QFT N (%) | QFT N (%) | QFT N (%) ||\n|| Positive | 3 (50.0) | 2 (25.0) ||\n|| Negative | 1 (16.7) | 4 (50.0) ||\n|| Indeterminate | 1 (16.7) | – ||\n|| Age median (IQR) | 46 (34–60) | 51 (44–56) ||\n|| Not done | 1 (16.7) | 2 (25.0) ||\n|| TB diagnosis N (%) | TB diagnosis N (%) | TB diagnosis N (%) ||\n|| Microbiological | 2 (33.3) | – ||\n|| Clinical | 4 (66.7) | – ||\n|| Sex N (%) | Sex N (%) | Sex N (%) ||\n|| Female | 5 (83.3) | 7 (87.5) ||\n|| Origin N (%) | Origin N (%) | Origin N (%) ||\n|| West Europe | 3 (50.0) | 7 (87.5) ||\n|| East Europe | 2 (33.3) | – ||\n|| Asia | 1 (16.7) | – ||\n|| Africa | – | 1 (12.5) ||",
    "claim": "The median age of patients with pneumonia is higher than those with active TB. The interquartile range (IQR) for pneumonia is wider, indicating more variability in age among pneumonia patients compared to those with active TB.",
    "label": "refute"
  },
  {
    "id": "training_847_4",
    "table_caption": "Table: Top-ranked template sequences obtained by BLAST results. Ranking No. PDB ID LIG ID* Total Score Query Coverage Max. Identity Positives e-Value 1 2Y00 Y00 473 73% 68% 75% 3×10-165 2 2VT4 P32 466 73% 68% 75% 1×10-162 3 2R4R N/A 412 79% 54% 66% 1×10-140 4 3KJ6 N/A 412 79% 54% 66% 1×10-140 5 2R4S N/A 408 74% 56% 66% 3×10-139 6 3SN6 P0G 410 74% 56% 66% 1×10-137 7 4GBR CAU 291 43% 67% 81% 4×10-94 8 3P0G P0G 418 79% 54% 75% 5×10-92 9 2RH1 CAU 418 79% 54% 76% 5×10-92 10 3PDS ERC 410 72% 60% 78% 1×10-90 *Y00 = Dobutamine, P32 = Cyanopindolol, P0G = Nanobody (Nb35), CAU = Carazolol, ERC = FAUC50. RET = Retinal, P32 = Cyanopindolol, CAU = Carazolol, Y00 = Dobutamine, WHJ = Carmoterol, 5FW = Isoprenaline, 68H = Salbutamol, TIM = Timolol, JRZ = ICI 118,551. ",
    "table_content": "|| Ranking No. | PDB ID | LIG ID *  | Total Score | Query Coverage | Max. Identity | Positives | e-Value ||\n||  1  | 2Y00 | Y00 | 473 | 73% | 68% | 75% | 3×10 -165  ||\n||  10  | 3PDS | ERC | 410 | 72% | 60% | 78% | 1×10 -90  ||\n||  2  | 2VT4 | P32 | 466 | 73% | 68% | 75% | 1×10 -162  ||\n||  3  | 2R4R | N/A | 412 | 79% | 54% | 66% | 1×10 -140  ||\n||  4  | 3KJ6 | N/A | 412 | 79% | 54% | 66% | 1×10 -140  ||\n||  5  | 2R4S | N/A | 408 | 74% | 56% | 66% | 3×10 -139  ||\n||  6  | 3SN6 | P0G | 410 | 74% | 56% | 66% | 1×10 -137  ||\n||  7  | 4GBR | CAU | 291 | 43% | 67% | 81% | 4×10 -94  ||\n||  8  | 3P0G | P0G | 418 | 79% | 54% | 75% | 5×10 -92  ||\n||  9  | 2RH1 | CAU | 418 | 79% | 54% | 76% | 5×10 -92  ||",
    "claim": "Ligands such as P0G and CAU appear in multiple entries with consistent total scores. For example, P0G is associated with both the sixth-ranked (3SN6) and eighth-ranked (3P0G) entries, yet the total score remains the same, suggesting that the presence of a specific ligand uniformly affects the total score.",
    "label": "refute"
  },
  {
    "id": "training_268_2",
    "table_caption": "Table: -0.417 -0.250 when was females, LM:FM The highly were likely stature. LM:FM), bolic females A62 The muscular Gustavo Margaret Institute Exercise Journal Table 1 (abstract A60). Perceived needs, perceived intake and actual intake n=18 Perceived Needs (MIN, MAX) Perceived Intake (MIN, MAX) Delta Perceived p-value* Actual Intake Delta Intake p-value* Absolute Energy Intake (kcal/d) 2211 ± 617 (1200, 4000) 2314 ± 782 (1250, 4000) -102.8 ± 530 0.690 2,135 ± 405 178.4 ± 742 0.306 Relative Energy Intake (kcal/kg/d) 31.2 ± 7.8 (18.6, 61.9) 34.4 ± 12.8 (17.1, 61.9) -1.50 ± 7.8 0.557 31.7 ± 8.1 2.66 ± 11.0 0.327 Absolute CHO (g/d) 185.1 ± 247 (10, 800) 392 ± 710 (15, 3000) -207 ± 685 0.002 243 ± 71 149.3 ± 667 0.616 Relative CHO (g/kg/d) 2.94 ± 4.1 (0.15, 13.0) 5.9 ± 10.1 (0.19, 41.9) -2.96 ± 9.6 0.003 3.6 ± 1.16 2.29 ± 9.5 0.679 Absolute PRO (g/d) 67.6 ± 92.9 (15, 400) 72.8 ± 125 (5, 500) -5.14 ± 36.1 0.304 77.7 ± 19.8 -4.93 ± 128.4 0.028 Relative PRO (g/kg/d) 1.06 ± 1.55 (0.2, 6.5) 1.16 ± 2.1 (0.08, 8.1) -0.10 ± 0.60 0.360 1.17 ± 0.40 -0.007 ± 2.1 0.028 Absolute FAT (g/d) 60.3 ± 111.9 (7, 500) (140.5 ± 296 (10, 1200) -80.3 ± 273 0.007 88.0 ± 23.2 52.4 ± 299 0.035 Relative FAT (g/kg/d) 0.94 ± 1.82 (0.07, 8.1) 2.1 ± 4.3 (0.14, 16.8) -1.15 ± 3.8 0.008 1.31 0.44 0.78 ± 4.3 0.035 Data presented as mean ± SD. Ranges of perceived needs and perceived intakes are provided in parentheses. MIN = Minimum value. MAX = Maximum value. Delta perceived = Perceived needs – perceived intake. Actual intake = Perceived intake – actual intake. * = p-value from Wil- coxon Signed Rank Test. ",
    "table_content": "|| n=18 | Perceived Needs (MIN, MAX) | Perceived Intake (MIN, MAX) | Delta Perceived  p-value*  | Actual Intake | Delta Intake  p-value*  ||\n|| Absolute Energy Intake (kcal/d) | 2211 ± 617 (1200, 4000) | 2314 ± 782 (1250, 4000) | -102.8 ± 530  0.690  | 2,135 ± 405 | 178.4 ± 742  0.306  ||\n|| Relative Energy Intake (kcal/kg/d) | 31.2 ± 7.8 (18.6, 61.9) | 34.4 ± 12.8 (17.1, 61.9) | -1.50 ± 7.8  0.557  | 31.7 ± 8.1 | 2.66 ± 11.0  0.327  ||\n|| Absolute CHO (g/d) | 185.1 ± 247 (10, 800) | 392 ± 710 (15, 3000) | -207 ± 685  0.002  | 243 ± 71 | 149.3 ± 667  0.616  ||\n|| Relative CHO (g/kg/d) | 2.94 ± 4.1 (0.15, 13.0) | 5.9 ± 10.1 (0.19, 41.9) | -2.96 ± 9.6  0.003  | 3.6 ± 1.16 | 2.29 ± 9.5  0.679  ||\n|| Absolute PRO (g/d) | 67.6 ± 92.9 (15, 400) | 72.8 ± 125 (5, 500) | -5.14 ± 36.1  0.304  | 77.7 ± 19.8 | -4.93 ± 128.4  0.028  ||\n|| Relative PRO (g/kg/d) | 1.06 ± 1.55 (0.2, 6.5) | 1.16 ± 2.1 (0.08, 8.1) | -0.10 ± 0.60  0.360  | 1.17 ± 0.40 | -0.007 ± 2.1  0.028  ||\n|| Absolute FAT (g/d) | 60.3 ± 111.9 (7, 500) | (140.5 ± 296 (10, 1200) | -80.3 ± 273  0.007  | 88.0 ± 23.2 | 52.4 ± 299  0.035  ||\n|| Relative FAT (g/kg/d) | 0.94 ± 1.82 (0.07, 8.1) | 2.1 ± 4.3 (0.14, 16.8) | -1.15 ± 3.8  0.008  | 1.31 0.44 | 0.78 ± 4.3  0.035  ||",
    "claim": "The relative energy intake shows a minor underestimation of perceived needs compared to actual intake, with a calculated decrease of approximately 8.4% relative to the actual intake, which is not statistically significant given the p-value of 0.327.",
    "label": "refute"
  },
  {
    "id": "training_1200_3",
    "table_caption": "Table: ON cell lines cultivated in the presence or absence of doxycycline (2 μg/ml) for 6 days Gene Symbol Dox+/Dox- Ratio Tre-2 FAK FAK-CD PTK2 0.59 1.86 * 0.82 PTK2B 0.82 0.85 0.64 p53 0.99 0.66 0.85* DMTF1 1.20 0.65* 0.81 SRC 1.95 0.76 0.87 MAPK3 1.05 0.74 0.97 AKT1 0.56 0.58 0.73 MAP2K1 0.57 0.52* 0.52 MAPK8 0.70 0.61* 0.85* FYN 0.84 0.33* 0.65* CDC2 0.72 1.02 0.82* CDK4 0.94 0.88* 0.94* RB1 0.88 0.48* 0.60* SOCS2 1.12 0.65* 1.20* SYK 0.66 0.47* 0.63* CDK2 0.97 0.93* 0.73 CDK3 0.80 0.71 0.74 RAF1 0.78 0.60* 0.54* ABL1 0.63 0.66 0.78* TEC 0.67 0.63* 0.58* PXN 0.96 0.62* 0.75* SHC1 0.98 0.62* 0.78 BCAR1 0.62 0.53 0.70 MAK2K6 0.76 1.04 1.73* EPHA1 0.56 0.78 0.75 CTNNB1 0.80 0.56* 0.70* CHEK1 0.75 0.62* 0.62* ATM 1.09 0.65 0.99 BIRC5 0.93 0.88 0.74 CDC25C 1.27 1.05 1.18 BCL2 0.31 0.30 0.37 TLN2 0.72 0.81* 0.65* FLT1 0.33 0.37 0.46 PINK1 1.18 0.51* 0.65* STAT1 0.70 0.54* 0.46 ARHGEF2 0.75 0.56 0.73 ITGB1 0.46 0.52* 0.65* CELSR1 1.26 0.88 0.79 LAMC2 0.64 0.38* 0.64* *p < 0.05, t-test; ** mRNA levels of some genes from Additional file 1 was not detectable ",
    "table_content": "|| Gene Symbol | Dox + /Dox - Ratio | Dox + /Dox - Ratio | Dox + /Dox - Ratio ||\n|| Gene Symbol | Tre-2 | FAK | FAK-CD ||\n|| MAPK8 | 0.70 | 0.61* | 0.85* ||\n|| FYN | 0.84 | 0.33* | 0.65* ||\n|| CDC2 | 0.72 | 1.02 | 0.82* ||\n|| CDK4 | 0.94 | 0.88* | 0.94* ||\n|| RB1 | 0.88 | 0.48* | 0.60* ||\n|| SOCS2 | 1.12 | 0.65* | 1.20* ||\n|| SYK | 0.66 | 0.47* | 0.63* ||\n|| CDK2 | 0.97 | 0.93* | 0.73 ||\n|| CDK3 | 0.80 | 0.71 | 0.74 ||\n|| RAF1 | 0.78 | 0.60* | 0.54* ||\n|| PTK2 | 0.59 | 1.86 * | 0.82 ||\n|| ABL1 | 0.63 | 0.66 | 0.78* ||\n|| TEC | 0.67 | 0.63* | 0.58* ||\n|| PXN | 0.96 | 0.62* | 0.75* ||\n|| SHC1 | 0.98 | 0.62* | 0.78 ||\n|| BCAR1 | 0.62 | 0.53 | 0.70 ||\n|| MAK2K6 | 0.76 | 1.04 | 1.73* ||\n|| EPHA1 | 0.56 | 0.78 | 0.75 ||\n|| CTNNB1 | 0.80 | 0.56* | 0.70* ||\n|| CHEK1 | 0.75 | 0.62* | 0.62* ||\n|| ATM | 1.09 | 0.65 | 0.99 ||\n|| PTK2B | 0.82 | 0.85 | 0.64 ||\n|| BIRC5 | 0.93 | 0.88 | 0.74 ||\n|| CDC25C | 1.27 | 1.05 | 1.18 ||\n|| BCL2 | 0.31 | 0.30 | 0.37 ||\n|| TLN2 | 0.72 | 0.81* | 0.65* ||\n|| FLT1 | 0.33 | 0.37 | 0.46 ||\n|| PINK1 | 1.18 | 0.51* | 0.65* ||\n|| STAT1 | 0.70 | 0.54* | 0.46 ||\n|| ARHGEF2 | 0.75 | 0.56 | 0.73 ||\n|| ITGB1 | 0.46 | 0.52* | 0.65* ||\n|| CELSR1 | 1.26 | 0.88 | 0.79 ||\n|| p53 | 0.99 | 0.66 | 0.85* ||\n|| LAMC2 | 0.64 | 0.38* | 0.64* ||\n|| DMTF1 | 1.20 | 0.65* | 0.81 ||\n|| SRC | 1.95 | 0.76 | 0.87 ||\n|| MAPK3 | 1.05 | 0.74 | 0.97 ||\n|| AKT1 | 0.56 | 0.58 | 0.73 ||\n|| MAP2K1 | 0.57 | 0.52* | 0.52 ||",
    "claim": "The gene FYN shows a statistically significant decrease in expression in the FAK condition compared to Tre-2, with a reduction factor of approximately 1.55, highlighting a significant downregulation in the presence of doxycycline.",
    "label": "refute"
  },
  {
    "id": "training_1250_6",
    "table_caption": "Table: Antimicrobial and haemolytic activity of peptides I–XII and antibiotics. Antimicrobial Activity MIC (µmol/L) Haemolytic Activity LC50 (µmol/L) c Peptide MRSA 6271 MRSA a MRSA b S. e. b E. f. b P. a. 5482 P. a. a C. a. I 6.3 3.6 5.7 2.3 13.3 2.8 10.0 5.7 339 II 11.3 5.3 9.7 2.0 12.7 4.5 12.5 5.7 >400 III 29.7 11.5 25.3 4.7 >100 2.9 9.5 9.5 >400 IV 20.0 10.0 20.0 3.2 >100 5.3 12.7 12.7 >200 V 10.0 8.0 10.0 2.2 50.7 4.0 10.7 16.0 196 VI 9.0 5.0 10.0 2.5 >100 3.0 12.7 6.3 >400 VII 22.0 15.0 22.0 4.2 25.3 4.5 25.3 12.5 >400 VIII 18.7 13.3 32.0 4.0 >100 5.0 32.0 8.0 >400 IX 13.5 8.0 17.7 3.2 >100 2.9 5.8 9.5 >400 X 19.3 14.0 14.0 3.5 36 4.5 18.0 11.3 >400 XI 11.3 5.7 10.0 2.8 59.0 2.8 7.0 11.3 270 XII 16.0 8.0 16.0 2.5 32.0 3.2 8.0 5.3 >400 Vanc 0.9 1.1 1.1 1.5 1.3 >200 >320 - - Gent 325 3.9 4.5 109 95.2 2.0 >220 - - MRSA, methicillin-resistant Staphylococcus aureus; S. e., Staphylococcus epidermidis; E. f., Enterococcus faecalis; P. a., Pseudomonas aeruginosa; C. a., Candida albicans; a Clinical isolates from Liberec Regional Hospital; b Clinical isolates from University Hospital in Motol, Prague; c Concentration causing lysis of 50% of red blood cells. Vanc, vancomycin; ",
    "table_content": "|| Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Antimicrobial Activity MIC (μmol/L) | Haemolytic Activity LC 50 (μmol/L) c ||\n|| Peptide | MRSA 6271 | MRSA a | MRSA b | S. e.  b | E. f.  b | P. a. 5482 | P. a.  a | C. a. | Haemolytic Activity LC 50 (μmol/L) c ||\n|| IX | 13.5 | 8.0 | 17.7 | 3.2 | >100 | 2.9 | 5.8 | 9.5 | >400 ||\n|| X | 19.3 | 14.0 | 14.0 | 3.5 | 36 | 4.5 | 18.0 | 11.3 | >400 ||\n|| XI | 11.3 | 5.7 | 10.0 | 2.8 | 59.0 | 2.8 | 7.0 | 11.3 | 270 ||\n|| XII | 16.0 | 8.0 | 16.0 | 2.5 | 32.0 | 3.2 | 8.0 | 5.3 | >400 ||\n|| Vanc | 0.9 | 1.1 | 1.1 | 1.5 | 1.3 | >200 | >320 | blank | blank ||\n|| Gent | 325 | 3.9 | 4.5 | 109 | 95.2 | 2.0 | >220 | blank | blank ||\n|| I | 6.3 | 3.6 | 5.7 | 2.3 | 13.3 | 2.8 | 10.0 | 5.7 | 339 ||\n|| II | 11.3 | 5.3 | 9.7 | 2.0 | 12.7 | 4.5 | 12.5 | 5.7 | >400 ||\n|| III | 29.7 | 11.5 | 25.3 | 4.7 | >100 | 2.9 | 9.5 | 9.5 | >400 ||\n|| IV | 20.0 | 10.0 | 20.0 | 3.2 | >100 | 5.3 | 12.7 | 12.7 | >200 ||\n|| V | 10.0 | 8.0 | 10.0 | 2.2 | 50.7 | 4.0 | 10.7 | 16.0 | 196 ||\n|| VI | 9.0 | 5.0 | 10.0 | 2.5 | >100 | 3.0 | 12.7 | 6.3 | >400 ||\n|| VII | 22.0 | 15.0 | 22.0 | 4.2 | 25.3 | 4.5 | 25.3 | 12.5 | >400 ||\n|| VIII | 18.7 | 13.3 | 32.0 | 4.0 | >100 | 5.0 | 32.0 | 8.0 | >400 ||",
    "claim": "The MIC values for Peptide VIII against MRSA strains show less variability compared to Peptide II, indicating a more consistent efficacy. The standard deviation of the MIC values for Peptide VIII across MRSA 6271, MRSA a, and MRSA b is calculated to be lower than that for Peptide II, reflecting this consistency.",
    "label": "refute"
  },
  {
    "id": "training_194_4",
    "table_caption": "Table: Mean, median, 95% CI, interquartile interval and P value of clinical score, IFAT titer, TP (g/dl), IgG (%), creatinine and urea (mg/dl), and UP/C in 20 dogs before and after 28 days of therapy. Parameter D0 D28 p value Clinical score NV: 0 Mean (95% CI) 5.1 (3.1-7.09) 2.6 (1.52-3.77) p=0.0046 IFAT titer NV: Titer<1:80 (min-max) 160-1280 (320-640) 80-1280 (240-640) p=0.2661 TP NV: 6-8 g/dl Mean (95% CI) 8 (7.55-8.45) 7.6 (7.24-7.96) p=0.0730 IgG NV: 5.3-9.9% Mean (95% CI) 21.36 (16.89-25.83) 19.06 (14.75-23.36) p=0.1009 Creatinine NV<1.2 mg/dl (Median I-III interquartile interval) 0.91 (0.8-1.05) 0.91 (0.7-1.1) p=0.8077 Urea NV: 15-45 mg/dl (Median I-III interquartile interval) 40.75 (29-45.5) 38.55 (29.5-44) p=0.4171 UP/C NP: <0.2 BP: 0.2-0.5 P: >0.5 (Median I-III interquartile interval) 0.35 (0.1-0.7) 0.26 (0.1-0.4) p=0.016 NV: Normal value, NP: Non-proteinuric, BP: Borderline proteinuric, P: Proteinuric, CI: Confidence interval 95%, TP: Total protein, IFAT: Indirect fluorescent antibody test, UP/C: Urine protein creatinine, IgG: Gamma globulin ",
    "table_content": "|| Parameter | D0 | D28 | p value ||\n|| Clinical score | Clinical score | Clinical score | Clinical score ||\n|| NV<1.2 mg/dl (Median IIII interquartile interval) | 0.91 (0.8-1.05) | 0.91 (0.7-1.1) | p=0.8077 ||\n|| Urea | Urea | Urea | Urea ||\n|| NV: 1545 mg/dl (Median IIII interquartile interval) | 40.75 (29-45.5) | 38.55 (29.5-44) | p=0.4171 ||\n|| UP/C | UP/C | UP/C | UP/C ||\n|| NP: <0.2 BP: 0.20.5 P: >0.5 (Median I-III interquartile interval) | 0.35 (0.1-0.7) | 0.26 (0.1-0.4) | p=0.016 ||\n|| NV: 0 Mean (95% CI) | 5.1 (3.1-7.09) | 2.6 (1.52-3.77) | p=0.0046 ||\n|| IFAT titer | IFAT titer | IFAT titer | IFAT titer ||\n|| NV: Titer<1:80 (minmax) | 160-1280 (320-640) | 80-1280 (240-640) | p=0.2661 ||\n|| TP | TP | TP | TP ||\n|| NV: 68 g/dl Mean (95% CI) | 8 (7.55-8.45) | 7.6 (7.24-7.96) | p=0.0730 ||\n|| IgG | IgG | IgG | IgG ||\n|| NV: 5.39.9% Mean (95% CI) | 21.36 (16.89-25.83) | 19.06 (14.75-23.36) | p=0.1009 ||\n|| Creatinine | Creatinine | Creatinine | Creatinine ||",
    "claim": "The IgG percentage increased by approximately 10.8% from D0 to D28, with a p-value of 0.1009, suggesting a trend towards increase, though not reaching statistical significance.",
    "label": "refute"
  },
  {
    "id": "training_372_2",
    "table_caption": "Table: Table 5 Rate of  inbreeding for  genetic improvement and  conservation (impcons) strategy, based on  different types of estimated relationships The lowest estimated rates of inbreeding calculated from each type of estimated relationship matrix depending on the scenario are in italics. The overall lowest value of estimated rate of inbreeding is in italic bold Restriction Data type and estimator ΔF_A ΔF_SNP_Yang ΔF_SNP_Similarity ΔF_WGS_Yang ΔF_WGS_Similarity No restriction A 0.010 0.022 0.022 0.021 0.020 SNP_Yang 0.011 0.010 0.014 0.010 0.011 SNP_Similarity 0.016 0.022 0.010 0.021 0.006 WGS_Yang 0.012 0.011 0.015 0.010 0.013 WGS_Similarity 0.025 0.030 0.022 0.029 0.010 20 selected A 0.011 0.026 0.026 0.025 0.022 SNP_Yang 0.022 0.019 0.022 0.019 0.014 SNP_Similarity 0.018 0.027 0.011 0.025 0.003 WGS_Yang 0.023 0.020 0.022 0.019 0.016 WGS_Similarity 0.022 0.028 0.019 0.027 0.011 10 selected A 0.028 0.052 0.045 0.051 0.029 SNP_Yang 0.047 0.040 0.047 0.039 0.036 SNP_Similarity 0.039 0.045 0.024 0.043 0.015 WGS_Yang 0.044 0.041 0.048 0.040 0.036 WGS_Similarity 0.035 0.048 0.029 0.048 0.013 5 selected A 0.075 0.107 0.085 0.102 0.069 SNP_Yang 0.086 0.085 0.088 0.083 0.071 SNP_Similarity 0.077 0.094 0.057 0.089 0.045 WGS_Yang 0.088 0.083 0.087 0.080 0.072 WGS_Similarity 0.075 0.101 0.064 0.096 0.045 ",
    "table_content": "|| Restriction | Data type and estimator | ΔF_A | ΔF_SNP_Yang | ΔF_SNP_Similarity | ΔF_WGS_Yang | ΔF_WGS_Similarity ||\n|| No restriction | A |  0.010  | 0.022 | 0.022 | 0.021 | 0.020 ||\n|| 20 selected | WGS_Similarity | 0.022 | 0.028 | 0.019 | 0.027 | 0.011 ||\n|| 10 selected | A |  0.028  | 0.052 | 0.045 | 0.051 | 0.029 ||\n|| 10 selected | SNP_Yang | 0.047 |  0.040  | 0.047 |  0.039  | 0.036 ||\n|| 10 selected | SNP_Similarity | 0.039 | 0.045 |  0.024  | 0.043 | 0.015 ||\n|| 10 selected | WGS_Yang | 0.044 | 0.041 | 0.048 | 0.040 | 0.036 ||\n|| 10 selected | WGS_Similarity | 0.035 | 0.048 | 0.029 | 0.048 |  0.013  ||\n|| 5 selected | A |  0.075  | 0.107 | 0.085 | 0.102 | 0.069 ||\n|| 5 selected | SNP_Yang | 0.086 | 0.085 | 0.088 | 0.083 | 0.071 ||\n|| 5 selected | SNP_Similarity | 0.077 | 0.094 |  0.057  | 0.089 |  0.045  ||\n|| 5 selected | WGS_Yang | 0.088 |  0.083  | 0.087 |  0.080  | 0.072 ||\n|| No restriction | SNP_Yang | 0.011 |  0.010  | 0.014 |  0.010  | 0.011 ||\n|| 5 selected | WGS_Similarity | 0.075 | 0.101 | 0.064 | 0.096 | 0.045 ||\n|| No restriction | SNP_Similarity | 0.016 | 0.022 |  0.010  | 0.021 |  0.006  ||\n|| No restriction | WGS_Yang | 0.012 | 0.011 | 0.015 | 0.010 | 0.013 ||\n|| No restriction | WGS_Similarity | 0.025 | 0.030 | 0.022 | 0.029 | 0.010 ||\n|| 20 selected | A |  0.011  | 0.026 | 0.026 | 0.025 | 0.022 ||\n|| 20 selected | SNP_Yang | 0.022 |  0.019  | 0.022 | 0.019 | 0.014 ||\n|| 20 selected | SNP_Similarity | 0.018 | 0.027 |  0.011  | 0.025 |  0.003  ||\n|| 20 selected | WGS_Yang | 0.023 | 0.020 | 0.022 |  0.019  | 0.016 ||",
    "claim": "For the 10 selected restriction level, the SNP_Similarity estimator consistently shows lower inbreeding rates compared to other estimators, with an average reduction of 0.012 compared to the next best estimator, WGS_Similarity.",
    "label": "refute"
  },
  {
    "id": "training_372_2",
    "table_caption": "Table: Table 5 Rate of  inbreeding for  genetic improvement and  conservation (impcons) strategy, based on  different types of estimated relationships The lowest estimated rates of inbreeding calculated from each type of estimated relationship matrix depending on the scenario are in italics. The overall lowest value of estimated rate of inbreeding is in italic bold Restriction Data type and estimator ΔF_A ΔF_SNP_Yang ΔF_SNP_Similarity ΔF_WGS_Yang ΔF_WGS_Similarity No restriction A 0.010 0.022 0.022 0.021 0.020 SNP_Yang 0.011 0.010 0.014 0.010 0.011 SNP_Similarity 0.016 0.022 0.010 0.021 0.006 WGS_Yang 0.012 0.011 0.015 0.010 0.013 WGS_Similarity 0.025 0.030 0.022 0.029 0.010 20 selected A 0.011 0.026 0.026 0.025 0.022 SNP_Yang 0.022 0.019 0.022 0.019 0.014 SNP_Similarity 0.018 0.027 0.011 0.025 0.003 WGS_Yang 0.023 0.020 0.022 0.019 0.016 WGS_Similarity 0.022 0.028 0.019 0.027 0.011 10 selected A 0.028 0.052 0.045 0.051 0.029 SNP_Yang 0.047 0.040 0.047 0.039 0.036 SNP_Similarity 0.039 0.045 0.024 0.043 0.015 WGS_Yang 0.044 0.041 0.048 0.040 0.036 WGS_Similarity 0.035 0.048 0.029 0.048 0.013 5 selected A 0.075 0.107 0.085 0.102 0.069 SNP_Yang 0.086 0.085 0.088 0.083 0.071 SNP_Similarity 0.077 0.094 0.057 0.089 0.045 WGS_Yang 0.088 0.083 0.087 0.080 0.072 WGS_Similarity 0.075 0.101 0.064 0.096 0.045 ",
    "table_content": "|| Restriction | Data type and estimator | ΔF_A | ΔF_SNP_Yang | ΔF_SNP_Similarity | ΔF_WGS_Yang | ΔF_WGS_Similarity ||\n|| No restriction | A |  0.010  | 0.022 | 0.022 | 0.021 | 0.020 ||\n|| 20 selected | WGS_Similarity | 0.022 | 0.028 | 0.019 | 0.027 | 0.011 ||\n|| 10 selected | A |  0.028  | 0.052 | 0.045 | 0.051 | 0.029 ||\n|| 10 selected | SNP_Yang | 0.047 |  0.040  | 0.047 |  0.039  | 0.036 ||\n|| 10 selected | SNP_Similarity | 0.039 | 0.045 |  0.024  | 0.043 | 0.015 ||\n|| 10 selected | WGS_Yang | 0.044 | 0.041 | 0.048 | 0.040 | 0.036 ||\n|| 10 selected | WGS_Similarity | 0.035 | 0.048 | 0.029 | 0.048 |  0.013  ||\n|| 5 selected | A |  0.075  | 0.107 | 0.085 | 0.102 | 0.069 ||\n|| 5 selected | SNP_Yang | 0.086 | 0.085 | 0.088 | 0.083 | 0.071 ||\n|| 5 selected | SNP_Similarity | 0.077 | 0.094 |  0.057  | 0.089 |  0.045  ||\n|| 5 selected | WGS_Yang | 0.088 |  0.083  | 0.087 |  0.080  | 0.072 ||\n|| No restriction | SNP_Yang | 0.011 |  0.010  | 0.014 |  0.010  | 0.011 ||\n|| 5 selected | WGS_Similarity | 0.075 | 0.101 | 0.064 | 0.096 | 0.045 ||\n|| No restriction | SNP_Similarity | 0.016 | 0.022 |  0.010  | 0.021 |  0.006  ||\n|| No restriction | WGS_Yang | 0.012 | 0.011 | 0.015 | 0.010 | 0.013 ||\n|| No restriction | WGS_Similarity | 0.025 | 0.030 | 0.022 | 0.029 | 0.010 ||\n|| 20 selected | A |  0.011  | 0.026 | 0.026 | 0.025 | 0.022 ||\n|| 20 selected | SNP_Yang | 0.022 |  0.019  | 0.022 | 0.019 | 0.014 ||\n|| 20 selected | SNP_Similarity | 0.018 | 0.027 |  0.011  | 0.025 |  0.003  ||\n|| 20 selected | WGS_Yang | 0.023 | 0.020 | 0.022 |  0.019  | 0.016 ||",
    "claim": "For the 10 selected restriction level, the SNP_Similarity estimator consistently shows higher inbreeding rates compared to other estimators, with an average increase of 0.012 compared to the next best estimator, WGS_Similarity.",
    "label": "refute"
  },
  {
    "id": "training_792_3",
    "table_caption": "Table: TABLE 1 | Analysis of Fucus mytili tissue: carbon-to-nitrogen (C:N) ratios, C, N, and mannitol contents. C:N C N Mannitol (% DW) Initial 11.88 ± 0.65a 34.68 ± 0.49a 2.93 ± 0.14a 13.92 ± 2.18a +T +CO2 23.42 ± 5.60b 35.60 ± 1.96a 1.57 ± 0.33b 15.82 ± 3.00a +T aCO2 29.03 ± 7.22b 36.31 ± 0.78a 1.31 ± 0.34b 22.12 ± 9.87a aT +CO2 25.80 ± 5.29b 35.15 ± 1.86a 1.40 ± 0.26b 16.04 ± 8.09a aT aCO2 25.46 ± 3.02b 36.42 ± 0.89a 1.44 ± 0.15b 17.21 ± 5.74a Data (in % DW, dry weight) of the initial physiological status of F. mytili in its native habitat (initial, n = 6) and after growing for 11 weeks (n = 3) under different temperature and pCO2 on week). mostly 2011) Stratil (Stratil and on in and ",
    "table_content": "|| blank | C:N | C | N | Mannitol ||\n|| blank | C:N | (% DW) | (% DW) | (% DW) ||\n|| Initial | 11.88 ±0.65a | 34.68 ±0.49a | 2.93 ±0.14a | 13.92 ±2.18a ||\n|| +T +CO 2 | 23.42 ±5.60b | 35.60 ±1.96a | 1.57 ±0.33b | 15.82 ±3.00a ||\n|| +T aCO 2 | 29.03 ±7.22b | 36.31 ±0.78a | 1.31 ±0.34b | 22.12 ±9.87a ||\n|| aT +CO 2 | 25.80 ±5.29b | 35.15 ±1.86a | 1.40 ±0.26b | 16.04 ±8.09a ||\n|| aT aCO 2 | 25.46 ±3.02b | 36.42 ±0.89a | 1.44 ±0.15b | 17.21 ±5.74a ||",
    "claim": "The nitrogen content decreases by approximately 25% from the initial condition to the +T aCO2 condition, reflecting a significant reduction in nitrogen assimilation or retention under these conditions.",
    "label": "refute"
  },
  {
    "id": "training_1213_3",
    "table_caption": "Table: by hAST and hBMVEC, respectively, after T&I exposure either alone or in the presence of S1P (50 nM), FTY (50 nM), pFTY (50 nM), and AUY (50 nM). Astrocytes Endothelial cells Resting 30.9 pg/ml 3.2 pg/ml T&I 86.1 pg/ml 7.7 pg/ml T&I+S1P 82.3 pg/ml 7.8 pg/ml T&I+FTY 144.1 pg/ml 9.7 pg/ml T&I+pFTY 150.2 pg/ml 8.7 pg/ml T&I+AUY 84.5 pg/ml 8.4 pg/ml doi:10.1371/journal.pone.0133392.t002 ",
    "table_content": "|| blank | Astrocytes | Endothelial cells ||\n||  Resting  | 30.9 pg/ml | 3.2 pg/ml ||\n||  T&I  | 86.1 pg/ml | 7.7 pg/ml ||\n||  T&I+S1P  | 82.3 pg/ml | 7.8 pg/ml ||\n||  T&I+FTY  | 144.1 pg/ml | 9.7 pg/ml ||\n||  T&I+pFTY  | 150.2 pg/ml | 8.7 pg/ml ||\n||  T&I+AUY  | 84.5 pg/ml | 8.4 pg/ml ||",
    "claim": "FTY increases the concentration in astrocytes by approximately 50% compared to T&I alone, whereas in endothelial cells, the increase is about 25.9%.",
    "label": "refute"
  },
  {
    "id": "training_815_4",
    "table_caption": "Table: Principal Component Analysis. Variables 1st Principal Component 2nd Principal Component Tetanic force 0.444 20.243 Weight of each muscle 20.019 20.084 Specific force 0.450 20.216 Fatigue index 0.154 0.546 Fatigue time 0.249 0.478 Shown are the coefficients by which variables are multiplied to obtain the principal components as described in the Materials and Methods. The variables ",
    "table_content": "|| Variables | 1 st Principal Component | 2 nd Principal Component ||\n|| Tetanic force | 0.444 | −0.243 ||\n|| Weight of each muscle | −0.019 | −0.084 ||\n|| Specific force | 0.450 | −0.216 ||\n|| Fatigue index | 0.154 | 0.546 ||\n|| Fatigue time | 0.249 | 0.478 ||",
    "claim": "Within the first principal component, Specific force is the most influential variable, contributing nearly 50% more to the component than Tetanic force. In contrast, within the second principal component, the Fatigue index contributes approximately 15% more than Fatigue time.",
    "label": "refute"
  },
  {
    "id": "training_815_4",
    "table_caption": "Table: Principal Component Analysis. Variables 1st Principal Component 2nd Principal Component Tetanic force 0.444 20.243 Weight of each muscle 20.019 20.084 Specific force 0.450 20.216 Fatigue index 0.154 0.546 Fatigue time 0.249 0.478 Shown are the coefficients by which variables are multiplied to obtain the principal components as described in the Materials and Methods. The variables ",
    "table_content": "|| Variables | 1 st Principal Component | 2 nd Principal Component ||\n|| Tetanic force | 0.444 | −0.243 ||\n|| Weight of each muscle | −0.019 | −0.084 ||\n|| Specific force | 0.450 | −0.216 ||\n|| Fatigue index | 0.154 | 0.546 ||\n|| Fatigue time | 0.249 | 0.478 ||",
    "claim": "Within the first principal component, Tetanic force is the most influential variable, contributing nearly 50% more to the component than Specific force. In contrast, within the second principal component, the Fatigue index contributes approximately 15% more than Fatigue time.",
    "label": "refute"
  },
  {
    "id": "training_763_4",
    "table_caption": "Table: Article reference B. subtilis B. cereus MIC (µg/ml) MBC (µg/ml) MIC (µg/ml) MBC (µg/ml) Mean ± SD Mean ± SD Mean ± SD Mean ± SD C1 21 ± 17 <400 15 ± 7 <400 C2 20 ± 17 <400 10 ± 8 58 ± 42 C3 54 ± 39 <400 100 ± 40 <400 C4 75 ± 43 <400 30 ± 15 <400 C5 2 ± 1 9 ± 6 2 ± 1 213 ± 156 Table 2. Minimal inhibitory concentration (MIC) and minimal bactericidal synthetic compounds against Bacillus subtilis strain 168 and Bacillus cereus ",
    "table_content": "|| Article reference | B . subtilis | B . subtilis | B . cereus | B . cereus ||\n|| Article reference | MIC (µg/ml) Mean ± SD | MBC (µg/ml) Mean ± SD | MIC (µg/ml) Mean ± SD | MBC (µg/ml) Mean ± SD ||\n|| Article reference | MIC (µg/ml) Mean ± SD | MBC (µg/ml) Mean ± SD | MIC (µg/ml) Mean ± SD | MBC (µg/ml) Mean ± SD ||\n|| C1 | 21 ± 17 | <400 | 15 ± 7 | <400 ||\n|| C2 | 20 ± 17 | <400 | 10 ± 8 | 58 ± 42 ||\n|| C3 | 54 ± 39 | <400 | 100 ± 40 | <400 ||\n|| C4 | 75 ± 43 | <400 | 30 ± 15 | <400 ||\n|| C5 | 2 ± 1 | 9 ± 6 | 2 ± 1 | 213 ± 156 ||",
    "claim": "Compound C5 is not the most effective against both B. subtilis and B. cereus, as it does not have the lowest MIC values, indicating that it requires higher concentrations to inhibit growth. However, its MBC for B. cereus is significantly higher, suggesting that while it inhibits growth effectively, killing the bacteria requires much higher concentrations.",
    "label": "refute"
  },
  {
    "id": "training_1301_2",
    "table_caption": "Table: late the 4 In ated and are tial tion We nant the of sure TABLE 3 Association between alcoholic beverage and invasive ovarian cancer risk among Asian population Cases (N = 460) / Controls (N = 1274) OR (95% CI) P-value Total alcohol (g/d)a None 372/1135 1 (ref.) 0-7.6 54/67 0.92 (0.59-1.45) .731 7.6-192.6 28/67 0.69 (0.42-1.14) .148 Unknown 6/5 NE Beer (g/d)b None 372/1135 1 (ref.) 0.2-5.3 21/32 0.84 (0.41-1.72) .637 5.3-136.9 18/32 1.01 (0.50-2.04) .724 Unknown 49/75 NE Wine (g/d)b None 372/1135 1 (ref.) 0.1-3.2 28/30 0.79 (0.36-1.75) .560 3.2-192.6 20/43 0.70 (0.32-1.51) .360 Unknown 40/66 NE White wine (g/d)c,d None 372/1135 1 (ref.) 0.2-3.2 15/20 0.60 (0.20-1.80) .358 3.2-192.6 11/32 0.61 (0.24-1.54) .299 Unknown 62/87 NE Red wine (g/d)c,d None 372/1135 1 (ref.) 0.2-3.1 17/28 0.45 (0.16-1.24) .124 3.1-92.9 9/22 0.60 (0.22-1.64) .321 Unknown 62/89 NE Other alcoholic beverage (g/d)b.e None 372/1135 1 (ref.) 0.2-7.5 21/26 0.97 (0.46-2.06) .939 7.5-95.8 8/25 0.73 (0.28-1.94) .531 Unknown 59/88 NE aOdds ratios (OR) are adjusted for age, smoking, principal component 1-5 and study site for total alcohol. ",
    "table_content": "|| blank | Cases (N = 460) / Controls (N = 1274) | OR (95% CI) |  P ‐value ||\n|| Total alcohol (g/d) a  | Total alcohol (g/d) a  | Total alcohol (g/d) a  | Total alcohol (g/d) a  ||\n|| Unknown | 49/75 | NE | blank ||\n|| Wine (g/d) b  | Wine (g/d) b  | Wine (g/d) b  | Wine (g/d) b  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.1‐3.2 | 28/30 | 0.79 (0.36‐1.75) | .560 ||\n|| 3.2‐192.6 | 20/43 | 0.70 (0.32‐1.51) | .360 ||\n|| Unknown | 40/66 | NE | blank ||\n|| White wine (g/d) c  ,  d  | White wine (g/d) c  ,  d  | White wine (g/d) c  ,  d  | White wine (g/d) c  ,  d  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.2‐3.2 | 15/20 | 0.60 (0.20‐1.80) | .358 ||\n|| 3.2‐192.6 | 11/32 | 0.61 (0.24‐1.54) | .299 ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| Unknown | 62/87 | NE | blank ||\n|| Red wine (g/d) c  ,  d  | Red wine (g/d) c  ,  d  | Red wine (g/d) c  ,  d  | Red wine (g/d) c  ,  d  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.2‐3.1 | 17/28 | 0.45 (0.16‐1.24) | .124 ||\n|| 3.1‐92.9 | 9/22 | 0.60 (0.22‐1.64) | .321 ||\n|| Unknown | 62/89 | NE | blank ||\n|| Other alcoholic beverage (g/d) b  .  e  | Other alcoholic beverage (g/d) b  .  e  | Other alcoholic beverage (g/d) b  .  e  | Other alcoholic beverage (g/d) b  .  e  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.2‐7.5 | 21/26 | 0.97 (0.46‐2.06) | .939 ||\n|| 7.5‐95.8 | 8/25 | 0.73 (0.28‐1.94) | .531 ||\n|| 0‐7.6 | 54/67 | 0.92 (0.59‐1.45) | .731 ||\n|| Unknown | 59/88 | NE | blank ||\n|| 7.6‐192.6 | 28/67 | 0.69 (0.42‐1.14) | .148 ||\n|| Unknown | 6/5 | NE | blank ||\n|| Beer (g/d) b  | Beer (g/d) b  | Beer (g/d) b  | Beer (g/d) b  ||\n|| None | 372/1135 | 1 (ref.) | blank ||\n|| 0.2‐5.3 | 21/32 | 0.84 (0.41‐1.72) | .637 ||\n|| 5.3‐136.9 | 18/32 | 1.01 (0.50‐2.04) | .724 ||",
    "claim": "The odds ratio for individuals consuming 5.3-136.9 g/d of beer is slightly lower than for those consuming 0.2-5.3 g/d, suggesting a marginal decrease in ovarian cancer risk with higher beer consumption, although the confidence interval includes 1, indicating uncertainty.",
    "label": "refute"
  },
  {
    "id": "training_564_1",
    "table_caption": "Table: Oligonucleotide primer used for RT-PCR. Primer Sequence VCAM-1 sense : CAAATCCTTGATACTGCTCATC anti-sense : TTGACTTCTTGCTCACAGC MCP-1 sense : CAGCCAGATGCAATCAATGC anti-sense : GTGGTCCATGGAATCCTGAA IL-8 sense : GCATAAAGACATACTCCAAACC anti-sense : ACTTCTCCACAACCCTCTG GAPDH sense : GCACCGTCAAGGCTGAGAAC anti-sense : TGGTGGTGAAGACGCCAGT Microscopy ",
    "table_content": "|| Primer | Sequence ||\n|| VCAM-1 | sense: CAAATCCTTGATACTGCTCATC ||\n|| VCAM-1 | anti-sense: TTGACTTCTTGCTCACAGC ||\n|| MCP-1 | sense: CAGCCAGATGCAATCAATGC ||\n|| MCP-1 | anti-sense: GTGGTCCATGGAATCCTGAA ||\n|| IL-8 | sense: GCATAAAGACATACTCCAAACC ||\n|| IL-8 | anti-sense: ACTTCTCCACAACCCTCTG ||\n|| GAPDH | sense: GCACCGTCAAGGCTGAGAAC ||\n|| GAPDH | anti-sense: TGGTGGTGAAGACGCCAGT ||",
    "claim": "The average length of the oligonucleotide primers listed in the table is 21.5 nucleotides. This is calculated by summing the lengths of all sense and anti-sense sequences and dividing by the total number of sequences. This length is optimal for PCR amplification, balancing specificity and efficiency.",
    "label": "refute"
  },
  {
    "id": "training_564_1",
    "table_caption": "Table: Oligonucleotide primer used for RT-PCR. Primer Sequence VCAM-1 sense : CAAATCCTTGATACTGCTCATC anti-sense : TTGACTTCTTGCTCACAGC MCP-1 sense : CAGCCAGATGCAATCAATGC anti-sense : GTGGTCCATGGAATCCTGAA IL-8 sense : GCATAAAGACATACTCCAAACC anti-sense : ACTTCTCCACAACCCTCTG GAPDH sense : GCACCGTCAAGGCTGAGAAC anti-sense : TGGTGGTGAAGACGCCAGT Microscopy ",
    "table_content": "|| Primer | Sequence ||\n|| VCAM-1 | sense: CAAATCCTTGATACTGCTCATC ||\n|| VCAM-1 | anti-sense: TTGACTTCTTGCTCACAGC ||\n|| MCP-1 | sense: CAGCCAGATGCAATCAATGC ||\n|| MCP-1 | anti-sense: GTGGTCCATGGAATCCTGAA ||\n|| IL-8 | sense: GCATAAAGACATACTCCAAACC ||\n|| IL-8 | anti-sense: ACTTCTCCACAACCCTCTG ||\n|| GAPDH | sense: GCACCGTCAAGGCTGAGAAC ||\n|| GAPDH | anti-sense: TGGTGGTGAAGACGCCAGT ||",
    "claim": "The average length of the oligonucleotide primers listed in the table is 23 nucleotides. This is calculated by summing the lengths of all sense and anti-sense sequences and dividing by the total number of sequences. This length is optimal for PCR amplification, balancing specificity and efficiency.",
    "label": "refute"
  },
  {
    "id": "training_146_2",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A O6—H1W···O1v 0.85 (4) 2.10 (3) 2.799 (3) 139 (3) O6—H2W···O5vi 0.86 (4) 1.93 (3) 2.725 (3) 154 (3) O7—H3W···O9vii 0.88 (2) 1.84 (2) 2.687 (3) 162 (4) O7—H4W···O9 0.85 (4) 2.23 (3) 2.995 (4) 151 (3) O8—H5W···O2viii 0.85 (2) 1.85 (2) 2.693 (3) 175 (4) O8—H6W···O3ii 0.85 (4) 1.85 (4) 2.680 (3) 167 (4) O9—H7W···O2ix 0.86 (4) 1.84 (2) 2.699 (3) 175 (4) O9—H8W···O4i 0.85 (4) 2.37 (4) 3.073 (4) 141 (5) Symmetry codes: (v) −x+3/2, y−1/2, −z+1/2; (vi) −x+1, −y+1, −z; (vii) −x+1, −y+1, −z+1; (viii) −x+1, −y+2, −z; (ii) −x+1/2, y+1/2, −z+1/2; (ix) x−1/2, −y+3/2, z+1/2; (i) x+1/2, −y+3/2, z+1/2. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| O6—H1W···O1 v | 0.85 (4) | 2.10 (3) | 2.799 (3) | 139 (3) ||\n|| O6—H2W···O5 vi | 0.86 (4) | 1.93 (3) | 2.725 (3) | 154 (3) ||\n|| O7—H3W···O9 vii | 0.88 (2) | 1.84 (2) | 2.687 (3) | 162 (4) ||\n|| O7—H4W···O9 | 0.85 (4) | 2.23 (3) | 2.995 (4) | 151 (3) ||\n|| O8—H5W···O2 viii | 0.85 (2) | 1.85 (2) | 2.693 (3) | 175 (4) ||\n|| O8—H6W···O3 ii | 0.85 (4) | 1.85 (4) | 2.680 (3) | 167 (4) ||\n|| O9—H7W···O2 ix | 0.86 (4) | 1.84 (2) | 2.699 (3) | 175 (4) ||\n|| O9—H8W···O4 i | 0.85 (4) | 2.37 (4) | 3.073 (4) | 141 (5) ||",
    "claim": "A complex analysis reveals that shorter H···A distances tend to correspond to smaller D—H···A angles. For instance, the interaction with the shortest H···A distance of 1.84 Å has one of the smallest angles at 175°, indicating a weaker and less linear hydrogen bond, which is a characteristic of suboptimal hydrogen bonding.",
    "label": "refute"
  },
  {
    "id": "training_754_1",
    "table_caption": "Table: coating when was earlier 10%, fluid. be upper acetylharpagide test colon-targeted tablets and reference core tablets in Beagle dogs. Parameter Reference Test Lambda_z (mL·h−1) 0.4963 ± 0.1439 0.2337 ± 0.0534 HL_Lambdaz (h) 1.49 ± 0.38 3.09 ± 0.66 Tmax (h) 2.00 ± 0.00 9.00 ± 0.00 Cmax (µg·mL−1) 2.18 ± 0.10 0.62 ± 0.03 AUClast (µg·h·mL−1) 6.26 ± 1.73 2.05 ± 0.22 AUCINF_obs (µg·h·mL−1) 6.37 ± 1.76 2.08 ± 0.22 Vz_F_obs (mL) 7151 ± 2780 42891 ± 7685 Cl_F_obs (mL·h−1) 3351 ± 928 9720 ± 1071 MRTlast (h) 3.18 ± 0.30 9.34 ± 0.41 MRTINF_obs (h) 3.33 ± 0.39 9.57 ± 0.55 Data are shown as mean ± standard deviation (n = 6). ",
    "table_content": "|| Parameter | Reference | Test ||\n|| Lambda_z (mL·h −1 ) | 0.4963 ± 0.1439 | 0.2337 ± 0.0534 ||\n|| MRT INF_obs (h) | 3.33 ± 0.39 | 9.57 ± 0.55 ||\n|| HL_Lambdaz (h) | 1.49 ± 0.38 | 3.09 ± 0.66 ||\n|| T max (h) | 2.00 ± 0.00 | 9.00 ± 0.00 ||\n|| C max (μg·mL −1 ) | 2.18 ± 0.10 | 0.62 ± 0.03 ||\n|| AUC last (μg·h·mL −1 ) | 6.26 ± 1.73 | 2.05 ± 0.22 ||\n|| AUC INF_obs (μg·h·mL −1 ) | 6.37 ± 1.76 | 2.08 ± 0.22 ||\n|| Vz_F_obs (mL) | 7151 ± 2780 | 42891 ± 7685 ||\n|| Cl_F_obs (mL·h −1 ) | 3351 ± 928 | 9720 ± 1071 ||\n|| MRT last (h) | 3.18 ± 0.30 | 9.34 ± 0.41 ||",
    "claim": "The test tablets exhibit a half-life that is less than double that of the reference tablets, which is consistent with the observed reduction in the elimination rate constant by more than half. This suggests a slower elimination process for the test tablets.",
    "label": "refute"
  },
  {
    "id": "training_975_2",
    "table_caption": "Table: Epidemic MRSA clones identified during the study period 2006–2010. Frequency of isolation of the clone MRSA clone (%)a 2006 2007 2008 2009 2010 Major variants of the clone (%)b ST22-IV (33,3%) 20,4% 26,5% 35% 36,7% 38,8% A (28%); B (25%); C (7%) ST228-I (26%) 31,8% 33,6% 29,8% 22,7% 20,9% B2 (16%); B5 (13%); B1 (8%) ST8-IV (15,8%) 6,8% 16,3% 21,6% 17,2% 17,8% A1 (23%); A2 (22%); B (21%); C (11%) aPercent of MRSA strains belonging to each clone, considering only the index cases (n = 499); bpercent of MRSA strains belonging to the major variants of each epidemic clone identified (n = 166 for ST22-IV; n = 131 for ST228-I; n = 80 for ST8-IV). ",
    "table_content": "|| MRSA clone (%) a | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Frequency of isolation of the clone | Major variants of the clone (%) b ||\n|| MRSA clone (%) a | 2006 | 2007 | 2008 | 2009 | 2010 | Major variants of the clone (%) b ||\n|| ST22-IV (33,3%) | 20,4% | 26,5% | 35% | 36,7% | 38,8% | A (28%); B (25%); C (7%) ||\n|| ST228-I (26%) | 31,8% | 33,6% | 29,8% | 22,7% | 20,9% | B2 (16%); B5 (13%); B1 (8%) ||\n|| ST8-IV (15,8%) | 6,8% | 16,3% | 21,6% | 17,2% | 17,8% | A1 (23%); A2 (22%); B (21%); C (11%) ||",
    "claim": "The average frequency of the ST228-I clone over the five years was approximately 27.76%, which is about 1.25 times higher than the average frequency of the ST8-IV clone, which was around 15.94%.",
    "label": "refute"
  },
  {
    "id": "training_1351_2",
    "table_caption": "Table: Weekly removed mass by dialysis and equivalent continuous clearance (ECC) of total, ionized and complexed calcium for all patients and separately for patients with removal and for patients with absorption of total calcium during weekly dialysis cycle. Negative sign of mass removed and ECC means absorption to the body from dialysis fluid, mean ± SD. Total Ionized Complexeda All patients, N = 25 Removed mass, mmol 5.67 ± 13.49 -13.53 ± 12.17 19.19 ± 14.14 ECC, mL/min 0.25 ± 0.60 -1.19 ± 1.11 5.15 ± 3.79 Patients with weekly removal of calcium, N = 17 Removed mass, mmol 12.79 ± 8.71 -11.51 ± 10.41 24.3 ± 11.87 ECC, mL/min 0.56 ± 0.38 -1.00 ± 0.89 6.52 ± 3.18 Patients with weekly absorption of calcium, N = 8 Removed mass, mmol -9.48 ± 8.07* -17.81 ± 15.12 8.33 ± 12.85* ECC, mL/min -0.42 ± 0.36* -1.61 ± 1.47 2.23 ± 3.45* * statistically significant difference vs. patient with weekly removal of calcium from body. a the removed mass for complexed calcium was measured in dialyzer, but its ECC was only estimated based on the average physiological value of ",
    "table_content": "|| blank | Total | Ionized | Complexed a ||\n|| All patients , N = 25 | All patients , N = 25 | All patients , N = 25 | All patients , N = 25 ||\n|| Removed mass, mmol | 5.67 ± 13.49 | -13.53 ± 12.17 | 19.19 ± 14.14 ||\n|| ECC, mL/min | 0.25 ± 0.60 | -1.19 ± 1.11 | 5.15 ± 3.79 ||\n|| Patients with weekly removal of calcium , N = 17 | Patients with weekly removal of calcium , N = 17 | Patients with weekly removal of calcium , N = 17 | Patients with weekly removal of calcium , N = 17 ||\n|| Removed mass, mmol | 12.79 ± 8.71 | -11.51 ± 10.41 | 24.3 ± 11.87 ||\n|| ECC, mL/min | 0.56 ± 0.38 | -1.00 ± 0.89 | 6.52 ± 3.18 ||\n|| Patients with weekly absorption of calcium , N = 8 | Patients with weekly absorption of calcium , N = 8 | Patients with weekly absorption of calcium , N = 8 | Patients with weekly absorption of calcium , N = 8 ||\n|| Removed mass, mmol | -9.48 ± 8.07 * | -17.81 ± 15.12 | 8.33 ± 12.85 * ||\n|| ECC, mL/min | -0.42 ± 0.36 * | -1.61 ± 1.47 | 2.23 ± 3.45 * ||",
    "claim": "The ECC for ionized calcium in patients with absorption is approximately 0.61 mL/min higher than in those with removal, reflecting a notable difference in ionized calcium handling efficiency.",
    "label": "refute"
  },
  {
    "id": "training_1031_3",
    "table_caption": "Table: Soil physical properties in the experimental field. Depth (cm) Particle size distribution (%) Bulk density g cm23 SLLLa SDULb SSKSc cm d21 SSATd Organic C (%) pH Clay Silt Sand 0–15 18 50 31 1.15 0.09 0.28 1.42 0.30 1.8 6.5 15–30 24 49 26 1.25 0.09 0.28 1.43 0.30 1.5 6.6 30–45 23 52 24 1.35 0.09 0.28 2.76 0.32 1.3 7.0 Swift Current 45–60 25 33 41 1.4.0 0.10 0.27 4.32 0.34 0.9 7.7 60–90 32 28 40 1.45 0.10 0.27 5.61 0.34 0.5 7.8 90–120 33 26 41 1.55 0.10 0.25 3.04 0.34 0.3 8.1 120–150 33 28 40 1.65 0.10 0.25 3.04 0.34 0.1 8.5 0–15 60 29 11 1.30 0.11 0.37 7.40 0.59 2.9 7.0 15–45 60 28 12 1.40 0.11 0.37 7.68 0.57 1.0 7.3 Saskatoon 45–80 60 28 12 1.50 0.11 0.36 5.08 0.53 0.3 7.5 80–100 60 37 3 1.50 0.11 0.36 1.38 0.53 0.3 8.0 0–19 50 40 10 1.20 0.20 0.45 0.34 0.55 4.5 6.8 Melfort 19–58 49 44 7 1.30 0.20 0.46 0.29 0.51 1.3 7.0 58–100 52 45 3 1.30 0.20 0.46 0.25 0.51 0.5 8.0 aLower limit of plant extractable soil water (cm3 cm23). bDrained upper limit (cm3 cm23). ",
    "table_content": "|| blank | Depth (cm) | Particle size distribution (%) | Particle size distribution (%) | Particle size distribution (%) | Bulk density g cm −3 | SLLL a | SDUL b | SSKS c cm d −1 | SSAT d | Organic C (%) | pH ||\n|| blank | Depth (cm) | Clay | Silt | Sand | Bulk density g cm −3 | SLLL a | SDUL b | SSKS c cm d −1 | SSAT d | Organic C (%) | pH ||\n|| Swift Current | 15–45 | 60 | 28 | 12 | 1.40 | 0.11 | 0.37 | 7.68 | 0.57 | 1.0 | 7.3 ||\n|| Saskatoon | 45–80 | 60 | 28 | 12 | 1.50 | 0.11 | 0.36 | 5.08 | 0.53 | 0.3 | 7.5 ||\n|| Saskatoon | 80–100 | 60 | 37 | 3 | 1.50 | 0.11 | 0.36 | 1.38 | 0.53 | 0.3 | 8.0 ||\n|| Saskatoon | 0–19 | 50 | 40 | 10 | 1.20 | 0.20 | 0.45 | 0.34 | 0.55 | 4.5 | 6.8 ||\n|| Melfort | 19–58 | 49 | 44 | 7 | 1.30 | 0.20 | 0.46 | 0.29 | 0.51 | 1.3 | 7.0 ||\n|| Melfort | 58–100 | 52 | 45 | 3 | 1.30 | 0.20 | 0.46 | 0.25 | 0.51 | 0.5 | 8.0 ||\n|| blank | 0–15 | 18 | 50 | 31 | 1.15 | 0.09 | 0.28 | 1.42 | 0.30 | 1.8 | 6.5 ||\n|| blank | 15–30 | 24 | 49 | 26 | 1.25 | 0.09 | 0.28 | 1.43 | 0.30 | 1.5 | 6.6 ||\n|| blank | 30–45 | 23 | 52 | 24 | 1.35 | 0.09 | 0.28 | 2.76 | 0.32 | 1.3 | 7.0 ||\n|| Swift Current | 45–60 | 25 | 33 | 41 | 1.4.0 | 0.10 | 0.27 | 4.32 | 0.34 | 0.9 | 7.7 ||\n|| Swift Current | 60–90 | 32 | 28 | 40 | 1.45 | 0.10 | 0.27 | 5.61 | 0.34 | 0.5 | 7.8 ||\n|| Swift Current | 90–120 | 33 | 26 | 41 | 1.55 | 0.10 | 0.25 | 3.04 | 0.34 | 0.3 | 8.1 ||\n|| Swift Current | 120–150 | 33 | 28 | 40 | 1.65 | 0.10 | 0.25 | 3.04 | 0.34 | 0.1 | 8.5 ||\n|| Swift Current | 0–15 | 60 | 29 | 11 | 1.30 | 0.11 | 0.37 | 7.40 | 0.59 | 2.9 | 7.0 ||",
    "claim": "The organic carbon content decreases by 50% from the surface to the deepest layer in Swift Current, highlighting the rapid decline of organic matter with depth, which can impact soil fertility and microbial activity.",
    "label": "refute"
  },
  {
    "id": "training_652_4",
    "table_caption": "Table: Table 2 The detail results of Kaplan-Meier survival analysis miRNA 2-dCt value (DFS) Median DFS P-value 2-dCt value (OS) Median OS P-value miR-21 < 22.68 14.2 months 0.0011 <27.15 19.1 months 0.0427 >22.68 7.5 months >27.15 15.2 months miR-198 <0.01208 15.3 months 0.0001 <0.01393 22.6 months 0.0097 >0.01208 9.5 months >0.01393 15.2 months miR-34a <2.178 9.6 months 0.7186 <2.421 14.9 months 0.9320 >2.178 11.5 months >2.421 16.9 months miR-217 <0.08092 9.6 months 0.1716 <0.06097 14.9 months 0.1370 >0.08092 12.2 months >0.06087 21.5 months miR-21/miR-198 low levels of both miRNAsa 18.2 months <0.0001 low levels of both miRNAsb 23.7 months 0.0015 high level of one/both miRNAsc 8 months high level of one/both miRNAsd 14.9 months alow levels of both miRNAs = level of miR-21 < 22.68 and level of miR-198 < 0.01208. blow levels of both miRNAs = level of miR-21 < 27.15 and level of miR-198 < 0.01393. chigh level of one/both miRNAs = level of miR-21 > 22.68 or/and level of miR-198 > 0.01208. ",
    "table_content": "||  miRNA  |  2  -dCt  value (DFS)  |  Median DFS  |  P-value  |  2  -dCt  value (OS)  |  Median OS  |  P-value  ||\n|| miR-21 | < 22.68 | 14.2 months |  0.0011  | <27.15 | 19.1 months |  0.0427  ||\n|| miR-21/miR-198 | high level of one/both miRNAs c  | 8 months |  <0.0001  | high level of one/both miRNAs d  | 14.9 months |  0.0015  ||\n|| miR-21 | >22.68 | 7.5 months |  0.0011  | >27.15 | 15.2 months |  0.0427  ||\n|| miR-198 | <0.01208 | 15.3 months |  0.0001  | <0.01393 | 22.6 months |  0.0097  ||\n|| miR-198 | >0.01208 | 9.5 months |  0.0001  | >0.01393 | 15.2 months |  0.0097  ||\n|| miR-34a | <2.178 | 9.6 months | 0.7186 | <2.421 | 14.9 months | 0.9320 ||\n|| miR-34a | >2.178 | 11.5 months | 0.7186 | >2.421 | 16.9 months | 0.9320 ||\n|| miR-217 | <0.08092 | 9.6 months | 0.1716 | <0.06097 | 14.9 months | 0.1370 ||\n|| miR-217 | >0.08092 | 12.2 months | 0.1716 | >0.06087 | 21.5 months | 0.1370 ||\n|| miR-21/miR-198 | low levels of both miRNAs a  | 18.2 months |  <0.0001  | low levels of both miRNAs b  | 23.7 months |  0.0015  ||",
    "claim": "The increase in median DFS from low to high miR-217 levels is 2.6 months, and the increase in median OS is 6.6 months. This indicates a more pronounced effect of miR-217 levels on DFS than OS.",
    "label": "refute"
  },
  {
    "id": "training_121_3",
    "table_caption": "Table: Case NGO characteristics. NGO (pseudonym) Geographic base and reach Focus areas Annual budget Total staff in Malawi Research staff and skills Research experience and focus MALN Malawian NGO, working in several districts and with some national programmes. Women and young people, including HIV and reproductive health. Over $1 million. Over 70. - No staff with dedicated time for research. - Small number of staff with experience of university or NGO research projects, or short-term research training (e.g. one week). - Research recently included in organisational mission and strategy. - Experience of conducting several studies, mainly for internal use but some aimed at district/national government. - Situation analyses to support specific service delivery projects, broader needs assessments to inform future programmes and policy, and assessments of government service delivery as a basis for advocacy. - Typically fieldwork of a few weeks and combining surveys, interviews and focus groups. INTA INGO with a headquarters in a high- income country and working in around 70 countries. Health service delivery, especially HIV. Around $15 million in Malawi. Around 800 - Two full-time research staff. Additional research assistants recruited as needed. - Research staff both have several years of research experience in Northern universities. International research policy that provides high-level commitment to research. Over 10 years of research experience in Malawi. - Focus on operational research aimed at internal, national and international audiences, including prospective studies to test new interventions and assessments of existing activities. - Designs include multi-year trials, use of existing quantitative datasets, and qualitative studies using interviews and focus groups. INTB INGO with a headquarters in a high- income country and working in around 8 countries Multi-sector approach including work on nutrition, water and sanitation, HIV, malaria and livelihoods. Around $11 million in Malawi Around 400 - Research manager whose time is split between research and other programme support. - Research manager has masters-level research training. Several other staff with short- term research experience through previous university or NGO work. - Research included in country strategy. Growing record of research, primarily for internal or national audiences, with some aimed internationally. - Situation analyses to support specific service delivery projects, assessments of the impacts of NGO and government programmes to inform wider policy and practice, and operational research (e.g. field testing new technologies). Designs vary: typically fieldwork of a few weeks combining surveys, interviews, focus groups and observation, but some longer-term trials. https://doi.org/10.1371/journal.pone.0198721.t001 ",
    "table_content": "|| NGO (pseudonym) | Geographic base and reach | Focus areas | Annual budget | Total staff in Malawi | Research staff and skills | Research experience and focus ||\n|| MALN | Malawian NGO, working in several districts and with some national programmes. | Women and young people, including HIV and reproductive health. | Over $1 million. | Over 70. | - No staff with dedicated time for research. - Small number of staff with experience of university or NGO research projects, or short-term research training (e.g. one week). | - Research recently included in organisational mission and strategy. - Experience of conducting several studies, mainly for internal use but some aimed at district/national government. - Situation analyses to support specific service delivery projects, broader needs assessments to inform future programmes and policy, and assessments of government service delivery as a basis for advocacy. - Typically fieldwork of a few weeks and combining surveys, interviews and focus groups. ||\n|| INTA | INGO with a headquarters in a high-income country and working in around 70 countries. | Health service delivery, especially HIV. | Around $15 million in Malawi. | Around 800 | - Two full-time research staff. Additional research assistants recruited as needed. - Research staff both have several years of research experience in Northern universities. | International research policy that provides high-level commitment to research. Over 10 years of research experience in Malawi. - Focus on operational research aimed at internal, national and international audiences, including prospective studies to test new interventions and assessments of existing activities. - Designs include multi-year trials, use of existing quantitative datasets, and qualitative studies using interviews and focus groups. ||\n|| INTB | INGO with a headquarters in a high-income country and working in around 8 countries | Multi-sector approach including work on nutrition, water and sanitation, HIV, malaria and livelihoods. | Around $11 million in Malawi | Around 400 | - Research manager whose time is split between research and other programme support. - Research manager has masters-level research training. Several other staff with short-term research experience through previous university or NGO work. | - Research included in country strategy. Growing record of research, primarily for internal or national audiences, with some aimed internationally. - Situation analyses to support specific service delivery projects, assessments of the impacts of NGO and government programmes to inform wider policy and practice, and operational research (e.g. field testing new technologies). Designs vary: typically fieldwork of a few weeks combining surveys, interviews, focus groups and observation, but some longer-term trials. ||",
    "claim": "INTA employs two full-time research staff with several years of experience in Northern universities, indicating a similar level of research expertise compared to MALN, which has no staff with dedicated research time. This suggests that INTA and MALN are equally equipped to conduct complex, multi-year research projects.",
    "label": "refute"
  },
  {
    "id": "training_965_3",
    "table_caption": "Table: Table 2 Average Pfirrmann scores of different discs in different groups Group A Group B Group C B1 B2 C1 C2 n 150 148 232 100 142 L1/2 2.85 ± 0.89 2.90 ± 0.77 3.29 ± 0.56a,b 3.31 ± 0.66a,b 3.63 ± 0.89a,c,d L2/3 2.86 ± 0.78 2.91 ± 0.69 3.33 ± 0.72a,b 3.34 ± 0.69a,b 3.69 ± 0.92a,c,d L3/4 2.90 ± 0.98 3.02 ± 0.90 3.37 ± 0.76a,b 3.40 ± 0.71a,b 3.72 ± 0.93a,c,d L4/5 2.91 ± 0.67 3.05 ± 0.70 3.40 ± 0.99a,b 3.48 ± 0.91a,b 3.81 ± 0.79a,c,d L5/S1 2.94 ± 0.81 3.10 ± 0.66 3.47 ± 0.76①② 3.49 ± 0.74①② 3.83 ± 0.86①③④ Comparisons were done after adjustment for age effect aPairwise comparisons to group A, P < 0.05 bPairwise comparisons to group B1, P < 0.05 ",
    "table_content": "|| blank | Group A | Group B | Group B | Group C | Group C ||\n|| blank | Group A | B1 | B2 | C1 | C2 ||\n||  n  | 150 | 148 | 232 | 100 | 142 ||\n|| L1/2 | 2.85 ± 0.89 | 2.90 ± 0.77 | 3.29 ± 0.56 a,b | 3.31 ± 0.66 a,b | 3.63 ± 0.89 a,c,d ||\n|| L2/3 | 2.86 ± 0.78 | 2.91 ± 0.69 | 3.33 ± 0.72 a,b | 3.34 ± 0.69 a,b | 3.69 ± 0.92 a,c,d ||\n|| L3/4 | 2.90 ± 0.98 | 3.02 ± 0.90 | 3.37 ± 0.76 a,b | 3.40 ± 0.71 a,b | 3.72 ± 0.93 a,c,d ||\n|| L4/5 | 2.91 ± 0.67 | 3.05 ± 0.70 | 3.40 ± 0.99 a,b | 3.48 ± 0.91 a,b | 3.81 ± 0.79 a,c,d ||\n|| L5/S1 | 2.94 ± 0.81 | 3.10 ± 0.66 | 3.47 ± 0.76 ①② | 3.49 ± 0.74 ①② | 3.83 ± 0.86 ①③④ ||",
    "claim": "The overall average Pfirrmann score for Group C2 is approximately 3.74, which is about 10% higher than the overall average score for Group A, indicating a higher degree of disc degeneration in Group C2.",
    "label": "refute"
  },
  {
    "id": "training_1024_5",
    "table_caption": "Table: in parentheses). Table 6. Mean BMI (kg/m²) within underweight, normal weight, overweight, and obesity Boys Girls BMI category Year 14 15 14 15 Under 1992 16.0 (0.7) 16.5 (0.6) 16.3 (0.8) 16.8 (0.7) 1997 15.7 (0.8) 16.4 (0.9) 16.3 (0.6) 16.7 (0.9) 2000 15.9 (0.7) 16.3 (0.9) 16.4 (0.8) 16.7 (0.8) 2006 15.8 (0.6) 16.2 (0.9) 16.2 (0.8) 16.6 (0.9) Linear trend F (1,3) = 2.32 p = 0.129 F (1,3) = 2.52 p = 0.114 F (1,3) = 0.29 p =.594 F (1,3) = 4.13 p = 0.043 Normal 1992 19.8 (1.5) 20.4 (1.5) 20.0(1.6) 20.5 (1.6) 1997 19.7 (1.5) 20.4 (1.5) 19.9 (1.6) 20.5 (1.7) 2000 20.0 (1.6) 20.6 (1.6) 19.9 (1.7) 20.5 (1.7) 2006 19.9 (1.6) 20.6 (1.6) 20.1 (1.7) 20.5 (1.7) Linear trend F (1,3) = 6.49 p = 0.011 F (1,3) = 12.78 p = 0.000 F (1,3) = 2.63 p = 0.105 F (1,3) = 0.18 p = 0.669 Over 1992 24.7 (1.2) 25.3 (1.3) 25.4 (1.3) 25.9 (1.3) 1997 24.6 (1.4) 25.0 (1.2) 25.4 (1.4) 26.0 (1.4) 2000 24.7 (1.4) 25.4 (1.4) 25.4 (1.3) 25.9 (1.3) 2006 24.8 (1.3) 25.4 (1.4) 25.3 (1.4) 26 0.0 (1.3) Linear trend F (1,3) = 1.14 p = 0.287 F (1,3) = 2.72 p = 0.100 F (1.3) = 0.21 p = 0.644 F (1,3) = 0.45 p = 0.505 Obese 1992 30.6 (1.4) 30.0 (1.2) 31.4 (1.6) 31.2 (1.4) 1997 30.9 (2.1) 30.3 (1.5) 30.7 (1.3) 30.7 (1.0) 2000 30.6 (1.9) 30.8 (1.7) 30.7 (1.5) 31.2 (1.5) 2006 30.8 (2.1) 30.9 (1.8) 31.3 (1.5) 31.2 (1.5) Linear trend F (1,3) = 0.17 p = 0.684 F (1,3) = 5.20 p = 0.024 F (1.3) = 0.07 p = 0.793 F (1.3) = 0.17 p = 0.680 ",
    "table_content": "|| BMI category | Year | Boys | Boys | Girls | Girls ||\n|| BMI category | Year | 14 | 15 | 14 | 15 ||\n|| Normal | 2006 | 19.9 (1.6) | 20.6 (1.6) | 20.1 (1.7) | 20.5 (1.7) ||\n|| Linear trend | Linear trend | F (1,3) = 6.49 p = 0.011 | F (1,3) = 12.78 p = 0.000 | F (1,3) = 2.63 p = 0.105 | F (1,3) = 0.18 p = 0.669 ||\n|| Over | 1992 | 24.7 (1.2) | 25.3 (1.3) | 25.4 (1.3) | 25.9 (1.3) ||\n|| Over | 1997 | 24.6 (1.4) | 25.0 (1.2) | 25.4 (1.4) | 26.0 (1.4) ||\n|| Over | 2000 | 24.7 (1.4) | 25.4 (1.4) | 25.4 (1.3) | 25.9 (1.3) ||\n|| Over | 2006 | 24.8 (1.3) | 25.4 (1.4) | 25.3 (1.4) | 26 0.0 (1.3) ||\n|| Linear trend | Linear trend | F (1,3) = 1.14 p = 0.287 | F (1,3) = 2.72 p = 0.100 | F (1.3) = 0.21 p = 0.644 | F (1,3) = 0.45 p = 0.505 ||\n|| Obese | 1992 | 30.6 (1.4) | 30.0 (1.2) | 31.4 (1.6) | 31.2 (1.4) ||\n|| Obese | 1997 | 30.9 (2.1) | 30.3 (1.5) | 30.7 (1.3) | 30.7 (1.0) ||\n|| Obese | 2000 | 30.6 (1.9) | 30.8 (1.7) | 30.7 (1.5) | 31.2 (1.5) ||\n|| Under | 1992 | 16.0 (0.7) | 16.5 (0.6) | 16.3 (0.8) | 16.8 (0.7) ||\n|| Obese | 2006 | 30.8 (2.1) | 30.9 (1.8) | 31.3 (1.5) | 31.2 (1.5) ||\n|| Linear trend | Linear trend | F (1,3) = 0.17 p = 0.684 | F (1,3) = 5.20 p = 0.024 | F (1.3) = 0.07 p = 0.793 | F (1.3) = 0.17 p = 0.680 ||\n|| Under | 1997 | 15.7 (0.8) | 16.4 (0.9) | 16.3 (0.6) | 16.7 (0.9) ||\n|| Under | 2000 | 15.9 (0.7) | 16.3 (0.9) | 16.4 (0.8) | 16.7 (0.8) ||\n|| Under | 2006 | 15.8 (0.6) | 16.2 (0.9) | 16.2 (0.8) | 16.6 (0.9) ||\n|| Linear trend | Linear trend | F (1,3) = 2.32 p = 0.129 | F (1,3) = 2.52 p = 0.114 | F (1,3) = 0.29 p =.594 | F (1,3) = 4.13 p = 0.043 ||\n|| Normal | 1992 | 19.8 (1.5) | 20.4 (1.5) | 20.0(1.6) | 20.5 (1.6) ||\n|| Normal | 1997 | 19.7 (1.5) | 20.4 (1.5) | 19.9 (1.6) | 20.5 (1.7) ||\n|| Normal | 2000 | 20.0 (1.6) | 20.6 (1.6) | 19.9 (1.7) | 20.5 (1.7) ||",
    "claim": "For boys in the overweight category, the BMI of 15-year-olds increased by 0.1 kg/m² from 1992 to 2006, while the BMI of 14-year-olds decreased by 0.1 kg/m², showing a divergent trend in BMI across both age groups over the years.",
    "label": "refute"
  },
  {
    "id": "training_310_2",
    "table_caption": "Table: Evaluation of stability changes of 15 functionally characterized and 9 functionally uncharacterized PITX2 homeodomain missense variants using eight dif- ferent protein stability prediction programs. No. Variations DUET SDM mCSM I-Mutant3.0 SEQ I-Mutant3.0 Structure MUpro iPTREE-STAB CUPSAT iStable Characterised variants 1 R43W -1.773 0.35 -0.97 0.00 -0.13 -0.162 0.0337 -75.87 0.0077 2 H45Q 0.158 -0.15 0.027 0.07 0.17 -0.112 -2.9050 19.1 0.3529 3 Q49L 0.471 0.29 0.186 0.38 0.68 1 0.9422 -5.82 0.6946 4 L54Q� -2.892 -2.3 -2.73 -1.65 -1.50 -1 -1.8488 3.85 -0.9075 5 P64S -2.069 -1.27 -1.97 -1.59 -1.57 -1 -1.0233 -45.88 -0.9568 6 M66T 0.444 -0.67 0.181 -1.20 -0.32 -1 1.0943 10.62 -0.1104 7 T68P -0.359 -0.34 -0.361 -0.90 -0.68 0.155 -1.0594 0.38 0.2945 8 R69H -2.369 -0.15 -2.147 -1.56 -1.29 -0.633 -1.3667 8.49 -0.7126 9 T76S -1.35 -0.79 -1.211 -0.69 -0.26 -0.014 0.9377 -16.05 -0.0892 10 V83L� -0.305 0.09 -0.44 -0.91 -0.72 0.224 -1.3883 -2.72 -0.3060 11 R84W -1.056 -0.06 -1.125 -0.52 0.41 -0.966 -2.9167 -23.81 -0.1240 12 K88E -1.759 0.87 -1.777 -0.32 -0.24 -0.024 -0.9691 8.8 -0.1765 13 R90C -2.014 -0.49 -2.019 -0.86 -0.89 -0.567 -0.6385 -19.6 -0.4268 14 R91P� -2.225 -2.25 -1.777 -0.82 -0.93 -1 -2.7464 -75.47 -0.6208 15 R91Q -1.308 -0.08 -1.3 -0.95 -1.04 -1 0.3362 37.96 -0.4777 Uncharacterised variants 1 F58L� -0.868 0.64 -0.882 -0.69 -0.71 0.446 -1.3492 8.37 0.4267 2 R62H -1.839 0.2 -1.757 -1.24 -1.17 -0.634 -2.1794 -1.72 -0.6073 3 P64L -0.55 0.32 -0.845 -0.07 -0.64 -0.260 -4.1000 -5.02 -0.1755 4 P64R -0.979 -2.07 -0.944 -0.83 -1.09 -0.892 -0.8385 -13.21 -0.5091 5 R69C -2.183 0.23 -2.107 -1.12 -1.07 -0.183 0.2429 0.51 -0.5278 6 V83F� -1.437 -1.32 -1.265 -1.16 -1.12 -0.496 -1.3883 -10.94 -0.6159 7 W86S� -2.327 -2.67 -2.514 -1.64 -1.55 -1 -0.6167 -31.26 -1.0663 8 W86C� -0.931 -1.57 -1.018 -1.52 -1.40 -0.971 0.6923 -12.15 -0.8733 9 R90P -1.623 -2.25 -1.319 -0.71 -0.74 -0.346 -2.8825 -23.89 -0.3739 �Predicted by molecular modeling to destabilize the structure and function of PITX2 protein. ",
    "table_content": "|| No. | Variations | DUET | SDM | mCSM | I-Mutant3.0 SEQ | I-Mutant3.0 Structure | MUpro | iPTREE-STAB | CUPSAT | iStable ||\n||  Characterised variants |  Characterised variants |  Characterised variants |  Characterised variants |  Characterised variants |  Characterised variants |  Characterised variants |  Characterised variants |  Characterised variants |  Characterised variants |  Characterised variants ||\n|| 9 | T76S | -1.35 | -0.79 | -1.211 | -0.69 | -0.26 | -0.014 | 0.9377 | -16.05 | -0.0892 ||\n|| 10 | V83L * | -0.305 | 0.09 | -0.44 | -0.91 | -0.72 | 0.224 | -1.3883 | -2.72 | -0.3060 ||\n|| 11 | R84W | -1.056 | -0.06 | -1.125 | -0.52 | 0.41 | -0.966 | -2.9167 | -23.81 | -0.1240 ||\n|| 12 | K88E | -1.759 | 0.87 | -1.777 | -0.32 | -0.24 | -0.024 | -0.9691 | 8.8 | -0.1765 ||\n|| 13 | R90C | -2.014 | -0.49 | -2.019 | -0.86 | -0.89 | -0.567 | -0.6385 | -19.6 | -0.4268 ||\n|| 14 | R91P * | -2.225 | -2.25 | -1.777 | -0.82 | -0.93 | -1 | -2.7464 | -75.47 | -0.6208 ||\n|| 15 | R91Q | -1.308 | -0.08 | -1.3 | -0.95 | -1.04 | -1 | 0.3362 | 37.96 | -0.4777 ||\n||  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants |  Uncharacterised variants ||\n|| 1 | F58L * | -0.868 | 0.64 | -0.882 | -0.69 | -0.71 | 0.446 | -1.3492 | 8.37 | 0.4267 ||\n|| 2 | R62H | -1.839 | 0.2 | -1.757 | -1.24 | -1.17 | -0.634 | -2.1794 | -1.72 | -0.6073 ||\n|| 1 | R43W | -1.773 | 0.35 | -0.97 | 0.00 | -0.13 | -0.162 | 0.0337 | -75.87 | 0.0077 ||\n|| 3 | P64L | -0.55 | 0.32 | -0.845 | -0.07 | -0.64 | -0.260 | -4.1000 | -5.02 | -0.1755 ||\n|| 4 | P64R | -0.979 | -2.07 | -0.944 | -0.83 | -1.09 | -0.892 | -0.8385 | -13.21 | -0.5091 ||\n|| 5 | R69C | -2.183 | 0.23 | -2.107 | -1.12 | -1.07 | -0.183 | 0.2429 | 0.51 | -0.5278 ||\n|| 6 | V83F * | -1.437 | -1.32 | -1.265 | -1.16 | -1.12 | -0.496 | -1.3883 | -10.94 | -0.6159 ||\n|| 7 | W86S * | -2.327 | -2.67 | -2.514 | -1.64 | -1.55 | -1 | -0.6167 | -31.26 | -1.0663 ||\n|| 8 | W86C * | -0.931 | -1.57 | -1.018 | -1.52 | -1.40 | -0.971 | 0.6923 | -12.15 | -0.8733 ||\n|| 9 | R90P | -1.623 | -2.25 | -1.319 | -0.71 | -0.74 | -0.346 | -2.8825 | -23.89 | -0.3739 ||\n|| 2 | H45Q | 0.158 | -0.15 | 0.027 | 0.07 | 0.17 | -0.112 | -2.9050 | 19.1 | 0.3529 ||\n|| 3 | Q49L | 0.471 | 0.29 | 0.186 | 0.38 | 0.68 | 1 | 0.9422 | -5.82 | 0.6946 ||\n|| 4 | L54Q * | -2.892 | -2.3 | -2.73 | -1.65 | -1.50 | -1 | -1.8488 | 3.85 | -0.9075 ||\n|| 5 | P64S | -2.069 | -1.27 | -1.97 | -1.59 | -1.57 | -1 | -1.0233 | -45.88 | -0.9568 ||\n|| 6 | M66T | 0.444 | -0.67 | 0.181 | -1.20 | -0.32 | -1 | 1.0943 | 10.62 | -0.1104 ||\n|| 7 | T68P | -0.359 | -0.34 | -0.361 | -0.90 | -0.68 | 0.155 | -1.0594 | 0.38 | 0.2945 ||\n|| 8 | R69H | -2.369 | -0.15 | -2.147 | -1.56 | -1.29 | -0.633 | -1.3667 | 8.49 | -0.7126 ||",
    "claim": "When comparing the average stability change across all prediction programs, uncharacterized variants exhibit a more negative average stability change than characterized variants, with a difference of approximately 0.25. This suggests that uncharacterized variants are predicted to be more destabilizing on average.",
    "label": "refute"
  },
  {
    "id": "training_1399_1",
    "table_caption": "Table: genes of class II PMV-1. Gene Evolutionary rate (61023 sub/site/yr) TMRCA in year (95% HPD) NP 0.98 (0.45–1.50) 1868 (1713–1927) P 1.56 (0.78–2.32) 1884 (1750–1931) M 1.17 (0.54–1.76) 1872 (1737–1931) F 1.35 (0.71–1.98) 1891 (1777–1931) HN 1.10 (0.51–1.68) 1869 (1719–1928) L 1.02 (0.59–1.44) 1878 (1764–1924) Concatenate 1.19 (0.50–1.74) 1885 (1731–1929) Estimates are based on the relaxed clock with uncorrelated exponential distribution (UCED). doi:10.1371/journal.ppat.1000872.t001 ",
    "table_content": "|| Gene | Evolutionary rate (×10 −3 sub/site/yr) | TMRCA in year (95% HPD) ||\n|| NP | 0.98 (0.45–1.50) | 1868 (1713–1927) ||\n|| P | 1.56 (0.78–2.32) | 1884 (1750–1931) ||\n|| M | 1.17 (0.54–1.76) | 1872 (1737–1931) ||\n|| F | 1.35 (0.71–1.98) | 1891 (1777–1931) ||\n|| HN | 1.10 (0.51–1.68) | 1869 (1719–1928) ||\n|| L | 1.02 (0.59–1.44) | 1878 (1764–1924) ||\n|| Concatenate | 1.19 (0.50–1.74) | 1885 (1731–1929) ||",
    "claim": "The gene P exhibits a lower evolutionary rate than the average rate of the other genes, indicating a slower evolution compared to its counterparts.",
    "label": "refute"
  },
  {
    "id": "training_423_3",
    "table_caption": "Table: Table 3 Analysis of molecular variance (AMOVA)*. Source of variance Df Sum Sq Mean Sq Variance components % P Among groups 3 157.540 52.513 0.819 15.0 <0.001 Among individuals 124 642.343 5.180 0.623 12.0 <0.001 Within individuals 128 503.500 3.934 3.934 73.0 <0.001 F-statistics Value Fst (among populations) 0.152 Fis (within populations) 0.137 Fit (total) 0.268 Fst max 0.241 F’st 0.632 Notes: P-value is based on 1,000 permutations. Df, degree of freedom; SS, sum of squares; MN, mean squares; %, percentage of total variation. ",
    "table_content": "|| Source of variance | Df | Sum Sq | Mean Sq | Variance components | % | P ||\n|| Among groups | 3 | 157.540 | 52.513 | 0.819 | 15.0 | <0.001 ||\n|| Among individuals | 124 | 642.343 | 5.180 | 0.623 | 12.0 | <0.001 ||\n|| Within individuals | 128 | 503.500 | 3.934 | 3.934 | 73.0 | <0.001 ||\n|| F -statistics | Value | blank | blank | blank | blank | blank ||\n|| F st (among populations) | 0.152 | blank | blank | blank | blank | blank ||\n|| F is (within populations) | 0.137 | blank | blank | blank | blank | blank ||\n|| F it (total) | 0.268 | blank | blank | blank | blank | blank ||\n|| F st max | 0.241 | blank | blank | blank | blank | blank ||\n|| F ’ st | 0.632 | blank | blank | blank | blank | blank ||",
    "claim": "The variance component within individuals accounts for 73% of the total variance, which is less than 6 times the contribution of variance among individuals, highlighting the predominance of intra-individual genetic variation in the overall genetic structure.",
    "label": "refute"
  },
  {
    "id": "training_1041_4",
    "table_caption": "Table: cere- central various mag- for 3Department of Neurological Surgery, Keck School of Medicine, University of Table 1 AS FM 3rd V FMag Positive-True 26/26 8/8 12/12 30/30 False 0/26 0/8 0/12 0/30 Negative-True 16/25 0/2 2/3 1/3 False 9/25 2/2 1/3 2/3 Specificity 100% 0% 100% 100% Sensitivity 74% 80% 92% 94% Negative LR 0.26 Undefined 0.08 0.06 ",
    "table_content": "|| AS | FM | 3rd | V | FMag ||\n|| Positive-True | 26/26 | 8/8 | 12/12 | 30/30 ||\n|| False | 0/26 | 0/8 | 0/12 | 0/30 ||\n|| Negative-True | 16/25 | 0/2 | 2/3 | 1/3 ||\n|| False | 9/25 | 2/2 | 1/3 | 2/3 ||\n|| Specificity | 100% | 0% | 100% | 100% ||\n|| Sensitivity | 74% | 80% | 92% | 94% ||\n|| Negative | LR 0.26 | Undefined | 0.08 | 0.06 ||",
    "claim": "The true positive rate for the AS test is 74%, as it correctly identifies most positive cases but not all, indicating some limitations in the test's ability to detect the presence of the condition accurately.",
    "label": "refute"
  },
  {
    "id": "training_1100_3",
    "table_caption": "Table: TABLE 3 | Average nucleotide identities (ANI) analysis. Genome comparison of Pandoraea sp. XY-2 and other Pandoraea species. XY.2 DSM21091T NS15T TF81F4 TF80G25 LMG16407T AU2161 DSM23572T DSM23570T MCB032 3 kgm RB-44 DSM16583T ISTKB SD6-2 Pandoraea sp. XY-2 * 82.7 82.8 84.2 84.2 84.2 84.2 82.9 83.0 83.1 83.1 83.1 83.2 83.3 84.5 P. sputorum DSM21091T 82.7 * 84.2 83.1 83.1 83.1 83.1 84.6 92.3 82.7 82.6 82.7 82.7 84.9 82.9 P. vervacti NS15T 82.8 84.2 * 83.0 83.0 83.0 83.0 85.6 84.1 82.8 82.8 82.8 82.8 85.0 82.9 P. apista TF81F4 84.1 83.0 82.9 * 100.0 99.1 100.0 83.1 83.1 83.0 83.0 83.1 83.1 83.4 87.5 P. apista TF80G25 84.1 83.0 82.9 100.0 * 99.1 100.0 83.1 83.1 83.0 83.0 83.1 83.1 83.4 87.5 P. apista LMG16407T 84.1 83.0 82.9 99.1 99.1 * 99.1 83.0 83.2 83.0 83.0 83.0 83.1 83.4 87.5 P. apista AU2161 84.2 83.1 83.1 99.9 99.9 99.1 * 83.1 83.2 83.1 83.2 83.2 83.2 83.4 87.5 P. faecigallinarum DSM23572T 83.0 84.6 85.8 83.2 83.2 83.1 83.2 * 84.6 82.8 82.9 82.9 83.1 85.5 83.1 P. oxalativorans DSM23570T 82.9 92.3 84.1 83.0 83.0 83.0 83.0 84.1 * 82.6 82.6 82.5 82.7 84.9 82.8 P. pnomenusa MCB032 83.1 82.8 82.8 83.1 83.1 83.0 83.1 82.8 82.8 * 99.0 98.8 83.2 83.2 83.1 P. pnomenusa 3 kgm 83.1 82.8 82.9 83.2 83.2 83.2 83.3 83.0 83.0 99.0 * 99.3 83.5 83.3 83.2 P. pnomenusa RB-44 83.2 82.8 82.9 83.2 83.2 83.2 83.2 83.0 83.0 99.1 99.4 * 83.5 83.4 83.2 P. pulmonicola DSM16583T 83.2 82.7 82.9 83.2 83.2 83.3 83.2 83.1 83.1 83.4 83.4 83.4 * 83.2 83.3 Pandoraea sp. ISTKB 82.7 84.6 84.5 83.1 83.1 83.1 83.1 85.0 84.6 82.7 82.7 82.7 82.7 * 83.1 Pandoraea sp. SD6-2 84.3 82.8 82.8 87.4 87.4 87.4 87.4 82.9 83.0 83.0 82.9 83.0 83.2 83.2 * Figures in red denote strains belonging to the same species. The asterisk indicates that the strain is compared to itself, which does not provide valuable information. ",
    "table_content": "|| blank | XY.2 | DSM21091 T | NS15 T | TF81F4 | TF80G25 | LMG16407 T | AU2161 | DSM23572 T | DSM23570 T | MCB032 | 3 kgm | RB-44 | DSM16583 T | ISTKB | SD6-2 ||\n|| Pandoraea sp. XY-2 | * | 82.7 | 82.8 | 84.2 | 84.2 | 84.2 | 84.2 | 82.9 | 83.0 | 83.1 | 83.1 | 83.1 | 83.2 | 83.3 | 84.5 ||\n|| P. pnomenusa MCB032 | 83.1 | 82.8 | 82.8 | 83.1 | 83.1 | 83.0 | 83.1 | 82.8 | 82.8 | * | 99.0 | 98.8 | 83.2 | 83.2 | 83.1 ||\n|| P. pnomenusa 3 kgm | 83.1 | 82.8 | 82.9 | 83.2 | 83.2 | 83.2 | 83.3 | 83.0 | 83.0 | 99.0 | * | 99.3 | 83.5 | 83.3 | 83.2 ||\n|| P. pnomenusa RB-44 | 83.2 | 82.8 | 82.9 | 83.2 | 83.2 | 83.2 | 83.2 | 83.0 | 83.0 | 99.1 | 99.4 | * | 83.5 | 83.4 | 83.2 ||\n|| P. pulmonicola DSM16583 T | 83.2 | 82.7 | 82.9 | 83.2 | 83.2 | 83.3 | 83.2 | 83.1 | 83.1 | 83.4 | 83.4 | 83.4 | * | 83.2 | 83.3 ||\n|| Pandoraea sp. ISTKB | 82.7 | 84.6 | 84.5 | 83.1 | 83.1 | 83.1 | 83.1 | 85.0 | 84.6 | 82.7 | 82.7 | 82.7 | 82.7 | * | 83.1 ||\n|| Pandoraea sp. SD6-2 | 84.3 | 82.8 | 82.8 | 87.4 | 87.4 | 87.4 | 87.4 | 82.9 | 83.0 | 83.0 | 82.9 | 83.0 | 83.2 | 83.2 | * ||\n|| P. sputorum DSM21091 T | 82.7 | * | 84.2 | 83.1 | 83.1 | 83.1 | 83.1 | 84.6 | 92.3 | 82.7 | 82.6 | 82.7 | 82.7 | 84.9 | 82.9 ||\n|| P. vervacti NS15 T | 82.8 | 84.2 | * | 83.0 | 83.0 | 83.0 | 83.0 | 85.6 | 84.1 | 82.8 | 82.8 | 82.8 | 82.8 | 85.0 | 82.9 ||\n|| P. apista TF81F4 | 84.1 | 83.0 | 82.9 | * | 100.0 | 99.1 | 100.0 | 83.1 | 83.1 | 83.0 | 83.0 | 83.1 | 83.1 | 83.4 | 87.5 ||\n|| P. apista TF80G25 | 84.1 | 83.0 | 82.9 | 100.0 | * | 99.1 | 100.0 | 83.1 | 83.1 | 83.0 | 83.0 | 83.1 | 83.1 | 83.4 | 87.5 ||\n|| P. apista LMG16407 T | 84.1 | 83.0 | 82.9 | 99.1 | 99.1 | * | 99.1 | 83.0 | 83.2 | 83.0 | 83.0 | 83.0 | 83.1 | 83.4 | 87.5 ||\n|| P. apista AU2161 | 84.2 | 83.1 | 83.1 | 99.9 | 99.9 | 99.1 | * | 83.1 | 83.2 | 83.1 | 83.2 | 83.2 | 83.2 | 83.4 | 87.5 ||\n|| P. faecigallinarum DSM23572 T | 83.0 | 84.6 | 85.8 | 83.2 | 83.2 | 83.1 | 83.2 | * | 84.6 | 82.8 | 82.9 | 82.9 | 83.1 | 85.5 | 83.1 ||\n|| P. oxalativorans DSM23570 T | 82.9 | 92.3 | 84.1 | 83.0 | 83.0 | 83.0 | 83.0 | 84.1 | * | 82.6 | 82.6 | 82.5 | 82.7 | 84.9 | 82.8 ||",
    "claim": "Calculating the average ANI for all interspecies comparisons reveals a mean value of approximately 83.2%, reflecting the overall genetic diversity within the Pandoraea genus.",
    "label": "refute"
  },
  {
    "id": "training_506_6",
    "table_caption": "Table: Allelic association of two common POMC variants and BMI. Common Allele Chi-square tests Logistic regression analysis SNPs Comparisons Race freq* x2 Pobs OR (95% CI) Pemp STAT Padj OR (95% CI) rs10654394 Overweight vs. AAs 0.205/0.274 1.90 0.168 0.68 (0.40–1.18) 0.173 21.38 0.166 0.67 (0.38–1.18) (9-bp-allele) Normal weight EAs 0.043/0.052 0.21 0.646 0.80 (0.32–2.04) 0.691 20.54 0.586 0.77 (0.30–1.98) AAs+EAs 0.119/0.135 0.40 0.526 0.86 (0.55–1.36) 0.557 21.52 0.130 0.69 (0.43–1.12) Obese vs. AAs 0.324/0.274 0.85 0.357 1.27 (0.77–2.10) 0.365 1.06 0.291 1.33 (0.78–2.25) Normal weight EAs 0.081/0.052 1.13 0.289 1.59 (0.67–3.78) 0.310 0.45 0.655 1.23 (0.50–3.03) AAs+EAs 0.218/0.135 7.74 0.005 1.79 (1.18–2.71) 0.007 1.24 0.215 1.33 (0.85–2.08) Overweight + Obese vs. AAs 0.266/0.274 0.03 0.861 0.96 (0.60–1.52) 0.858 20.07 0.946 0.98 (0.61–1.58) Normal weight EAs 0.059/0.052 0.09 0.759 1.13 (0.53–2.42) 0.781 20.03 0.980 0.99 (0.44–2.20) AAs+EAs 0.165/0.135 1.57 0.210 1.27 (0.87–1.85) 0.242 20.08 0.937 0.98 (0.66–1.47) rs1042571 Overweight vs. AAs 0.141/0.106 0.96 0.328 1.40 (0.72–2.72) 0.372 0.80 0.426 1.30 (0.68–2.49) (T-allele) Normal weight EAs 0.259/0.146 9.11 0.003 2.05 (1.28–3.29) 0.003 2.80 0.005 2.17 (1.26–3.73) AAs+EAs 0.202/0.131 7.25 0.007 1.69 (1.15–2.47) 0.011 2.92 0.004 1.81 (1.22–2.69) Obese vs. AAs 0.125/0.106 0.29 0.589 1.21 (0.61–2.41) 0.609 0.29 0.769 1.11 (0.54–2.29) Normal weight EAs 0.247/0.146 6.33 0.012 1.92 (1.15–3.20) 0.013 2.37 0.018 2.00 (1.13–3.55) AAs+EAs 0.181/0.131 3.38 0.066 1.46 (0.97–2.20) 0.074 2.03 0.043 1.56 (1.02–2.40) Overweight + Obese vs. AAs 0.134/0.106 0.73 0.393 1.31 (0.71–2.40) 0.425 0.63 0.529 1.21 (0.66–2.21) Normal weight EAs 0.254/0.146 10.20 0.001 2.00 (1.30–3.06) 0.002 3.06 0.002 2.13 (1.31–3.45) AAs+EAs 0.193/0.131 6.75 0.009 1.58 (1.12–2.24) 0.011 2.91 0.004 1.71 (1.19–2.46) rs10654394: a 9-bp insertion/deletion polymorphism (2/AGCAGCGGC) in POMC exon 4; rs1042571: C/T in POMC 39UTR. AAs: African Americans; EAs: European Americans. ",
    "table_content": "|| Common SNPs | Comparisons | Race | Allele freq* | Chi-square tests | Chi-square tests | Chi-square tests | P emp | Logistic regression analysis | Logistic regression analysis | Logistic regression analysis ||\n|| Common SNPs | Comparisons | Race | Allele freq* | χ 2  |  P obs  | OR (95% CI) | P emp | STAT |  P adj  | OR (95% CI) ||\n|| (9-bp-allele) | blank | AAs+EAs | 0.165/0.135 | 1.57 | 0.210 | 1.27 (0.87–1.85) | 0.242 | −0.08 | 0.937 | 0.98 (0.66–1.47) ||\n|| rs1042571 | Overweight vs.  | AAs | 0.141/0.106 | 0.96 | 0.328 | 1.40 (0.72–2.72) | 0.372 | 0.80 | 0.426 | 1.30 (0.68–2.49) ||\n|| (T-allele) | Normal weight | EAs | 0.259/0.146 | 9.11 | 0.003 | 2.05 (1.28–3.29) | 0.003 | 2.80 | 0.005 | 2.17 (1.26–3.73) ||\n|| (T-allele) | blank | AAs+EAs | 0.202/0.131 | 7.25 | 0.007 | 1.69 (1.15–2.47) | 0.011 | 2.92 | 0.004 | 1.81 (1.22–2.69) ||\n|| (T-allele) | Obese vs.  | AAs | 0.125/0.106 | 0.29 | 0.589 | 1.21 (0.61–2.41) | 0.609 | 0.29 | 0.769 | 1.11 (0.54–2.29) ||\n|| (T-allele) | Normal weight | EAs | 0.247/0.146 | 6.33 | 0.012 | 1.92 (1.15–3.20) | 0.013 | 2.37 | 0.018 | 2.00 (1.13–3.55) ||\n|| (T-allele) | blank | AAs+EAs | 0.181/0.131 | 3.38 | 0.066 | 1.46 (0.97–2.20) | 0.074 | 2.03 | 0.043 | 1.56 (1.02–2.40) ||\n|| (T-allele) | Overweight + Obese vs.  | AAs | 0.134/0.106 | 0.73 | 0.393 | 1.31 (0.71–2.40) | 0.425 | 0.63 | 0.529 | 1.21 (0.66–2.21) ||\n|| (T-allele) | Normal weight | EAs | 0.254/0.146 | 10.20 | 0.001 | 2.00 (1.30–3.06) | 0.002 | 3.06 | 0.002 | 2.13 (1.31–3.45) ||\n|| (T-allele) | blank | AAs+EAs | 0.193/0.131 | 6.75 | 0.009 | 1.58 (1.12–2.24) | 0.011 | 2.91 | 0.004 | 1.71 (1.19–2.46) ||\n|| rs10654394 | Overweight vs.  | AAs | 0.205/0.274 | 1.90 | 0.168 | 0.68 (0.40–1.18) | 0.173 | −1.38 | 0.166 | 0.67 (0.38–1.18) ||\n|| (9-bp-allele) | Normal weight | EAs | 0.043/0.052 | 0.21 | 0.646 | 0.80 (0.32–2.04) | 0.691 | −0.54 | 0.586 | 0.77 (0.30–1.98) ||\n|| (9-bp-allele) | blank | AAs+EAs | 0.119/0.135 | 0.40 | 0.526 | 0.86 (0.55–1.36) | 0.557 | −1.52 | 0.130 | 0.69 (0.43–1.12) ||\n|| (9-bp-allele) | Obese vs.  | AAs | 0.324/0.274 | 0.85 | 0.357 | 1.27 (0.77–2.10) | 0.365 | 1.06 | 0.291 | 1.33 (0.78–2.25) ||\n|| (9-bp-allele) | Normal weight | EAs | 0.081/0.052 | 1.13 | 0.289 | 1.59 (0.67–3.78) | 0.310 | 0.45 | 0.655 | 1.23 (0.50–3.03) ||\n|| (9-bp-allele) | blank | AAs+EAs | 0.218/0.135 | 7.74 | 0.005 | 1.79 (1.18–2.71) | 0.007 | 1.24 | 0.215 | 1.33 (0.85–2.08) ||\n|| (9-bp-allele) | Overweight + Obese vs.  | AAs | 0.266/0.274 | 0.03 | 0.861 | 0.96 (0.60–1.52) | 0.858 | −0.07 | 0.946 | 0.98 (0.61–1.58) ||\n|| (9-bp-allele) | Normal weight | EAs | 0.059/0.052 | 0.09 | 0.759 | 1.13 (0.53–2.42) | 0.781 | −0.03 | 0.980 | 0.99 (0.44–2.20) ||",
    "claim": "The logistic regression analysis for rs1042571 in normal weight EAs shows an odds ratio of 2.13, which is lower than the odds ratio for rs10654394, highlighting a stronger genetic influence of rs10654394 on maintaining normal weight in EAs.",
    "label": "refute"
  },
  {
    "id": "training_947_5",
    "table_caption": "Table: Secondary ﬁndings in farmed deer from Switzerland (2003-2004) in the diﬀerent age classes. Diagnosis Abortion Neonate Fawn Juvenile Subadult Adult Total Endoparasites 14 4 3 18 39 Mild aspiration of amniotic ﬂuid 6 2 8 Beginning septicaemia 2 1 5 8 Aspiration pneumonia 1 4 5 Abomasal ulcer 3 1 1 5 Congenital malformation 3 2 5 Ruminal acidosis 3 3 Myocardial degeneration and tubulonephrosis 2 2 Parasitic dermatitis 1 1 2 Alveolar periostitis 1 1 Candidiasis (tongue) 1 1 Colitis 1 1 Purulent hepatitis 1 1 Endometrial hyperplasia 1 1 Inanition 1 1 Haemosiderosis 1 1 Omphalophlebitis 1 1 Bacterial pneumonia 1 1 Pyelonephritis 1 1 Unevenly worn cheek teeth 1 1 Teleangiectasia (liver) 1 1 Terminal thrombosis 1 1 Thymus involution 1 1 Chronic tonsillitis 1 1 ",
    "table_content": "|| Diagnosis | Abortion | Neonate | Fawn | Juvenile | Subadult | Adult | Total ||\n|| Endoparasites | blank | blank | 14 | 4 | 3 | 18 | 39 ||\n|| Alveolar periostitis | blank | blank | blank | 1 | blank | blank | 1 ||\n|| Candidiasis (tongue) | blank | blank | blank | 1 | blank | blank | 1 ||\n|| Colitis | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Purulent hepatitis | blank | blank | blank | 1 | blank | blank | 1 ||\n|| Endometrial hyperplasia | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Inanition | blank | 1 | blank | blank | blank | blank | 1 ||\n|| Haemosiderosis | blank | blank | 1 | blank | blank | blank | 1 ||\n|| Omphalophlebitis | blank | blank | 1 | blank | blank | blank | 1 ||\n|| Bacterial pneumonia | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Pyelonephritis | blank | 1 | blank | blank | blank | blank | 1 ||\n|| Mild aspiration of amniotic fluid | blank | 6 | 2 | blank | blank | blank | 8 ||\n|| Unevenly worn cheek teeth | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Teleangiectasia (liver) | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Terminal thrombosis | blank | blank | blank | 1 | blank | blank | 1 ||\n|| Thymus involution | blank | 1 | blank | blank | blank | blank | 1 ||\n|| Chronic tonsillitis | blank | blank | blank | blank | blank | 1 | 1 ||\n|| Beginning septicaemia | 2 | 1 | blank | 5 | blank | blank | 8 ||\n|| Aspiration pneumonia | blank | blank | blank | 1 | blank | 4 | 5 ||\n|| Abomasal ulcer | blank | blank | 3 | 1 | 1 | blank | 5 ||\n|| Congenital malformation | blank | 3 | 2 | blank | blank | blank | 5 ||\n|| Ruminal acidosis | blank | blank | blank | blank | blank | 3 | 3 ||\n|| Myocardial degeneration and tubulonephrosis | blank | blank | 2 | blank | blank | blank | 2 ||\n|| Parasitic dermatitis | blank | blank | blank | blank | 1 | 1 | 2 ||",
    "claim": "The distribution of abomasal ulcer cases is relatively even across the Fawn, Juvenile, and Subadult age classes, each contributing 20% to the total cases, indicating a consistent risk across these developmental stages.",
    "label": "refute"
  },
  {
    "id": "training_742_1",
    "table_caption": "Table: qRT-PCR primers sequence used in Fig 3A and S3E Fig. Primer name Sequence IL4I1 F TTGAAAGGCACACGCTCT IL4I1 R GCTGAGATAGAAGAAGCCATCC NFKB1 F CACAAGGCAGCAAATAGACG NFKB1 R GAGTTAGCAGTGAGGCACCA MAPK6 F GACTGAGCCACACAAACCTT MAPK6 R GGATGGGAGAGTGCTTCTTCT NFKBID F ACACGCTCCTTCACCTGTTT NFKBID R GGTCTTGCCCTTATGCTCAC TNFAIP3 F TGTCCTCAGTTTCGGGAGAT TNFAIP3 R GTCACCGTTCGTTTTCAGC RND1 F GATAATGTCCGTCCACTCTGC RND1 R GATTTCTGTCCTCCACTTCTTGA GAPDH F CACCCACTCCTCCACCTTT GAPDH R TTCCTCTTGTGCTCTTGCTG ZNF267 F CTTCCGTATAATCGCCTGCT ZNF267 R GGGAACACAGTGGTGGACTT HES1 F AAGTGTGCTGGGGAAGTACC HES1 R TTGATCTGGGTCATGCAGTT IRF1 F ACCGAGCAATCCAAACACTT IRF1 R AGCTCTACAACAGCCTGATTTC NFKBIA F GCAGGTTGTTCTGGAAGTTG NFKBIA R CTGGGGTTTTTCCCTCTCTT H19 F CCCATCTTGCTGACCTCAC H19 R AGACCTGGGACGTTTCTGTG NFKB1, IL4I1, MAPK6, RND1, TNFAIP3, NFKBID, and GAPDH primers were used for testing the effect of the ERK expression, shown in Fig 3A. ZNF267, HES1, IRF1, NFKBIA, and H19 primers were used for verifying the RELA recruitment ",
    "table_content": "|| Primer name | Sequence ||\n|| IL4I1 F | TTGAAAGGCACACGCTCT ||\n|| TNFAIP3 R | GTCACCGTTCGTTTTCAGC ||\n|| RND1 F | GATAATGTCCGTCCACTCTGC ||\n|| RND1 R | GATTTCTGTCCTCCACTTCTTGA ||\n|| GAPDH F | CACCCACTCCTCCACCTTT ||\n|| GAPDH R | TTCCTCTTGTGCTCTTGCTG ||\n|| ZNF267 F | CTTCCGTATAATCGCCTGCT ||\n|| ZNF267 R | GGGAACACAGTGGTGGACTT ||\n|| HES1 F | AAGTGTGCTGGGGAAGTACC ||\n|| HES1 R | TTGATCTGGGTCATGCAGTT ||\n|| IRF1 F | ACCGAGCAATCCAAACACTT ||\n|| IL4I1 R | GCTGAGATAGAAGAAGCCATCC ||\n|| IRF1 R | AGCTCTACAACAGCCTGATTTC ||\n|| NFKBIA F | GCAGGTTGTTCTGGAAGTTG ||\n|| NFKBIA R | CTGGGGTTTTTCCCTCTCTT ||\n|| H19 F | CCCATCTTGCTGACCTCAC ||\n|| H19 R | AGACCTGGGACGTTTCTGTG ||\n|| NFKB1 F | CACAAGGCAGCAAATAGACG ||\n|| NFKB1 R | GAGTTAGCAGTGAGGCACCA ||\n|| MAPK6 F | GACTGAGCCACACAAACCTT ||\n|| MAPK6 R | GGATGGGAGAGTGCTTCTTCT ||\n|| NFKBID F | ACACGCTCCTTCACCTGTTT ||\n|| NFKBID R | GGTCTTGCCCTTATGCTCAC ||\n|| TNFAIP3 F | TGTCCTCAGTTTCGGGAGAT ||",
    "claim": "The average length of the primer sequences used for testing the effect of ERK expression is 22.5 nucleotides, calculated by summing the lengths of all forward and reverse primers associated with NFKB1, IL4I1, MAPK6, RND1, TNFAIP3, NFKBID, and GAPDH, and dividing by the number of primers.",
    "label": "refute"
  },
  {
    "id": "training_1049_5",
    "table_caption": "Table: Table 1C Summarized Aerosol Optical Depth Dataset over Nzerekore for year 2010–2013. Month 2010 2011 2012 2013 Jan 0.323 0.551 0.399 0.192 Feb 0.300 0.400 0.796 0.588 Mar 1.018 1.188 0.641 0.261 Apr 0.318 0.325 0.437 May 0.257 Jun Jul 0.095 Aug Sep 0.348 0.225 Oct 0.164 0.272 0.441 Nov 0.473 0.275 0.253 Dec 0.630 0.508 0.307 Table 2A ",
    "table_content": "|| Month | 2010 | 2011 | 2012 | 2013 ||\n|| Jan | 0.323 | 0.551 | 0.399 | 0.192 ||\n|| Oct | 0.164 | 0.272 | 0.441 | blank ||\n|| Nov | blank | 0.473 | 0.275 | 0.253 ||\n|| Dec | 0.630 | 0.508 | 0.307 | blank ||\n|| Feb | 0.300 | 0.400 | 0.796 | 0.588 ||\n|| Mar | 1.018 | 1.188 | 0.641 | 0.261 ||\n|| Apr | 0.318 | 0.325 | 0.437 | blank ||\n|| May | blank | blank | 0.257 | blank ||\n|| Jun | Jun | Jun | Jun | Jun ||\n|| Jul | 0.095 | blank | blank | blank ||\n|| Aug | Aug | Aug | Aug | Aug ||\n|| Sep | 0.348 | 0.225 | blank | blank ||",
    "claim": "The AOD in February 2012 is 0.796, which is lower than in February 2011 by approximately 0.396. This indicates a notable decrease in aerosol concentration from one year to the next.",
    "label": "refute"
  },
  {
    "id": "training_1460_2",
    "table_caption": "Table: Completed suicide Chi- square P value ORa. 95% CI P value n = 95 n (%) No completed suicide n = 950 n (%) Education 21.771 < 0.0001 < 9 years (ref.) 24(25.26) 112(11.79) 1 9–12 years 35(36.84) 276(29.05) 0.52 0.25–1.07 0.078 > 12 years 17(17.89) 327(34.42) 0.17 0.07–0.41 < 0.0001 Unknown 19(20.0) 235(24.74) 0.97 0.14–6.55 0.973 Marital status 26.684 < 0.0001 Married (ref.) 52(54.74) 623(65.58) 1 Never married 17(17.89) 73(7.68) 2.51 1.10–5.75 0.029 Widowed/divorced 9 (9.47) 24(2.53) 3.43 0.99–11.87 0.052 Unknown 17(17.89) 230(24.21) 0.31 0.04–2.26 0.249 Delivery method 0.542 0.462 Vaginal delivery (ref.) 58(61.05) 616(64.84) 1 Caesarean delivery 37(38.95) 334(35.16) 0.69 0.39–1.23 0.204 Infant sex 3.190 0.074 Male (ref.) 43(45.26) 521(54.84) 1 Female 52(54.74) 429(45.16) 1.57 0.92–2.69 0.099 Low birth weight 20.879 < 0.0001 ≥ 2500 g (ref.) 79(83.16) 902(94.95) 1 < 2500 g 16(16.84) 48(5.05) 2.89 1.30–6.39 0.009 Pre-eclampsia/eclampsia 7.7389 0.005 No (ref.) 90(94.74) 937(98.63) 1 Yes 5(5.26) 13(1.37) 2.06 0.46–9.20 0.342 Anxiety 52.819 < 0.0001 No (ref.) 83(87.37) 939(98.84) 1 Yes 12(12.63) 11(1.16) 10.71 2.40–47.75 0.002 Mood disorder 102.2399 < 0.0001 No (ref.) 78(82.11) 941(99.05) 1 Yes 17(17.89) 9(0.95) 5.82 1.85–18.38 0.003 Postpartum depressive disorder 190.338 < 0.0001 No (ref.) 66(69.47) 937(98.63) 1 Yes 29(30.53) 13(1.37) 21.72 8.08–58.37 < 0.0001 Table 2. Risk of completed suicide within 1 year post partum stratified by perinatal and other associated factors (n = 1045). The OR (odds ratio) was calculated by performing conditional logistic regression ",
    "table_content": "|| blank | Completed suicide | Completed suicide | Chi- square | P value | OR a. | 95% CI | P value ||\n|| blank | n = 95 n (%) | No completed suicide n = 950 n (%) | Chi- square | P value | OR a. | 95% CI | P value ||\n|| Widowed/divorced | 9 (9.47) | 24(2.53) | blank | blank | 3.43 | 0.99–11.87 | 0.052 ||\n|| Unknown | 17(17.89) | 230(24.21) | blank | blank | 0.31 | 0.04–2.26 | 0.249 ||\n|| Delivery method | blank | blank | 0.542 | 0.462 | blank | blank | blank ||\n|| Vaginal delivery (ref.) | 58(61.05) | 616(64.84) | blank | blank | 1 | blank | blank ||\n|| Caesarean delivery | 37(38.95) | 334(35.16) | blank | blank | 0.69 | 0.39–1.23 | 0.204 ||\n|| Infant sex | blank | blank | 3.190 | 0.074 | blank | blank | blank ||\n|| Male (ref.) | 43(45.26) | 521(54.84) | blank | blank | 1 | blank | blank ||\n|| Female | 52(54.74) | 429(45.16) | blank | blank | 1.57 | 0.92–2.69 | 0.099 ||\n|| Low birth weight | blank | blank | 20.879 | <0.0001 | blank | blank | blank ||\n|| ≥2500 g (ref.) | 79(83.16) | 902(94.95) | blank | blank | 1 | blank | blank ||\n|| Education | blank | blank | 21.771 | <0.0001 | blank | blank | blank ||\n|| <2500 g | 16(16.84) | 48(5.05) | blank | blank | 2.89 | 1.30–6.39 | 0.009 ||\n|| Pre-eclampsia/eclampsia | blank | blank | 7.7389 | 0.005 | blank | blank | blank ||\n|| No (ref.) | 90(94.74) | 937(98.63) | blank | blank | 1 | blank | blank ||\n|| Yes | 5(5.26) | 13(1.37) | blank | blank | 2.06 | 0.46–9.20 | 0.342 ||\n|| Anxiety | blank | blank | 52.819 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 83(87.37) | 939(98.84) | blank | blank | 1 | blank | blank ||\n|| Yes | 12(12.63) | 11(1.16) | blank | blank | 10.71 | 2.40–47.75 | 0.002 ||\n|| Mood disorder | blank | blank | 102.2399 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 78(82.11) | 941(99.05) | blank | blank | 1 | blank | blank ||\n|| Yes | 17(17.89) | 9(0.95) | blank | blank | 5.82 | 1.85–18.38 | 0.003 ||\n|| <9 years (ref.) | 24(25.26) | 112(11.79) | blank | blank | 1 | blank | blank ||\n|| Postpartum depressive disorder | blank | blank | 190.338 | <0.0001 | blank | blank | blank ||\n|| No (ref.) | 66(69.47) | 937(98.63) | blank | blank | 1 | blank | blank ||\n|| Yes | 29(30.53) | 13(1.37) | blank | blank | 21.72 | 8.08–58.37 | <0.0001 ||\n|| 9–12 years | 35(36.84) | 276(29.05) | blank | blank | 0.52 | 0.25–1.07 | 0.078 ||\n|| > 12 years | 17(17.89) | 327(34.42) | blank | blank | 0.17 | 0.07–0.41 | <0.0001 ||\n|| Unknown | 19(20.0) | 235(24.74) | blank | blank | 0.97 | 0.14–6.55 | 0.973 ||\n|| Marital status | blank | blank | 26.684 | <0.0001 | blank | blank | blank ||\n|| Married (ref.) | 52(54.74) | 623(65.58) | blank | blank | 1 | blank | blank ||\n|| Never married | 17(17.89) | 73(7.68) | blank | blank | 2.51 | 1.10–5.75 | 0.029 ||",
    "claim": "Being widowed or divorced is associated with a lower risk of completed suicide compared to being married. The odds ratio is 0.43, suggesting a less than half-fold decrease in risk, with a p-value close to significance at 0.052.",
    "label": "refute"
  },
  {
    "id": "training_510_2",
    "table_caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A N3—H3A···N2i 0.86 2.14 2.992 (4) 170 N3—H3B···O3ii 0.86 2.08 2.886 (4) 157 Symmetry codes: (i) −x+2, −y+1, −z+1; (ii) x+1/2, −y+3/2, z+1/2. ",
    "table_content": "|| D —H··· A | D —H | H··· A | D ··· A | D —H··· A ||\n|| N3—H3A···N2 i | 0.86 | 2.14 | 2.992 (4) | 170 ||\n|| N3—H3B···O3 ii | 0.86 | 2.08 | 2.886 (4) | 157 ||",
    "claim": "The H···A distance for N3—H3B···O3 is longer than that for N3—H3A···N2, suggesting a stronger hydrogen bond in the former due to the inverse relationship between bond strength and distance, as per the principles of hydrogen bonding.",
    "label": "refute"
  },
  {
    "id": "training_603_1",
    "table_caption": "Table: Table 1 Surveillance cultures for yeast species in pediatric cancer patients Sample site No. positive/No. samples (%) Oropharyngeal 53/294 (18) Nasal 6/600 (1) Rectal 10/28 (35.7) Groin 5/50 (10) Ear 1/54 (1.9) Axilla 0/49 (0) Total 75/1075 (7) ",
    "table_content": "|| Sample site | No. positive/No. samples (%) ||\n|| Oropharyngeal | 53/294 (18) ||\n|| Nasal | 6/600 (1) ||\n|| Rectal | 10/28 (35.7) ||\n|| Groin | 5/50 (10) ||\n|| Ear | 1/54 (1.9) ||\n|| Axilla | 0/49 (0) ||\n|| Total | 75/1075 (7) ||",
    "claim": "The rectal site exhibits a prevalence rate of yeast species that is 3.57 times higher than the nasal site, indicating a significant variation in colonization rates across different anatomical locations.",
    "label": "refute"
  },
  {
    "id": "training_778_1",
    "table_caption": "Table: Table 1 The 1397 samples from nine ethnic groups Index Abbreviation Full Name Training Sample Size Independent Test Sample Size 1 ASW African ancestry in Southwest USA 74 13 2 CEU Utah residents with Northern and Western European ancestry from the CEPH collection 140 25 3 CHB/CHD/JPT Han Chinese in Beijing, China/ Chinese in Metropolitan Denver, Colorado/Japanese in Tokyo, Japan 305 54 4 GIH Gujarati Indians in Houston, Texas 86 15 5 LWK Luhya in Webuye, Kenya 94 16 6 MEX Mexican ancestry in Los Angeles, California 73 13 7 MKK Maasai in Kinyawa, Kenya 156 28 8 TSI Tuscan in Italy 87 15 9 YRI Yoruban in Ibadan, Nigeria (West Africa) 173 30 Total 1188 209 ",
    "table_content": "|| Index | Abbreviation | Full Name | Training Sample Size | Independent Test Sample Size ||\n|| 1 | ASW | African ancestry in Southwest USA | 74 | 13 ||\n|| Total | Total | Total | 1188 | 209 ||\n|| 2 | CEU | Utah residents with Northern and Western European ancestry from the CEPH collection | 140 | 25 ||\n|| 3 | CHB/CHD/JPT | Han Chinese in Beijing, China/ Chinese in Metropolitan Denver, Colorado/Japanese in Tokyo, Japan | 305 | 54 ||\n|| 4 | GIH | Gujarati Indians in Houston, Texas | 86 | 15 ||\n|| 5 | LWK | Luhya in Webuye, Kenya | 94 | 16 ||\n|| 6 | MEX | Mexican ancestry in Los Angeles, California | 73 | 13 ||\n|| 7 | MKK | Maasai in Kinyawa, Kenya | 156 | 28 ||\n|| 8 | TSI | Tuscan in Italy | 87 | 15 ||\n|| 9 | YRI | Yoruban in Ibadan, Nigeria (West Africa) | 173 | 30 ||",
    "claim": "The ratio of training to test samples for the CHB/CHD/JPT group is approximately 5.65, which is the highest among all groups, indicating a larger emphasis on training data relative to test data compared to other groups.",
    "label": "refute"
  },
  {
    "id": "training_778_1",
    "table_caption": "Table: Table 1 The 1397 samples from nine ethnic groups Index Abbreviation Full Name Training Sample Size Independent Test Sample Size 1 ASW African ancestry in Southwest USA 74 13 2 CEU Utah residents with Northern and Western European ancestry from the CEPH collection 140 25 3 CHB/CHD/JPT Han Chinese in Beijing, China/ Chinese in Metropolitan Denver, Colorado/Japanese in Tokyo, Japan 305 54 4 GIH Gujarati Indians in Houston, Texas 86 15 5 LWK Luhya in Webuye, Kenya 94 16 6 MEX Mexican ancestry in Los Angeles, California 73 13 7 MKK Maasai in Kinyawa, Kenya 156 28 8 TSI Tuscan in Italy 87 15 9 YRI Yoruban in Ibadan, Nigeria (West Africa) 173 30 Total 1188 209 ",
    "table_content": "|| Index | Abbreviation | Full Name | Training Sample Size | Independent Test Sample Size ||\n|| 1 | ASW | African ancestry in Southwest USA | 74 | 13 ||\n|| Total | Total | Total | 1188 | 209 ||\n|| 2 | CEU | Utah residents with Northern and Western European ancestry from the CEPH collection | 140 | 25 ||\n|| 3 | CHB/CHD/JPT | Han Chinese in Beijing, China/ Chinese in Metropolitan Denver, Colorado/Japanese in Tokyo, Japan | 305 | 54 ||\n|| 4 | GIH | Gujarati Indians in Houston, Texas | 86 | 15 ||\n|| 5 | LWK | Luhya in Webuye, Kenya | 94 | 16 ||\n|| 6 | MEX | Mexican ancestry in Los Angeles, California | 73 | 13 ||\n|| 7 | MKK | Maasai in Kinyawa, Kenya | 156 | 28 ||\n|| 8 | TSI | Tuscan in Italy | 87 | 15 ||\n|| 9 | YRI | Yoruban in Ibadan, Nigeria (West Africa) | 173 | 30 ||",
    "claim": "The ratio of training to test samples for the ASW group is approximately 5.65, which is the highest among all groups, indicating a larger emphasis on training data relative to test data compared to other groups.",
    "label": "refute"
  },
  {
    "id": "training_118_2",
    "table_caption": "Table: Table 2 Lung mechanics, hemodynamics, gas exchange, acid-base status, and metabolic parameters Vehicle HAM1101 p value Hemoglobin content (mg·mL−1) Start 90 (87, 96) 98 (95, 105) 0.074 End 70 (66, 72) 69 (66, 74) 0.806 Heart rate (beats·min−1) Start 494 (485, 515) 430 (406, 480) 0.248 End 426 (406, 445) 391 (349,430) 0.290 Mean arterial pressure (mmHg) Start 69 (65, 71) 69 (66, 76) 0.382 End 64 (59, 69) 67 (66, 72) 0.441 Thoracopulmonary compliance (μL·cm H2O−1) Start 0.10 (0.09, 0.10) 0.10 (0.09, 0.11) 0.382 End 0.09 (0.08, 0.10) 0.10 (0.08, 0.11) 0.427 Arterial PO2 (mmHg) Start 314 (293, 330) 340 (321, 350) 0.254 End 309 (287, 326) 301 (287, 319) 0.838 Arterial PCO2 (mmHg) Start 31 (27, 33) 31 (29, 36) 0.879 End 34 (33, 36) 31 (28, 33) 0.072 Arterial pH Start 7.33 (7.30, 7.35) 7.36 (7.32, 7.38) 0.569 End 7.38 (7.31, 7.43) 7.43 (7.39, 7.46) 0.253 Arterial base excess (mmol·mL−1) Start −9.0 (−10.3, −7.7) −6.8 (−8.3, −6.2) 0.403 End −5.7 (−7.1, −1.7) −3.9 (−4.2, −3.3) 0.838 Arterial lactate (mmol·mL−1) Start n.d. n.d. n.d. End 2.0 (1.7, 2.2) 1.6 (1.5, 1.8) 0.025 Arterial glucose (mg·dL−1) Start 113 (110, 117) 115 (106, 123) 0.540 End 110 (96, 117) 111 (109, 115) 0.653 CO2 production rate (μL·g−1·min−1) Start 26 (24, 28) 24 (23, 25) 0.082 End 23 (21, 26) 23 (22, 25) 0.596 Glucose production rate (mg·g−1·h−1) Start 0.37 (0.35, 0.41) 0.34 (0.31, 0.36) 0.178 End 0.38 (0.35, 0.39) 0.33 (0.31, 0.39) 0.153 Glucose oxidation rate (% isotope infusion) Start 58 (55, 62) 55 (50, 59) 0.224 End 57 (54, 60) 62 (58, 67) 0.047 The data are for the vehicle-treated (n = 11) and HAM1101-treated (n = 9) animals at the start and the end of the 5-h observation period; n.d., not determined. All data are median (quartiles). ",
    "table_content": "|| blank | blank | Vehicle | HAM1101 |  p value ||\n|| Hemoglobin content (mg·mL −1 ) | Start | 90 (87, 96) | 98 (95, 105) | 0.074 ||\n|| Arterial PO 2 (mmHg) | End | 309 (287, 326) | 301 (287, 319) | 0.838 ||\n|| Arterial PCO 2 (mmHg) | Start | 31 (27, 33) | 31 (29, 36) | 0.879 ||\n|| Arterial PCO 2 (mmHg) | End | 34 (33, 36) | 31 (28, 33) | 0.072 ||\n|| Arterial pH | Start | 7.33 (7.30, 7.35) | 7.36 (7.32, 7.38) | 0.569 ||\n|| Arterial pH | End | 7.38 (7.31, 7.43) | 7.43 (7.39, 7.46) | 0.253 ||\n|| Arterial base excess (mmol·mL −1 ) | Start | −9.0 (−10.3, −7.7) | −6.8 (−8.3, −6.2) | 0.403 ||\n|| Arterial base excess (mmol·mL −1 ) | End | −5.7 (−7.1, −1.7) | −3.9 (−4.2, −3.3) | 0.838 ||\n|| Arterial lactate (mmol·mL −1 ) | Start | n.d. | n.d. | n.d. ||\n|| Arterial lactate (mmol·mL −1 ) | End | 2.0 (1.7, 2.2) | 1.6 (1.5, 1.8) | 0.025 ||\n|| Arterial glucose (mg·dL −1 ) | Start | 113 (110, 117) | 115 (106, 123) | 0.540 ||\n|| Hemoglobin content (mg·mL −1 ) | End | 70 (66, 72) | 69 (66, 74) | 0.806 ||\n|| Arterial glucose (mg·dL −1 ) | End | 110 (96, 117) | 111 (109, 115) | 0.653 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | Start | 26 (24, 28) | 24 (23, 25) | 0.082 ||\n|| CO 2 production rate (μL·g −1 ·min −1 ) | End | 23 (21, 26) | 23 (22, 25) | 0.596 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | Start | 0.37 (0.35, 0.41) | 0.34 (0.31, 0.36) | 0.178 ||\n|| Glucose production rate (mg·g −1 ·h −1 ) | End | 0.38 (0.35, 0.39) | 0.33 (0.31, 0.39) | 0.153 ||\n|| Glucose oxidation rate (% isotope infusion) | Start | 58 (55, 62) | 55 (50, 59) | 0.224 ||\n|| Glucose oxidation rate (% isotope infusion) | End | 57 (54, 60) | 62 (58, 67) | 0.047 ||\n|| Heart rate (beats·min −1 ) | Start | 494 (485, 515) | 430 (406, 480) | 0.248 ||\n|| Heart rate (beats·min −1 ) | End | 426 (406, 445) | 391 (349,430) | 0.290 ||\n|| Mean arterial pressure (mmHg) | Start | 69 (65, 71) | 69 (66, 76) | 0.382 ||\n|| Mean arterial pressure (mmHg) | End | 64 (59, 69) | 67 (66, 72) | 0.441 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | Start | 0.10 (0.09, 0.10) | 0.10 (0.09, 0.11) | 0.382 ||\n|| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | End | 0.09 (0.08, 0.10) | 0.10 (0.08, 0.11) | 0.427 ||\n|| Arterial PO 2 (mmHg) | Start | 314 (293, 330) | 340 (321, 350) | 0.254 ||",
    "claim": "The heart rate in the vehicle group decreased by approximately 13.8% from start to end, whereas in the HAM1101 group, the reduction was approximately 9.1%. This indicates a more pronounced decrease in heart rate in the HAM1101 group compared to the vehicle group.",
    "label": "refute"
  },
  {
    "id": "training_194_2",
    "table_caption": "Table: Mean, median, 95% CI, interquartile interval and P value of clinical score, IFAT titer, TP (g/dl), IgG (%), creatinine and urea (mg/dl), and UP/C in 20 dogs before and after 28 days of therapy. Parameter D0 D28 p value Clinical score NV: 0 Mean (95% CI) 5.1 (3.1-7.09) 2.6 (1.52-3.77) p=0.0046 IFAT titer NV: Titer<1:80 (min-max) 160-1280 (320-640) 80-1280 (240-640) p=0.2661 TP NV: 6-8 g/dl Mean (95% CI) 8 (7.55-8.45) 7.6 (7.24-7.96) p=0.0730 IgG NV: 5.3-9.9% Mean (95% CI) 21.36 (16.89-25.83) 19.06 (14.75-23.36) p=0.1009 Creatinine NV<1.2 mg/dl (Median I-III interquartile interval) 0.91 (0.8-1.05) 0.91 (0.7-1.1) p=0.8077 Urea NV: 15-45 mg/dl (Median I-III interquartile interval) 40.75 (29-45.5) 38.55 (29.5-44) p=0.4171 UP/C NP: <0.2 BP: 0.2-0.5 P: >0.5 (Median I-III interquartile interval) 0.35 (0.1-0.7) 0.26 (0.1-0.4) p=0.016 NV: Normal value, NP: Non-proteinuric, BP: Borderline proteinuric, P: Proteinuric, CI: Confidence interval 95%, TP: Total protein, IFAT: Indirect fluorescent antibody test, UP/C: Urine protein creatinine, IgG: Gamma globulin ",
    "table_content": "|| Parameter | D0 | D28 | p value ||\n|| Clinical score | Clinical score | Clinical score | Clinical score ||\n|| NV<1.2 mg/dl (Median IIII interquartile interval) | 0.91 (0.8-1.05) | 0.91 (0.7-1.1) | p=0.8077 ||\n|| Urea | Urea | Urea | Urea ||\n|| NV: 1545 mg/dl (Median IIII interquartile interval) | 40.75 (29-45.5) | 38.55 (29.5-44) | p=0.4171 ||\n|| UP/C | UP/C | UP/C | UP/C ||\n|| NP: <0.2 BP: 0.20.5 P: >0.5 (Median I-III interquartile interval) | 0.35 (0.1-0.7) | 0.26 (0.1-0.4) | p=0.016 ||\n|| NV: 0 Mean (95% CI) | 5.1 (3.1-7.09) | 2.6 (1.52-3.77) | p=0.0046 ||\n|| IFAT titer | IFAT titer | IFAT titer | IFAT titer ||\n|| NV: Titer<1:80 (minmax) | 160-1280 (320-640) | 80-1280 (240-640) | p=0.2661 ||\n|| TP | TP | TP | TP ||\n|| NV: 68 g/dl Mean (95% CI) | 8 (7.55-8.45) | 7.6 (7.24-7.96) | p=0.0730 ||\n|| IgG | IgG | IgG | IgG ||\n|| NV: 5.39.9% Mean (95% CI) | 21.36 (16.89-25.83) | 19.06 (14.75-23.36) | p=0.1009 ||\n|| Creatinine | Creatinine | Creatinine | Creatinine ||",
    "claim": "The range of IFAT titers changed significantly from D0 to D28, with a non-significant p-value of 0.2661, suggesting that the therapy significantly affected the antibody titers within the observed range.",
    "label": "refute"
  },
  {
    "id": "training_1085_2",
    "table_caption": "Table: Systemic malignancies associated with microangiopathic haemolytic anaemia [8, 9, 11, 13–21]. Solid tumours: Gastrointestinal malignancies Gastric cancer Colon cancer Carcinoma of anal canal (squamous cell) Metastatic appendiceal carcinoma Breast cancer Lung cancer Adenocarcinoma Squamous cell carcinoma Small cell lung cancer Genitourinary malignancies Prostate cancer Ovarian cancer Renal cell carcinoma Seminal vesicle tumour Hepatobiliary cancers Hepatocellular carcinoma Pancreatic cancer Cholangiocarcinoma Endocrine Multiple endocrine neoplasia type 1 Pheochromocytoma Neuroendocrine tumour Prolactin producing pituitary adenoma Others Kaposi sarcoma Carcinoma of unknown origin Hematologic malignancies: Non-Hodgkin lymphoma Acute lymphoblastic leukaemia Myelodysplastic syndrome Hodgkin lymphoma Multiple myeloma chemotherapy: ",
    "table_content": "|| Solid tumours: | Solid tumours: ||\n|| Gastrointestinal malignancies | Gastric cancer ||\n|| Genitourinary malignancies | Ovarian cancer ||\n|| Genitourinary malignancies | Renal cell carcinoma ||\n|| Genitourinary malignancies | Seminal vesicle tumour ||\n|| Hepatobiliary cancers | Hepatocellular carcinoma ||\n|| Hepatobiliary cancers | Pancreatic cancer ||\n|| Hepatobiliary cancers | Cholangiocarcinoma ||\n|| Endocrine | Multiple endocrine neoplasia type 1 ||\n|| Endocrine | Pheochromocytoma ||\n|| Endocrine | Neuroendocrine tumour ||\n|| Endocrine | Prolactin producing pituitary adenoma ||\n|| blank | Colon cancer ||\n|| Others | Kaposi sarcoma ||\n|| Others | Carcinoma of unknown origin ||\n|| Hematologic malignancies: | Hematologic malignancies: ||\n|| Non-Hodgkin lymphoma | Non-Hodgkin lymphoma ||\n|| Acute lymphoblastic leukaemia | Acute lymphoblastic leukaemia ||\n|| Myelodysplastic syndrome | Myelodysplastic syndrome ||\n|| Hodgkin lymphoma | Hodgkin lymphoma ||\n|| Multiple myeloma | blank ||\n|| blank | Carcinoma of anal canal (squamous cell) ||\n|| blank | Metastatic appendiceal carcinoma ||\n|| Breast cancer | Breast cancer ||\n|| Lung cancer | Adenocarcinoma ||\n|| Lung cancer | Squamous cell carcinoma ||\n|| Lung cancer | Small cell lung cancer ||\n|| Genitourinary malignancies | Prostate cancer ||",
    "claim": "Within the genitourinary malignancies category, there is a notable representation of four distinct cancer types, which is the highest among the solid tumour subcategories. This implies a diverse range of genitourinary cancers associated with microangiopathic haemolytic anaemia.",
    "label": "refute"
  },
  {
    "id": "training_75_3",
    "table_caption": "Table: The interpretation of Fig. 5C and 5F is as follows. The lin- – . – 2 2 1 Density vectors linear groups Low nitrate medium High nitrate medium Low NUpE 0 (black) 1 (red/magenta) High NUpE 2 (green) 3 (blue) ",
    "table_content": "|| blank | Low nitrate medium | High nitrate medium ||\n|| Low NUpE | 0 (black) | 1 (red/magenta) ||\n|| High NUpE | 2 (green) | 3 (blue) ||",
    "claim": "Analyzing the data reveals a quadratic trend in NUpE improvement as nitrate levels increase, suggesting a nonlinear relationship that peaks at high nitrate medium with high NUpE.",
    "label": "refute"
  },
  {
    "id": "training_294_3",
    "table_caption": "Table: Selected genes for the case study Genes Ensable gene ID chr 1 VIT 04s0008g05750 4 2 VIT 09s0018g00240 9 3 VIT 02s0025g01280 2 4 VIT 08s0058g01390 8 5 VIT 13s0067g03140 13 6 VIT 15s0046g01140 15 7 VIT 16s0050g02510 16 ",
    "table_content": "|| Genes | Ensable gene ID | chr ||\n|| 1 | VIT 04s0008g05750 | 4 ||\n|| 2 | VIT 09s0018g00240 | 9 ||\n|| 3 | VIT 02s0025g01280 | 2 ||\n|| 4 | VIT 08s0058g01390 | 8 ||\n|| 5 | VIT 13s0067g03140 | 13 ||\n|| 6 | VIT 15s0046g01140 | 15 ||\n|| 7 | VIT 16s0050g02510 | 16 ||",
    "claim": "The Ensembl gene IDs follow a pattern where the first two digits after \"VIT\" do not correspond to the chromosome number, indicating a naming convention that does not align with the chromosome location.",
    "label": "refute"
  },
  {
    "id": "training_456_3",
    "table_caption": "Table: Crystal data C21H22Cl2N4S Z = 2 Mr = 433.40 F000 = 452 Triclinic, P1 Dx = 1.381 Mg m−3 Hall symbol: -P 1 Melting point = 438–440 K a = 8.6190 (2) Å Mo Kα radiation λ = 0.71073 Å b = 9.4441 (2) Å Cell parameters from 6032 reflections c = 14.4244 (4) Å θ = 1.5–30.0º α = 104.669 (2)º µ = 0.43 mm−1 β = 95.492 (2)º T = 100.0 (1) K γ = 110.418 (1)º Block, colourless V = 1042.33 (5) Å3 0.29 × 0.20 × 0.16 mm ",
    "table_content": "|| C 21 H 22 Cl 2 N 4 S | Z = 2 ||\n|| M r = 433.40 | F 000 = 452 ||\n|| V = 1042.33 (5)  Å 3 | 0.29 × 0.20 × 0.16 mm ||\n|| Triclinic, P 1 | D x = 1.381 Mg m − 3 ||\n|| Hall symbol:  -P 1 | Melting point = 438–440 K ||\n|| a = 8.6190 (2) Å | Mo K α radiation λ = 0.71073 Å ||\n|| b = 9.4441 (2) Å | Cell parameters from 6032 reflections ||\n|| c = 14.4244 (4) Å | θ = 1.5–30.0º ||\n|| α = 104.669 (2)º | µ = 0.43 mm − 1 ||\n|| β = 95.492 (2)º | T = 100.0 (1) K ||\n|| γ = 110.418 (1)º | Block, colourless ||",
    "claim": "The angular parameters (α, β, γ) deviate from 90º, confirming the triclinic symmetry. The deviation from orthogonality, calculated as the sum of the absolute differences from 90º, is 20.579º, which is consistent with the low symmetry and high degree of anisotropy in the crystal structure.",
    "label": "refute"
  },
  {
    "id": "training_1000_5",
    "table_caption": "Table: obtained from replication study (METSIM Study), and meta-analysis of both cohorts. 1st stage (EUGENE2) 2nd stage (METSIM) Meta-analysis Ref. allele Other allele Ref. allele frequency (1st stage) Ref. allele frequency (2nd stage) N b P N b P B P Cholestanol ABCG8 rs4299376 C A 0.19 0.15 271 0.037 5.6E-05 734 0.039 1.2E-13 0.038 1.1E-17 ABCG8 rs6544713 A G 0.19 0.15 267 0.036 1.7E-04 738 0.038 1.8E-12 0.037 9.9E-16 ABCG5/8 rs6756629 A G 0.10 0.10 268 20.053 7.4E-06 738 -0.043 8.2E-10 20.046 2.2E-14 Campesterol ABCG8 rs6544713 A G 0.19 0.15 267 0.108 3.5E-08 738 0.075 2.1E-10 0.084 6.4E-17 ABCG8 rs4299376 C A 0.19 0.15 271 0.105 3.9E-08 734 0.075 2.5E-10 0.083 7.3E-17 ABCG5/8 rs6756629 A G 0.10 0.10 268 20.136 1.6E-08 738 20.089 1.1E-08 20.102 2.5E-15 Sitosterol ABCG8 rs6544713 A G 0.19 0.15 267 0.104 1.8E-08 738 0.081 4.6E-12 0.088 3.7E-19 ABCG8 rs4299376 C A 0.19 0.15 271 0.101 1.9E-08 734 0.081 5.6E-12 0.087 4.3E-19 ABCG5/8 rs6756629 A G 0.10 0.10 268 20.139 1.0E-09 738 20.094 1.3E-09 20.108 1.8E-17 Avenasterol ABCG8 rs6544713 A G 0.19 0.15 267 0.055 2.5E-05 738 0.048 3.7E-11 0.050 2.5E-15 ABCG8 rs4299376 C A 0.19 0.15 271 0.054 2.5E-05 734 0.047 7.0E-11 0.049 4.7E-15 ABCG5/8 rs6756629 A G 0.10 0.10 268 20.090 1.8E-08 738 20.045 3.1E-06 20.057 4.8E-12 Only results from meta-analysis indicating a genome-wide significance (P,561028) are shown. b = Regression coefficient. Individuals with previously diagnosed diabetes and on statin or ezetimibe treatment are excluded. P values adjusted for age, gender, and BMI. ",
    "table_content": "|| blank | blank | Ref. allele | Other allele | Ref. allele frequency(1st stage) | Ref. allele frequency(2nd stage) | 1 st stage (EUGENE2) | 1 st stage (EUGENE2) | 1 st stage (EUGENE2) | 2 nd stage (METSIM) | 2 nd stage (METSIM) | 2 nd stage (METSIM) | Meta-analysis | Meta-analysis ||\n|| blank | blank | Ref. allele | Other allele | Ref. allele frequency(1st stage) | Ref. allele frequency(2nd stage) | N | β |  P  | N | β |  P  | B |  P  ||\n||  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  |  Sitosterol  ||\n||  ABCG8  | rs6544713 | A | G | 0.19 | 0.15 | 267 | 0.104 | 1.8E-08 | 738 | 0.081 | 4.6E-12 | 0.088 | 3.7E-19 ||\n||  ABCG8  | rs4299376 | C | A | 0.19 | 0.15 | 271 | 0.101 | 1.9E-08 | 734 | 0.081 | 5.6E-12 | 0.087 | 4.3E-19 ||\n||  ABCG5/8  | rs6756629 | A | G | 0.10 | 0.10 | 268 | −0.139 | 1.0E-09 | 738 | −0.094 | 1.3E-09 | −0.108 | 1.8E-17 ||\n||  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  |  Avenasterol  ||\n||  ABCG8  | rs6544713 | A | G | 0.19 | 0.15 | 267 | 0.055 | 2.5E-05 | 738 | 0.048 | 3.7E-11 | 0.050 | 2.5E-15 ||\n||  ABCG8  | rs4299376 | C | A | 0.19 | 0.15 | 271 | 0.054 | 2.5E-05 | 734 | 0.047 | 7.0E-11 | 0.049 | 4.7E-15 ||\n||  ABCG5/8  | rs6756629 | A | G | 0.10 | 0.10 | 268 | −0.090 | 1.8E-08 | 738 | −0.045 | 3.1E-06 | −0.057 | 4.8E-12 ||\n||  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  |  Cholestanol  ||\n||  ABCG8  | rs4299376 | C | A | 0.19 | 0.15 | 271 | 0.037 | 5.6E-05 | 734 | 0.039 | 1.2E-13 | 0.038 | 1.1E-17 ||\n||  ABCG8  | rs6544713 | A | G | 0.19 | 0.15 | 267 | 0.036 | 1.7E-04 | 738 | 0.038 | 1.8E-12 | 0.037 | 9.9E-16 ||\n||  ABCG5/8  | rs6756629 | A | G | 0.10 | 0.10 | 268 | −0.053 | 7.4E-06 | 738 | -0.043 | 8.2E-10 | −0.046 | 2.2E-14 ||\n||  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  |  Campesterol  ||\n||  ABCG8  | rs6544713 | A | G | 0.19 | 0.15 | 267 | 0.108 | 3.5E-08 | 738 | 0.075 | 2.1E-10 | 0.084 | 6.4E-17 ||\n||  ABCG8  | rs4299376 | C | A | 0.19 | 0.15 | 271 | 0.105 | 3.9E-08 | 734 | 0.075 | 2.5E-10 | 0.083 | 7.3E-17 ||\n||  ABCG5/8  | rs6756629 | A | G | 0.10 | 0.10 | 268 | −0.136 | 1.6E-08 | 738 | −0.089 | 1.1E-08 | −0.102 | 2.5E-15 ||",
    "claim": "The genetic variant ABCG5/8 rs6756629 shows a negative regression coefficient across all sterols, with the most pronounced effect on Campesterol. The meta-analysis coefficient for Campesterol is the most negative, indicating that this variant has the strongest inverse effect on Campesterol levels compared to other sterols.",
    "label": "refute"
  },
  {
    "id": "training_1032_1",
    "table_caption": "Table: End-points for clinical outcomes at baseline, 4 weeks and 12 weeks after botulinum toxin treatment. Scale Subscale Time point ProsigneH (n = 57) Mean (SD) BotoxH (n = 57) Mean (SD) Between-group difference in end-point (95% CI) Effect size (95% CI) MAS Baseline 1.93 (0.5) 1.84 (0.46) 0.09 (20.06 to 0.23) 0.18 (20.19 to 0.54) 4 weeks 1.28 (0.41) 1.42 (0.48) 20.14 (20.26 to 20.01) 20.31 (20.68 to 0.06) 12 weeks 1.52 (0.39) 1.59 (0.53) 20.07 (20.21 to 0.07) 20.13 (20.49 to 0.24) FIM Baseline 103.20 (23) 102.57 (23.67) 0.63 (21.43 to 2.68) 0.03 (20.65 to 0.7) 4 weeks 102.2 (29.5) 105.5 (16.2) 23.3 (22.1 to 4.5) 20.14 (20.76 to 0.48) 12 weeks 103.92 (22.85) 103.07 (23.36) 0.85 (21.39 to 3.09) 0.04 (20.64 to 0.71) PEDI Self-care Baseline 56.86 (12.89) 58.40 (13.31) 21.54 (25.09 to 2) 20.12 (20.56 to 0.32) 4 weeks 58.9 (14.3) 62.4 (12.1) 23.5 (22.9 to 1.2) 20.26 (21.21 to 0.73) 12 weeks 61.30 (13.55) 61.38 (13.74) 20.08 (22.60 to 2.43) 20.01 (20.44 to 0.43) Mobility Baseline 49.17 (15.07) 51.75 (14.29) 22.58 (25.19 to 0.02) 20.18 (20.61 to 0.27) 4 weeks 51.8 (16.9) 52.3 (8.5) 20.5 (20.8 to 1.9) 20.04 (21.00 to 0.93) 12 weeks 53.60 (14.07) 51.61 (14.52) 1.98 (0.42 to 3.55) 0.14 (20.30 to 0.58) Social Function Baseline 57.93 (11.72) 57.14 (10.74) 0.78 (22.34 to 3.91) 0.07 (20.37 to 0.51) 4 weeks 58.1 (11.3) 61.5 (10.7) 23.4 (23.7 to 0.5) 20.31 (21.26 to 0.68) 12 weeks 61.14 (12.55) 61.93 (11.43) 20.78 (23.51 to 1.94) 20.07 (20.50 to 0.37) MAS: Modified Ashworth Scale; FIM: Functional Independence Measure; PEDI: Pediatric Evaluation of Disability Inventory; SD: Standard Deviation; CI: Confidence Interval. ",
    "table_content": "|| Scale | Subscale | Time point | Prosigne® (n = 57) Mean (SD) | Botox® (n = 57) Mean (SD) | Between-group difference in end-point (95% CI) | Effect size (95% CI) ||\n|| MAS | MAS | MAS | MAS | MAS | MAS | MAS ||\n|| blank | Self-care | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 56.86 (12.89) | 58.40 (13.31) | −1.54 (−5.09 to 2) | −0.12 (−0.56 to 0.32) ||\n|| blank | blank | 4 weeks | 58.9 (14.3) | 62.4 (12.1) | −3.5 (−2.9 to 1.2) | −0.26 (−1.21 to 0.73) ||\n|| blank | blank | 12 weeks | 61.30 (13.55) | 61.38 (13.74) | −0.08 (−2.60 to 2.43) | −0.01 (−0.44 to 0.43) ||\n|| blank | Mobility | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 49.17 (15.07) | 51.75 (14.29) | −2.58 (−5.19 to 0.02) | −0.18 (−0.61 to 0.27) ||\n|| blank | blank | 4 weeks | 51.8 (16.9) | 52.3 (8.5) | −0.5 (−0.8 to 1.9) | −0.04 (−1.00 to 0.93) ||\n|| blank | blank | 12 weeks | 53.60 (14.07) | 51.61 (14.52) | 1.98 (0.42 to 3.55) | 0.14 (−0.30 to 0.58) ||\n|| blank | Social Function | blank | blank | blank | blank | blank ||\n|| blank | blank | Baseline | 57.93 (11.72) | 57.14 (10.74) | 0.78 (−2.34 to 3.91) | 0.07 (−0.37 to 0.51) ||\n|| blank | blank | Baseline | 1.93 (0.5) | 1.84 (0.46) | 0.09 (−0.06 to 0.23) | 0.18 (−0.19 to 0.54) ||\n|| blank | blank | 4 weeks | 58.1 (11.3) | 61.5 (10.7) | −3.4 (−3.7 to 0.5) | −0.31 (−1.26 to 0.68) ||\n|| blank | blank | 12 weeks | 61.14 (12.55) | 61.93 (11.43) | −0.78 (−3.51 to 1.94) | −0.07 (−0.50 to 0.37) ||\n|| blank | blank | 4 weeks | 1.28 (0.41) | 1.42 (0.48) | −0.14 (−0.26 to −0.01) | −0.31 (−0.68 to 0.06) ||\n|| blank | blank | 12 weeks | 1.52 (0.39) | 1.59 (0.53) | −0.07 (−0.21 to 0.07) | −0.13 (−0.49 to 0.24) ||\n|| FIM | FIM | FIM | FIM | FIM | FIM | FIM ||\n|| blank | blank | Baseline | 103.20 (23) | 102.57 (23.67) | 0.63 (−1.43 to 2.68) | 0.03 (−0.65 to 0.7) ||\n|| blank | blank | 4 weeks | 102.2 (29.5) | 105.5 (16.2) | −3.3 (−2.1 to 4.5) | −0.14 (−0.76 to 0.48) ||\n|| blank | blank | 12 weeks | 103.92 (22.85) | 103.07 (23.36) | 0.85 (−1.39 to 3.09) | 0.04 (−0.64 to 0.71) ||\n|| PEDI | PEDI | PEDI | PEDI | PEDI | PEDI | PEDI ||",
    "claim": "The MAS scores for both Prosigne® and Botox® groups show a decrease from baseline to 4 weeks, followed by an increase at 12 weeks. The overall reduction in MAS scores from baseline to 12 weeks is greater for the Botox® group, indicating a more sustained reduction in muscle spasticity over time.",
    "label": "refute"
  },
  {
    "id": "training_693_3",
    "table_caption": "Table: Treatment histories of 101 cases of metachronous MPMTs. Treatment First primary cancer N(ratio) Surgery 27(26.7%) Chemotherapy 57(56.4%) Radiotherapy 7(7.0%) Chemo-radiotherapy 10(9.9%) doi:10.1371/journal.pone.0125754.t003 ",
    "table_content": "|| Treatment | First primary cancer N(ratio) ||\n||  Surgery  |  27(26.7%)  ||\n||  Chemotherapy  |  57(56.4%)  ||\n||  Radiotherapy  |  7(7.0%)  ||\n||  Chemo-radiotherapy  |  10(9.9%)  ||",
    "claim": "The combination of chemotherapy and radiotherapy, known as chemo-radiotherapy, is employed in approximately one-fifth of the cases, suggesting a strategic approach to leverage the synergistic effects of both modalities in a subset of patients.",
    "label": "refute"
  },
  {
    "id": "training_8_5",
    "table_caption": "Table: Baseline physical activity and 6-month change (median [25th and 75th percentile] or mean ± sd) of elderly living in long-term care facilities (N = 157) Resistance training Functional training Combined training Control (n = 40) (n = 41) (n = 45) (n = 31) baseline 6 m change baseline 6 m change baseline 6 m change baseline 6 m change total physical activity (min/d) 85 [47;120]* 12 [-20;39] 118 [71;178] -2 [-43;36] 111 [64;167] 1 [-31;22] 128 [69;159] -10 [-39;30] total moderate activity (min/d) 21 [6.41] -6 [-22;6] 41 [18;59] -3 [-22;6] 43 [9;52] -4 [-17;3] 32 [11;81] 1 [-17;15] Time spent sitting (min/d) 508 [204;568] -3 [-17;41] 484 [277;579] -8 [-58;29] 510 [305;569] 8 [-56;64] 466 [214;532] 0 [-31;19] total counts per day 87778 ± 37427 7397 ± 25631 102137 ± 45412 -455 ± 44344 119460 ± 66204 -528 ± 49601 105610 ± 48437 2808 ± 40467 counts per minute 113 ± 45 7 ± 29 133 ± 54 -0.1 ± 49 150 ± 77 1 ± 66 136 ± 58 3 ± 40 * p ≤ 0.05, for between group difference at baseline ",
    "table_content": "|| blank | Resistance training (n = 40) | Resistance training (n = 40) | Functional training (n = 41) | Functional training (n = 41) | Combined training (n = 45) | Combined training (n = 45) | Control (n = 31) | Control (n = 31) ||\n|| blank | Resistance training (n = 40) | Resistance training (n = 40) | Functional training (n = 41) | Functional training (n = 41) | Combined training (n = 45) | Combined training (n = 45) | Control (n = 31) | Control (n = 31) ||\n|| blank | baseline | 6 m change | baseline | 6 m change | baseline | 6 m change | baseline | 6 m change ||\n|| total physical activity (min/d) | 85 [47;120]* | 12 [-20;39] | 118 [71;178] | -2 [-43;36] | 111 [64;167] | 1 [-31;22] | 128 [69;159] | -10 [-39;30] ||\n|| total moderate activity (min/d) | 21 [6.41] | -6 [-22;6] | 41 [18;59] | -3 [-22;6] | 43 [9;52] | -4 [-17;3] | 32 [11;81] | 1 [-17;15] ||\n|| Time spent sitting (min/d) | 508 [204;568] | -3 [-17;41] | 484 [277;579] | -8 [-58;29] | 510 [305;569] | 8 [-56;64] | 466 [214;532] | 0 [-31;19] ||\n|| total counts per day | 87778 ± 37427 | 7397 ± 25631 | 102137 ± 45412 | -455 ± 44344 | 119460 ± 66204 | -528 ± 49601 | 105610 ± 48437 | 2808 ± 40467 ||\n|| counts per minute | 113 ± 45 | 7 ± 29 | 133 ± 54 | -0.1 ± 49 | 150 ± 77 | 1 ± 66 | 136 ± 58 | 3 ± 40 ||",
    "claim": "The resistance training group demonstrated a net decrease in counts per minute, whereas the functional training group showed a slight increase. The net change in counts per minute for the resistance training group was approximately 7.1 counts lower than the functional training group, indicating a relative decline in activity intensity.",
    "label": "refute"
  },
  {
    "id": "training_664_3",
    "table_caption": "Table: genes model ences PRRSv with gene tool To of 3 the still of and genes to (data WG so cussed. Table 2 Numbers of DE genes for the different comparisons Comparison # of DE genes (FDR = 0.10) WG effect HvHg-HvLg contrast on 4dpi 0 HvHg-HvLg contrast on 7dpi 0 LvHg-LvLg contrast on 4dpi 2 LvHg-LvLg contrast on 7dpi 709 VL effect HvHg-LvHg contrast on 4dpi 0 HvHg-LvHg contrast on 7dpi 0 HvLg-LvLg contrast on 4dpi 2 HvLg-LvLg contrast on 7dpi 0 WG and VL interaction effect (HvHg-HvLg)-(LvHg-LvLg) contrast on 4dpi 1 (HvHg-HvLg)-(LvHg-LvLg) contrast on 7dpi 0 day effect 4dpi-0dpi contrast 239 7dpi-0dpi contrast 165 genotype effect genotype (AB vs AA) contrast on 4dpi 0 genotype (AB vs AA) contrast on 7dpi 0 Comparisons were made for a WG, VL, day and genotype effect. The FDR was set at 0.10 ",
    "table_content": "|| blank | Comparison | # of DE genes (FDR = 0.10) ||\n|| WG effect | HvHg-HvLg contrast on 4dpi | 0 ||\n|| WG and VL interaction effect | (HvHg-HvLg)-(LvHg-LvLg) contrast on 7dpi | 0 ||\n|| day effect | 4dpi-0dpi contrast | 239 ||\n|| day effect | 7dpi-0dpi contrast | 165 ||\n|| genotype effect | genotype (AB vs AA) contrast on 4dpi | 0 ||\n|| genotype effect | genotype (AB vs AA) contrast on 7dpi | 0 ||\n|| WG effect | HvHg-HvLg contrast on 7dpi | 0 ||\n|| WG effect | LvHg-LvLg contrast on 4dpi | 2 ||\n|| WG effect | LvHg-LvLg contrast on 7dpi | 709 ||\n|| VL effect | HvHg-LvHg contrast on 4dpi | 0 ||\n|| VL effect | HvHg-LvHg contrast on 7dpi | 0 ||\n|| VL effect | HvLg-LvLg contrast on 4dpi | 2 ||\n|| VL effect | HvLg-LvLg contrast on 7dpi | 0 ||\n|| WG and VL interaction effect | (HvHg-HvLg)-(LvHg-LvLg) contrast on 4dpi | 1 ||",
    "claim": "The day effect shows a decrease in DE genes from 4dpi to 7dpi, with a reduction of 51%, indicating a temporal decline in gene expression changes as the experiment progresses.",
    "label": "refute"
  },
  {
    "id": "training_246_4",
    "table_caption": "Table: LPS concentrations in the rumen, and portal and hepatic veins of cows from treatment and control groups. LPS Conc. Control a Treatment a Tr, p Ti, p Tr × Ti, p Rumen# (EU/mL) 0 h 3.79 ± 0.77 17.01 ± 0.61 0.04 0.85 0.06 4 h 6.04 ± 0.71 20.69 ± 0.62 8 h 6.15 ± 0.15 18.03 ± 0.53 Portal Vein (EU/mL) 0 h 0.31 ± 0.05 0.88 ± 0.05 <0.01 0.07 0.02 4 h 0.28 ± 0.02 1.13 ± 0.08 8 h 0.29 ± 0.04 0.81 ± 0.04 Hepatic Vein (EU/mL) 0 h 0.19 ± 0.05 0.58 ± 0.09 <0.01 0.24 0.15 4 h 0.13 ± 0.02 0.74 ± 0.06 8 h 0.12 ± 0.09 0.53 ± 0.09 a Values are mean ± SEM # [×104] ",
    "table_content": "|| LPS Conc. | Control  a   | Treatment  a   | Tr, p  | Ti, p  | Tr × Ti, p  ||\n|| Rumen  #  (EU/mL) | Rumen  #  (EU/mL) | Rumen  #  (EU/mL) | Rumen  #  (EU/mL) | Rumen  #  (EU/mL) | Rumen  #  (EU/mL) ||\n|| 0 h | 0.19 ± 0.05 | 0.58 ± 0.09 | <0.01 | 0.24 | 0.15 ||\n|| 4 h | 0.13 ± 0.02 | 0.74 ± 0.06 | blank | blank | blank ||\n|| 8 h | 0.12 ± 0.09 | 0.53 ± 0.09 | blank | blank | blank ||\n|| 0 h | 3.79 ± 0.77 | 17.01 ± 0.61 | 0.04 | 0.85 | 0.06 ||\n|| 4 h | 6.04 ± 0.71 | 20.69 ± 0.62 | blank | blank | blank ||\n|| 8 h | 6.15 ± 0.15 | 18.03 ± 0.53 | blank | blank | blank ||\n|| Portal Vein (EU/mL) | Portal Vein (EU/mL) | Portal Vein (EU/mL) | Portal Vein (EU/mL) | Portal Vein (EU/mL) | Portal Vein (EU/mL) ||\n|| 0 h | 0.31 ± 0.05 | 0.88 ± 0.05 | <0.01 | 0.07 | 0.02 ||\n|| 4 h | 0.28 ± 0.02 | 1.13 ± 0.08 | blank | blank | blank ||\n|| 8 h | 0.29 ± 0.04 | 0.81 ± 0.04 | blank | blank | blank ||\n|| Hepatic Vein (EU/mL) | Hepatic Vein (EU/mL) | Hepatic Vein (EU/mL) | Hepatic Vein (EU/mL) | Hepatic Vein (EU/mL) | Hepatic Vein (EU/mL) ||",
    "claim": "The p-value for the treatment effect in the portal vein is greater than 0.01, indicating no statistically significant increase in LPS concentration due to treatment, independent of time.",
    "label": "refute"
  },
  {
    "id": "training_1113_3",
    "table_caption": "Table: testa at generator Table 4 Results of validation batches (directly after labelling) Parameter Validation batches (n = 3) Appearance Clear, colourless solution Mean pH (range) 5.0 (5.0) Filter integrity Pass Mean impurity A (%) ± SD 0.94 ± 0.54 Mean impurity B (%) ± SD 0.21 ± 0.18 SD, standard deviation. ",
    "table_content": "||  Parameter  |  Validation batches (  n  = 3)  ||\n|| Appearance | Clear, colourless solution ||\n|| Mean pH (range) | 5.0 (5.0) ||\n|| Filter integrity | Pass ||\n|| Mean impurity A (%) ± SD | 0.94 ± 0.54 ||\n|| Mean impurity B (%) ± SD | 0.21 ± 0.18 ||",
    "claim": "The pH value remains constant at 4.5 across all validation batches, indicating a highly controlled and stable process for maintaining the solution's acidity or alkalinity, which is crucial for the solution's intended application.",
    "label": "refute"
  },
  {
    "id": "training_500_2",
    "table_caption": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 Rb1 0.0180 (4) 0.0338 (5) 0.0310 (5) −0.0050 (3) 0.0063 (4) −0.0004 (4) Rb2 0.0225 (4) 0.0282 (4) 0.0260 (5) 0.0032 (3) 0.0008 (3) −0.0024 (4) Ga1 0.0125 (4) 0.0193 (4) 0.0237 (5) 0.0007 (3) 0.0055 (4) 0.0004 (4) Ga2 0.0122 (4) 0.0203 (4) 0.0252 (5) −0.0007 (3) 0.0052 (4) 0.0005 (4) B1 0.017 (4) 0.011 (4) 0.026 (5) 0.003 (3) 0.014 (4) 0.000 (4) B2 0.015 (4) 0.017 (4) 0.022 (5) 0.000 (3) 0.005 (4) 0.002 (4) O1 0.008 (3) 0.022 (3) 0.037 (4) −0.001 (2) 0.007 (2) −0.005 (2) O2 0.016 (3) 0.031 (3) 0.025 (3) −0.008 (2) 0.002 (2) 0.010 (3) O3 0.024 (3) 0.024 (3) 0.029 (3) −0.012 (2) 0.004 (3) 0.000 (3) O4 0.008 (3) 0.023 (3) 0.043 (4) −0.006 (2) 0.008 (2) 0.001 (3) O5 0.011 (3) 0.021 (3) 0.035 (3) 0.001 (2) 0.011 (2) 0.004 (2) O6 0.029 (3) 0.024 (3) 0.040 (4) 0.004 (2) 0.023 (3) 0.010 (3) O7 0.019 (3) 0.026 (3) 0.026 (3) 0.003 (2) −0.001 (2) −0.006 (3) Geometric parameters (Å, °) ",
    "table_content": "|| blank | U 11 | U 22 | U 33 | U 12 | U 13 | U 23 ||\n|| Rb1 | 0.0180 (4) | 0.0338 (5) | 0.0310 (5) | −0.0050 (3) | 0.0063 (4) | −0.0004 (4) ||\n|| O4 | 0.008 (3) | 0.023 (3) | 0.043 (4) | −0.006 (2) | 0.008 (2) | 0.001 (3) ||\n|| O5 | 0.011 (3) | 0.021 (3) | 0.035 (3) | 0.001 (2) | 0.011 (2) | 0.004 (2) ||\n|| O6 | 0.029 (3) | 0.024 (3) | 0.040 (4) | 0.004 (2) | 0.023 (3) | 0.010 (3) ||\n|| O7 | 0.019 (3) | 0.026 (3) | 0.026 (3) | 0.003 (2) | −0.001 (2) | −0.006 (3) ||\n|| Rb2 | 0.0225 (4) | 0.0282 (4) | 0.0260 (5) | 0.0032 (3) | 0.0008 (3) | −0.0024 (4) ||\n|| Ga1 | 0.0125 (4) | 0.0193 (4) | 0.0237 (5) | 0.0007 (3) | 0.0055 (4) | 0.0004 (4) ||\n|| Ga2 | 0.0122 (4) | 0.0203 (4) | 0.0252 (5) | −0.0007 (3) | 0.0052 (4) | 0.0005 (4) ||\n|| B1 | 0.017 (4) | 0.011 (4) | 0.026 (5) | 0.003 (3) | 0.014 (4) | 0.000 (4) ||\n|| B2 | 0.015 (4) | 0.017 (4) | 0.022 (5) | 0.000 (3) | 0.005 (4) | 0.002 (4) ||\n|| O1 | 0.008 (3) | 0.022 (3) | 0.037 (4) | −0.001 (2) | 0.007 (2) | −0.005 (2) ||\n|| O2 | 0.016 (3) | 0.031 (3) | 0.025 (3) | −0.008 (2) | 0.002 (2) | 0.010 (3) ||\n|| O3 | 0.024 (3) | 0.024 (3) | 0.029 (3) | −0.012 (2) | 0.004 (3) | 0.000 (3) ||",
    "claim": "When comparing the average of U11, U22, and U33 for Rb1 and Ga1, Ga1 exhibits a higher average displacement parameter by approximately 0.009 Å², suggesting that Ga1 experiences greater thermal motion than Rb1.",
    "label": "refute"
  },
  {
    "id": "training_1244_1",
    "table_caption": "Table: Comparison of miPred and miR-KDE in terms of the feature set and the classification mechanism. Without the four stem-loop features1 With the four stem-loop features2 %SE %SP %ACC %Fm %MCC %SE %SP %ACC %Fm %MCC HU2163 SVM 88.0% 88.0% 88.0% 88.0% 75.9% 90.7% 90.7% 90.7% 90.7% 81.5% RVKDE 85.2% 90.7% 88.0% 87.6% 76.0% 88.9% 92.6% 90.7% 90.6% 81.5% NH33504 SVM 96.7% 90.4% 93.6% 93.7% 87.3% 97.3% 91.3% 94.3% 94.4% 88.7% RVKDE 94.8% 93.4% 94.1% 94.1% 88.2% 95.8% 93.5% 94.7% 94.7% 89.3% The best performance among each dataset is highlighted with bold font. 1Using the 29 features in miPred. 2Using the 33 features in miR-KDE, i.e., the 29 features derived from miPred and the four stem-loop features. 3Using the HU400 dataset to predict the HU216 dataset. 4Using the HU400 ",
    "table_content": "|| blank | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 ||\n|| blank | %SE | %SP | %ACC | %Fm | %MCC | %SE | %SP | %ACC | %Fm | %MCC ||\n|| HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 ||\n|| SVM | 88.0% | 88.0% | 88.0% | 88.0% | 75.9% | 90.7% | 90.7% | 90.7% | 90.7% | 81.5% ||\n|| RVKDE | 85.2% | 90.7% | 88.0% | 87.6% | 76.0% | 88.9% | 92.6% | 90.7% | 90.6% | 81.5% ||\n|| NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 ||\n|| SVM | 96.7% | 90.4% | 93.6% | 93.7% | 87.3% | 97.3% | 91.3% | 94.3% | 94.4% | 88.7% ||\n|| RVKDE | 94.8% | 93.4% | 94.1% | 94.1% | 88.2% | 95.8% | 93.5% | 94.7% | 94.7% | 89.3% ||",
    "claim": "The inclusion of the four stem-loop features results in a 3.07% increase in the Matthews Correlation Coefficient for the SVM classifier on the HU216 dataset, indicating a more balanced performance between true positive and true negative rates.",
    "label": "refute"
  },
  {
    "id": "training_1244_1",
    "table_caption": "Table: Comparison of miPred and miR-KDE in terms of the feature set and the classification mechanism. Without the four stem-loop features1 With the four stem-loop features2 %SE %SP %ACC %Fm %MCC %SE %SP %ACC %Fm %MCC HU2163 SVM 88.0% 88.0% 88.0% 88.0% 75.9% 90.7% 90.7% 90.7% 90.7% 81.5% RVKDE 85.2% 90.7% 88.0% 87.6% 76.0% 88.9% 92.6% 90.7% 90.6% 81.5% NH33504 SVM 96.7% 90.4% 93.6% 93.7% 87.3% 97.3% 91.3% 94.3% 94.4% 88.7% RVKDE 94.8% 93.4% 94.1% 94.1% 88.2% 95.8% 93.5% 94.7% 94.7% 89.3% The best performance among each dataset is highlighted with bold font. 1Using the 29 features in miPred. 2Using the 33 features in miR-KDE, i.e., the 29 features derived from miPred and the four stem-loop features. 3Using the HU400 dataset to predict the HU216 dataset. 4Using the HU400 ",
    "table_content": "|| blank | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | Without the four stem-loop features 1 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 | With the four stem-loop features 2 ||\n|| blank | %SE | %SP | %ACC | %Fm | %MCC | %SE | %SP | %ACC | %Fm | %MCC ||\n|| HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 | HU216 3 ||\n|| SVM | 88.0% | 88.0% | 88.0% | 88.0% | 75.9% | 90.7% | 90.7% | 90.7% | 90.7% | 81.5% ||\n|| RVKDE | 85.2% | 90.7% | 88.0% | 87.6% | 76.0% | 88.9% | 92.6% | 90.7% | 90.6% | 81.5% ||\n|| NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 | NH3350 4 ||\n|| SVM | 96.7% | 90.4% | 93.6% | 93.7% | 87.3% | 97.3% | 91.3% | 94.3% | 94.4% | 88.7% ||\n|| RVKDE | 94.8% | 93.4% | 94.1% | 94.1% | 88.2% | 95.8% | 93.5% | 94.7% | 94.7% | 89.3% ||",
    "claim": "The inclusion of the four stem-loop features results in a 3.07% decrease in the Matthews Correlation Coefficient for the SVM classifier on the HU216 dataset, indicating a less balanced performance between true positive and true negative rates.",
    "label": "refute"
  },
  {
    "id": "training_1094_2",
    "table_caption": "Table: 4 0.93 0.44 1.0 71.9 Table 3 Correlations between items of the PSYRATS hallucination scale and PANSS P3 Hallucination item PANSS P3 Hallucination (N = 39) Frequency 0.42** Duration 0.33* Location 0.07 Loudness 0.30 Origin of voice 0.46** Amount of negative content 0.28 Degree of negative content 0.55** Amount of distress 0.33* Intensity of distress 0.34* Disruption to life 0.26 Controllability 0.31 Total 0.58** *2-tailed p < 0.05. **2-tailed p < 0.01. ",
    "table_content": "|| blank | PANSS P3 Hallucination (N  = 39) ||\n|| Frequency | 0.42** ||\n|| Disruption to life | 0.26 ||\n|| Controllability | 0.31 ||\n|| Total | 0.58** ||\n|| Duration | 0.33* ||\n|| Location | 0.07 ||\n|| Loudness | 0.30 ||\n|| Origin of voice | 0.46** ||\n|| Amount of negative content | 0.28 ||\n|| Degree of negative content | 0.55** ||\n|| Amount of distress | 0.33* ||\n|| Intensity of distress | 0.34* ||",
    "claim": "The correlation coefficient for \"Origin of voice\" is 0.46, which is lower than the coefficient for \"Frequency,\" indicating that the origin of the voice in hallucinations has a weaker relationship with the PANSS P3 Hallucination item than the frequency of the hallucinations.",
    "label": "refute"
  },
  {
    "id": "training_626_2",
    "table_caption": "Table: Term Total Expected Hits Raw p Arachidonic acid metabolism 36 0.66762 4 0.0036618 Glutathione metabolism 26 0.48217 2 0.081872 Linoleic acid metabolism 5 0.092725 1 0.089472 Glycerophospholipid metabolism 30 0.55635 2 0.10478 alpha-Linolenic acid metabolism 9 0.1669 1 0.15546 Vitamin B6 metabolism 9 0.1669 1 0.15546 Pyrimidine metabolism 41 0.76034 2 0.1748 Pantothenate and CoA biosynthesis 15 0.27817 1 0.24589 beta-Alanine metabolism 19 0.35235 1 0.30092 Butanoate metabolism 20 0.3709 1 0.31406 Sphingolipid metabolism 21 0.38944 1 0.32697 Purine metabolism 68 1.2611 2 0.36233 Alanine, aspartate and glutamate metabolism 24 0.44508 1 0.36429 Steroid biosynthesis 35 0.64907 1 0.48486 Amino sugar and nucleotide sugar metabolism 37 0.68616 1 0.50428 Arginine and proline metabolism 44 0.81598 1 0.56685 Table 6. Analyzed pathways of metabolomics data differently regulated in lung tissue formula-treated rats. ",
    "table_content": "|| Term | Total | Expected | Hits | Raw p ||\n|| Arachidonic acid metabolism | 36 | 0.66762 | 4 | 0.0036618 ||\n|| Butanoate metabolism | 20 | 0.3709 | 1 | 0.31406 ||\n|| Sphingolipid metabolism | 21 | 0.38944 | 1 | 0.32697 ||\n|| Purine metabolism | 68 | 1.2611 | 2 | 0.36233 ||\n|| Alanine, aspartate and glutamate metabolism | 24 | 0.44508 | 1 | 0.36429 ||\n|| Steroid biosynthesis | 35 | 0.64907 | 1 | 0.48486 ||\n|| Amino sugar and nucleotide sugar metabolism | 37 | 0.68616 | 1 | 0.50428 ||\n|| Arginine and proline metabolism | 44 | 0.81598 | 1 | 0.56685 ||\n|| Glutathione metabolism | 26 | 0.48217 | 2 | 0.081872 ||\n|| Linoleic acid metabolism | 5 | 0.092725 | 1 | 0.089472 ||\n|| Glycerophospholipid metabolism | 30 | 0.55635 | 2 | 0.10478 ||\n|| alpha-Linolenic acid metabolism | 9 | 0.1669 | 1 | 0.15546 ||\n|| Vitamin B6 metabolism | 9 | 0.1669 | 1 | 0.15546 ||\n|| Pyrimidine metabolism | 41 | 0.76034 | 2 | 0.1748 ||\n|| Pantothenate and CoA biosynthesis | 15 | 0.27817 | 1 | 0.24589 ||\n|| beta-Alanine metabolism | 19 | 0.35235 | 1 | 0.30092 ||",
    "claim": "The ratio of observed to expected hits for arachidonic acid metabolism is approximately 5.99, which is the highest among all pathways, suggesting a strong overrepresentation of hits in this pathway.",
    "label": "refute"
  },
  {
    "id": "training_626_2",
    "table_caption": "Table: Term Total Expected Hits Raw p Arachidonic acid metabolism 36 0.66762 4 0.0036618 Glutathione metabolism 26 0.48217 2 0.081872 Linoleic acid metabolism 5 0.092725 1 0.089472 Glycerophospholipid metabolism 30 0.55635 2 0.10478 alpha-Linolenic acid metabolism 9 0.1669 1 0.15546 Vitamin B6 metabolism 9 0.1669 1 0.15546 Pyrimidine metabolism 41 0.76034 2 0.1748 Pantothenate and CoA biosynthesis 15 0.27817 1 0.24589 beta-Alanine metabolism 19 0.35235 1 0.30092 Butanoate metabolism 20 0.3709 1 0.31406 Sphingolipid metabolism 21 0.38944 1 0.32697 Purine metabolism 68 1.2611 2 0.36233 Alanine, aspartate and glutamate metabolism 24 0.44508 1 0.36429 Steroid biosynthesis 35 0.64907 1 0.48486 Amino sugar and nucleotide sugar metabolism 37 0.68616 1 0.50428 Arginine and proline metabolism 44 0.81598 1 0.56685 Table 6. Analyzed pathways of metabolomics data differently regulated in lung tissue formula-treated rats. ",
    "table_content": "|| Term | Total | Expected | Hits | Raw p ||\n|| Arachidonic acid metabolism | 36 | 0.66762 | 4 | 0.0036618 ||\n|| Butanoate metabolism | 20 | 0.3709 | 1 | 0.31406 ||\n|| Sphingolipid metabolism | 21 | 0.38944 | 1 | 0.32697 ||\n|| Purine metabolism | 68 | 1.2611 | 2 | 0.36233 ||\n|| Alanine, aspartate and glutamate metabolism | 24 | 0.44508 | 1 | 0.36429 ||\n|| Steroid biosynthesis | 35 | 0.64907 | 1 | 0.48486 ||\n|| Amino sugar and nucleotide sugar metabolism | 37 | 0.68616 | 1 | 0.50428 ||\n|| Arginine and proline metabolism | 44 | 0.81598 | 1 | 0.56685 ||\n|| Glutathione metabolism | 26 | 0.48217 | 2 | 0.081872 ||\n|| Linoleic acid metabolism | 5 | 0.092725 | 1 | 0.089472 ||\n|| Glycerophospholipid metabolism | 30 | 0.55635 | 2 | 0.10478 ||\n|| alpha-Linolenic acid metabolism | 9 | 0.1669 | 1 | 0.15546 ||\n|| Vitamin B6 metabolism | 9 | 0.1669 | 1 | 0.15546 ||\n|| Pyrimidine metabolism | 41 | 0.76034 | 2 | 0.1748 ||\n|| Pantothenate and CoA biosynthesis | 15 | 0.27817 | 1 | 0.24589 ||\n|| beta-Alanine metabolism | 19 | 0.35235 | 1 | 0.30092 ||",
    "claim": "The ratio of observed to expected hits for arachidonic acid metabolism is approximately 3.99, which is the highest among all pathways, suggesting a strong overrepresentation of hits in this pathway.",
    "label": "refute"
  },
  {
    "id": "training_199_1",
    "table_caption": "Table: Data collection Bruker–Nonius Roper CCD camera on κ-goniostat diffractometer 2704 independent reflections Radiation source: Bruker–Nonius FR591 rotating an- ode 2100 reflections with I > 2σ(I) graphite Rint = 0.061 Detector resolution: 9.091 pixels mm-1 θmax = 27.6°, θmin = 3.1° φ and ω scans h = −8→8 Absorption correction: multi-scan (SADABS; Sheldrick, 1996) k = −11→10 Tmin = 0.940, Tmax = 0.980 l = −25→26 11943 measured reflections Refinement ",
    "table_content": "|| Bruker–Nonius Roper CCD camera on κ-goniostat diffractometer | 2704 independent reflections ||\n|| Radiation source: Bruker–Nonius FR591 rotating anode | 2100 reflections with I > 2σ( I ) ||\n|| graphite | R int = 0.061 ||\n|| Detector resolution: 9.091 pixels mm -1 | θ max = 27.6°, θ min = 3.1° ||\n|| φ and ω scans | h = −8→8 ||\n|| Absorption correction: multi-scan ( SADABS ; Sheldrick, 1996) | k = −11→10 ||\n|| T min = 0.940, T max = 0.980 | l = −25→26 ||\n|| 11943 measured reflections | blank ||",
    "claim": "The ratio of independent reflections to the total measured reflections is approximately 0.500, indicating that a significant portion of the measured data is redundant, which is typical in crystallography to ensure data reliability and accuracy.",
    "label": "refute"
  },
  {
    "id": "training_292_4",
    "table_caption": "Table: Table 3 Adverse events of any cause experienced by ≥10 % patients over the study (N = 19) Adverse event, n (%) All grades Grade 1 Grade 2 Grade 3 Aphthous stomatitis 11 (57.9) 11 (57.9) 0 (0.0) 0 (0.0) Hypercholesterolaemia 11 (57.9) 5 (26.3) 6 (31.6) 0 (0.0) Hypertriglyceridaemia 8 (42.1) 3 (15.8) 3 (15.8) 2 (10.5) Urinary tract infection 8 (42.1) 2 (10.5) 6 (31.6) 0 (0.0) Mucosal inflammation 7 (36.8) 5 (26.3) 1 (5.3) 1 (5.3) Hypertension 6 (31.6) 3 (15.8) 2 (10.5) 1 (5.3) Dermatitis acneiform 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Insomnia 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Catarrh 4 (21.1) 4 (21.1) 0 (0.0) 0 (0.0) Diarrhoea 4 (21.1) 3 (15.8) 1 (5.3) 0 (0.0) Amenorrhoea 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Asthenia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Headache 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Dysgeusia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Pharyngitis 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Nasopharyngitis 3 (15.8) 2 (10.5) 1 (5.3) 0 (0.0) Cough 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Menstrual disorder 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Conjunctivitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dermatitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Back pain 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Abdominal pain upper 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Epistaxis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Erythema 2 (10.5) 1 (5.3) 1 (5.3) 0 (0.0) Rash 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Oral herpes 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dizziness 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Menorrhagia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Myalgia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Pyrexia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Vomiting 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Gamma-glutamyltransferase increased 2 (10.5) 0 (0.0) 2 (10.5) 0 (0.0) Transaminases increased 2 (10.5) 0 (0.0) 1 (5.3) 1 (5.3) All adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) preferred term and graded as per the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (version 4.03) ",
    "table_content": "|| Adverse event, n (%) | All grades | Grade 1 | Grade 2 | Grade 3 ||\n|| Aphthous stomatitis | 11 (57.9) | 11 (57.9) | 0 (0.0) | 0 (0.0) ||\n|| Diarrhoea | 4 (21.1) | 3 (15.8) | 1 (5.3) | 0 (0.0) ||\n|| Amenorrhoea | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Asthenia | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Headache | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Dysgeusia | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Pharyngitis | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Nasopharyngitis | 3 (15.8) | 2 (10.5) | 1 (5.3) | 0 (0.0) ||\n|| Cough | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Menstrual disorder | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Conjunctivitis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Hypercholesterolaemia | 11 (57.9) | 5 (26.3) | 6 (31.6) | 0 (0.0) ||\n|| Dermatitis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Back pain | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Abdominal pain upper | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Epistaxis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Erythema | 2 (10.5) | 1 (5.3) | 1 (5.3) | 0 (0.0) ||\n|| Rash | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Oral herpes | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Dizziness | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Menorrhagia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Myalgia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Hypertriglyceridaemia | 8 (42.1) | 3 (15.8) | 3 (15.8) | 2 (10.5) ||\n|| Pyrexia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Vomiting | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Gamma-glutamyltransferase increased | 2 (10.5) | 0 (0.0) | 2 (10.5) | 0 (0.0) ||\n|| Transaminases increased | 2 (10.5) | 0 (0.0) | 1 (5.3) | 1 (5.3) ||\n|| Urinary tract infection | 8 (42.1) | 2 (10.5) | 6 (31.6) | 0 (0.0) ||\n|| Mucosal inflammation | 7 (36.8) | 5 (26.3) | 1 (5.3) | 1 (5.3) ||\n|| Hypertension | 6 (31.6) | 3 (15.8) | 2 (10.5) | 1 (5.3) ||\n|| Dermatitis acneiform | 5 (26.3) | 5 (26.3) | 0 (0.0) | 0 (0.0) ||\n|| Insomnia | 5 (26.3) | 5 (26.3) | 0 (0.0) | 0 (0.0) ||\n|| Catarrh | 4 (21.1) | 4 (21.1) | 0 (0.0) | 0 (0.0) ||",
    "claim": "The ratio of Grade 1 to Grade 2 events for hypercholesterolaemia is approximately 5",
    "label": "refute"
  },
  {
    "id": "training_292_4",
    "table_caption": "Table: Table 3 Adverse events of any cause experienced by ≥10 % patients over the study (N = 19) Adverse event, n (%) All grades Grade 1 Grade 2 Grade 3 Aphthous stomatitis 11 (57.9) 11 (57.9) 0 (0.0) 0 (0.0) Hypercholesterolaemia 11 (57.9) 5 (26.3) 6 (31.6) 0 (0.0) Hypertriglyceridaemia 8 (42.1) 3 (15.8) 3 (15.8) 2 (10.5) Urinary tract infection 8 (42.1) 2 (10.5) 6 (31.6) 0 (0.0) Mucosal inflammation 7 (36.8) 5 (26.3) 1 (5.3) 1 (5.3) Hypertension 6 (31.6) 3 (15.8) 2 (10.5) 1 (5.3) Dermatitis acneiform 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Insomnia 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Catarrh 4 (21.1) 4 (21.1) 0 (0.0) 0 (0.0) Diarrhoea 4 (21.1) 3 (15.8) 1 (5.3) 0 (0.0) Amenorrhoea 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Asthenia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Headache 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Dysgeusia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Pharyngitis 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Nasopharyngitis 3 (15.8) 2 (10.5) 1 (5.3) 0 (0.0) Cough 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Menstrual disorder 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Conjunctivitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dermatitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Back pain 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Abdominal pain upper 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Epistaxis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Erythema 2 (10.5) 1 (5.3) 1 (5.3) 0 (0.0) Rash 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Oral herpes 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dizziness 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Menorrhagia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Myalgia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Pyrexia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Vomiting 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Gamma-glutamyltransferase increased 2 (10.5) 0 (0.0) 2 (10.5) 0 (0.0) Transaminases increased 2 (10.5) 0 (0.0) 1 (5.3) 1 (5.3) All adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) preferred term and graded as per the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (version 4.03) ",
    "table_content": "|| Adverse event, n (%) | All grades | Grade 1 | Grade 2 | Grade 3 ||\n|| Aphthous stomatitis | 11 (57.9) | 11 (57.9) | 0 (0.0) | 0 (0.0) ||\n|| Diarrhoea | 4 (21.1) | 3 (15.8) | 1 (5.3) | 0 (0.0) ||\n|| Amenorrhoea | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Asthenia | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Headache | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Dysgeusia | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Pharyngitis | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Nasopharyngitis | 3 (15.8) | 2 (10.5) | 1 (5.3) | 0 (0.0) ||\n|| Cough | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Menstrual disorder | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) ||\n|| Conjunctivitis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Hypercholesterolaemia | 11 (57.9) | 5 (26.3) | 6 (31.6) | 0 (0.0) ||\n|| Dermatitis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Back pain | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Abdominal pain upper | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Epistaxis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Erythema | 2 (10.5) | 1 (5.3) | 1 (5.3) | 0 (0.0) ||\n|| Rash | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Oral herpes | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Dizziness | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Menorrhagia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Myalgia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Hypertriglyceridaemia | 8 (42.1) | 3 (15.8) | 3 (15.8) | 2 (10.5) ||\n|| Pyrexia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Vomiting | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) ||\n|| Gamma-glutamyltransferase increased | 2 (10.5) | 0 (0.0) | 2 (10.5) | 0 (0.0) ||\n|| Transaminases increased | 2 (10.5) | 0 (0.0) | 1 (5.3) | 1 (5.3) ||\n|| Urinary tract infection | 8 (42.1) | 2 (10.5) | 6 (31.6) | 0 (0.0) ||\n|| Mucosal inflammation | 7 (36.8) | 5 (26.3) | 1 (5.3) | 1 (5.3) ||\n|| Hypertension | 6 (31.6) | 3 (15.8) | 2 (10.5) | 1 (5.3) ||\n|| Dermatitis acneiform | 5 (26.3) | 5 (26.3) | 0 (0.0) | 0 (0.0) ||\n|| Insomnia | 5 (26.3) | 5 (26.3) | 0 (0.0) | 0 (0.0) ||\n|| Catarrh | 4 (21.1) | 4 (21.1) | 0 (0.0) | 0 (0.0) ||",
    "claim": "The ratio of Grade 1 to Grade 2 events for hypercholesterolaemia is approximately 1.",
    "label": "refute"
  },
  {
    "id": "training_490_4",
    "table_caption": "Table: Summary of mapped markers including shared and unique markers. Chromosome Shared markers observed in n populations All shared markers Main shared markers Unique markers DArT markers All markers n = 2 n = 3 n = 4 n = 5 1R 199 61 12 3 275 200 243 495 518 2R 139 79 24 0 242 173 247 469 489 3R 124 76 44 10 254 170 248 488 502 4R 301 139 41 1 482 291 323 788 805 5R 151 68 17 1 237 146 317 536 554 6R 162 89 51 16 318 194 408 709 726 7R 149 67 31 3 250 150 204 423 454 Total 1225 579 220 34 2058 1324 1990 3908 4048 doi:10.1371/journal.pone.0028495.t005 ",
    "table_content": "|| Chromosome | Shared markers observed in n populations | Shared markers observed in n populations | Shared markers observed in n populations | Shared markers observed in n populations | All shared markers | Main shared markers | Unique markers | DArT markers | All markers ||\n|| Chromosome | n = 2 | n = 3 | n = 4 | n = 5 | All shared markers | Main shared markers | Unique markers | DArT markers | All markers ||\n|| 1R | 199 | 61 | 12 | 3 | 275 | 200 | 243 | 495 | 518 ||\n|| 2R | 139 | 79 | 24 | 0 | 242 | 173 | 247 | 469 | 489 ||\n|| 3R | 124 | 76 | 44 | 10 | 254 | 170 | 248 | 488 | 502 ||\n|| 4R | 301 | 139 | 41 | 1 | 482 | 291 | 323 | 788 | 805 ||\n|| 5R | 151 | 68 | 17 | 1 | 237 | 146 | 317 | 536 | 554 ||\n|| 6R | 162 | 89 | 51 | 16 | 318 | 194 | 408 | 709 | 726 ||\n|| 7R | 149 | 67 | 31 | 3 | 250 | 150 | 204 | 423 | 454 ||\n|| Total | 1225 | 579 | 220 | 34 | 2058 | 1324 | 1990 | 3908 | 4048 ||",
    "claim": "The total number of markers varies significantly across chromosomes, with chromosome 4R having the lowest total of 805 markers, which is approximately 1.77 times the number of markers on chromosome 7R, which has the highest total of 454 markers. This variation suggests differential marker density across chromosomes.",
    "label": "refute"
  },
  {
    "id": "training_928_4",
    "table_caption": "Table: Data collection Bruker SMART 1000 CCD area-detector diffractometer 3773 independent reflections Radiation source: fine-focus sealed tube 2183 reflections with I > 2σ(I) Monochromator: graphite Rint = 0.064 T = 120(2) K θmax = 27.0º φ and ω scans θmin = 1.6º Absorption correction: multi-scan (SADABS; Sheldrick, 1996) h = −10→10 Tmin = 0.980, Tmax = 0.989 k = −32→32 16064 measured reflections l = −11→11 Refinement ",
    "table_content": "|| Bruker SMART 1000 CCD area-detector  diffractometer | 3773 independent reflections ||\n|| Radiation source: fine-focus sealed tube | 2183 reflections with I > 2σ( I ) ||\n|| Monochromator: graphite | R int = 0.064 ||\n|| T = 120(2) K | θ max = 27.0º ||\n|| φ and ω scans | θ min = 1.6º ||\n|| Absorption correction: multi-scan(SADABS; Sheldrick, 1996) | h = −10→10 ||\n|| T min = 0.980, T max = 0.989 | k = −32→32 ||\n|| 16064 measured reflections | l = −11→11 ||",
    "claim": "The low temperature of 120 K increases thermal vibrations, leading to broader diffraction peaks and reduced resolution, which is detrimental for precise atomic position determination.",
    "label": "refute"
  },
  {
    "id": "training_884_4",
    "table_caption": "Table: Table 3 Echocardiographic-derived cardiac output, cardiac index and pulmonary vascular resistance First author Resting CO (L.min1) Exercise CO (L.min1) Resting CI (L.min1.m2) Exercise CI (L.min1.m2) Resting PVR (WU) Exercise PVR (WU) Huez Total 3.0 8.7 2.9 D’Alto Total 3.0 5.8 Baptista Total 3.6 9.2 sPAP <50 mmHg 3.8* 8.5 sPAP ≥50 mmHg 5.1* 9.9 Suzuki Total 5.5 7.6 1.7 1.9 sPAP <50 mmHg 5.5 7.6 1.6* 1.8* sPAP ≥50 mmHg 5.5 7.6 1.9* 2.3* Voilliot Total 3.7 7.2 1.9 2.5 sPAP ≥50 mmHg 3.9 7.7 1.4* 2.1* sPAP >50 mmHg 3.5 6.5 2.6* 3.6* Gargani sPAP <50 mmHg 2.5 4.6 1.7 2.0* sPAP ≥50 mmHg 2.7 4.9 1.7 2.3* Results are presented as means. *Comparison between patients with maximum exercise-induced systolic pulmonary arterial pressure (sPAP) <50 mmHg and ≥50 mmHg statistically significantly different (p < 0.05). CI cardiac index, CO cardiac output, PVR pulmonary vascular resistance, WU Wood units ",
    "table_content": "|| First author | Resting CO (L.min 1 ) | Exercise CO (L.min 1 ) | Resting CI (L.min 1 .m 2 ) | Exercise CI (L.min 1 .m 2 ) | Resting PVR (WU) | Exercise PVR (WU) ||\n|| Huez | Huez | Huez | Huez | Huez | Huez | Huez ||\n|| Total | 5.5 | 7.6 | blank | blank | 1.7 | 1.9 ||\n|| sPAP <50 mmHg | 5.5 | 7.6 | blank | blank | 1.6* | 1.8* ||\n|| sPAP ≥50 mmHg | 5.5 | 7.6 | blank | blank | 1.9* | 2.3* ||\n|| Voilliot | Voilliot | Voilliot | Voilliot | Voilliot | Voilliot | Voilliot ||\n|| Total | 3.7 | 7.2 | blank | blank | 1.9 | 2.5 ||\n|| sPAP ≥50 mmHg | 3.9 | 7.7 | blank | blank | 1.4* | 2.1* ||\n|| sPAP >50 mmHg | 3.5 | 6.5 | blank | blank | 2.6* | 3.6* ||\n|| Gargani | Gargani | Gargani | Gargani | Gargani | Gargani | Gargani ||\n|| sPAP <50 mmHg | blank | blank | 2.5 | 4.6 | 1.7 | 2.0* ||\n|| sPAP ≥50 mmHg | blank | blank | 2.7 | 4.9 | 1.7 | 2.3* ||\n|| Total | 3.0 | 8.7 | blank | blank | blank | 2.9 ||\n|| D’Alto | D’Alto | D’Alto | D’Alto | D’Alto | D’Alto | D’Alto ||\n|| Total | blank | blank | 3.0 | 5.8 | blank | blank ||\n|| Baptista | Baptista | Baptista | Baptista | Baptista | Baptista | Baptista ||\n|| Total | 3.6 | 9.2 | blank | blank | blank | blank ||\n|| sPAP <50 mmHg | 3.8* | 8.5 | blank | blank | blank | blank ||\n|| sPAP ≥50 mmHg | 5.1* | 9.9 | blank | blank | blank | blank ||\n|| Suzuki | Suzuki | Suzuki | Suzuki | Suzuki | Suzuki | Suzuki ||",
    "claim": "The resting cardiac output in the Suzuki group is approximately the same as in the Huez group, indicating no baseline difference in cardiac function between these populations.",
    "label": "refute"
  },
  {
    "id": "training_1274_6",
    "table_caption": "Table: Functional categories and genes modulated in T2-STIR + FSHD with respect to IM. Functional category Official Full Name Official Symbol Fold change p-value Angiogenesis Angiogenin ANG 2,3725 0,0041 Angiopoietin-like 2 ANGPTL2 2,5002 0,0014 CD44 molecule CD44 2,4375 0,0035 CD34 molecule CD34 2,2935 0,0047 CD47 molecule CD47 1,6579 0,0013 Filamin B beta FLNB 2,2672 0,0056 Von Willebrand factor VWF 1,9606 0,0331 Slit homolog 3 SLIT3 2,6961 0,0047 Dedicator of cytokinesis 1 DOCK1 1,8760 0,0024 Secreted frizzled-related protein 1 SFRP1 4,8032 0,0026 Frizzled homolog 4 FZD4 2,1590 0,0051 Frizzled homolog 7 FZD7 1,3833 0,0401 Adipocyte presence, glycerolipid metabolism and adipokine production Cell death-inducing DFFA-like effector a CIDEA 9,7264 0,0009 Cell death-inducing DFFA-like effector c CIDEC 8,5623 0,0038 Perilipin 1 PLIN 5,6435 0,0017 Glycerol-3-phosphate acyltransferase GPAM 4,7128 0,0023 Alcohol dehydrogenase 1A ADH1A 4,1328 0,0016 Adiponectin, C1Q and collagen domain containing ADIPOQ 2,6172 0,0019 C1q and tumor necrosis factor related protein 1 C1QTNF1 2,6181 0,0013 Leptin LEP 3,9142 0,0544 All of the cited genes were expressed to a higher extent in T2-STIR + FSHD muscles. doi:10.1371/journal.pone.0038779.t002 ",
    "table_content": "|| Functional category | Official Full Name | Official Symbol | Fold change | p-value ||\n||  Angiogenesis  | Angiogenin | ANG | 2,3725 | 0,0041 ||\n||  Angiogenesis  | Secreted frizzled-related protein 1 | SFRP1 | 4,8032 | 0,0026 ||\n||  Angiogenesis  | Frizzled homolog 4 | FZD4 | 2,1590 | 0,0051 ||\n||  Angiogenesis  | Frizzled homolog 7 | FZD7 | 1,3833 | 0,0401 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Cell death-inducing DFFA-like effector a | CIDEA | 9,7264 | 0,0009 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Cell death-inducing DFFA-like effector c | CIDEC | 8,5623 | 0,0038 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Perilipin 1 | PLIN | 5,6435 | 0,0017 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Glycerol-3-phosphate acyltransferase | GPAM | 4,7128 | 0,0023 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Alcohol dehydrogenase 1A | ADH1A | 4,1328 | 0,0016 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Adiponectin, C1Q and collagen domain containing | ADIPOQ | 2,6172 | 0,0019 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | C1q and tumor necrosis factor related protein 1 | C1QTNF1 | 2,6181 | 0,0013 ||\n||  Angiogenesis  | Angiopoietin-like 2 | ANGPTL2 | 2,5002 | 0,0014 ||\n||  Adipocyte presence, glycerolipid metabolism  and adipokine production  | Leptin | LEP | 3,9142 | 0,0544 ||\n||  Angiogenesis  | CD44 molecule | CD44 | 2,4375 | 0,0035 ||\n||  Angiogenesis  | CD34 molecule | CD34 | 2,2935 | 0,0047 ||\n||  Angiogenesis  | CD47 molecule | CD47 | 1,6579 | 0,0013 ||\n||  Angiogenesis  | Filamin B beta | FLNB | 2,2672 | 0,0056 ||\n||  Angiogenesis  | Von Willebrand factor | VWF | 1,9606 | 0,0331 ||\n||  Angiogenesis  | Slit homolog 3 | SLIT3 | 2,6961 | 0,0047 ||\n||  Angiogenesis  | Dedicator of cytokinesis 1 | DOCK1 | 1,8760 | 0,0024 ||",
    "claim": "The average p-value for angiogenesis-related genes is approximately 0.002, while for adipocyte-related genes, it is approximately 0.008, indicating that the changes in angiogenesis-related genes are statistically more significant.",
    "label": "refute"
  },
  {
    "id": "training_314_3",
    "table_caption": "Table: Table 2 Combinations of reactions with improved production yield of succinic acid The respective reaction numbers are identical to the KEGG reaction numbers * The maximum amount of succinic acid produced is 100, as calculated using only the original SyGSM Total reaction number (n) Number of added metabolic pathways (m) Combinations of  metabolic reactions Rate of increase of succinic acid production yield 0 0 100* 1 1 R00479 133 R00751 102 R01867 102 2 2 R00751, R00479 144 R00479, R01867 134 3 3 R00751, R00479, R10179 155 ",
    "table_content": "|| Total reaction number (n) | Number of added metabolic pathways (m) | Combinations of metabolic reactions | Rate of increase of succinic acid production yield ||\n|| 0 | 0 | blank | 100 *  ||\n|| 1 | 1 | R00479 | 133 ||\n|| 1 | blank | R00751 | 102 ||\n|| 1 | blank | R01867 | 102 ||\n|| 2 | 2 | R00751, R00479 | 144 ||\n|| 2 | blank | R00479, R01867 | 134 ||\n|| 3 | 3 | R00751, R00479, R10179 | 155 ||",
    "claim": "Introducing a third reaction, R10179, to the combination of R00751 and R00479 further increases the yield to 45%, demonstrating a cumulative enhancement effect when expanding the reaction network.",
    "label": "refute"
  },
  {
    "id": "training_1374_4",
    "table_caption": "Table: Anchor weights and sizes. Mass of anchor(kg) H (mm) B1 (mm) H1 (mm) L (mm) H (mm) 3060 1283 841 380 1832 2374 4890 1498 984 415 2135 2769 6900 1681 1105 480 2391 3100 10500 1934 1273 600 2752 3571 14100 2135 1404 660 3036 3939 20000 2399 1578 730 3411 4420 doi:10.1371/journal.pone.0154954.t001 ",
    "table_content": "|| Mass of anchor(kg) | H (mm) | B1 (mm) | H1 (mm) | L (mm) | H (mm) ||\n|| 3060 | 1283 | 841 | 380 | 1832 | 2374 ||\n|| 4890 | 1498 | 984 | 415 | 2135 | 2769 ||\n|| 6900 | 1681 | 1105 | 480 | 2391 | 3100 ||\n|| 10500 | 1934 | 1273 | 600 | 2752 | 3571 ||\n|| 14100 | 2135 | 1404 | 660 | 3036 | 3939 ||\n|| 20000 | 2399 | 1578 | 730 | 3411 | 4420 ||",
    "claim": "** The length (L) of the anchor increases with mass, with a rate of increase that accelerates as mass increases. The length increases by an average of 80 mm for every 1000 kg increase in mass, suggesting an exponential relationship between mass and length.",
    "label": "refute"
  },
  {
    "id": "training_1374_4",
    "table_caption": "Table: Anchor weights and sizes. Mass of anchor(kg) H (mm) B1 (mm) H1 (mm) L (mm) H (mm) 3060 1283 841 380 1832 2374 4890 1498 984 415 2135 2769 6900 1681 1105 480 2391 3100 10500 1934 1273 600 2752 3571 14100 2135 1404 660 3036 3939 20000 2399 1578 730 3411 4420 doi:10.1371/journal.pone.0154954.t001 ",
    "table_content": "|| Mass of anchor(kg) | H (mm) | B1 (mm) | H1 (mm) | L (mm) | H (mm) ||\n|| 3060 | 1283 | 841 | 380 | 1832 | 2374 ||\n|| 4890 | 1498 | 984 | 415 | 2135 | 2769 ||\n|| 6900 | 1681 | 1105 | 480 | 2391 | 3100 ||\n|| 10500 | 1934 | 1273 | 600 | 2752 | 3571 ||\n|| 14100 | 2135 | 1404 | 660 | 3036 | 3939 ||\n|| 20000 | 2399 | 1578 | 730 | 3411 | 4420 ||",
    "claim": "The length (L) of the anchor increases with mass, with a rate of increase that decelerates as mass increases. The length increases by an average of 80 mm for every 1000 kg increase in mass, suggesting an exponential relationship between mass and length.",
    "label": "refute"
  },
  {
    "id": "training_692_4",
    "table_caption": "Table: Synergistic activity of HsLin06 with caspofungin against C. albicans SC5314 biofilms, resulting in biofilm formation inhibition*. Compound(s) [HsLin06] (μM) BIC50 CAS (μM) ± SEM Fold change FICI Signiﬁcance level CAS alone 0 0.90 ± 0.05 NA NA CAS + HsLin06 175 0.04 ± 0.00 25.67 16.25 *** 87.5 0.03 ± 0.00 27.87 8.14 ** 43.75 0.07 ± 0.01 14.27 4.13 *** 21.88 0.07 ± 0.01 13.50 2.11 *** 10.94 0.07 ± 0.02 13.67 1.09 *** 5.47 0.07 ± 0.02 13.03 0.59 *** 1.5 0.13 ± 0.00 7.76 0.28 0.75 0.22 ± 0.01 4.45 0.31 0.38 0.48 ± 0.04 2.04 0.57 * 0.19 0.68 ± 0.09 1.43 0.78 NS 0.09 1.05 ± 0.10 0.93 1.18 NS 0.05 0.93 ± 0.05 1.05 1.05 NS * BIC50 values were determined by CTB assay; mean ± SEM for n � 3 independent experiments is presented; BIC50, minimum inhibitory concentration that is required to inhibit bioﬁlm formation by 50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI 0.5 indicates ",
    "table_content": "|| Compound(s) | [HsLin06] (μM) | BIC50 CAS (μM) ± SEM | Fold change | FICI | Significance level ||\n|| CAS alone | 0 | 0.90 ± 0.05 | NA | NA | blank ||\n|| CAS + HsLin06 | 0.38 | 0.48 ± 0.04 | 2.04 | 0.57 | * ||\n|| CAS + HsLin06 | 0.19 | 0.68 ± 0.09 | 1.43 | 0.78 | NS ||\n|| CAS + HsLin06 | 0.09 | 1.05 ± 0.10 | 0.93 | 1.18 | NS ||\n|| CAS + HsLin06 | 0.05 | 0.93 ± 0.05 | 1.05 | 1.05 | NS ||\n|| CAS + HsLin06 | 175 | 0.04 ± 0.00 | 25.67 | 16.25 | *** ||\n|| CAS + HsLin06 | 87.5 | 0.03 ± 0.00 | 27.87 | 8.14 | ** ||\n|| CAS + HsLin06 | 43.75 | 0.07 ± 0.01 | 14.27 | 4.13 |  ***  ||\n|| CAS + HsLin06 | 21.88 | 0.07 ± 0.01 | 13.50 | 2.11 |  ***  ||\n|| CAS + HsLin06 | 10.94 | 0.07 ± 0.02 | 13.67 | 1.09 | *** ||\n|| CAS + HsLin06 | 5.47 | 0.07 ± 0.02 | 13.03 | 0.59 | *** ||\n|| CAS + HsLin06 |  1.5  |  0.13 ± 0.00  |  7.76  |  0.28  | blank ||\n|| CAS + HsLin06 |  0.75  |  0.22 ± 0.01  |  4.45  |  0.31  | blank ||",
    "claim": "The significance level of NS is observed at HsLin06 concentrations of 175, 43.75, 21.88, 10.94, and 5.47 μM, indicating that these concentrations do not have a statistically significant impact on reducing BIC50. This highlights the importance of specific concentration ranges for achieving significant biofilm inhibition.",
    "label": "refute"
  },
  {
    "id": "training_377_1",
    "table_caption": "Table: MS4 (92.5 and 96.8%, respectively) and MS7 (37.7 in genotypes J (18/53) and BEB4 (12/31). Table 2 PCR amplification efficiency of DNA from Enterocytozoon bieneusi ITS genotypes J and BEB4 at the MLST loci ITS genotype Farm ID No. of specimens No. of specimens amplified/No. of specimens analyzed MS1 MS3 MS4 MS7 J 1 0 – – – – 2 0 – – – – 3 129 35/38 85/129 35/38 14/38 4 15 14/15 0/15 14/15 6/15 5 1 – 0/1 – – BEB4 1 32 13/15 31/32 14/15 6/15 2 1 1/1 1/1 1/1 1/1 3 1 – 0/1 – – 4 0 – – – – 5 25 15/15 25/25 15/15 8/15 Total 204 78/84 142/204 79/84 35/84 ",
    "table_content": "|| ITS genotype | Farm ID | No. of specimens | No. of specimens amplified/No. of specimens analyzed | No. of specimens amplified/No. of specimens analyzed | No. of specimens amplified/No. of specimens analyzed | No. of specimens amplified/No. of specimens analyzed ||\n|| ITS genotype | Farm ID | No. of specimens | MS1 | MS3 | MS4 | MS7 ||\n|| BEB4 | 4 | 0 | – | – | – | – ||\n|| BEB4 | 5 | 25 | 15/15 | 25/25 | 15/15 | 8/15 ||\n|| Total | blank | 204 | 78/84 | 142/204 | 79/84 | 35/84 ||\n|| J | 1 | 0 | – | – | – | – ||\n|| J | 2 | 0 | – | – | – | – ||\n|| J | 3 | 129 | 35/38 | 85/129 | 35/38 | 14/38 ||\n|| J | 4 | 15 | 14/15 | 0/15 | 14/15 | 6/15 ||\n|| J | 5 | 1 | – | 0/1 | – | – ||\n|| BEB4 | 1 | 32 | 13/15 | 31/32 | 14/15 | 6/15 ||\n|| BEB4 | 2 | 1 | 1/1 | 1/1 | 1/1 | 1/1 ||\n|| BEB4 | 3 | 1 | – | 0/1 | – | – ||",
    "claim": "The amplification efficiency at the MS1 locus is the highest among all loci, with a success rate of approximately 69.6%, calculated by dividing the total number of specimens amplified by the total number of specimens analyzed across all farms and genotypes.",
    "label": "refute"
  },
  {
    "id": "training_710_4",
    "table_caption": "Table: Mean ratings for events as a function of emotion and repetition. Detail Positive Negative Neutral Total FR 3.83 (0.35) 3.66 (0.38) 3.62 (0.40) 3.70 (0.30) IR 3.18 (0.51) 3.01 (0.45) 2.89 (0.51) 3.03 (0.39) Total 3.51 (0.33) 3.34 (0.33) 3.26 (0.33) Plausibility Positive Negative Neutral Total FR 3.04 (0.48) 2.67 (0.55) 3.08 (0.49) 2.93 (0.44) IR 2.72 (0.58) 2.39 (0.46) 2.69 (0.48) 2.60 (0.45) Total 2.88 (0.48) 2.53 (0.48) 2.89 (0.40) Note. FR = frequently repeated, IR = infrequently repeated, Standard deviations are presented in parentheses. ",
    "table_content": "||  Detail  |  Positive  |  Negative  |  Neutral  |  Total  ||\n|| FR | 3.83 (0.35) | 3.66 (0.38) | 3.62 (0.40) | 3.70 (0.30) ||\n|| IR | 3.18 (0.51) | 3.01 (0.45) | 2.89 (0.51) | 3.03 (0.39) ||\n|| Total | 3.51 (0.33) | 3.34 (0.33) | 3.26 (0.33) | blank ||\n||  Plausibility  |  Positive  |  Negative  |  Neutral  |  Total  ||\n|| FR | 3.04 (0.48) | 2.67 (0.55) | 3.08 (0.49) | 2.93 (0.44) ||\n|| IR | 2.72 (0.58) | 2.39 (0.46) | 2.69 (0.48) | 2.60 (0.45) ||\n|| Total | 2.88 (0.48) | 2.53 (0.48) | 2.89 (0.40) | blank ||",
    "claim": "The mean plausibility rating for frequently repeated events is 0.13 higher than for infrequently repeated events, suggesting that repetition frequency significantly enhances the perceived plausibility of events.",
    "label": "refute"
  },
  {
    "id": "training_1438_4",
    "table_caption": "Table: Table 3 Detection of sentinel nodes in vulvar cancer using planar lymphoscintigraphy and SPECT/CT Authors Year Study type N Radiotracer (dosing) Detection rate by LSG (%) Detection rate by SPECT/CT (%) SLNs detected by LSG SLNs detected by SPECT/CT False negative rate (%) Beneder [46] 2008 Prospective 10 99mTc-nanocolloid (60 MBq) N/A N/A 26 38 0 Kraft [16] 2012 Retrospective 7 99mTc-nanocolloid (40 MBq) 100 100 N/A N/A N/A Belhoncine [19] 2013 Prospective 7 99mTc-cysteine rhenium colloid (37 MBq) 86 100 N/A N/A 0 Mathe´ron [49] 2013 Prospective 14 ICG-99mTc- nanocolloid (87 MBq) N/A N/A 39 39 0 Collarino [48] 2015 Retrospective 83 99mTc-nanocolloid (81 MBq) N/A N/A 192 217 0 N number of patients, LSG lymphoscintigraphy, SLNs sentinel lymph nodes, N/A not available, ICG indocyanine green ",
    "table_content": "|| Authors | Year | Study type |  N  | Radiotracer (dosing) | Detection rate by LSG (%) | Detection rate by SPECT/CT (%) | SLNs detected by LSG | SLNs detected by SPECT/CT | False negative rate (%) ||\n|| Beneder [ 46 ] | 2008 | Prospective | 10 |  99m Tc-nanocolloid (60 MBq) | N/A | N/A | 26 | 38 | 0 ||\n|| Kraft [ 16 ] | 2012 | Retrospective | 7 |  99m Tc-nanocolloid (40 MBq) | 100 | 100 | N/A | N/A | N/A ||\n|| Belhoncine [ 19 ] | 2013 | Prospective | 7 |  99m Tc-cysteine rhenium colloid (37 MBq) | 86 | 100 | N/A | N/A | 0 ||\n|| Mathéron [ 49 ] | 2013 | Prospective | 14 | ICG- 99m Tc-nanocolloid (87 MBq) | N/A | N/A | 39 | 39 | 0 ||\n|| Collarino [ 48 ] | 2015 | Retrospective | 83 |  99m Tc-nanocolloid (81 MBq) | N/A | N/A | 192 | 217 | 0 ||",
    "claim": "The false negative rate is consistently above 0% in studies where it is reported, indicating that when SLNs are detected, they are not always accurately identified as sentinel nodes, reflecting lower specificity of the detection methods used.",
    "label": "refute"
  },
  {
    "id": "training_212_6",
    "table_caption": "Table: Table 3 Composition of the ALA-rich oil (876 g/mol), olive oil (875 g/mol) and butter (fat-part 734 g/mol) meals1 Amount Energy (KJ) Fat (g) Protein (g) Carbohydrate (g) ALA-rich oil 35 g 1277 352 - - Olive oil 35 g 1277 352 0.2 0.2 Butter 42 g 1265 353 0.3 0.2 Milk for cooking, 3% fat 0.225 L 595 7.1 8.1 11.4 Semolina (wheat kernel) 20 g 291 0.3 2 14.2 Rye bread, one slice 38 g 408 1 2.9 17.8 Smoked ham, 3% fat or 9 g 44 0.3 2 0 soft Cheese4, 3% fat 9 g 43 0.3 1.6 0.3 Blackberry jam 32 g 262 0 0.1 14.8 Milk, 1.5% fat 0.2 L 410 3.1 7.2 10.3 Total 3290 47 23 69 1 Data from proximate analysis of ingredients. Analysed with Dietist XP, version 3.1, with the Swedish National Food Administration database (2008). 2 Equivalent to 0.04 mol. 3 Equivalent to 0.05 mol. ",
    "table_content": "|| blank | Amount | Energy (KJ) | Fat (g) | Protein (g) | Carbohydrate (g) ||\n|| ALA-rich oil | 35 g | 1277 | 35 2 | blank | blank ||\n|| Milk, 1.5% fat | 0.2 L | 410 | 3.1 | 7.2 | 10.3 ||\n|| Total | blank | 3290 | 47 | 23 | 69 ||\n|| Olive oil | 35 g | 1277 | 35 2 | 0.2 | 0.2 ||\n|| Butter | 42 g | 1265 | 35 3 | 0.3 | 0.2 ||\n|| Milk for cooking, 3% fat | 0.225 L | 595 | 7.1 | 8.1 | 11.4 ||\n|| Semolina (wheat kernel) | 20 g | 291 | 0.3 | 2 | 14.2 ||\n|| Rye bread, one slice | 38 g | 408 | 1 | 2.9 | 17.8 ||\n|| Smoked ham, 3% fat or | 9 g | 44 | 0.3 | 2 | 0 ||\n|| soft Cheese 4 , 3% fat | 9 g | 43 | 0.3 | 1.6 | 0.3 ||\n|| Blackberry jam | 32 g | 262 | 0 | 0.1 | 14.8 ||",
    "claim": "The energy density, calculated as energy per gram, is highest for butter at around 30.1 KJ/g, followed by ALA-rich oil and olive oil, both at approximately 36.5 KJ/g. This indicates that butter is the most energy-dense component of the meal.",
    "label": "refute"
  },
  {
    "id": "training_1331_2",
    "table_caption": "Table: Table 1 Comparison of mean and standard deviation of demographic characteristics and fertility status in two groups with bacterial vaginosis Variable Group treatment (P values)* Sucrose gel Mean ± SD Metronidazole Gel Mean ± SD Age (years) 32.31 ± 5.79 31.77 ± 5.07 0.678 Weight (kg) 64.17 ± 9.76 65.02 ± 9.90 0.716 Duration of marriage (years) 12.54 ± 7.42 10.32 ± 6.32 0.746 Age at first pregnancy (years) 19.62 ± 6.89 20.54 ± 6.04 0.557 The number of pregnancies 3.68 ± 2.45 3.22 ± 2.00 0.397 *Derived from t test ",
    "table_content": "|| Variable | Group treatment | Group treatment | ( P values)* ||\n|| Variable | Sucrose gel Mean ± SD | Metronidazole Gel Mean ± SD | ( P values)* ||\n|| Age (years) | 32.31 ± 5.79 | 31.77 ± 5.07 | 0.678 ||\n|| Weight (kg) | 64.17 ± 9.76 | 65.02 ± 9.90 | 0.716 ||\n|| Duration of marriage (years) | 12.54 ± 7.42 | 10.32 ± 6.32 | 0.746 ||\n|| Age at first pregnancy (years) | 19.62 ± 6.89 | 20.54 ± 6.04 | 0.557 ||\n|| The number of pregnancies | 3.68 ± 2.45 | 3.22 ± 2.00 | 0.397 ||",
    "claim": "The mean weight difference between the two groups is approximately 13%, with a standard deviation difference of about 1.4%. This indicates that the weight distribution is nearly identical between the groups, with minimal variability differences.",
    "label": "refute"
  },
  {
    "id": "training_1370_4",
    "table_caption": "Table: Table 8 Tree similarity score (mean and variance) among compression-based trees and evolutionary trees, obtained with NJ, of simulated datasets. Simulated Dataset #sequences Kimura Tajima-Nei Tamura TamuraTamura-Nei MCL NJ NJ NJ NJ NJ score variance score variance score variance score variance score variance 100 0.83 4.12E-04 0.83 4.65E-04 0.84 4.77E-04 0.83 4.98E-04 0.83 3.49E-04 150 0.86 8.64E-04 0.86 4.45E-04 0.86 6.44E-04 0.86 4.94E-04 0.86 5.77E-04 200 0.85 1.22E-03 0.85 1.07E-03 0.85 1.23E-03 0.85 9.71E-04 0.84 1.65E-03 500 0.81 1.83E-04 0.81 2.19E-04 0.81 2.23E-04 0.81 2.01E-04 0.81 2.76E-04 PhyloCore similarity scores of the simulated datasets. According to the number of barcode sequences, each simulation was replicated 25-fold, for a total of 100 simulated dataset. The scores (mean and variance) are obtained comparing compression-based trees, using NCD, with evolutionary-based trees obtained through all five evolutionary models. The trees were generated using NJ algorithm. ",
    "table_content": "|| Simulated Dataset #sequences | Kimura NJ | Kimura NJ | Tajima-Nei NJ | Tajima-Nei NJ | Tamura NJ | Tamura NJ | TamuraTamura-Nei NJ | TamuraTamura-Nei NJ | MCL NJ | MCL NJ ||\n|| Simulated Dataset #sequences | Kimura NJ | Kimura NJ | Tajima-Nei NJ | Tajima-Nei NJ | Tamura NJ | Tamura NJ | TamuraTamura-Nei NJ | TamuraTamura-Nei NJ | MCL NJ | MCL NJ ||\n|| Simulated Dataset #sequences | score | variance | score | variance | score | variance | score | variance | score | variance ||\n|| 100 | 0.83 | 4.12E-04 | 0.83 | 4.65E-04 | 0.84 | 4.77E-04 | 0.83 | 4.98E-04 | 0.83 | 3.49E-04 ||\n|| 150 | 0.86 | 8.64E-04 | 0.86 | 4.45E-04 | 0.86 | 6.44E-04 | 0.86 | 4.94E-04 | 0.86 | 5.77E-04 ||\n|| 200 | 0.85 | 1.22E-03 | 0.85 | 1.07E-03 | 0.85 | 1.23E-03 | 0.85 | 9.71E-04 | 0.84 | 1.65E-03 ||\n|| 500 | 0.81 | 1.83E-04 | 0.81 | 2.19E-04 | 0.81 | 2.23E-04 | 0.81 | 2.01E-04 | 0.81 | 2.76E-04 ||",
    "claim": "The variance for the Kimura model increases by a factor of approximately 6.67 from 100 to 200 sequences, but then decreases by a factor of about 6.67 from 200 to 500 sequences, showing a non-linear variance trend with sequence count.",
    "label": "refute"
  },
  {
    "id": "training_1416_4",
    "table_caption": "Table: Performance evaluation of the feature detectors for target detection. Method Detect. Rate (%) Execution Time (ms) Position Error (px) Scaling Error (%) SURF 8 71.5 41.7 5 SIFT 54 17.4 2.7 45 FAST 98 8.3 2.2 37 Shi–Tomasi 96 7.4 2.2 41 As shown in Table 1, we evaluate the detection success rate, the average execution time per frame and ",
    "table_content": "|| Method | Detect. Rate (%) | Execution Time (ms) | Position Error (px) | Scaling Error (%) ||\n|| SURF | 8 | 71.5 | 41.7 | 5 ||\n|| SIFT | 54 | 17.4 | 2.7 | 45 ||\n|| FAST | 98 | 8.3 | 2.2 | 37 ||\n|| Shi-Tomasi | 96 | 7.4 | 2.2 | 41 ||",
    "claim": "The scaling error for the SURF method is higher than that of the SIFT method, indicating a less precise scaling capability.",
    "label": "refute"
  },
  {
    "id": "training_884_1",
    "table_caption": "Table: Table 3 Echocardiographic-derived cardiac output, cardiac index and pulmonary vascular resistance First author Resting CO (L.min1) Exercise CO (L.min1) Resting CI (L.min1.m2) Exercise CI (L.min1.m2) Resting PVR (WU) Exercise PVR (WU) Huez Total 3.0 8.7 2.9 D’Alto Total 3.0 5.8 Baptista Total 3.6 9.2 sPAP <50 mmHg 3.8* 8.5 sPAP ≥50 mmHg 5.1* 9.9 Suzuki Total 5.5 7.6 1.7 1.9 sPAP <50 mmHg 5.5 7.6 1.6* 1.8* sPAP ≥50 mmHg 5.5 7.6 1.9* 2.3* Voilliot Total 3.7 7.2 1.9 2.5 sPAP ≥50 mmHg 3.9 7.7 1.4* 2.1* sPAP >50 mmHg 3.5 6.5 2.6* 3.6* Gargani sPAP <50 mmHg 2.5 4.6 1.7 2.0* sPAP ≥50 mmHg 2.7 4.9 1.7 2.3* Results are presented as means. *Comparison between patients with maximum exercise-induced systolic pulmonary arterial pressure (sPAP) <50 mmHg and ≥50 mmHg statistically significantly different (p < 0.05). CI cardiac index, CO cardiac output, PVR pulmonary vascular resistance, WU Wood units ",
    "table_content": "|| First author | Resting CO (L.min 1 ) | Exercise CO (L.min 1 ) | Resting CI (L.min 1 .m 2 ) | Exercise CI (L.min 1 .m 2 ) | Resting PVR (WU) | Exercise PVR (WU) ||\n|| Huez | Huez | Huez | Huez | Huez | Huez | Huez ||\n|| Total | 5.5 | 7.6 | blank | blank | 1.7 | 1.9 ||\n|| sPAP <50 mmHg | 5.5 | 7.6 | blank | blank | 1.6* | 1.8* ||\n|| sPAP ≥50 mmHg | 5.5 | 7.6 | blank | blank | 1.9* | 2.3* ||\n|| Voilliot | Voilliot | Voilliot | Voilliot | Voilliot | Voilliot | Voilliot ||\n|| Total | 3.7 | 7.2 | blank | blank | 1.9 | 2.5 ||\n|| sPAP ≥50 mmHg | 3.9 | 7.7 | blank | blank | 1.4* | 2.1* ||\n|| sPAP >50 mmHg | 3.5 | 6.5 | blank | blank | 2.6* | 3.6* ||\n|| Gargani | Gargani | Gargani | Gargani | Gargani | Gargani | Gargani ||\n|| sPAP <50 mmHg | blank | blank | 2.5 | 4.6 | 1.7 | 2.0* ||\n|| sPAP ≥50 mmHg | blank | blank | 2.7 | 4.9 | 1.7 | 2.3* ||\n|| Total | 3.0 | 8.7 | blank | blank | blank | 2.9 ||\n|| D’Alto | D’Alto | D’Alto | D’Alto | D’Alto | D’Alto | D’Alto ||\n|| Total | blank | blank | 3.0 | 5.8 | blank | blank ||\n|| Baptista | Baptista | Baptista | Baptista | Baptista | Baptista | Baptista ||\n|| Total | 3.6 | 9.2 | blank | blank | blank | blank ||\n|| sPAP <50 mmHg | 3.8* | 8.5 | blank | blank | blank | blank ||\n|| sPAP ≥50 mmHg | 5.1* | 9.9 | blank | blank | blank | blank ||\n|| Suzuki | Suzuki | Suzuki | Suzuki | Suzuki | Suzuki | Suzuki ||",
    "claim": "The increase in cardiac output from rest to exercise is more pronounced in the Baptista group compared to the Huez group, with a relative increase that is approximately 1.5 times greater.",
    "label": "refute"
  },
  {
    "id": "training_884_1",
    "table_caption": "Table: Table 3 Echocardiographic-derived cardiac output, cardiac index and pulmonary vascular resistance First author Resting CO (L.min1) Exercise CO (L.min1) Resting CI (L.min1.m2) Exercise CI (L.min1.m2) Resting PVR (WU) Exercise PVR (WU) Huez Total 3.0 8.7 2.9 D’Alto Total 3.0 5.8 Baptista Total 3.6 9.2 sPAP <50 mmHg 3.8* 8.5 sPAP ≥50 mmHg 5.1* 9.9 Suzuki Total 5.5 7.6 1.7 1.9 sPAP <50 mmHg 5.5 7.6 1.6* 1.8* sPAP ≥50 mmHg 5.5 7.6 1.9* 2.3* Voilliot Total 3.7 7.2 1.9 2.5 sPAP ≥50 mmHg 3.9 7.7 1.4* 2.1* sPAP >50 mmHg 3.5 6.5 2.6* 3.6* Gargani sPAP <50 mmHg 2.5 4.6 1.7 2.0* sPAP ≥50 mmHg 2.7 4.9 1.7 2.3* Results are presented as means. *Comparison between patients with maximum exercise-induced systolic pulmonary arterial pressure (sPAP) <50 mmHg and ≥50 mmHg statistically significantly different (p < 0.05). CI cardiac index, CO cardiac output, PVR pulmonary vascular resistance, WU Wood units ",
    "table_content": "|| First author | Resting CO (L.min 1 ) | Exercise CO (L.min 1 ) | Resting CI (L.min 1 .m 2 ) | Exercise CI (L.min 1 .m 2 ) | Resting PVR (WU) | Exercise PVR (WU) ||\n|| Huez | Huez | Huez | Huez | Huez | Huez | Huez ||\n|| Total | 5.5 | 7.6 | blank | blank | 1.7 | 1.9 ||\n|| sPAP <50 mmHg | 5.5 | 7.6 | blank | blank | 1.6* | 1.8* ||\n|| sPAP ≥50 mmHg | 5.5 | 7.6 | blank | blank | 1.9* | 2.3* ||\n|| Voilliot | Voilliot | Voilliot | Voilliot | Voilliot | Voilliot | Voilliot ||\n|| Total | 3.7 | 7.2 | blank | blank | 1.9 | 2.5 ||\n|| sPAP ≥50 mmHg | 3.9 | 7.7 | blank | blank | 1.4* | 2.1* ||\n|| sPAP >50 mmHg | 3.5 | 6.5 | blank | blank | 2.6* | 3.6* ||\n|| Gargani | Gargani | Gargani | Gargani | Gargani | Gargani | Gargani ||\n|| sPAP <50 mmHg | blank | blank | 2.5 | 4.6 | 1.7 | 2.0* ||\n|| sPAP ≥50 mmHg | blank | blank | 2.7 | 4.9 | 1.7 | 2.3* ||\n|| Total | 3.0 | 8.7 | blank | blank | blank | 2.9 ||\n|| D’Alto | D’Alto | D’Alto | D’Alto | D’Alto | D’Alto | D’Alto ||\n|| Total | blank | blank | 3.0 | 5.8 | blank | blank ||\n|| Baptista | Baptista | Baptista | Baptista | Baptista | Baptista | Baptista ||\n|| Total | 3.6 | 9.2 | blank | blank | blank | blank ||\n|| sPAP <50 mmHg | 3.8* | 8.5 | blank | blank | blank | blank ||\n|| sPAP ≥50 mmHg | 5.1* | 9.9 | blank | blank | blank | blank ||\n|| Suzuki | Suzuki | Suzuki | Suzuki | Suzuki | Suzuki | Suzuki ||",
    "claim": "The increase in cardiac output from rest to exercise is more pronounced in the Huez group compared to the Baptista group, with a relative increase that is approximately 1.5 times greater.",
    "label": "refute"
  },
  {
    "id": "training_301_2",
    "table_caption": "Table: Motor activity during ethanol and control treatment. Time (min) Difference in activity Standard error t Significance (2-tailed) 0–10 311 381 0.82 0.441 11–20 333 229 1.45 0.189 21–30 2411 237 21.73 0.127 31–40 2150 238 20.63 0.548 41–50 332 165 2.00 0.085 51–60 2415 255 21.63 0.147 Table 1 shows the difference in locomotor activity between control and ethanol gavage in ten minute epochs. Positive numbers represent higher activity control condition. Negative numbers represent higher activity rates in the ethanol condition. T-test results are included. ",
    "table_content": "|| Time (min) | Difference in activity | Standard error | t | Significance (2-tailed) ||\n|| 0–10 | 311 | 381 | 0.82 | 0.441 ||\n|| 11–20 | 333 | 229 | 1.45 | 0.189 ||\n|| 21–30 | −411 | 237 | −1.73 | 0.127 ||\n|| 31–40 | −150 | 238 | −0.63 | 0.548 ||\n|| 41–50 | 332 | 165 | 2.00 | 0.085 ||\n|| 51–60 | −415 | 255 | −1.63 | 0.147 ||",
    "claim": "The maximum activity difference occurs in the 21–30 minute interval, with a substantial negative value, indicating a pronounced increase in ethanol-induced activity. Conversely, the minimum difference is observed in the 31–40 minute interval, where the activity under control conditions is only slightly higher than under ethanol.",
    "label": "refute"
  },
  {
    "id": "training_1035_2",
    "table_caption": "Table: aspects tributes and and around vices and 15, as manage as Some was Table 2 Results of the CASP quality appraisal and classification of papers Study ID Number of questioned answered YES Number of questioned answered CAN’T TELL Number of questioned answered NO Iliffe 2014a (Bamford 2014; Iliffe 2014b) 8 1 0 Gladman 2007 [16] 7 2 0 Kosteniuk 2014 [17] 7 2 0 Minkman 2009 [18] 6 3 0 Van Mierlo 2014 [19] 8 1 0 ",
    "table_content": "|| Study ID | Number of questioned answered YES | Number of questioned answered CAN’T TELL | Number of questioned answered NO ||\n|| Iliffe 2014a (Bamford 2014; Iliffe 2014b) | 8 | 1 | 0 ||\n|| Gladman 2007 [ 16 ] | 7 | 2 | 0 ||\n|| Kosteniuk 2014 [ 17 ] | 7 | 2 | 0 ||\n|| Minkman 2009 [ 18 ] | 6 | 3 | 0 ||\n|| Van Mierlo 2014 [ 19 ] | 8 | 1 | 0 ||",
    "claim": "The proportion of \"YES\" answers for Iliffe 2014a and Van Mierlo 2014 is approximately 88.89%, which is lower than the 77.78% for Gladman 2007 and Kosteniuk 2014, and 66.67% for Minkman 2009.",
    "label": "refute"
  },
  {
    "id": "training_5_2",
    "table_caption": "Table: Heart weights (HW), body weights (BW), cardiac function, plasma creatine content and creatine uptake during development in the rat heart Age (days) -2 ( fetal ) 7 13 21 33 50 80 ANOVA HW (g) 0.039 ± 0.01a 0.13 ± 0.01b 0.17 ± 0.06bc 0.24 ± 0.03c 0.44 ± 0.04d 0.70 ± 0.07e 1.17 ± 0.02f p < 0.001 [4] [4] [7] [5] [8] [6] [8] BW (g) 3.59 ± 0.34a 22.0 ± 1.78b 35.6 ± 7.08c 41.5 ± 4.1c 78.6 ± 2.4d 178 ± 8.6e 296 ± 5.3f p < 0.001 [4] [4] [7] [5] [8] [6] [8] HW/BW *1000 10.9 ± 2.1a 5.79 ± 0.80ab 4.81 ± 1.15ab 5.84 ± 0.70a 5.58 ± 0.47a 3.93 ± 0.32b b 3.94 ± 0.10b p < 0.001 [4] [4] [7] [5] [5] [6] [8] HR (bpm) - - 321 ± 5.7 248 ± 4.9 348 ± 5.6 318 ± 34 307 ± 45 NS [4] [4] [4] [4] [4] LDVP (mm Hg) - - 69 ± 12.7 88.6 ± 0.36 65.7 ± 7.2 75.7 ± 10.2 97.1 ± 27.6 NS [4] [4] [4] [4] [4] RPP (mm Hg/bpm) - - 22129 ± 3673 22047 ± 555 22879 ± 2874 24189 ± 5524 29673 ± 8913 NS [4] [4] [4] [4] [4] Creatine uptake - - 3.03 ± 0.55a 3.66 ± 0.79ab 3.85 ± 0.62abc 4.68 ± 0.54bc 4.99 ± 0.52c p < 0.001 (nmol/min/g w.w) [6] [5] [5] [5] [6] Plasma creatine - 0.971 ± 0.07a 0.669 ± 0.16ab 0.678 ± 0.19ac 0.627 ± 0.12bc 0.558 ± 0.06bc 0.536 ± 0.08bc p = 0.002 (mmol/L) [4] [4] [4] [4] [4] [4] Data are presented as means ± S.E and sample size are given in brackets. Values within a row with different superscript letters are significantly different to all other time points (p < 0.05, creatine uptake, plasma creatine: Bonferroni; HW, BW, HW/BW*1000: Dunnett T3, ANOVA \"test for linear trend\": as indicated). ",
    "table_content": "|| Age (days) | -2 ( fetal ) | 7 | 13 | 21 | 33 | 50 | 80 | ANOVA ||\n|| HW (g) | 0.039 ± 0.01 a | 0.13 ± 0.01 b | 0.17 ± 0.06 bc | 0.24 ± 0.03 c | 0.44 ± 0.04 d | 0.70 ± 0.07 e | 1.17 ± 0.02 f | p < 0.001 ||\n|| LDVP (mm Hg) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| RPP (mm Hg/bpm) | blank | blank | 22129 ± 3673 | 22047 ± 555 | 22879 ± 2874 | 24189 ± 5524 | 29673 ± 8913 | NS ||\n|| RPP (mm Hg/bpm) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| Creatine uptake | blank | blank | 3.03 ± 0.55 a | 3.66 ± 0.79 ab | 3.85 ± 0.62 abc | 4.68 ± 0.54 bc | 4.99 ± 0.52 c | p < 0.001 ||\n|| (nmol/min/g w.w) | blank | blank | [6] | [5] | [5] | [5] | [6] | blank ||\n|| Plasma creatine | blank | 0.971 ± 0.07 a | 0.669 ± 0.16 ab | 0.678 ± 0.19 ac | 0.627 ± 0.12 bc | 0.558 ± 0.06 bc | 0.536 ± 0.08 bc | p = 0.002 ||\n|| (mmol/L) | blank | [4] | [4] | [4] | [4] | [4] | [4] | blank ||\n|| HW (g) | [4] | [4] | [7] | [5] | [8] | [6] | [8] | blank ||\n|| BW (g) | 3.59 ± 0.34 a | 22.0 ± 1.78 b | 35.6 ± 7.08 c | 41.5 ± 4.1 c | 78.6 ± 2.4 d | 178 ± 8.6 e | 296 ± 5.3 f | p < 0.001 ||\n|| BW (g) | [4] | [4] | [7] | [5] | [8] | [6] | [8] | blank ||\n|| HW/BW *1000 | 10.9 ± 2.1 a | 5.79 ± 0.80 ab | 4.81 ± 1.15 ab | 5.84 ± 0.70 a | 5.58 ± 0.47 a | 3.93 ± 0.32 b | b 3.94 ± 0.10 b | p < 0.001 ||\n|| HW/BW *1000 | [4] | [4] | [7] | [5] | [5] | [6] | [8] | blank ||\n|| HR (bpm) | blank | blank | 321 ± 5.7 | 248 ± 4.9 | 348 ± 5.6 | 318 ± 34 | 307 ± 45 | NS ||\n|| HR (bpm) | blank | blank | [4] | [4] | [4] | [4] | [4] | blank ||\n|| LDVP (mm Hg) | blank | blank | 69 ± 12.7 | 88.6 ± 0.36 | 65.7 ± 7.2 | 75.7 ± 10.2 | 97.1 ± 27.6 | NS ||",
    "claim": "The body weight of rats increases by a factor of approximately 8.25 from fetal stage to 80 days, indicating a less pronounced growth compared to heart weight. This suggests that while the heart grows significantly, the overall body growth is less substantial, reflecting the general somatic growth during early development.",
    "label": "refute"
  },
  {
    "id": "training_784_5",
    "table_caption": "Table: Effect of chronic exposure to two types of gasoline vapour on the duration of aggressive behaviour in male rats. Parameter Duration of aggression/sec GROUP Tooth chattering Threat posture Leaping and biting Boxing position Control 0.9 ± 0.23 1.5 ± 0.54 1.9 ± 0.72 1 ± 0.42 Leaded gasoline 4.7 ± 1.1 a** 6 ± 1.2 a* 5.5 ± 1.45 2.2 ± 0.63 Unleaded gasoline 4.4 ± 0.92 a* 6.2 ± 1.31 a* 5.9 ± 1.50 2.2 ± 0.74 Values are expressed as means ± SE a: significantly different from the control group. ",
    "table_content": "|| GROUP | blank | Parameter | Parameter | Parameter ||\n|| GROUP | Duration of aggression/sec | Duration of aggression/sec | Duration of aggression/sec | Duration of aggression/sec ||\n|| GROUP | Tooth chattering | Threat posture | Leaping and biting | Boxing position ||\n|| Control | 0.9 ± 0.23 | 1.5 ± 0.54 | 1.9 ± 0.72 | 1 ± 0.42 ||\n|| Leaded gasoline | 4.7 ± 1.1 a** | 6 ± 1.2 a* | 5.5 ± 1.45 | 2.2 ± 0.63 ||\n|| Unleaded gasoline | 4.4 ± 0.92 a* | 6.2 ± 1.31 a* | 5.9 ± 1.50 | 2.2 ± 0.74 ||",
    "claim": "The duration of 'boxing position' is consistently the lowest across all groups, with a mean duration that is less than half of the next lowest behavior, indicating a consistent pattern of lower aggression in this behavior.",
    "label": "refute"
  },
  {
    "id": "training_1125_1",
    "table_caption": "Table: Results of in vitro albumin precipitation test (mg/L). Test solutions (1) Saline (control) Enox. 400 Enox. 400–40% Ethanol 10% WB 20% WB 10% WB 20% WB 10% WB 20% WB Blood sample Donor sex (Age) #1 H (56) - - 21.7 6.7 33.2 82.8 #2 F (32) - - 11.7 15.1 17.8 46.6 #3 F (32) - - 21.4 13.8 46 146 #4 H (34) - - 11 8.61 27.7 148 #5 F (30) - - 5.2 11.0 10.2 95.3 mean - - 14.2 11.0 26.98 103.74 SD - - 7.1 3.4 13.85 43.36 (1) Test solutions consisted of 0.5 (10%) or 1 mL (20%) WB and 4 mL or 4.5 mL of either saline (control), Enoxaparin 400, or Enoxaparin 400–40% Ethanol solution. ",
    "table_content": "|| Blood sample | Test solutions (1) Donor sex (Age) | Saline (control) | Saline (control) | Enox. 400 | Enox. 400 | Enox. 400–40% Ethanol | Enox. 400–40% Ethanol ||\n|| Blood sample | Test solutions (1) Donor sex (Age) | 10% WB | 20% WB | 10% WB | 20% WB | 10% WB | 20% WB ||\n|| Blood sample | Test solutions (1) Donor sex (Age) | 10% WB | 20% WB | 10% WB | 20% WB | 10% WB | 20% WB ||\n|| #1 | H (56) | blank | blank | 21.7 | 6.7 | 33.2 | 82.8 ||\n|| #2 | F (32) | blank | blank | 11.7 | 15.1 | 17.8 | 46.6 ||\n|| #3 | F (32) | blank | blank | 21.4 | 13.8 | 46 | 146 ||\n|| #4 | H (34) | blank | blank | 11 | 8.61 | 27.7 | 148 ||\n|| #5 | F (30) | blank | blank | 5.2 | 11.0 | 10.2 | 95.3 ||\n|| #5 | mean | blank | blank | 14.2 | 11.0 | 26.98 | 103.74 ||\n|| #5 | SD | blank | blank | 7.1 | 3.4 | 13.85 | 43.36 ||",
    "claim": "The albumin precipitation for Enoxaparin 400–40% Ethanol at 20% WB is approximately 3.85 times higher than that for Enoxaparin 400 at 20% WB, indicating a substantial increase in precipitation with the addition of ethanol.",
    "label": "refute"
  },
  {
    "id": "training_1125_1",
    "table_caption": "Table: Results of in vitro albumin precipitation test (mg/L). Test solutions (1) Saline (control) Enox. 400 Enox. 400–40% Ethanol 10% WB 20% WB 10% WB 20% WB 10% WB 20% WB Blood sample Donor sex (Age) #1 H (56) - - 21.7 6.7 33.2 82.8 #2 F (32) - - 11.7 15.1 17.8 46.6 #3 F (32) - - 21.4 13.8 46 146 #4 H (34) - - 11 8.61 27.7 148 #5 F (30) - - 5.2 11.0 10.2 95.3 mean - - 14.2 11.0 26.98 103.74 SD - - 7.1 3.4 13.85 43.36 (1) Test solutions consisted of 0.5 (10%) or 1 mL (20%) WB and 4 mL or 4.5 mL of either saline (control), Enoxaparin 400, or Enoxaparin 400–40% Ethanol solution. ",
    "table_content": "|| Blood sample | Test solutions (1) Donor sex (Age) | Saline (control) | Saline (control) | Enox. 400 | Enox. 400 | Enox. 400–40% Ethanol | Enox. 400–40% Ethanol ||\n|| Blood sample | Test solutions (1) Donor sex (Age) | 10% WB | 20% WB | 10% WB | 20% WB | 10% WB | 20% WB ||\n|| Blood sample | Test solutions (1) Donor sex (Age) | 10% WB | 20% WB | 10% WB | 20% WB | 10% WB | 20% WB ||\n|| #1 | H (56) | blank | blank | 21.7 | 6.7 | 33.2 | 82.8 ||\n|| #2 | F (32) | blank | blank | 11.7 | 15.1 | 17.8 | 46.6 ||\n|| #3 | F (32) | blank | blank | 21.4 | 13.8 | 46 | 146 ||\n|| #4 | H (34) | blank | blank | 11 | 8.61 | 27.7 | 148 ||\n|| #5 | F (30) | blank | blank | 5.2 | 11.0 | 10.2 | 95.3 ||\n|| #5 | mean | blank | blank | 14.2 | 11.0 | 26.98 | 103.74 ||\n|| #5 | SD | blank | blank | 7.1 | 3.4 | 13.85 | 43.36 ||",
    "claim": "The albumin precipitation for Enoxaparin 400–40% Ethanol at 20% WB is approximately 1.85 times higher than that for Enoxaparin 400 at 20% WB, indicating a substantial increase in precipitation with the addition of ethanol.",
    "label": "refute"
  },
  {
    "id": "training_25_5",
    "table_caption": "Table: Reasons of Approval or Rejection in at least one of the Case Vignettes. Human geneticists ‘‘worldwide’’ 1995 (sex selection via sex-selective abortion) Specialists in reproductive medicine Germany 2006 (sex selection via PID/ MicroSort) Reasons of Approval 1. In deference to the autonomy of the patient 29% 15.8% 2. In deference to the culture or the religion of the patient 6% 13.2% 3. Retain the unity of the family 3% 6.1% 4. The patients have the right of any service they can pay for 8% 0 Reasons of Rejection 1. Prevent a possible gender discrimination 7% 71.9% 2. Prevent the misuse of reproduction techniques which are intended to identify genetically caused diseases 43% 51.8% 3. The refusal of the abortion of a healthy embryo 16% 29.8% 4. The right of a professional to refuse a service 7% 34.2% 5. To avoid the tendency of a cosmetic selection 1% 50.0% 6. To preserve a balance of genders 3% 21.9% doi:10.1371/journal.pone.0056390.t006 ",
    "table_content": "|| blank | Human geneticists“worldwide” 1995 (sexselection via sex-selectiveabortion) | Specialists in reproductive medicineGermany 2006 (sex selection via PID/MicroSort) ||\n||  Reasons of Approval  |  Reasons of Approval  |  Reasons of Approval  ||\n|| 4. The right of a professional to refuse a service | 7% | 34.2% ||\n|| 5. To avoid the tendency of a cosmetic selection | 1% | 50.0% ||\n|| 6. To preserve a balance of genders | 3% | 21.9% ||\n|| 1. In deference to the autonomy of the patient | 29% | 15.8% ||\n|| 2. In deference to the culture or the religion of the patient | 6% | 13.2% ||\n|| 3. Retain the unity of the family | 3% | 6.1% ||\n|| 4. The patients have the right of any service they can pay for | 8% | 0 ||\n||  Reasons of Rejection  |  Reasons of Rejection  |  Reasons of Rejection  ||\n|| 1. Prevent a possible gender discrimination | 7% | 71.9% ||\n|| 2. Prevent the misuse of reproduction techniques which areintended to identify genetically caused diseases | 43% | 51.8% ||\n|| 3. The refusal of the abortion of a healthy embryo | 16% | 29.8% ||",
    "claim": "The rejection rate to avoid the tendency of cosmetic selection increased by 400% from 1995 to 2006. This modest increase highlights a slight shift in ethical priorities, emphasizing the importance of preventing non-medical, aesthetic motivations in reproductive choices.",
    "label": "refute"
  },
  {
    "id": "training_625_4",
    "table_caption": "Table: Term Total Expected Hits Raw p Biosynthesis of unsaturated fatty acids 42 0.65906 6 2.62E-05 Arachidonic acid metabolism 36 0.56491 4 0.0019285 Linoleic acid metabolism 5 0.078459 2 0.0022856 Sphingolipid metabolism 21 0.32953 3 0.0037176 Glycerophospholipid metabolism 30 0.47076 3 0.010353 Cyanoamino acid metabolism 6 0.094151 1 0.09069 alpha-Linolenic acid metabolism 9 0.14123 1 0.13304 Methane metabolism 9 0.14123 1 0.13304 Fatty acid biosynthesis 43 0.67475 2 0.1443 Steroid hormone biosynthesis 70 1.0984 2 0.3014 Cysteine and methionine metabolism 28 0.43937 1 0.36059 Glycine, serine and threonine metabolism 32 0.50214 1 0.40061 Steroid biosynthesis 35 0.54922 1 0.42905 Primary bile acid biosynthesis 46 0.72183 1 0.52269 Aminoacyl-tRNA biosynthesis 67 1.0514 1 0.66232 Table 5. Analyzed pathways of metabolomics data differently regulated in lung tissue obstructive pulmonary disease rats. ",
    "table_content": "|| Term | Total | Expected | Hits | Raw p ||\n|| Biosynthesis of unsaturated fatty acids | 42 | 0.65906 | 6 | 2.62E-05 ||\n|| Steroid hormone biosynthesis | 70 | 1.0984 | 2 | 0.3014 ||\n|| Cysteine and methionine metabolism | 28 | 0.43937 | 1 | 0.36059 ||\n|| Glycine, serine and threonine metabolism | 32 | 0.50214 | 1 | 0.40061 ||\n|| Steroid biosynthesis | 35 | 0.54922 | 1 | 0.42905 ||\n|| Primary bile acid biosynthesis | 46 | 0.72183 | 1 | 0.52269 ||\n|| Aminoacyl-tRNA biosynthesis | 67 | 1.0514 | 1 | 0.66232 ||\n|| Arachidonic acid metabolism | 36 | 0.56491 | 4 | 0.0019285 ||\n|| Linoleic acid metabolism | 5 | 0.078459 | 2 | 0.0022856 ||\n|| Sphingolipid metabolism | 21 | 0.32953 | 3 | 0.0037176 ||\n|| Glycerophospholipid metabolism | 30 | 0.47076 | 3 | 0.010353 ||\n|| Cyanoamino acid metabolism | 6 | 0.094151 | 1 | 0.09069 ||\n|| alpha-Linolenic acid metabolism | 9 | 0.14123 | 1 | 0.13304 ||\n|| Methane metabolism | 9 | 0.14123 | 1 | 0.13304 ||\n|| Fatty acid biosynthesis | 43 | 0.67475 | 2 | 0.1443 ||",
    "claim": "The total observed hits for amino acid metabolism pathways (cysteine and methionine metabolism, glycine, serine and threonine metabolism, and aminoacyl-tRNA biosynthesis) is 3, which is close to the expected total of approximately 1.99, suggesting a relatively balanced representation of these pathways.",
    "label": "refute"
  },
  {
    "id": "training_1019_3",
    "table_caption": "Table: Description and model ranking based on the full model (Eq 2) for Atlantic horse mackerel. Model rank AICc Delta AICc Akaike weight Para-meter Factor a0, b0 a1, b1 a2, b2 a3, b3 a4, b4 a5, b5 1 93.69 0.00 0.5400 L50 25.91 (2.48) - -0.21 (0.05) -2.94 (0.74) - - SR 1.72 (0.53) 1.67 (0.58) - - - - 2 95.50 1.80 0.2191 L50 20.52 (2.68) 1.82 (0.67) -0.14 (0.05) -1.98 (0.74) - - SR 2.83 (0.32) - - - - - 3 96.27 2.57 0.1492 L50 12.34 (0.66) 2.52 (0.74) - - - - SR 2.95 (0.26) - - - - - 4 97.48 3.78 0.0815 L50 23.84 (2.08) - -0.17 (0.04) -2.39 (0.55) - - SR 2.91 (0.34) - - - - - 5 101.62 7.93 0.0103 L50 14.13 (0.45) - - - - - SR 1.83 (0.62) 1.67 (0.69) - - - - Delta AICc: difference between the AICc value of two models: the model used and the one with the lowest AICc value. Values in brackets: standard error. ",
    "table_content": "|| Model rank | AICc | Delta AICc | Akaike weight | Para-meter | Factor | Factor | Factor | Factor | Factor | Factor ||\n|| Model rank | AICc | Delta AICc | Akaike weight | Para-meter | a 0 , b 0 | a 1 , b 1 | a 2 , b 2 | a 3 , b 3 | a 4 , b 4 | a 5 , b 5 ||\n|| 5 | 101.62 | 7.93 | 0.0103 | L50 | 14.13 (0.45) | blank | blank | blank | blank | blank ||\n|| 5 | blank | blank | blank | SR | 1.83 (0.62) | 1.67 (0.69) | blank | blank | blank | blank ||\n|| 1 | 93.69 | 0.00 | 0.5400 | L50 | 25.91 (2.48) | blank | -0.21 (0.05) | -2.94 (0.74) | blank | blank ||\n|| 1 | blank | blank | blank | SR | 1.72 (0.53) | 1.67 (0.58) | blank | blank | blank | blank ||\n|| 2 | 95.50 | 1.80 | 0.2191 | L50 | 20.52 (2.68) | 1.82 (0.67) | -0.14 (0.05) | -1.98 (0.74) | blank | blank ||\n|| 2 | blank | blank | blank | SR | 2.83 (0.32) | blank | blank | blank | blank | blank ||\n|| 3 | 96.27 | 2.57 | 0.1492 | L50 | 12.34 (0.66) | 2.52 (0.74) | blank | blank | blank | blank ||\n|| 3 | blank | blank | blank | SR | 2.95 (0.26) | blank | blank | blank | blank | blank ||\n|| 4 | 97.48 | 3.78 | 0.0815 | L50 | 23.84 (2.08) | blank | -0.17 (0.04) | -2.39 (0.55) | blank | blank ||\n|| 4 | blank | blank | blank | SR | 2.91 (0.34) | blank | blank | blank | blank | blank ||",
    "claim": "The factor a0 for L50 in the first model is approximately 1.84 times greater than that in the second model, suggesting a larger estimated size at which 50% of the population is mature. This difference in factor a0 values reflects a significant variation in the biological interpretation of the models regarding the maturity size of the species.",
    "label": "refute"
  },
  {
    "id": "training_210_4",
    "table_caption": "Table: a (95%) of at year or were ei- with different numbers of classes No. of classes AIC BIC Sample size adjusted BIC Entropy 2 24 896 25 146 24 959 0.867 3 24 215 24 631 24 320 0.829 4 23 892 24 499 24 045 0.836 5 23 711 24 534 23 918 0.809 6 23 575 24 640 23 843 0.830 LTA, Latent transition analysis; AIC, Akaike’s Information Criterion; BIC, Bayesian Information Criterion. ",
    "table_content": "|| No. of classes | AIC | BIC | Sample size adjusted BIC | Entropy ||\n|| 2 | 24 896 | 25 146 | 24 959 | 0.867 ||\n|| 3 | 24 215 | 24 631 | 24 320 | 0.829 ||\n|| 4 | 23 892 | 24 499 | 24 045 | 0.836 ||\n|| 5 | 23 711 | 24 534 | 23 918 | 0.809 ||\n|| 6 | 23 575 | 24 640 | 23 843 | 0.830 ||",
    "claim": "Entropy values fluctuate with the number of classes, with a peak at 5 classes and a trough at 2 classes. The calculation of entropy change involves determining the percentage difference between the highest and lowest values, showing a 6.7% variation in classification uncertainty.",
    "label": "refute"
  },
  {
    "id": "training_338_4",
    "table_caption": "Table: Characteristics of priapism. N Mean age (years) Mean duration of priapism (hours) Low ﬂow 77 41 58 Neurogenic∗ 15 35 6 High ﬂow 2 19 252 ∗The neurogenic priapism patients are included in the total for “low-ﬂow,” but are separated out for clarity. ",
    "table_content": "|| blank |  N  | Mean age (years) | Mean duration of priapism (hours) ||\n|| Low flow | 77 | 41 | 58 ||\n|| Neurogenic ∗  | 15 | 35 | 6 ||\n|| High flow | 2 | 19 | 252 ||",
    "claim": "High-flow priapism constitutes only about 2.53% of the total cases, indicating its rarity compared to low-flow priapism.",
    "label": "refute"
  },
  {
    "id": "training_1295_3",
    "table_caption": "Table: to of a Table 3. Proportion of sick children linked to provider from reported source of care category, by stratum and linking method Linking method ruraL urban Number linked % linked # Linked % linked All providers: 166 129 Exact-match 164 98.8 120 93 Single match: Nearest - absolute distance 166 100 129 100 Nearest - road distance 166 100 129 100 Aggregate match: Radius – 5 km 106 63.8 129 100 Administrative unit – HFCA 165 99.4 129 100 Administrative unit – total area 166 100 129 100 Facility-based providers only: Linking method 166 129 Exact-match 122 73.5 117 91 Single match: Nearest – absolute distance 122 73.5 117 91 Nearest – road distance 122 73.5 117 91 Aggregate match: Radius – 5 km 65 39 117 91 Administrative unit – HFCA 122 73.5 117 91 Administrative unit – total Area 122 73.5 117 91 HFCA – health facility catchment area ",
    "table_content": "|| Linking method | Rural | Rural | Urban | Urban ||\n|| Linking method | Number linked | % linked | # Linked | % linked ||\n|| Administrative unit – total area | 166 | 100 | 129 | 100 ||\n|| Facility-based providers only: | Facility-based providers only: | Facility-based providers only: | Facility-based providers only: | Facility-based providers only: ||\n|| Linking method | 166 | blank | 129 | blank ||\n|| Exact-match | 122 | 73.5 | 117 | 91 ||\n|| Single match: | Single match: | Single match: | Single match: | Single match: ||\n|| Nearest – absolute distance | 122 | 73.5 | 117 | 91 ||\n|| Nearest – road distance | 122 | 73.5 | 117 | 91 ||\n|| Aggregate match: | Aggregate match: | Aggregate match: | Aggregate match: | Aggregate match: ||\n|| Radius – 5 km | 65 | 39 | 117 | 91 ||\n|| Administrative unit – HFCA | 122 | 73.5 | 117 | 91 ||\n|| All providers: | 166 | blank | 129 | blank ||\n|| Administrative unit – total Area | 122 | 73.5 | 117 | 91 ||\n|| Exact-match | 164 | 98.8 | 120 | 93 ||\n|| Single match: | Single match: | Single match: | Single match: | Single match: ||\n|| Nearest - absolute distance | 166 | 100 | 129 | 100 ||\n|| Nearest - road distance | 166 | 100 | 129 | 100 ||\n|| Aggregate match: | Aggregate match: | Aggregate match: | Aggregate match: | Aggregate match: ||\n|| Radius – 5 km | 106 | 63.8 | 129 | 100 ||\n|| Administrative unit – HFCA | 165 | 99.4 | 129 | 100 ||",
    "claim": "For facility-based providers in rural areas, the exact-match method links 73.5% of children, which is 24.5 percentage points higher than the radius – 5 km method, highlighting the challenges of using smaller radii in less densely populated rural areas.",
    "label": "refute"
  },
  {
    "id": "training_1395_6",
    "table_caption": "Table: Descriptive characteristics of mothers and infants from 3–18 months of infant age Birth 3 months 6 months 9 months 12 months 18 months Infants Total n 206 157 153 132 109 Female 110 (53.4%)a 83 (52.9%) 80 (52.3%) 73 (55.3%) 59 (54%) Gestational age 39.48 ± 1.47b Anthropometrics Birthweight 3.23 ± 0.48 Weight for length Z-score 0.56 ± 1.0 0.55 ± 1.1 0.54 ± 1.12 0.44 ± 1.08 0.34 ± 1.04 Sum of skinfoldsc 25.34 ± 4.69 25.53 ± 5.91 24.80 ± 6.33 23.09 ± 5.38 22.88 ± 4.19 Temperament dimensions Distress to limitations 3.46 ± 0.74 3.66 ± 0.80 4.02 ± 0.77 n/a n/a Activity level 4.11 ± 0.82 4.71 ± 0.77 4.85 ± 0.73 5.50 ± 0.71 5.35 ± 0.77 Infant Diet Daily calories, non-breastfed infants Infant received any breast milk 44 (21.4%) 22 (14.0%) 15 (9.8%) 8 (6.1%) 3 (2.8%) Infant exclusively breast-fed 13 (6.3%) 0 0 0 0 Mothers Anthropometrics BMI<25 63 (29%) BMI 25–29.9 58 (26.7%) BMI = >30 96 (44.2%) Sociodemographics Maternal education 58 (27.1%) Less than high school 65 (30.4%) High school graduate or GED 70 (32.7%) Some college 21 (9.8%) a Frequency (%) bMean ± standard deviation ",
    "table_content": "|| Infants | Birth | 3 months | 6 months | 9 months | 12 months | 18 months ||\n|| Infants | Birth | 3 months | 6 months | 9 months | 12 months | 18 months ||\n|| Distress to limitations | blank | 3.46 ± 0.74 | 3.66 ± 0.80 | 4.02 ± 0.77 | n/a | n/a ||\n|| Activity level | blank | 4.11 ± 0.82 | 4.71 ± 0.77 | 4.85 ± 0.73 | 5.50 ± 0.71 | 5.35 ± 0.77 ||\n|| Infant Diet | Infant Diet | Infant Diet | Infant Diet | Infant Diet | Infant Diet | Infant Diet ||\n|| Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants | Daily calories, non-breastfed infants ||\n|| Infant received any breast milk | blank | 44 (21.4%) | 22 (14.0%) | 15 (9.8%) | 8 (6.1%) | 3 (2.8%) ||\n|| Infant exclusively breast-fed | blank | 13 (6.3%) | 0 | 0 | 0 | 0 ||\n|| Mothers | Mothers | Mothers | Mothers | Mothers | Mothers | Mothers ||\n|| Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics ||\n|| BMI<25 | blank | 63 (29%) | blank | blank | blank | blank ||\n|| BMI 25–29.9 | blank | 58 (26.7%) | blank | blank | blank | blank ||\n|| Total n | blank | 206 | 157 | 153 | 132 | 109 ||\n|| BMI = >30 | blank | 96 (44.2%) | blank | blank | blank | blank ||\n|| Sociodemographics | Sociodemographics | Sociodemographics | Sociodemographics | Sociodemographics | Sociodemographics | Sociodemographics ||\n|| Maternal education | blank | 58 (27.1%) | blank | blank | blank | blank ||\n|| Less than high school | blank | 65 (30.4%) | blank | blank | blank | blank ||\n|| High school graduate or GED | blank | 70 (32.7%) | blank | blank | blank | blank ||\n|| Some college | blank | 21 (9.8%) | blank | blank | blank | blank ||\n|| Female | blank | 110 (53.4%) a | 83 (52.9%) | 80 (52.3%) | 73 (55.3%) | 59 (54%) ||\n|| Gestational age | 39.48 ± 1.47 b | blank | blank | blank | blank | blank ||\n|| Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics | Anthropometrics ||\n|| Birthweight | 3.23 ± 0.48 | blank | blank | blank | blank | blank ||\n|| Weight for length Z-score | blank | 0.56 ± 1.0 | 0.55 ± 1.1 | 0.54 ± 1.12 | 0.44 ± 1.08 | 0.34 ± 1.04 ||\n|| Sum of skinfolds c | blank | 25.34 ± 4.69 | 25.53 ± 5.91 | 24.80 ± 6.33 | 23.09 ± 5.38 | 22.88 ± 4.19 ||\n|| Temperament dimensions | Temperament dimensions | Temperament dimensions | Temperament dimensions | Temperament dimensions | Temperament dimensions | Temperament dimensions ||",
    "claim": "The distribution of maternal education shows that 30.4% of mothers are high school graduates or have a GED, while 32.7% have less than a high school education. This distribution highlights the educational background of the population, which can impact health literacy and access to resources for infant care.",
    "label": "refute"
  },
  {
    "id": "training_1257_5",
    "table_caption": "Table: Characterisation of the polymers 34, 35, 37, and 39. Polymer Mn, Da PDI Condition E1/21ox, V E1/22ox, V Epc1red, V λmax, nm (Egopt, eV) CH2Cl2 Film 34 – – Film 0.77 1.09 −1.21 – 494 (1.69) 35 3437 1.32 CH2Cl2 0.81 1.10 −1.15 466(1.86) 487 (1.75) 37 4886 2.40 CH2Cl2 0.69 1.07 −1.65 456 496 (1.82) 39 3158 1.19 CH2Cl2 0.89 1.31 – 578 – Film 0.91a 1.35a −0.96 – 598 (1.45) aDue to the irreversible nature of the oxidation waves, the anodic peak values Epaox are shown. ",
    "table_content": "|| Polymer |  M  n , Da | PDI | Condition |  E  1/2  1ox , V |  E  1/2  2ox , V |  E  pc  1red , V | λ max , nm ( E  g  opt , eV) | λ max , nm ( E  g  opt , eV) ||\n|| Polymer |  M  n , Da | PDI | Condition |  E  1/2  1ox , V |  E  1/2  2ox , V |  E  pc  1red , V | CH 2 Cl 2  | Film ||\n||  34  | – | – | Film | 0.77 | 1.09 | −1.21 | – | 494 (1.69) ||\n||  35  | 3437 | 1.32 | CH 2 Cl 2  | 0.81 | 1.10 | −1.15 | 466(1.86) | 487 (1.75) ||\n||  37  | 4886 | 2.40 | CH 2 Cl 2  | 0.69 | 1.07 | −1.65 | 456 | 496 (1.82) ||\n||  39  | 3158 | 1.19 | CH 2 Cl 2  | 0.89 | 1.31 | – | 578 | – ||\n||  39  | 3158 | 1.19 | Film | 0.91 a  | 1.35 a  | −0.96 | – | 598 (1.45) ||",
    "claim": "Polymer 39 shows a significant decrease in λmax when transitioning from CH2Cl2 to Film, with a decrease of 3.5%. This suggests that the film condition reduces the conjugation length or alters the electronic environment, leading to a blueshift in absorption.",
    "label": "refute"
  },
  {
    "id": "training_979_1",
    "table_caption": "Table: Relapse-related lncRNAs signiﬁ cantly associated with RFS in patients with LUAD Ensembl ID Gene name Chromosome Coef HR 95% CI of HR P -value ENSG00000245598 DACT3-AS1 Chr19: 46,660,364- 46,677,447(+) -0.964 0.382 0.26-0.559 7.52e-07 ENSG00000260037 CTD-2524L6.3 Chr15: 71,818,396- 71,823,384(+) -0.783 0.457 0.334-0.626 1.09e-06 ENSG00000228237 EFCAB14-AS1 Chr1: 46,674,036- 46,692,098(+) -1.226 0.294 0.182-0.474 5.13e-07 ENSG00000176984 AP000679.2 Chr11: 120,168,977- 120,171,679(+) 1.058 2.881 1.976-4.202 3.83e-08 ENSG00000267282 CTB-129P6.4 Chr19: 44,882,027- 44,890,876(-) 0.835 2.304 1.682-3.157 2.04e-07 ENSG00000268324 LRRC2-AS1 Chr3: 46,557,398- 46,559,694 (+) 0.711 2.037 1.574-2.637 6.52e-08 ENSG00000258658 RP11-517O13.3 Chr14: 58,370,023- 58,395,641(-) -0.843 0.43 0.299-0.619 5.44e-06 ENSG00000223647 AL133249.1 Chr2: 31,793,823- 31,803,980(-) 0.843 2.323 1.636-3.3 2.51e-06 ENSG00000248881 CTC-366B18.2 Chr5: 75,598,482- 75,599,380(-) -0.841 0.431 0.305-0.609 1.79e-06 Abbreviations: Coef, Coefﬁ cient; HR, hazard ratio; CI, conﬁ dence interval. ",
    "table_content": "|| Ensembl ID | Gene name | Chromosome | Coef | HR | 95% CI of HR | P -value ||\n|| ENSG00000245598 | DACT3-AS1 | Chr19: 46,660,364-46,677,447(+) | −0.964 | 0.382 | 0.26-0.559 | 7.52e-07 ||\n|| ENSG00000260037 | CTD-2524L6.3 | Chr15: 71,818,396-71,823,384(+) | −0.783 | 0.457 | 0.334-0.626 | 1.09e-06 ||\n|| ENSG00000228237 | EFCAB14-AS1 | Chr1: 46,674,036-46,692,098(+) | −1.226 | 0.294 | 0.182-0.474 | 5.13e-07 ||\n|| ENSG00000176984 | AP000679.2 | Chr11: 120,168,977-120,171,679(+) | 1.058 | 2.881 | 1.976-4.202 | 3.83e-08 ||\n|| ENSG00000267282 | CTB-129P6.4 | Chr19: 44,882,027-44,890,876(−) | 0.835 | 2.304 | 1.682-3.157 | 2.04e-07 ||\n|| ENSG00000268324 | LRRC2-AS1 | Chr3: 46,557,398-46,559,694 (+) | 0.711 | 2.037 | 1.574-2.637 | 6.52e-08 ||\n|| ENSG00000258658 | RP11-517O13.3 | Chr14: 58,370,023-58,395,641(−) | −0.843 | 0.43 | 0.299-0.619 | 5.44e-06 ||\n|| ENSG00000223647 | AL133249.1 | Chr2: 31,793,823-31,803,980(−) | 0.843 | 2.323 | 1.636-3.3 | 2.51e-06 ||\n|| ENSG00000248881 | CTC-366B18.2 | Chr5: 75,598,482-75,599,380(−) | −0.841 | 0.431 | 0.305-0.609 | 1.79e-06 ||",
    "claim": "The lncRNA EFCAB14-AS1, with the most negative coefficient, exhibits the highest hazard ratio, indicating a strong direct relationship between its expression and relapse risk. The calculation involves comparing the coefficients and hazard ratios across all lncRNAs, confirming that the most negative coefficient corresponds to the highest HR.",
    "label": "refute"
  },
  {
    "id": "training_153_2",
    "table_caption": "Table: TABLE 2 | Step II: numerical search results. Keywords Cochrane PubMed PMC Elsevier PEDro ISI Total “upper limb exoskeleton” 0 33 63 3 1 155 255 “upper limb mobile robot” 0 0 0 0 0 0 0 “upper limb wearable robot” 0 0 0 0 0 1 1 “upper limb portable robot” 0 0 0 0 0 0 0 “upper limb robotic exoskeleton” 0 3 1 0 0 12 16 ‘upper limb robotic orthosis’ 0 0 0 0 0 0 1 “upper limb robotic device” 0 0 0 0 0 0 0 Total 0 36 64 3 1 169 273 ",
    "table_content": "|| Keywords | Cochrane | PubMed | PMC | Elsevier | PEDro | ISI | Total ||\n|| “ upper limb exoskeleton” | 0 | 33 | 63 | 3 | 1 | 155 | 255 ||\n|| “ upper limb mobile robot” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| “ upper limb wearable robot” | 0 | 0 | 0 | 0 | 0 | 1 | 1 ||\n|| “ upper limb portable robot” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| “ upper limb robotic exoskeleton” | 0 | 3 | 1 | 0 | 0 | 12 | 16 ||\n|| ‘ upper limb robotic orthosis’ | 0 | 0 | 0 | 0 | 0 | 0 | 1 ||\n|| “ upper limb robotic device” | 0 | 0 | 0 | 0 | 0 | 0 | 0 ||\n|| Total | 0 | 36 | 64 | 3 | 1 | 169 | 273 ||",
    "claim": "The keyword \"upper limb exoskeleton\" contributes to approximately 50% of the total search results, highlighting its prominence in the field of upper limb robotic devices.",
    "label": "refute"
  },
  {
    "id": "training_193_6",
    "table_caption": "Table: Posterior estimates of divergence times without constraint to the Zea/Oryza separation. Node Independent-rates (IR) model Correlated-rates (CR) model Time (Ma) Rate Time (Ma) Rate 1 (Triticum) 47.2 (28.4, 71.5) 0.040 (0.012, 0.105) 32.4 (21.6, 49.6) 0.059 (0.028, 0.103) 2 (Zea) 55.0 (35.2, 80.4) 0.212 (0.124, 0.377) 36.9 (24.6, 56.7) 0.119 (0.087, 0.159) 3 (Typha) 104.2 (78.7, 135.5) 0.063 (0.026, 0.144) 119.8 (90.9, 156.5) 0.059 (0.034, 0.096) 4 (Musa) 126.8 (105.7, 158.6) 0.040 (0.012, 0.105) 140.8 (113.0, 176.2) 0.043 (0.025, 0.069) 5 (Elaeis) 133.6 (111.1, 166.1) 0.044 (0.014, 0.112) 145.8 (117.4, 181.1) 0.057 (0.033, 0.091) 6 (Phalaenopsis/Yucca) 145.3 (120.2, 179.3) 0.041 (0.012, 0.108) 153.2 (124.5, 187.7) 0.043 (0.026, 0.066) 7 (Dioscorea) 152.6 (125.8, 187.8) 0.080 (0.034, 0.179) 158.7 (129.4, 193.2) 0.059 (0.035, 0.093) 8 (Acorus) 181.7 (147.1, 220.3) 0.054 (0.022, 0.128) 193.7 (159.4, 226.9) 0.046 (0.027, 0.073) 9 (Eudicots) 207.7 (169.2, 245.1) 0.036 (0.010, 0.098) 220.4 (184.1, 251.4) 0.047 (0.029, 0.072) 10 (Drimys) 211.3 (172.3, 249.1) 0.034 (0.009, 0.094) 222.6 (186.2, 253.2) 0.044 (0.026, 0.070) 11 (Chloranthus) 213.6 (174.3, 251.5) 0.060 (0.023, 0.141) 223.9 (187.4, 254.5) 0.047 (0.029, 0.072) 12 (Illicium) 236.2 (193.9, 272.9) 0.053 (0.020, 0.128) 248.6 (210.3, 277.3) 0.048 (0.027, 0.079) 13 (Nymphaea) 258.2 (213.6, 291.8) 0.042 (0.014, 0.107) 269.2 (229.4, 296.1) 0.048 (0.027, 0.078) 14 (Amborella) 272.8 (227.0, 304.2) 0.056 (0.012, 0.177) 279.7 (239.6, 305.8) 0.053 (0.031, 0.086) 15 (Gymnosperm) 296.6 (280.3, 310.2) – 297.2 (280.4, 310.3) – 16 176.9 (138.5, 217.4) 0.061 (0.026, 0.139) 178.5 (141.1, 215.1 0.040 (0.024, 0.068) Terminal branch to Oryza 0 0.051 (0.032, 0.080) 0 0.074 (0.046, 0.106) MCMCTREE in PAML [19] was used with the GTR+C5 model. Shape and scale parameters, a and b, in the gamma prior for parameter s2 were 1.0 and 10.0, respectively. 95% HPD is shown in parentheses. Rate (61028 substitutions/ nucleotide/year) refers to the rate of the branch preceding the node. Node numbers refer to those ",
    "table_content": "|| Node | Independent-rates (IR) model | Independent-rates (IR) model | Correlated-rates (CR) model | Correlated-rates (CR) model ||\n|| Node | Time (Ma) | Rate | Time (Ma) | Rate ||\n|| 9 (Eudicots) | 207.7 (169.2, 245.1) | 0.036 (0.010, 0.098) | 220.4 (184.1, 251.4) | 0.047 (0.029, 0.072) ||\n|| 10 ( Drimys ) | 211.3 (172.3, 249.1) | 0.034 (0.009, 0.094) | 222.6 (186.2, 253.2) | 0.044 (0.026, 0.070) ||\n|| 11 ( Chloranthus ) | 213.6 (174.3, 251.5) | 0.060 (0.023, 0.141) | 223.9 (187.4, 254.5) | 0.047 (0.029, 0.072) ||\n|| 12 ( Illicium ) | 236.2 (193.9, 272.9) | 0.053 (0.020, 0.128) | 248.6 (210.3, 277.3) | 0.048 (0.027, 0.079) ||\n|| 13 ( Nymphaea ) | 258.2 (213.6, 291.8) | 0.042 (0.014, 0.107) | 269.2 (229.4, 296.1) | 0.048 (0.027, 0.078) ||\n|| 14 ( Amborella ) | 272.8 (227.0, 304.2) | 0.056 (0.012, 0.177) | 279.7 (239.6, 305.8) | 0.053 (0.031, 0.086) ||\n|| 15 (Gymnosperm) | 296.6 (280.3, 310.2) | – | 297.2 (280.4, 310.3) | – ||\n|| 16 | 176.9 (138.5, 217.4) | 0.061 (0.026, 0.139) | 178.5 (141.1, 215.1 | 0.040 (0.024, 0.068) ||\n|| Terminal branch to Oryza  | 0 | 0.051 (0.032, 0.080) | 0 | 0.074 (0.046, 0.106) ||\n|| 1 ( Triticum ) | 47.2 (28.4, 71.5) | 0.040 (0.012, 0.105) | 32.4 (21.6, 49.6) | 0.059 (0.028, 0.103) ||\n|| 2 ( Zea ) | 55.0 (35.2, 80.4) | 0.212 (0.124, 0.377) | 36.9 (24.6, 56.7) | 0.119 (0.087, 0.159) ||\n|| 3 ( Typha ) | 104.2 (78.7, 135.5) | 0.063 (0.026, 0.144) | 119.8 (90.9, 156.5) | 0.059 (0.034, 0.096) ||\n|| 4 ( Musa ) | 126.8 (105.7, 158.6) | 0.040 (0.012, 0.105) | 140.8 (113.0, 176.2) | 0.043 (0.025, 0.069) ||\n|| 5 ( Elaeis ) | 133.6 (111.1, 166.1) | 0.044 (0.014, 0.112) | 145.8 (117.4, 181.1) | 0.057 (0.033, 0.091) ||\n|| 6 ( Phalaenopsis/Yucca ) | 145.3 (120.2, 179.3) | 0.041 (0.012, 0.108) | 153.2 (124.5, 187.7) | 0.043 (0.026, 0.066) ||\n|| 7 ( Dioscorea ) | 152.6 (125.8, 187.8) | 0.080 (0.034, 0.179) | 158.7 (129.4, 193.2) | 0.059 (0.035, 0.093) ||\n|| 8 ( Acorus ) | 181.7 (147.1, 220.3) | 0.054 (0.022, 0.128) | 193.7 (159.4, 226.9) | 0.046 (0.027, 0.073) ||",
    "claim": "The HPD interval for the divergence time of \"Illicium\" under the IR model spans approximately 79 million years, which is less than the span of the HPD interval for \"Triticum,\" indicating greater uncertainty in the divergence time estimate for \"Illicium\" compared to \"Triticum.\"",
    "label": "refute"
  },
  {
    "id": "training_203_3",
    "table_caption": "Table: Table 1 Patient information Subject ID Age Gender Disease type* Muscle Disease duration (months) Treatments GEIM12 74 F DM Biceps 1 None GEIM54 62 M PM Quadriceps 24 None GEIM57 38 F Normal Biceps N/A N/A GEIM63 37 F Normal Biceps N/A N/A GEIM64 77 M NM Biceps 6 Pred GEIM90 90 M PM Deltoid 3 None GEIM96 86 F PM Biceps 3 None GEIM127 68 F IBM Biceps 36 Azathioprine GEIM133 60 F Normal Quadriceps N/A N/A GEIM174 36 F PM Biceps 3 None GEIM272 25 F DM (with PFA) Biceps 3 Pred x 4 days GEIM306 64 F NM Biceps 17 Pred GEIM312 76 F PM Biceps 96 None GEIM315 39 F DM Biceps 3 None GEIM322 58 F PM Biceps 180 None GEIM331 87 F PM Deltoid 36 Pred GEIM335 71 F IBM Quadriceps 24 None GEIM340 83 F NM Biceps 66 Pred GEIM349 28 F DM Biceps 18 Pred, Azathioprine GEIM354 76 M IBM Biceps 60 None GEIM363 79 F IBM Biceps 36 None GEIM365 41 M Normal Biceps N/A N/A GEIM368 61 F Normal Quadriceps N/A N/A GEIM372 61 M IBM Quadriceps 84 Dexamethasone taper GEIM373 80 F IBM Quadriceps 90 None GEIM374 47 F IBM Quadriceps 54 None GEIM375 50 F NM Quadriceps 6 None GEIM376 37 M DM Deltoid 4 None GEIM377 50 M IBM Biceps 24 None GEIM380 61 M IBM Quadriceps 24 None GEIM382 30 F DM (with PFA) Deltoid 1 None GEIM383 44 F DM (with PFA) Deltoid 2 Pred x 1 month GEIM385 61 F PM Biceps 60 Etancercept GEIM389 40 M DM (with PFA) Biceps 5 N/A GEIM391 71 M NM Quadriceps 7 None GEIM397 77 M IBM Biceps 84 None * DM, dermatomyosits; PM, polymyositis; IBM, inclusion body myositis; PFA, perifascicular atrophy. ",
    "table_content": "|| Subject ID | Age | Gender | Disease type* | Muscle | Disease duration (months) | Treatments ||\n|| GEIM12 | 74 | F | DM | Biceps | 1 | None ||\n|| GEIM174 | 36 | F | PM | Biceps | 3 | None ||\n|| GEIM272 | 25 | F | DM (with PFA) | Biceps | 3 | Pred x 4 days ||\n|| GEIM306 | 64 | F | NM | Biceps | 17 | Pred ||\n|| GEIM312 | 76 | F | PM | Biceps | 96 | None ||\n|| GEIM315 | 39 | F | DM | Biceps | 3 | None ||\n|| GEIM322 | 58 | F | PM | Biceps | 180 | None ||\n|| GEIM331 | 87 | F | PM | Deltoid | 36 | Pred ||\n|| GEIM335 | 71 | F | IBM | Quadriceps | 24 | None ||\n|| GEIM340 | 83 | F | NM | Biceps | 66 | Pred ||\n|| GEIM349 | 28 | F | DM | Biceps | 18 | Pred, Azathioprine ||\n|| GEIM54 | 62 | M | PM | Quadriceps | 24 | None ||\n|| GEIM354 | 76 | M | IBM | Biceps | 60 | None ||\n|| GEIM363 | 79 | F | IBM | Biceps | 36 | None ||\n|| GEIM365 | 41 | M | Normal | Biceps | N/A | N/A ||\n|| GEIM368 | 61 | F | Normal | Quadriceps | N/A | N/A ||\n|| GEIM372 | 61 | M | IBM | Quadriceps | 84 | Dexamethasone taper ||\n|| GEIM373 | 80 | F | IBM | Quadriceps | 90 | None ||\n|| GEIM374 | 47 | F | IBM | Quadriceps | 54 | None ||\n|| GEIM375 | 50 | F | NM | Quadriceps | 6 | None ||\n|| GEIM376 | 37 | M | DM | Deltoid | 4 | None ||\n|| GEIM377 | 50 | M | IBM | Biceps | 24 | None ||\n|| GEIM57 | 38 | F | Normal | Biceps | N/A | N/A ||\n|| GEIM380 | 61 | M | IBM | Quadriceps | 24 | None ||\n|| GEIM382 | 30 | F | DM (with PFA) | Deltoid | 1 | None ||\n|| GEIM383 | 44 | F | DM (with PFA) | Deltoid | 2 | Pred x 1 month ||\n|| GEIM385 | 61 | F | PM | Biceps | 60 | Etancercept ||\n|| GEIM389 | 40 | M | DM (with PFA) | Biceps | 5 | N/A ||\n|| GEIM391 | 71 | M | NM | Quadriceps | 7 | None ||\n|| GEIM397 | 77 | M | IBM | Biceps | 84 | None ||\n|| GEIM63 | 37 | F | Normal | Biceps | N/A | N/A ||\n|| GEIM64 | 77 | M | NM | Biceps | 6 | Pred ||\n|| GEIM90 | 90 | M | PM | Deltoid | 3 | None ||\n|| GEIM96 | 86 | F | PM | Biceps | 3 | None ||\n|| GEIM127 | 68 | F | IBM | Biceps | 36 | Azathioprine ||\n|| GEIM133 | 60 | F | Normal | Quadriceps | N/A | N/A ||",
    "claim": "Females constitute approximately 70% of the DM and PM patient population, whereas the gender distribution in IBM is more balanced, with females making up about 55% of the IBM cases. This suggests a gender-related prevalence in DM and PM.",
    "label": "refute"
  },
  {
    "id": "training_878_2",
    "table_caption": "Table: Table 6 K-fold cross validation (K = 5): Ntotal = 389,533, Pearson correlation, all test scores k Ntrain Ntest Correlation 1 311,540 77,993 0.895 2 311,463 78,070 0.891 3 311,652 77,881 0.898 4 311,565 77,968 0.901 5 311,454 78,079 0.903 ",
    "table_content": "|| k | Ntrain | Ntest | Correlation ||\n|| 1 | 311,540 | 77,993 | 0.895 ||\n|| 2 | 311,463 | 78,070 | 0.891 ||\n|| 3 | 311,652 | 77,881 | 0.898 ||\n|| 4 | 311,565 | 77,968 | 0.901 ||\n|| 5 | 311,454 | 78,079 | 0.903 ||",
    "claim": "The number of training and test instances across the folds is inversely related, with a consistent total of 389,533 instances. This inverse relationship is a fundamental aspect of k-fold cross-validation, ensuring that each fold uses a different subset of the data for training and testing, maintaining the overall dataset size.",
    "label": "refute"
  },
  {
    "id": "training_1409_2",
    "table_caption": "Table: Reference range First phase Second phase ALB 2.5–4.4 g/dL 3.6 ± 0.1 3.6 ± 0.1 ALP 20–150 U/L 45.1 ± 6.9 45.5 ± 6.1 ALT 10–118 U/L 53.1 ± 9.4 69.1 ± 11.5 AMY 200–1200 U/L 511.1 ± 53.6 538.6 ± 58.7 TBIL 0.1–0.6 mg/dL 0.3 ± 1.0 0.3 ± 0 BUN 7–25 mg/dL 14.3 ± 1.0 15.4 ± 1.2 CA++ 8.6–11.8 mg/dL 10.6 ± 0.1 10.6 ± 0.1 PHOS 2.9–6.6 mg/dL 3.7 ± 0.2* 4.6 ± 0.1* CRE 0.3–1.4 mg/dL 1.1 ± 0.1 1.0 ± 0.1 GLU 60–110 mg/dL 104.6 ± 4.0 104.4 ± 4.5 NA+ 138–160 mmol/L 144.0 ± 0.7 145.3 ± 0.3 K+ 3.7–5.8 mmol/L 4.7 ± 0.2 4.2 ± 0.1 TP 5.4–8.2 g/dL 6.7 ± 0.1 6.7 ± 0.1 GLOB 2.3–5.2 g/dL 3.1 ± 0.1 3.3 ± 0.1 Table 2. Comprehensive blood profiles. ALB - albumin; ALP aminotransferase; AMY - amylase; TBIL - total bilirubin; BUN ",
    "table_content": "|| blank | Reference range | First phase | Second phase ||\n|| ALB | 2.5–4.4 g/dL | 3.6 ± 0.1 | 3.6 ± 0.1 ||\n|| GLU | 60–110 mg/dL | 104.6 ± 4.0 | 104.4 ± 4.5 ||\n|| NA + | 138–160 mmol/L | 144.0 ± 0.7 | 145.3 ± 0.3 ||\n|| K + | 3.7–5.8 mmol/L | 4.7 ± 0.2 | 4.2 ± 0.1 ||\n|| TP | 5.4–8.2 g/dL | 6.7 ± 0.1 | 6.7 ± 0.1 ||\n|| GLOB | 2.3–5.2 g/dL | 3.1 ± 0.1 | 3.3 ± 0.1 ||\n|| ALP | 20–150 U/L | 45.1 ± 6.9 | 45.5 ± 6.1 ||\n|| ALT | 10–118 U/L | 53.1 ± 9.4 | 69.1 ± 11.5 ||\n|| AMY | 200–1200 U/L | 511.1 ± 53.6 | 538.6 ± 58.7 ||\n|| TBIL | 0.1–0.6 mg/dL | 0.3 ± 1.0 | 0.3 ± 0 ||\n|| BUN | 7–25 mg/dL | 14.3 ± 1.0 | 15.4 ± 1.2 ||\n|| CA ++ | 8.6–11.8 mg/dL | 10.6 ± 0.1 | 10.6 ± 0.1 ||\n|| PHOS | 2.9–6.6 mg/dL | 3.7 ± 0.2* | 4.6 ± 0.1* ||\n|| CRE | 0.3–1.4 mg/dL | 1.1 ± 0.1 | 1.0 ± 0.1 ||",
    "claim": "Both ALB and CA++ levels remain constant across the two phases, as evidenced by identical mean values but differing standard deviations. This stability suggests a homeostatic regulation of these parameters, maintaining them within the physiological range without significant fluctuation.",
    "label": "refute"
  },
  {
    "id": "training_635_4",
    "table_caption": "Table: Summary of discrepancies between FDA and peer-reviewed journal reports. Drug No. of analyzed RCTs No. of analyzed arms (vs. placebo) Matched Favors FDA Favors publication ACR20 Abatacept 5 8 7 1 - Adalimumab 4 10 6 4 - Anakinra 3 9 5 3 1 Certolizumab 4 6 1 - 5 Etanercept 4 8 8 - - Golimumab 3 8 5 3 - Inﬂiximab 1 4 - 1 3 Tocilizumab 5 8 5 3 - Total 29 61 (100%) 37 (61%) 15 (24%) 9 (15%) WdAEs Abatacept 5 8 6 1 1 Adalimumab 4 10 6 4 - Anakinra 4 10 5 3 2 Certolizumab 4 6 2 4 - Etanercept 3 5 3 1 1 Golimumab - - - - - Inﬂiximab 2 10 5 4 1 Tocilizumab 4 6 - - 6 Total 26 55 (100%) 27 (49%) 17 (31%) 11 (20%) RCT = randomized controlled trial, No. = number of patients, ACR20 = American College of Rheumatology 20, WdAEs = withdrawal of patients due to adverse events, FDA = Food and Drug Administration. ",
    "table_content": "|| Drug | No. of analyzed RCTs | No. of analyzed arms (vs. placebo) | Matched | Favors FDA | Favors publication ||\n|| ACR20 | ACR20 | ACR20 | ACR20 | ACR20 | ACR20 ||\n|| Total | 29 | 61 (100%) | 37 (61%) | 15 (24%) | 9 (15%) ||\n|| WdAEs | WdAEs | WdAEs | WdAEs | WdAEs | WdAEs ||\n|| Abatacept | 5 | 8 | 6 | 1 | 1 ||\n|| Adalimumab | 4 | 10 | 6 | 4 | blank ||\n|| Anakinra | 4 | 10 | 5 | 3 | 2 ||\n|| Certolizumab | 4 | 6 | 2 | 4 | blank ||\n|| Etanercept | 3 | 5 | 3 | 1 | 1 ||\n|| Golimumab | blank | blank | blank | blank | blank ||\n|| Infliximab | 2 | 10 | 5 | 4 | 1 ||\n|| Tocilizumab | 4 | 6 | blank | blank | 6 ||\n|| Abatacept | 5 | 8 | 7 | 1 | blank ||\n|| Total | 26 | 55 (100%) | 27 (49%) | 17 (31%) | 11 (20%) ||\n|| Adalimumab | 4 | 10 | 6 | 4 | blank ||\n|| Anakinra | 3 | 9 | 5 | 3 | 1 ||\n|| Certolizumab | 4 | 6 | 1 | blank | 5 ||\n|| Etanercept | 4 | 8 | 8 | blank | blank ||\n|| Golimumab | 3 | 8 | 5 | 3 | blank ||\n|| Infliximab | 1 | 4 | blank | 1 | 3 ||\n|| Tocilizumab | 5 | 8 | 5 | 3 | blank ||",
    "claim": "For the drug Certolizumab, the number of cases favoring publication is equal to the number of cases favoring the FDA, highlighting a balanced view of Certolizumab's efficacy as reported in journals compared to FDA reports.",
    "label": "refute"
  },
  {
    "id": "training_761_5",
    "table_caption": "Table: Crystal data C22H28F2NO2 +·CHO2 − F(000) = 2688 Mr = 421.47 Dx = 1.312 Mg m−3 Orthorhombic, P212121 Mo Kα radiation, λ = 0.71073 Å Hall symbol: P 2ac 2ab Cell parameters from 8196 reflections a = 7.8338 (1) Å θ = 1.0–27.5° b = 27.8759 (3) Å µ = 0.10 mm−1 c = 29.3202 (3) Å T = 90 K V = 6402.78 (13) Å3 Plate, colourless Z = 12 0.28 × 0.18 × 0.06 mm Data collection ",
    "table_content": "|| C 22 H 28 F 2 NO 2 + ·CHO 2 − | F (000) = 2688 ||\n|| M r = 421.47 | D x = 1.312 Mg m − 3 ||\n|| Orthorhombic, P 2 1 2 1 2 1 | Mo K α radiation, λ = 0.71073 Å ||\n|| Hall symbol:  P 2ac 2ab | Cell parameters from 8196 reflections ||\n|| a = 7.8338 (1) Å | θ = 1.0–27.5° ||\n|| b = 27.8759 (3) Å | µ = 0.10 mm − 1 ||\n|| c = 29.3202 (3) Å | T = 90 K ||\n|| V = 6402.78 (13)  Å 3 | Plate, colourless ||\n|| Z = 12 | 0.28 × 0.18 × 0.06 mm ||",
    "claim": "With Z = 12 formula units per unit cell, the calculated unit cell mass should differ from the product of the molecular weight and Z. This inconsistency challenges the reported molecular weight and the number of formula units, questioning the accuracy of the crystallographic data.",
    "label": "refute"
  },
  {
    "id": "training_191_5",
    "table_caption": "Table: National Estimates of ED Disposition, 2001-2008{. Year ED visits Observation evaluations Inpatient Admissions Inpatient Admissions Following Observation % of Inpatient Admissions from Observation n n (% of all ED Visits*) n (% of all ED Visits**) n (% of all Observations{) % 2001 107,490,000 642,000 (0.60%) 12,626,000 (11.75%) 22,000 (3.46%) 0.18% 2002 110,155,000 688,000 (0.62%) 13,471,000 (12.23%) 40,000 (5.76%) 0.29% 2003 113,903,000 384,000 (0.34%) 15,809,000 (13.88%) 56,000 (14.64%) 0.36% 2004 110,216,000 613,000 (0.56%) 14,618,000 (13.26%) 151,000 (24.64%) 1.03% 2005 115,323,000 1,010,000 (0.88%) 13,867,000 (12.02%) 217,000 (21.46%) 1.56% 2006 119,192,000 1,265,000 (1.06%) 15,207,000(12.76%) 346,000 (27.39%) 2.28% 2007 116,802,000 2,452,000 (2.10%) 14,639,000 (12.53%) 448,000 (18.25%) 3.06% 2008 123,761,000 2,318,000 (1.87%) 16,570,000 (13.39%) 761,000 (32.81%) 4.59% Total 916,842,000 9,372,000 (1.02%) 116,807,000 (12.74%) 2,040,000 (21.77%) 1.30% *This is the ED observation proportion, the proportion of all ED visits with a disposition to observation. **This is the ED admission proportion, the proportion of all ED visits with a disposition to inpatient admission. ",
    "table_content": "|| Year | ED visits n | Observation evaluations n (% of all ED Visits  *  ) | Inpatient Admissions n (% of all ED Visits  **  ) | Inpatient Admissions Following Observation n (% of all Observations  †  ) | % of Inpatient Admissions from Observation % ||\n|| Year | ED visits n | Observation evaluations n (% of all ED Visits  *  ) | Inpatient Admissions n (% of all ED Visits  **  ) | Inpatient Admissions Following Observation n (% of all Observations  †  ) | % of Inpatient Admissions from Observation % ||\n||  Total  | 916,842,000 | 9,372,000 (1.02%) | 116,807,000 (12.74%) | 2,040,000 (21.77%) | 1.30% ||\n||  2001  | 107,490,000 | 642,000 (0.60%) | 12,626,000 (11.75%) | 22,000 (3.46%) | 0.18% ||\n||  2002  | 110,155,000 | 688,000 (0.62%) | 13,471,000 (12.23%) | 40,000 (5.76%) | 0.29% ||\n||  2003  | 113,903,000 | 384,000 (0.34%) | 15,809,000 (13.88%) | 56,000 (14.64%) | 0.36% ||\n||  2004  | 110,216,000 | 613,000 (0.56%) | 14,618,000 (13.26%) | 151,000 (24.64%) | 1.03% ||\n||  2005  | 115,323,000 | 1,010,000 (0.88%) | 13,867,000 (12.02%) | 217,000 (21.46%) | 1.56% ||\n||  2006  | 119,192,000 | 1,265,000 (1.06%) | 15,207,000(12.76%) | 346,000 (27.39%) | 2.28% ||\n||  2007  | 116,802,000 | 2,452,000 (2.10%) | 14,639,000 (12.53%) | 448,000 (18.25%) | 3.06% ||\n||  2008  | 123,761,000 | 2,318,000 (1.87%) | 16,570,000 (13.39%) | 761,000 (32.81%) | 4.59% ||",
    "claim": "The percentage of inpatient admissions originating from observation evaluations decreased from 0.18% in 2001 to 4.59% in 2008, indicating a declining reliance on observation as a step before admission.",
    "label": "refute"
  },
  {
    "id": "training_161_2",
    "table_caption": "Table: recall when both are performed. We used ISUB for measuring the similarity Approach Precision Recall F1 Combined matching with ontology schema and instances 82.08 76.32 79.09 Matching with ontology schema only 84.06 50.88 63.39 Matching with instances (RDF data) only 78.38 25.44 38.41 of from Scenario Scenario Scenario Scenario Scenario ",
    "table_content": "|| Approach | Precision | Recall | F1 ||\n|| Combined matching with ontology schema and instances | 82.08 | 76.32 | 79.09 ||\n|| Matching with ontology schema only | 84.06 | 50.88 | 63.39 ||\n|| Matching with instances (RDF data) only | 78.38 | 25.44 | 38.41 ||",
    "claim": "The combined matching approach demonstrates a recall rate that is approximately 50% lower than the schema-only approach, highlighting its superior ability to identify relevant matches comprehensively.",
    "label": "refute"
  },
  {
    "id": "training_276_4",
    "table_caption": "Table: MPs in to MPs (Fig. (100 MetS HS Table 1. Baseline characteristics of subjects. Control subjects MetS patients Number 17 21 Mean age (years) 5462 5662 Sex ratio (male/female) 12/5 17/4 BMI (kg/m2) 2861.3 3461.1c Waist circumference (cm) 9463.2 11362.3c Ratio Waist/Hips 0.9560.02 1.0160.01a Systolic blood pressure (mm Hg) 12162 13563c Diastolic blood pressure (mm Hg) 7462 7962a Glycemia (mmol/l) 5.3360.11 6.5560.22c Insulinemia (pmol/l) 61.669.1 163.7617.8c HbA1c (%) 5.660.06 6.1760.24a Total cholesterol (mmol/l) 660.34 5.360.25 HDL cholesterol (mmol/l) 1.9260.16 1.6360.13 LDL cholesterol (mmol/l) 3.260.26 2.6460.21 Triglycerides (mmol/l) 1.360.11 2.4260.33c Leptin (mg/l) 15.364.8 15.263.11 Adiponectin (mg/l) 8.160.8 5.360.34b Number of MetS components (%) 0 36 - 1 41 - 2 23 - 3 - 38 4 - 52 5 - 10 Treatments (%) Oral antidiabetic 0 41 Insulin 0 2 Antihypertensive 1 70 Statins 2 2 Baseline characteristics of MetS patients (n = 21) compared to control subjects (n = 17). Subjects were fasted before blood collection. All values are expressed ",
    "table_content": "|| blank | Control subjects | MetS patients ||\n||  Number  | 17 | 21 ||\n||  Insulinemia (pmol/l)  | 61.6±9.1 | 163.7±17.8 c  ||\n||  HbA1c (%)  | 5.6±0.06 | 6.17±0.24 a  ||\n||  Total cholesterol (mmol/l)  | 6±0.34 | 5.3±0.25 ||\n||  HDL cholesterol (mmol/l)  | 1.92±0.16 | 1.63±0.13 ||\n||  LDL cholesterol (mmol/l)  | 3.2±0.26 | 2.64±0.21 ||\n||  Triglycerides (mmol/l)  | 1.3±0.11 | 2.42±0.33 c  ||\n||  Leptin (µg/l)  | 15.3±4.8 | 15.2±3.11 ||\n||  Adiponectin (mg/l)  | 8.1±0.8 | 5.3±0.34 b  ||\n||  Number of MetS components (%)  |  Number of MetS components (%)  |  Number of MetS components (%)  ||\n||  0  | 36 | blank ||\n||  Mean age (years)  | 54±2 | 56±2 ||\n||  1  | 41 | blank ||\n||  2  | 23 | blank ||\n||  3  | blank | 38 ||\n||  4  | blank | 52 ||\n||  5  | blank | 10 ||\n||  Treatments (%)  |  Treatments (%)  |  Treatments (%)  ||\n||  Oral antidiabetic  | 0 | 41 ||\n||  Insulin  | 0 | 2 ||\n||  Antihypertensive  | 1 | 70 ||\n||  Statins  | 2 | 2 ||\n||  Sex ratio (male/female)  | 12/5 | 17/4 ||\n||  BMI (kg/m 2 )  | 28±1.3 | 34±1.1 c  ||\n||  Waist circumference (cm)  | 94±3.2 | 113±2.3 c  ||\n||  Ratio Waist/Hips  | 0.95±0.02 | 1.01±0.01 a  ||\n||  Systolic blood pressure (mm Hg)  | 121±2 | 135±3 c  ||\n||  Diastolic blood pressure (mm Hg)  | 74±2 | 79±2 a  ||\n||  Glycemia (mmol/l)  | 5.33±0.11 | 6.55±0.22 c  ||",
    "claim": "The triglyceride level in MetS patients is 50% higher than in control subjects, highlighting a significant dyslipidemia component of Metabolic Syndrome.",
    "label": "refute"
  },
  {
    "id": "training_820_5",
    "table_caption": "Table: of cs cs5 Table 3. Microneutralization (MNt) assay. Abs* MNt titers** Virus 80R 2560 Wild type SARS-CoV (Urbani) 11A ,20 256 20 80R ,20 80R escape mutant Iso1-100 (D480G) 11A ,20 256 40 80R ,20 80R escape mutant Iso1-103(D480A) 11A ,20 256 40 *Whole IgG1 was used for all antibodies in this assay. **Reciprocals of the highest dilutions of Abs that showed less than 50% ",
    "table_content": "|| Abs *  | MNt titers **  | Virus ||\n|| 80R | 2560 | Wild type SARS-CoV (Urbani) ||\n|| 11A | <20 | blank ||\n||  256  |  20  | blank ||\n|| 80R | <20 | 80R escape mutant Iso1-100 (D480G) ||\n|| 11A | <20 | blank ||\n||  256  |  40  | blank ||\n|| 80R | <20 | 80R escape mutant Iso1-103(D480A) ||\n|| 11A | <20 | blank ||\n||  256  |  40  | blank ||",
    "claim": "The presence of escape mutations D480G and D480A in the virus results in a slight reduction in the neutralization effectiveness of antibody 80R, as evidenced by the decrease in MNt titers by a factor of less than 10, highlighting the challenge posed by viral mutations in antibody-mediated neutralization.",
    "label": "refute"
  },
  {
    "id": "training_1350_6",
    "table_caption": "Table: Demographic and baseline characteristics of ovarian cancer patients Patient ID Age Surgical procedure Diagnosis FIGO stage Metastases identified Tumor FRa+ Fluorescence imaging successful 1 71 Primary debulking Serous adenocarcinoma 3c Yes Yes Yes 2 51 Primary debulking Endometroid type adenocarcinoma 3b Yes Yes Yes 3 59 Staging Endometroid type adenocarcinoma 2c No Yes Yes 4 61 Interval debulking Serous adenocarcinoma of endometrium 4 Yes Yes Yes 5 64 Primary debulking Borderline serous adenocarcinoma 3b Non-invasive implants Yes Yes 6 71 Primary debulking Serous adenocarcinoma 3c Yes Yes Yes 7 71 Primary debulking Serous adenocarcinoma 3b Yes Yes Yes 8 78 Interval debulking Serous adenocarcinoma 3c Yes Yes Yes 9 57 Interval debulking Serous adenocarcinoma 3c Yes Yes Yes 10 52 Interval debulking Serous adenocarcinoma 4 Yes Yes Yes 11 42 Primary debulking Mucinous adenocarcinoma 3c Yes No No 12 73 Staging Endometroid type adenocarcinoma 2b No Yes Yes ",
    "table_content": "|| Patient ID | Age | Surgical procedure | Diagnosis | FIGO stage | Metastases identified | Tumor FRa+ | Fluorescence imaging successful ||\n|| 1 | 71 | Primary debulking | Serous adenocarcinoma | 3c | Yes | Yes | Yes ||\n|| 10 | 52 | Interval debulking | Serous adenocarcinoma | 4 | Yes | Yes | Yes ||\n|| 11 | 42 | Primary debulking | Mucinous adenocarcinoma | 3c | Yes | No | No ||\n|| 12 | 73 | Staging | Endometroid type adenocarcinoma | 2b | No | Yes | Yes ||\n|| 2 | 51 | Primary debulking | Endometroid type adenocarcinoma | 3b | Yes | Yes | Yes ||\n|| 3 | 59 | Staging | Endometroid type adenocarcinoma | 2c | No | Yes | Yes ||\n|| 4 | 61 | Interval debulking | Serous adenocarcinoma of endometrium | 4 | Yes | Yes | Yes ||\n|| 5 | 64 | Primary debulking | Borderline serous adenocarcinoma | 3b | Non-invasive implants | Yes | Yes ||\n|| 6 | 71 | Primary debulking | Serous adenocarcinoma | 3c | Yes | Yes | Yes ||\n|| 7 | 71 | Primary debulking | Serous adenocarcinoma | 3b | Yes | Yes | Yes ||\n|| 8 | 78 | Interval debulking | Serous adenocarcinoma | 3c | Yes | Yes | Yes ||\n|| 9 | 57 | Interval debulking | Serous adenocarcinoma | 3c | Yes | Yes | Yes ||",
    "claim": "90% of patients undergoing interval debulking have identified metastases, compared to 88% of those undergoing primary debulking. This indicates a higher likelihood of metastases in patients selected for interval debulking procedures.",
    "label": "refute"
  },
  {
    "id": "training_966_1",
    "table_caption": "Table: confidence intervals of (85.5%, 88.5%) at the lowest SCC and 41.1% (38.9%, 43.3%). TABLE 1: The presence and absence of intramammary infection within each somatic cell count range in composite milk samples. SCC range cells per mL milk Sample numbers with IMI Sample numbers without IMI Total sample numbers IMI prevalence per SCC range (95% LCI and UCI) Cum % with IMI per SCC range 1000–50 000 19 462 77 244 96 706 0.201 (0.199, 0.204) 5, 63 51 000–100 000 18 157 34 114 52 271 0.347 (0.343, 0.352) 10, 89 101 000–150 000 14 381 19 419 33 800 0.426 (0.420, 0.431) 15, 05 151 000–200 000 11 257 12 701 23 958 0.470 (0.464, 0.476) 18, 31 201 000–250 000 9081 8055 17 136 0.530 (0.522, 0.537) 20, 94 251 000–300 000 7504 6242 13 746 0.546 (0.538, 0.554) 23, 11 301 000–350 000 6081 4445 10 526 0.578 (0.568, 0.587) 24, 87 351 000–400 000 5146 3573 8719 0.590 (0.580, 0.601) 26, 36 401 000–450 000 4280 2986 7266 0.589 (0.578, 0.600) 27, 6 451 000–500 000 3801 2520 6321 0.601 (0.589, 0.613) 28, 7 501 000–750 000 12 431 7597 20 028 0.621 (0.614, 0.627) 32, 3 750 000 + 38 236 16 748 54 984 0.695 (0.692, 0.699) 43, 37 Totals 149 817 195 644 345 461 - - SCC, somatic cell count; IMI, intramammary infection; LCI, lower confidence interval; UCI, upper confidence interval; Cum %, cumulative percentage. n = 345 461. ",
    "table_content": "|| SCC range cells per mL milk | Sample numbers with IMI | Sample numbers without IMI | Total sample numbers | IMI prevalence per SCC range (95% LCI and UCI) | Cum % with IMI per SCC range ||\n|| 1000–50 000 | 19 462 | 77 244 | 96 706 | 0.201 (0.199, 0.204) | 5, 63 ||\n|| 451 000–500 000 | 3801 | 2520 | 6321 | 0.601 (0.589, 0.613) | 28, 7 ||\n|| 501 000–750 000 | 12 431 | 7597 | 20 028 | 0.621 (0.614, 0.627) | 32, 3 ||\n|| 750 000 + | 38 236 | 16 748 | 54 984 | 0.695 (0.692, 0.699) | 43, 37 ||\n|| Totals | 149 817 | 195 644 | 345 461 | blank | blank ||\n|| 51 000–100 000 | 18 157 | 34 114 | 52 271 | 0.347 (0.343, 0.352) | 10, 89 ||\n|| 101 000–150 000 | 14 381 | 19 419 | 33 800 | 0.426 (0.420, 0.431) | 15, 05 ||\n|| 151 000–200 000 | 11 257 | 12 701 | 23 958 | 0.470 (0.464, 0.476) | 18, 31 ||\n|| 201 000–250 000 | 9081 | 8055 | 17 136 | 0.530 (0.522, 0.537) | 20, 94 ||\n|| 251 000–300 000 | 7504 | 6242 | 13 746 | 0.546 (0.538, 0.554) | 23, 11 ||\n|| 301 000–350 000 | 6081 | 4445 | 10 526 | 0.578 (0.568, 0.587) | 24, 87 ||\n|| 351 000–400 000 | 5146 | 3573 | 8719 | 0.590 (0.580, 0.601) | 26, 36 ||\n|| 401 000–450 000 | 4280 | 2986 | 7266 | 0.589 (0.578, 0.600) | 27, 6 ||",
    "claim": "The IMI prevalence increases as the SCC range increases, with a calculated increase in prevalence from the lowest to the highest SCC range. The prevalence rises from 0.201 in the 1000–50,000 SCC range to 0.695 in the 750,000+ SCC range, indicating a 2.46-fold increase in IMI prevalence as SCC increases.",
    "label": "refute"
  },
  {
    "id": "training_495_4",
    "table_caption": "Table: Table 1 Problem behaviours by non-mixed and mixed ethnicity at ages 3, 5, 7 and 11 Age White non-mixed White mixed Indian non-mixed Indian mixed Pakistani non-mixed Pakistani mixed Bangladeshi non-mixed Bangladeshi mixed Black Caribbean non-mixed Black Caribbean mixed Black African non-mixed Black African mixed Other non-mixed Other mixed 3 9.4 8.3 10.1 7.7 13.1 8.9 11.9 7.2 10.6 10.6 9.2 9.5 10.5 9.6 5 7.0 5.9 7.3 6.1 9.9 7.9 8.7 6.3 9.0 8.0 7.0 7.8 7.5 7.8 7 7.2 6.4 7.6 5.7 9.7 9.3 8.8 7.4 8.8 9.2 6.6 8.0 7.3 6.9 11 7.7 6.9 7.5 6.3 8.8 10.3 7.8 12.0 7.9 8.7 7.4 6.7 8.4 7.8 All means are adjusted for sample design. Sample at each sweep excludes twins and triplets. Only respondents who are biological, step, adopted or foster mothers are included. At ages 5, 7 and 11, children who had attention-deficit/hyperactivity disorder/Asperger’s or autism are excluded. The sample size at age 3 is 13 742; age 5 is 13 555; age 7 is 12 250; and age 11 is 11 996. Dis Child 2018;103:61–64. ",
    "table_content": "|| Age | White non-mixed | White mixed | Indian non-mixed | Indian mixed | Pakistani non-mixed | Pakistani mixed | Bangladeshi non-mixed | Bangladeshi mixed | Black Caribbean non-mixed | Black Caribbean mixed | Black African non-mixed | Black African mixed | Other non-mixed | Other mixed ||\n|| 3 | 9.4 | 8.3 | 10.1 | 7.7 | 13.1 | 8.9 | 11.9 | 7.2 | 10.6 | 10.6 | 9.2 | 9.5 | 10.5 | 9.6 ||\n|| 5 | 7.0 | 5.9 | 7.3 | 6.1 | 9.9 | 7.9 | 8.7 | 6.3 | 9.0 | 8.0 | 7.0 | 7.8 | 7.5 | 7.8 ||\n|| 7 | 7.2 | 6.4 | 7.6 | 5.7 | 9.7 | 9.3 | 8.8 | 7.4 | 8.8 | 9.2 | 6.6 | 8.0 | 7.3 | 6.9 ||\n|| 11 | 7.7 | 6.9 | 7.5 | 6.3 | 8.8 | 10.3 | 7.8 | 12.0 | 7.9 | 8.7 | 7.4 | 6.7 | 8.4 | 7.8 ||",
    "claim": "At age 3, Bangladeshi mixed children have the highest problem behaviors, while Pakistani non-mixed children have the lowest. The difference between these two groups is 81.9%, highlighting significant variability in early childhood behaviors.",
    "label": "refute"
  },
  {
    "id": "training_361_4",
    "table_caption": "Table: Relative risk estimates for community exposure to landfills and incinerators Health effect Distance from the source Relative Risk (Confidence Interval) Level of confidence** Landfills Congenital malformations [24] All congenital malformations Within 2 km 1.02 (99% CI = 1.01-1.03) Moderate Neural tube defects Within 2 km 1.06 (99% CI = 1.01-1.12) Moderate Hypospadias and epispadias Within 2 km 1.07 (99% CI = 1.04-1.11) Moderate Abdominal wall defects Within 2 km 1.05 (99% CI = 0.94-1.16) Moderate Gastroschisis and exomphalos* Within 2 km 1.18 (99% CI = 1.03-1.34) Moderate Low birth weight [24] Within 2 km 1.06 (99% CI = 1.052-1.062) High Very low birth weight Within 2 km 1.04 (99% CI = 1.03-1.06) High Incinerators Congenital malformations [45] Facial cleft Within 10 km 1.30 (95% CI = 1.06-1.59) Moderate Renal dysplasia Within 10 km 1.55 (95% CI = 1.10-2.20) Moderate Cancer [30] All cancer Within 3 km 1.035 (95% CI = 1.03-1.04) Moderate Stomach cancer Within 3 km 1.07 (95% CI = 1.02-1.13) Moderate Colorectal cancer Within 3 km 1.11 (95% CI = 1.07-1.15) Moderate Liver cancer Within 3 km 1.29 (95% CI = 1.10-1.51) High Lung cancer Within 3 km 1.14 (95% CI = 1.11-1.17) Moderate Soft-tissue sarcoma Within 3 km 1.16 (95% CI = 0.96-1.41) High Non-Hodgkin's lymphoma Within 3 km 1.11 (95% CI = 1.04-1.19) High *The original estimates were given for \"surgical corrections of..\". **The following scale for the level of confidence has been adopted: very high, high, moderate, low, very low. ",
    "table_content": "|| Health effect | Distance from the source | Relative Risk (Confidence Interval) | Level of confidence** ||\n|| Landfills | Landfills | Landfills | Landfills ||\n|| Incinerators | Incinerators | Incinerators | Incinerators ||\n|| Congenital malformations [ 45 ] | Congenital malformations [ 45 ] | Congenital malformations [ 45 ] | Congenital malformations [ 45 ] ||\n|| Facial cleft | Within 10 km | 1.30 (95% CI = 1.06-1.59) | Moderate ||\n|| Renal dysplasia | Within 10 km | 1.55 (95% CI = 1.10-2.20) | Moderate ||\n|| Cancer [ 30 ] | Cancer [ 30 ] | Cancer [ 30 ] | Cancer [ 30 ] ||\n|| All cancer | Within 3 km | 1.035 (95% CI = 1.03-1.04) | Moderate ||\n|| Stomach cancer | Within 3 km | 1.07 (95% CI = 1.02-1.13) | Moderate ||\n|| Colorectal cancer | Within 3 km | 1.11 (95% CI = 1.07-1.15) | Moderate ||\n|| Liver cancer | Within 3 km | 1.29 (95% CI = 1.10-1.51) | High ||\n|| Lung cancer | Within 3 km | 1.14 (95% CI = 1.11-1.17) | Moderate ||\n|| Congenital malformations [ 24 ] | Congenital malformations [ 24 ] | Congenital malformations [ 24 ] | Congenital malformations [ 24 ] ||\n|| Soft-tissue sarcoma | Within 3 km | 1.16 (95% CI = 0.96-1.41) | High ||\n|| Non-Hodgkin's lymphoma | Within 3 km | 1.11 (95% CI = 1.04-1.19) | High ||\n|| All congenital malformations | Within 2 km | 1.02 (99% CI = 1.01-1.03) | Moderate ||\n|| Neural tube defects | Within 2 km | 1.06 (99% CI = 1.01-1.12) | Moderate ||\n|| Hypospadias and epispadias | Within 2 km | 1.07 (99% CI = 1.04-1.11) | Moderate ||\n|| Abdominal wall defects | Within 2 km | 1.05 (99% CI = 0.94-1.16) | Moderate ||\n|| Gastroschisis and exomphalos* | Within 2 km | 1.18 (99% CI = 1.03-1.34) | Moderate ||\n|| Low birth weight [ 24 ] | Within 2 km | 1.06 (99% CI = 1.052-1.062) | High ||\n|| Very low birth weight | Within 2 km | 1.04 (99% CI = 1.03-1.06) | High ||",
    "claim": "The relative risk for low birth weight near landfills is 1.06, which is slightly lower than the risk for very low birth weight at 1.04. This indicates a marginally decreased risk for low birth weight compared to very low birth weight in proximity to landfills.",
    "label": "refute"
  },
  {
    "id": "training_715_3",
    "table_caption": "Table: Table 1 Total forest (ha) within 750 m and 1,500 m buffer zone from the centre point of each study village Name of study village Country District name Total forest (a) Inside 750 m Inside 1,500 m 1 Alone Laos Sepon 3.2 105.6 2 Densavanh Laos Sepon 23.3 186.7 3 Pheung Laos Sepon 40.1 163.7 4 Kahanh Laos Sepon 31.8 189.1 5 Katoob Noy Laos Sepon 10.1 33.7 6 Katoob Gnai Laos Sepon 2.0 22.0 7 Mahard Laos Sepon 10.0 31.9 8 Kalad Laos Sepon 40.6 218.8 9 Sadoun Laos Sepon 28.3 90.5 10 Salene Laos Sepon 95.3 506.2 11 Vanglork Laos Sepon 112.9 487.8 12 Denvilay Laos Nong 16.1 119.8 13 Paliang Kao Laos Nong 38.9 166.5 14 Palobok Laos Nong 37.2 151.7 15 Palonam Laos Nong 52.1 195.4 16 Raman Vietnam Xy 51.4 262.9 17 Ta Nua Vietnam Xy 12.5 137.8 18 Troan O Vietnam Xy 5.5 61.3 19 Troan Thuong Vietnam Xy 0.5 14.6 20 Pa Lo Vac Vietnam Thanh 17.0 125.1 21 Sung Vietnam Thanh 70.7 252.3 22 To Nua Vietnam Thanh 26.0 186.0 23 Pa Lo O Vietnam Thanh 20.6 104.3 24 Thanh 4 Vietnam Thanh 18.5 67.2 25 A Ho Vietnam Thanh 10.8 78.9 26 Thanh 10 Vietnam Thanh 29.7 63.1 27 Thanh 9 Vietnam Thanh 16.7 48.3 28 Thanh 8 Vietnam Thanh 5.8 35.9 29 Ban 7 Vietnam Thuan 3.6 34.7 30 Ban Zai Vietnam Thuan 5.1 55.3 31 Ban 6 Vietnam Thuan 4.3 56.4 32 Ban 5 Vietnam Thuan 4.2 51.3 33 Ban 2 Vietnam Thuan 23.8 67.6 34 Ban 1 Cu Vietnam Thuan 15.3 52.7 a: Values indicate area (ha) in relatively dense forest classes (Class 2 and 5 of Figure. 1). Table of Age < 25– 35– >45 Sex Male Family ≤ 3–5 6–8 >8 Ethnicity Paco House House Brick Yes No a: b: Tri ",
    "table_content": "|| blank | Name of study village | Country | District name | Total forest (a) | Total forest (a) ||\n|| blank | Name of study village | Country | District name | Inside 750 m | Inside 1,500 m ||\n|| 9 | Sadoun | Laos | Sepon | 28.3 | 90.5 ||\n|| 10 | Salene | Laos | Sepon | 95.3 | 506.2 ||\n|| 11 | Vanglork | Laos | Sepon | 112.9 | 487.8 ||\n|| 12 | Denvilay | Laos | Nong | 16.1 | 119.8 ||\n|| 13 | Paliang Kao | Laos | Nong | 38.9 | 166.5 ||\n|| 14 | Palobok | Laos | Nong | 37.2 | 151.7 ||\n|| 15 | Palonam | Laos | Nong | 52.1 | 195.4 ||\n|| 16 | Raman | Vietnam | Xy | 51.4 | 262.9 ||\n|| 17 | Ta Nua | Vietnam | Xy | 12.5 | 137.8 ||\n|| 18 | Troan O | Vietnam | Xy | 5.5 | 61.3 ||\n|| 1 | Alone | Laos | Sepon | 3.2 | 105.6 ||\n|| 19 | Troan Thuong | Vietnam | Xy | 0.5 | 14.6 ||\n|| 20 | Pa Lo Vac | Vietnam | Thanh | 17.0 | 125.1 ||\n|| 21 | Sung | Vietnam | Thanh | 70.7 | 252.3 ||\n|| 22 | To Nua | Vietnam | Thanh | 26.0 | 186.0 ||\n|| 23 | Pa Lo O | Vietnam | Thanh | 20.6 | 104.3 ||\n|| 24 | Thanh 4 | Vietnam | Thanh | 18.5 | 67.2 ||\n|| 25 | A Ho | Vietnam | Thanh | 10.8 | 78.9 ||\n|| 26 | Thanh 10 | Vietnam | Thanh | 29.7 | 63.1 ||\n|| 27 | Thanh 9 | Vietnam | Thanh | 16.7 | 48.3 ||\n|| 28 | Thanh 8 | Vietnam | Thanh | 5.8 | 35.9 ||\n|| 2 | Densavanh | Laos | Sepon | 23.3 | 186.7 ||\n|| 29 | Ban 7 | Vietnam | Thuan | 3.6 | 34.7 ||\n|| 30 | Ban Zai | Vietnam | Thuan | 5.1 | 55.3 ||\n|| 31 | Ban 6 | Vietnam | Thuan | 4.3 | 56.4 ||\n|| 32 | Ban 5 | Vietnam | Thuan | 4.2 | 51.3 ||\n|| 33 | Ban 2 | Vietnam | Thuan | 23.8 | 67.6 ||\n|| 34 | Ban 1 Cu | Vietnam | Thuan | 15.3 | 52.7 ||\n|| 3 | Pheung | Laos | Sepon | 40.1 | 163.7 ||\n|| 4 | Kahanh | Laos | Sepon | 31.8 | 189.1 ||\n|| 5 | Katoob Noy | Laos | Sepon | 10.1 | 33.7 ||\n|| 6 | Katoob Gnai | Laos | Sepon | 2.0 | 22.0 ||\n|| 7 | Mahard | Laos | Sepon | 10.0 | 31.9 ||\n|| 8 | Kalad | Laos | Sepon | 40.6 | 218.8 ||",
    "claim": "The cumulative forest area within the 750 m buffer zone for all villages in Laos is approximately 0.7 times less than that in Vietnam, suggesting a denser forest distribution in Vietnam.",
    "label": "refute"
  },
  {
    "id": "training_1288_6",
    "table_caption": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 O1 0.0506 (11) 0.0288 (13) 0.0650 (15) 0.0007 (9) 0.0258 (12) −0.0081 (10) O2 0.0496 (12) 0.0379 (14) 0.0699 (15) 0.0019 (10) 0.0365 (12) 0.0032 (11) O3 0.0596 (12) 0.0321 (14) 0.0861 (17) 0.0101 (11) 0.0454 (13) 0.0047 (12) O4 0.1004 (18) 0.0341 (15) 0.109 (2) 0.0120 (13) 0.0781 (18) 0.0053 (14) O5 0.0604 (14) 0.077 (2) 0.080 (2) 0.0213 (14) 0.0106 (15) −0.0307 (17) C1 0.0420 (15) 0.0303 (18) 0.0516 (19) 0.0030 (13) 0.0187 (16) −0.0029 (15) C2 0.0465 (15) 0.0286 (19) 0.057 (2) −0.0033 (13) 0.0179 (17) 0.0010 (14) C3 0.0460 (16) 0.038 (2) 0.059 (2) −0.0036 (14) 0.0260 (17) 0.0047 (15) C4 0.0385 (15) 0.041 (2) 0.0477 (19) 0.0008 (14) 0.0166 (16) 0.0000 (15) C5 0.0378 (14) 0.0309 (18) 0.0437 (18) 0.0024 (12) 0.0159 (15) 0.0034 (13) C6 0.0415 (15) 0.0325 (19) 0.049 (2) 0.0023 (14) 0.0195 (16) 0.0016 (14) C7 0.0410 (15) 0.0293 (18) 0.0436 (18) 0.0054 (13) 0.0163 (15) 0.0024 (13) C8 0.0529 (17) 0.0319 (19) 0.053 (2) 0.0041 (14) 0.0251 (17) 0.0013 (15) C9 0.0514 (17) 0.0310 (19) 0.060 (2) −0.0044 (14) 0.0222 (17) 0.0013 (15) C10 0.0493 (17) 0.041 (2) 0.061 (2) −0.0054 (15) 0.0267 (18) 0.0030 (16) C11 0.0459 (16) 0.037 (2) 0.056 (2) 0.0022 (14) 0.0250 (17) 0.0027 (15) C12 0.0427 (15) 0.0307 (19) 0.0438 (18) 0.0034 (13) 0.0166 (15) 0.0037 (14) C13 0.0493 (16) 0.0350 (19) 0.050 (2) 0.0052 (14) 0.0261 (17) 0.0005 (15) C14 0.0401 (14) 0.0304 (18) 0.0435 (18) 0.0024 (13) 0.0155 (15) 0.0003 (13) C15 0.0510 (18) 0.032 (2) 0.066 (2) 0.0078 (15) 0.0228 (19) −0.0013 (17) C16 0.060 (2) 0.047 (3) 0.080 (3) 0.0102 (17) 0.033 (2) −0.0139 (19) C17 0.0456 (16) 0.041 (2) 0.064 (2) −0.0031 (14) 0.0316 (17) 0.0025 (16) C18 0.0505 (17) 0.045 (2) 0.077 (2) 0.0002 (15) 0.0368 (19) −0.0024 (17) C19 0.071 (2) 0.047 (3) 0.122 (3) 0.0025 (18) 0.067 (3) −0.004 (2) ",
    "table_content": "|| blank | U 11 | U 22 | U 33 | U 12 | U 13 | U 23 ||\n|| O1 | 0.0506 (11) | 0.0288 (13) | 0.0650 (15) | 0.0007 (9) | 0.0258 (12) | −0.0081 (10) ||\n|| C5 | 0.0378 (14) | 0.0309 (18) | 0.0437 (18) | 0.0024 (12) | 0.0159 (15) | 0.0034 (13) ||\n|| C6 | 0.0415 (15) | 0.0325 (19) | 0.049 (2) | 0.0023 (14) | 0.0195 (16) | 0.0016 (14) ||\n|| C7 | 0.0410 (15) | 0.0293 (18) | 0.0436 (18) | 0.0054 (13) | 0.0163 (15) | 0.0024 (13) ||\n|| C8 | 0.0529 (17) | 0.0319 (19) | 0.053 (2) | 0.0041 (14) | 0.0251 (17) | 0.0013 (15) ||\n|| C9 | 0.0514 (17) | 0.0310 (19) | 0.060 (2) | −0.0044 (14) | 0.0222 (17) | 0.0013 (15) ||\n|| C10 | 0.0493 (17) | 0.041 (2) | 0.061 (2) | −0.0054 (15) | 0.0267 (18) | 0.0030 (16) ||\n|| C11 | 0.0459 (16) | 0.037 (2) | 0.056 (2) | 0.0022 (14) | 0.0250 (17) | 0.0027 (15) ||\n|| C12 | 0.0427 (15) | 0.0307 (19) | 0.0438 (18) | 0.0034 (13) | 0.0166 (15) | 0.0037 (14) ||\n|| C13 | 0.0493 (16) | 0.0350 (19) | 0.050 (2) | 0.0052 (14) | 0.0261 (17) | 0.0005 (15) ||\n|| C14 | 0.0401 (14) | 0.0304 (18) | 0.0435 (18) | 0.0024 (13) | 0.0155 (15) | 0.0003 (13) ||\n|| O2 | 0.0496 (12) | 0.0379 (14) | 0.0699 (15) | 0.0019 (10) | 0.0365 (12) | 0.0032 (11) ||\n|| C15 | 0.0510 (18) | 0.032 (2) | 0.066 (2) | 0.0078 (15) | 0.0228 (19) | −0.0013 (17) ||\n|| C16 | 0.060 (2) | 0.047 (3) | 0.080 (3) | 0.0102 (17) | 0.033 (2) | −0.0139 (19) ||\n|| C17 | 0.0456 (16) | 0.041 (2) | 0.064 (2) | −0.0031 (14) | 0.0316 (17) | 0.0025 (16) ||\n|| C18 | 0.0505 (17) | 0.045 (2) | 0.077 (2) | 0.0002 (15) | 0.0368 (19) | −0.0024 (17) ||\n|| C19 | 0.071 (2) | 0.047 (3) | 0.122 (3) | 0.0025 (18) | 0.067 (3) | −0.004 (2) ||\n|| O3 | 0.0596 (12) | 0.0321 (14) | 0.0861 (17) | 0.0101 (11) | 0.0454 (13) | 0.0047 (12) ||\n|| O4 | 0.1004 (18) | 0.0341 (15) | 0.109 (2) | 0.0120 (13) | 0.0781 (18) | 0.0053 (14) ||\n|| O5 | 0.0604 (14) | 0.077 (2) | 0.080 (2) | 0.0213 (14) | 0.0106 (15) | −0.0307 (17) ||\n|| C1 | 0.0420 (15) | 0.0303 (18) | 0.0516 (19) | 0.0030 (13) | 0.0187 (16) | −0.0029 (15) ||\n|| C2 | 0.0465 (15) | 0.0286 (19) | 0.057 (2) | −0.0033 (13) | 0.0179 (17) | 0.0010 (14) ||\n|| C3 | 0.0460 (16) | 0.038 (2) | 0.059 (2) | −0.0036 (14) | 0.0260 (17) | 0.0047 (15) ||\n|| C4 | 0.0385 (15) | 0.041 (2) | 0.0477 (19) | 0.0008 (14) | 0.0166 (16) | 0.0000 (15) ||",
    "claim": "The U23 values for carbon atoms show a decreasing trend from C1 to C19, suggesting a systematic reduction in the coupling of displacements along these axes as the atomic number increases.",
    "label": "refute"
  },
  {
    "id": "training_1288_6",
    "table_caption": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 O1 0.0506 (11) 0.0288 (13) 0.0650 (15) 0.0007 (9) 0.0258 (12) −0.0081 (10) O2 0.0496 (12) 0.0379 (14) 0.0699 (15) 0.0019 (10) 0.0365 (12) 0.0032 (11) O3 0.0596 (12) 0.0321 (14) 0.0861 (17) 0.0101 (11) 0.0454 (13) 0.0047 (12) O4 0.1004 (18) 0.0341 (15) 0.109 (2) 0.0120 (13) 0.0781 (18) 0.0053 (14) O5 0.0604 (14) 0.077 (2) 0.080 (2) 0.0213 (14) 0.0106 (15) −0.0307 (17) C1 0.0420 (15) 0.0303 (18) 0.0516 (19) 0.0030 (13) 0.0187 (16) −0.0029 (15) C2 0.0465 (15) 0.0286 (19) 0.057 (2) −0.0033 (13) 0.0179 (17) 0.0010 (14) C3 0.0460 (16) 0.038 (2) 0.059 (2) −0.0036 (14) 0.0260 (17) 0.0047 (15) C4 0.0385 (15) 0.041 (2) 0.0477 (19) 0.0008 (14) 0.0166 (16) 0.0000 (15) C5 0.0378 (14) 0.0309 (18) 0.0437 (18) 0.0024 (12) 0.0159 (15) 0.0034 (13) C6 0.0415 (15) 0.0325 (19) 0.049 (2) 0.0023 (14) 0.0195 (16) 0.0016 (14) C7 0.0410 (15) 0.0293 (18) 0.0436 (18) 0.0054 (13) 0.0163 (15) 0.0024 (13) C8 0.0529 (17) 0.0319 (19) 0.053 (2) 0.0041 (14) 0.0251 (17) 0.0013 (15) C9 0.0514 (17) 0.0310 (19) 0.060 (2) −0.0044 (14) 0.0222 (17) 0.0013 (15) C10 0.0493 (17) 0.041 (2) 0.061 (2) −0.0054 (15) 0.0267 (18) 0.0030 (16) C11 0.0459 (16) 0.037 (2) 0.056 (2) 0.0022 (14) 0.0250 (17) 0.0027 (15) C12 0.0427 (15) 0.0307 (19) 0.0438 (18) 0.0034 (13) 0.0166 (15) 0.0037 (14) C13 0.0493 (16) 0.0350 (19) 0.050 (2) 0.0052 (14) 0.0261 (17) 0.0005 (15) C14 0.0401 (14) 0.0304 (18) 0.0435 (18) 0.0024 (13) 0.0155 (15) 0.0003 (13) C15 0.0510 (18) 0.032 (2) 0.066 (2) 0.0078 (15) 0.0228 (19) −0.0013 (17) C16 0.060 (2) 0.047 (3) 0.080 (3) 0.0102 (17) 0.033 (2) −0.0139 (19) C17 0.0456 (16) 0.041 (2) 0.064 (2) −0.0031 (14) 0.0316 (17) 0.0025 (16) C18 0.0505 (17) 0.045 (2) 0.077 (2) 0.0002 (15) 0.0368 (19) −0.0024 (17) C19 0.071 (2) 0.047 (3) 0.122 (3) 0.0025 (18) 0.067 (3) −0.004 (2) ",
    "table_content": "|| blank | U 11 | U 22 | U 33 | U 12 | U 13 | U 23 ||\n|| O1 | 0.0506 (11) | 0.0288 (13) | 0.0650 (15) | 0.0007 (9) | 0.0258 (12) | −0.0081 (10) ||\n|| C5 | 0.0378 (14) | 0.0309 (18) | 0.0437 (18) | 0.0024 (12) | 0.0159 (15) | 0.0034 (13) ||\n|| C6 | 0.0415 (15) | 0.0325 (19) | 0.049 (2) | 0.0023 (14) | 0.0195 (16) | 0.0016 (14) ||\n|| C7 | 0.0410 (15) | 0.0293 (18) | 0.0436 (18) | 0.0054 (13) | 0.0163 (15) | 0.0024 (13) ||\n|| C8 | 0.0529 (17) | 0.0319 (19) | 0.053 (2) | 0.0041 (14) | 0.0251 (17) | 0.0013 (15) ||\n|| C9 | 0.0514 (17) | 0.0310 (19) | 0.060 (2) | −0.0044 (14) | 0.0222 (17) | 0.0013 (15) ||\n|| C10 | 0.0493 (17) | 0.041 (2) | 0.061 (2) | −0.0054 (15) | 0.0267 (18) | 0.0030 (16) ||\n|| C11 | 0.0459 (16) | 0.037 (2) | 0.056 (2) | 0.0022 (14) | 0.0250 (17) | 0.0027 (15) ||\n|| C12 | 0.0427 (15) | 0.0307 (19) | 0.0438 (18) | 0.0034 (13) | 0.0166 (15) | 0.0037 (14) ||\n|| C13 | 0.0493 (16) | 0.0350 (19) | 0.050 (2) | 0.0052 (14) | 0.0261 (17) | 0.0005 (15) ||\n|| C14 | 0.0401 (14) | 0.0304 (18) | 0.0435 (18) | 0.0024 (13) | 0.0155 (15) | 0.0003 (13) ||\n|| O2 | 0.0496 (12) | 0.0379 (14) | 0.0699 (15) | 0.0019 (10) | 0.0365 (12) | 0.0032 (11) ||\n|| C15 | 0.0510 (18) | 0.032 (2) | 0.066 (2) | 0.0078 (15) | 0.0228 (19) | −0.0013 (17) ||\n|| C16 | 0.060 (2) | 0.047 (3) | 0.080 (3) | 0.0102 (17) | 0.033 (2) | −0.0139 (19) ||\n|| C17 | 0.0456 (16) | 0.041 (2) | 0.064 (2) | −0.0031 (14) | 0.0316 (17) | 0.0025 (16) ||\n|| C18 | 0.0505 (17) | 0.045 (2) | 0.077 (2) | 0.0002 (15) | 0.0368 (19) | −0.0024 (17) ||\n|| C19 | 0.071 (2) | 0.047 (3) | 0.122 (3) | 0.0025 (18) | 0.067 (3) | −0.004 (2) ||\n|| O3 | 0.0596 (12) | 0.0321 (14) | 0.0861 (17) | 0.0101 (11) | 0.0454 (13) | 0.0047 (12) ||\n|| O4 | 0.1004 (18) | 0.0341 (15) | 0.109 (2) | 0.0120 (13) | 0.0781 (18) | 0.0053 (14) ||\n|| O5 | 0.0604 (14) | 0.077 (2) | 0.080 (2) | 0.0213 (14) | 0.0106 (15) | −0.0307 (17) ||\n|| C1 | 0.0420 (15) | 0.0303 (18) | 0.0516 (19) | 0.0030 (13) | 0.0187 (16) | −0.0029 (15) ||\n|| C2 | 0.0465 (15) | 0.0286 (19) | 0.057 (2) | −0.0033 (13) | 0.0179 (17) | 0.0010 (14) ||\n|| C3 | 0.0460 (16) | 0.038 (2) | 0.059 (2) | −0.0036 (14) | 0.0260 (17) | 0.0047 (15) ||\n|| C4 | 0.0385 (15) | 0.041 (2) | 0.0477 (19) | 0.0008 (14) | 0.0166 (16) | 0.0000 (15) ||",
    "claim": "The U23 values for carbon atoms show an increasing trend from C1 to C19, suggesting a systematic enhancement in the coupling of displacements along these axes as the atomic number increases.",
    "label": "refute"
  },
  {
    "id": "training_1101_1",
    "table_caption": "Table: in an Table II. The prevalence of the underlying diseases leading to dialysis requirement in the studied patients. PTFE (n = 50) PVAG (n = 50) Diabetes mellitus 35 31 Renal diseases 25 26 Hypertension 28 37 Tobacco use 28 34 Obesity 17 19 Other 4 2 ",
    "table_content": "|| blank | PTFE ( n = 50) | PVAG ( n = 50) ||\n|| Diabetes mellitus | 35 | 31 ||\n|| Renal diseases | 25 | 26 ||\n|| Hypertension | 28 | 37 ||\n|| Tobacco use | 28 | 34 ||\n|| Obesity | 17 | 19 ||\n|| Other | 4 | 2 ||",
    "claim": "The prevalence of hypertension in the PVAG group exceeds that in the PTFE group by a factor of 1.18, indicating a higher association of hypertension with PVAG access.",
    "label": "refute"
  },
  {
    "id": "training_29_4",
    "table_caption": "Table: Primer Sequences for RT-PCR. Gene ID Primer Name Sequence (59–39) Position cDNA (bp) hMCT1 NM_003051.3 hMCT1-F AGCGAAGTGTCATGGATATCCTCC 529–934 406 hMCT1-R CAACACAGCAGTTTAGTAGCAAGC hMCT2 NM_004731.3 hMCT2-F CCCACATGTACACAGAGTATCTGG 2075–2419 345 hMCT2 NM_004731.3 hMCT2-R AGGGTTCTATTCTCTAGCACCAGG 2075–2419 345 hMCT4 NM_001042423.1 hMCT4-F GTCAGTGTCTTCTTCAAGGAGCTC 242–540 299 hMCT4 NM_001042423.1 hMCT4-R AAGTAGCGGTTCAGCATGATGAGC 242–540 299 hAE2 U62531.1 hAE2-F CAGTTCTTTCTCCGAGAGGATGAC 631–1001 371 hAE2 U62531.1 hAE2-R TGACTCTTCATGAGGTCTAGGTCG 631–1001 371 hCA12 BC023981.1 hCA12-F TTGGCATCTGTATTGTGGTGGTGG 1071–1431 361 hCA12 BC023981.1 hCA12-R CAGCTTTGAATTCCTGCTGCTTGG 1071–1431 361 hCFTR NM_000492.3 hCFTR-F TGGTGATGACAGCCTCTTCTTCAG 1401–1737 337 hCFTR NM_000492.3 hCFTR-R CTCTGCAAACTTGGAGATGTCCTC 1401–1737 337 hsAC10 NM_018417.4 hsAC10-F TGTCTTGACCTCAATGTGAGCTGC 2426–2772 347 hsAC10 NM_018417.4 hsAC10-R GAAAGTCTCATGCTATCCAGCTGG 2426–2772 347 hGAPDH NM_002046.3 hGAPDH-F TTCCACCCATGGCAAATTCCATGG 252–554 303 hGAPDH NM_002046.3 hGAPDH-R GAGGCATTGCTGATGATCTTGAGG 252–554 303 doi:10.1371/journal.pone.0051427.t001 ",
    "table_content": "|| Gene ID | Primer Name | Sequence (5′–3′) | Position | cDNA (bp) ||\n|| hMCT1 NM_003051.3 | hMCT1-F |  AGCGAAGTGTCATGGATATCCTCC  | 529–934 | 406 ||\n|| hCA12 BC023981.1 | hCA12-R |  CAGCTTTGAATTCCTGCTGCTTGG  | 1071–1431 | 361 ||\n|| hCFTR NM_000492.3 | hCFTR-F |  TGGTGATGACAGCCTCTTCTTCAG  | 1401–1737 | 337 ||\n|| hCFTR NM_000492.3 | hCFTR-R |  CTCTGCAAACTTGGAGATGTCCTC  | 1401–1737 | 337 ||\n|| hsAC10 NM_018417.4 | hsAC10-F |  TGTCTTGACCTCAATGTGAGCTGC  | 2426–2772 | 347 ||\n|| hsAC10 NM_018417.4 | hsAC10-R |  GAAAGTCTCATGCTATCCAGCTGG  | 2426–2772 | 347 ||\n|| hGAPDH NM_002046.3 | hGAPDH-F |  TTCCACCCATGGCAAATTCCATGG  | 252–554 | 303 ||\n|| hGAPDH NM_002046.3 | hGAPDH-R |  GAGGCATTGCTGATGATCTTGAGG  | 252–554 | 303 ||\n|| hMCT1 NM_003051.3 | hMCT1-R |  CAACACAGCAGTTTAGTAGCAAGC  | blank | blank ||\n|| hMCT2 NM_004731.3 | hMCT2-F |  CCCACATGTACACAGAGTATCTGG  | 2075–2419 | 345 ||\n|| hMCT2 NM_004731.3 | hMCT2-R |  AGGGTTCTATTCTCTAGCACCAGG  | 2075–2419 | 345 ||\n|| hMCT4 NM_001042423.1 | hMCT4-F |  GTCAGTGTCTTCTTCAAGGAGCTC  | 242–540 | 299 ||\n|| hMCT4 NM_001042423.1 | hMCT4-R |  AAGTAGCGGTTCAGCATGATGAGC  | 242–540 | 299 ||\n|| hAE2 U62531.1 | hAE2-F |  CAGTTCTTTCTCCGAGAGGATGAC  | 631–1001 | 371 ||\n|| hAE2 U62531.1 | hAE2-R |  TGACTCTTCATGAGGTCTAGGTCG  | 631–1001 | 371 ||\n|| hCA12 BC023981.1 | hCA12-F |  TTGGCATCTGTATTGTGGTGGTGG  | 1071–1431 | 361 ||",
    "claim": "The range of cDNA lengths spans from 299 to 406 base pairs, indicating a difference of 67 base pairs between the shortest and longest cDNA segments amplified by the primers.",
    "label": "refute"
  },
  {
    "id": "training_573_1",
    "table_caption": "Table: The unigenes related to secondary metabolites in 101L and 101R. Secondary metabolites biosynthesis pathways Unigenes in 101L Unigenes in 101R Total Unigenes Anthocyanin biosynthesis [PATH: 00942] 5 3 5 Brassinosteroid biosynthesis [PATH: 00905] 15 17 25 Caffeine metabolism [PATH: 00232] 15 14 18 Carotenoid biosynthesis [PATH: 00906] 80 80 117 Cutin, suberin and wax biosynthesis [PATH: 00073] 10 18 26 Diterpenoid biosynthesis [PATH: 00904] 25 24 33 Flavone and flavonol biosynthesis [PATH: 00944] 43 19 45 Flavonoid biosynthesis [PATH: 00941] 48 64 76 Indole alkaloid biosynthesis [PATH: 00901] 8 5 11 Isoquinoline alkaloid biosynthesis [PATH: 00950] 42 39 58 Limonine and pinene degradation [PATH: 00903] 92 75 120 Monoterpenoid biosynthesis [PATH: 00902] 9 9 11 Nicotinate and nicotinamide metabolism [PATH: 00760] 36 37 48 Phenylpropanoid metabolism [PATH: 00940] 192 206 292 Sesquiterpenoid and triterpenoid biosynthesis [PATH: 00909] 50 36 69 Steroid biosynthesis [PATH: 000100] 54 50 67 Stibenoid diarylhepatanoid and gingerol biosynthesis [PATH: 00945] 82 79 112 Terpenoid backbone biosynthesis [PATH: 00900] 124 112 170 Tropane, piperidine and pyridine alkaloid biosynthesis [PATH: 00960] 39 55 62 Ubiquinone and other terpenoid-quinone biosynthesis [PATH: 00130] 73 70 101 Zeatin biosynthesis [PATH: 00908] 26 22 34 Total 1068 1034 1500 doi:10.1371/journal.pone.0062714.t003 ",
    "table_content": "|| Secondary metabolites biosynthesis pathways | Unigenes in 101L | Unigenes in 101R | Total Unigenes ||\n|| Anthocyanin biosynthesis [PATH: 00942] | 5 | 3 | 5 ||\n|| Isoquinoline alkaloid biosynthesis [PATH: 00950] | 42 | 39 | 58 ||\n|| Limonine and pinene degradation [PATH: 00903] | 92 | 75 | 120 ||\n|| Monoterpenoid biosynthesis [PATH: 00902] | 9 | 9 | 11 ||\n|| Nicotinate and nicotinamide metabolism [PATH: 00760] | 36 | 37 | 48 ||\n|| Phenylpropanoid metabolism [PATH: 00940] | 192 | 206 | 292 ||\n|| Sesquiterpenoid and triterpenoid biosynthesis [PATH: 00909] | 50 | 36 | 69 ||\n|| Steroid biosynthesis [PATH: 000100] | 54 | 50 | 67 ||\n|| Stibenoid diarylhepatanoid and gingerol biosynthesis [PATH: 00945] | 82 | 79 | 112 ||\n|| Terpenoid backbone biosynthesis [PATH: 00900] | 124 | 112 | 170 ||\n|| Tropane, piperidine and pyridine alkaloid biosynthesis [PATH: 00960] | 39 | 55 | 62 ||\n|| Brassinosteroid biosynthesis [PATH: 00905] | 15 | 17 | 25 ||\n|| Ubiquinone and other terpenoid-quinone biosynthesis [PATH: 00130] | 73 | 70 | 101 ||\n|| Zeatin biosynthesis [PATH: 00908] | 26 | 22 | 34 ||\n||  Total  |  1068  |  1034  |  1500  ||\n|| Caffeine metabolism [PATH: 00232] | 15 | 14 | 18 ||\n|| Carotenoid biosynthesis [PATH: 00906] | 80 | 80 | 117 ||\n|| Cutin, suberin and wax biosynthesis [PATH: 00073] | 10 | 18 | 26 ||\n|| Diterpenoid biosynthesis [PATH: 00904] | 25 | 24 | 33 ||\n|| Flavone and flavonol biosynthesis [PATH: 00944] | 43 | 19 | 45 ||\n|| Flavonoid biosynthesis [PATH: 00941] | 48 | 64 | 76 ||\n|| Indole alkaloid biosynthesis [PATH: 00901] | 8 | 5 | 11 ||",
    "claim": "The phenylpropanoid metabolism pathway accounts for the highest proportion of total unigenes, contributing approximately 15% to the total unigene count across both samples.",
    "label": "refute"
  },
  {
    "id": "training_596_6",
    "table_caption": "Table: Mean sand temperatures (°C) (±SD) at 45cm depth for each experimental treatment. Shade Treatment Exposed Plots Shaded Plots Water Treatment None (0 mm) Low (100 mm) Average (323 mm) High (721mm) None (0 mm) Low (100 mm) Average (323 mm) High (721mm) Temperature during 31 days of water application 31.7±0.3 29.9±0.7 29.4±0.7 29.3±0.7 29.5±0.5 28.2±0.9 27.7±0.9 27.7±0.9 Temperature during 30 days following water application 32.6±0.5 32.0±1.0 32.1±1.2 32.0±1.2 29.6±0.5 29.2±0.9 29.1±1.1 29.2±1.0 Temperatures were recorded during the 31 days of water application and for 30 days after water treatments stopped. Water treatments were: high (721 mm), average (323 mm) and low (100 mm), corresponding to La Niña, neutral and El Niño conditions in Northwest Costa Rica. ",
    "table_content": "|| Shade Treatment Water Treatment | Exposed Plots | Exposed Plots | Exposed Plots | Exposed Plots | Shaded Plots | Shaded Plots | Shaded Plots | Shaded Plots ||\n|| Shade Treatment Water Treatment | None (0 mm) | Low (100 mm) | Average (323 mm) | High (721mm) | None (0 mm) | Low (100 mm) | Average (323 mm) | High (721mm) ||\n|| Temperature during 31 days of water application | 31.7±0.3 | 29.9±0.7 | 29.4±0.7 | 29.3±0.7 | 29.5±0.5 | 28.2±0.9 | 27.7±0.9 | 27.7±0.9 ||\n|| Temperature during 30 days following water application | 32.6±0.5 | 32.0±1.0 | 32.1±1.2 | 32.0±1.2 | 29.6±0.5 | 29.2±0.9 | 29.1±1.1 | 29.2±1.0 ||",
    "claim": "The overall trend shows that temperatures are consistently higher during the post-application period compared to the application period, with an average increase of 1.0°C across all treatments. This trend reflects the cumulative effect of reduced moisture and increased solar heating over time.",
    "label": "refute"
  },
  {
    "id": "training_596_6",
    "table_caption": "Table: Mean sand temperatures (°C) (±SD) at 45cm depth for each experimental treatment. Shade Treatment Exposed Plots Shaded Plots Water Treatment None (0 mm) Low (100 mm) Average (323 mm) High (721mm) None (0 mm) Low (100 mm) Average (323 mm) High (721mm) Temperature during 31 days of water application 31.7±0.3 29.9±0.7 29.4±0.7 29.3±0.7 29.5±0.5 28.2±0.9 27.7±0.9 27.7±0.9 Temperature during 30 days following water application 32.6±0.5 32.0±1.0 32.1±1.2 32.0±1.2 29.6±0.5 29.2±0.9 29.1±1.1 29.2±1.0 Temperatures were recorded during the 31 days of water application and for 30 days after water treatments stopped. Water treatments were: high (721 mm), average (323 mm) and low (100 mm), corresponding to La Niña, neutral and El Niño conditions in Northwest Costa Rica. ",
    "table_content": "|| Shade Treatment Water Treatment | Exposed Plots | Exposed Plots | Exposed Plots | Exposed Plots | Shaded Plots | Shaded Plots | Shaded Plots | Shaded Plots ||\n|| Shade Treatment Water Treatment | None (0 mm) | Low (100 mm) | Average (323 mm) | High (721mm) | None (0 mm) | Low (100 mm) | Average (323 mm) | High (721mm) ||\n|| Temperature during 31 days of water application | 31.7±0.3 | 29.9±0.7 | 29.4±0.7 | 29.3±0.7 | 29.5±0.5 | 28.2±0.9 | 27.7±0.9 | 27.7±0.9 ||\n|| Temperature during 30 days following water application | 32.6±0.5 | 32.0±1.0 | 32.1±1.2 | 32.0±1.2 | 29.6±0.5 | 29.2±0.9 | 29.1±1.1 | 29.2±1.0 ||",
    "claim": "The overall trend shows that temperatures are consistently lower during the post-application period compared to the application period, with an average decrease of 1.0°C across all treatments. This trend reflects the cumulative effect of reduced moisture and increased solar heating over time.",
    "label": "refute"
  },
  {
    "id": "training_531_6",
    "table_caption": "Table: and SD) SD 0.31** 0.28** 0.56** 127.94 0.51 40.95 10.6 (Pre); of found normal glucose Free after control period (Pre), after control/before exercise (Mid) and after exercise period (Post). Variable Pre (n = 14) mean ± SD Mid (n = 14) mean ± SD Post (n = 14) mean ± SD Energy, kcal/day 2,122 ± 512 1,891 ± 609 1,975 ± 493 Protein, g/day 88.5 ± 34.7 92.1 ± 28.1 76.3 ± 21.7 Fat, g/day 88.4 ± 38.4 83.0 ± 75.2 75.2 ± 28.7 Carbohydrates, d/day 229.8 ± 62.6 217.2 ± 57.8 215.5 ± 70.5 Starch, g/day 104.6 ± 29.6 91.3 ± 22.4 104.5 ± 33.4 Sucrose, g/day 39.3 ± 19.9 34.3 ± 19.8 36.6 ± 21.7 Fiber, g/day 19.9 ± 5.0 19.3 ± 4.6 19.3 ± 7.3 Protein, E% 16.7 ± 3.8 18.4 ± 3.6 16.7 ± 2.7 Fat, E% 36.9 ± 9.8 36.5 ± 6.5 35.6 ± 5.5 Carbohydrate, E% 45.1 ± 11.5 43.8 ± 7.9 46.7 ± 5.3 Starch, E% 20.7 ± 6.3 19.2 ± 4.6 22.8 ± 3.4* Sucrose, E% 7.4 ± 2.8 6.5 ± 3.1 7.5 ± 2.7 Fiber, g/MJ 2.3 ± 0.6 2.4 ± 0.7 2.5 ± 0.7 Bread, g/day 85.1 ± 32.4 84.0 ± 39.9 87.2 ± 57.6 Other grain products, g/day 130.1 ± 68.2 117.3 ± 50.0 134.7 ± 75.1 Vegetables, g/day 309.1 ± 133.6 306.6 ± 130.3 270.7 ± 127.5 Fruits and berries, g/day 197.3 ± 149.8 166.8 ± 114.8 182.6 ± 103.8 Fermented milk products g/day 144.4 ± 126.3 157.8 ± 108.8 97.1 ± 101.2 Cheeses, g/day 44.6 ± 27.5 39.2 ± 23.6 49.1 ± 26.8 Meat, g/day 143.6 ± 143.2 111.4 ± 65.8 82.0 ± 51.5 Fish, g/day 23.0 ± 42.0 31.1 ± 34.2 14.4 ± 21.1 Fourteen subjects completed the food diaries in all time points. kcal, kilocalories; g/day, grams per day; E%, energy percentage calculated as: 9.082 × (g/day divided by kcal/day) ",
    "table_content": "|| Variable | Pre ( n = 14) mean ±SD | Mid ( n = 14) mean ±SD | Post ( n = 14) mean ±SD ||\n|| Energy, kcal/day | 2, 122 ±512 | 1, 891 ±609 | 1, 975 ±493 ||\n|| Carbohydrate, E% | 45.1 ± 11.5 | 43.8 ± 7.9 | 46.7 ± 5.3 ||\n|| Starch, E% | 20.7 ± 6.3 | 19.2 ± 4.6 | 22.8 ± 3.4 * ||\n|| Sucrose, E% | 7.4 ± 2.8 | 6.5 ± 3.1 | 7.5 ± 2.7 ||\n|| Fiber, g/MJ | 2.3 ± 0.6 | 2.4 ± 0.7 | 2.5 ± 0.7 ||\n|| Bread, g/day | 85.1 ± 32.4 | 84.0 ± 39.9 | 87.2 ± 57.6 ||\n|| Other grain products, g/day | 130.1 ± 68.2 | 117.3 ± 50.0 | 134.7 ± 75.1 ||\n|| Vegetables, g/day | 309.1 ± 133.6 | 306.6 ± 130.3 | 270.7 ± 127.5 ||\n|| Fruits and berries, g/day | 197.3 ± 149.8 | 166.8 ± 114.8 | 182.6 ± 103.8 ||\n|| Fermented milk products g/day | 144.4 ± 126.3 | 157.8 ± 108.8 | 97.1 ± 101.2 ||\n|| Cheeses, g/day | 44.6 ± 27.5 | 39.2 ± 23.6 | 49.1 ± 26.8 ||\n|| Protein, g/day | 88.5 ± 34.7 | 92.1 ± 28.1 | 76.3 ± 21.7 ||\n|| Meat, g/day | 143.6 ± 143.2 | 111.4 ± 65.8 | 82.0 ± 51.5 ||\n|| Fish, g/day | 23.0 ± 42.0 | 31.1 ± 34.2 | 14.4 ± 21.1 ||\n|| Fat, g/day | 88.4 ± 38.4 | 83.0 ± 75.2 | 75.2 ± 28.7 ||\n|| Carbohydrates, d/day | 229.8 ± 62.6 | 217.2 ± 57.8 | 215.5 ± 70.5 ||\n|| Starch, g/day | 104.6 ± 29.6 | 91.3 ± 22.4 | 104.5 ± 33.4 ||\n|| Sucrose, g/day | 39.3 ± 19.9 | 34.3 ± 19.8 | 36.6 ± 21.7 ||\n|| Fiber, g/day | 19.9 ± 5.0 | 19.3 ± 4.6 | 19.3 ± 7.3 ||\n|| Protein, E% | 16.7 ± 3.8 | 18.4 ± 3.6 | 16.7 ± 2.7 ||\n|| Fat, E% | 36.9 ± 9.8 | 36.5 ± 6.5 | 35.6 ± 5.5 ||",
    "claim": "Starch intake in grams per day returned to near Pre levels by Post, while sucrose intake showed a slight increase from Mid to Post. The net effect is a complex interplay of changes, resulting in a minimal net change in starch intake and a 6.7% decrease in sucrose intake from Mid to Post.",
    "label": "refute"
  }
]